nct_id,downcase_mesh_term,official_title,brief_title,all_conditions,study_first_submitted_date,primary_completion_date,completion_date,study_type,overall_status,study_phases,funded_bys,sponsors_name,investigators,intervention_types,location,minimum_age_num,maximum_age_num,category_age,category,sub_category,URL
NCT00001159,graves disease,Evaluation of Patients With Thyroid Function Disorders,Evaluation of Patients With Thyroid Disorders,Grave's Disease|Hyperthyroidism|Hypothyroidism,1999-11-03,,,Observational,Recruiting,,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"National Institutes of Health Clinical Center, 9000 Rockville Pike",,United States,6.0,120.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT00001159
NCT00001159,goiter,Evaluation of Patients With Thyroid Function Disorders,Evaluation of Patients With Thyroid Disorders,Grave's Disease|Hyperthyroidism|Hypothyroidism,1999-11-03,,,Observational,Recruiting,,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"National Institutes of Health Clinical Center, 9000 Rockville Pike",,United States,6.0,120.0,[0-17]|[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00001159
NCT00001277,parathyroid neoplasms,Studies of Hyperparathyroidism and Related Disorders,Studies of Elevated Parathyroid Activity,Hypercalcemia|Hyperparathyroidism|MEN1|Multiple Endocrine Neoplasia|Parathyroid Neoplasm,1999-11-03,2020-03-11,2020-12-23,Interventional,Completed,Not Applicable,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"National Institutes of Health Clinical Center, 9000 Rockville Pike",Drug|Drug,United States,2.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00001277
NCT00004048,thyroid neoplasms,Phase I/II Radioimmunotherapy With High-Dose 90Y-Labeled Humanized MN-14 Alone or Combined With Doxorubicin and Peripheral Blood Stem Cell Rescue (PBSCR) in Medullary Thyroid Cancer (MTC) Grant Application Title: Radioimmunotherapy of MTC With Y-90 Humanized MN14 Anti-CEA Mab and Doxorubicin,Radioimmunotherapy With or Without Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Thyroid Cancer,Head and Neck Cancer,1999-12-10,2002-05-31,2002-05-31,Interventional,Completed,Phase 1/Phase 2,Garden State Cancer Center at the Center for Molecular Medicine and Immunology,Garden State Cancer Center at the Center for Molecular Medicine and Immunology,Garden State Cancer Center|St. Joseph's Hospital and Medical Center,Biological|Drug|Procedure|Procedure|Radiation|Radiation,United States,16.0,80.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00004048
NCT00004074,"thyroid cancer, papillary",A Phase I Trial of Herceptin and Interleukin-12,Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu,Advanced Adult Primary Liver Cancer|Anaplastic Thyroid Cancer|Bone Metastases|Carcinoma of the Appendix|Distal Urethral Cancer|Fallopian Tube Cancer|Gastrinoma|Glucagonoma|Inflammatory Breast Cancer|Insulinoma|Liver Metastases|Localized Unresectable Adult Primary Liver Cancer|Lung Metastases|Male Breast Cancer|Malignant Pericardial Effusion|Malignant Pleural Effusion|Metastatic Gastrointestinal Carcinoid Tumor|Metastatic Parathyroid Cancer|Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter|Newly Diagnosed Carcinoma of Unknown Primary|Occult Non-small Cell Lung Cancer|Pancreatic Polypeptide Tumor|Primary Peritoneal Cavity Cancer|Proximal Urethral Cancer|Pulmonary Carcinoid Tumor|Recurrent Adenoid Cystic Carcinoma of the Oral Cavity|Recurrent Adrenocortical Carcinoma|Recurrent Adult Primary Liver Cancer|Recurrent Anal Cancer|Recurrent Bladder Cancer|Recurrent Breast Cancer|Recurrent Carcinoma of Unknown Primary|Recurrent Cervical Cancer|Recurrent Colon Cancer|Recurrent Endometrial Carcinoma|Recurrent Esophageal Cancer|Recurrent Extrahepatic Bile Duct Cancer|Recurrent Gallbladder Cancer|Recurrent Gastric Cancer|Recurrent Gastrointestinal Carcinoid Tumor|Recurrent Islet Cell Carcinoma|Recurrent Malignant Testicular Germ Cell Tumor|Recurrent Mucoepidermoid Carcinoma of the Oral Cavity|Recurrent Non-small Cell Lung Cancer|Recurrent Ovarian Epithelial Cancer|Recurrent Pancreatic Cancer|Recurrent Parathyroid Cancer|Recurrent Prostate Cancer|Recurrent Rectal Cancer|Recurrent Renal Cell Cancer|Recurrent Salivary Gland Cancer|Recurrent Small Intestine Cancer|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Thyroid Cancer|Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter|Recurrent Urethral Cancer|Recurrent Vaginal Cancer|Recurrent Vulvar Cancer|Skin Metastases|Small Intestine Adenocarcinoma|Somatostatinoma|Stage IIIA Anal Cancer|Stage IIIA Breast Cancer|Stage III Adenoid Cystic Carcinoma of the Oral Cavity|Stage III Adrenocortical Carcinoma|Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Anal Cancer|Stage IIIB Breast Cancer|Stage III Bladder Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage III Cervical Cancer|Stage III Colon Cancer|Stage III Endometrial Carcinoma|Stage III Esophageal Cancer|Stage III Follicular Thyroid Cancer|Stage III Gastric Cancer|Stage III Malignant Testicular Germ Cell Tumor|Stage III Mucoepidermoid Carcinoma of the Oral Cavity|Stage III Ovarian Epithelial Cancer|Stage III Pancreatic Cancer|Stage III Papillary Thyroid Cancer|Stage III Prostate Cancer|Stage III Rectal Cancer|Stage III Renal Cell Cancer|Stage III Salivary Gland Cancer|Stage III Squamous Cell Carcinoma of the Larynx|Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage III Squamous Cell Carcinoma of the Nasopharynx|Stage III Squamous Cell Carcinoma of the Oropharynx|Stage III Vaginal Cancer|Stage III Vulvar Cancer|Stage IVA Cervical Cancer|Stage IV Adenoid Cystic Carcinoma of the Oral Cavity|Stage IV Adrenocortical Carcinoma|Stage IV Anal Cancer|Stage IVA Vaginal Cancer|Stage IVB Cervical Cancer|Stage IV Bladder Cancer|Stage IV Breast Cancer|Stage IVB Vaginal Cancer|Stage IVB Vulvar Cancer|Stage IV Colon Cancer|Stage IV Endometrial Carcinoma|Stage IV Esophageal Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Gastric Cancer|Stage IV Mucoepidermoid Carcinoma of the Oral Cavity|Stage IV Non-small Cell Lung Cancer|Stage IV Ovarian Epithelial Cancer|Stage IV Pancreatic Cancer|Stage IV Papillary Thyroid Cancer|Stage IV Prostate Cancer|Stage IV Rectal Cancer|Stage IV Renal Cell Cancer|Stage IV Salivary Gland Cancer|Stage IV Squamous Cell Carcinoma of the Larynx|Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Stage IV Squamous Cell Carcinoma of the Oropharynx|Thyroid Gland Medullary Carcinoma|Unresectable Extrahepatic Bile Duct Cancer|Unresectable Gallbladder Cancer|Urethral Cancer Associated With Invasive Bladder Cancer|WDHA Syndrome,1999-12-10,2009-02-28,,Interventional,Completed,Phase 1,National Cancer Institute (NCI),National Cancer Institute (NCI),Ohio State University Medical Center,Biological|Biological,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT00004074
NCT00004074,"adenocarcinoma, follicular",A Phase I Trial of Herceptin and Interleukin-12,Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu,Advanced Adult Primary Liver Cancer|Anaplastic Thyroid Cancer|Bone Metastases|Carcinoma of the Appendix|Distal Urethral Cancer|Fallopian Tube Cancer|Gastrinoma|Glucagonoma|Inflammatory Breast Cancer|Insulinoma|Liver Metastases|Localized Unresectable Adult Primary Liver Cancer|Lung Metastases|Male Breast Cancer|Malignant Pericardial Effusion|Malignant Pleural Effusion|Metastatic Gastrointestinal Carcinoid Tumor|Metastatic Parathyroid Cancer|Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter|Newly Diagnosed Carcinoma of Unknown Primary|Occult Non-small Cell Lung Cancer|Pancreatic Polypeptide Tumor|Primary Peritoneal Cavity Cancer|Proximal Urethral Cancer|Pulmonary Carcinoid Tumor|Recurrent Adenoid Cystic Carcinoma of the Oral Cavity|Recurrent Adrenocortical Carcinoma|Recurrent Adult Primary Liver Cancer|Recurrent Anal Cancer|Recurrent Bladder Cancer|Recurrent Breast Cancer|Recurrent Carcinoma of Unknown Primary|Recurrent Cervical Cancer|Recurrent Colon Cancer|Recurrent Endometrial Carcinoma|Recurrent Esophageal Cancer|Recurrent Extrahepatic Bile Duct Cancer|Recurrent Gallbladder Cancer|Recurrent Gastric Cancer|Recurrent Gastrointestinal Carcinoid Tumor|Recurrent Islet Cell Carcinoma|Recurrent Malignant Testicular Germ Cell Tumor|Recurrent Mucoepidermoid Carcinoma of the Oral Cavity|Recurrent Non-small Cell Lung Cancer|Recurrent Ovarian Epithelial Cancer|Recurrent Pancreatic Cancer|Recurrent Parathyroid Cancer|Recurrent Prostate Cancer|Recurrent Rectal Cancer|Recurrent Renal Cell Cancer|Recurrent Salivary Gland Cancer|Recurrent Small Intestine Cancer|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Thyroid Cancer|Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter|Recurrent Urethral Cancer|Recurrent Vaginal Cancer|Recurrent Vulvar Cancer|Skin Metastases|Small Intestine Adenocarcinoma|Somatostatinoma|Stage IIIA Anal Cancer|Stage IIIA Breast Cancer|Stage III Adenoid Cystic Carcinoma of the Oral Cavity|Stage III Adrenocortical Carcinoma|Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Anal Cancer|Stage IIIB Breast Cancer|Stage III Bladder Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage III Cervical Cancer|Stage III Colon Cancer|Stage III Endometrial Carcinoma|Stage III Esophageal Cancer|Stage III Follicular Thyroid Cancer|Stage III Gastric Cancer|Stage III Malignant Testicular Germ Cell Tumor|Stage III Mucoepidermoid Carcinoma of the Oral Cavity|Stage III Ovarian Epithelial Cancer|Stage III Pancreatic Cancer|Stage III Papillary Thyroid Cancer|Stage III Prostate Cancer|Stage III Rectal Cancer|Stage III Renal Cell Cancer|Stage III Salivary Gland Cancer|Stage III Squamous Cell Carcinoma of the Larynx|Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage III Squamous Cell Carcinoma of the Nasopharynx|Stage III Squamous Cell Carcinoma of the Oropharynx|Stage III Vaginal Cancer|Stage III Vulvar Cancer|Stage IVA Cervical Cancer|Stage IV Adenoid Cystic Carcinoma of the Oral Cavity|Stage IV Adrenocortical Carcinoma|Stage IV Anal Cancer|Stage IVA Vaginal Cancer|Stage IVB Cervical Cancer|Stage IV Bladder Cancer|Stage IV Breast Cancer|Stage IVB Vaginal Cancer|Stage IVB Vulvar Cancer|Stage IV Colon Cancer|Stage IV Endometrial Carcinoma|Stage IV Esophageal Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Gastric Cancer|Stage IV Mucoepidermoid Carcinoma of the Oral Cavity|Stage IV Non-small Cell Lung Cancer|Stage IV Ovarian Epithelial Cancer|Stage IV Pancreatic Cancer|Stage IV Papillary Thyroid Cancer|Stage IV Prostate Cancer|Stage IV Rectal Cancer|Stage IV Renal Cell Cancer|Stage IV Salivary Gland Cancer|Stage IV Squamous Cell Carcinoma of the Larynx|Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Stage IV Squamous Cell Carcinoma of the Oropharynx|Thyroid Gland Medullary Carcinoma|Unresectable Extrahepatic Bile Duct Cancer|Unresectable Gallbladder Cancer|Urethral Cancer Associated With Invasive Bladder Cancer|WDHA Syndrome,1999-12-10,2009-02-28,,Interventional,Completed,Phase 1,National Cancer Institute (NCI),National Cancer Institute (NCI),Ohio State University Medical Center,Biological|Biological,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT00004074
NCT00004074,parathyroid neoplasms,A Phase I Trial of Herceptin and Interleukin-12,Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu,Advanced Adult Primary Liver Cancer|Anaplastic Thyroid Cancer|Bone Metastases|Carcinoma of the Appendix|Distal Urethral Cancer|Fallopian Tube Cancer|Gastrinoma|Glucagonoma|Inflammatory Breast Cancer|Insulinoma|Liver Metastases|Localized Unresectable Adult Primary Liver Cancer|Lung Metastases|Male Breast Cancer|Malignant Pericardial Effusion|Malignant Pleural Effusion|Metastatic Gastrointestinal Carcinoid Tumor|Metastatic Parathyroid Cancer|Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter|Newly Diagnosed Carcinoma of Unknown Primary|Occult Non-small Cell Lung Cancer|Pancreatic Polypeptide Tumor|Primary Peritoneal Cavity Cancer|Proximal Urethral Cancer|Pulmonary Carcinoid Tumor|Recurrent Adenoid Cystic Carcinoma of the Oral Cavity|Recurrent Adrenocortical Carcinoma|Recurrent Adult Primary Liver Cancer|Recurrent Anal Cancer|Recurrent Bladder Cancer|Recurrent Breast Cancer|Recurrent Carcinoma of Unknown Primary|Recurrent Cervical Cancer|Recurrent Colon Cancer|Recurrent Endometrial Carcinoma|Recurrent Esophageal Cancer|Recurrent Extrahepatic Bile Duct Cancer|Recurrent Gallbladder Cancer|Recurrent Gastric Cancer|Recurrent Gastrointestinal Carcinoid Tumor|Recurrent Islet Cell Carcinoma|Recurrent Malignant Testicular Germ Cell Tumor|Recurrent Mucoepidermoid Carcinoma of the Oral Cavity|Recurrent Non-small Cell Lung Cancer|Recurrent Ovarian Epithelial Cancer|Recurrent Pancreatic Cancer|Recurrent Parathyroid Cancer|Recurrent Prostate Cancer|Recurrent Rectal Cancer|Recurrent Renal Cell Cancer|Recurrent Salivary Gland Cancer|Recurrent Small Intestine Cancer|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Thyroid Cancer|Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter|Recurrent Urethral Cancer|Recurrent Vaginal Cancer|Recurrent Vulvar Cancer|Skin Metastases|Small Intestine Adenocarcinoma|Somatostatinoma|Stage IIIA Anal Cancer|Stage IIIA Breast Cancer|Stage III Adenoid Cystic Carcinoma of the Oral Cavity|Stage III Adrenocortical Carcinoma|Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Anal Cancer|Stage IIIB Breast Cancer|Stage III Bladder Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage III Cervical Cancer|Stage III Colon Cancer|Stage III Endometrial Carcinoma|Stage III Esophageal Cancer|Stage III Follicular Thyroid Cancer|Stage III Gastric Cancer|Stage III Malignant Testicular Germ Cell Tumor|Stage III Mucoepidermoid Carcinoma of the Oral Cavity|Stage III Ovarian Epithelial Cancer|Stage III Pancreatic Cancer|Stage III Papillary Thyroid Cancer|Stage III Prostate Cancer|Stage III Rectal Cancer|Stage III Renal Cell Cancer|Stage III Salivary Gland Cancer|Stage III Squamous Cell Carcinoma of the Larynx|Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage III Squamous Cell Carcinoma of the Nasopharynx|Stage III Squamous Cell Carcinoma of the Oropharynx|Stage III Vaginal Cancer|Stage III Vulvar Cancer|Stage IVA Cervical Cancer|Stage IV Adenoid Cystic Carcinoma of the Oral Cavity|Stage IV Adrenocortical Carcinoma|Stage IV Anal Cancer|Stage IVA Vaginal Cancer|Stage IVB Cervical Cancer|Stage IV Bladder Cancer|Stage IV Breast Cancer|Stage IVB Vaginal Cancer|Stage IVB Vulvar Cancer|Stage IV Colon Cancer|Stage IV Endometrial Carcinoma|Stage IV Esophageal Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Gastric Cancer|Stage IV Mucoepidermoid Carcinoma of the Oral Cavity|Stage IV Non-small Cell Lung Cancer|Stage IV Ovarian Epithelial Cancer|Stage IV Pancreatic Cancer|Stage IV Papillary Thyroid Cancer|Stage IV Prostate Cancer|Stage IV Rectal Cancer|Stage IV Renal Cell Cancer|Stage IV Salivary Gland Cancer|Stage IV Squamous Cell Carcinoma of the Larynx|Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Stage IV Squamous Cell Carcinoma of the Oropharynx|Thyroid Gland Medullary Carcinoma|Unresectable Extrahepatic Bile Duct Cancer|Unresectable Gallbladder Cancer|Urethral Cancer Associated With Invasive Bladder Cancer|WDHA Syndrome,1999-12-10,2009-02-28,,Interventional,Completed,Phase 1,National Cancer Institute (NCI),National Cancer Institute (NCI),Ohio State University Medical Center,Biological|Biological,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00004074
NCT00004089,thyroid neoplasms,A Multicenter Phase II Study of Intensified Concomitant Chemoradiotherapy for Patients With Anaplastic Thyroid Cancer,Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Thyroid Cancer,Head and Neck Cancer,1999-12-10,2002-04-30,2002-04-30,Interventional,Completed,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),"Robert H. Lurie Comprehensive Cancer Center, Northwestern University|University of Illinois at Chicago|University of Chicago Cancer Research Center",Biological|Drug|Drug|Drug|Procedure|Radiation,United States,15.0,80.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00004089
NCT00004340,hyperparathyroidism,,Phase II Randomized Study of the Effects of Growth Hormone on Children and Adolescents on Maintenance Dialysis,End Stage Renal Disease|Renal Osteodystrophy,1999-10-18,,,Interventional,Completed,Phase 2,National Center for Research Resources (NCRR),"National Center for Research Resources (NCRR)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|University of California, Los Angeles",University of California Los Angeles School of Medicine,Drug|Drug,United States,1.0,18.0,[0-17]|[18-65],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00004340
NCT00004351,hypoparathyroidism,,Study of Phenotype and Genotype Correlations in Patients With Contiguous Gene Deletion Syndromes,Angelman Syndrome|Chromosome Abnormalities|DiGeorge Syndrome|Prader-Willi Syndrome|Shprintzen Syndrome|Smith-Magenis Syndrome|Williams Syndrome,1999-10-18,,,Observational,Completed,,Office of Rare Diseases (ORD),Baylor College of Medicine|National Institute of Neurological Disorders and Stroke (NINDS),Baylor College of Medicine,,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00004351
NCT00004660,hyperthyroidism,Phase II Randomized Controlled Study of Sequential Orbital Radiotherapy for Graves' Ophthalmopathy,Randomized Study of Sequential Orbital Radiotherapy for Graves' Ophthalmopathy,Graves' Disease,2000-02-24,1998-01-31,1998-01-31,Interventional,Completed,Not Applicable,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Mayo Clinic|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Mayo Clinic,Radiation|Radiation,United States,30.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT00004660
NCT00004660,graves ophthalmopathy,Phase II Randomized Controlled Study of Sequential Orbital Radiotherapy for Graves' Ophthalmopathy,Randomized Study of Sequential Orbital Radiotherapy for Graves' Ophthalmopathy,Graves' Disease,2000-02-24,1998-01-31,1998-01-31,Interventional,Completed,Not Applicable,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Mayo Clinic|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Mayo Clinic,Radiation|Radiation,United States,30.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT00004660
NCT00004660,graves disease,Phase II Randomized Controlled Study of Sequential Orbital Radiotherapy for Graves' Ophthalmopathy,Randomized Study of Sequential Orbital Radiotherapy for Graves' Ophthalmopathy,Graves' Disease,2000-02-24,1998-01-31,1998-01-31,Interventional,Completed,Not Applicable,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Mayo Clinic|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Mayo Clinic,Radiation|Radiation,United States,30.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT00004660
NCT00004660,goiter,Phase II Randomized Controlled Study of Sequential Orbital Radiotherapy for Graves' Ophthalmopathy,Randomized Study of Sequential Orbital Radiotherapy for Graves' Ophthalmopathy,Graves' Disease,2000-02-24,1998-01-31,1998-01-31,Interventional,Completed,Not Applicable,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Mayo Clinic|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Mayo Clinic,Radiation|Radiation,United States,30.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00004660
NCT00005102,hypoparathyroidism,Immunologic Evaluation in Patients With DiGeorge Syndrome or Velocardiofacial Syndrome,Immunologic Evaluation in Patients With DiGeorge Syndrome or Velocardiofacial Syndrome,"Abnormalities, Multiple|Chromosome Abnormalities|Conotruncal Cardiac Defects|DiGeorge Syndrome|Shprintzen Syndrome",2000-04-06,,,Observational,Unknown status,,National Center for Research Resources (NCRR),Children's Hospital of Philadelphia|National Center for Research Resources (NCRR),Children's Hospital of Philadelphia,,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00005102
NCT00037193,hyperparathyroidism,Acute Regulation of Parathyroid Hormone by Dietary Phosphate,Acute Regulation of Parathyroid Hormone by Dietary Phosphate,Secondary Hyperparathyroidism,2002-05-16,,,Observational,Completed,,National Center for Research Resources (NCRR),National Center for Research Resources (NCRR),Washington University Medical School,,United States,21.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00037193
NCT00037635,hyperparathyroidism,A Phase 3 Study to Assess the Efficacy and Safety of an Oral Calcimimetic Agent (AMG 073) in Secondary Hyperparathyroidism of End Stage Renal Disease Treated With Hemodialysis,A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Dialysis Patients,End Stage Renal Disease|Secondary Hyperparathyroidism,2002-05-17,2003-03-31,2003-03-31,Interventional,Completed,Phase 3,Amgen,Amgen,,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00037635
NCT00042432,hyperparathyroidism,A Study of an Investigational Medication for Secondary Hyperparathyroidism in Chronic Renal Insufficiency Patients,Study for Secondary Hyperparathyroidism in Chronic Renal Insufficiency Patients,Chronic Renal Insufficiency|Secondary Hyperparathyroidism,2002-07-29,2003-03-31,2003-08-31,Interventional,Completed,Phase 2,Amgen,Amgen,,Drug,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00042432
NCT00042653,hyperparathyroidism,"A Placebo-controlled, Double-blind, Multicenter Study to Assess the Efficacy and Safety of an Oral Calcimimetic Agent (AMG 073) in Secondary Hyperparathyroidism of Chronic Kidney Disease (Hemodialysis and Peritoneal Dialysis)",A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Patients on Dialysis,End Stage Renal Disease|Secondary Hyperparathyroidism,2002-08-02,2003-07-31,2003-07-31,Interventional,Completed,Phase 3,Amgen,Amgen,,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00042653
NCT00053547,hyperparathyroidism,Safety and Effectiveness of Zemplar Injection in Decreasing iPTH Levels in Pediatric ESRD Subjects on Hemodialysis,Safety and Effectiveness of Zemplar Injection in Decreasing iPTH Levels in Pediatric ESRD Subjects on Hemodialysis,End Stage Renal Disease|Secondary Hyperparathyroidism,2003-01-30,,,Interventional,Completed,Phase 4,Abbott,Abbott,Stanford University Medical Center|Miami Children's Hospital|The Children's Hospital of Buffalo|Texas Children's Hospital|University of Texas at Houston|Medical College of Wisconsin,Drug,United States,2.0,20.0,[0-17]|[18-65],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00053547
NCT00060242,"thyroid carcinoma, anaplastic",Phase II Trial Of Combretastatin A-4 Phosphate (CA4P) In Advanced Anaplastic Carcinoma Of The Thyroid,Combretastatin A4 Phosphate in Treating Patients With Advanced Anaplastic Thyroid Cancer,Head and Neck Cancer,2003-05-06,2007-02-28,2008-01-31,Interventional,Completed,Phase 2,Case Comprehensive Cancer Center,Case Comprehensive Cancer Center|National Cancer Institute (NCI),"Josephine Ford Cancer Center at Henry Ford Hospital|Ireland Cancer Center at University Hosptials Case Medical Center, Case Comprehensive Cancer Center|Hillman Cancer Center at University of Pittsburgh Cancer Institute",Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT00060242
NCT00061906,thyroid neoplasms,Phase II Study Of Celecoxib In Metastatic Differentiated Thyroid Carcinoma,Celecoxib in Treating Patients With Progressive Metastatic Differentiated Thyroid Cancer,Head and Neck Cancer,2003-06-05,2006-06-30,2006-06-30,Interventional,Completed,Phase 2,Ohio State University Comprehensive Cancer Center,Ohio State University Comprehensive Cancer Center,Ohio State University Comrehensive Cancer Center|University of Texas - MD Anderson Cancer Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00061906
NCT00068497,"thyroid cancer, papillary","Single Agent ZD-1839 (NSC-715055, IND-61187) in Patients With Advanced Head and Neck Carcinoma or Non-Small Cell Lung Cancer Aged 75 Years and Older (and in a Cohort of Patients 50 Years Old and Younger)",Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer,Anaplastic Thyroid Cancer|Insular Thyroid Cancer|Metastatic Parathyroid Cancer|Recurrent Adenoid Cystic Carcinoma of the Oral Cavity|Recurrent Basal Cell Carcinoma of the Lip|Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Recurrent Lymphoepithelioma of the Nasopharynx|Recurrent Lymphoepithelioma of the Oropharynx|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Recurrent Mucoepidermoid Carcinoma of the Oral Cavity|Recurrent Non-small Cell Lung Cancer|Recurrent Parathyroid Cancer|Recurrent Salivary Gland Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Thyroid Cancer|Recurrent Verrucous Carcinoma of the Larynx|Stage IIIB Non-small Cell Lung Cancer|Stage III Follicular Thyroid Cancer|Stage III Papillary Thyroid Cancer|Stage III Salivary Gland Cancer|Stage III Squamous Cell Carcinoma of the Hypopharynx|Stage III Squamous Cell Carcinoma of the Larynx|Stage III Verrucous Carcinoma of the Larynx|Stage IVA Adenoid Cystic Carcinoma of the Oral Cavity|Stage IVA Basal Cell Carcinoma of the Lip|Stage IVA Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage IVA Follicular Thyroid Cancer|Stage IVA Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage IVA Lymphoepithelioma of the Oropharynx|Stage IVA Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage IVA Mucoepidermoid Carcinoma of the Oral Cavity|Stage IVA Papillary Thyroid Cancer|Stage IVA Salivary Gland Cancer|Stage IVA Squamous Cell Carcinoma of the Larynx|Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVA Squamous Cell Carcinoma of the Oropharynx|Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVA Verrucous Carcinoma of the Larynx|Stage IVA Verrucous Carcinoma of the Oral Cavity|Stage IVB Adenoid Cystic Carcinoma of the Oral Cavity|Stage IVB Basal Cell Carcinoma of the Lip|Stage IVB Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage IVB Follicular Thyroid Cancer|Stage IVB Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage IVB Lymphoepithelioma of the Oropharynx|Stage IVB Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage IVB Mucoepidermoid Carcinoma of the Oral Cavity|Stage IVB Papillary Thyroid Cancer|Stage IVB Salivary Gland Cancer|Stage IVB Squamous Cell Carcinoma of the Larynx|Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVB Squamous Cell Carcinoma of the Oropharynx|Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVB Verrucous Carcinoma of the Larynx|Stage IVB Verrucous Carcinoma of the Oral Cavity|Stage IVC Adenoid Cystic Carcinoma of the Oral Cavity|Stage IVC Basal Cell Carcinoma of the Lip|Stage IVC Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage IVC Follicular Thyroid Cancer|Stage IVC Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage IVC Lymphoepithelioma of the Oropharynx|Stage IVC Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage IVC Mucoepidermoid Carcinoma of the Oral Cavity|Stage IVC Papillary Thyroid Cancer|Stage IVC Salivary Gland Cancer|Stage IVC Squamous Cell Carcinoma of the Larynx|Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVC Squamous Cell Carcinoma of the Oropharynx|Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVC Verrucous Carcinoma of the Larynx|Stage IVC Verrucous Carcinoma of the Oral Cavity|Stage IV Lymphoepithelioma of the Nasopharynx|Stage IV Non-small Cell Lung Cancer|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Thryoid Gland Nonmedullary Carcinoma|Thyroid Gland Medullary Carcinoma|Tongue Cancer|Untreated Metastatic Squamous Neck Cancer With Occult Primary,2003-09-10,2007-12-31,,Interventional,Completed,Not Applicable,National Cancer Institute (NCI),National Cancer Institute (NCI),Southwest Oncology Group,Drug,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT00068497
NCT00068497,parathyroid neoplasms,"Single Agent ZD-1839 (NSC-715055, IND-61187) in Patients With Advanced Head and Neck Carcinoma or Non-Small Cell Lung Cancer Aged 75 Years and Older (and in a Cohort of Patients 50 Years Old and Younger)",Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer,Anaplastic Thyroid Cancer|Insular Thyroid Cancer|Metastatic Parathyroid Cancer|Recurrent Adenoid Cystic Carcinoma of the Oral Cavity|Recurrent Basal Cell Carcinoma of the Lip|Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Recurrent Lymphoepithelioma of the Nasopharynx|Recurrent Lymphoepithelioma of the Oropharynx|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Recurrent Mucoepidermoid Carcinoma of the Oral Cavity|Recurrent Non-small Cell Lung Cancer|Recurrent Parathyroid Cancer|Recurrent Salivary Gland Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Thyroid Cancer|Recurrent Verrucous Carcinoma of the Larynx|Stage IIIB Non-small Cell Lung Cancer|Stage III Follicular Thyroid Cancer|Stage III Papillary Thyroid Cancer|Stage III Salivary Gland Cancer|Stage III Squamous Cell Carcinoma of the Hypopharynx|Stage III Squamous Cell Carcinoma of the Larynx|Stage III Verrucous Carcinoma of the Larynx|Stage IVA Adenoid Cystic Carcinoma of the Oral Cavity|Stage IVA Basal Cell Carcinoma of the Lip|Stage IVA Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage IVA Follicular Thyroid Cancer|Stage IVA Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage IVA Lymphoepithelioma of the Oropharynx|Stage IVA Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage IVA Mucoepidermoid Carcinoma of the Oral Cavity|Stage IVA Papillary Thyroid Cancer|Stage IVA Salivary Gland Cancer|Stage IVA Squamous Cell Carcinoma of the Larynx|Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVA Squamous Cell Carcinoma of the Oropharynx|Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVA Verrucous Carcinoma of the Larynx|Stage IVA Verrucous Carcinoma of the Oral Cavity|Stage IVB Adenoid Cystic Carcinoma of the Oral Cavity|Stage IVB Basal Cell Carcinoma of the Lip|Stage IVB Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage IVB Follicular Thyroid Cancer|Stage IVB Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage IVB Lymphoepithelioma of the Oropharynx|Stage IVB Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage IVB Mucoepidermoid Carcinoma of the Oral Cavity|Stage IVB Papillary Thyroid Cancer|Stage IVB Salivary Gland Cancer|Stage IVB Squamous Cell Carcinoma of the Larynx|Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVB Squamous Cell Carcinoma of the Oropharynx|Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVB Verrucous Carcinoma of the Larynx|Stage IVB Verrucous Carcinoma of the Oral Cavity|Stage IVC Adenoid Cystic Carcinoma of the Oral Cavity|Stage IVC Basal Cell Carcinoma of the Lip|Stage IVC Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage IVC Follicular Thyroid Cancer|Stage IVC Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage IVC Lymphoepithelioma of the Oropharynx|Stage IVC Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage IVC Mucoepidermoid Carcinoma of the Oral Cavity|Stage IVC Papillary Thyroid Cancer|Stage IVC Salivary Gland Cancer|Stage IVC Squamous Cell Carcinoma of the Larynx|Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVC Squamous Cell Carcinoma of the Oropharynx|Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVC Verrucous Carcinoma of the Larynx|Stage IVC Verrucous Carcinoma of the Oral Cavity|Stage IV Lymphoepithelioma of the Nasopharynx|Stage IV Non-small Cell Lung Cancer|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Thryoid Gland Nonmedullary Carcinoma|Thyroid Gland Medullary Carcinoma|Tongue Cancer|Untreated Metastatic Squamous Neck Cancer With Occult Primary,2003-09-10,2007-12-31,,Interventional,Completed,Not Applicable,National Cancer Institute (NCI),National Cancer Institute (NCI),Southwest Oncology Group,Drug,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00068497
NCT00068497,"adenocarcinoma, follicular","Single Agent ZD-1839 (NSC-715055, IND-61187) in Patients With Advanced Head and Neck Carcinoma or Non-Small Cell Lung Cancer Aged 75 Years and Older (and in a Cohort of Patients 50 Years Old and Younger)",Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer,Anaplastic Thyroid Cancer|Insular Thyroid Cancer|Metastatic Parathyroid Cancer|Recurrent Adenoid Cystic Carcinoma of the Oral Cavity|Recurrent Basal Cell Carcinoma of the Lip|Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Recurrent Lymphoepithelioma of the Nasopharynx|Recurrent Lymphoepithelioma of the Oropharynx|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Recurrent Mucoepidermoid Carcinoma of the Oral Cavity|Recurrent Non-small Cell Lung Cancer|Recurrent Parathyroid Cancer|Recurrent Salivary Gland Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Thyroid Cancer|Recurrent Verrucous Carcinoma of the Larynx|Stage IIIB Non-small Cell Lung Cancer|Stage III Follicular Thyroid Cancer|Stage III Papillary Thyroid Cancer|Stage III Salivary Gland Cancer|Stage III Squamous Cell Carcinoma of the Hypopharynx|Stage III Squamous Cell Carcinoma of the Larynx|Stage III Verrucous Carcinoma of the Larynx|Stage IVA Adenoid Cystic Carcinoma of the Oral Cavity|Stage IVA Basal Cell Carcinoma of the Lip|Stage IVA Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage IVA Follicular Thyroid Cancer|Stage IVA Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage IVA Lymphoepithelioma of the Oropharynx|Stage IVA Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage IVA Mucoepidermoid Carcinoma of the Oral Cavity|Stage IVA Papillary Thyroid Cancer|Stage IVA Salivary Gland Cancer|Stage IVA Squamous Cell Carcinoma of the Larynx|Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVA Squamous Cell Carcinoma of the Oropharynx|Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVA Verrucous Carcinoma of the Larynx|Stage IVA Verrucous Carcinoma of the Oral Cavity|Stage IVB Adenoid Cystic Carcinoma of the Oral Cavity|Stage IVB Basal Cell Carcinoma of the Lip|Stage IVB Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage IVB Follicular Thyroid Cancer|Stage IVB Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage IVB Lymphoepithelioma of the Oropharynx|Stage IVB Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage IVB Mucoepidermoid Carcinoma of the Oral Cavity|Stage IVB Papillary Thyroid Cancer|Stage IVB Salivary Gland Cancer|Stage IVB Squamous Cell Carcinoma of the Larynx|Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVB Squamous Cell Carcinoma of the Oropharynx|Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVB Verrucous Carcinoma of the Larynx|Stage IVB Verrucous Carcinoma of the Oral Cavity|Stage IVC Adenoid Cystic Carcinoma of the Oral Cavity|Stage IVC Basal Cell Carcinoma of the Lip|Stage IVC Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage IVC Follicular Thyroid Cancer|Stage IVC Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage IVC Lymphoepithelioma of the Oropharynx|Stage IVC Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage IVC Mucoepidermoid Carcinoma of the Oral Cavity|Stage IVC Papillary Thyroid Cancer|Stage IVC Salivary Gland Cancer|Stage IVC Squamous Cell Carcinoma of the Larynx|Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVC Squamous Cell Carcinoma of the Oropharynx|Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVC Verrucous Carcinoma of the Larynx|Stage IVC Verrucous Carcinoma of the Oral Cavity|Stage IV Lymphoepithelioma of the Nasopharynx|Stage IV Non-small Cell Lung Cancer|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Thryoid Gland Nonmedullary Carcinoma|Thyroid Gland Medullary Carcinoma|Tongue Cancer|Untreated Metastatic Squamous Neck Cancer With Occult Primary,2003-09-10,2007-12-31,,Interventional,Completed,Not Applicable,National Cancer Institute (NCI),National Cancer Institute (NCI),Southwest Oncology Group,Drug,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT00068497
NCT00073710,hyperparathyroidism,"A Phase IV, Single-Center, Active-Controlled Cross-Over Pilot Study to Evaluate the Effects of Zemplar Injection and Calcijex on Intestinal Absorption of Calcium",Study to Evaluate the Effects of Zemplar Injection and Calcijex on Intestinal Absorption of Calcium,Chronic Kidney Disease|Secondary Hyperparathyroidism,2003-12-03,,,Interventional,Completed,Phase 4,Abbott,Abbott,Creighton University,Drug|Procedure|Drug,United States,20.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00073710
NCT00077103,"thyroid carcinoma, anaplastic",Phase II Trial of Combined Modality Combretastatin A-4 Phosphate (CA4P)-Based Therapy for Patients With Newly Diagnosed Anaplastic Thyroid Cancer [Induction Chemotherapy With Doxorubicin/Cisplatin; Combined Modality Therapy With CA4P and Radiation; Followed by 2 Cycles of CA4P Consolidation],Induction Chemotherapy Using Doxorubicin and Cisplatin Followed by Combretastatin A4 Phosphate and Radiation Therapy in Treating Patients With Newly Diagnosed Regionally Advanced Anaplastic Thyroid Cancer,Head and Neck Cancer,2004-02-10,2007-02-28,2007-12-31,Interventional,Terminated,Phase 1/Phase 2,Case Comprehensive Cancer Center,Case Comprehensive Cancer Center|National Cancer Institute (NCI),"Josephine Ford Cancer Center at Henry Ford Hospital|Ireland Cancer Center at University Hosptials Case Medical Center, Case Comprehensive Cancer Center|Hillman Cancer Center at University of Pittsburgh Cancer Institute",Biological|Biological|Drug|Drug|Drug|Radiation,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT00077103
NCT00085293,"adenocarcinoma, follicular",Phase II Study of Decitabine in Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Radioiodine,Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131,Recurrent Thyroid Cancer|Stage IVA Follicular Thyroid Cancer|Stage IVA Papillary Thyroid Cancer|Stage IVB Follicular Thyroid Cancer|Stage IVB Papillary Thyroid Cancer|Stage IVC Follicular Thyroid Cancer|Stage IVC Papillary Thyroid Cancer,2004-06-10,2014-01-31,2014-05-31,Interventional,Completed,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),University of Colorado at Denver|Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center|M D Anderson Cancer Center,Drug|Radiation|Biological|Radiation|Procedure,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT00085293
NCT00085293,"thyroid cancer, papillary",Phase II Study of Decitabine in Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Radioiodine,Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131,Recurrent Thyroid Cancer|Stage IVA Follicular Thyroid Cancer|Stage IVA Papillary Thyroid Cancer|Stage IVB Follicular Thyroid Cancer|Stage IVB Papillary Thyroid Cancer|Stage IVC Follicular Thyroid Cancer|Stage IVC Papillary Thyroid Cancer,2004-06-10,2014-01-31,2014-05-31,Interventional,Completed,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),University of Colorado at Denver|Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center|M D Anderson Cancer Center,Drug|Radiation|Biological|Radiation|Procedure,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT00085293
NCT00094484,hyperparathyroidism,"A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Cinacalcet HCl in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Not Receiving Dialysis",Cinacalcet HCl in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Not Receiving Dialysis,Chronic Kidney Disease|Kidney Disease,2004-10-19,,,Interventional,Completed,Phase 3,Amgen,Amgen,,Drug,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00094484
NCT00095693,"adenocarcinoma, follicular",Phase II Study of BAY 43-9006 in Patients With Metastatic Thyroid Carcinoma,"Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer",Anaplastic Thyroid Cancer|Insular Thyroid Cancer|Recurrent Thyroid Cancer|Stage III Follicular Thyroid Cancer|Stage III Papillary Thyroid Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Papillary Thyroid Cancer,2004-11-05,2005-08-31,2011-12-31,Interventional,Terminated,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Ohio State University Medical Center,Drug|Other|Other|Radiation|Procedure|Procedure,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT00095693
NCT00095693,"thyroid cancer, papillary",Phase II Study of BAY 43-9006 in Patients With Metastatic Thyroid Carcinoma,"Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer",Anaplastic Thyroid Cancer|Insular Thyroid Cancer|Recurrent Thyroid Cancer|Stage III Follicular Thyroid Cancer|Stage III Papillary Thyroid Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Papillary Thyroid Cancer,2004-11-05,2005-08-31,2011-12-31,Interventional,Terminated,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Ohio State University Medical Center,Drug|Other|Other|Radiation|Procedure|Procedure,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT00095693
NCT00095836,thyroid neoplasms,A Phase II Study of ZD 1839 (IRESSA®) in Patients With Advanced Thyroid Cancer,Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy,Head and Neck Cancer,2004-11-09,2011-03-31,2011-03-31,Interventional,Completed,Phase 2,Massachusetts General Hospital,AstraZeneca|Brigham and Women's Hospital|Dana-Farber Cancer Institute|Massachusetts General Hospital|National Cancer Institute (NCI),Massachusetts General Hospital Cancer Center|Dana-Farber Cancer Institute,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00095836
NCT00098813,"adenocarcinoma, follicular","A Phase II Study of Single Agent Depsipeptide (FK228) in Radioiodine (RAI)-Refractory Metastatic Non-medullary (Papillary, Follicular, and Hurthle Cell Variants) Thyroid Carcinoma",Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine,Recurrent Thyroid Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Papillary Thyroid Cancer,2004-12-08,2009-08-31,2009-08-31,Interventional,Completed,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Memorial Sloan-Kettering Cancer Center at Suffolk,Drug|Other|Procedure,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT00098813
NCT00098813,"thyroid cancer, papillary","A Phase II Study of Single Agent Depsipeptide (FK228) in Radioiodine (RAI)-Refractory Metastatic Non-medullary (Papillary, Follicular, and Hurthle Cell Variants) Thyroid Carcinoma",Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine,Recurrent Thyroid Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Papillary Thyroid Cancer,2004-12-08,2009-08-31,2009-08-31,Interventional,Completed,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Memorial Sloan-Kettering Cancer Center at Suffolk,Drug|Other|Procedure,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT00098813
NCT00098852,thyroid neoplasms,A Pilot Study of Rosiglitazone in Patients With Incurable Differentiated Thyroid Cancer,Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer,Head and Neck Cancer,2004-12-08,2010-06-30,,Interventional,Unknown status,Phase 2,National Cancer Institute (NCI),"National Cancer Institute (NCI)|University of California, San Francisco",UCSF Helen Diller Family Comprehensive Cancer Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00098852
NCT00100828,thyroid neoplasms,Phase II Trial of Irinotecan for Treatment of Metastatic Medullary Thyroid Cancer,Irinotecan in Treating Patients With Metastatic or Inoperable Thyroid Cancer,Head and Neck Cancer,2005-01-06,2008-11-30,2008-11-30,Interventional,Terminated,Phase 2,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,National Cancer Institute (NCI)|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|University of Michigan Comprehensive Cancer Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00100828
NCT00103155,thyroid neoplasms,Radiofrequency Ablation for Low Risk Papillary Thyroid Cancer: A Pilot Study,Radiofrequency Ablation in Treating Patients Who Are Undergoing Surgery for Thyroid Cancer,Head and Neck Cancer,2005-02-07,,,Interventional,Unknown status,Phase 1,National Cancer Institute (NCI),"National Cancer Institute (NCI)|University of California, San Francisco",UCSF Comprehensive Cancer Center,Procedure|Procedure,United States,21.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00103155
NCT00104871,"adenocarcinoma, follicular",A Phase II Study of Bortezomib in Metastatic Papillary Thyroid Carcinoma or Follicular Thyroid Carcinoma,Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy,Insular Thyroid Cancer|Recurrent Thyroid Cancer|Stage II Follicular Thyroid Cancer|Stage II Papillary Thyroid Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Papillary Thyroid Cancer,2005-03-03,2010-05-31,2014-04-30,Interventional,Completed,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),"University of Colorado at Denver Health Sciences Center|Lombardi Comprehensive Cancer Center at Georgetown University|Emory University|Massachusetts General Hospital Cancer Center|Dana-Farber Harvard Cancer Center|Cleveland Clinic Foundation|Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center|Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center|M D Anderson Cancer Center",Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT00104871
NCT00104871,"thyroid cancer, papillary",A Phase II Study of Bortezomib in Metastatic Papillary Thyroid Carcinoma or Follicular Thyroid Carcinoma,Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy,Insular Thyroid Cancer|Recurrent Thyroid Cancer|Stage II Follicular Thyroid Cancer|Stage II Papillary Thyroid Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Papillary Thyroid Cancer,2005-03-03,2010-05-31,2014-04-30,Interventional,Completed,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),"University of Colorado at Denver Health Sciences Center|Lombardi Comprehensive Cancer Center at Georgetown University|Emory University|Massachusetts General Hospital Cancer Center|Dana-Farber Harvard Cancer Center|Cleveland Clinic Foundation|Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center|Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center|M D Anderson Cancer Center",Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT00104871
NCT00105274,hypoparathyroidism,Intermediate Phenotype and Genetic Mechanisms for Psychosis and Cognitive Disturbance in 22q11.2-Hemideletion Syndrome,Velocardiofacial (VCFS; 22q11.2; DiGeorge) Syndrome Study,22q11.2 Syndrome|DiGeorge Syndrome|Velocardiofacial Syndrome,2005-03-10,,2010-02-02,Observational,Completed,,National Institutes of Health Clinical Center (CC),National Institute of Mental Health (NIMH),"National Institutes of Health Clinical Center, 9000 Rockville Pike",,United States,18.0,50.0,[18-65],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00105274
NCT00108394,hyperparathyroidism,Osteopenia and Renal Osteodystrophy: Evaluation and Management,Osteopenia and Renal Osteodystrophy: Evaluation and Management,Osteopenia|Renal Osteodystrophy,2005-04-14,,2007-09-30,Interventional,Completed,Phase 4,VA Office of Research and Development,US Department of Veterans Affairs,VA Puget Sound Health Care System,Drug,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00108394
NCT00110929,hyperparathyroidism,A Study to Compare the Efficacy and Safety of an Oral Calcimimetic Agent (AMG 073) When Two Different Vitamin D Regimens Are Used in Subjects With Secondary Hyperparathyroidism of End-Stage Renal Disease (ESRD),Treatment for Patients With Secondary Hyperparathyroidism of End-Stage Renal Disease (ESRD),End Stage Renal Disease,2005-05-16,,,Interventional,Completed,Phase 2,Amgen,Amgen,,Drug,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00110929
NCT00117052,hyperparathyroidism,SENSOR: Study to InvestigatE Cinacalcet TreatmeNt in Haemodialysis Patients With SecOndary HyperparathyRoidism,SENSOR: Study to Investigate Cinacalcet Treatment in Haemodialysis Patients With Secondary Hyperparathyroidism,End Stage Renal Disease|Secondary Hyperparathyroidism,2005-06-30,2005-11-30,2006-02-28,Interventional,Completed,Phase 3,Amgen,Amgen,,Drug,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00117052
NCT00118248,"adenocarcinoma, follicular",A Phase II Trial of 17-Allylaminogeldanamycin (17AAG) in Advanced Medullary and Differentiated Thyroid Carcinoma,Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer,Recurrent Thyroid Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Papillary Thyroid Cancer|Thyroid Gland Medullary Carcinoma,2005-07-08,2009-08-31,2012-04-30,Interventional,Completed,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Mayo Clinic,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT00118248
NCT00118248,"thyroid cancer, papillary",A Phase II Trial of 17-Allylaminogeldanamycin (17AAG) in Advanced Medullary and Differentiated Thyroid Carcinoma,Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer,Recurrent Thyroid Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Papillary Thyroid Cancer|Thyroid Gland Medullary Carcinoma,2005-07-08,2009-08-31,2012-04-30,Interventional,Completed,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Mayo Clinic,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT00118248
NCT00123461,hyperparathyroidism,"A Phase 4, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Study to Assess the Efficacy and Safety of Doxercalciferol Capsules in Vitamin D-replete Subjects With Chronic Kidney Disease (CKD) Stages 3 or 4 With Secondary Hyperparathyroidism (SHPT).","Study of Safety and Efficacy of Doxercalciferol in Patients With Chronic Kidney Disease, Stage 3 or 4, and Secondary Hyperparathyroidism",Chronic Renal Insufficiency|Renal Failure|Secondary Hyperparathyroidism,2005-07-21,2007-10-31,2007-10-31,Interventional,Completed,Phase 4,Sanofi,"Genzyme, a Sanofi Company","AKDHC Medical Research Services|UCLA Diabetes Reseach Center|Apex Research of Riverside|George Washington University Hospital|Discovery Medical Research Group|Nephrology Associates|Georgia Kidney Associates, Inc.|Michigan Kidney Consultants, P.C.|Twin Cities Clinical Research|Montefiore Medical Center|University of Rochester Medical Center|Wake Nephrology Associates, PA|Wake Forest University School of Medicine|Altru Health System Research Center|DaVita Lewiston Dialysis Center|Temple University|Virginia Commonwealth University|Instituto Renal del Este|Jose Cangiano, MD",Drug,Puerto Rico|United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00123461
NCT00132431,hyperparathyroidism,Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism,START: Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism,Chronic Kidney Disease|Kidney Disease|Secondary Hyperparathyroidism,2005-08-19,,2005-07-31,Interventional,Completed,Phase 4,Amgen,Amgen,,Drug,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00132431
NCT00134043,"adenocarcinoma, follicular",Phase II Study of Histone Deacetylase Inhibitor SAHA (Vorinostat) in Patients With Metastatic Thyroid Carcinoma,Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer,Insular Thyroid Cancer|Recurrent Thyroid Cancer|Stage II Follicular Thyroid Cancer|Stage II Papillary Thyroid Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Papillary Thyroid Cancer|Thyroid Gland Medullary Carcinoma,2005-08-22,2009-03-31,2009-03-31,Interventional,Completed,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Ohio State University Medical Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT00134043
NCT00134043,"thyroid cancer, papillary",Phase II Study of Histone Deacetylase Inhibitor SAHA (Vorinostat) in Patients With Metastatic Thyroid Carcinoma,Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer,Insular Thyroid Cancer|Recurrent Thyroid Cancer|Stage II Follicular Thyroid Cancer|Stage II Papillary Thyroid Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Papillary Thyroid Cancer|Thyroid Gland Medullary Carcinoma,2005-08-22,2009-03-31,2009-03-31,Interventional,Completed,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Ohio State University Medical Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT00134043
NCT00135304,hyperparathyroidism,ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism: A Comparison of Sensipar® and Low Dose Vitamin D vs. Escalating Doses of Vitamin D Alone,ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism,Secondary Hyperparathyroidism,2005-08-24,2006-10-31,2006-12-31,Interventional,Completed,Phase 4,Amgen,Amgen,,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00135304
NCT00145366,graves disease,"Pretreatment With Recombinant Human Thyrotropin (rhTSH) for the Effect on Thyroid Size and Function, and for the Effect of Radioiodine Treatment in Patients With Nodular Goiter. Prospective, Randomized Double-blinded Trials.","rhTSH, Thyroid Size, and Radioiodine Therapy in Benign Goiter",Benign Nontoxic and Toxic Goiter|Graves' Disease,2005-09-02,,2005-07-31,Interventional,Completed,Phase 2,Odense University Hospital,Odense University Hospital,"Department of Endocrinology, Odense University Hospital",Drug,Denmark,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT00145366
NCT00145366,hyperthyroidism,"Pretreatment With Recombinant Human Thyrotropin (rhTSH) for the Effect on Thyroid Size and Function, and for the Effect of Radioiodine Treatment in Patients With Nodular Goiter. Prospective, Randomized Double-blinded Trials.","rhTSH, Thyroid Size, and Radioiodine Therapy in Benign Goiter",Benign Nontoxic and Toxic Goiter|Graves' Disease,2005-09-02,,2005-07-31,Interventional,Completed,Phase 2,Odense University Hospital,Odense University Hospital,"Department of Endocrinology, Odense University Hospital",Drug,Denmark,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT00145366
NCT00145366,goiter,"Pretreatment With Recombinant Human Thyrotropin (rhTSH) for the Effect on Thyroid Size and Function, and for the Effect of Radioiodine Treatment in Patients With Nodular Goiter. Prospective, Randomized Double-blinded Trials.","rhTSH, Thyroid Size, and Radioiodine Therapy in Benign Goiter",Benign Nontoxic and Toxic Goiter|Graves' Disease,2005-09-02,,2005-07-31,Interventional,Completed,Phase 2,Odense University Hospital,Odense University Hospital,"Department of Endocrinology, Odense University Hospital",Drug,Denmark,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00145366
NCT00147433,hypothyroidism,Are IQs Low in Offspring of Euthyroid Women With Low T4?,The Effect of Thyroid Hormone Levels in Pregnant Women on the Intelligence Quotient (IQ) of Their Children,Child Development Disorders|Pregnancy|Subclinical Hypothyroidism,2005-09-02,,2008-11-30,Observational,Unknown status,,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Foundation for Blood Research,,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT00147433
NCT00150111,graves disease,B Cell Depletion With the Anti-CD20 Monoclonal Antibody Rituximab in the Treatment of Graves' Disease,Rituximab in the Treatment of Graves' Disease,Graves´ Disease|Thyroid Associated Ophthalmopathy,2005-09-06,,2006-10-31,Interventional,Completed,Phase 1/Phase 2,Odense University Hospital,Odense University Hospital,"Department of Endocrinology, Odense University Hospital|Department of Hematology, Odense University Hospital",Drug|Drug|Biological,Denmark,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT00150111
NCT00150111,goiter,B Cell Depletion With the Anti-CD20 Monoclonal Antibody Rituximab in the Treatment of Graves' Disease,Rituximab in the Treatment of Graves' Disease,Graves´ Disease|Thyroid Associated Ophthalmopathy,2005-09-06,,2006-10-31,Interventional,Completed,Phase 1/Phase 2,Odense University Hospital,Odense University Hospital,"Department of Endocrinology, Odense University Hospital|Department of Hematology, Odense University Hospital",Drug|Drug|Biological,Denmark,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00150111
NCT00150111,graves ophthalmopathy,B Cell Depletion With the Anti-CD20 Monoclonal Antibody Rituximab in the Treatment of Graves' Disease,Rituximab in the Treatment of Graves' Disease,Graves´ Disease|Thyroid Associated Ophthalmopathy,2005-09-06,,2006-10-31,Interventional,Completed,Phase 1/Phase 2,Odense University Hospital,Odense University Hospital,"Department of Endocrinology, Odense University Hospital|Department of Hematology, Odense University Hospital",Drug|Drug|Biological,Denmark,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT00150111
NCT00150111,hyperthyroidism,B Cell Depletion With the Anti-CD20 Monoclonal Antibody Rituximab in the Treatment of Graves' Disease,Rituximab in the Treatment of Graves' Disease,Graves´ Disease|Thyroid Associated Ophthalmopathy,2005-09-06,,2006-10-31,Interventional,Completed,Phase 1/Phase 2,Odense University Hospital,Odense University Hospital,"Department of Endocrinology, Odense University Hospital|Department of Hematology, Odense University Hospital",Drug|Drug|Biological,Denmark,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT00150111
NCT00150124,hyperthyroidism,The Influence of Continuous Block-replacement Therapy on the Effect of Radioiodine in Patients With Hyperthyroidism,Block-replacement Therapy During Radioiodine Therapy,Graves' Disease|Toxic Nodular Goitre,2005-09-06,2008-12-31,2009-03-31,Interventional,Completed,Phase 4,Odense University Hospital,Steen Bonnema,"Department of Endocrinology, Odense University Hospital",Drug|Drug,Denmark,18.0,85.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT00150124
NCT00150124,graves disease,The Influence of Continuous Block-replacement Therapy on the Effect of Radioiodine in Patients With Hyperthyroidism,Block-replacement Therapy During Radioiodine Therapy,Graves' Disease|Toxic Nodular Goitre,2005-09-06,2008-12-31,2009-03-31,Interventional,Completed,Phase 4,Odense University Hospital,Steen Bonnema,"Department of Endocrinology, Odense University Hospital",Drug|Drug,Denmark,18.0,85.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT00150124
NCT00150124,"goiter, nodular",The Influence of Continuous Block-replacement Therapy on the Effect of Radioiodine in Patients With Hyperthyroidism,Block-replacement Therapy During Radioiodine Therapy,Graves' Disease|Toxic Nodular Goitre,2005-09-06,2008-12-31,2009-03-31,Interventional,Completed,Phase 4,Odense University Hospital,Steen Bonnema,"Department of Endocrinology, Odense University Hospital",Drug|Drug,Denmark,18.0,85.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00150124
NCT00150137,hyperthyroidism,The Influence of Continuous Treatment With Antithyroid Drugs on the Effect of Radioiodine in Patients With Hyperthyroidism,Antithyroid Drugs During Radioiodine Therapy,Graves Disease|Toxic Nodular Goitre,2005-09-06,,2004-12-31,Interventional,Completed,Phase 4,Odense University Hospital,Odense University Hospital,"Department of Endocrinology, Odense University Hospital",Drug,Denmark,18.0,85.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT00150137
NCT00150137,"goiter, nodular",The Influence of Continuous Treatment With Antithyroid Drugs on the Effect of Radioiodine in Patients With Hyperthyroidism,Antithyroid Drugs During Radioiodine Therapy,Graves Disease|Toxic Nodular Goitre,2005-09-06,,2004-12-31,Interventional,Completed,Phase 4,Odense University Hospital,Odense University Hospital,"Department of Endocrinology, Odense University Hospital",Drug,Denmark,18.0,85.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00150137
NCT00150150,thyroid neoplasms,Ultrasound Guided Interstitial Laser Photocoagulation on Benign Thyroid Nodules,Laser Therapy of Benign Thyroid Nodules,Benign Solitary Solid|Cystic Thyroid Nodules,2005-09-06,,2006-03-31,Interventional,Unknown status,Phase 3,Odense University Hospital,Odense University Hospital,"Department of Endocrinology, Odense University Hospital",Procedure,Denmark,20.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00150150
NCT00150150,thyroid nodule,Ultrasound Guided Interstitial Laser Photocoagulation on Benign Thyroid Nodules,Laser Therapy of Benign Thyroid Nodules,Benign Solitary Solid|Cystic Thyroid Nodules,2005-09-06,,2006-03-31,Interventional,Unknown status,Phase 3,Odense University Hospital,Odense University Hospital,"Department of Endocrinology, Odense University Hospital",Procedure,Denmark,20.0,70.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT00150150
NCT00161109,hypoparathyroidism,Genetics and Psychopathology in the 22q11 Deletion Syndrome,Genetics and Psychopathology in the 22q11 Deletion Syndrome,Chromosome 22q11.2 Deletion Syndrome,2005-09-08,,2012-10-31,Observational,Unknown status,,UMC Utrecht,Children's Hospital of Philadelphia|Netherlands Brain Foundation|UMC Utrecht,"Children's Hospital of Philadelphia, Dpt of Genetics and Dpt of Child and Adolescent Psychiatry|UMC Utrecht, Dpt of Child and Adolescent Psychiatry",,Netherlands|United States,8.0,20.0,[0-17]|[18-65],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00161109
NCT00174057,graves disease,,"The Role of TSH Receptor, PPAR-r, IGF-1R, IGF and Cytokines in Different Stages of Graves'Ophthalmopathy",Graves' Ophthalmopathy,2005-09-13,,2006-07-31,Observational,Unknown status,,National Taiwan University Hospital,National Taiwan University Hospital,Shu Lang Liao,,Taiwan,20.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT00174057
NCT00174057,graves ophthalmopathy,,"The Role of TSH Receptor, PPAR-r, IGF-1R, IGF and Cytokines in Different Stages of Graves'Ophthalmopathy",Graves' Ophthalmopathy,2005-09-13,,2006-07-31,Observational,Unknown status,,National Taiwan University Hospital,National Taiwan University Hospital,Shu Lang Liao,,Taiwan,20.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT00174057
NCT00174057,goiter,,"The Role of TSH Receptor, PPAR-r, IGF-1R, IGF and Cytokines in Different Stages of Graves'Ophthalmopathy",Graves' Ophthalmopathy,2005-09-13,,2006-07-31,Observational,Unknown status,,National Taiwan University Hospital,National Taiwan University Hospital,Shu Lang Liao,,Taiwan,20.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00174057
NCT00174057,hyperthyroidism,,"The Role of TSH Receptor, PPAR-r, IGF-1R, IGF and Cytokines in Different Stages of Graves'Ophthalmopathy",Graves' Ophthalmopathy,2005-09-13,,2006-07-31,Observational,Unknown status,,National Taiwan University Hospital,National Taiwan University Hospital,Shu Lang Liao,,Taiwan,20.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT00174057
NCT00175149,hyperparathyroidism,"The Efficacy of 1,25 Dihydroxycholecalciferol on the Cardiovascular System in Patients With Renal Dysfunction",Active Vitamin D Effect on Left Ventricular Hypertrophy,Chronic Kidney Disease|Left Ventricular Hypertrophy|Secondary Hyperparathyroidism,2005-09-11,2008-12-31,2008-12-31,Interventional,Terminated,Phase 4,University of Aarhus,Per Ivarsen,"Department of Renal Medicne C, Skejby Hospital",Drug,Denmark,18.0,80.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00175149
NCT00189501,hyperparathyroidism,"A Multi-Center, Observational Registry of Subjects With Secondary Hyperparathyroidism (HPT) and Chronic Kidney Disease (CKD)","A Multi-Center, Observational Registry of Subjects With Secondary Hyperparathyroidism (HPT) and Chronic Kidney Disease (CKD)",Nephrology,2005-09-12,,,Observational,Completed,,Amgen,Amgen,,Drug,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00189501
NCT00209235,pseudopseudohypoparathyroidism,Natural History Study of Albright Hereditary Osteodystrophy: Includes Substudies on Effects of Growth Hormone in Patients With Pseudohypoparathyroidism Type 1a and Cognitive & Behavioral Studies in Albright Hereditary Osteodystrophy,"Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments",Albright Hereditary Osteodystrophy|Pseudohypoparathyroidism Type 1A,2005-09-13,2026-10-31,2027-12-31,Interventional,Recruiting,Not Applicable,Connecticut Children's Medical Center,"Connecticut Children's Medical Center|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|Johns Hopkins University|UConn Health",Connecticut Children's Medical Center,Behavioral,United States,2.0,89.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,pseudohypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00209235
NCT00211939,hyperparathyroidism,CARE-2 (Calcium Acetate (PhosLo®)/Sevelamer(Renagel®) Evaluation Study 2),CARE-2 (Calcium Acetate [PhosLo®]/Sevelamer[Renagel®] Evaluation Study 2) for Heart Calcification in Dialysis Patients,"Arteriosclerosis|Calcinosis|Hyperparathyroidism, Secondary",2005-09-13,2006-12-31,2007-03-31,Interventional,Completed,Phase 4,Nabi Biopharmaceuticals,Nabi Biopharmaceuticals,University of Texas Health Sciences Center,Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00211939
NCT00213720,hyperthyroidism,Place de l'Iode RadioActif Dans l'HyperThyroïdiE Sub-clinique (PIRHATES)/ Evaluation of the Interest of Subclinical Hyperthyroidism Treatment,Treatment of Subclinical Hyperthyroidism,Atrial Fibrillation|Subclinical Hyperthyroidism,2005-09-13,2019-11-30,2020-01-31,Observational,Terminated,,"University Hospital, Strasbourg, France","University Hospital, Strasbourg, France",Patrick Roger|Philippe Thiéblot|Jean-Marcel Brun|Jean-Louis Wemeau|Marie-Pierre Teissier|Jacques Orgiazzi|Bernard Conte-Delvox|CH de Montbrison|Jacques Bringer|Marc Klein|Michel Rodier|Laurence Leenhardt|Richard Marechaud|Brigitte Delemer|Claire Schvartz|Jean-Marc Kuhn|Bruno Estour|Centre Paul Strauss|Hopitaux Universitaires de Strasbourg|Philippe Caron|Pierre Lecomte,,France,50.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT00213720
NCT00257920,hyperparathyroidism,"A Phase 4, Single-Center, Open-Label, Randomized, Active-Controlled, Cross-over Pilot Study to Evaluate the Effects of Two Vitamin D Analogs, Zemplar® Injection and Hectorol® Injection, on Intestinal Absorption of Calcium in CKD Stage 5 Subjects on Hemodialysis",A Study of Zemplar® Injection and Hectorol® Injection on Intestinal Absorption of Calcium in Chronic Kidney Disease,"Chronic Kidney Disease, Stage 5|Secondary Hyperparathyroidism",2005-11-22,2008-01-31,,Interventional,Completed,Phase 4,Abbott,Abbott,,Drug|Drug,United States,20.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00257920
NCT00261950,hyperparathyroidism,Bone Histomorphometry Assessment For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease,Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease,Secondary Hyperparathyroidism,2005-12-02,2011-05-31,2011-05-31,Interventional,Completed,Phase 2,Amgen,Amgen,Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug,"Belgium|Czech Republic|Hungary|Italy|Macedonia, The Former Yugoslav Republic of|Poland|Portugal|Spain|Switzerland|Turkey|United Kingdom|United States",18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00261950
NCT00278005,hypoparathyroidism,Incidence of Infection in the Patient With DiGeorge Syndrome Following Surgery for Congenital Heart Disease,Infection in DiGeorge Following CHD Surgery,Congenital Heart Defects|DiGeorge Syndrome,2006-01-13,2008-03-31,2008-03-31,Observational,Terminated,,Children's Healthcare of Atlanta,Children's Healthcare of Atlanta,Children's Healthcare of Atlanta,,United States,0.0,15.0,[0-17],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00278005
NCT00285467,hyperparathyroidism,Comparison of Cholecalciferol Versus Doxercalciferol in the Treatment of Secondary Hyperparathyroidism in CKD,Cholecalciferol Versus Doxercalciferol in the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease,Renal Osteodystrophy,2006-01-31,2009-12-31,2009-12-31,Interventional,Completed,Not Applicable,Indiana University,Indiana University School of Medicine,Indiana University School of Medicine,Drug|Drug,United States,18.0,82.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00285467
NCT00287144,postpartum thyroiditis,Observations of Leng Term Effects From Post Partum Thyroiditis.,Post Partum Thyroiditis 2: Long Term Observations,Hypothyroidism,2006-02-02,2015-12-31,2016-12-31,Observational,Withdrawn,,Sykehuset Telemark,Sykehuset Telemark,Sykehuset Telemark HF,,Norway,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroiditis,Other thyroiditis,https://clinicaltrials.gov/ct2/show/NCT00287144
NCT00287144,"thyroiditis, autoimmune",Observations of Leng Term Effects From Post Partum Thyroiditis.,Post Partum Thyroiditis 2: Long Term Observations,Hypothyroidism,2006-02-02,2015-12-31,2016-12-31,Observational,Withdrawn,,Sykehuset Telemark,Sykehuset Telemark,Sykehuset Telemark HF,,Norway,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT00287144
NCT00287287,"adenocarcinoma, follicular",Phase II Trial of REVLIMID® (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary & Follicular Thyroid Carcinomas,REVLIMID® (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary and Follicular Thyroid Carcinomas,Thyroid Neoplasms,2006-02-03,2010-07-06,2010-07-06,Interventional,Completed,Phase 2,University of Kentucky,Celgene Corporation|Kenneth Ain,University of Kentucky Markey Cancer Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT00287287
NCT00288522,hyperthyroidism,"A Phase II, Single Centre, Randomized, Double-blind, Parallel and Placebo Controlled, Pilot Study to Evaluate the Efficacy and Safety of Somatuline Autogel 60mg in Patients With Active Thyroid-associated Ophthalmopathy of Moderate Intensity.",Lanreotide (Somatuline Autogel) in Thyroid-associated Ophthalmopathy Treatment,Thyroid-Associated Ophthalmopathy,2006-02-07,2007-04-30,2007-04-30,Interventional,Terminated,Phase 2,Ipsen,Ipsen,Hospital General d'Alacant,Drug,Spain,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT00288522
NCT00288522,graves ophthalmopathy,"A Phase II, Single Centre, Randomized, Double-blind, Parallel and Placebo Controlled, Pilot Study to Evaluate the Efficacy and Safety of Somatuline Autogel 60mg in Patients With Active Thyroid-associated Ophthalmopathy of Moderate Intensity.",Lanreotide (Somatuline Autogel) in Thyroid-associated Ophthalmopathy Treatment,Thyroid-Associated Ophthalmopathy,2006-02-07,2007-04-30,2007-04-30,Interventional,Terminated,Phase 2,Ipsen,Ipsen,Hospital General d'Alacant,Drug,Spain,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT00288522
NCT00288522,graves disease,"A Phase II, Single Centre, Randomized, Double-blind, Parallel and Placebo Controlled, Pilot Study to Evaluate the Efficacy and Safety of Somatuline Autogel 60mg in Patients With Active Thyroid-associated Ophthalmopathy of Moderate Intensity.",Lanreotide (Somatuline Autogel) in Thyroid-associated Ophthalmopathy Treatment,Thyroid-Associated Ophthalmopathy,2006-02-07,2007-04-30,2007-04-30,Interventional,Terminated,Phase 2,Ipsen,Ipsen,Hospital General d'Alacant,Drug,Spain,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT00288522
NCT00288522,goiter,"A Phase II, Single Centre, Randomized, Double-blind, Parallel and Placebo Controlled, Pilot Study to Evaluate the Efficacy and Safety of Somatuline Autogel 60mg in Patients With Active Thyroid-associated Ophthalmopathy of Moderate Intensity.",Lanreotide (Somatuline Autogel) in Thyroid-associated Ophthalmopathy Treatment,Thyroid-Associated Ophthalmopathy,2006-02-07,2007-04-30,2007-04-30,Interventional,Terminated,Phase 2,Ipsen,Ipsen,Hospital General d'Alacant,Drug,Spain,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00288522
NCT00288873,hyperparathyroidism,Characterization of Hyperparathyroidism and Vitamin D Deficiency in Obesity,Characterization of Hyperparathyroidism and Vitamin D Deficiency in Obesity,Obesity|Secondary Hyperparathyroidism|Vitamin D Deficiency,2006-02-06,2007-07-31,2007-07-31,Interventional,Completed,Phase 4,Weill Medical College of Cornell University,Weill Medical College of Cornell University,Weill Cornell Medical College,Drug|Drug,United States,18.0,65.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00288873
NCT00297297,thyroid nodule,"Preoperative Selection of Solitary Solid Cold Thyroid Nodules - A Prospective Study on the Value of Sonography, Cytology, Immunostaining and Molecular Profiling",Improved Preoperative Selection of Cold Thyroid Nodules,Thyroid Nodules,2006-02-27,,2011-03-31,Observational,Unknown status,,Herlev Hospital,Herlev Hospital,"Outpatient clinic of The Department of Endocrinology, Herlev University Hospital",Other,Denmark,20.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT00297297
NCT00297297,thyroid neoplasms,"Preoperative Selection of Solitary Solid Cold Thyroid Nodules - A Prospective Study on the Value of Sonography, Cytology, Immunostaining and Molecular Profiling",Improved Preoperative Selection of Cold Thyroid Nodules,Thyroid Nodules,2006-02-27,,2011-03-31,Observational,Unknown status,,Herlev Hospital,Herlev Hospital,"Outpatient clinic of The Department of Endocrinology, Herlev University Hospital",Other,Denmark,20.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00297297
NCT00307840,hyperparathyroidism,Initial Dosing of Paricalcitol Based on iPTH Parathyroid Hormone Levels in Hemodialysis Patients With Secondary Hyperparathyroidism,Initial Dosing of Paricalcitol in Secondary Hyperparathyroidism,Secondary Hyperparathyroidism,2006-03-27,,2005-07-31,Interventional,Completed,Phase 4,Papageorgiou General Hospital,Papageorgiou General Hospital,,Drug,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00307840
NCT00316823,thyroid nodule,Gene Expression Analysis in Thyroid Nodule FNA Samples,Genetic Analysis in Diagnosing Thyroid Cancer in Patients With Thyroid Nodules,Head and Neck Cancer,2006-04-19,2009-12-31,,Interventional,Completed,Not Applicable,National Cancer Institute (NCI),"National Cancer Institute (NCI)|University of California, San Francisco",UCSF Helen Diller Family Comprehensive Cancer Center,Genetic|Genetic|Genetic|Other|Other|Procedure,United States,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT00316823
NCT00316823,thyroid neoplasms,Gene Expression Analysis in Thyroid Nodule FNA Samples,Genetic Analysis in Diagnosing Thyroid Cancer in Patients With Thyroid Nodules,Head and Neck Cancer,2006-04-19,2009-12-31,,Interventional,Completed,Not Applicable,National Cancer Institute (NCI),"National Cancer Institute (NCI)|University of California, San Francisco",UCSF Helen Diller Family Comprehensive Cancer Center,Genetic|Genetic|Genetic|Other|Other|Procedure,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00316823
NCT00322322,hyperthyroidism,Early Administration of L-carnitine in Hemodialysis Patients: Double Blind Randomized Trial Versus Placebo,Early Administration of L-carnitine in Hemodialysis Patients,Complication of Hemodialysis|Hyperthyroidism Treated or Under Control,2006-05-03,2010-06-30,2010-06-30,Interventional,Completed,Phase 3,Assistance Publique - Hôpitaux de Paris,Assistance Publique - Hôpitaux de Paris,"Assistance Publique Hopitaux de Paris|HOPITAL LA PITIE SALPETRIERE, service de Néphrologie",Drug,France,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT00322322
NCT00325104,hyperparathyroidism,Cinacalcet Actions in Familial Primary Hyperparathyroidism,Cinacalcet to Treat Familial Primary Hyperparathyroidism,Familial Primary Hyperparathyroidism|Hypercalcemia,2006-05-11,,2007-03-31,Interventional,Completed,Phase 3,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"National Institutes of Health Clinical Center, 9000 Rockville Pike",Procedure|Procedure,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00325104
NCT00335062,hyperthyroidism,TSH Receptor Antibody Heterogeneity in Children and Adolescents With Graves' Disease,TSH Receptor Antibody Heterogeneity in Children and Adolescents With Graves' Disease,Graves' Disease,2006-06-06,2010-02-28,2010-02-28,Observational,Completed,,Boston Children's Hospital,Boston Children's Hospital,Childrens' Hospital Boston,,United States,2.0,21.0,[0-17]|[18-65],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT00335062
NCT00335062,goiter,TSH Receptor Antibody Heterogeneity in Children and Adolescents With Graves' Disease,TSH Receptor Antibody Heterogeneity in Children and Adolescents With Graves' Disease,Graves' Disease,2006-06-06,2010-02-28,2010-02-28,Observational,Completed,,Boston Children's Hospital,Boston Children's Hospital,Childrens' Hospital Boston,,United States,2.0,21.0,[0-17]|[18-65],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00335062
NCT00335062,graves disease,TSH Receptor Antibody Heterogeneity in Children and Adolescents With Graves' Disease,TSH Receptor Antibody Heterogeneity in Children and Adolescents With Graves' Disease,Graves' Disease,2006-06-06,2010-02-28,2010-02-28,Observational,Completed,,Boston Children's Hospital,Boston Children's Hospital,Childrens' Hospital Boston,,United States,2.0,21.0,[0-17]|[18-65],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT00335062
NCT00342641,thyroid neoplasms,Associations of Hematologic Malignancies and Thyroid Cancer With HCV Infection Among US Military Veterans,Association Between Hepatitis C Virus Infection and Hematologic and Thyroid Cancers,Hepatitis C Virus,2006-06-19,,2011-12-13,Observational,Completed,,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),Houston Veterans AFfairs Medical Center,,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00342641
NCT00345839,hyperparathyroidism,EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events,E.V.O.L.V.E. Trial™: EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events,Chronic Kidney Disease|Secondary Hyperparathyroidism,2006-06-27,2012-04-10,2012-04-10,Interventional,Completed,Phase 3,Amgen,Amgen,,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00345839
NCT00348413,graves disease,"Comparison of Efficacy and Safety of Intravenous Pulsed Methylprednisolone and Oral Methotrexate Versus Intravenous Pulsed Methylprednisolone and Oral Placebo in the Treatment of Active Moderate and Severe Thyroid Eye Disease - a Prospective, Randomized, Double-blind, Parallel, Controlled Multidisciplinary Clinical Trial and Imaging Study.",Thyroid Treatment Trial,Graves Ophthalmopathy,2006-07-03,2008-07-31,2008-07-31,Interventional,Completed,Not Applicable,Singapore National Eye Centre,International Stem Cell Forum|Singapore National Eye Centre,Singapore National Centre,Drug,Singapore,21.0,60.0,[18-65],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT00348413
NCT00348413,goiter,"Comparison of Efficacy and Safety of Intravenous Pulsed Methylprednisolone and Oral Methotrexate Versus Intravenous Pulsed Methylprednisolone and Oral Placebo in the Treatment of Active Moderate and Severe Thyroid Eye Disease - a Prospective, Randomized, Double-blind, Parallel, Controlled Multidisciplinary Clinical Trial and Imaging Study.",Thyroid Treatment Trial,Graves Ophthalmopathy,2006-07-03,2008-07-31,2008-07-31,Interventional,Completed,Not Applicable,Singapore National Eye Centre,International Stem Cell Forum|Singapore National Eye Centre,Singapore National Centre,Drug,Singapore,21.0,60.0,[18-65],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00348413
NCT00348413,hyperthyroidism,"Comparison of Efficacy and Safety of Intravenous Pulsed Methylprednisolone and Oral Methotrexate Versus Intravenous Pulsed Methylprednisolone and Oral Placebo in the Treatment of Active Moderate and Severe Thyroid Eye Disease - a Prospective, Randomized, Double-blind, Parallel, Controlled Multidisciplinary Clinical Trial and Imaging Study.",Thyroid Treatment Trial,Graves Ophthalmopathy,2006-07-03,2008-07-31,2008-07-31,Interventional,Completed,Not Applicable,Singapore National Eye Centre,International Stem Cell Forum|Singapore National Eye Centre,Singapore National Centre,Drug,Singapore,21.0,60.0,[18-65],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT00348413
NCT00352170,hyperparathyroidism,Calcium and Vitamin D Malnutrition in Elderly Women,Calcium and Vitamin D Malnutrition in Elderly Women,Osteoporosis|Secondary Hyperparathyroidism,2006-07-12,2005-07-31,2005-07-31,Interventional,Completed,Phase 3,Creighton University,Creighton University|GlaxoSmithKline,,Dietary Supplement|Dietary Supplement|Dietary Supplement,,55.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00352170
NCT00360074,hypothyroidism,"A Randomised, Controlled, Crossover Study: Treatment With Thyroxin Compared to Thyroxin + Triiodothyronin in Patients With Secondary Hypothyroidism",Phase 4 Study in Secondary Hypothyroidism: Body Weight Adapted Thyroxin Treatment and Triiodothyronine Supplementation,Hyperlipidemias|Hypopituitarism|Secondary Hypothyroidism,2006-08-02,,2007-04-30,Interventional,Completed,Phase 4,University Hospital Freiburg,University Hospital Freiburg,"University Hospital Freiburg, Department of Medicine",Drug,Germany,18.0,75.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT00360074
NCT00364234,hyperparathyroidism,Low Magnitute Mechanical Stimuli Effects on Bone Structure in ESRD,Low Magnitude Mechanical Stimuli Effects on Bone Structure in ESRD,Renal Osteodystrophy,2006-08-14,2007-09-30,2007-09-30,Interventional,Completed,Not Applicable,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Childen's Hospital of Philadelphia,Device,United States,21.0,65.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00364234
NCT00374712,hyperparathyroidism,Study of Klotho Gene Polymorphisms in the Regulation of Serum Phosphate Levels in Hemodialysis Patients,Klotho Gene Polymorphism in Dialyzed Patients With Hyperphosphatemia,Chronic Kidney Disease|End Stage Renal Disease|Hyperphosphatemia|Renal Osteodystrophy,2005-09-12,,2007-11-30,Observational,Terminated,,Assistance Publique - Hôpitaux de Paris,"Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France",Clinique de l'Orangerie - Service de Néphrologie et Dialyse,,France,18.0,80.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00374712
NCT00381641,"thyroid cancer, papillary","Phase II Trial of Sunitinib (SU11248) in Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers and Medullary Thyroid Cancers",Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery,Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Carcinoma|Refractory Thyroid Gland Carcinoma|Stage III Thyroid Gland Follicular Carcinoma AJCC v7|Stage III Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVB Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7|Stage IV Thyroid Gland Follicular Carcinoma AJCC v7|Stage IV Thyroid Gland Medullary Carcinoma AJCC v7|Stage IV Thyroid Gland Papillary Carcinoma AJCC v7|Thyroid Gland Hurthle Cell Carcinoma|Unresectable Thyroid Gland Carcinoma,2006-09-26,2016-12-31,,Interventional,Active not recruiting,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),University of Chicago Comprehensive Cancer Center|Decatur Memorial Hospital|NorthShore University HealthSystem-Evanston Hospital|Ingalls Memorial Hospital|Duly Health and Care Joliet|Loyola University Medical Center|Illinois CancerCare-Peoria|Central Illinois Hematology Oncology Center|Southern Illinois University School of Medicine|Fort Wayne Medical Oncology and Hematology Inc-Parkview|Northern Indiana Cancer Research Consortium|University of Maryland/Greenebaum Cancer Center|University of Michigan Comprehensive Cancer Center|Oncology Care Associates PLLC|Mercy Hospital Saint Louis|M D Anderson Cancer Center|Medical College of Wisconsin,Other|Other|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT00381641
NCT00381641,"adenocarcinoma, follicular","Phase II Trial of Sunitinib (SU11248) in Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers and Medullary Thyroid Cancers",Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery,Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Carcinoma|Refractory Thyroid Gland Carcinoma|Stage III Thyroid Gland Follicular Carcinoma AJCC v7|Stage III Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVB Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7|Stage IV Thyroid Gland Follicular Carcinoma AJCC v7|Stage IV Thyroid Gland Medullary Carcinoma AJCC v7|Stage IV Thyroid Gland Papillary Carcinoma AJCC v7|Thyroid Gland Hurthle Cell Carcinoma|Unresectable Thyroid Gland Carcinoma,2006-09-26,2016-12-31,,Interventional,Active not recruiting,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),University of Chicago Comprehensive Cancer Center|Decatur Memorial Hospital|NorthShore University HealthSystem-Evanston Hospital|Ingalls Memorial Hospital|Duly Health and Care Joliet|Loyola University Medical Center|Illinois CancerCare-Peoria|Central Illinois Hematology Oncology Center|Southern Illinois University School of Medicine|Fort Wayne Medical Oncology and Hematology Inc-Parkview|Northern Indiana Cancer Research Consortium|University of Maryland/Greenebaum Cancer Center|University of Michigan Comprehensive Cancer Center|Oncology Care Associates PLLC|Mercy Hospital Saint Louis|M D Anderson Cancer Center|Medical College of Wisconsin,Other|Other|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT00381641
NCT00385983,thyroid neoplasms,Total Thyroidectomy With Harmonic Scalpel® Versus Standard Surgery. Open Multicentric Randomized Controlled Trial,Total Thyroidectomy With Harmonic Scalpel®,Goiter|Thyroid Neoplasm|Thyroid Nodule,2006-10-10,,,Interventional,Unknown status,Phase 4,Brazilian Society of Head and Neck Surgery,Brazilian Society of Head and Neck Surgery|Johnson & Johnson,Hospital Araujo Jorge|Hospital Erasto Gaertner|Instituto Nacional de Cancer INCA|Hospital do Cancer de Natal|Hospital do Cancer AC Camargo|Hospital Heliopolis|Hospital Sao Paulo-UNIFESP|Instituto Arnaldo Vieira de Carvalho|Santa Casa de Misericordia,Device,Brazil,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00385983
NCT00388297,hypothyroidism,A Randomized Trial of Thyroxine Therapy for Subclinical Hypothyroidism or Hypothyroxinemia Diagnosed During Pregnancy,Thyroid Therapy for Mild Thyroid Deficiency in Pregnancy,Hypothyroxinemia|Pregnancy|Subclinical Hypothyroidism,2006-10-12,2015-08-31,2015-10-31,Interventional,Completed,Phase 3,The George Washington University Biostatistics Center,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Neurological Disorders and Stroke (NINDS)|The George Washington University Biostatistics Center,University of Alabama - Birmingham|Northwestern University|Wayne State University|Columbia University|University of North Carolina - Chapel Hill|Case Western University|Ohio State University|Oregon Health & Sciences University|University of Pittsburgh Magee Womens Hospital|Brown University|University of Texas - Southwest|University of Texas Medical Branch - Galveston|University of Texas-Houston|University of Utah Medical Center,Drug|Drug,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT00388297
NCT00390325,thyroid neoplasms,Phase II Study of Sorafenib (BAY 43-9006) in Patients With Metastatic Medullary Thyroid Carcinoma,"Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer",Hereditary Thyroid Gland Medullary Carcinoma|Locally Advanced Thyroid Gland Medullary Carcinoma|Multiple Endocrine Neoplasia Type 2A|Multiple Endocrine Neoplasia Type 2B|Recurrent Thyroid Gland Medullary Carcinoma|Sporadic Thyroid Gland Medullary Carcinoma|Stage III Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVB Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7|Stage IV Thyroid Gland Medullary Carcinoma AJCC v7,2006-10-18,2017-01-30,,Interventional,Active not recruiting,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Washington University School of Medicine|Duke University Medical Center|Ohio State University Comprehensive Cancer Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00390325
NCT00397475,hyperparathyroidism,Evaluation of Colecalciferol Substitution in Dialysis Patients,Evaluation of Colecalciferol Substitution in Dialysis Patients,"Hyperparathyroidism, Secondary|RENAL INSUFFICIENCY, CHRONIC",2006-11-07,,2007-03-31,Interventional,Completed,Not Applicable,"University Hospital, Saarland","University Hospital, Saarland","University Hospital of Saarland, Dpt. of Internal Medicine IV, Div. of Nephrology and Hypertension",Drug,Germany,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00397475
NCT00400465,thyroid nodule,Is the Routine Pressure Dressing After Thyroidectomy Necessary? A Prospective Randomized Controlled Study,Is the Routine Pressure Dressing After Thyroidectomy Necessary?,Goiter|Graves Disease|Thyroid Neoplasms|Thyroid Nodules,2006-11-14,2007-08-31,2007-09-30,Interventional,Completed,Phase 4,Khon Kaen University,Khon Kaen University,"Deapartment of Otolaryngology, Srinagarind Hospital, Khonkaen University",Procedure|Procedure,Thailand,0.0,120.0,[0-17]|[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT00400465
NCT00400465,hyperthyroidism,Is the Routine Pressure Dressing After Thyroidectomy Necessary? A Prospective Randomized Controlled Study,Is the Routine Pressure Dressing After Thyroidectomy Necessary?,Goiter|Graves Disease|Thyroid Neoplasms|Thyroid Nodules,2006-11-14,2007-08-31,2007-09-30,Interventional,Completed,Phase 4,Khon Kaen University,Khon Kaen University,"Deapartment of Otolaryngology, Srinagarind Hospital, Khonkaen University",Procedure|Procedure,Thailand,0.0,120.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT00400465
NCT00415233,thyroid neoplasms,"Multicentre Randomised Trial of High Dose Versus Low Dose Radioiodine, With or Without Recombinant Human Thyroid Stimulating Hormone, for Remnant Ablation Following Surgery for Differentiated Thyroid Cancer [HILO]",High Dose vs Low Dose I 131 +/- rhTSH for Differentiated Thyroid Cancer,Head and Neck Cancer,2006-12-20,2011-06-30,2025-07-31,Interventional,Active not recruiting,Phase 3,"University College, London","University College, London",Sussex Cancer Centre at Royal Sussex County Hospital|Addenbrooke's Hospital|Kent and Canterbury Hospital|Castle Hill Hospital|Derbyshire Royal Infirmary|Royal Devon and Exeter Hospital|Gloucestershire Royal Hospital|St. Luke's Cancer Centre at Royal Surrey County Hospital|Ipswich Hospital|Leeds Cancer Centre at St. James's University Hospital|Leicester Royal Infirmary|Guy's Hospital|Royal Marsden - London|Maidstone Hospital|Christie Hospital|James Cook University Hospital|Newcastle Upon Tyne Hospitals NHS Trust|Northampton General Hospital|Mount Vernon Cancer Centre at Mount Vernon Hospital|Norfolk and Norwich University Hospital|Dorset Cancer Centre|Cancer Research Centre at Weston Park Hospital|University Hospital of North Staffordshire|Velindre Cancer Center at Velindre Hospital|Glan Clwyd Hospital,Biological|Radiation,United Kingdom,16.0,80.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00415233
NCT00415584,hyperparathyroidism,"Cinacalcet for Treatment of Persistent Secondary Hyperparathyroidism in Renal Transplant Recipients: Effect on Renal Function, Serum Calcium and Bone Histomorphometry",Cinacalcet to Treat Hypercalcemia in Renal Transplant Recipients,Hypercalcemia|Secondary Hyperparathyroidism,2006-12-21,2009-11-30,2009-11-30,Interventional,Terminated,Phase 1/Phase 2,Montefiore Medical Center,Montefiore Medical Center,Montefiore Medical Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00415584
NCT00416949,thyroid neoplasms,Dose-Response in Radionuclide Therapy of Thyroid Cancer,Iodine I 131 in Treating Patients With Thyroid Cancer,Head and Neck Cancer,2006-12-27,2009-10-31,2009-10-31,Interventional,Terminated,Not Applicable,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,National Cancer Institute (NCI)|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,Device,United States,18.0,100.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00416949
NCT00418600,hyperparathyroidism,"A Phase 4, Multi-Center, Open-Label, Randomized Study to Determine Clinically Appropriate Doses of Hectorol® Capsules When Converting From Hectorol® Injection for the Treatment of SHPT in Stage 5 CKD Subjects on Hemodialysis","A Phase 4, Conversion Study of Hectorol® Injection to Hectorol® Capsules in Stage 5 CKD Patients on Dialysis",Secondary Hyperparathyroidism,2007-01-03,2007-06-30,2007-08-31,Interventional,Completed,Phase 4,Sanofi,"Genzyme, a Sanofi Company",,Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00418600
NCT00424151,hyperthyroidism,Rituximab Treatment of Graves' Dysthyroid Ophthalmopathy Phase I/II,Rituximab Treatment of Graves' Dysthyroid Ophthalmopathy,Graves' Dysthyroid Ophthalmopathy|Thyroid Related Orbitopathy,2007-01-17,2009-03-31,2009-03-31,Interventional,Completed,Phase 1/Phase 2,"Silkiss, Rona Z., M.D., FACS","Coleman, Morton M.D.|Lauer, Simeon, M.D.|Reier, Alice M.D.|Silkiss, Rona Z., M.D., FACS","Rona Z. Silkiss, MD, FACS|Simeon A. Lauer, MD",Drug,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT00424151
NCT00424151,graves disease,Rituximab Treatment of Graves' Dysthyroid Ophthalmopathy Phase I/II,Rituximab Treatment of Graves' Dysthyroid Ophthalmopathy,Graves' Dysthyroid Ophthalmopathy|Thyroid Related Orbitopathy,2007-01-17,2009-03-31,2009-03-31,Interventional,Completed,Phase 1/Phase 2,"Silkiss, Rona Z., M.D., FACS","Coleman, Morton M.D.|Lauer, Simeon, M.D.|Reier, Alice M.D.|Silkiss, Rona Z., M.D., FACS","Rona Z. Silkiss, MD, FACS|Simeon A. Lauer, MD",Drug,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT00424151
NCT00424151,graves ophthalmopathy,Rituximab Treatment of Graves' Dysthyroid Ophthalmopathy Phase I/II,Rituximab Treatment of Graves' Dysthyroid Ophthalmopathy,Graves' Dysthyroid Ophthalmopathy|Thyroid Related Orbitopathy,2007-01-17,2009-03-31,2009-03-31,Interventional,Completed,Phase 1/Phase 2,"Silkiss, Rona Z., M.D., FACS","Coleman, Morton M.D.|Lauer, Simeon, M.D.|Reier, Alice M.D.|Silkiss, Rona Z., M.D., FACS","Rona Z. Silkiss, MD, FACS|Simeon A. Lauer, MD",Drug,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT00424151
NCT00424151,goiter,Rituximab Treatment of Graves' Dysthyroid Ophthalmopathy Phase I/II,Rituximab Treatment of Graves' Dysthyroid Ophthalmopathy,Graves' Dysthyroid Ophthalmopathy|Thyroid Related Orbitopathy,2007-01-17,2009-03-31,2009-03-31,Interventional,Completed,Phase 1/Phase 2,"Silkiss, Rona Z., M.D., FACS","Coleman, Morton M.D.|Lauer, Simeon, M.D.|Reier, Alice M.D.|Silkiss, Rona Z., M.D., FACS","Rona Z. Silkiss, MD, FACS|Simeon A. Lauer, MD",Drug,United States,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00424151
NCT00430547,graves disease,Thyroid-Associated Ophthalmopathy Subtypes and Orbital Antibodies,Thyroid-Associated Ophthalmopathy Subtypes and Orbital Antibodies,Graves' Ophthalmopathy,2007-02-01,,2006-01-31,Interventional,Completed,Not Applicable,Barwon Health,"Barwon Health|National Health and Medical Research Council, Australia|University of Melbourne",Barwon Health - The Geelong Hospital,Drug,Australia,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT00430547
NCT00430547,hyperthyroidism,Thyroid-Associated Ophthalmopathy Subtypes and Orbital Antibodies,Thyroid-Associated Ophthalmopathy Subtypes and Orbital Antibodies,Graves' Ophthalmopathy,2007-02-01,,2006-01-31,Interventional,Completed,Not Applicable,Barwon Health,"Barwon Health|National Health and Medical Research Council, Australia|University of Melbourne",Barwon Health - The Geelong Hospital,Drug,Australia,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT00430547
NCT00430547,graves ophthalmopathy,Thyroid-Associated Ophthalmopathy Subtypes and Orbital Antibodies,Thyroid-Associated Ophthalmopathy Subtypes and Orbital Antibodies,Graves' Ophthalmopathy,2007-02-01,,2006-01-31,Interventional,Completed,Not Applicable,Barwon Health,"Barwon Health|National Health and Medical Research Council, Australia|University of Melbourne",Barwon Health - The Geelong Hospital,Drug,Australia,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT00430547
NCT00430547,goiter,Thyroid-Associated Ophthalmopathy Subtypes and Orbital Antibodies,Thyroid-Associated Ophthalmopathy Subtypes and Orbital Antibodies,Graves' Ophthalmopathy,2007-02-01,,2006-01-31,Interventional,Completed,Not Applicable,Barwon Health,"Barwon Health|National Health and Medical Research Council, Australia|University of Melbourne",Barwon Health - The Geelong Hospital,Drug,Australia,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00430547
NCT00431496,hyperparathyroidism,A Study To Assess Achievement of NKF K/DOQI Targets Using Sensipar (Cinacalcet) in Australian Subjects With End Stage Renal Disease (ESRD) Who Are Being Treated With Aranesp for Anaemia Management,A Study of Cinacalcet to Improve Achievement of National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI) Targets in Patients With End Stage Renal Disease (ESRD),Anemia|Secondary Hyperparathyroidism,2007-02-01,2009-06-30,2009-10-31,Interventional,Completed,Phase 4,Amgen,Amgen,,Drug,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00431496
NCT00432146,goiter,Positive Effect of Lugol's Solution on the Blood Flow and Microvessel Density of Thyroid Gland in the Patients With Graves' Disease,Effect of Lugol's Solution in the Patients With Graves' Disease,Graves Disease,2007-02-05,,2006-09-30,Observational,Completed,,Istanbul University,Istanbul University,,Drug,,14.0,61.0,[0-17]|[18-65],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00432146
NCT00432146,hyperthyroidism,Positive Effect of Lugol's Solution on the Blood Flow and Microvessel Density of Thyroid Gland in the Patients With Graves' Disease,Effect of Lugol's Solution in the Patients With Graves' Disease,Graves Disease,2007-02-05,,2006-09-30,Observational,Completed,,Istanbul University,Istanbul University,,Drug,,14.0,61.0,[0-17]|[18-65],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT00432146
NCT00432939,hyperparathyroidism,Primary Hyperparathyroidism: Non-classical Manifestations,Primary Hyperparathyroidism: Non-classical Manifestations,Primary Hyperparathyroidism,2007-02-06,2009-11-30,2012-12-31,Observational,Completed,,Columbia University,Columbia University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Metabolic Bone Diseases Unit,,United States,50.0,75.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00432939
NCT00437931,hypothyroidism,,Color Flow Doppler Ultrasound in Subclinical Thyroid Dysfunction,Hyperthyroidism|Subclinical Hypothyroidism|Thyroid Dysfunction,2007-02-19,2008-02-29,2008-02-29,Observational,Completed,,"HaEmek Medical Center, Israel","HaEmek Medical Center, Israel","Haemek Medical Center, Department of Radiology",,Israel,18.0,75.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT00437931
NCT00439127,thyroid neoplasms,Is the Thyroglobulin Measurement Under Thyroxine of Prognostic Value Before rhTSH-Aided Radioiodine Ablation in Differentiated Thyroid Carcinoma?,OnT4-Thyroglobulin Assay Before rhTSH-Aided Radioiodine Ablation,Differentiated Thyroid Carcinoma,2007-02-22,,2007-01-31,Observational,Completed,,Oncology Institute of Southern Switzerland,Oncology Institute of Southern Switzerland,,,,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00439127
NCT00446329,hyperparathyroidism,,Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis,Secondary Hyperparathyroidism,2007-03-09,,,Interventional,Terminated,Phase 4,Papageorgiou General Hospital,Papageorgiou General Hospital,Papageorgiou General Hospital,Drug,Greece,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00446329
NCT00454350,hyperparathyroidism,"A Randomized , Open-Label, Cross-over, Pharmacokinetic Study of Doxercalciferol and Paricalcitol Following Multiple Intravenous Injections in Chronic Kidney Disease Subjects on Hemodialysis",A Phase 4 Pharmacokinetic Study of Hectorol Injection and Zemplar Injection in CKD Subjects on Hemodialysis,Secondary Hyperparathyroidism,2007-03-28,,2007-07-31,Interventional,Completed,Phase 4,Sanofi,"Genzyme, a Sanofi Company",,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00454350
NCT00459498,thyroid neoplasms,Significant Intracellular NIS Protein Associated With Low Levels of NIS Messenger RNA in Malignant Thyroid Tumors,Expression of NIS Protein and mRNA in Thyroid Tumors,Tumors,2007-04-10,,2006-10-31,Observational,Completed,,University of Sao Paulo,Fundação de Amparo à Pesquisa do Estado de São Paulo|University of Sao Paulo,,,,18.0,80.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00459498
NCT00463021,hyperparathyroidism,"A Phase 4, Multi Center, Open-Label, Randomized Study to Determine Clinically Appropriate Doses of Hectorol® (Doxercalciferol Capsules) When Converting From Zemplar® (Paricalcitol Injection) for the Treatment of Secondary Hyperparathyroidism in Stage 5 Chronic Kidney Disease (CKD) Subjects on Hemodialysis.",A Phase 4 Study to Determine Dosing of Hectorol® Capsules When Converting From Zemplar® Injection,Secondary Hyperparathyroidism,2007-04-18,,2007-12-31,Interventional,Completed,Phase 4,Sanofi,"Genzyme, a Sanofi Company",,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00463021
NCT00469599,hyperparathyroidism,Treatment of Secondary Hyperparathyroidism in the Uremic Patient. A Study Comparing Alfacalcidol and Paricalcitol,Treatment of Secondary Hyperparathyroidism in the Uremic Patient,Chronic Kidney Disease|Secondary Hyperparathyroidism|Vitamin D Deficiency,2007-05-03,2010-09-30,2010-10-31,Interventional,Terminated,Not Applicable,Zealand University Hospital,Zealand University Hospital,Aalborg University Hospital|Århus University Hospital Skejby|Hospital of Southwest Denmark Esbjerg|Holbæk County Hospital|Holstebro County Hospital|Odense University Hospital|Roskilde County Hospital|Viborg County Hospital,Drug|Drug,Denmark,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00469599
NCT00470496,"adenocarcinoma, follicular","A Phase I Study of Surgery Plus Intraoperative Photodynamic Therapy (PDT) in Patients With Resectable, Primary or Recurrent Head and Neck Cancer",Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer,Recurrent Adenoid Cystic Carcinoma of the Oral Cavity|Recurrent Basal Cell Carcinoma of the Lip|Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Recurrent Lymphoepithelioma of the Nasopharynx|Recurrent Lymphoepithelioma of the Oropharynx|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Recurrent Mucoepidermoid Carcinoma of the Oral Cavity|Recurrent Salivary Gland Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Thyroid Cancer|Recurrent Verrucous Carcinoma of the Larynx|Recurrent Verrucous Carcinoma of the Oral Cavity|Stage I Adenoid Cystic Carcinoma of the Oral Cavity|Stage I Basal Cell Carcinoma of the Lip|Stage I Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage I Follicular Thyroid Cancer|Stage II Adenoid Cystic Carcinoma of the Oral Cavity|Stage II Basal Cell Carcinoma of the Lip|Stage II Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage II Follicular Thyroid Cancer|Stage II Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage II Lymphoepithelioma of the Nasopharynx|Stage II Lymphoepithelioma of the Oropharynx|Stage II Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage II Mucoepidermoid Carcinoma of the Oral Cavity|Stage I Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage II Papillary Thyroid Cancer|Stage II Salivary Gland Cancer|Stage II Squamous Cell Carcinoma of the Hypopharynx|Stage II Squamous Cell Carcinoma of the Larynx|Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage II Squamous Cell Carcinoma of the Oropharynx|Stage II Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage II Verrucous Carcinoma of the Larynx|Stage II Verrucous Carcinoma of the Oral Cavity|Stage I Lymphoepithelioma of the Nasopharynx|Stage I Lymphoepithelioma of the Oropharynx|Stage I Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage I Mucoepidermoid Carcinoma of the Oral Cavity|Stage I Papillary Thyroid Cancer|Stage I Salivary Gland Cancer|Stage I Squamous Cell Carcinoma of the Hypopharynx|Stage I Squamous Cell Carcinoma of the Larynx|Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage I Squamous Cell Carcinoma of the Oropharynx|Stage I Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage I Verrucous Carcinoma of the Larynx|Stage I Verrucous Carcinoma of the Oral Cavity,2007-05-03,2011-10-28,2018-08-30,Interventional,Completed,Phase 1,Roswell Park Cancer Institute,National Cancer Institute (NCI)|Roswell Park Cancer Institute,Roswell Park Cancer Institute,Drug|Drug|Procedure,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT00470496
NCT00470496,"thyroid cancer, papillary","A Phase I Study of Surgery Plus Intraoperative Photodynamic Therapy (PDT) in Patients With Resectable, Primary or Recurrent Head and Neck Cancer",Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer,Recurrent Adenoid Cystic Carcinoma of the Oral Cavity|Recurrent Basal Cell Carcinoma of the Lip|Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Recurrent Lymphoepithelioma of the Nasopharynx|Recurrent Lymphoepithelioma of the Oropharynx|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Recurrent Mucoepidermoid Carcinoma of the Oral Cavity|Recurrent Salivary Gland Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Thyroid Cancer|Recurrent Verrucous Carcinoma of the Larynx|Recurrent Verrucous Carcinoma of the Oral Cavity|Stage I Adenoid Cystic Carcinoma of the Oral Cavity|Stage I Basal Cell Carcinoma of the Lip|Stage I Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage I Follicular Thyroid Cancer|Stage II Adenoid Cystic Carcinoma of the Oral Cavity|Stage II Basal Cell Carcinoma of the Lip|Stage II Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage II Follicular Thyroid Cancer|Stage II Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage II Lymphoepithelioma of the Nasopharynx|Stage II Lymphoepithelioma of the Oropharynx|Stage II Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage II Mucoepidermoid Carcinoma of the Oral Cavity|Stage I Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage II Papillary Thyroid Cancer|Stage II Salivary Gland Cancer|Stage II Squamous Cell Carcinoma of the Hypopharynx|Stage II Squamous Cell Carcinoma of the Larynx|Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage II Squamous Cell Carcinoma of the Oropharynx|Stage II Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage II Verrucous Carcinoma of the Larynx|Stage II Verrucous Carcinoma of the Oral Cavity|Stage I Lymphoepithelioma of the Nasopharynx|Stage I Lymphoepithelioma of the Oropharynx|Stage I Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage I Mucoepidermoid Carcinoma of the Oral Cavity|Stage I Papillary Thyroid Cancer|Stage I Salivary Gland Cancer|Stage I Squamous Cell Carcinoma of the Hypopharynx|Stage I Squamous Cell Carcinoma of the Larynx|Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage I Squamous Cell Carcinoma of the Oropharynx|Stage I Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage I Verrucous Carcinoma of the Larynx|Stage I Verrucous Carcinoma of the Oral Cavity,2007-05-03,2011-10-28,2018-08-30,Interventional,Completed,Phase 1,Roswell Park Cancer Institute,National Cancer Institute (NCI)|Roswell Park Cancer Institute,Roswell Park Cancer Institute,Drug|Drug|Procedure,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT00470496
NCT00480428,thyroid nodule,Study to Improve Thyroid Doses From Fallout Exposure in Kazakhstan,Radiation Exposure and Thyroid Disease in Kazakhstan,Other Thyroid Disease|Thyroid Cancer|Thyroid Nodules,2007-05-30,,2017-08-17,Observational,Completed,,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),Semipalatinsk State Medical Academy,,Kazakhstan,65.0,90.0,[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT00480428
NCT00498238,hypothyroidism,The Effect of Levothyroxine on Arterial Stiffness and Lipid Profile in Patients,The Effect of Levothyroxine on Arterial Stiffness and Lipid Profile in Patients With Subclinical Hypothyroidism,Subclinical Hypothyroidism,2007-07-06,,2005-09-30,Interventional,Completed,Not Applicable,Assaf-Harofeh Medical Center,Assaf-Harofeh Medical Center,,Drug,,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT00498238
NCT00505011,graves disease,"Study of the Influence of the GST, CYP and TP53 Gene Polymorphisms in the Risk of Graves' Disease and Its Outcome.",Genetic Polymorphisms Associated With Cigarette Smoking and Risk of Graves' Disease,Graves' Disease,2007-07-18,,2007-02-28,Observational,Completed,,"University of Campinas, Brazil","Fundação de Amparo à Pesquisa do Estado de São Paulo|University of Campinas, Brazil",,,,2.0,120.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT00505011
NCT00505011,hyperthyroidism,"Study of the Influence of the GST, CYP and TP53 Gene Polymorphisms in the Risk of Graves' Disease and Its Outcome.",Genetic Polymorphisms Associated With Cigarette Smoking and Risk of Graves' Disease,Graves' Disease,2007-07-18,,2007-02-28,Observational,Completed,,"University of Campinas, Brazil","Fundação de Amparo à Pesquisa do Estado de São Paulo|University of Campinas, Brazil",,,,2.0,120.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT00505011
NCT00505011,goiter,"Study of the Influence of the GST, CYP and TP53 Gene Polymorphisms in the Risk of Graves' Disease and Its Outcome.",Genetic Polymorphisms Associated With Cigarette Smoking and Risk of Graves' Disease,Graves' Disease,2007-07-18,,2007-02-28,Observational,Completed,,"University of Campinas, Brazil","Fundação de Amparo à Pesquisa do Estado de São Paulo|University of Campinas, Brazil",,,,2.0,120.0,[0-17]|[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00505011
NCT00507897,thyroid neoplasms,,Hemodynamic Parameters in Euthyroid Patients With Thyroid Nodules,Thyroid Nodules,2007-07-25,,2007-12-31,Observational,Terminated,,Yaroslavl State Medical Academy,Yaroslavl State Medical Academy,Yaroslavl State Medical Academy,,Russian Federation,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00507897
NCT00507897,thyroid nodule,,Hemodynamic Parameters in Euthyroid Patients With Thyroid Nodules,Thyroid Nodules,2007-07-25,,2007-12-31,Observational,Terminated,,Yaroslavl State Medical Academy,Yaroslavl State Medical Academy,Yaroslavl State Medical Academy,,Russian Federation,0.0,120.0,[0-17]|[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT00507897
NCT00509483,goiter,Long-Term Follow-up and Outcome of Administering Recombinant Human Thyrotropin as an Adjuvant of Therapy With Radioiodine in the Outpatient Treatment of Multinodular Goitres,Three-Year Follow-up of Radioiodine Therapy for Goitre,Tratment of Multinodular Goitre,2007-07-27,,2006-12-31,Interventional,Completed,Not Applicable,University of Sao Paulo,Fundação de Amparo à Pesquisa do Estado de São Paulo|University of Sao Paulo,,Radiation,,20.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00509483
NCT00519896,"adenocarcinoma, follicular",Phase II Study of Sunitinib in Iodine Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of Thyroid With Functional Imaging Correlation,Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer,Recurrent Thyroid Cancer|Stage IVA Follicular Thyroid Cancer|Stage IVA Papillary Thyroid Cancer|Stage IVB Follicular Thyroid Cancer|Stage IVB Papillary Thyroid Cancer|Stage IVC Follicular Thyroid Cancer|Stage IVC Papillary Thyroid Cancer|Thyroid Gland Medullary Carcinoma,2007-08-21,2015-05-31,2015-09-30,Interventional,Completed,Phase 2,University of Washington,National Cancer Institute (NCI)|University of Washington,Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT00519896
NCT00519896,"thyroid cancer, papillary",Phase II Study of Sunitinib in Iodine Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of Thyroid With Functional Imaging Correlation,Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer,Recurrent Thyroid Cancer|Stage IVA Follicular Thyroid Cancer|Stage IVA Papillary Thyroid Cancer|Stage IVB Follicular Thyroid Cancer|Stage IVB Papillary Thyroid Cancer|Stage IVC Follicular Thyroid Cancer|Stage IVC Papillary Thyroid Cancer|Thyroid Gland Medullary Carcinoma,2007-08-21,2015-05-31,2015-09-30,Interventional,Completed,Phase 2,University of Washington,National Cancer Institute (NCI)|University of Washington,Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT00519896
NCT00522028,hyperparathyroidism,"Asymptomatic Primary Hyperparathyroidism: A Prospective, Randomized Trial","Asymptomatic Primary Hyperparathyroidism: A Prospective, Randomized Trial",Primary Hyperparathyroidism,2007-08-28,2016-01-31,2016-01-31,Observational,Completed,,Oslo University Hospital,"Göteborg University|Haukeland University Hospital|Karolinska University Hospital|Oslo University Hospital|Rigshospitalet, Denmark|Rikshospitalet University Hospital|St. Olavs Hospital|Uppsala University Hospital",Oslo University Hospital - Rikshospitalet,,Norway,50.0,80.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00522028
NCT00525135,thyroid neoplasms,"A Phase II Trial of Valproic Acid (Depakote ER ®) in Patients With Advanced Thyroid Cancers of Follicular Origin, Who Are Thyroglobulin Positive/RAI Unresponsive",Valproic Acid (Depakote ER) in Patients With Advanced Thyroid Cancer,Head and Neck Cancer,2007-08-28,2009-03-31,2009-03-31,Interventional,Terminated,Phase 2,"University of California, San Francisco","National Cancer Institute (NCI)|University of California, San Francisco",UCSF Comprehensive Cancer Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00525135
NCT00527085,hyperparathyroidism,"A Multicenter, Randomized, Placebo-controlled, Double-blind, 12-month Study to Assess the Effects of an Oral Calcimimetic Agent (AMG 073) on Renal Osteodystrophy in Hemodialysis Patients With Secondary Hyperparathyroidism",12-month Study of AMG 073 in Renal Osteodystrophy,Renal Osteodystrophy,2007-09-06,2003-08-31,2003-08-31,Interventional,Completed,Phase 2,Amgen,Amgen,,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00527085
NCT00528502,parathyroid diseases,Prevention of Laryngeal Reflexes in Minimal Invasive Parathyroid Surgery by the Use of Topical Lidocaine,Lidocaine Supplement for Minimal Invasive Parathyroid Surgery,Parathyroid Disease,2007-09-11,2008-01-31,2008-01-31,Interventional,Withdrawn,Phase 3,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center,,Drug|Drug,,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT00528502
NCT00528788,hyperparathyroidism,Effect of Doxercalciferol on Endothelial Cell Function in End Stage Renal Disease,How Vitamin D Analogues Affect Endothelial Cells in Patients on Dialysis,"Hyperparathyroidism, Secondary|Kidney Failure, Chronic",2007-09-10,2012-08-31,2012-08-31,Interventional,Completed,Phase 4,Duke University,"Duke University|Genzyme, a Sanofi Company",Duke University Medical Center Dialysis Unit,Drug,United States,18.0,80.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00528788
NCT00531713,hypothyroidism,"Effect of T4-T3 Combination Therapy Versus T4 Monotherapy in Patients With Hypothyroidism,a Double Blind Randomized Cross-Over Study.",Effect of T4-T3 Combination Therapy Versus T4 Monotherapy in Patients With Hypothyroidism,Depression|Quality of Life,2007-09-18,,2007-03-31,Interventional,Completed,Phase 4,Copenhagen University Hospital at Herlev,Copenhagen University Hospital at Herlev,"Dept of endocrinology , Herlev Hospital",Drug,Denmark,18.0,75.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT00531713
NCT00535561,hypothyroidism,"Iron Deficiency Anemia Can be an Indication for Treatment of Subclinical Hypothyroidism: A Randomized, Double Blinded Study",Iron Deficiency Anemia Can be an Indication for Treatment of Subclinical Hypothyroidism,Iron Deficiency Anemia|Subclinical Hypothyroidism,2007-09-25,,2007-09-30,Interventional,Completed,Phase 1,Duzce University,Duzce University,Duzce University School of Medicine,Drug|Drug,Turkey,23.0,73.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT00535561
NCT00537797,thyroid nodule,Limited Neck FDG-PET Imaging for Indeterminate Thyroid Nodules,Accuracy of FDG-PET Scanning to Diagnose Malignant Thyroid Nodules,Thyroid Neoplasms,2007-09-28,2011-09-30,2014-02-28,Interventional,Completed,Not Applicable,Washington University School of Medicine,Washington University School of Medicine,Washington University School of Medicine|St. Louis University School of Medicine|VAMC,Other,United States,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT00537797
NCT00537979,hyperparathyroidism,"Prospective, Non-randomized, Multicenter Study to Assess the Efficacy and Safety of Oral or Intravenous Paricalcitol Administered Over 6 Months to Patients With Secondary Hyperparathyroidism on Dialysis",Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyperparathyroidism on Dialysis,Dialysis|Secondary Hyperparathyroidism,2007-09-28,2010-07-31,2010-07-31,Interventional,Completed,Phase 4,Abbott,Abbott,Site Ref # / Investigator 19391|Site Ref # / Investigator 19389|Site Ref # / Investigator 19390|Site Ref # / Investigator 19393|Site Ref # / Investigator 19395|Site Ref # / Investigator 19392|Site Ref # / Investigator 19397|Site Ref # / Investigator 19396|Site Ref # / Investigator 19394|Site Ref # / Investigator 19399|Site Ref # / Investigator 19398|Site Ref # / Investigator 19388,Drug|Drug,Mexico,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00537979
NCT00552253,thyroid neoplasms,Levothyroxine Treatment in Thyroid Benign Nodular Goiter,Levothyroxine Treatment in Thyroid Benign Nodular Goiter,Thyroid Nodule,2007-10-30,2008-07-31,2008-07-31,Interventional,Completed,Not Applicable,National Taiwan University Hospital,National Taiwan University Hospital,National Taiwan University Hospital,Drug,Taiwan,20.0,90.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00552253
NCT00552253,goiter,Levothyroxine Treatment in Thyroid Benign Nodular Goiter,Levothyroxine Treatment in Thyroid Benign Nodular Goiter,Thyroid Nodule,2007-10-30,2008-07-31,2008-07-31,Interventional,Completed,Not Applicable,National Taiwan University Hospital,National Taiwan University Hospital,National Taiwan University Hospital,Drug,Taiwan,20.0,90.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00552253
NCT00556530,hypoparathyroidism,Genetic Modifiers of 22q11.2 Deletion Syndrome,Examining Genetic Factors That Affect the Severity of 22q11.2 Deletion Syndrome,22q11.2 Deletion Syndrome|DiGeorge Syndrome,2007-11-08,2022-06-06,2025-07-31,Observational,Recruiting,,Albert Einstein College of Medicine,"Albert Einstein College of Medicine|National Heart, Lung, and Blood Institute (NHLBI)",Albert Einstein College of Medicine|Children's Hospital of Philadelphia,,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00556530
NCT00559949,"thyroid cancer, papillary",Phase 2 Study of Selumetinib Hydrogen Sulfate in Iodine-131 Refractory Papillary Thyroid Carcinoma and Papillary Thyroid Carcinoma With Follicular Elements,Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine,Recurrent Thyroid Gland Carcinoma|Stage III Thyroid Gland Papillary Carcinoma|Stage II Thyroid Gland Papillary Carcinoma|Stage I Thyroid Gland Papillary Carcinoma|Stage IV Thyroid Gland Papillary Carcinoma,2007-11-16,2016-08-31,2016-08-31,Interventional,Completed,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Moffitt Cancer Center|University of Chicago Comprehensive Cancer Center|UNC Lineberger Comprehensive Cancer Center|Fox Chase Cancer Center|Vanderbilt University/Ingram Cancer Center|University Health Network-Princess Margaret Hospital,Other|Drug,Canada|United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT00559949
NCT00560300,hyperparathyroidism,Regulation of Bone Formation in Renal Osteodystrophy,Regulation of Bone Formation in Renal Osteodystrophy,Renal Osteodystrophy|Secondary Hyperparathyroidism,2007-11-13,,2006-11-30,Interventional,Completed,Phase 2,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),,Drug|Drug|Drug|Drug,,2.0,21.0,[0-17]|[18-65],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00560300
NCT00571077,thyroid nodule,Electrical Impedance Scanning of Thyroid Nodules Prior to Thyroid Surgery: a Prospective Study,Electrical Impedance Scanning of Thyroid Nodules Prior to Thyroid Surgery: a Prospective Study,Thyroid Neoplasms|Thyroid Nodules,2007-12-10,,2007-12-31,Observational,Completed,,Hadassah Medical Organization,Hadassah Medical Organization|Walter Reed Army Medical Center,Walter Reed Army MEdicla Center|Hadassah-Hebrew University Medical Center,Device,Israel|United States,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT00571077
NCT00571090,thyroid neoplasms,Evaluation of Thyroid Fine Needle Aspiration Biopsies: Prediction of Thyroid Cancer From Ultrasonographic Characteristics of Thyroid Nodules,Prediction of Thyroid Cancer From Ultrasonographic Characteristics of Thyroid Nodules,Thyroid Nodule,2007-12-10,2012-07-31,2013-07-31,Observational,Completed,,Istanbul Science University,Group Florence Nightingale|Istanbul Science University,Group Florence Nightingale,Procedure,Turkey,15.0,89.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00571090
NCT00576407,hypoparathyroidism,Phase II Study of Thymus Transplantation in Complete DiGeorge Syndrome #668,Thymus Transplantation in DiGeorge Syndrome #668,Complete Typical DiGeorge Anomaly|DiGeorge Syndrome,2007-12-17,2009-04-30,2017-12-31,Interventional,Completed,Phase 2,Enzyvant Therapeutics GmBH,Enzyvant Therapeutics GmBH|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health (NIH),Duke University Medical Center,Biological,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00576407
NCT00576836,hypoparathyroidism,"Dose Study of Thymus Transplantation in DiGeorge Anomaly, IND 9836, #932.1",Thymus Transplantation Dose in DiGeorge #932,Complete DiGeorge Anomaly|Complete DiGeorge Syndrome|DiGeorge Anomaly|DiGeorge Syndrome,2007-12-17,2010-11-30,2019-12-31,Interventional,Completed,Phase 2,Enzyvant Therapeutics GmBH,Enzyvant Therapeutics GmBH|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health (NIH),Duke University Medical Center,Biological|Other,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00576836
NCT00579527,hypoparathyroidism,"Phase I/II Trial of Thymus Transplantation With Immunosuppression, #950",Phase I/II Thymus Transplantation With Immunosuppression #950,Complete Atypical DiGeorge Anomaly|Complete Atypical DiGeorge Syndrome|Complete DiGeorge Anomaly|Complete DiGeorge Syndrome|DiGeorge Anomaly,2007-12-20,2011-12-31,2017-12-31,Interventional,Completed,Phase 1/Phase 2,Enzyvant Therapeutics GmBH,Enzyvant Therapeutics GmBH|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health (NIH),Duke University Medical Center,Biological|Other|Procedure|Drug|Drug|Drug|Drug|Drug|Drug,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00579527
NCT00579709,hypoparathyroidism,"Thymus Transplantation With Immunosuppression, #884",Thymus Transplantation With Immunosuppression,Complete DiGeorge Anomaly|Complete DiGeorge Syndrome|DiGeorge Anomaly|DiGeorge Syndrome,2007-12-20,2006-12-31,2019-12-31,Interventional,Completed,Phase 1,Enzyvant Therapeutics GmBH,Enzyvant Therapeutics GmBH|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health (NIH),Duke University Medical Center,Biological,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00579709
NCT00580320,parathyroid neoplasms,Phase I Trial of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma,Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma,Carcinoid Tumors|Melanoma|Parathyroid Carcinoma|Small Cell Carcinoma of the Lung|Soft Tissue Sarcoma,2007-12-18,2009-10-31,2013-11-30,Interventional,Completed,Phase 1,Virginia Commonwealth University,Virginia Commonwealth University,Dartmouth Hitchcock Medical Center|Massey Cancer Center/Virginia Commonwealth University,Drug,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00580320
NCT00587158,hyperparathyroidism,Oral Paricalcitol in Kidney Transplant Recipients Receiving a Corticosteroid-free Immunosuppressive Regimen,Oral Paricalcitol in Kidney Transplant Recipients,"Hyperparathyroidism, Secondary|Renal Disease, End Stage|Transplant; Failure, Kidney",2007-12-21,2011-11-30,2011-11-30,Interventional,Completed,Not Applicable,Mayo Clinic,Abbott|Mayo Clinic,Mayo Clinic|Mayo Clinic,Drug|Other,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00587158
NCT00588432,hyperthyroidism,Characterization of Skeletal Muscle Using Magnetic Resonance Elastography (MRE),Characterization of Skeletal Muscle Using Magnetic Resonance Elastography (MRE),Hyperthyroid Myopathy|Immobilization|Myofacial Pain|Stroke,2007-12-26,2009-09-30,2009-09-30,Observational,Completed,,Mayo Clinic,Mayo Clinic,Mayo Clinic,,United States,18.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT00588432
NCT00595335,goiter,Phase 2/3 Study of Rituximab for Graves' Ophthalmopathy,Trial of Rituximab for Graves' Ophthalmopathy,Thyroid-associated Ophthalmopathy,2008-01-01,2013-03-31,2013-09-30,Interventional,Completed,Phase 2/Phase 3,Mayo Clinic,National Center for Research Resources (NCRR)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Rebecca Bahn,Mayo Clinic,Drug|Drug|Drug,United States,18.0,80.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00595335
NCT00595335,graves ophthalmopathy,Phase 2/3 Study of Rituximab for Graves' Ophthalmopathy,Trial of Rituximab for Graves' Ophthalmopathy,Thyroid-associated Ophthalmopathy,2008-01-01,2013-03-31,2013-09-30,Interventional,Completed,Phase 2/Phase 3,Mayo Clinic,National Center for Research Resources (NCRR)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Rebecca Bahn,Mayo Clinic,Drug|Drug|Drug,United States,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT00595335
NCT00595335,hyperthyroidism,Phase 2/3 Study of Rituximab for Graves' Ophthalmopathy,Trial of Rituximab for Graves' Ophthalmopathy,Thyroid-associated Ophthalmopathy,2008-01-01,2013-03-31,2013-09-30,Interventional,Completed,Phase 2/Phase 3,Mayo Clinic,National Center for Research Resources (NCRR)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Rebecca Bahn,Mayo Clinic,Drug|Drug|Drug,United States,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT00595335
NCT00595335,graves disease,Phase 2/3 Study of Rituximab for Graves' Ophthalmopathy,Trial of Rituximab for Graves' Ophthalmopathy,Thyroid-associated Ophthalmopathy,2008-01-01,2013-03-31,2013-09-30,Interventional,Completed,Phase 2/Phase 3,Mayo Clinic,National Center for Research Resources (NCRR)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Rebecca Bahn,Mayo Clinic,Drug|Drug|Drug,United States,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT00595335
NCT00601328,hyperparathyroidism,"A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalency Study of Calcitriol Tablets, 0.25 mg, Under Fasting Conditions",Bioequivalency Study of Calcitriol Tablets Under Fasting Conditions,Hypocalcemia|Secondary Hyperparathyroidism,2008-01-15,2003-08-31,2003-08-31,Interventional,Completed,Not Applicable,West-Ward Pharmaceutical,Roxane Laboratories,"Bio-Kinetic Clinical Applications, Inc.",Drug,United States,18.0,45.0,[18-65],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00601328
NCT00639405,parathyroid neoplasms,Localization of Parathyroid Adenomas Using MRI and SPECT Fusion Software in Patients With Persistent or Recurrent Hyperparathyroidism,Evaluation of MRI and SPECT Fusion Software to Localize Parathyroid Adenomas,Parathyroid Diseases|Parathyroid Neoplasm,2008-03-12,2008-08-31,2008-08-31,Observational,Terminated,,State University of New York - Upstate Medical University,State University of New York - Upstate Medical University,SUNY Upstate Medical University,,United States,18.0,80.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00639405
NCT00646282,hyperparathyroidism,Mineral Metabolism and Vascular Effects of Vitamin D Therapy in Kidney,Mineral Metabolism and Vascular Effects of Vitamin D Therapy in Kidney Transplant Patients,"Hyperparathyroidism, Secondary",2008-03-25,2010-01-31,2010-01-31,Interventional,Terminated,Phase 4,Emory University,Emory University,Emory University,Drug,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00646282
NCT00651625,thyroid neoplasms,Randomized Controlled Trial of the Reciprocating Procedure Device Versus the Conventional Syringe in Syringe-and-Needle Procedures,Reciprocating Medical Devices - a Study of a New Safety Device,Cancer|Osteoarthritis|Rheumatoid Arthritis|Thyroid Nodule|Trauma,2008-03-21,2010-01-31,2010-08-31,Interventional,Completed,Not Applicable,University of New Mexico,University of New Mexico,University of New Mexico Health Sciences Center,Device|Device,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00651625
NCT00654238,"thyroid carcinoma, anaplastic",Phase II Study of BAY 43-9006 in Patients With Metastatic Thyroid Cancer,Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer,Metastatic Anaplastic Thyroid Cancer|Metastatic Differentiated Thyroid Cancer|Metastatic Medullary Thyroid Cancer|Metastatic Poorly Differentiated Thyroid Cancer,2008-04-01,2010-12-31,2011-03-31,Interventional,Completed,Phase 2,University of Pennsylvania,University of Pennsylvania,University of Pennsylvania - Abramson Comprehensive Cancer Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT00654238
NCT00664430,hyperparathyroidism,Efficacy and Safety of Paricalcitol on the Treatment of Secondary Hyperparathyroidism in Calcitriol Resistant Dialysis Subjects,Efficacy and Safety of Paricalcitol on the Treatment of Secondary Hyperparathyroidism in Calcitriol Resistant Dialysis Subjects,Dialysis|Secondary Hyperparathyroidism,2008-04-21,2009-06-30,2009-06-30,Interventional,Terminated,Phase 4,Abbott,Abbott|Statistika Consultoria Ltda,Site Reference ID/Investigator# 7118|Site Reference ID/Investigator# 7114,Drug|Drug,Brazil,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00664430
NCT00665795,hyperthyroidism,Morphometric Analysis of Orbital Structures in Graves´ Orbitopathy Using Multidetector Computed Tomography Scan and Color Doppler Imaging.,Morphometric Analysis of Orbital Structures in Graves´ Orbitopathy,Dysthyroid Orbitopathy,2008-04-22,2013-11-30,2013-11-30,Observational,Completed,,University of Sao Paulo,University of Sao Paulo,General Hospital - University of Sao Paulo - School of Medicine,,Brazil,20.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT00665795
NCT00665795,graves disease,Morphometric Analysis of Orbital Structures in Graves´ Orbitopathy Using Multidetector Computed Tomography Scan and Color Doppler Imaging.,Morphometric Analysis of Orbital Structures in Graves´ Orbitopathy,Dysthyroid Orbitopathy,2008-04-22,2013-11-30,2013-11-30,Observational,Completed,,University of Sao Paulo,University of Sao Paulo,General Hospital - University of Sao Paulo - School of Medicine,,Brazil,20.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT00665795
NCT00665795,goiter,Morphometric Analysis of Orbital Structures in Graves´ Orbitopathy Using Multidetector Computed Tomography Scan and Color Doppler Imaging.,Morphometric Analysis of Orbital Structures in Graves´ Orbitopathy,Dysthyroid Orbitopathy,2008-04-22,2013-11-30,2013-11-30,Observational,Completed,,University of Sao Paulo,University of Sao Paulo,General Hospital - University of Sao Paulo - School of Medicine,,Brazil,20.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00665795
NCT00667576,hyperparathyroidism,Late Phase 2 Study of Paricalcitol Injection: Dose-response Study of Paricalcitol Injection in Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism (Examination of Initial Dose and Incremental Dose),Dose-response Study of Paricalcitol Injection in Chronic Kidney Disease Patients Receiving Hemodialysis,Chronic Kidney Disease on Hemodialysis|Secondary Hyperparathyroidism,2008-04-24,2009-03-31,2009-03-31,Interventional,Completed,Phase 2,Abbott,"Abbott|Abbott Japan Co.,Ltd",,Drug|Drug,Japan,20.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00667576
NCT00674154,hyperparathyroidism,Effect of Vitamin D Treatment in Primary Hyperparathyroidism,Effect of Vitamin D Treatment in Primary Hyperparathyroidism,Hypercalcemia|Primary Hyperparathyroidism|Vitamin D Deficiency,2008-05-05,2013-08-31,2013-08-31,Interventional,Completed,Phase 2/Phase 3,University of Aarhus,University of Aarhus,"Osteoporoseklinikken, Aarhus University Hospital, THG",Drug,Denmark,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00674154
NCT00677469,goiter,Low Doses of Cholestyramine in the Treatment of Hyperthyroidism,Low Doses of Cholestyramine in the Treatment of Hyperthyroidism,Graves Disease,2008-05-12,2008-01-31,2008-01-31,Interventional,Completed,Not Applicable,Shiraz University of Medical Sciences,Shiraz University of Medical Sciences,Endocrine and Metabolism Research Center,Drug|Drug|Drug,"Iran, Islamic Republic of",20.0,60.0,[18-65],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00677469
NCT00677469,hyperthyroidism,Low Doses of Cholestyramine in the Treatment of Hyperthyroidism,Low Doses of Cholestyramine in the Treatment of Hyperthyroidism,Graves Disease,2008-05-12,2008-01-31,2008-01-31,Interventional,Completed,Not Applicable,Shiraz University of Medical Sciences,Shiraz University of Medical Sciences,Endocrine and Metabolism Research Center,Drug|Drug|Drug,"Iran, Islamic Republic of",20.0,60.0,[18-65],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT00677469
NCT00697528,graves disease,Color Doppler Imaging of Orbital Venous Flow in Grave's Orbitopathy,Color Doppler Imaging of Orbital Venous Flow in Grave's Orbitopathy,Graves' Disease|Graves' Ophthalmopathy,2008-06-11,2008-12-31,2008-12-31,Observational,Completed,,University of Sao Paulo,University of Sao Paulo,Hospital das Clínicas da Universidade São Paulo,,Brazil,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT00697528
NCT00697528,goiter,Color Doppler Imaging of Orbital Venous Flow in Grave's Orbitopathy,Color Doppler Imaging of Orbital Venous Flow in Grave's Orbitopathy,Graves' Disease|Graves' Ophthalmopathy,2008-06-11,2008-12-31,2008-12-31,Observational,Completed,,University of Sao Paulo,University of Sao Paulo,Hospital das Clínicas da Universidade São Paulo,,Brazil,18.0,70.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00697528
NCT00697528,hyperthyroidism,Color Doppler Imaging of Orbital Venous Flow in Grave's Orbitopathy,Color Doppler Imaging of Orbital Venous Flow in Grave's Orbitopathy,Graves' Disease|Graves' Ophthalmopathy,2008-06-11,2008-12-31,2008-12-31,Observational,Completed,,University of Sao Paulo,University of Sao Paulo,Hospital das Clínicas da Universidade São Paulo,,Brazil,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT00697528
NCT00697528,graves ophthalmopathy,Color Doppler Imaging of Orbital Venous Flow in Grave's Orbitopathy,Color Doppler Imaging of Orbital Venous Flow in Grave's Orbitopathy,Graves' Disease|Graves' Ophthalmopathy,2008-06-11,2008-12-31,2008-12-31,Observational,Completed,,University of Sao Paulo,University of Sao Paulo,Hospital das Clínicas da Universidade São Paulo,,Brazil,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT00697528
NCT00701805,hyperparathyroidism,Phase II Study of Paricalcitol Injection Extension Long-term Safety Study of Paricalcitol Injection in Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism,Long-term Safety Study of Paricalcitol Injection in Chronic Kidney Disease Patients With Hemodialysis (HD),Hemodialysis|Secondary Hyperparathyroidism,2008-06-17,2009-12-31,2009-12-31,Interventional,Completed,Phase 2,Abbott,"Abbott|Abbott Japan Co.,Ltd",,Drug,Japan,20.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00701805
NCT00729157,"thyroid cancer, papillary",A Phase II Study of Single Agent Intravenous (IV) VEGF Trap in Patients With Poor Prognostic Recurrent and/or Metastatic Thyroid Cancer After RAI Therapy,Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy,Recurrent Thyroid Gland Carcinoma|Stage III Thyroid Gland Follicular Carcinoma|Stage III Thyroid Gland Papillary Carcinoma|Stage IV Thyroid Gland Follicular Carcinoma|Stage IV Thyroid Gland Papillary Carcinoma,2008-08-06,2012-10-31,2012-11-30,Interventional,Completed,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Memorial Sloan-Kettering Cancer Center,Radiation|Other|Other|Procedure|Biological,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT00729157
NCT00729157,"adenocarcinoma, follicular",A Phase II Study of Single Agent Intravenous (IV) VEGF Trap in Patients With Poor Prognostic Recurrent and/or Metastatic Thyroid Cancer After RAI Therapy,Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy,Recurrent Thyroid Gland Carcinoma|Stage III Thyroid Gland Follicular Carcinoma|Stage III Thyroid Gland Papillary Carcinoma|Stage IV Thyroid Gland Follicular Carcinoma|Stage IV Thyroid Gland Papillary Carcinoma,2008-08-06,2012-10-31,2012-11-30,Interventional,Completed,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Memorial Sloan-Kettering Cancer Center,Radiation|Other|Other|Procedure|Biological,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT00729157
NCT00742716,hyperparathyroidism,"An Open Label, Four Week, Dose Escalating Pharmacokinetic, Pharmacodynamic, Efficacy and Safety Study of CTA018 Injection in Subjects With Stage 5 Chronic Kidney Disease With Secondary Hyperparathyroidism on Hemodialysis",Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease,Chronic Kidney Disease|Chronic Renal Failure|Chronic Renal Insufficiency|Secondary Hyperparathyroidism,2008-08-26,2010-02-28,2010-06-30,Interventional,Completed,Phase 2,"OPKO Health, Inc.","OPKO IP Holdings II, Inc.","Pines Clinical Research, Inc.|Boise Kidney and Hypertension Institute|Western New England Renal & Transplant Associates (WNERTA)|Southeast Renal Research Institute|U.S. Renal Care|Capital District Heatlth Authority: Centre for Clinical Research|St. Joseph's Health Care London|St. Michael's Hospital|Humber River Regional Hospital|Hôpital Charles-Lemoyne|Hôpital du Sacré-Coeur de Montréal|Hospital de Verdun",Drug,Canada|United States,18.0,80.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00742716
NCT00752401,hyperparathyroidism,"VITA-D: Cholecalciferol Substitution in Vitamin D Deficient Kidney Transplant Recipients: A Randomized, Placebo-controlled Study to Evaluate the Posttransplant Outcome",Vitamin D3 Substitution in Vitamin D Deficient Kidney Transplant Recipients,Kidney Transplantation|Renal Osteodystrophy|Vitamin D Deficiency,2008-09-11,2014-07-31,2014-07-31,Interventional,Unknown status,Phase 3,Medical University of Vienna,Medical University of Vienna,"Medical University of Vienna, Department of Internal Medicine III, Division of Nephrology and Dialysis",Drug|Drug,Austria,18.0,85.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00752401
NCT00754442,hyperparathyroidism,Clinical and Molecular Characterization of Suspected Partial 25-hydroxyvitamin D-1-alpha-hydroxylase Deficiency,Suspected Deficient Activation of Vitamin D in Patients With Secondary Hyperparathyroidism,Secondary Hyperparathyroidism,2008-09-17,2008-08-31,2008-08-31,Interventional,Completed,Not Applicable,"University of Maryland, Baltimore","University of Maryland, Baltimore",University of Maryland School of Medicine Division of Endocrinology,Drug,United States,40.0,59.0,[18-65],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00754442
NCT00768820,hypoparathyroidism,"The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome (VCFS), Williams Syndrome (WS)and Fragile X Syndrome Characterization, Treatment and Examining the Connection to Developmental and Molecular Factors",The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome,Fragile X Syndrome|Velocardiofacial Syndrome|Williams Syndrome,2008-10-07,2022-12-31,2022-12-31,Interventional,Recruiting,Phase 4,The Chaim Sheba Medical Center,The Chaim Sheba Medical Center,Schneider Children's Mediac Center of Israel,Drug,Israel,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00768820
NCT00781417,hyperparathyroidism,Prevention of Secondary Hyperparathyroidism With Vitamin D in Stage II/III Chronic Kidney Disease,Prevention of Secondary Hyperparathyroidism With Vitamin D in Stage II/III Chronic Kidney Disease,Kidney Disease,2008-10-28,2011-10-31,2011-12-31,Interventional,Completed,Not Applicable,Atlanta VA Medical Center,Atlanta VA Medical Center|Emory University,Atlanta VAMC,Dietary Supplement|Other,United States,18.0,85.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00781417
NCT00782366,goiter,Proof-of-Principle Trial of Communication to Patients Receiving Predictive Genetic Risk Assessment,Predictive Genetic Risk Assessment Trial,Atrial Fibrillation|Breast Cancer|Celiac Disease|Colon Cancer|Diabetes Type 2|Graves Disease|Lung Cancer|Myocardial Infarction|Obesity|Osteoarthritis|Prostate Cancer,2008-10-29,2010-01-31,2010-01-31,Observational,Completed,,Mayo Clinic,Mayo Clinic,Mayo Clinic,Genetic,United States,18.0,65.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00782366
NCT00782366,hyperthyroidism,Proof-of-Principle Trial of Communication to Patients Receiving Predictive Genetic Risk Assessment,Predictive Genetic Risk Assessment Trial,Atrial Fibrillation|Breast Cancer|Celiac Disease|Colon Cancer|Diabetes Type 2|Graves Disease|Lung Cancer|Myocardial Infarction|Obesity|Osteoarthritis|Prostate Cancer,2008-10-29,2010-01-31,2010-01-31,Observational,Completed,,Mayo Clinic,Mayo Clinic,Mayo Clinic,Genetic,United States,18.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT00782366
NCT00784173,hypoparathyroidism,Middle and Inner Ear Malformation in Children With Velocardiofacial Syndrome,Middle and Inner Ear Malformation in Children With Velocardiofacial Syndrome,Ear Malformations in the Velocardiofacial Syndrome,2008-10-31,2007-03-31,2007-06-30,Observational,Completed,,Pontificia Universidade Catolica de Sao Paulo,Pontificia Universidade Catolica de Sao Paulo,,,,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00784173
NCT00792857,hyperparathyroidism,"Single-Dose, Two-Period, Open Label, Dose Determination, Randomized, Cross-Over Study of CTAP201 Injection and Doxercalciferol (Hectorol) Injection in Subjects With Stage 5 CKD and SHPT on Hemodialysis",Comparison of I.V. CTAP201 and Doxercalciferol (Hectorol) in Subjects With Chronic Kidney Disease (CKD) and Secondary Hyperparathyroidism (SHPT),Chronic Kidney Disease|Chronic Renal Failure|Chronic Renal Insufficiency|Secondary Hyperparathyroidism,2008-11-14,2009-09-30,2009-10-31,Interventional,Completed,Phase 1,"OPKO Health, Inc.","OPKO IP Holdings II, Inc.",Pivotal Reseach Centers|Western New England Renal and Transplant Associates|University of Cincinnati|Northeast Clinical Research|Vanderbilt University|Southwest Houston Research Ltd.,Drug|Drug,United States,18.0,80.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00792857
NCT00796913,goiter,Prospective Randomized Study of Therapy Withdrawal vs Continued Low Dose Medical Therapy in Patients With Graves' Disease Entering Remission During ATD Therapy,Remission Induction and Sustenance in Graves' Disease 2,Graves Disease|Hyperthyroidism,2008-11-21,2015-05-15,2015-05-15,Interventional,Completed,Not Applicable,Aalborg University Hospital,Aalborg University Hospital,,Other,,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00796913
NCT00803712,hyperparathyroidism,Randomized Trial to Evaluate the Efficacy and Safety of Cinacalcet Treatment in Combination With Low Dose Vitamin D for the Treatment of Subjects With Secondary Hyperparathyroidism (SHPT) Recently Initiating Hemodialysis,20070360 Incident Dialysis,Chronic Kidney Disease|Secondary Hyperparathyroidism,2008-11-26,2010-12-09,2011-07-05,Interventional,Completed,Phase 4,Amgen,Amgen,,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00803712
NCT00804830,"thyroid carcinoma, anaplastic",Phase 2 Study With Avastin and Doxorubicin Postoperatively for Patients With Anaplastic Thyroid Cancer,Avastin and Doxorubicin Postoperatively for Patients With Anaplastic Thyroid Cancer,Carcinoma|Metastatic Cancer|Thyroid Cancer|Thyroid Neoplasms,2008-12-08,2012-12-31,2014-12-31,Interventional,Terminated,Phase 2,Region Skane,Region Skane,"Jubileumskliniken, Sahlgrenska universitetsjukhuset|Dep of Oncology, Lund University Hospital|Karolinska University Hospital",Drug,Sweden,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT00804830
NCT00822289,thyroid neoplasms,Effect of Radioactive Iodine on Eradication of Helicobacter Pylori in Patients Treated for Thyroid Diseases,The Effect of Radioactive Iodine Administration for Thyroid Diseases on H.Pylori Eradication,Helicobacter Pylori Infected Patients|Hyperthyroidism|Thyroid Cancer Patients,2009-01-13,,,Observational,Unknown status,,Rabin Medical Center,Rabin Medical Center,,,,18.0,85.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00822289
NCT00823303,hyperparathyroidism,A Phase 4 Randomized Multicenter Open Label Trial of Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3 or 4 Ckd Patients With Secondary Hyperparathyroidism,Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3/4 Chronic Kidney Disease (CKD) With Secondary Hyperparathyroidism (SHPT),Chronic Kidney Disease|Secondary Hyperparathyroidism,2008-12-12,2013-05-31,2013-09-30,Interventional,Completed,Phase 4,Washington University School of Medicine,"Abbott|Feinberg School of Medicine, Northwestern University|Henry Ford Hospital|NorthShore University HealthSystem|Washington University School of Medicine",Northwestern University|Northshore University Health System|Henry Ford Hospital|Washington University,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00823303
NCT00828347,hyperparathyroidism,A Study of Maintenance Therapy After Intravenous Maxacalcitol for Secondary Hyperparathyroidism,Maintenance Vitamin D Therapy for Secondary Hyperparathyroidism (2HPT),Secondary Hyperparathyroidism,2009-01-22,2009-07-31,2009-07-31,Interventional,Completed,Not Applicable,Kumamoto University,Kumamoto University,Kumamoto University Hospital,Drug|Drug,Japan,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00828347
NCT00849888,hypoparathyroidism,"Phase I Serum-Free Cultured Thymus Transplantation in DiGeorge Anomaly, IND9836",Serum-Free Thymus Transplantation in DiGeorge Anomaly,DiGeorge Anomaly,2009-02-22,2011-02-28,2011-02-28,Interventional,Terminated,Phase 1,Enzyvant Therapeutics GmBH,Enzyvant Therapeutics GmBH|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health (NIH),,Biological|Other,,0.0,2.0,[0-17],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00849888
NCT00858104,thyroid neoplasms,Multicentric Randomized Controlled Study of Percutaneous Laser Ablation Versus Follow Up in Benign Thyroid Nodules. Long Term Results,Percutaneous Laser Ablation in Benign Thyroid Nodules.Long Term Results,Thyroid Nodule,2009-03-06,2010-03-31,2013-05-31,Interventional,Completed,Phase 4,Elesta S.R.L.,Elesta S.R.L.,Ospedale Regina Apostolorum|Azienda Ospedaliera di Perugia - Osp. S.Maria della Misericordia|Azienda Ospedaliero-Universitaria di Pisa - Presidio di Cisanello|Arcispedale S. Maria Nuova,Procedure,Italy,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00858104
NCT00859612,hyperparathyroidism,Renal Osteodystrophy: A Fresh Approach,Renal Osteodystrophy: A Fresh Approach,Renal Osteodystrophy,2009-03-09,2014-02-28,2014-02-28,Observational,Completed,,University of Kentucky,"Hartmut Malluche, MD",University of Kentucky,,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00859612
NCT00877630,thyroid neoplasms,Minimal Invasiveness of Endoscopic Thyroidectomy,Minimal Invasiveness of Endoscopic Thyroidectomy,Thyroid Nodule,2009-04-07,2007-05-31,2007-05-31,Observational,Completed,,Second Military Medical University,Second Military Medical University,Minimally Invasive Surgical Center of Changzhang Hospital,,China,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00877630
NCT00877981,hyperparathyroidism,Open Compared to Video-Assisted Minimal-Invasive Parathyroid Surgery in Primary Hyperparathyroidism,Open Versus Video-Assisted Minimal-Invasive Parathyroid Surgery,Primary Hyperparathyroidism,2009-04-07,2007-04-30,2007-10-31,Interventional,Completed,Not Applicable,Uppsala University,Lund University|University of Aarhus|Uppsala University,"Unit of Breast and Endocrine Surgery, Surgical Department P, Aarhus University Hospital|Department of Surgery, Lund University Hospital|Uppsala University Hospital, Dept of surgery",Procedure,Denmark|Sweden,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00877981
NCT00887107,"thyroid cancer, papillary",Sorafenib as Adjuvant to Radioiodine Therapy in Non-Medullary Thyroid Carcinoma,Sorafenib as Adjuvant to Radioiodine Therapy in Non-Medullary Thyroid Carcinoma,Thyroid Cancer,2009-04-22,,,Interventional,Completed,Phase 2,Leiden University Medical Center,Leiden University Medical Center,Leiden University Medical Center,Drug,Netherlands,18.0,80.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT00887107
NCT00888069,hyperparathyroidism,"A Randomized, Open-Label, Single-Dose Pilot Study of Oral and i.v. CTAP101 Evaluating PK and Safety in Stage 3 and 4 CKD Subjects With Vitamin D Insufficiency and SHPT",Pharmacokinetics and Safety Pilot Study of Single-Dose Oral and Intravenous CTAP101 in Stage 3 and 4 Chronic Kidney Disease Subjects,Chronic Kidney Disease|Chronic Renal Failure|Chronic Renal Insufficiency|Secondary Hyperparathyroidism,2009-04-23,2009-11-30,2009-12-31,Interventional,Completed,Phase 1,"OPKO Health, Inc.","OPKO IP Holdings II, Inc.",Pivotal Research Centers|Research by Design|Western New England Renal & Transplant Associates|Twin Cities Clinical Research|DCI|MetroHealth Medical Center|Northeast Clinical Research|Southeast Renal Research Institute|Vanderbilt University Medical Center|Southwest Houston Research Ltd|Purity Dialysis Centers / Nephrology Associates|Gunderson Clinic Ltd.,Drug|Drug,United States,18.0,80.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00888069
NCT00891813,hyperparathyroidism,Effectiveness and Safety of a 6-Month Treatment With IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH/100 as Initial Dose,Effectiveness and Safety of IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH/100 as Initial Dose,"Hemodialysis|Hypercalcemia|Parathyroid Hormone|Renal Insufficiency, Chronic|Secondary Hyperparathyroidism",2009-04-29,2010-09-30,2010-09-30,Interventional,Completed,Phase 4,Abbott,Abbott,Site Reference ID/Investigator# 21401|Site Reference ID/Investigator# 23857|Site Reference ID/Investigator# 10941,Drug,Peru,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00891813
NCT00902122,thyroid neoplasms,"Open-Label, Multi-Center, Randomized, Active-Controlled, Phase 4 Study of rAd-p53 Gene Mono-Therapy, With Concurrent Radioactive Iodine , or Combination With Surgery in Subjects With Advanced Malignant Thyroid Tumors",rAd-p53 Gene Therapy for Advanced Malignant Thyroid Tumors,Advanced Malignant Thyroid Tumors,2009-05-12,2012-08-31,2012-08-31,Interventional,Unknown status,Phase 4,"Shenzhen SiBiono GeneTech Co.,Ltd","Shenzhen SiBiono GeneTech Co.,Ltd","West China Hospital, Sichuan University",Drug|Procedure|Drug|Radiation,China,18.0,85.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00902122
NCT00916955,hypoparathyroidism,Genetic Modifiers for 22q11.2 Syndrome,Genetic Modifiers for 22q11.2 Syndrome,22q11.2 Deletion Syndrome,2008-03-24,2015-02-28,2015-02-28,Observational,Completed,,State University of New York - Upstate Medical University,Albert Einstein College of Medicine|State University of New York - Upstate Medical University,VCFS International Center,Other,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00916955
NCT00917189,hypoparathyroidism,Computer-Based Cognitive Remediation in Adolescents With VCFS,Computerized Cognitive Skills Training for Adolescents With Velocardiofacial Syndrome,Velocardiofacial Syndrome,2009-06-08,2015-04-30,2015-04-30,Interventional,Completed,Not Applicable,State University of New York - Upstate Medical University,National Institute of Mental Health (NIMH)|State University of New York - Upstate Medical University,SUNY Upstate Medical University,Behavioral,United States,12.0,16.0,[0-17],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00917189
NCT00917241,hyperthyroidism,Prevention Relapse of Graves' Disease by Treatment With Intrathyroid Injection of Dexamethasone,Prevention Relapse of Graves' Disease by Intrathyroid Injection of Dexamethasone,Graves' Disease,2009-06-09,2008-12-31,2009-03-31,Interventional,Completed,Phase 4,Nanjing Medical University,Xiao-Ming Mao,,Drug|Drug,,18.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT00917241
NCT00917241,graves disease,Prevention Relapse of Graves' Disease by Treatment With Intrathyroid Injection of Dexamethasone,Prevention Relapse of Graves' Disease by Intrathyroid Injection of Dexamethasone,Graves' Disease,2009-06-09,2008-12-31,2009-03-31,Interventional,Completed,Phase 4,Nanjing Medical University,Xiao-Ming Mao,,Drug|Drug,,18.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT00917241
NCT00917241,goiter,Prevention Relapse of Graves' Disease by Treatment With Intrathyroid Injection of Dexamethasone,Prevention Relapse of Graves' Disease by Intrathyroid Injection of Dexamethasone,Graves' Disease,2009-06-09,2008-12-31,2009-03-31,Interventional,Completed,Phase 4,Nanjing Medical University,Xiao-Ming Mao,,Drug|Drug,,18.0,65.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00917241
NCT00921050,hypothyroidism,"Randomized Double Blind Levothyroxine vs Placebo, Mind (NEUROPSI) Improvement in Elderly With Persistent TSH 4-10 mUI/L",Subclinical Hypothyroidism and Mind in the Elderly,Subclinical Hypothyroidism,2009-06-15,2012-03-31,2012-03-31,Interventional,Completed,Phase 2/Phase 3,Universidad Autonoma de Nuevo Leon,Universidad Autonoma de Nuevo Leon,"Endocrinology, Outpatient Hospital Clinic|Community Health Center (Fomerrey 19)",Drug|Drug,Mexico,60.0,95.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT00921050
NCT00928408,hyperparathyroidism,PRIMARA: A Prospective Descriptive Observational Study to Review Mimpara (Cinacalcet) Use in Patients With Primary Hyperparathyroidism in Clinical Practice,PRIMARA: A Prospective Descriptive Observational Study to Review Mimpara (Cinacalcet) Use in Patients With Primary Hyperparathyroidism in Clinical Practice,"Hyperparathyroidism, Primary",2009-06-25,2011-12-31,2012-02-29,Observational,Completed,,Amgen,Amgen,,Drug,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00928408
NCT00936650,hyperparathyroidism,"A Double-Blind, Randomized, Placebo-Controlled, Multicenter Dose-Titration Study to Assess the Efficacy and Safety of Twice-Daily Dose Regimens of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism (PHPT)",A Study to Assess the Efficacy and Safety of Twice-Daily Dose Regimens of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism (PHPT),"Hyperparathyroidism, Primary",2009-06-04,2001-03-31,2001-06-30,Interventional,Completed,Phase 2,Amgen,Amgen,,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00936650
NCT00936988,hyperparathyroidism,"A Multicenter, Open-label Extension Study to Assess the Long-term Safety and Efficacy of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism","A Multicenter, Open-label Extension Study to Assess the Long-term Safety and Efficacy of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism","Hyperparathyroidism, Primary",2009-06-04,2005-06-30,2005-12-31,Interventional,Completed,Phase 2,Amgen,Amgen,,Drug,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00936988
NCT00946296,goiter,Impact of SSKI Pre-Treatment on Blood Loss in Thyroidectomy for Graves Disease,Impact of SSKI Pre-Treatment on Blood Loss in Thyroidectomy for Graves Disease,Graves Disease|Hyperthyroidism,2009-07-22,2013-04-30,2013-04-30,Interventional,Completed,Phase 4,"University of Massachusetts, Worcester","University of Massachusetts, Worcester",UMASS Memorial Health Care,Drug,United States,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00946296
NCT00958113,hyperthyroidism,Autoimmune Thyroid Disease Genetic Study,Autoimmune Thyroid Disease Genetic Study,Graves' Disease|Hashimoto's Disease,2009-08-11,2013-02-28,2015-05-31,Observational,Completed,,"University of Colorado, Denver","University of Colorado, Denver",University of Colorado Denver,,United States,7.0,120.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT00958113
NCT00958113,hashimoto disease,Autoimmune Thyroid Disease Genetic Study,Autoimmune Thyroid Disease Genetic Study,Graves' Disease|Hashimoto's Disease,2009-08-11,2013-02-28,2015-05-31,Observational,Completed,,"University of Colorado, Denver","University of Colorado, Denver",University of Colorado Denver,,United States,7.0,120.0,[0-17]|[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT00958113
NCT00958113,goiter,Autoimmune Thyroid Disease Genetic Study,Autoimmune Thyroid Disease Genetic Study,Graves' Disease|Hashimoto's Disease,2009-08-11,2013-02-28,2015-05-31,Observational,Completed,,"University of Colorado, Denver","University of Colorado, Denver",University of Colorado Denver,,United States,7.0,120.0,[0-17]|[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00958113
NCT00958113,graves disease,Autoimmune Thyroid Disease Genetic Study,Autoimmune Thyroid Disease Genetic Study,Graves' Disease|Hashimoto's Disease,2009-08-11,2013-02-28,2015-05-31,Observational,Completed,,"University of Colorado, Denver","University of Colorado, Denver",University of Colorado Denver,,United States,7.0,120.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT00958113
NCT00958451,hyperparathyroidism,Response of Secondary Hyperparathyroidism to Paricalcitol Versus Ergocalciferol in Patients With Stage 3 and 4 Chronic Kidney Disease With Vitamin D Deficiency: a Randomized Controlled Trial,Vitamin D Deficiency in Chronic Kidney Disease (CKD) Patients,Chronic Kidney Disease|Secondary Hyperparathyroidism,2009-08-11,2011-01-31,2011-01-31,Interventional,Completed,Phase 4,Salem Veterans Affairs Medical Center,Abbott|Salem Veterans Affairs Medical Center,VA Medical Center,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00958451
NCT00961701,hyperparathyroidism,Atherogenic Lipoprotein Phenotype and LDL Size and Subclasses in Patients With Primary Hyperparathyroidism,Lipids Profile in Primary Hyperparathyroidism,Primary Hyperparathyroidism,2009-08-18,2010-10-31,2016-10-31,Observational,Terminated,,"HaEmek Medical Center, Israel","HaEmek Medical Center, Israel|University of Palermo|University of Zurich","Endocrine Institute , Haemek Medical Center",,Israel,18.0,85.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00961701
NCT00962221,hypothyroidism,Atherogenic Lipoprotein Phenotype and LDL Size and Subclasses in Patients With Subclinical Hypothyroidism,Lipids Profile in Subclinical Hypothyroidism,Subclinical Hypothyroidism,2009-08-18,2011-10-31,2012-10-31,Observational,Terminated,,"HaEmek Medical Center, Israel","HaEmek Medical Center, Israel|University of Palermo|University of Zurich","Endocrine Institute, Haemek Medical Center",Procedure,Israel,18.0,85.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT00962221
NCT00973336,hyperparathyroidism,Primary Hyperparathyroidism: Does a Systematic Treatment Improve the Calcium and Bone Metabolism After Successful Surgery in Patients Without Osteoporosis?,Primary Hyperparathyroidism: Does a Systematic Treatment Improve the Calcium and Bone Metabolism After Surgery?,Bone Metabolism|Primary Hyperparathyroidism,2009-09-08,2017-09-30,2017-09-30,Interventional,Unknown status,Phase 2,Medical University of Vienna,Medical University of Vienna,Medical University of Vienna,Drug,Austria,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00973336
NCT00975221,hyperparathyroidism,A Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Cinacalcet for the Treatment of Hypercalcemia in Subjects With Primary Hyperparathyroidism Unable to Undergo Parathyroidectomy,Efficacy and Safety Study of Cinacalcet for the Treatment of Hypercalcemia in Patients With Primary Hyperparathyroidism Unable to Undergo Parathyroidectomy,"Hypercalcemia|Hyperparathyroidism, Primary",2009-09-10,2012-07-12,2012-12-21,Interventional,Completed,Phase 3,Amgen,Amgen,Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug|Drug,Australia|Canada|Hungary|Poland|Portugal|Russian Federation|United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00975221
NCT00977080,hyperparathyroidism,The IMPACT SHPT Study: Study to Evaluate the Improved Management of iPTH With Paricalcitol-centered Therapy vs. Cinacalcet Therapy With Low-dose Vitamin D in Hemodialysis Patients With Secondary Hyperparathyroidism,Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D,Chronic Kidney Disease|Hemodialysis|Secondary Hyperparathyroidism,2009-09-14,2011-05-31,2011-05-31,Interventional,Completed,Phase 4,Abbott,Abbott,Site Reference ID/Investigator# 22781|Site Reference ID/Investigator# 24342|Site Reference ID/Investigator# 21142|Site Reference ID/Investigator# 22762|Site Reference ID/Investigator# 22758|Site Reference ID/Investigator# 21442|Site Reference ID/Investigator# 23688|Site Reference ID/Investigator# 21370|Site Reference ID/Investigator# 25902|Site Reference ID/Investigator# 21146|Site Reference ID/Investigator# 26743|Site Reference ID/Investigator# 22788|Site Reference ID/Investigator# 22722|Site Reference ID/Investigator# 23147|Site Reference ID/Investigator# 22778|Site Reference ID/Investigator# 21369|Site Reference ID/Investigator# 22786|Site Reference ID/Investigator# 21144|Site Reference ID/Investigator# 21443|Site Reference ID/Investigator# 21145|Site Reference ID/Investigator# 22505|Site Reference ID/Investigator# 22759|Site Reference ID/Investigator# 22796|Site Reference ID/Investigator# 22770|Site Reference ID/Investigator# 22772|Site Reference ID/Investigator# 21147|Site Reference ID/Investigator# 22982|Site Reference ID/Investigator# 21143|Site Reference ID/Investigator# 22506|Site Reference ID/Investigator# 22776|Site Reference ID/Investigator# 22311|Site Reference ID/Investigator# 22310|Site Reference ID/Investigator# 21624|Site Reference ID/Investigator# 22363|Site Reference ID/Investigator# 23105|Site Reference ID/Investigator# 23909|Site Reference ID/Investigator# 22462|Site Reference ID/Investigator# 21748|Site Reference ID/Investigator# 33268|Site Reference ID/Investigator# 35903|Site Reference ID/Investigator# 21742|Site Reference ID/Investigator# 21744|Site Reference ID/Investigator# 21368|Site Reference ID/Investigator# 22362|Site Reference ID/Investigator# 38970|Site Reference ID/Investigator# 22322|Site Reference ID/Investigator# 22463|Site Reference ID/Investigator# 22323|Site Reference ID/Investigator# 39262|Site Reference ID/Investigator# 22312|Site Reference ID/Investigator# 21746|Site Reference ID/Investigator# 39180|Site Reference ID/Investigator# 22314|Site Reference ID/Investigator# 21367|Site Reference ID/Investigator# 21745|Site Reference ID/Investigator# 21842|Site Reference ID/Investigator# 22309|Site Reference ID/Investigator# 21843|Site Reference ID/Investigator# 38903|Site Reference ID/Investigator# 38531|Site Reference ID/Investigator# 22464|Site Reference ID/Investigator# 23910|Site Reference ID/Investigator# 24643|Site Reference ID/Investigator# 24642|Site Reference ID/Investigator# 21361|Site Reference ID/Investigator# 21364|Site Reference ID/Investigator# 22366|Site Reference ID/Investigator# 38343|Site Reference ID/Investigator# 21362|Site Reference ID/Investigator# 21363|Site Reference ID/Investigator# 22367|Site Reference ID/Investigator# 38462|Site Reference ID/Investigator# 21365|Site Reference ID/Investigator# 23913|Site Reference ID/Investigator# 23782|Site Reference ID/Investigator# 22364|Site Reference ID/Investigator# 23912|Site Reference ID/Investigator# 21747|Site Reference ID/Investigator# 23102|Site Reference ID/Investigator# 23104|Site Reference ID/Investigator# 23103|Site Reference ID/Investigator# 41982|Site Reference ID/Investigator# 40222,Drug|Drug,Czech Republic|Denmark|Germany|Greece|Italy|Netherlands|Portugal|Russian Federation|Spain|Sweden|United Kingdom|United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00977080
NCT00982722,hyperparathyroidism,Vitamin D Supplementation After Successful Parathyroid Surgery for Primary Hyperparathyroidism,Vitamin D Supplementation After Parathyroid Surgery,Primary Hyperparathyroidism,2009-09-22,2018-05-04,2018-05-04,Interventional,Completed,Not Applicable,Karolinska University Hospital,Karolinska University Hospital,Karolinska UH|Karolinska University Hospital,Drug|Drug,Sweden,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00982722
NCT00990704,hyperparathyroidism,"Phase II, Open Study, Exploratory Examination of Efficacy and Safety of Paricalcitol Injection and Maxacalcitol Injection in Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism",Paricalcitol Compared to Maxacalcitol in Chronic Kidney Disease Patients With Secondary Hyperparathyroidism,Hemodialysis|Secondary Hyperparathyroidism,2009-10-05,2010-05-31,2010-05-31,Interventional,Completed,Phase 2,Abbott,Abbott,Site Ref # / Investigator 53794|Site Ref # / Investigator 53787|Site Ref # / Investigator 53786|Site Ref # / Investigator 53792|Site Ref # / Investigator 53784|Site Ref # / Investigator 53796|Site Ref # / Investigator 53795|Site Ref # / Investigator 21561|Site Ref # / Investigator 53789|Site Ref # / Investigator 53790|Site Ref # / Investigator 53793|Site Ref # / Investigator 53785|Site Ref # / Investigator 53788|Site Ref # / Investigator 53791,Drug|Drug,Japan,20.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00990704
NCT00995163,hyperparathyroidism,Mineral and Bone Disorders Outcomes Study for Japanese Chronic Kidney Disease Stage 5D Patients (MBD-5D),Mineral and Bone Disorders Outcomes in Stage 5D of Chronic Kidney Disease,"End Stage Renal Disease|Hyperparathyroidism, Secondary",2009-10-14,2011-01-31,2011-01-31,Observational,Completed,,"Kyowa Kirin Co., Ltd.","Kyowa Kirin Co., Ltd.",,,Japan,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00995163
NCT00999037,hyperparathyroidism,FGF-23 (Fibroblast Growth Factor 23) Regulation in Chronic Kidney Disease,FGF-23 (Fibroblast Growth Factor 23) Regulation in Chronic Kidney Disease,Secondary Hyperparathyroidism,2009-10-20,2015-06-30,2015-06-30,Interventional,Completed,Not Applicable,"University of California, Los Angeles","Loma Linda University|University of California, Los Angeles",UCLA,Drug|Other,United States,6.0,21.0,[0-17]|[18-65],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00999037
NCT01012414,hyperparathyroidism,The Effect of Vitamin D Supplementation on Markers of Inflammation in High-Risk Cardiovascular Patients With Low Levels of Serum 25-Hydroxyvitamin D,Effect of Vitamin D Supplement on Inflammation Markers in High-Risk Cardiovascular Patients With Chronic Kidney Disease,Chronic Kidney Disease|Coronary Artery Disease|Hypovitaminosis D|Secondary Hyperparathyroidism,2009-11-11,2011-05-31,2011-05-31,Interventional,Terminated,Phase 3,Thomas Jefferson University,Abbott|Thomas Jefferson University,Thomas Jefferson University,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01012414
NCT01025128,hyperparathyroidism,,Vitamin D Status in Males in Jerusalem Area and Its Correlation to Parathyroid Hormone (PTH) Level and Bone Mineral Density,Osteomalacia|Secondary Hyperparathyroidism|Vitamin D Deficiency,2009-12-01,2014-07-31,2014-07-31,Interventional,Completed,Phase 4,Clalit Health Services,Clalit Health Services,"Endocrinology Clinic, Clalit Health Services",Drug,Israel,18.0,70.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01025128
NCT01039818,hyperthyroidism,Comparison of Different Doses of 131I in Severe Graves' Hyperthyroidism: A Clinical Trial With Historical Control,Comparison of Different Doses of 131I in Severe Graves' Hyperthyroidism,Graves Disease,2009-12-24,2011-08-31,2011-08-31,Interventional,Completed,Phase 3,Hospital de Clinicas de Porto Alegre,Federal University of Rio Grande do Sul|Hospital de Clinicas de Porto Alegre,"Thyroid Unit, Endocrine Division, Hospital de Clínicas de Porto Alegre",Radiation|Radiation,Brazil,18.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01039818
NCT01039818,goiter,Comparison of Different Doses of 131I in Severe Graves' Hyperthyroidism: A Clinical Trial With Historical Control,Comparison of Different Doses of 131I in Severe Graves' Hyperthyroidism,Graves Disease,2009-12-24,2011-08-31,2011-08-31,Interventional,Completed,Phase 3,Hospital de Clinicas de Porto Alegre,Federal University of Rio Grande do Sul|Hospital de Clinicas de Porto Alegre,"Thyroid Unit, Endocrine Division, Hospital de Clínicas de Porto Alegre",Radiation|Radiation,Brazil,18.0,65.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01039818
NCT01056419,goiter,,The Effect of Early Total Thyroidectomy in the Course of Graves' Orbitopathy,Graves' Ophthalmopathy,2010-01-25,2010-06-30,2010-08-31,Interventional,Unknown status,Phase 4,Ankara University,Ankara University,"Ankara University, Medical School, Ibni Sina Hospital, Endocrinology and Metabolic Diseases Department",Procedure|Drug,Turkey,18.0,75.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01056419
NCT01056419,graves disease,,The Effect of Early Total Thyroidectomy in the Course of Graves' Orbitopathy,Graves' Ophthalmopathy,2010-01-25,2010-06-30,2010-08-31,Interventional,Unknown status,Phase 4,Ankara University,Ankara University,"Ankara University, Medical School, Ibni Sina Hospital, Endocrinology and Metabolic Diseases Department",Procedure|Drug,Turkey,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT01056419
NCT01056419,graves ophthalmopathy,,The Effect of Early Total Thyroidectomy in the Course of Graves' Orbitopathy,Graves' Ophthalmopathy,2010-01-25,2010-06-30,2010-08-31,Interventional,Unknown status,Phase 4,Ankara University,Ankara University,"Ankara University, Medical School, Ibni Sina Hospital, Endocrinology and Metabolic Diseases Department",Procedure|Drug,Turkey,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT01056419
NCT01056419,hyperthyroidism,,The Effect of Early Total Thyroidectomy in the Course of Graves' Orbitopathy,Graves' Ophthalmopathy,2010-01-25,2010-06-30,2010-08-31,Interventional,Unknown status,Phase 4,Ankara University,Ankara University,"Ankara University, Medical School, Ibni Sina Hospital, Endocrinology and Metabolic Diseases Department",Procedure|Drug,Turkey,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01056419
NCT01057732,hyperparathyroidism,The Effect of Parathyroidectomy on Cardiovascular Risk Factors in Patients With Primary Hyperparathyroidism,Effects of Parathyroidectomy on Cardiovascular Risk Factors in Primary Hyperparathyroidism,Primary Hyperparathyroidism,2010-01-25,2006-06-30,2006-12-31,Observational,Completed,,"HaEmek Medical Center, Israel","HaEmek Medical Center, Israel","Endocrine Institute, Haemek Medical Center",,Israel,18.0,80.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01057732
NCT01060982,parathyroid neoplasms,"Observation of Histological Changes in Parathyroid Adenomas Following High Intensity Focused Ultrasound (HIFU)Treatment Procedure: A Monocentre, Open, Uncontrolled Study",Observation of Histological Changes in Parathyroid Adenomas Following High Intensity Focused Ultrasound (HIFU) Treatment Procedure,Primary Parathyroid Adenomas,2010-02-01,2013-01-31,2013-01-31,Interventional,Completed,Not Applicable,Theraclion,Theraclion,Hôpital Privé des Peupliers|Cochin Hospital,Device,France,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01060982
NCT01073462,hyperparathyroidism,Postmarketing Observational Study to Evaluate the Effect of Zemplar (Paricalcitol IV) on Cardiac Morbidity in Patients With Chronic Kidney Disease Stage 5 Over 2 Years.,Study to Evaluate the Effect of Intravenous (IV) Paricalcitol (Zemplar) on Cardiac Morbidity in Patients With Chronic Kidney Disease (CKD) Stage 5 Over 2 Years,Cardiac Morbidity|Chronic Kidney Disease Stage V|Secondary Hyperparathyroidism,2010-02-20,2013-06-30,2013-06-30,Observational,Completed,,AbbVie,"AbbVie (prior sponsor, Abbott)|Assign Data Management and Biostatistics GmbH",Site Reference ID/Investigator# 27447|Site Reference ID/Investigator# 49182|Site Reference ID/Investigator# 27483|Site Reference ID/Investigator# 52742|Site Reference ID/Investigator# 27487|Site Reference ID/Investigator# 36983|Site Reference ID/Investigator# 27484|Site Reference ID/Investigator# 27485|Site Reference ID/Investigator# 27446|Site Reference ID/Investigator# 53469|Site Reference ID/Investigator# 27482|Site Reference ID/Investigator# 10981,,Austria,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01073462
NCT01081665,hyperparathyroidism,"A Two-year, Post-marketing Observational Study to Follow-up Patients With End Stage Renal Disease Undergoing Haemodialysis, Receiving Zemplar for Prevention and Treatment of Secondary Hyperparathyroidism",Follow-up Patients With End Stage Renal Disease Receiving Zemplar to Prevent and Treat Secondary Hyperparathyroidism,Chronic Kidney Failure|Secondary Hyperparathyroidism,2010-02-27,2011-02-28,2011-02-28,Observational,Completed,,Abbott,Abbott,Site Reference ID/Investigator# 32055|Site Reference ID/Investigator# 32050|Site Reference ID/Investigator# 32051|Site Reference ID/Investigator# 32049|Site Reference ID/Investigator# 5283|Site Reference ID/Investigator# 32056|Site Reference ID/Investigator# 32057|Site Reference ID/Investigator# 32058|Site Reference ID/Investigator# 32077|Site Reference ID/Investigator# 32076|Site Reference ID/Investigator# 32059|Site Reference ID/Investigator# 32053|Site Reference ID/Investigator# 32060|Site Reference ID/Investigator# 32061|Site Reference ID/Investigator# 32062|Site Reference ID/Investigator# 32048|Site Reference ID/Investigator# 32054|Site Reference ID/Investigator# 32063|Site Reference ID/Investigator# 32075,,Greece,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01081665
NCT01083186,hyperparathyroidism,Paricalcitol Oral Therapy in Predialysis CKD Patients. The Greek Experience,Paricalcitol Oral Therapy in Predialysis CKD Patients. The Greek Experience,Chronic Kidney Failure|Secondary Hyperparathyroidism,2010-02-20,2012-01-31,2012-01-31,Observational,Completed,,AbbVie,"AbbVie (prior sponsor, Abbott)",Site Reference ID/Investigator# 47002|Site Reference ID/Investigator# 43772|Site Reference ID/Investigator# 27492|Site Reference ID/Investigator# 43769|Site Reference ID/Investigator# 38257|Site Reference ID/Investigator# 47003|Site Reference ID/Investigator# 27497|Site Reference ID/Investigator# 47004|Site Reference ID/Investigator# 27489|Site Reference ID/Investigator# 27495|Site Reference ID/Investigator# 43773|Site Reference ID/Investigator# 27498|Site Reference ID/Investigator# 38259|Site Reference ID/Investigator# 22121|Site Reference ID/Investigator# 43771|Site Reference ID/Investigator# 43767|Site Reference ID/Investigator# 27496|Site Reference ID/Investigator# 43768|Site Reference ID/Investigator# 27491|Site Reference ID/Investigator# 27494|Site Reference ID/Investigator# 27493|Site Reference ID/Investigator# 38255|Site Reference ID/Investigator# 43770|Site Reference ID/Investigator# 39839,,Greece,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01083186
NCT01083550,"thyroid cancer, papillary",Decision Aid on Radioactive Iodine Treatment for Early Stage Papillary Thyroid Cancer (Randomized Controlled Trial),Decision Making on Radioactive Iodine Treatment for Papillary Thyroid Cancer,Thyroid Cancer,2010-02-24,2016-11-30,2016-11-30,Interventional,Completed,Phase 2/Phase 3,"University Health Network, Toronto","Canadian Institutes of Health Research (CIHR)|Ontario Ministry of Health and Long Term Care|University Health Network, Toronto",University Health Network,Other,Canada,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT01083550
NCT01083849,hyperparathyroidism,Long-Term Therapy Outcomes When Treating CKD-patients With Paricalcitol in German Clinical Practice (TOP Study),Long-Term Therapy Outcomes When Treating Chronic Kidney Disease (CKD) Patients With Paricalcitol in German and Austrian Clinical Practice,Kidney Insufficiency|Secondary Hyperparathyroidism,2010-02-25,2013-12-31,2013-12-31,Observational,Completed,,AbbVie,"AbbVie (prior sponsor, Abbott)",Site Reference ID/Investigator# 64522|Site Reference ID/Investigator# 53506|Site Reference ID/Investigator# 53524|Site Reference ID/Investigator# 74733|Site Reference ID/Investigator# 64523|Site Reference ID/Investigator# 53525|Site Reference ID/Investigator# 53526|Site Reference ID/Investigator# 69662|Site Reference ID/Investigator# 53508|Site Reference ID/Investigator# 53523|Site Reference ID/Investigator# 53507|Site Reference ID/Investigator# 28352|Site Reference ID/Investigator# 28359|Site Reference ID/Investigator# 28305|Site Reference ID/Investigator# 28306|Site Reference ID/Investigator# 28003|Site Reference ID/Investigator# 81613|Site Reference ID/Investigator# 28017|Site Reference ID/Investigator# 28301|Site Reference ID/Investigator# 28296|Site Reference ID/Investigator# 28021|Site Reference ID/Investigator# 28024|Site Reference ID/Investigator# 28303|Site Reference ID/Investigator# 54050|Site Reference ID/Investigator# 28022|Site Reference ID/Investigator# 30862|Site Reference ID/Investigator# 28007|Site Reference ID/Investigator# 28304|Site Reference ID/Investigator# 28014|Site Reference ID/Investigator# 28023|Site Reference ID/Investigator# 28134|Site Reference ID/Investigator# 28037|Site Reference ID/Investigator# 43903|Site Reference ID/Investigator# 99777|Site Reference ID/Investigator# 28284|Site Reference ID/Investigator# 124118|Site Reference ID/Investigator# 54054|Site Reference ID/Investigator# 48864|Site Reference ID/Investigator# 72343|Site Reference ID/Investigator# 28029|Site Reference ID/Investigator# 28287|Site Reference ID/Investigator# 28276|Site Reference ID/Investigator# 28351|Site Reference ID/Investigator# 28280|Site Reference ID/Investigator# 48865|Site Reference ID/Investigator# 28300|Site Reference ID/Investigator# 28011|Site Reference ID/Investigator# 124119|Site Reference ID/Investigator# 28019|Site Reference ID/Investigator# 28135|Site Reference ID/Investigator# 28286|Site Reference ID/Investigator# 28353|Site Reference ID/Investigator# 28044|Site Reference ID/Investigator# 48863|Site Reference ID/Investigator# 28013|Site Reference ID/Investigator# 28025|Site Reference ID/Investigator# 28290|Site Reference ID/Investigator# 10982|Site Reference ID/Investigator# 28291|Site Reference ID/Investigator# 28036|Site Reference ID/Investigator# 28302|Site Reference ID/Investigator# 54051|Site Reference ID/Investigator# 28278|Site Reference ID/Investigator# 99778|Site Reference ID/Investigator# 99776|Site Reference ID/Investigator# 124120|Site Reference ID/Investigator# 28275|Site Reference ID/Investigator# 43904|Site Reference ID/Investigator# 28277|Site Reference ID/Investigator# 28297|Site Reference ID/Investigator# 28307|Site Reference ID/Investigator# 28295|Site Reference ID/Investigator# 28294|Site Reference ID/Investigator# 48862|Site Reference ID/Investigator# 28042|Site Reference ID/Investigator# 28282|Site Reference ID/Investigator# 28033|Site Reference ID/Investigator# 54052|Site Reference ID/Investigator# 28005|Site Reference ID/Investigator# 28020|Site Reference ID/Investigator# 28293|Site Reference ID/Investigator# 28018|Site Reference ID/Investigator# 28298|Site Reference ID/Investigator# 28292|Site Reference ID/Investigator# 48882|Site Reference ID/Investigator# 28299|Site Reference ID/Investigator# 28279,,Austria|Germany,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01083849
NCT01084356,parathyroid neoplasms,Evaluation of a New CZT System for Imaging in Routine Nuclear Medicine Examination,Evaluation of a New CZT System,Parathyroid Adenoma|Thyroid Adenoma,2010-03-09,2011-03-31,,Observational,Unknown status,,Tel-Aviv Sourasky Medical Center,Tel-Aviv Sourasky Medical Center,"Department of Nuclear Medicine, Tel Aviv Sourasky Medical Center",,Israel,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01084356
NCT01084356,thyroid neoplasms,Evaluation of a New CZT System for Imaging in Routine Nuclear Medicine Examination,Evaluation of a New CZT System,Parathyroid Adenoma|Thyroid Adenoma,2010-03-09,2011-03-31,,Observational,Unknown status,,Tel-Aviv Sourasky Medical Center,Tel-Aviv Sourasky Medical Center,"Department of Nuclear Medicine, Tel Aviv Sourasky Medical Center",,Israel,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01084356
NCT01087619,hyperparathyroidism,Primary Hyperparathyroidism in Patients Older Than 65 Years: A Prospective Randomized Trial of Surgical Treatment Compared With Follow-up,Surgery for Primary Hyperparathyroidism (pHPT) in Patients Older Than 65 Years Compared With Follow-up,Primary Hyperparathyroidism,2010-03-15,2023-12-31,2025-12-31,Interventional,Recruiting,Not Applicable,Region Skane,Region Skane,"Skåne University Hospital, Department of Surgery, Lund",Procedure,Sweden,66.0,120.0,[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01087619
NCT01089335,"thyroid cancer, papillary",Sentinel Node Investigation in Patients With Highly Differentiated Papillary Thyroid Carcinoma and in Patients With Thyroid Neoplasia of Unclear Malignant Potential,Sentinel Lymphnode in Patients With Papillary Thyroid Carcinoma and in Patients With Suspected Thyroid Neoplasia,Thyroid Cancer|Thyroid Neoplasms,2010-03-16,2018-12-31,2018-12-31,Observational,Completed,,Region Skane,Region Skane,"Department of Surgery and Department of Imaging, Skåne University Hospital",Procedure,Sweden,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT01089335
NCT01100723,hyperparathyroidism,Trial to Optimize Mineral Outcomes in End Stage Renal Disease (ESRD) Patients,Trial to Optimize Mineral Outcomes in Dialysis Patients,Chronic Kidney Disease|Secondary Hyperparathyroidism,2010-04-07,2011-08-31,2011-08-31,Interventional,Completed,Phase 4,"University of Colorado, Denver","University of Colorado, Denver","Lynchburg Nephrology Associates, P.L.L.C.",Other,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01100723
NCT01101113,hyperparathyroidism,Phase 4 Study of Cinacalcet Efficacy in Combination With Vitamin D for the Treatment of Secondary Hyperparathyroidism in Peritoneal Dialysis Patients,Cinacalcet stUdy for Peritoneal Dialysis Patients In Double Arm on the Lowing Effect OF iPTH Level,Secondary Hyperparathyroidism,2010-04-04,2012-03-31,2012-06-30,Interventional,Completed,Phase 4,Seoul National University Hospital,Jeil-Kirin Pharmaceutical Inc.|Seoul National University Hospital,Seoul National University Hospital|Kyungpook National University|Gil Hospital|Hallym University Sacred Hospital|Seoul National University Bundang Hospital|Eulji University|Samsung Medical Center,Drug|Drug,"Korea, Republic of",18.0,70.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01101113
NCT01102127,thyroid nodule,Accuracy of Ultrasound Elastastography in Thyroid Nodular Disease.,Elastography in Thyroid Nodules,Nodular Goiter|Thyroid Cancer,2010-04-12,2010-09-30,2010-09-30,Observational,Completed,,Castilla-León Health Service,Castilla-León Health Service,Complejo Asistencial de León,Device,Spain,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT01102127
NCT01103206,hyperparathyroidism,Evaluation of a Parathyroid Hormone Suppression Test With Cinacalcet. Comparison: 1- With the Results of the Intravenous Calcium Suppression Test in Healthy Controls; 2- Between Healthy Controls and Patients With Primary Hyperparathyroidism.,Evaluation of a Cincalcet Suppression Test,Parathyroid Hormone Suppression Test With Cinacalcet,2010-04-12,2013-02-28,2013-02-28,Interventional,Completed,Phase 4,"University Hospital, Rouen","Institut National de la Santé Et de la Recherche Médicale, France|University Hospital, Rouen",University hospital,Drug|Drug|Drug,France,18.0,70.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01103206
NCT01103557,"thyroid cancer, papillary",The Effectiveness of Prophylactic Selective Lateral Neck Dissection in Papillary Thyroid Carcinoma Patients With Central Neck Metastasis,Prophylactic Selective Lateral Neck Dissection in Patients With Papillary Thyroid Carcinoma,Lymphatic Metastasis|Thyroid Neoplasm,2010-04-12,,,Interventional,Completed,Not Applicable,Pusan National University Hospital,Pusan National University Hospital,,Procedure,,20.0,76.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT01103557
NCT01106443,thyroid neoplasms,Central Compartment Neck Dissection Total Thyroidectomy: a Randomized Controlled Trial,Central Compartment Neck Dissection With Thyroidectomy,Indeterminate Thyroid Nodules,2010-04-14,2013-07-31,2016-10-31,Interventional,Terminated,Not Applicable,University of Alberta,University of Alberta,University of Alberta|Dalhouise University,Procedure|Procedure|Procedure|Procedure,Canada,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01106443
NCT01106443,thyroid nodule,Central Compartment Neck Dissection Total Thyroidectomy: a Randomized Controlled Trial,Central Compartment Neck Dissection With Thyroidectomy,Indeterminate Thyroid Nodules,2010-04-14,2013-07-31,2016-10-31,Interventional,Terminated,Not Applicable,University of Alberta,University of Alberta,University of Alberta|Dalhouise University,Procedure|Procedure|Procedure|Procedure,Canada,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT01106443
NCT01109420,"thyroid cancer, papillary",Clinical and Genetic Studies in Familial Non-Medullary Thyroid Cancer,Clinical and Genetic Studies in Familial Non-medullary Thyroid Cancer,Non-Medullary Thyroid Cancer,2010-04-22,,,Observational,Recruiting,,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"National Institutes of Health Clinical Center, 9000 Rockville Pike",,United States,7.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT01109420
NCT01114503,goiter,"A Randomised, Comparator Controlled, Two Part, Open-label Study to Evaluate the Safety, Tolerability and Pharmacodynamics of Multiple Doses of Otelixizumab in Patients With Thyroid Orbitopathy",A Safety and Tolerability Study of Otelixizumab in Thyroid Eye Disease,Graves Ophthalmopathy,2010-04-29,2012-08-29,2012-08-29,Interventional,Terminated,Phase 2,GlaxoSmithKline,GlaxoSmithKline,GSK Investigational Site,Drug|Drug|Drug|Drug|Drug|Drug,United Kingdom,18.0,75.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01114503
NCT01114503,hyperthyroidism,"A Randomised, Comparator Controlled, Two Part, Open-label Study to Evaluate the Safety, Tolerability and Pharmacodynamics of Multiple Doses of Otelixizumab in Patients With Thyroid Orbitopathy",A Safety and Tolerability Study of Otelixizumab in Thyroid Eye Disease,Graves Ophthalmopathy,2010-04-29,2012-08-29,2012-08-29,Interventional,Terminated,Phase 2,GlaxoSmithKline,GlaxoSmithKline,GSK Investigational Site,Drug|Drug|Drug|Drug|Drug|Drug,United Kingdom,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01114503
NCT01114503,graves disease,"A Randomised, Comparator Controlled, Two Part, Open-label Study to Evaluate the Safety, Tolerability and Pharmacodynamics of Multiple Doses of Otelixizumab in Patients With Thyroid Orbitopathy",A Safety and Tolerability Study of Otelixizumab in Thyroid Eye Disease,Graves Ophthalmopathy,2010-04-29,2012-08-29,2012-08-29,Interventional,Terminated,Phase 2,GlaxoSmithKline,GlaxoSmithKline,GSK Investigational Site,Drug|Drug|Drug|Drug|Drug|Drug,United Kingdom,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT01114503
NCT01115543,hyperparathyroidism,A Randomized Trial Comparing Pulse Calcitriol and Alfacalcidol for the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients,Efficacy and Safety of Alfacalcidol Compared to Calcitriol for Treatment of Secondary Hyperparathyroidism,End Stage Renal Disease|Secondary Hyperparathyroidism,2010-05-01,2009-08-31,2009-08-31,Interventional,Completed,Phase 4,Mahidol University,Mahidol University,Siriraj Medical School,Drug,Thailand,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01115543
NCT01118065,thyroid neoplasms,"A Phase II Study to Investigate the Efficacy of RAD001 (Afinitor®, Everolimus) in Patients With Irresectable Recurrent or Metastatic Differentiated, Undifferentiated (Anaplastic) and Medullary Thyroid Carcinoma","Everolimus in Treating Patients With Progressive or Recurrent, Unresectable, or Metastatic Thyroid Cancer",Head and Neck Cancer,2010-05-05,2012-05-31,,Interventional,Unknown status,Phase 2,National Cancer Institute (NCI),Leiden University Medical Center,Leiden University Medical Center,Drug,Netherlands,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01118065
NCT01127503,hypoparathyroidism,"A Double-Blind, Placebo-Controlled, Multi-Center, Randomized Trial of the Safety and Efficacy of Metyrosine (Demser®) for the Treatment of Psychotic Disorders in Patients With Velo-Cardio-Facial Syndrome",Metyrosine (Demser®) for the Treatment of Psychotic Disorders in Patients With Velocardiofacial Syndrome,Psychosis|Velo-cardio-facial Syndrome,2010-05-19,2010-11-30,2011-09-30,Interventional,Terminated,Phase 2,"Bausch Health Americas, Inc.","Bausch Health Americas, Inc.",VCFS International Center,Drug|Drug,United States,16.0,65.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01127503
NCT01134315,hyperparathyroidism,"A Prospective, Multicenter Study to Evaluate the Safety of Paricalcitol Capsules as Determined by Hypercalcemia in Pediatric Patients Ages 0 to 16 With Chronic Kidney Disease (CKD) Stage 5 Receiving Peritoneal Dialysis (PD) Within Current Clinical Practice",Study to Evaluate Safety of Vitamin D Receptor Activators in Patients Ages 0 to 16 With Chronic Kidney Disease Stage 5 Receiving Peritoneal Dialysis Within Current Clinical Practice,End-Stage Renal Disease|Secondary Hyperparathyroidism,2010-05-28,2012-05-31,2012-05-31,Observational,Terminated,,AbbVie,"AbbVie (prior sponsor, Abbott)|North America Pediatric Renal Trials and Collaborative Studies (NAPRTCS)",Site Reference ID/Investigator# 37082|Site Reference ID/Investigator# 26762|Site Reference ID/Investigator# 28529|Site Reference ID/Investigator# 26748|Site Reference ID/Investigator# 37582|Site Reference ID/Investigator# 39973|Site Reference ID/Investigator# 26769|Site Reference ID/Investigator# 26768|Site Reference ID/Investigator# 26747|Site Reference ID/Investigator# 26749|Site Reference ID/Investigator# 26751|Site Reference ID/Investigator# 26765|Site Reference ID/Investigator# 28528|Site Reference ID/Investigator# 26763|Site Reference ID/Investigator# 28526|Site Reference ID/Investigator# 26758|Site Reference ID/Investigator# 40382|Site Reference ID/Investigator# 26759,Drug|Drug,United States,0.0,16.0,[0-17],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01134315
NCT01134549,hyperparathyroidism,"A Double-Blind, Randomized, Placebo-Controlled, Rising Single Intravenous Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of KAI-4169 in Healthy Male Volunteers","Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Healthy Male Volunteers","Hyperparathyroidism, Secondary",2010-05-28,2010-07-31,2010-07-31,Interventional,Completed,Phase 1,KAI Pharmaceuticals,KAI Pharmaceuticals|Nucleus Network Ltd,,Drug|Drug,Australia,18.0,45.0,[18-65],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01134549
NCT01134562,hyperparathyroidism,"A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety and Tolerability of Single Ascending Doses of KAI-4169 in Hemodialysis Subjects With Secondary Hyperparathyroidism","Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism","Hyperparathyroidism, Secondary",2010-05-28,2011-04-02,2011-04-02,Interventional,Completed,Phase 1,KAI Pharmaceuticals,KAI Pharmaceuticals,,Drug|Drug,Australia|United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01134562
NCT01137097,thyroid neoplasms,Value of Sentinel Lymph Node Biopsy to Lateral Neck Lymph Node in Thyroid Carcinoma: Prospective Study,Lateral Neck Sentinel Lymph Node Biopsy(LSLNB)in PTC,Thyroid Neoplasm,2010-06-02,2011-01-31,2011-01-31,Interventional,Completed,Phase 2/Phase 3,Samsung Medical Center,Samsung Medical Center,Samsung Medical Center,Procedure,"Korea, Republic of",18.0,80.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01137097
NCT01138475,hyperparathyroidism,"A Prospective, Randomized, Double-Blind, Double-Dummy,Placebo-Controlled, Parallel-Group, Pilot Trial Of Paricalcitol and Cholecalciferol(Vitamin D3) in the Treatment Of Secondary Hyperparathyroidism in Patients After ROUX-EN-Y Gastric Bypass Surgery",Trial Of Paricalcitol and Cholecalciferol(Vitamin D3) in the Treatment Of Secondary Hyperparathyroidism in Patients After ROUX-EN-Y Gastric Bypass Surgery,Gastric Bypass|Parathyroid Hormone,2010-06-04,2015-08-31,2015-08-31,Interventional,Completed,Phase 3,William Beaumont Hospitals,"Abbott|Kerstyn C. Zalesin, M.D.",William Beaumont Health Center,Drug|Drug|Drug,United States,18.0,100.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01138475
NCT01149291,hyperparathyroidism,"A 18 Months, Post-marketing Observational Study to Follow-up Patients With End Stage Renal Disease Undergoing Hemodialysis, Receiving sVDRA's for Prevention and Treatment of Secondary Hyperparathyroidism","A Study to Follow-up Patients With End Stage Renal Disease Undergoing Hemodialysis, Receiving Selective Vitamin D Receptor Activator's for Prevention and Treatment of Secondary Hyperparathyroidism",End Stage Renal Disease|Secondary Hyperparathyroidism,2010-06-22,2014-12-31,2014-12-31,Observational,Completed,,AbbVie,"AbbVie (prior sponsor, Abbott)",Site Reference ID/Investigator# 37822|Site Reference ID/Investigator# 68286|Site Reference ID/Investigator# 40677|Site Reference ID/Investigator# 85153|Site Reference ID/Investigator# 40672|Site Reference ID/Investigator# 40674|Site Reference ID/Investigator# 40678|Site Reference ID/Investigator# 40686|Site Reference ID/Investigator# 61585|Site Reference ID/Investigator# 63764|Site Reference ID/Investigator# 63765|Site Reference ID/Investigator# 63766|Site Reference ID/Investigator# 69973|Site Reference ID/Investigator# 63763|Site Reference ID/Investigator# 48127|Site Reference ID/Investigator# 64444|Site Reference ID/Investigator# 40684|Site Reference ID/Investigator# 48132|Site Reference ID/Investigator# 68283|Site Reference ID/Investigator# 68281|Site Reference ID/Investigator# 68282|Site Reference ID/Investigator# 69974,,Turkey,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01149291
NCT01153360,euthyroid sick syndromes,Peri-operative Oral Triiodothyronine Replacement Therapy to Decrease the Risk of Transient Atrial Fibrillation After Off-pump Coronary Artery Bypass Surgery,Peri-operative Oral Triiodothyronine Replacement Therapy to Decrease the Risk of Transient Atrial Fibrillation After Off-pump Coronary Artery Bypass Surgery,Non-thyroidal Illness Syndrome,2010-06-29,2011-08-31,2011-09-30,Interventional,Completed,Not Applicable,Yonsei University,Yonsei University,Severance Hospital,Drug|Drug,"Korea, Republic of",20.0,75.0,[18-65]|[65 and more],Euthyroid Sick Syndromes,Euthyroid Sick Syndromes,https://clinicaltrials.gov/ct2/show/NCT01153360
NCT01163565,hyperthyroidism,A Prospective Randomized Equivalence Trial to Evaluate the Safety of the Ligasure in Thyroid Surgery,A Prospective Randomized Equivalence Trial to Evaluate the Safety of the Ligasure in Thyroid Surgery,Grave's Disease|Multinodular Goitre|Thyroid Nodule,2010-07-14,2012-09-30,2012-12-31,Interventional,Completed,Not Applicable,University of Alberta,Medtronic - MITG|University of Alberta,Walter C Mackenzie Health Sciences Centre,Device,Canada,18.0,85.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01163565
NCT01163565,graves disease,A Prospective Randomized Equivalence Trial to Evaluate the Safety of the Ligasure in Thyroid Surgery,A Prospective Randomized Equivalence Trial to Evaluate the Safety of the Ligasure in Thyroid Surgery,Grave's Disease|Multinodular Goitre|Thyroid Nodule,2010-07-14,2012-09-30,2012-12-31,Interventional,Completed,Not Applicable,University of Alberta,Medtronic - MITG|University of Alberta,Walter C Mackenzie Health Sciences Centre,Device,Canada,18.0,85.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT01163565
NCT01163565,thyroid neoplasms,A Prospective Randomized Equivalence Trial to Evaluate the Safety of the Ligasure in Thyroid Surgery,A Prospective Randomized Equivalence Trial to Evaluate the Safety of the Ligasure in Thyroid Surgery,Grave's Disease|Multinodular Goitre|Thyroid Nodule,2010-07-14,2012-09-30,2012-12-31,Interventional,Completed,Not Applicable,University of Alberta,Medtronic - MITG|University of Alberta,Walter C Mackenzie Health Sciences Centre,Device,Canada,18.0,85.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01163565
NCT01163565,goiter,A Prospective Randomized Equivalence Trial to Evaluate the Safety of the Ligasure in Thyroid Surgery,A Prospective Randomized Equivalence Trial to Evaluate the Safety of the Ligasure in Thyroid Surgery,Grave's Disease|Multinodular Goitre|Thyroid Nodule,2010-07-14,2012-09-30,2012-12-31,Interventional,Completed,Not Applicable,University of Alberta,Medtronic - MITG|University of Alberta,Walter C Mackenzie Health Sciences Centre,Device,Canada,18.0,85.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01163565
NCT01164176,thyroid neoplasms,An Open Label Multi-Center Phase II Study of RAD001 in Advanced Thyroid Cancer,Everolimus in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer,Head and Neck Cancer,2010-07-15,2014-10-31,2014-10-31,Interventional,Completed,Phase 2,Yonsei University,Yonsei University,Hallym University Sacred Heart Hospital|Yeungnam University Medical Center|National Cancer Center - Korea|Kosin Medical Center Gospel Hospital|Seoul National University Hospital|Yonsei Cancer Center at Yonsei University Medical Center|Gangnam Severance Hospital,Drug|Other,"Korea, Republic of",18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01164176
NCT01167309,hyperparathyroidism,"LEO 27847 - Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Secondary Hyperparathyroidism Patients With Chronic Kidney Disease","LEO 27847 - Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Secondary Hyperparathyroidism Patients",Secondary Hyperparathyroidism,2010-07-02,2011-10-31,2011-12-31,Interventional,Completed,Phase 1,LEO Pharma,LEO Pharma,CRS Clinical Research Services Kiel GmbH|Centralny Szpital Kliniczny MON,Drug,Germany|Poland,18.0,75.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01167309
NCT01171690,hypoparathyroidism,Pilot Study of Teriparatide for Postsurgical Hypoparathyroidism,Teriparatide for Postsurgical Hypoparathyroidism,Hypoparathyroidism Post-surgical,2010-07-27,2013-12-31,2013-12-31,Interventional,Terminated,Phase 2,Mayo Clinic,Mayo Clinic,Mayo Clinic,Drug,United States,18.0,80.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01171690
NCT01178450,hyperparathyroidism,"A Prospective, Randomized Trial to Compare Subtotal Parathyroidectomy Versus Cinacalcet in the Treatment of Persistent Secondary Hyperparathyroidism Post Renal Transplantation",Parathyroidectomy vs Cinacalcet in the Treatment of Secondary Hyperparathyroidism Post Renal Transplantation,Secondary Hyperparathyroidism,2010-04-19,2014-09-30,2014-09-30,Interventional,Completed,Phase 4,Hospital Universitari de Bellvitge,Josep M Cruzado,Hospital Universitari de Bellvitge|Hospital Clinic de Barcelona,Procedure|Drug,Spain,18.0,80.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01178450
NCT01181531,hyperparathyroidism,"A Multicenter, Randomized, Open Label Study to Compare the Efficacy of Cinacalcet Versus Traditional Vitamin D Therapy for Management of Secondary Hyperparathyroidism Among Subjects Undergoing Hemodialysis",Compare the Efficacy of Cinacalcet vs Traditional Vitamin D for Secondary Hyperparathyroidism (SHPT) Among Subjects Undergoing Hemodialysis,"Hyperparathyroidism, Secondary",2010-08-12,2012-07-17,2012-08-14,Interventional,Completed,Phase 4,Amgen,Amgen,,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01181531
NCT01182285,thyroid neoplasms,A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Origin,A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Cell Origin,Thyroid Neoplasm,2010-08-13,2015-09-28,2016-04-28,Interventional,Completed,Phase 2,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),"National Institutes of Health Clinical Center, 9000 Rockville Pike",Drug|Drug,United States,18.0,100.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01182285
NCT01182584,goiter,Application of Digital Infrared Thermal Imaging in Thyroid Disease and Associated Ophthalmopathy and Dermopathy,Application of Digital Infrared Thermal Imaging (DITI) in Graves' Disease,Graves' Disease,2010-08-12,2011-10-31,2011-12-31,Observational,Unknown status,,National Taiwan University Hospital,National Taiwan University Hospital,National Taiwan University,,Taiwan,16.0,60.0,[0-17]|[18-65],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01182584
NCT01182584,graves disease,Application of Digital Infrared Thermal Imaging in Thyroid Disease and Associated Ophthalmopathy and Dermopathy,Application of Digital Infrared Thermal Imaging (DITI) in Graves' Disease,Graves' Disease,2010-08-12,2011-10-31,2011-12-31,Observational,Unknown status,,National Taiwan University Hospital,National Taiwan University Hospital,National Taiwan University,,Taiwan,16.0,60.0,[0-17]|[18-65],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT01182584
NCT01182584,hyperthyroidism,Application of Digital Infrared Thermal Imaging in Thyroid Disease and Associated Ophthalmopathy and Dermopathy,Application of Digital Infrared Thermal Imaging (DITI) in Graves' Disease,Graves' Disease,2010-08-12,2011-10-31,2011-12-31,Observational,Unknown status,,National Taiwan University Hospital,National Taiwan University Hospital,National Taiwan University,,Taiwan,16.0,60.0,[0-17]|[18-65],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01182584
NCT01208051,"thyroid cancer, papillary",Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer,Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer,Refractory Differentiated Thyroid Gland Carcinoma|Refractory Thyroid Gland Follicular Carcinoma|Refractory Thyroid Gland Hurthle Cell Carcinoma|Refractory Thyroid Gland Papillary Carcinoma|Unresectable Thyroid Gland Carcinoma,2010-09-22,2020-02-01,2020-02-01,Interventional,Completed,Phase 1/Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),City of Hope Comprehensive Cancer Center|USC / Norris Comprehensive Cancer Center|University of California Davis Comprehensive Cancer Center P2C|University of California Davis Comprehensive Cancer Center|City of Hope South Pasadena|University of Colorado Hospital|Moffitt Cancer Center|Northwestern University|University of Chicago Comprehensive Cancer Center|Decatur Memorial Hospital|NorthShore University HealthSystem-Evanston Hospital|Ingalls Memorial Hospital|UC Comprehensive Cancer Center at Silver Cross|Illinois CancerCare-Peoria|Fort Wayne Medical Oncology and Hematology Inc-Parkview|Indiana University/Melvin and Bren Simon Cancer Center|University of Maryland/Greenebaum Cancer Center|University of Michigan Comprehensive Cancer Center|Wayne State University/Karmanos Cancer Institute|Minnesota Oncology Hematology PA-Minneapolis|Metro Minnesota Community Oncology Research Consortium|Washington University School of Medicine|Mercy Hospital Saint Louis|Rutgers Cancer Institute of New Jersey|UNC Lineberger Comprehensive Cancer Center|Penn State Children's Hospital|Fox Chase Cancer Center|Vanderbilt University/Ingram Cancer Center|M D Anderson Cancer Center|University of Wisconsin Hospital and Clinics|Tom Baker Cancer Centre|London Regional Cancer Program|University Health Network-Princess Margaret Hospital,Drug|Drug|Other|Drug,Canada|United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT01208051
NCT01208051,"adenocarcinoma, follicular",Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer,Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer,Refractory Differentiated Thyroid Gland Carcinoma|Refractory Thyroid Gland Follicular Carcinoma|Refractory Thyroid Gland Hurthle Cell Carcinoma|Refractory Thyroid Gland Papillary Carcinoma|Unresectable Thyroid Gland Carcinoma,2010-09-22,2020-02-01,2020-02-01,Interventional,Completed,Phase 1/Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),City of Hope Comprehensive Cancer Center|USC / Norris Comprehensive Cancer Center|University of California Davis Comprehensive Cancer Center P2C|University of California Davis Comprehensive Cancer Center|City of Hope South Pasadena|University of Colorado Hospital|Moffitt Cancer Center|Northwestern University|University of Chicago Comprehensive Cancer Center|Decatur Memorial Hospital|NorthShore University HealthSystem-Evanston Hospital|Ingalls Memorial Hospital|UC Comprehensive Cancer Center at Silver Cross|Illinois CancerCare-Peoria|Fort Wayne Medical Oncology and Hematology Inc-Parkview|Indiana University/Melvin and Bren Simon Cancer Center|University of Maryland/Greenebaum Cancer Center|University of Michigan Comprehensive Cancer Center|Wayne State University/Karmanos Cancer Institute|Minnesota Oncology Hematology PA-Minneapolis|Metro Minnesota Community Oncology Research Consortium|Washington University School of Medicine|Mercy Hospital Saint Louis|Rutgers Cancer Institute of New Jersey|UNC Lineberger Comprehensive Cancer Center|Penn State Children's Hospital|Fox Chase Cancer Center|Vanderbilt University/Ingram Cancer Center|M D Anderson Cancer Center|University of Wisconsin Hospital and Clinics|Tom Baker Cancer Centre|London Regional Cancer Program|University Health Network-Princess Margaret Hospital,Drug|Drug|Other|Drug,Canada|United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT01208051
NCT01219855,hyperparathyroidism,"A Randomized, Double Blind, Placebo-Controlled, Repeat Dose, Safety, Efficacy and Pharmacokinetic/Pharmacodynamic Study of CTAP101 Capsules in Subjects With Chronic Kidney Disease, Vitamin D Insufficiency and Secondary Hyperparathyroidism",Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT),Chronic Kidney Disease|Secondary Hyperparathyroidism|Vitamin D Insufficiency,2010-10-11,2011-11-30,2011-11-30,Interventional,Completed,Phase 2/Phase 3,"OPKO Health, Inc.","OPKO Health, Inc.","OPKO Health, Inc",Drug|Drug|Drug|Drug|Drug,United States,18.0,85.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01219855
NCT01220050,hyperparathyroidism,"A PROSPECTIVE, PILOT, CROSS-OVER STUDY TO ASSESS THE EFFICACY OF PARICALCITOL IN REDUCING PARATHYROID HORMONE LEVELS AND AMELIORATING MARKERS OF BONE REMODELLING IN RENAL TRANSPLANT RECIPIENTS WITH SECONDARY HYPERPARATHYROIDISM",Paricalcitol in Reducing Parathyroid Hormone Levels and Ameliorating Markers of Bone Remodelling in Renal Transplant Recipients With Secondary Hyperparathyroidism,Renal Transplant|Secondary Hyperparathyroidism,2010-10-11,2012-07-31,2013-02-28,Interventional,Completed,Phase 2,Mario Negri Institute for Pharmacological Research,Mario Negri Institute for Pharmacological Research,Mario Negri Institute - Clinical Research Center for Rare Diseases,Drug|Drug,Italy,18.0,80.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01220050
NCT01222026,hyperparathyroidism,Primary Hyperparathyroidism: Does a Systematic Treatment Improve the Calcium- and Bone Metabolism After Successful Surgery? - Part I,Systematic Treatment After Successful Surgical Treatment for Primary Hyperparathyroidism With Strontium Ranelate,Osteopenia|Osteoporosis|Primary Hyperparathyroidism,2010-10-15,2014-12-31,2014-12-31,Interventional,Completed,Phase 4,Medical University of Vienna,Medical University of Vienna|National Bank of Austria,"Medical University Vienna, General Hospital Vienna (AKH Wien)",Drug|Drug,Austria,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01222026
NCT01224782,hyperparathyroidism,"Evaluation of Treatment With Zemplar Capsules in the Therapy of Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) Stage 3 or 4 in the Conditions of Routine Clinical Practice. A Multi-country, Multi-center Post Marketing Observational Study in Routine Clinical Use in Eastern European Countries.",Evaluation of Treatment With Zemplar Capsules in the Therapy of Secondary Hyperparathyroidism (SHPT),Chronic Kidney Disease|Secondary Hyperparathyroidism,2010-09-27,2013-08-31,2013-08-31,Observational,Completed,,AbbVie,"AbbVie (prior sponsor, Abbott)",Site Reference ID/Investigator# 66544|Site Reference ID/Investigator# 47685|Site Reference ID/Investigator# 66546|Site Reference ID/Investigator# 47683|Site Reference ID/Investigator# 66543|Site Reference ID/Investigator# 47684|Site Reference ID/Investigator# 66542|Site Reference ID/Investigator# 66545|Site Reference ID/Investigator# 47687|Site Reference ID/Investigator# 43449|Site Reference ID/Investigator# 46744|Site Reference ID/Investigator# 73353|Site Reference ID/Investigator# 47690|Site Reference ID/Investigator# 46742|Site Reference ID/Investigator# 49542|Site Reference ID/Investigator# 67442|Site Reference ID/Investigator# 67443|Site Reference ID/Investigator# 51003|Site Reference ID/Investigator# 51004|Site Reference ID/Investigator# 43522|Site Reference ID/Investigator# 43523|Site Reference ID/Investigator# 43524|Site Reference ID/Investigator# 45483|Site Reference ID/Investigator# 43453|Site Reference ID/Investigator# 46743|Site Reference ID/Investigator# 51008|Site Reference ID/Investigator# 47842|Site Reference ID/Investigator# 68462|Site Reference ID/Investigator# 51009|Site Reference ID/Investigator# 51005|Site Reference ID/Investigator# 51011|Site Reference ID/Investigator# 48210|Site Reference ID/Investigator# 45487|Site Reference ID/Investigator# 51012|Site Reference ID/Investigator# 51002|Site Reference ID/Investigator# 43448|Site Reference ID/Investigator# 45485|Site Reference ID/Investigator# 42992|Site Reference ID/Investigator# 42879|Site Reference ID/Investigator# 42880|Site Reference ID/Investigator# 42881|Site Reference ID/Investigator# 42882|Site Reference ID/Investigator# 42883|Site Reference ID/Investigator# 42963|Site Reference ID/Investigator# 42970|Site Reference ID/Investigator# 42877|Site Reference ID/Investigator# 42878|Site Reference ID/Investigator# 42973|Site Reference ID/Investigator# 42975|Site Reference ID/Investigator# 42976|Site Reference ID/Investigator# 42981|Site Reference ID/Investigator# 42982|Site Reference ID/Investigator# 42980|Site Reference ID/Investigator# 63623|Site Reference ID/Investigator# 43009|Site Reference ID/Investigator# 43002|Site Reference ID/Investigator# 43003|Site Reference ID/Investigator# 43006|Site Reference ID/Investigator# 42991|Site Reference ID/Investigator# 42988|Site Reference ID/Investigator# 42989|Site Reference ID/Investigator# 42999|Site Reference ID/Investigator# 43000|Site Reference ID/Investigator# 42979|Site Reference ID/Investigator# 42984|Site Reference ID/Investigator# 42985|Site Reference ID/Investigator# 42987|Site Reference ID/Investigator# 42994|Site Reference ID/Investigator# 42995,,Bulgaria|Czech Republic|Romania,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01224782
NCT01225016,thyroid neoplasms,Characterization of Thyroid Nodules Using Contrast Enhanced Ultrasound,Characterization of Thyroid Nodules Using Contrast Enhanced Ultrasound,Thyroid Nodules,2010-10-14,2011-12-31,2011-12-31,Interventional,Withdrawn,Not Applicable,University of Alabama at Birmingham,University of Alabama at Birmingham,Universith of Alabama at Birmingham,Drug,United States,19.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01225016
NCT01225016,thyroid nodule,Characterization of Thyroid Nodules Using Contrast Enhanced Ultrasound,Characterization of Thyroid Nodules Using Contrast Enhanced Ultrasound,Thyroid Nodules,2010-10-14,2011-12-31,2011-12-31,Interventional,Withdrawn,Not Applicable,University of Alabama at Birmingham,University of Alabama at Birmingham,Universith of Alabama at Birmingham,Drug,United States,19.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT01225016
NCT01226914,thyroid neoplasms,"A Randomized, Double-Blind, Placebo-Controlled Trial Comparing Wound Drainage and Post-operative Complications With and Without the Use of EVICEL™ Fibrin Sealant in Thyroidectomy",A Trial Comparing Wound Drainage and Post-operative Complications With and Without the Use of EVICEL™ Fibrin Sealant in Thyroidectomy,Goiter|Thyroid Neoplasm,2010-10-21,2014-07-31,2014-07-31,Interventional,Completed,Not Applicable,Medical University of South Carolina,"Ethicon, Inc.|Medical University of South Carolina",,Drug,,18.0,99.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01226914
NCT01227499,goiter,Differential Diagnosis Value of Peak Systolic Velocity of Thyroid Superior Artery Using Color Flow Doppler Sonography in Transient Thyrotoxicosis Caused by Thyroiditis and Graves Disease,Differential Diagnosis of STA-PSV in Thyrotoxicosis,Graves Disease|Peak Systolic Velocity of Superior Thyroid Artery|Thyroiditis|Thyrotoxicosis,2010-10-22,2011-11-30,2011-11-30,Observational,Completed,,Huashan Hospital,Fudan University|xiaolong zhao|Zhongda Hospital,Xiaolong Zhao,,China,15.0,85.0,[0-17]|[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01227499
NCT01228786,hyperparathyroidism,Transcriptional and Translational Regulation of Vitamin D Receptor (VDR) and Calcium Sensing Receptor (CaSR) in Patients With Sporadic Primary Hyperparathyroidism,"Regulation of Vitamin D Receptor (VDR),Calcium Sensing Receptor (CaSR), Cyclin D1,Ki67 and Proliferating Cell Nuclear Antigen (PCNA) in Primary Hyperparathyroidism",Primary Hyperparathyroidism (PHPT),2010-10-26,2012-12-31,2013-06-30,Observational,Unknown status,,Postgraduate Institute of Medical Education and Research,Postgraduate Institute of Medical Education and Research,PGIMER,,India,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01228786
NCT01229865,thyroid neoplasms,,Safety and Efficacy of VB-111 in Subjects With Advanced Differentiated Thyroid Cancer,Differential Thyroid Cancer,2010-10-26,2014-10-31,2016-06-30,Interventional,Completed,Phase 2,Vascular Biogenics Ltd. operating as VBL Therapeutics,Vascular Biogenics Ltd. operating as VBL Therapeutics,Mayo Clinic|Massachusetts General Hospital|Mayo Clinic,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01229865
NCT01254565,hyperparathyroidism,"A Double-Blind, Randomized, Placebo-Controlled Multiple Ascending Dose Study to Assess the Safety, Tolerability and Efficacy of KAI-4169 in Hemodialysis Subjects With Secondary Hyperparathyroidism","Safety, Tolerability and Efficacy of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism",Secondary Hyperparathyroidism,2010-12-03,2011-07-31,2011-08-24,Interventional,Completed,Phase 2,KAI Pharmaceuticals,KAI Pharmaceuticals,,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01254565
NCT01265992,hyperparathyroidism,Post Marketing Observational Study to Assess Patient Management Practices and Quality of Life With the Capsules Form of Paricalcitol in the Treatment of SHPT in Stage 3 - 5 Chronic Kidney Disease Patients Not Yet on Dialysis Under Conditions of Usual Clinical Care (CAPITOL),Study to Assess Patient Management Practices and Quality of Life With Paricalcitol Capsules in the Treatment of Secondary Hyperparathyroidism in Stage 3-5 Chronic Kidney Disease Patients Not Yet on Dialysis,Chronic Kidney Disease|Secondary Hyperparathyroidism,2010-11-29,2012-11-30,2012-11-30,Observational,Completed,,AbbVie,"AbbVie (prior sponsor, Abbott)|Pharma Consulting Group AB",Site Reference ID/Investigator# 47723|Site Reference ID/Investigator# 41084|Site Reference ID/Investigator# 45190|Site Reference ID/Investigator# 41085|Site Reference ID/Investigator# 41087|Site Reference ID/Investigator# 45188|Site Reference ID/Investigator# 41088|Site Reference ID/Investigator# 57782|Site Reference ID/Investigator# 41089|Site Reference ID/Investigator# 45191,,Sweden,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01265992
NCT01269749,hyperthyroidism,Radioactive Iodide Therapy for Pediatric Graves' Disease,Radioactive Iodide Therapy for Pediatric Graves' Disease,Graves' Disease,2010-10-29,2016-06-30,2016-06-30,Interventional,Completed,Phase 2,University of Florida,Baylor College of Medicine|University of Florida,University of Florida|Texas Childrens Hospital,Radiation|Drug,United States,0.0,18.0,[0-17]|[18-65],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01269749
NCT01269749,goiter,Radioactive Iodide Therapy for Pediatric Graves' Disease,Radioactive Iodide Therapy for Pediatric Graves' Disease,Graves' Disease,2010-10-29,2016-06-30,2016-06-30,Interventional,Completed,Phase 2,University of Florida,Baylor College of Medicine|University of Florida,University of Florida|Texas Childrens Hospital,Radiation|Drug,United States,0.0,18.0,[0-17]|[18-65],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01269749
NCT01269749,graves disease,Radioactive Iodide Therapy for Pediatric Graves' Disease,Radioactive Iodide Therapy for Pediatric Graves' Disease,Graves' Disease,2010-10-29,2016-06-30,2016-06-30,Interventional,Completed,Phase 2,University of Florida,Baylor College of Medicine|University of Florida,University of Florida|Texas Childrens Hospital,Radiation|Drug,United States,0.0,18.0,[0-17]|[18-65],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT01269749
NCT01270425,thyroid neoplasms,Sonographic Characterization of the Thyroid Gland in Patients With Systemic Sclerosis With and Without Hashimoto Thyroiditis,Sonographic and Laboratory Evaluation of the Thyroid Gland in Patients With Systemic Sclerosis,Hashimoto Thyroiditis|Systemic Sclerosis|Thyroid Nodules,2011-01-04,2011-12-31,2012-11-30,Observational,Completed,,Meir Medical Center,Meir Medical Center,Meir Medical Center,,Israel,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01270425
NCT01270425,thyroiditis,Sonographic Characterization of the Thyroid Gland in Patients With Systemic Sclerosis With and Without Hashimoto Thyroiditis,Sonographic and Laboratory Evaluation of the Thyroid Gland in Patients With Systemic Sclerosis,Hashimoto Thyroiditis|Systemic Sclerosis|Thyroid Nodules,2011-01-04,2011-12-31,2012-11-30,Observational,Completed,,Meir Medical Center,Meir Medical Center,Meir Medical Center,,Israel,18.0,120.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT01270425
NCT01270425,thyroid nodule,Sonographic Characterization of the Thyroid Gland in Patients With Systemic Sclerosis With and Without Hashimoto Thyroiditis,Sonographic and Laboratory Evaluation of the Thyroid Gland in Patients With Systemic Sclerosis,Hashimoto Thyroiditis|Systemic Sclerosis|Thyroid Nodules,2011-01-04,2011-12-31,2012-11-30,Observational,Completed,,Meir Medical Center,Meir Medical Center,Meir Medical Center,,Israel,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT01270425
NCT01272414,goiter,,Use of Botox in the Management of Thyroid Related Upper Eyelid Retraction,Graves Ophthalmopathy,2011-01-06,2012-01-31,2012-02-29,Interventional,Withdrawn,Phase 4,University of Toronto,Allergan|University of Toronto,Mount Sinai Hospital,Drug|Drug,Canada,18.0,65.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01272414
NCT01272414,graves disease,,Use of Botox in the Management of Thyroid Related Upper Eyelid Retraction,Graves Ophthalmopathy,2011-01-06,2012-01-31,2012-02-29,Interventional,Withdrawn,Phase 4,University of Toronto,Allergan|University of Toronto,Mount Sinai Hospital,Drug|Drug,Canada,18.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT01272414
NCT01272414,hyperthyroidism,,Use of Botox in the Management of Thyroid Related Upper Eyelid Retraction,Graves Ophthalmopathy,2011-01-06,2012-01-31,2012-02-29,Interventional,Withdrawn,Phase 4,University of Toronto,Allergan|University of Toronto,Mount Sinai Hospital,Drug|Drug,Canada,18.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01272414
NCT01273597,hyperparathyroidism,Post-marketing Observational Study to Evaluate the Time to Achieving the Maintenance Dose of Paricalcitol i.v. in the Treatment of Chronic Kidney Disease (CKD) 5 Stage Patients With (Severe) Secondary Hyperparathyroidism in Hungary,Observational Study to Evaluate the Time to Achieving the Maintenance Dose of Zemplar® (Paricalcitol Injection) in the Treatment of Patients Suffering From End-stage Renal Disease and Severe Over-reactivity of the Parathyroid Glands,"Kidney Failure, Chronic",2010-11-22,2011-11-30,2011-11-30,Observational,Completed,,AbbVie,"AbbVie (prior sponsor, Abbott)|Planimeter Ltd",Site Reference ID/Investigator# 46593|Site Reference ID/Investigator# 46585|Site Reference ID/Investigator# 46594|Site Reference ID/Investigator# 47722|Site Reference ID/Investigator# 46592|Site Reference ID/Investigator# 58644|Site Reference ID/Investigator# 46595|Site Reference ID/Investigator# 46588|Site Reference ID/Investigator# 46597|Site Reference ID/Investigator# 46590|Site Reference ID/Investigator# 46591,,Hungary,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01273597
NCT01280214,graves ophthalmopathy,Peribulbar and Subconjunctival Kenalog Injection for Thyroid Orbitopathy,Local Triamcinolone Injection in Active Thyroid Orbitopathy,Thyroid Disease,2011-01-15,2013-02-28,2013-02-28,Interventional,Unknown status,Not Applicable,"HaEmek Medical Center, Israel","HaEmek Medical Center, Israel",,Drug,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT01280214
NCT01280214,hyperthyroidism,Peribulbar and Subconjunctival Kenalog Injection for Thyroid Orbitopathy,Local Triamcinolone Injection in Active Thyroid Orbitopathy,Thyroid Disease,2011-01-15,2013-02-28,2013-02-28,Interventional,Unknown status,Not Applicable,"HaEmek Medical Center, Israel","HaEmek Medical Center, Israel",,Drug,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01280214
NCT01280214,graves disease,Peribulbar and Subconjunctival Kenalog Injection for Thyroid Orbitopathy,Local Triamcinolone Injection in Active Thyroid Orbitopathy,Thyroid Disease,2011-01-15,2013-02-28,2013-02-28,Interventional,Unknown status,Not Applicable,"HaEmek Medical Center, Israel","HaEmek Medical Center, Israel",,Drug,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT01280214
NCT01280214,goiter,Peribulbar and Subconjunctival Kenalog Injection for Thyroid Orbitopathy,Local Triamcinolone Injection in Active Thyroid Orbitopathy,Thyroid Disease,2011-01-15,2013-02-28,2013-02-28,Interventional,Unknown status,Not Applicable,"HaEmek Medical Center, Israel","HaEmek Medical Center, Israel",,Drug,,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01280214
NCT01286753,"thyroid cancer, papillary","An Open-Label, Multi-Center Phase II Study of the BRAF Inhibitor Vemurafenib in Patients With Metastatic or Unresectable Papillary Thyroid Cancer (PTC) Positive for the BRAF V600 Mutation and Resistant to Radioactive Iodine",A Study of Vemurafenib (RO5185426) in Participants With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation,Neoplasms,2011-01-28,2014-11-30,2015-05-31,Interventional,Completed,Phase 2,Hoffmann-La Roche,Hoffmann-La Roche,,Drug,France|Italy|Netherlands|United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT01286753
NCT01290029,hyperparathyroidism,"An Open-label, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Cinacalcet HCl in Pediatric Subjects Aged 28 Days to Less Than 6 Years With Chronic Kidney Disease Receiving Dialysis",Study to Evaluate Cinacalcet in Children With Chronic Kidney Disease,"Chronic Kidney Disease|Hyperparathyroidism, Secondary|Secondary Hyperparathyroidism",2011-01-20,2015-09-23,2015-09-23,Interventional,Completed,Phase 1,Amgen,Amgen,Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug,Germany|United Kingdom|United States,0.0,2190.0,[0-17],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01290029
NCT01291498,parathyroid neoplasms,High Intensity Focused Ultrasound (HIFU) for Parathyroid Adenoma,High Intensity Focused Ultrasound (HIFU) for Parathyroid Adenoma,Parathyroid Adenomas,2011-02-07,2013-06-30,2013-06-30,Interventional,Terminated,Not Applicable,Oxford University Hospitals NHS Trust,Oxford University Hospitals NHS Trust|Theraclion,John Radcliffe Hospital,Device,United Kingdom,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01291498
NCT01295333,hyperthyroidism,"Assessing the Impact of the Early and Systematic Hormonal Replacement After Radio-isotopic Ablation of Graves'hyperthyroïdism on Quality of Life, Efficiency and Tolerance","Assessing the Impact of the Early and Systematic Hormonal Replacement After Radio-isotopic Ablation of Graves'hyperthyroïdism on Quality of Life, Efficiency and Tolerance",Graves Disease (Basedow's Disease),2011-01-27,2014-11-30,2014-12-31,Interventional,Completed,Phase 3,Assistance Publique Hopitaux De Marseille,Assistance Publique Hopitaux De Marseille,Assistance Publique Hopitaux de Marseille,Drug|Drug,France,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01295333
NCT01295333,goiter,"Assessing the Impact of the Early and Systematic Hormonal Replacement After Radio-isotopic Ablation of Graves'hyperthyroïdism on Quality of Life, Efficiency and Tolerance","Assessing the Impact of the Early and Systematic Hormonal Replacement After Radio-isotopic Ablation of Graves'hyperthyroïdism on Quality of Life, Efficiency and Tolerance",Graves Disease (Basedow's Disease),2011-01-27,2014-11-30,2014-12-31,Interventional,Completed,Phase 3,Assistance Publique Hopitaux De Marseille,Assistance Publique Hopitaux De Marseille,Assistance Publique Hopitaux de Marseille,Drug|Drug,France,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01295333
NCT01295333,graves disease,"Assessing the Impact of the Early and Systematic Hormonal Replacement After Radio-isotopic Ablation of Graves'hyperthyroïdism on Quality of Life, Efficiency and Tolerance","Assessing the Impact of the Early and Systematic Hormonal Replacement After Radio-isotopic Ablation of Graves'hyperthyroïdism on Quality of Life, Efficiency and Tolerance",Graves Disease (Basedow's Disease),2011-01-27,2014-11-30,2014-12-31,Interventional,Completed,Phase 3,Assistance Publique Hopitaux De Marseille,Assistance Publique Hopitaux De Marseille,Assistance Publique Hopitaux de Marseille,Drug|Drug,France,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT01295333
NCT01297699,graves disease,"Clinical Trial Phase III, Parallel Group, Randomized, Placebo-controlled, Double-blind, Multicenter Study to Evaluate the Efficacy and Safety of Tocilizumab Administration in Patients With Moderate-to-severe or Sight-threatening Graves' Ophthalmopathy (GO), That Had Not Responded Adequately to Treatment With Intravenous Corticoid Pulses.",Tocilizumab Treatment in Graves´ Ophthalmopathy (Graves´ Orbitopathy or Thyroid Eye Disease),Graves´ Ophthalmopathy|Thyroid Associated Ophthalmopathies|Thyroid Eye Disease,2011-02-16,2015-10-31,2015-12-31,Interventional,Completed,Phase 3,Hospital Clinico Universitario de Santiago,Fundación Ramón Domínguez|Hospital Clinico Universitario de Santiago,Hospital Clínico de Santiago|Hospital Santa Creu i Sant Pau|Hospital Clínico San Carlos|Hospital Universitario Ramón y Cajal|Centro Oftalmológico Moreiras|Hospital Universitario Virgen del Rocío|Hospital Universitario Virgen Macarena|Hospital Universitario La Fe|Hospital Clínico Universitario Lozano Blesa,Drug|Drug,Spain,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT01297699
NCT01297699,hyperthyroidism,"Clinical Trial Phase III, Parallel Group, Randomized, Placebo-controlled, Double-blind, Multicenter Study to Evaluate the Efficacy and Safety of Tocilizumab Administration in Patients With Moderate-to-severe or Sight-threatening Graves' Ophthalmopathy (GO), That Had Not Responded Adequately to Treatment With Intravenous Corticoid Pulses.",Tocilizumab Treatment in Graves´ Ophthalmopathy (Graves´ Orbitopathy or Thyroid Eye Disease),Graves´ Ophthalmopathy|Thyroid Associated Ophthalmopathies|Thyroid Eye Disease,2011-02-16,2015-10-31,2015-12-31,Interventional,Completed,Phase 3,Hospital Clinico Universitario de Santiago,Fundación Ramón Domínguez|Hospital Clinico Universitario de Santiago,Hospital Clínico de Santiago|Hospital Santa Creu i Sant Pau|Hospital Clínico San Carlos|Hospital Universitario Ramón y Cajal|Centro Oftalmológico Moreiras|Hospital Universitario Virgen del Rocío|Hospital Universitario Virgen Macarena|Hospital Universitario La Fe|Hospital Clínico Universitario Lozano Blesa,Drug|Drug,Spain,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01297699
NCT01297699,goiter,"Clinical Trial Phase III, Parallel Group, Randomized, Placebo-controlled, Double-blind, Multicenter Study to Evaluate the Efficacy and Safety of Tocilizumab Administration in Patients With Moderate-to-severe or Sight-threatening Graves' Ophthalmopathy (GO), That Had Not Responded Adequately to Treatment With Intravenous Corticoid Pulses.",Tocilizumab Treatment in Graves´ Ophthalmopathy (Graves´ Orbitopathy or Thyroid Eye Disease),Graves´ Ophthalmopathy|Thyroid Associated Ophthalmopathies|Thyroid Eye Disease,2011-02-16,2015-10-31,2015-12-31,Interventional,Completed,Phase 3,Hospital Clinico Universitario de Santiago,Fundación Ramón Domínguez|Hospital Clinico Universitario de Santiago,Hospital Clínico de Santiago|Hospital Santa Creu i Sant Pau|Hospital Clínico San Carlos|Hospital Universitario Ramón y Cajal|Centro Oftalmológico Moreiras|Hospital Universitario Virgen del Rocío|Hospital Universitario Virgen Macarena|Hospital Universitario La Fe|Hospital Clínico Universitario Lozano Blesa,Drug|Drug,Spain,18.0,75.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01297699
NCT01306656,hyperparathyroidism,Randomized Controlled Trial of Vitamin D Repletion Regimens in Primary Hyperparathyroidism,Vitamin D Repletion in Primary Hyperparathyroidism,Primary Hyperparathyroidism|Vitamin D Deficiency,2011-02-10,2017-02-28,2017-02-28,Interventional,Completed,Phase 4,Columbia University,Columbia University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Columbia University Medical Center,Drug|Other|Dietary Supplement,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01306656
NCT01306916,hyperparathyroidism,Coexisting Thyroid Disease and Hyperparathyroidism,Coexisting Thyroid Disease and Hyperparathyroidism,Hyperthyroidism,2011-01-12,2010-12-31,2012-07-31,Observational,Completed,,Walter Reed Army Medical Center,Walter Reed Army Medical Center,Walter Reed Army Medical Center,,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01306916
NCT01307761,thyroid nodule,An Easy Sonographic Scoring System for Predicting Malignant Thyroid Nodules,An Easy Sonographic Scoring System for Predicting Malignant Thyroid Nodules,Thyroid Cancer,2011-02-21,2012-12-31,2013-08-31,Observational,Unknown status,,Far Eastern Memorial Hospital,Far Eastern Memorial Hospital,Far Eastern Memorial Hospital,,Taiwan,18.0,90.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT01307761
NCT01308320,thyroid neoplasms,Dose-dependent Effect of Fentanyl on Cough Attenuation During Emergence From General Anaesthesia,Dose-dependent Effect of Fentanyl on Cough Attenuation During Emergence From General Anaesthesia,Thyroid Neoplasm,2011-03-03,2010-07-31,2010-07-31,Interventional,Completed,Phase 4,Yonsei University,Yonsei University,Severance Hospital,Drug|Drug,"Korea, Republic of",20.0,59.0,[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01308320
NCT01320813,thyroid neoplasms,Randomized Trial Comparing Complication Rates Associated With Robot-assisted Thyroidectomy to External Thyroidectomy,Trial Comparing Complication Rates Associated With Robot-assisted Thyroidectomy to External Thyroidectomy,Goiter|Graves Disease|Thyroiditis|Thyroid Nodule,2011-03-22,2013-09-30,2013-09-30,Interventional,Terminated,Not Applicable,Centre Hospitalier Universitaire de Nīmes,Centre Hospitalier Universitaire de Nīmes,CHU de Nîmes - Hôpital Universitaire Carémeau,Procedure|Procedure,France,18.0,85.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01320813
NCT01320813,hyperthyroidism,Randomized Trial Comparing Complication Rates Associated With Robot-assisted Thyroidectomy to External Thyroidectomy,Trial Comparing Complication Rates Associated With Robot-assisted Thyroidectomy to External Thyroidectomy,Goiter|Graves Disease|Thyroiditis|Thyroid Nodule,2011-03-22,2013-09-30,2013-09-30,Interventional,Terminated,Not Applicable,Centre Hospitalier Universitaire de Nīmes,Centre Hospitalier Universitaire de Nīmes,CHU de Nîmes - Hôpital Universitaire Carémeau,Procedure|Procedure,France,18.0,85.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01320813
NCT01322165,hypoparathyroidism,National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions,National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions,"Bicuspid Aortic Valve With Coarctation|Bicuspid Aortic Valve With Family History|Bicuspid Aortic Valve Without Known Family History|Ehlers-Danlos Syndrome|Familial Thoracic Aortic Aneurysm and Dissections|FBN1, TGFBR1, TGFBR2, ACTA2 or MYH11 Genetic Mutation|Loeys-Dietz Syndrome|Marfan Syndrome|Other Aneur/Diss of Thoracic Aorta Not Due to Trauma, <50yo|Other Congenital Heart Disease|Shprintzen-Goldberg Syndrome|Turner Syndrome",2011-03-22,2015-09-30,2016-09-30,Observational,Completed,,"National Heart, Lung, and Blood Institute (NHLBI)","National Heart, Lung, and Blood Institute (NHLBI)|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)",Queens Medical Center|Johns Hopkins University|The New York Presbyterian Hospital-Weill Cornell Medical Center|Oregon Health & Science University|University of Pennsylvania School of Medicine|Baylor College of Medicine|University of Texas Medical School at Houston,,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01322165
NCT01329666,hyperparathyroidism,Early Effect of Vitamin D in Primary Hyperparathyroidism,Primary Hyperparathyroidism (PHPT): Early Effect of Vitamin D,Hypercalcemia|Osteopenia|Osteoporosis|Primary Hyperparathyroidism|Vitamin D Deficiency,2011-04-04,2015-01-31,2015-01-31,Interventional,Withdrawn,Phase 2/Phase 3,Columbia University,Columbia University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Columbia University Medical Center,Dietary Supplement|Dietary Supplement,United States,45.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01329666
NCT01335802,hypothyroidism,Relation Between Thyroid Hormone Stimulated Mitochondrial Function and Spontaneous Abortion and Complications of Pregnancy in Subclinical Hypothyroidism,Relation Between Subclinical Hypothyroidism and Outcome of Pregnancy,"Abortion, Spontaneous|Pregnancy Complications|Subclinical Hypothyroidism",2011-04-11,2015-09-30,2016-12-31,Observational,Completed,,Naestved Hospital,Naestved Hospital|University of Copenhagen,Naestved Hospital,Genetic,Denmark,18.0,50.0,[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01335802
NCT01335828,thyroid neoplasms,"""ShearWave"" Elastography Interest in the Management of Thyroid Nodules",Elastography Interest in the Management of Thyroid Nodules,Thyroid Nodules,2010-11-10,2012-10-31,2012-11-30,Interventional,Completed,Phase 2/Phase 3,"University Hospital, Grenoble",AdministrateurCIC,Clinical Investigation Center - Technological Innovation - Inserm 803 - University Hospital France,Device,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01335828
NCT01335828,thyroid nodule,"""ShearWave"" Elastography Interest in the Management of Thyroid Nodules",Elastography Interest in the Management of Thyroid Nodules,Thyroid Nodules,2010-11-10,2012-10-31,2012-11-30,Interventional,Completed,Phase 2/Phase 3,"University Hospital, Grenoble",AdministrateurCIC,Clinical Investigation Center - Technological Innovation - Inserm 803 - University Hospital France,Device,France,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT01335828
NCT01341782,hyperparathyroidism,Comparison of Efficacy and Safety of Paricalcitol Injection With Maxacalcitol Injection in Adult Japanese Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism,Comparison of Efficacy and Safety of Paricalcitol Injection With Maxacalcitol Injection in Adult Japanese Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism,Hemodialysis|Secondary Hyperparathyroidism,2011-04-25,2012-04-30,2012-04-30,Interventional,Completed,Phase 3,AbbVie,"AbbVie (prior sponsor, Abbott)",Site Reference ID/Investigator# 53485|Site Reference ID/Investigator# 51571|Site Reference ID/Investigator# 52963|Site Reference ID/Investigator# 52966|Site Reference ID/Investigator# 51578|Site Reference ID/Investigator# 52965|Site Reference ID/Investigator# 53782|Site Reference ID/Investigator# 57483|Site Reference ID/Investigator# 57487|Site Reference ID/Investigator# 53484|Site Reference ID/Investigator# 54385|Site Reference ID/Investigator# 51581|Site Reference ID/Investigator# 59164|Site Reference ID/Investigator# 51574|Site Reference ID/Investigator# 51575|Site Reference ID/Investigator# 52751|Site Reference ID/Investigator# 62025|Site Reference ID/Investigator# 54384|Site Reference ID/Investigator# 52745|Site Reference ID/Investigator# 51569|Site Reference ID/Investigator# 52964|Site Reference ID/Investigator# 53483|Site Reference ID/Investigator# 51582|Site Reference ID/Investigator# 54388|Site Reference ID/Investigator# 51576|Site Reference ID/Investigator# 51577|Site Reference ID/Investigator# 51580|Site Reference ID/Investigator# 52747|Site Reference ID/Investigator# 52748|Site Reference ID/Investigator# 52750|Site Reference ID/Investigator# 51570|Site Reference ID/Investigator# 54387|Site Reference ID/Investigator# 52746|Site Reference ID/Investigator# 51579|Site Reference ID/Investigator# 62024|Site Reference ID/Investigator# 51572|Site Reference ID/Investigator# 52752|Site Reference ID/Investigator# 53482|Site Reference ID/Investigator# 59162|Site Reference ID/Investigator# 59966|Site Reference ID/Investigator# 53783|Site Reference ID/Investigator# 54383|Site Reference ID/Investigator# 52749|Site Reference ID/Investigator# 52962|Site Reference ID/Investigator# 59163,Drug|Drug|Drug|Drug,Japan,20.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01341782
NCT01341886,thyroid neoplasms,,Effect of Metformin on Decrement in Levothyroxin Dose Required for Thyroid Stimulating Hormone (TSH) Suppression in Patients With Differentiated Thyroid Cancer,Malignant Neoplasm of Thyroid Stage I|Malignant Neoplasm of Thyroid Stage II,2011-04-18,2011-04-30,2011-04-30,Interventional,Completed,Not Applicable,Mashhad University of Medical Sciences,Mashhad University of Medical Sciences,Mashad University of Medical Sciences,Drug,"Iran, Islamic Republic of",0.0,80.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01341886
NCT01368042,hyperparathyroidism,Quality of Life in Greek Hemodialysis Patients Receiving Zemplar i.v (QualitiZe),Quality of Life in Greek Hemodialysis Patients Receiving Zemplar Intravenous,Chronic Kidney Disease|Secondary Hyperparathyroidism,2011-06-06,2013-06-30,2013-06-30,Observational,Completed,,AbbVie,"AbbVie (prior sponsor, Abbott)",Site Reference ID/Investigator# 56803|Site Reference ID/Investigator# 53424|Site Reference ID/Investigator# 53425|Site Reference ID/Investigator# 56805|Site Reference ID/Investigator# 56802|Site Reference ID/Investigator# 66291|Site Reference ID/Investigator# 56809|Site Reference ID/Investigator# 50442|Site Reference ID/Investigator# 77554|Site Reference ID/Investigator# 77553|Site Reference ID/Investigator# 53422,,Greece,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01368042
NCT01369953,hyperparathyroidism,Informed Consent for Whole Genome Sequencing: Civic Ideals and Social Norms Referenced by Early Participants,Informed Consent for Whole Genome Sequencing: Ideals and Norms Referenced by Early Participants,Coffin - Sins Syndrome|Coronary Artery Disease|Dubouitz Syndrome|Familial Isolated Hyperparathyroidism|Proteus Syndrome,2011-06-08,,2014-01-31,Observational,Completed,,National Institutes of Health Clinical Center (CC),National Human Genome Research Institute (NHGRI),"National Human Genome Research Institute (NHGRI), 9000 Rockville Pike",,United States,18.0,65.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01369953
NCT01379196,hyperthyroidism,Use of Azithromycin as Immunomodulatory Therapy in Grave&Apos;s Orbitopathy,Use of Azithromycin as Immunomodulatory Therapy in Grave&Apos;s Orbitopathy,Graves Ophthalmopathy,2011-05-11,2014-11-30,2014-12-31,Interventional,Withdrawn,Phase 1/Phase 2,Rabin Medical Center,Rabin Medical Center,,Drug,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01379196
NCT01379196,goiter,Use of Azithromycin as Immunomodulatory Therapy in Grave&Apos;s Orbitopathy,Use of Azithromycin as Immunomodulatory Therapy in Grave&Apos;s Orbitopathy,Graves Ophthalmopathy,2011-05-11,2014-11-30,2014-12-31,Interventional,Withdrawn,Phase 1/Phase 2,Rabin Medical Center,Rabin Medical Center,,Drug,,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01379196
NCT01379196,graves disease,Use of Azithromycin as Immunomodulatory Therapy in Grave&Apos;s Orbitopathy,Use of Azithromycin as Immunomodulatory Therapy in Grave&Apos;s Orbitopathy,Graves Ophthalmopathy,2011-05-11,2014-11-30,2014-12-31,Interventional,Withdrawn,Phase 1/Phase 2,Rabin Medical Center,Rabin Medical Center,,Drug,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT01379196
NCT01382212,hyperparathyroidism,"A Phase 3, Open-Label, Multicenter Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis",A Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis,End-Stage Renal Disease|Secondary Hyperparathyroidism,2011-06-24,2015-04-30,2015-04-30,Interventional,Completed,Phase 3,AbbVie,"AbbVie (prior sponsor, Abbott)",,Drug,,10.0,16.0,[0-17],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01382212
NCT01382966,hyperparathyroidism,"The Association of Serum Sclerostin Levels,Echocardiographic Parameters, Arteriovenous Fistula Thrombosis and Carpal Tunnel Syndrome in Maintenance Hemodialysis Patients","Serum Sclerostin Levels, Cardiovascular Parameters and Carpal Tunnel Syndrome in Maintenance Hemodialysis Patients",Chronic Kidney Disease|Left Ventricular Hypertrophy|Renal Osteodystrophy,2011-06-21,2011-09-30,2011-10-31,Observational,Unknown status,,RFM Renal Treatment Services,RFM Renal Treatment Services,Rfm Renal Tedavi Merkezi,,Turkey,18.0,75.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01382966
NCT01384786,goiter,The Incidence of Thyroid Cancer in 4474 Patients Treated for Hyperthyroidism or Goiter,The Incidence of Thyroid Cancer in 4474 Patients Treated for Hyperthyroidism or Goiter,Hyperthyreosis and Goiter|Thyroid Cancer,2011-06-28,,2005-07-31,Observational,Completed,,Copenhagen University Hospital at Herlev,Copenhagen University Hospital at Herlev,herlev Hospital,,Denmark,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01384786
NCT01384786,hyperthyroidism,The Incidence of Thyroid Cancer in 4474 Patients Treated for Hyperthyroidism or Goiter,The Incidence of Thyroid Cancer in 4474 Patients Treated for Hyperthyroidism or Goiter,Hyperthyreosis and Goiter|Thyroid Cancer,2011-06-28,,2005-07-31,Observational,Completed,,Copenhagen University Hospital at Herlev,Copenhagen University Hospital at Herlev,herlev Hospital,,Denmark,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01384786
NCT01395134,goiter,Randomized Controlled Trial of Visualization Versus Neuromonitoring of the External Branch of the Superior Laryngeal Nerve During Thyroidectomy.,Visualization Versus Neuromonitoring of the External Branch of the Superior Laryngeal Nerve During Thyroidectomy.,"Goiter,|Thyroid,",2011-07-13,2010-06-30,2010-12-31,Interventional,Completed,Not Applicable,Jagiellonian University,Jagiellonian University,"Jagiellonian University, College of Medicine, Department of Endocrine Surgery, 3rd Chair of General Surgery",Device,Poland,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01395134
NCT01396733,thyroid neoplasms,Clinical Trial to Evaluate Efficacy of Redifferentiation Therapy Using Alpha-lipoic Acid in Thyroid Cancer Patients With Decreased Radioactive Iodine Uptake,Redifferentiation Therapy Using Alpha Lipoic Acid in Thyroid Cancer,Cancer|Thyroid,2011-07-18,2012-12-31,2013-12-31,Interventional,Withdrawn,Phase 2,Asan Medical Center,Asan Medical Center,Asan Medical Center,Drug,"Korea, Republic of",20.0,75.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01396733
NCT01398774,pseudopseudohypoparathyroidism,Altered Resting Energy Expenditure as a Cause of Obesity in Pseudohypoparathyroidism 1a: A Pilot Study,Energy Expenditure and Body Composition in Pseudohypoparathyroidism 1a,Albright Hereditary Osteodystrophy|Pseudohypoparathyroidism Type 1A,2011-07-19,2015-09-30,2017-11-20,Observational,Terminated,,Children's Hospital of Philadelphia,Children's Hospital of Philadelphia,Children's Hospital of Philadelphia,,United States,5.0,45.0,[0-17]|[18-65],Parathyroid diseases,pseudohypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01398774
NCT01401478,hyperparathyroidism,"Prospective, Open-label, Multicenter Effectiveness and Safety Observational Study of Zemplar in Patients With Stage 5 Chronic Kidney Disease and Hyperparathyroidism on Hemodialysis in the Russian Federation",Observational Program of Zemplar in Patients With End Stage Chronic Kidney Disease and Parathyroid Disorder on Hemodialysis in the Russian Federation,Secondary Hyperparathyroidism,2011-07-22,2013-01-31,2013-01-31,Observational,Completed,,AbbVie,"AbbVie (prior sponsor, Abbott)|Almedis",Site Reference ID/Investigator# 57348|Site Reference ID/Investigator# 57347|Site Reference ID/Investigator# 58347|Site Reference ID/Investigator# 67404|Site Reference ID/Investigator# 57344|Site Reference ID/Investigator# 57346|Site Reference ID/Investigator# 58356|Site Reference ID/Investigator# 58348|Site Reference ID/Investigator# 57342|Site Reference ID/Investigator# 57364|Site Reference ID/Investigator# 69687|Site Reference ID/Investigator# 57363|Site Reference ID/Investigator# 69688,,Russian Federation,18.0,65.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01401478
NCT01408368,graves disease,Five-year Follow up of a Randomized Clinical Trial of Bilateral Subtotal Thyroidectomy Versus Total Thyroidectomy for Graves' Disease.,Subtotal Versus Total Thyroidectomy for Graves' Disease,Goiter|Thyroid,2011-08-02,2009-12-31,2010-12-31,Interventional,Completed,Not Applicable,Jagiellonian University,Jagiellonian University,"Jagiellonian University, College of Medicine, Department of Endocrine Surgery, 3rd Chair of General Surgery",Procedure|Procedure,Poland,18.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT01408368
NCT01408368,hyperthyroidism,Five-year Follow up of a Randomized Clinical Trial of Bilateral Subtotal Thyroidectomy Versus Total Thyroidectomy for Graves' Disease.,Subtotal Versus Total Thyroidectomy for Graves' Disease,Goiter|Thyroid,2011-08-02,2009-12-31,2010-12-31,Interventional,Completed,Not Applicable,Jagiellonian University,Jagiellonian University,"Jagiellonian University, College of Medicine, Department of Endocrine Surgery, 3rd Chair of General Surgery",Procedure|Procedure,Poland,18.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01408368
NCT01409798,hyperparathyroidism,The Midwest Head and Neck Cancer Consortium Multi-Institutional Parathyroid Registry,The Midwest Head and Neck Cancer Consortium Multi-Institutional Parathyroid Registry,Primary Hyperparathyroidism,2011-08-02,2014-12-31,2015-11-30,Observational,Completed,,University of Nebraska,University of Nebraska,University of Iowa|Kansas University Medical Center|University of Minnesota|University Of Missiouri|University of Nebraska Medical Center|Sanford School of Medicine,,United States,19.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01409798
NCT01413113,"thyroid cancer, papillary","A Phase I Clinical Trial of Pazopanib in Combination With Escalating Doses of Radioactive 131I in Patients With Well-Differentiated Thyroid Carcinoma Refractory to Radioiodine, Despite Having Some Uptake",Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery,Recurrent Thyroid Cancer|Stage IVA Follicular Thyroid Cancer|Stage IVA Papillary Thyroid Cancer|Stage IVB Follicular Thyroid Cancer|Stage IVB Papillary Thyroid Cancer|Stage IVC Follicular Thyroid Cancer|Stage IVC Papillary Thyroid Cancer,2011-07-20,2013-11-30,2015-10-31,Interventional,Completed,Phase 1,University of Washington,GlaxoSmithKline|National Cancer Institute (NCI)|National Comprehensive Cancer Network|University of Washington,Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium,Drug|Radiation,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT01413113
NCT01413113,"adenocarcinoma, follicular","A Phase I Clinical Trial of Pazopanib in Combination With Escalating Doses of Radioactive 131I in Patients With Well-Differentiated Thyroid Carcinoma Refractory to Radioiodine, Despite Having Some Uptake",Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery,Recurrent Thyroid Cancer|Stage IVA Follicular Thyroid Cancer|Stage IVA Papillary Thyroid Cancer|Stage IVB Follicular Thyroid Cancer|Stage IVB Papillary Thyroid Cancer|Stage IVC Follicular Thyroid Cancer|Stage IVC Papillary Thyroid Cancer,2011-07-20,2013-11-30,2015-10-31,Interventional,Completed,Phase 1,University of Washington,GlaxoSmithKline|National Cancer Institute (NCI)|National Comprehensive Cancer Network|University of Washington,Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium,Drug|Radiation,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT01413113
NCT01414114,hyperparathyroidism,"A Single-arm, Open-label, Multicenter, Dose Titration Study of KAI-4169 to Treat Secondary Hyperparathyroidism in Hemodialysis Subjects With Chronic Kidney Disease-Mineral and Bone Disorder",Etelcalcetide to Treat Secondary Hyperparathyroidism in Hemodialysis Patients With Chronic Kidney Disease-Mineral and Bone Disorder,Secondary Hyperparathyroidism,2011-08-09,2012-05-21,2012-05-21,Interventional,Completed,Phase 2,KAI Pharmaceuticals,KAI Pharmaceuticals,,Drug,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01414114
NCT01421407,hyperparathyroidism,Efficacy and Safety of High Intensity Focused Ultrasound (HIFU) Device to Treat Uncontrolled Secondary Hyperparathyroidism in Chronic Haemodialysis Patients,Efficacy and Safety of High Intensity Focused Ultrasound (HIFU) Device to Treat Secondary Hyperparathyroidism,End Stage Renal Disease|Parathyroid Hyperplasia|Secondary Hyperparathyroidism,2011-08-19,2014-01-31,2014-01-31,Interventional,Withdrawn,Not Applicable,Theraclion,Theraclion,"Ospedale generale regionale ""Miulli""|Ospedale Maggiore Policlinico Mangiagalli e Regina Elena|Hospital Universitario Marquès de Valdecilla",Device,Italy|Spain,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01421407
NCT01426724,hyperparathyroidism,"Effects of Active Form of Vitamin D on Renal Blood Flow, Glomerular Filtration Rate, Proteinuria and Inflammation in Patients With Chronic Kidney Disease and Hyperparathyroidism","Effects of Vitamin D on Renal Blood Flow, Proteinuria and Inflammation in Patients With Chronic Kidney Disease",Chronic Kidney Disease|Secondary Hyperparathyroidism,2011-08-29,2013-08-31,2013-08-31,Interventional,Withdrawn,Not Applicable,University of Virginia,University of Virginia,University of Virginia,Drug,United States,18.0,75.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01426724
NCT01428167,hashimoto disease,Is There Any Association Between Thyroid Cancer and Hashimotos Thyroiditis?,Hashimotos Thyroiditis and Thyroid Cancer,Hashimotos Thyroiditis|Thyroid Cancer,2011-08-10,2012-05-31,2012-05-31,Observational,Completed,,"The University of Texas Medical Branch, Galveston","The University of Texas Medical Branch, Galveston","University of Texas Medical Branch, Galveston , Endocrine Department",,United States,18.0,80.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT01428167
NCT01436994,hyperthyroidism,A Randomised Study of Two Anti-thyroid Drug Treatment Regimens in Young People,Antithyroid Drug Treatment of Thyrotoxicosis in Young People,Paediatric Thyrotoxicosis,2011-08-18,2014-12-31,2015-11-30,Interventional,Completed,Phase 3,Newcastle-upon-Tyne Hospitals NHS Trust,Newcastle-upon-Tyne Hospitals NHS Trust,Royal Aberdeen Children's Hospital|Birmingham Children's Hospital|Addebrookes Hospital|Wales College of Medicine|University Hospital|Ninewells Hospital|Royal Hospital for Sick Children|Royal Hospital for Sick Children|Hereford Hospital|Crosshouse Hospital|Alder Hey Children's Hospital|St Bart's Hospital|St George's Hospital|Royal Manchester Children's Hospital|Royal Victoria Infirmary|Norfolk & Norwich University Hospitals|Oxford Radcliffe Hospitals|Sheffield Children's Hospital,Procedure|Procedure|Drug|Drug|Drug,United Kingdom,2.0,16.0,[0-17],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01436994
NCT01439867,hyperparathyroidism,"An Open-label, Single-arm Study to Assess the Safety & Tolerability of Cinacalcet in Addition to Standard of Care in Pediatric Subjects Age 28 Days to < 6 Yrs With Chronic Kidney Disease & Secondary Hyperparathyroidism Receiving Dialysis",Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism,"Chronic Kidney Disease|Hyperparathyroidism, Secondary",2011-09-22,2016-06-03,2016-06-03,Interventional,Terminated,Phase 2,Amgen,Amgen,Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug|Drug,Belgium|Czechia|France|Germany|Hungary|Italy|Mexico|Netherlands|New Zealand|Poland|Russian Federation|Slovakia|United States,0.0,2189.0,[0-17],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01439867
NCT01441154,struma ovarii,Pharmacokinetic and Pharmacodynamic Studies of Liothyronine. A Study on the Metabolic Effects of Thyroid Hormone,Metabolic Effects of Synthetic Thyroid Hormone for Thyroid Cancer Treatment,Follicular Thyroid Cancer|Hurthle Cell Thyroid Cancer|Malignant Struma Ovarii|Papillary Thyroid Cancer|Tall Cell Variant Thyroid Cancer,2011-09-24,2013-12-12,2013-12-12,Observational,Completed,,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"National Institutes of Health Clinical Center, 9000 Rockville Pike",,United States,18.0,99.0,[18-65]|[65 and more],Thyroid neoplasms,Struma ovarii,https://clinicaltrials.gov/ct2/show/NCT01441154
NCT01447368,hyperparathyroidism,Comparison of Medical Therapy (Oral Cinacalcet) Versus Surgical Therapy (Total Parathyroidectomy) on Vascular/Valvular Calcification in Chronic Peritoneal Dialysis Patients With Secondary Hyperparathyroidism - A Pilot Randomized Study,Cinacalcet Versus Parathyroidectomy in Peritoneal Dialysis Patients,Kidney Failure|Secondary Hyperparathyroidism|Vascular Diseases,2011-10-04,2017-05-22,2017-05-22,Interventional,Completed,Phase 4,The University of Hong Kong,The University of Hong Kong,Queen Mary Hospital and Tung Wah Hospital,Drug|Procedure,Hong Kong,18.0,75.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01447368
NCT01453634,hyperparathyroidism,"A Randomized, Open Label, Four Week, Pharmacodynamic/Pharmacokinetic, Efficacy, and Safety Study of Lunacalcipol (CTA018) Injection in Subjects With Stage 5 Chronic Kidney Disease With Secondary Hyperparathyroidism on Hemodialysis","Four Week, Pharmacodynamic/Pharmacokinetic, Efficacy, and Safety Study of Lunacalcipol (CTA018)",Hemodialysis (HD)|Secondary Hyperparathyroidism (SHPT)|Stage 5 Chronic Kidney Disease (CKD),2011-10-13,2013-07-31,2013-07-31,Interventional,Withdrawn,Phase 2,"OPKO Health, Inc.","OPKO Health, Inc.",,Drug|Drug,,18.0,80.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01453634
NCT01458600,hyperthyroidism,Adjuvant Treatment of Graves´ Ophthalmopathy With NSAID (aGO Study),Adjuvant Treatment of Graves´ Ophthalmopathy With NSAID (aGO Study),Graves´ Disease,2011-10-19,2016-02-29,2016-02-29,Interventional,Completed,Phase 4,Region Skane,Mikael Lantz,"Departmenty of Endocrinology, Skane University Hospital|Department of Endocrinology, Karolinska Hospital|Department of Internal Medicine, section of Endocrinology, Sodersjukhuset",Drug|Drug|Drug|Drug|Drug,Sweden,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01458600
NCT01458600,graves disease,Adjuvant Treatment of Graves´ Ophthalmopathy With NSAID (aGO Study),Adjuvant Treatment of Graves´ Ophthalmopathy With NSAID (aGO Study),Graves´ Disease,2011-10-19,2016-02-29,2016-02-29,Interventional,Completed,Phase 4,Region Skane,Mikael Lantz,"Departmenty of Endocrinology, Skane University Hospital|Department of Endocrinology, Karolinska Hospital|Department of Internal Medicine, section of Endocrinology, Sodersjukhuset",Drug|Drug|Drug|Drug|Drug,Sweden,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT01458600
NCT01458600,graves ophthalmopathy,Adjuvant Treatment of Graves´ Ophthalmopathy With NSAID (aGO Study),Adjuvant Treatment of Graves´ Ophthalmopathy With NSAID (aGO Study),Graves´ Disease,2011-10-19,2016-02-29,2016-02-29,Interventional,Completed,Phase 4,Region Skane,Mikael Lantz,"Departmenty of Endocrinology, Skane University Hospital|Department of Endocrinology, Karolinska Hospital|Department of Internal Medicine, section of Endocrinology, Sodersjukhuset",Drug|Drug|Drug|Drug|Drug,Sweden,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT01458600
NCT01458600,goiter,Adjuvant Treatment of Graves´ Ophthalmopathy With NSAID (aGO Study),Adjuvant Treatment of Graves´ Ophthalmopathy With NSAID (aGO Study),Graves´ Disease,2011-10-19,2016-02-29,2016-02-29,Interventional,Completed,Phase 4,Region Skane,Mikael Lantz,"Departmenty of Endocrinology, Skane University Hospital|Department of Endocrinology, Karolinska Hospital|Department of Internal Medicine, section of Endocrinology, Sodersjukhuset",Drug|Drug|Drug|Drug|Drug,Sweden,18.0,75.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01458600
NCT01460030,parathyroid neoplasms,An Intra-individual Titration Study of KRN1493 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism,An Intra-individual Titration Study of KRN1493 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism,Hypercalcemia|Parathyroid Carcinoma|Primary Hyperparathyroidism,2011-10-25,2013-02-28,2013-02-28,Interventional,Completed,Phase 3,"Kyowa Kirin Co., Ltd.","Kyowa Kirin Co., Ltd.",,Drug,Japan,20.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01460030
NCT01460030,hyperparathyroidism,An Intra-individual Titration Study of KRN1493 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism,An Intra-individual Titration Study of KRN1493 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism,Hypercalcemia|Parathyroid Carcinoma|Primary Hyperparathyroidism,2011-10-25,2013-02-28,2013-02-28,Interventional,Completed,Phase 3,"Kyowa Kirin Co., Ltd.","Kyowa Kirin Co., Ltd.",,Drug,Japan,20.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01460030
NCT01465867,hashimoto disease,Selenium Supplementation Treatment in Euthyroid Pregnant Women With Autoimmune Thyroid Disease: Effects on Obstetrical Complications,Selenium Supplementation in Pregnancy,Auto-immune Thyroiditis|Infertility|Pregnancy,2011-11-02,2017-06-30,2018-01-31,Interventional,Completed,Not Applicable,University of Roma La Sapienza,University of Roma La Sapienza,"Azienda ospedaliero-universitaria Careggi|Istituto Auxologico Italiano|Ospedale Maggiore Policlinico|University Federico II|University ""Piemonte Orientale, A. Avogadro""|Torvergata University of Rome - Ospedale S. Eugenio|European Hospital|Ospedale S. Giovanni Calibita Fatebenefratelli|Department of Experimental Medicine, ""Sapienza"" University of Rome|Department of Gynecological/Obstetric/Urological Sciences, ""Sapienza"" University of Rome|Dpt of Experimental Medicine",Dietary Supplement|Other|Other|Other,Italy,18.0,38.0,[18-65],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT01465867
NCT01471288,thyroid neoplasms,Evaluation of the Effect of Carum Carvi on Levels of Plasma Thyroid Hormones and TSH Level in Patients on Thyroid Hormone Therapy and Normal Controls.,Effect of Carum Carvi on Thyroid Hormones and TSH Level,Thyroid Cancer Patients,2011-07-21,2011-12-31,,Interventional,Unknown status,Phase 1/Phase 2,Mashhad University of Medical Sciences,Mashhad University of Medical Sciences|Pharmaceutical Research Center,"Nuclear Medicine Department, Ghaem Hospital",Drug|Drug,"Iran, Islamic Republic of",18.0,65.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01471288
NCT01479088,hyperparathyroidism,"Twelve-month, Multicenter, Intra-subject Controlled (Retrospective-prospective), Open-label, Active-treatment Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Cinacalcet Hydrochloride for the Treatment of Secondary Hyperparathyroidism (SHPT) in Paediatric Subjects With Chronic Kidney Disease (CKD) on Dialysis, Followed by 12-month Study Extension.",Cinacalcet in Paediatric Secondary Hyperparathyroidism (SHPT) Due to Chronic Kidney Disease (CKD),Secondary Hyperparathyroidism,2011-11-22,2013-12-31,2013-12-31,Interventional,Unknown status,Phase 2/Phase 3,Istituto Giannina Gaslini,ENRICO VERRINA,U.O. Nefrologia e Dialisi- Ospedale Giovanni XXIII|U.O. Nefrologia e Dialisi - Istituto di Ricovero e Cura a Carattere Scientifico Giannina Gaslini|U.O. Nefrologia e Dialisi Pediatrica - Clinica De Marchi|U.O. Nefrologia e Dialisi - Ospedale Santobono|U.O. Nefrologia e Dialisi - Ospedale Bambino Gesù,Drug,Italy,2.0,18.0,[0-17]|[18-65],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01479088
NCT01484379,hyperparathyroidism,Surgical Approach for Primary Hyperparathyroidism in the Elderly - a Prospective Study,Surgical Approach for Primary Hyperparathyroidism in the Elderly,Multigland Disease in Primary Hyperparathyroidism,2011-12-01,2015-11-30,2015-11-30,Interventional,Withdrawn,Not Applicable,Rambam Health Care Campus,Rambam Health Care Campus,Rambam Health Care Campus,Procedure,Israel,65.0,120.0,[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01484379
NCT01486667,hypothyroidism,"Effect of Thyroxin Treatment in Sub Clinical Hypothyroidism Patients, on the Apnea Hypopnea Index Score, Lipid Profiles and Highly Sensitive CRP : A Randomized Double Blind Controlled Trial","Thyroxin Treatment in Sub Clinical Hypothyroidism, on the Apnea Hypopnea Index Score, Lipids and Highly Sensitive CRP",Dyslipidemia,2011-12-03,2013-10-31,,Interventional,Unknown status,Phase 3,King Saud University,King Saud University,University Sleep Disorders Center,Drug|Drug,Saudi Arabia,18.0,80.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01486667
NCT01506947,hyperparathyroidism,"A Prospective, Non-randomised, Single-arm, Open-Label Pilot Clinical Study Evaluating the Effect of PTH Lowering on Erythropoietin Consumption in Calcitriol-Resistant Patients",A Pilot Clinical Study Evaluating the Effect of Parathyroid Hormone (PTH) Lowering On Erythropoietin Consumption in Calcitriol-Resistant Patients,Moderate to Severe Secondary Hyperparathyroidism|Stage 5 Chronic Kidney Diseases,2011-12-28,2016-04-07,2016-04-07,Interventional,Completed,Phase 4,AbbVie,"AbbVie (prior sponsor, Abbott)",,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01506947
NCT01528904,hypothyroidism,Fetal Thyroid Hormones Concentration In Hyperthyroid or Hypothyroid Pregnant Women,Maternal Autoimmune Thyroid Disease and Fetal Thyroxin,Hypothyroidism in Pregnancy|Pregnancy Complicated by Hyperthyroidism,2012-01-12,2011-03-31,2011-06-30,Observational,Completed,,University of Belgrade,University of Belgrade,Clinic for Gynecology and Obstetrics,,Serbia,23.0,45.0,[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01528904
NCT01528904,hyperthyroidism,Fetal Thyroid Hormones Concentration In Hyperthyroid or Hypothyroid Pregnant Women,Maternal Autoimmune Thyroid Disease and Fetal Thyroxin,Hypothyroidism in Pregnancy|Pregnancy Complicated by Hyperthyroidism,2012-01-12,2011-03-31,2011-06-30,Observational,Completed,,University of Belgrade,University of Belgrade,Clinic for Gynecology and Obstetrics,,Serbia,23.0,45.0,[18-65],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01528904
NCT01530919,hyperparathyroidism,Minimally Invasive Radioguided Parathyroidectomy,Minimally Invasive Radioguided Parathyroidectomy,Primary Hyperparathyroidism,2011-11-30,2009-12-31,2017-04-30,Observational,Completed,,University of Louisville,Jewish Hospital and St. Mary's Healthcare|Norton Healthcare|University of Louisville,University of Louisville,Procedure,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01530919
NCT01534169,graves disease,Function of Regulatory T Cells Improved by Treatment With an Intrathyroid Injection of Dexamethasone in Graves' Patients,Function of Regulatory T Cells Improved by Dexamethasone in Graves' Patients,Graves' Disease,2012-02-09,2012-03-31,2012-11-30,Interventional,Completed,Phase 1,Nanjing Medical University,Xiao-Ming Mao,Nanjing First Hospital Affiliated to Nanjing Medical University,Drug,China,20.0,60.0,[18-65],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT01534169
NCT01534169,goiter,Function of Regulatory T Cells Improved by Treatment With an Intrathyroid Injection of Dexamethasone in Graves' Patients,Function of Regulatory T Cells Improved by Dexamethasone in Graves' Patients,Graves' Disease,2012-02-09,2012-03-31,2012-11-30,Interventional,Completed,Phase 1,Nanjing Medical University,Xiao-Ming Mao,Nanjing First Hospital Affiliated to Nanjing Medical University,Drug,China,20.0,60.0,[18-65],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01534169
NCT01534169,hyperthyroidism,Function of Regulatory T Cells Improved by Treatment With an Intrathyroid Injection of Dexamethasone in Graves' Patients,Function of Regulatory T Cells Improved by Dexamethasone in Graves' Patients,Graves' Disease,2012-02-09,2012-03-31,2012-11-30,Interventional,Completed,Phase 1,Nanjing Medical University,Xiao-Ming Mao,Nanjing First Hospital Affiliated to Nanjing Medical University,Drug,China,20.0,60.0,[18-65],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01534169
NCT01539486,parathyroid diseases,Relationship of Preoperative PTH and Ex-Vivo Gamma Counts in Minimally Invasive Parathyroidectomy,Relationship of Preoperative Parathyroid Hormone (PTH) and Ex-Vivo Gamma Counts in Minimally Invasive Parathyroidectomy,Parathyroid Disease,2012-02-21,2023-12-31,2023-12-31,Observational,Active not recruiting,,University of Arkansas,University of Arkansas,University of Arkansas for Medical Sciences,,United States,18.0,90.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT01539486
NCT01539499,parathyroid diseases,Complications of Endocrine Surgery: Data From the United Health System Consortium,Complications of Endocrine Surgery: Data From the United HealthSystem Consortium,Endocrine Gland|Parathyroid Disease|Thyroid Disease,2012-02-21,2017-08-31,2017-08-31,Observational,Completed,,University of Arkansas,University of Arkansas,University of Arkansas for Medical Sciences,,United States,18.0,90.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT01539499
NCT01545622,parathyroid diseases,Surgeon Compared to Nuclear Radiology Readers for Tc-99m Sestamibi Scans for Parathyroid Disease,Surgeon Compared to Nuclear Radiology Readers for Tc-99m Sestamibi Scans for Parathyroid Disease,Parathyroid Disease,2012-02-21,2016-09-01,2016-09-01,Observational,Completed,,University of Arkansas,University of Arkansas,University of Arkansas for Medical Sciences,,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT01545622
NCT01558115,hyperparathyroidism,Denosumab in Primary Hyperparathyroidism,Denosumab in Primary Hyperparathyroidism,Primary Hyperparathyroidism,2012-03-16,2014-10-31,2014-10-31,Interventional,Completed,Phase 4,Columbia University,Amgen|John P. Bilezikian|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health (NIH),Columbia University Medical Center,Drug|Other,United States,40.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01558115
NCT01560299,hyperthyroidism,,Evaluation of Optimal Time of Methimazole Discontinuation Before Radio-iodine Therapy in Hyperthyroid Grave's Patients,Graves Disease,2012-03-01,2012-01-31,2012-01-31,Interventional,Completed,Not Applicable,Mashhad University of Medical Sciences,Mashhad University of Medical Sciences,Mashad University of Medical Sciences,Drug|Drug|Drug,"Iran, Islamic Republic of",18.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01560299
NCT01560299,goiter,,Evaluation of Optimal Time of Methimazole Discontinuation Before Radio-iodine Therapy in Hyperthyroid Grave's Patients,Graves Disease,2012-03-01,2012-01-31,2012-01-31,Interventional,Completed,Not Applicable,Mashhad University of Medical Sciences,Mashhad University of Medical Sciences,Mashad University of Medical Sciences,Drug|Drug|Drug,"Iran, Islamic Republic of",18.0,65.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01560299
NCT01571843,hyperparathyroidism,Effect of Mechanical Loading on Radius Bone Density and Microarchitecture in Primary Hyperparathyroidism,Radius Loading in Primary Hyperparathyroidism,"Bone Diseases, Metabolic|Bone Loss, Postmenopausal|Osteoporosis, Postmenopausal|Primary Hyperparathyroidism",2012-04-03,2014-10-31,2014-10-31,Interventional,Completed,Not Applicable,Columbia University,Columbia University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health (NIH),Columbia University Medical Center,Other|Other,United States,45.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01571843
NCT01574287,parathyroid neoplasms,Amino Acid Transport Imaging of Parathyroid Adenomas With Anti-3-[18F]FACBC,Anti-3-[18F]FACBC Imaging of Parathyroid Adenomas,Parathyroid Disease,2012-03-31,2019-05-15,2019-05-15,Interventional,Completed,Not Applicable,Emory University,"David M. Schuster, MD",Emory University,Drug,United States,18.0,99.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01574287
NCT01574859,hypothyroidism,Central Hypothyroidism and Cardiovascular Risk Factors,Central Hypothyroidism and Cardiovascular Risk,Hypopituitarism,2012-04-07,2012-11-30,2013-03-31,Observational,Completed,,"Rigshospitalet, Denmark","Rigshospitalet, Denmark",Rigshospitalet,Other,Denmark,0.0,120.0,[0-17]|[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01574859
NCT01576146,hyperparathyroidism,A Multicenter Open-label Extension Study to Assess the Long-term Safety and Efficacy of KAI-4169 (Also Known as AMG 416) in the Treatment of Chronic Kidney Disease-Mineral and Bone Disorder in Patients With Secondary Hyperparathyroidism,Open-label Study to Assess the Long-term Safety and Efficacy of Etelcalcetide (Also Known as AMG 416 or KAI-4169) in Patients With Secondary Hyperparathyroidism,Secondary Hyperparathyroidism,2012-04-05,2014-05-01,2014-05-01,Interventional,Terminated,Phase 2,KAI Pharmaceuticals,KAI Pharmaceuticals,,Drug,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01576146
NCT01579344,thyroid neoplasms,Lacrimal Drainage System Obstruction Associated to Radioactive Iodine Therapy for Thyroid Carcinoma,Lacrimal Drainage System Obstruction Associated to Radioactive Iodine Therapy for Thyroid Carcinoma,Lacrimal Apparatus Disease,2012-04-15,2014-03-31,,Interventional,Unknown status,Not Applicable,University of Sao Paulo,Fabricio Lopes da Fonseca,University of Sao Paulo; Ophthalmology Department,Drug,Brazil,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01579344
NCT01579539,graves ophthalmopathy,The Effect of Intravenous Glucocorticoids on the Tearfilm in Eyes With Thyroid-associated Ophthalmopathy,The Effect of Intravenous Glucocorticoids on the Tearfilm in Eyes With Thyroid-associated Ophthalmopathy,Dry Eye Syndrome|Thyroid-associated Ophthalmopathy,2012-04-13,2017-05-18,2017-05-18,Interventional,Completed,Phase 3,Medical University of Vienna,Medical University of Vienna,"Department of Clinical Pharmacology, Medical University of Vienna",Drug|Drug,Austria,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT01579539
NCT01579539,hyperthyroidism,The Effect of Intravenous Glucocorticoids on the Tearfilm in Eyes With Thyroid-associated Ophthalmopathy,The Effect of Intravenous Glucocorticoids on the Tearfilm in Eyes With Thyroid-associated Ophthalmopathy,Dry Eye Syndrome|Thyroid-associated Ophthalmopathy,2012-04-13,2017-05-18,2017-05-18,Interventional,Completed,Phase 3,Medical University of Vienna,Medical University of Vienna,"Department of Clinical Pharmacology, Medical University of Vienna",Drug|Drug,Austria,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01579539
NCT01579539,goiter,The Effect of Intravenous Glucocorticoids on the Tearfilm in Eyes With Thyroid-associated Ophthalmopathy,The Effect of Intravenous Glucocorticoids on the Tearfilm in Eyes With Thyroid-associated Ophthalmopathy,Dry Eye Syndrome|Thyroid-associated Ophthalmopathy,2012-04-13,2017-05-18,2017-05-18,Interventional,Completed,Phase 3,Medical University of Vienna,Medical University of Vienna,"Department of Clinical Pharmacology, Medical University of Vienna",Drug|Drug,Austria,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01579539
NCT01579539,graves disease,The Effect of Intravenous Glucocorticoids on the Tearfilm in Eyes With Thyroid-associated Ophthalmopathy,The Effect of Intravenous Glucocorticoids on the Tearfilm in Eyes With Thyroid-associated Ophthalmopathy,Dry Eye Syndrome|Thyroid-associated Ophthalmopathy,2012-04-13,2017-05-18,2017-05-18,Interventional,Completed,Phase 3,Medical University of Vienna,Medical University of Vienna,"Department of Clinical Pharmacology, Medical University of Vienna",Drug|Drug,Austria,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT01579539
NCT01598727,hyperparathyroidism,A Phase I Feasibility Study of Intra-operative Near Infra-red Fluorescent Imaging in Thyroid/Parathyroid Surgery With the Fluobeam(TM) System of Fluoptics,Near Infrared Fluorescent Imaging in Thyroid and Parathyroid Surgery With the Fluobeam(TM) System of Fluoptics,Primary Hyperparathyroidism,2012-05-03,2013-01-31,2013-04-30,Interventional,Completed,Phase 1,Sheffield Teaching Hospitals NHS Foundation Trust,"Fluoptics Ltd, Grenoble, France|Sheffield Teaching Hospitals NHS Foundation Trust",Department of General Surgery,Device,United Kingdom,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01598727
NCT01599273,goiter,,Treatment of Upper Eyelid Retraction Related to Thyroid-associated Ophthalmopathy Using Subconjunctival Triamcinolone Injections,Thyroid-associated Ophthalmopathy,2012-05-10,2014-08-31,2014-08-31,Interventional,Completed,Phase 4,Yonsei University,Yonsei University,Severance hospital,Drug,"Korea, Republic of",19.0,75.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01599273
NCT01599273,graves ophthalmopathy,,Treatment of Upper Eyelid Retraction Related to Thyroid-associated Ophthalmopathy Using Subconjunctival Triamcinolone Injections,Thyroid-associated Ophthalmopathy,2012-05-10,2014-08-31,2014-08-31,Interventional,Completed,Phase 4,Yonsei University,Yonsei University,Severance hospital,Drug,"Korea, Republic of",19.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT01599273
NCT01599273,graves disease,,Treatment of Upper Eyelid Retraction Related to Thyroid-associated Ophthalmopathy Using Subconjunctival Triamcinolone Injections,Thyroid-associated Ophthalmopathy,2012-05-10,2014-08-31,2014-08-31,Interventional,Completed,Phase 4,Yonsei University,Yonsei University,Severance hospital,Drug,"Korea, Republic of",19.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT01599273
NCT01599273,hyperthyroidism,,Treatment of Upper Eyelid Retraction Related to Thyroid-associated Ophthalmopathy Using Subconjunctival Triamcinolone Injections,Thyroid-associated Ophthalmopathy,2012-05-10,2014-08-31,2014-08-31,Interventional,Completed,Phase 4,Yonsei University,Yonsei University,Severance hospital,Drug,"Korea, Republic of",19.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01599273
NCT01609946,thyroid neoplasms,Evaluation of Realtime-Elastography for Differentiation of Thyroid Nodules: a Multicenter Study,Realtime-Elastography (RTE) and Thyroid Nodules,Thyroid Nodules,2012-05-30,2013-12-31,2014-12-31,Interventional,Completed,Not Applicable,Johann Wolfgang Goethe University Hospital,Johannes Vermehren,Caritas-Krankenhaus|Klinikum Bielefeld|Klinikum der J. W. Goethe-Universität|Bürgerhospital|Helfenstein Klinik|Universitätsklinikum Leipzig|Klinikum am Steinberg|Endokrinologie und Diabetologie im Zentrum|Universitätsklinikum Ulm|Deutsche Klinik für Diagnostik,Device|Procedure,Germany,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01609946
NCT01609946,thyroid nodule,Evaluation of Realtime-Elastography for Differentiation of Thyroid Nodules: a Multicenter Study,Realtime-Elastography (RTE) and Thyroid Nodules,Thyroid Nodules,2012-05-30,2013-12-31,2014-12-31,Interventional,Completed,Not Applicable,Johann Wolfgang Goethe University Hospital,Johannes Vermehren,Caritas-Krankenhaus|Klinikum Bielefeld|Klinikum der J. W. Goethe-Universität|Bürgerhospital|Helfenstein Klinik|Universitätsklinikum Leipzig|Klinikum am Steinberg|Endokrinologie und Diabetologie im Zentrum|Universitätsklinikum Ulm|Deutsche Klinik für Diagnostik,Device|Procedure,Germany,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT01609946
NCT01611896,hyperthyroidism,"GRAves Selenium Supplementation Trial (GRASS) - an Investigator-initiated Randomised, Blinded, Multicentre Clinical Trial of Selenium Supplementation Versus Placebo in Patients With Graves' Hyperthyroidism",Selenium Supplementation Versus Placebo in Patients With Graves' Hyperthyroidism,Graves' Hyperthyroidism,2012-05-29,2021-08-31,2021-08-31,Interventional,Active not recruiting,Not Applicable,"Rigshospitalet, Denmark","Bispebjerg Hospital|Copenhagen Trial Unit, Center for Clinical Intervention Research|Danish Council for Independent Research|Herlev Hospital|Hillerod Hospital, Denmark|Hospital of South West Denmark|Hvidovre University Hospital|Odense University Hospital|Rigshospitalet, Denmark|The Danish Council for Strategic Research","Department of Endocrinology and Gastroenterology, Bispebjerg Hospital|Department of Medical Endocrinology, Rigshospitalet|Department of Endocrinology, Hospital of Southwest Denmark|Department of Medicine, Gentofte Hospital|Department of Internal Medicine O 106, Endocrine Unit, Herlev Hospital|Department of Cardiology and Endocrinology, Endocrine Unit, Hillerød Hospital|Department of Endocrinology, Section 541, Hvidovre Hospital|Department of Endocrinology and Metabolism, Odense University Hospital",Dietary Supplement|Other,Denmark,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01611896
NCT01616108,hyperthyroidism,Bupivacaine Injection of Eye Muscles to Treat Strabismus,Bupivacaine Injection of Eye Muscles to Treat Strabismus,"Esotropia|Exotropia|Graves Disease|Ptosis, Eyelid|Strabismus",2012-06-07,2019-09-30,2020-09-30,Interventional,Unknown status,Phase 2/Phase 3,Smith-Kettlewell Eye Research Institute,Eidactics|Smith-Kettlewell Eye Research Institute|Strabismus Research Foundation|Sutter Health,Strabismus Research Foundation,Drug,United States,8.0,95.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01616108
NCT01616108,goiter,Bupivacaine Injection of Eye Muscles to Treat Strabismus,Bupivacaine Injection of Eye Muscles to Treat Strabismus,"Esotropia|Exotropia|Graves Disease|Ptosis, Eyelid|Strabismus",2012-06-07,2019-09-30,2020-09-30,Interventional,Unknown status,Phase 2/Phase 3,Smith-Kettlewell Eye Research Institute,Eidactics|Smith-Kettlewell Eye Research Institute|Strabismus Research Foundation|Sutter Health,Strabismus Research Foundation,Drug,United States,8.0,95.0,[0-17]|[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01616108
NCT01617694,thyroid neoplasms,,Comparison Between Remifentanil Target-controlled Infusion and Dexmedetomidine Bolus Administration for Smooth Emergence From General Sevoflurane Anesthesia,Thyroid Neoplasm,2012-06-05,2011-11-30,2011-11-30,Interventional,Completed,Not Applicable,Yonsei University,Yonsei University,Severance hospital,Drug|Drug,"Korea, Republic of",20.0,60.0,[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01617694
NCT01633853,hyperparathyroidism,"Study of Vitamin D2 Virus 1,25(OH)2-Vitamin D3 in the Treatment of Chronic Kidney Disease Mineral and Bone Disease",Efficacy of Vitamin D2 to Treat Chronic Kidney Disease Mineral and Bone Disorder,Vitamin D Deficiency,2012-06-29,2015-09-30,2015-09-30,Interventional,Completed,Phase 4,Capital Medical University,"Beijing Municipal Science & Technology Commission|Dongliang Zhang, MD",Beijing Friedship Hospital,Drug|Drug,China,18.0,75.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01633853
NCT01638533,thyroid neoplasms,"A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients With, Lymphomas, Chronic Lymphocytic Leukemia, and Select Solid Tumors and Varying Degrees of Liver Dysfunction","Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction",Glioma|Hematopoietic and Lymphoid Cell Neoplasm|Lymphoma|Metastatic Malignant Solid Neoplasm|Neuroendocrine Neoplasm|Recurrent Adult Soft Tissue Sarcoma|Recurrent Bladder Carcinoma|Recurrent Breast Carcinoma|Recurrent Chronic Lymphocytic Leukemia|Recurrent Colorectal Carcinoma|Recurrent Head and Neck Carcinoma|Recurrent Lung Carcinoma|Recurrent Malignant Solid Neoplasm|Recurrent Melanoma|Recurrent Pancreatic Carcinoma|Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Recurrent Prostate Carcinoma|Recurrent Renal Cell Carcinoma|Recurrent Thyroid Gland Carcinoma|Refractory Chronic Lymphocytic Leukemia|Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Stage IIIA Breast Cancer AJCC v7|Stage IIIA Colorectal Cancer AJCC v7|Stage IIIA Cutaneous Melanoma AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIB Colorectal Cancer AJCC v7|Stage IIIB Cutaneous Melanoma AJCC v7|Stage III Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7|Stage IIIC Colorectal Cancer AJCC v7|Stage IIIC Cutaneous Melanoma AJCC v7|Stage III Colorectal Cancer AJCC v7|Stage III Cutaneous Melanoma AJCC v7|Stage III Lung Cancer AJCC v7|Stage III Pancreatic Cancer AJCC v6 and v7|Stage III Prostate Cancer AJCC v7|Stage III Renal Cell Cancer AJCC v7|Stage III Soft Tissue Sarcoma AJCC v7|Stage IVA Colorectal Cancer AJCC v7|Stage IVB Colorectal Cancer AJCC v7|Stage IV Breast Cancer AJCC v6 and v7|Stage IV Colorectal Cancer AJCC v7|Stage IV Cutaneous Melanoma AJCC v6 and v7|Stage IV Lung Cancer AJCC v7|Stage IV Pancreatic Cancer AJCC v6 and v7|Stage IV Prostate Cancer AJCC v7|Stage IV Renal Cell Cancer AJCC v7|Stage IV Soft Tissue Sarcoma AJCC v7|Unresectable Solid Neoplasm,2012-07-09,2018-11-29,,Interventional,Active not recruiting,Phase 1,National Cancer Institute (NCI),Celgene Corporation|National Cancer Institute (NCI),City of Hope Comprehensive Cancer Center|University of California Davis Comprehensive Cancer Center|Emory University Hospital/Winship Cancer Institute|University of Chicago Comprehensive Cancer Center|Johns Hopkins University/Sidney Kimmel Cancer Center|National Cancer Institute Developmental Therapeutics Clinic|Wayne State University/Karmanos Cancer Institute|Mayo Clinic in Rochester|Case Western Reserve University|Penn State Milton S Hershey Medical Center|Thomas Jefferson University Hospital|University Health Network-Princess Margaret Hospital,Other|Drug,Canada|United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01638533
NCT01647503,parathyroid neoplasms,Identification of Differentially Expressed Proteins in Parathyroid Tumors and Their Clinical Correlation With the Disease,Differentially Expressed Proteins in Sporadic Parathyroid Tumors,Hypercalcemia|Primary Hyperparathyroidism,2012-07-18,2015-09-30,,Observational,Unknown status,,Postgraduate Institute of Medical Education and Research,Postgraduate Institute of Medical Education and Research,PGIMER,,India,15.0,65.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01647503
NCT01647503,hyperparathyroidism,Identification of Differentially Expressed Proteins in Parathyroid Tumors and Their Clinical Correlation With the Disease,Differentially Expressed Proteins in Sporadic Parathyroid Tumors,Hypercalcemia|Primary Hyperparathyroidism,2012-07-18,2015-09-30,,Observational,Unknown status,,Postgraduate Institute of Medical Education and Research,Postgraduate Institute of Medical Education and Research,PGIMER,,India,15.0,65.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01647503
NCT01648569,thyroid neoplasms,Proper Extent of Surgery for Papillary Microcarcinoma,Long-term Outcomes of Total Thyroidectomy Versus Less Than Total Thyroidectomy for Papillary Thyroid Microcarcinoma,Papillary Thyroid Microcarcinoma,2012-07-18,2012-05-31,2012-07-31,Observational,Completed,,Korean Association of Endocrine Surgeons,Korean Association of Endocrine Surgeons,Yonsei University College of Medicidine,,"Korea, Republic of",10.0,60.0,[0-17]|[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01648569
NCT01649206,thyroid neoplasms,Thyroid Nodules Treated With Percutaneous Radiofrequency Thermal Ablation: a Comparative Study,Percutaneous Radiofrequency Thermal Ablation in Compressive Thyroid Nodules,Thyroid Nodule,2012-07-16,2011-01-31,2011-06-30,Interventional,Completed,Phase 3,Federico II University,Federico II University,"""Federico II"" University of Naples, Department of Clinical and Molecular Endocrinology and Oncology",Procedure,Italy,18.0,87.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01649206
NCT01651000,hyperparathyroidism,"A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of CTAP101 Capsules to Treat Secondary Hyperparathyroidism in Subjects With Stage 3 or 4 Chronic Kidney Disease and Vitamin D Insufficiency",Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency,"Chronic Kidney Disease|Hyperparathyroidism, Secondary|Vitamin D Deficiency",2012-07-23,2014-07-31,2014-07-31,Interventional,Completed,Phase 3,"OPKO Health, Inc.","OPKO IP Holdings II, Inc.",OPKO Renal,Drug|Other,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01651000
NCT01653379,hyperparathyroidism,"A Phase 2A, Open-label, Dose-ranging and Pharmacokinetic Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis",A Phase 2A Dose-ranging and Pharmacokinetic Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism,Secondary Hyperparathyroidism,2012-07-25,2014-07-31,2014-07-31,Interventional,Completed,Phase 2,Deltanoid Pharmaceuticals,Deltanoid Pharmaceuticals,,Drug,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01653379
NCT01655719,thyroid neoplasms,Phase 2 Study of Pioglitazone in Thyroid Cancers That Contain the PAX8-PPARgamma Fusion Gene,Pioglitazone in Thyroid Cancers,Thyroid Cancers That Contain the PAX8-PPARgamma Fusion Gene,2012-07-25,2017-03-31,2017-03-31,Interventional,Completed,Phase 2,University of Michigan,National Cancer Institute (NCI)|University of Michigan,University of Colorado|University of Michigan|University of Pennsylvania|University of Texas MD Anderson Cancer Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01655719
NCT01660126,hypothyroidism,Multi-modal Effects of Thyroid Hormone Replacement for Untreated Older Adults With Subclinical Hypothyroidism; a Randomised Placebo-controlled Trial,Thyroid Hormone Replacement for Subclinical Hypothyroidism,Subclinical Hypothyroidism,2012-08-06,2016-11-18,2016-11-18,Interventional,Completed,Phase 4,NHS Greater Glasgow and Clyde,Leiden University Medical Center|NHS Greater Glasgow and Clyde|University College Cork|University of Bern|University of Glasgow,"Glasgow Royal Infirmary, NHS Greater Glasgow and Clyde",Drug|Drug,United Kingdom,65.0,120.0,[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01660126
NCT01661179,thyroid neoplasms,"A Phase I/II, Open-label Study to Evaluate the Safety and Tolerability of Vandetanib 300 mg/Day in Japanese Patients With Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma",Evaluate the Safety and Tolerability of Vandetanib in Japanese Patients With Medullary Thyroid Carcinoma,"Unresectable Locally Advanced or Metastatic, Medullary Thyroid Carcinoma",2012-07-17,2013-12-31,2014-07-31,Interventional,Completed,Phase 1/Phase 2,Sanofi,"Genzyme, a Sanofi Company",Research Site|Research Site|Research Site|Research Site,Drug,Japan,20.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01661179
NCT01665651,hyperparathyroidism,Effect of Kidney Yin/Yang Replenishment on Bone Metabolism in Patients With Renal Osteodystrophy,Kidney Yin/Yang Replenishment on Patients With Renal Osteodystrophy,"Renal Insufficiency, Chronic|Renal Osteodystrophy",2012-08-08,2017-05-31,2017-05-31,Interventional,Withdrawn,Phase 2,Shanghai University of Traditional Chinese Medicine,Bing Shu|Huadong Hospital|Longhua Hospital|The First Affiliated Hospital of Anhui University of Chinese Medicine,The first affiliated hospital of Anhui University of TCM|Huadong hospital affiliated to Fudan University|Longhua Hospital affiliated to Shanghai Uni of TCM,Drug|Drug|Drug|Drug,China,20.0,50.0,[18-65],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01665651
NCT01675089,hyperparathyroidism,A Prospective and Randomized Trial of Zoledronic Acid to Prevent Bone Loss in the First Year After Kidney Transplantation,Zoledronic Acid to Prevent Bone Loss After Kidney Transplantation,Renal Osteodystrophy,2012-08-23,2013-07-31,2014-05-31,Interventional,Completed,Phase 4,University of Sao Paulo General Hospital,University of Sao Paulo General Hospital,Hospital das Clinicas - Faculdade de Medicina da Universidade de São Paulo,Drug,Brazil,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01675089
NCT01690806,thyroid neoplasms,Dexamethasone for the Prevention of Recurrent Laryngeal Nerve Palsy (and Not Only) After Thyroid Surgery. A Randomized Double-blind Placebo-controlled Trial.,Dexamethasone for the Prevention of Recurrent Laryngeal Nerve Palsy,Benign Neoplasm of Thyroid Gland|Malignant Neoplasm of Thyroid,2012-09-19,2012-01-31,2012-03-31,Observational,Completed,,Università degli Studi dell'Aquila,Università degli Studi dell'Aquila,ospedale San Salvatore-Reparto di Chirurgia Generale Universitaria,,Italy,0.0,75.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01690806
NCT01704079,hyperparathyroidism,"A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of CTAP101 Capsules to Treat Secondary Hyperparathyroidism in Subjects With Stage 3 or 4 Chronic Kidney Disease and Vitamin D Insufficiency",Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency,"Chronic Kidney Disease|Hyperparathyroidism, Secondary|Vitamin D Deficiency",2012-10-06,2014-08-31,2014-09-30,Interventional,Completed,Phase 3,"OPKO Health, Inc.","OPKO IP Holdings II, Inc.",OPKO Renal,Drug|Other,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01704079
NCT01704586,thyroid neoplasms,Clinical Evaluation of a I-124 PET/CT Based Remnant Radioiodine Ablation Decision Concept in Differentiated Thyroid Cancer Using PROBE Design,I-124 PET/CT Based Remnant Radioiodine Ablation Decision Concept in Differentiated Thyroid Cancer,Differentiated Thyroid Carcinoma,2012-10-04,2021-05-31,2025-11-30,Interventional,Recruiting,Not Applicable,University of Wuerzburg,"Deutsche Krebshilfe e.V., Bonn (Germany)|University of Wuerzburg","Clinic of Nuclear Medicine, University Clinic Essen|University Clinic Würzburg",Radiation|Radiation,Germany,18.0,80.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01704586
NCT01725113,hyperparathyroidism,"A Randomized, Prospective, Cross-Over Study of Calcitriol vs. Paricalcitol in the Treatment of Mineral and Bone Disease in Hemodialysis Patients",Management of Mineral and Bone Disease in Hemodialysis-Calcitriol vs. Paricalcitol,Hypercalcemia|Hyperphosphatemia|Kidney Failure|Secondary Hyperparathyroidism,2012-11-07,2013-12-31,2015-10-31,Interventional,Terminated,Phase 4,Winthrop University Hospital,Winthrop University Hospital,Winthrop University Hospital,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01725113
NCT01727973,goiter,"Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy: a Prospective, Uncontrolled Pilot Study",Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy,"Autoimmune Diseases|Endocrine System Diseases|Eye Diseases|Eye Diseases, Hereditary|Graves Disease|Graves Ophthalmopathy|Hyperthyroidism|Immune System Diseases|Thyroid Diseases",2012-11-12,2013-11-30,2013-11-30,Interventional,Completed,Phase 1/Phase 2,Sun Yat-sen University,Sun Yat-sen University,Zhongshan Ophthalmic Center,Drug,China,18.0,60.0,[18-65],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01727973
NCT01738243,graves disease,Phase IV Study of Hyaluronic Acid Gels for Upper Lid Retraction in Active Stage Thyroid Eye Disease,Hyaluronic Acid Gels for Upper Lid Retraction in Active Stage Thyroid Eye Disease,Thyroid Eye Disease,2012-10-06,2021-09-30,2021-09-30,Interventional,Terminated,Phase 4,"University of California, Los Angeles","University of California, Los Angeles",Jules Stein Eye Institute|The Jules Stein Eye Institute at UCLA,Drug|Drug,United States,21.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT01738243
NCT01738243,goiter,Phase IV Study of Hyaluronic Acid Gels for Upper Lid Retraction in Active Stage Thyroid Eye Disease,Hyaluronic Acid Gels for Upper Lid Retraction in Active Stage Thyroid Eye Disease,Thyroid Eye Disease,2012-10-06,2021-09-30,2021-09-30,Interventional,Terminated,Phase 4,"University of California, Los Angeles","University of California, Los Angeles",Jules Stein Eye Institute|The Jules Stein Eye Institute at UCLA,Drug|Drug,United States,21.0,65.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01738243
NCT01738243,hyperthyroidism,Phase IV Study of Hyaluronic Acid Gels for Upper Lid Retraction in Active Stage Thyroid Eye Disease,Hyaluronic Acid Gels for Upper Lid Retraction in Active Stage Thyroid Eye Disease,Thyroid Eye Disease,2012-10-06,2021-09-30,2021-09-30,Interventional,Terminated,Phase 4,"University of California, Los Angeles","University of California, Los Angeles",Jules Stein Eye Institute|The Jules Stein Eye Institute at UCLA,Drug|Drug,United States,21.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01738243
NCT01739972,hypothyroidism,"Desiccated Thyroid Extract Compared to Levothyroxine in the Treatment of Hypothyroidism: A Randomized, Double-blind, Crossover Study.",Desiccated Thyroid Extract and Levothyroxine for Hypothyroidism Treatment,Primary Hypothyroidism.,2012-11-28,2014-05-31,2014-05-31,Interventional,Unknown status,Not Applicable,Walter Reed National Military Medical Center,Walter Reed National Military Medical Center,"Walter Reed National Military Medical Center, Endocrinology|Walter Reed National Military Medical Center",Drug|Drug,United States,18.0,65.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01739972
NCT01741064,hyperparathyroidism,Secondary Hyperparathyroidism Related Vascular and Bone Morbidity After Renal Transplantation - a 6 Year Follow up Retrospective Cohort Study.,Morbidity Related to Secondary Hyperparathyroidism After Renal Transplantation,Disorder Related to Renal Transplantation|Secondary Hyperparathyroidism,2012-11-30,2012-10-31,2012-10-31,Observational,Completed,,Skane University Hospital,Karolinska University Hospital|Skane University Hospital,,,,18.0,85.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01741064
NCT01744769,thyroid neoplasms,Effects of Thyroid Hormone Withdrawal on Metabolic and Cardiovascular Parameters During Radioactive Iodine Therapy in Differentiated Thyroid Cancer,Effects of Thyroid Hormone Withdrawal on Metabolic Parameters During Radioactive Iodine Therapy in Thyroid Cancer,Hypothyroidism,2012-12-05,2013-05-31,2013-05-31,Observational,Unknown status,,Konkuk University Medical Center,Konkuk University Medical Center,Konkuk University Medical Center,,"Korea, Republic of",18.0,80.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01744769
NCT01750593,thyroid neoplasms,Efficacy of Radiofrequency Ablation in Thyroid Nodules,Radiofrequency Ablation in Thyroid Nodules,Thyroid Nodules,2012-10-07,2014-01-31,2014-06-30,Interventional,Unknown status,Not Applicable,Bezmialem Vakif University,Bezmialem Vakif University,Bezmialem Vakif University medical Faculty|Bezmialem Vakif University|Bezmialem Vakif University,Procedure,Turkey,18.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01750593
NCT01750593,thyroid nodule,Efficacy of Radiofrequency Ablation in Thyroid Nodules,Radiofrequency Ablation in Thyroid Nodules,Thyroid Nodules,2012-10-07,2014-01-31,2014-06-30,Interventional,Unknown status,Not Applicable,Bezmialem Vakif University,Bezmialem Vakif University,Bezmialem Vakif University medical Faculty|Bezmialem Vakif University|Bezmialem Vakif University,Procedure,Turkey,18.0,70.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT01750593
NCT01756534,thyroid neoplasms,The Effectiveness of an Oxidized Cellulose Patch Hemostatic Agent in Thyroid Surgery: a Prospective Randomized Controlled Study,Oxidized Cellulose Hemostatic Agent in Thyroid Surgery: a Prospective Randomized Controlled Study,Goiter|Thyroid Diseases|Thyroid Nodule,2012-12-19,2013-03-31,2013-12-31,Interventional,Unknown status,Not Applicable,Tel-Aviv Sourasky Medical Center,Tel-Aviv Sourasky Medical Center,Tel Aviv Medical Center,Device,Israel,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01756534
NCT01757834,thyroid neoplasms,Efficacy of Shear Wave Ultrasound Elastography in Noninvasive Diagnosis of Thyroid Nodules,Shear Wave Ultrasound Elastography in Noninvasive Diagnosis of Thyroid Nodules,Thyroid Nodule,2012-12-12,2015-07-31,2015-08-31,Interventional,Unknown status,Not Applicable,University of Washington,National Cancer Institute (NCI)|University of Washington,University of Washington Medical Center,Device,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01757834
NCT01760421,hashimoto disease,The Effect of Hydroxychloroquine Treatment in Hashimoto's Thyroiditis,The Effect of Hydroxychloroquine Treatment in Hashimoto's Thyroiditis,Hashimoto Thyroiditis,2011-10-20,2012-12-31,2013-08-31,Interventional,Completed,Not Applicable,National Taiwan University Hospital,National Taiwan University Hospital,"Department of Internal Medicine, National Taiwan University Hospital",Drug,Taiwan,20.0,60.0,[18-65],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT01760421
NCT01776502,hyperparathyroidism,"A Prospective, Non Randomized, Open, Multicenter Trial to Evaluate Non Specific Symptoms and Quality of Life (SF 36) Before and After Surgery for Mild Primary Hyperparathyroidism",Evaluation of Non Specific Symptoms and Quality of Life Before and After Surgery for Mild Primary Hyperparathyroidism,Primary Hyperparathyroidism,2012-10-24,2010-06-30,2011-06-30,Observational,Completed,,Nantes University Hospital,Nantes University Hospital,Angers University Hospital|Limoges University Hospital|Marseille University Hospital|Nantes University Hospital,,France,0.0,50.0,[0-17]|[18-65],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01776502
NCT01778400,thyroid neoplasms,Single Session Treatment of RFA Versus EA for Predominantly Cystic Thyroid Nodules: A Randomized Controlled Trial,RFA (Radiofrequency Ablation) Versus EA (Ethanol Ablation) for Predominantly Cystic Thyroid Nodules,Thyroid Nodule,2013-01-25,2013-05-31,2014-01-31,Interventional,Unknown status,Not Applicable,Asan Medical Center,Asan Medical Center,Asan Medical Center,Procedure|Procedure,"Korea, Republic of",20.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01778400
NCT01779817,hyperthyroidism,"Assessment of Intellectual, Psychological and Behavioural Developments Between 6 and 9 Years of the Children Born to Hyperthyroid Mothers During Pregnancy","Assessment of Intellectual, Psychological and Behavioural Developments Between 6 and 9 Years of the Children Born to Hyperthyroid Mothers During Their Pregnancy",Hyperthyroid,2013-01-28,2019-01-31,2019-01-31,Interventional,Unknown status,Phase 4,"University Hospital, Angers","University Hospital, Angers",University Hospital of Amiens|University Hospital of Angers|Civil Hospices of Lyon|University Hospital of Kremlin Bicetre|University Hospital of Lille|University Hospital of Marseille|University Hospital of Nantes|Hospital of Saint Antoine|University Hospital of Cochin|University Hospital of Poitiers|University Hospital of Reims|University Hospital of Strasbourg|University Hospital of Toulouse,Behavioral,France,6.0,9.0,[0-17],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01779817
NCT01781923,hypoparathyroidism,A Remediation Program for Children at High-Risk of Schizophrenia: 22q11.2 Deletion Syndrome,Cognitive Remediation in 22q11DS,22q11.2 Deletion Syndrome|Velo-Cardio-Facial Syndrome,2013-01-29,2015-06-30,2015-06-30,Interventional,Completed,Not Applicable,Duke University,Duke University|Harvard University|National Institute of Mental Health (NIMH)|University of Pittsburgh,Duke University Health Systems,Behavioral|Behavioral,United States,11.0,17.0,[0-17],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01781923
NCT01783002,hyperparathyroidism,"Pre-operative Parathyroid Imaging: a Comparison of 11C-Methionine PET, 18F-FDG PET AND SPEC-CT for the Detection of Hyperfunctional Parathyroid Tissues",11C Methionine PET for the Detection of Hyperfunctional Parathyroid Tissues,Primary Hyperparathyroidism,2013-01-04,2018-03-31,2018-07-31,Interventional,Unknown status,Phase 2,University of British Columbia,British Columbia Cancer Agency|University of British Columbia,British Columbia Cancer Agency,Radiation|Radiation|Radiation,Canada,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01783002
NCT01785849,hyperparathyroidism,"A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis",Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease on Hemodialysis,"Hyperparathyroidism, Secondary",2013-02-05,2014-05-22,2014-06-12,Interventional,Completed,Phase 3,Amgen,Amgen,Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug|Drug,Australia|Austria|Belgium|Canada|Czechia|France|Germany|Hungary|Israel|Italy|Poland|Russian Federation|Spain|United Kingdom|United States,18.0,100.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01785849
NCT01785875,hyperparathyroidism,A Multicenter Single-arm Extension Study to Describe the Long-term Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis,Extension Study of Etelcalcetide in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis,"Hyperparathyroidism, Secondary",2013-02-05,2015-07-01,2015-07-01,Interventional,Completed,Phase 3,Amgen,Amgen,Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug,Australia|Austria|Belgium|Canada|Czechia|France|Germany|Hungary|Israel|Italy|Netherlands|Poland|Russian Federation|Spain|Sweden|United Kingdom|United States,18.0,100.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01785875
NCT01788046,hyperparathyroidism,"A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis",Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis,"Hyperparathyroidism, Secondary",2013-02-07,2014-04-14,2014-05-09,Interventional,Completed,Phase 3,Amgen,Amgen,Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug|Drug,Australia|Belgium|Canada|Czechia|France|Germany|Hungary|Israel|Italy|Netherlands|Poland|Russian Federation|Spain|Sweden|United States,18.0,100.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01788046
NCT01788982,thyroid neoplasms,A Phase II Study Exploring the Safety and Efficacy of Nintedanib (BIBF1120) as Second Line Therapy for Patients With Either Differentiated or Medullary Thyroid Cancer Progressing After First Line Therapy.,Nintedanib(BIBF1120) in Thyroid Cancer,Differentiated Thyroid Cancer (DTC)|Medullary Thyroid Cancer (MTC),2013-02-08,2019-08-28,2019-08-28,Interventional,Completed,Phase 2,European Organisation for Research and Treatment of Cancer - EORTC,European Organisation for Research and Treatment of Cancer - EORTC,"A.Z. St. Jan|Hopitaux Universitaires Bordet-Erasme - Institut Jules Bordet|Cliniques Universitaires Saint-Luc|Universitair Ziekenhuis Antwerpen|Universitair Ziekenhuis Gent|U.Z. Leuven - Campus Gasthuisberg|Odense University Hospital|CHU d'Angers|Institut Bergonie|Centre Regional Francois Baclesse|Centre Georges-Francois-Leclerc|Centre Leon Berard|Assitance Publique - Hopitaux de Paris - Hopital Saint-Louis|Assistance Publique - Hopitaux de Paris - La Pitié Salpétrière|Centre Jean Godinot|Institut Gustave Roussy|Ludwig-Maximilians-Universitaet Muenchen - Klinikum der Universitaet Muenchen - Campus Grosshadern|Universitaetsklinikum Wuerzburg|Fondazione IRCCS Istituto Nazionale dei Tumori|Azienda Ospedaliera Universitaria ""Federico II""|University Medical Center Groningen|Leiden University Medical Centre|Radboud University Medical Center Nijmegen|Maria Sklodowska-Curie Memorial Cancer Centre|Hospital General Vall D'Hebron|Royal Marsden Hospital - Sutton, Surrey|NHS Greater Glasgow and Clyde - Beatson West of Scotland Cancer Centre - Gartnavel General Hospital",Drug|Drug,Belgium|Denmark|France|Germany|Italy|Netherlands|Poland|Spain|United Kingdom,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01788982
NCT01789541,hyperthyroidism,Observational Prospective Case-control Study on Prevalence and Impact of Subclinical Hyperthyroidism in Patients Undergoing Atrial Fibrillation Ablation,Is a Low Thyreotropin Level Predictive of Recurrent Arrhythmia After Catheter Ablative Surgery?,Atrial Fibrillation|Subclinical Hyperthyroidism,2013-02-05,2015-10-31,2015-11-30,Observational,Completed,,Karolinska Institutet,Karolinska Institutet,"Stockholm Arrhythmia Center|Hjärtkliniken, Karolinska Universitetssjukhuset Huddinge",,Sweden,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01789541
NCT01794676,parathyroid diseases,A Pilot Study of Genetic Evaluation of Families With Endocrine Cancers,Genetic Evaluation of Families With Endocrine Cancers,MEN1 Syndrome|Pancreatic Cancer|Parathyroid Disease|Thymic Cancer,2013-02-15,2015-09-30,2015-10-31,Observational,Completed,,Jersey Shore University Medical Center,Jersey Shore University Medical Center|Rutgers Cancer Institute of New Jersey|Rutgers University,Jersey Shore University Medical Center,Genetic,United States,13.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT01794676
NCT01798966,hyperthyroidism,The Effects of Orbital Decompression Surgery on Intraocular Pressure Patterns in Patient With Thyroid Eye Disease Undergoing 24 Hour Continuous IOP Monitoring With the SENSIMED Triggerfish®,Twenty-four Hour Intraocular Pressure Patterns in Patients With Uncontrolled Thyroid Eye Disease,Thyroid Eye Disease,2013-02-21,2013-06-30,2013-06-30,Interventional,Completed,Not Applicable,Sensimed AG,"Sensimed AG|University of California, San Diego","Shiley Eye Center, University of California, San Diego",Device,United States,18.0,90.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01798966
NCT01798966,goiter,The Effects of Orbital Decompression Surgery on Intraocular Pressure Patterns in Patient With Thyroid Eye Disease Undergoing 24 Hour Continuous IOP Monitoring With the SENSIMED Triggerfish®,Twenty-four Hour Intraocular Pressure Patterns in Patients With Uncontrolled Thyroid Eye Disease,Thyroid Eye Disease,2013-02-21,2013-06-30,2013-06-30,Interventional,Completed,Not Applicable,Sensimed AG,"Sensimed AG|University of California, San Diego","Shiley Eye Center, University of California, San Diego",Device,United States,18.0,90.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01798966
NCT01798966,graves disease,The Effects of Orbital Decompression Surgery on Intraocular Pressure Patterns in Patient With Thyroid Eye Disease Undergoing 24 Hour Continuous IOP Monitoring With the SENSIMED Triggerfish®,Twenty-four Hour Intraocular Pressure Patterns in Patients With Uncontrolled Thyroid Eye Disease,Thyroid Eye Disease,2013-02-21,2013-06-30,2013-06-30,Interventional,Completed,Not Applicable,Sensimed AG,"Sensimed AG|University of California, San Diego","Shiley Eye Center, University of California, San Diego",Device,United States,18.0,90.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT01798966
NCT01805856,parathyroid diseases,Antimicrobial Prophylaxis for the Prevention of Surgical Site Infection in Thyroid and Parathyroid Surgery,Antimicrobial Prophylaxis in Thyroid and Parathyroid Surgery,Parathyroid Disease|Thyroid Disease,2013-03-05,2012-05-31,2012-05-31,Interventional,Completed,Not Applicable,Ito Hospital,Ito Hospital,Ito Hospital,Drug|Drug,Japan,10.0,90.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT01805856
NCT01809444,graves ophthalmopathy,"The Effect of Prednisone Versus Doxycycline in Active, Moderately Severe Graves' Orbitopathy: A Randomized, Multi-center, Double-blind, Parallel-controlled Trial",Prednisone Versus Doxycycline in the Treatment of Graves' Orbitopathy,Thyroid Associated Opthalmopathies,2012-12-02,2016-01-31,2016-01-31,Interventional,Unknown status,Phase 2/Phase 3,Sun Yat-sen University,Sun Yat-sen University,"Peking Union Medical College Hospital|Zhongshan Ophthalmic Center|JOINT SHANTOU INTERNATIONALL EYE CENTER of Shantou University and the Chinese University of Hong Kong|Shenzhen Eye Hospital|Henan Eye Institue, Henan, China|The second xiangya hospital of central south university",Drug|Drug,China,18.0,60.0,[18-65],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT01809444
NCT01809444,hyperthyroidism,"The Effect of Prednisone Versus Doxycycline in Active, Moderately Severe Graves' Orbitopathy: A Randomized, Multi-center, Double-blind, Parallel-controlled Trial",Prednisone Versus Doxycycline in the Treatment of Graves' Orbitopathy,Thyroid Associated Opthalmopathies,2012-12-02,2016-01-31,2016-01-31,Interventional,Unknown status,Phase 2/Phase 3,Sun Yat-sen University,Sun Yat-sen University,"Peking Union Medical College Hospital|Zhongshan Ophthalmic Center|JOINT SHANTOU INTERNATIONALL EYE CENTER of Shantou University and the Chinese University of Hong Kong|Shenzhen Eye Hospital|Henan Eye Institue, Henan, China|The second xiangya hospital of central south university",Drug|Drug,China,18.0,60.0,[18-65],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01809444
NCT01809444,graves disease,"The Effect of Prednisone Versus Doxycycline in Active, Moderately Severe Graves' Orbitopathy: A Randomized, Multi-center, Double-blind, Parallel-controlled Trial",Prednisone Versus Doxycycline in the Treatment of Graves' Orbitopathy,Thyroid Associated Opthalmopathies,2012-12-02,2016-01-31,2016-01-31,Interventional,Unknown status,Phase 2/Phase 3,Sun Yat-sen University,Sun Yat-sen University,"Peking Union Medical College Hospital|Zhongshan Ophthalmic Center|JOINT SHANTOU INTERNATIONALL EYE CENTER of Shantou University and the Chinese University of Hong Kong|Shenzhen Eye Hospital|Henan Eye Institue, Henan, China|The second xiangya hospital of central south university",Drug|Drug,China,18.0,60.0,[18-65],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT01809444
NCT01809444,goiter,"The Effect of Prednisone Versus Doxycycline in Active, Moderately Severe Graves' Orbitopathy: A Randomized, Multi-center, Double-blind, Parallel-controlled Trial",Prednisone Versus Doxycycline in the Treatment of Graves' Orbitopathy,Thyroid Associated Opthalmopathies,2012-12-02,2016-01-31,2016-01-31,Interventional,Unknown status,Phase 2/Phase 3,Sun Yat-sen University,Sun Yat-sen University,"Peking Union Medical College Hospital|Zhongshan Ophthalmic Center|JOINT SHANTOU INTERNATIONALL EYE CENTER of Shantou University and the Chinese University of Hong Kong|Shenzhen Eye Hospital|Henan Eye Institue, Henan, China|The second xiangya hospital of central south university",Drug|Drug,China,18.0,60.0,[18-65],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01809444
NCT01811212,"adenocarcinoma, follicular",Phase II Study of Cabozantinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on Prior VEGFR-Targeted Therapy,Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer,Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Carcinoma|Stage III Thyroid Gland Follicular Carcinoma|Stage III Thyroid Gland Papillary Carcinoma|Stage II Thyroid Gland Follicular Carcinoma|Stage II Thyroid Gland Papillary Carcinoma|Stage I Thyroid Gland Follicular Carcinoma|Stage I Thyroid Gland Papillary Carcinoma|Stage IVA Thyroid Gland Follicular Carcinoma|Stage IVA Thyroid Gland Papillary Carcinoma|Stage IVB Thyroid Gland Follicular Carcinoma|Stage IVB Thyroid Gland Papillary Carcinoma|Stage IVC Thyroid Gland Follicular Carcinoma|Stage IVC Thyroid Gland Papillary Carcinoma|Tall Cell Variant Thyroid Gland Papillary Carcinoma|Thyroid Gland Oncocytic Follicular Carcinoma,2013-03-12,2015-07-13,2017-10-09,Interventional,Completed,Phase 2,National Cancer Institute (NCI),Exelixis|National Cancer Institute (NCI),MedStar Georgetown University Hospital|Mayo Clinic in Florida|University of Chicago Comprehensive Cancer Center|Massachusetts General Hospital Cancer Center|Mayo Clinic|Ohio State University Comprehensive Cancer Center|M D Anderson Cancer Center,Drug|Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT01811212
NCT01821781,hypoparathyroidism,A Study of Hematopoietic Stem Cell Transplantation (HSCT) in Immune Function Disorders Using a Reduced Intensity Preparatory Regime,Immune Disorder HSCT Protocol,Autoimmune Lymphoproliferative Syndrome|Chediak-Higashi Syndrome|Chronic Granulomatous Disease|Common Variable Immune Deficiency|DiGeorge Syndrome|Hemophagocytic Lymphohistiocytosis|Hyper-IgM|Immune Deficiency Disorders|Immune Dysregulatory Disorders|IPEX|Severe Combined Immunodeficiency|Wiskott-Aldrich Syndrome|X-linked Agammaglobulinemia|X-linked Lymphoproliferative Syndrome,2013-03-19,2024-03-31,2024-03-31,Interventional,Recruiting,Phase 2,Washington University School of Medicine,Washington University School of Medicine,Washington University,Drug,United States,0.0,21.0,[0-17]|[18-65],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01821781
NCT01830504,thyroid neoplasms,A Multicenter Phase II Pilot Open Label Study to Evaluate the Efficacy and Safety of BKM120 in the Treatment of Patients With Advanced or Metastatic Differentiated Thyroid Cancers,A Multicenter Phase II Pilot Open Label,Thyroid Cancers,2013-04-04,2013-04-30,2017-01-31,Interventional,Unknown status,Phase 2,Hospices Civils de Lyon,Hospices Civils de Lyon,Hospices Civils de Lyon,Drug,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01830504
NCT01832753,hypothyroidism,Levothyroxine Treatment and Cardiometabolic Outcomes in Adolescents With Down Syndrome,Treatment Trial of Subclinical Hypothyroidism in Down Syndrome,Down Syndrome|Subclinical Hypothyroidism,2013-04-09,2017-10-18,2017-10-18,Interventional,Completed,Not Applicable,Children's Hospital of Philadelphia,Children's Hospital of Philadelphia|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Children's National Medical Center|The Children's Hospital of Philadelphia,Drug,United States,8.0,20.0,[0-17]|[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01832753
NCT01837433,thyroiditis,Efficiency and Safety Study of Short-term Prednisone to Treat Moderate and Severe Subacute Thyroiditis,Short-term Prednisone to Treat STA Study(SPTSS),Subacute Thyroiditis,2013-04-06,2014-12-31,2014-12-31,Interventional,Completed,Phase 4,Xinqiao Hospital of Chongqing,Xinqiao Hospital of Chongqing,"The Second Affiliated Hospital, Third Military Medical University",Drug|Drug,China,18.0,70.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT01837433
NCT01837745,thyroid neoplasms,Differentiated Thyroid Cancer: is There a Need for Radioiodine Ablation in Low Risk Patients?,Differentiated Thyroid Cancer: is There a Need for Radioiodine Ablation in Low Risk Patients?,Low Risk Differentiated Thyroid Cancer,2013-04-16,2020-03-31,2022-05-12,Interventional,Active not recruiting,Phase 3,"Gustave Roussy, Cancer Campus, Grand Paris","Gustave Roussy, Cancer Campus, Grand Paris",Institut Gustave Roussy,Drug|Drug|Other,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01837745
NCT01838031,hypothyroidism,Randomized Thyroid Screening Protocol During Pregnancy: a Multi-center Prospective Controlled Study,Thyroid Screening Protocol During Pregnancy: a Multi-center Prospective Controlled Study,Subclinical Hypothyroidism,2013-04-14,2013-09-30,2013-09-30,Interventional,Completed,Not Applicable,Peking Union Medical College Hospital,Beijing Municipal Science & Technology Commission|Peking Union Medical College Hospital,Peking Union Medical College Hospital,Other,China,18.0,42.0,[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01838031
NCT01838629,thyroid neoplasms,,the Effect of Universal Salt Iodization on Thyroid Diseases,Thyroid Nodule,2013-04-19,2012-06-30,2012-06-30,Observational [Patient Registry],Completed,,Hangzhou Center of Disease Control and Prevention,Weimin Xu,Hangzhou Center of Disease Control and Prevention,,China,6.0,86.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01838629
NCT01853579,hypothyroidism,Thyroid Hormone Replacement for Subclinical Hypothyroidism (TRUST) - Subanalysis on Subclinical Hypothyroidism and Depression,The TRUST Study - Depression Substudy,Depression|Subclinical Hypothyroidism,2013-05-06,2018-04-05,2018-04-05,Interventional,Completed,Phase 4,"University Hospital Inselspital, Berne","Leiden University Medical Center|University Hospital Inselspital, Berne|University of Bern","Leiden University Medical Center|Department of General Internal Medicine|University Clinic for General Internal Medicine, Bern University Hospital",Drug|Drug,Netherlands|Switzerland,65.0,120.0,[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01853579
NCT01856920,thyroid neoplasms,A Phase 2 Study of GI-6207 in Patients With Recurrent Medullary Thyroid Cancer,QUILT-3.006 for Recurrent Medullary Thyroid Cancer,Medullary Thyroid Cancer (MTC),2013-05-08,2019-12-31,2020-03-01,Interventional,Unknown status,Phase 2,"NantCell, Inc.","NantCell, Inc.|National Cancer Institute (NCI)",NIH Clinical Center,Biological,United States,18.0,100.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01856920
NCT01868750,thyroid neoplasms,"A Phase 2, Placebo-controlled, Randomized Study to Evaluate the Effect of Pre-operative Vitamin D Supplementation on Hypocalcemia Following Total or Near-total Thyroidectomy",Phase II Pre-operative Vitamin D Supplementation to Prevent Post-thyroidectomy Hypocalcemia,Hypocalcemia|Thyroid Nodules,2013-05-30,2021-07-08,2021-07-08,Interventional,Completed,Phase 2,University of Virginia,"David Shonka, MD",University of Virginia,Dietary Supplement|Dietary Supplement,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01868750
NCT01868750,thyroid nodule,"A Phase 2, Placebo-controlled, Randomized Study to Evaluate the Effect of Pre-operative Vitamin D Supplementation on Hypocalcemia Following Total or Near-total Thyroidectomy",Phase II Pre-operative Vitamin D Supplementation to Prevent Post-thyroidectomy Hypocalcemia,Hypocalcemia|Thyroid Nodules,2013-05-30,2021-07-08,2021-07-08,Interventional,Completed,Phase 2,University of Virginia,"David Shonka, MD",University of Virginia,Dietary Supplement|Dietary Supplement,United States,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT01868750
NCT01868997,goiter,"A Multicenter, Double-Masked, Placebo-Controlled, Efficacy And Safety Study Of RV 001, An Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), Administered Every 3 Weeks (q3W) By Intravenous (IV) Infusion In Patients Suffering From Active Thyroid Eye Disease (TED)",Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease,Thyroid Associated Ophthalmopathies|Thyroid-Associated Ophthalmopathy,2013-05-02,2016-03-31,2017-02-22,Interventional,Completed,Phase 2,"Horizon Pharma USA, Inc.","Horizon Pharma USA, Inc.","Jules Stein Eye Institute at UCLA|University of Denver|Emory University Department of Ophthalmology|University of Iowa Hospitals and Clinics, Department of Ophthalmology|Kellogg Eye Center at University of Michigan|Washington University Department of Ophthalmology|University of Nebraska Medical Center Department of Ophthalmology|Casey Eye Institute at Oregon Health and Science University|Hamilton Eye Institute at University of Tennessee|Eye Wellness Center|Medical College of Wisconsin, The Eye Institute|Johannes Gutenberg University Medical Center|Fondazione Ca' Granda Ospedale Policlinico Graves GO Center|University of Pisa, Azienda Ospedaliera|Moorfields Eye Hospital",Drug|Drug,Germany|Italy|United Kingdom|United States,18.0,75.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01868997
NCT01868997,hyperthyroidism,"A Multicenter, Double-Masked, Placebo-Controlled, Efficacy And Safety Study Of RV 001, An Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), Administered Every 3 Weeks (q3W) By Intravenous (IV) Infusion In Patients Suffering From Active Thyroid Eye Disease (TED)",Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease,Thyroid Associated Ophthalmopathies|Thyroid-Associated Ophthalmopathy,2013-05-02,2016-03-31,2017-02-22,Interventional,Completed,Phase 2,"Horizon Pharma USA, Inc.","Horizon Pharma USA, Inc.","Jules Stein Eye Institute at UCLA|University of Denver|Emory University Department of Ophthalmology|University of Iowa Hospitals and Clinics, Department of Ophthalmology|Kellogg Eye Center at University of Michigan|Washington University Department of Ophthalmology|University of Nebraska Medical Center Department of Ophthalmology|Casey Eye Institute at Oregon Health and Science University|Hamilton Eye Institute at University of Tennessee|Eye Wellness Center|Medical College of Wisconsin, The Eye Institute|Johannes Gutenberg University Medical Center|Fondazione Ca' Granda Ospedale Policlinico Graves GO Center|University of Pisa, Azienda Ospedaliera|Moorfields Eye Hospital",Drug|Drug,Germany|Italy|United Kingdom|United States,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01868997
NCT01868997,graves disease,"A Multicenter, Double-Masked, Placebo-Controlled, Efficacy And Safety Study Of RV 001, An Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), Administered Every 3 Weeks (q3W) By Intravenous (IV) Infusion In Patients Suffering From Active Thyroid Eye Disease (TED)",Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease,Thyroid Associated Ophthalmopathies|Thyroid-Associated Ophthalmopathy,2013-05-02,2016-03-31,2017-02-22,Interventional,Completed,Phase 2,"Horizon Pharma USA, Inc.","Horizon Pharma USA, Inc.","Jules Stein Eye Institute at UCLA|University of Denver|Emory University Department of Ophthalmology|University of Iowa Hospitals and Clinics, Department of Ophthalmology|Kellogg Eye Center at University of Michigan|Washington University Department of Ophthalmology|University of Nebraska Medical Center Department of Ophthalmology|Casey Eye Institute at Oregon Health and Science University|Hamilton Eye Institute at University of Tennessee|Eye Wellness Center|Medical College of Wisconsin, The Eye Institute|Johannes Gutenberg University Medical Center|Fondazione Ca' Granda Ospedale Policlinico Graves GO Center|University of Pisa, Azienda Ospedaliera|Moorfields Eye Hospital",Drug|Drug,Germany|Italy|United Kingdom|United States,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT01868997
NCT01880203,thyroid neoplasms,Diagnostic Value of Molecular Cytological Analysis (CMA) and Shear Wave Elastography ShearWave (SWE) in Patients With a Thyroid Nodule With Indeterminate Cytology: Feasibility Study,Diagnostic Value of Molecular Cytological Analysis (CMA) and Shear Wave Elastography ShearWave (SWE) in Patients With a Thyroid Nodule With Indeterminate Cytology: Feasibility Study,Indeterminate Cytology|Surgery Indication|Thyroid Node,2013-06-14,2015-09-30,2015-11-30,Interventional,Completed,Not Applicable,Centre Francois Baclesse,Centre Francois Baclesse|Fondation avenir|laboratoire Genzyme,Centre François BACLESSE|CHU|Hôpital Américain de Paris|Hôpital Pitié-salpétrière,Procedure,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01880203
NCT01880203,thyroid nodule,Diagnostic Value of Molecular Cytological Analysis (CMA) and Shear Wave Elastography ShearWave (SWE) in Patients With a Thyroid Nodule With Indeterminate Cytology: Feasibility Study,Diagnostic Value of Molecular Cytological Analysis (CMA) and Shear Wave Elastography ShearWave (SWE) in Patients With a Thyroid Nodule With Indeterminate Cytology: Feasibility Study,Indeterminate Cytology|Surgery Indication|Thyroid Node,2013-06-14,2015-09-30,2015-11-30,Interventional,Completed,Not Applicable,Centre Francois Baclesse,Centre Francois Baclesse|Fondation avenir|laboratoire Genzyme,Centre François BACLESSE|CHU|Hôpital Américain de Paris|Hôpital Pitié-salpétrière,Procedure,France,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT01880203
NCT01884649,hashimoto disease,Fetuin A as a New Marker of Inflammation in Hashimoto Thyroiditis,Fetuin A in Hashimoto Thyroiditis,Hashimoto Thyroiditis,2013-06-17,2012-10-31,2012-10-31,Observational [Patient Registry],Completed,,Istanbul Medeniyet University,Istanbul Medeniyet University,,,,20.0,120.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT01884649
NCT01885533,graves disease,POST-RADIOIODINE GRAVES' MANAGEMENT,Post-Radioiodine Graves' Management: The PRAGMA-Study,Graves' Disease,2013-02-15,2015-02-28,2015-12-31,Observational,Completed,,Newcastle-upon-Tyne Hospitals NHS Trust,Cardiff and Vale University Health Board|Newcastle-upon-Tyne Hospitals NHS Trust|Royal Devon and Exeter NHS Foundation Trust,Newcastle upon Tyne Hospitals NHS Foundation Trust|Newcastle upon Tyne Hospitals NHS Foundation Trust,,United Kingdom,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT01885533
NCT01885533,goiter,POST-RADIOIODINE GRAVES' MANAGEMENT,Post-Radioiodine Graves' Management: The PRAGMA-Study,Graves' Disease,2013-02-15,2015-02-28,2015-12-31,Observational,Completed,,Newcastle-upon-Tyne Hospitals NHS Trust,Cardiff and Vale University Health Board|Newcastle-upon-Tyne Hospitals NHS Trust|Royal Devon and Exeter NHS Foundation Trust,Newcastle upon Tyne Hospitals NHS Foundation Trust|Newcastle upon Tyne Hospitals NHS Foundation Trust,,United Kingdom,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01885533
NCT01885533,hyperthyroidism,POST-RADIOIODINE GRAVES' MANAGEMENT,Post-Radioiodine Graves' Management: The PRAGMA-Study,Graves' Disease,2013-02-15,2015-02-28,2015-12-31,Observational,Completed,,Newcastle-upon-Tyne Hospitals NHS Trust,Cardiff and Vale University Health Board|Newcastle-upon-Tyne Hospitals NHS Trust|Royal Devon and Exeter NHS Foundation Trust,Newcastle upon Tyne Hospitals NHS Foundation Trust|Newcastle upon Tyne Hospitals NHS Foundation Trust,,United Kingdom,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01885533
NCT01889134,hyperparathyroidism,Osteoprotegerin/sRANKL Ratio and Bone Mineral Density in Patients With Primary Hyperparathyroidism Treated With Parathyroidectomy or Alendronate,OPG/Soluble RANKL (sRANKL) and Bone Mineral Density in Primary Hyperparathyroidism,Primary Hyperparathyroidism,2013-06-21,2012-06-30,2012-10-31,Interventional,Completed,Not Applicable,Wroclaw Medical University,"Ministry of Science and Higher Education, Poland|Wroclaw Medical University","Department of Endocrinology, Diabetology and Isotope Therapy, Wroclaw Medical University",Drug|Procedure,Poland,25.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01889134
NCT01893450,graves disease,"Comparison of the Effect of Bromocriptine and Pentoxifylline in Mild to Moderate Autoimmune Ophthalmopathy. A Randomized, Controlled, Single Blind, Clinical Trial.",Bromocriptine and Pentoxifylline in Ophthalmopathy Autoimmune Treatment,Graves Ophthalmopathy,2013-06-28,2013-06-30,2013-06-30,Interventional,Terminated,Not Applicable,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,Drug|Drug|Drug,Mexico,18.0,45.0,[18-65],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT01893450
NCT01893450,goiter,"Comparison of the Effect of Bromocriptine and Pentoxifylline in Mild to Moderate Autoimmune Ophthalmopathy. A Randomized, Controlled, Single Blind, Clinical Trial.",Bromocriptine and Pentoxifylline in Ophthalmopathy Autoimmune Treatment,Graves Ophthalmopathy,2013-06-28,2013-06-30,2013-06-30,Interventional,Terminated,Not Applicable,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,Drug|Drug|Drug,Mexico,18.0,45.0,[18-65],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01893450
NCT01893450,hyperthyroidism,"Comparison of the Effect of Bromocriptine and Pentoxifylline in Mild to Moderate Autoimmune Ophthalmopathy. A Randomized, Controlled, Single Blind, Clinical Trial.",Bromocriptine and Pentoxifylline in Ophthalmopathy Autoimmune Treatment,Graves Ophthalmopathy,2013-06-28,2013-06-30,2013-06-30,Interventional,Terminated,Not Applicable,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,Drug|Drug|Drug,Mexico,18.0,45.0,[18-65],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01893450
NCT01896232,hyperparathyroidism,"A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism",Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet,Chronic Kidney Disease|Secondary Hyperparathyroidism,2013-07-08,2014-11-12,2015-01-08,Interventional,Completed,Phase 3,Amgen,Amgen,Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug|Drug|Drug|Drug,Austria|Belgium|Canada|Czechia|Denmark|Estonia|France|Germany|Greece|Hungary|Italy|Latvia|Lithuania|New Zealand|Poland|Portugal|Russian Federation|Spain|Sweden|Switzerland|Turkey|United States,18.0,85.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01896232
NCT01922843,hyperparathyroidism,"A Phase 2B, Double-blind, Randomized, Placebo-controlled, Proof-of-concept Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis",A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis,"Hyperparathyroidism, Secondary|Kidney Failure, Chronic",2013-08-12,2014-05-31,2014-06-30,Interventional,Completed,Phase 2,Deltanoid Pharmaceuticals,Deltanoid Pharmaceuticals,,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01922843
NCT01927406,graves disease,The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.,The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.,Glaucoma|Ocular Hypertension|Thyroid Eye Disease,2013-08-16,2016-12-31,2016-12-31,Interventional,Withdrawn,Phase 4,Stanford University,Stanford University,Stanford Hospital and Clinics,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT01927406
NCT01927406,goiter,The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.,The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.,Glaucoma|Ocular Hypertension|Thyroid Eye Disease,2013-08-16,2016-12-31,2016-12-31,Interventional,Withdrawn,Phase 4,Stanford University,Stanford University,Stanford Hospital and Clinics,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01927406
NCT01927406,hyperthyroidism,The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.,The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.,Glaucoma|Ocular Hypertension|Thyroid Eye Disease,2013-08-16,2016-12-31,2016-12-31,Interventional,Withdrawn,Phase 4,Stanford University,Stanford University,Stanford Hospital and Clinics,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01927406
NCT01927887,"thyroid cancer, papillary",Pre-Operative Nodal Staging of Thyroid Cancer Using Ultra-Small Superparamagnetic Iron Oxide Magnetic Resonance Imaging (USPIO MRI): Preliminary Study,Pre-Operative Nodal Staging of Thyroid Cancer Using USPIO MRI: Preliminary Study,Follicular Thyroid Cancer Lymph Node Metastasis|Metastatic Medullary Thyroid Cancer|Papillary Carcinoma of Thyroid Gland,2013-08-20,2015-04-30,2016-04-30,Interventional,Completed,Not Applicable,Massachusetts General Hospital,Massachusetts General Hospital,Massachusetts General Hospital,Drug|Device,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT01927887
NCT01932970,hyperparathyroidism,"A Multicenter, Multiple-dose, Single-arm Study to Switch Hemodialysis Subjects With Secondary Hyperparathyroidism From Oral Cinacalcet HCl to Intravenous AMG 416",Study to Assess the Impact on Calcium Levels When Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) Switch From Cinacalcet to Etelcalcetide,"Hyperparathyroidism, Secondary",2013-08-28,2014-01-14,2017-02-14,Interventional,Completed,Phase 3,Amgen,Amgen,Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug,United States,18.0,100.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01932970
NCT01939977,hyperparathyroidism,Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Renal Transplantation.,Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Kidney Transplantation.,Secondary Hyperparathyroidism Due to Renal Causes,2013-08-28,2015-09-30,2015-12-31,Interventional,Completed,Phase 4,Fundación Senefro,AbbVie|Effice Servicios Para la Investigacion S.L.|Fundación Senefro,Hospital Universitari Germans Trias I Pujol de Badalona|Hospital Universitari de Bellvitge|Hospital Universitario Marqués de Valdecilla|Hospital Del Mar|Fundació Puigvert-Iuna|Hospital Universitari Vall D'Hebron|Hospital Puerta Del Mar|Hospital Reina Sofía|Complexo Hospitalario Universitario A Coruna|Complejo Hospitalario Universitario de Canarias|Hospital Ramón Y Cajal|Hospital Universitario 12 de Octubre|Complejo Hospitalario Regional de Málaga|Hospital Virgen Del Rocío|Hospital Universitari I Politècnic La Fe|Hospital Universitario Miguel Servet,Drug|Drug,Spain,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01939977
NCT01945762,thyroid neoplasms,"European, Observational, Prospective Study to Evaluate the Benefit/Risk of Vandetanib in RET Mutation Negative and Positive Patients With Symptomatic, Aggressive, Sporadic, Unresectable, Locally Advanced/Metastatic Medullary Thyroid Cancer",Observational Study to Evaluate Vandetanib in RET -/+ Patients With Metastatic Medullary Thyroid Cancer,"Advanced/Metastatic Medullary Thyroid Cancer (MTC)|Symptomatic, Aggressive, Sporadic, Unresectable, Locally",2013-09-10,2020-06-18,2020-06-18,Observational,Completed,,Sanofi,"Genzyme, a Sanofi Company|Worldwide Clinical Trials",investigational Site Belgium|investigational Site France|investigational Site Germany|investigational Site Italy|investigational Site Luxembourg|investigational Site Netherlands|investigational Site Spain|investigational Site United Kingdom,Drug,Belgium|France|Germany|Italy|Luxembourg|Netherlands|Spain|United Kingdom,18.0,99.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01945762
NCT01950260,graves disease,Prevention of Overt Hypothyroidism Following Radioactive Iodine Therapy for Graves' Disease,Early Levothyroxine Post Radioactive Iodine,Graves' Disease,2013-09-23,2017-04-30,2017-04-30,Interventional,Completed,Phase 2/Phase 3,Mayo Clinic,Mayo Clinic,Mayo Clinic in Rochester,Drug|Other,United States,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT01950260
NCT01950260,hyperthyroidism,Prevention of Overt Hypothyroidism Following Radioactive Iodine Therapy for Graves' Disease,Early Levothyroxine Post Radioactive Iodine,Graves' Disease,2013-09-23,2017-04-30,2017-04-30,Interventional,Completed,Phase 2/Phase 3,Mayo Clinic,Mayo Clinic,Mayo Clinic in Rochester,Drug|Other,United States,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01950260
NCT01950260,goiter,Prevention of Overt Hypothyroidism Following Radioactive Iodine Therapy for Graves' Disease,Early Levothyroxine Post Radioactive Iodine,Graves' Disease,2013-09-23,2017-04-30,2017-04-30,Interventional,Completed,Phase 2/Phase 3,Mayo Clinic,Mayo Clinic,Mayo Clinic in Rochester,Drug|Other,United States,18.0,70.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01950260
NCT01969019,graves ophthalmopathy,A Randomized Trial of Intravenous Pulse Versus Sequential Steroid Therapy for Patients With Graves' Orbitopathy,"A Prospective, Randomized Trial of Intravenous Pulse Versus Sequential Steroid Therapy for Patients With Graves' Orbitopathy",Graves' Ophthalmopathy,2013-10-21,2013-10-31,2013-10-31,Interventional,Unknown status,Phase 4,Ruijin Hospital,Ruijin Hospital,"Shanghai Institute of Endocrine and Metabolic Diseases Department of Endocrine and Metabolic Diseases, Ruijin Hospital",Drug,China,18.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT01969019
NCT01969019,graves disease,A Randomized Trial of Intravenous Pulse Versus Sequential Steroid Therapy for Patients With Graves' Orbitopathy,"A Prospective, Randomized Trial of Intravenous Pulse Versus Sequential Steroid Therapy for Patients With Graves' Orbitopathy",Graves' Ophthalmopathy,2013-10-21,2013-10-31,2013-10-31,Interventional,Unknown status,Phase 4,Ruijin Hospital,Ruijin Hospital,"Shanghai Institute of Endocrine and Metabolic Diseases Department of Endocrine and Metabolic Diseases, Ruijin Hospital",Drug,China,18.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT01969019
NCT01969019,goiter,A Randomized Trial of Intravenous Pulse Versus Sequential Steroid Therapy for Patients With Graves' Orbitopathy,"A Prospective, Randomized Trial of Intravenous Pulse Versus Sequential Steroid Therapy for Patients With Graves' Orbitopathy",Graves' Ophthalmopathy,2013-10-21,2013-10-31,2013-10-31,Interventional,Unknown status,Phase 4,Ruijin Hospital,Ruijin Hospital,"Shanghai Institute of Endocrine and Metabolic Diseases Department of Endocrine and Metabolic Diseases, Ruijin Hospital",Drug,China,18.0,65.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01969019
NCT01969019,hyperthyroidism,A Randomized Trial of Intravenous Pulse Versus Sequential Steroid Therapy for Patients With Graves' Orbitopathy,"A Prospective, Randomized Trial of Intravenous Pulse Versus Sequential Steroid Therapy for Patients With Graves' Orbitopathy",Graves' Ophthalmopathy,2013-10-21,2013-10-31,2013-10-31,Interventional,Unknown status,Phase 4,Ruijin Hospital,Ruijin Hospital,"Shanghai Institute of Endocrine and Metabolic Diseases Department of Endocrine and Metabolic Diseases, Ruijin Hospital",Drug,China,18.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01969019
NCT01985204,hypothyroidism,Assessment of the Improvement of the Cardiovascular Risk Profile in Obese Women After Correction of Iodine Deficiency,Iodine Supplementation in Obesity,Iodine Deficiency|Subclinical Hypothyroidism,2013-10-31,2014-06-30,2014-07-31,Interventional,Completed,Not Applicable,Swiss Federal Institute of Technology,Swiss Federal Institute of Technology,"Universite Caddi Ayad, Faculte de Medecine et de Pharmacie|University Cadi Ayyad, Faculte des Sciences",Dietary Supplement|Dietary Supplement,Morocco,20.0,50.0,[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01985204
NCT01996072,hyperparathyroidism,A Pilot & Feasibility Study of the Imaging Potential of EC17 in Subjects Undergoing Parathyroidectomy for Primary Hyperparathyroidism.,EC17 for Intraoperative Imaging for Parathyroidectomy,Primary Hyperparathyroidism,2013-11-21,2014-09-30,2014-09-30,Interventional,Completed,Phase 1,University of Pennsylvania,University of Pennsylvania,Hospital of the University of Pennsylvania,Drug,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01996072
NCT01999790,graves disease,Comparison Study Between Two Techniques for Correction of Upper Lid Retraction in Patients With Grave's Orbitopathy,Comparison Study Between Two Techniques for Correction of Upper Lid Retraction in Patients With Grave's Orbitopathy,Graves Ophthalmopathy,2013-11-17,2014-12-31,2015-02-28,Interventional,Unknown status,Not Applicable,University of Sao Paulo,University of Sao Paulo,Hospital das Clinicas - FMUSP,Procedure|Procedure,Brazil,21.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT01999790
NCT01999790,goiter,Comparison Study Between Two Techniques for Correction of Upper Lid Retraction in Patients With Grave's Orbitopathy,Comparison Study Between Two Techniques for Correction of Upper Lid Retraction in Patients With Grave's Orbitopathy,Graves Ophthalmopathy,2013-11-17,2014-12-31,2015-02-28,Interventional,Unknown status,Not Applicable,University of Sao Paulo,University of Sao Paulo,Hospital das Clinicas - FMUSP,Procedure|Procedure,Brazil,21.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01999790
NCT01999790,hyperthyroidism,Comparison Study Between Two Techniques for Correction of Upper Lid Retraction in Patients With Grave's Orbitopathy,Comparison Study Between Two Techniques for Correction of Upper Lid Retraction in Patients With Grave's Orbitopathy,Graves Ophthalmopathy,2013-11-17,2014-12-31,2015-02-28,Interventional,Unknown status,Not Applicable,University of Sao Paulo,University of Sao Paulo,Hospital das Clinicas - FMUSP,Procedure|Procedure,Brazil,21.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01999790
NCT02017080,hyperthyroidism,Efficacy Of Non Invasive Diagnostic Procedures In Evaluating The Influence Of Maternal Autoimmune Thyroid Gland Disease On Fetus,Fetal Thyroid Ultrasound And Fetal Thyroid Hormones,Hypothyroidism in Pregnancy|Pregnancy Complicated by Hyperthyroidism,2013-12-15,2019-12-31,2020-01-31,Observational,Unknown status,,University of Belgrade,University of Belgrade,"Clinic for Gynecology and Obstetrics , Clinical Center of Serbia",,Serbia,20.0,45.0,[18-65],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02017080
NCT02017080,hypothyroidism,Efficacy Of Non Invasive Diagnostic Procedures In Evaluating The Influence Of Maternal Autoimmune Thyroid Gland Disease On Fetus,Fetal Thyroid Ultrasound And Fetal Thyroid Hormones,Hypothyroidism in Pregnancy|Pregnancy Complicated by Hyperthyroidism,2013-12-15,2019-12-31,2020-01-31,Observational,Unknown status,,University of Belgrade,University of Belgrade,"Clinic for Gynecology and Obstetrics , Clinical Center of Serbia",,Serbia,20.0,45.0,[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT02017080
NCT02024906,hypothyroidism,Effect of Soy Intake on Cardiovascular Disease Biomarkers in Subclinical Hypothyroid Participants,Effect of Soy Intake on Cardiovascular Disease Biomarkers in Subclinical Hypothyroid Participants,Cardiovascular Disease|Subclinical Hypothyroid,2013-12-27,2015-09-30,2015-09-30,Interventional,Withdrawn,Not Applicable,University of Kansas Medical Center,"Jill Hamilton-Reeves, PhD RD LD|Soy Nutrition Institute",University of Kansas Medical Center,Dietary Supplement|Dietary Supplement,United States,25.0,70.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT02024906
NCT02041260,thyroid neoplasms,A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting,A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting,Differentiated Thyroid Cancer (DTC)|Poorly Differentiated Thyroid Cancer,2014-01-17,2022-05-31,2022-05-31,Interventional,Active not recruiting,Phase 2,Thomas Jefferson University,Thomas Jefferson University,Abramson Cancer Center of the University of Pennsylvania,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02041260
NCT02054572,hyperparathyroidism,"An Open-label, Single-dose Study to Evaluate the Pharmacokinetics, Biotransformation and Excretion of [¹⁴C]AMG 416 in Patients With End Stage Renal Disease Receiving Dialysis",Pharmacokinetics and Excretion of [¹⁴C]Etelcalcetide (AMG 416) in Patients With End Stage Renal Disease (ESRD) Receiving Dialysis,Secondary Hyperparathyroidism in Patients With ESRD on Hemodialysis,2014-02-03,2014-04-15,2014-08-15,Interventional,Completed,Phase 1,Amgen,Amgen,DaVita Clinical Research Center,Drug,United States,18.0,80.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02054572
NCT02055989,thyroid neoplasms,"A Phase I/II Study of the Use of Intensity Modulated Radiotherapy (IMRT) in Cancer of the Thyroid, Larynx and Hypopharynx","A Phase I/II Study of the Use of Intensity Modulated Radiotherapy (IMRT) in Cancer of the Thyroid, Larynx and Hypopharynx","Locally Advanced Larynx, Hypopharyngeal Squamous Cell Cancers|Locally Advanced Thyroid Cancers",2014-02-04,2011-12-31,,Interventional,Completed,Phase 1/Phase 2,Royal Marsden NHS Foundation Trust,Royal Marsden NHS Foundation Trust,Royal Marsden Hospital,Radiation|Radiation,United Kingdom,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02055989
NCT02056730,hyperparathyroidism,The Study of Efficacy and Safety of Calcium Sensing Receptor in Chronic Dialysis Patients,The Study of Efficacy and Safety of REGPARA Drug in Dialysis Patients Have High Blood Levels of Parathyroid,"Hyperparathyroidism, Secondary",2014-01-28,2015-02-28,2015-02-28,Interventional,Completed,Phase 4,Chulalongkorn University,Chulalongkorn University,Chulalongkorn Memorial Hospital,Drug,Thailand,18.0,80.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02056730
NCT02059655,goiter,Prostaglandin F2-alpha Eye Drops (Bimatoprost) in Thyroid Eye Disease: a Randomised Controlled Double Blind Crossover Trial,Prostaglandin F2-alpha Eye Drops in Thyroid Eye Disease (Bima Study),Graves' Ophthalmopathy,2014-02-07,2016-03-31,2016-03-31,Interventional,Completed,Phase 4,Cardiff University,Cardiff University|National Institute for Social Care and Health Research,University Hospital of Wales,Drug|Drug,United Kingdom,18.0,75.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02059655
NCT02059655,hyperthyroidism,Prostaglandin F2-alpha Eye Drops (Bimatoprost) in Thyroid Eye Disease: a Randomised Controlled Double Blind Crossover Trial,Prostaglandin F2-alpha Eye Drops in Thyroid Eye Disease (Bima Study),Graves' Ophthalmopathy,2014-02-07,2016-03-31,2016-03-31,Interventional,Completed,Phase 4,Cardiff University,Cardiff University|National Institute for Social Care and Health Research,University Hospital of Wales,Drug|Drug,United Kingdom,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02059655
NCT02059655,graves ophthalmopathy,Prostaglandin F2-alpha Eye Drops (Bimatoprost) in Thyroid Eye Disease: a Randomised Controlled Double Blind Crossover Trial,Prostaglandin F2-alpha Eye Drops in Thyroid Eye Disease (Bima Study),Graves' Ophthalmopathy,2014-02-07,2016-03-31,2016-03-31,Interventional,Completed,Phase 4,Cardiff University,Cardiff University|National Institute for Social Care and Health Research,University Hospital of Wales,Drug|Drug,United Kingdom,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT02059655
NCT02059655,graves disease,Prostaglandin F2-alpha Eye Drops (Bimatoprost) in Thyroid Eye Disease: a Randomised Controlled Double Blind Crossover Trial,Prostaglandin F2-alpha Eye Drops in Thyroid Eye Disease (Bima Study),Graves' Ophthalmopathy,2014-02-07,2016-03-31,2016-03-31,Interventional,Completed,Phase 4,Cardiff University,Cardiff University|National Institute for Social Care and Health Research,University Hospital of Wales,Drug|Drug,United Kingdom,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02059655
NCT02061111,hypothyroidism,NeoThyr - the Role of Mitochondria-dysfunction in Newborns of Mothers With Autoimmune Thyroid Disease,NeoThyr - the Role of Mitochondria-dysfunction in Newborns of Mothers With Autoimmune Thyroid Disease,Alteration of Mitochondrial Membrane|Autoimmune Thyroid Disease|Subclinical Hypothyroidism,2014-01-22,2017-12-31,2022-11-30,Observational,Active not recruiting,,Naestved Hospital,Naestved Hospital|Region Zealand|University of Southern Denmark,Gynaecologic-Obstetrics Department Naestved Hospital,,Denmark,18.0,50.0,[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT02061111
NCT02070211,hypoparathyroidism,"Indicated Prevention With Long-chain Polyunsaturated Omega-3 Fatty Acids in Patients With 22q11 Microdeletion Syndrome Genetically at High Risk for Psychosis: A Randomised, Double Blind, Placebo-controlled Treatment Trial.",Indicated Prevention With Long-chain Polyunsaturated Omega-3 Fatty Acids in Patients With 22q11 Microdeletion Syndrome.,22q11 Deletion Syndrome,2014-02-17,2016-06-30,2016-06-30,Interventional,Unknown status,Phase 2/Phase 3,Bambino Gesù Hospital and Research Institute,Bambino Gesù Hospital and Research Institute|National Alliance for Research on Schizophrenia and Depression|Orygen,Bambino Gesù Hospital and Research Institute,Dietary Supplement|Other|Dietary Supplement,Holy See (Vatican City State),12.0,26.0,[0-17]|[18-65],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02070211
NCT02089542,hyperparathyroidism,Development of a Clinical Protocol to Use Intra-operative Near Infra-red Fluorescent Imaging in Thyroid and Parathyroid Surgery,Intra-operative Infra-red Fluorescent Imaging in Thyroid and Parathyroid Surgery,Bilateral Neck Exploration for Primary Hyperparathyroidism|Total Thyroidectomy,2014-03-13,2016-06-30,2016-10-31,Interventional,Completed,Phase 1/Phase 2,Sheffield Teaching Hospitals NHS Foundation Trust,Sheffield Teaching Hospitals NHS Foundation Trust,Department of General Surgery,Other,United Kingdom,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02089542
NCT02090907,hypothyroidism,Effects of Levothyroxine on Endothelial Function of Patients With Subclinical Hypothyroidism,Effects of Levothyroxine on Endothelial Function of Patients With Subclinical Hypothyroidism,Subclinical Hypothyroidism,2014-03-12,2014-02-28,2014-02-28,Interventional,Completed,Phase 2/Phase 3,Isfahan University of Medical Sciences,Isfahan University of Medical Sciences,Khorshid endocrinology clinic,Drug|Drug,"Iran, Islamic Republic of",18.0,65.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT02090907
NCT02102204,hyperparathyroidism,A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis,Extension Study of Etelcalcetide for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on Hemodialysis,"Hyperparathyroidism, Secondary",2014-03-03,2016-11-04,2017-06-26,Interventional,Completed,Phase 3,Amgen,Amgen,Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug,Australia|Austria|Belgium|Canada|Czechia|Denmark|France|Germany|Greece|Hungary|Israel|Italy|Latvia|Lithuania|Netherlands|New Zealand|Poland|Portugal|Russian Federation|Spain|Sweden|Switzerland|Turkey|United States,18.0,110.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02102204
NCT02107794,graves disease,Shared Decision Making in Graves Disease - Graves Disease (GD) Choice,Shared Decision Making in Graves Disease - Graves Disease (GD) Choice,Graves' Disease|Hyperthyroidism|Thyroid Disease,2014-03-24,2015-04-30,2015-04-30,Interventional,Completed,Not Applicable,Mayo Clinic,Mayo Clinic,Mayo Clinic,Other,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02107794
NCT02107794,goiter,Shared Decision Making in Graves Disease - Graves Disease (GD) Choice,Shared Decision Making in Graves Disease - Graves Disease (GD) Choice,Graves' Disease|Hyperthyroidism|Thyroid Disease,2014-03-24,2015-04-30,2015-04-30,Interventional,Completed,Not Applicable,Mayo Clinic,Mayo Clinic,Mayo Clinic,Other,United States,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02107794
NCT02109250,thyroid neoplasms,CAPRELSA® REGISTRY: a Belgian Registry to Evaluate the Use of Vandetanib (Caprelsa®) in Current Clinical Practice,CAPRELSA® REGISTRY: a Belgian Registry to Evaluate the Use of Vandetanib (Caprelsa®) in Current Clinical Practice,Metastatic Medullary Thyroid Cancer,2014-03-27,2015-06-30,2015-06-30,Observational [Patient Registry],Completed,,Sanofi,"Genzyme, a Sanofi Company",Clinique du Sud Luxembourg|AZ Klina|Institut Jules Bordet|UZ Brussel|UCL St-Luc|UZ Gent|AZ Delta|CH de Wallonie,Drug,Belgium,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02109250
NCT02112370,thyroid neoplasms,Phase 3 Study of Ropivacaine (With Epinephrine) in BABA Endoscopic and Robotic Thyroidectomy,Efficacy of Ropivacaine (With Epinephrine) in BABA Endoscopic and Robotic Thyroidectomy,Goiter|Thyroid Neoplasm,2014-04-07,2016-05-31,2016-06-30,Interventional,Completed,Phase 3,Seoul National University Hospital,Seoul National University Bundang Hospital|Seoul National University Hospital,Seoul National University Bundang Hospital|Seoul National University Hospital,Drug|Other,"Korea, Republic of",18.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02112370
NCT02112643,graves disease,Selenium - ITEDS: A North American Study,Selenium in Mild Thyroid Eye Disease in North America,Thyroid Associated Ophthalmopathies,2014-04-08,2016-11-16,2016-11-16,Interventional,Withdrawn,Phase 3,Columbia University,Columbia University|International Thyroid Eye Disease Society,,Drug|Dietary Supplement,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02112643
NCT02112643,hyperthyroidism,Selenium - ITEDS: A North American Study,Selenium in Mild Thyroid Eye Disease in North America,Thyroid Associated Ophthalmopathies,2014-04-08,2016-11-16,2016-11-16,Interventional,Withdrawn,Phase 3,Columbia University,Columbia University|International Thyroid Eye Disease Society,,Drug|Dietary Supplement,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02112643
NCT02112643,goiter,Selenium - ITEDS: A North American Study,Selenium in Mild Thyroid Eye Disease in North America,Thyroid Associated Ophthalmopathies,2014-04-08,2016-11-16,2016-11-16,Interventional,Withdrawn,Phase 3,Columbia University,Columbia University|International Thyroid Eye Disease Society,,Drug|Dietary Supplement,,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02112643
NCT02114619,hyperthyroidism,The Effect of Different Calculated Doses of I-131 in Treatment of Patients With Grave's Disease,Comparative Study of Different I-131 Doses in Graves' Disease,Graves' Disease,2014-04-12,2014-12-31,2016-12-31,Interventional,Unknown status,Not Applicable,Mashhad University of Medical Sciences,Mashhad University of Medical Sciences,"Nuclear Medicine Research Center, Ghaem Hospital",Drug|Drug|Drug,"Iran, Islamic Republic of",18.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02114619
NCT02114619,graves disease,The Effect of Different Calculated Doses of I-131 in Treatment of Patients With Grave's Disease,Comparative Study of Different I-131 Doses in Graves' Disease,Graves' Disease,2014-04-12,2014-12-31,2016-12-31,Interventional,Unknown status,Not Applicable,Mashhad University of Medical Sciences,Mashhad University of Medical Sciences,"Nuclear Medicine Research Center, Ghaem Hospital",Drug|Drug|Drug,"Iran, Islamic Republic of",18.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02114619
NCT02114619,goiter,The Effect of Different Calculated Doses of I-131 in Treatment of Patients With Grave's Disease,Comparative Study of Different I-131 Doses in Graves' Disease,Graves' Disease,2014-04-12,2014-12-31,2016-12-31,Interventional,Unknown status,Not Applicable,Mashhad University of Medical Sciences,Mashhad University of Medical Sciences,"Nuclear Medicine Research Center, Ghaem Hospital",Drug|Drug|Drug,"Iran, Islamic Republic of",18.0,65.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02114619
NCT02126683,"thyroiditis, autoimmune",The Effect of Plaquenil on Serum Inflammatory Markers and Goiter in Euthyroid Young Women With Hashimoto's Thyroiditis,The Effect of Plaquenil on Serum Inflammatory Markers and Goiter in Euthyroid Young Women With Hashimoto's Thyroiditis,Hashimoto's Thyroiditis,2014-04-28,2016-02-29,2016-09-30,Interventional,Unknown status,Not Applicable,National Taiwan University Hospital,National Taiwan University Hospital,National Taiwan University Hospital,Drug,Taiwan,18.0,35.0,[18-65],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT02126683
NCT02133404,hyperparathyroidism,"Phase II Study of ASP7991 -A Double-blind, Cinacalcet Hydrochloride-controlled, Dose-ascending Study in Secondary Hyperparathyroidism Patients Undergoing Hemodialysis -",A Study to Evaluate the Effect of ASP7991 in Secondary Hyperparathyroidism Patients Undergoing Hemodialysis,Secondary Hyperparathyroidism,2014-04-29,2014-11-10,2014-11-10,Interventional,Completed,Phase 2,Astellas Pharma Inc,Astellas Pharma Inc,,Drug|Drug|Drug,Japan,20.0,79.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02133404
NCT02138214,"thyroid cancer, papillary",Thyroid Gland Removal With or Without Central Lymph Node Dissection in Treating Patients With Node Negative Thyroid Cancer,Central Neck Dissection in Patients With Clinical Node Negative Thyroid Cancer,Stage III Papillary Thyroid Cancer|Stage II Papillary Thyroid Cancer|Stage I Papillary Thyroid Cancer,2014-05-12,2019-10-30,2020-10-26,Interventional,Completed,Phase 2,"University of Wisconsin, Madison","National Cancer Institute (NCI)|University of Wisconsin, Madison",University of Wisconsin,Procedure|Procedure|Other,United States,21.0,73.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT02138214
NCT02138838,hyperparathyroidism,"A Randomized, Open-label, Controlled Study to Assess the Efficacy and Safety of Cinacalcet HCl in Pediatric Subjects With Secondary Hyperparathyroidism and Chronic Kidney Disease Receiving Dialysis",Efficacy and Safety of Cinacalcet in Pediatric Patients With Secondary Hyperparathyroidism (SHPT) and Chronic Kidney Disease (CKD) on Dialysis,"Chronic Kidney Disease, Secondary Hyperparathyroidism",2014-04-01,2016-06-23,2016-06-23,Interventional,Terminated,Phase 3,Amgen,Amgen,Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug|Dietary Supplement,Belgium|Czechia|France|Germany|Greece|Hungary|Italy|Lithuania|New Zealand|Poland|Portugal|Russian Federation|Slovakia|Spain|Ukraine|United States,6.0,17.0,[0-17],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02138838
NCT02140476,goiter,Comparative Analysis Between A Bipolar Vessel Sealing and Cutting Device and the Tie and Suture Technique in Thyroidectomy: A Two Institution Randomized Clinical Trial,Comparative Analysis Between Bipolar Device and Conventional Tie & Suture Technique in Thyroidectomy,Papillary Thyroid Cancer|Thyroid Goiter,2014-05-09,2015-05-31,2015-07-31,Interventional,Unknown status,Not Applicable,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,Ethicon Endo-Surgery|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|University of Sao Paulo,"Hospital Das Clinicas, Universidad de Sao Paulo|Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán",Device|Procedure,Brazil|Mexico,18.0,65.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02140476
NCT02143271,hyperparathyroidism,A Single-dose Phase 1 Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Peritoneal Dialysis,Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Peritoneal Dialysis,Secondary Hyperparathyroidism,2014-05-14,2014-12-31,2014-12-31,Interventional,Completed,Phase 1,"Kyowa Kirin Co., Ltd.","Kyowa Kirin Co., Ltd.",Kyowa Hakko Kirin,Drug,Japan,20.0,74.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02143271
NCT02143726,thyroid neoplasms,Randomized Phase II Study of Sorafenib With or Without Everolimus in Patients With Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer,"Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer",Refractory Hurthle Cell Thyroid Cancer,2014-05-19,2021-01-28,2024-08-06,Interventional,Active not recruiting,Phase 2,Alliance for Clinical Trials in Oncology,Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|Novartis,Mayo Clinic in Florida|Northwestern University|Siouxland Regional Cancer Center|University of Michigan Comprehensive Cancer Center|Mayo Clinic|Nebraska Methodist Hospital|Memorial Sloan Kettering Basking Ridge|Memorial Sloan Kettering Monmouth|Memorial Sloan Kettering Bergen|Memorial Sloan Kettering Commack|Memorial Sloan Kettering Westchester|Memorial Sloan Kettering Cancer Center|Memorial Sloan Kettering Sleepy Hollow|Memorial Sloan Kettering Nassau|Southeastern Medical Oncology Center-Clinton|Southeastern Medical Oncology Center-Goldsboro|Wayne Memorial Hospital|Southeastern Medical Oncology Center-Jacksonville|Ohio State University Comprehensive Cancer Center|Fox Chase Cancer Center|Mercy Health System,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02143726
NCT02147782,hyperparathyroidism,Continuous Clinical Observation on Bone Metabolism Induced by Chronic Renal Insufficiency in Different Stages,Clinical Observation on Bone Metabolism Induced by Chronic Renal Insufficiency,Chronic Renal Insufficiency|Renal Osteodystrophy,2014-05-13,2022-12-31,2022-12-31,Observational [Patient Registry],Recruiting,,Shanghai University of Traditional Chinese Medicine,Anhui Provincial Hospital|Huadong Hospital|Longhua Hospital|Shanghai University of Traditional Chinese Medicine,Anhui Province Hospital of TCM|Jiangsu Province Hospital of TCM|Longhua hospital affiliated to Shanghai University of TCM|Huadong Hospital Affiliated to Fudan University,,China,20.0,50.0,[18-65],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02147782
NCT02150772,thyroid neoplasms,Shear Wave Elastography in the Diagnosis and Risk-stratification of Thyroid Nodules - a Prospective Study,The Diagnostic Value of Shear Wave Elastography,Thyroid Nodule,2014-04-14,2016-03-31,2016-03-31,Interventional,Completed,Not Applicable,University of Aarhus,University of Aarhus,"Øre-Næse-Halsafdeling H, Aarhus University Hospital",Procedure,Denmark,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02150772
NCT02152995,"thyroid cancer, papillary","A Phase 2 Study of Trametinib in Combination With Radioiodine (RAI) for RAS Mutant or RAS/RAF Wild-Type, RAI-Refractory Recurrent and/or Metastatic Thyroid Cancers",Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer,Metastatic Thyroid Gland Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Carcinoma|Refractory Thyroid Gland Carcinoma|Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7|Stage IV Thyroid Gland Follicular Carcinoma AJCC v7|Stage IV Thyroid Gland Papillary Carcinoma AJCC v7,2014-05-29,2021-08-25,2023-01-12,Interventional,Active not recruiting,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Memorial Sloan Kettering Cancer Center,Procedure|Other|Radiation|Other|Other|Procedure|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT02152995
NCT02152995,"adenocarcinoma, follicular","A Phase 2 Study of Trametinib in Combination With Radioiodine (RAI) for RAS Mutant or RAS/RAF Wild-Type, RAI-Refractory Recurrent and/or Metastatic Thyroid Cancers",Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer,Metastatic Thyroid Gland Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Carcinoma|Refractory Thyroid Gland Carcinoma|Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7|Stage IV Thyroid Gland Follicular Carcinoma AJCC v7|Stage IV Thyroid Gland Papillary Carcinoma AJCC v7,2014-05-29,2021-08-25,2023-01-12,Interventional,Active not recruiting,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Memorial Sloan Kettering Cancer Center,Procedure|Other|Radiation|Other|Other|Procedure|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT02152995
NCT02155049,graves disease,Phase 3 Study of Treatment of Soft Tissue Expansion and Exophthalmos in Inactive Thyroid Eye Disease Patients Using Drops of Prostaglandin Analogues.,Treatment of Soft Tissue Expansion in Inactive Thyroid Eye Disease Patients Using Drops of Prostaglandin Analogues,Thyroid Associated Ophthalmopathies,2014-05-21,2017-05-31,2017-05-31,Interventional,Completed,Phase 3,Rabin Medical Center,Rabin Medical Center,"Ophthalmology clinics, Rabin Medical Center",Drug,Israel,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02155049
NCT02155049,hyperthyroidism,Phase 3 Study of Treatment of Soft Tissue Expansion and Exophthalmos in Inactive Thyroid Eye Disease Patients Using Drops of Prostaglandin Analogues.,Treatment of Soft Tissue Expansion in Inactive Thyroid Eye Disease Patients Using Drops of Prostaglandin Analogues,Thyroid Associated Ophthalmopathies,2014-05-21,2017-05-31,2017-05-31,Interventional,Completed,Phase 3,Rabin Medical Center,Rabin Medical Center,"Ophthalmology clinics, Rabin Medical Center",Drug,Israel,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02155049
NCT02155049,goiter,Phase 3 Study of Treatment of Soft Tissue Expansion and Exophthalmos in Inactive Thyroid Eye Disease Patients Using Drops of Prostaglandin Analogues.,Treatment of Soft Tissue Expansion in Inactive Thyroid Eye Disease Patients Using Drops of Prostaglandin Analogues,Thyroid Associated Ophthalmopathies,2014-05-21,2017-05-31,2017-05-31,Interventional,Completed,Phase 3,Rabin Medical Center,Rabin Medical Center,"Ophthalmology clinics, Rabin Medical Center",Drug,Israel,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02155049
NCT02169687,thyroid neoplasms,"Pilot, Monocentric, Non-comparative Study of the Effectiveness and Safety of High Intensity Focused Ultrasound Device in Patients With Autonomous Hyperfunctioning Thyroid Nodules",High Intensity Focused Ultrasound Device in Patients With Autonomous Hyperfunctioning Thyroid Nodules,Autonomous Hyperfunctioning Thyroid Nodules,2014-05-05,2007-10-31,2007-10-31,Interventional,Terminated,Early Phase 1,Theraclion,Groupe Hospitalier Pitie-Salpetriere|Hôpital Saint Louis Paris|Theraclion,Hôpital Pitié Salpetrière,Device,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02169687
NCT02169687,thyroid nodule,"Pilot, Monocentric, Non-comparative Study of the Effectiveness and Safety of High Intensity Focused Ultrasound Device in Patients With Autonomous Hyperfunctioning Thyroid Nodules",High Intensity Focused Ultrasound Device in Patients With Autonomous Hyperfunctioning Thyroid Nodules,Autonomous Hyperfunctioning Thyroid Nodules,2014-05-05,2007-10-31,2007-10-31,Interventional,Terminated,Early Phase 1,Theraclion,Groupe Hospitalier Pitie-Salpetriere|Hôpital Saint Louis Paris|Theraclion,Hôpital Pitié Salpetrière,Device,France,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT02169687
NCT02186405,hypothyroidism,Effects of Levothyroxine Treatment on Hemodynamic and Isotopic Renal Functions in Subclinical Hypothyroidism,Effects of Levothyroxine Treatment on Hemodynamic and Renal Functions in Subclinical Hypothyroidism,Subclinical hypothyroïdism,2014-07-08,2016-10-31,2017-06-30,Interventional,Withdrawn,Phase 4,Centre Hospitalier Universitaire de Nice,Centre Hospitalier Universitaire de Nice,Nephrology Department,Drug,France,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT02186405
NCT02190214,goiter,Thyroid Disorders in Malaysian: A Nationwide Multicentre Study,Thyroid Disorders in Malaysia: A Nationwide Multicentre Study,Genetic Susceptibility|Graves Disease|Hashimoto's Thyroiditis|Hyperthyroidism|Hypothyroidism|Iodine Deficiency|Subclinical Hyperthyroidism|Subclinical Hypothyroidism,2014-07-09,2016-09-30,2016-09-30,Observational,Completed,,International Islamic University Malaysia,International Islamic University Malaysia|International Medical University|Malaysian Endocrine and Metabolic Society|National University of Malaysia|University of Malaya,,,,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02190214
NCT02190214,thyroiditis,Thyroid Disorders in Malaysian: A Nationwide Multicentre Study,Thyroid Disorders in Malaysia: A Nationwide Multicentre Study,Genetic Susceptibility|Graves Disease|Hashimoto's Thyroiditis|Hyperthyroidism|Hypothyroidism|Iodine Deficiency|Subclinical Hyperthyroidism|Subclinical Hypothyroidism,2014-07-09,2016-09-30,2016-09-30,Observational,Completed,,International Islamic University Malaysia,International Islamic University Malaysia|International Medical University|Malaysian Endocrine and Metabolic Society|National University of Malaysia|University of Malaya,,,,18.0,120.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT02190214
NCT02194920,graves disease,Arathyroid Reimplantation in Forearm Subcutaneous Tissue During Thyroidectomy: a Simple Way to Avoid Ipoparathyroidism and Evaluate Graft Function,Parathyroid Reimplantation in Forearm Subcutaneous Tissue During Thyroidectomy: a Simple Way to Avoid Ipoparathyroidism and Evaluate Graft Function,Graves Diseases|Multinodular Goiter|Thyroid Carcinoma|Thyroid Goiter,2014-07-03,2014-10-31,2014-11-30,Observational,Completed,,University of Roma La Sapienza,University of Roma La Sapienza,"General Surgery Unit, ICOT Hospital",Procedure,Italy,0.0,120.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02194920
NCT02194920,hyperthyroidism,Arathyroid Reimplantation in Forearm Subcutaneous Tissue During Thyroidectomy: a Simple Way to Avoid Ipoparathyroidism and Evaluate Graft Function,Parathyroid Reimplantation in Forearm Subcutaneous Tissue During Thyroidectomy: a Simple Way to Avoid Ipoparathyroidism and Evaluate Graft Function,Graves Diseases|Multinodular Goiter|Thyroid Carcinoma|Thyroid Goiter,2014-07-03,2014-10-31,2014-11-30,Observational,Completed,,University of Roma La Sapienza,University of Roma La Sapienza,"General Surgery Unit, ICOT Hospital",Procedure,Italy,0.0,120.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02194920
NCT02203682,goiter,The Effect of Subantimicrobial Dose Doxycycline in Mild Thyroid-Associated Ophthalmopathy,Doxycycline Treatment in Mild Thyroid-Associated Ophthalmopathy,"Autoimmune Diseases|Endocrine System Diseases|Eye Diseases, Hereditary|Graves Disease|Graves Ophthalmopathy|Hyperthyroidism|Immune System Diseases|Thyroid-associated Ophthalmopathy|Thyroid Diseases",2014-07-28,2022-07-31,2022-07-31,Interventional,Recruiting,Phase 2,Sun Yat-sen University,Sun Yat-sen University,Zhongshan Ophthalmic Center,Drug|Drug,China,18.0,70.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02203682
NCT02205801,graves disease,A Randomized Control Trial Comparing Bilateral Superficial Cervical Plexus Block and Local Wound Infiltration in Thyroidectomy and Parathyroidectomy,Study of the Efficacy of Local Analgesia as an Adjunct to General Anesthesia in Thyroidectomy and Parathyroidectomy,"Goiter, Nodular|Graves' Disease|Hyperparathyroidism|Thyroid Neoplasms|Thyroid Nodule",2014-07-29,2017-02-10,2017-02-17,Interventional,Completed,Not Applicable,University of Chicago,University of Chicago,University of Chicago Medical Center,Procedure|Procedure|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02205801
NCT02205801,hyperthyroidism,A Randomized Control Trial Comparing Bilateral Superficial Cervical Plexus Block and Local Wound Infiltration in Thyroidectomy and Parathyroidectomy,Study of the Efficacy of Local Analgesia as an Adjunct to General Anesthesia in Thyroidectomy and Parathyroidectomy,"Goiter, Nodular|Graves' Disease|Hyperparathyroidism|Thyroid Neoplasms|Thyroid Nodule",2014-07-29,2017-02-10,2017-02-17,Interventional,Completed,Not Applicable,University of Chicago,University of Chicago,University of Chicago Medical Center,Procedure|Procedure|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02205801
NCT02210741,goiter,Next-generation Sequencing (NGS) of Peripheral Blood Immune Repertoire in Graves' Disease,Next-generation Sequencing (NGS) of Peripheral Blood Immune Repertoire in Graves' Disease,Graves Disease,2014-08-04,2024-02-29,2024-02-29,Observational,Not yet recruiting,,National Taiwan University Hospital,National Taiwan University Hospital,National Taiwan University Hospital,,Taiwan,20.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02210741
NCT02210741,hyperthyroidism,Next-generation Sequencing (NGS) of Peripheral Blood Immune Repertoire in Graves' Disease,Next-generation Sequencing (NGS) of Peripheral Blood Immune Repertoire in Graves' Disease,Graves Disease,2014-08-04,2024-02-29,2024-02-29,Observational,Not yet recruiting,,National Taiwan University Hospital,National Taiwan University Hospital,National Taiwan University Hospital,,Taiwan,20.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02210741
NCT02216656,hyperparathyroidism,"A Randomized, Double-blind, Parallel-group, Dose-finding Study of KHK7580 for Secondary Hyperparathyroidism Patients Receiving Hemodialysis",Phase 2 Study of KHK7580,Secondary Hyperparathyroidism,2014-08-11,2015-02-28,2015-02-28,Interventional,Completed,Phase 2,"Kyowa Kirin Co., Ltd.","Kyowa Kirin Co., Ltd.","For additional information regarding investigative sites for this trial, contact Kyowa Hakko Kirin",Drug|Drug|Drug|Drug|Drug,Japan,20.0,74.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02216656
NCT02227264,hyperparathyroidism,Primary Hyperparathyroidism: Short-term Calcimimetics Treatment - Relevance for Parathyroid Surgery Decisions?,Primary Hyperparathyroidism: Short-term Calcimimetics Treatment - Relevance for Parathyroid Surgery Decisions?,Primary Hyperparathyroidism,2014-08-17,2021-12-31,2021-12-31,Interventional,Unknown status,Not Applicable,Karolinska University Hospital,Karolinska Institutet|Karolinska University Hospital,Karolinska University Hospital,Drug|Procedure,Sweden,40.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02227264
NCT02246504,thyroid neoplasms,Registry - Use of a High Intensity Focused Ultrasound (HIFU) in Patients With Non-malignant Thyroid Nodules.,Registry - Use of a High Intensity Focused Ultrasound (HIFU) in Patients With Non-malignant Thyroid Nodules.,Non-malignant Thyroid Nodule,2014-09-16,2017-03-07,2017-03-07,Interventional,Completed,Not Applicable,Theraclion,Theraclion,"Clinic of thyroid and metabolite bone disease of the Acad. of Ivan Penchev UDHATE - 2, Zdrave street",Device,Bulgaria,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02246504
NCT02246504,thyroid nodule,Registry - Use of a High Intensity Focused Ultrasound (HIFU) in Patients With Non-malignant Thyroid Nodules.,Registry - Use of a High Intensity Focused Ultrasound (HIFU) in Patients With Non-malignant Thyroid Nodules.,Non-malignant Thyroid Nodule,2014-09-16,2017-03-07,2017-03-07,Interventional,Completed,Not Applicable,Theraclion,Theraclion,"Clinic of thyroid and metabolite bone disease of the Acad. of Ivan Penchev UDHATE - 2, Zdrave street",Device,Bulgaria,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT02246504
NCT02258347,thyroid neoplasms,Use of a High Intensity Focused Ultrasound (HIFU) in Patients With Non-malignant Thyroid Nodules.,HIFU in Patients With Non-malignant Thyroid Nodules,Non-malignant Thyroid Nodules,2014-09-26,2015-10-13,2015-10-13,Interventional,Completed,Not Applicable,Theraclion,Theraclion,Istituto in tecnologie avanzate e modelli assistenziali in oncologia,Device,Italy,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02258347
NCT02258347,thyroid nodule,Use of a High Intensity Focused Ultrasound (HIFU) in Patients With Non-malignant Thyroid Nodules.,HIFU in Patients With Non-malignant Thyroid Nodules,Non-malignant Thyroid Nodules,2014-09-26,2015-10-13,2015-10-13,Interventional,Completed,Not Applicable,Theraclion,Theraclion,Istituto in tecnologie avanzate e modelli assistenziali in oncologia,Device,Italy,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT02258347
NCT02268734,thyroid neoplasms,Molecular Profile of Metastatic Sporadic Medullary Thyroid Cancer (sMTC) Patients and Possible Correlation With Vandetanib Therapy,Molecular Profile of Metastatic Sporadic Medullary Thyroid Cancer Patients and Correlation With Vandetanib,Metastatic Sporadic Medullary Thyroid Cancer,2014-09-04,2017-12-31,2018-12-31,Observational,Completed,,"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","Fondazione IRCCS Istituto Nazionale dei Tumori, Milano",,Italy,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02268734
NCT02273570,hyperparathyroidism,"Single-center, Open-label, Randomized Study of Anemia Management Improvement in End Stage Renal Disease (ESRD) Patients With Secondary Hyperparathyroidism",Optimal Anemia Treatment in End Stage Renal Disease (ERSD),"Hyperparathyroidism, Secondary",2014-06-27,2016-12-31,2017-03-31,Interventional,Unknown status,Not Applicable,Azienda Ospedaliera Sant'Anna,Amgen|Azienda Ospedaliera Sant'Anna,Azienda Ospedaliera Sant'Anna,Drug|Drug,Italy,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02273570
NCT02274623,hyperparathyroidism,"Effect of CTAP101 Capsules on Serum Calcium, Plasma Intact Parathyroid Hormone and Vitamin D Metabolites in Patients With Advanced Breast or Prostate Carcinomas With Metastases to Bone and Receiving Ongoing Therapy With Denosumab or Zoledronic Acid",Effect of CTAP101 Capsules on Ca/iPTH in Advanced Breast/Prostate Cancer Patients Treated With Denosumab/Zoledronic Acid,"Bone Neoplasms|Breast Cancer|Hyperparathyroidism, Secondary|Hypocalcemia|Prostate Cancer",2014-10-22,2017-02-27,2017-03-17,Interventional,Completed,Phase 1,"OPKO Health, Inc.","OPKO Health, Inc.","Coast Hematology-Oncology Associates|Mount Sinai Medical Center, Comprehensive Cancer Center|Research by Design LLC|Roswell Park Cancer Institute|University of Cincinnati Cancer Institute|Inova Dwight and Martha Schar Cancer Center",Drug,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02274623
NCT02282813,hyperparathyroidism,"A Long-term Safety and Efficacy Study of CTAP101 Capsules in Subjects With Stages 3 or 4 Chronic Kidney Disease, Secondary Hyperparathyroidism and Vitamin D Insufficiency (Extension of Study CTAP101-CL-3001 or CTAP101-CL-3002)",Extension Study of CTAP101-CL-3001 or CTAP101-CL-3002,"Chronic Kidney Disease|Hyperparathyroidism, Secondary|Vitamin D Deficiency",2014-10-31,2015-05-31,2015-05-31,Interventional,Completed,Phase 3,"OPKO Health, Inc.","OPKO Health, Inc.",,Drug|Drug|Drug|Drug,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02282813
NCT02289144,"thyroid carcinoma, anaplastic",Ceritinib in Mutation and Oncogene Directed Therapy in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer,Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer,"Locally Advanced Anaplastic, Undifferentiated Thyroid Cancer|Metastatic Anaplastic Thyroid Cancer",2014-10-06,2019-01-31,2019-01-31,Interventional,Withdrawn,Phase 2,University of Texas Southwestern Medical Center,Novartis|University of Texas Southwestern Medical Center,UT Southwestern Medical Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT02289144
NCT02290704,graves ophthalmopathy,Changes of Retinal Oxygen Saturation in Patients With Graves' Ophthalmopathy Under Different Managing Conditions and in Normal People,Retinal Oxygen Saturation in Patients With Graves' Ophthalmopathy and in Normal People,Graves' Ophthalmopathy,2014-11-03,2017-11-30,2017-11-30,Observational,Unknown status,,Sun Yat-sen University,Sun Yat-sen University,Zhongshan Ophthalmic Center,,China,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT02290704
NCT02290704,graves disease,Changes of Retinal Oxygen Saturation in Patients With Graves' Ophthalmopathy Under Different Managing Conditions and in Normal People,Retinal Oxygen Saturation in Patients With Graves' Ophthalmopathy and in Normal People,Graves' Ophthalmopathy,2014-11-03,2017-11-30,2017-11-30,Observational,Unknown status,,Sun Yat-sen University,Sun Yat-sen University,Zhongshan Ophthalmic Center,,China,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02290704
NCT02290704,goiter,Changes of Retinal Oxygen Saturation in Patients With Graves' Ophthalmopathy Under Different Managing Conditions and in Normal People,Retinal Oxygen Saturation in Patients With Graves' Ophthalmopathy and in Normal People,Graves' Ophthalmopathy,2014-11-03,2017-11-30,2017-11-30,Observational,Unknown status,,Sun Yat-sen University,Sun Yat-sen University,Zhongshan Ophthalmic Center,,China,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02290704
NCT02290704,hyperthyroidism,Changes of Retinal Oxygen Saturation in Patients With Graves' Ophthalmopathy Under Different Managing Conditions and in Normal People,Retinal Oxygen Saturation in Patients With Graves' Ophthalmopathy and in Normal People,Graves' Ophthalmopathy,2014-11-03,2017-11-30,2017-11-30,Observational,Unknown status,,Sun Yat-sen University,Sun Yat-sen University,Zhongshan Ophthalmic Center,,China,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02290704
NCT02316691,hyperthyroidism,B-cell Depletion Therapy With Rituximab for Thyroid Eye Disease,B-cell Depletion Therapy With Rituximab for Thyroid Eye Disease,Thyroid Eye Disease,2014-12-08,2019-11-30,2019-11-30,Observational,Terminated,,University of Pittsburgh,University of Pittsburgh,University of Pittsburgh,,United States,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02316691
NCT02316691,graves disease,B-cell Depletion Therapy With Rituximab for Thyroid Eye Disease,B-cell Depletion Therapy With Rituximab for Thyroid Eye Disease,Thyroid Eye Disease,2014-12-08,2019-11-30,2019-11-30,Observational,Terminated,,University of Pittsburgh,University of Pittsburgh,University of Pittsburgh,,United States,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02316691
NCT02316691,goiter,B-cell Depletion Therapy With Rituximab for Thyroid Eye Disease,B-cell Depletion Therapy With Rituximab for Thyroid Eye Disease,Thyroid Eye Disease,2014-12-08,2019-11-30,2019-11-30,Observational,Terminated,,University of Pittsburgh,University of Pittsburgh,University of Pittsburgh,,United States,18.0,75.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02316691
NCT02316743,hypothyroidism,Beneficial Effects of Levothyroxine Supplementation in Patients With Systolic Heart Failure and Subclinical Hypothyroidism,Effects of Levothyroxine Supplementation in Patients With Systolic Heart Failure and Subclinical Hypothyroidism,Sub-clinical Hypothyroidism|Systolic Heart Failure,2013-05-10,2015-06-30,2015-07-31,Interventional,Unknown status,Phase 4,Université de Sherbrooke,Université de Sherbrooke,Centre Hospitalier Universitaire de Sherbrooke,Drug,Canada,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT02316743
NCT02319538,"thyroiditis, autoimmune",Surgical Treatment of Hashimotos Disease. Effect on Antibodies and Clinical Symptoms.,Hashimoto - a Surgical Disease. Total Thyroidectomy Makes Antibodies Disappear and Ameliorates Symptoms,Hashimoto's Disease,2014-12-15,2017-07-15,2017-07-15,Interventional,Completed,Not Applicable,Sykehuset Telemark,Haukeland University Hospital|Helse Stavanger HF|Sykehuset Telemark,"Telemark Hospital Trust, surgical department",Procedure,Norway,18.0,120.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT02319538
NCT02332135,hyperparathyroidism,The Efficacy and Safety of Microwave Ablation for Mild-to-moderate Secondary Hyperparathyroidism Patients Undergoing Hemodialysis,The Efficacy and Safety of Microwave Ablation for Mild-to-moderate Secondary Hyperparathyroidism Patients Undergoing Hemodialysis,Maintenance Hemodialysis|Secondary Hyperparathyroidism,2015-01-04,2017-03-31,2018-03-31,Interventional,Unknown status,Not Applicable,Beijing Friendship Hospital,Wenhu Liu,Beijing Friedship Hospital,Procedure|Drug,China,18.0,75.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02332135
NCT02338934,hyperparathyroidism,An Open-label Study of Combination of Cinacalcet and Active Vitamin D Analogue in the Management of Severe Secondary Hyperparathyroidism in Haemodialysis Patients,Cinacalcet in Management of Secondary Hyperparathyroidism in Haemodialysis Patients,Secondary Hyperparathyroidism,2015-01-11,2017-01-31,2017-01-31,Interventional,Unknown status,Phase 4,"Penang Hospital, Malaysia","Ministry of Health, Malaysia|Penang Hospital, Malaysia","Clinical Research Centre, Penang Hospital|Penang Hospital",Drug,Malaysia,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02338934
NCT02339142,graves disease,Combined Radiotherapy and Intravenous Steroids for Early Progressive Thyroid Eye Disease,Combined Radiotherapy and Intravenous Steroids for Early Progressive Thyroid Eye Disease,Graves Ophthalmopathy,2015-01-12,2018-12-31,2019-12-31,Interventional,Unknown status,Phase 4,University of British Columbia,University of British Columbia,,Radiation|Drug,,35.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02339142
NCT02339142,goiter,Combined Radiotherapy and Intravenous Steroids for Early Progressive Thyroid Eye Disease,Combined Radiotherapy and Intravenous Steroids for Early Progressive Thyroid Eye Disease,Graves Ophthalmopathy,2015-01-12,2018-12-31,2019-12-31,Interventional,Unknown status,Phase 4,University of British Columbia,University of British Columbia,,Radiation|Drug,,35.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02339142
NCT02339142,hyperthyroidism,Combined Radiotherapy and Intravenous Steroids for Early Progressive Thyroid Eye Disease,Combined Radiotherapy and Intravenous Steroids for Early Progressive Thyroid Eye Disease,Graves Ophthalmopathy,2015-01-12,2018-12-31,2019-12-31,Interventional,Unknown status,Phase 4,University of British Columbia,University of British Columbia,,Radiation|Drug,,35.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02339142
NCT02341417,hyperparathyroidism,A Multicenter Single-arm Extension Study to Characterize the Long-term Safety of Cinacalcet Hydrochloride in the Treatment of Secondary Hyperparathyroidism in Pediatric Subjects With Chronic Kidney Disease on Dialysis,Extension Study of Cinacalcet for Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Patients With Chronic Kidney Disease on Dialysis,"Secondary Hyperparathyroidism, Chronic Kidney Disease",2014-12-02,2017-03-15,2017-03-15,Interventional,Completed,Phase 3,Amgen,Amgen,Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug,Belgium|Czechia|France|Germany|Greece|Hungary|Italy|Poland|Russian Federation|Ukraine|United States,0.0,18.0,[0-17]|[18-65],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02341417
NCT02352766,thyroid neoplasms,Role of NGS-based ThyroSeq Panel in Cancer Diagnosis in Thyroid Nodules,Role of NGS-based ThyroSeq Panel in Cancer Diagnosis in Thyroid Nodules,Thyroid Nodule,2015-01-28,2019-02-15,2019-02-15,Observational,Completed,,University of Pittsburgh,"Duke University|Johns Hopkins University|Medstar Health Research Institute|Ohio State University|University of Cincinnati|University of Colorado, Denver|University of Pennsylvania|University of Pittsburgh|University of Wisconsin, Madison",University of Pittsburgh,,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02352766
NCT02373995,goiter,Investigation of Novel Biomarkers and Definition of the Role of the Microbiome In Graves' Orbitopathy,Role of the Microbiome in Graves' Orbitopathy,Graves' Disease,2015-01-29,2015-07-31,2016-12-31,Interventional,Unknown status,Phase 1/Phase 2,"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","Cultech Ltd, Port Talbot, UK|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|IDRA Laboratory, Parco Tecnologico Padano s.r.l, Lodi, Italy|School of Medicine and School of Biosciences, Cardiff University, Cardiff, UK|Universität Duisburg-Essen",Fondazione Ca' Granda Ospedale Maggiore Policlinico,Biological,Italy,18.0,65.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02373995
NCT02373995,graves ophthalmopathy,Investigation of Novel Biomarkers and Definition of the Role of the Microbiome In Graves' Orbitopathy,Role of the Microbiome in Graves' Orbitopathy,Graves' Disease,2015-01-29,2015-07-31,2016-12-31,Interventional,Unknown status,Phase 1/Phase 2,"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","Cultech Ltd, Port Talbot, UK|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|IDRA Laboratory, Parco Tecnologico Padano s.r.l, Lodi, Italy|School of Medicine and School of Biosciences, Cardiff University, Cardiff, UK|Universität Duisburg-Essen",Fondazione Ca' Granda Ospedale Maggiore Policlinico,Biological,Italy,18.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT02373995
NCT02373995,graves disease,Investigation of Novel Biomarkers and Definition of the Role of the Microbiome In Graves' Orbitopathy,Role of the Microbiome in Graves' Orbitopathy,Graves' Disease,2015-01-29,2015-07-31,2016-12-31,Interventional,Unknown status,Phase 1/Phase 2,"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","Cultech Ltd, Port Talbot, UK|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|IDRA Laboratory, Parco Tecnologico Padano s.r.l, Lodi, Italy|School of Medicine and School of Biosciences, Cardiff University, Cardiff, UK|Universität Duisburg-Essen",Fondazione Ca' Granda Ospedale Maggiore Policlinico,Biological,Italy,18.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02373995
NCT02373995,hyperthyroidism,Investigation of Novel Biomarkers and Definition of the Role of the Microbiome In Graves' Orbitopathy,Role of the Microbiome in Graves' Orbitopathy,Graves' Disease,2015-01-29,2015-07-31,2016-12-31,Interventional,Unknown status,Phase 1/Phase 2,"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","Cultech Ltd, Port Talbot, UK|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|IDRA Laboratory, Parco Tecnologico Padano s.r.l, Lodi, Italy|School of Medicine and School of Biosciences, Cardiff University, Cardiff, UK|Universität Duisburg-Essen",Fondazione Ca' Granda Ospedale Maggiore Policlinico,Biological,Italy,18.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02373995
NCT02376088,hyperthyroidism,Characteristics of Islet β-cell Functions in Chinese Patients With Graves' Disease,Characteristics of Islet β-cell Functions in Chinese Patients With Graves' Disease,Graves Disease,2015-02-18,2014-06-30,2014-06-30,Observational,Completed,,Qilu Hospital of Shandong University,Weikai Hou,,Drug,,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02376088
NCT02376088,goiter,Characteristics of Islet β-cell Functions in Chinese Patients With Graves' Disease,Characteristics of Islet β-cell Functions in Chinese Patients With Graves' Disease,Graves Disease,2015-02-18,2014-06-30,2014-06-30,Observational,Completed,,Qilu Hospital of Shandong University,Weikai Hou,,Drug,,18.0,75.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02376088
NCT02378298,graves disease,Rituximab (RTX) Therapy in Steroid Resistant Patients or Patients Relapsing After Intravenous Steroids With Active TAO,Rituximab (RTX) Therapy in Patients With Active TAO,"Ophthalmopathy, Thyroid-Associated",2015-01-20,2020-02-01,2022-03-31,Interventional,Active not recruiting,Phase 4,Göteborg University,"Göteborg University|Sahlgrenska University Hospital, Sweden","Center for Endocrinology and Metabolism, Sahlgrenska University Hospital|MedTech West, Institute of Neuro Science and Physiology, Department for Clinical Neuro Science and Rehabilitation, Sahlgrenska Academy, University of Gothenburg|Department of Ophthalmology, Sahlgrenska University Hospital/Mölndal|Department of Rheumatology, Sahlgrenska University Hospital/Mölndal|Department of Radiology, Karolinska University Hospital",Drug|Drug|Drug,Sweden,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02378298
NCT02378298,graves ophthalmopathy,Rituximab (RTX) Therapy in Steroid Resistant Patients or Patients Relapsing After Intravenous Steroids With Active TAO,Rituximab (RTX) Therapy in Patients With Active TAO,"Ophthalmopathy, Thyroid-Associated",2015-01-20,2020-02-01,2022-03-31,Interventional,Active not recruiting,Phase 4,Göteborg University,"Göteborg University|Sahlgrenska University Hospital, Sweden","Center for Endocrinology and Metabolism, Sahlgrenska University Hospital|MedTech West, Institute of Neuro Science and Physiology, Department for Clinical Neuro Science and Rehabilitation, Sahlgrenska Academy, University of Gothenburg|Department of Ophthalmology, Sahlgrenska University Hospital/Mölndal|Department of Rheumatology, Sahlgrenska University Hospital/Mölndal|Department of Radiology, Karolinska University Hospital",Drug|Drug|Drug,Sweden,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT02378298
NCT02378298,hyperthyroidism,Rituximab (RTX) Therapy in Steroid Resistant Patients or Patients Relapsing After Intravenous Steroids With Active TAO,Rituximab (RTX) Therapy in Patients With Active TAO,"Ophthalmopathy, Thyroid-Associated",2015-01-20,2020-02-01,2022-03-31,Interventional,Active not recruiting,Phase 4,Göteborg University,"Göteborg University|Sahlgrenska University Hospital, Sweden","Center for Endocrinology and Metabolism, Sahlgrenska University Hospital|MedTech West, Institute of Neuro Science and Physiology, Department for Clinical Neuro Science and Rehabilitation, Sahlgrenska Academy, University of Gothenburg|Department of Ophthalmology, Sahlgrenska University Hospital/Mölndal|Department of Rheumatology, Sahlgrenska University Hospital/Mölndal|Department of Radiology, Karolinska University Hospital",Drug|Drug|Drug,Sweden,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02378298
NCT02378298,goiter,Rituximab (RTX) Therapy in Steroid Resistant Patients or Patients Relapsing After Intravenous Steroids With Active TAO,Rituximab (RTX) Therapy in Patients With Active TAO,"Ophthalmopathy, Thyroid-Associated",2015-01-20,2020-02-01,2022-03-31,Interventional,Active not recruiting,Phase 4,Göteborg University,"Göteborg University|Sahlgrenska University Hospital, Sweden","Center for Endocrinology and Metabolism, Sahlgrenska University Hospital|MedTech West, Institute of Neuro Science and Physiology, Department for Clinical Neuro Science and Rehabilitation, Sahlgrenska Academy, University of Gothenburg|Department of Ophthalmology, Sahlgrenska University Hospital/Mölndal|Department of Rheumatology, Sahlgrenska University Hospital/Mölndal|Department of Radiology, Karolinska University Hospital",Drug|Drug|Drug,Sweden,18.0,70.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02378298
NCT02381457,hypoparathyroidism,SNP-based Microdeletion and Aneuploidy RegisTry,SNP-based Microdeletion and Aneuploidy RegisTry (SMART),1p36 Deletion Syndrome|22q11 Deletion Syndrome|Angelman Syndrome|Cri-du-Chat Syndrome|DiGeorge Syndrome|Monosomy X|Prader-Willi Syndrome|Sex Chromosome Abnormalities|Trisomy 13|Trisomy 18|Trisomy 21,2015-03-02,2020-06-30,2020-06-30,Observational [Patient Registry],Completed,,"Natera, Inc.","Children's Hospital of Philadelphia|George Washington University|Montefiore Medical Center|Natera, Inc.|University of California, San Francisco","University of California, San Francisco|Cooper University Hospital|Virtua|St. Peter's University|Complete Women's Healthcare|North Shore University Hospital|Madonna Perinatal|Long Island Jewish Medical Center|New York University|Icahn School of Medicine Mt Sinai|Columbia University|Montefiore Medical Center|Suffolk OB|North Austin Maternal Fetal Medicine|Zeid Women's Health Center|University of Utah|Royal Prince Alfred|Royal College Surgeons in Ireland|Dexeus|Sahlgrenska University Hospital|St. George University Hospital",,Australia|Ireland|Spain|Sweden|United Kingdom|United States,18.0,48.0,[18-65],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02381457
NCT02381925,parathyroid neoplasms,Multicenter Registry Comparing Preoperative Imaging for Primary Hyperparathyroidism,Multicenter Registry Comparing Preoperative Imaging for Primary Hyperparathyroidism,Parathyroid Adenoma,2015-03-03,2016-06-30,2016-12-31,Observational [Patient Registry],Withdrawn,,Duke University,"Duke University|University of Arkansas|University of California, Los Angeles",,,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02381925
NCT02381925,hyperparathyroidism,Multicenter Registry Comparing Preoperative Imaging for Primary Hyperparathyroidism,Multicenter Registry Comparing Preoperative Imaging for Primary Hyperparathyroidism,Parathyroid Adenoma,2015-03-03,2016-06-30,2016-12-31,Observational [Patient Registry],Withdrawn,,Duke University,"Duke University|University of Arkansas|University of California, Los Angeles",,,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02381925
NCT02384668,graves disease,"The DAGMAR Study. D-vitamin And Graves' Disease; Morbidity And Relapse Reduction: A Randomised, Clinical Trial.",D-vitamin And Graves' Disease; Morbidity And Relapse Reduction,Graves' Disease,2015-01-09,2021-01-31,2021-01-31,Interventional,Unknown status,Not Applicable,University of Aarhus,"Aarhus University Hospital|Herning Hospital|Randers Regional Hospital|Regional Hospital Holstebro|Regionshospitalet Horsens|Regionshospitalet Silkeborg|Regionshospitalet Viborg, Skive|University of Aarhus","Department of Endocrinology and Internal Medicine, Aarhus University Hospital|Gentofte Hospital|Department of Internal Medicine, Regionshospitalet Herning|Department of Internal Medicine, Regionshospitalet Holstebro|Department of Internal Medicine, Regionshospitalet Horsens|Department of Internal Medicine, Regionhospitalet Randers|Department of Internal Medicine, Diagnostisk Center, Regionshospitalet Silkeborg|Department of Internal Medicine, Regionshospitalet Viborg",Dietary Supplement|Dietary Supplement,Denmark,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02384668
NCT02384668,goiter,"The DAGMAR Study. D-vitamin And Graves' Disease; Morbidity And Relapse Reduction: A Randomised, Clinical Trial.",D-vitamin And Graves' Disease; Morbidity And Relapse Reduction,Graves' Disease,2015-01-09,2021-01-31,2021-01-31,Interventional,Unknown status,Not Applicable,University of Aarhus,"Aarhus University Hospital|Herning Hospital|Randers Regional Hospital|Regional Hospital Holstebro|Regionshospitalet Horsens|Regionshospitalet Silkeborg|Regionshospitalet Viborg, Skive|University of Aarhus","Department of Endocrinology and Internal Medicine, Aarhus University Hospital|Gentofte Hospital|Department of Internal Medicine, Regionshospitalet Herning|Department of Internal Medicine, Regionshospitalet Holstebro|Department of Internal Medicine, Regionshospitalet Horsens|Department of Internal Medicine, Regionhospitalet Randers|Department of Internal Medicine, Diagnostisk Center, Regionshospitalet Silkeborg|Department of Internal Medicine, Regionshospitalet Viborg",Dietary Supplement|Dietary Supplement,Denmark,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02384668
NCT02384668,hyperthyroidism,"The DAGMAR Study. D-vitamin And Graves' Disease; Morbidity And Relapse Reduction: A Randomised, Clinical Trial.",D-vitamin And Graves' Disease; Morbidity And Relapse Reduction,Graves' Disease,2015-01-09,2021-01-31,2021-01-31,Interventional,Unknown status,Not Applicable,University of Aarhus,"Aarhus University Hospital|Herning Hospital|Randers Regional Hospital|Regional Hospital Holstebro|Regionshospitalet Horsens|Regionshospitalet Silkeborg|Regionshospitalet Viborg, Skive|University of Aarhus","Department of Endocrinology and Internal Medicine, Aarhus University Hospital|Gentofte Hospital|Department of Internal Medicine, Regionshospitalet Herning|Department of Internal Medicine, Regionshospitalet Holstebro|Department of Internal Medicine, Regionshospitalet Horsens|Department of Internal Medicine, Regionhospitalet Randers|Department of Internal Medicine, Diagnostisk Center, Regionshospitalet Silkeborg|Department of Internal Medicine, Regionshospitalet Viborg",Dietary Supplement|Dietary Supplement,Denmark,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02384668
NCT02393183,graves disease,"The Effect of a New Antioxidant Combination (ASTED) on Mild Thyroid Eye Disease, a Placebo Controlled Randomized Clinical Trial",The Effect of a New Antioxidant Combination (ASTED) on Mild Thyroid Eye Disease (TED),Thyroid Eye Disease,2015-03-07,2022-06-15,2022-12-15,Interventional,Withdrawn,Phase 2/Phase 3,Iran University of Medical Sciences,Iran University of Medical Sciences,Rassoul Akram Hospital,Drug|Dietary Supplement|Other,"Iran, Islamic Republic of",18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02393183
NCT02393183,hyperthyroidism,"The Effect of a New Antioxidant Combination (ASTED) on Mild Thyroid Eye Disease, a Placebo Controlled Randomized Clinical Trial",The Effect of a New Antioxidant Combination (ASTED) on Mild Thyroid Eye Disease (TED),Thyroid Eye Disease,2015-03-07,2022-06-15,2022-12-15,Interventional,Withdrawn,Phase 2/Phase 3,Iran University of Medical Sciences,Iran University of Medical Sciences,Rassoul Akram Hospital,Drug|Dietary Supplement|Other,"Iran, Islamic Republic of",18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02393183
NCT02393183,goiter,"The Effect of a New Antioxidant Combination (ASTED) on Mild Thyroid Eye Disease, a Placebo Controlled Randomized Clinical Trial",The Effect of a New Antioxidant Combination (ASTED) on Mild Thyroid Eye Disease (TED),Thyroid Eye Disease,2015-03-07,2022-06-15,2022-12-15,Interventional,Withdrawn,Phase 2/Phase 3,Iran University of Medical Sciences,Iran University of Medical Sciences,Rassoul Akram Hospital,Drug|Dietary Supplement|Other,"Iran, Islamic Republic of",18.0,70.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02393183
NCT02393690,"adenocarcinoma, follicular",Randomized Double-Blind Phase II Study of Radioactive Iodine (RAI) in Combination With Placebo or Selumetinib for the Treatment of RAI-Avid Recurrent/Metastatic Thyroid Cancers,Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer,Metastatic Thyroid Gland Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Carcinoma|Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7|Stage IV Thyroid Gland Follicular Carcinoma AJCC v7|Stage IV Thyroid Gland Papillary Carcinoma AJCC v7,2015-03-16,2020-07-17,2022-12-31,Interventional,Active not recruiting,Phase 2,Academic and Community Cancer Research United,Academic and Community Cancer Research United|National Cancer Institute (NCI),UC San Diego Moores Cancer Center|Hoag Memorial Hospital|University of Colorado Hospital|MedStar Georgetown University Hospital|Dana-Farber Cancer Institute|Mayo Clinic in Rochester|Memorial Sloan Kettering Cancer Center|Duke University Medical Center|Ohio State University Comprehensive Cancer Center|Vanderbilt University/Ingram Cancer Center|M D Anderson Cancer Center,Radiation|Other|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT02393690
NCT02393690,"thyroid cancer, papillary",Randomized Double-Blind Phase II Study of Radioactive Iodine (RAI) in Combination With Placebo or Selumetinib for the Treatment of RAI-Avid Recurrent/Metastatic Thyroid Cancers,Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer,Metastatic Thyroid Gland Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Carcinoma|Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7|Stage IV Thyroid Gland Follicular Carcinoma AJCC v7|Stage IV Thyroid Gland Papillary Carcinoma AJCC v7,2015-03-16,2020-07-17,2022-12-31,Interventional,Active not recruiting,Phase 2,Academic and Community Cancer Research United,Academic and Community Cancer Research United|National Cancer Institute (NCI),UC San Diego Moores Cancer Center|Hoag Memorial Hospital|University of Colorado Hospital|MedStar Georgetown University Hospital|Dana-Farber Cancer Institute|Mayo Clinic in Rochester|Memorial Sloan Kettering Cancer Center|Duke University Medical Center|Ohio State University Comprehensive Cancer Center|Vanderbilt University/Ingram Cancer Center|M D Anderson Cancer Center,Radiation|Other|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT02393690
NCT02397109,hyperthyroidism,Study Of The Agreement Between The mDixon TSE Sequence And Conventional MRI Sequences In The Evaluation Of Dysimmune Orbitopathies,mDixon TSE MRI Sequence And Conventional MRI Sequences In Dysimmune Orbitopathies (DDX),Dysthyroid Ophthalmopathies,2015-03-19,2020-09-30,2020-09-30,Observational,Completed,,Fondation Ophtalmologique Adolphe de Rothschild,Fondation Ophtalmologique Adolphe de Rothschild,Fondation Ophtalmologique Adolphe de Rothschild,,France,18.0,90.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02397109
NCT02397109,goiter,Study Of The Agreement Between The mDixon TSE Sequence And Conventional MRI Sequences In The Evaluation Of Dysimmune Orbitopathies,mDixon TSE MRI Sequence And Conventional MRI Sequences In Dysimmune Orbitopathies (DDX),Dysthyroid Ophthalmopathies,2015-03-19,2020-09-30,2020-09-30,Observational,Completed,,Fondation Ophtalmologique Adolphe de Rothschild,Fondation Ophtalmologique Adolphe de Rothschild,Fondation Ophtalmologique Adolphe de Rothschild,,France,18.0,90.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02397109
NCT02397109,graves disease,Study Of The Agreement Between The mDixon TSE Sequence And Conventional MRI Sequences In The Evaluation Of Dysimmune Orbitopathies,mDixon TSE MRI Sequence And Conventional MRI Sequences In Dysimmune Orbitopathies (DDX),Dysthyroid Ophthalmopathies,2015-03-19,2020-09-30,2020-09-30,Observational,Completed,,Fondation Ophtalmologique Adolphe de Rothschild,Fondation Ophtalmologique Adolphe de Rothschild,Fondation Ophtalmologique Adolphe de Rothschild,,France,18.0,90.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02397109
NCT02398721,thyroid nodule,A Prospective Randomized Study on Health-related Quality of Life of Patients With Incidental Small (<2cm) Asymptomatic Thyroid Nodules and Cost-effectiveness Analysis in Managing Small Incidental Thyroid Nodules,Study on HRQOL and Cost-effectiveness Analysis in Management of Patients With <2cm Thyroid Nodules,Thyroid Nodules,2015-03-20,2017-07-31,2018-02-28,Interventional,Completed,Not Applicable,The University of Hong Kong,The University of Hong Kong,Queen Mary Hospital,Other,Hong Kong,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT02398721
NCT02398721,thyroid neoplasms,A Prospective Randomized Study on Health-related Quality of Life of Patients With Incidental Small (<2cm) Asymptomatic Thyroid Nodules and Cost-effectiveness Analysis in Managing Small Incidental Thyroid Nodules,Study on HRQOL and Cost-effectiveness Analysis in Management of Patients With <2cm Thyroid Nodules,Thyroid Nodules,2015-03-20,2017-07-31,2018-02-28,Interventional,Completed,Not Applicable,The University of Hong Kong,The University of Hong Kong,Queen Mary Hospital,Other,Hong Kong,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02398721
NCT02399475,hypothyroidism,"The Thyroid Axis in Older Individuals With Persistent Subclinical Hypothyroidism: a Mechanistic, Randomized, Double-Blind, Cross-Over Study of Levothyroxine and Liothyronine Administration",Mechanistic Study of Subclinical Hypothyroidism In the Elderly,Subclinical Hypothyroidism,2015-02-03,2019-09-30,2019-09-30,Interventional,Completed,Not Applicable,University of Pennsylvania,National Institute on Aging (NIA)|University of Pennsylvania,University of Pennsylvania,Drug|Drug|Drug,United States,70.0,120.0,[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT02399475
NCT02408887,"thyroid cancer, papillary",Randomized Controlled Trial of Total Thyroidectomy With and Without Prophylactic Central Neck Lymph Node Dissection in Patients With Low-risk Papillary Thyroid Cancer,Total Thyroidectomy With and Without Prophylactic Central Neck Lymph Node Dissection in People With Low-risk Papillary Thyroid Cancer,Endocrine Malignancy|Low-risk Papillary Thyroid Cancer|Thyroid Cancer,2015-04-03,2019-03-26,2019-05-07,Interventional,Terminated,Phase 2,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),"National Institutes of Health Clinical Center, 9000 Rockville Pike",Procedure|Procedure,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT02408887
NCT02410928,thyroid neoplasms,Comparison of the Vocal Cord Imaging Techniques After Thyroidectomy,Comparison of the Vocal Cord Imaging Techniques After Thyroidectomy,Thyroid Nodule,2015-02-14,2015-06-30,2015-07-31,Interventional,Completed,Not Applicable,Diskapi Teaching and Research Hospital,Diskapi Teaching and Research Hospital,Diskapi Yildirim Beyazit Teaching and Research Hospital,Device|Device|Device,Turkey,19.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02410928
NCT02417389,hyperparathyroidism,Efficacy of a Calcimimetic (Cinacalcet) in the Long Term Control of Patients With Primary Hyperparathyroidism,Efficacy of Cinacalcet in the Control of Primary Hyperparathyroidism,"Hyperparathyroidism, Primary|Osteoporosis",2015-04-08,2011-10-31,2012-12-31,Interventional,Completed,Phase 4,Istituto Auxologico Italiano,Istituto Auxologico Italiano,Istituto Auxologico Italiano IRCCS,Drug|Drug,Italy,50.0,75.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02417389
NCT02422368,goiter,"The Effect of a New Antioxidant Combination (ASTED) on Moderate to Severe Thyroid Eye Disease, a Double Blind Placebo Controlled Randomized Clinical Trial",The Effect of a New Antioxidant Combination (ASTED) on Moderate to Severe Thyroid Eye Disease,Thyroid Eye Disease,2015-04-11,2024-06-30,2024-11-30,Interventional,Withdrawn,Phase 2/Phase 3,Iran University of Medical Sciences,Iran University of Medical Sciences,Private Thyroid eye disease clinic|Rassoul Akram Hospital,Drug|Drug,"Iran, Islamic Republic of",18.0,70.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02422368
NCT02422368,hyperthyroidism,"The Effect of a New Antioxidant Combination (ASTED) on Moderate to Severe Thyroid Eye Disease, a Double Blind Placebo Controlled Randomized Clinical Trial",The Effect of a New Antioxidant Combination (ASTED) on Moderate to Severe Thyroid Eye Disease,Thyroid Eye Disease,2015-04-11,2024-06-30,2024-11-30,Interventional,Withdrawn,Phase 2/Phase 3,Iran University of Medical Sciences,Iran University of Medical Sciences,Private Thyroid eye disease clinic|Rassoul Akram Hospital,Drug|Drug,"Iran, Islamic Republic of",18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02422368
NCT02422368,graves disease,"The Effect of a New Antioxidant Combination (ASTED) on Moderate to Severe Thyroid Eye Disease, a Double Blind Placebo Controlled Randomized Clinical Trial",The Effect of a New Antioxidant Combination (ASTED) on Moderate to Severe Thyroid Eye Disease,Thyroid Eye Disease,2015-04-11,2024-06-30,2024-11-30,Interventional,Withdrawn,Phase 2/Phase 3,Iran University of Medical Sciences,Iran University of Medical Sciences,Private Thyroid eye disease clinic|Rassoul Akram Hospital,Drug|Drug,"Iran, Islamic Republic of",18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02422368
NCT02430584,hypoparathyroidism,Whole Blood Specimen Collection From Pregnant Subjects,Whole Blood Specimen Collection From Pregnant Subjects,DiGeorge Syndrome|Down Syndrome|Edwards Syndrome|Klinefelter Syndrome|Patau Syndrome|Perinatal Infections|Turner Syndrome,2015-04-27,2021-03-31,2021-05-31,Observational,Active not recruiting,,"Progenity, Inc.","Progenity, Inc.",Regional Obstetrical Consultants,Other,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02430584
NCT02430857,hypothyroidism,Osteopathy and Latent Hypothyroidism: Effectiveness of Osteopathic Treatment on TSH in Patients With Latent Hypothyroidism,Osteopathy and Latent Hypothyroidism,Latent Hypothyroidism,2015-04-27,2015-10-31,2016-01-31,Interventional,Unknown status,Not Applicable,"Diekmann, Emanuel Amier",Emanuel Amier Diekmann,,Other,,18.0,65.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT02430857
NCT02432274,thyroid neoplasms,Phase 1/2 Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma,Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma,Differentiated Thyroid Cancer (DTC)|Osteosarcoma|Solid Malignant Tumors|Tumors,2015-04-22,2019-07-18,2022-03-31,Interventional,Active not recruiting,Phase 1/Phase 2,Eisai Inc.,Eisai Limited|Merck Sharp & Dohme Corp.,Texas Children's Hospital|CHU Strasbourg - Hopital Hautepierre|Centre Oscar Lambret Lille|Centre Leon Berard|CHU Nantes - Hopital Mere-Enfant|Institut Curie - Centre de Lutte Contre le Cancer (CLCC) de Paris|Institut Gustave Roussy|CHU de Toulouse - Hopital des Enfants|Universitaetsklinikum Muenster|Kinderklinik des Olga hospitals|Istituto Ortopedico Rizzoli|Fondazione IRCCS Istituto Nazionale dei Tumori|Ospedale Pediatrico Bambino Gesu|Hospital Universitari Vall d'Hebron|Hospital Infantil Universitario Nino Jesus|Hospital Universitario y Politecnico La Fe Hospital La Fe Valencia|Birmingham Children's Hospital|University College London Hospital|Royal Victoria Infirmary,Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug,France|Germany|Italy|Spain|United Kingdom|United States,2.0,25.0,[0-17]|[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02432274
NCT02432599,parathyroid neoplasms,Interest of the F18-choline as a Second Line of the Tracer for Detection of Parathyroid Adenomas,Interest of the F18-choline as a Second Line of the Tracer for Detection of Parathyroid Adenomas,Hyperparathyroidism,2015-04-29,2017-02-28,2017-02-28,Interventional,Completed,Phase 2,Centre Francois Baclesse,Centre Francois Baclesse,CHU|Centre François Baclesse,Radiation,France,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02432599
NCT02440581,hyperparathyroidism,Renal Osteodystrophy: A Fresh Approach,Renal Osteodystrophy: An Individual Management Approach,"Kidney Failure, Chronic",2015-05-07,2023-06-30,2023-06-30,Interventional,Active not recruiting,Not Applicable,University of Kentucky,"Hartmut Malluche, MD|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Wright State University",University of Kentucky,Drug|Drug|Drug,United States,21.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02440581
NCT02452073,euthyroid sick syndromes,,An Analysis of the Relative Risk for Low Triiodothyronine Syndrome in Patients With Chronic Radiation Enteritis,The Clinical Incidence of Low Triiodothyronine Syndrome,2015-05-15,2015-01-31,2015-04-30,Observational,Completed,,"Jinling Hospital, China",Shengxian Fan,,Other,,0.0,120.0,[0-17]|[18-65]|[65 and more],Euthyroid Sick Syndromes,Euthyroid Sick Syndromes,https://clinicaltrials.gov/ct2/show/NCT02452073
NCT02460328,hypoparathyroidism,Resolution of Primary Immune Defect in 22q11.2 Deletion Syndrome,Resolution of Primary Immune Defect in 22q11.2 Deletion Syndrome,22q11.2 Deletion Syndrome|Immune Defect,2015-04-10,2016-02-29,2016-02-29,Observational,Completed,,Mahidol University,Mahidol University,Siriraj Hospital,,Thailand,0.0,15.0,[0-17],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02460328
NCT02462512,thyroid neoplasms,Validation of Diagnostic Performance of Ultrasound Elastography for Detection of Thyroid Cancer,Diagnostic Performance of Ultrasound Elastography for Detection of Thyroid Cancer,Elastography|Thyroid Nodule,2015-04-20,2016-03-31,2017-08-31,Observational,Unknown status,,Seoul St. Mary's Hospital,Dong Jun Lim,Seoul St Mary's Hospital,,"Korea, Republic of",18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02462512
NCT02463409,pseudohypoparathyroidism,Effects of Theophylline on cAMP Signaling in Children With Pseudohypoparathyroidism Type 1a,Theophylline as a Treatment for Children With Pseudohypoparathyroidism Type 1a (Albright Hereditary Osteodystrophy),Albright Hereditary Osteodystrophy|Pseudohypoparathyroidism Type 1a,2015-05-20,2016-10-31,2016-10-31,Interventional,Completed,Phase 2,Vanderbilt University Medical Center,Massachusetts General Hospital|Vanderbilt University Medical Center,Vanderbilt Unversity,Drug,United States,10.0,21.0,[0-17]|[18-65],Parathyroid diseases,pseudohypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02463409
NCT02464072,hyperparathyroidism,Randomized Clinical Trial of Subtotal Parathyroidectomy or Total Parathyroidectomy With Immediate Heterotopic Autograft in Chronic Renal Disease Patients Stage V Under Dialysis,Subtotal Parathyroidectomy or Total Parathyroidectomy With Autograft in Chronic Kidney Disease Patients Under Dialysis,"Hyperparathyroidism, Secondary",2015-05-18,2021-03-31,2021-03-31,Interventional,Unknown status,Not Applicable,University of Sao Paulo General Hospital,University of Sao Paulo General Hospital,University of Sao Paulo General Hospital,Procedure|Procedure|Procedure,Brazil,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02464072
NCT02491502,thyroid neoplasms,Treatment of Benign Thyroid Nodules With FastScan High Intensity Focused Ultrasound (HIFU),Treatment of Benign Thyroid Nodules With FastScan HIFU,Benign Thyroid Nodules,2015-06-24,2020-04-30,2020-07-31,Interventional,Completed,Not Applicable,Theraclion,Theraclion,University Hospital of Endocrinology USBALE,Device,Bulgaria,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02491502
NCT02491502,thyroid nodule,Treatment of Benign Thyroid Nodules With FastScan High Intensity Focused Ultrasound (HIFU),Treatment of Benign Thyroid Nodules With FastScan HIFU,Benign Thyroid Nodules,2015-06-24,2020-04-30,2020-07-31,Interventional,Completed,Not Applicable,Theraclion,Theraclion,University Hospital of Endocrinology USBALE,Device,Bulgaria,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT02491502
NCT02491567,hyperthyroidism,Study of DNA Methylation in Children and Adolescents With Autoimmune Thyroid Diseases,DNA Methylation and Autoimmune Thyroid Diseases,Graves Disease|Hashimoto Thyroiditis,2014-12-23,2016-09-30,2018-04-30,Observational,Completed,,Aristotle University Of Thessaloniki,Aristotle University Of Thessaloniki,"Unit of Pediatric Endocrinology, Diabetes and Metabolism-4th Department of Pediatrics, Medical School of Aristotle University of Thessaloniki",,Greece,4.0,18.0,[0-17]|[18-65],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02491567
NCT02491567,goiter,Study of DNA Methylation in Children and Adolescents With Autoimmune Thyroid Diseases,DNA Methylation and Autoimmune Thyroid Diseases,Graves Disease|Hashimoto Thyroiditis,2014-12-23,2016-09-30,2018-04-30,Observational,Completed,,Aristotle University Of Thessaloniki,Aristotle University Of Thessaloniki,"Unit of Pediatric Endocrinology, Diabetes and Metabolism-4th Department of Pediatrics, Medical School of Aristotle University of Thessaloniki",,Greece,4.0,18.0,[0-17]|[18-65],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02491567
NCT02491567,thyroiditis,Study of DNA Methylation in Children and Adolescents With Autoimmune Thyroid Diseases,DNA Methylation and Autoimmune Thyroid Diseases,Graves Disease|Hashimoto Thyroiditis,2014-12-23,2016-09-30,2018-04-30,Observational,Completed,,Aristotle University Of Thessaloniki,Aristotle University Of Thessaloniki,"Unit of Pediatric Endocrinology, Diabetes and Metabolism-4th Department of Pediatrics, Medical School of Aristotle University of Thessaloniki",,Greece,4.0,18.0,[0-17]|[18-65],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT02491567
NCT02500342,hypothyroidism,Effect of Thyroid Hormone Replacement on Fatigability in Untreated Older Adults With Subclinical Hypothyroidism,Effect of Thyroid Hormone Replacement on Fatigability in Untreated Older Adults With Subclinical Hypothyroidism,Fatigue|Mental Fatigue|Thyroid Dysfunction,2015-06-18,2018-04-05,2018-04-05,Interventional,Completed,Phase 4,"University Hospital Inselspital, Berne","University College Cork|University Hospital Inselspital, Berne|University of Lausanne Hospitals","University College Cork, National University of Ireland|Department of General Internal Medicine|Clinic for General Internal Medicine, Bern University Hospital Bern",Drug|Drug,Ireland|Switzerland,65.0,120.0,[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT02500342
NCT02516774,"thyroid carcinoma, anaplastic","A Phase I Trial Assessing Adalimumab (Humira®), a Tumor Necrosis Factor α Inhibitor Combined to Chemotherapy and Radiotherapy in Patients With Anaplastic Thyroid Cancers",A Trial of Adalimumab Combined to Chemotherapy and Radiotherapy in Patients With Anaplastic Thyroid Cancers,Anaplastic Thyroid Cancers,2015-04-29,2015-12-31,2015-12-31,Interventional,Withdrawn,Phase 1,"Gustave Roussy, Cancer Campus, Grand Paris","Gustave Roussy, Cancer Campus, Grand Paris",Gustave Roussy Cancer Campus Grand Paris,Drug,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT02516774
NCT02523209,hyperparathyroidism,Analysis of Bone Microarchitecture With HR-pQCT of Patients With Chronic Kidney Disease (CKD) Candidates for Renal Transplantation - A Monocentric Study,Analysis of Bone Microarchitecture With HR-pQCT of Patients With Chronic Kidney Disease (CKD) Candidates for Renal Transplantation,"Chronic Kidney Diseases|Hyperparathyroidism, Secondary",2015-07-15,2017-04-30,2017-04-30,Observational,Completed,,Centre Hospitalier Universitaire de Saint Etienne,Centre Hospitalier Universitaire de Saint Etienne,Chu Saint-Etienne,Device|Device,France,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02523209
NCT02525796,hyperparathyroidism,Evaluating Alternative Medical Therapies in Primary Hyperparathyroidism,Evaluating Alternative Medical Therapies in Primary Hyperparathyroidism,Primary Hyperparathyroidism,2015-08-14,2021-10-01,2021-10-02,Interventional,Completed,Phase 2/Phase 3,Brigham and Women's Hospital,Brigham and Women's Hospital,Brigham and Women's Hospital,Drug|Drug|Drug|Drug,United States,18.0,80.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02525796
NCT02535975,graves ophthalmopathy,,The Effects of Metformin in Patients With Mild Graves' Ophthalmopathy,Mild Graves' Ophthalmopathy,2015-08-12,2019-10-31,2019-10-31,Interventional,Unknown status,Not Applicable,Yonsei University,Yonsei University,"Endocrinology, Internal Medicine, Yonsei University College of Medicine",Drug|Drug,"Korea, Republic of",18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT02535975
NCT02535975,hyperthyroidism,,The Effects of Metformin in Patients With Mild Graves' Ophthalmopathy,Mild Graves' Ophthalmopathy,2015-08-12,2019-10-31,2019-10-31,Interventional,Unknown status,Not Applicable,Yonsei University,Yonsei University,"Endocrinology, Internal Medicine, Yonsei University College of Medicine",Drug|Drug,"Korea, Republic of",18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02535975
NCT02535975,goiter,,The Effects of Metformin in Patients With Mild Graves' Ophthalmopathy,Mild Graves' Ophthalmopathy,2015-08-12,2019-10-31,2019-10-31,Interventional,Unknown status,Not Applicable,Yonsei University,Yonsei University,"Endocrinology, Internal Medicine, Yonsei University College of Medicine",Drug|Drug,"Korea, Republic of",18.0,80.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02535975
NCT02535975,graves disease,,The Effects of Metformin in Patients With Mild Graves' Ophthalmopathy,Mild Graves' Ophthalmopathy,2015-08-12,2019-10-31,2019-10-31,Interventional,Unknown status,Not Applicable,Yonsei University,Yonsei University,"Endocrinology, Internal Medicine, Yonsei University College of Medicine",Drug|Drug,"Korea, Republic of",18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02535975
NCT02536287,hyperparathyroidism,Comparison of Total Parathyroidectomy With Autotransplantation Versus Total Parathyroidectomy Without Autotransplantation:A Randomized Clinical Trial,Comparison of Total Parathyroidectomy With and Without Autotransplantation,Secondary Hyperparathyroidism,2015-08-22,2016-12-31,2018-12-31,Interventional,Unknown status,Phase 3,The Second Hospital of Anhui Medical University,The Second Hospital of Anhui Medical University,the Second Affiliated Hospital of Anhui Medical University,Procedure|Procedure,China,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02536287
NCT02539498,hyperparathyroidism,Characterization of Bone Architectural Parameters Assessed by High-Resolution Peripheral Quantitative Computed Tomography in Post-menopausal Women Affected With Primary Hyperparathyroidism,Bone Architectural Parameters in Postmenopausal Women Affected With Primary Hyperparathyroidism,Bone Disease|Primary Hyperparathyroidism,2015-04-27,2016-12-31,2016-12-31,Interventional,Completed,Not Applicable,Assistance Publique - Hôpitaux de Paris,Assistance Publique - Hôpitaux de Paris,Hopital Lariboisiere|Hopital Cochin|Hopital Europeen Georges Pompidou,Device,France,0.0,81.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02539498
NCT02549391,hyperparathyroidism,"Phase 3 Study of KHK7580 (A Randomized, Double-Blind, Intra-Subject Dose-Adjustment, Parallel-Group Study of KHK7580 and Cinacalcet Hydrochloride in Subjects With Secondary Hyperparathyroidism Receiving Hemodialysis)",Phase 3 Study of KHK7580,Secondary Hyperparathyroidism,2015-09-09,2016-11-30,2016-11-30,Interventional,Completed,Phase 2/Phase 3,"Kyowa Kirin Co., Ltd.","Kyowa Kirin Co., Ltd.","For additional information regarding investigative sites for this trial, contact Kyowa Hakko Kirin",Drug|Drug,Japan,20.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02549391
NCT02549404,hyperparathyroidism,Phase 3 Study of KHK7580 (A Long-term Study of KHK7580 in Subjects With Secondary Hyperparathyroidism Receiving Hemodialysis),Phase 3 Study of KHK7580,Secondary Hyperparathyroidism,2015-09-09,2016-12-06,2016-12-28,Interventional,Completed,Phase 3,"Kyowa Kirin Co., Ltd.","Kyowa Kirin Co., Ltd.","For additional information regarding investigative sites for this trial, contact Kyowa Hakko Kirin",Drug,Japan,20.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02549404
NCT02549417,hyperparathyroidism,Phase 3 Study of KHK7580 (A Clinical Study of KHK7580 in Subjects With Secondary Hyperparathyroidism Receiving Peritoneal Dialysis),Phase 3 Study of KHK7580,Secondary Hyperparathyroidism,2015-09-09,2016-12-22,2016-12-22,Interventional,Completed,Phase 3,"Kyowa Kirin Co., Ltd.","Kyowa Kirin Co., Ltd.","For additional information regarding investigative sites for this trial, contact Kyowa Hakko Kirin",Drug,Japan,20.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02549417
NCT02551120,hypoparathyroidism,"Characterization of Patients With Idiopathic Hypoparathyroidism, Autosomal Dominant Hypocalcaemia and Pseudohypoparathyroidism",Characterization of Patients With Non-surgical Hypoparathyroidism and Pseudohypoparathyroidism,Autosomal Dominant Hypocalcaemia|Idiopathic Hypoparathyroidism|Pseudohypoparathyroidism,2015-06-17,2017-08-31,2020-08-31,Observational,Unknown status,,University of Aarhus,University of Aarhus,Aarhus University Hospital,,Denmark,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02551120
NCT02556216,hyperparathyroidism,Systematic Study of Parameters of Chronic Kidney Disease Mineral and Bone Disorder (CKD-MBD),Systematic Study of Parameters of Chronic Kidney Disease Mineral and Bone Disorder (CKD-MBD),Renal Osteodystrophy,2015-08-06,2019-01-31,2019-07-31,Observational,Unknown status,,Hannover Medical School,Hannover Medical School|University of Jena,Hannover Medical School,,Germany,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02556216
NCT02609685,thyroid neoplasms,Active Surveillance of Papillary Thyroid Microcarcinoma,Active Surveillance of Papillary Thyroid Microcarcinoma,Papillary Thyroid Microcarcinoma,2015-11-18,2030-12-31,2030-12-31,Interventional,Recruiting,Not Applicable,Cedars-Sinai Medical Center,Cedars-Sinai Medical Center,Cedars-Sinai Medical Center,Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02609685
NCT02620085,graves disease,Bio-psycho-social Correlates of Psychological Distress in Patients With Graves' Disease in Euthyroid Status,Thyroid Disease and Personality Study,Graves' Disease,2015-11-04,2021-07-31,2021-07-31,Observational,Unknown status,,National Taiwan University Hospital,National Taiwan University Hospital,Shyang-Rong Shih,Procedure,Taiwan,20.0,85.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02620085
NCT02620085,goiter,Bio-psycho-social Correlates of Psychological Distress in Patients With Graves' Disease in Euthyroid Status,Thyroid Disease and Personality Study,Graves' Disease,2015-11-04,2021-07-31,2021-07-31,Observational,Unknown status,,National Taiwan University Hospital,National Taiwan University Hospital,Shyang-Rong Shih,Procedure,Taiwan,20.0,85.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02620085
NCT02620085,hyperthyroidism,Bio-psycho-social Correlates of Psychological Distress in Patients With Graves' Disease in Euthyroid Status,Thyroid Disease and Personality Study,Graves' Disease,2015-11-04,2021-07-31,2021-07-31,Observational,Unknown status,,National Taiwan University Hospital,National Taiwan University Hospital,Shyang-Rong Shih,Procedure,Taiwan,20.0,85.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02620085
NCT02645786,thyroid neoplasms,Cardiac Effects of Thyrotropin Over-Suppression With Levothyroxine in Young Women With Differentiated Thyroid Cancer,Thyrotropin Over-suppression and Heart,Heart Diseases|Malignant Neoplasm of Thyroid|Thyrotoxicosis on Thyroxine Therapy,2015-12-20,2013-11-30,2014-04-30,Observational,Completed,,Chuncheon Sacred Heart Hospital,Chuncheon Sacred Heart Hospital,,,,32.0,51.0,[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02645786
NCT02645786,thyrotoxicosis,Cardiac Effects of Thyrotropin Over-Suppression With Levothyroxine in Young Women With Differentiated Thyroid Cancer,Thyrotropin Over-suppression and Heart,Heart Diseases|Malignant Neoplasm of Thyroid|Thyrotoxicosis on Thyroxine Therapy,2015-12-20,2013-11-30,2014-04-30,Observational,Completed,,Chuncheon Sacred Heart Hospital,Chuncheon Sacred Heart Hospital,,,,32.0,51.0,[18-65],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02645786
NCT02652884,hypoparathyroidism,Evaluation of Potential Benefits of Using Steroids in the Postoperative Transient Hypoparathyroidism Total Thyroidectomy,Steroids in the Postoperative Transient Hypoparathyroidism Total Thyroidectomy,Transient Hypoparathyroidism,2016-01-05,2016-12-31,2017-12-31,Interventional,Unknown status,Phase 4,Hospital Italiano de Buenos Aires,Hospital Italiano de Buenos Aires,Hospital Italiano de Buenos Aires,Drug|Drug,Argentina,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02652884
NCT02658552,thyroid nodule,A Prospective Evaluation of High Intensity Focused Ultrasound (HIFU) in the Treatment of Benign Thyroid Nodules,A Prospective Evaluation of High Intensity Focused Ultrasound (HIFU) in the Treatment of Benign Thyroid Nodules,Benign Thyroid Nodules,2016-01-06,2016-02-29,2016-07-31,Interventional,Completed,Not Applicable,The University of Hong Kong,The University of Hong Kong,Queen Mary Hospital,Device,Hong Kong,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT02658552
NCT02658552,thyroid neoplasms,A Prospective Evaluation of High Intensity Focused Ultrasound (HIFU) in the Treatment of Benign Thyroid Nodules,A Prospective Evaluation of High Intensity Focused Ultrasound (HIFU) in the Treatment of Benign Thyroid Nodules,Benign Thyroid Nodules,2016-01-06,2016-02-29,2016-07-31,Interventional,Completed,Not Applicable,The University of Hong Kong,The University of Hong Kong,Queen Mary Hospital,Device,Hong Kong,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02658552
NCT02665325,thyroid neoplasms,Cognitive Functions and Mood During Thyrotropin Suppressive Therapy in Patients With Differentiated Thyroid Carcinoma,Cognitive Functions During Thyrotropin Suppressive Therapy in Patients With Differentiated Thyroid Carcinoma,Cognitive Impairment,2016-01-17,2017-12-31,2018-12-31,Observational,Unknown status,,The Affiliated Hospital of Inner Mongolia Medical University,National Natural Science Foundation of China|The Affiliated Hospital of Inner Mongolia Medical University,Shan Jin,Drug,China,18.0,65.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02665325
NCT02681328,thyroid neoplasms,Randomized Trial Comparing Performance of Molecular Markers for Indeterminate Thyroid Nodules,Randomized Trial Comparing Performance of Molecular Markers for Indeterminate Thyroid Nodules,Thyroid,2016-02-10,2022-08-01,2023-12-01,Observational,Recruiting,,Jonsson Comprehensive Cancer Center,Jonsson Comprehensive Cancer Center,Jonsson Comprehensive Cancer Center at UCLA,Other|Other|Other|Other,United States,18.0,100.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02681328
NCT02681328,thyroid nodule,Randomized Trial Comparing Performance of Molecular Markers for Indeterminate Thyroid Nodules,Randomized Trial Comparing Performance of Molecular Markers for Indeterminate Thyroid Nodules,Thyroid,2016-02-10,2022-08-01,2023-12-01,Observational,Recruiting,,Jonsson Comprehensive Cancer Center,Jonsson Comprehensive Cancer Center,Jonsson Comprehensive Cancer Center at UCLA,Other|Other|Other|Other,United States,18.0,100.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT02681328
NCT02685514,hyperthyroidism,A Prospective Evaluation of High Intensity Focused Ultrasound (HIFU) in the Treatment of Relapsed Graves' Disease,A Evaluation of High Intensity Focused Ultrasound (HIFU) in the Treatment of Relapsed Graves' Disease,Rrelapsed Graves' Disease,2016-02-14,2016-04-30,2016-04-30,Interventional,Completed,Not Applicable,The University of Hong Kong,The University of Hong Kong,Queen Mary Hospital,Device,Hong Kong,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02685514
NCT02685514,goiter,A Prospective Evaluation of High Intensity Focused Ultrasound (HIFU) in the Treatment of Relapsed Graves' Disease,A Evaluation of High Intensity Focused Ultrasound (HIFU) in the Treatment of Relapsed Graves' Disease,Rrelapsed Graves' Disease,2016-02-14,2016-04-30,2016-04-30,Interventional,Completed,Not Applicable,The University of Hong Kong,The University of Hong Kong,Queen Mary Hospital,Device,Hong Kong,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02685514
NCT02685514,graves disease,A Prospective Evaluation of High Intensity Focused Ultrasound (HIFU) in the Treatment of Relapsed Graves' Disease,A Evaluation of High Intensity Focused Ultrasound (HIFU) in the Treatment of Relapsed Graves' Disease,Rrelapsed Graves' Disease,2016-02-14,2016-04-30,2016-04-30,Interventional,Completed,Not Applicable,The University of Hong Kong,The University of Hong Kong,Queen Mary Hospital,Device,Hong Kong,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02685514
NCT02693808,graves ophthalmopathy,New Treatment for Patients With Temporal Hollowing After Lateral Wall Decompression,New Treatment for Patients With Temporal Hollowing After Lateral Wall Decompression,Thyroid-Associated Ophthalmopathy,2015-12-04,2018-01-31,2018-05-31,Interventional,Completed,Not Applicable,Haukeland University Hospital,Haukeland University Hospital,Department of Ophthalmology Haukeland University Hospital,Procedure|Procedure,Norway,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT02693808
NCT02693808,graves disease,New Treatment for Patients With Temporal Hollowing After Lateral Wall Decompression,New Treatment for Patients With Temporal Hollowing After Lateral Wall Decompression,Thyroid-Associated Ophthalmopathy,2015-12-04,2018-01-31,2018-05-31,Interventional,Completed,Not Applicable,Haukeland University Hospital,Haukeland University Hospital,Department of Ophthalmology Haukeland University Hospital,Procedure|Procedure,Norway,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02693808
NCT02693808,goiter,New Treatment for Patients With Temporal Hollowing After Lateral Wall Decompression,New Treatment for Patients With Temporal Hollowing After Lateral Wall Decompression,Thyroid-Associated Ophthalmopathy,2015-12-04,2018-01-31,2018-05-31,Interventional,Completed,Not Applicable,Haukeland University Hospital,Haukeland University Hospital,Department of Ophthalmology Haukeland University Hospital,Procedure|Procedure,Norway,18.0,80.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02693808
NCT02693808,hyperthyroidism,New Treatment for Patients With Temporal Hollowing After Lateral Wall Decompression,New Treatment for Patients With Temporal Hollowing After Lateral Wall Decompression,Thyroid-Associated Ophthalmopathy,2015-12-04,2018-01-31,2018-05-31,Interventional,Completed,Not Applicable,Haukeland University Hospital,Haukeland University Hospital,Department of Ophthalmology Haukeland University Hospital,Procedure|Procedure,Norway,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02693808
NCT02697578,hyperparathyroidism,Artificial Intelligence: to Analyse CKD-MBD in Hemodialysis and Cardiovascular Risk,Artificial Intelligence: a New Alternative to Analyse CKD-MBD in Hemodialysis,Chronic Kidney Disease Mineral and Bone Disorder,2016-02-23,2018-12-19,2018-12-19,Observational,Completed,,Maimónides Biomedical Research Institute of Córdoba,Maimónides Biomedical Research Institute of Córdoba,Hospital Universitario Reina Sofía,,Spain,18.0,90.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02697578
NCT02708368,hyperparathyroidism,Investigation to Develop Standard Operating Procedures (SOP) for the Determination of Innovative CKD-MBD(Chronic Kidney Disease - Mineral Bone Disorder)-Serum-(Plasma-)Parameters,SOP's for CKD-MBD-Biomarkers,Chronic Kidney Diseases,2016-02-29,2016-09-30,2016-09-30,Observational,Unknown status,,RWTH Aachen University,RWTH Aachen University,"Department of Medicine, Division of Cardiology, Pulmonary Diseases and Vascular Medicine at the University Hospital, RWTH Aachen|Clinic for Nephrology and Diabetology, Hospital St. Franziskus (Maria-Hilf-Clinic)",Other,Germany,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02708368
NCT02710799,thyroid neoplasms,Evaluation of the Effectivity of Teleconsultations for Improving the Referrals From Primary Care to Specialized Care of Patients With Chronic Endocrinological Conditions,Evaluation of the Effects of Teleconsultations on a Endocrinology Referral List,Diabetes Mellitus|Goiter|Hyperthyroidism|Hypothyroidism|Obesity|Thyroid Nodule,2016-03-07,2016-06-30,2016-06-30,Interventional,Completed,Not Applicable,Hospital de Clinicas de Porto Alegre,Hospital de Clinicas de Porto Alegre|Programa de Pesquisa e Pós-Graduação em Epidemiologia da UFRGS|Secretaria Estadual da Saúde do Estado do Rio Grande do Sul|TelessaúdeRS / UFRGS,Secretaria Estadual da Saúde,Other|Other,Brazil,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02710799
NCT02713256,graves disease,An Open Label Study to Evaluate the Safety and Efficacy of 12 Week Treatment With CFZ533 in Patients With Graves' Disease,A Study to Evaluate the Safety and Effect of CFZ533 on Patients With Graves' Disease,Graves' Disease,2016-03-15,2017-04-24,2017-04-24,Interventional,Completed,Phase 2,Novartis,Novartis Pharmaceuticals,Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site,Drug,Germany|United States,18.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02713256
NCT02713256,hyperthyroidism,An Open Label Study to Evaluate the Safety and Efficacy of 12 Week Treatment With CFZ533 in Patients With Graves' Disease,A Study to Evaluate the Safety and Effect of CFZ533 on Patients With Graves' Disease,Graves' Disease,2016-03-15,2017-04-24,2017-04-24,Interventional,Completed,Phase 2,Novartis,Novartis Pharmaceuticals,Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site,Drug,Germany|United States,18.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02713256
NCT02713256,goiter,An Open Label Study to Evaluate the Safety and Efficacy of 12 Week Treatment With CFZ533 in Patients With Graves' Disease,A Study to Evaluate the Safety and Effect of CFZ533 on Patients With Graves' Disease,Graves' Disease,2016-03-15,2017-04-24,2017-04-24,Interventional,Completed,Phase 2,Novartis,Novartis Pharmaceuticals,Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site,Drug,Germany|United States,18.0,65.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02713256
NCT02714946,thyroid neoplasms,Prospective Randomized Comparative Study of the Effectiveness and Safety of Ultrasound-guided Laser and Radiofrequency Ablation for the Treatment of Benign Thyroid Nodules,Laser Ablation Versus Radiofrequency Ablation for Thyroid Nodules,Thyroid Nodule,2016-02-19,2019-09-30,2020-01-31,Interventional,Unknown status,Not Applicable,Campus Bio-Medico University,Campus Bio-Medico University,Santa Maria Goretti Hospital,Device|Device,Italy,18.0,65.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02714946
NCT02721992,goiter,A Prospective Study on the Association Between Graves' Orbitopathy and Hypercholesterolemia,Graves' Orbitopathy and Hypercholesterolemia,Graves' Ophthalmopathy|Hypercholesterolemia,2016-03-17,2017-06-30,2017-06-30,Observational,Completed,,University of Pisa,University of Pisa,Ospedale Cisanello-Endocrinology I and II,Other,Italy,18.0,80.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02721992
NCT02721992,hyperthyroidism,A Prospective Study on the Association Between Graves' Orbitopathy and Hypercholesterolemia,Graves' Orbitopathy and Hypercholesterolemia,Graves' Ophthalmopathy|Hypercholesterolemia,2016-03-17,2017-06-30,2017-06-30,Observational,Completed,,University of Pisa,University of Pisa,Ospedale Cisanello-Endocrinology I and II,Other,Italy,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02721992
NCT02721992,graves disease,A Prospective Study on the Association Between Graves' Orbitopathy and Hypercholesterolemia,Graves' Orbitopathy and Hypercholesterolemia,Graves' Ophthalmopathy|Hypercholesterolemia,2016-03-17,2017-06-30,2017-06-30,Observational,Completed,,University of Pisa,University of Pisa,Ospedale Cisanello-Endocrinology I and II,Other,Italy,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02721992
NCT02721992,graves ophthalmopathy,A Prospective Study on the Association Between Graves' Orbitopathy and Hypercholesterolemia,Graves' Orbitopathy and Hypercholesterolemia,Graves' Ophthalmopathy|Hypercholesterolemia,2016-03-17,2017-06-30,2017-06-30,Observational,Completed,,University of Pisa,University of Pisa,Ospedale Cisanello-Endocrinology I and II,Other,Italy,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT02721992
NCT02724176,"thyroid cancer, papillary",Potential Role for Carbon Nanoparticles to Guide Central Neck Dissection in Patients With Papillary Thyroid Cancer,Potential Role for Carbon Nanoparticles to Guide Central Neck Dissection in Patients With Papillary Thyroid Cancer,Thyroid Cancer,2016-03-18,2016-01-31,2016-01-31,Interventional,Completed,Not Applicable,Beijing Cancer Hospital,Beijing Cancer Hospital,,Drug,,18.0,75.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT02724176
NCT02725879,hashimoto disease,"Association of Serum Fibroblast Growth Factor 21 (FGF-21) Levels With Resting Metabolic Rate (RMR), in Children and Adolescents With Hashimoto's Thyroiditis.",FGF-21 Levels and RMR in Children and Adolescents With Hashimoto's Thyroiditis (THYROMETABOL),Thyroiditis Hashimoto,2016-01-09,2020-09-30,2020-12-31,Observational,Unknown status,,Aristotle University Of Thessaloniki,Aristotle University Of Thessaloniki,"2nd Department of Paediatrics, School of Medicine Faculty of Health Sciences, Aristotle University of Thessaloniki, AHEPA Hospital Thessaloniki, Greece",Other,Greece,5.0,18.0,[0-17]|[18-65],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT02725879
NCT02727738,graves disease,Randomized Open Clinical Study to Evaluate the Efficacy of Selenium Plus Methimazole for Treatment of Graves' Hyperthyroidism,Treatment of Graves' Hyperthyroidism With Selenium Plus Methimazole,Graves' Disease,2015-06-30,2015-09-30,2015-12-31,Interventional,Completed,Not Applicable,University of Pisa,University of Pisa,Endocrinology Unit,Dietary Supplement|Drug,Italy,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02727738
NCT02727738,hyperthyroidism,Randomized Open Clinical Study to Evaluate the Efficacy of Selenium Plus Methimazole for Treatment of Graves' Hyperthyroidism,Treatment of Graves' Hyperthyroidism With Selenium Plus Methimazole,Graves' Disease,2015-06-30,2015-09-30,2015-12-31,Interventional,Completed,Not Applicable,University of Pisa,University of Pisa,Endocrinology Unit,Dietary Supplement|Drug,Italy,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02727738
NCT02727738,goiter,Randomized Open Clinical Study to Evaluate the Efficacy of Selenium Plus Methimazole for Treatment of Graves' Hyperthyroidism,Treatment of Graves' Hyperthyroidism With Selenium Plus Methimazole,Graves' Disease,2015-06-30,2015-09-30,2015-12-31,Interventional,Completed,Not Applicable,University of Pisa,University of Pisa,Endocrinology Unit,Dietary Supplement|Drug,Italy,18.0,70.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02727738
NCT02764554,thyroid neoplasms,Post-Marketing Surveillance of Lenvima in Korean Patients,Post-Marketing Surveillance of Lenvima in Korean Patients,Differentiated Thyroid Carcinoma (DTC),2016-05-04,2021-09-29,2021-09-29,Observational,Completed,,Eisai Inc.,Eisai Korea Inc.,Eisai Trial Site #18|Eisai Trial Site #30|Eisai Trial Site #14|Eisai Trial Site #27|Eisai Trial Site #34|Eisai Trial Site #21|Eisai Trial Site #24|Eisai Trial Site #15|Eisai Trial Site #16|Eisai Trial Site #17|Eisai Trial Site #20|Eisai Trial Site #22|Eisai Trial Site #37|Eisai Trial Site #36|Eisai Trial Site #4|Eisai Trial Site #13|Eisai Trial Site #25|Eisai Trial Site #26|Eisai Trial Site #32|Eisai Trial Site #19|Eisai Trial Site #1|Eisai Trial Site #23|Eisai Trial Site #29|Eisai Trial Site #31|Eisai Trial Site #33|Eisai Trial Site #35|Eisai Trial Site #38|Eisai Trial Site #39|Eisai Trial Site #8|Eisai Trial Site #9|Eisai Trial Site #12|Eisai Trial Site #6,,"Korea, Republic of",0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02764554
NCT02766660,goiter,"Optic Disc, Macula, and Retinal Nerve Fiber Layer Measurements Obtained by OCT in Thyroid Associated Ophthalmopathy","Optic Disc, Macula, and Retinal Nerve Fiber Layer Measurements Obtained by OCT in Thyroid Associated Ophthalmopathy",Thyroid Associated Ophthalmopathy,2016-04-24,2013-01-31,2013-01-31,Interventional,Completed,Not Applicable,Neon Hospital,Neon Hospital|Ondokuz Mayıs University,,Device,,12.0,73.0,[0-17]|[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02766660
NCT02766660,graves ophthalmopathy,"Optic Disc, Macula, and Retinal Nerve Fiber Layer Measurements Obtained by OCT in Thyroid Associated Ophthalmopathy","Optic Disc, Macula, and Retinal Nerve Fiber Layer Measurements Obtained by OCT in Thyroid Associated Ophthalmopathy",Thyroid Associated Ophthalmopathy,2016-04-24,2013-01-31,2013-01-31,Interventional,Completed,Not Applicable,Neon Hospital,Neon Hospital|Ondokuz Mayıs University,,Device,,12.0,73.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT02766660
NCT02766660,graves disease,"Optic Disc, Macula, and Retinal Nerve Fiber Layer Measurements Obtained by OCT in Thyroid Associated Ophthalmopathy","Optic Disc, Macula, and Retinal Nerve Fiber Layer Measurements Obtained by OCT in Thyroid Associated Ophthalmopathy",Thyroid Associated Ophthalmopathy,2016-04-24,2013-01-31,2013-01-31,Interventional,Completed,Not Applicable,Neon Hospital,Neon Hospital|Ondokuz Mayıs University,,Device,,12.0,73.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02766660
NCT02766660,hyperthyroidism,"Optic Disc, Macula, and Retinal Nerve Fiber Layer Measurements Obtained by OCT in Thyroid Associated Ophthalmopathy","Optic Disc, Macula, and Retinal Nerve Fiber Layer Measurements Obtained by OCT in Thyroid Associated Ophthalmopathy",Thyroid Associated Ophthalmopathy,2016-04-24,2013-01-31,2013-01-31,Interventional,Completed,Not Applicable,Neon Hospital,Neon Hospital|Ondokuz Mayıs University,,Device,,12.0,73.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02766660
NCT02772705,graves disease,Comparison of Standardized Update Value Using Single-photo Emission Computed Tomography and Computed Tomography Between Grave's Disease (Hyperthyroidism) Patients and Normal Humans,Comparison of SUV Using SPECT/CT Between Grave's Disease Patients and Normal Humans,Emission-Computed|Hyperthyroidism|Single-Photon|Tomography,2016-05-09,2016-08-31,2017-01-31,Observational,Unknown status,,West China Hospital,"Air Force Military Medical University, China|Beijing Tongren Hospital|Guangzhou Panyu Central Hospital|Hebei General Hospital|The First Affiliated Hospital of Zhengzhou University|Tianjin Medical University General Hospital|West China Hospital|Zhejiang Cancer Hospital",Beijing Tongren Hospital|Guangzhou Panyu Central Hospital|Hebei General Hospital|The First Affiliated Hospital of Zhengzhou University|The People's Hospital of Inner Mongolia Autonomous Region|Fourth Military Medical Universit|West China Hospital|Tianjin Medical University General Hospital|Zhejiang Cancer Hospital,,China,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02772705
NCT02772705,goiter,Comparison of Standardized Update Value Using Single-photo Emission Computed Tomography and Computed Tomography Between Grave's Disease (Hyperthyroidism) Patients and Normal Humans,Comparison of SUV Using SPECT/CT Between Grave's Disease Patients and Normal Humans,Emission-Computed|Hyperthyroidism|Single-Photon|Tomography,2016-05-09,2016-08-31,2017-01-31,Observational,Unknown status,,West China Hospital,"Air Force Military Medical University, China|Beijing Tongren Hospital|Guangzhou Panyu Central Hospital|Hebei General Hospital|The First Affiliated Hospital of Zhengzhou University|Tianjin Medical University General Hospital|West China Hospital|Zhejiang Cancer Hospital",Beijing Tongren Hospital|Guangzhou Panyu Central Hospital|Hebei General Hospital|The First Affiliated Hospital of Zhengzhou University|The People's Hospital of Inner Mongolia Autonomous Region|Fourth Military Medical Universit|West China Hospital|Tianjin Medical University General Hospital|Zhejiang Cancer Hospital,,China,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02772705
NCT02778412,thyroid nodule,Determination of the Utility of Plasma Circulating Tumor DNA (ctDNA) Measurements for Detection of Thyroid Cancer in Patients Undergoing Diagnostic Fine Needle Aspirations of the Thyroid,ctDNA in Patients With Thyroid Nodules,Thyroid Adenoma|Thyroid Cancer|Thyroiditis|Thyroid Nodules,2016-05-16,2017-08-31,2017-08-31,Observational,Terminated,,Pathway Genomics,Pathway Genomics,Thyroid & Endocrine Center of Florida,,United States,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT02778412
NCT02784223,thyroid neoplasms,Diagnostic Value of 18F-Choline PET/CT in Patients With a Thyroid Nodule With an Indeterminate Cytology: Pilot Study,Diagnostic Value of 18F-Choline PET/CT in Patients With a Thyroid Nodule With an Indeterminate Cytology: Pilot Study,Thyroid Gland,2016-05-24,2019-03-28,2019-03-28,Interventional,Completed,Not Applicable,Centre Francois Baclesse,Canceropôle Nord Ouest|Centre Francois Baclesse,Centre François Baclesse,Device,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02784223
NCT02784223,thyroid nodule,Diagnostic Value of 18F-Choline PET/CT in Patients With a Thyroid Nodule With an Indeterminate Cytology: Pilot Study,Diagnostic Value of 18F-Choline PET/CT in Patients With a Thyroid Nodule With an Indeterminate Cytology: Pilot Study,Thyroid Gland,2016-05-24,2019-03-28,2019-03-28,Interventional,Completed,Not Applicable,Centre Francois Baclesse,Canceropôle Nord Ouest|Centre Francois Baclesse,Centre François Baclesse,Device,France,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT02784223
NCT02787486,hypoparathyroidism,"A Clinical Study to Evaluate the Relative Clinical Sensitivity, Specificity, and Performance of the a Laboratory Developed Test as a Screening Test for Fetal Chromosomal Aneuploidy, Infectious and Other Diseases, and RhD Genotyping in the General Population of Pregnant Women",Expanded Noninvasive Genomic Medical Assessment: The Enigma Study,Aneuploidy|Chromosome Deletion|DiGeorge Syndrome|Down Syndrome|Edwards Syndrome|Klinefelter Syndrome|Patau Syndrome|Turner Syndrome,2016-05-26,2018-09-30,2018-09-30,Observational,Completed,,"Progenity, Inc.","Progenity, Inc.","Valley Perinatal|Heinen Obstectrics & Gynecology|Newlife Wellness OBGYN|Lakeshore Women's Specialists|Cincinnati Obgyn|James D. Kasten, M.D., Inc.|Regional Obstetrical Consultants|Texas Maternal-Fetal Medicine",Other,United States,18.0,54.0,[18-65],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02787486
NCT02798965,hyperthyroidism,Prevalence of Circulating Parvovirus Genome in Recently Diagnosed Graves' Disease: a Case-control Study,Prevalence of Circulating Parvovirus Genome in Recently Diagnosed Graves' Disease: a Case-control Study,Graves Disease,2016-06-09,2014-05-31,2014-05-31,Interventional,Completed,Not Applicable,"Centre Hospitalier Universitaire, Amiens","Centre Hospitalier Universitaire, Amiens",CHU Amiens,Biological,France,18.0,99.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02798965
NCT02798965,goiter,Prevalence of Circulating Parvovirus Genome in Recently Diagnosed Graves' Disease: a Case-control Study,Prevalence of Circulating Parvovirus Genome in Recently Diagnosed Graves' Disease: a Case-control Study,Graves Disease,2016-06-09,2014-05-31,2014-05-31,Interventional,Completed,Not Applicable,"Centre Hospitalier Universitaire, Amiens","Centre Hospitalier Universitaire, Amiens",CHU Amiens,Biological,France,18.0,99.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02798965
NCT02824016,hypothyroidism,A Prospective Multicentric Evaluation of the Rate of Incidence of Hypothyroidism After Supraclavicular Irradiation for Breast Cancer,Evaluation of Hypothyroidism Incidence After Breast Cancer Supraclavicular Irradiation,Irradiation; Adverse Effect|Irradiation Hypothyroidism,2014-08-25,2015-07-31,2020-07-31,Interventional,Completed,Not Applicable,Institut Jean-Godinot,Institut Jean-Godinot,Institut Jean Godinot|Centre Paul Strauss|Institut de Cancerologie de Lorraine,Biological|Radiation,France,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT02824016
NCT02824718,hypoparathyroidism,A Randomized Crossover TrIal to Compare Recombinant Human rhPTH(1-34) to the ASsociation Alfacalcidol/Hydrochlorothiazide in the Treatment of Severe Primary Hypoparathyroidism,Recombinant Human rhPTH(1-34) VS Association Alfacalcidol/Hydrochlorothiazide in Severe Primary Hypoparathyroidism,Autosomal Dominant Hypocalcemia OR Primary Hypoparathyroidism Related to Other Cause But Complicated by Hypercalciuria Under Treatment,2016-07-01,2020-05-28,2020-05-28,Interventional,Completed,Phase 2,Assistance Publique - Hôpitaux de Paris,"Assistance Publique - Hôpitaux de Paris|Ministry of Health, France",AP-HP Hopital Europeen Georges Pompidou,Drug|Drug|Drug|Drug,France,18.0,80.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02824718
NCT02830789,hyperparathyroidism,Investigation of the Optimal Calcium Supplement Following Roux-en-Y Gastric Bypass in Order to Treat Secondary Hyperparathyroidism: A Clinical Randomized Trial,Investigation of the Optimal Calcium Supplement Following Roux-en-Y Gastric Bypass,"Hyperparathyroidism, Secondary|Roux-en-Y Gastric Bypass",2016-07-06,2017-05-31,2017-05-31,Interventional,Completed,Not Applicable,University of Aarhus,University of Aarhus,"Department of Enodocrinology and Internal Medicine, Aarhus University Hospital",Dietary Supplement|Dietary Supplement|Dietary Supplement|Procedure,Denmark,20.0,70.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02830789
NCT02831179,thyroid neoplasms,A Phase 1 Study of Veliparib (ABT-888) in Combination With Capecitabine and Temozolomide in Advanced Well-Differentiated Neuroendocrine Tumors,"Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor",Functional Pancreatic Neuroendocrine Tumor|Malignant Somatostatinoma|Merkel Cell Carcinoma|Metastatic Adrenal Gland Pheochromocytoma|Metastatic Carcinoid Tumor|Multiple Endocrine Neoplasia Type 1|Multiple Endocrine Neoplasia Type 2A|Multiple Endocrine Neoplasia Type 2B|Neuroendocrine Neoplasm|Non-Functional Pancreatic Neuroendocrine Tumor|Pancreatic Glucagonoma|Pancreatic Insulinoma|Recurrent Adrenal Cortex Carcinoma|Recurrent Adrenal Gland Pheochromocytoma|Recurrent Merkel Cell Carcinoma|Somatostatin-Producing Neuroendocrine Tumor|Stage III Adrenal Cortex Carcinoma|Stage IIIA Merkel Cell Carcinoma|Stage IIIB Merkel Cell Carcinoma|Stage III Thyroid Gland Medullary Carcinoma|Stage IV Adrenal Cortex Carcinoma|Stage IVA Thyroid Gland Medullary Carcinoma|Stage IVB Thyroid Gland Medullary Carcinoma|Stage IVC Thyroid Gland Medullary Carcinoma|Stage IV Merkel Cell Carcinoma|Thymic Carcinoid Tumor|VIP-Producing Neuroendocrine Tumor|Well Differentiated Adrenal Cortex Carcinoma|Zollinger Ellison Syndrome,2016-07-10,2019-02-28,2020-02-29,Interventional,Withdrawn,Phase 1,Vanderbilt-Ingram Cancer Center,National Cancer Institute (NCI)|Vanderbilt-Ingram Cancer Center,,Drug|Drug|Drug|Other|Other,,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02831179
NCT02833857,hyperparathyroidism,"An Open-label, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Etelcalcetide (AMG 416) in Paediatric Subjects Aged 2 to Less Than 18 Years With Secondary Hyperparathyroidism (sHPT) Receiving Maintenance Haemodialysis",A Single-dose Study in Paediatric Patients Aged 2 to Less Than 18 Years With Secondary Hyperparathyroidism (sHPT) Receiving Haemodialysis,"Chronic Kidney Disease, Secondary Hyperparathyroidism",2016-06-09,2018-10-31,2018-10-31,Interventional,Completed,Phase 1,Amgen,Amgen,Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug,Belgium|Germany|Lithuania|Poland|United Kingdom|United States,2.0,17.0,[0-17],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02833857
NCT02839655,thyroid neoplasms,Prospective Study Assessing Thyroidectomy Using Robot,Prospective Study Assessing Thyroidectomy Using Robot,Patients With Thyroid Cancer,2016-07-12,2018-05-15,2022-08-31,Interventional,Active not recruiting,Phase 2,"Gustave Roussy, Cancer Campus, Grand Paris","Gustave Roussy, Cancer Campus, Grand Paris",Gustave Roussy,Device,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02839655
NCT02843542,hyperthyroidism,Localization of Parathyroid Adenoma by Fluorocholine Positron Emission Tomography/MRI (PET/MRI): A Prospective Pilot Study,Localization of Parathyroid Adenoma by Fluorocholine PET/MRI (Positron Emission Tomography -MRI),Primary Hyperthyroidism,2016-07-14,2018-08-31,2018-12-31,Interventional,Unknown status,Not Applicable,Assuta Medical Center,Assuta Medical Center,Assuta Medical Center,Device|Device,Israel,18.0,50.0,[18-65],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02843542
NCT02843542,parathyroid neoplasms,Localization of Parathyroid Adenoma by Fluorocholine Positron Emission Tomography/MRI (PET/MRI): A Prospective Pilot Study,Localization of Parathyroid Adenoma by Fluorocholine PET/MRI (Positron Emission Tomography -MRI),Primary Hyperthyroidism,2016-07-14,2018-08-31,2018-12-31,Interventional,Unknown status,Not Applicable,Assuta Medical Center,Assuta Medical Center,Assuta Medical Center,Device|Device,Israel,18.0,50.0,[18-65],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02843542
NCT02845336,graves disease,An Open Label Trial of Celecoxib in the Treatment of Mild Thyroid Eye Disease,Celecoxib for Thyroid Eye Disease,Thyroid Eye Disease,2016-07-20,2019-06-30,2019-06-30,Interventional,Terminated,Phase 2,Johns Hopkins University,Johns Hopkins University,"Wilmer Eye Institute, Johns Hopkins University",Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02845336
NCT02845336,goiter,An Open Label Trial of Celecoxib in the Treatment of Mild Thyroid Eye Disease,Celecoxib for Thyroid Eye Disease,Thyroid Eye Disease,2016-07-20,2019-06-30,2019-06-30,Interventional,Terminated,Phase 2,Johns Hopkins University,Johns Hopkins University,"Wilmer Eye Institute, Johns Hopkins University",Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02845336
NCT02845336,hyperthyroidism,An Open Label Trial of Celecoxib in the Treatment of Mild Thyroid Eye Disease,Celecoxib for Thyroid Eye Disease,Thyroid Eye Disease,2016-07-20,2019-06-30,2019-06-30,Interventional,Terminated,Phase 2,Johns Hopkins University,Johns Hopkins University,"Wilmer Eye Institute, Johns Hopkins University",Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02845336
NCT02854345,hyperparathyroidism,Preliminary Study Concerning the Validity of Parathyroid Exploration on a Discovery NM 530c CZT Camera,Preliminary Study Concerning the Validity of Parathyroid Exploration on a CZT Camera,Primary Hyperparathyroidism,2016-07-29,2019-03-31,2019-09-30,Interventional,Unknown status,Not Applicable,Centre Hospitalier Universitaire de Besancon,Centre Hospitalier Universitaire de Besancon,CHU Besancon,Device,France,18.0,80.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02854345
NCT02859896,hyperparathyroidism,"An Open-Label, Randomized, Parallel Group Study to Assess the Safety and Efficacy of Hectorol® (Doxercalciferol Capsules) in Pediatric Patients With Chronic Kidney Disease Stages 3 and 4 With Secondary Hyperparathyroidism Not Yet on Dialysis",Safety and Efficacy of Hectorol in Pediatric Patients With Chronic Kidney Disease Stage 3 and 4 With Secondary Hyperparathyroidism Not Yet on Dialysis,Secondary Hyperparathyroidism-Chronic Kidney Disease,2016-08-04,2025-11-12,2025-11-12,Interventional,Active not recruiting,Phase 3,Sanofi,Sanofi,Investigational Site Number :8400022|Investigational Site Number :8400023|Investigational Site Number :8400033|Investigational Site Number :8400005|Investigational Site Number :8400029|Investigational Site Number :8400006|Investigational Site Number :8400008|Investigational Site Number :8400020|Investigational Site Number :8400036|Investigational Site Number :8400014|Investigational Site Number :8400015|Investigational Site Number :8400010|Investigational Site Number :8400016|Investigational Site Number :8400017|Investigational Site Number :8400007|Investigational Site Number :8400021|Investigational Site Number :8400034|Investigational Site Number :8400025|Investigational Site Number :8400004|Investigational Site Number :8400035|Investigational Site Number :8400028|Investigational Site Number :8400027|Investigational Site Number :8400024|Investigational Site Number :8400013|Investigational Site Number :8400019|Investigational Site Number :8400026|Investigational Site Number :8400009|Investigational Site Number :8400001|Investigational Site Number :1520004|Investigational Site Number :1520003,Drug|Drug,Chile|United States,5.0,18.0,[0-17]|[18-65],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02859896
NCT02862470,"thyroid carcinoma, anaplastic",Anaplastic Thyroid Cancer and Follicular Thyroid Cancer-derived Exosomal Analysis Via Treatment of Lovastatin and Vildagliptin and Pilot Prognostic Study Via Urine Exosomal Biological Markers in Thyroid Cancer Patients,Anaplastic Thyroid Cancer and Follicular Thyroid Cancer-derived Exosomal Analysis Via Treatment of Lovastatin and Vildagliptin and Pilot Prognostic Study Via Urine Exosomal Biological Markers in Thyroid Cancer Patients,Thyroid Cancer,2016-07-27,2018-10-31,2020-08-24,Observational [Patient Registry],Completed,,National Taiwan University Hospital,National Taiwan University Hospital,,,,20.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT02862470
NCT02862470,"adenocarcinoma, follicular",Anaplastic Thyroid Cancer and Follicular Thyroid Cancer-derived Exosomal Analysis Via Treatment of Lovastatin and Vildagliptin and Pilot Prognostic Study Via Urine Exosomal Biological Markers in Thyroid Cancer Patients,Anaplastic Thyroid Cancer and Follicular Thyroid Cancer-derived Exosomal Analysis Via Treatment of Lovastatin and Vildagliptin and Pilot Prognostic Study Via Urine Exosomal Biological Markers in Thyroid Cancer Patients,Thyroid Cancer,2016-07-27,2018-10-31,2020-08-24,Observational [Patient Registry],Completed,,National Taiwan University Hospital,National Taiwan University Hospital,,,,20.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT02862470
NCT02890472,hypoparathyroidism,Research of Thymix Dysgenesis in Prenatal Examination of Deletion 22q11 Syndrome,Prenatal Examination of Deletion 22q11 Syndrome : Thymic Dysgenesis THYMI Study,22q11 Deletion Syndrome Di George Syndrome,2016-08-26,2020-07-01,2020-12-31,Observational,Completed,,Centre Hospitalier Universitaire de Nīmes,Centre Hospitalier Universitaire de Nīmes,CHUNimes,,France,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02890472
NCT02895061,hyperparathyroidism,Effectiveness Between Daily Versus Pulse Oral Alfacalcidol for Secondary Hyperparathyroidism in Chronic Hemodialysis Patients: A Randomized Controlled Trial and Multicenter Study,Effectiveness of Oral Alfacalcidol for Secondary Hyperparathyroidism in Chronic Hemodialysis Patients.,"Alfacalcidol, Secondary Hyperparathyroidism, Hemodialysis",2016-09-04,2015-10-31,2016-01-31,Interventional,Completed,Not Applicable,Phramongkutklao College of Medicine and Hospital,Phramongkutklao College of Medicine and Hospital,,Drug,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02895061
NCT02895906,hypoparathyroidism,"A 5-Week, Multi-center, Open-label Study to Assess the Safety and Efficacy of NFC-1 in Subjects Aged 12-17 Years With 22q11.2 Deletion Syndrome and Commonly Associated Neuropsychiatric Conditions (Anxiety, ADHD, ASD)",Safety and Efficacy Study of NFC-1 in Subjects Aged 12-17 Years With 22q11.2DS & Associated Neuropsychiatric Conditions,22q11.2 Deletion Syndrome,2016-08-29,2017-04-13,2017-04-20,Interventional,Completed,Phase 1,Cerecor Inc,"Aevi Genomic Medicine, LLC, a Cerecor company",Children's Hospital of Philadelphia,Drug,United States,12.0,17.0,[0-17],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02895906
NCT02904330,graves disease,"K1-70 - A Phase I, Single Ascending Intramuscular Dose or Single Ascending Intravenous Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Subjects With Graves' Disease",K1-70 - A Study in Subjects With Graves' Disease,Graves' Disease,2016-08-18,2021-04-30,2021-04-30,Interventional,Completed,Phase 1,AV7 Limited,AV7 Limited,Royal Liverpool University Hospital Clinical Research Unit|Medicines Evaluation Unit,Drug,United Kingdom,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02904330
NCT02904330,hyperthyroidism,"K1-70 - A Phase I, Single Ascending Intramuscular Dose or Single Ascending Intravenous Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Subjects With Graves' Disease",K1-70 - A Study in Subjects With Graves' Disease,Graves' Disease,2016-08-18,2021-04-30,2021-04-30,Interventional,Completed,Phase 1,AV7 Limited,AV7 Limited,Royal Liverpool University Hospital Clinical Research Unit|Medicines Evaluation Unit,Drug,United Kingdom,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02904330
NCT02904330,goiter,"K1-70 - A Phase I, Single Ascending Intramuscular Dose or Single Ascending Intravenous Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Subjects With Graves' Disease",K1-70 - A Study in Subjects With Graves' Disease,Graves' Disease,2016-08-18,2021-04-30,2021-04-30,Interventional,Completed,Phase 1,AV7 Limited,AV7 Limited,Royal Liverpool University Hospital Clinical Research Unit|Medicines Evaluation Unit,Drug,United Kingdom,18.0,75.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02904330
NCT02915172,thyroid neoplasms,A Phase I Trial of Lenvatinib (Multi-kinase Inhibitor) and Capecitabine (Anti-metabolite) in Patients With Advanced Malignancies,Lenvatinib and Capecitabine in Patients With Advanced Malignancies,Advanced Cancer|Malignant Neoplasm of Breast|Malignant Neoplasms of Bone and Articular Cartilage|Malignant Neoplasms of Digestive Organs|Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System|Malignant Neoplasms of Female Genital Organs|Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites|Malignant Neoplasms of Independent (Primary) Multiple Sites|Malignant Neoplasms of Lip Oral Cavity and Pharynx|Malignant Neoplasms of Male Genital Organs|Malignant Neoplasms of Mesothelial and Soft Tissue|Malignant Neoplasms of Respiratory and Intrathoracic Organs|Malignant Neoplasms of Thyroid and Other Endocrine Glands|Malignant Neoplasms of Urinary Tract,2016-09-23,2022-12-31,,Interventional,Withdrawn,Phase 1,M.D. Anderson Cancer Center,Eisai Inc.|M.D. Anderson Cancer Center,,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02915172
NCT02946918,hypothyroidism,Levothyroxine Replacement With Liquid Gel Capsules or Tablets in Post-thyroidectomy Stage in Low Risk Differentiated Thyroid Cancer Patients,Levothyroxine Replacement With Liquid Gel Capsules vs Tablets Post-thyroidectomy,Postsurgical Hypothyroidism|Thyroid Cancer,2016-10-21,2019-11-04,2019-11-04,Interventional,Terminated,Phase 4,University of Texas Southwestern Medical Center,Akrimax Pharmaceuticals|University of Texas Southwestern Medical Center,University of Texas Southwestern Medical Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT02946918
NCT02953288,thyroid nodule,Differential Diagnosis and Clinical Treatment Strategies of Thyroid Nodules.,Differential Diagnosis and Clinical Treatment Strategies of Thyroid Nodules.,Thyroid Cancer,2016-11-01,2017-06-30,2018-12-31,Observational,Unknown status,,Shanghai 10th People's Hospital,Shanghai 10th People's Hospital,"Department of Endocrinology, Shanghai Tenth People's Hospital",,China,18.0,65.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT02953288
NCT02966093,thyroid neoplasms,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131 I-Refractory Differentiated Thyroid Cancer in China",A Trial of Lenvatinib (E7080) in Radioiodine (131 I)-Refractory Differentiated Thyroid Cancer in China,Differentiated Thyroid Cancer (DTC),2016-11-15,2019-07-31,2021-12-29,Interventional,Completed,Phase 3,Eisai Inc.,"Eisai Co., Ltd.",1002 Eisai Trial Site|1006 Eisai Trial Site|1020 Eisai Trial Site|1026 Eisai Trial Site|1025 Eisai Trial Site|1012 Eisai Trial Site|1003 Eisai Trial Site|1027 Eisai Trial Site|1018 Eisai Trial Site|1023 Eisai Trial Site|1016 Eisai Trial Site|1021 Eisai Trial Site|1008 Eisai Trial Site|1014 Eisai Trial Site|1022 Eisai Trial Site|1015 Eisai Trial Site|1004 Eisai Trial Site|1017 Eisai Trial Site|1019 Eisai Trial Site|1011 Eisai Trial Site|1007 Eisai Trial Site|1001 Eisai Trial Site|1010 Eisai Trial Site|1005 Eisai Trial Site,Drug|Drug,China,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02966093
NCT02973802,goiter,"Safety and Proof of Principle Study of ATX-GD-59 in Male and Female Subjects With Graves' Disease Not Currently Treated With Anti-thyroid Therapy: An Open Label Study, With an Upward Titration Over Five Dose Levels Administered by Intradermal Injection",ATX-GD-59 in Patients With Graves Disease Not Treated With Anti-thyroid Therapy,Graves Disease,2016-11-14,2018-02-14,2018-02-14,Interventional,Completed,Phase 1,Apitope International NV,"Apitope International NV|European Commission|Quintiles, Inc.",Queen Elizabeth Hospital|University Hospital of Wales|Royal Devon and Exeter Hospital|St James's University Hospital|Hammersmith Hospital|Kings College Hospital|The Christie|Royal Victoria Infirmary,Biological,United Kingdom,18.0,65.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02973802
NCT02973802,hyperthyroidism,"Safety and Proof of Principle Study of ATX-GD-59 in Male and Female Subjects With Graves' Disease Not Currently Treated With Anti-thyroid Therapy: An Open Label Study, With an Upward Titration Over Five Dose Levels Administered by Intradermal Injection",ATX-GD-59 in Patients With Graves Disease Not Treated With Anti-thyroid Therapy,Graves Disease,2016-11-14,2018-02-14,2018-02-14,Interventional,Completed,Phase 1,Apitope International NV,"Apitope International NV|European Commission|Quintiles, Inc.",Queen Elizabeth Hospital|University Hospital of Wales|Royal Devon and Exeter Hospital|St James's University Hospital|Hammersmith Hospital|Kings College Hospital|The Christie|Royal Victoria Infirmary,Biological,United Kingdom,18.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02973802
NCT02973997,"adenocarcinoma, follicular","Combination Targeted Therapy With Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers: A Phase II Study",Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC),Columnar Cell Variant Thyroid Gland Papillary Carcinoma|Follicular Variant Thyroid Gland Papillary Carcinoma|Metastatic Thyroid Gland Follicular Carcinoma|Metastatic Thyroid Gland Papillary Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Follicular Carcinoma|Recurrent Thyroid Gland Papillary Carcinoma|Stage III Differentiated Thyroid Gland Carcinoma AJCC v7|Stage III Thyroid Gland Follicular Carcinoma AJCC v7|Stage III Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7|Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v7|Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVC Differentiated Thyroid Gland Carcinoma AJCC v7|Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7|Stage IV Thyroid Gland Follicular Carcinoma AJCC v7|Stage IV Thyroid Gland Papillary Carcinoma AJCC v7|Tall Cell Variant Thyroid Gland Papillary Carcinoma|Thyroid Gland Hurthle Cell Carcinoma|Unresectable Differentiated Thyroid Gland Carcinoma|Unresectable Thyroid Gland Carcinoma,2016-11-23,2022-10-08,2024-09-30,Interventional,Active not recruiting,Phase 2,Academic and Community Cancer Research United,Academic and Community Cancer Research United|National Cancer Institute (NCI),Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center|University of Colorado Hospital|Massachusetts General Hospital Cancer Center|University of Michigan Comprehensive Cancer Center|Memorial Sloan Kettering Cancer Center|Ohio State University Comprehensive Cancer Center|M D Anderson Cancer Center,Other|Drug|Drug|Biological,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT02973997
NCT02989103,hyperthyroidism,Hyperthyroid Follow-Up Study,Hyperthyroid Follow-Up Study,All-Cause Mortality|Circulatory and Other Disease Mortality|Thyroid and Other Cancer Mortality,2016-12-06,2020-09-01,2020-10-28,Observational,Completed,,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),"Social and Scientific Systems, Inc.",,United States,18.0,105.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02989103
NCT02989428,hyperparathyroidism,Cardiovascular Health in Patients With Primary Hyperparathyroidism: Effect of Parathyroidectomy on Cardiovascular Health: A Randomized Controlled Trial,Effect of Parathyroidectomy on Cardiovascular Health,Primary Hyperparathyroidism,2016-12-02,2018-09-01,2018-09-01,Interventional,Completed,Not Applicable,University of Aarhus,University of Aarhus,Aarhus University Hospital,Procedure,Denmark,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02989428
NCT02993302,goiter,Effects Of Oral Alfacalcidol On Maturation Of Dendritic Cells In Graves' Disease Patients,Effects Of Oral Alfacalcidol On Maturation Of Dendritic Cells In Graves' Disease Patients,Graves Disease,2016-12-07,2015-03-31,2015-03-31,Interventional,Completed,Phase 2,Dr Cipto Mangunkusumo General Hospital,Dr Cipto Mangunkusumo General Hospital|Indonesia University,,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02993302
NCT02993302,hyperthyroidism,Effects Of Oral Alfacalcidol On Maturation Of Dendritic Cells In Graves' Disease Patients,Effects Of Oral Alfacalcidol On Maturation Of Dendritic Cells In Graves' Disease Patients,Graves Disease,2016-12-07,2015-03-31,2015-03-31,Interventional,Completed,Phase 2,Dr Cipto Mangunkusumo General Hospital,Dr Cipto Mangunkusumo General Hospital|Indonesia University,,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02993302
NCT03002623,"thyroid carcinoma, anaplastic",A Phase II Trial of CUDC-907 in Patients With Metastatic and Locally Advanced Thyroid Cancer,CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer,Differentiated Thyroid Cancer|Poorly Differentiated and Undifferentiated Thyroid Cancer|Thyroid Neoplasms,2016-12-22,2018-02-12,2018-02-12,Interventional,Terminated,Phase 2,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),National Institutes of Health Clinical Center,Drug,United States,18.0,99.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT03002623
NCT03004209,hashimoto disease,Effect of Erythropoietin in Refractory Autoimmune Encephalitis Patients,Effect of Erythropoietin in Refractory Autoimmune Encephalitis Patients,Autoimmune Encephalitis,2016-12-21,2018-02-06,2018-02-06,Interventional,Withdrawn,Phase 4,Seoul National University Hospital,Seoul National University Hospital,Seoul National University Hospital,Drug,"Korea, Republic of",18.0,85.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT03004209
NCT03009279,thyroid neoplasms,Relationship of Metabolic Syndrome and Its Components With Thyroid Nodule(s),Relationship of Metabolic Syndrome and Its Components With Thyroid Nodule(s),Metabolic Syndrome|Thyroid Nodule,2016-12-26,2017-11-30,2017-12-31,Observational,Unknown status,,Qianfoshan Hospital,Lin Liao,,,,15.0,90.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03009279
NCT03009357,goiter,"Clinical Application of Continuous Monitoring Data for the Pulse Rate, Exercise, and Calorie Intake by Wearable Activity Trackers in the Patients With Thyrotoxicosis",Clinical Application of Pulse Rate-monitoring Activity Trackers in Thyrotoxicosis,Graves Disease|Thyroiditis|Thyrotoxicosis,2016-12-29,2017-06-30,2017-08-31,Observational,Completed,,Seoul National University Bundang Hospital,Seoul National University Bundang Hospital,Seoul National University Bundang Hospital,,"Korea, Republic of",20.0,60.0,[18-65],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03009357
NCT03011736,hyperparathyroidism,"Single-Arm, Non-inferiority Study of Omission of Intraoperative Intact Parathyroid Hormone (PTH) During Minimally Invasive Parathyroidectomy for Primary Hyperparathyroidism",Omission of Intact Parathyroid Hormone Testing During Surgery in Treating Patients With Primary Hyperparathyroidism,Parathyroid Gland Adenoma|Primary Hyperparathyroidism,2017-01-04,2018-07-12,2018-12-24,Interventional,Completed,Not Applicable,Roswell Park Cancer Institute,Roswell Park Cancer Institute,Roswell Park Cancer Institute,Other|Procedure,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03011736
NCT03012620,thyroid neoplasms,Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types,Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types,"Carcinoma, Neuroendocrine|Central Nervous System Neoplasm|Neoplasms, Germ Cell and Embryonal|NK/T-cell Lymphoma|Ovarian Neoplasm|Sarcoma|Thyroid Neoplasm",2017-01-02,2023-01-31,2023-12-31,Interventional,Active not recruiting,Phase 2,UNICANCER,"Ligue contre le cancer, France|Merck Sharp & Dohme Corp.|National Cancer Institute, France|UNICANCER",Gustave Roussy Cancer Campus,Drug,France,15.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03012620
NCT03013257,goiter,"A Randomized, Open-label, Parallel-group Study to Explore the Efficacy of High-intensity Focused Ultrasound (HIFU) Versus Fixed-dose Radioiodine-131 in the Treatment of Relapsed Graves' Disease",HIFU vs RAI in the Relapsed Graves' Disease,Graves Disease,2017-01-04,2022-04-30,2022-12-31,Interventional,Recruiting,Not Applicable,The University of Hong Kong,The University of Hong Kong,Queen Mary Hospital,Device,Hong Kong,18.0,70.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03013257
NCT03013257,hyperthyroidism,"A Randomized, Open-label, Parallel-group Study to Explore the Efficacy of High-intensity Focused Ultrasound (HIFU) Versus Fixed-dose Radioiodine-131 in the Treatment of Relapsed Graves' Disease",HIFU vs RAI in the Relapsed Graves' Disease,Graves Disease,2017-01-04,2022-04-30,2022-12-31,Interventional,Recruiting,Not Applicable,The University of Hong Kong,The University of Hong Kong,Queen Mary Hospital,Device,Hong Kong,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03013257
NCT03023748,hyperparathyroidism,Providing Intravenous Paricalcitol Treatment to the Sick and Poor Chronic Hemodialysis Patients With Severe Secondary Hyperparathyroidism Resistant to Existing Vitamin D Analogs,Intravenous Paricalcitol in Chronic Hemodialysis Patients,Endstage Renal Disease|Secondary Hyperparathyroidism,2017-01-07,2017-12-31,2018-01-31,Interventional,Unknown status,Phase 4,The University of Hong Kong,AbbVie|The University of Hong Kong,Queen Mary Hospital and Tung Wah Hospital,Drug,Hong Kong,18.0,75.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03023748
NCT03027557,parathyroid neoplasms,Treatment of Primary Hyperparathyroidism With Denosumab and Cinacalcet.,Treatment of Primary Hyperparathyroidism With Denosumab and Cinacalcet.,Parathyroid Adenoma|Parathyroid Hyperplasia|Primary Hyperparathyroidism,2017-01-16,2019-04-01,2019-09-12,Interventional,Completed,Phase 3,Aalborg University Hospital,Aalborg University|Peter Vestergaard,Aalborg University Hospital,Drug|Drug|Other|Other,Denmark,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03027557
NCT03027557,hyperparathyroidism,Treatment of Primary Hyperparathyroidism With Denosumab and Cinacalcet.,Treatment of Primary Hyperparathyroidism With Denosumab and Cinacalcet.,Parathyroid Adenoma|Parathyroid Hyperplasia|Primary Hyperparathyroidism,2017-01-16,2019-04-01,2019-09-12,Interventional,Completed,Phase 3,Aalborg University Hospital,Aalborg University|Peter Vestergaard,Aalborg University Hospital,Drug|Drug|Other|Other,Denmark,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03027557
NCT03032198,thyroid neoplasms,"""Clinical Evaluation of Opto-Acoustic Tomography for Detection and Diagnostic Differentiation of Thyroid Nodules""","""Clinical Evaluation of Opto-Acoustic Tomography for Detection and Diagnostic Differentiation of Thyroid Nodules""",Feasibility Study for Thyroid Indication,2017-01-20,2018-06-17,2019-04-19,Interventional,Terminated,Not Applicable,Seno Medical Instruments Inc.,Seno Medical Instruments Inc.,Invision Sally Jobe|UT Health Science Center,Device,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03032198
NCT03032198,thyroid nodule,"""Clinical Evaluation of Opto-Acoustic Tomography for Detection and Diagnostic Differentiation of Thyroid Nodules""","""Clinical Evaluation of Opto-Acoustic Tomography for Detection and Diagnostic Differentiation of Thyroid Nodules""",Feasibility Study for Thyroid Indication,2017-01-20,2018-06-17,2019-04-19,Interventional,Terminated,Not Applicable,Seno Medical Instruments Inc.,Seno Medical Instruments Inc.,Invision Sally Jobe|UT Health Science Center,Device,United States,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03032198
NCT03036956,hypothyroidism,The Prevalence of Sub Clinical Hypothyroidism During Early Pregnancy in Pakistan,The Prevalence of Sub Clinical Hypothyroidism During Early Pregnancy in Pakistan,Subclinical Hypothyroidism,2017-01-26,2018-01-31,2018-01-31,Observational,Completed,,Abbott,Abbott|Dimension Research,Isra University hospital|Pakistam Insititute of Medical science|Atia Hospital Hospital|Boluvard Hospital|MediCell Hospital|Services Hospital|Sir Ganga Ram hospital|Welcare Medical Centre|Lady Reading hospital,,Pakistan,18.0,45.0,[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03036956
NCT03039439,parathyroid neoplasms,Molecular and Immunohistochemical Profiling of Tumor From Patients With Parathyroid Tumors for Evaluation of Targeted Agents,Molecular and Immunohistochemical Profiling of Tumors in Patients With Parathyroid Tumors,Parathyroid Gland Adenoma|Parathyroid Gland Atypical Adenoma|Parathyroid Gland Carcinoma|Primary Hyperparathyroidism,2017-01-30,2020-11-30,2020-11-30,Observational,Unknown status,,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center|National Cancer Institute (NCI),M D Anderson Cancer Center,Procedure|Other,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03039439
NCT03039439,hyperparathyroidism,Molecular and Immunohistochemical Profiling of Tumor From Patients With Parathyroid Tumors for Evaluation of Targeted Agents,Molecular and Immunohistochemical Profiling of Tumors in Patients With Parathyroid Tumors,Parathyroid Gland Adenoma|Parathyroid Gland Atypical Adenoma|Parathyroid Gland Carcinoma|Primary Hyperparathyroidism,2017-01-30,2020-11-30,2020-11-30,Observational,Unknown status,,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center|National Cancer Institute (NCI),M D Anderson Cancer Center,Procedure|Other,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03039439
NCT03046524,parathyroid neoplasms,Parathyroid Cancer Versus Atypical Parathyroid Neoplasm; Investigating Their Clinical Characteristics and Biological Behavior,Parathyroid Cancer Versus Atypical Parathyroid Neoplasm; Investigating Their Clinical Characteristics and Biological Behavior,Parathyroid Carcinoma|Parathyroid Neoplasm,2017-02-02,2017-10-16,2017-10-16,Observational,Completed,,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center,University of Texas MD Anderson Cancer Center,Other,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03046524
NCT03051126,parathyroid diseases,Establishment of a Parathyroid Tissue Bank,Establishment of a Parathyroid Tissue Bank,Parathyroid Disease,2017-02-02,2025-07-01,2025-07-01,Observational,Recruiting,,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center,University of Texas MD Anderson Cancer Center,Other,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT03051126
NCT03052075,hyperparathyroidism,Percent Change in Baseline Bone Mineral Density (BMD) After Parathyroidectomy in Patients With Primary Hyperparathyroidism,Percent Change in Baseline Bone Mineral Density (BMD) After Parathyroidectomy in Patients With Primary Hyperparathyroidism,Primary Hyperparathyroidism,2017-02-10,2020-09-30,2020-09-30,Observational,Unknown status,,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center,University of Texas MD Anderson Cancer Center,Other,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03052075
NCT03057925,thyroid neoplasms,Ultrasound-guided Percutaneous Microwave Ablation for Benign Thyroid Nodules,Ultrasound-guided Percutaneous Microwave Ablation for Benign Thyroid Nodules,Thyroid Nodule,2017-02-12,2017-12-31,2018-12-31,Interventional,Unknown status,Not Applicable,First Affiliated Hospital of Wenzhou Medical University,First Affiliated Hospital of Wenzhou Medical University|Wenjun Wu,The First Affiliated Hospital of Wenzhou Medical University,Device,China,18.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03057925
NCT03061318,thyroid neoplasms,Validation of a Multi-Genetic Test for the Diagnosis of Indeterminate Thyroid Nodules,Validation of a Multi-Genetic Test for the Diagnosis of Indeterminate Thyroid Nodules,Indeterminate Thyroid Cytology,2017-02-17,2017-08-30,2017-08-30,Observational,Completed,,Pontificia Universidad Catolica de Chile,Hernán González,Centro de Diagnóstico Plaza Italia|Clínica Alemana de Santiago|Hospital Clínico de la Pontificia Universidad Católica de Chile|Clínica San Carlos de Apoquindo|Clínica Santa María|Fundación Arturo López Pérez|Hospital del Salvador|Hospital San Juan de Dios|Hospital Clínico de la Universidad de Chile,,Chile,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03061318
NCT03061318,thyroid nodule,Validation of a Multi-Genetic Test for the Diagnosis of Indeterminate Thyroid Nodules,Validation of a Multi-Genetic Test for the Diagnosis of Indeterminate Thyroid Nodules,Indeterminate Thyroid Cytology,2017-02-17,2017-08-30,2017-08-30,Observational,Completed,,Pontificia Universidad Catolica de Chile,Hernán González,Centro de Diagnóstico Plaza Italia|Clínica Alemana de Santiago|Hospital Clínico de la Pontificia Universidad Católica de Chile|Clínica San Carlos de Apoquindo|Clínica Santa María|Fundación Arturo López Pérez|Hospital del Salvador|Hospital San Juan de Dios|Hospital Clínico de la Universidad de Chile,,Chile,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03061318
NCT03063190,hyperparathyroidism,Evaluation of Cholecalciferol Supplementation in Chronic Kidney Disease Patients With Restless Leg Syndrome,Cholecalciferol Supplementation in Restless Leg Syndrome in Patients With Chronic Kidney Disease,"Adynamic Bone Disease|Hyperparathyroidism, Secondary|Renal Disease Bone|Renal Disease, End Stage|Restless Leg Disorder|Vitamin D Deficiency",2017-02-21,2022-03-31,2023-03-31,Interventional,Withdrawn,Phase 4,University of Sao Paulo General Hospital,University of Sao Paulo General Hospital,Hospital das Clinicas,Drug|Drug,Brazil,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03063190
NCT03066076,goiter,Prospective Randomized Clinical Trial of Total Thyroidectomy (Tx) Versus Thionamides (Anti-Thyroid Drugs) in Patients With Moderate-to-Severe Graves' Ophthalmopathy - a 1-year Follow-up,Total Thyroidectomy Versus Thionamides in Patients With Moderate-to-Severe Graves' Ophthalmopathy,Graves Disease|Graves Ophthalmopathy|Graves' Ophthalmopathy Worsened,2017-01-27,2019-02-01,2019-06-01,Interventional,Unknown status,Phase 3,Medical University of Vienna,Medical University of Vienna,Department of Surgery and Department of Ophthalmology Medical University Vienna,Drug|Procedure,Austria,18.0,85.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03066076
NCT03066076,hyperthyroidism,Prospective Randomized Clinical Trial of Total Thyroidectomy (Tx) Versus Thionamides (Anti-Thyroid Drugs) in Patients With Moderate-to-Severe Graves' Ophthalmopathy - a 1-year Follow-up,Total Thyroidectomy Versus Thionamides in Patients With Moderate-to-Severe Graves' Ophthalmopathy,Graves Disease|Graves Ophthalmopathy|Graves' Ophthalmopathy Worsened,2017-01-27,2019-02-01,2019-06-01,Interventional,Unknown status,Phase 3,Medical University of Vienna,Medical University of Vienna,Department of Surgery and Department of Ophthalmology Medical University Vienna,Drug|Procedure,Austria,18.0,85.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03066076
NCT03072160,thyroid neoplasms,Phase II Trial of Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer,Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer,Medullary Thyroid Cancer (MTC),2017-03-03,2019-11-22,2019-11-22,Interventional,Completed,Phase 2,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),National Institutes of Health Clinical Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03072160
NCT03082742,hyperparathyroidism,The Effect of Thiazide and Loop Diuretic on Mineral and Bone Disorder in Chronic Kidney Disease Patients,The Effect of Diuretics on Mineral and Bone Disorder in Chronic Kidney Disease Patients,Chronic Kidney Disease|Secondary Hyperparathyroidism,2017-02-27,2018-06-30,2018-06-30,Interventional,Unknown status,Not Applicable,University of Sao Paulo General Hospital,University of Sao Paulo General Hospital,Hospital das Clinicas,Drug|Drug,Brazil,18.0,80.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03082742
NCT03091140,hyperparathyroidism,Alterations in Muscle's Functional Characteristics After Parathyroid Surgery for Primary Hyperparathyroidism.,Alterations in Muscle's Functional Characteristics After Parathyroid Surgery for Primary Hyperparathyroidism.,"Hyperparathyroidism, Primary|Parathyroidectomy",2017-03-03,2018-12-31,2018-12-31,Observational,Completed,,Aristotle University Of Thessaloniki,Aristotle University Of Thessaloniki,"AHEPA University General Hospital, Aristotle University of Thessaloniki",,Greece,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03091140
NCT03093909,thyroid neoplasms,Phase I Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases,Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases,Malignant Neoplasm of Bone and Articular Cartilage|Malignant Neoplasm of Male Genital Organs|Malignant Neoplasm of Respiratory and Intrathoracic Organ Carcinoma|Malignant Neoplasms of Female Genital Organs|Malignant Neoplasms of Independent (Primary) Multiple Sites|Malignant Neoplasms of Lip Oral Cavity and Pharynx|Malignant Neoplasms of Mesothelial and Soft Tissue|Malignant Neoplasms of Thyroid and Other Endocrine Glands|Malignant Neoplasms of Urinary Tract|Melanoma and Other Malignant Neoplasms of Skin,2017-03-21,2021-11-30,2022-11-30,Interventional,Recruiting,Phase 1,M.D. Anderson Cancer Center,Gateway for Cancer Research|James B. and Lois R. Archer Charitable Foundation|M.D. Anderson Cancer Center,The University of Texas MD Anderson Cancer Center,Drug,United States,12.0,50.0,[0-17]|[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03093909
NCT03094416,hypothyroidism,An Open-label Therapeutic Efficacy Study of Tirosint (Levothyroxine Sodium) Capsules in Thyroidectomized Patients Taking Proton Pump Inhibitors,Levothyroxine Sodium in Thyroidectomized Patients Taking Proton Pump Inhibitors,Hypothyroidism;Postablative,2017-03-17,2020-06-15,2020-06-15,Interventional,Completed,Phase 4,IBSA Institut Biochimique SA,IBSA Institut Biochimique SA,"California Head and Neck Specialists|Coastal Metabolic Research Centre|Washington Hospital Center|MedStar Union Memorial Hospital|NYC Health + Hospitals/ Queens|Diabetes & Endocrinology Consultants, PC|Carolina Ear Nose and Throat Clinic|Virginia Commonwealth University|Stonesifer Endocrine Care & Clinical Research Inc., PS",Drug|Drug|Drug,United States,18.0,65.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03094416
NCT03096613,hypothyroidism,"Efficacy and Safety of Levothyroxine (L-T4) Replacement on Exercise Capability in Chronic Systolic Heart Failure Patients With Subclinical Hypothyroidism: A 24-week, Multi-center, Open Label, Randomized, Parallel Group Trial",Thyroid Hormone Replacement for Subclinical Hypothyroidism and Chronic Heart Failure (ThyroHeart-CHF),Heart Failure|Subclinical Hypothyroidism,2017-03-25,2019-02-28,2019-02-28,Interventional,Unknown status,Phase 4,"Chinese Academy of Medical Sciences, Fuwai Hospital","Chinese Academy of Medical Sciences, Fuwai Hospital|Henan Provincial People's Hospital|The First Hospital of Hebei Medical University|The Luhe Teaching Hospital of the Capital Medical University|Tianjin Medical University Second Hospital","Chinese Academy of Medical Sciences, Fuwai Hospital",Drug,China,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03096613
NCT03098225,graves disease,"A Phase IV, Randomized, Multi-center Clinical Trial to Compare the Efficacy of Orbital Radiotherapy in Association With Intravenous Glucocorticoids vs Intravenous Glucocorticoids Alone for Moderately Severe and Active Graves' Orbitopathy",A Trial to Evaluate the Efficacy of Orbital Radiotherapy in Graves' Orbitopathy,Thyroid Associated Ophthalmopathy,2017-03-21,2024-03-31,2024-03-31,Interventional,Not yet recruiting,Phase 4,University of Pisa,University of Pisa,,Radiation|Drug,,35.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT03098225
NCT03098225,graves ophthalmopathy,"A Phase IV, Randomized, Multi-center Clinical Trial to Compare the Efficacy of Orbital Radiotherapy in Association With Intravenous Glucocorticoids vs Intravenous Glucocorticoids Alone for Moderately Severe and Active Graves' Orbitopathy",A Trial to Evaluate the Efficacy of Orbital Radiotherapy in Graves' Orbitopathy,Thyroid Associated Ophthalmopathy,2017-03-21,2024-03-31,2024-03-31,Interventional,Not yet recruiting,Phase 4,University of Pisa,University of Pisa,,Radiation|Drug,,35.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT03098225
NCT03098225,goiter,"A Phase IV, Randomized, Multi-center Clinical Trial to Compare the Efficacy of Orbital Radiotherapy in Association With Intravenous Glucocorticoids vs Intravenous Glucocorticoids Alone for Moderately Severe and Active Graves' Orbitopathy",A Trial to Evaluate the Efficacy of Orbital Radiotherapy in Graves' Orbitopathy,Thyroid Associated Ophthalmopathy,2017-03-21,2024-03-31,2024-03-31,Interventional,Not yet recruiting,Phase 4,University of Pisa,University of Pisa,,Radiation|Drug,,35.0,75.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03098225
NCT03098225,hyperthyroidism,"A Phase IV, Randomized, Multi-center Clinical Trial to Compare the Efficacy of Orbital Radiotherapy in Association With Intravenous Glucocorticoids vs Intravenous Glucocorticoids Alone for Moderately Severe and Active Graves' Orbitopathy",A Trial to Evaluate the Efficacy of Orbital Radiotherapy in Graves' Orbitopathy,Thyroid Associated Ophthalmopathy,2017-03-21,2024-03-31,2024-03-31,Interventional,Not yet recruiting,Phase 4,University of Pisa,University of Pisa,,Radiation|Drug,,35.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03098225
NCT03102099,thyroid nodule,Application Value of Contrast-enhanced Ultrasound-guided Fine-needle Aspiration Biopsy in the Evaluation of Thyroid Nodules,Contrast-enhanced Ultrasound-guided Fine-needle Aspiration Biopsy in the Evaluation of Thyroid Nodules,Thyroid Nodules,2017-03-10,2018-06-30,2019-06-30,Observational,Unknown status,,Peking University Third Hospital,Peking University Third Hospital,Peking University Third Hospital,Procedure|Procedure,China,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03102099
NCT03102099,thyroid neoplasms,Application Value of Contrast-enhanced Ultrasound-guided Fine-needle Aspiration Biopsy in the Evaluation of Thyroid Nodules,Contrast-enhanced Ultrasound-guided Fine-needle Aspiration Biopsy in the Evaluation of Thyroid Nodules,Thyroid Nodules,2017-03-10,2018-06-30,2019-06-30,Observational,Unknown status,,Peking University Third Hospital,Peking University Third Hospital,Peking University Third Hospital,Procedure|Procedure,China,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03102099
NCT03102177,hypothyroidism,Hypothyroidism Treatment in Aging and Thyroid Cancer,"Effect of Age, Weight and Sex on Levothyroxine Pharmacokinetics",Hypothyroidism Primary,2017-03-27,2013-11-30,2016-07-26,Interventional,Completed,Early Phase 1,Georgetown University,Georgetown University,,Drug,,21.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03102177
NCT03103607,graves disease,Evaluation of the Disappearance of Graves' Orbitopathy in the Long Term,Disappearance of Graves' Orbitopathy,Thyroid Eye Disease,2017-03-27,2014-12-31,2016-02-28,Observational,Completed,,University of Pisa,University of Pisa,,Diagnostic Test|Diagnostic Test,,18.0,100.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT03103607
NCT03103607,goiter,Evaluation of the Disappearance of Graves' Orbitopathy in the Long Term,Disappearance of Graves' Orbitopathy,Thyroid Eye Disease,2017-03-27,2014-12-31,2016-02-28,Observational,Completed,,University of Pisa,University of Pisa,,Diagnostic Test|Diagnostic Test,,18.0,100.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03103607
NCT03103607,hyperthyroidism,Evaluation of the Disappearance of Graves' Orbitopathy in the Long Term,Disappearance of Graves' Orbitopathy,Thyroid Eye Disease,2017-03-27,2014-12-31,2016-02-28,Observational,Completed,,University of Pisa,University of Pisa,,Diagnostic Test|Diagnostic Test,,18.0,100.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03103607
NCT03105648,thyroid neoplasms,Diagnostic and Prognostic Significance of Computerized Cytologic Morphometry of the Thyroid Neoplasm,Diagnostic and Prognostic Significance of Computerized Cytologic Morphometry of the Thyroid Neoplasm,Computerized Cytomorphometry,2017-04-04,2026-04-20,2026-04-20,Observational,Recruiting,,National Taiwan University Hospital,National Taiwan University Hospital,National Taiwan University Hospital,Other,Taiwan,20.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03105648
NCT03106337,thyroid neoplasms,A Multivariate Analysis of Factors Predictive of Carcinoma in Follicular Neoplasms of the Thyroid Gland,Diagnostic Accuracy of Shear-Wave Elastography for the Preoperative Risk Stratification of Follicular Lesions of the Thyroid,Follicular Neoplasm|Thyroid Nodule,2014-04-25,2012-04-30,2012-04-30,Interventional,Completed,Not Applicable,Massachusetts General Hospital,Massachusetts General Hospital,Massachusetts General Hospital,Device,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03106337
NCT03106935,hypothyroidism,Effect of Levothyroxine Treatment on Pregnancy Outcome in RPL Women With Subclinical Hypothyroidism,Recurrent Pregnancy Loss and Thyroid Disease,Recurrent Pregnancy Loss,2017-02-27,2017-12-31,2018-06-30,Interventional,Unknown status,Early Phase 1,Second Affiliated Hospital of Soochow University,Second Affiliated Hospital of Soochow University,Second Affiliated Hospital of Soochow University,Drug,China,18.0,39.0,[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03106935
NCT03107078,graves disease,"Using A Novel Classification System in Intravenous Glucocorticoids Therapy of TAO: A Multi-central, Randomized, Open, Superior Trial","Using A Novel Classification System in Intravenous GCs Therapy of TAO: A Multi-central, Randomized, Open, Superior Trial",Thyroid Associated Ophthalmopathy,2017-03-08,2019-10-01,2021-10-01,Interventional,Unknown status,Phase 4,The Third Affiliated Hospital of Southern Medical University,Huadu District People's Hospital of Guangzhou|Jie Shen|The Fifth Affiliated Hospital of Southern Medical University|Zhujiang Hospital,the Third Affiliated Hospital of Southern Medical University,Drug,China,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT03107078
NCT03107078,graves ophthalmopathy,"Using A Novel Classification System in Intravenous Glucocorticoids Therapy of TAO: A Multi-central, Randomized, Open, Superior Trial","Using A Novel Classification System in Intravenous GCs Therapy of TAO: A Multi-central, Randomized, Open, Superior Trial",Thyroid Associated Ophthalmopathy,2017-03-08,2019-10-01,2021-10-01,Interventional,Unknown status,Phase 4,The Third Affiliated Hospital of Southern Medical University,Huadu District People's Hospital of Guangzhou|Jie Shen|The Fifth Affiliated Hospital of Southern Medical University|Zhujiang Hospital,the Third Affiliated Hospital of Southern Medical University,Drug,China,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT03107078
NCT03107078,goiter,"Using A Novel Classification System in Intravenous Glucocorticoids Therapy of TAO: A Multi-central, Randomized, Open, Superior Trial","Using A Novel Classification System in Intravenous GCs Therapy of TAO: A Multi-central, Randomized, Open, Superior Trial",Thyroid Associated Ophthalmopathy,2017-03-08,2019-10-01,2021-10-01,Interventional,Unknown status,Phase 4,The Third Affiliated Hospital of Southern Medical University,Huadu District People's Hospital of Guangzhou|Jie Shen|The Fifth Affiliated Hospital of Southern Medical University|Zhujiang Hospital,the Third Affiliated Hospital of Southern Medical University,Drug,China,18.0,80.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03107078
NCT03107078,hyperthyroidism,"Using A Novel Classification System in Intravenous Glucocorticoids Therapy of TAO: A Multi-central, Randomized, Open, Superior Trial","Using A Novel Classification System in Intravenous GCs Therapy of TAO: A Multi-central, Randomized, Open, Superior Trial",Thyroid Associated Ophthalmopathy,2017-03-08,2019-10-01,2021-10-01,Interventional,Unknown status,Phase 4,The Third Affiliated Hospital of Southern Medical University,Huadu District People's Hospital of Guangzhou|Jie Shen|The Fifth Affiliated Hospital of Southern Medical University|Zhujiang Hospital,the Third Affiliated Hospital of Southern Medical University,Drug,China,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03107078
NCT03108222,hyperparathyroidism,Phosphorus Absorption in Healthy Adults and in Patients With Moderate Chronic Kidney Disease,Phosphorus Absorption in Healthy Adults and in Patients With Moderate Chronic Kidney Disease,Chronic Kidney Disease Mineral and Bone Disorder,2017-04-05,2019-08-30,2019-12-31,Observational,Unknown status,,Purdue University,Purdue University,Purdue University Nutrition Science Department,Other,United States,30.0,75.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03108222
NCT03109847,thyroid neoplasms,Pilot Study of Metformin to Mitigate Sequelae of Radioactive Iodine Treatment for Well-Differentiated Thyroid Cancers,Metformin Hydrochloride in Mitigating Side Effects of Radioactive Iodine Treatment in Patients With Differentiated Thyroid Cancer,Thyroid,2017-03-06,2022-01-31,2022-01-31,Interventional,Active not recruiting,Phase 2,Thomas Jefferson University,Sidney Kimmel Cancer Center at Thomas Jefferson University,Sidney Kimmel Cancer Center at Thomas Jefferson University,Drug|Other|Other,United States,18.0,90.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03109847
NCT03110835,graves disease,Use of Low-dose Radioiodine for Ablation of Thyroid Remnants in Patients With Graves' Disease Following Thyroidectomy,Low-dose Radioiodine Ablation in Graves' Disease,Thyroid Diseases,2017-03-14,2017-03-28,2017-03-28,Observational,Completed,,University of Pisa,University of Pisa,,Radiation,,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT03110835
NCT03110835,hyperthyroidism,Use of Low-dose Radioiodine for Ablation of Thyroid Remnants in Patients With Graves' Disease Following Thyroidectomy,Low-dose Radioiodine Ablation in Graves' Disease,Thyroid Diseases,2017-03-14,2017-03-28,2017-03-28,Observational,Completed,,University of Pisa,University of Pisa,,Radiation,,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03110835
NCT03110835,goiter,Use of Low-dose Radioiodine for Ablation of Thyroid Remnants in Patients With Graves' Disease Following Thyroidectomy,Low-dose Radioiodine Ablation in Graves' Disease,Thyroid Diseases,2017-03-14,2017-03-28,2017-03-28,Observational,Completed,,University of Pisa,University of Pisa,,Radiation,,18.0,80.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03110835
NCT03110848,graves disease,"A Phase II, Open-labeled, Ophthalmological External Investigator-blinded, Single-center, Randomized, Superiority, Non Profit, Pilot Clinical Trial to Evaluate the Effects of Atorvastatin on Graves' Orbitopathy (GO) in Hypercholesterolemic Patients With Moderate-to-severe and Active GO Subjected to Intravenous Glucocorticoid Therapy: the STAGO Study",Effects of Atorvastatin in Graves' Orbitopathy (GO),Hypercholesterolemia|Thyroid Associated Ophthalmopathy,2017-03-23,2021-04-30,2021-04-30,Interventional,Completed,Phase 2,University of Pisa,University of Pisa,Ospedale Cisanello-Endocrinology I and II,Drug|Drug,Italy,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT03110848
NCT03110848,graves ophthalmopathy,"A Phase II, Open-labeled, Ophthalmological External Investigator-blinded, Single-center, Randomized, Superiority, Non Profit, Pilot Clinical Trial to Evaluate the Effects of Atorvastatin on Graves' Orbitopathy (GO) in Hypercholesterolemic Patients With Moderate-to-severe and Active GO Subjected to Intravenous Glucocorticoid Therapy: the STAGO Study",Effects of Atorvastatin in Graves' Orbitopathy (GO),Hypercholesterolemia|Thyroid Associated Ophthalmopathy,2017-03-23,2021-04-30,2021-04-30,Interventional,Completed,Phase 2,University of Pisa,University of Pisa,Ospedale Cisanello-Endocrinology I and II,Drug|Drug,Italy,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT03110848
NCT03110848,hyperthyroidism,"A Phase II, Open-labeled, Ophthalmological External Investigator-blinded, Single-center, Randomized, Superiority, Non Profit, Pilot Clinical Trial to Evaluate the Effects of Atorvastatin on Graves' Orbitopathy (GO) in Hypercholesterolemic Patients With Moderate-to-severe and Active GO Subjected to Intravenous Glucocorticoid Therapy: the STAGO Study",Effects of Atorvastatin in Graves' Orbitopathy (GO),Hypercholesterolemia|Thyroid Associated Ophthalmopathy,2017-03-23,2021-04-30,2021-04-30,Interventional,Completed,Phase 2,University of Pisa,University of Pisa,Ospedale Cisanello-Endocrinology I and II,Drug|Drug,Italy,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03110848
NCT03110848,goiter,"A Phase II, Open-labeled, Ophthalmological External Investigator-blinded, Single-center, Randomized, Superiority, Non Profit, Pilot Clinical Trial to Evaluate the Effects of Atorvastatin on Graves' Orbitopathy (GO) in Hypercholesterolemic Patients With Moderate-to-severe and Active GO Subjected to Intravenous Glucocorticoid Therapy: the STAGO Study",Effects of Atorvastatin in Graves' Orbitopathy (GO),Hypercholesterolemia|Thyroid Associated Ophthalmopathy,2017-03-23,2021-04-30,2021-04-30,Interventional,Completed,Phase 2,University of Pisa,University of Pisa,Ospedale Cisanello-Endocrinology I and II,Drug|Drug,Italy,18.0,75.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03110848
NCT03114267,thyroiditis,Involvement of Viral Infections in the Pathogenesis of Chronic Lymphocytic Thyroiditis,Involvement of Viral Infections in the Pathogenesis of Chronic Lymphocytic Thyroiditis,Autoimmune Diseases|Chronic Lymphocytic Thyroiditis,2017-04-11,2015-01-06,2015-01-06,Observational,Completed,,"Centre Hospitalier Universitaire, Amiens","Centre Hospitalier Universitaire, Amiens",CHU Amiens Picardie,Other,France,18.0,120.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT03114267
NCT03115515,hypothyroidism,"Randomized, Prospective Trial Comparing the Safety and Efficacy of Empiric Levothyroxine (LT4) Dose Increase Versus Individualized LT4 Dose Increase in Hypothyroid Women During Pregnancy",Safety and Efficacy of Empiric Levothyroxine (LT4) Dose Increase Versus Individualized LT4 Dose Increase in Hypothyroid Women During Pregnancy,Pregnancy Related|Thyroid,2017-04-07,2018-02-28,2018-02-28,Interventional,Completed,Not Applicable,Medstar Health Research Institute,Medstar Health Research Institute,Medstar Washington Hospital Center,Drug,United States,18.0,45.0,[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03115515
NCT03120221,hypothyroidism,Iodine Status in Pregnant Women in Israel,Iodine Status in Pregnant Women in Israel,Iodine-Deficiency; Hypothyroidism,2017-04-01,2018-12-31,2018-12-31,Observational,Unknown status,,Clalit Health Services,Clalit Health Services,Women Health Service|Women Health Center,Diagnostic Test,Israel,18.0,45.0,[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03120221
NCT03122496,"thyroid carcinoma, anaplastic",A Pilot Study of Durvalumab (MEDI4736) With Tremelimumab in Combination With Image Guided Stereotactic Body Radiotherapy (SBRT) in the Treatment of Metastatic Anaplastic Thyroid Cancer,Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer,Metastatic Anaplastic Thyroid Cancer,2017-04-18,2023-04-30,2023-04-30,Interventional,Active not recruiting,Phase 1,Memorial Sloan Kettering Cancer Center,AstraZeneca|Memorial Sloan Kettering Cancer Center,Memoral Sloan Kettering Basking Ridge|Memoral Sloan Kettering Monmouth|Memorial Sloan Kettering Bergen|Memorial Sloan Kettering Commack|Memoral Sloan Kettering Westchester|Memorial Sloan Kettering Cancer Center|Memorial Sloan Kettering @ Rockville|Memorial Sloan Kettering Nassau,Drug|Drug|Radiation,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT03122496
NCT03122847,hyperthyroidism,The Effect of 4.5 Gram Methylprednisolone Administered Once Weekly for 12 Weeks on Bone Metabolism in Graves´ Ophthalmopathy,Glucocorticoids and Bone in Graves' Ophthalmopathy,Graves Ophthalmopathy,2017-04-18,2022-07-31,2023-07-31,Observational,Active not recruiting,,Aarhus University Hospital,Odense University Hospital|Torben Harsløf,Aarhus University Hospital|Odense University Hospital,Drug,Denmark,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03122847
NCT03122847,goiter,The Effect of 4.5 Gram Methylprednisolone Administered Once Weekly for 12 Weeks on Bone Metabolism in Graves´ Ophthalmopathy,Glucocorticoids and Bone in Graves' Ophthalmopathy,Graves Ophthalmopathy,2017-04-18,2022-07-31,2023-07-31,Observational,Active not recruiting,,Aarhus University Hospital,Odense University Hospital|Torben Harsløf,Aarhus University Hospital|Odense University Hospital,Drug,Denmark,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03122847
NCT03122847,graves disease,The Effect of 4.5 Gram Methylprednisolone Administered Once Weekly for 12 Weeks on Bone Metabolism in Graves´ Ophthalmopathy,Glucocorticoids and Bone in Graves' Ophthalmopathy,Graves Ophthalmopathy,2017-04-18,2022-07-31,2023-07-31,Observational,Active not recruiting,,Aarhus University Hospital,Odense University Hospital|Torben Harsløf,Aarhus University Hospital|Odense University Hospital,Drug,Denmark,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT03122847
NCT03123406,hyperparathyroidism,"A Multi-center Study Evaluating Efficacy and Safety of Cinacalcet Hydrochloride(HCL) in Calcium, Phosphorus and Intact Parathyroid Hormone(iPTH) Serum Levels in Chinese Chronic Kidney Disease(CKD) Hemodialysis(HD) Patients With Mild, Moderate and Severe Secondary Hyperparathyroidism(SHPT)","Efficacy and Safety of Cinacalcet in Ca, P and iPTH Levels in Patients With Mild, Moderate and Severe SHPT","Hyperparathyroidism; Secondary, Renal",2017-03-29,2019-04-20,2019-09-06,Interventional,Completed,Phase 4,"Kyowa Hakko Kirin China Pharmaceutical Co., LTD.","Kyowa Hakko Kirin China Pharmaceutical Co., LTD.",Nanjing Jinling Hospital,Drug,China,18.0,75.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03123406
NCT03128255,thyroid neoplasms,"I-124 PET/US for Benign Thyroid Diseases - Blinded, Multicentric Assessment of Augmented Thyroid Work-up Versus Regular Thyroid Diagnostics",Fusion UltraSound Imaging Of the Thyroid GlaNd With I-124 PET. Evaluation of Nodule Allocation.,Thyroid Diseases|Thyroid Goitre|Thyroid Nodule,2017-04-20,2017-07-31,2018-04-30,Observational,Unknown status,,Jena University Hospital,GE Healthcare|Jena University Hospital,University Hospital Jena,Other,Germany,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03128255
NCT03128255,goiter,"I-124 PET/US for Benign Thyroid Diseases - Blinded, Multicentric Assessment of Augmented Thyroid Work-up Versus Regular Thyroid Diagnostics",Fusion UltraSound Imaging Of the Thyroid GlaNd With I-124 PET. Evaluation of Nodule Allocation.,Thyroid Diseases|Thyroid Goitre|Thyroid Nodule,2017-04-20,2017-07-31,2018-04-30,Observational,Unknown status,,Jena University Hospital,GE Healthcare|Jena University Hospital,University Hospital Jena,Other,Germany,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03128255
NCT03131206,thyroid neoplasms,A Phase 1/2 Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer,A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer,ALK-positive Non-small Cell Lung Cancer (NSCLC)|RET-positive Non-small Cell Lung Cancer (NSCLC)|RET-positive Thyroid Cancer,2017-04-19,2018-11-08,2019-04-08,Interventional,Terminated,Phase 1/Phase 2,Dana-Farber Cancer Institute,"Dana-Farber Cancer Institute|Genentech, Inc.","University of California, Irvine|Beth Israel Deaconess Medical Center|Brigham and Women's Hospital|Dana Farber Cancer Institute",Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03131206
NCT03131726,goiter,Treatment of Graves´Ophthalmopathy With Simvastatin (GO-DS),Treatment of Graves´Ophthalmopathy With Simvastatin (GO-DS),Graves Ophthalmopathy|Thyroid Associated Ophthalmopathy|Thyroid Associated Orbitopathy,2017-03-10,2024-01-26,2024-03-30,Interventional,Recruiting,Phase 3,Lund University,Lund University,"Dpt. of Endocrinology, SUS Malmö",Drug,Sweden,18.0,70.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03131726
NCT03131726,hyperthyroidism,Treatment of Graves´Ophthalmopathy With Simvastatin (GO-DS),Treatment of Graves´Ophthalmopathy With Simvastatin (GO-DS),Graves Ophthalmopathy|Thyroid Associated Ophthalmopathy|Thyroid Associated Orbitopathy,2017-03-10,2024-01-26,2024-03-30,Interventional,Recruiting,Phase 3,Lund University,Lund University,"Dpt. of Endocrinology, SUS Malmö",Drug,Sweden,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03131726
NCT03131726,graves disease,Treatment of Graves´Ophthalmopathy With Simvastatin (GO-DS),Treatment of Graves´Ophthalmopathy With Simvastatin (GO-DS),Graves Ophthalmopathy|Thyroid Associated Ophthalmopathy|Thyroid Associated Orbitopathy,2017-03-10,2024-01-26,2024-03-30,Interventional,Recruiting,Phase 3,Lund University,Lund University,"Dpt. of Endocrinology, SUS Malmö",Drug,Sweden,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT03131726
NCT03134976,hypothyroidism,Wound Complications in Head and Neck Surgery,Wound Complications in Head and Neck Surgery,Head and Neck Cancer|Hypothyroidism; Surgery|Laryngeal Cancer|Laryngeal Fistula|Wound Heal,2017-04-20,2020-04-01,2020-05-01,Observational,Completed,,University of Michigan,University of Michigan,University of Michigan,Drug,United States,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03134976
NCT03137316,hyperparathyroidism,Prevalence of Secondary Hyperparathyroidism Among Patients With Diabetic Nephropathy,Prevalence of Secondary Hyperparathyroidism Among Patients With Diabetic Nephropathy,Diabetic Nephropathies|Secondary Hyperparathyroidism,2017-04-28,2017-02-28,2017-03-01,Observational,Completed,,Benha University,Benha University|New Jeddah Clinic Hospital,,Diagnostic Test,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03137316
NCT03157466,euthyroid sick syndromes,Diaphragmatic Efficiency After Thyroid Hormone Replacement Therapy in Ventilated Patients With the Nonthyroidal Illness Syndrome: a Physiological Study,Respiratory Muscle Function After Thyroid Hormone Replacement Therapy in Nonthyroidal Illness Syndrome,Respiratory Failure|Thyroid Diseases,2017-05-12,2018-05-01,2018-05-01,Observational,Completed,,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,Fondazione Policlinico Universitario Agostino Gemelli,,Italy,18.0,120.0,[18-65]|[65 and more],Euthyroid Sick Syndromes,Euthyroid Sick Syndromes,https://clinicaltrials.gov/ct2/show/NCT03157466
NCT03158961,thyroid neoplasms,A Prospective Evaluation of the Feasibility and Safety of the Transoral Endoscopic Thyroidectomy Vestibular Approach (TOETVA) as a Treatment for Benign Thyroid Nodules,The Feasibility and Safety of the TOETVA for Benign Thyroid Nodules,Thyroid Diseases,2017-05-15,2019-05-31,2019-07-31,Interventional,Completed,Not Applicable,The University of Hong Kong,The University of Hong Kong,Queen Mary Hospital,Procedure,Hong Kong,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03158961
NCT03158961,thyroid nodule,A Prospective Evaluation of the Feasibility and Safety of the Transoral Endoscopic Thyroidectomy Vestibular Approach (TOETVA) as a Treatment for Benign Thyroid Nodules,The Feasibility and Safety of the TOETVA for Benign Thyroid Nodules,Thyroid Diseases,2017-05-15,2019-05-31,2019-07-31,Interventional,Completed,Not Applicable,The University of Hong Kong,The University of Hong Kong,Queen Mary Hospital,Procedure,Hong Kong,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03158961
NCT03160482,thyroid neoplasms,Evaluation of PACE4 Isoforms as Biomarkers in Thyroid Cancer,PACE4 in Thyroid Cancer,Thyroid Nodule,2017-05-16,2018-01-15,2018-01-15,Observational,Completed,,Université de Sherbrooke,Robert Day,CIUSSS de l'Estrie - CHUS,Diagnostic Test,Canada,18.0,100.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03160482
NCT03162627,thyroid neoplasms,"Evaluation of the Combination of Selumetinib and Olaparib in Endometrial, Ovarian and Other Solid Tumors With Ras Pathway Alterations, and Ovarian Tumors With PARP Resistance",Selumetinib and Olaparib in Solid Tumors,Malignant Neoplasm of Breast|Malignant Neoplasms of Digestive Organs|Malignant Neoplasms of Female Genital Organs|Malignant Neoplasms of Male Genital Organs|Malignant Neoplasms of Thyroid and Other Endocrine Glands,2017-05-18,2026-08-30,2026-08-30,Interventional,Recruiting,Phase 1,M.D. Anderson Cancer Center,AstraZeneca|M.D. Anderson Cancer Center,University of Texas MD Anderson Cancer Center,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03162627
NCT03167385,thyroid neoplasms,The Effectiveness and Safety of Apatinib Mesylate in Locally Advanced/Metastatic Differentiated Thyroid Carcinoma: a Phase 2 Trial.,Phase 2 Trial of Apatinib Mesylate in Locally Advanced/Metastatic Differentiated Thyroid Carcinoma,Differentiated Thyroid Carcinoma,2017-05-24,2019-01-31,2020-12-31,Interventional,Unknown status,Phase 2,Tianjin Medical University Cancer Institute and Hospital,Tianjin Medical University Cancer Institute and Hospital,Tianjin Medical University Cancer Institute and Hospital,Drug,China,18.0,75.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03167385
NCT03174925,thyroid neoplasms,Elastography in Thyroid Nodule Evaluation,Ultrasound Elastography in Imaging Patients With Thyroid Nodules,Malignant Thyroid Gland Neoplasm|Thyroid Gland Nodule,2017-05-18,2018-02-13,2019-02-13,Interventional,Completed,Not Applicable,Stanford University,Stanford University,"Stanford University, School of Medicine",Device,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03174925
NCT03178253,hypothyroidism,Hypothyroidism in Patients With Type 2 Diabetes With Early Diabetic Nephropathy,Hypothyroidism in Patients With Type 2 Diabetes With Early Diabetic Nephropathy,Hypothyroidism in Diabetes,2017-06-03,2017-06-30,2018-06-30,Observational,Unknown status,,Assiut University,Assiut University,Maria Hamdy,,Egypt,40.0,70.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03178253
NCT03182699,hyperparathyroidism,Effect of Etelcalcetide on Cardiac Hypertrophy in Hemodialysis Patients: A Randomized Controlled Trial,Effect of Etelcalcetide on Cardiac Hypertrophy in Hemodialysis Patients,Chronic Kidney Disease Requiring Chronic Dialysis|Left Ventricular Hypertrophy|Secondary Hyperparathyroidism,2017-05-31,2019-12-20,2019-12-20,Interventional,Completed,Phase 4,Medical University of Vienna,Amgen|Rainer Oberbauer,Medical University of Vienna|Wiener Dialysezentrum,Diagnostic Test|Diagnostic Test|Diagnostic Test|Diagnostic Test|Diagnostic Test,Austria,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03182699
NCT03183752,thyroid neoplasms,The Role of Insulin Resistance and the Effect of Metformin Use on Volume of Benign Thyroid Nodules,Insulin Resistance and Metformin Use on Volume of Benign Thyroid Nodules,Insulin Resistance|Thyroid Nodule,2017-06-08,2018-10-17,2019-04-17,Interventional,Completed,Not Applicable,Hospital Universitário Clementino Fraga Filho,Hospital Universitário Clementino Fraga Filho,Patricia Santos,Drug|Drug,Brazil,18.0,80.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03183752
NCT03194087,hyperparathyroidism,the Study on Difference Prognostic for Low Parathyroid Hormone Levels and Severe Secondary Hyperparathyroidism in Hemodialysis Patients,the Study on Prognostic for Hemodialysis Patients,Secondary Hyperparathyroidism,2017-05-31,2019-01-01,2019-01-01,Observational,Unknown status,,Beijing Friendship Hospital,Beijing Friendship Hospital,Beijing Friendship hospital,,China,18.0,80.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03194087
NCT03195296,hyperthyroidism,T and B Cells Infiltrating Orbital Tissues in Graves' Orbitopathy (GO) and Their Relation With GO Features,T and B Cells in Graves' Orbitopathy,Graves Ophthalmopathy,2017-06-19,2017-05-31,2017-05-31,Observational,Completed,,University of Pisa,University of Pisa,,Other,,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03195296
NCT03195296,goiter,T and B Cells Infiltrating Orbital Tissues in Graves' Orbitopathy (GO) and Their Relation With GO Features,T and B Cells in Graves' Orbitopathy,Graves Ophthalmopathy,2017-06-19,2017-05-31,2017-05-31,Observational,Completed,,University of Pisa,University of Pisa,,Other,,18.0,80.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03195296
NCT03195296,graves disease,T and B Cells Infiltrating Orbital Tissues in Graves' Orbitopathy (GO) and Their Relation With GO Features,T and B Cells in Graves' Orbitopathy,Graves Ophthalmopathy,2017-06-19,2017-05-31,2017-05-31,Observational,Completed,,University of Pisa,University of Pisa,,Other,,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT03195296
NCT03199677,thyroid neoplasms,"An Exploratory Single-center, Open-label , Clinical Study of Apatinib in Patients With Local Progressive/Metastatic Refractory Thyroid Cancer",A Clinical Study of Apatinib in Patients With Local Progressive/Metastatic Refractory Thyroid Cancer,Refractory Cancer,2017-06-16,2018-06-30,2018-06-30,Interventional,Unknown status,Phase 2,Chinese Academy of Medical Sciences,Chinese Academy of Medical Sciences,"Cancer Hospital, Chinese Academy of Medical Sciences",Drug,China,18.0,75.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03199677
NCT03211117,"thyroid carcinoma, anaplastic",Phase 2 Study of Pembrolizumab Combined With Chemoradiation Therapy in Anaplastic Thyroid Cancer,"Pembrolizumab, Chemotherapy, and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer",Thyroid Gland Undifferentiated (Anaplastic) Carcinoma,2017-07-06,2018-02-12,2019-03-28,Interventional,Completed,Phase 2,Mayo Clinic,Mayo Clinic|National Cancer Institute (NCI),Mayo Clinic,Drug|Drug|Radiation|Other|Biological|Procedure,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT03211117
NCT03226171,hyperparathyroidism,Dose Adjustment Trial of SK-1403 in Hemodialysis Patients With Secondary Hyperparathyroidism,Dose Adjustment Trial of SK-1403 in Hemodialysis Patients With Secondary Hyperparathyroidism,Secondary Hyperparathyroidism,2017-07-20,2018-09-11,2018-09-11,Interventional,Completed,Phase 2,"Sanwa Kagaku Kenkyusho Co., Ltd.","Sanwa Kagaku Kenkyusho Co., Ltd.",Investigational site (there may be other sites in this country),Drug,Japan,20.0,79.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03226171
NCT03239769,thyroid neoplasms,"A Study to Evaluate and Compare the Surgical Outcomes, Aesthetic Effects and Incision Length of Different Access Procedures in Patients With DTC",Compare the Aesthetic Effect of Different Thyroidectomies,Differentiated Thyroid Carcinoma (DTC),2017-08-01,2015-06-01,2015-06-01,Interventional,Completed,Not Applicable,Beijing Cancer Hospital,Beijing Cancer Hospital,,Procedure,,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03239769
NCT03244956,thyroid neoplasms,Efficacy of a Selective MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors Associated With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer With RAS or BRAFV600E Mutation,Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer,Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation,2017-08-07,2021-11-18,2022-12-31,Interventional,Active not recruiting,Phase 2,"Gustave Roussy, Cancer Campus, Grand Paris","Gustave Roussy, Cancer Campus, Grand Paris",Gustave Roussy,Drug|Drug|Radiation|Drug,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03244956
NCT03249012,hypoparathyroidism,Comparing the Quality of Life Associated With Empiric Calcium Repletion and Parathormone (PTH) Based Calcium Repletion for Post Thyroidectomy Hypoparathyroidism,Quality of Life Related to Different Treatment Protocols for Post-thyroidectomy Hypoparathyroidism,Hypoparathyroidism Postprocedural|Quality of Life,2017-08-09,2022-09-01,2022-09-01,Interventional,Recruiting,Not Applicable,CHU de Quebec-Universite Laval,CHU de Quebec-Universite Laval,CHU de Quebec,Other|Other,Canada,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03249012
NCT03257930,thyroid neoplasms,Percutaneous Ethanol Injection for Benign Cystic Thyroid Nodules,Percutaneous Ethanol Injection for Benign Cystic Thyroid Nodules,Thyroid Nodule,2017-08-17,2018-07-11,2019-01-01,Interventional,Completed,Phase 1,Assiut University,hassan harby mohamed,Assiut University,Drug,Egypt,15.0,60.0,[0-17]|[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03257930
NCT03268785,hypoparathyroidism,Intra-operative Rapid Identification of Lymph Node and Parathyroid by Fine Needle Puncture for Thyroid Carcinoma,Intra-operative Rapid Identification of Lymph Node and Parathyroid,Hypocalcemia|Hypoparathyroidism Postprocedural|Parathyroid; Absent|Thyroid Cancer,2017-08-28,2018-08-01,2020-08-01,Interventional,Unknown status,Not Applicable,Xijing Hospital,Xijing Hospital,Xijing hospital|Xijing Hospital,Diagnostic Test,China,18.0,60.0,[18-65],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03268785
NCT03271892,"thyroid cancer, papillary",Deciding on Active Surveillance as an Alternative Option to Surgery in the Primary Management of Low Risk Papillary Thyroid Cancer,Deciding on Active Surveillance or Surgery for Primary Management of Low Risk Papillary Thyroid Cancer,Thyroid Cancer Stage I,2017-08-28,2026-05-11,2026-12-31,Observational,Recruiting,,"University Health Network, Toronto","Canadian Cancer Society (CCS)|Ontario Ministry of Health and Long Term Care|University Health Network, Toronto",University Health Network|University Health Network,,Canada,18.0,100.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT03271892
NCT03274258,thyroid neoplasms,Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma,Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma,Kidney Medullary Carcinoma|Loss of INI 1 Protein Expression|Stage III Renal Cell Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v8,2017-09-05,2022-07-31,2023-07-31,Interventional,Active not recruiting,Phase 2,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center|National Cancer Institute (NCI),M D Anderson Cancer Center,Biological|Biological,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03274258
NCT03278964,hyperthyroidism,"Comparative Morphometric, Functional and Psychosocial Analysis Between the Results of Two Surgical Techniques of Orbital Decompression in Patients With Graves Orbitopathy",Analysis Between the Results of Two Surgical Techniques of Orbital Decompression in Patients With Graves Orbitopathy,Graves Ophthalmopathy,2017-09-04,2019-01-31,2019-01-31,Interventional,Completed,Not Applicable,University of Sao Paulo General Hospital,University of Sao Paulo General Hospital,University of Sao Paulo General Hospital,Procedure,Brazil,21.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03278964
NCT03278964,graves disease,"Comparative Morphometric, Functional and Psychosocial Analysis Between the Results of Two Surgical Techniques of Orbital Decompression in Patients With Graves Orbitopathy",Analysis Between the Results of Two Surgical Techniques of Orbital Decompression in Patients With Graves Orbitopathy,Graves Ophthalmopathy,2017-09-04,2019-01-31,2019-01-31,Interventional,Completed,Not Applicable,University of Sao Paulo General Hospital,University of Sao Paulo General Hospital,University of Sao Paulo General Hospital,Procedure,Brazil,21.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT03278964
NCT03278964,goiter,"Comparative Morphometric, Functional and Psychosocial Analysis Between the Results of Two Surgical Techniques of Orbital Decompression in Patients With Graves Orbitopathy",Analysis Between the Results of Two Surgical Techniques of Orbital Decompression in Patients With Graves Orbitopathy,Graves Ophthalmopathy,2017-09-04,2019-01-31,2019-01-31,Interventional,Completed,Not Applicable,University of Sao Paulo General Hospital,University of Sao Paulo General Hospital,University of Sao Paulo General Hospital,Procedure,Brazil,21.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03278964
NCT03280264,parathyroid neoplasms,An Intra-Subject Dose-Adjustment Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism Who Are Unable to Undergo Parathyroidectomy or Relapse After Parathyroidectomy,Phase 3 Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism,Parathyroid Carcinoma|Primary Hyperparathyroidism,2017-09-07,2019-04-09,2019-04-09,Interventional,Completed,Phase 3,"Kyowa Kirin Co., Ltd.","Kyowa Kirin Co., Ltd.",Osaka City University Hospital,Drug,Japan,20.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03280264
NCT03280264,hyperparathyroidism,An Intra-Subject Dose-Adjustment Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism Who Are Unable to Undergo Parathyroidectomy or Relapse After Parathyroidectomy,Phase 3 Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism,Parathyroid Carcinoma|Primary Hyperparathyroidism,2017-09-07,2019-04-09,2019-04-09,Interventional,Completed,Phase 3,"Kyowa Kirin Co., Ltd.","Kyowa Kirin Co., Ltd.",Osaka City University Hospital,Drug,Japan,20.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03280264
NCT03283098,hyperparathyroidism,"A Phase 1, Multiple Dose, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pharmacokinetics, Safety and Tolerability of AMG 416 Administered Intravenously to Chinese Subjects With Chronic Kidney Disease on Hemodialysis","A Phase 1 Study to Evaluate PK, Safety and Tolerability of AMG 416",Secondary Hyperparathyroidism,2017-08-31,2019-02-04,2019-02-04,Interventional,Completed,Phase 1,Amgen,Amgen,Research Site|Research Site|Research Site|Research Site|Research Site,Drug|Drug,China,18.0,70.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03283098
NCT03284060,hypoparathyroidism,Social Cognition Training and Cognitive Remediation : a New Tool for 22q11.2 Deletion Syndrome,Social Cognition Training and Cognitive Remediation,22q11.2 Deletion Syndrome,2017-09-13,2018-03-09,2019-05-21,Interventional,Terminated,Not Applicable,Hôpital le Vinatier,Hôpital le Vinatier,Hopital Vinatier,Behavioral,France,5.0,13.0,[0-17],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03284060
NCT03285854,hyperparathyroidism,Assessing Calcium Balance in Children With Chronic Kidney Disease to Optimise Treatment Strategies,Calcium Balance Studies in Children With CKD and on Dialysis,Chronic Kidney Disease Mineral and Bone Disorder,2017-09-12,2021-12-30,2022-12-30,Observational,Active not recruiting,,Great Ormond Street Hospital for Children NHS Foundation Trust,"Athens General Children's Hospital ""Pan. & Aglaia Kyriakou""|Cukurova University|Great Ormond Street Hospital for Children NHS Foundation Trust|University of Kiel",Great Ormond Street Hospital for Children NHS Foundation Trust,Diagnostic Test,United Kingdom,0.0,18.0,[0-17]|[18-65],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03285854
NCT03295955,thyroid neoplasms,Comparing Efficacy of Postoperative Antibiotic Use in Transoral Thyroidectomy: a Prospective Randomized Controlled Trial Study,Comparing Efficacy of Postoperative Oral Antibiotic Use in Trans-Oral Thyroidectomy,Surgical Wound Infection|Thyroid Nodule,2017-09-20,2018-09-03,2018-12-03,Interventional,Unknown status,Not Applicable,Seoul National University Hospital,Seoul National University Hospital,Jin Wook Yi,Drug,"Korea, Republic of",20.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03295955
NCT03298867,hyperthyroidism,"A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating Teprotumumab (HZN-001) Treatment in Subjects With Active Thyroid Eye Disease","Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study",Graves' Orbitopathy|Thyroid Eye Disease,2017-09-27,2019-02-13,2020-11-30,Interventional,Completed,Phase 3,"Horizon Pharma USA, Inc.","Horizon Pharma USA, Inc.","Macro, Llc|Cedars-Sinai Medical Center|The Lennar Foundation Medical|Bascom Palmer Eye Institute|Kellogg Eye Center at University of Michigan|Casey Eye Institute at Oregon Health and Science University|Hamilton Eye Institute at University of Tennessee Health Science Center|Eye Wellness Center|Medical College of Wisconsin, The Eye Institute|University Hospital Essen, Department of Ophthalmology|Johannes Gutenberg University Medical Center|Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico|University of Pisa, Department of Clinical and Experimental Medicine|University of Pisa,Department of Clinical and Experimental Medicine, Endocrinology Unit",Biological|Other,Germany|Italy|United States,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03298867
NCT03298867,goiter,"A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating Teprotumumab (HZN-001) Treatment in Subjects With Active Thyroid Eye Disease","Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study",Graves' Orbitopathy|Thyroid Eye Disease,2017-09-27,2019-02-13,2020-11-30,Interventional,Completed,Phase 3,"Horizon Pharma USA, Inc.","Horizon Pharma USA, Inc.","Macro, Llc|Cedars-Sinai Medical Center|The Lennar Foundation Medical|Bascom Palmer Eye Institute|Kellogg Eye Center at University of Michigan|Casey Eye Institute at Oregon Health and Science University|Hamilton Eye Institute at University of Tennessee Health Science Center|Eye Wellness Center|Medical College of Wisconsin, The Eye Institute|University Hospital Essen, Department of Ophthalmology|Johannes Gutenberg University Medical Center|Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico|University of Pisa, Department of Clinical and Experimental Medicine|University of Pisa,Department of Clinical and Experimental Medicine, Endocrinology Unit",Biological|Other,Germany|Italy|United States,18.0,80.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03298867
NCT03298867,graves disease,"A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating Teprotumumab (HZN-001) Treatment in Subjects With Active Thyroid Eye Disease","Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study",Graves' Orbitopathy|Thyroid Eye Disease,2017-09-27,2019-02-13,2020-11-30,Interventional,Completed,Phase 3,"Horizon Pharma USA, Inc.","Horizon Pharma USA, Inc.","Macro, Llc|Cedars-Sinai Medical Center|The Lennar Foundation Medical|Bascom Palmer Eye Institute|Kellogg Eye Center at University of Michigan|Casey Eye Institute at Oregon Health and Science University|Hamilton Eye Institute at University of Tennessee Health Science Center|Eye Wellness Center|Medical College of Wisconsin, The Eye Institute|University Hospital Essen, Department of Ophthalmology|Johannes Gutenberg University Medical Center|Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico|University of Pisa, Department of Clinical and Experimental Medicine|University of Pisa,Department of Clinical and Experimental Medicine, Endocrinology Unit",Biological|Other,Germany|Italy|United States,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT03298867
NCT03299244,hyperparathyroidism,"A Multicenter, Multiple-dose, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet Hydrochloride With Intravenous Doses of Etelcalcetide (AMG 416) in Asian Hemodialysis Subjects With Secondary Hyperparathyroidism",Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT),Chronic Kidney Disease|Secondary Hyperparathyroidism,2017-09-15,2020-04-08,2020-04-08,Interventional,Completed,Phase 3,Amgen,Amgen,Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug|Drug,"China|Hong Kong|India|Korea, Republic of|Malaysia|Taiwan",18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03299244
NCT03300284,"thyroid cancer, papillary",Decision Making and Psychological Outcomes in Low-Risk Papillary Thyroid Cancer,Decision Making and Psychological Outcomes in Low-Risk Papillary Thyroid Cancer,Thyroid Cancer,2017-09-28,2022-08-31,2022-08-31,Observational,Active not recruiting,,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Hartford Healthcare (Data Collection)|Memoral Sloan Kettering Monmouth (Consent and Follow up)|MAIMONIDES MEDICAL CENTER (Data collection only)|NYU Langone Health|Memorial Sloan Kettering Cancer Center|Lehigh Valley Health Network,Behavioral,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT03300284
NCT03303053,goiter,"A Multi-center, Open Label, Randomised Parallel- Group Study to Compare the Efficacy of Cholestyramine Plus Standard Treatment Versus Prednisolone Plus Standard Treatment Versus Standard Treatment Alone in Treatment of Overt Hyperthyroidism",Efficacy and Safety of Cholestyramine and Prednisolone as Adjunctive Therapy in Treatment of Overt Hyperthyroidism,Graves Disease|Hyperthyroidism,2017-09-13,2018-03-01,2018-03-01,Interventional,Unknown status,Phase 3,"Clinical Research Centre, Malaysia","Clinical Research Centre, Malaysia|Ministry of Health, Malaysia",Hospital Queen Elizabeth 2|Hospital Ampang|Hospital Putrajaya,Drug|Drug|Drug,Malaysia,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03303053
NCT03307694,thyroid nodule,Multi-Angle Compound Shear Wave Elasticity Imaging for the Characterization of Thyroid Nodules,Thyroid Ultrasound Elasticity (TrUE) Imaging,"Cancer, Thyroid",2017-10-03,2018-07-13,2018-07-13,Observational,Completed,,Emory University,Emory University,Emory Univeristy Hospital Midtown,Diagnostic Test|Diagnostic Test|Diagnostic Test,United States,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03307694
NCT03307694,thyroid neoplasms,Multi-Angle Compound Shear Wave Elasticity Imaging for the Characterization of Thyroid Nodules,Thyroid Ultrasound Elasticity (TrUE) Imaging,"Cancer, Thyroid",2017-10-03,2018-07-13,2018-07-13,Observational,Completed,,Emory University,Emory University,Emory Univeristy Hospital Midtown,Diagnostic Test|Diagnostic Test|Diagnostic Test,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03307694
NCT03309384,hypoparathyroidism,Intraoperative Monitoring (Parathormone Values and Continuous Neuromonitoring) to Predict Postoperative Complications After Total Thyroidectomy,Intraoperative Monitoring to Predict Postoperative Complications After Thyroidectomy,Endocrine Procedural Complications|Laryngeal Injury|Parathyroid; Deficiency|Thyroid,2017-09-06,2026-03-20,2026-03-20,Observational [Patient Registry],Recruiting,,"Central Hospital, Nancy, France","Central Hospital, Nancy, France",CHU Nancy,,France,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03309384
NCT03309631,thyroid neoplasms,Clinical Validation of ThyroidPrint: A Gene Expression Signature for Diagnosis of Indeterminate Thyroid Nodules,Clinical Validation of ThyroidPrint: A Gene Expression Signature for Diagnosis of Indeterminate Thyroid Nodules,Indeterminate Thyroid Cytology,2017-10-01,2018-03-30,2018-06-30,Observational,Unknown status,,Pontificia Universidad Catolica de Chile,Geneprodx|Pontificia Universidad Catolica de Chile,Avantt Research|Stanford University|Lee Moffit Cancer Center|Tulane University|Universidad de Cincinnati|University of Texas MD Anderson Cancer Center,Diagnostic Test,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03309631
NCT03309631,thyroid nodule,Clinical Validation of ThyroidPrint: A Gene Expression Signature for Diagnosis of Indeterminate Thyroid Nodules,Clinical Validation of ThyroidPrint: A Gene Expression Signature for Diagnosis of Indeterminate Thyroid Nodules,Indeterminate Thyroid Cytology,2017-10-01,2018-03-30,2018-06-30,Observational,Unknown status,,Pontificia Universidad Catolica de Chile,Geneprodx|Pontificia Universidad Catolica de Chile,Avantt Research|Stanford University|Lee Moffit Cancer Center|Tulane University|Universidad de Cincinnati|University of Texas MD Anderson Cancer Center,Diagnostic Test,United States,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03309631
NCT03324022,hyperthyroidism,Observing the Relationship of Fibroblast Growth Factor and Fibroblast in Thyroid Eye Disease,Observing the Relationship of Fibroblast Growth Factor and Fibroblast in Thyroid Eye Disease,Graves Ophthalmopathy,2017-10-16,2017-12-25,2020-12-25,Observational,Unknown status,,National Taiwan University Hospital,National Taiwan University Hospital,"National Taiwan University Hospital Taipei, Taiwan",,Taiwan,20.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03324022
NCT03324022,goiter,Observing the Relationship of Fibroblast Growth Factor and Fibroblast in Thyroid Eye Disease,Observing the Relationship of Fibroblast Growth Factor and Fibroblast in Thyroid Eye Disease,Graves Ophthalmopathy,2017-10-16,2017-12-25,2020-12-25,Observational,Unknown status,,National Taiwan University Hospital,National Taiwan University Hospital,"National Taiwan University Hospital Taipei, Taiwan",,Taiwan,20.0,80.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03324022
NCT03324022,graves disease,Observing the Relationship of Fibroblast Growth Factor and Fibroblast in Thyroid Eye Disease,Observing the Relationship of Fibroblast Growth Factor and Fibroblast in Thyroid Eye Disease,Graves Ophthalmopathy,2017-10-16,2017-12-25,2020-12-25,Observational,Unknown status,,National Taiwan University Hospital,National Taiwan University Hospital,"National Taiwan University Hospital Taipei, Taiwan",,Taiwan,20.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT03324022
NCT03324334,graves disease,Prevalence of Graves Disease in Patients With Ulcerative Colitis,Prevalence of Graves Disease in Patients With Ulcerative Colitis,Ulcerative Colitis,2017-10-24,2018-10-01,2019-02-28,Observational,Unknown status,,Assiut University,Assiut University,,Diagnostic Test|Diagnostic Test,,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT03324334
NCT03324334,hyperthyroidism,Prevalence of Graves Disease in Patients With Ulcerative Colitis,Prevalence of Graves Disease in Patients With Ulcerative Colitis,Ulcerative Colitis,2017-10-24,2018-10-01,2019-02-28,Observational,Unknown status,,Assiut University,Assiut University,,Diagnostic Test|Diagnostic Test,,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03324334
NCT03324334,goiter,Prevalence of Graves Disease in Patients With Ulcerative Colitis,Prevalence of Graves Disease in Patients With Ulcerative Colitis,Ulcerative Colitis,2017-10-24,2018-10-01,2019-02-28,Observational,Unknown status,,Assiut University,Assiut University,,Diagnostic Test|Diagnostic Test,,18.0,70.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03324334
NCT03324893,hyperparathyroidism,18F-Fluorocholine PET/MRI for the Localization of Parathyroid Adenomas,FCH PET/MRI Parathyroid Localization,"18F-fluorocholine|Hyperparathyroidism, Primary|Positron-Emission Tomography",2017-10-17,2021-06-30,2021-06-30,Interventional,Active not recruiting,Not Applicable,"University Health Network, Toronto","University Health Network, Toronto",UHN,Diagnostic Test,Canada,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03324893
NCT03327636,thyroid neoplasms,A Prospective Randomized Trial Comparing Ultrasound-guided High Intensity Focused Ultrasound (HIFU) Ablation With Active Surveillance (AS) in the Management of Low-risk Papillary Thyroid Microcarcinoma (PTMC),A Trial Comparing USG-HIFU vs AS in Management of Low-risk PTMC,Papillary Thyroid Microcarcinoma,2017-10-25,2024-08-31,2024-12-31,Interventional,Suspended,Not Applicable,The University of Hong Kong,The University of Hong Kong,Queen Mary Hospital,Device,Hong Kong,19.0,74.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03327636
NCT03331172,thyroid neoplasms,Efficacy and Safety of High Intensity Focused Ultrasound (HIFU) Reapplication in Benign Thyroid Nodules That Had Less-than Adequate Shrinkage Following Single-session HIFU Treatment.,HIFU Reapplication in Benign Nodules,Thyroid Nodule,2017-10-27,2018-06-30,2018-08-30,Interventional,Completed,Not Applicable,The University of Hong Kong,The University of Hong Kong,Queen Mary Hospital,Device,Hong Kong,19.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03331172
NCT03363347,"thyroid cancer, papillary",Association Between BRAF V600E and Redifferentiation Therapy in Patients With Radioiodine-refractory Papillary Thyroid Cancer,BRAF V600E and Redifferentiation Therapy in Radioiodine-refractory Papillary Thyroid Cancer,Thyroid Cancer,2017-11-20,2014-12-31,2014-12-31,Observational,Completed,,Heidelberg University,Heidelberg University,,Drug,,24.0,69.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT03363347
NCT03375359,hypoparathyroidism,"First Trimester Screening for Trisomy 21, 18, 13 and 22q11.2 Deletion Syndrome - ReFaPo02","First Trimester Screening for Trisomy 21, 18, 13 and 22q11.2 Deletion Syndrome",Pregnancy,2017-12-12,2022-08-31,2022-08-31,Observational,Recruiting,,University Hospital Tuebingen,University Hospital Tuebingen,"University Hospital Tuebingen, Department of Women's Health",Diagnostic Test,Germany,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03375359
NCT03382158,goiter,"International Pleuropulmonary Blastoma Registry for PPB, DICER1 and Associated Conditions",International PPB/DICER1 Registry,Ciliary Body Medulloepithelioma|Cystic Nephroma|DICER1 Syndrome|Embryonal Rhabdomyosarcoma|Nasal Chondromesenchymal Hamartoma|Neuroblastoma|Nodular Hyperplasia of Thyroid|Pineoblastoma|Pituitary Cancer|Pleuropulmonary Blastoma|Renal Sarcoma|Sertoli-Leydig Cell Tumor|Wilms Tumor,2017-10-11,2023-12-06,2026-12-06,Observational,Recruiting,,Children's Hospitals and Clinics of Minnesota,"Beijing Children's Hospital|Children's Hospitals and Clinics of Minnesota|Children's National Research Institute|Dana-Farber Cancer Institute|Emory University|ResourcePath, LLC|University of Cambridge|Washington University School of Medicine",Children's Minnesota,,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03382158
NCT03387943,thyroid neoplasms,"A Prospective, Multicenter, Open Label Phase Ⅱ Clinical Trial of Doxorubicin Hydrochloride Liposome Injection Combined With Cisplatin in the Treatment of Advanced Poorly Differentiated Thyroid Carcinoma",PLD Combined With Cisplatin in the Treatment of Advanced Poorly Differentiated Thyroid Carcinoma,Poorly Differentiated Thyroid Carcinoma,2017-12-11,2018-12-31,2019-12-31,Interventional,Unknown status,Phase 2,"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","CSPC ZhongQi Pharmaceutical Technology Co., Ltd.",Zhejiang Cancer Hospital,Drug|Drug,China,18.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03387943
NCT03395925,thyroid neoplasms,Evaluation of the Thyroid Volume After Radiofrequency Ablation of Thyroid Nodules and Recurrent Thyroid,Evaluation of the Thyroid Volume After Radiofrequency Ablation of Thyroid Nodules and Recurrent Thyroid,Thyroid Nodule,2017-12-17,2021-10-30,2022-01-30,Interventional,Active not recruiting,Not Applicable,Olympus Surgical Technologies Europe,Olympus Surgical Technologies Europe,Johann-Wolfgang Goethe University,Device,Germany,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03395925
NCT03420963,thyroid neoplasms,Ex-Vivo Expanded Allogeneic NK Cells for the Treatment of Solid Tumors of Pediatric Origin in Children and Young Adults,"Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors",Recurrent Cutaneous Melanoma|Recurrent Lip and Oral Cavity Carcinoma|Recurrent Malignant Endocrine Neoplasm|Recurrent Malignant Female Reproductive System Neoplasm|Recurrent Malignant Male Reproductive System Neoplasm|Recurrent Malignant Mesothelioma|Recurrent Malignant Neoplasm of Multiple Primary Sites|Recurrent Malignant Oral Neoplasm|Recurrent Malignant Pharyngeal Neoplasm|Recurrent Malignant Skin Neoplasm|Recurrent Malignant Soft Tissue Neoplasm|Recurrent Malignant Solid Neoplasm|Recurrent Malignant Thyroid Gland Neoplasm|Recurrent Malignant Urinary System Neoplasm|Refractory Cutaneous Melanoma|Refractory Malignant Bone Neoplasm|Refractory Malignant Endocrine Neoplasm|Refractory Malignant Female Reproductive System Neoplasm|Refractory Malignant Male Reproductive System Neoplasm|Refractory Malignant Mesothelioma|Refractory Malignant Neoplasm of Multiple Primary Sites|Refractory Malignant Oral Neoplasm|Refractory Malignant Pharyngeal Neoplasm|Refractory Malignant Skin Neoplasm|Refractory Malignant Soft Tissue Neoplasm|Refractory Malignant Solid Neoplasm|Refractory Malignant Thyroid Gland Neoplasm|Refractory Malignant Urinary System Neoplasm,2018-01-29,2022-12-01,2022-12-01,Interventional,Recruiting,Phase 1,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center|National Cancer Institute (NCI),M D Anderson Cancer Center,Biological|Drug|Drug,United States,12.0,40.0,[0-17]|[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03420963
NCT03425747,hypoparathyroidism,CALCIUM CITRATE vs CALCIUM CARBONATE FOR THE MANAGEMENT OF CHRONIC HYPOPARATHYROIDISM,Efficacy of Calcium Citrate Versus Calcium Carbonate for the Management of Chronic Hypoparathyroidism,Chronic Hypoparathyroidism,2018-01-27,2020-04-01,2020-04-01,Interventional,Completed,Phase 4,Campus Bio-Medico University,Campus Bio-Medico University,Campus Bio-Medico University,Drug|Drug,Italy,18.0,75.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03425747
NCT03434067,hyperparathyroidism,The Application of Rapid PTH Test Paper in Operation of Hyperparathyroidism,The Application of Rapid PTH Test Paper in Operation of Hyperparathyroidism,Hyperthyroidism|Immunochromatographic|PTH|Thyroidectomy,2018-01-27,2018-06-30,2018-12-30,Observational [Patient Registry],Unknown status,,Fujian Medical University,"Bo Wang,MD",Wen-xin ZHAO,,China,18.0,70.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03434067
NCT03435952,thyroid neoplasms,A Phase Ib Investigation of Pembrolizumab in Combination With Intratumoral Injection of Clostridium Novyi-NT in Patients With Treatment-Refractory Solid Tumors,Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT,Malignant Neoplasm of Breast|Malignant Neoplasms of Digestive Organs|Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System|Malignant Neoplasms of Female Genital Organs|Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites|Malignant Neoplasms of Independent (Primary) Multiple Sites|Malignant Neoplasms of Lip Oral Cavity and Pharynx|Malignant Neoplasms of Male Genital Organs|Malignant Neoplasms of Mesothelial and Soft Tissue|Malignant Neoplasms of Respiratory and Intrathoracic Organs|Malignant Neoplasms of Thyroid and Other Endocrine Glands|Malignant Neoplasms of Urinary Tract,2018-02-09,2024-10-01,2024-10-01,Interventional,Recruiting,Phase 1,M.D. Anderson Cancer Center,"BioMed Valley Discoveries, Inc|M.D. Anderson Cancer Center|Merck Sharp & Dohme Corp.",University of Texas MD Anderson Cancer Center,Drug|Biological|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03435952
NCT03440697,hypoparathyroidism,Pathogenetic Basis of Aortopathy and Aortic Valve Disease,Pathogenetic Basis of Aortopathy and Aortic Valve Disease,Aortic Valve Disease|Aortopathies|Arterial Tortuosity Syndrome|Ascending Aortic Aneurysm|Ascending Aortic Disease|Autosomal Recessive Cutis Laxa|Congenital Contractural Arachnodactyly|Descending Aortic Aneurysm|Descending Aortic Disease|Ehlers-Danlos Syndrome|Loeys-Dietz Syndrome|Marfan Syndrome|PHACE Syndrome|Shprintzen-Goldberg Syndrome|Thoracic Aortic Aneurysm|Thoracic Aortic Disease|Thoracic Aortic Dissection|Thoracic Aortic Rupture|Turner Syndrome,2017-10-06,2025-12-31,2028-12-31,Observational,Recruiting,,Indiana University,Indiana University,IU School of Medicine,,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03440697
NCT03447093,hashimoto disease,The Oral Microbiota in Autoimmune Thyroiditis is Distinctive And Predictive,The Oral Microbiota is Associated With Autoimmune Thyroiditis,Microbiota,2018-02-08,2019-12-31,2021-12-31,Observational,Unknown status,,First Affiliated Hospital of Harbin Medical University,First Affiliated Hospital of Harbin Medical University,First affiliated hospital of Harbin medical university,Drug|Drug,China,18.0,65.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT03447093
NCT03461211,graves disease,"Multicenter, Safety and Efficacy, Open-Label Extension Study Evaluating Teprotumumab (HZN-001) Treatment in Subjects With Thyroid Eye Disease",Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study,Thyroid Eye Disease,2018-03-05,2020-06-08,2021-02-17,Interventional,Completed,Phase 3,"Horizon Pharma USA, Inc.","Horizon Pharma USA, Inc.","Macro, Llc|Cedars-Sinai Medical Center|Bascom Palmer Eye Institute|Kellogg Eye Center at University of Michigan|Casey Eye Institute at Oregon Health and Science|Hamilton Eye Institute at University of Tennessee Health|Eye Wellness Center|Medical College of Wisconsin, The Eye Institute|University Hospital Essen, Department of Ophthalmology|Johannes Gutenberg University Medical Center|Fondazione IRCCS Ca Granda Ospedale Maggiore|University of Pisa, Department of Clinical and Experimental Medicine|Azienda Ospedaliero Universitaria Pisana",Biological,Germany|Italy|United States,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT03461211
NCT03461211,goiter,"Multicenter, Safety and Efficacy, Open-Label Extension Study Evaluating Teprotumumab (HZN-001) Treatment in Subjects With Thyroid Eye Disease",Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study,Thyroid Eye Disease,2018-03-05,2020-06-08,2021-02-17,Interventional,Completed,Phase 3,"Horizon Pharma USA, Inc.","Horizon Pharma USA, Inc.","Macro, Llc|Cedars-Sinai Medical Center|Bascom Palmer Eye Institute|Kellogg Eye Center at University of Michigan|Casey Eye Institute at Oregon Health and Science|Hamilton Eye Institute at University of Tennessee Health|Eye Wellness Center|Medical College of Wisconsin, The Eye Institute|University Hospital Essen, Department of Ophthalmology|Johannes Gutenberg University Medical Center|Fondazione IRCCS Ca Granda Ospedale Maggiore|University of Pisa, Department of Clinical and Experimental Medicine|Azienda Ospedaliero Universitaria Pisana",Biological,Germany|Italy|United States,18.0,80.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03461211
NCT03461211,hyperthyroidism,"Multicenter, Safety and Efficacy, Open-Label Extension Study Evaluating Teprotumumab (HZN-001) Treatment in Subjects With Thyroid Eye Disease",Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study,Thyroid Eye Disease,2018-03-05,2020-06-08,2021-02-17,Interventional,Completed,Phase 3,"Horizon Pharma USA, Inc.","Horizon Pharma USA, Inc.","Macro, Llc|Cedars-Sinai Medical Center|Bascom Palmer Eye Institute|Kellogg Eye Center at University of Michigan|Casey Eye Institute at Oregon Health and Science|Hamilton Eye Institute at University of Tennessee Health|Eye Wellness Center|Medical College of Wisconsin, The Eye Institute|University Hospital Essen, Department of Ophthalmology|Johannes Gutenberg University Medical Center|Fondazione IRCCS Ca Granda Ospedale Maggiore|University of Pisa, Department of Clinical and Experimental Medicine|Azienda Ospedaliero Universitaria Pisana",Biological,Germany|Italy|United States,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03461211
NCT03464149,hyperparathyroidism,Intact Versus Biointact Assays for Longitudinal Assessment of Parathyroid Hormone - The Longitudinal PTH Study,The Longitudinal PTH-Study,CKD-MBD - Chronic Kidney Disease Mineral and Bone Disorder|Kidney Replacement|Secondary Hyperparathyroidism,2018-02-12,2018-12-05,2019-08-07,Observational,Completed,,Medical University of Vienna,Medical University of Vienna,"Department of Internal Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna, Austria",Diagnostic Test,Austria,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03464149
NCT03469310,parathyroid neoplasms,Minimizing Narcotic Analgesics After Thyroid or Parathyroid Surgery,Minimizing Narcotic Analgesics After Endocrine Surgery,Parathyroid Adenoma|Parathyroid Diseases|Parathyroid Hyperplasia|Thyroid Cancer|Thyroid Diseases|Thyroid Goitre|Thyroid Neoplasms|Thyroid Nodule,2018-03-07,2019-12-21,2020-10-02,Interventional,Completed,Phase 4,DHR Health Institute for Research and Development,Minerva A Romero Arenas,GME General Surgery Clinic,Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03469310
NCT03469310,goiter,Minimizing Narcotic Analgesics After Thyroid or Parathyroid Surgery,Minimizing Narcotic Analgesics After Endocrine Surgery,Parathyroid Adenoma|Parathyroid Diseases|Parathyroid Hyperplasia|Thyroid Cancer|Thyroid Diseases|Thyroid Goitre|Thyroid Neoplasms|Thyroid Nodule,2018-03-07,2019-12-21,2020-10-02,Interventional,Completed,Phase 4,DHR Health Institute for Research and Development,Minerva A Romero Arenas,GME General Surgery Clinic,Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03469310
NCT03484416,thyroid neoplasms,Routine Low-dose Calcium and Vitamin D Supplementation for Preventing Symptomatic Postthyroidectomy Hypocalcemia,Routine Calcium for Preventing Hypocalcemia,Thyroid Neoplasm,2018-03-25,2017-05-30,2017-05-30,Interventional,Completed,Not Applicable,Ewha Womans University Mokdong Hospital,Ewha Womans University Mokdong Hospital,Ewha Womans University Medical Center,Drug,"Korea, Republic of",20.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03484416
NCT03498183,thyroid nodule,Value of the Combination Ultrasonography With Ti-RADS Score / Dual Tracer Scintigraphy MIBI-Tc99m/Iodine-123 in the Detection of Malignancy of Thyroid Nodules (Sup or Egal to 15 mm) Classified Bethesda III or IV on Cytology,Value of the Combination Ultrasonography With Ti-RADS Score / Dual Tracer Scintigraphy MIBI-Tc99m/Iodine-123 in the Detection of Malignancy of Thyroid Nodules (≥15 mm) Classified Bethesda III or IV on Cytology,Malignancy of Thyroid Nodules,2018-03-29,2021-07-01,2021-07-01,Interventional,Recruiting,Phase 2/Phase 3,Nantes University Hospital,Nantes University Hospital,Centre Hospitalier et Universitaire (chu)|CHU|CHU|CHU|Hospices Civils|CHU|Assistance publique des Hôpitaux de Paris,Drug,France,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03498183
NCT03498183,thyroid neoplasms,Value of the Combination Ultrasonography With Ti-RADS Score / Dual Tracer Scintigraphy MIBI-Tc99m/Iodine-123 in the Detection of Malignancy of Thyroid Nodules (Sup or Egal to 15 mm) Classified Bethesda III or IV on Cytology,Value of the Combination Ultrasonography With Ti-RADS Score / Dual Tracer Scintigraphy MIBI-Tc99m/Iodine-123 in the Detection of Malignancy of Thyroid Nodules (≥15 mm) Classified Bethesda III or IV on Cytology,Malignancy of Thyroid Nodules,2018-03-29,2021-07-01,2021-07-01,Interventional,Recruiting,Phase 2/Phase 3,Nantes University Hospital,Nantes University Hospital,Centre Hospitalier et Universitaire (chu)|CHU|CHU|CHU|Hospices Civils|CHU|Assistance publique des Hôpitaux de Paris,Drug,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03498183
NCT03498417,hyperthyroidism,Serum Antibodies Against the Insulin-like Growth Factor-1 Receptor (IGF-1R) in Graves' Disease and Graves' Orbitopathy,Anti-insulin-like Growth Factor-1 Receptor (IGF-1R) Antibodies in Graves' Disease and Graves' Orbitopathy,Autoimmune Thyroiditis|Graves Disease|Graves Ophthalmopathy,2018-03-30,2018-07-20,2018-07-20,Observational,Completed,,University of Pisa,University of Pisa,"Endocrinology Unit I, University of Pisa",Diagnostic Test,Italy,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03498417
NCT03498417,goiter,Serum Antibodies Against the Insulin-like Growth Factor-1 Receptor (IGF-1R) in Graves' Disease and Graves' Orbitopathy,Anti-insulin-like Growth Factor-1 Receptor (IGF-1R) Antibodies in Graves' Disease and Graves' Orbitopathy,Autoimmune Thyroiditis|Graves Disease|Graves Ophthalmopathy,2018-03-30,2018-07-20,2018-07-20,Observational,Completed,,University of Pisa,University of Pisa,"Endocrinology Unit I, University of Pisa",Diagnostic Test,Italy,18.0,80.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03498417
NCT03515863,graves ophthalmopathy,Natural History and Genetic Risk Factors of Thyroid Associated Ophthalmopathy (TAO),Natural History and Risk Factors of TAO,Thyroid Associated Ophthalmopathy,2018-04-23,2021-05-09,2022-05-09,Observational,Recruiting,,Sun Yat-sen University,Sun Yat-sen University,"Zhognshan Ophthalmic Center, Sun Yat-sen University|the First People's Hospital of Zhaoqing",Genetic|Device|Other,China,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT03515863
NCT03515863,hyperthyroidism,Natural History and Genetic Risk Factors of Thyroid Associated Ophthalmopathy (TAO),Natural History and Risk Factors of TAO,Thyroid Associated Ophthalmopathy,2018-04-23,2021-05-09,2022-05-09,Observational,Recruiting,,Sun Yat-sen University,Sun Yat-sen University,"Zhognshan Ophthalmic Center, Sun Yat-sen University|the First People's Hospital of Zhaoqing",Genetic|Device|Other,China,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03515863
NCT03515863,goiter,Natural History and Genetic Risk Factors of Thyroid Associated Ophthalmopathy (TAO),Natural History and Risk Factors of TAO,Thyroid Associated Ophthalmopathy,2018-04-23,2021-05-09,2022-05-09,Observational,Recruiting,,Sun Yat-sen University,Sun Yat-sen University,"Zhognshan Ophthalmic Center, Sun Yat-sen University|the First People's Hospital of Zhaoqing",Genetic|Device|Other,China,18.0,80.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03515863
NCT03515863,graves disease,Natural History and Genetic Risk Factors of Thyroid Associated Ophthalmopathy (TAO),Natural History and Risk Factors of TAO,Thyroid Associated Ophthalmopathy,2018-04-23,2021-05-09,2022-05-09,Observational,Recruiting,,Sun Yat-sen University,Sun Yat-sen University,"Zhognshan Ophthalmic Center, Sun Yat-sen University|the First People's Hospital of Zhaoqing",Genetic|Device|Other,China,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT03515863
NCT03516747,parathyroid neoplasms,Ultrasound Guided Fine Needle Aspiration of Parathyroid Gland as a Pre Operative Localization Tool to Identify Pathological Parathyroid,Preoperational Fine Needle Aspiration of Pathological Parathyroid Gland,Hypercalcemia|Parathyroid Adenoma,2018-04-03,2020-04-09,2020-08-09,Interventional,Withdrawn,Not Applicable,"HaEmek Medical Center, Israel","HaEmek Medical Center, Israel",Haemek Medical Center,Diagnostic Test|Diagnostic Test|Diagnostic Test|Diagnostic Test,Israel,18.0,99.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03516747
NCT03517267,thyroid neoplasms,Validation of the New Thyroid Imaging Reporting and Data System (TIRADS) From 2017 Risk Assessment of Thyroid Nodules in Comparison to the American Thyroid Association (ATA) Guidelines From 2015,Thyroid Imaging Reporting and Data System (TIRADS ) Versus Thyroid Association (ATA) Guidelines,Thyroid Nodule,2018-03-28,2019-06-30,2019-06-30,Observational [Patient Registry],Unknown status,,Rambam Health Care Campus,Rambam Health Care Campus,Rambam Medical Center,Diagnostic Test,Israel,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03517267
NCT03517579,hyperthyroidism,Personalized Treatment Planning for Radio-iodine Therapy of Thyroid Disease,Personalized Treatment in Thyroid Disorders,Graves Disease|Thyroid Cancer,2018-04-03,2024-10-15,2024-12-15,Interventional,Recruiting,Not Applicable,Johns Hopkins University,Johns Hopkins University,Johns Hopkins Hospital,Device,United States,21.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03517579
NCT03517579,goiter,Personalized Treatment Planning for Radio-iodine Therapy of Thyroid Disease,Personalized Treatment in Thyroid Disorders,Graves Disease|Thyroid Cancer,2018-04-03,2024-10-15,2024-12-15,Interventional,Recruiting,Not Applicable,Johns Hopkins University,Johns Hopkins University,Johns Hopkins Hospital,Device,United States,21.0,65.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03517579
NCT03530462,thyroiditis,The Usage of Neuropsychological Tests and Multi-mode Magnetic Resonance Imaging in Patients With Autoimmune Encephalitis for Cognitive Neural Mechanism,To Explore Cognitive Neural Mechanism of Autoimmune Encephalitis by Using Neuropsychological Tests and Multi-modal MRI,Autoimmune Encephalitis|Cognitive Impairment,2018-03-18,2018-02-28,2018-02-28,Observational,Completed,,First Affiliated Hospital of Zhejiang University,First Affiliated Hospital of Zhejiang University,"The First Affiliated Hospital, Zhejiang University",Drug|Drug|Drug|Drug,China,16.0,60.0,[0-17]|[18-65],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT03530462
NCT03535090,graves disease,High-dose Intravenous Methylprednisolone Therapy in Patients With Graves' Orbitopathy is Associated With the Increased Activity of Factor VIII,Coagulation After Intravenous Methylprednisolone Administration,Blood Coagulation|Graves' Disease|Graves Ophthalmopathy|Venous Thromboembolism,2018-04-29,2014-12-31,2014-12-31,Observational,Completed,,Medical University of Warsaw,Piotr Miskiewicz,,Drug,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT03535090
NCT03535090,goiter,High-dose Intravenous Methylprednisolone Therapy in Patients With Graves' Orbitopathy is Associated With the Increased Activity of Factor VIII,Coagulation After Intravenous Methylprednisolone Administration,Blood Coagulation|Graves' Disease|Graves Ophthalmopathy|Venous Thromboembolism,2018-04-29,2014-12-31,2014-12-31,Observational,Completed,,Medical University of Warsaw,Piotr Miskiewicz,,Drug,,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03535090
NCT03535090,hyperthyroidism,High-dose Intravenous Methylprednisolone Therapy in Patients With Graves' Orbitopathy is Associated With the Increased Activity of Factor VIII,Coagulation After Intravenous Methylprednisolone Administration,Blood Coagulation|Graves' Disease|Graves Ophthalmopathy|Venous Thromboembolism,2018-04-29,2014-12-31,2014-12-31,Observational,Completed,,Medical University of Warsaw,Piotr Miskiewicz,,Drug,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03535090
NCT03535974,thyroid neoplasms,Evaluation of the Efficacy of a Supplement With Spirulina for Amelioration of Benign Thyroid Nodules,Efficacy of a Spirulina Supplement for Amelioration of Benign ThYroid Nodules,Benign Thyroid Nodule,2018-05-02,2018-12-20,2018-12-21,Interventional,Completed,Not Applicable,Fundatia Bio-Forum,Fundatia Bio-Forum,Fundatia Bio-Forum,Dietary Supplement|Dietary Supplement,Romania,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03535974
NCT03535974,thyroid nodule,Evaluation of the Efficacy of a Supplement With Spirulina for Amelioration of Benign Thyroid Nodules,Efficacy of a Spirulina Supplement for Amelioration of Benign ThYroid Nodules,Benign Thyroid Nodule,2018-05-02,2018-12-20,2018-12-21,Interventional,Completed,Not Applicable,Fundatia Bio-Forum,Fundatia Bio-Forum,Fundatia Bio-Forum,Dietary Supplement|Dietary Supplement,Romania,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03535974
NCT03543891,thyroid neoplasms,Correlation Study of Thyroid Cancer and Intestinal Microbiota,Intestinal Microbiota and Thyroid Cancer,Microbiota,2018-05-21,2018-02-28,2018-04-30,Observational,Completed,,First Affiliated Hospital of Harbin Medical University,First Affiliated Hospital of Harbin Medical University,First affiliated hospital of Harbin medical university,Other,China,18.0,65.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03543891
NCT03566537,thyroid nodule,Alterations in Quality of Life After Thyroidectomy for Benign Thyroid Disease,Alterations in Quality of Life After Thyroidectomy for Benign Thyroid Disease,Benign Thyroid Nodule|Quality of Life,2018-06-11,2020-06-11,2021-01-11,Observational [Patient Registry],Completed,,Aristotle University Of Thessaloniki,Aristotle University Of Thessaloniki,Ahepa Hospital,Procedure,Greece,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03566537
NCT03566537,thyroid neoplasms,Alterations in Quality of Life After Thyroidectomy for Benign Thyroid Disease,Alterations in Quality of Life After Thyroidectomy for Benign Thyroid Disease,Benign Thyroid Nodule|Quality of Life,2018-06-11,2020-06-11,2021-01-11,Observational [Patient Registry],Completed,,Aristotle University Of Thessaloniki,Aristotle University Of Thessaloniki,Ahepa Hospital,Procedure,Greece,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03566537
NCT03569787,hypothyroidism,A Retrospective Cohort Study of Hyperprolactinaemia Management in Reproductive Services at University Hospital of Coventry and Warwickshire (UHCW),Hyperprolactinaemia Management in Reproductive Services at University Hospital of Coventry and Warwickshire,Hyperprolactinemia|Subclinical hypothyroïdism|Subfertility,2018-04-30,2017-12-01,2017-12-01,Observational,Completed,,University Hospitals Coventry and Warwickshire NHS Trust,University Hospitals Coventry and Warwickshire NHS Trust,Megan Crowe,Diagnostic Test,United Kingdom,0.0,120.0,[0-17]|[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03569787
NCT03574051,hypothyroidism,Distinct Shifts in the Microbiota Are Associated With Iodine-131 Therapy and Hypothyroidism,the Microbiota Are Associated With Iodine-131 Therapy and Hypothyroidism,Microbiota,2018-06-19,2020-05-01,2022-05-01,Interventional,Recruiting,Early Phase 1,First Affiliated Hospital of Harbin Medical University,First Affiliated Hospital of Harbin Medical University,First affiliated hospital of Harbin medical university,Drug,China,18.0,65.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03574051
NCT03588884,hyperparathyroidism,"An Open-Label, Repeated-Dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of Oral CTAP101 Capsules, Immediate- Release (IR) Calcifediol, High-Dose Cholecalciferol, and Paricalcitol Plus Low-Dose Cholecalciferol in Patients With Secondary Hyperparathyroidism, Stage 3 or 4 Chronic Kidney Disease and Vitamin D Insufficiency","Repeated-dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of CTAP101, Immediate-release Calcifediol, High-dose Cholecalciferol, and Paricalcitol Plus Low-dose Cholecalciferol in Patients With Secondary Hyperparathyroidism, Chronic Kidney Disease 3-4 and Vitamin D Insufficiency",CKD Stage 3|CKD Stage 4|Secondary Hyperparathyroidism Due to Renal Causes|Vitamin D Deficiency,2018-06-28,2020-04-24,2020-04-24,Interventional,Completed,Phase 4,"OPKO Health, Inc.","OPKO Health, Inc.","National Institute of Clinical Research, Inc.|Research by Design, LLC|Spaulding Clinical Research",Drug|Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03588884
NCT03590080,goiter,Blood Pressure Profile and NT-proBNP Dynamics in Response to Intravenous Methylprednisolone Pulse Therapy of Severe Graves' Orbitopathy,Impact of Intravenous Methylprednisolone Treatment on Blood Pressure,Blood Pressure|Graves Disease|Graves Ophthalmopathy|Heart Failure|Hypertension,2018-06-30,2015-12-30,2015-12-30,Observational,Completed,,Medical University of Warsaw,Medical University of Warsaw,,Drug,,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03590080
NCT03590080,hyperthyroidism,Blood Pressure Profile and NT-proBNP Dynamics in Response to Intravenous Methylprednisolone Pulse Therapy of Severe Graves' Orbitopathy,Impact of Intravenous Methylprednisolone Treatment on Blood Pressure,Blood Pressure|Graves Disease|Graves Ophthalmopathy|Heart Failure|Hypertension,2018-06-30,2015-12-30,2015-12-30,Observational,Completed,,Medical University of Warsaw,Medical University of Warsaw,,Drug,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03590080
NCT03602261,hyperparathyroidism,"A Multi-Center, Randomized, Two-Cohort Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of CTAP101 (Calcifediol) Extended-Release Capsules to Treat Secondary Hyperparathyroidism in Subjects With Vitamin D Insufficiency and Chronic Kidney Disease Requiring Regular Hemodialysis.","Safety, Efficacy, PK and PD of CTAP101 (Calcifediol) ER Capsules for SHPT in HD Patients VDI",Chronic Kidney Diseases|Secondary Hyperparathyroidism Due to Renal Causes|Stage 5 Chronic Kidney Disease|Vitamin D Deficiency,2018-07-13,2023-03-31,2023-03-31,Interventional,Active not recruiting,Phase 2,"OPKO Health, Inc.","OPKO Health, Inc.","AKDHC Medical Research Services|AKDHC Medical Research Services|AKDHC Medical Research Services|AKDHC Medical Research Services|WCCT Global, Inc.|Hacienda Dialysis Center|California Institute of Renal Research CKD/Dialysis & Transplant Division|Long Beach Quest Dialysis Center|Ontario Dialysis Center|North America Research Institute, Inc.|Laurel Canyon Dialysis, LLC|University of Colorado Denver Anschutz Medical Campus|Research by Design, LLC|Northshore University Health|Renal and Transplant Associates of New England|Southwest MS Nephrology|Southwest Houston Research LTD|Kidney & Hypertension Specialists",Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03602261
NCT03605472,hyperparathyroidism,Comparison of Cervical Ultrasound and Echoscintigraphy for Preoperative Localization Diagnosis in Primary Hyperparathyroidism,Comparison of Cervical Ultrasound and Echoscintigraphy for Preoperative Localization Diagnosis in Primary Hyperparathyroidism,Primary Hyperparathyroidism,2018-07-20,2019-10-05,2020-03-05,Interventional,Unknown status,Not Applicable,CHU de Reims,CHU de Reims,Damien JOLLY,Other,France,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03605472
NCT03606824,hypothyroidism,Thyroid Hormone Replacement for Subclinical Hypothyroidism and Dyslipidemia in Patients With Atherosclerotic Cardiovascular Diseases (ThyroHeart-Lipid Study),Thyroid Hormone Replacement for Subclinical Hypothyroidism and Dyslipidemia in ASCVD (ThyroHeart-Lipid Study),ASCVD|Dyslipidemia|Statin|Subclinical hypothyroïdism,2018-07-11,2020-02-28,2020-05-31,Interventional,Unknown status,Not Applicable,China National Center for Cardiovascular Diseases,"Beijing Chao Yang Hospital|Beijing Friendship Hospital|Chinese Academy of Medical Sciences, Fuwai Hospital|Peking University Third Hospital|Shaochun.Li|Xuanwu Hospital, Beijing","Fuwai Hospital, China National Center for Cardiovascular Diseases",Drug|Drug,China,18.0,75.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03606824
NCT03614988,hypothyroidism,Comparative Evaluation of Evening Versus Morning Levothyroxine Administration in Treatment of Hypothyroidism in Elderly,Evaluation of Evening Versus Morning Levothyroxine Intake in Elderly,Aging|Interaction Drug Food|Primary Hypothyroidism,2018-07-30,2019-11-30,2020-03-31,Interventional,Unknown status,Not Applicable,Hospital de Clinicas de Porto Alegre,Federal University of Rio Grande do Sul|Hospital de Clinicas de Porto Alegre,Hospital de Clinicas de Porto Alegre,Other|Other,Brazil,60.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03614988
NCT03626246,hyperparathyroidism,Pathogenesis of Compromised Bone Quality and Mechanics in Chronic Kidney Disease,Pathogenesis of Compromised Bone Quality and Mechanics in Chronic Kidney Disease,Chronic Kidney Disease|Chronic Kidney Disease Mineral and Bone Disorder|End Stage Kidney Disease|Renal Osteodystrophy|Secondary Hyperparathyroidism,2018-08-08,2020-02-28,2020-02-28,Observational,Completed,,Columbia University,Columbia University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Columbia/CUMC,Other,United States,40.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03626246
NCT03626948,hyperparathyroidism,SK-1403 Long-term Treatment Study - Long-term Study in Patients With Secondary Hyperparathyroidism Receiving Hemodialysis -,SK-1403 Long-term Treatment Study; Long-term Study in Patients With Secondary Hyperparathyroidism Receiving Hemodialysis,Secondary Hyperparathyroidism,2018-08-08,2020-02-04,2020-02-05,Interventional,Completed,Phase 3,"Sanwa Kagaku Kenkyusho Co., Ltd.","Sanwa Kagaku Kenkyusho Co., Ltd.",Investigational site (there may be other sites in this country),Drug,Japan,20.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03626948
NCT03633708,hyperparathyroidism,"Phase 3, Randomized, Open-label, Controlled, Multiple Dose, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Etelcalcetide in Pediatric Subjects 28 Days to < 18 Years of Age With Secondary Hyperparathyroidism and Chronic Kidney Disease Receiving Maintenance Hemodialysis",A Study of Etelcalcetide in Pediatric Subjects With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis,Chronic Kidney Disease|Secondary Hyperparathyroidism,2018-08-14,2023-01-31,2023-01-31,Interventional,Recruiting,Phase 3,Amgen,Amgen,Childrens Hospital of Los Angeles|Childrens Hospital Colorado|Childrens Mercy Hospital|Mount Sinai Kidney Center - B1 Renal Treatment|Cincinnati Childrens Hospital Medical Center|Cleveland Clinic|The Childrens Hospital at Oklahoma University Medical Center|Childrens Hospital of Philadelphia|Childrens Medical Center Dallas|Primary Childrens Hospital Outpatient Services|Hospital Italiano|Fresenius Escobar|Centro Infantil Del Rinon|Fortis Flt Lt Rajan Dhall Hospital|All India Institute of Medical Sciences|Sir Ganga Ram Hospital|Manipal Hospital|KLES Dr Prabhakar Kore Hospital and Medical Research Centre|NRS Medical College and Hospital|Seoul National University Hospital|Pusan National University Yangsan Hospital|Hospital Raja Perempuan Zainab II|Hospital TuanKu Jaafar|Hospital Wanita Dan Kanak-Kanak Kuala Lumpur|SBHI Pediatrics city clinical hospital of Saint Vladimir|Municipal Children Hospital 1|State Budgetary Healthcare Institution Samara Regional Clinical Hospital na V D Seredavin|National University Hospital|Kaohsiung Veterans General Hospital|National Cheng Kung University Hospital|National Taiwan University Hospital|Linkou Chang Gung Memorial Hospital|Hacettepe Universitesi Tip Fakultesi Ihsan Dogramaci Cocuk Hastanesi|Baskent Universitesi Ankara Hastanesi|Gazi Universitesi Tip Fakultesi|Istanbul Universitesi Cerrahpasa Tip Fakultesi|Ege Universitesi Tip Fakultesi|Erciyes Universitesi Tip Fakultesi Mustafa Eraslan ve Fevzi Mercan Cocuk Hastanesi|National Childrens Specializated Hospital OKHMATDIT,Drug,"Argentina|India|Korea, Republic of|Malaysia|Russian Federation|Singapore|Taiwan|Turkey|Ukraine|United States",0.0,18.0,[0-17]|[18-65],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03633708
NCT03641638,"thyroiditis, autoimmune",Correlation Between Different Levels of Thyroid Peroxidase Antibody and Postpartum Thyroiditis in Early Pregancy,Correlation Between Different Levels of Thyroid Peroxidase Antibody and Postpartum Thyroiditis in Early Pregnancy,Postpartum Thyroiditis,2018-07-08,2020-10-31,2020-12-31,Observational,Unknown status,,China National Nuclear Corporation 416 Hospital,China National Nuclear Corporation 416 Hospital,China National Nuclear corporation 416 Hospital,,China,18.0,35.0,[18-65],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT03641638
NCT03643081,hyperparathyroidism,"Evaluation of the Interest of the Medical Device Called ""Fluobeam"" in the Localization, Visualization of the Parathyroid Glands for Patients With Mild Primary Hyperparathyroidism. A Randomized Controled Prospective Open -Labeled Monocentric Study.","Evaluation of the Interest of the Medical Device Called ""Fluobeam"" in the Localization, Visualization of the Parathyroid Glands for Patients With Mild Primary Hyperparathyroidism",Mild Primary Hyperparathyroidism,2018-08-21,2024-06-30,2024-06-30,Interventional,Recruiting,Not Applicable,Nantes University Hospital,Nantes University Hospital,CHU de Nantes,Device,France,18.0,80.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03643081
NCT03646383,thyroid neoplasms,Study of the Feasibility of Radiofrequency Ablation of Benign Thyroid Nodules by Percutaneous Radiological Approach,Study of the Feasibility of Radiofrequency Ablation of Benign Thyroid Nodules,Benign Thyroid Nodules,2018-03-25,2021-12-31,2021-12-31,Interventional,Recruiting,Not Applicable,"University Hospital, Toulouse","University Hospital, Toulouse","CHU Toulouse, Hôpital Larrey",Procedure,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03646383
NCT03646383,thyroid nodule,Study of the Feasibility of Radiofrequency Ablation of Benign Thyroid Nodules by Percutaneous Radiological Approach,Study of the Feasibility of Radiofrequency Ablation of Benign Thyroid Nodules,Benign Thyroid Nodules,2018-03-25,2021-12-31,2021-12-31,Interventional,Recruiting,Not Applicable,"University Hospital, Toulouse","University Hospital, Toulouse","CHU Toulouse, Hôpital Larrey",Procedure,France,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03646383
NCT03660800,hyperparathyroidism,"An Open-label, Single-Dose, Safety, Tolerability and Pharmacokinetic Study of Oral CTAP101 (Calcifediol) Extended-release Capsules in Japanese and Non-Japanese Healthy Subjects",Pharmacokinetics and Safety Study of CTAP101 Capsules in Japanese and Non-Japanese Healthy Subjects and Non-Japanese Healthy Subjects,Secondary Hyperparathyroidism|Vitamin D Insufficiency,2018-08-23,2018-10-24,2019-01-22,Interventional,Completed,Phase 1,"OPKO Health, Inc.","OPKO Health, Inc.","WCCT Global, Inc.",Drug,United States,18.0,55.0,[18-65],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03660800
NCT03667157,goiter,Influence of Methylprednisolone Pulse Therapy on Liver Function in Patients With Graves' Orbitopathy,Liver Function After Intravenous Methylprednisolone Administration,"Acute Liver Failure|Acute Liver Injury|Acute Liver Injury, Drug Induced|Dysthyroid Ophthalmopathy|Dysthyroid Orbitopathy|Glucocorticoids Toxicity|Graves Disease|Graves Ophthalmopathy|Liver Diseases|Liver Dysfunction|Liver Failure|Liver Injury|Liver Insufficiency|Methylprednisolone Adverse Reaction",2018-09-08,2016-10-30,2016-10-30,Interventional,Completed,Phase 4,Medical University of Warsaw,Medical University of Warsaw,,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03667157
NCT03667157,hyperthyroidism,Influence of Methylprednisolone Pulse Therapy on Liver Function in Patients With Graves' Orbitopathy,Liver Function After Intravenous Methylprednisolone Administration,"Acute Liver Failure|Acute Liver Injury|Acute Liver Injury, Drug Induced|Dysthyroid Ophthalmopathy|Dysthyroid Orbitopathy|Glucocorticoids Toxicity|Graves Disease|Graves Ophthalmopathy|Liver Diseases|Liver Dysfunction|Liver Failure|Liver Injury|Liver Insufficiency|Methylprednisolone Adverse Reaction",2018-09-08,2016-10-30,2016-10-30,Interventional,Completed,Phase 4,Medical University of Warsaw,Medical University of Warsaw,,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03667157
NCT03669432,thyroid neoplasms,Phase II Randomized Controlled Trial Of Postoperative Intensity Modulated Radiotherapy (IMRT) in Locally Advanced Thyroid Cancers.,To Study the Impact of Radiation Treatment After Surgery in Patient With Locally Advanced Thyroid Cancer.,Radiation Toxicity|Thyroid Cancer Stage IV,2018-05-04,2026-07-31,2026-07-31,Interventional,Active not recruiting,Not Applicable,Tata Memorial Hospital,Department of Atomic Energy|Tata Memorial Hospital,Gouri Pantvaidya,Radiation|Procedure,India,18.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03669432
NCT03676647,thyroid neoplasms,Retrospective-Prospective Collection of Thyroid Specimens After FNA,Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules,Thyroid Gland Nodule,2018-09-17,2023-12-31,2023-12-31,Observational,Recruiting,,City of Hope Medical Center,City of Hope Medical Center|National Cancer Institute (NCI),City of Hope Medical Center,Other,United States,19.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03676647
NCT03699098,hypothyroidism,The Incidence and Risk Factors of Radiotherapy Induced Hypothyroidism in Head and Neck Cancer,The Incidence and Risk Factors of Radiotherapy Induced Hypothyroidism in Head and Neck Cancer With Long Term Follow up,Head and Neck Cancer,2018-10-02,2018-06-01,2018-06-05,Interventional,Completed,Not Applicable,Cairo University,Cairo University,"Department of clinical oncology and nuclear medicine, Cairo university",Diagnostic Test,Egypt,18.0,70.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03699098
NCT03700762,thyroid neoplasms,Application of Ultrasonic Gray-scale Ratio in Differentiating Benign From Malignant Thyroid Nodules.,Application of Ultrasonic Gray-scale Ratio in Differentiating Benign From Malignant Thyroid Nodules.,Thyroid Nodule,2018-07-07,2019-10-01,2020-10-01,Observational,Unknown status,,First People's Hospital of Hangzhou,First People's Hospital of Hangzhou,The first people's hospital of Hangzhou,Diagnostic Test,China,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03700762
NCT03708627,hyperthyroidism,The Role of Bimatoprost in Graves' Periorbitopathy,Bimatoprost as a Treatment for Graves' Orbitopathy,Graves Ophthalmopathy,2018-10-13,2022-05-31,2022-06-30,Interventional,Recruiting,Early Phase 1,Johns Hopkins University,Johns Hopkins University,University of Washington,Drug,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03708627
NCT03708627,graves disease,The Role of Bimatoprost in Graves' Periorbitopathy,Bimatoprost as a Treatment for Graves' Orbitopathy,Graves Ophthalmopathy,2018-10-13,2022-05-31,2022-06-30,Interventional,Recruiting,Early Phase 1,Johns Hopkins University,Johns Hopkins University,University of Washington,Drug,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT03708627
NCT03708627,goiter,The Role of Bimatoprost in Graves' Periorbitopathy,Bimatoprost as a Treatment for Graves' Orbitopathy,Graves Ophthalmopathy,2018-10-13,2022-05-31,2022-06-30,Interventional,Recruiting,Early Phase 1,Johns Hopkins University,Johns Hopkins University,University of Washington,Drug,United States,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03708627
NCT03712683,hypothyroidism,Prevalence of Subclinical Hypothyroidism in Women With Unexplained Infertility and the Effect of Thyroxin on Pregnancy Rate,Thyroxin in Subclinical Hypothyroidism,Pregnancy Loss|Sub Clinical Hypothyroidism,2018-10-17,2017-07-01,2017-07-01,Interventional,Completed,Not Applicable,Hawler Medical University,Hawler Medical University,,Drug,,18.0,42.0,[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03712683
NCT03713671,hyperparathyroidism,The Effect of Quadriceps Femoris Muscle Fatigue Protocol on Gait and Balance Parameters Before and After Parathyroidectomy in Patients With Primary Hyperparathyroidism,Gait and Balance Parameters Before and After Parathyroidectomy in Patients With Primary Hyperparathyroidism,Primary Hyperparathyroidism,2018-10-18,2022-01-10,2022-01-30,Interventional,Recruiting,Not Applicable,Recep Tayyip Erdogan University Training and Research Hospital,Ankara Education and Research Hospital|Hacettepe University|Recep Tayyip Erdogan University Training and Research Hospital,Ankara Education and Research Hospital,Diagnostic Test,Turkey,45.0,65.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03713671
NCT03716128,hyperparathyroidism,Diagnosis of Renal Osteodystrophy in Patients With Reduced Renal Function Can 18F-PET Replace Bone Histomorphometry,Diagnosis of Renal Osteodystrophy in Patients With Reduced Renal Function,Renal Osteodystrophy,2018-09-26,2020-10-31,2020-10-31,Observational,Unknown status,,Herlev Hospital,Ditte Hansen|Universiteit Antwerpen|University of Copenhagen,Herlev Hospital,Diagnostic Test,Denmark,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03716128
NCT03718403,pseudopseudohypoparathyroidism,Effect of Theophylline in Pseudohypoparathyroidism,Effect of Theophylline in Pseudohypoparathyroidism,Php1C|PHP Ia|PHP IB,2017-09-08,2030-04-10,2032-04-10,Interventional,Not yet recruiting,Phase 4,Massachusetts General Hospital,Massachusetts General Hospital,,Drug,,5.0,21.0,[0-17]|[18-65],Parathyroid diseases,pseudohypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03718403
NCT03724188,hyperparathyroidism,Impact of Parathyroidectomy on Vascular Calcification and Clinical Outcome in Hemodialysis Patients,Impact of Parathyroidectomy on Vascular Calcification and Clinical Outcome in Hemodialysis Patients,Hyperparathyroidism Tertiary,2018-10-24,2022-12-30,2022-12-30,Observational,Recruiting,,Mansoura General Hospital,Mansoura General Hospital,Faculty of medicine - Mansoura university,Procedure,Egypt,18.0,80.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03724188
NCT03732157,hyperparathyroidism,"Feasibility of Parathyroidectomy With Exploration of 4 Parathyroid Glands in Outpatients, for Treatment of Primary Hyperparathyroidism",Feasibility of Parathyroidectomy With Exploration of 4 Parathyroid Glands in Outpatients,Primary Hyperparathyroidism,2018-09-18,2019-07-31,2019-07-31,Observational,Unknown status,,Assistance Publique - Hôpitaux de Paris,Assistance Publique - Hôpitaux de Paris,,Procedure|Procedure,,19.0,100.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03732157
NCT03732495,thyroid neoplasms,"A Prospective, Multicentre Phase II Study of the Efficacy of Lenvatinib Combined With Denosumab in the Treatment of Patients With Predominant Bone Metastatic Radioiodine Refractory Differentiated Thyroid Carcinomas (LENVOS)",Study of the Efficacy of Lenvatinib Combined With Denosumab in the Treatment of Patients With Predominant Bone Metastatic Radioiodine Refractory Differentiated Thyroid Carcinomas,Thyroid Cancer Metastatic,2018-10-31,2022-12-15,2023-01-15,Interventional,Recruiting,Phase 2,Centre Leon Berard,Centre Leon Berard,CHU Angers|CHRU Besançon|CHU Bordeaux - Hôpital Saint-André|Institut Bergonie|Hospices Civils de Lyon - Groupement Hospitalier Est|Centre Geogres François Leclerc|Centre Léon Bérard|Centre Antoine Lacassagne|APHP Saint Louis|APHP La Pitié Salpétrière|Institut Jean Godinot|Institut du Cancer Strasbourg (ICANS)|Institut Universitaire du Cancer de Toulouse - Oncopole|Institut Gustave Roussy,Drug,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03732495
NCT03753919,"thyroid cancer, papillary","A Phase II Study of Durvalumab (MEDI4736) Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma - The DUTHY Trial","Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial",Metastatic Thyroid Cancer|Metastatic Thyroid Follicular Carcinoma|Metastatic Thyroid Papillary Carcinoma,2018-11-20,2022-07-31,2022-12-31,Interventional,Recruiting,Phase 2,Grupo Espanol de Tumores Neuroendocrinos,Grupo Espanol de Tumores Neuroendocrinos|MFAR,Instituto Catalán de Oncología de Hospitalet|Hospital Provincial de Castellón|Hospital Clínic Barcelona|Hospital Universitari Vall d'Hebron|MD Anderson Cancer Center|Hospital Clínico San Carlos|Hospital Universitario 12 de Octubre|Hospital Universitario HM Sanchinarro|Hospital Universitario La Paz|Hospital Universitario Ramón y Cajal|Hospital General Universitario Morales Meseguer|Hospital Universitario Virgen de la Victoria|Clínica Universidad de Navarra|Instituto Valenciano de Oncología|Complejo Hospitalario Universitario de Vigo (CHUVI),Drug|Drug,Spain,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT03753919
NCT03753919,"adenocarcinoma, follicular","A Phase II Study of Durvalumab (MEDI4736) Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma - The DUTHY Trial","Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial",Metastatic Thyroid Cancer|Metastatic Thyroid Follicular Carcinoma|Metastatic Thyroid Papillary Carcinoma,2018-11-20,2022-07-31,2022-12-31,Interventional,Recruiting,Phase 2,Grupo Espanol de Tumores Neuroendocrinos,Grupo Espanol de Tumores Neuroendocrinos|MFAR,Instituto Catalán de Oncología de Hospitalet|Hospital Provincial de Castellón|Hospital Clínic Barcelona|Hospital Universitari Vall d'Hebron|MD Anderson Cancer Center|Hospital Clínico San Carlos|Hospital Universitario 12 de Octubre|Hospital Universitario HM Sanchinarro|Hospital Universitario La Paz|Hospital Universitario Ramón y Cajal|Hospital General Universitario Morales Meseguer|Hospital Universitario Virgen de la Victoria|Clínica Universidad de Navarra|Instituto Valenciano de Oncología|Complejo Hospitalario Universitario de Vigo (CHUVI),Drug|Drug,Spain,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT03753919
NCT03761290,pseudopseudohypoparathyroidism,Glucose Homeostasis and Beta Cell Function in Pseudohypoparathyroidism,Glucose Homeostasis in Pseudohypoparathyroidism,Albright Hereditary Osteodystrophy|Pseudohypoparathyroidism and Pseudopseudohypoparathyroidism|Pseudohypoparathyroidism Type Ia,2018-11-29,2021-04-30,2021-04-30,Observational,Terminated,,Vanderbilt University Medical Center,Vanderbilt University Medical Center,Vanderbilt University Medical Center,,United States,6.0,50.0,[0-17]|[18-65],Parathyroid diseases,pseudohypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03761290
NCT03764007,hyperparathyroidism,18F-Fluorocholine for the Detection of Parathyroid Adenomas,18F-Fluorocholine for the Detection of Parathyroid Adenomas,"Hyperparathyroidism, Primary",2018-11-30,2021-05-31,2021-05-31,Interventional,Completed,Phase 2/Phase 3,"University of California, San Francisco",Thomas Hope,"University of California, San Francisco",Drug|Procedure,United States,13.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03764007
NCT03764007,parathyroid neoplasms,18F-Fluorocholine for the Detection of Parathyroid Adenomas,18F-Fluorocholine for the Detection of Parathyroid Adenomas,"Hyperparathyroidism, Primary",2018-11-30,2021-05-31,2021-05-31,Interventional,Completed,Phase 2/Phase 3,"University of California, San Francisco",Thomas Hope,"University of California, San Francisco",Drug|Procedure,United States,13.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03764007
NCT03772496,thyroid neoplasms,"A Multicenter, Double-blind, Prospective Cohort Study of Diagnostic Significance of Circulating Tumor Cells in Patients With Thyroid Nodules",Diagnostic Significance of CTCs in Patients With Thyroid Nodules (Circulating Tumor Cells),Diagnoses Disease|Thyroid Nodule,2018-11-23,2019-12-20,2020-02-20,Interventional,Unknown status,Not Applicable,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","Beijing Chao Yang Hospital|Cancer Institute and Hospital, Chinese Academy of Medical Sciences|China-Japan Friendship Hospital|Chinese PLA General Hospital","Cancer Hospital, Chinese Academy of Medical Science",Diagnostic Test|Diagnostic Test,China,18.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03772496
NCT03773120,"adenocarcinoma, follicular",Effectiveness of Intraoperative Neuromonitoring of the External Branch of the Superior Laryngeal Nerve During Thyroid Surgery,Effectiveness of Intraoperative Neuromonitoring of External Branch of Superior Laryngeal Nerve During Thyroid Surgery,"Carcinoma, Papillary, Follicular",2018-04-12,2019-07-23,2019-07-23,Interventional,Terminated,Not Applicable,Seoul National University Hospital,Seoul National University Hospital,Seoul National University Hospital,Device,"Korea, Republic of",18.0,79.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT03773120
NCT03774771,hyperparathyroidism,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter, 6-week Dose-Ranging Study to Assess the Safety, Pharmacokinetics, and Clinical Effects of an Oral Calcimimetic Agent (AMG 073) in Primary Hyperparathyroidism","Safety, Pharmacokinetics, and Clinical Effects of Cinacalcet (AMG 073) in Primary Hyperparathyroidism",Primary Hyperparathyroidism,2018-12-11,1999-12-13,1999-12-13,Interventional,Completed,Phase 2,Amgen,Amgen,,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03774771
NCT03774862,thyroid neoplasms,Clinicopathological Importance of Colorectal Medullary Carcinoma: Retrospective Cohort Study,Clinicopathological Importance of Colorectal Medullary Carcinoma: Retrospective Cohort Study,Colorectal Medullary Carcinoma,2018-09-05,2017-12-31,2018-08-01,Observational,Completed,,"V.K.V. American Hospital, Istanbul","V.K.V. American Hospital, Istanbul",,,,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03774862
NCT03776058,hyperparathyroidism,"A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Safety, Tolerability, and Clinical Effects of Twice-daily Doses of an Oral Calcimimetic Agent (AMG 073) in Subjects With Primary Hyperparathyroidism (HPT)","Safety, Tolerability, and Clinical Effects of Twice-daily Doses of Cinacalcet (AMG 073) in Adults With Primary Hyperparathyroidism (HPT)",Primary Hyperparathyroidism,2018-12-13,2000-12-26,2000-12-26,Interventional,Completed,Phase 2,Amgen,Amgen,,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03776058
NCT03801980,hyperparathyroidism,Phase 3 Study of SK-1403 ; Double-blinded Parallel Group in Patients With Secondary Hyperparathyroidism Receiving Hemodialysis,Phase 3 Study of SK-1403,Secondary Hyperparathyroidism,2019-01-08,2019-12-17,2019-12-21,Interventional,Completed,Phase 3,"Sanwa Kagaku Kenkyusho Co., Ltd.","Sanwa Kagaku Kenkyusho Co., Ltd.",Investigational site (there may be other sites in this country),Drug|Drug,Japan,20.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03801980
NCT03808779,thyroid neoplasms,"A Multicenter, Randomized and Controlled Trial of Radiofrequency Ablation vs. Conventional Surgery as Treatment of Papillary Thyroid Microcarcinoma (PTMC)",A Multicenter Trial of Radiofrequency Ablation vs. Surgery as Treatment of Papillary Thyroid Microcarcinoma.,Papillary Thyroid Microcarcinoma,2019-01-13,2024-02-01,2024-02-01,Interventional,Recruiting,Not Applicable,"Second Affiliated Hospital, School of Medicine, Zhejiang University","Second Affiliated Hospital, School of Medicine, Zhejiang University","General Surgery Department, Tianjin Medical University General Hospital|Department of Ultrasound, Second Affiliated Hospital, School of Medicine, Zhejiang University|Interventional Oncology Centre, State Institution ""Grigoriev Intstitute for Medical Radiology NAMS of Ukraine""",Procedure|Procedure,China|Ukraine,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03808779
NCT03813173,"thyroid cancer, papillary",Central Cervical Dissection for Clinical Node Negative Papillary Thyroid Carcinoma: a Prospective Study,Central Cervical Dissection for Clinical Node Negative Papillary Thyroid Carcinoma,Lymph Node Metastases,2019-01-16,2040-12-31,2040-12-31,Interventional,Not yet recruiting,Not Applicable,Zhejiang University,Zhejiang University,,Procedure,,18.0,80.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT03813173
NCT03813706,"thyroid cancer, papillary",Prospective Study for the Dissection of Lymph Node Posterior to Right Recurrent Laryngeal Nerve for Papillary Thyroid Carcinoma,the Dissection of Lymph Node Posterior to Right Recurrent Laryngeal Nerve for Papillary Thyroid Carcinoma,Lymph Node Metastases,2019-01-16,2040-12-31,2040-12-31,Interventional,Not yet recruiting,Not Applicable,Zhejiang University,Zhejiang University,,Procedure,,18.0,80.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT03813706
NCT03822507,hyperparathyroidism,"A Phase 3, Randomized, Double-Blind, Intra-Subject Dose-Adjustment, Parallel-Group Study of KHK7580 and Cinacalcet Hydrochloride in Subjects With Secondary Hyperparathyroidism Receiving Hemodialysis",Study of KHK7580 in Subjects With Secondary Hyperparathyroidism in Asia,Secondary Hyperparathyroidism,2019-01-29,2021-09-23,2021-09-23,Interventional,Completed,Phase 3,"Kyowa Kirin Co., Ltd.","Kyowa Hakko Kirin China Pharmaceutical Co., LTD.|Kyowa Kirin Co., Ltd.|Kyowa Kirin Korea Co., Ltd.",Research site_29|Research site_34|Research site_25|Research site_22|Research site_23|Research site_30|Research site_28|Research site_32|Research site_33|Research site_24|Research site_26|Research site_27|Research site_31|Research site_11|Research site_21|Research site_13|Research site_15|Research site_12|Research site_18|Research site_14|Research site_17|Research site_19|Research site_20|Research site_16|Research site_2|Research site_3|Research site_5|Research site_9|Research site_4|Research site_7|Research site_10|Research site_1|Research site_6|Research site_8,Drug|Drug,"China|Hong Kong|Korea, Republic of|Taiwan",18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03822507
NCT03830242,"thyroid cancer, papillary","Diagnostic Significance of Single Center, Open and Prospective Evaluation of <Sup>18<Sup>F-FDG PET/CT Dynamic Imaging in Detecting Metastatic Central Lymph Nodes in Patients With Papillary Thyroid Cancer",Diagnostic Significance of FDG PET/CT Dynamic Imaging in Detecting Metastatic Lymph Nodes With Papillary Thyroid Cancer.,Lymph Node Metastases|Positron-Emission Tomography|Thyroid Cancer,2018-12-17,2022-12-31,2022-12-31,Interventional,Recruiting,Not Applicable,"Fifth Affiliated Hospital, Sun Yat-Sen University","Fifth Affiliated Hospital, Sun Yat-Sen University","Fifth Affiliated Hospital, Sun Yat-Sen University",Diagnostic Test|Diagnostic Test,China,18.0,65.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT03830242
NCT03831620,hyperparathyroidism,The Crosstalk Between Calcium-sensing Receptor Signaling and Endocannabinoid System in Primary Hyperparathyroidism,The Crosstalk Between Calcium-sensing Receptor Signaling and Endocannabinoid System in Primary Hyperparathyroidism,Primary Hyperparathyroidism,2019-01-25,2022-07-31,2022-07-31,Observational [Patient Registry],Recruiting,,"University Hospital Inselspital, Berne","University Hospital Inselspital, Berne","Department of visceral surgery and transplant surgery, Berne University Hospital",,Switzerland,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03831620
NCT03835728,thyroiditis,Exploratory Study of Efficacy of Ocrelizumab in Autoimmune Encephalitis,Efficacy of Ocrelizumab in Autoimmune Encephalitis,Autoimmune Encephalitis,2019-02-05,2020-10-02,2020-10-02,Interventional,Terminated,Phase 2,University of Texas Southwestern Medical Center,"Genentech, Inc.|University of Texas Southwestern Medical Center",UT Southwestern Medical Center,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT03835728
NCT03836300,hypoparathyroidism,Piloting an Early Intervention Program for Infants With Rare Neurogenetic Disorders,Parent-Infant Inter(X)Action Intervention (PIXI),Angelman Syndrome|Chromosome 22q11.2 Deletion Syndrome|Down Syndrome|Duchenne Muscular Dystrophy|Dup15Q Syndrome|Fragile X Syndrome|Klinefelter Syndrome|Phelan-McDermid Syndrome|Prader-Willi Syndrome|Rett Syndrome|Smith Magenis Syndrome|Tuberous Sclerosis|Turner Syndrome|Williams Syndrome,2019-02-07,2022-12-01,2022-12-31,Interventional,Enrolling by invitation,Not Applicable,RTI International,"RTI International|University of North Carolina, Chapel Hill",RTI International,Behavioral,United States,0.0,99.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03836300
NCT03845647,thyroid neoplasms,"Significance of Single Center, Open and Prospective Evaluation of Contralateral Central Lymph Node Dissection in Unilateral cN0 Differentiated Thyroid Carcinoma.",Significance of Contralateral Central Lymph Node Dissection in Unilateral cN0 Differentiated Thyroid Carcinoma.,Differentiated Thyroid Carcinoma|Lymph Node Dissection|Lymph Node Metastases,2019-02-17,2020-12-28,2020-12-28,Interventional,Unknown status,Not Applicable,"Fifth Affiliated Hospital, Sun Yat-Sen University","Fifth Affiliated Hospital, Sun Yat-Sen University","Fifth Affiliated Hospital, Sun Yat-Sen University",Procedure,China,18.0,65.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03845647
NCT03866382,thyroid neoplasms,"A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)",Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors,"Bladder Adenocarcinoma|Bladder Clear Cell Adenocarcinoma|Bladder Mixed Adenocarcinoma|Bladder Neuroendocrine Carcinoma|Bladder Small Cell Neuroendocrine Carcinoma|Bladder Squamous Cell Carcinoma|Bladder Urachal Adenocarcinoma|Chromophobe Renal Cell Carcinoma|Collecting Duct Carcinoma|Infiltrating Bladder Lymphoepithelioma-Like Carcinoma|Infiltrating Bladder Urothelial Carcinoma|Infiltrating Bladder Urothelial Carcinoma, Nested Variant|Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant|Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant|Infiltrating Bladder Urothelial Carcinoma With Giant Cells|Kidney Medullary Carcinoma|Large Cell Neuroendocrine Carcinoma|Metastatic Bladder Carcinoma|Metastatic Bladder Large Cell Neuroendocrine Carcinoma|Metastatic Bladder Small Cell Neuroendocrine Carcinoma|Metastatic Bladder Squamous Cell Carcinoma|Metastatic Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant|Metastatic Infiltrating Bladder Urothelial Carcinoma, Lipid-Rich Variant|Metastatic Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant|Metastatic Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant|Metastatic Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant|Metastatic Kidney Medullary Carcinoma|Metastatic Malignant Genitourinary System Neoplasm|Metastatic Penile Carcinoma|Metastatic Prostate Small Cell Neuroendocrine Carcinoma|Metastatic Sarcomatoid Renal Cell Carcinoma|Metastatic Urethral Carcinoma|Papillary Renal Cell Carcinoma|Sarcomatoid Renal Cell Carcinoma|Stage IVA Bladder Cancer AJCC v8|Stage IVA Prostate Cancer AJCC v8|Stage IVB Bladder Cancer AJCC v8|Stage IV Bladder Cancer AJCC v8|Stage IVB Prostate Cancer AJCC v8|Stage IV Penile Cancer AJCC v8|Stage IV Prostate Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v8|Stage IV Urethral Cancer AJCC v8|Testicular Leydig Cell Tumor|Testicular Sertoli Cell Tumor|Urethral Clear Cell Adenocarcinoma",2019-03-06,2023-02-28,2023-02-28,Interventional,Recruiting,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),University of Alabama at Birmingham Cancer Center|Anchorage Associates in Radiation Medicine|Anchorage Radiation Therapy Center|Alaska Breast Care and Surgery LLC|Alaska Oncology and Hematology LLC|Alaska Women's Cancer Care|Anchorage Oncology Centre|Katmai Oncology Group|Providence Alaska Medical Center|Kingman Regional Medical Center|Cancer Center at Saint Joseph's|Mayo Clinic Hospital in Arizona|Mayo Clinic in Arizona|University of Arizona Cancer Center-Orange Grove Campus|Banner University Medical Center - Tucson|University of Arizona Cancer Center-North Campus|Mercy Hospital Fort Smith|CHI Saint Vincent Cancer Center Hot Springs|Mission Hope Medical Oncology - Arroyo Grande|PCR Oncology|Providence Saint Joseph Medical Center/Disney Family Cancer Center|Community Cancer Institute|University Oncology Associates|Epic Care-Dublin|Bay Area Breast Surgeons Inc|Epic Care Partners in Cancer Care|Marin Cancer Care Inc|Los Angeles County-USC Medical Center|USC / Norris Comprehensive Cancer Center|UCLA / Jonsson Comprehensive Cancer Center|Contra Costa Regional Medical Center|USC Norris Oncology/Hematology-Newport Beach|Alta Bates Summit Medical Center - Summit Campus|Bay Area Tumor Institute|Pacific Central Coast Health Center-San Luis Obispo|Mission Hope Medical Oncology - Santa Maria|Epic Care Cyberknife Center|Penrose-Saint Francis Healthcare|Rocky Mountain Cancer Centers-Penrose|Porter Adventist Hospital|Mercy Medical Center|Southwest Oncology PC|Saint Anthony Hospital|Littleton Adventist Hospital|Longmont United Hospital|Rocky Mountain Cancer Centers-Longmont|Parker Adventist Hospital|Saint Mary Corwin Medical Center|MedStar Georgetown University Hospital|Mount Sinai Comprehensive Cancer Center at Aventura|Holy Cross Hospital|Mayo Clinic in Florida|Mount Sinai Medical Center|Orlando Health Cancer Institute|Emory University Hospital Midtown|Emory University Hospital/Winship Cancer Institute|Emory Saint Joseph's Hospital|Emory Johns Creek Hospital|Saint Alphonsus Cancer Care Center-Boise|Saint Luke's Cancer Institute - Boise|Saint Alphonsus Cancer Care Center-Caldwell|Kootenai Health - Coeur d'Alene|Walter Knox Memorial Hospital|Saint Luke's Cancer Institute - Fruitland|Idaho Urologic Institute-Meridian|Saint Luke's Cancer Institute - Meridian|Saint Alphonsus Medical Center-Nampa|Saint Luke's Cancer Institute - Nampa|Kootenai Clinic Cancer Services - Post Falls|Kootenai Cancer Clinic|Saint Luke's Cancer Institute - Twin Falls|Saint Anthony's Health|Rush - Copley Medical Center|Illinois CancerCare-Bloomington|Loyola Center for Health at Burr Ridge|Illinois CancerCare-Canton|Memorial Hospital of Carbondale|SIH Cancer Institute|Illinois CancerCare-Carthage|Northwestern University|Rush University Medical Center|University of Illinois|University of Chicago Comprehensive Cancer Center|Carle on Vermilion|Cancer Care Specialists of Illinois - Decatur|Decatur Memorial Hospital|Illinois CancerCare-Dixon|Carle Physician Group-Effingham|Crossroads Cancer Center|Illinois CancerCare-Eureka|Illinois CancerCare-Galesburg|Western Illinois Cancer Treatment Center|Loyola Medicine Homer Glen|Illinois CancerCare-Kewanee Clinic|Northwestern Medicine Lake Forest Hospital|Illinois CancerCare-Macomb|Carle Physician Group-Mattoon/Charleston|Loyola University Medical Center|Marjorie Weinberg Cancer Center at Loyola-Gottlieb|Good Samaritan Regional Health Center|UC Comprehensive Cancer Center at Silver Cross|Cancer Care Center of O'Fallon|University of Chicago Medicine-Orland Park|Illinois CancerCare-Ottawa Clinic|Illinois CancerCare-Pekin|Illinois CancerCare-Peoria|Methodist Medical Center of Illinois|Illinois CancerCare-Peru|Valley Radiation Oncology|Illinois CancerCare-Princeton|Southern Illinois University School of Medicine|Springfield Clinic|Memorial Medical Center|Southwest Illinois Health Services LLP|Carle Cancer Center|The Carle Foundation Hospital|Illinois CancerCare - Washington|Rush-Copley Healthcare Center|Reid Health|Mary Greeley Medical Center|McFarland Clinic PC - Ames|McFarland Clinic PC-Boone|Medical Oncology and Hematology Associates-West Des Moines|Mercy Cancer Center-West Lakes|Alegent Health Mercy Hospital|Greater Regional Medical Center|Medical Oncology and Hematology Associates-Laurel|Mercy Medical Center - Des Moines|McFarland Clinic PC-Trinity Cancer Center|McFarland Clinic PC-Jefferson|McFarland Clinic PC-Marshalltown|Mercy Medical Center-West Lakes|Cancer Center of Kansas - Chanute|Cancer Center of Kansas - Dodge City|Cancer Center of Kansas - El Dorado|University of Kansas Clinical Research Center|Central Care Cancer Center - Garden City|Central Care Cancer Center - Great Bend|HaysMed University of Kansas Health System|Cancer Center of Kansas-Independence|Cancer Center of Kansas-Kingman|Lawrence Memorial Hospital|Cancer Center of Kansas-Liberal|Cancer Center of Kansas-Manhattan|Cancer Center of Kansas - McPherson|Cancer Center of Kansas - Newton|Olathe Health Cancer Center|Cancer Center of Kansas - Parsons|Ascension Via Christi - Pittsburg|Cancer Center of Kansas - Pratt|Cancer Center of Kansas - Salina|Salina Regional Health Center|University of Kansas Health System Saint Francis Campus|Cancer Center of Kansas - Wellington|University of Kansas Hospital-Westwood Cancer Center|Cancer Center of Kansas-Wichita Medical Arts Tower|Ascension Via Christi Hospitals Wichita|Cancer Center of Kansas - Wichita|Cancer Center of Kansas - Winfield|Flaget Memorial Hospital|Commonwealth Cancer Center-Corbin|Saint Joseph Radiation Oncology Resource Center|Saint Joseph Hospital East|University of Kentucky/Markey Cancer Center|Saint Joseph London|Jewish Hospital|Saints Mary and Elizabeth Hospital|UofL Health Medical Center Northeast|Jewish Hospital Medical Center South|Hematology/Oncology Clinic PLLC|Ochsner High Grove|Ochsner Medical Center Kenner|East Jefferson General Hospital|LSU Healthcare Network / Metairie Multi-Specialty Clinic|Louisiana State University Health Science Center|Tulane University Health Sciences Center|Ochsner Medical Center Jefferson|Greater Baltimore Medical Center|National Institutes of Health Clinical Center|Lahey Hospital and Medical Center|Lahey Medical Center-Peabody|Mercy Medical Center|Winchester Hospital|Saint Joseph Mercy Hospital|IHA Hematology Oncology Consultants-Brighton|Saint Joseph Mercy Brighton|Henry Ford Cancer Institute-Downriver|IHA Hematology Oncology Consultants-Canton|Saint Joseph Mercy Canton|Caro Cancer Center|IHA Hematology Oncology Consultants-Chelsea|Saint Joseph Mercy Chelsea|Hematology Oncology Consultants-Clarkston|Newland Medical Associates-Clarkston|Henry Ford Macomb Hospital-Clinton Township|Henry Ford Medical Center-Fairlane|Henry Ford Hospital|Ascension Saint John Hospital|Great Lakes Cancer Management Specialists-Doctors Park|Genesee Cancer and Blood Disease Treatment Center|Genesee Hematology Oncology PC|Genesys Hurley Cancer Institute|Hurley Medical Center|Academic Hematology Oncology Specialists|Great Lakes Cancer Management Specialists-Van Elslander Cancer Center|Michigan Breast Specialists-Grosse Pointe Woods|Allegiance Health|Sparrow Hospital|Hope Cancer Clinic|Saint Mary Mercy Hospital|Great Lakes Cancer Management Specialists-Macomb Medical Campus|Michigan Breast Specialists-Macomb Township|Saint Mary's Oncology/Hematology Associates of Marlette|Henry Ford Medical Center-Columbus|21st Century Oncology-Pontiac|Hope Cancer Center|Newland Medical Associates-Pontiac|Saint Joseph Mercy Oakland|Huron Medical Center PC|Lake Huron Medical Center|Great Lakes Cancer Management Specialists-Rochester Hills|Ascension Saint Mary's Hospital|Oncology Hematology Associates of Saginaw Valley PC|Henry Ford Macomb Health Center - Shelby Township|Bhadresh Nayak MD PC-Sterling Heights|Ascension Saint Joseph Hospital|Advanced Breast Care Center PLLC|Great Lakes Cancer Management Specialists-Macomb Professional Building|Macomb Hematology Oncology PC|Michigan Breast Specialists-Warren|Saint John Macomb-Oakland Hospital|Henry Ford West Bloomfield Hospital|Saint Mary's Oncology/Hematology Associates of West Branch|Huron Gastroenterology PC|IHA Hematology Oncology Consultants-Ann Arbor|Riverwood Healthcare Center|Essentia Health Saint Joseph's Medical Center|Fairview Ridges Hospital|Minnesota Oncology - Burnsville|Cambridge Medical Center|Mercy Hospital|Essentia Health - Deer River Clinic|Essentia Health Saint Mary's - Detroit Lakes Clinic|Essentia Health Cancer Center|Essentia Health Saint Mary's Medical Center|Miller-Dwan Hospital|Fairview Southdale Hospital|Lake Region Healthcare Corporation-Cancer Care|Essentia Health - Fosston|Unity Hospital|Essentia Health Hibbing Clinic|Fairview Clinics and Surgery Center Maple Grove|Minnesota Oncology Hematology PA-Maplewood|Saint John's Hospital - Healtheast|Abbott-Northwestern Hospital|Hennepin County Medical Center|Health Partners Inc|Monticello Cancer Center|New Ulm Medical Center|Essentia Health - Park Rapids|Fairview Northland Medical Center|North Memorial Medical Health Center|Mayo Clinic in Rochester|Park Nicollet Clinic - Saint Louis Park|Regions Hospital|United Hospital|Essentia Health Sandstone|Saint Francis Regional Medical Center|Lakeview Hospital|Essentia Health Virginia Clinic|Ridgeview Medical Center|Rice Memorial Hospital|Minnesota Oncology Hematology PA-Woodbury|Fairview Lakes Medical Center|University of Mississippi Medical Center|Saint Louis Cancer and Breast Institute-Ballwin|Central Care Cancer Center - Bolivar|Parkland Health Center-Bonne Terre|Cox Cancer Center Branson|Saint Francis Medical Center|Southeast Cancer Center|Siteman Cancer Center at West County Hospital|Parkland Health Center - Farmington|Capital Region Southwest Campus|Freeman Health System|Mercy Hospital Joplin|Truman Medical Centers|University of Kansas Cancer Center - Lee's Summit|Delbert Day Cancer Institute at PCRMC|Mercy Clinic-Rolla-Cancer and Hematology|Heartland Regional Medical Center|Saint Louis Cancer and Breast Institute-South City|Washington University School of Medicine|Mercy Hospital South|Siteman Cancer Center-South County|Missouri Baptist Medical Center|Siteman Cancer Center at Christian Hospital|Mercy Hospital Saint Louis|Siteman Cancer Center at Saint Peters Hospital|Sainte Genevieve County Memorial Hospital|Mercy Hospital Springfield|CoxHealth South Hospital|Missouri Baptist Sullivan Hospital|Missouri Baptist Outpatient Center-Sunset Hills|Mercy Hospital Washington|Community Hospital of Anaconda|Billings Clinic Cancer Center|Bozeman Deaconess Hospital|Benefis Healthcare- Sletten Cancer Institute|Great Falls Clinic|Saint Peter's Community Hospital|Kalispell Regional Medical Center|Saint Patrick Hospital - Community Hospital|Community Medical Hospital|Nebraska Medicine-Bellevue|CHI Health Saint Francis|CHI Health Good Samaritan|Saint Elizabeth Regional Medical Center|Nebraska Methodist Hospital|Nebraska Medicine-Village Pointe|Alegent Health Immanuel Medical Center|Alegent Health Bergan Mercy Medical Center|Alegent Health Lakeside Hospital|Creighton University Medical Center|University of Nebraska Medical Center|Midlands Community Hospital|Carson Tahoe Regional Medical Center|Cancer and Blood Specialists-Henderson|Comprehensive Cancer Centers of Nevada - Henderson|Comprehensive Cancer Centers of Nevada-Horizon Ridge|Las Vegas Cancer Center-Henderson|OptumCare Cancer Care at Seven Hills|Comprehensive Cancer Centers of Nevada-Southeast Henderson|GenesisCare USA - Henderson|Las Vegas Urology - Green Valley|Las Vegas Urology - Pebble|Urology Specialists of Nevada - Green Valley|Las Vegas Urology - Pecos|Desert West Surgery|OptumCare Cancer Care at Charleston|University Medical Center of Southern Nevada|Hope Cancer Care of Nevada|Cancer and Blood Specialists-Shadow|Radiation Oncology Centers of Nevada Central|Urology Specialists of Nevada - Central|GenesisCare USA - Las Vegas|HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway|Sunrise Hospital and Medical Center|HealthCare Partners Medical Group Oncology/Hematology-San Martin|Las Vegas Prostate Cancer Center|Las Vegas Urology - Sunset|Urology Specialists of Nevada - Southwest|Radiation Oncology Centers of Nevada Southeast|Ann M Wierman MD LTD|Cancer and Blood Specialists-Tenaya|Comprehensive Cancer Centers of Nevada - Northwest|GenesisCare USA - Vegas Tenaya|HealthCare Partners Medical Group Oncology/Hematology-Tenaya|Las Vegas Urology - Cathedral Rock|Las Vegas Urology - Smoke Ranch|OptumCare Cancer Care at MountainView|Urology Specialists of Nevada - Northwest|Alliance for Childhood Diseases/Cure 4 the Kids Foundation|Comprehensive Cancer Centers of Nevada - Town Center|Comprehensive Cancer Centers of Nevada-Summerlin|Summerlin Hospital Medical Center|Las Vegas Cancer Center-Medical Center|Comprehensive Cancer Centers of Nevada|GenesisCare USA - Fort Apache|OptumCare Cancer Care at Fort Apache|HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills|Comprehensive Cancer Centers of Nevada - Central Valley|University Cancer Center|Hope Cancer Care of Nevada-Pahrump|Renown Regional Medical Center|Saint Mary's Regional Medical Center|Radiation Oncology Associates|Memorial Sloan Kettering Basking Ridge|Memorial Sloan Kettering Monmouth|Memorial Sloan Kettering Bergen|New York-Presbyterian/Brooklyn Methodist Hospital|Maimonides Medical Center|Roswell Park Cancer Institute|Memorial Sloan Kettering Commack|Memorial Sloan Kettering Westchester|Northwell Health/Center for Advanced Medicine|NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center|Memorial Sloan Kettering Cancer Center|NYP/Weill Cornell Medical Center|University of Rochester|State University of New York Upstate Medical University|Memorial Sloan Kettering Nassau|UNC Lineberger Comprehensive Cancer Center|Margaret R Pardee Memorial Hospital|Essentia Health Cancer Center-South University Clinic|Essentia Health - Jamestown Clinic|Indu and Raj Soin Medical Center|Strecker Cancer Center-Belpre|Saint Elizabeth Boardman Hospital|Dayton Physicians LLC-Miami Valley South|Miami Valley Hospital South|Adena Regional Medical Center|University of Cincinnati Cancer Center-UC Medical Center|Good Samaritan Hospital - Cincinnati|Oncology Hematology Care Inc-Kenwood|Bethesda North Hospital|TriHealth Cancer Institute-Westside|TriHealth Cancer Institute-Anderson|Ohio State University Comprehensive Cancer Center|Mount Carmel East Hospital|Columbus Oncology and Hematology Associates Inc|Riverside Methodist Hospital|Grant Medical Center|The Mark H Zangmeister Center|Mount Carmel Health Center West|Doctors Hospital|Good Samaritan Hospital - Dayton|Miami Valley Hospital|Dayton Physician LLC-Miami Valley Hospital North|Miami Valley Hospital North|Delaware Health Center-Grady Cancer Center|Grady Memorial Hospital|Dublin Methodist Hospital|Armes Family Cancer Center|Blanchard Valley Hospital|Orion Cancer Care|Atrium Medical Center-Middletown Regional Hospital|Dayton Physicians LLC-Atrium|Central Ohio Breast and Endocrine Surgery|Dayton Physicians LLC-Wayne|Wayne Hospital|Mount Carmel Grove City Hospital|Greater Dayton Cancer Center|First Dayton Cancer Care|Kettering Medical Center|Fairfield Medical Center|Saint Rita's Medical Center|OhioHealth Mansfield Hospital|Marietta Memorial Hospital|OhioHealth Marion General Hospital|Knox Community Hospital|Licking Memorial Hospital|Newark Radiation Oncology|Mercy Health Perrysburg Cancer Center|Southern Ohio Medical Center|Springfield Regional Cancer Center|Springfield Regional Medical Center|Saint Vincent Mercy Medical Center|Mercy Health - Saint Anne Hospital|Dayton Physicians LLC-Upper Valley|Upper Valley Medical Center|Saint Joseph Warren Hospital|University of Cincinnati Cancer Center-West Chester|Saint Ann's Hospital|Saint Elizabeth Youngstown Hospital|Genesis Healthcare System Cancer Care Center|Cancer Centers of Southwest Oklahoma Research|University of Oklahoma Health Sciences Center|Mercy Hospital Oklahoma City|Oklahoma Cancer Specialists and Research Institute-Tulsa|Saint Alphonsus Medical Center-Baker City|Saint Charles Health System|Clackamas Radiation Oncology Center|Providence Cancer Institute Clackamas Clinic|Bay Area Hospital|Providence Newberg Medical Center|Saint Alphonsus Medical Center-Ontario|Providence Portland Medical Center|Providence Saint Vincent Medical Center|Oregon Health and Science University|Saint Charles Health System-Redmond|Lehigh Valley Hospital-Cedar Crest|Lehigh Valley Hospital - Muhlenberg|Pocono Medical Center|UPMC Hillman Cancer Center Erie|Saint Vincent Hospital|UPMC Cancer Centers - Arnold Palmer Pavilion|Lehigh Valley Hospital-Hazleton|Jefferson Hospital|Forbes Hospital|UPMC Cancer Center - Monroeville|UPMC Hillman Cancer Center - Monroeville|Arnold Palmer Cancer Center Medical Oncology Norwin|Allegheny Valley Hospital|Allegheny General Hospital|West Penn Hospital|University of Pittsburgh Cancer Institute (UPCI)|UPMC-Shadyside Hospital|UPMC-Passavant Hospital|UPMC-Saint Clair Hospital Cancer Center|Wexford Health and Wellness Pavilion|Medical University of South Carolina|Vanderbilt-Ingram Cancer Center Cool Springs|Vanderbilt Breast Center at One Hundred Oaks|Vanderbilt University/Ingram Cancer Center|Saint Joseph Regional Cancer Center|UT Southwestern/Simmons Cancer Center-Dallas|UT Southwestern/Simmons Cancer Center-Fort Worth|UT Southwestern Clinical Center at Richardson/Plano|Providence Regional Cancer System-Aberdeen|Overlake Medical Center|PeaceHealth Saint Joseph Medical Center|Harrison HealthPartners Hematology and Oncology-Bremerton|Harrison Medical Center|Highline Medical Center-Main Campus|Providence Regional Cancer System-Centralia|Swedish Cancer Institute-Edmonds|Saint Elizabeth Hospital|Providence Regional Cancer Partnership|Saint Francis Hospital|Swedish Cancer Institute-Issaquah|Kadlec Clinic Hematology and Oncology|Providence Regional Cancer System-Lacey|Saint Clare Hospital|PeaceHealth Saint John Medical Center|Harrison HealthPartners Hematology and Oncology-Poulsbo|Valley Medical Center|Pacific Gynecology Specialists|Swedish Medical Center-Ballard Campus|Swedish Medical Center-First Hill|Swedish Medical Center-Cherry Hill|PeaceHealth United General Medical Center|Providence Regional Cancer System-Shelton|Franciscan Research Center-Northwest Medical Plaza|Northwest Medical Specialties PLLC|PeaceHealth Southwest Medical Center|Providence Saint Mary Regional Cancer Center|North Star Lodge Cancer Center at Yakima Valley Memorial Hospital|Providence Regional Cancer System-Yelm|Duluth Clinic Ashland|Northwest Wisconsin Cancer Center|Aurora Cancer Care-Southern Lakes VLCC|Aurora Saint Luke's South Shore|Marshfield Medical Center-EC Cancer Center|Mayo Clinic Health System-Eau Claire Clinic|Aurora Health Care Germantown Health Center|Aurora Cancer Care-Grafton|Aurora BayCare Medical Center|Aurora Cancer Care-Kenosha South|Aurora Bay Area Medical Group-Marinette|Marshfield Medical Center-Marshfield|Aurora Cancer Care-Milwaukee|Aurora Saint Luke's Medical Center|Aurora Sinai Medical Center|Marshfield Clinic-Minocqua Center|ProHealth D N Greenwald Center|Cancer Center of Western Wisconsin|ProHealth Oconomowoc Memorial Hospital|Vince Lombardi Cancer Clinic - Oshkosh|Aurora Cancer Care-Racine|Marshfield Medical Center-Rice Lake|Vince Lombardi Cancer Clinic-Sheboygan|Marshfield Clinic Stevens Point Center|Aurora Medical Center in Summit|Vince Lombardi Cancer Clinic-Two Rivers|ProHealth Waukesha Memorial Hospital|UW Cancer Center at ProHealth Care|Aurora Cancer Care-Milwaukee West|Aurora West Allis Medical Center|Marshfield Medical Center - Weston|Billings Clinic-Cody|Welch Cancer Center|Pan American Center for Oncology Trials LLC,Drug|Biological|Biological,Puerto Rico|United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03866382
NCT03872284,hashimoto disease,Study of Neuro-ophthalmology Disorders in Autoimmune Encephalitis (NODE),Neuro-ophthalmology and Autoimmune Encephalitis (NODE),Autoimmune Encephalitis,2019-03-11,2027-01-24,2027-01-24,Observational,Recruiting,,Hospices Civils de Lyon,Hospices Civils de Lyon,Hospices Civils de Lyon,Other,France,18.0,70.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT03872284
NCT03878953,hypoparathyroidism,"A Phase 3, Open-label Clinical Study of rhPTH(1-84) Treatment in Japanese Subjects With Chronic Hypoparathyroidism",A Clinical Study of rhPTH(1-84) Treatment in Japanese Participants With Chronic Hypoparathyroidism,Chronic Hypoparathyroidism,2019-03-15,2023-05-31,2023-05-31,Interventional,Not yet recruiting,Phase 3,Takeda,Shire,Fujita Health University Hospital|University of Occupational and Environmental Health Japan|Osaka City University Hospital|Shimane University Hospital|Tokushima University Hospital|University of Tokyo Hospital|The Cancer Institute Hospital of JFCR|Toranomon Hospital|Keio University Hospital|Tokyo Women's Medical University Hospital,Drug,Japan,20.0,85.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03878953
NCT03880578,hypothyroidism,Influence of Radioiodine Treatment on Thyroid Function and Quality of Life of Patients,Quality of Life After Interventional Thyroid Treatment,Quality of Life|Thyroid; Deficiency,2019-03-14,2022-03-15,2022-03-15,Observational,Completed,,Klinikum Lüdenscheid,Klinikum Lüdenscheid,Department of Nuclear Medicine Klinikum Luedenscheid,Drug,Germany,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03880578
NCT03884140,thyroid neoplasms,Clinical Diagnostic Evaluation of Thyroid Nodules,Clinical Diagnostic Approach for Cases of Thyroid Nodules,Thyroid Nodule,2019-03-19,2022-06-01,2022-09-01,Observational [Patient Registry],Not yet recruiting,,Assiut University,Assiut University,,,,18.0,75.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03884140
NCT03887611,thyroid neoplasms,A Multi-center Study of Differential Diagnosis Thyroid Nodules by Ultrasound Artificial Intelligence and Ultrasound Elastography,Application of Ultrasound Artificial Intelligence and Elastography in Differential Diagnosis of Thyroid Nodules,Thyroid Nodule,2019-03-21,2020-01-18,2020-03-18,Observational,Unknown status,,Tongji Hospital,"Affiliated Hospital of Jiangsu University|Anqing People's Hospital|Enshi State Central Hospital|Huai'an First People's Hospital|Huainan People's Hospital|Huangshi Central Hospital, China|Jiangxia District First People's Hospital|Lianyungang Third People's Hospital|Macheng People's Hospital|Taizhou Hospital|The Central Hospital of Lishui City|The First People's Hospital of Yichang|The Second Hospital of Anhui Medical University|The Second People's Hospital of Yichang|Wenzhou Central Hospital|WISCO General Hospital|Wuhan Hospital of Traditional Chinese and Western Medicine|Xiangyang Central Hospital|Xiangyang First People's Hospital|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|Xin-Wu Cui|Xuzhou First People's Hospital",Xin-Wu Cui,Device,China,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03887611
NCT03889431,goiter,Community Salt Testing and Relation of Iodine Intake to Visual Information Processing of Ethiopian Infants,Community Salt Testing and Relation of Iodine Intake to Visual Information Processing of Ethiopian Infants,Infant Development|Iodine Deficiency Goiter,2019-03-20,2013-01-30,2013-08-10,Interventional,Completed,Not Applicable,Oklahoma State University,Oklahoma State University,Hawassa University,Dietary Supplement|Other,Ethiopia,18.0,45.0,[18-65],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03889431
NCT03891043,goiter,Oral Supplementation With Selenium in Patients With Mild Thyroid Orbitopathy to Reduce Its,Oral Supplementation With Selenium in Patients With Mild Thyroid Orbitopathy,Thyroid Orbitopathy,2019-03-15,2016-04-30,2016-04-30,Interventional,Completed,Not Applicable,Instituto de Oftalmología Fundación Conde de Valenciana,Instituto de Oftalmología Fundación Conde de Valenciana,,Dietary Supplement|Other,,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03891043
NCT03891043,hyperthyroidism,Oral Supplementation With Selenium in Patients With Mild Thyroid Orbitopathy to Reduce Its,Oral Supplementation With Selenium in Patients With Mild Thyroid Orbitopathy,Thyroid Orbitopathy,2019-03-15,2016-04-30,2016-04-30,Interventional,Completed,Not Applicable,Instituto de Oftalmología Fundación Conde de Valenciana,Instituto de Oftalmología Fundación Conde de Valenciana,,Dietary Supplement|Other,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03891043
NCT03891043,graves disease,Oral Supplementation With Selenium in Patients With Mild Thyroid Orbitopathy to Reduce Its,Oral Supplementation With Selenium in Patients With Mild Thyroid Orbitopathy,Thyroid Orbitopathy,2019-03-15,2016-04-30,2016-04-30,Interventional,Completed,Not Applicable,Instituto de Oftalmología Fundación Conde de Valenciana,Instituto de Oftalmología Fundación Conde de Valenciana,,Dietary Supplement|Other,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT03891043
NCT03896958,"thyroid carcinoma, anaplastic",The PIONEER Initiative: Precision Insights On N-of-1 Effectiveness Research. Tissue Ownership by the Individual With the Return of Actionable Information to the Individual Patient and Physician (Precision Oncology),The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology),"Adenocarcinoma Lung|Adrenal Cancer|Breast Cancer|Bronchoalveolar Cell Lung Cancer|Cancer, Advanced|Cancer, All Types|Cancer, Anal|Cancer, Anaplastic Thyroid|Cancer, Bile Duct|Cancer, Bladder|Cancer Cords Vocal|Cancer Differentiated Poorly|Cancer, Metastatic|Cancer of Brain and Nervous System|Cancer of Cervix|Cancer of Colon|Cancer of Esophagus|Cancer of Head and Neck|Cancer of Kidney|Cancer of Larynx|Cancer of Liver|Cancer of Lung|Cancer of Neck|Cancer of Pancreas|Cancer of Prostate|Cancer of Rectum|Cancer of Stomach|Cancer of Vulva, Disseminated|Cancer, Other|Cancers Cell Neuroendocrine|Cancer Skin|Cancer Unknown Primary|Cholangiocarcinoma|GIST|Glioblastoma Multiforme|Hepatocellular Carcinoma|Melanoma|Oligodendroglioma|Renal Cell Carcinoma|Sarcoma|Small-cell Lung Cancer|Squamous Cell Carcinoma|Testicular Cancer|Transitional Cell Carcinoma|Uterine Cancer",2019-03-26,2024-03-12,2024-03-12,Observational,Recruiting,,SpeciCare,Georgia Institute of Technology|Netnoids|Northeast Georgia Hospital System|Predictive Oncology|SpeciCare|University of Washington,Specicare,,United States,1.0,99.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT03896958
NCT03898622,hypothyroidism,"Supplementation of Thyroid Hormone for TSH Control in Patients With Chronic Kidney Disease Without Renal Replacement Therapy: Randomized, Double-blind Clinical Trial at Guadalajara Civil Hospital.",Supplementation of Thyroid Hormone for TSH Control in Patients With Chronic Kidney Disease Without TRR.,Chronic Kidney Diseases|Subclinical Hypothyroidism,2018-08-28,2019-01-31,2019-03-01,Interventional,Completed,Phase 3,Hospital Civil de Guadalajara,Hospital Civil de Guadalajara,"Kidney health clinic, Civil Hospital of Guadalajara",Drug,Mexico,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03898622
NCT03910049,hypoparathyroidism,Does Indocyanine Imaging Scoring Predicts Postoperative PTH Levels at 24 Hours After Total Thyroidectomy,Does Indocyanine Imaging Scoring Predicts Postoperative Parathormone Levels at 24 Hours After Total Thyroidectomy,Parathyroid; Deficiency|Thyroid,2019-02-19,2019-04-26,2019-04-26,Observational,Completed,,Aristotle University Of Thessaloniki,Aristotle University Of Thessaloniki,"Unit of Endocrine Surgery, Interbalkan Medical Center, Thessaloniki, Greece|1st Propedeutic Department of Surgery, AHEPA University General Hospital, Aristotle University of Thessaloniki",Drug,Greece,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03910049
NCT03922321,graves disease,"A Phase 2a, Multicenter, Open-Label Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy",Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy (GO),Graves' Ophthalmopathy,2019-04-17,2020-02-29,2020-05-21,Interventional,Completed,Phase 2,Immunovant Sciences GmbH,Immunovant Sciences GmbH,"UBC/VGH Eye Care Center|Toronto Retina Institute|University of Ottwa Eye Institute|CIUSSS de I'Est-de-I'lle-de-Montreal, Installation Maisonneuve- Rosemont",Drug,Canada,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT03922321
NCT03922321,goiter,"A Phase 2a, Multicenter, Open-Label Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy",Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy (GO),Graves' Ophthalmopathy,2019-04-17,2020-02-29,2020-05-21,Interventional,Completed,Phase 2,Immunovant Sciences GmbH,Immunovant Sciences GmbH,"UBC/VGH Eye Care Center|Toronto Retina Institute|University of Ottwa Eye Institute|CIUSSS de I'Est-de-I'lle-de-Montreal, Installation Maisonneuve- Rosemont",Drug,Canada,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03922321
NCT03922321,hyperthyroidism,"A Phase 2a, Multicenter, Open-Label Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy",Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy (GO),Graves' Ophthalmopathy,2019-04-17,2020-02-29,2020-05-21,Interventional,Completed,Phase 2,Immunovant Sciences GmbH,Immunovant Sciences GmbH,"UBC/VGH Eye Care Center|Toronto Retina Institute|University of Ottwa Eye Institute|CIUSSS de I'Est-de-I'lle-de-Montreal, Installation Maisonneuve- Rosemont",Drug,Canada,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03922321
NCT03922321,graves ophthalmopathy,"A Phase 2a, Multicenter, Open-Label Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy",Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy (GO),Graves' Ophthalmopathy,2019-04-17,2020-02-29,2020-05-21,Interventional,Completed,Phase 2,Immunovant Sciences GmbH,Immunovant Sciences GmbH,"UBC/VGH Eye Care Center|Toronto Retina Institute|University of Ottwa Eye Institute|CIUSSS de I'Est-de-I'lle-de-Montreal, Installation Maisonneuve- Rosemont",Drug,Canada,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT03922321
NCT03924804,thyroid neoplasms,Effect of Different Infusion Volume on Perioperative Bladder and Blood Volume in Patients Undergoing Daytime Surgery.,Effect of Different Infusion Volume on Perioperative Bladder and Blood Volume in Patients Undergoing Daytime Surgery.,Cholecystolithiasis and Thyroid Nodule,2019-04-18,2022-08-30,2022-09-30,Interventional,Recruiting,Not Applicable,"China Medical University, China","China Medical University, China",the First Hospital of China Medical University,Drug|Drug|Drug,China,18.0,65.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03924804
NCT03924804,thyroid nodule,Effect of Different Infusion Volume on Perioperative Bladder and Blood Volume in Patients Undergoing Daytime Surgery.,Effect of Different Infusion Volume on Perioperative Bladder and Blood Volume in Patients Undergoing Daytime Surgery.,Cholecystolithiasis and Thyroid Nodule,2019-04-18,2022-08-30,2022-09-30,Interventional,Recruiting,Not Applicable,"China Medical University, China","China Medical University, China",the First Hospital of China Medical University,Drug|Drug|Drug,China,18.0,65.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03924804
NCT03931109,hyperparathyroidism,Circulating microRNA Signatures in Primary Hyperparathyroidism,Circulating miRNA in Primary Hyperparathyroidism,"Osteoporosis, Postmenopausal|Primary Hyperparathyroidism",2019-04-15,2022-04-30,2022-04-30,Observational [Patient Registry],Active not recruiting,,University of Pennsylvania,University of Pennsylvania,Perelman Center for Advanced Medicine/ Hospital of the University of Pennsylvania,,United States,50.0,100.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03931109
NCT03935984,hyperparathyroidism,Improving the Sensitivity of Sestamibi SPECT-CT Parathyroid Scan With Calcitonin Pre-treatment for Primary Hyperparathyroidism,Calcitonin Pre-treatment to Improve SPECT-CT Sensitivity,Hypercalcemia|Primary Hyperparathyroidism,2019-04-30,2021-04-01,2021-10-01,Interventional,Unknown status,Phase 4,ProMedica Health System,ProMedica Health System|University of Toledo Health Science Campus,ProMedica Toledo Hospital,Drug,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03935984
NCT03937349,hyperparathyroidism,Impact of Parathyroidectomy on Cardiovascular Calcification in Dialysis-dependent Patients: a Prospective Cohort Study,Impact of Parathyroidectomy on Cardiovascular Calcification in Dialysis-dependent Patients,Chronic Kidney Disease Mineral and Bone Disorder|Dialysis|Secondary Hyperparathyroidism|Vascular Calcification,2019-05-01,2022-12-31,2022-12-31,Observational,Recruiting,,"Saint Petersburg State University, Russia","Saint Petersburg State University, Russia","Saint-Petersburg State University, Clinic of advanced medical technologies n.a. N.I.Pirogov",,Russian Federation,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03937349
NCT03938545,goiter,"ASCEND GO-2: A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled Study of RVT-1401 for the Treatment of Patients With Active, Moderate to Severe Graves' Ophthalmopathy","ASCEND GO-2: Study of RVT-1401 for the Treatment of Patients With Active, Moderate to Severe Graves' Ophthalmopathy ( GO )",Graves' Ophthalmopathy (GO),2019-05-01,2021-02-02,2021-04-15,Interventional,Terminated,Phase 2,Immunovant Sciences GmbH,Immunovant Sciences GmbH,"Multispecialty Aesthetic Clinical Research Organziation (MACRO)|Doheny Eye Center UCLA|University of Miami Miller School of Medicine Bascom Palmer Eye Institute|University of Iowa Hospitals & Clinics - Eye Clinic|University of Michigan - Kellogg Eye Center|Mayo Clinic|Washington University School of Medicine - Center for Advanced Medicine (CAM) - Eye Center|University of Rochester Medical Center|Oregon Health & Science University (OHSU) - Casey Eye Institute (CEI)-Marquam Hill|Eye Wellness Center|Eyelid Center of Utah|West Virginia University Eye Institute|University of British Columbia|Toronto Retina Institute|University of Ottawa Eye Institute|Ophthalmology University Center- Hôpital Maisonneuve-Rosemont|Universitat Duisburg-Essen|Orbitazentrum Frankfurt|Universitätsmedizin Mainz|ARNAS Garibaldi, Presidio di Nesima|Fondazione IRCCS Cà Granda-Ospedale Maggiore Policlinico|Unità Operativa di Endocrinologia 2, Azienda Ospedaliero-Universitaria Pisana|Hospital Universitari de Bellvitge|Centro de Oftalmologia Barraquer|University Hospital Ramon y Cajal",Drug|Other,Canada|Germany|Italy|Spain|United States,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03938545
NCT03938545,graves ophthalmopathy,"ASCEND GO-2: A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled Study of RVT-1401 for the Treatment of Patients With Active, Moderate to Severe Graves' Ophthalmopathy","ASCEND GO-2: Study of RVT-1401 for the Treatment of Patients With Active, Moderate to Severe Graves' Ophthalmopathy ( GO )",Graves' Ophthalmopathy (GO),2019-05-01,2021-02-02,2021-04-15,Interventional,Terminated,Phase 2,Immunovant Sciences GmbH,Immunovant Sciences GmbH,"Multispecialty Aesthetic Clinical Research Organziation (MACRO)|Doheny Eye Center UCLA|University of Miami Miller School of Medicine Bascom Palmer Eye Institute|University of Iowa Hospitals & Clinics - Eye Clinic|University of Michigan - Kellogg Eye Center|Mayo Clinic|Washington University School of Medicine - Center for Advanced Medicine (CAM) - Eye Center|University of Rochester Medical Center|Oregon Health & Science University (OHSU) - Casey Eye Institute (CEI)-Marquam Hill|Eye Wellness Center|Eyelid Center of Utah|West Virginia University Eye Institute|University of British Columbia|Toronto Retina Institute|University of Ottawa Eye Institute|Ophthalmology University Center- Hôpital Maisonneuve-Rosemont|Universitat Duisburg-Essen|Orbitazentrum Frankfurt|Universitätsmedizin Mainz|ARNAS Garibaldi, Presidio di Nesima|Fondazione IRCCS Cà Granda-Ospedale Maggiore Policlinico|Unità Operativa di Endocrinologia 2, Azienda Ospedaliero-Universitaria Pisana|Hospital Universitari de Bellvitge|Centro de Oftalmologia Barraquer|University Hospital Ramon y Cajal",Drug|Other,Canada|Germany|Italy|Spain|United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT03938545
NCT03938545,graves disease,"ASCEND GO-2: A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled Study of RVT-1401 for the Treatment of Patients With Active, Moderate to Severe Graves' Ophthalmopathy","ASCEND GO-2: Study of RVT-1401 for the Treatment of Patients With Active, Moderate to Severe Graves' Ophthalmopathy ( GO )",Graves' Ophthalmopathy (GO),2019-05-01,2021-02-02,2021-04-15,Interventional,Terminated,Phase 2,Immunovant Sciences GmbH,Immunovant Sciences GmbH,"Multispecialty Aesthetic Clinical Research Organziation (MACRO)|Doheny Eye Center UCLA|University of Miami Miller School of Medicine Bascom Palmer Eye Institute|University of Iowa Hospitals & Clinics - Eye Clinic|University of Michigan - Kellogg Eye Center|Mayo Clinic|Washington University School of Medicine - Center for Advanced Medicine (CAM) - Eye Center|University of Rochester Medical Center|Oregon Health & Science University (OHSU) - Casey Eye Institute (CEI)-Marquam Hill|Eye Wellness Center|Eyelid Center of Utah|West Virginia University Eye Institute|University of British Columbia|Toronto Retina Institute|University of Ottawa Eye Institute|Ophthalmology University Center- Hôpital Maisonneuve-Rosemont|Universitat Duisburg-Essen|Orbitazentrum Frankfurt|Universitätsmedizin Mainz|ARNAS Garibaldi, Presidio di Nesima|Fondazione IRCCS Cà Granda-Ospedale Maggiore Policlinico|Unità Operativa di Endocrinologia 2, Azienda Ospedaliero-Universitaria Pisana|Hospital Universitari de Bellvitge|Centro de Oftalmologia Barraquer|University Hospital Ramon y Cajal",Drug|Other,Canada|Germany|Italy|Spain|United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT03938545
NCT03938545,hyperthyroidism,"ASCEND GO-2: A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled Study of RVT-1401 for the Treatment of Patients With Active, Moderate to Severe Graves' Ophthalmopathy","ASCEND GO-2: Study of RVT-1401 for the Treatment of Patients With Active, Moderate to Severe Graves' Ophthalmopathy ( GO )",Graves' Ophthalmopathy (GO),2019-05-01,2021-02-02,2021-04-15,Interventional,Terminated,Phase 2,Immunovant Sciences GmbH,Immunovant Sciences GmbH,"Multispecialty Aesthetic Clinical Research Organziation (MACRO)|Doheny Eye Center UCLA|University of Miami Miller School of Medicine Bascom Palmer Eye Institute|University of Iowa Hospitals & Clinics - Eye Clinic|University of Michigan - Kellogg Eye Center|Mayo Clinic|Washington University School of Medicine - Center for Advanced Medicine (CAM) - Eye Center|University of Rochester Medical Center|Oregon Health & Science University (OHSU) - Casey Eye Institute (CEI)-Marquam Hill|Eye Wellness Center|Eyelid Center of Utah|West Virginia University Eye Institute|University of British Columbia|Toronto Retina Institute|University of Ottawa Eye Institute|Ophthalmology University Center- Hôpital Maisonneuve-Rosemont|Universitat Duisburg-Essen|Orbitazentrum Frankfurt|Universitätsmedizin Mainz|ARNAS Garibaldi, Presidio di Nesima|Fondazione IRCCS Cà Granda-Ospedale Maggiore Policlinico|Unità Operativa di Endocrinologia 2, Azienda Ospedaliero-Universitaria Pisana|Hospital Universitari de Bellvitge|Centro de Oftalmologia Barraquer|University Hospital Ramon y Cajal",Drug|Other,Canada|Germany|Italy|Spain|United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03938545
NCT03941184,goiter,Determining the Association Between Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity,Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity,"Addison Disease|Ankylosing Spondylitis|Antiphospholipid Antibody Syndrome|Celiac Disease|Crohn Disease|Dermatomyositis|Graves Disease|Guillain-Barre Syndrome|Hashimoto Thyroiditis|Hepatitis, Autoimmune|Multiple Sclerosis|Myasthenia Gravis|Pernicious Anemia|Polymyalgia Rheumatica|Polymyositis|Primary Biliary Cirrhosis|Psoriasis|Raynaud|Rheumatoid Arthritis|SCAD|Sjögren Syndrome|Systemic Lupus Erythematosus|Systemic Sclerosis|Takayasu Arteritis|Type 1 Diabetes Mellitus|Ulcerative Colitis|Uveitis|Vasculitis|Vitiligo",2019-04-01,2020-11-10,2020-11-10,Observational,Completed,,Mayo Clinic,Mayo Clinic,Mayo Clinic,,United States,18.0,110.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03941184
NCT03941184,hyperthyroidism,Determining the Association Between Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity,Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity,"Addison Disease|Ankylosing Spondylitis|Antiphospholipid Antibody Syndrome|Celiac Disease|Crohn Disease|Dermatomyositis|Graves Disease|Guillain-Barre Syndrome|Hashimoto Thyroiditis|Hepatitis, Autoimmune|Multiple Sclerosis|Myasthenia Gravis|Pernicious Anemia|Polymyalgia Rheumatica|Polymyositis|Primary Biliary Cirrhosis|Psoriasis|Raynaud|Rheumatoid Arthritis|SCAD|Sjögren Syndrome|Systemic Lupus Erythematosus|Systemic Sclerosis|Takayasu Arteritis|Type 1 Diabetes Mellitus|Ulcerative Colitis|Uveitis|Vasculitis|Vitiligo",2019-04-01,2020-11-10,2020-11-10,Observational,Completed,,Mayo Clinic,Mayo Clinic,Mayo Clinic,,United States,18.0,110.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03941184
NCT03941184,hashimoto disease,Determining the Association Between Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity,Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity,"Addison Disease|Ankylosing Spondylitis|Antiphospholipid Antibody Syndrome|Celiac Disease|Crohn Disease|Dermatomyositis|Graves Disease|Guillain-Barre Syndrome|Hashimoto Thyroiditis|Hepatitis, Autoimmune|Multiple Sclerosis|Myasthenia Gravis|Pernicious Anemia|Polymyalgia Rheumatica|Polymyositis|Primary Biliary Cirrhosis|Psoriasis|Raynaud|Rheumatoid Arthritis|SCAD|Sjögren Syndrome|Systemic Lupus Erythematosus|Systemic Sclerosis|Takayasu Arteritis|Type 1 Diabetes Mellitus|Ulcerative Colitis|Uveitis|Vasculitis|Vitiligo",2019-04-01,2020-11-10,2020-11-10,Observational,Completed,,Mayo Clinic,Mayo Clinic,Mayo Clinic,,United States,18.0,110.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT03941184
NCT03948191,graves disease,"A Double-masked, Methylprednisolone-control, Efficacy and Safety Study of 99Tc-MDP for Thyroid Associated Ophthalmopathy.",99Tc-MDP for Thyroid-Associated Ophthalmopathy,Thyroid-Associated Ophthalmopathy,2019-05-10,2018-12-30,2019-03-31,Interventional,Completed,Phase 4,Dalian University,Dalian University,Affiliated Zhongshan Hospital of Dalian University,Drug|Drug,China,18.0,76.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT03948191
NCT03948191,hyperthyroidism,"A Double-masked, Methylprednisolone-control, Efficacy and Safety Study of 99Tc-MDP for Thyroid Associated Ophthalmopathy.",99Tc-MDP for Thyroid-Associated Ophthalmopathy,Thyroid-Associated Ophthalmopathy,2019-05-10,2018-12-30,2019-03-31,Interventional,Completed,Phase 4,Dalian University,Dalian University,Affiliated Zhongshan Hospital of Dalian University,Drug|Drug,China,18.0,76.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03948191
NCT03948191,goiter,"A Double-masked, Methylprednisolone-control, Efficacy and Safety Study of 99Tc-MDP for Thyroid Associated Ophthalmopathy.",99Tc-MDP for Thyroid-Associated Ophthalmopathy,Thyroid-Associated Ophthalmopathy,2019-05-10,2018-12-30,2019-03-31,Interventional,Completed,Phase 4,Dalian University,Dalian University,Affiliated Zhongshan Hospital of Dalian University,Drug|Drug,China,18.0,76.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03948191
NCT03948191,graves ophthalmopathy,"A Double-masked, Methylprednisolone-control, Efficacy and Safety Study of 99Tc-MDP for Thyroid Associated Ophthalmopathy.",99Tc-MDP for Thyroid-Associated Ophthalmopathy,Thyroid-Associated Ophthalmopathy,2019-05-10,2018-12-30,2019-03-31,Interventional,Completed,Phase 4,Dalian University,Dalian University,Affiliated Zhongshan Hospital of Dalian University,Drug|Drug,China,18.0,76.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT03948191
NCT03957616,thyroiditis,Incidence of Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis in France Between 2016 and 2018,Incidence of Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis,Autoimmune Encephalitis|Paraneoplastic Neurological Syndrome,2019-05-17,2019-05-30,2019-07-31,Observational,Unknown status,,Hospices Civils de Lyon,Hospices Civils de Lyon,Centre de référence des syndromes neurologiques paranéoplasiques et encéphalites auto-immunes,,France,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT03957616
NCT03960437,hyperparathyroidism,The Effect of Etelcalcetide on Bone-tissue Properties and Calcification Propensity in End Stage Kidney Disease,The Effect of Etelcalcetide on CKD-MBD,"Chronic Kidney Disease Mineral and Bone Disorder|Hyperparathyroidism; Secondary, Renal|Renal Osteodystrophy|Vascular Calcification",2019-05-21,2021-12-31,2021-12-31,Interventional,Recruiting,Phase 2,Columbia University,"Thomas Nickolas, MD MS",Columbia University Medical Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03960437
NCT03960554,hyperparathyroidism,"The Effects of 12-months of Denosumab on Bone Density, Quality and Strength in Prevalent Kidney Transplant Recipients",The Effects of 12-months of Denosumab on Bone Density in Prevalent Kidney Transplant Recipients,Kidney Transplant; Complications|Osteoporosis|Renal Osteodystrophy,2019-05-21,2021-12-02,2021-12-02,Interventional,Terminated,Phase 2,Columbia University,"Thomas Nickolas, MD MS","Northwestern University, Feinburg School of Medicine|NorthShore University HealthSystem|Columbia University Medical Center",Drug|Other,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03960554
NCT03969108,goiter,Diagnostic Accuracy Study of Indocyanine Green for Parathyroid Perfusion Assessment,Diagnostic Accuracy Study of Indocyanine Green for Parathyroid Perfusion Assessment,Graves Disease|Thyroid Cancer|Thyroid Goiter,2019-05-24,2019-11-12,2019-11-13,Interventional,Completed,Phase 4,"University Health Network, Toronto","University Health Network, Toronto",University Health Network,Drug,Canada,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03969108
NCT03969108,hyperthyroidism,Diagnostic Accuracy Study of Indocyanine Green for Parathyroid Perfusion Assessment,Diagnostic Accuracy Study of Indocyanine Green for Parathyroid Perfusion Assessment,Graves Disease|Thyroid Cancer|Thyroid Goiter,2019-05-24,2019-11-12,2019-11-13,Interventional,Completed,Phase 4,"University Health Network, Toronto","University Health Network, Toronto",University Health Network,Drug,Canada,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03969108
NCT03969329,hyperparathyroidism,"Phase 3, Single-arm, Open-label, Multidose, Titration, Pharmacokinetic, Pharmacodynamic, and Safety Study of Etelcalcetide in Children and Adolescents ≥ 2 to < 18 Years of Age With Secondary Hyperparathyroidism and Chronic Kidney Disease Receiving Maintenance Hemodialysis",A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis,Secondary Hyperparathyroidism,2019-05-29,2026-08-02,2026-08-02,Interventional,Recruiting,Phase 3,Amgen,Amgen,"Universitair Ziekenhuis Gent|Fakultni nemocnice v Motole|Hospices Civils de Lyon Hopital Femme Mere Enfant|Hôpital Armand Trousseau|Kindernierenzentrum Bonn|Universitätsklinikum Hamburg-Eppendorf|Medizinische Hochschule Hannover|Zentrum für Kinder und Jugendmedizin des Universitätsklinikums Heidelberg|Universitätsklinikum Köln|General Children Hospital Panagioti and Aglaias Kyriakou|Ippokrateio General Hospital of Thessaloniki|Semmelweis Egyetem|Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont Altalanos Orvostudomanyi Kar|Azienda Ospedaliera Universitaria Meyer|Childrens Hospital, Affiliate of Vilnius University Hospital Santaros Klinikos|Uniwersytecki Szpital Dzieciecy w Krakowie|Centro Hospitalar Universitario do Porto - Hospital de Santo Antonio|Hospital Universitari Vall d Hebron|Royal Hospital for Sick Children|Great Ormond Street Hospital for Children",Drug,Belgium|Czechia|France|Germany|Greece|Hungary|Italy|Lithuania|Poland|Portugal|Spain|United Kingdom,2.0,17.0,[0-17],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03969329
NCT03980132,hyperthyroidism,"Randomized Clinical Trial, Blinded for the Researcher and Multicenter, to Evaluate the Efficacy and Safety of Preoperative Preparation With Lugol Solution in Euthyroid Patients With Graves-Basedow Disease.",Preoperative Preparation With Lugol Solution in Patients With Graves-Basedow Disease.,"Hyperthyroidism, Autoimmune",2019-05-30,2023-01-31,2023-09-30,Interventional,Recruiting,Phase 4,Fundación de Investigación Biomédica - Hospital Universitario de La Princesa,Jesús María Villar del Moral,Hospital Universitario de Bellvitge|Hospital Universitario Donostia|Hospital Clínico Universitario|Hospital Universitario Insular de Gran Canaria|Hospital Universitario Puerta de Hierro|Hospital Clínico Universitario Virgen de la Arrixaca|Hospital Universitario de Cruces|Hospital Universitario de Basurto|Hospital Universitario del Mar|Hospital Clinic|Hospital Universitario Virgen de las Nieves|Hospital Universitario de La princesa|Hospital General Universitario Gregorio Marañón|Hospital Universitario Ramón y Cajal|Hospital Universitario Fundación Jiménez Díaz|Hospital Universitario 12 de Octubre|Complejo Asistencial Universitario de Salamanca|Hospital Universitario Virgen Macarena|Hospital Universitario Virgen del Rocío|Hospital Clínico Universitario|Hospital Clínico Universitario Lozano Blesa,Drug,Spain,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03980132
NCT03980132,goiter,"Randomized Clinical Trial, Blinded for the Researcher and Multicenter, to Evaluate the Efficacy and Safety of Preoperative Preparation With Lugol Solution in Euthyroid Patients With Graves-Basedow Disease.",Preoperative Preparation With Lugol Solution in Patients With Graves-Basedow Disease.,"Hyperthyroidism, Autoimmune",2019-05-30,2023-01-31,2023-09-30,Interventional,Recruiting,Phase 4,Fundación de Investigación Biomédica - Hospital Universitario de La Princesa,Jesús María Villar del Moral,Hospital Universitario de Bellvitge|Hospital Universitario Donostia|Hospital Clínico Universitario|Hospital Universitario Insular de Gran Canaria|Hospital Universitario Puerta de Hierro|Hospital Clínico Universitario Virgen de la Arrixaca|Hospital Universitario de Cruces|Hospital Universitario de Basurto|Hospital Universitario del Mar|Hospital Clinic|Hospital Universitario Virgen de las Nieves|Hospital Universitario de La princesa|Hospital General Universitario Gregorio Marañón|Hospital Universitario Ramón y Cajal|Hospital Universitario Fundación Jiménez Díaz|Hospital Universitario 12 de Octubre|Complejo Asistencial Universitario de Salamanca|Hospital Universitario Virgen Macarena|Hospital Universitario Virgen del Rocío|Hospital Clínico Universitario|Hospital Clínico Universitario Lozano Blesa,Drug,Spain,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03980132
NCT03980132,graves disease,"Randomized Clinical Trial, Blinded for the Researcher and Multicenter, to Evaluate the Efficacy and Safety of Preoperative Preparation With Lugol Solution in Euthyroid Patients With Graves-Basedow Disease.",Preoperative Preparation With Lugol Solution in Patients With Graves-Basedow Disease.,"Hyperthyroidism, Autoimmune",2019-05-30,2023-01-31,2023-09-30,Interventional,Recruiting,Phase 4,Fundación de Investigación Biomédica - Hospital Universitario de La Princesa,Jesús María Villar del Moral,Hospital Universitario de Bellvitge|Hospital Universitario Donostia|Hospital Clínico Universitario|Hospital Universitario Insular de Gran Canaria|Hospital Universitario Puerta de Hierro|Hospital Clínico Universitario Virgen de la Arrixaca|Hospital Universitario de Cruces|Hospital Universitario de Basurto|Hospital Universitario del Mar|Hospital Clinic|Hospital Universitario Virgen de las Nieves|Hospital Universitario de La princesa|Hospital General Universitario Gregorio Marañón|Hospital Universitario Ramón y Cajal|Hospital Universitario Fundación Jiménez Díaz|Hospital Universitario 12 de Octubre|Complejo Asistencial Universitario de Salamanca|Hospital Universitario Virgen Macarena|Hospital Universitario Virgen del Rocío|Hospital Clínico Universitario|Hospital Clínico Universitario Lozano Blesa,Drug,Spain,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT03980132
NCT03986593,thyroid neoplasms,Cone-beam Computed Tomography Guided Percutaneous Cryoablation of Bone Metastases From Endocrine Tumors,Cryoablation of Bone Metastases From Endocrine Tumors,Adrenal Neoplasm|Bone Metastases|Neoplasm Metastasis|Neuroendocrine Tumors|Pheochromocytoma|Thyroid Neoplasm,2019-05-22,2022-06-15,2023-06-15,Interventional,Recruiting,Not Applicable,Instituto do Cancer do Estado de São Paulo,Instituto do Cancer do Estado de São Paulo|University of Sao Paulo General Hospital,Instituto do Cancer do Estado de São Paulo,Device,Brazil,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03986593
NCT04009863,goiter,"A Randomized, Open-label, Parallel-group Study to Determine the Efficacy of Sequential High-intensity Focused Ultrasound (HIFU) Ablation Versus Fixed-dose Radioiodine-131 Therapy in Moderate-sized Non-toxic Multinodular Goiter",HIFU Ablation vs Fixed-dose RAI-131 Therapy in Moderate-sized Non-toxic MNG,High Intensity Focused Ultrasound|Non Toxic Multinodular Goiter|RAI,2019-06-26,2023-04-30,2023-09-30,Interventional,Not yet recruiting,Not Applicable,The University of Hong Kong,The University of Hong Kong,Queen Mary Hospital,Device|Radiation,Hong Kong,18.0,70.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04009863
NCT04012476,hypoparathyroidism,Determination of Parathyroid Function by Fluorescence With Indocyanine Green (ICG) After Total Thyroidectomy,Determination of Parathyroid Function by Fluorescence With Indocyanine Green (ICG) After Total Thyroidectomy,Hypocalcemia|Hypoparathyroidism Postprocedural|Total Thyroidectomy,2019-06-28,2020-03-31,2020-10-31,Interventional,Unknown status,Phase 4,Hospital Son Espases,Hospital Son Espases|Universitat de les Illes Balears,Hospital Universitari Son Espases,Drug,Spain,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04012476
NCT04013100,parathyroid neoplasms,Cohort Trial on Perioperative Localization Techniques of Parathyroid Adenomas,Cohort Trial on Perioperative Localization Techniques of Parathyroid Adenomas,Primary Hyperparathyroidism,2019-07-05,2029-12-31,2029-12-31,Observational [Patient Registry],Not yet recruiting,,IHU Strasbourg,IHU Strasbourg,,Diagnostic Test,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04013100
NCT04013100,hyperparathyroidism,Cohort Trial on Perioperative Localization Techniques of Parathyroid Adenomas,Cohort Trial on Perioperative Localization Techniques of Parathyroid Adenomas,Primary Hyperparathyroidism,2019-07-05,2029-12-31,2029-12-31,Observational [Patient Registry],Not yet recruiting,,IHU Strasbourg,IHU Strasbourg,,Diagnostic Test,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04013100
NCT04013139,hyperparathyroidism,Evaluation of the Relationship Between Cardiopulmonary Exercise Testing (CPET ) Abnormalities and Ca-P Status in CKD Stage3-5,Relationship Between Cardiopulmonary Exercise Testing and Ca-P in Chronic Kidney Disease (CKD),Ckd-Mbd,2019-06-23,2021-08-01,2021-10-01,Observational,Completed,,Shahid Beheshti University of Medical Sciences,Shahid Beheshti University of Medical Sciences,Nooshin Dalili,Diagnostic Test,"Iran, Islamic Republic of",18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04013139
NCT04019379,hyperparathyroidism,Calcium and Phosphorus Whole-Body Balance and Kinetics in Patients With Moderate Chronic Kidney Disease,Calcium and Phosphorus Whole-Body Balance and Kinetics in Patients With Moderate Chronic Kidney Disease,Chronic Kidney Disease Mineral and Bone Disorder|Chronic Kidney Diseases|Phosphorus and Calcium Disorders,2019-07-09,2020-10-28,2022-12-01,Interventional,Active not recruiting,Not Applicable,University of Minnesota,Indiana University|University of Minnesota,Indiana CTSI CRC,Other|Other,United States,30.0,75.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04019379
NCT04025034,graves ophthalmopathy,Deep Lateral Wall Partial Rim-Sparing Orbital Decompression With Ultrasonic Bone Removal for Treatment of Thyroid-Related Orbitopathy,Deep Lateral Wall Partial Rim-Sparing Orbital Decompression for Treatment of Thyroid-Related Orbitopathy,"Exophthalmos|Orbitopathy, Graves|Surgery",2019-07-15,2017-12-31,2019-01-01,Interventional,Completed,Not Applicable,Hospital Universitario 12 de Octubre,Hospital del Río Hortega|Hospital Universitario 12 de Octubre|The Queen Elizabeth Hospital,,Procedure,,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT04025034
NCT04025034,hyperthyroidism,Deep Lateral Wall Partial Rim-Sparing Orbital Decompression With Ultrasonic Bone Removal for Treatment of Thyroid-Related Orbitopathy,Deep Lateral Wall Partial Rim-Sparing Orbital Decompression for Treatment of Thyroid-Related Orbitopathy,"Exophthalmos|Orbitopathy, Graves|Surgery",2019-07-15,2017-12-31,2019-01-01,Interventional,Completed,Not Applicable,Hospital Universitario 12 de Octubre,Hospital del Río Hortega|Hospital Universitario 12 de Octubre|The Queen Elizabeth Hospital,,Procedure,,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04025034
NCT04025034,goiter,Deep Lateral Wall Partial Rim-Sparing Orbital Decompression With Ultrasonic Bone Removal for Treatment of Thyroid-Related Orbitopathy,Deep Lateral Wall Partial Rim-Sparing Orbital Decompression for Treatment of Thyroid-Related Orbitopathy,"Exophthalmos|Orbitopathy, Graves|Surgery",2019-07-15,2017-12-31,2019-01-01,Interventional,Completed,Not Applicable,Hospital Universitario 12 de Octubre,Hospital del Río Hortega|Hospital Universitario 12 de Octubre|The Queen Elizabeth Hospital,,Procedure,,18.0,80.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04025034
NCT04025034,graves disease,Deep Lateral Wall Partial Rim-Sparing Orbital Decompression With Ultrasonic Bone Removal for Treatment of Thyroid-Related Orbitopathy,Deep Lateral Wall Partial Rim-Sparing Orbital Decompression for Treatment of Thyroid-Related Orbitopathy,"Exophthalmos|Orbitopathy, Graves|Surgery",2019-07-15,2017-12-31,2019-01-01,Interventional,Completed,Not Applicable,Hospital Universitario 12 de Octubre,Hospital del Río Hortega|Hospital Universitario 12 de Octubre|The Queen Elizabeth Hospital,,Procedure,,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04025034
NCT04031638,thyroid neoplasms,Prospective and Retrospective Thyroid Cancer Database,Thyroid Cancer Database,Patients With a Thyroid Tumor Who Received Radioactive Iodine Treatment,2019-07-01,2025-01-01,2025-01-01,Observational,Recruiting,,Centre Georges Francois Leclerc,Centre Georges Francois Leclerc,"Methodology, Biostatistics and Data Management",Other,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04031638
NCT04040946,parathyroid neoplasms,Phase III Trial Comparing 2 Diagnostic Strategies for Preoperative Localization of Parathyroid Adenoma in Primary Hyperparathyroidism:TEMP / CT With Tc99m-sestaMIBI or PET / CT With F18-choline in First Intention,Trial Comparing 2 Diagnostic Strategies for Preoperative Localization of Parathyroid Adenoma in Primary Hyperparathyroidism:TEMP / CT With Tc99m-sestaMIBI or PET / CT With F18-choline in First Intention,F18-choline|Hyperparathyroidism|Parathyroid Adenoma,2019-07-29,2022-09-30,2023-03-31,Interventional,Recruiting,Phase 3,Centre Francois Baclesse,Centre Francois Baclesse|Fondation de l'Avenir,CHU Brest|Centre François Baclesse|Centre Eugène Marquis|CHU,Diagnostic Test|Diagnostic Test,France,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04040946
NCT04046354,thyroid nodule,Clinical Trial of Microwave Ablation System,Microwave vs. Radiofrequency Ablation for Benign Thyroid Nodules: A Multicenter Randomized Controlled Trial Study,Ablation|Benign Thyroid Nodules,2019-08-05,2020-11-19,2021-12-31,Interventional,Active not recruiting,Not Applicable,Chinese PLA General Hospital,Chinese PLA General Hospital,Chinese PLA General Hospital,Device|Device,China,18.0,75.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04046354
NCT04046354,thyroid neoplasms,Clinical Trial of Microwave Ablation System,Microwave vs. Radiofrequency Ablation for Benign Thyroid Nodules: A Multicenter Randomized Controlled Trial Study,Ablation|Benign Thyroid Nodules,2019-08-05,2020-11-19,2021-12-31,Interventional,Active not recruiting,Not Applicable,Chinese PLA General Hospital,Chinese PLA General Hospital,Chinese PLA General Hospital,Device|Device,China,18.0,75.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04046354
NCT04053114,struma ovarii,MOLecular Characterization and Treatment of THYroid Carcinoma on Struma Ovarii,MOLecular Characterization and Treatment of THYroid Carcinoma on Struma Ovarii,Ovarian Cancer,2019-07-04,2019-12-31,2020-05-31,Observational,Unknown status,,Institut Bergonié,Institut Bergonié,Institut Bergonié,Other,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Struma ovarii,https://clinicaltrials.gov/ct2/show/NCT04053114
NCT04064827,hyperparathyroidism,"A Phase 3, Prospective, Open-Label, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Paricalcitol Oral Solution for the Treatment of Secondary Hyperparathyroidism in Pediatric Subjects Ages 0 to 9 Years With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis","A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)",Chronic Kidney Disease (CKD)|Secondary Hyperparathyroidism (SHPT),2019-08-20,2024-03-09,2026-10-30,Interventional,Recruiting,Phase 3,AbbVie,AbbVie,"Arkansas Children's Hospital /ID# 225417|University of California, Los Angeles /ID# 140668|Children's National Medical Center /ID# 225991|Holtz Childrens Hospital, University of Miami /ID# 225636|Nicklaus Children's Hospital /ID# 210517|Emory Midtown Infectious Disease Clinic /ID# 140665|Boston Children's Hospital /ID# 162863|Levine Children's Specialty Center- Charlotte /ID# 216057|Children's Hospital of Philadelphia - Main /ID# 213802|University of Texas Southwestern Medical Center /ID# 210495|University of Utah /ID# 140669|Seattle Children's Hospital /ID# 162861|School of Medicine University of Puerto Rico-Medical Science Campus /ID# 140663",Drug,Puerto Rico|United States,0.0,9.0,[0-17],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04064827
NCT04075851,thyroiditis,The Prevalence of Serum Thyroid Hormone Autoantibodies in Autoimmune Thyroid Diseases,The Prevalence of Serum Thyroid Hormone Autoantibodies in Autoimmune Thyroid Diseases,Autoimmune Thyroid Disease,2019-08-29,2022-08-01,2022-08-01,Observational,Recruiting,,Shandong Provincial Hospital,Shandong Provincial Hospital,Shandong Province Hospital,,China,18.0,65.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT04075851
NCT04080505,goiter,Does the Use of Pre-operative SSKI Actually Reduce Vascularity and Improve Surgical Outcomes for Total Thyroidectomy in Graves' Disease?,Does Potassium Iodide (SSKI) Reduce Vascularity in Graves' Thyroidectomy?,Graves Disease,2019-09-04,2021-12-31,2022-12-31,Interventional,Recruiting,Phase 3,Columbia University,Columbia University,Columbia University Medical Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04080505
NCT04080505,hyperthyroidism,Does the Use of Pre-operative SSKI Actually Reduce Vascularity and Improve Surgical Outcomes for Total Thyroidectomy in Graves' Disease?,Does Potassium Iodide (SSKI) Reduce Vascularity in Graves' Thyroidectomy?,Graves Disease,2019-09-04,2021-12-31,2022-12-31,Interventional,Recruiting,Phase 3,Columbia University,Columbia University,Columbia University Medical Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04080505
NCT04085419,hyperparathyroidism,Management of Osteoporosis in Patients With Primary Hyperparathyroidism,Osteoporosis in Primary Hyperparathyroidism,Osteoporosis|Primary Hyperparathyroidism,2019-09-02,2022-05-31,2022-05-31,Interventional,Enrolling by invitation,Phase 4,University Medical Centre Ljubljana,University Medical Centre Ljubljana,Endocrinology Department,Drug|Drug,Slovenia,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04085419
NCT04085913,parathyroid neoplasms,Intraoperative Injection of Exparel Effect on Postoperative Opioid Use in Thyroid and Parathyroid Surgery,Exparel Injection Effect on Postoperative Opioid Usage,Parathyroid Adenoma|Thyroid,2019-06-21,2023-07-31,2023-07-31,Interventional,Enrolling by invitation,Early Phase 1,University of Missouri-Columbia,University of Missouri-Columbia,University of Missouri,Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04085913
NCT04096612,graves disease,The Therapeutic Effect of Dysthyroid Optic Neuropathy,The Therapeutic Effect of Dysthyroid Optic Neuropathy,Thyroid Eye Disease,2018-12-27,2018-12-31,2019-12-31,Interventional,Unknown status,Not Applicable,Sun Yat-sen University,Sun Yat-sen University,Zhongshan Opthalmic Center,Procedure,China,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04096612
NCT04096612,goiter,The Therapeutic Effect of Dysthyroid Optic Neuropathy,The Therapeutic Effect of Dysthyroid Optic Neuropathy,Thyroid Eye Disease,2018-12-27,2018-12-31,2019-12-31,Interventional,Unknown status,Not Applicable,Sun Yat-sen University,Sun Yat-sen University,Zhongshan Opthalmic Center,Procedure,China,18.0,70.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04096612
NCT04096612,hyperthyroidism,The Therapeutic Effect of Dysthyroid Optic Neuropathy,The Therapeutic Effect of Dysthyroid Optic Neuropathy,Thyroid Eye Disease,2018-12-27,2018-12-31,2019-12-31,Interventional,Unknown status,Not Applicable,Sun Yat-sen University,Sun Yat-sen University,Zhongshan Opthalmic Center,Procedure,China,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04096612
NCT04106596,thyroiditis,Immunogenetic Characteristics in Autoimmune Encephalitis and Related Disorders: HLA Analysis,HLA Analysis in Autoimmune Encephalitis and Related Disorders,Autoimmune Cerebellar Ataxia|Autoimmune Encephalitis|Imbic Encephalitis|Stiff-person Syndrome,2019-09-25,2020-02-01,2020-10-01,Observational,Unknown status,,Hospices Civils de Lyon,Hospices Civils de Lyon,Centre de référence des syndromes neurologiques paranéoplasiques et encéphalites auto-immunes,,France,18.0,120.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT04106596
NCT04106843,thyroid neoplasms,"A Phase II Study to Evaluate the Effects of 177Lu-DOTATATE in Patients With Unresectable and Progressive Rare Metastatic Endocrine Carcinomas: Medullary Thyroid Cancer, Parathyroid Carcinoma, Pituitary Carcinoma, and Malignant Pheochromocytoma/Paraganglioma","Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers",Locally Advanced Adrenal Gland Pheochromocytoma|Locally Advanced Paraganglioma|Metastatic Adrenal Gland Pheochromocytoma|Metastatic Paraganglioma|Metastatic Parathyroid Gland Carcinoma|Pituitary Gland Carcinoma|Somatostatin Receptor Positive|Stage III Thyroid Gland Medullary Carcinoma AJCC v8|Stage IVA Thyroid Gland Medullary Carcinoma AJCC v8|Stage IVB Thyroid Gland Medullary Carcinoma AJCC v8|Stage IVC Thyroid Gland Medullary Carcinoma AJCC v8|Stage IV Thyroid Gland Medullary Carcinoma AJCC v8|Unresectable Adrenal Gland Pheochromocytoma|Unresectable Paraganglioma,2019-09-25,2020-09-03,2020-09-03,Interventional,Withdrawn,Phase 2,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center|National Cancer Institute (NCI),M D Anderson Cancer Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04106843
NCT04126954,hyperparathyroidism,Multicentric Retrospective Study on the Use of Cinacalcet in an Off-label Phosphocalcic Context,Study on the Use of Cinacalcet in Phosphocalcic Context.,"Hyperparathyroidism, Primary|Hyperparathyroidism, Secondary",2019-10-11,2021-01-31,2023-12-31,Observational,Not yet recruiting,,Hospices Civils de Lyon,Hospices Civils de Lyon,"Endocrinologie Diabète et Maladies Métaboliques - Hôpital Gabriel Montpied|Service de Néphrologie Pédiatrique -Hôpital Jeanne de Flandre|Service d'Endocrinologie Pédiatrique - Hôpital de la mère et de l'Enfant|Pole Femme Mère Enfant - Pédiatrie spécialisée - Centre Hospitalier Universitaire|Service de Néphrologie pédiatrique - Clinique Médicale Pédiatrique|Service d'endocrinologie et Diabétologie Pédiatrique-Hôpital Robert Debré|Service de Diabétologie et endocrinologie pédiatriques - Centre Hospitalier Universitaire|Pôle Néphrologie-Urologie-Diabétologie-Endocrinologie|Service d'Endocrinologie, Maladies Osseuses, Gynécologie, Génétique|Unité Endocrinologie, Nutrition, Diabétologie -Hôpital Bretonneau",Other,France,0.0,99.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04126954
NCT04129281,thyroid neoplasms,Prospective Active Surveillance Versus Surgery in Thyroid Papillary Microcarcinoma,Active Surveillance Versus Surgery in Thyroid Papillary Microcarcinoma,Papillary Microcarcinoma of the Thyroid,2019-10-15,2022-01-23,2023-02-23,Interventional,Recruiting,Not Applicable,"National Cancer Institute, Naples","National Cancer Institute, Naples",Istitute Nazionale Tumori - Fondazione G. Pascale,Procedure,Italy,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04129281
NCT04135573,hyperthyroidism,Mechanism of NK Cell Disfunction in Graves' Disease,The Relationship Between NK Cell and Graves' Disease,Graves Disease,2019-01-03,2022-06-30,2022-06-30,Observational [Patient Registry],Active not recruiting,,Shandong Provincial Hospital,Shandong Provincial Hospital,Shandong Provincial Hospital,,China,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04135573
NCT04135573,goiter,Mechanism of NK Cell Disfunction in Graves' Disease,The Relationship Between NK Cell and Graves' Disease,Graves Disease,2019-01-03,2022-06-30,2022-06-30,Observational [Patient Registry],Active not recruiting,,Shandong Provincial Hospital,Shandong Provincial Hospital,Shandong Provincial Hospital,,China,18.0,75.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04135573
NCT04141540,hypoparathyroidism,"Translational 22q11.2:""Molecular Variants Associated With Schizophrenia: Differential Analysis of Monozygotic Twins With Variable Phenotypic 22q11.2 Microdeletional Syndrom""",Molecular Variants Associated With Schizophrenia: Differential Analysis of Monozygotic Twins With Variable Phenotypic 22q11,Di George Syndrome,2019-10-24,2020-11-30,2020-12-30,Interventional,Completed,Not Applicable,Hôpital le Vinatier,Hôpital le Vinatier,Hopital Vinatier,Genetic,France,18.0,45.0,[18-65],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04141540
NCT04146259,hypoparathyroidism,Changes in Circulating Sclerostin Levels During Acute Postsurgical Hypoparathyroidism,Changes in Circulating Sclerostin Levels During Acute Postsurgical Hypoparathyroidism,Hypoparathyroidism Postprocedural,2019-10-29,2018-12-31,2019-08-01,Observational,Completed,,University of Athens,University of Athens,Symeon Tournis,Drug,Greece,19.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04146259
NCT04171622,"thyroid carcinoma, anaplastic",Lenvatinib in Combination With Pembrolizumab for Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer,Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer,Metastatic Thyroid Gland Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8|Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8|Thyroid Gland Squamous Cell Carcinoma|Unresectable Thyroid Gland Carcinoma,2019-11-19,2022-08-31,2022-08-31,Interventional,Not yet recruiting,Phase 2,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center|National Cancer Institute (NCI),M D Anderson Cancer Center,Drug|Biological,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT04171622
NCT04175522,thyroiditis,"A Phase 2a, Prospective, Open-label, Single-arm, Single Center, Proof of Concept Study to Evaluate the Safety and Efficacy of IGIV 10% in Patients With Autoimmune Encephalitis",Safety and Efficacy of IGIV 10% in Patients With Autoimmune Encephalitis:,Autoimmune Encephalitis,2019-11-21,2020-06-11,2020-06-11,Interventional,Completed,Phase 2,Green Cross Corporation,Green Cross Corporation,Seoul National University Hospital,Drug,"Korea, Republic of",12.0,120.0,[0-17]|[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT04175522
NCT04178928,hypothyroidism,Can Levothyroxine Treatment Reduce the Development of Cardio-metabolic Disorder in Subclinical Hypothyroidism?,Can Levothyroxine Treatment Reduce the Development of Cardio-metabolic Disorder in Subclinical Hypothyroidism?,Subclinical hypothyroïdism,2019-11-25,2021-01-31,2021-02-28,Interventional,Unknown status,Phase 1/Phase 2,Ain Shams University,Ain Shams University,,Drug,,5.0,15.0,[0-17],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04178928
NCT04180007,thyroid neoplasms,Evaluating the Safety and Efficacy of Radioactive Iodine (RAI) Treatment of Metastatic and Advanced Differentiated Thyroid Cancers by Pretreatment With Apatinib for the Neoadjuvant Regimen,Study of Neoadjuvant Regimen for Radioactive Iodine Treatment of Metastatic and Advanced Differentiated Thyroid Cancers,Apatinib|Metastasis|Thyroid,2019-11-24,2020-04-10,2020-05-30,Interventional,Unknown status,Phase 2,"Nanjing First Hospital, Nanjing Medical University","Nanjing First Hospital, Nanjing Medical University",Nanjing First Hospital,Drug,China,18.0,99.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04180007
NCT04193332,hypoparathyroidism,Near Infrared (NIR) Autofluorescence Image-guided Thyroid Surgery Can Prevent Post-thyroidectomy Hypoparathyroidism,Near Infrared (NIR) Autofluorescence Image-guided Thyroid Surgery,Hypocalcemia|Hypoparathyroidism Postprocedural|Surgery--Complications,2019-12-06,2023-10-01,2023-12-01,Interventional,Recruiting,Not Applicable,"Rigshospitalet, Denmark","Cluster for molecular imaging, Denmark|Dept of Otorhinolaryngology and Maxillofacial Surgery, Zealand University Hospital, Denmark|Rigshospitalet, Denmark","Rigshospitalet|Dept of Otorhinolaryngology and Maxillofacial Surgery, Zealand University Hospital, Denmark",Device,Denmark,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04193332
NCT04216732,thyroid neoplasms,Utilization of the Natural History of Medullary Thyroid Carcinoma to Inform Advanced Disease Management,Natural History of Medullary Thyroid Cancer to Inform Advanced Disease Management,Advanced Thyroid Gland Medullary Carcinoma|Stage III Thyroid Gland Medullary Carcinoma AJCC v8|Stage IVA Thyroid Gland Medullary Carcinoma AJCC v8|Stage IVB Thyroid Gland Medullary Carcinoma AJCC v8|Stage IVC Thyroid Gland Medullary Carcinoma AJCC v8|Stage IV Thyroid Gland Medullary Carcinoma AJCC v8,2019-11-14,2023-09-01,2023-09-01,Observational,Recruiting,,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center|National Cancer Institute (NCI),University of California San Francisco|M D Anderson Cancer Center,Other|Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04216732
NCT04233398,thyroid nodule,"A Multi-center, Randomized, Controlled Trial of High Intensity Focused Ultrasound (HIFU) Treatment of Benign Thyroid Nodules",HIFU Treatment of Benign Thyroid Nodules,Thyroid Nodule (Benign),2020-01-15,2023-11-30,2023-11-30,Interventional,Not yet recruiting,Not Applicable,Theraclion,Theraclion,,Device,,18.0,70.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04233398
NCT04233398,thyroid neoplasms,"A Multi-center, Randomized, Controlled Trial of High Intensity Focused Ultrasound (HIFU) Treatment of Benign Thyroid Nodules",HIFU Treatment of Benign Thyroid Nodules,Thyroid Nodule (Benign),2020-01-15,2023-11-30,2023-11-30,Interventional,Not yet recruiting,Not Applicable,Theraclion,Theraclion,,Device,,18.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04233398
NCT04239521,hyperthyroidism,"The Epidemiology, Management, and the Associated Burden of Mental Health, Atopic and Autoimmune Conditions, and Common Infections in Alopecia Areata","The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata",Acute Bronchitis|Allergic Rhinitis|Alopecia Areata|Ankylosing Spondylitis|Anxiety Disorders|Asthma|Atopic Dermatitis|Celiac Disease|Crohn Disease|Depressive Episode|Gastrointestinal Infection|Genital Infection|Graves Disease|Hashimoto Thyroiditis|Herpes Simplex|Herpes Zoster|Infection|Infection Viral|Influenza|Lower Resp Tract Infection|Multiple Sclerosis|Pernicious Anemia|Pneumonia|Polymyalgia Rheumatica|Psoriasis|Psoriatic Arthritis|Recurrent Depressive Disorder|Rheumatoid Arthritis|Sjogren's Syndrome|Skin Infection|Systemic Lupus Erythematosus|Type 1 Diabetes|Ulcerative Colitis|Upper Respiratory Tract Infection|Urinary Tract Infections|Vitiligo,2020-01-09,2021-10-31,2021-12-31,Observational,Active not recruiting,,Momentum Data,Momentum Data|Pfizer|University of Oxford|University of Surrey,Momentum Data Ltd,Other,United Kingdom,0.0,120.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04239521
NCT04239521,goiter,"The Epidemiology, Management, and the Associated Burden of Mental Health, Atopic and Autoimmune Conditions, and Common Infections in Alopecia Areata","The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata",Acute Bronchitis|Allergic Rhinitis|Alopecia Areata|Ankylosing Spondylitis|Anxiety Disorders|Asthma|Atopic Dermatitis|Celiac Disease|Crohn Disease|Depressive Episode|Gastrointestinal Infection|Genital Infection|Graves Disease|Hashimoto Thyroiditis|Herpes Simplex|Herpes Zoster|Infection|Infection Viral|Influenza|Lower Resp Tract Infection|Multiple Sclerosis|Pernicious Anemia|Pneumonia|Polymyalgia Rheumatica|Psoriasis|Psoriatic Arthritis|Recurrent Depressive Disorder|Rheumatoid Arthritis|Sjogren's Syndrome|Skin Infection|Systemic Lupus Erythematosus|Type 1 Diabetes|Ulcerative Colitis|Upper Respiratory Tract Infection|Urinary Tract Infections|Vitiligo,2020-01-09,2021-10-31,2021-12-31,Observational,Active not recruiting,,Momentum Data,Momentum Data|Pfizer|University of Oxford|University of Surrey,Momentum Data Ltd,Other,United Kingdom,0.0,120.0,[0-17]|[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04239521
NCT04239521,"thyroiditis, autoimmune","The Epidemiology, Management, and the Associated Burden of Mental Health, Atopic and Autoimmune Conditions, and Common Infections in Alopecia Areata","The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata",Acute Bronchitis|Allergic Rhinitis|Alopecia Areata|Ankylosing Spondylitis|Anxiety Disorders|Asthma|Atopic Dermatitis|Celiac Disease|Crohn Disease|Depressive Episode|Gastrointestinal Infection|Genital Infection|Graves Disease|Hashimoto Thyroiditis|Herpes Simplex|Herpes Zoster|Infection|Infection Viral|Influenza|Lower Resp Tract Infection|Multiple Sclerosis|Pernicious Anemia|Pneumonia|Polymyalgia Rheumatica|Psoriasis|Psoriatic Arthritis|Recurrent Depressive Disorder|Rheumatoid Arthritis|Sjogren's Syndrome|Skin Infection|Systemic Lupus Erythematosus|Type 1 Diabetes|Ulcerative Colitis|Upper Respiratory Tract Infection|Urinary Tract Infections|Vitiligo,2020-01-09,2021-10-31,2021-12-31,Observational,Active not recruiting,,Momentum Data,Momentum Data|Pfizer|University of Oxford|University of Surrey,Momentum Data Ltd,Other,United Kingdom,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT04239521
NCT04248114,thyroid neoplasms,The Natural Neck Crease as an Anatomic Landmark for Thyroid Surgery Incision,Skin-crease Thyroidectomy,Thyroid Nodule,2020-01-28,2018-08-31,2018-08-31,Observational,Completed,,Western Galilee Hospital-Nahariya,Western Galilee Hospital-Nahariya,,Diagnostic Test,,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04248114
NCT04267965,hyperparathyroidism,"Changes of Pulmonary Function, Voice and Swallowing Symptoms After Total Parathyroidectomy for Secondary Hyperparathyroidism in the Presence of Intact Recurrent Laryngeal Nerve","Pulmonary Function, Voice and Swallowing Symptoms After Parathyroidectomy",Secondary Hyperparathyroidism Due to Renal Causes,2020-01-22,2019-07-31,2019-07-31,Observational [Patient Registry],Completed,,Chang Gung Memorial Hospital,Chang Gung Memorial Hospital,Fong-Fu Chou,Procedure,Taiwan,20.0,80.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04267965
NCT04268407,thyroid neoplasms,2-day Prophylactic Antibiotic is Effective in Transoral Endoscopic Thyroidectomy,2-day Prophylactic Antibiotic is Effective in Transoral Endoscopic Thyroidectomy,Thyroid Nodule,2020-02-07,2021-07-31,2021-12-31,Interventional,Unknown status,Not Applicable,Chang Gung Memorial Hospital,Chang Gung Memorial Hospital,,Drug,,20.0,80.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04268407
NCT04270110,hypothyroidism,Assessment of Bone Mineral Density in Patients With Subclinical Hypothyroidism,Assessment of Bone Mineral Density in Patients With Subclinical Hypothyroidism,Subclinical hypothyroïdism,2020-01-16,2020-12-01,2021-12-31,Observational,Unknown status,,Assiut University,Assiut University,Assiut university Hospital,,Egypt,0.0,55.0,[0-17]|[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04270110
NCT04281875,hypoparathyroidism,Assessing Benefits of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Total Thyroidectomy.,Assessing Benefits of NIRAF Detection for Identifying Parathyroid Glands During Total Thyroidectomy.,Postoperative Hypoparathyroidism|Thyroid Cancer|Thyroid Neoplasms,2020-02-19,2023-03-31,2023-09-30,Interventional,Recruiting,Not Applicable,Vanderbilt-Ingram Cancer Center,National Cancer Institute (NCI)|Vanderbilt-Ingram Cancer Center,Vanderbilt University Medical Center,Device,United States,18.0,99.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04281875
NCT04284774,thyroid neoplasms,NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tipifarnib in Patients With Tumors Harboring HRAS Genomic Alterations,"Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial",Malignant Solid Neoplasm|Recurrent Adrenal Gland Pheochromocytoma|Recurrent Ectomesenchymoma|Recurrent Ependymoma|Recurrent Ewing Sarcoma|Recurrent Hepatoblastoma|Recurrent Kidney Wilms Tumor|Recurrent Langerhans Cell Histiocytosis|Recurrent Malignant Germ Cell Tumor|Recurrent Malignant Glioma|Recurrent Medulloblastoma|Recurrent Melanoma|Recurrent Neuroblastoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Osteosarcoma|Recurrent Peripheral Primitive Neuroectodermal Tumor|Recurrent Rhabdoid Tumor|Recurrent Rhabdoid Tumor of the Kidney|Recurrent Rhabdomyosarcoma|Recurrent Soft Tissue Sarcoma|Recurrent Thyroid Gland Carcinoma|Recurrent WHO Grade 2 Glioma|Refractory Adrenal Gland Pheochromocytoma|Refractory Ependymoma|Refractory Ewing Sarcoma|Refractory Hepatoblastoma|Refractory Langerhans Cell Histiocytosis|Refractory Malignant Germ Cell Tumor|Refractory Malignant Glioma|Refractory Medulloblastoma|Refractory Melanoma|Refractory Neuroblastoma|Refractory Non-Hodgkin Lymphoma|Refractory Osteosarcoma|Refractory Peripheral Primitive Neuroectodermal Tumor|Refractory Rhabdoid Tumor|Refractory Rhabdoid Tumor of the Kidney|Refractory Rhabdomyosarcoma|Refractory Soft Tissue Sarcoma|Refractory Thyroid Gland Carcinoma|Refractory WHO Grade 2 Glioma,2020-02-25,2027-09-30,2027-09-30,Interventional,Recruiting,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Children's Hospital of Alabama|Providence Alaska Medical Center|Banner Children's at Desert|Phoenix Childrens Hospital|Banner University Medical Center - Tucson|Arkansas Children's Hospital|Kaiser Permanente Downey Medical Center|City of Hope Comprehensive Cancer Center|Loma Linda University Medical Center|Miller Children's and Women's Hospital Long Beach|Children's Hospital Los Angeles|Cedars Sinai Medical Center|Mattel Children's Hospital UCLA|Valley Children's Hospital|UCSF Benioff Children's Hospital Oakland|Kaiser Permanente-Oakland|Children's Hospital of Orange County|Lucile Packard Children's Hospital Stanford University|University of California Davis Comprehensive Cancer Center|Rady Children's Hospital - San Diego|Naval Medical Center -San Diego|UCSF Medical Center-Mission Bay|Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center|Children's Hospital Colorado|Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center|Connecticut Children's Medical Center|Yale University|Alfred I duPont Hospital for Children|MedStar Georgetown University Hospital|Children's National Medical Center|Broward Health Medical Center|Golisano Children's Hospital of Southwest Florida|University of Florida Health Science Center - Gainesville|Memorial Regional Hospital/Joe DiMaggio Children's Hospital|Nemours Children's Clinic-Jacksonville|University of Miami Miller School of Medicine-Sylvester Cancer Center|Nicklaus Children's Hospital|Miami Cancer Institute|AdventHealth Orlando|Arnold Palmer Hospital for Children|Nemours Children's Hospital|Sacred Heart Hospital|Johns Hopkins All Children's Hospital|Tampa General Hospital|Saint Joseph's Hospital/Children's Hospital-Tampa|Saint Mary's Hospital|Children's Healthcare of Atlanta - Egleston|Memorial Health University Medical Center|Kapiolani Medical Center for Women and Children|Saint Luke's Cancer Institute - Boise|Lurie Children's Hospital-Chicago|University of Illinois|University of Chicago Comprehensive Cancer Center|Loyola University Medical Center|Saint Jude Midwest Affiliate|Southern Illinois University School of Medicine|Riley Hospital for Children|Saint Vincent Hospital and Health Care Center|Blank Children's Hospital|University of Iowa/Holden Comprehensive Cancer Center|University of Kentucky/Markey Cancer Center|Norton Children's Hospital|Children's Hospital New Orleans|Ochsner Medical Center Jefferson|Eastern Maine Medical Center|Maine Children's Cancer Program|University of Maryland/Greenebaum Cancer Center|Sinai Hospital of Baltimore|Johns Hopkins University/Sidney Kimmel Cancer Center|National Institutes of Health Clinical Center|Massachusetts General Hospital Cancer Center|Dana-Farber Cancer Institute|UMass Memorial Medical Center - University Campus|C S Mott Children's Hospital|Wayne State University/Karmanos Cancer Institute|Helen DeVos Children's Hospital at Spectrum Health|Bronson Methodist Hospital|Beaumont Children's Hospital-Royal Oak|Children's Hospitals and Clinics of Minnesota - Minneapolis|University of Minnesota/Masonic Cancer Center|Mayo Clinic in Rochester|University of Mississippi Medical Center|Children's Mercy Hospitals and Clinics|Cardinal Glennon Children's Medical Center|Washington University School of Medicine|Mercy Hospital Saint Louis|Children's Hospital and Medical Center of Omaha|University of Nebraska Medical Center|University Medical Center of Southern Nevada|Sunrise Hospital and Medical Center|Alliance for Childhood Diseases/Cure 4 the Kids Foundation|Summerlin Hospital Medical Center|Renown Regional Medical Center|Dartmouth Hitchcock Medical Center|Hackensack University Medical Center|Morristown Medical Center|Saint Peter's University Hospital|Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital|Albany Medical Center|Montefiore Medical Center - Moses Campus|Roswell Park Cancer Institute|NYU Winthrop Hospital|The Steven and Alexandra Cohen Children's Medical Center of New York|Laura and Isaac Perlmutter Cancer Center at NYU Langone|NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center|Memorial Sloan Kettering Cancer Center|NYP/Weill Cornell Medical Center|University of Rochester|Stony Brook University Medical Center|State University of New York Upstate Medical University|New York Medical College|Mission Hospital|UNC Lineberger Comprehensive Cancer Center|Carolinas Medical Center/Levine Cancer Institute|Novant Health Presbyterian Medical Center|Duke University Medical Center|East Carolina University|Wake Forest University Health Sciences|Sanford Broadway Medical Center|Children's Hospital Medical Center of Akron|Cincinnati Children's Hospital Medical Center|Rainbow Babies and Childrens Hospital|Cleveland Clinic Foundation|Nationwide Children's Hospital|Dayton Children's Hospital|ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital|University of Oklahoma Health Sciences Center|Legacy Emanuel Children's Hospital|Oregon Health and Science University|Lehigh Valley Hospital-Cedar Crest|Geisinger Medical Center|Children's Hospital of Philadelphia|Saint Christopher's Hospital for Children|Children's Hospital of Pittsburgh of UPMC|Rhode Island Hospital|Prisma Health Richland Hospital|BI-LO Charities Children's Cancer Center|Sanford USD Medical Center - Sioux Falls|T C Thompson Children's Hospital|East Tennessee Childrens Hospital|Saint Jude Children's Research Hospital|The Children's Hospital at TriStar Centennial|Vanderbilt University/Ingram Cancer Center|Dell Children's Medical Center of Central Texas|Driscoll Children's Hospital|Medical City Dallas Hospital|UT Southwestern/Simmons Cancer Center-Dallas|El Paso Children's Hospital|Cook Children's Medical Center|Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center|M D Anderson Cancer Center|Covenant Children's Hospital|UMC Cancer Center / UMC Health System|Children's Hospital of San Antonio|Methodist Children's Hospital of South Texas|University of Texas Health Science Center at San Antonio|Scott and White Memorial Hospital|Primary Children's Hospital|University of Vermont and State Agricultural College|Children's Hospital of The King's Daughters|Naval Medical Center - Portsmouth|Virginia Commonwealth University/Massey Cancer Center|Seattle Children's Hospital|Providence Sacred Heart Medical Center and Children's Hospital|Mary Bridge Children's Hospital and Health Center|Madigan Army Medical Center|West Virginia University Healthcare|University of Wisconsin Carbone Cancer Center|Marshfield Medical Center-Marshfield|Children's Hospital of Wisconsin|University Pediatric Hospital,Drug,Puerto Rico|United States,12.0,21.0,[0-17]|[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04284774
NCT04288115,hypothyroidism,"Discontinuation of Levothyroxine Therapy for Patients With Subclinical Hypothyroidism: a Pilot Randomized, Double-blinded, Placebo-controlled Study",Discontinuation of Levothyroxine Therapy for Patients With Subclinical Hypothyroidism,Subclinical Hypothyroidism,2020-02-14,2022-05-31,2022-12-31,Interventional,Recruiting,Phase 4,VA Office of Research and Development,Central Arkansas Veterans Healthcare System|VA Office of Research and Development,"Central Arkansas Veterans Healthcare System Eugene J. Towbin Healthcare Center, Little Rock, AR",Drug|Other,United States,18.0,89.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04288115
NCT04288531,hypothyroidism,"Observational Study on the Impact of Iodine Supplementation on Maternal and Child's Thyroid Hormone Homeostasis and on the Child's Psychomotor Development, in the Portuguese Minho Region (IodineMinho)","Iodine Impact on Thyroid Function and Psychomotor Development, Observational Study in the Portuguese Minho Region",Hypothyroidism in Pregnancy|Iodine Deficiency|Nutrient Deficiency|Pregnancy Related|Psychomotor Impairment|Thyroid,2020-02-25,2024-01-10,2025-01-10,Observational,Recruiting,,University of Minho,"Administração Regional de Saúde do Norte, Portugal|Clinical Academic Center (2CA-Braga)|Hospital de Braga|Instituto Nacional de Saúde Dr Ricardo Jorge, Portugal|University of Minho",Usf Maxisaude|Usf Braga Norte|Usf Ruães|Usf S. Lourenço|Usf Gualtar|Usf + Carandá|Usf Manuel Rocha Peixoto|Usf Bracara Augusta|Usf Do Minho|Usf S. João de Braga,Dietary Supplement,Portugal,18.0,50.0,[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04288531
NCT04298684,thyroid neoplasms,Efficacy of Metformin Versus Sitagliptin on Benign Thyroid Nodules Size in Type 2 Diabetes: a 2-years Prospective Multicentric Study,Efficacy of Metformin Versus Sitagliptin on Benign Thyroid Nodules in Type 2 Diabetes,"Diabetes Mellitus, Type 2|Thyroid Nodule (Benign)",2020-02-05,2022-02-01,2024-07-01,Interventional,Not yet recruiting,Phase 4,Centre Hospitalier Universitaire de Pointe-a-Pitre,Centre Hospitalier Universitaire de Pointe-a-Pitre,CHU Bordeaux|CHU Limoges|University Hospital Center of Guadeloupe|CHU de la Réunion,Drug|Drug,France|Guadeloupe|Réunion,18.0,65.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04298684
NCT04298684,thyroid nodule,Efficacy of Metformin Versus Sitagliptin on Benign Thyroid Nodules Size in Type 2 Diabetes: a 2-years Prospective Multicentric Study,Efficacy of Metformin Versus Sitagliptin on Benign Thyroid Nodules in Type 2 Diabetes,"Diabetes Mellitus, Type 2|Thyroid Nodule (Benign)",2020-02-05,2022-02-01,2024-07-01,Interventional,Not yet recruiting,Phase 4,Centre Hospitalier Universitaire de Pointe-a-Pitre,Centre Hospitalier Universitaire de Pointe-a-Pitre,CHU Bordeaux|CHU Limoges|University Hospital Center of Guadeloupe|CHU de la Réunion,Drug|Drug,France|Guadeloupe|Réunion,18.0,65.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04298684
NCT04299425,hyperparathyroidism,Evaluating Impact of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy,Evaluating Impact of NIRAF Detection for Identifying Parathyroid Glands During Parathyroidectomy,Hypercalcemia|Parathyroid Adenoma|Parathyroid Cancer|Parathyroid Hyperplasia|Parathyroid Neoplasms|Primary Hyperparathyroidism,2020-03-04,2023-03-31,2023-09-30,Interventional,Recruiting,Not Applicable,Vanderbilt-Ingram Cancer Center,National Cancer Institute (NCI)|Vanderbilt-Ingram Cancer Center,Vanderbilt University Medical Center,Device,United States,18.0,99.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04299425
NCT04304794,thyrotoxicosis,Prevention of Iodinated Contrast Media Induced Hyperthyroidism in Patients With Euthyroid Goiter,Iodinated Contrast Media Induced Hyperthyroidism,Contrast Media Adverse Reaction|Hyperthyroidism; Goiter|Hyperthyroidism/Thyrotoxicosis|Iodine Induced Thyrotoxicosis|Thyrotoxicosis of Other Specified Origin,2020-03-03,2020-02-20,2020-02-20,Observational,Completed,,Medical University of Warsaw,"Institute of Cardiology, Warsaw, Poland|Medical University of Warsaw",,Procedure|Drug,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04304794
NCT04304794,goiter,Prevention of Iodinated Contrast Media Induced Hyperthyroidism in Patients With Euthyroid Goiter,Iodinated Contrast Media Induced Hyperthyroidism,Contrast Media Adverse Reaction|Hyperthyroidism; Goiter|Hyperthyroidism/Thyrotoxicosis|Iodine Induced Thyrotoxicosis|Thyrotoxicosis of Other Specified Origin,2020-03-03,2020-02-20,2020-02-20,Observational,Completed,,Medical University of Warsaw,"Institute of Cardiology, Warsaw, Poland|Medical University of Warsaw",,Procedure|Drug,,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04304794
NCT04305561,hyperparathyroidism,Comparison of CEUS With Conventional Ultrasound (US) to Dual-tracer 99mTcO4-/99mTc-MIBI Subtraction Scintigraphy With SPECT/CT for Localizing Pathological Parathyroid Glands in Patients With Primary Hyperparathyroidism,Preoperative Localization Strategies in Primary Hyperparathyroidism,Primary Hyperparathyroidism,2020-01-24,2021-12-31,2021-12-31,Interventional,Completed,Not Applicable,Odense University Hospital,Odense University Hospital,Odense University Hospital,Procedure,Denmark,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04305561
NCT04311606,hyperthyroidism,Anti-VEGF Therapy for Acute Thyroid Eye Disease (AcTED Study),Anti-VEGF Therapy for Acute Thyroid Eye Disease,Thyroid Eye Disease,2020-03-12,2025-09-30,2027-01-01,Interventional,Recruiting,Phase 2,Massachusetts Eye and Ear Infirmary,Massachusetts Eye and Ear Infirmary|Regeneron Pharmaceuticals,Mass Eye and Ear,Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04311606
NCT04311606,graves disease,Anti-VEGF Therapy for Acute Thyroid Eye Disease (AcTED Study),Anti-VEGF Therapy for Acute Thyroid Eye Disease,Thyroid Eye Disease,2020-03-12,2025-09-30,2027-01-01,Interventional,Recruiting,Phase 2,Massachusetts Eye and Ear Infirmary,Massachusetts Eye and Ear Infirmary|Regeneron Pharmaceuticals,Mass Eye and Ear,Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04311606
NCT04311606,goiter,Anti-VEGF Therapy for Acute Thyroid Eye Disease (AcTED Study),Anti-VEGF Therapy for Acute Thyroid Eye Disease,Thyroid Eye Disease,2020-03-12,2025-09-30,2027-01-01,Interventional,Recruiting,Phase 2,Massachusetts Eye and Ear Infirmary,Massachusetts Eye and Ear Infirmary|Regeneron Pharmaceuticals,Mass Eye and Ear,Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04311606
NCT04312646,thyroid neoplasms,Added Value of Ultrasound Elasatography in Characterization of Thyroid Nodules,Elastography in Thyroid Nodules,Thyroid Nodule,2020-03-16,2021-04-01,2022-04-01,Observational,Unknown status,,Assiut University,Assiut University,,Device,,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04312646
NCT04329455,thyroid nodule,Evaluation of Endoscopic Thyroidectomy Via Axillo-breast Approach in Thyroid Nodules,Evaluation of Endoscopic Thyroidectomy Via Axillo-breast Approach in Thyroid Nodules,Safety and Cosmetic Issues in Endoscopic Thyroidectomy,2020-03-30,2022-04-01,2023-04-01,Observational,Recruiting,,Assiut University,Assiut University,Ahmed Gamal,Procedure,Egypt,18.0,55.0,[18-65],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04329455
NCT04329455,thyroid neoplasms,Evaluation of Endoscopic Thyroidectomy Via Axillo-breast Approach in Thyroid Nodules,Evaluation of Endoscopic Thyroidectomy Via Axillo-breast Approach in Thyroid Nodules,Safety and Cosmetic Issues in Endoscopic Thyroidectomy,2020-03-30,2022-04-01,2023-04-01,Observational,Recruiting,,Assiut University,Assiut University,Ahmed Gamal,Procedure,Egypt,18.0,55.0,[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04329455
NCT04333342,graves disease,Clinical Usefulness of Monitoring Heart Rate Using Wearable Devices in the Patients of Graves' Disease Who Discontinue Anti-thyroid Drugs,Heart Rate Monitoring by Wearable Devices in Graves' Disease,Graves' Disease in Remission (Disorder),2020-03-11,2021-09-30,2021-12-31,Interventional,Recruiting,Not Applicable,Seoul National University Bundang Hospital,Seoul National University Bundang Hospital,Chungbuk National University Hospital|Chung-Ang University Hospital|Eulji University Nowon Eulji Medical Center|Korea University Guro Hospital|Seoul National University Hospital|The Catholic University of Korea Eunpyeong St. Mary's Hospital,Device,"Korea, Republic of",20.0,60.0,[18-65],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04333342
NCT04333342,goiter,Clinical Usefulness of Monitoring Heart Rate Using Wearable Devices in the Patients of Graves' Disease Who Discontinue Anti-thyroid Drugs,Heart Rate Monitoring by Wearable Devices in Graves' Disease,Graves' Disease in Remission (Disorder),2020-03-11,2021-09-30,2021-12-31,Interventional,Recruiting,Not Applicable,Seoul National University Bundang Hospital,Seoul National University Bundang Hospital,Chungbuk National University Hospital|Chung-Ang University Hospital|Eulji University Nowon Eulji Medical Center|Korea University Guro Hospital|Seoul National University Hospital|The Catholic University of Korea Eunpyeong St. Mary's Hospital,Device,"Korea, Republic of",20.0,60.0,[18-65],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04333342
NCT04333342,hyperthyroidism,Clinical Usefulness of Monitoring Heart Rate Using Wearable Devices in the Patients of Graves' Disease Who Discontinue Anti-thyroid Drugs,Heart Rate Monitoring by Wearable Devices in Graves' Disease,Graves' Disease in Remission (Disorder),2020-03-11,2021-09-30,2021-12-31,Interventional,Recruiting,Not Applicable,Seoul National University Bundang Hospital,Seoul National University Bundang Hospital,Chungbuk National University Hospital|Chung-Ang University Hospital|Eulji University Nowon Eulji Medical Center|Korea University Guro Hospital|Seoul National University Hospital|The Catholic University of Korea Eunpyeong St. Mary's Hospital,Device,"Korea, Republic of",20.0,60.0,[18-65],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04333342
NCT04339127,thyroiditis,Study of 12 Cases of Autoimmune Encephalitis With Anti-NMDA Receptor Antibodies Following Herpetic Encephalitis and Review of the Literature,Autoimmune Encephalitis With Anti-NMDA Receptor Antibodies Following Herpetic Encephalitis,Anti NMDA Receptor Encephalitis|Autoimmune Encephalitis|Herpetic Encephalitis,2020-04-06,2020-06-01,2020-10-01,Observational,Unknown status,,Hospices Civils de Lyon,Hospices Civils de Lyon,Hospice Civils de Lyon,Other,France,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT04339127
NCT04339205,hashimoto disease,Diffusion Imaging in Acute Auto-immune Encephalitis : a Cohort of 80 Patients,Diffusion Imaging in Acute Auto-immune Encephalitis,Auto-immune Encephalitis,2020-04-06,2020-03-01,2020-07-01,Observational,Recruiting,,Hospices Civils de Lyon,Hospices Civils de Lyon,Hospices Civils de Lyon,Other,France,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT04339205
NCT04344886,hyperparathyroidism,Optimization and Individualization of Diagnostic Scintigraphy Protocol and Minimally Invasive Radio-guided Parathyroid Surgery Using Quantitative Analysis of Scintigraphy Results on Hybrid SPECT-CT Imaging,Optimization and Individualization of Diagnostic Scintigraphy Protocol and Minimally Invasive Radio-guided Parathyroid Surgery,Parathyroid Adenoma|Parathyroid Diseases|Primary Hyperparathyroidism|Thyroid Disease,2020-04-09,2020-11-30,2020-12-31,Interventional,Unknown status,Not Applicable,University Hospital Ostrava,University Hospital Ostrava,University Hospital Ostrava,Procedure|Procedure|Procedure|Procedure,Czechia,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04344886
NCT04344886,parathyroid neoplasms,Optimization and Individualization of Diagnostic Scintigraphy Protocol and Minimally Invasive Radio-guided Parathyroid Surgery Using Quantitative Analysis of Scintigraphy Results on Hybrid SPECT-CT Imaging,Optimization and Individualization of Diagnostic Scintigraphy Protocol and Minimally Invasive Radio-guided Parathyroid Surgery,Parathyroid Adenoma|Parathyroid Diseases|Primary Hyperparathyroidism|Thyroid Disease,2020-04-09,2020-11-30,2020-12-31,Interventional,Unknown status,Not Applicable,University Hospital Ostrava,University Hospital Ostrava,University Hospital Ostrava,Procedure|Procedure|Procedure|Procedure,Czechia,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04344886
NCT04354896,hypothyroidism,The Effect of Thyroid Hormone Therapy on Muscle Mass and Function in Older Adults With Subclinical Hypothyroidism - a Substudy of TRUST and IEMO Trials,The Effect of Thyroid Hormone Therapy on Muscle Mass and Function in Older Adults With Subclinical Hypothyroidism,Sarcopenia|Subclinical Hypothyroidism,2020-04-08,2018-05-04,2018-05-04,Interventional,Completed,Phase 4,"University Hospital Inselspital, Berne","Leiden University Medical Center|University Hospital Inselspital, Berne|University of Lausanne Hospitals","Department of Gerontology and Geriatrics, Leiden University Medical Center|Department of Public Health and Primary Care, Leiden University Medical Center|Institute for Evidence-Based Medicine in Old Age|Department of General Internal Medicine|Clinic for General Internal Medicine, Bern University Hospital Bern",Drug|Drug,Netherlands|Switzerland,65.0,120.0,[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04354896
NCT04359979,goiter,Treatment With Tamsulosin for Upper Eyelid Retraction Related to Thyroid Eye Disease.,Tamsulosin for Thyroid Lid Retraction,Eyelid Diseases|Thyroid Eye Disease,2020-04-21,2021-05-31,2021-12-31,Interventional,Recruiting,Not Applicable,Sheba Medical Center,Sheba Medical Center,Sheba Medical Center,Drug,Israel,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04359979
NCT04359979,graves disease,Treatment With Tamsulosin for Upper Eyelid Retraction Related to Thyroid Eye Disease.,Tamsulosin for Thyroid Lid Retraction,Eyelid Diseases|Thyroid Eye Disease,2020-04-21,2021-05-31,2021-12-31,Interventional,Recruiting,Not Applicable,Sheba Medical Center,Sheba Medical Center,Sheba Medical Center,Drug,Israel,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04359979
NCT04359979,hyperthyroidism,Treatment With Tamsulosin for Upper Eyelid Retraction Related to Thyroid Eye Disease.,Tamsulosin for Thyroid Lid Retraction,Eyelid Diseases|Thyroid Eye Disease,2020-04-21,2021-05-31,2021-12-31,Interventional,Recruiting,Not Applicable,Sheba Medical Center,Sheba Medical Center,Sheba Medical Center,Drug,Israel,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04359979
NCT04373226,hypoparathyroidism,Study of Arithmetic Abilities of Children With 22q11.2 Deletion Syndrome Aged From 4 to 11 Years Old,Arithmetic Abilities in Children With 22q11.2DS,22q11.2 Deletion Syndrome,2020-04-30,2023-07-20,2023-10-20,Interventional,Recruiting,Not Applicable,Hôpital le Vinatier,Hôpital le Vinatier,Hopital Vinatier,Behavioral,France,4.0,11.0,[0-17],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04373226
NCT04376203,thyroid neoplasms,What is the Relation of Microbiome to Papillary Thyroid Microcarcinoma Development?,Microbiome and Papillary Thyroid Microcarcinoma,Microbiome|Papillary Thyroid Microcarcinoma,2020-05-02,2022-05-30,2023-05-30,Observational,Not yet recruiting,,University of Ioannina,University of Ioannina,,Procedure,,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04376203
NCT04383795,hyperthyroidism,A Prospective Study Analyzing the Change of Gut Microbiome With Antithyroid Drug Treatment of Graves' Disease,Change of Gut Microbiome in the Treatment of Graves' Disease,Graves' Disease,2020-05-07,2021-05-04,2023-05-04,Observational,Recruiting,,Seoul St. Mary's Hospital,Seoul St. Mary's Hospital,Seoul St. Mary hospital,Drug,"Korea, Republic of",19.0,69.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04383795
NCT04383795,graves disease,A Prospective Study Analyzing the Change of Gut Microbiome With Antithyroid Drug Treatment of Graves' Disease,Change of Gut Microbiome in the Treatment of Graves' Disease,Graves' Disease,2020-05-07,2021-05-04,2023-05-04,Observational,Recruiting,,Seoul St. Mary's Hospital,Seoul St. Mary's Hospital,Seoul St. Mary hospital,Drug,"Korea, Republic of",19.0,69.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04383795
NCT04383795,goiter,A Prospective Study Analyzing the Change of Gut Microbiome With Antithyroid Drug Treatment of Graves' Disease,Change of Gut Microbiome in the Treatment of Graves' Disease,Graves' Disease,2020-05-07,2021-05-04,2023-05-04,Observational,Recruiting,,Seoul St. Mary's Hospital,Seoul St. Mary's Hospital,Seoul St. Mary hospital,Drug,"Korea, Republic of",19.0,69.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04383795
NCT04391439,hyperthyroidism,Increased Heart Rhythm in Response to High-dose Intravenous Methylprednisolone Pulse Therapy of Moderate-to-severe Graves' Orbitopathy,Heart Rhythm After Intravenous Methylprednisolone Administration,Blood Pressure|Graves Disease|Graves Ophthalmopathy|Heart Failure|Heart Rhythm Disorder|Hypertension,2020-05-05,2020-02-20,2020-02-20,Observational,Completed,,Medical University of Warsaw,Medical University of Warsaw,,Drug,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04391439
NCT04391439,goiter,Increased Heart Rhythm in Response to High-dose Intravenous Methylprednisolone Pulse Therapy of Moderate-to-severe Graves' Orbitopathy,Heart Rhythm After Intravenous Methylprednisolone Administration,Blood Pressure|Graves Disease|Graves Ophthalmopathy|Heart Failure|Heart Rhythm Disorder|Hypertension,2020-05-05,2020-02-20,2020-02-20,Observational,Completed,,Medical University of Warsaw,Medical University of Warsaw,,Drug,,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04391439
NCT04396158,thyroid neoplasms,Effect of Radioiodine Therapy on Ovarian Reserve in Female Patients With Differentiated Thyroid Cancer,Effect of Radioiodine Therapy on Ovarian Reserve in Female Patients With Differentiated Thyroid Cancer,Ovarian Insufficiency|Radiation Exposure,2020-05-16,2021-06-15,2021-12-15,Interventional,Not yet recruiting,Not Applicable,Assiut University,Assiut University,,Radiation,,15.0,45.0,[0-17]|[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04396158
NCT04396912,hypoparathyroidism,"Post-thyroidectomy Vocal Cord Paralysis Along With Hypocalcemia: Prospective, Matched-randomized Observational Cohort Compatible With STROBE Guidelines",Post-thyroidectomy Vocal Cord Paralysis Along With Hypocalcemia: STROBE - Guided Prospective Cohort,"Calcium Deficiency|Iatrogenic Hypocalcemia|Iatrogenic Hypoparathyroidism|Multinodular Goiter|PTH|Thyroid Cancer|Thyroid Cancer, Papillary|Thyroid Neoplasms|Thyroid Nodule|Vocal Cord; Injury, Superficial|Vocal Cord Paralysis|Vocal Cord Paresis",2020-05-15,2021-06-01,2021-06-01,Observational,Recruiting,,Umraniye Education and Research Hospital,Umraniye Education and Research Hospital,"Umraniye Education and Research Hospital, Health Sciences University",Procedure,Turkey,17.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04396912
NCT04410601,goiter,Pre-and Post-operative Risk Factors Affecting the Incidence and Severity of Dysphagia Following Total Thyroidectomy: An International Multi-centric Prospective Randomized Controlled Clinical Trial (RCT),Post-thyroidectomy Dysphagia: An International Multicentric CONSORT - Compatible RCT,"Dysphagia Comes and Goes|Dysphagia, Esophageal|Dysphagia, Oral Phase|Thyroid Cancer|Thyroid Goiter|Thyroiditis|Thyroid Neoplasms|Thyroid Nodule (Benign)",2020-05-15,2021-06-30,2021-06-30,Interventional,Recruiting,Not Applicable,Umraniye Education and Research Hospital,Umraniye Education and Research Hospital,"Umraniye Education and Research Hospital, Health Sciences University",Procedure,Turkey,17.0,120.0,[0-17]|[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04410601
NCT04410601,thyroid nodule,Pre-and Post-operative Risk Factors Affecting the Incidence and Severity of Dysphagia Following Total Thyroidectomy: An International Multi-centric Prospective Randomized Controlled Clinical Trial (RCT),Post-thyroidectomy Dysphagia: An International Multicentric CONSORT - Compatible RCT,"Dysphagia Comes and Goes|Dysphagia, Esophageal|Dysphagia, Oral Phase|Thyroid Cancer|Thyroid Goiter|Thyroiditis|Thyroid Neoplasms|Thyroid Nodule (Benign)",2020-05-15,2021-06-30,2021-06-30,Interventional,Recruiting,Not Applicable,Umraniye Education and Research Hospital,Umraniye Education and Research Hospital,"Umraniye Education and Research Hospital, Health Sciences University",Procedure,Turkey,17.0,120.0,[0-17]|[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04410601
NCT04411290,goiter,"Correlation of Malignancy Predictors, Bethesda (I-VI) and TI-RADS Scores (I-V) With Final Histopathology in Patients Undergoing Total Thyroidectomy 34 Years After Chernobyl Disaster: Multi-centric Trial","Malignancy Predictors, Bethesda and TI-RADS Scores Correlated With Final Histopathology in Thyroid Diseases","Aspiration|Multifocal Dysplasia|Multinodular Goiter, Adolescent|Solitary Thyroid Nodule|Thyroid Cancer, Papillary|Thyroid Carcinoma|Thyroid Diseases|Thyroid Goiter|Thyroid Neoplasms|Thyroid Nodule|Thyroid Papillary Carcinoma",2020-05-15,2021-06-01,2021-06-01,Observational,Enrolling by invitation,,Umraniye Education and Research Hospital,Umraniye Education and Research Hospital,"Umraniye Education and Research Hospital, Health Sciences Universit",Procedure,Turkey,17.0,120.0,[0-17]|[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04411290
NCT04412694,hypoparathyroidism,The Impact of Preoperative Oral Dexamethasone Supplementation on the Biochemical Parameters and Results of Surgical Treatment in Patients With Nontoxic Multinodular Goiter Undergoing Total Thyroidectomy.,The Effect of Preoperative Oral Dexamethasone Supplementation on the Outcome of Thyroidectomised Patients.,Hypocalcemia|Hypoparathyroidism Postprocedural|Postoperative Complications|Postoperative Nausea|Postoperative Pain|Vitamin D Deficiency|Voice Hoarseness,2020-05-23,2022-09-30,2022-12-31,Interventional,Recruiting,Phase 4,Medical University of Lodz,Medical University of Lodz,"Department of General and Oncological Surgery, Medical University of Lodz",Drug|Drug|Diagnostic Test|Diagnostic Test|Diagnostic Test|Diagnostic Test|Procedure|Other|Other|Other|Other|Other|Other|Other|Other,Poland,18.0,100.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04412694
NCT04424485,"thyroid cancer, papillary",Near-infrared (NIR) Fluorescence Imaging With Indocyanine Green (ICG) for Identification of Sentinel Lymph Nodes and Parathyroid Glands During Total Thyroidectomy: Prospective Randomized Clinical Trial,Near-infrared Fluorescence With Indocyanine Green for Identification of Sentinels and Parathyroids During Thyroidectomy,"Lymph Node Metastases|Sentinel Lymph Node|Thyroid Cancer|Thyroid Carcinoma, Papillary|Thyroid Metastases|Thyroid Neoplasms",2020-06-02,2021-06-01,2021-06-01,Interventional,Recruiting,Not Applicable,Umraniye Education and Research Hospital,Umraniye Education and Research Hospital,"Umraniye Education and Research Hospital, Department of General Surgery",Procedure|Procedure|Diagnostic Test|Diagnostic Test,Turkey,17.0,80.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT04424485
NCT04433936,hyperthyroidism,Corneal Tomographic Analysis Among Patients With Thyroid Gland Dysfunction.,Corneal Tomographic Parameters in TGD,Corneal Ectasia|Keratoconus|Thyroid Eye Disease,2020-06-13,2018-06-01,2018-06-01,Observational,Completed,,Mansoura University,Ameera Gamal Abdelhameed,Mansoura University,Diagnostic Test,Egypt,0.0,120.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04433936
NCT04433936,graves disease,Corneal Tomographic Analysis Among Patients With Thyroid Gland Dysfunction.,Corneal Tomographic Parameters in TGD,Corneal Ectasia|Keratoconus|Thyroid Eye Disease,2020-06-13,2018-06-01,2018-06-01,Observational,Completed,,Mansoura University,Ameera Gamal Abdelhameed,Mansoura University,Diagnostic Test,Egypt,0.0,120.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04433936
NCT04433936,goiter,Corneal Tomographic Analysis Among Patients With Thyroid Gland Dysfunction.,Corneal Tomographic Parameters in TGD,Corneal Ectasia|Keratoconus|Thyroid Eye Disease,2020-06-13,2018-06-01,2018-06-01,Observational,Completed,,Mansoura University,Ameera Gamal Abdelhameed,Mansoura University,Diagnostic Test,Egypt,0.0,120.0,[0-17]|[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04433936
NCT04450472,euthyroid sick syndromes,Nonthyroidal Illness Syndrome in Patients With Short Bowel Syndrome,Nonthyroidal Illness Syndrome in SBS,Nonthyroidal Illness Syndrome|Short Bowel Syndrome,2020-06-25,2018-12-31,2018-12-31,Observational,Completed,,"Jinling Hospital, China","Jinling Hospital, China",,,,18.0,120.0,[18-65]|[65 and more],Euthyroid Sick Syndromes,Euthyroid Sick Syndromes,https://clinicaltrials.gov/ct2/show/NCT04450472
NCT04458233,thyroid neoplasms,FNA Guided Ultrasonography Needle Technique Axial Vs Lateral Approach Study,FNA Guided Ultrasonography Needle Technique Axial Vs Lateral Approach Study,Thyroid Nodule,2020-06-30,2021-06-01,2021-07-01,Interventional,Recruiting,Not Applicable,Ziv Hospital,Ziv Hospital,Ziv Medical Center,Procedure,Israel,18.0,85.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04458233
NCT04463316,hypoparathyroidism,GROWing Up With Rare GENEtic Syndromes ….When Children With Complex Genetic Syndromes Reach Adult Age,GROWing Up With Rare GENEtic Syndromes,"17p- Deletiesyndrome|1q25-32 Deletie|22q11 Deletion Syndrome|46, XY DSD|Albright Hereditaire Osteodystrofie|Allan-Herndon-Dudley Syndrome|Bardet Biedl Syndrome|CHARGE Syndrome|Congenital Adrenal Hyperplasia|Congenital Hypopituitarism|Cornelia de Lange Syndrome|Disorders of Sex Development|Jacobsen Syndrome / 11 q Syndrome|Kallmann Syndrome|Klinefelter (XXY-)Syndrome|Myrhe Syndrome|Neurofibromatosis|Noonan Syndrome|Ohdo Syndrome|POLR3A Mutatie|Prader-Willi Syndrome|PWS-like Syndrome|Rare Bone Disorders|Rett Syndrome|Saethre-Chotzen Syndrome|Silver Russel Syndrome|Tuberous Sclerosis|Turner Syndrome|VCF Syndrome|Williams-Beuren Syndrome|XXXX Syndrome (Tetra-X Syndrome)|XXXXY Syndrome|XXYY Syndrome",2020-07-02,2030-01-01,2030-01-01,Observational,Recruiting,,Erasmus Medical Center,dr. Laura C. G. de Graaff-Herder,Erasmus Medical Center,Diagnostic Test,Netherlands,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04463316
NCT04463719,thyroid nodule,Adequate Selection of Patients for Thyroid Biopsy: Evaluation of a Shared Decision Making Conversation Aid,AIM2: Adequate Selection of Patients for Thyroid Biopsy: Evaluation of a Shared Decision Making Conversation Aid,Thyroid Cancer|Thyroid Nodules,2020-07-06,2022-06-30,2025-06-30,Interventional,Not yet recruiting,Not Applicable,University of Florida,National Cancer Institute (NCI)|University of Florida,University of Florida|Mayo Clinic,Behavioral|Behavioral,United States,18.0,99.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04463719
NCT04467021,thyroid neoplasms,Cancer Therapy Risk-Reduction With Intensive Systolic BP Management (CARISMA) - a Phase II Study,"Cancer and Blood Pressure Management, CARISMA Study",Cardiovascular Disorder|Chronic Kidney Disease|Metastatic Renal Cell Carcinoma|Metastatic Thyroid Gland Medullary Carcinoma|Stage IVA Thyroid Gland Medullary Carcinoma AJCC v8|Stage IVB Thyroid Gland Medullary Carcinoma AJCC v8|Stage IVC Thyroid Gland Medullary Carcinoma AJCC v8|Stage IV Renal Cell Cancer AJCC v8|Stage IV Thyroid Gland Medullary Carcinoma AJCC v8,2020-07-07,2023-02-01,2023-02-01,Interventional,Recruiting,Not Applicable,Eastern Cooperative Oncology Group,ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI),Siteman Cancer Center at West County Hospital|Washington University School of Medicine|Montefiore Medical Center-Einstein Campus|Montefiore Medical Center-Weiler Hospital|Montefiore Medical Center - Moses Campus|University of Pennsylvania/Abramson Cancer Center|University of Pittsburgh Cancer Institute (UPCI)|UT Southwestern/Simmons Cancer Center-Dallas|Aurora Cancer Care-Southern Lakes VLCC|Aurora Saint Luke's South Shore|Aurora Health Care Germantown Health Center|Aurora Cancer Care-Grafton|Aurora BayCare Medical Center|Aurora Cancer Care-Kenosha South|Aurora Bay Area Medical Group-Marinette|Aurora Cancer Care-Milwaukee|Aurora Saint Luke's Medical Center|Aurora Sinai Medical Center|Vince Lombardi Cancer Clinic - Oshkosh|Aurora Cancer Care-Racine|Vince Lombardi Cancer Clinic-Sheboygan|Aurora Medical Center in Summit|Vince Lombardi Cancer Clinic-Two Rivers|Aurora Cancer Care-Milwaukee West|Aurora West Allis Medical Center,Other|Other|Other|Other|Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04467021
NCT04472026,thyroid nodule,Adequate Selection of Patients for Thyroid Biopsy: Evaluation of a Shared Decision Making Conversation Aid,AIM1: Adequate Selection of Patients for Thyroid Biopsy: Evaluation of a Shared Decision Making Conversation Aid,Thyroid Cancer|Thyroid Nodules,2020-07-10,2022-06-30,2025-06-30,Interventional,Recruiting,Not Applicable,University of Florida,National Cancer Institute (NCI)|University of Florida,University of Florida|Mayo Clinic,Behavioral,United States,18.0,99.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04472026
NCT04477798,thyroid neoplasms,Protein Classifier for Thyroid Indeterminate Nodules： a Multi-center Prospective Clinical Study,Protein Classifier for Thyroid Indeterminate Nodules,Thyroid Nodule,2020-07-10,2021-07-01,2021-12-31,Interventional,Recruiting,Not Applicable,Zhejiang University,Luo Dingcun,Hangzhou First People's Hospital Affiliated to Zhejiang University Medical College,Diagnostic Test,China,18.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04477798
NCT04482907,thyroid neoplasms,Randomized Placebo Controlled Clinical Study of Anethum Graveolens L. (Dill) in Thyroiditis and Nodular Goiter Patients,Effect of Dill in Thyroiditis and Nodular Goiter Patients,Thyroid Nodule,2020-07-16,2019-12-16,2020-04-05,Interventional,Completed,Not Applicable,Bezmialem Vakif University,Bezmialem Vakif University,Sabahattin Destek,Dietary Supplement,Turkey,18.0,76.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04482907
NCT04482907,"goiter, nodular",Randomized Placebo Controlled Clinical Study of Anethum Graveolens L. (Dill) in Thyroiditis and Nodular Goiter Patients,Effect of Dill in Thyroiditis and Nodular Goiter Patients,Thyroid Nodule,2020-07-16,2019-12-16,2020-04-05,Interventional,Completed,Not Applicable,Bezmialem Vakif University,Bezmialem Vakif University,Sabahattin Destek,Dietary Supplement,Turkey,18.0,76.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04482907
NCT04482907,thyroiditis,Randomized Placebo Controlled Clinical Study of Anethum Graveolens L. (Dill) in Thyroiditis and Nodular Goiter Patients,Effect of Dill in Thyroiditis and Nodular Goiter Patients,Thyroid Nodule,2020-07-16,2019-12-16,2020-04-05,Interventional,Completed,Not Applicable,Bezmialem Vakif University,Bezmialem Vakif University,Sabahattin Destek,Dietary Supplement,Turkey,18.0,76.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT04482907
NCT04484116,hyperparathyroidism,USEFULNESS OF IOPTH AS A PREDICTOR FOR SUCCESSFUL PARATHYROIDECTOMY IN SECONDARY HYPERPARATHYROIDISM: A COHORT STUDY,IOPTH Usefulness for Predicting Successful Surgery in Secondary Hyperparathyroidism,Secondary Hyperparathyroidism,2020-07-20,2019-11-30,2019-11-30,Observational,Completed,,Hospital General Ajusco Medio,Hospital General Ajusco Medio,Hospital General Ajusco Medio,Diagnostic Test,Mexico,18.0,90.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04484116
NCT04488406,goiter,Genetics and Epigenetics of Graves' Orbitopathy,Genetics and Epigenetics of Graves' Orbitopathy,Graves Ophthalmopathy,2020-07-17,2020-03-31,2020-03-31,Observational,Completed,,University of Pisa,University of Pisa,Ospedale Cisanello-Endocrinology I and II,Other,Italy,18.0,85.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04488406
NCT04488406,graves disease,Genetics and Epigenetics of Graves' Orbitopathy,Genetics and Epigenetics of Graves' Orbitopathy,Graves Ophthalmopathy,2020-07-17,2020-03-31,2020-03-31,Observational,Completed,,University of Pisa,University of Pisa,Ospedale Cisanello-Endocrinology I and II,Other,Italy,18.0,85.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04488406
NCT04488406,hyperthyroidism,Genetics and Epigenetics of Graves' Orbitopathy,Genetics and Epigenetics of Graves' Orbitopathy,Graves Ophthalmopathy,2020-07-17,2020-03-31,2020-03-31,Observational,Completed,,University of Pisa,University of Pisa,Ospedale Cisanello-Endocrinology I and II,Other,Italy,18.0,85.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04488406
NCT04488640,thyroid neoplasms,Compliance of Thyroid Fine Needle Aspiration Biopsy and Trucut Biopsy Results With Thyroid Imaging Reporting and Data System Score and Surgical Pathology,Compliance of Thyroid Fine Needle Aspiration Biopsy and Trucut Biopsy Results With TIRADS Score and Surgical Pathology,Thyroid Nodule,2020-07-15,2020-01-01,2020-05-01,Observational,Completed,,Bezmialem Vakif University,Bezmialem Vakif University,,Procedure,,24.0,85.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04488640
NCT04509011,hypoparathyroidism,Randomized Controlled Trial of Fluobeam® LX Compared With Clinical Assessment of Parathyroid Glands to Counteract Postoperatively Failing Parathyroid Function With Low Blood Calcium After Thyroid Surgery,Autofluorescence vs Clinical Assessment of Parathyroid Glands During Thyroid Surgery,Hypoparathyroidism Postprocedural,2020-08-04,2022-12-31,2023-07-31,Interventional,Recruiting,Not Applicable,Region Skane,"Haukeland University Hospital|Hospital Rudolfstiftung|Jagiellonian University|Region Skane|Sahlgrenska University Hospital, Sweden","Rudolfstiftung|Haukeland University Hospital|Jagiellonian University Medical College|Sahlgrenska University Hospital|Skåne University Hospital, Department of Surgery, Lund",Device,Austria|Norway|Poland|Sweden,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04509011
NCT04514484,thyroid neoplasms,Pilot Trial of Nivolumab Plus Cabozantinib for Advanced Solid Tumors in Patients With HIV Infection,Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV,Advanced Differentiated Thyroid Gland Carcinoma|Advanced Head and Neck Carcinoma|Advanced Hepatocellular Carcinoma|Advanced Kaposi Sarcoma|Advanced Lung Non-Small Cell Carcinoma|Advanced Lung Small Cell Carcinoma|Advanced Malignant Solid Neoplasm|Advanced Melanoma|Advanced Ovarian Carcinoma|Advanced Prostate Carcinoma|Advanced Renal Cell Carcinoma|Advanced Thyroid Gland Medullary Carcinoma|Advanced Urothelial Carcinoma|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Castration-Resistant Prostate Carcinoma|Clinical Stage III Cutaneous Melanoma AJCC v8|Clinical Stage IV Cutaneous Melanoma AJCC v8|HIV Infection|Metastatic Differentiated Thyroid Gland Carcinoma|Metastatic Head and Neck Carcinoma|Metastatic Hepatocellular Carcinoma|Metastatic Kaposi Sarcoma|Metastatic Lung Non-Small Cell Carcinoma|Metastatic Lung Small Cell Carcinoma|Metastatic Malignant Solid Neoplasm|Metastatic Melanoma|Metastatic Ovarian Carcinoma|Metastatic Prostate Carcinoma|Metastatic Renal Cell Carcinoma|Metastatic Thyroid Gland Medullary Carcinoma|Metastatic Triple-Negative Breast Carcinoma|Metastatic Urothelial Carcinoma|Pathologic Stage IIIA Cutaneous Melanoma AJCC v8|Pathologic Stage IIIB Cutaneous Melanoma AJCC v8|Pathologic Stage IIIC Cutaneous Melanoma AJCC v8|Pathologic Stage III Cutaneous Melanoma AJCC v8|Pathologic Stage IIID Cutaneous Melanoma AJCC v8|Pathologic Stage IV Cutaneous Melanoma AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8|Recurrent Differentiated Thyroid Gland Carcinoma|Recurrent Head and Neck Carcinoma|Recurrent Hepatocellular Carcinoma|Recurrent Kaposi Sarcoma|Recurrent Lung Non-Small Cell Carcinoma|Recurrent Lung Small Cell Carcinoma|Recurrent Malignant Solid Neoplasm|Recurrent Melanoma|Recurrent Ovarian Carcinoma|Recurrent Prostate Carcinoma|Recurrent Renal Cell Carcinoma|Recurrent Thyroid Gland Medullary Carcinoma|Recurrent Triple-Negative Breast Carcinoma|Recurrent Urothelial Carcinoma|Refractory Differentiated Thyroid Gland Carcinoma|Stage IIIA1 Ovarian Cancer AJCC v8|Stage IIIA2 Ovarian Cancer AJCC v8|Stage IIIA Hepatocellular Carcinoma AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIA Ovarian Cancer AJCC v8|Stage IIIA Prostate Cancer AJCC v8|Stage IIIB Hepatocellular Carcinoma AJCC v8|Stage IIIB Lung Cancer AJCC v8|Stage IIIB Ovarian Cancer AJCC v8|Stage IIIB Prostate Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8|Stage IIIC Ovarian Cancer AJCC v8|Stage IIIC Prostate Cancer AJCC v8|Stage III Differentiated Thyroid Gland Carcinoma AJCC v8|Stage III Hepatocellular Carcinoma AJCC v8|Stage III Lung Cancer AJCC v8|Stage III Ovarian Cancer AJCC v8|Stage III Prostate Cancer AJCC v8|Stage III Renal Cell Cancer AJCC v8|Stage III Thyroid Gland Medullary Carcinoma AJCC v8|Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v8|Stage IVA Hepatocellular Carcinoma AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVA Ovarian Cancer AJCC v8|Stage IVA Prostate Cancer AJCC v8|Stage IVA Thyroid Gland Medullary Carcinoma AJCC v8|Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v8|Stage IVB Hepatocellular Carcinoma AJCC v8|Stage IVB Lung Cancer AJCC v8|Stage IVB Ovarian Cancer AJCC v8|Stage IVB Prostate Cancer AJCC v8|Stage IVB Thyroid Gland Medullary Carcinoma AJCC v8|Stage IVC Thyroid Gland Medullary Carcinoma AJCC v8|Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8|Stage IV Hepatocellular Carcinoma AJCC v8|Stage IV Lung Cancer AJCC v8|Stage IV Ovarian Cancer AJCC v8|Stage IV Prostate Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v8|Stage IV Thyroid Gland Medullary Carcinoma AJCC v8|Triple-Negative Breast Carcinoma,2020-08-14,2025-11-02,2025-11-02,Interventional,Recruiting,Phase 1,National Cancer Institute (NCI),National Cancer Institute (NCI),Northwestern University|Montefiore Medical Center-Einstein Campus|University of Pittsburgh Cancer Institute (UPCI),Drug|Biological,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04514484
NCT04522622,hyperparathyroidism,Treatment of Adynamic Bone Disorder With Parathyroid Hormone in Patients With Chronic Kidney Disease,Treatment of Adynamic Bone Disorder With Parathyroid Hormone in Chronic Kidney Disease,Adynamic Bone Disease|Cardiac Disease|Chronic Kidney Disease-Mineral and Bone Disorder|Chronic Kidney Diseases,2020-08-13,2024-02-01,2025-02-01,Interventional,Recruiting,Phase 4,Herlev Hospital,"Ditte Hansen|Odense University Hospital|Rigshospitalet, Denmark|Steno Diabetes Center Copenhagen|Universiteit Antwerpen","Steno Diabetes Center Copenhagen|Herlev and Gentofte Hospital, Herlev Hospital|Odense University Hospital",Drug|Diagnostic Test|Procedure|Diagnostic Test|Other|Other,Denmark,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04522622
NCT04523974,hyperparathyroidism,Preemptive Surgical Intervention and Precise Efficacy Evaluation for Hyperparathyroidism Secondary to Chronic Kidney Disease,Preemptive and Precise Intervention for CKD-SHPT,"Hyperparathyroidism; Secondary, Renal",2020-08-17,2022-09-30,2022-12-31,Observational,Not yet recruiting,,Shanghai Zhongshan Hospital,Shanghai Zhongshan Hospital,,Procedure,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04523974
NCT04548284,hyperthyroidism,Periorbitally Injected Glucocorticoids for Mild TAO: A Randomized Controlled Study,Study of Therapeutic Value of Periorbital Injection of Glucocorticoid in Mild TAO,Thyroid Associated Ophthalmopathy,2020-09-07,2023-06-30,2023-12-31,Interventional,Recruiting,Phase 3,Sun Yat-sen University,Sun Yat-sen University,"Zhongshan Ophthalmic Center, Sun Yat-sen University",Drug,China,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04548284
NCT04548284,goiter,Periorbitally Injected Glucocorticoids for Mild TAO: A Randomized Controlled Study,Study of Therapeutic Value of Periorbital Injection of Glucocorticoid in Mild TAO,Thyroid Associated Ophthalmopathy,2020-09-07,2023-06-30,2023-12-31,Interventional,Recruiting,Phase 3,Sun Yat-sen University,Sun Yat-sen University,"Zhongshan Ophthalmic Center, Sun Yat-sen University",Drug,China,18.0,80.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04548284
NCT04548284,graves disease,Periorbitally Injected Glucocorticoids for Mild TAO: A Randomized Controlled Study,Study of Therapeutic Value of Periorbital Injection of Glucocorticoid in Mild TAO,Thyroid Associated Ophthalmopathy,2020-09-07,2023-06-30,2023-12-31,Interventional,Recruiting,Phase 3,Sun Yat-sen University,Sun Yat-sen University,"Zhongshan Ophthalmic Center, Sun Yat-sen University",Drug,China,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04548284
NCT04548284,graves ophthalmopathy,Periorbitally Injected Glucocorticoids for Mild TAO: A Randomized Controlled Study,Study of Therapeutic Value of Periorbital Injection of Glucocorticoid in Mild TAO,Thyroid Associated Ophthalmopathy,2020-09-07,2023-06-30,2023-12-31,Interventional,Recruiting,Phase 3,Sun Yat-sen University,Sun Yat-sen University,"Zhongshan Ophthalmic Center, Sun Yat-sen University",Drug,China,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT04548284
NCT04560127,thyroid neoplasms,"A Single-arm, Non-randomized, Single-center Study to Evaluate Camrelizumab in Combination With Apatinib in Patients With Radioactive Iodine-refractory Differentiated Thyroid Cancer",Camrelizumab in Combination With Apatinib in Patients With Radioactive Iodine-refractory Differentiated Thyroid Cancer,Radioactive Iodine-refractory Differentiated Thyroid Cancer,2020-09-17,2022-12-31,2023-06-30,Interventional,Recruiting,Phase 2,Peking Union Medical College Hospital,Peking Union Medical College Hospital,Peking Union Medical College Hospital,Drug,China,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04560127
NCT04564924,hyperparathyroidism,To Investigate the Bone and Muscle Abnormalities in Patients With Chronic Kidney Disease Compared to Healthy Volunteers With MRI,To Investigate the Bone and Muscle Abnormalities in Patients With Chronic Kidney Disease With MRI,Chronic Kidney Disease-Mineral and Bone Disorder,2020-09-14,2021-09-30,2022-01-30,Observational,Recruiting,,Tongji Hospital,Tongji Hospital,Tongji Hospital,Radiation,China,18.0,70.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04564924
NCT04569604,pseudopseudohypoparathyroidism,Impaired Quality of Life and Cognitive Function in Patients With Hypoparathyroidism Might be Explained by Disturbed Capillary Flow Patterns in the Brain,QoL and Cognitive Function in Patients With Hypoparathyroidism,Hypoparathyroidism|Pseudo Hypoparathyroidism,2019-09-02,2020-10-01,2021-12-01,Observational,Completed,,University of Aarhus,University of Aarhus,"Clinic for Osteoporosis, Aarhus University Hospital",Diagnostic Test|Diagnostic Test|Diagnostic Test|Diagnostic Test|Diagnostic Test,Denmark,18.0,70.0,[18-65]|[65 and more],Parathyroid diseases,pseudohypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04569604
NCT04570033,parathyroid neoplasms,The Utility of 18F-fluorocholine PET/CT in the Imaging of Parathyroid Adenomas,The Utility of 18F-fluorocholine PET/CT in the Imaging of Parathyroid Adenomas,Hyperparathyroidism|Parathyroid Adenoma,2020-09-21,2020-01-01,2020-01-01,Interventional,Completed,Not Applicable,"Military Institute of Medicine, Poland","Medical University of Warsaw|Military Institute of Medicine, Poland",,Diagnostic Test,,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04570033
NCT04574258,thyroid neoplasms,Contrast-enhanced Ultrasound in Thyroid Tumor by Sonozoid,Prospective Multicenter Study on Clinical Application of Sonozoid in Thyroid Tumor,Ultrasound,2020-09-18,2021-05-01,2021-08-01,Observational,Completed,,Chinese PLA General Hospital,Chinese PLA General Hospital,Chinese PLA General Hospital,,China,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04574258
NCT04574947,thyroid neoplasms,Intravenous Or Topical Lidocaine And Neuromonitoring in Thyroid Surgery (IOLANT Study),Lidocaine And Neuromonitoring in Thyroid Surgery,Anesthesia|Parathyroid Neoplasms|Thyroid Neoplasm,2020-09-24,2021-11-15,2021-12-01,Interventional,Recruiting,Phase 4,"Saint Petersburg State University, Russia","Saint Petersburg State University, Russia",St. Petersburg State University Hospital,Drug|Drug|Procedure|Procedure,Russian Federation,45.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04574947
NCT04577664,hyperthyroidism,Total Versus Subtotal Thyroidectomy in Graves' Disease : A Randomized Controlled Trial,Total Versus Subtotal Thyroidectomy in Graves' Disease At AUH,Thyroid Goiter,2020-07-28,2021-11-30,2021-12-31,Interventional,Not yet recruiting,Not Applicable,Assiut University,Assiut University,,Procedure|Procedure,,18.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04577664
NCT04577664,graves disease,Total Versus Subtotal Thyroidectomy in Graves' Disease : A Randomized Controlled Trial,Total Versus Subtotal Thyroidectomy in Graves' Disease At AUH,Thyroid Goiter,2020-07-28,2021-11-30,2021-12-31,Interventional,Not yet recruiting,Not Applicable,Assiut University,Assiut University,,Procedure|Procedure,,18.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04577664
NCT04577664,goiter,Total Versus Subtotal Thyroidectomy in Graves' Disease : A Randomized Controlled Trial,Total Versus Subtotal Thyroidectomy in Graves' Disease At AUH,Thyroid Goiter,2020-07-28,2021-11-30,2021-12-31,Interventional,Not yet recruiting,Not Applicable,Assiut University,Assiut University,,Procedure|Procedure,,18.0,65.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04577664
NCT04580199,thyroid neoplasms,"Surgical (Total or Hemithyroidectomy)Versus Non Surgical (Ethanol Ablation ,RF Ablation ,Laser Ablation) Management of Thyroid Nodule",Surgical Versus Non Surgical Management of Thyroid Nodule,Thyroid Nodule,2020-10-02,2021-12-01,2022-12-01,Interventional,Not yet recruiting,Not Applicable,Assiut University,Mahmoud Fahd,,Procedure,,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04580199
NCT04583735,hyperthyroidism,"A Phase 4, Randomized, Double-masked, Placebo-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of TEPEZZA® in Treating Patients With Chronic (Inactive) Thyroid Eye Disease",A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease,Chronic (Inactive) Thyroid Eye Disease|Thyroid Eye Disease,2020-10-06,2022-09-30,2023-04-30,Interventional,Recruiting,Phase 4,"Horizon Pharma USA, Inc.","Horizon Therapeutics USA, Inc.",Perlman Medical Offices / UCSD|MACRO Trials|Univ of Colorado Dept of Ophthalmology|Bascom Palmer Eye Institute / Univ of Miami|Mayo Clinic|Washington University|Hamilton Eye Institute / U Tennessee|Neuro-Eye Clinical Trials|Medical College of Wisconsin,Biological|Drug,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04583735
NCT04583735,goiter,"A Phase 4, Randomized, Double-masked, Placebo-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of TEPEZZA® in Treating Patients With Chronic (Inactive) Thyroid Eye Disease",A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease,Chronic (Inactive) Thyroid Eye Disease|Thyroid Eye Disease,2020-10-06,2022-09-30,2023-04-30,Interventional,Recruiting,Phase 4,"Horizon Pharma USA, Inc.","Horizon Therapeutics USA, Inc.",Perlman Medical Offices / UCSD|MACRO Trials|Univ of Colorado Dept of Ophthalmology|Bascom Palmer Eye Institute / Univ of Miami|Mayo Clinic|Washington University|Hamilton Eye Institute / U Tennessee|Neuro-Eye Clinical Trials|Medical College of Wisconsin,Biological|Drug,United States,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04583735
NCT04583735,graves disease,"A Phase 4, Randomized, Double-masked, Placebo-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of TEPEZZA® in Treating Patients With Chronic (Inactive) Thyroid Eye Disease",A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease,Chronic (Inactive) Thyroid Eye Disease|Thyroid Eye Disease,2020-10-06,2022-09-30,2023-04-30,Interventional,Recruiting,Phase 4,"Horizon Pharma USA, Inc.","Horizon Therapeutics USA, Inc.",Perlman Medical Offices / UCSD|MACRO Trials|Univ of Colorado Dept of Ophthalmology|Bascom Palmer Eye Institute / Univ of Miami|Mayo Clinic|Washington University|Hamilton Eye Institute / U Tennessee|Neuro-Eye Clinical Trials|Medical College of Wisconsin,Biological|Drug,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04583735
NCT04598815,hyperthyroidism,"A Phase II, Randomized, Superiority, Adaptive, Open-label, Single-center, Clinical Trial to Evaluate the Efficacy of Sirolimus (Rapamycin) in Patients With Graves' Disease and Moderate-to-severe and Active Graves' Orbitopathy (GO)",Sirolimus for Graves' Orbitopathy (GO),Graves Ophthalmopathy,2020-10-16,2025-01-01,2025-01-01,Interventional,Not yet recruiting,Phase 2,University of Pisa,University of Pisa,Ospedale Cisanello-Endocrinology II,Drug,Italy,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04598815
NCT04598815,graves disease,"A Phase II, Randomized, Superiority, Adaptive, Open-label, Single-center, Clinical Trial to Evaluate the Efficacy of Sirolimus (Rapamycin) in Patients With Graves' Disease and Moderate-to-severe and Active Graves' Orbitopathy (GO)",Sirolimus for Graves' Orbitopathy (GO),Graves Ophthalmopathy,2020-10-16,2025-01-01,2025-01-01,Interventional,Not yet recruiting,Phase 2,University of Pisa,University of Pisa,Ospedale Cisanello-Endocrinology II,Drug,Italy,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04598815
NCT04598815,goiter,"A Phase II, Randomized, Superiority, Adaptive, Open-label, Single-center, Clinical Trial to Evaluate the Efficacy of Sirolimus (Rapamycin) in Patients With Graves' Disease and Moderate-to-severe and Active Graves' Orbitopathy (GO)",Sirolimus for Graves' Orbitopathy (GO),Graves Ophthalmopathy,2020-10-16,2025-01-01,2025-01-01,Interventional,Not yet recruiting,Phase 2,University of Pisa,University of Pisa,Ospedale Cisanello-Endocrinology II,Drug,Italy,18.0,75.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04598815
NCT04601298,"thyroid cancer, papillary",The Risk Stratification of Papillary Thyroid Cancer With Bethesda Category III（AUS/FLUS）by Thyroid Fine-Needle Aspiration（FNA）Could be Assisted by Tumor Size for Precision Treatment,The Risk Stratification of Papillary Thyroid Cancer With AUS/FLUS by FNA,Atypia of Undetermined Significance|FLUS|Thyroid Cancer,2020-09-29,2020-09-30,2020-09-30,Observational,Completed,,Shanghai 10th People's Hospital,Shanghai 10th People's Hospital,Shanghai 10Th People'S Hospital,Other,China,18.0,77.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT04601298
NCT04604808,hypoparathyroidism,Observational Prospective Study on the Effects of Hypoparathyroidism on Post-thyroidectomy Health-related Quality of Life (QoL-hPTP),Study on the Effects of Hypoparathyroidism on Post-thyroidectomy Health-related Quality of Life (QoL-hPTP),Hypoparathyroidism Postprocedural,2020-09-29,2021-03-31,2021-11-30,Observational,Completed,,Fundación de Investigación Biomédica - Hospital Universitario de La Princesa,Fundación de Investigación Biomédica - Hospital Universitario de La Princesa,Hospital Universitario de La princesa,,Spain,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04604808
NCT04608253,hyperparathyroidism,A Retrospective Analysis of the Diagnostic Performance of 11C-choline PET/CT for Detection of Hyperfunctioning Parathyroid Glands After Prior Negative or Discordant Imaging in Primary Hyperparathyroidism,A Retrospective Analysis of the Diagnostic Performance of 11C-choline PET/CT in Primary Hyperparathyroidism,Primary Hyperparathyroidism|Primary Hyperparathyroidism Due to Adenoma,2020-10-27,2019-12-31,2020-08-01,Observational,Completed,,University Medical Center Groningen,University Medical Center Groningen,,Diagnostic Test,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04608253
NCT04610723,graves disease,Immunological Follow-up of Patients With Basedow's Orbitopathy : SIPO,Immunological Follow-up of Patients With Basedow's Orbitopathy,Graves Orbitopathy,2020-10-26,2021-11-01,2021-11-30,Observational,Completed,,"University Hospital, Montpellier","University Hospital, Montpellier",Uhmontpellier,,France,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04610723
NCT04610723,graves ophthalmopathy,Immunological Follow-up of Patients With Basedow's Orbitopathy : SIPO,Immunological Follow-up of Patients With Basedow's Orbitopathy,Graves Orbitopathy,2020-10-26,2021-11-01,2021-11-30,Observational,Completed,,"University Hospital, Montpellier","University Hospital, Montpellier",Uhmontpellier,,France,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT04610723
NCT04610723,goiter,Immunological Follow-up of Patients With Basedow's Orbitopathy : SIPO,Immunological Follow-up of Patients With Basedow's Orbitopathy,Graves Orbitopathy,2020-10-26,2021-11-01,2021-11-30,Observational,Completed,,"University Hospital, Montpellier","University Hospital, Montpellier",Uhmontpellier,,France,18.0,80.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04610723
NCT04610723,hyperthyroidism,Immunological Follow-up of Patients With Basedow's Orbitopathy : SIPO,Immunological Follow-up of Patients With Basedow's Orbitopathy,Graves Orbitopathy,2020-10-26,2021-11-01,2021-11-30,Observational,Completed,,"University Hospital, Montpellier","University Hospital, Montpellier",Uhmontpellier,,France,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04610723
NCT04614389,thyroid neoplasms,Utility of Contrast-Enhanced Sonography and Shear Wave Elastography in Conjunction With ACR TI-RADS for the Evaluation of Thyroid Nodules,Utility of Contrast-Enhanced Sonography and Shear Wave Elastography,Thyroid Nodule,2019-09-25,2021-04-30,2021-07-01,Interventional,Recruiting,Not Applicable,University of Southern California,Siemens Medical Solutions USA - CSG|University of Southern California,USC Department of Radiology,Other|Other|Device,United States,18.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04614389
NCT04632524,goiter,Evaluation of the Role of Low Dose Magnesium Sulfate in Anesthesia for Toxic Goiter Resection: A Randomized Controlled Trial,Evaluation of the Role of Low Dose Magnesium Sulfate in Anesthesia for Toxic Goiter Resection,Haemodynamic Stability,2020-08-30,2021-12-20,2022-01-30,Interventional,Recruiting,Phase 4,Fayoum University Hospital,Fayoum University Hospital,Atef,Drug,Egypt,20.0,70.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04632524
NCT04637360,hyperparathyroidism,To Study the Bone Turnover Markers and Bone Density Changes in Hyperperparathyroid Dialysis Patients Under Calcium Sensing Receptor Agonist Cinacalcet Treatment,Bone Markers and Bone Density Changes in Hyperperparathyroid Dialysis Patients Under Cinacalcet Treatment,"Hyperparathyroidism; Secondary, Renal",2020-11-06,2018-12-31,2020-06-30,Interventional,Completed,Not Applicable,Min-Sheng General Hospital,En Chu Kong Hospital|Min-Sheng General Hospital|National Taiwan University|Taichung Tzu Chi Hospital|Taipei Medical University|Taipei Medical University Shuang Ho Hospital,Min sheng general hospital,Drug|Drug,Taiwan,20.0,80.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04637360
NCT04639388,hypoparathyroidism,Characterize the Behavioral Prodromes of Psychotic Disorders in Children With 22q11.2DS Aged From 4 to 13 Years Old,Understanding of Psychotic Disorders in Children With 22q11.2DS,22q11.2 Deletion Syndrome,2020-10-01,2024-10-31,2025-01-31,Interventional,Recruiting,Not Applicable,Hôpital le Vinatier,Hôpital le Vinatier,Hopital Vinatier,Behavioral,France,4.0,13.0,[0-17],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04639388
NCT04639960,hypoparathyroidism,Effects of Modulation of the Dopaminergic System Using Risperidone on Memory and Executive Processes in Individuals With 22q11.2 Deletion Syndrome,Neuroprotective Effects of Risperdal on Brain and Cognition in 22q11 Deletion Syndrome,22q11.2 Deletion Syndrome,2020-11-03,2021-05-01,2021-05-01,Interventional,Terminated,Not Applicable,"University of Geneva, Switzerland","University of Geneva, Switzerland",Developmental imaging and psychopathology lab,Drug|Drug,Switzerland,11.0,25.0,[0-17]|[18-65],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04639960
NCT04647006,thyroid neoplasms,"Comparison of Transoral Endoscopic Thyroidectomy Vestibular Approach and Open Conventional Thyroidectomy for Inflammatory Responses, Pain and Patient Satisfaction: A Prospective Study",Comparison of TOETVA and Conventional Thyroidectomy,Surgery|Thyroid|Thyroid Nodule,2020-10-06,2020-01-28,2020-03-30,Interventional,Completed,Not Applicable,Basaksehir Cam & Sakura Şehir Hospital,MUnlu|Sisli Hamidiye Etfal Training and Research Hospital,Sisli Etfal Research Hospiatl,Procedure,Turkey,18.0,65.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04647006
NCT04647500,hypoparathyroidism,Effects of Modulation of the Dopaminergic System Using Methylphenidate on Memory and Executive Processes in Individuals With 22q11.2 Deletion Syndrome,Effects of Methylphenidate on Brain and Cognition in 22q11 Deletion Syndrome,22q11.2 Deletion Syndrome,2020-11-03,2022-09-30,2022-09-30,Interventional,Recruiting,Not Applicable,"University of Geneva, Switzerland","University of Geneva, Switzerland",Developmental imaging and psychopathology lab,Drug,Switzerland,8.0,25.0,[0-17]|[18-65],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04647500
NCT04662190,graves disease,Eficàcia i Seguretat de la descompressió orbitària en Orbitopatia distiroïdal Utilitzant Models Individualitzats d'impressió 3D Per la planificació i simulació de la Cirurgia.,Evaluation of the Efficacy and Safety of 3D Printing for Orbital Surgery.,"Surgical Procedure, Unspecified|Thyroid Associated Ophthalmopathy",2020-12-06,2022-07-31,2022-11-30,Interventional,Recruiting,Not Applicable,Althaia Xarxa Assistencial Universitària de Manresa,Althaia Xarxa Assistencial Universitària de Manresa|Societat Catalana d'Oftalmologia,Eduard Pedemonte Sarrias,Device|Procedure,Spain,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04662190
NCT04662190,hyperthyroidism,Eficàcia i Seguretat de la descompressió orbitària en Orbitopatia distiroïdal Utilitzant Models Individualitzats d'impressió 3D Per la planificació i simulació de la Cirurgia.,Evaluation of the Efficacy and Safety of 3D Printing for Orbital Surgery.,"Surgical Procedure, Unspecified|Thyroid Associated Ophthalmopathy",2020-12-06,2022-07-31,2022-11-30,Interventional,Recruiting,Not Applicable,Althaia Xarxa Assistencial Universitària de Manresa,Althaia Xarxa Assistencial Universitària de Manresa|Societat Catalana d'Oftalmologia,Eduard Pedemonte Sarrias,Device|Procedure,Spain,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04662190
NCT04662190,goiter,Eficàcia i Seguretat de la descompressió orbitària en Orbitopatia distiroïdal Utilitzant Models Individualitzats d'impressió 3D Per la planificació i simulació de la Cirurgia.,Evaluation of the Efficacy and Safety of 3D Printing for Orbital Surgery.,"Surgical Procedure, Unspecified|Thyroid Associated Ophthalmopathy",2020-12-06,2022-07-31,2022-11-30,Interventional,Recruiting,Not Applicable,Althaia Xarxa Assistencial Universitària de Manresa,Althaia Xarxa Assistencial Universitària de Manresa|Societat Catalana d'Oftalmologia,Eduard Pedemonte Sarrias,Device|Procedure,Spain,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04662190
NCT04662190,graves ophthalmopathy,Eficàcia i Seguretat de la descompressió orbitària en Orbitopatia distiroïdal Utilitzant Models Individualitzats d'impressió 3D Per la planificació i simulació de la Cirurgia.,Evaluation of the Efficacy and Safety of 3D Printing for Orbital Surgery.,"Surgical Procedure, Unspecified|Thyroid Associated Ophthalmopathy",2020-12-06,2022-07-31,2022-11-30,Interventional,Recruiting,Not Applicable,Althaia Xarxa Assistencial Universitària de Manresa,Althaia Xarxa Assistencial Universitària de Manresa|Societat Catalana d'Oftalmologia,Eduard Pedemonte Sarrias,Device|Procedure,Spain,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT04662190
NCT04663451,hyperthyroidism,"An Assessment of the Occurrence of Hypothyroidism in Patients Treated With RAI For Hyperthyroidism, And it's Prognostic Factors.",An Assessment of the Occurrence of Hypothyroidism in Patients Treated With RAI for Hyperthyroidism.,Nodule Solitary Thyroid|Radioactive Iodine-Induced Hypothyroidism|Toxic Multinodular Goiter,2020-11-26,2020-11-24,2021-05-31,Observational,Active not recruiting,,Universitair Ziekenhuis Brussel,Universitair Ziekenhuis Brussel,Universitair Ziekenhuis Brussel,Radiation,Belgium,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04663451
NCT04663451,hypothyroidism,"An Assessment of the Occurrence of Hypothyroidism in Patients Treated With RAI For Hyperthyroidism, And it's Prognostic Factors.",An Assessment of the Occurrence of Hypothyroidism in Patients Treated With RAI for Hyperthyroidism.,Nodule Solitary Thyroid|Radioactive Iodine-Induced Hypothyroidism|Toxic Multinodular Goiter,2020-11-26,2020-11-24,2021-05-31,Observational,Active not recruiting,,Universitair Ziekenhuis Brussel,Universitair Ziekenhuis Brussel,Universitair Ziekenhuis Brussel,Radiation,Belgium,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04663451
NCT04666103,thyroid nodule,Preserving Function Integrity of Neck Anatomy in Thyroid Surgery: A Randomized Clinical Trial,Function Integrity of Neck Anatomy in Thyroid Surgery,Ablation; Retina|Thyroid Carcinoma|Thyroid Nodule (Benign),2020-12-07,2021-12-31,2026-12-12,Interventional,Recruiting,Not Applicable,Wuhan University,Wuhan University,Zhongnan Hospital of Wuhan University,Procedure,China,18.0,75.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04666103
NCT04671719,pseudopseudohypoparathyroidism,Autotaxin in Patients With GNAS/PTH Abnormalities,Determination of Circulating Autotaxin in Patients With GNAS or PTH Abnormalities,Adult Children|Albright Syndrome|Fibrous Dysplasia|Hyperparathyroidism|Hypoparathyroidism|Pseudo Hypoparathyroidism,2020-12-11,2024-03-10,2024-03-10,Observational,Recruiting,,Hospices Civils de Lyon,Hospices Civils de Lyon,"Centre de compétence des maladies rares de l'insulino-sécrétion et de l'insulino-sensibilité|Centre de référence Dysplasie Fibreuse des os Service rhumatologie et pathologie osseuse Hôpital Edouard Herriot, Lyon|Centre de Référence des Maladies Rares du Métabolisme du Calcium et du Phosphate Service d'Endocrinologie et Diabète de l'Enfant Hôpital Bicêtre Paris Saclay",Biological,France,10.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,pseudohypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04671719
NCT04680650,thyroid neoplasms,Comparison of Anesthesia Effects of Sevoflurane and Propofol Combined With Dexmedetomidine in Intraoperative Neuromonitoring During Thyroidectomy,Comparison of Anesthesia Effects of Sevoflurane and Propofol Combined With Dexmedetomidine in Intraoperative Neuromonitoring During Thyroidectomy,Thyroid Nodule,2020-12-11,2021-03-31,2021-03-31,Interventional,Active not recruiting,Not Applicable,Affiliated Cancer Hospital & Institute of Guangzhou Medical University,Affiliated Cancer Hospital & Institute of Guangzhou Medical University,Cancer Center of Guangzhou Medical University,Drug|Drug,China,18.0,65.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04680650
NCT04682340,goiter,Analysis of Bisphenol A Concentration in Serum in Women of Reproductive Age With Autoimmune Thyroid Disease,Analysis of BPA Concentration in Serum in Women of Reproductive Age With Autoimmune Thyroid Disease,Graves Disease|Hashimoto Disease|Hyperthyroidism|Hypothyroidism,2020-12-13,2021-10-30,2022-01-19,Observational,Completed,,Jagiellonian University,Jagiellonian University,Jagiellonian University Medical College,Diagnostic Test,Poland,18.0,45.0,[18-65],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04682340
NCT04683575,thyroid neoplasms,Distribution of Selenium in Patients With Differentiated Thyroid Carcinoma and Effect of Selenium Supplement on Prognosis of Patients With Differentiated Thyroid Carcinoma.,Clinical Study on the Effect of Selenium Yeast Capsule on Prognosis of Differentiated Thyroid Carcinoma,Metastasis|Recurrence|Selenium Deficiency|Thyroid Cancer TNM Staging,2020-11-26,2025-12-31,2025-12-31,Interventional,Not yet recruiting,Phase 4,Qianfoshan Hospital,Qianfoshan Hospital,The First affiliated hospital of Shandong First Medical University,Drug|Drug,China,18.0,75.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04683575
NCT04686006,hyperthyroidism,"Effectiveness of Classical Potassium Iodide Therapy for the Treatment of Untreated Patients With Graves' Hyperthyroidism, Avoiding Thionamide Drugs With Serious Side Effects of Agranulocytosis, Liver Injury, Vasculitis, Embryopathy or Frequent Side Effects of Skin Eruption",Effective Iodide Therapy for Untreated Patients With Graves' Hyperthyroidism Avoiding Thionamide Drugs With Many Side Effects,Graves Disease,2020-12-22,2005-07-01,,Observational,Completed,,Kyushu University,Kyushu University,,Drug,,15.0,90.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04686006
NCT04686006,goiter,"Effectiveness of Classical Potassium Iodide Therapy for the Treatment of Untreated Patients With Graves' Hyperthyroidism, Avoiding Thionamide Drugs With Serious Side Effects of Agranulocytosis, Liver Injury, Vasculitis, Embryopathy or Frequent Side Effects of Skin Eruption",Effective Iodide Therapy for Untreated Patients With Graves' Hyperthyroidism Avoiding Thionamide Drugs With Many Side Effects,Graves Disease,2020-12-22,2005-07-01,,Observational,Completed,,Kyushu University,Kyushu University,,Drug,,15.0,90.0,[0-17]|[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04686006
NCT04690842,hypoparathyroidism,Implementation of PTH Measurement Intra / Post Thyroidectomy to Improve Post Surgical Safety in Pediatric Patients,Improving Safety in Pediatric Thyroidectomy by PTH Measurements,Hypoparathyroidism Postprocedural,2020-12-28,2020-04-30,2020-04-30,Observational,Completed,,Hospital de Niños R. Gutierrez de Buenos Aires,Hospital de Niños R. Gutierrez de Buenos Aires,,Diagnostic Test,,2.0,19.0,[0-17]|[18-65],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04690842
NCT04704414,hyperthyroidism,Exophthalmometry With 3D Face Scanners,Exophthalmometry With 3D Face Scanners,Exophthalmos|Graves Ophthalmopathy|Orbital Fractures|Orbital Tumor,2021-01-06,2021-12-31,2022-12-31,Interventional,Recruiting,Not Applicable,University of Zurich,University of Zurich,"Ophthalmology Department, University Hospital Zurich",Device,Switzerland,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04704414
NCT04704414,graves disease,Exophthalmometry With 3D Face Scanners,Exophthalmometry With 3D Face Scanners,Exophthalmos|Graves Ophthalmopathy|Orbital Fractures|Orbital Tumor,2021-01-06,2021-12-31,2022-12-31,Interventional,Recruiting,Not Applicable,University of Zurich,University of Zurich,"Ophthalmology Department, University Hospital Zurich",Device,Switzerland,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04704414
NCT04704414,goiter,Exophthalmometry With 3D Face Scanners,Exophthalmometry With 3D Face Scanners,Exophthalmos|Graves Ophthalmopathy|Orbital Fractures|Orbital Tumor,2021-01-06,2021-12-31,2022-12-31,Interventional,Recruiting,Not Applicable,University of Zurich,University of Zurich,"Ophthalmology Department, University Hospital Zurich",Device,Switzerland,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04704414
NCT04708626,"thyroiditis, autoimmune",Epidemiology of Autoimmune Encephalitides and Paraneoplastic Neurological Syndromes in Sweden,Epidemiology of Autoimmune Encephalitides and Paraneoplastic Neurological Syndromes in Sweden,Autoimmune Encephalitis|Paraneoplastic Neurological Syndrome,2021-01-11,2022-02-28,2022-04-30,Observational,Active not recruiting,,Uppsala University,Uppsala University,Uppsala University,Other|Other,Sweden,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT04708626
NCT04714918,hyperparathyroidism,Chinese Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Prevalence Survey,Chinese CKD-MBD Prevalence Survey (CRISS-MBD),Chronic Kidney Disease-Mineral and Bone Disorder|Chronic Kidney Diseases,2021-01-14,2021-11-28,2021-11-28,Observational,Recruiting,,Peking Union Medical College Hospital,Limeng Chen,"Peking Union Medical College Hospital|The First Affiliated Hospital, Chongqing Medical University|Fujian Provincial Hospital|The Seventh Affiliated Hospital, Sun Yat-sen University|Xiangya Hospital of Central South University|The First Hospital of China Medical University|People's Hospital of Ningxia Hui Autonomous Region|People's Hospital of Xinjiang Uygur Autonomous Region|The Second Affiliated Hospital Zhejiang University School of Medicine",,China,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04714918
NCT04730726,thyroid neoplasms,In Vivo Multispectral Optoacoustic Imaging of Thyroid Nodules,In Vivo Multispectral Optoacoustic Imaging of Thyroid Nodules,Thyroid Nodule,2021-01-26,2021-12-01,2022-04-01,Interventional,Recruiting,Not Applicable,University Medical Center Groningen,University Medical Center Groningen,University Medical Center Groningen,Device,Netherlands,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04730726
NCT04731740,"thyroid carcinoma, anaplastic",Pembrolizumab in Combination With Standard 1st Line Therapy (Lenvatinib / Chemotherapy) for Locally Advanced or Metastatic Poorly Differentiated or Anaplastic Thyroid Cancer,Pembrolizumab and Lenvatinib/Chemotherapy for Poorly Differentiated/Anaplastic Thyroid Cancer,Metastatic Thyroid Gland Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Thyroid Gland Anaplastic Carcinoma by AJCC V8 Stage,2021-01-26,2023-12-28,2023-12-28,Interventional,Suspended,Phase 2,"Saint Petersburg State University, Russia","Saint Petersburg State University, Russia",Saint-Petersburg State University (SPSU) N.I.Pirogov Clinic of High Medical Technologies,Drug|Biological|Drug,Russian Federation,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT04731740
NCT04737330,hyperthyroidism,"A Two-year Multi-center Phase 3 Study to Investigate the Efficacy and Safety of Secukinumab in Adult Patients With Active, Moderate to Severe Thyroid Eye Disease (ORBIT), With a Randomized, Parallel-group, Double-blind, Placebo-controlled, 16-week Treatment Period, and a Follow-up/Retreatment Period",A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED),Graves Orbitopathy|Thyroid Eye Disease,2020-11-20,2023-04-27,2025-02-05,Interventional,Recruiting,Phase 3,Novartis,Novartis Pharmaceuticals,Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site,Drug|Drug,Germany,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04737330
NCT04737330,graves disease,"A Two-year Multi-center Phase 3 Study to Investigate the Efficacy and Safety of Secukinumab in Adult Patients With Active, Moderate to Severe Thyroid Eye Disease (ORBIT), With a Randomized, Parallel-group, Double-blind, Placebo-controlled, 16-week Treatment Period, and a Follow-up/Retreatment Period",A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED),Graves Orbitopathy|Thyroid Eye Disease,2020-11-20,2023-04-27,2025-02-05,Interventional,Recruiting,Phase 3,Novartis,Novartis Pharmaceuticals,Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site,Drug|Drug,Germany,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04737330
NCT04737330,goiter,"A Two-year Multi-center Phase 3 Study to Investigate the Efficacy and Safety of Secukinumab in Adult Patients With Active, Moderate to Severe Thyroid Eye Disease (ORBIT), With a Randomized, Parallel-group, Double-blind, Placebo-controlled, 16-week Treatment Period, and a Follow-up/Retreatment Period",A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED),Graves Orbitopathy|Thyroid Eye Disease,2020-11-20,2023-04-27,2025-02-05,Interventional,Recruiting,Phase 3,Novartis,Novartis Pharmaceuticals,Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site,Drug|Drug,Germany,18.0,80.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04737330
NCT04740502,hyperparathyroidism,Surgical Approach and Outcomes in Patients With Primary Hyperparathyroidism and Unclear Preoperative Localisation Studies,Surgical Outcomes in Patients With Primary Hyperparathyroidism and Unclear Preoperative Localisation Studies,Primary Hyperparathyroidism,2021-02-01,2019-12-31,2020-12-31,Interventional,Completed,Not Applicable,University of Cagliari,University of Cagliari,Policlinico di Monserrato|Policlinico di Monserrato,Procedure,Italy,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04740502
NCT04750460,hyperparathyroidism,"The Effect of Teriparatide on the Early Postoperative Hypocalcemia After Parathyroidectomy in Dialysis Patients: a Pilot, Randomized Trial",Injection of Teriparatide to Prevent Hypocalcemia After Parathyroidectomy in Dialysis Patients (TeriCa).,Chronic Kidney Disease-Mineral and Bone Disorder|Dialysis|Hypocalcemia|Hypoparathyroidism|Secondary Hyperparathyroidism,2021-02-02,2021-07-31,2021-07-31,Interventional,Enrolling by invitation,Phase 3,"Saint Petersburg State University, Russia","Saint Petersburg State University, Russia",Saint-Petersburg State University Hospital,Drug,Russian Federation,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04750460
NCT04759053,thyroid neoplasms,"Effectiveness of Core-Needle US Guided Biopsy as Primary Tool For Diagnosis of Thyroid Nodules, A Prospective Study",Effectiveness of Core-Needle US Guided Biopsy as Primary Tool For Diagnosis of Thyroid Nodules,Thyroid Diseases|Thyroid Gland; Node|Thyroid Nodule,2021-02-09,2018-01-01,2018-02-01,Interventional,Completed,Not Applicable,Kafrelsheikh University,Alexandria University|Kafrelsheikh University,,Procedure|Procedure,,18.0,65.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04759053
NCT04763122,thyroid neoplasms,Decline in Radioiodine Use But Not Total Thyroidectomy in Thyroid Cancer Patients Treated in United Arab Emirates- A Retrospective Study,Thyroid Cancer in United Arab Emirates,Cancer|Thyroid,2021-02-09,2018-12-31,2020-12-31,Observational,Completed,,Tawam Hospital,Tawam Hospital,,Other,,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04763122
NCT04767763,hypothyroidism,Association of Continuous Veno-venous Hemodiafiltration With Citrate Anticoagulation to Thyroid Function in Critically Ill Patients,Thyroid Function in Critically Ill Patients With Acute Kidney Injury,Secondary Hypothyroidism,2021-02-17,2020-02-01,2020-02-01,Observational,Completed,,Medical University of Gdansk,Medical University of Gdansk,Medical University of Gdansk - Departament of Anesthesiology and Intensive Care,Diagnostic Test,Poland,0.0,120.0,[0-17]|[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04767763
NCT04776993,goiter,"A Phase III, Randomized, Controlled, Open Label, no Profit, Single-center Intervention Study to Compare the Effect of a Conservative (Antithyroid Drugs) and an Ablative Approach (Radioiodine or Total Thyroidectomy) for the Treatment of Hyperthyroidism in Patients With Graves' Disease and Moderate-to-severe and Active Graves' Orbitopathy (GO) Treated With Intravenous Glucocorticoids (ABLAGO Study)",A Conservative vs an Ablative Approach for Treatment of Hyperthyroidism in Patients With Graves' Orbitopathy,Graves' Orbitopathy,2021-02-25,2022-10-30,2024-10-30,Interventional,Not yet recruiting,Phase 3,University of Pisa,University of Pisa,Endocrinology Unit II,Drug|Procedure,Italy,18.0,75.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04776993
NCT04776993,graves ophthalmopathy,"A Phase III, Randomized, Controlled, Open Label, no Profit, Single-center Intervention Study to Compare the Effect of a Conservative (Antithyroid Drugs) and an Ablative Approach (Radioiodine or Total Thyroidectomy) for the Treatment of Hyperthyroidism in Patients With Graves' Disease and Moderate-to-severe and Active Graves' Orbitopathy (GO) Treated With Intravenous Glucocorticoids (ABLAGO Study)",A Conservative vs an Ablative Approach for Treatment of Hyperthyroidism in Patients With Graves' Orbitopathy,Graves' Orbitopathy,2021-02-25,2022-10-30,2024-10-30,Interventional,Not yet recruiting,Phase 3,University of Pisa,University of Pisa,Endocrinology Unit II,Drug|Procedure,Italy,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT04776993
NCT04776993,graves disease,"A Phase III, Randomized, Controlled, Open Label, no Profit, Single-center Intervention Study to Compare the Effect of a Conservative (Antithyroid Drugs) and an Ablative Approach (Radioiodine or Total Thyroidectomy) for the Treatment of Hyperthyroidism in Patients With Graves' Disease and Moderate-to-severe and Active Graves' Orbitopathy (GO) Treated With Intravenous Glucocorticoids (ABLAGO Study)",A Conservative vs an Ablative Approach for Treatment of Hyperthyroidism in Patients With Graves' Orbitopathy,Graves' Orbitopathy,2021-02-25,2022-10-30,2024-10-30,Interventional,Not yet recruiting,Phase 3,University of Pisa,University of Pisa,Endocrinology Unit II,Drug|Procedure,Italy,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04776993
NCT04776993,hyperthyroidism,"A Phase III, Randomized, Controlled, Open Label, no Profit, Single-center Intervention Study to Compare the Effect of a Conservative (Antithyroid Drugs) and an Ablative Approach (Radioiodine or Total Thyroidectomy) for the Treatment of Hyperthyroidism in Patients With Graves' Disease and Moderate-to-severe and Active Graves' Orbitopathy (GO) Treated With Intravenous Glucocorticoids (ABLAGO Study)",A Conservative vs an Ablative Approach for Treatment of Hyperthyroidism in Patients With Graves' Orbitopathy,Graves' Orbitopathy,2021-02-25,2022-10-30,2024-10-30,Interventional,Not yet recruiting,Phase 3,University of Pisa,University of Pisa,Endocrinology Unit II,Drug|Procedure,Italy,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04776993
NCT04782856,goiter,Energy Metabolism in Thyroidectomized Patients,Energy Metabolism in Thyroidectomized Patients,Hypothyroidism|Thyroid Cancer|Thyroid Goiter,2021-03-01,2023-05-31,2023-05-31,Interventional,Recruiting,Phase 2,Virginia Commonwealth University,Virginia Commonwealth University,Virginia Commonwealth University,Drug|Drug|Drug,United States,18.0,89.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04782856
NCT04785443,hypoparathyroidism,Contribution of Indocyanine Green Angiography in the Detection of Parathyroids and the Prevention of Hypoparathyroidism Post Total Thyroidectomy,Contribution of ICG Angiography in the Detection of Parathyroids and the Prevention of Hypoparathyroidism Post Total Thyroidectomy,Thyroid Diseases,2021-02-25,2024-06-30,2025-03-31,Interventional,Recruiting,Phase 3,"University Hospital, Brest","University Hospital, Brest",CHRU de Brest,Drug|Procedure,France,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04785443
NCT04789993,goiter,Additional Autoimmune Diseases With Type 1 Diabetes in Children and Adolescents at Diabetes Diagnostic and During Follow-up : a Monocentric Study in France,Additional Autoimmune Diseases With Type 1 Diabetes in Pediatrics at Diabetes Diagnosis and During Follow-up,Addison Disease|Autoimmune Diseases|Celiac Disease|Graves Disease|Hashimoto Disease|Type 1 Diabetes|Vitiligo,2021-02-20,2021-03-31,2021-04-30,Observational,Enrolling by invitation,,"Central Hospital, Nancy, France","Central Hospital, Nancy, France",Hôpital d'Enfants de Brabois,Other,France,6.0,120.0,[0-17]|[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04789993
NCT04789993,hyperthyroidism,Additional Autoimmune Diseases With Type 1 Diabetes in Children and Adolescents at Diabetes Diagnostic and During Follow-up : a Monocentric Study in France,Additional Autoimmune Diseases With Type 1 Diabetes in Pediatrics at Diabetes Diagnosis and During Follow-up,Addison Disease|Autoimmune Diseases|Celiac Disease|Graves Disease|Hashimoto Disease|Type 1 Diabetes|Vitiligo,2021-02-20,2021-03-31,2021-04-30,Observational,Enrolling by invitation,,"Central Hospital, Nancy, France","Central Hospital, Nancy, France",Hôpital d'Enfants de Brabois,Other,France,6.0,120.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04789993
NCT04798092,hyperparathyroidism,Impact of Parathyroidectomy on Renal Function in Patients With Primary Hyperparathyroidism,Impact of Parathyroidectomy on Renal Function,Primary Hyperparathyroidism,2021-01-29,2022-01-31,2022-01-31,Observational,Recruiting,,"Central Hospital, Nancy, France","Central Hospital, Nancy, France",CHRU Nancy,Procedure,France,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04798092
NCT04806672,euthyroid sick syndromes,Euthyroid Sick Syndrome (ESS)….. Can it Influence Morbidity and Mortality in Moderate to Severe Traumatic Brain Injury Patients or Correlate With Glial Fibrillary Acidic Protein (GFAP) Level.,Euthyroid Sick Syndrome (ESS) Effect on Traumatic Brain Injury Patients and Its Relation With GFAP Level,Euthyroid Sick Syndromes in Traumatic Brain Injury Patient and GFAP Level,2021-03-14,2021-12-31,2022-04-30,Observational,Not yet recruiting,,Minia University,Minia University,,,,18.0,60.0,[18-65],Euthyroid Sick Syndromes,Euthyroid Sick Syndromes,https://clinicaltrials.gov/ct2/show/NCT04806672
NCT04809454,hyperthyroidism,Frequency of Florid Hyperthyroidism In Patients Taking Iodinated Salt: A Cross Sectional Study,Frequency of Florid Hyperthyroidism In Patients Taking Iodinated Salt,Thyroid Dysfunction,2021-03-16,2022-03-31,2022-03-31,Observational,Not yet recruiting,,"Services Institute of Medical Sciences, Pakistan","Services Institute of Medical Sciences, Pakistan",Mehwish Iftikhar,,Pakistan,18.0,60.0,[18-65],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04809454
NCT04823728,hashimoto disease,Immunogenetic Characteristics in Autoimmune Encephalitis and Related Disorders: HLA Analysis: Part II,HLA Analysis in Autoimmune Encephalitis and Related Disorders: Part II,Autoimmune Encephalitis|Paraneoplastic Neurological Syndrome,2021-03-26,2024-12-31,2025-12-31,Observational,Recruiting,,Hospices Civils de Lyon,Hospices Civils de Lyon,Hôpital Neurologique,Genetic,France,18.0,120.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT04823728
NCT04842994,thyroid neoplasms,"Phase III, Assessor Blinded, Randomised Controlled Trial of Use of Intraoperative Neuromonitoring (IONM) in Thyroid Cancer Surgery(ACTION)",Trial on Intraoperative Neuromonitoring (IONM) in Thyroid Cancer Surgery.,Malignant Neoplasm of Thyroid Gland,2020-10-06,2024-08-31,2024-08-31,Interventional,Recruiting,Not Applicable,Tata Memorial Hospital,Tata Memorial Hospital,Tata Memorial Hospital,Device,India,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04842994
NCT04844164,hyperparathyroidism,"Prospective Non-randomised Controlled Study of Vitamin D Metabolism in Patients With Endocrine Disorders (Acromegaly, Cushing's Disease, Primary Hyperparathyroidism, Diabetes Mellitus Type 1) Treated With Cholecalciferol Bolus Dose",Vitamin D Metabolism in Patients With Endocrine Disorders,"Acromegaly|Diabetes Mellitus, Type 1|Pituitary ACTH Hypersecretion|Primary Hyperparathyroidism",2021-04-09,2021-05-15,2021-06-01,Interventional,Recruiting,Phase 1,"Endocrinology Research Centre, Moscow","Endocrinology Research Centre, Moscow|Russian Science Foundation","Endocrinology Research Centre, Moscow",Drug,Russian Federation,18.0,60.0,[18-65],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04844164
NCT04846010,hypothyroidism,Treating Sequalae Caused by Post-acute Sequelae of SARS (Severe Acute Respiratory Syndrome)-CoV-2 Infection,"Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2","Anxiety Disorders|Depression|Depression, Anxiety|Depression, Bipolar|Gastro Esophageal Reflux|GERD|Glomerulonephritis|Hepatitis|Insomnia|Post Infection Glomerulonephritis|Post-Infectious Arthritis|Post-Infectious Disorder (Disorder)|Post-Infectious Hypothyroidism|Post Infectious Osteoarthritis|Post-Infectious Parkinsonism|Post-Infectious Peripheral Neuralgia|Post-Infectious Polyneuritis|Sequelae of; Infection",2021-03-31,2022-05-01,2022-10-01,Interventional,Recruiting,Phase 1/Phase 2,"All Natural Medicine Clinic, LLC","All Natural Medicine Clinic, LLC","All Natural Medicine Clinic, LLC",Combination Product|Combination Product|Combination Product|Combination Product|Combination Product|Combination Product|Combination Product,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04846010
NCT04856488,graves disease,Preoperative Lugol's Solution in Graves' Disease and Toxic Nodular Goiter,Preoperative Lugol's Solution in Graves' Disease and Toxic Nodular Goiter,Hyperthyroidism,2021-04-06,2023-08-31,2024-02-29,Interventional,Recruiting,Phase 3,Karolinska University Hospital,Jan Calissendorff,"Department of Endocrinology, Karolinska University Hospital",Drug,Sweden,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04856488
NCT04856488,"goiter, nodular",Preoperative Lugol's Solution in Graves' Disease and Toxic Nodular Goiter,Preoperative Lugol's Solution in Graves' Disease and Toxic Nodular Goiter,Hyperthyroidism,2021-04-06,2023-08-31,2024-02-29,Interventional,Recruiting,Phase 3,Karolinska University Hospital,Jan Calissendorff,"Department of Endocrinology, Karolinska University Hospital",Drug,Sweden,18.0,75.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04856488
NCT04876534,graves disease,"Multicenter, Randomized, Observer-blind, Controlled Study of the Anti-IL-6 Receptor Antibody Tocilizumab (TCZ) or Methylprednisolone (MP) Treatment in Patients With Active Moderate-severe Graves' Orbitopathy",Tocilizumab in Active Moderate-severe Graves' Orbitopathy,Graves Ophthalmopathy,2021-05-03,2022-12-18,2023-12-18,Interventional,Recruiting,Phase 2,"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","Azienda Ospedaliera ""Sant'Andrea""|Azienda Ospedaliero, Universitaria Pisana|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|Istituto Auxologico Italiano|Mauriziano Umberto I Hospital","Istituto Auxologico Italiano|Azienda Ospedaliero, Universitaria Pisana|Azienda Ospedaliera ""Sant'Andrea""|Mauriziano Umberto I Hospital",Drug|Drug,Italy,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04876534
NCT04876534,goiter,"Multicenter, Randomized, Observer-blind, Controlled Study of the Anti-IL-6 Receptor Antibody Tocilizumab (TCZ) or Methylprednisolone (MP) Treatment in Patients With Active Moderate-severe Graves' Orbitopathy",Tocilizumab in Active Moderate-severe Graves' Orbitopathy,Graves Ophthalmopathy,2021-05-03,2022-12-18,2023-12-18,Interventional,Recruiting,Phase 2,"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","Azienda Ospedaliera ""Sant'Andrea""|Azienda Ospedaliero, Universitaria Pisana|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|Istituto Auxologico Italiano|Mauriziano Umberto I Hospital","Istituto Auxologico Italiano|Azienda Ospedaliero, Universitaria Pisana|Azienda Ospedaliera ""Sant'Andrea""|Mauriziano Umberto I Hospital",Drug|Drug,Italy,18.0,75.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04876534
NCT04876534,hyperthyroidism,"Multicenter, Randomized, Observer-blind, Controlled Study of the Anti-IL-6 Receptor Antibody Tocilizumab (TCZ) or Methylprednisolone (MP) Treatment in Patients With Active Moderate-severe Graves' Orbitopathy",Tocilizumab in Active Moderate-severe Graves' Orbitopathy,Graves Ophthalmopathy,2021-05-03,2022-12-18,2023-12-18,Interventional,Recruiting,Phase 2,"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","Azienda Ospedaliera ""Sant'Andrea""|Azienda Ospedaliero, Universitaria Pisana|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|Istituto Auxologico Italiano|Mauriziano Umberto I Hospital","Istituto Auxologico Italiano|Azienda Ospedaliero, Universitaria Pisana|Azienda Ospedaliera ""Sant'Andrea""|Mauriziano Umberto I Hospital",Drug|Drug,Italy,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04876534
NCT04877613,thyroid neoplasms,Phase I Trial of GFRα4 CAR T Cells in Adult Patients With Recurrent or Metastatic Medullary Thyroid Cancer,GFRα4 CAR T Cells in MTC Patients,Metastatic Medullary Thyroid Cancer,2021-05-03,2039-06-01,2039-06-01,Interventional,Recruiting,Phase 1,University of Pennsylvania,University of Pennsylvania,University of Pennsylvania,Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04877613
NCT04879173,hyperthyroidism,The Clinical Value of Microvascular Ultrasonography in Real-time Differential Diagnosis of Thyrotoxic Patients Between Hyperthyroidism and Thyroiditis,Clinical Value of Microvascular Ultrasonography in Real-time Differential Diagnosis of Thyrotoxic Patients,Hyperthyroidism/Thyrotoxicosis,2021-05-04,2021-10-31,2022-10-31,Observational,Recruiting,,Seoul St. Mary's Hospital,Dong Jun Lim,Seoul St. Mary hospital,Device,"Korea, Republic of",0.0,120.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04879173
NCT04879355,thyroid neoplasms,The Use of Spinal Needles for Ultrasound-guided Fine Needle Aspiration From Thyroid Nodules - a Protocol for a Multicentre Randomised Controlled Trial,Spinal Needles in Ultrasound-guided Fine Needle Aspirations From Thyroid Nodules,Thyroid Nodule,2021-03-07,2022-11-01,2023-12-01,Interventional,Not yet recruiting,Not Applicable,Zealand University Hospital,"Herlev Hospital|Preben Homøe|Rigshospitalet, Denmark",,Device|Device,,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04879355
NCT04883294,thyroid neoplasms,Validation of the Diagnostic Accuracy of the Electronic Nose in the Detection of Thyroid Cancer,Validation of the Diagnostic Accuracy of the Electronic Nose in the Detection of Thyroid Cancer,Thyroid Neoplasm,2021-05-11,2024-01-01,2025-01-01,Observational,Not yet recruiting,,Maastricht University Medical Center,Maastricht University Medical Center,,Diagnostic Test,,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04883294
NCT04895631,parathyroid neoplasms,18F-Fluorocholine Positron Emission Tomography (PET) for the Detection of Parathyroid Adenomas,18F-Fluorocholine Positron Emission Tomography (PET) for the Detection of Parathyroid Adenomas,"Hyperparathyroidism, Primary",2021-05-13,2026-06-30,2027-06-30,Interventional,Recruiting,Phase 3,"University of California, San Francisco",Thomas Hope,"University of California, San Francisco",Drug|Procedure,United States,13.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04895631
NCT04895631,hyperparathyroidism,18F-Fluorocholine Positron Emission Tomography (PET) for the Detection of Parathyroid Adenomas,18F-Fluorocholine Positron Emission Tomography (PET) for the Detection of Parathyroid Adenomas,"Hyperparathyroidism, Primary",2021-05-13,2026-06-30,2027-06-30,Interventional,Recruiting,Phase 3,"University of California, San Francisco",Thomas Hope,"University of California, San Francisco",Drug|Procedure,United States,13.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04895631
NCT04905641,parathyroid neoplasms,The Feasibility of Bilateral Intermediate Cervical Plexus Block for Thyroidectomy/Parathyroidectomy Under Moderate Sedation; Retrospective Study,The Feasibility of Bilateral Intermediate Cervical Plexus Block for Thyroidectomy/Parathyroidectomy,Parathyroid Adenoma|Thyroid Nodule,2021-05-26,2017-05-25,2017-07-31,Observational,Completed,,Mahidol University,Mahidol University,"Faculty of Medicine Siriraj Hospital, Mahidol University",Procedure,Thailand,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04905641
NCT04905641,thyroid neoplasms,The Feasibility of Bilateral Intermediate Cervical Plexus Block for Thyroidectomy/Parathyroidectomy Under Moderate Sedation; Retrospective Study,The Feasibility of Bilateral Intermediate Cervical Plexus Block for Thyroidectomy/Parathyroidectomy,Parathyroid Adenoma|Thyroid Nodule,2021-05-26,2017-05-25,2017-07-31,Observational,Completed,,Mahidol University,Mahidol University,"Faculty of Medicine Siriraj Hospital, Mahidol University",Procedure,Thailand,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04905641
NCT04916262,thyroid neoplasms,Correlation Between TCM Syndrome Factors and TSH Changes of Thyroid Hormone Withdrawal Before Iodine Therapy in Postoperative Patients With Thyroid Cancer,Correlation Between TCM Syndrome Factors and TSH Changes of Thyroid Hormone Withdrawal Before Iodine Therapy in Postoperative Patients With Thyroid Cancer,Differentiated Thyroid Carcinoma|TCM Syndrome Type,2021-05-24,2021-12-01,2022-01-01,Observational,Not yet recruiting,,Qianfoshan Hospital,Qianfoshan Hospital,,,,18.0,75.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04916262
NCT04919694,hyperthyroidism,The Therapeutic Effect of Combination of Orbital Compression Surgery and Strabismus Surgery in Patients With Moderate to Severe Thyroid Associated Ophthalmopathy,Combination of Orbital Compression Surgery and Strabismus Surgery for Thyroid Associated Ophthalmopathy,Thyroid Associated Ophthalmopathy,2021-01-19,2023-12-31,2023-12-31,Interventional,Not yet recruiting,Not Applicable,Sun Yat-sen University,Sun Yat-sen University,"Zhongshan Ophthalmic Center, Sun Yat-sen University",Procedure|Procedure,China,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04919694
NCT04919694,goiter,The Therapeutic Effect of Combination of Orbital Compression Surgery and Strabismus Surgery in Patients With Moderate to Severe Thyroid Associated Ophthalmopathy,Combination of Orbital Compression Surgery and Strabismus Surgery for Thyroid Associated Ophthalmopathy,Thyroid Associated Ophthalmopathy,2021-01-19,2023-12-31,2023-12-31,Interventional,Not yet recruiting,Not Applicable,Sun Yat-sen University,Sun Yat-sen University,"Zhongshan Ophthalmic Center, Sun Yat-sen University",Procedure|Procedure,China,18.0,80.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04919694
NCT04919694,graves disease,The Therapeutic Effect of Combination of Orbital Compression Surgery and Strabismus Surgery in Patients With Moderate to Severe Thyroid Associated Ophthalmopathy,Combination of Orbital Compression Surgery and Strabismus Surgery for Thyroid Associated Ophthalmopathy,Thyroid Associated Ophthalmopathy,2021-01-19,2023-12-31,2023-12-31,Interventional,Not yet recruiting,Not Applicable,Sun Yat-sen University,Sun Yat-sen University,"Zhongshan Ophthalmic Center, Sun Yat-sen University",Procedure|Procedure,China,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04919694
NCT04919694,graves ophthalmopathy,The Therapeutic Effect of Combination of Orbital Compression Surgery and Strabismus Surgery in Patients With Moderate to Severe Thyroid Associated Ophthalmopathy,Combination of Orbital Compression Surgery and Strabismus Surgery for Thyroid Associated Ophthalmopathy,Thyroid Associated Ophthalmopathy,2021-01-19,2023-12-31,2023-12-31,Interventional,Not yet recruiting,Not Applicable,Sun Yat-sen University,Sun Yat-sen University,"Zhongshan Ophthalmic Center, Sun Yat-sen University",Procedure|Procedure,China,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT04919694
NCT04922892,hyperparathyroidism,Total Parathyroidectomy With Autotransplantation Versus Total Parathyroidectomy Alone for Secondary Hyperparathyroidism,Total Parathyroidectomy With Autotransplantation Versus Total Parathyroidectomy Alone for Secondary Hyperparathyroidism,Secondary Hyperparathyroidism;Parathyroidectomy,2021-06-07,2023-05-31,2028-05-31,Interventional,Recruiting,Not Applicable,The Second Hospital of Nanjing Medical University,The Second Hospital of Nanjing Medical University,NanjingMU,Procedure,China,18.0,70.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04922892
NCT04927416,thyroid neoplasms,The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer,The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer,Metastic Thyroid Cancer,2021-06-15,2030-11-30,2030-11-30,Interventional,Recruiting,Phase 2,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),National Institutes of Health Clinical Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04927416
NCT04927468,graves disease,The Management of Large-angle Strabismus in Grave's Ophthalmopathy With Supramaximal Rectus Recession,Supramaximal Rectus Recession for Strabismus in Grave's Ophthalmopathy,"Graves Ophthalmopathy|Strabismus, Mechanical",2021-06-08,2023-07-01,2023-07-01,Interventional,Not yet recruiting,Not Applicable,Sun Yat-sen University,Sun Yat-sen University,,Procedure|Procedure,,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04927468
NCT04927468,goiter,The Management of Large-angle Strabismus in Grave's Ophthalmopathy With Supramaximal Rectus Recession,Supramaximal Rectus Recession for Strabismus in Grave's Ophthalmopathy,"Graves Ophthalmopathy|Strabismus, Mechanical",2021-06-08,2023-07-01,2023-07-01,Interventional,Not yet recruiting,Not Applicable,Sun Yat-sen University,Sun Yat-sen University,,Procedure|Procedure,,18.0,80.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04927468
NCT04927468,hyperthyroidism,The Management of Large-angle Strabismus in Grave's Ophthalmopathy With Supramaximal Rectus Recession,Supramaximal Rectus Recession for Strabismus in Grave's Ophthalmopathy,"Graves Ophthalmopathy|Strabismus, Mechanical",2021-06-08,2023-07-01,2023-07-01,Interventional,Not yet recruiting,Not Applicable,Sun Yat-sen University,Sun Yat-sen University,,Procedure|Procedure,,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04927468
NCT04932135,goiter,Resting Heart Rate Monitoring for Optimized Treatment and Surveillance of Hyperthyroidism,Resting Heart Rate Monitoring for Optimized Treatment and Surveillance of Hyperthyroidism,Graves Disease|Hyperthyroidism,2021-06-14,2022-12-31,2023-03-31,Observational,Recruiting,,"University Hospital, Basel, Switzerland","University Hospital, Basel, Switzerland",University Hospital Basel,Diagnostic Test,Switzerland,18.0,80.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04932135
NCT04936854,graves ophthalmopathy,Prospective Comparison of Sirolimus Against Corticosteroids in Treatment of Patients With Active Thyroid Eye Disease,Sirolimus vs Corticosteroids in Treatment of Thyroid Eye Disease,Thyroid-Associated Ophthalmopathy,2021-06-15,2026-01-31,2026-05-31,Interventional,Not yet recruiting,Phase 2,Haukeland University Hospital,Haukeland University Hospital,,Drug|Drug,,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT04936854
NCT04936854,hyperthyroidism,Prospective Comparison of Sirolimus Against Corticosteroids in Treatment of Patients With Active Thyroid Eye Disease,Sirolimus vs Corticosteroids in Treatment of Thyroid Eye Disease,Thyroid-Associated Ophthalmopathy,2021-06-15,2026-01-31,2026-05-31,Interventional,Not yet recruiting,Phase 2,Haukeland University Hospital,Haukeland University Hospital,,Drug|Drug,,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04936854
NCT04936854,goiter,Prospective Comparison of Sirolimus Against Corticosteroids in Treatment of Patients With Active Thyroid Eye Disease,Sirolimus vs Corticosteroids in Treatment of Thyroid Eye Disease,Thyroid-Associated Ophthalmopathy,2021-06-15,2026-01-31,2026-05-31,Interventional,Not yet recruiting,Phase 2,Haukeland University Hospital,Haukeland University Hospital,,Drug|Drug,,18.0,80.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04936854
NCT04936854,graves disease,Prospective Comparison of Sirolimus Against Corticosteroids in Treatment of Patients With Active Thyroid Eye Disease,Sirolimus vs Corticosteroids in Treatment of Thyroid Eye Disease,Thyroid-Associated Ophthalmopathy,2021-06-15,2026-01-31,2026-05-31,Interventional,Not yet recruiting,Phase 2,Haukeland University Hospital,Haukeland University Hospital,,Drug|Drug,,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04936854
NCT04942769,"thyroiditis, autoimmune",Study on the Effect of Selenium Supplementation on the Structure and Function of Autoimmune Thyroiditis,Study on the Effect of Selenium Supplementation on the Structure and Function of Autoimmune Thyroiditis,Selenium,2021-06-24,2021-07-30,2021-10-30,Interventional,Recruiting,Not Applicable,Beijing Chao Yang Hospital,Beijing Chao Yang Hospital,"Beijing Chao-Yang Hospital, Capital Medical University",Drug,China,18.0,75.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT04942769
NCT04948671,hyperparathyroidism,Primary Hyperparathyroidism and Gut Microbiota Unravelling an Unexpected Relationship: the HYPOGEUM Study,Primary Hyperparathyroidism and Gut Microbiota,"Hyperparathyroidism, Primary",2021-06-28,2023-02-28,2024-02-28,Observational,Recruiting,,Centre Hospitalier Universitaire Vaudois,Centre Hospitalier Universitaire Vaudois|The Novartis Foundation,Patrizia D'amelio,Other,Switzerland,30.0,80.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04948671
NCT04953195,hypothyroidism,Effect of Thyroid Replacement Therapy on Thyroid Structure in Patients With Subclinical Hypothyroidism,Thyroid Replacement Therapy in Patients With Subclinical Hypothyroidism,Subclinical Hypothyroidisms,2021-06-25,2021-09-15,2021-10-30,Interventional,Recruiting,Phase 4,Beijing Chao Yang Hospital,Beijing Chao Yang Hospital,"Beijing Chao-Yang Hospital, Capital Medical University",Drug,China,18.0,75.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04953195
NCT04969926,hyperparathyroidism,Natural History Study of Parathyroid Disorders,Natural History Study of Parathyroid Disorders,"Inheritable Bone Diseases|Multiple Endocrine Neoplasia, Type 1|Parathyroid Cancer|Primary Hyperparathyroidism|Pseudohypoparathyroidism",2021-07-20,2031-01-22,2031-01-22,Observational,Recruiting,,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),National Institutes of Health Clinical Center,,United States,6.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04969926
NCT04969926,parathyroid neoplasms,Natural History Study of Parathyroid Disorders,Natural History Study of Parathyroid Disorders,"Inheritable Bone Diseases|Multiple Endocrine Neoplasia, Type 1|Parathyroid Cancer|Primary Hyperparathyroidism|Pseudohypoparathyroidism",2021-07-20,2031-01-22,2031-01-22,Observational,Recruiting,,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),National Institutes of Health Clinical Center,,United States,6.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04969926
NCT04976816,hyperthyroidism,Local Betamethasone Versus Triamcinolone Injection in Management of Thyroid-Related Upper Lid Retraction With and Without Proptosis,Local Betamethasone Versus Triamcinolone Injection in Management of Thyroid Eye Disease,Thyroid Eye Disease,2021-07-13,2022-12-31,2023-01-31,Interventional,Not yet recruiting,Phase 4,Assiut University,Assiut University,,Procedure|Procedure|Procedure|Procedure,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04976816
NCT04976816,goiter,Local Betamethasone Versus Triamcinolone Injection in Management of Thyroid-Related Upper Lid Retraction With and Without Proptosis,Local Betamethasone Versus Triamcinolone Injection in Management of Thyroid Eye Disease,Thyroid Eye Disease,2021-07-13,2022-12-31,2023-01-31,Interventional,Not yet recruiting,Phase 4,Assiut University,Assiut University,,Procedure|Procedure|Procedure|Procedure,,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04976816
NCT04976816,graves disease,Local Betamethasone Versus Triamcinolone Injection in Management of Thyroid-Related Upper Lid Retraction With and Without Proptosis,Local Betamethasone Versus Triamcinolone Injection in Management of Thyroid Eye Disease,Thyroid Eye Disease,2021-07-13,2022-12-31,2023-01-31,Interventional,Not yet recruiting,Phase 4,Assiut University,Assiut University,,Procedure|Procedure|Procedure|Procedure,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04976816
NCT04988802,hypothyroidism,The Effect of Dietary Supplements for Pregnant Women on Levothyroxine Absorption,The Effect of Dietary Supplements for Pregnant Women on Levothyroxine Absorption,Hypothyroidism Primary,2021-07-25,2022-07-30,2022-09-30,Interventional,Recruiting,Not Applicable,University Hospital Dubrava,University Hospital Dubrava,Dubrava University Hospital,Dietary Supplement|Other,Croatia,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04988802
NCT04994080,hyperparathyroidism,"A Multi-center, Randomized, Double-blind, Parallel Grouping, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Paricalcitol Soft Capsules in the Treatment of Secondary Hyperparathyroidism in Subjects With Stage 3 and Stage 4 Chronic Kidney Disease",A Study to Assess the Efficacy and Safety of Paricalcitol in the Treatment of Chronic Kidney Disease With Secondary Hyperparathyroidism,Secondary Hyperparathyroidism,2021-07-21,2023-03-31,2023-03-31,Interventional,Not yet recruiting,Phase 3,"Chengdu Suncadia Medicine Co., Ltd.","Chengdu Suncadia Medicine Co., Ltd.",,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04994080
NCT04998968,hypoparathyroidism,Quality of Life in Patients With Permanent Hypoparathyroidism After Total Thyroidectomy in a Swedish Population Based Cohort,Quality in Patients With Permanent Hypoparathyroidism After Total Thyroidectomy,Permanent Hypoparathyroidism,2021-08-09,2021-12-31,2022-05-31,Observational,Enrolling by invitation,,Uppsala University,Uppsala University,Uppsala University Hospital,,Sweden,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04998968
NCT05002998,graves disease,"A Phase 3b/4, Double-masked, Randomized, International, Parallel-assignment, Multicenter Trial in Patients With Thyroid Eye Disease to Evaluate the Safety and Tolerability of Different Dosing Durations of Teprotumumab",TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study,Thyroid Eye Disease,2021-07-19,2025-08-31,2025-08-31,Interventional,Recruiting,Phase 4,"Horizon Pharma USA, Inc.","Horizon Therapeutics USA, Inc.",University of Colorado - Eye Center|Bascom Palmer Eye Institute|Washington University in St. Louis|University of Nebraska Medical Center,Drug|Drug,United States,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT05002998
NCT05002998,goiter,"A Phase 3b/4, Double-masked, Randomized, International, Parallel-assignment, Multicenter Trial in Patients With Thyroid Eye Disease to Evaluate the Safety and Tolerability of Different Dosing Durations of Teprotumumab",TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study,Thyroid Eye Disease,2021-07-19,2025-08-31,2025-08-31,Interventional,Recruiting,Phase 4,"Horizon Pharma USA, Inc.","Horizon Therapeutics USA, Inc.",University of Colorado - Eye Center|Bascom Palmer Eye Institute|Washington University in St. Louis|University of Nebraska Medical Center,Drug|Drug,United States,18.0,80.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT05002998
NCT05002998,hyperthyroidism,"A Phase 3b/4, Double-masked, Randomized, International, Parallel-assignment, Multicenter Trial in Patients With Thyroid Eye Disease to Evaluate the Safety and Tolerability of Different Dosing Durations of Teprotumumab",TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study,Thyroid Eye Disease,2021-07-19,2025-08-31,2025-08-31,Interventional,Recruiting,Phase 4,"Horizon Pharma USA, Inc.","Horizon Therapeutics USA, Inc.",University of Colorado - Eye Center|Bascom Palmer Eye Institute|Washington University in St. Louis|University of Nebraska Medical Center,Drug|Drug,United States,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT05002998
NCT05007093,thyroid neoplasms,An Exploratory Study on Efficacy of Anlotinib Hydrochloride in the Treatment of Locally Advanced or Metastatic Differentiated Thyroid Cancer,Study on the Treatment of Differentiated Thyroid Carcinoma With Anlotinib,DTC - Differentiated Thyroid Cancer,2021-08-09,2023-12-07,2023-12-07,Interventional,Recruiting,Phase 2,Peking Union Medical College Hospital,Yansong Lin,Peking Union Medical College Hospital,Drug,China,18.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05007093
NCT05012033,goiter,Evaluation of High Dose Prednisolone Pharmacokinetics in the Acute and Chronic Setting,Evaluation of High Dose Prednisolone Pharmacokinetics in the Acute and Chronic Setting,Asthma|COPD Exacerbation Acute|Inflammatory Disease|Thyroid Eye Disease|Vasculitis,2021-07-30,2026-03-26,2026-03-26,Observational,Not yet recruiting,,Imperial College London,Imperial College London,Imperial College Healthcare NHS Trust,Other,United Kingdom,18.0,75.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT05012033
NCT05012033,graves disease,Evaluation of High Dose Prednisolone Pharmacokinetics in the Acute and Chronic Setting,Evaluation of High Dose Prednisolone Pharmacokinetics in the Acute and Chronic Setting,Asthma|COPD Exacerbation Acute|Inflammatory Disease|Thyroid Eye Disease|Vasculitis,2021-07-30,2026-03-26,2026-03-26,Observational,Not yet recruiting,,Imperial College London,Imperial College London,Imperial College Healthcare NHS Trust,Other,United Kingdom,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT05012033
NCT05012033,hyperthyroidism,Evaluation of High Dose Prednisolone Pharmacokinetics in the Acute and Chronic Setting,Evaluation of High Dose Prednisolone Pharmacokinetics in the Acute and Chronic Setting,Asthma|COPD Exacerbation Acute|Inflammatory Disease|Thyroid Eye Disease|Vasculitis,2021-07-30,2026-03-26,2026-03-26,Observational,Not yet recruiting,,Imperial College London,Imperial College London,Imperial College Healthcare NHS Trust,Other,United Kingdom,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT05012033
NCT05015127,hyperthyroidism,"A Randomized, Double-blind, Placebo-controlled, Phase 2/3 Operational Seamless Design Clinical Study to Evaluate the Efficacy and Safety of HBM9161 Subcutaneous Injection in Chinese Patients With Active, Moderate to Severe Thyroid Eye Disease (TED)",A Study to Evaluate the Efficacy and Safety of HBM9161 on Moderate to Severe Thyroid Eye Disease,Thyroid Ophthalmopathy,2021-08-03,2022-10-31,2022-12-31,Interventional,Recruiting,Phase 2/Phase 3,Harbour BioMed (Guangzhou) Co. Ltd.,Harbour BioMed (Guangzhou) Co. Ltd.,"Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine",Drug|Drug|Drug|Drug,China,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT05015127
NCT05015127,goiter,"A Randomized, Double-blind, Placebo-controlled, Phase 2/3 Operational Seamless Design Clinical Study to Evaluate the Efficacy and Safety of HBM9161 Subcutaneous Injection in Chinese Patients With Active, Moderate to Severe Thyroid Eye Disease (TED)",A Study to Evaluate the Efficacy and Safety of HBM9161 on Moderate to Severe Thyroid Eye Disease,Thyroid Ophthalmopathy,2021-08-03,2022-10-31,2022-12-31,Interventional,Recruiting,Phase 2/Phase 3,Harbour BioMed (Guangzhou) Co. Ltd.,Harbour BioMed (Guangzhou) Co. Ltd.,"Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine",Drug|Drug|Drug|Drug,China,18.0,70.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT05015127
NCT05015127,graves disease,"A Randomized, Double-blind, Placebo-controlled, Phase 2/3 Operational Seamless Design Clinical Study to Evaluate the Efficacy and Safety of HBM9161 Subcutaneous Injection in Chinese Patients With Active, Moderate to Severe Thyroid Eye Disease (TED)",A Study to Evaluate the Efficacy and Safety of HBM9161 on Moderate to Severe Thyroid Eye Disease,Thyroid Ophthalmopathy,2021-08-03,2022-10-31,2022-12-31,Interventional,Recruiting,Phase 2/Phase 3,Harbour BioMed (Guangzhou) Co. Ltd.,Harbour BioMed (Guangzhou) Co. Ltd.,"Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine",Drug|Drug|Drug|Drug,China,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT05015127
NCT05017142,hashimoto disease,Swiss Pediatric Inflammatory Bain Disease Cohort Study,Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD),"Acute Disseminated Encephalomyelitis|Anti-AMPAR-1/2 Associated Autoimmune Encephalitis|Anti-CASPR-2 Associated Autoimmune Encephalitis|Anti-GABAR-1/2 Associated Autoimmune Encephalitis|Anti-GAD65 Associated Autoimmune Encephalitis|Anti-Lgi-1 Associated Autoimmune Encephalitis|Anti-NMDAR Encephalitis|CNS Lupus|CNS Sarcoidosis|CNS Vasculitis|Hashimoto Encephalitis|Multiple Sclerosis|Neuromyelitis Optica Spectrum Disorder|Onconeuronal Antibody (Hu, Ri, Yo, Amphiphysin, CRMP-5, Ma-1, Ma-2, SOX-1) Associated Autoimmune Encephalitis|Optic Neuritis|Rasmussen Encephalitis|Transverse Myelitis",2021-08-04,2071-01-01,2071-01-01,Observational [Patient Registry],Recruiting,,University of Bern,"Novartis|Roche Pharma (Switzerland) Ltd|Schweizerische Multiple Sklerose Gesellschaft|University Hospital Inselspital, Berne|University of Bern","Kantonsspital Aarau|Kantonsspital Graubünden|Children's Hospital of Eastern Switzerland|Pediatric Institute of Southern Switzerland, Ospedale San Giovanni|University Children's Hospital Lausanne (CHUV)|Kinderspital Winterthur|University Children's Hospital Basel, UKBB|University Children's Hospital, Inselspital Bern|Institute of Social and Preventive Medicine, University of Bern|University Hospitals of Geneva (HUG)|Luzerner Kantonsspital|University Children's Hospital Zurich",,Switzerland,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT05017142
NCT05019118,hypothyroidism,"Dietary Intervention With Únicla Dairy Products, Naturally Enriched With Selenium and Omega-3 Fatty Acids, May Improve Thyroid-stimulating Hormone (TSH) Levels in Women With Subclinical Hypothyroidism",Dietary Intervention With Únicla Dairy Products (DANTIAN),Subclinical Hypothyroidism,2021-08-13,2021-12-30,2022-05-30,Interventional,Not yet recruiting,Not Applicable,Cooperativas Lacteas Unidas,Cooperativas Lacteas Unidas|Galician South Health Research Institute,Nursing University School of Ourense,Other|Other|Other|Other|Other|Other,Spain,40.0,65.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT05019118
NCT05022641,hyperparathyroidism,Evaluating Impact of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy,Evaluating Impact of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy,Hypercalcemia|Parathyroid Adenoma|Parathyroid Cancer|Parathyroid Neoplasms|Primary Hyperparathyroidism,2021-08-22,2023-08-31,2023-08-31,Interventional,Recruiting,Not Applicable,University of Michigan,National Cancer Institute (NCI)|University of Michigan|Vanderbilt University,The University of Michigan,Device,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT05022641
NCT05043233,hyperthyroidism,The Observation Study of Graves' Disease Cohort,Observation in the Treatment of Graves' Disease,Patient Acceptance of Health Care,2021-08-30,2024-10-01,2025-10-01,Observational [Patient Registry],Recruiting,,Shanghai Jiao Tong University School of Medicine,Shanghai Jiao Tong University School of Medicine,"Ruijin hospital, Shanghai Jiaotong University School of Medicine",Drug,China,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT05043233
NCT05043233,goiter,The Observation Study of Graves' Disease Cohort,Observation in the Treatment of Graves' Disease,Patient Acceptance of Health Care,2021-08-30,2024-10-01,2025-10-01,Observational [Patient Registry],Recruiting,,Shanghai Jiao Tong University School of Medicine,Shanghai Jiao Tong University School of Medicine,"Ruijin hospital, Shanghai Jiaotong University School of Medicine",Drug,China,18.0,70.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT05043233
NCT05043233,graves disease,The Observation Study of Graves' Disease Cohort,Observation in the Treatment of Graves' Disease,Patient Acceptance of Health Care,2021-08-30,2024-10-01,2025-10-01,Observational [Patient Registry],Recruiting,,Shanghai Jiao Tong University School of Medicine,Shanghai Jiao Tong University School of Medicine,"Ruijin hospital, Shanghai Jiaotong University School of Medicine",Drug,China,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT05043233
NCT05049603,hyperthyroidism,"Phase III, Double-blinded, Multicenter, Randomized Clinical Trial to Evaluate the Effects of Atorvastatin on Moderate-to-severe and Active Graves' Orbitopathy (GO) Treated With Intravenous Glucocorticoids: the STAGO-2 Study",A Randomized Clinical Trial to Evaluate the Effects of Atorvastatin on Graves' Orbitopathy (GO): the STAGO-2 Study,Graves' Orbitopathy,2021-09-02,2023-12-31,2024-12-31,Interventional,Not yet recruiting,Phase 3,University of Pisa,Università degli Studi dell'Insubria|University of Catania|University of Messina|University of Pisa,Ospedale Cisanello-Endocrinology II,Drug|Other,Italy,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT05049603
NCT05049603,goiter,"Phase III, Double-blinded, Multicenter, Randomized Clinical Trial to Evaluate the Effects of Atorvastatin on Moderate-to-severe and Active Graves' Orbitopathy (GO) Treated With Intravenous Glucocorticoids: the STAGO-2 Study",A Randomized Clinical Trial to Evaluate the Effects of Atorvastatin on Graves' Orbitopathy (GO): the STAGO-2 Study,Graves' Orbitopathy,2021-09-02,2023-12-31,2024-12-31,Interventional,Not yet recruiting,Phase 3,University of Pisa,Università degli Studi dell'Insubria|University of Catania|University of Messina|University of Pisa,Ospedale Cisanello-Endocrinology II,Drug|Other,Italy,18.0,75.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT05049603
NCT05049603,graves disease,"Phase III, Double-blinded, Multicenter, Randomized Clinical Trial to Evaluate the Effects of Atorvastatin on Moderate-to-severe and Active Graves' Orbitopathy (GO) Treated With Intravenous Glucocorticoids: the STAGO-2 Study",A Randomized Clinical Trial to Evaluate the Effects of Atorvastatin on Graves' Orbitopathy (GO): the STAGO-2 Study,Graves' Orbitopathy,2021-09-02,2023-12-31,2024-12-31,Interventional,Not yet recruiting,Phase 3,University of Pisa,Università degli Studi dell'Insubria|University of Catania|University of Messina|University of Pisa,Ospedale Cisanello-Endocrinology II,Drug|Other,Italy,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT05049603
NCT05049603,graves ophthalmopathy,"Phase III, Double-blinded, Multicenter, Randomized Clinical Trial to Evaluate the Effects of Atorvastatin on Moderate-to-severe and Active Graves' Orbitopathy (GO) Treated With Intravenous Glucocorticoids: the STAGO-2 Study",A Randomized Clinical Trial to Evaluate the Effects of Atorvastatin on Graves' Orbitopathy (GO): the STAGO-2 Study,Graves' Orbitopathy,2021-09-02,2023-12-31,2024-12-31,Interventional,Not yet recruiting,Phase 3,University of Pisa,Università degli Studi dell'Insubria|University of Catania|University of Messina|University of Pisa,Ospedale Cisanello-Endocrinology II,Drug|Other,Italy,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT05049603
NCT05059470,thyroid neoplasms,IMRT Followed by Pembrolizumab in the Adjuvant Setting in Anaplastic Cancer of the Thyroid (IMPAACT): Phase II Trial Adjuvant Pembrolizumab After IMRT in ATC,IMRT Followed by Pembrolizumab in the Adjuvant Setting in Anaplastic Cancer of the Thyroid (IMPAACT): Phase II Trial Adjuvant Pembrolizumab After IMRT in ATC,Thyroid,2021-09-15,2023-10-01,2023-10-01,Interventional,Active not recruiting,Phase 2,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center,M D Anderson Cancer Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05059470
NCT05068687,thyroid neoplasms,"Peroperative Assessment of Tumour Resection Margins Using High-resolution 18F-FDG-PET/CT in Malignancies of the Head and Neck, a Pilot Study",Peroperative Assessment of Malignancies of the Head and Neck Using High-resolution 18F-FDG-PET/CT,Head and Neck Neoplasms|Skin Neoplasm|Thyroid Neoplasm,2021-09-24,2022-09-30,2022-09-30,Interventional,Recruiting,Not Applicable,"University Hospital, Ghent","University Hospital, Ghent|XEOS Medical",Ghent University Hospital,Diagnostic Test,Belgium,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05068687
NCT05070091,thyroiditis,The Impact of Pituitary-thyroid and Pituitary-adrenal Axes Function on COVID-19 Clinical Course.,The Impact of Pituitary-thyroid and Pituitary-adrenal Axes Function on COVID-19 Clinical Course.,Adrenal Insufficiency|COVID-19|Hyperthyroidism|Hypothyroidism|Low Triiodothyronine Syndrome|Subacute Thyroiditis,2021-10-04,2021-12-01,2021-12-01,Observational,Completed,,Medical University of Gdansk,"Medical University of Gdansk|National Center for Research and Development, Poland",7 Szpital Marynarki Wojennej|Medical University of Gdansk,,Poland,18.0,120.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT05070091
NCT05096195,hyperparathyroidism,"Denosumab for the Prevention of Fragility Fractures in Hemodialysis: a Pilot Study for an Innovative, Randomized-controlled Trial, Embedded in Routine Care",PRevEnting FracturEs in Renal Disease - 1,Chronic Kidney Disease-Mineral and Bone Disorder|Dialysis; Complications|Fragility Fracture|Kidney Diseases,2021-09-21,2023-04-30,2023-09-30,Interventional,Not yet recruiting,Phase 4,"Western University, Canada","Academic Medical Organization of Southwestern Ontario|ICES|The Kidney Foundation of Canada|Western University|Western University, Canada",,Drug|Other|Diagnostic Test,,40.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT05096195
NCT05098600,hypothyroidism,"The Epidemiology, Management and Associated Conditions in Alopecia Areata in Czech Republic: A University-clinic-based Retrospective Cohort Study","The Epidemiology, Management and Comorbidities in Alopecia Areata in Czech Republic","Alopecia Areata|Alopecia Areata (& Ophiasis)|Alopecia Barbae|Alopecia Diffuse|Alopecia Totalis|Alopecia Universalis|Anemia, Pernicious|Ankylosing Spondylitis|Atopic Asthma|Atopic Dermatitis|Atopic Rhinitis|Autoimmune Diseases|Autoimmune Hyperthyroidism|Autoimmune Hypothyroidism|COVID-19 Pandemic|Crohn Disease|Diabetes Mellitus, Type 1|Down Syndrome|Infections|Inflammatory Bowel Diseases|Lupus Erythematosus|Multiple Sclerosis|Psoriasis|Rheumatoid Arthritis|Ulcerative Colitis|Vaccine Reaction|Vitiligo",2021-10-16,2021-12-31,2022-01-10,Observational,Active not recruiting,,Faculty Hospital Kralovske Vinohrady,Faculty Hospital Kralovske Vinohrady,Teaching Hospital of Royal Vineguards,Other,Czechia,0.0,120.0,[0-17]|[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT05098600
NCT05098600,goiter,"The Epidemiology, Management and Associated Conditions in Alopecia Areata in Czech Republic: A University-clinic-based Retrospective Cohort Study","The Epidemiology, Management and Comorbidities in Alopecia Areata in Czech Republic","Alopecia Areata|Alopecia Areata (& Ophiasis)|Alopecia Barbae|Alopecia Diffuse|Alopecia Totalis|Alopecia Universalis|Anemia, Pernicious|Ankylosing Spondylitis|Atopic Asthma|Atopic Dermatitis|Atopic Rhinitis|Autoimmune Diseases|Autoimmune Hyperthyroidism|Autoimmune Hypothyroidism|COVID-19 Pandemic|Crohn Disease|Diabetes Mellitus, Type 1|Down Syndrome|Infections|Inflammatory Bowel Diseases|Lupus Erythematosus|Multiple Sclerosis|Psoriasis|Rheumatoid Arthritis|Ulcerative Colitis|Vaccine Reaction|Vitiligo",2021-10-16,2021-12-31,2022-01-10,Observational,Active not recruiting,,Faculty Hospital Kralovske Vinohrady,Faculty Hospital Kralovske Vinohrady,Teaching Hospital of Royal Vineguards,Other,Czechia,0.0,120.0,[0-17]|[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT05098600
NCT05098600,hyperthyroidism,"The Epidemiology, Management and Associated Conditions in Alopecia Areata in Czech Republic: A University-clinic-based Retrospective Cohort Study","The Epidemiology, Management and Comorbidities in Alopecia Areata in Czech Republic","Alopecia Areata|Alopecia Areata (& Ophiasis)|Alopecia Barbae|Alopecia Diffuse|Alopecia Totalis|Alopecia Universalis|Anemia, Pernicious|Ankylosing Spondylitis|Atopic Asthma|Atopic Dermatitis|Atopic Rhinitis|Autoimmune Diseases|Autoimmune Hyperthyroidism|Autoimmune Hypothyroidism|COVID-19 Pandemic|Crohn Disease|Diabetes Mellitus, Type 1|Down Syndrome|Infections|Inflammatory Bowel Diseases|Lupus Erythematosus|Multiple Sclerosis|Psoriasis|Rheumatoid Arthritis|Ulcerative Colitis|Vaccine Reaction|Vitiligo",2021-10-16,2021-12-31,2022-01-10,Observational,Active not recruiting,,Faculty Hospital Kralovske Vinohrady,Faculty Hospital Kralovske Vinohrady,Teaching Hospital of Royal Vineguards,Other,Czechia,0.0,120.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT05098600
NCT05108298,thyroid neoplasms,Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials,Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials,"Bone Cancer, NOS|Breast Cancer, NOS|Cervical Cancer, NOS|CNS Primary Tumor, NOS|Colorectal Cancer, NOS|Leukemia, NOS|Lymphoma, NOS|Melanoma|Miscellaneous Neoplasm, NOS|Non-Rhabdomyosarcoma Soft Tissue Sarcoma, NOS|Testicular Nonseminomatous Germ Cell Tumor, NOS|Thyroid Cancer, NOS",2021-10-05,2023-03-31,2024-10-31,Observational,Recruiting,,Eastern Cooperative Oncology Group,Eastern Cooperative Oncology Group,Wake Forest School of Medicine,Other,United States,18.0,39.0,[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05108298
NCT05110040,goiter,A Multi-model Image of Immunosuppressive Agents in Thyroid Associated Ophthalmopathy.,Multi-model Image of Immunosuppressive Agents in TAO,Thyroid Associated Ophthalmopathy,2021-10-27,2024-12-01,2025-12-01,Interventional,Recruiting,Not Applicable,Sun Yat-sen University,Sun Yat-sen University,Zhongshan Ophthalmic Center,Drug,China,18.0,70.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT05110040
NCT05110040,hyperthyroidism,A Multi-model Image of Immunosuppressive Agents in Thyroid Associated Ophthalmopathy.,Multi-model Image of Immunosuppressive Agents in TAO,Thyroid Associated Ophthalmopathy,2021-10-27,2024-12-01,2025-12-01,Interventional,Recruiting,Not Applicable,Sun Yat-sen University,Sun Yat-sen University,Zhongshan Ophthalmic Center,Drug,China,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT05110040
NCT05110040,graves disease,A Multi-model Image of Immunosuppressive Agents in Thyroid Associated Ophthalmopathy.,Multi-model Image of Immunosuppressive Agents in TAO,Thyroid Associated Ophthalmopathy,2021-10-27,2024-12-01,2025-12-01,Interventional,Recruiting,Not Applicable,Sun Yat-sen University,Sun Yat-sen University,Zhongshan Ophthalmic Center,Drug,China,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT05110040
NCT05110040,graves ophthalmopathy,A Multi-model Image of Immunosuppressive Agents in Thyroid Associated Ophthalmopathy.,Multi-model Image of Immunosuppressive Agents in TAO,Thyroid Associated Ophthalmopathy,2021-10-27,2024-12-01,2025-12-01,Interventional,Recruiting,Not Applicable,Sun Yat-sen University,Sun Yat-sen University,Zhongshan Ophthalmic Center,Drug,China,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT05110040
NCT05112211,graves disease,A Multi-model Image to Evaluate the Efficacy of Doxycycline in Thyroid Associated Ophthalmopathy,Multi-model Image of Doxycycline in TAO,Thyroid Associated Ophthalmopathy,2021-10-27,2023-12-01,2024-12-01,Interventional,Recruiting,Not Applicable,Sun Yat-sen University,Sun Yat-sen University,Zhongshan Ophthalmic Center,Drug,China,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT05112211
NCT05112211,graves ophthalmopathy,A Multi-model Image to Evaluate the Efficacy of Doxycycline in Thyroid Associated Ophthalmopathy,Multi-model Image of Doxycycline in TAO,Thyroid Associated Ophthalmopathy,2021-10-27,2023-12-01,2024-12-01,Interventional,Recruiting,Not Applicable,Sun Yat-sen University,Sun Yat-sen University,Zhongshan Ophthalmic Center,Drug,China,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT05112211
NCT05112211,goiter,A Multi-model Image to Evaluate the Efficacy of Doxycycline in Thyroid Associated Ophthalmopathy,Multi-model Image of Doxycycline in TAO,Thyroid Associated Ophthalmopathy,2021-10-27,2023-12-01,2024-12-01,Interventional,Recruiting,Not Applicable,Sun Yat-sen University,Sun Yat-sen University,Zhongshan Ophthalmic Center,Drug,China,18.0,70.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT05112211
NCT05112211,hyperthyroidism,A Multi-model Image to Evaluate the Efficacy of Doxycycline in Thyroid Associated Ophthalmopathy,Multi-model Image of Doxycycline in TAO,Thyroid Associated Ophthalmopathy,2021-10-27,2023-12-01,2024-12-01,Interventional,Recruiting,Not Applicable,Sun Yat-sen University,Sun Yat-sen University,Zhongshan Ophthalmic Center,Drug,China,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT05112211
NCT05117853,hypoparathyroidism,The Use of Autofluorescence and Indocyanine Green to Avoid Hypocalcemia After Total Thyroidectomy: A Randomized Clinical Trial,Autofluorescence and Indocyanine Green to Avoid Hypocalcemia After Thyroidectomy,Hypoparathyroidism Postprocedural|Thyroid Disease,2021-10-21,2024-10-31,2025-05-31,Interventional,Recruiting,Phase 3,Onze Lieve Vrouw Hospital,Onze Lieve Vrouw Hospital,Onze Lieve Vrouw Hospital,Drug|Procedure,Belgium,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT05117853
NCT05118542,goiter,"Effect of Hyperthyroidism and Its Treatment in Graves' Disease to Early Marker of Atherosclerosis: Review on the Pathway of Insulin Resistance, Lipid, Inflammation, and Endothelial Dysfunction to Pulse Wave Velocity and Carotid Intima-Media Thickness",Effect of Hyperthyroidism and Its Treatment in Graves' Disease to Early Marker of Atherosclerosis,Atherosclerosis of Artery|Graves Disease|Hyperthyroidism|Pathophysiology,2021-10-06,2020-06-01,2020-08-01,Interventional,Completed,Phase 3,Indonesia University,Indonesia University,University of Indonesia,Drug|Drug,Indonesia,18.0,65.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT05118542
NCT05119296,"thyroid carcinoma, anaplastic",Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer,Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer,Thyroid Cancer,2021-10-29,2024-11-30,2026-11-30,Interventional,Recruiting,Phase 2,Stanford University,Merck Sharp & Dohme Corp.|Stanford University,Stanford University,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT05119296
NCT05126147,graves disease,A Randomized Controlled Trial on the Effect of Hydroxychloroquine in Graves' Orbitopathy,Hydroxychloroquine in Graves' Orbitopathy,Graves Ophthalmopathy,2021-10-05,2023-12-01,2024-12-01,Interventional,Not yet recruiting,Phase 4,National Taiwan University Hospital,National Taiwan University Hospital,National Taiwan University Hospital,Drug,Taiwan,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT05126147
NCT05126147,goiter,A Randomized Controlled Trial on the Effect of Hydroxychloroquine in Graves' Orbitopathy,Hydroxychloroquine in Graves' Orbitopathy,Graves Ophthalmopathy,2021-10-05,2023-12-01,2024-12-01,Interventional,Not yet recruiting,Phase 4,National Taiwan University Hospital,National Taiwan University Hospital,National Taiwan University Hospital,Drug,Taiwan,18.0,75.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT05126147
NCT05126147,hyperthyroidism,A Randomized Controlled Trial on the Effect of Hydroxychloroquine in Graves' Orbitopathy,Hydroxychloroquine in Graves' Orbitopathy,Graves Ophthalmopathy,2021-10-05,2023-12-01,2024-12-01,Interventional,Not yet recruiting,Phase 4,National Taiwan University Hospital,National Taiwan University Hospital,National Taiwan University Hospital,Drug,Taiwan,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT05126147
NCT05126706,thyroid neoplasms,Validating Efficacy for Digital Lifestyle Management for Weight Loss Control After Thyroidectomy in Thyroid Cancer Patients,Digital Lifestyle Management for Weight Loss Control After Thyroidectomy in Thyroid Cancer Patients,"Weight Change, Body",2021-09-26,2024-08-30,2024-08-30,Interventional,Recruiting,Not Applicable,Seoul National University Hospital,Seoul National University Hospital,Seoul National University Hospital,Behavioral,"Korea, Republic of",19.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05126706
NCT05130476,hypoparathyroidism,Intraoperative Near-infrared Imaging Techniques for Identifying and Preserving Viable Parathyroid Glands During Total and Completion Thyroidectomy: a Matched Cohort Study,Near-infrared Imaging Techniques for Identifying and Preserving Viable Parathyroid Glands During Thyroidectomy,Hypoparathyroidism Postprocedural,2021-11-08,2023-09-30,2025-03-31,Interventional,Recruiting,Not Applicable,Odense University Hospital,Odense University Hospital,Odense University Hospital,Procedure,Denmark,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT05130476
NCT05142904,thyroid nodule,Ultrasound-guided Radiofrequency Ablation Versus Radioactive Iodine as Treatment for Hyperthyroidism Caused by Solitary Autonomous Thyroid Nodules,Radiofrequency Ablation Versus I-131 for Solitary Autonomous Thyroid Nodules,"Autonomous Thyroid Function|Iodine Adverse Reaction|Iodine Hyperthyroidism|Radiofrequency Ablation|Thyroid Nodule; Hyperthyroidism|Thyroid Nodule, Toxic or With Hyperthyroidism",2021-11-05,2023-12-31,2028-12-31,Interventional,Recruiting,Phase 3,Rijnstate Hospital,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Rijnstate Hospital|University of Twente|ZonMw: The Netherlands Organisation for Health Research and Development,"Rijnstate Hospital|Amsterdam UMC, location VUMC",Device|Drug|Drug,Netherlands,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT05142904
NCT05142904,hyperthyroidism,Ultrasound-guided Radiofrequency Ablation Versus Radioactive Iodine as Treatment for Hyperthyroidism Caused by Solitary Autonomous Thyroid Nodules,Radiofrequency Ablation Versus I-131 for Solitary Autonomous Thyroid Nodules,"Autonomous Thyroid Function|Iodine Adverse Reaction|Iodine Hyperthyroidism|Radiofrequency Ablation|Thyroid Nodule; Hyperthyroidism|Thyroid Nodule, Toxic or With Hyperthyroidism",2021-11-05,2023-12-31,2028-12-31,Interventional,Recruiting,Phase 3,Rijnstate Hospital,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Rijnstate Hospital|University of Twente|ZonMw: The Netherlands Organisation for Health Research and Development,"Rijnstate Hospital|Amsterdam UMC, location VUMC",Device|Drug|Drug,Netherlands,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT05142904
NCT05142904,thyroid neoplasms,Ultrasound-guided Radiofrequency Ablation Versus Radioactive Iodine as Treatment for Hyperthyroidism Caused by Solitary Autonomous Thyroid Nodules,Radiofrequency Ablation Versus I-131 for Solitary Autonomous Thyroid Nodules,"Autonomous Thyroid Function|Iodine Adverse Reaction|Iodine Hyperthyroidism|Radiofrequency Ablation|Thyroid Nodule; Hyperthyroidism|Thyroid Nodule, Toxic or With Hyperthyroidism",2021-11-05,2023-12-31,2028-12-31,Interventional,Recruiting,Phase 3,Rijnstate Hospital,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Rijnstate Hospital|University of Twente|ZonMw: The Netherlands Organisation for Health Research and Development,"Rijnstate Hospital|Amsterdam UMC, location VUMC",Device|Drug|Drug,Netherlands,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05142904
NCT05149898,hypoparathyroidism,"Open-Label, Tolerability and Efficacy Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With 22q11.2 Deletion Syndrome",Open-Label Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With 22q11.2 Deletion Syndrome,22Q Deletion Syndrome,2021-10-05,2022-11-30,2022-12-31,Interventional,Active not recruiting,Phase 1/Phase 2,"Zynerba Pharmaceuticals, Inc.","Zynerba Pharmaceuticals, Inc.",Greenwood Genetic Center|Lady Cilento Children's Hospital - South Brisbane|Genetics Clinics Australia,Drug,Australia|United States,4.0,17.0,[0-17],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT05149898
NCT05176639,hyperthyroidism,"A Multiple Ascending Dose (MAD) Safety, Tolerability and Efficacy Study of VRDN 001, a Humanized Monoclonal Antibody Directed Against the IGF-1 Receptor, in Normal Healthy Volunteers (NHVs) and Subjects With Thyroid Eye Disease (TED)","A Safety, Tolerability and Efficacy Study of VRDN 001 in Healthy Volunteers and Persons With Thyroid Eye Disease (TED)",Thyroid Eye Disease,2021-12-15,2023-06-30,2023-12-31,Interventional,Recruiting,Phase 1/Phase 2,"Viridian Therapeutics, Inc.","Viridian Therapeutics, Inc.","Sarasota Retina Institute|TKL Research, Inc.|Neuro-Eye Clinical Trials",Drug|Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT05176639
NCT05176639,goiter,"A Multiple Ascending Dose (MAD) Safety, Tolerability and Efficacy Study of VRDN 001, a Humanized Monoclonal Antibody Directed Against the IGF-1 Receptor, in Normal Healthy Volunteers (NHVs) and Subjects With Thyroid Eye Disease (TED)","A Safety, Tolerability and Efficacy Study of VRDN 001 in Healthy Volunteers and Persons With Thyroid Eye Disease (TED)",Thyroid Eye Disease,2021-12-15,2023-06-30,2023-12-31,Interventional,Recruiting,Phase 1/Phase 2,"Viridian Therapeutics, Inc.","Viridian Therapeutics, Inc.","Sarasota Retina Institute|TKL Research, Inc.|Neuro-Eye Clinical Trials",Drug|Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT05176639
NCT05176639,graves disease,"A Multiple Ascending Dose (MAD) Safety, Tolerability and Efficacy Study of VRDN 001, a Humanized Monoclonal Antibody Directed Against the IGF-1 Receptor, in Normal Healthy Volunteers (NHVs) and Subjects With Thyroid Eye Disease (TED)","A Safety, Tolerability and Efficacy Study of VRDN 001 in Healthy Volunteers and Persons With Thyroid Eye Disease (TED)",Thyroid Eye Disease,2021-12-15,2023-06-30,2023-12-31,Interventional,Recruiting,Phase 1/Phase 2,"Viridian Therapeutics, Inc.","Viridian Therapeutics, Inc.","Sarasota Retina Institute|TKL Research, Inc.|Neuro-Eye Clinical Trials",Drug|Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT05176639
NCT05177939,thyroiditis,Phase III Study to Evaluate the Efficacy and Safety of NPB-01 in Patients With Autoimmune Encephalitis Refractory to Steroid Pulse Therapy,Phase III Clinical Study of NPB-01 in Patients With Autoimmune Encephalitis,Autoimmune Encephalitis,2021-12-03,2024-05-31,2024-10-31,Interventional,Not yet recruiting,Phase 3,"Nihon Pharmaceutical Co., Ltd","Nihon Pharmaceutical Co., Ltd",,Drug|Drug,,15.0,120.0,[0-17]|[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT05177939
NCT05180214,goiter,The Effect of Adding Ketorolac to Bupivacaine in Superficial Cervical Plexus Block in Thyroid Surgery.,Analgesia for Thyroidectomy Using Bilateral Superficial Cervical Plexus Block With Bupivacaine Only or Adding Ketorolac to it.,Thyroid Goiter|Thyroid Nodule,2021-12-17,2021-08-19,2021-09-15,Interventional,Completed,Phase 2,Sohag University,Sohag University,Sohag University Faculty of Medicine,Drug|Drug,Egypt,20.0,50.0,[18-65],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT05180214
NCT05180214,thyroid neoplasms,The Effect of Adding Ketorolac to Bupivacaine in Superficial Cervical Plexus Block in Thyroid Surgery.,Analgesia for Thyroidectomy Using Bilateral Superficial Cervical Plexus Block With Bupivacaine Only or Adding Ketorolac to it.,Thyroid Goiter|Thyroid Nodule,2021-12-17,2021-08-19,2021-09-15,Interventional,Completed,Phase 2,Sohag University,Sohag University,Sohag University Faculty of Medicine,Drug|Drug,Egypt,20.0,50.0,[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05180214
NCT05186883,hypoparathyroidism,Treatment of Postoperative Hypoparathyroidism Using Cultured Allogenic Parathyroid Cells,Treatment of Postoperative Hypoparathyroidism Using Cultured Allogenic Parathyroid Cells,Postoperative Hypoparathyroidism,2021-12-01,2023-12-31,2023-12-31,Interventional,Not yet recruiting,Phase 1/Phase 2,Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus,Belarusian State Medical University|Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus,,Biological|Other,,18.0,70.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT05186883
NCT05189314,thyroid neoplasms,Clinical Outcomes and Quality of Life Measures After Surgical Resection and Radiofrequency Ablation of Benign Thyroid Nodules,RFA of Benign Thyroid Nodules: Clinical Outcomes and Quality of Life Study,Thyroid Nodules,2021-12-28,2023-08-30,2024-08-30,Observational,Recruiting,,Columbia University,Columbia University,Columbia University,Procedure|Procedure,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05189314
NCT05189314,thyroid nodule,Clinical Outcomes and Quality of Life Measures After Surgical Resection and Radiofrequency Ablation of Benign Thyroid Nodules,RFA of Benign Thyroid Nodules: Clinical Outcomes and Quality of Life Study,Thyroid Nodules,2021-12-28,2023-08-30,2024-08-30,Observational,Recruiting,,Columbia University,Columbia University,Columbia University,Procedure|Procedure,United States,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT05189314
NCT05189808,thyroid nodule,Radiofrequency Ablation for Indeterminate Bethesda III Thyroid Nodules,Radiofrequency Ablation for BIII Thyroid Nodules,Indeterminate Bethesda III Thyroid Nodules,2021-12-28,2023-08-31,2024-08-31,Observational,Recruiting,,Columbia University,Columbia University,Columbia University,Procedure,United States,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT05189808
NCT05189808,thyroid neoplasms,Radiofrequency Ablation for Indeterminate Bethesda III Thyroid Nodules,Radiofrequency Ablation for BIII Thyroid Nodules,Indeterminate Bethesda III Thyroid Nodules,2021-12-28,2023-08-31,2024-08-31,Observational,Recruiting,,Columbia University,Columbia University,Columbia University,Procedure,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05189808
NCT05189821,thyroid neoplasms,RFA Treatment for Papillary Thyroid Microcarcinoma Cohort,RFA Treatment for Papillary Thyroid Microcarcinoma,Papillary Thyroid Microcarcinoma,2021-12-28,2025-11-30,2026-11-30,Observational,Recruiting,,Columbia University,Columbia University,Columbia University,Procedure,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05189821
NCT05199103,hyperthyroidism,"Single-centre, Safety and Efficacy, Open-label Study Evaluating Antithymocyte Globulin Treatment in Subjects With Graves Orbitopathy",Antithymocyte Globulin as a Second Line Therapy in Graves Orbitopathy,Graves Orbitopathy,2021-12-27,2023-12-31,2023-12-31,Interventional,Recruiting,Not Applicable,Medical University of Silesia,Medical University of Silesia,"Department of Internal Medicine and Oncological Chemotherapy, Medical Faculty in Katowice, Medical University of Silesia",Drug,Poland,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT05199103
NCT05199103,graves disease,"Single-centre, Safety and Efficacy, Open-label Study Evaluating Antithymocyte Globulin Treatment in Subjects With Graves Orbitopathy",Antithymocyte Globulin as a Second Line Therapy in Graves Orbitopathy,Graves Orbitopathy,2021-12-27,2023-12-31,2023-12-31,Interventional,Recruiting,Not Applicable,Medical University of Silesia,Medical University of Silesia,"Department of Internal Medicine and Oncological Chemotherapy, Medical Faculty in Katowice, Medical University of Silesia",Drug,Poland,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT05199103
NCT05199103,graves ophthalmopathy,"Single-centre, Safety and Efficacy, Open-label Study Evaluating Antithymocyte Globulin Treatment in Subjects With Graves Orbitopathy",Antithymocyte Globulin as a Second Line Therapy in Graves Orbitopathy,Graves Orbitopathy,2021-12-27,2023-12-31,2023-12-31,Interventional,Recruiting,Not Applicable,Medical University of Silesia,Medical University of Silesia,"Department of Internal Medicine and Oncological Chemotherapy, Medical Faculty in Katowice, Medical University of Silesia",Drug,Poland,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT05199103
NCT05199103,goiter,"Single-centre, Safety and Efficacy, Open-label Study Evaluating Antithymocyte Globulin Treatment in Subjects With Graves Orbitopathy",Antithymocyte Globulin as a Second Line Therapy in Graves Orbitopathy,Graves Orbitopathy,2021-12-27,2023-12-31,2023-12-31,Interventional,Recruiting,Not Applicable,Medical University of Silesia,Medical University of Silesia,"Department of Internal Medicine and Oncological Chemotherapy, Medical Faculty in Katowice, Medical University of Silesia",Drug,Poland,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT05199103
NCT05214274,hypoparathyroidism,The Status of Diagnosis and Treatment of Chronic Hypoparathyroidism in Chinese Adults: a Multicenter Registry Study,Multicenter Registry Study of Chronic Hypoparathyroidism in Chinese Adults,Chronic Hypoparathyroidism,2021-12-24,2022-12-31,2022-12-31,Observational,Recruiting,,Peking University,"Central South University|First Affiliated Hospital of Xinjiang Medical University|First Affiliated Hospital, Sun Yat-Sen University|First Hospital of China Medical University|Peking Union Medical College Hospital|Peking University|Shanghai 6th People's Hospital|West China Hospital","Peking Union Medical College Hospital|The First Hospital of China Medical University|The First Affiliated Hospital , Sun Yat-sen University|The Second Xiangya Hospital of Central South University|Shanghai Sixth People's Hospital|West China Hospital of Sichuan University|The First Affiliated Hospital of Xinjiang Medical University",Other,China,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT05214274
NCT05216718,thyroid neoplasms,Prospective Randomized Controlled Study on Mini-flap Bilateral Axillo-breast Approach Robotic Thyroidectomy : Effect on Postoperative Pain and Sensation,Mini-flap BABA (Bilateral Axillo-breast Approach) Robotic Thyroidectomy is Safe,Thyroid Nodule,2021-12-30,2022-12-31,2023-12-01,Interventional,Not yet recruiting,Not Applicable,Inje University,Inje University,Dong sik Bae,Procedure|Procedure,"Korea, Republic of",19.0,69.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05216718
NCT05221008,hyperparathyroidism,"Study on Tolerability, Pharmacokinetics and Pharmacodynamics of SHR6508 in Chinese Patients With Secondary Hyperparathyroidism of Chronic Kidney Disease Treated by Maintenance Hemodialysis",A Trial of SHR6508 in Secondary Hyperparathyroidism,Secondary Hyperparathyroidism,2022-01-07,2022-09-01,2022-09-30,Interventional,Not yet recruiting,Phase 1,"Shanghai Hengrui Pharmaceutical Co., Ltd.","Shanghai Hengrui Pharmaceutical Co., Ltd.",,Drug|Drug|Drug|Drug,,18.0,70.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT05221008
NCT05225883,thyroiditis,GEnome-wide Association Study in N-methyl-D-Aspartate Receptor and Other autoiMmune Encephalitis.,GWAS in NMDAR Encephalitis,Autoimmune Encephalitis,2022-01-25,2023-12-31,2025-12-31,Observational,Recruiting,,Hospices Civils de Lyon,Hospices Civils de Lyon,Centre de référence des syndromes neurologiques paranéoplasiques et encéphalites auto-immunes,Genetic,France,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT05225883
NCT05229341,thyroid nodule,Evaluation of DNA Methylation Signatures in Diagnosis and Management of Thyroid Nodules,Evaluation of DNA Methylation Signatures for the Diagnosis and Management of Thyroid Nodules,Thyroid Gland Carcinoma,2022-02-04,2026-10-22,2026-10-22,Interventional,Recruiting,Not Applicable,City of Hope Medical Center,City of Hope Medical Center|National Cancer Institute (NCI),City of Hope Medical Center,Procedure|Other|Procedure,United States,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT05229341
NCT05239221,hypoparathyroidism,"A Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZP-3601, a Synthetic Parathyroid Hormone Analog, in Healthy Subjects and in Subjects With Hypoparathyroidism",AZP-3601 SAD and MAD Study in Healthy Subjects and Subjects With Hypoparathyroidism,Chronic Hypoparathyroidism,2022-01-07,2022-12-31,2023-01-31,Interventional,Recruiting,Phase 1,Amolyt Pharma,Amolyt Pharma,Amolyt Pharma Investigational Site Hungary|PRA-EDS,Drug|Drug,Hungary|Netherlands,18.0,75.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT05239221
NCT05241626,graves disease,Anterior Segment Optical Coherence Tomography Study of the Tear Film and Cornea in Thyroid Eye Diseases.,AS-OCT of the Cornea in Thyroid Diseases,Thyroid Eye Disease,2022-02-04,2022-10-29,2022-10-29,Observational,Enrolling by invitation,,Minia University,Minia University,Minia Faculty of medicine|Minia University hospital,Diagnostic Test,Egypt,0.0,120.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT05241626
NCT05241626,goiter,Anterior Segment Optical Coherence Tomography Study of the Tear Film and Cornea in Thyroid Eye Diseases.,AS-OCT of the Cornea in Thyroid Diseases,Thyroid Eye Disease,2022-02-04,2022-10-29,2022-10-29,Observational,Enrolling by invitation,,Minia University,Minia University,Minia Faculty of medicine|Minia University hospital,Diagnostic Test,Egypt,0.0,120.0,[0-17]|[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT05241626
NCT05241626,hyperthyroidism,Anterior Segment Optical Coherence Tomography Study of the Tear Film and Cornea in Thyroid Eye Diseases.,AS-OCT of the Cornea in Thyroid Diseases,Thyroid Eye Disease,2022-02-04,2022-10-29,2022-10-29,Observational,Enrolling by invitation,,Minia University,Minia University,Minia Faculty of medicine|Minia University hospital,Diagnostic Test,Egypt,0.0,120.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT05241626
NCT05242055,hyperparathyroidism,"A Prospective, Cohort, and Observational Study of the Effect of Integrated Diagnosis and Treatment of Chronic Kidney Disease (CKD) on Clinical Outcomes in Real World Clinical Practice",Integrated Diagnosis and Treatment of CKD on Outcomes,Anemia|Chronic Kidney Disease-Mineral and Bone Disorder|Chronic Kidney Diseases|Hyperglycemia|Hyperlipidemias|Hypertension|Malnutrition,2022-01-29,2026-12-31,2026-12-31,Observational [Patient Registry],Not yet recruiting,,Capital Medical University,Capital Medical University,,Other,,18.0,100.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT05242055
NCT05264857,thyroid neoplasms,Decision Aid for Management of Thyroid Nodules and Early Thyroid Cancer,Decision Aid and Thyroid Nodules Management,Thyroid Nodule,2022-02-17,2026-09-30,2026-09-30,Interventional,Recruiting,Not Applicable,Stony Brook University,Stony Brook University,Stony Brook University Cancer Center,Behavioral,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05264857
NCT05276063,graves disease,"A Phase 2b, Randomized, Double-Mask, Placebo-Controlled, Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)","A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)",Endocrine System Diseases|Exophthalmos|Eye Diseases|Graves Ophthalmopathy|Graves Orbitopathy|Hashimoto|IGF1R|Orbital Diseases|Proptosis|Thyroid Associated Ophthalmopathy|Thyroid Diseases|Thyroid Eye Disease,2022-03-02,2023-05-15,2025-06-13,Interventional,Not yet recruiting,Phase 2/Phase 3,"VasaraGen, Inc.","VasaraGen, Inc.",,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT05276063
NCT05276063,hyperthyroidism,"A Phase 2b, Randomized, Double-Mask, Placebo-Controlled, Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)","A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)",Endocrine System Diseases|Exophthalmos|Eye Diseases|Graves Ophthalmopathy|Graves Orbitopathy|Hashimoto|IGF1R|Orbital Diseases|Proptosis|Thyroid Associated Ophthalmopathy|Thyroid Diseases|Thyroid Eye Disease,2022-03-02,2023-05-15,2025-06-13,Interventional,Not yet recruiting,Phase 2/Phase 3,"VasaraGen, Inc.","VasaraGen, Inc.",,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT05276063
NCT05276063,goiter,"A Phase 2b, Randomized, Double-Mask, Placebo-Controlled, Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)","A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)",Endocrine System Diseases|Exophthalmos|Eye Diseases|Graves Ophthalmopathy|Graves Orbitopathy|Hashimoto|IGF1R|Orbital Diseases|Proptosis|Thyroid Associated Ophthalmopathy|Thyroid Diseases|Thyroid Eye Disease,2022-03-02,2023-05-15,2025-06-13,Interventional,Not yet recruiting,Phase 2/Phase 3,"VasaraGen, Inc.","VasaraGen, Inc.",,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT05276063
NCT05276856,hypothyroidism,Rate of Recovery of Secondary Hypothyroidism in Patients With Pituitary Disorders.,Recovery Rate in Secondary Hypothyroidism,Secondary Hypothyroidism,2022-02-28,2022-11-01,2022-12-15,Observational,Not yet recruiting,,Nova Scotia Health Authority,Nova Scotia Health Authority,,Drug,,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT05276856
NCT05280379,thyroid neoplasms,Trained Immunity of Myeloid Cells and Their Progenitors in Patients With Non-medullary Thyroid Carcinoma and Colon Carcinoma,Trained Immunity in Thyroid Carcinoma and Colon Carcinoma,"Colon Carcinoma|Thyroid Cancer, Nonmedullary",2022-02-24,2024-04-07,2025-04-07,Observational,Not yet recruiting,,Radboud University Medical Center,Radboud University Medical Center,,Other,,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05280379
NCT05280600,thyroiditis,Developing Advanced Neuroimaging for Clinical Evaluation of Autoimmune Encephalitis,Developing Advanced Neuroimaging for Clinical Evaluation of Autoimmune Encephalitis,Anti-N-Methyl-D-Aspartate Receptor Encephalitis|Autoimmune Encephalitis,2022-02-10,2024-02-28,2026-02-28,Observational,Not yet recruiting,,King's College London,Action Medical Research|Guy's and St Thomas' NHS Foundation Trust|King's College London,Guy's and St Thomas' NHS Foundation Trust,Other,United Kingdom,8.0,24.0,[0-17]|[18-65],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT05280600
NCT05286801,thyroid neoplasms,A Phase 2 Study of Tiragolumab (NSC# 827799) and Atezolizumab (NSC# 783608) in Patients With Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors,Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors,Atypical Teratoid/Rhabdoid Tumor|Epithelioid Sarcoma|Kidney Medullary Carcinoma|Malignant Solid Neoplasm|Poorly Differentiated Chordoma|Recurrent Atypical Teratoid/Rhabdoid Tumor|Recurrent Chordoma|Recurrent Epithelioid Sarcoma|Recurrent Kidney Medullary Carcinoma|Recurrent Rhabdoid Tumor|Refractory Atypical Teratoid/Rhabdoid Tumor|Refractory Chordoma|Refractory Epithelioid Sarcoma|Refractory Kidney Medullary Carcinoma|Refractory Rhabdoid Tumor|Rhabdoid Tumor,2022-03-15,2025-07-31,2025-07-31,Interventional,Not yet recruiting,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),,Biological|Biological,,12.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05286801
NCT05290493,hypoparathyroidism,"A Randomized, Placebo-Controlled Crossover Trial to Assess the Safety and Efficacy of NB-001 in Children and Adolescents With 22q11 Deletion Syndrome",NB-001 in Children and Adolescents With 22q11 Deletion Syndrome,22q11 Deletion Syndrome,2022-01-26,2022-12-31,2023-01-30,Interventional,Recruiting,Phase 2,"Nobias Therapeutics, Inc.","Nobias Therapeutics, Inc.",Children's Hospital of Philadelphia (CHOP)|Seattle Children's Hospital|The Hospital for Sick Children (SickKids),Drug|Other,Canada|United States,6.0,17.0,[0-17],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT05290493
NCT05299437,thyroid neoplasms,Personalized Therapy of Metastatic Thyroid Cancer: Biological Characterization and Optimization With 124I PET Dosimetry,Metastatic Thyroid Cancer Therapy Optimization With 124I PET Dosimetry,Metastatic Differentiated Thyroid Cancer,2022-03-07,2024-03-30,2024-09-30,Interventional,Recruiting,Phase 2,"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano",Associazione Italiana per la Ricerca sul Cancro|Carlo Chiesa,"Nuclear Medicine, Ospedale Sacro Cuore - Don Calabria|Nuclear Medicine, Fondazione IRCCS Istituto Nazionale Tumori",Drug,Italy,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05299437
NCT05299632,parathyroid neoplasms,Pre-operative Localization of Parathyroid Adenomas Using F-18 PSMA PET/CT: A Pilot Study,F-18 PSMA for Localization of Parathyroid Adenoma,Hyperparathyroidism,2022-03-09,2023-03-31,2023-12-31,Observational,Recruiting,,Emory University,Emory University,Emory Saint Joseph's Hospital|Emory University Hospital (EUH)|Emory Johns Creek Hospital,Diagnostic Test|Diagnostic Test,United States,18.0,99.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05299632
NCT05316922,hypothyroidism,Protection From Iatrogenic Hypothyroidism Patients With MBL and Pediatric Patients With HL and Non-HL Needing Radiotherapy on Thyroid Site,TSH Suppression During Radiotherapy on Thyroid Site to Prevent Iatrogenic Hypothyroidism in Pediatric Cancer Patients,Hypothyroidism; Irradiation,2021-09-14,2029-09-30,2029-09-30,Interventional,Recruiting,Phase 3,"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","Fondazione IRCCS Istituto Nazionale dei Tumori, Milano",Fondazione IRCCS Istituto Nazionale dei Tumori,Drug,Italy,0.0,120.0,[0-17]|[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT05316922
NCT05329935,hypoparathyroidism,Congenital Athymia Patient Registry of RETHYMIC,Congenital Athymia Patient Registry,Complete DiGeorge Anomaly|Complete DiGeorge Syndrome|Congenital Athymia,2022-03-24,2026-04-30,2026-04-30,Observational,Recruiting,,Enzyvant Therapeutics GmBH,Enzyvant Therapeutics GmBH,Duke University School of Medicine,Biological,United States,0.0,21.0,[0-17]|[18-65],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT05329935
NCT05345119,graves disease,"An Observational, Retrospective, Single-center, Clinical Study to Evaluate the Efficacy of Sirolimus (Rapamycin) in Patients With Graves' Disease and Moderate-to-severe and Active Graves' Orbitopathy (GO)",Sirolimus in Graves' Orbitopathy,Graves Ophthalmopathy,2022-04-19,2021-06-15,2021-06-15,Observational,Completed,,University of Pisa,University of Pisa,Endocrinologia II,Drug|Drug,Italy,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT05345119
NCT05345119,goiter,"An Observational, Retrospective, Single-center, Clinical Study to Evaluate the Efficacy of Sirolimus (Rapamycin) in Patients With Graves' Disease and Moderate-to-severe and Active Graves' Orbitopathy (GO)",Sirolimus in Graves' Orbitopathy,Graves Ophthalmopathy,2022-04-19,2021-06-15,2021-06-15,Observational,Completed,,University of Pisa,University of Pisa,Endocrinologia II,Drug|Drug,Italy,18.0,75.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT05345119
NCT05345119,hyperthyroidism,"An Observational, Retrospective, Single-center, Clinical Study to Evaluate the Efficacy of Sirolimus (Rapamycin) in Patients With Graves' Disease and Moderate-to-severe and Active Graves' Orbitopathy (GO)",Sirolimus in Graves' Orbitopathy,Graves Ophthalmopathy,2022-04-19,2021-06-15,2021-06-15,Observational,Completed,,University of Pisa,University of Pisa,Endocrinologia II,Drug|Drug,Italy,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT05345119
NCT05347082,hyperparathyroidism,Resolution of Hyperparathyroidism With High-dose Vitamin D Improves Osteoporosis in Multi-treated Postmenopausal Women,Frequency of Hyperparathyroidism in Postmenopausal Osteoporosis and Its Treatment,"Hyperparathyroidism, Primary|Hyperparathyroidism, Secondary|Hypovitaminosis D|Postmenopausal Osteoporosis|Postmenopause",2022-04-17,2021-12-29,2022-02-20,Interventional,Completed,Not Applicable,Hospital Regional 1o de Octubre,"Hospital Regional 1o de Octubre|National Polytechnic Institute, Mexico|Universidad Nacional Autonoma de Mexico",Peri-postmenopause and bone metabolism clinic. Regional Hospital October 1st ISSSTE,Drug,Mexico,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT05347082
NCT02378233,thyroid diseases,A Double-blinded Randomised Study of Iodine Supplementation to Lactating Women in an Iodine-sufficient Area in Sweden and Evaluation of Maternal and Neonatal Iodine Levels and Thyroid Function,Iodine Status in Swedish Lactating Women - Effect of Iodine Supplementation in the Thyroid Function of Mother and Infant,Lactation|Thyroid Gland; Node,2015-01-19,2017-12-31,2023-12-31,Interventional,Active not recruiting,Not Applicable,Göteborg University,"Göteborg University|Sahlgrenska University Hospital, Sweden",Health Care center,Dietary Supplement|Dietary Supplement,Sweden,18.0,40.0,[18-65],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT02378233
NCT02742597,thyroid diseases,Patient-Centred Innovations for Persons With Multimorbidity - Ontario,Patient-Centred Innovations for Persons With Multimorbidity - Ontario,Alzheimer's Disease|Anxiety|Arthritis|Asthma|Cancer|Cardiovascular Disease|Chronic Bronchitis|Chronic Hepatitis|Chronic Obstructive Pulmonary Disease (COPD)|Crohn's Disease|Dementia|Depression|Diabetes|Diverticulosis|Gastroesophageal Reflux|Heart Failure|HIV|Hyperlipidemia|Hypertension|Irritable Bowel|Kidney Disease|Multimorbidity|Musculoskeletal Pain|Osteoporosis|Rheumatoid Arthritis|Stroke|Thyroid Disorder|Transient Ischemic Attacks|Ulcer|Ulcerative Colitis|Urinary Tract Problem,2016-03-21,2019-04-07,2022-03-30,Interventional,Active not recruiting,Not Applicable,Lawson Health Research Institute,"Canadian Institutes of Health Research (CIHR)|Lawson Health Research Institute|Michael Garron Hospital|Mount Sinai Hospital, Canada|Providence Healthcare|Sunnybrook Health Sciences Centre|Toronto Central Community Care Access Centre|Unity Health Toronto|Université de Sherbrooke|University Health Network, Toronto|Western University, Canada|Women's College Hospital",Western University|Mount Sinai Hospital|Providence Healthcare|St. Michael's Hospital|Sunnybrook Health Sciences Centre|Toronto Central Community Care Access Centre|Toronto East General Hospital|University Hospital Network|Women's College Hospital,Behavioral,Canada,18.0,80.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT02742597
NCT02789800,thyroid diseases,Patient-Centred Innovations for Persons With Multimorbidity - Quebec,Patient-Centred Innovations for Persons With Multimorbidity - Quebec,Alzheimer's Disease|Anxiety|Arthritis|Asthma|Cancer|Cardiovascular Disease|Chronic Bronchitis|Chronic Hepatitis|Chronic Obstructive Pulmonary Disease (COPD)|Crohn's Disease|Dementia|Depression|Diabetes|Diverticulosis|Gastroesophageal Reflux|Heart Failure|HIV|Hyperlipidemia|Hypertension|Irritable Bowel|Kidney Disease|Musculoskeletal Pain|Osteoporosis|Rheumatoid Arthritis|Stroke|Thyroid Disorder|Transient Ischemic Attacks|Ulcer|Ulcerative Colitis|Urinary Tract Problem,2016-03-16,2022-04-01,2022-04-02,Interventional,Active not recruiting,Not Applicable,Université de Sherbrooke,"Agence de la Sante et des Services Sociaux du Saguenay-Lac-Saint-Jean|Canadian Institutes of Health Research (CIHR)|Université de Sherbrooke|Western University, Canada",Université de Sherbrooke|CIUSSS du Sageunay-Lac-Saint-Jean,Behavioral,Canada,18.0,80.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT02789800
NCT02966405,thyroid diseases,The Establish of Trimester-specific Reference Ranges for Thyroid Tests in Pregnant Women and the Influence of Thyroid Disorders on Pregnancy and Its Outcomes.,The Establish of Specific Reference Ranges for Thyroid Tests in Pregnant Women,Diseases Pregnancy Thyroid,2016-10-24,2020-12-31,2020-12-31,Observational [Patient Registry],Recruiting,,Peking University International Hospital,Xiaomei Zhang,Peking University International Hospital|Peking University International Hospital,,China,19.0,45.0,[18-65],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT02966405
NCT03149354,thyroid diseases,Prevalence of Thyroid Function Abnormalities in HIV-infected Patients: State of Play in 2012,Prevalence of Thyroid Function Abnormalities in HIV-infected Patients,HIV Infections|Thyroid,2017-05-04,2022-12-19,2022-12-19,Interventional,Recruiting,Not Applicable,"Centre Hospitalier Universitaire, Amiens","Centre Hospitalier Universitaire, Amiens",CHU Amiens Picardie,Other,France,18.0,120.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT03149354
NCT03922087,thyroid diseases,Huizhou Mother-infant Cohort,No-worry Baby Project,"Allergic Disorder|Anemia in Pregnancy|Asthma|Complications, Pregnancy|Depression|Gestational Diabetes Mellitus in Pregnancy|Gestational Hypertension|Immune System Diseases|Neurodevelopmental Disorders|Obesity|Obstetric Labor Complications|Reproductive Disorder|Thyroid Disease Pregnancy",2019-04-13,2021-12-31,2025-12-31,Observational,Recruiting,,Sun Yat-sen University,Huizhou No.1 Maternal and Child Care Service Cencer|Sun Yat-sen University,School of Public Health of Sun Yat-sen University (North Campus),Other,China,18.0,49.0,[18-65],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT03922087
NCT03932487,thyroid diseases,"The Relationship Between Urine Iodine, Urine Bisphenol A and Autoimmune Thyroid Disease in Reproductive Women","The Relationship Between Urine Iodine, Urine Bisphenol A and Autoimmune Thyroid Disease in Reproductive Women",The Effect of Iodine and BPA on AITD in Reproduction Women,2019-04-24,2022-10-01,2022-10-01,Observational,Recruiting,,Peking University International Hospital,Xiaomei Zhang,Peking University international hospital,Other,China,20.0,45.0,[18-65],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT03932487
NCT04019509,thyroid diseases,The Influence of Different Thyroid Autoantibodies on Thyroid Function and Pregnancy Outcome After Assisted Reproductive Technology,The Influence of Different Thyroid Autoantibodies on Thyroid Function and Pregnancy Outcome After Assisted Reproductive Technology,Fertility Disorders|Thyroid Dysfunction,2019-07-10,2022-01-01,2022-09-01,Interventional,Recruiting,Not Applicable,Universitair Ziekenhuis Brussel,Universitair Ziekenhuis Brussel,UZ Brussel,Diagnostic Test|Other,Belgium,18.0,36.0,[18-65],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04019509
NCT04208503,thyroid diseases,Ultrasound and Functional Thyroid Evaluation in Preterm Infants Born Between 24 and 32 Weeks of Gestation,Ultrasound and Functional Thyroid Evaluation,Gland; Functional Disturbance|Thyroid,2019-12-13,2021-12-30,2021-12-31,Observational [Patient Registry],Recruiting,,"Princess Anna Mazowiecka Hospital, Warsaw, Poland","Princess Anna Mazowiecka Hospital, Warsaw, Poland",Department of Neonatology and Neonatal Intensive Care Warsaw Medical University|Department of Neonatology and Neonatal Intensive Care Warsaw Medical University,Diagnostic Test,Poland,0.0,12.0,[0-17],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04208503
NCT04323007,thyroid diseases,Thyroid Dysfunction in Patients With Nephrotic Syndrome,Thyroid Dysfunction in Patients With Nephrotic Syndrome,Thyroid Dysfunction,2020-01-12,2021-10-01,2022-10-01,Interventional,Not yet recruiting,Not Applicable,Assiut University,Assiut University|Merna Makram,,Diagnostic Test,,18.0,80.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04323007
NCT04388956,thyroid diseases,Diagnosis of Thyroid Tumors by Multiple Ultrasonic Factors.,Thyroid Disease Diagnosis by Mutiple Ultrasonic Factors.,Diagnoses Disease|Nodule|Thyroid,2020-05-12,2022-12-31,2022-12-31,Observational [Patient Registry],Recruiting,,National Taiwan University Hospital,National Taiwan University Hospital,National Taiwan University Hospital,,Taiwan,0.0,120.0,[0-17]|[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04388956
NCT04571736,thyroid diseases,Interest of Improving Preoperative Medical Information by Video Support and Personalized and Secure Web Platform: Pilot Study in Thyroid Surgery (AMEDOP),Pilot Study for Thyroid Surgery by Preoperative Video Support and Personalized and Secure Web Platform,Thyroid,2020-07-27,2022-11-30,2022-11-30,Interventional,Recruiting,Not Applicable,"University Hospital, Montpellier","EDOP|University Hospital, Montpellier",CHU Gui de Chauliac,Other,France,18.0,75.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04571736
NCT04585126,thyroid diseases,Effect of Ultrasound-guided Intermediate Cervical Block on Recurrent Laryngeal Nerve Monitoring During Thyroid Surgery : a Randomised Non-inferiority Study,Effect of Cervical Block on Recurrent Laryngeal Nerve Monitoring During Thyroid Surgery,Thyroid Surgery,2020-10-02,2021-11-30,2021-11-30,Interventional,Recruiting,Not Applicable,"University Hospital, Caen","Centre Francois Baclesse|University Hospital, Caen",Caen University Hospital,Drug,France,18.0,120.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04585126
NCT04615988,thyroid diseases,Correlation of Serum Vitamin D Level With the Development of Endocrine Autoimmune Complications During Treatment With Immune Checkpoint Inhibitors,Correlation Vitamin D Level to Endocrine Autoimmune Toxicity Due to Immune Checkpoint Inhibitors,Cancer|PD-1|Thyroid,2020-10-29,2022-12-31,2024-06-30,Observational,Recruiting,,Icahn School of Medicine at Mount Sinai,Icahn School of Medicine at Mount Sinai,Mount Sinai Hospital /Tisch Cancer Cancer/Ruttenberg Treatment Center,,United States,18.0,120.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04615988
NCT04658524,thyroid diseases,Evaluation of Thyroid Function in Patients With Chronic Kidney Disease,Evaluation of Thyroid Function in Patients With Chronic Kidney Disease,Chronic Kidney Disease|Thyroid Dysfunction,2020-11-20,2019-11-30,2025-12-30,Observational,Active not recruiting,,Rio de Janeiro State University,Rio de Janeiro State University,Ana Beatriz Winter Tavares,Diagnostic Test,Brazil,18.0,100.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04658524
NCT04684953,thyroid diseases,Implantation of Thyroid Gland After Total Thyroidectomy in Quadriceps Femoris Muscle,Thyroid Autotransplantation in Quadriceps Femoris Muscle,Thyroid,2020-12-22,2022-10-31,2022-12-31,Interventional,Not yet recruiting,Not Applicable,Assiut University,Assiut University,,Procedure|Drug,,15.0,40.0,[0-17]|[18-65],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04684953
NCT04708704,thyroid diseases,Investigation of Photodegraded Edible Food Dyes in Drinking Water on Thyroid Function,Photodegraded Edible Food Dyes,Thyroid; Functional Disturbance,2020-12-21,2023-12-31,2024-12-31,Interventional,Not yet recruiting,Not Applicable,Yale University,Yale University,Yale University,Dietary Supplement|Dietary Supplement|Dietary Supplement,United States,18.0,120.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04708704
NCT04845867,thyroid diseases,Thyroid HEmorrhage DetectOr Study,Thyroid HEmorrhage DetectOr Study,Thyroid,2021-04-13,2022-06-30,2022-08-31,Observational [Patient Registry],Not yet recruiting,,ISAR-M GmbH,CRI-The Clinical Research Institute GmbH|ISAR-M GmbH,,Device,,18.0,120.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04845867
NCT04936698,thyroid diseases,The Prevalence and Risk Factors for Thyroid Dysfunction in Pregnant Women in Taiwan,The Prevalence and Risk Factors for Thyroid Dysfunction in Pregnant Women in Taiwan,Thyroid Disease Pregnancy,2021-06-17,2022-03-31,2022-03-31,Observational,Recruiting,,Chang Gung Memorial Hospital,Chang Gung Memorial Hospital,Chang Gung Memorial hospital,Drug|Drug,Taiwan,18.0,50.0,[18-65],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04936698
NCT04991493,thyroid diseases,Effect of Tramadol on Postoperative Sore Throat in Thyroid Surgery Under General Anesthesia With Endotracheal Intubation: A Randomized Controlled Trial,Effect of Tramadol on Postoperative Sore Throat After General Anesthesia,Intubation Intratracheal|Post-operative Sore Throat|Thyroid Surgery,2021-07-27,2023-07-31,2023-12-31,Interventional,Recruiting,Phase 4,Affiliated Cancer Hospital of Shantou University Medical College,Affiliated Cancer Hospital of Shantou University Medical College,Affiliated Cancer Hospital of Shantou University Medical College Medical,Drug|Other,China,18.0,65.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04991493
NCT05016518,thyroid diseases,Comparison of Quality of Recovery (QoR)-15 Scores According to the Use of Anesthetics During Total Intravenous Anesthesia in Female Patients Undergoing Thyroid Surgery,Comparison of Quality of Recovery (QoR)-15 Scores Between Propofol and Remimazolam Anesthesia,Patients Undergoing Thyroid Surgery for Neoplasm,2021-08-10,2022-06-30,2022-07-04,Interventional,Recruiting,Not Applicable,Gangnam Severance Hospital,Gangnam Severance Hospital,Gangnam Severance Hospital,Drug|Drug,"Korea, Republic of",20.0,65.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT05016518
NCT05103774,thyroid diseases,Thyroid Functions in Children With Congenital Heart Diseases,Thyroid Functions in Children With Congenital Heart Diseases,Value of Thyroid Functions in Children With Congenital Heart Diseases,2021-10-18,2022-11-01,2022-11-15,Observational,Not yet recruiting,,Sohag University,Sohag University,Hospital of Sohag University,Diagnostic Test,Egypt,1.0,12.0,[0-17],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT05103774
NCT05126108,thyroid diseases,Evaluation of the Decurarisation Kinetics of Rocuronium in Cervical Surgery,Decurarisation Kinetics of Rocuronium in Cervical Surgery,Equiring General Anesthesia With Intubation With a Nerve Integrity Monitor (NIM) Tube|Non-morbidly Obese Patients (BMI<35)|Thyroid and Parathyroid Surgery,2021-11-08,2022-05-31,2022-05-31,Observational,Not yet recruiting,,Assistance Publique - Hôpitaux de Paris,Assistance Publique - Hôpitaux de Paris,Surgical anesthesia service - Cochin Hospital,Procedure|Other,France,18.0,120.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT05126108
NCT05151120,thyroid diseases,Harmonization of Thyroid-stimulating Hormone Immunoassays Reagents - Blood Collection From Patients With Thyroid Disorders,Harmonization of Thyroid-stimulating Hormone Immunoassays Reagents,"Thyroid Disorders|Thyroid Stimulating; Hormone, C",2021-10-21,2023-09-01,2023-09-01,Observational,Not yet recruiting,,Hospices Civils de Lyon,Hospices Civils de Lyon,Service D'endocrinologie - Hôpital Louis Pradel - Hospices Civils de Lyon|Service de Médecine Nucléaire - Hôpital Louis Pradel - Hospices Civils de Lyon,Biological,France,18.0,120.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT05151120
NCT05251194,thyroid diseases,The Effect of McGrath Video Laryngoscope on the Glottic View at Thyroid Surgery Position in Tracheal Intubation,The Effect of McGrath Video Laryngoscope on the Glottic View at Thyroid Surgery Position,Thyroid Surgery,2022-02-11,2022-06-30,2022-08-31,Interventional,Not yet recruiting,Not Applicable,Seoul National University Hospital,Seoul National University Hospital|SMG-SNU Boramae Medical Center,Seoul Metropolitan Government Seoul National University Boramae Medical Center,Device,"Korea, Republic of",19.0,120.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT05251194
NCT05323539,thyroid diseases,Comparison of Thyroid Volumes by Ultrasonography in Patients With and Without Endometrioma,Comparison of Thyroid Volumes in Patients With and Without Endometrioma,Endometrioma|Thyroid,2022-04-05,2022-05-31,2022-05-31,Interventional,Active not recruiting,Not Applicable,Adana City Training and Research Hospital,Adana City Training and Research Hospital,Adana City Education and Research Hospital,Other,Turkey,18.0,45.0,[18-65],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT05323539
NCT00001159,hyperthyroidism,Evaluation of Patients With Thyroid Function Disorders,Evaluation of Patients With Thyroid Disorders,Grave's Disease|Hyperthyroidism|Hypothyroidism,1999-11-03,,,Observational,Recruiting,,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"National Institutes of Health Clinical Center, 9000 Rockville Pike",,United States,6.0,120.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT00001159
NCT00001159,hypothyroidism,Evaluation of Patients With Thyroid Function Disorders,Evaluation of Patients With Thyroid Disorders,Grave's Disease|Hyperthyroidism|Hypothyroidism,1999-11-03,,,Observational,Recruiting,,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"National Institutes of Health Clinical Center, 9000 Rockville Pike",,United States,6.0,120.0,[0-17]|[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT00001159
NCT00001160,tall cell variant thyroid cancer,Studies on Thyroid Nodules and Thyroid Cancer,Studies on Tumors of the Thyroid,Follicular Thyroid Cancer|Hurthle Cell Thyroid Cancer|Papillary Thyroid Cancer|Tall Cell Variant Thyroid Cancer|Thyroid Cancer,1999-11-03,,,Observational,Recruiting,,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),National Institutes of Health Clinical Center,,United States,6.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT00001160
NCT00001160,follicular thyroid cancer,Studies on Thyroid Nodules and Thyroid Cancer,Studies on Tumors of the Thyroid,Follicular Thyroid Cancer|Hurthle Cell Thyroid Cancer|Papillary Thyroid Cancer|Tall Cell Variant Thyroid Cancer|Thyroid Cancer,1999-11-03,,,Observational,Recruiting,,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),National Institutes of Health Clinical Center,,United States,6.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT00001160
NCT00001160,hurthle cell thyroid cancer,Studies on Thyroid Nodules and Thyroid Cancer,Studies on Tumors of the Thyroid,Follicular Thyroid Cancer|Hurthle Cell Thyroid Cancer|Papillary Thyroid Cancer|Tall Cell Variant Thyroid Cancer|Thyroid Cancer,1999-11-03,,,Observational,Recruiting,,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),National Institutes of Health Clinical Center,,United States,6.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Hurthle cell thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00001160
NCT00001242,pseudohypoparathyroidism,Studies of States With Resistance to Vitamin D and Parathyroid Hormone,Studies of States With Resistance to Vitamin D and Parathyroid Hormone,Hypocalcemia|Osteomalacia|Pseudohypoparathyroidism|Pseudopseudohpoparathyroidism|Rickets,1999-11-03,,,Observational,Recruiting,,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"National Institutes of Health Clinical Center, 9000 Rockville Pike",,United States,2.0,100.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,pseudohypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00001242
NCT00001277,hyperparathyroidism,Studies of Hyperparathyroidism and Related Disorders,Studies of Elevated Parathyroid Activity,Hypercalcemia|Hyperparathyroidism|MEN1|Multiple Endocrine Neoplasia|Parathyroid Neoplasm,1999-11-03,2020-03-11,2020-12-23,Interventional,Completed,Not Applicable,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"National Institutes of Health Clinical Center, 9000 Rockville Pike",Drug|Drug,United States,2.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00001277
NCT00001304,hypoparathyroidism,Treatment of Hypoparathyroidism With Synthetic Human Parathyroid Hormone 1-34,Treatment of Hypoparathyroidism With Synthetic Human Parathyroid Hormone 1-34,Hypoparathyroidism,1999-11-03,2014-03-31,2014-04-30,Interventional,Completed,Phase 2,National Institutes of Health Clinical Center (CC),Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),"National Institutes of Health Clinical Center, 9000 Rockville Pike",Drug|Drug,United States,17.0,69.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00001304
NCT00001394,parathyroid neoplasms,Use of Hypocalcemic Intraarterial Infusion Into the Thyroid/Parathyroid Bed to Localize Occult Parathyroid Adenomas,Using X-Ray Dye to Locate Hidden Parathyroid Tumors,Parathyroid Neoplasms,1999-11-03,,2005-07-31,Observational,Completed,,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00001394
NCT00001730,thyroid neoplasms,A Dosimetry Study of Radioiodine (131-I) Uptake Following the Administration of Thyrogen and Hypothyroid States During Thyroid Hormone Withdrawal,Study of Radioiodine (131-I) Uptake Following Administration of Thyrogen and Hypothyroid States During Thyroid Hormone Withdrawal.,Hypothyroidism|Thyroid Neoplasms,1999-11-03,,2000-04-30,Interventional,Completed,Phase 4,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Drug,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00001730
NCT00001730,hypothyroidism,A Dosimetry Study of Radioiodine (131-I) Uptake Following the Administration of Thyrogen and Hypothyroid States During Thyroid Hormone Withdrawal,Study of Radioiodine (131-I) Uptake Following Administration of Thyrogen and Hypothyroid States During Thyroid Hormone Withdrawal.,Hypothyroidism|Thyroid Neoplasms,1999-11-03,,2000-04-30,Interventional,Completed,Phase 4,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Drug,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT00001730
NCT00004074,anaplastic thyroid cancer,A Phase I Trial of Herceptin and Interleukin-12,Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu,Advanced Adult Primary Liver Cancer|Anaplastic Thyroid Cancer|Bone Metastases|Carcinoma of the Appendix|Distal Urethral Cancer|Fallopian Tube Cancer|Gastrinoma|Glucagonoma|Inflammatory Breast Cancer|Insulinoma|Liver Metastases|Localized Unresectable Adult Primary Liver Cancer|Lung Metastases|Male Breast Cancer|Malignant Pericardial Effusion|Malignant Pleural Effusion|Metastatic Gastrointestinal Carcinoid Tumor|Metastatic Parathyroid Cancer|Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter|Newly Diagnosed Carcinoma of Unknown Primary|Occult Non-small Cell Lung Cancer|Pancreatic Polypeptide Tumor|Primary Peritoneal Cavity Cancer|Proximal Urethral Cancer|Pulmonary Carcinoid Tumor|Recurrent Adenoid Cystic Carcinoma of the Oral Cavity|Recurrent Adrenocortical Carcinoma|Recurrent Adult Primary Liver Cancer|Recurrent Anal Cancer|Recurrent Bladder Cancer|Recurrent Breast Cancer|Recurrent Carcinoma of Unknown Primary|Recurrent Cervical Cancer|Recurrent Colon Cancer|Recurrent Endometrial Carcinoma|Recurrent Esophageal Cancer|Recurrent Extrahepatic Bile Duct Cancer|Recurrent Gallbladder Cancer|Recurrent Gastric Cancer|Recurrent Gastrointestinal Carcinoid Tumor|Recurrent Islet Cell Carcinoma|Recurrent Malignant Testicular Germ Cell Tumor|Recurrent Mucoepidermoid Carcinoma of the Oral Cavity|Recurrent Non-small Cell Lung Cancer|Recurrent Ovarian Epithelial Cancer|Recurrent Pancreatic Cancer|Recurrent Parathyroid Cancer|Recurrent Prostate Cancer|Recurrent Rectal Cancer|Recurrent Renal Cell Cancer|Recurrent Salivary Gland Cancer|Recurrent Small Intestine Cancer|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Thyroid Cancer|Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter|Recurrent Urethral Cancer|Recurrent Vaginal Cancer|Recurrent Vulvar Cancer|Skin Metastases|Small Intestine Adenocarcinoma|Somatostatinoma|Stage IIIA Anal Cancer|Stage IIIA Breast Cancer|Stage III Adenoid Cystic Carcinoma of the Oral Cavity|Stage III Adrenocortical Carcinoma|Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Anal Cancer|Stage IIIB Breast Cancer|Stage III Bladder Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage III Cervical Cancer|Stage III Colon Cancer|Stage III Endometrial Carcinoma|Stage III Esophageal Cancer|Stage III Follicular Thyroid Cancer|Stage III Gastric Cancer|Stage III Malignant Testicular Germ Cell Tumor|Stage III Mucoepidermoid Carcinoma of the Oral Cavity|Stage III Ovarian Epithelial Cancer|Stage III Pancreatic Cancer|Stage III Papillary Thyroid Cancer|Stage III Prostate Cancer|Stage III Rectal Cancer|Stage III Renal Cell Cancer|Stage III Salivary Gland Cancer|Stage III Squamous Cell Carcinoma of the Larynx|Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage III Squamous Cell Carcinoma of the Nasopharynx|Stage III Squamous Cell Carcinoma of the Oropharynx|Stage III Vaginal Cancer|Stage III Vulvar Cancer|Stage IVA Cervical Cancer|Stage IV Adenoid Cystic Carcinoma of the Oral Cavity|Stage IV Adrenocortical Carcinoma|Stage IV Anal Cancer|Stage IVA Vaginal Cancer|Stage IVB Cervical Cancer|Stage IV Bladder Cancer|Stage IV Breast Cancer|Stage IVB Vaginal Cancer|Stage IVB Vulvar Cancer|Stage IV Colon Cancer|Stage IV Endometrial Carcinoma|Stage IV Esophageal Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Gastric Cancer|Stage IV Mucoepidermoid Carcinoma of the Oral Cavity|Stage IV Non-small Cell Lung Cancer|Stage IV Ovarian Epithelial Cancer|Stage IV Pancreatic Cancer|Stage IV Papillary Thyroid Cancer|Stage IV Prostate Cancer|Stage IV Rectal Cancer|Stage IV Renal Cell Cancer|Stage IV Salivary Gland Cancer|Stage IV Squamous Cell Carcinoma of the Larynx|Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Stage IV Squamous Cell Carcinoma of the Oropharynx|Thyroid Gland Medullary Carcinoma|Unresectable Extrahepatic Bile Duct Cancer|Unresectable Gallbladder Cancer|Urethral Cancer Associated With Invasive Bladder Cancer|WDHA Syndrome,1999-12-10,2009-02-28,,Interventional,Completed,Phase 1,National Cancer Institute (NCI),National Cancer Institute (NCI),Ohio State University Medical Center,Biological|Biological,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT00004074
NCT00004074,thyroid gland medullary carcinoma,A Phase I Trial of Herceptin and Interleukin-12,Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu,Advanced Adult Primary Liver Cancer|Anaplastic Thyroid Cancer|Bone Metastases|Carcinoma of the Appendix|Distal Urethral Cancer|Fallopian Tube Cancer|Gastrinoma|Glucagonoma|Inflammatory Breast Cancer|Insulinoma|Liver Metastases|Localized Unresectable Adult Primary Liver Cancer|Lung Metastases|Male Breast Cancer|Malignant Pericardial Effusion|Malignant Pleural Effusion|Metastatic Gastrointestinal Carcinoid Tumor|Metastatic Parathyroid Cancer|Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter|Newly Diagnosed Carcinoma of Unknown Primary|Occult Non-small Cell Lung Cancer|Pancreatic Polypeptide Tumor|Primary Peritoneal Cavity Cancer|Proximal Urethral Cancer|Pulmonary Carcinoid Tumor|Recurrent Adenoid Cystic Carcinoma of the Oral Cavity|Recurrent Adrenocortical Carcinoma|Recurrent Adult Primary Liver Cancer|Recurrent Anal Cancer|Recurrent Bladder Cancer|Recurrent Breast Cancer|Recurrent Carcinoma of Unknown Primary|Recurrent Cervical Cancer|Recurrent Colon Cancer|Recurrent Endometrial Carcinoma|Recurrent Esophageal Cancer|Recurrent Extrahepatic Bile Duct Cancer|Recurrent Gallbladder Cancer|Recurrent Gastric Cancer|Recurrent Gastrointestinal Carcinoid Tumor|Recurrent Islet Cell Carcinoma|Recurrent Malignant Testicular Germ Cell Tumor|Recurrent Mucoepidermoid Carcinoma of the Oral Cavity|Recurrent Non-small Cell Lung Cancer|Recurrent Ovarian Epithelial Cancer|Recurrent Pancreatic Cancer|Recurrent Parathyroid Cancer|Recurrent Prostate Cancer|Recurrent Rectal Cancer|Recurrent Renal Cell Cancer|Recurrent Salivary Gland Cancer|Recurrent Small Intestine Cancer|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Thyroid Cancer|Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter|Recurrent Urethral Cancer|Recurrent Vaginal Cancer|Recurrent Vulvar Cancer|Skin Metastases|Small Intestine Adenocarcinoma|Somatostatinoma|Stage IIIA Anal Cancer|Stage IIIA Breast Cancer|Stage III Adenoid Cystic Carcinoma of the Oral Cavity|Stage III Adrenocortical Carcinoma|Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Anal Cancer|Stage IIIB Breast Cancer|Stage III Bladder Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage III Cervical Cancer|Stage III Colon Cancer|Stage III Endometrial Carcinoma|Stage III Esophageal Cancer|Stage III Follicular Thyroid Cancer|Stage III Gastric Cancer|Stage III Malignant Testicular Germ Cell Tumor|Stage III Mucoepidermoid Carcinoma of the Oral Cavity|Stage III Ovarian Epithelial Cancer|Stage III Pancreatic Cancer|Stage III Papillary Thyroid Cancer|Stage III Prostate Cancer|Stage III Rectal Cancer|Stage III Renal Cell Cancer|Stage III Salivary Gland Cancer|Stage III Squamous Cell Carcinoma of the Larynx|Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage III Squamous Cell Carcinoma of the Nasopharynx|Stage III Squamous Cell Carcinoma of the Oropharynx|Stage III Vaginal Cancer|Stage III Vulvar Cancer|Stage IVA Cervical Cancer|Stage IV Adenoid Cystic Carcinoma of the Oral Cavity|Stage IV Adrenocortical Carcinoma|Stage IV Anal Cancer|Stage IVA Vaginal Cancer|Stage IVB Cervical Cancer|Stage IV Bladder Cancer|Stage IV Breast Cancer|Stage IVB Vaginal Cancer|Stage IVB Vulvar Cancer|Stage IV Colon Cancer|Stage IV Endometrial Carcinoma|Stage IV Esophageal Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Gastric Cancer|Stage IV Mucoepidermoid Carcinoma of the Oral Cavity|Stage IV Non-small Cell Lung Cancer|Stage IV Ovarian Epithelial Cancer|Stage IV Pancreatic Cancer|Stage IV Papillary Thyroid Cancer|Stage IV Prostate Cancer|Stage IV Rectal Cancer|Stage IV Renal Cell Cancer|Stage IV Salivary Gland Cancer|Stage IV Squamous Cell Carcinoma of the Larynx|Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Stage IV Squamous Cell Carcinoma of the Oropharynx|Thyroid Gland Medullary Carcinoma|Unresectable Extrahepatic Bile Duct Cancer|Unresectable Gallbladder Cancer|Urethral Cancer Associated With Invasive Bladder Cancer|WDHA Syndrome,1999-12-10,2009-02-28,,Interventional,Completed,Phase 1,National Cancer Institute (NCI),National Cancer Institute (NCI),Ohio State University Medical Center,Biological|Biological,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, medullary",https://clinicaltrials.gov/ct2/show/NCT00004074
NCT00004074,recurrent thyroid cancer,A Phase I Trial of Herceptin and Interleukin-12,Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu,Advanced Adult Primary Liver Cancer|Anaplastic Thyroid Cancer|Bone Metastases|Carcinoma of the Appendix|Distal Urethral Cancer|Fallopian Tube Cancer|Gastrinoma|Glucagonoma|Inflammatory Breast Cancer|Insulinoma|Liver Metastases|Localized Unresectable Adult Primary Liver Cancer|Lung Metastases|Male Breast Cancer|Malignant Pericardial Effusion|Malignant Pleural Effusion|Metastatic Gastrointestinal Carcinoid Tumor|Metastatic Parathyroid Cancer|Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter|Newly Diagnosed Carcinoma of Unknown Primary|Occult Non-small Cell Lung Cancer|Pancreatic Polypeptide Tumor|Primary Peritoneal Cavity Cancer|Proximal Urethral Cancer|Pulmonary Carcinoid Tumor|Recurrent Adenoid Cystic Carcinoma of the Oral Cavity|Recurrent Adrenocortical Carcinoma|Recurrent Adult Primary Liver Cancer|Recurrent Anal Cancer|Recurrent Bladder Cancer|Recurrent Breast Cancer|Recurrent Carcinoma of Unknown Primary|Recurrent Cervical Cancer|Recurrent Colon Cancer|Recurrent Endometrial Carcinoma|Recurrent Esophageal Cancer|Recurrent Extrahepatic Bile Duct Cancer|Recurrent Gallbladder Cancer|Recurrent Gastric Cancer|Recurrent Gastrointestinal Carcinoid Tumor|Recurrent Islet Cell Carcinoma|Recurrent Malignant Testicular Germ Cell Tumor|Recurrent Mucoepidermoid Carcinoma of the Oral Cavity|Recurrent Non-small Cell Lung Cancer|Recurrent Ovarian Epithelial Cancer|Recurrent Pancreatic Cancer|Recurrent Parathyroid Cancer|Recurrent Prostate Cancer|Recurrent Rectal Cancer|Recurrent Renal Cell Cancer|Recurrent Salivary Gland Cancer|Recurrent Small Intestine Cancer|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Thyroid Cancer|Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter|Recurrent Urethral Cancer|Recurrent Vaginal Cancer|Recurrent Vulvar Cancer|Skin Metastases|Small Intestine Adenocarcinoma|Somatostatinoma|Stage IIIA Anal Cancer|Stage IIIA Breast Cancer|Stage III Adenoid Cystic Carcinoma of the Oral Cavity|Stage III Adrenocortical Carcinoma|Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Anal Cancer|Stage IIIB Breast Cancer|Stage III Bladder Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage III Cervical Cancer|Stage III Colon Cancer|Stage III Endometrial Carcinoma|Stage III Esophageal Cancer|Stage III Follicular Thyroid Cancer|Stage III Gastric Cancer|Stage III Malignant Testicular Germ Cell Tumor|Stage III Mucoepidermoid Carcinoma of the Oral Cavity|Stage III Ovarian Epithelial Cancer|Stage III Pancreatic Cancer|Stage III Papillary Thyroid Cancer|Stage III Prostate Cancer|Stage III Rectal Cancer|Stage III Renal Cell Cancer|Stage III Salivary Gland Cancer|Stage III Squamous Cell Carcinoma of the Larynx|Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage III Squamous Cell Carcinoma of the Nasopharynx|Stage III Squamous Cell Carcinoma of the Oropharynx|Stage III Vaginal Cancer|Stage III Vulvar Cancer|Stage IVA Cervical Cancer|Stage IV Adenoid Cystic Carcinoma of the Oral Cavity|Stage IV Adrenocortical Carcinoma|Stage IV Anal Cancer|Stage IVA Vaginal Cancer|Stage IVB Cervical Cancer|Stage IV Bladder Cancer|Stage IV Breast Cancer|Stage IVB Vaginal Cancer|Stage IVB Vulvar Cancer|Stage IV Colon Cancer|Stage IV Endometrial Carcinoma|Stage IV Esophageal Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Gastric Cancer|Stage IV Mucoepidermoid Carcinoma of the Oral Cavity|Stage IV Non-small Cell Lung Cancer|Stage IV Ovarian Epithelial Cancer|Stage IV Pancreatic Cancer|Stage IV Papillary Thyroid Cancer|Stage IV Prostate Cancer|Stage IV Rectal Cancer|Stage IV Renal Cell Cancer|Stage IV Salivary Gland Cancer|Stage IV Squamous Cell Carcinoma of the Larynx|Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Stage IV Squamous Cell Carcinoma of the Oropharynx|Thyroid Gland Medullary Carcinoma|Unresectable Extrahepatic Bile Duct Cancer|Unresectable Gallbladder Cancer|Urethral Cancer Associated With Invasive Bladder Cancer|WDHA Syndrome,1999-12-10,2009-02-28,,Interventional,Completed,Phase 1,National Cancer Institute (NCI),National Cancer Institute (NCI),Ohio State University Medical Center,Biological|Biological,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Recurrent Thyroid Cancer,https://clinicaltrials.gov/ct2/show/NCT00004074
NCT00004361,hypoparathyroidism,,Study of the Relationship Between Calcium Levels and Intact Parathyroid Hormone (iPTH) in Adults With Repaired or Palliated Conotruncal Cardiac Defects,"Conotruncal Cardiac Defects|Heart Defects, Congenital|Hypoparathyroidism|Pulmonary Atresia|Pulmonary Valve Stenosis|Tetralogy of Fallot",1999-10-18,,,Observational,Completed,,Office of Rare Diseases (ORD),Ann & Robert H Lurie Children's Hospital of Chicago|National Center for Research Resources (NCRR),,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00004361
NCT00004661,pseudohypoparathyroidism,,Study of the Regulation of Parathyroid Hormone Secretion in Pseudohypoparathyroidism,Pseudohypoparathyroidism,2000-02-24,,,Observational,Completed,,Office of Rare Diseases (ORD),"National Center for Research Resources (NCRR)|University of California, Los Angeles",,,,12.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,pseudohypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00004661
NCT00004843,hyperparathyroidism,A Randomized Study of Surgery vs No Surgery in Patients With Mild Asymptomatic,A Randomized Study of Surgery vs No Surgery in Patients With Mild Asymptomatic Primary Hyperparathyroidism,Hyperparathyroidism,2000-02-24,1999-03-30,1999-03-30,Interventional,Completed,Not Applicable,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Henry Ford Hospital|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),,Procedure|Other,,50.0,75.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00004843
NCT00005184,hypothyroidism,,Immunogenetic Factors of Coronary Heart Disease,Cardiovascular Diseases|Coronary Disease|Diabetes Mellitus|Heart Diseases|Hypertension|Hypothyroidism|Obesity,2000-05-25,,1989-11-30,Observational,Completed,,"National Heart, Lung, and Blood Institute (NHLBI)","National Heart, Lung, and Blood Institute (NHLBI)",,,,0.0,100.0,[0-17]|[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT00005184
NCT00006329,hyperparathyroidism,,Comparison of Two Methods of Parathyroidectomy for Primary Hyperparathyroidism,Hyperparathyroidism,2000-10-04,,,Interventional,Completed,Phase 2/Phase 3,National Center for Research Resources (NCRR),National Center for Research Resources (NCRR),"Univ. of Michigan Hosp, Dept. of Surgery",Procedure,United States,12.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00006329
NCT00037518,parathyroid neoplasms,An Assessment of the Calcimimetic Agent AMG 073 for the Treatment of Subjects With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism.,A Study of an Investigational Medication for Severe Primary Hyperparathyroidism or Parathyroid Cancer,Hyperparathyroidism|Parathyroid Neoplasms,2002-05-17,,,Interventional,Completed,Phase 4,Amgen,Amgen,,Drug,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00037518
NCT00037518,hyperparathyroidism,An Assessment of the Calcimimetic Agent AMG 073 for the Treatment of Subjects With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism.,A Study of an Investigational Medication for Severe Primary Hyperparathyroidism or Parathyroid Cancer,Hyperparathyroidism|Parathyroid Neoplasms,2002-05-17,,,Interventional,Completed,Phase 4,Amgen,Amgen,,Drug,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00037518
NCT00068497,insular thyroid cancer,"Single Agent ZD-1839 (NSC-715055, IND-61187) in Patients With Advanced Head and Neck Carcinoma or Non-Small Cell Lung Cancer Aged 75 Years and Older (and in a Cohort of Patients 50 Years Old and Younger)",Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer,Anaplastic Thyroid Cancer|Insular Thyroid Cancer|Metastatic Parathyroid Cancer|Recurrent Adenoid Cystic Carcinoma of the Oral Cavity|Recurrent Basal Cell Carcinoma of the Lip|Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Recurrent Lymphoepithelioma of the Nasopharynx|Recurrent Lymphoepithelioma of the Oropharynx|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Recurrent Mucoepidermoid Carcinoma of the Oral Cavity|Recurrent Non-small Cell Lung Cancer|Recurrent Parathyroid Cancer|Recurrent Salivary Gland Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Thyroid Cancer|Recurrent Verrucous Carcinoma of the Larynx|Stage IIIB Non-small Cell Lung Cancer|Stage III Follicular Thyroid Cancer|Stage III Papillary Thyroid Cancer|Stage III Salivary Gland Cancer|Stage III Squamous Cell Carcinoma of the Hypopharynx|Stage III Squamous Cell Carcinoma of the Larynx|Stage III Verrucous Carcinoma of the Larynx|Stage IVA Adenoid Cystic Carcinoma of the Oral Cavity|Stage IVA Basal Cell Carcinoma of the Lip|Stage IVA Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage IVA Follicular Thyroid Cancer|Stage IVA Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage IVA Lymphoepithelioma of the Oropharynx|Stage IVA Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage IVA Mucoepidermoid Carcinoma of the Oral Cavity|Stage IVA Papillary Thyroid Cancer|Stage IVA Salivary Gland Cancer|Stage IVA Squamous Cell Carcinoma of the Larynx|Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVA Squamous Cell Carcinoma of the Oropharynx|Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVA Verrucous Carcinoma of the Larynx|Stage IVA Verrucous Carcinoma of the Oral Cavity|Stage IVB Adenoid Cystic Carcinoma of the Oral Cavity|Stage IVB Basal Cell Carcinoma of the Lip|Stage IVB Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage IVB Follicular Thyroid Cancer|Stage IVB Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage IVB Lymphoepithelioma of the Oropharynx|Stage IVB Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage IVB Mucoepidermoid Carcinoma of the Oral Cavity|Stage IVB Papillary Thyroid Cancer|Stage IVB Salivary Gland Cancer|Stage IVB Squamous Cell Carcinoma of the Larynx|Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVB Squamous Cell Carcinoma of the Oropharynx|Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVB Verrucous Carcinoma of the Larynx|Stage IVB Verrucous Carcinoma of the Oral Cavity|Stage IVC Adenoid Cystic Carcinoma of the Oral Cavity|Stage IVC Basal Cell Carcinoma of the Lip|Stage IVC Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage IVC Follicular Thyroid Cancer|Stage IVC Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage IVC Lymphoepithelioma of the Oropharynx|Stage IVC Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage IVC Mucoepidermoid Carcinoma of the Oral Cavity|Stage IVC Papillary Thyroid Cancer|Stage IVC Salivary Gland Cancer|Stage IVC Squamous Cell Carcinoma of the Larynx|Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVC Squamous Cell Carcinoma of the Oropharynx|Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVC Verrucous Carcinoma of the Larynx|Stage IVC Verrucous Carcinoma of the Oral Cavity|Stage IV Lymphoepithelioma of the Nasopharynx|Stage IV Non-small Cell Lung Cancer|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Thryoid Gland Nonmedullary Carcinoma|Thyroid Gland Medullary Carcinoma|Tongue Cancer|Untreated Metastatic Squamous Neck Cancer With Occult Primary,2003-09-10,2007-12-31,,Interventional,Completed,Not Applicable,National Cancer Institute (NCI),National Cancer Institute (NCI),Southwest Oncology Group,Drug,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Poorly differentiated thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00068497
NCT00068497,anaplastic thyroid cancer,"Single Agent ZD-1839 (NSC-715055, IND-61187) in Patients With Advanced Head and Neck Carcinoma or Non-Small Cell Lung Cancer Aged 75 Years and Older (and in a Cohort of Patients 50 Years Old and Younger)",Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer,Anaplastic Thyroid Cancer|Insular Thyroid Cancer|Metastatic Parathyroid Cancer|Recurrent Adenoid Cystic Carcinoma of the Oral Cavity|Recurrent Basal Cell Carcinoma of the Lip|Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Recurrent Lymphoepithelioma of the Nasopharynx|Recurrent Lymphoepithelioma of the Oropharynx|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Recurrent Mucoepidermoid Carcinoma of the Oral Cavity|Recurrent Non-small Cell Lung Cancer|Recurrent Parathyroid Cancer|Recurrent Salivary Gland Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Thyroid Cancer|Recurrent Verrucous Carcinoma of the Larynx|Stage IIIB Non-small Cell Lung Cancer|Stage III Follicular Thyroid Cancer|Stage III Papillary Thyroid Cancer|Stage III Salivary Gland Cancer|Stage III Squamous Cell Carcinoma of the Hypopharynx|Stage III Squamous Cell Carcinoma of the Larynx|Stage III Verrucous Carcinoma of the Larynx|Stage IVA Adenoid Cystic Carcinoma of the Oral Cavity|Stage IVA Basal Cell Carcinoma of the Lip|Stage IVA Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage IVA Follicular Thyroid Cancer|Stage IVA Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage IVA Lymphoepithelioma of the Oropharynx|Stage IVA Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage IVA Mucoepidermoid Carcinoma of the Oral Cavity|Stage IVA Papillary Thyroid Cancer|Stage IVA Salivary Gland Cancer|Stage IVA Squamous Cell Carcinoma of the Larynx|Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVA Squamous Cell Carcinoma of the Oropharynx|Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVA Verrucous Carcinoma of the Larynx|Stage IVA Verrucous Carcinoma of the Oral Cavity|Stage IVB Adenoid Cystic Carcinoma of the Oral Cavity|Stage IVB Basal Cell Carcinoma of the Lip|Stage IVB Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage IVB Follicular Thyroid Cancer|Stage IVB Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage IVB Lymphoepithelioma of the Oropharynx|Stage IVB Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage IVB Mucoepidermoid Carcinoma of the Oral Cavity|Stage IVB Papillary Thyroid Cancer|Stage IVB Salivary Gland Cancer|Stage IVB Squamous Cell Carcinoma of the Larynx|Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVB Squamous Cell Carcinoma of the Oropharynx|Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVB Verrucous Carcinoma of the Larynx|Stage IVB Verrucous Carcinoma of the Oral Cavity|Stage IVC Adenoid Cystic Carcinoma of the Oral Cavity|Stage IVC Basal Cell Carcinoma of the Lip|Stage IVC Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage IVC Follicular Thyroid Cancer|Stage IVC Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage IVC Lymphoepithelioma of the Oropharynx|Stage IVC Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage IVC Mucoepidermoid Carcinoma of the Oral Cavity|Stage IVC Papillary Thyroid Cancer|Stage IVC Salivary Gland Cancer|Stage IVC Squamous Cell Carcinoma of the Larynx|Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVC Squamous Cell Carcinoma of the Oropharynx|Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVC Verrucous Carcinoma of the Larynx|Stage IVC Verrucous Carcinoma of the Oral Cavity|Stage IV Lymphoepithelioma of the Nasopharynx|Stage IV Non-small Cell Lung Cancer|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Thryoid Gland Nonmedullary Carcinoma|Thyroid Gland Medullary Carcinoma|Tongue Cancer|Untreated Metastatic Squamous Neck Cancer With Occult Primary,2003-09-10,2007-12-31,,Interventional,Completed,Not Applicable,National Cancer Institute (NCI),National Cancer Institute (NCI),Southwest Oncology Group,Drug,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT00068497
NCT00068497,thyroid gland medullary carcinoma,"Single Agent ZD-1839 (NSC-715055, IND-61187) in Patients With Advanced Head and Neck Carcinoma or Non-Small Cell Lung Cancer Aged 75 Years and Older (and in a Cohort of Patients 50 Years Old and Younger)",Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer,Anaplastic Thyroid Cancer|Insular Thyroid Cancer|Metastatic Parathyroid Cancer|Recurrent Adenoid Cystic Carcinoma of the Oral Cavity|Recurrent Basal Cell Carcinoma of the Lip|Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Recurrent Lymphoepithelioma of the Nasopharynx|Recurrent Lymphoepithelioma of the Oropharynx|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Recurrent Mucoepidermoid Carcinoma of the Oral Cavity|Recurrent Non-small Cell Lung Cancer|Recurrent Parathyroid Cancer|Recurrent Salivary Gland Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Thyroid Cancer|Recurrent Verrucous Carcinoma of the Larynx|Stage IIIB Non-small Cell Lung Cancer|Stage III Follicular Thyroid Cancer|Stage III Papillary Thyroid Cancer|Stage III Salivary Gland Cancer|Stage III Squamous Cell Carcinoma of the Hypopharynx|Stage III Squamous Cell Carcinoma of the Larynx|Stage III Verrucous Carcinoma of the Larynx|Stage IVA Adenoid Cystic Carcinoma of the Oral Cavity|Stage IVA Basal Cell Carcinoma of the Lip|Stage IVA Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage IVA Follicular Thyroid Cancer|Stage IVA Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage IVA Lymphoepithelioma of the Oropharynx|Stage IVA Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage IVA Mucoepidermoid Carcinoma of the Oral Cavity|Stage IVA Papillary Thyroid Cancer|Stage IVA Salivary Gland Cancer|Stage IVA Squamous Cell Carcinoma of the Larynx|Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVA Squamous Cell Carcinoma of the Oropharynx|Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVA Verrucous Carcinoma of the Larynx|Stage IVA Verrucous Carcinoma of the Oral Cavity|Stage IVB Adenoid Cystic Carcinoma of the Oral Cavity|Stage IVB Basal Cell Carcinoma of the Lip|Stage IVB Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage IVB Follicular Thyroid Cancer|Stage IVB Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage IVB Lymphoepithelioma of the Oropharynx|Stage IVB Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage IVB Mucoepidermoid Carcinoma of the Oral Cavity|Stage IVB Papillary Thyroid Cancer|Stage IVB Salivary Gland Cancer|Stage IVB Squamous Cell Carcinoma of the Larynx|Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVB Squamous Cell Carcinoma of the Oropharynx|Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVB Verrucous Carcinoma of the Larynx|Stage IVB Verrucous Carcinoma of the Oral Cavity|Stage IVC Adenoid Cystic Carcinoma of the Oral Cavity|Stage IVC Basal Cell Carcinoma of the Lip|Stage IVC Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage IVC Follicular Thyroid Cancer|Stage IVC Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage IVC Lymphoepithelioma of the Oropharynx|Stage IVC Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage IVC Mucoepidermoid Carcinoma of the Oral Cavity|Stage IVC Papillary Thyroid Cancer|Stage IVC Salivary Gland Cancer|Stage IVC Squamous Cell Carcinoma of the Larynx|Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVC Squamous Cell Carcinoma of the Oropharynx|Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVC Verrucous Carcinoma of the Larynx|Stage IVC Verrucous Carcinoma of the Oral Cavity|Stage IV Lymphoepithelioma of the Nasopharynx|Stage IV Non-small Cell Lung Cancer|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Thryoid Gland Nonmedullary Carcinoma|Thyroid Gland Medullary Carcinoma|Tongue Cancer|Untreated Metastatic Squamous Neck Cancer With Occult Primary,2003-09-10,2007-12-31,,Interventional,Completed,Not Applicable,National Cancer Institute (NCI),National Cancer Institute (NCI),Southwest Oncology Group,Drug,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, medullary",https://clinicaltrials.gov/ct2/show/NCT00068497
NCT00068497,recurrent thyroid cancer,"Single Agent ZD-1839 (NSC-715055, IND-61187) in Patients With Advanced Head and Neck Carcinoma or Non-Small Cell Lung Cancer Aged 75 Years and Older (and in a Cohort of Patients 50 Years Old and Younger)",Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer,Anaplastic Thyroid Cancer|Insular Thyroid Cancer|Metastatic Parathyroid Cancer|Recurrent Adenoid Cystic Carcinoma of the Oral Cavity|Recurrent Basal Cell Carcinoma of the Lip|Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Recurrent Lymphoepithelioma of the Nasopharynx|Recurrent Lymphoepithelioma of the Oropharynx|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Recurrent Mucoepidermoid Carcinoma of the Oral Cavity|Recurrent Non-small Cell Lung Cancer|Recurrent Parathyroid Cancer|Recurrent Salivary Gland Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Thyroid Cancer|Recurrent Verrucous Carcinoma of the Larynx|Stage IIIB Non-small Cell Lung Cancer|Stage III Follicular Thyroid Cancer|Stage III Papillary Thyroid Cancer|Stage III Salivary Gland Cancer|Stage III Squamous Cell Carcinoma of the Hypopharynx|Stage III Squamous Cell Carcinoma of the Larynx|Stage III Verrucous Carcinoma of the Larynx|Stage IVA Adenoid Cystic Carcinoma of the Oral Cavity|Stage IVA Basal Cell Carcinoma of the Lip|Stage IVA Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage IVA Follicular Thyroid Cancer|Stage IVA Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage IVA Lymphoepithelioma of the Oropharynx|Stage IVA Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage IVA Mucoepidermoid Carcinoma of the Oral Cavity|Stage IVA Papillary Thyroid Cancer|Stage IVA Salivary Gland Cancer|Stage IVA Squamous Cell Carcinoma of the Larynx|Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVA Squamous Cell Carcinoma of the Oropharynx|Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVA Verrucous Carcinoma of the Larynx|Stage IVA Verrucous Carcinoma of the Oral Cavity|Stage IVB Adenoid Cystic Carcinoma of the Oral Cavity|Stage IVB Basal Cell Carcinoma of the Lip|Stage IVB Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage IVB Follicular Thyroid Cancer|Stage IVB Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage IVB Lymphoepithelioma of the Oropharynx|Stage IVB Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage IVB Mucoepidermoid Carcinoma of the Oral Cavity|Stage IVB Papillary Thyroid Cancer|Stage IVB Salivary Gland Cancer|Stage IVB Squamous Cell Carcinoma of the Larynx|Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVB Squamous Cell Carcinoma of the Oropharynx|Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVB Verrucous Carcinoma of the Larynx|Stage IVB Verrucous Carcinoma of the Oral Cavity|Stage IVC Adenoid Cystic Carcinoma of the Oral Cavity|Stage IVC Basal Cell Carcinoma of the Lip|Stage IVC Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage IVC Follicular Thyroid Cancer|Stage IVC Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage IVC Lymphoepithelioma of the Oropharynx|Stage IVC Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage IVC Mucoepidermoid Carcinoma of the Oral Cavity|Stage IVC Papillary Thyroid Cancer|Stage IVC Salivary Gland Cancer|Stage IVC Squamous Cell Carcinoma of the Larynx|Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVC Squamous Cell Carcinoma of the Oropharynx|Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVC Verrucous Carcinoma of the Larynx|Stage IVC Verrucous Carcinoma of the Oral Cavity|Stage IV Lymphoepithelioma of the Nasopharynx|Stage IV Non-small Cell Lung Cancer|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Thryoid Gland Nonmedullary Carcinoma|Thyroid Gland Medullary Carcinoma|Tongue Cancer|Untreated Metastatic Squamous Neck Cancer With Occult Primary,2003-09-10,2007-12-31,,Interventional,Completed,Not Applicable,National Cancer Institute (NCI),National Cancer Institute (NCI),Southwest Oncology Group,Drug,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Recurrent Thyroid Cancer,https://clinicaltrials.gov/ct2/show/NCT00068497
NCT00080574,thyroid cancer,The Effects of Thyroid Hormone on Cytochrome P450 and P-Glycoprotein Activity in Thyroid Cancer Patients,The Effect of Thyroid Hormone on Drug Elimination in Cancer Patients,Thyroid Cancer,2004-04-07,,2005-11-30,Interventional,Completed,Phase 2,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Procedure,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00080574
NCT00085293,recurrent thyroid cancer,Phase II Study of Decitabine in Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Radioiodine,Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131,Recurrent Thyroid Cancer|Stage IVA Follicular Thyroid Cancer|Stage IVA Papillary Thyroid Cancer|Stage IVB Follicular Thyroid Cancer|Stage IVB Papillary Thyroid Cancer|Stage IVC Follicular Thyroid Cancer|Stage IVC Papillary Thyroid Cancer,2004-06-10,2014-01-31,2014-05-31,Interventional,Completed,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),University of Colorado at Denver|Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center|M D Anderson Cancer Center,Drug|Radiation|Biological|Radiation|Procedure,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Recurrent Thyroid Cancer,https://clinicaltrials.gov/ct2/show/NCT00085293
NCT00094055,thyroid neoplasms,Phase 2 Study of the Anti-Angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer Who Are Refractory to or Not Suitable Candidates for 131 I Treatment,Study of the Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer,Thyroid Neoplasms,2004-10-08,2009-01-31,2009-01-31,Interventional,Completed,Phase 2,Pfizer,Pfizer,Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00094055
NCT00094237,hypothyroidism,Subclinical Thyroid Dysfunction and Risk of Myocardial Infarction and Stroke,Subclinical Thyroid Dysfunction and Risk of Myocardial Infarction and Stroke,Cardiovascular Diseases|Cerebrovascular Accident|Heart Diseases|Hypothyroidism|Myocardial Infarction,2004-10-15,2007-07-31,2007-07-31,Observational,Completed,,"University of North Carolina, Chapel Hill","National Heart, Lung, and Blood Institute (NHLBI)|University of North Carolina, Chapel Hill",,,,50.0,79.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT00094237
NCT00095693,insular thyroid cancer,Phase II Study of BAY 43-9006 in Patients With Metastatic Thyroid Carcinoma,"Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer",Anaplastic Thyroid Cancer|Insular Thyroid Cancer|Recurrent Thyroid Cancer|Stage III Follicular Thyroid Cancer|Stage III Papillary Thyroid Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Papillary Thyroid Cancer,2004-11-05,2005-08-31,2011-12-31,Interventional,Terminated,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Ohio State University Medical Center,Drug|Other|Other|Radiation|Procedure|Procedure,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Poorly differentiated thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00095693
NCT00095693,anaplastic thyroid cancer,Phase II Study of BAY 43-9006 in Patients With Metastatic Thyroid Carcinoma,"Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer",Anaplastic Thyroid Cancer|Insular Thyroid Cancer|Recurrent Thyroid Cancer|Stage III Follicular Thyroid Cancer|Stage III Papillary Thyroid Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Papillary Thyroid Cancer,2004-11-05,2005-08-31,2011-12-31,Interventional,Terminated,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Ohio State University Medical Center,Drug|Other|Other|Radiation|Procedure|Procedure,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT00095693
NCT00095693,recurrent thyroid cancer,Phase II Study of BAY 43-9006 in Patients With Metastatic Thyroid Carcinoma,"Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer",Anaplastic Thyroid Cancer|Insular Thyroid Cancer|Recurrent Thyroid Cancer|Stage III Follicular Thyroid Cancer|Stage III Papillary Thyroid Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Papillary Thyroid Cancer,2004-11-05,2005-08-31,2011-12-31,Interventional,Terminated,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Ohio State University Medical Center,Drug|Other|Other|Radiation|Procedure|Procedure,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Recurrent Thyroid Cancer,https://clinicaltrials.gov/ct2/show/NCT00095693
NCT00098345,thyroid cancer,"An Open Label, Two Stage, Phase II Study to Evaluate the Efficacy and Tolerability of ZD6474 in Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Carcinoma.",Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer,Thyroid Cancer,2004-12-07,2008-02-29,2017-04-19,Interventional,Completed,Phase 2,Sanofi,"Genzyme, a Sanofi Company",Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug,France|United States,18.0,130.0,[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00098345
NCT00098813,recurrent thyroid cancer,"A Phase II Study of Single Agent Depsipeptide (FK228) in Radioiodine (RAI)-Refractory Metastatic Non-medullary (Papillary, Follicular, and Hurthle Cell Variants) Thyroid Carcinoma",Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine,Recurrent Thyroid Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Papillary Thyroid Cancer,2004-12-08,2009-08-31,2009-08-31,Interventional,Completed,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Memorial Sloan-Kettering Cancer Center at Suffolk,Drug|Other|Procedure,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Recurrent Thyroid Cancer,https://clinicaltrials.gov/ct2/show/NCT00098813
NCT00104871,insular thyroid cancer,A Phase II Study of Bortezomib in Metastatic Papillary Thyroid Carcinoma or Follicular Thyroid Carcinoma,Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy,Insular Thyroid Cancer|Recurrent Thyroid Cancer|Stage II Follicular Thyroid Cancer|Stage II Papillary Thyroid Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Papillary Thyroid Cancer,2005-03-03,2010-05-31,2014-04-30,Interventional,Completed,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),"University of Colorado at Denver Health Sciences Center|Lombardi Comprehensive Cancer Center at Georgetown University|Emory University|Massachusetts General Hospital Cancer Center|Dana-Farber Harvard Cancer Center|Cleveland Clinic Foundation|Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center|Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center|M D Anderson Cancer Center",Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Poorly differentiated thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00104871
NCT00104871,recurrent thyroid cancer,A Phase II Study of Bortezomib in Metastatic Papillary Thyroid Carcinoma or Follicular Thyroid Carcinoma,Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy,Insular Thyroid Cancer|Recurrent Thyroid Cancer|Stage II Follicular Thyroid Cancer|Stage II Papillary Thyroid Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Papillary Thyroid Cancer,2005-03-03,2010-05-31,2014-04-30,Interventional,Completed,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),"University of Colorado at Denver Health Sciences Center|Lombardi Comprehensive Cancer Center at Georgetown University|Emory University|Massachusetts General Hospital Cancer Center|Dana-Farber Harvard Cancer Center|Cleveland Clinic Foundation|Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center|Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center|M D Anderson Cancer Center",Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Recurrent Thyroid Cancer,https://clinicaltrials.gov/ct2/show/NCT00104871
NCT00111735,hypothyroidism,"What is the Optimal Serum TSH Concentration During Thyroxine Treatment for Primary Hypothyroidism? Effects of Fine Titration of Thyroxine Dosage on Wellbeing, Quality of Life and Cognitive Function",Thyroxine Titration Study,Hypothyroidism,2005-05-24,,2005-03-31,Interventional,Unknown status,Phase 4,Sir Charles Gairdner Hospital,Sir Charles Gairdner Hospital,Sir Charles Gairdner Hospital,Drug,Australia,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT00111735
NCT00115739,thyroid cancer,Phase II Trial Evaluating Gleevec (Imatinib Mesylate Formerly Known as STI571) in Patients With Anaplastic Thyroid Cancer,Trial Evaluating Gleevec in Patients With Anaplastic Thyroid Carcinoma,Thyroid Cancer,2005-06-23,2008-05-31,2010-08-31,Interventional,Terminated,Phase 2,University of Michigan Rogel Cancer Center,University of Michigan Rogel Cancer Center,University of Michigan Cancer Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00115739
NCT00115895,thyroid neoplasms,Effect of the Radioiodine Dose in Thyroid Ablation- A Randomized Comparison of 1110 MBq to 3700 MBq,The Dose of Radioactive Iodine Needed to Ablate the Thyroid Remnant Left Behind After Thyroidectomy,Thyroid Neoplasms,2005-06-26,2004-10-31,2020-09-30,Interventional,Unknown status,Phase 3,University of Helsinki,Helsinki University Central Hospital|University of Helsinki,"Helsinki University Central Hospital, Department of Oncology",Drug,Finland,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00115895
NCT00118248,thyroid gland medullary carcinoma,A Phase II Trial of 17-Allylaminogeldanamycin (17AAG) in Advanced Medullary and Differentiated Thyroid Carcinoma,Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer,Recurrent Thyroid Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Papillary Thyroid Cancer|Thyroid Gland Medullary Carcinoma,2005-07-08,2009-08-31,2012-04-30,Interventional,Completed,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Mayo Clinic,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, medullary",https://clinicaltrials.gov/ct2/show/NCT00118248
NCT00118248,recurrent thyroid cancer,A Phase II Trial of 17-Allylaminogeldanamycin (17AAG) in Advanced Medullary and Differentiated Thyroid Carcinoma,Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer,Recurrent Thyroid Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Papillary Thyroid Cancer|Thyroid Gland Medullary Carcinoma,2005-07-08,2009-08-31,2012-04-30,Interventional,Completed,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Mayo Clinic,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Recurrent Thyroid Cancer,https://clinicaltrials.gov/ct2/show/NCT00118248
NCT00121628,thyroid cancer,"A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer","A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer",Thyroid Cancer,2005-07-12,2006-11-30,2010-10-31,Interventional,Completed,Phase 2,Amgen,Amgen,,Drug,,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00121628
NCT00123760,thyroid neoplasms,"A Phase I/II, Phase III and Extended Phase III Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Cancer or Suspected Cancer",Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Cancer or Suspected Cancer,Brain Neoplasms|Colorectal Neoplasms|Lung Neoplasms|Lymphoma|Thyroid Neoplasms,2005-07-22,2008-12-31,2008-12-31,Interventional,Completed,Phase 2/Phase 3,AHS Cancer Control Alberta,AHS Cancer Control Alberta|Cross Cancer Institute,Cross Cancer Institute,Procedure,Canada,15.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00123760
NCT00124527,thyroid cancer,Phase 2 Clinical Trial of Bi-weekly Dosing of Irofulven Plus Capecitabine in Patients With Anaplastic or Locally Advanced/Metastatic Differentiated Thyroid Cancer,Study of Irofulven Plus Capecitabine in Patients With Advanced Thyroid Cancer,Thyroid Cancer,2005-07-26,2006-08-31,2006-08-31,Interventional,Completed,Phase 2,Eisai Inc.,Eisai Inc.,,Drug,Argentina|France|Peru|Russian Federation|Ukraine|United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00124527
NCT00126568,anaplastic thyroid cancer,Phase II Trial of BAY 43-9006 in Patients With Advanced Anaplastic Carcinoma of the Thyroid,Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer,Anaplastic Thyroid Cancer|Recurrent Thyroid Cancer,2005-08-02,2011-09-30,2011-09-30,Interventional,Terminated,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Case Western Reserve University,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT00126568
NCT00126568,recurrent thyroid cancer,Phase II Trial of BAY 43-9006 in Patients With Advanced Anaplastic Carcinoma of the Thyroid,Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer,Anaplastic Thyroid Cancer|Recurrent Thyroid Cancer,2005-08-02,2011-09-30,2011-09-30,Interventional,Terminated,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Case Western Reserve University,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Recurrent Thyroid Cancer,https://clinicaltrials.gov/ct2/show/NCT00126568
NCT00134043,insular thyroid cancer,Phase II Study of Histone Deacetylase Inhibitor SAHA (Vorinostat) in Patients With Metastatic Thyroid Carcinoma,Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer,Insular Thyroid Cancer|Recurrent Thyroid Cancer|Stage II Follicular Thyroid Cancer|Stage II Papillary Thyroid Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Papillary Thyroid Cancer|Thyroid Gland Medullary Carcinoma,2005-08-22,2009-03-31,2009-03-31,Interventional,Completed,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Ohio State University Medical Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Poorly differentiated thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00134043
NCT00134043,thyroid gland medullary carcinoma,Phase II Study of Histone Deacetylase Inhibitor SAHA (Vorinostat) in Patients With Metastatic Thyroid Carcinoma,Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer,Insular Thyroid Cancer|Recurrent Thyroid Cancer|Stage II Follicular Thyroid Cancer|Stage II Papillary Thyroid Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Papillary Thyroid Cancer|Thyroid Gland Medullary Carcinoma,2005-08-22,2009-03-31,2009-03-31,Interventional,Completed,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Ohio State University Medical Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, medullary",https://clinicaltrials.gov/ct2/show/NCT00134043
NCT00134043,recurrent thyroid cancer,Phase II Study of Histone Deacetylase Inhibitor SAHA (Vorinostat) in Patients With Metastatic Thyroid Carcinoma,Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer,Insular Thyroid Cancer|Recurrent Thyroid Cancer|Stage II Follicular Thyroid Cancer|Stage II Papillary Thyroid Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Papillary Thyroid Cancer|Thyroid Gland Medullary Carcinoma,2005-08-22,2009-03-31,2009-03-31,Interventional,Completed,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Ohio State University Medical Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Recurrent Thyroid Cancer,https://clinicaltrials.gov/ct2/show/NCT00134043
NCT00144079,thyroid neoplasms,Phase 3 Trial of Adjuvant External Beam Radiotherapy for Locally Invasive Differentiated Thyroid Carcinoma,Multicenter Study Differentiated Thyroid Carcinoma,Thyroid Neoplasms,2005-09-01,,2010-01-31,Interventional,Completed,Phase 3,University Hospital Muenster,"Deutsche Krebshilfe e.V., Bonn (Germany)|University Hospital Muenster","Department of Nuclear Medicine|Department of Nuclear Medicine, Wien University Hospital|Department of Nuclear Medicine, University Halle-Wittenberg|Department of Nuclear medicine, Saarland University|Department of Nuclear Medicine, Cologne University|Department of Nuclear Medicine, Münster University Hospital|Department of Nuclear Medicine, Katharinen-Hospital|Department of Nuclear Medicine, Helios-Klinikum Wuppertal|Department of Nuclear Medicine, Würzburg University|Department of Nuclear Medicine, Zürich University Hospital",Procedure,Austria|Germany|Switzerland,18.0,69.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00144079
NCT00148213,thyroid neoplasms,Clinical Evaluation of a New Highly Sensitive Thyroglobulin Assay in Differentiated Thyroid Carcinoma,Clinical Evaluation of a New Highly Sensitive Thyroglobulin Assay in Differentiated Thyroid Carcinoma,Thyroid Neoplasms,2005-09-06,,2005-06-30,Observational,Completed,,University Hospital Muenster,"Nichols Institute Diagnostika GmbH, Bad Vilbel, Germany|University Hospital Muenster","Department of Nuclear Medicine, Münster University Hospital",,Germany,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00148213
NCT00150137,graves disease,The Influence of Continuous Treatment With Antithyroid Drugs on the Effect of Radioiodine in Patients With Hyperthyroidism,Antithyroid Drugs During Radioiodine Therapy,Graves Disease|Toxic Nodular Goitre,2005-09-06,,2004-12-31,Interventional,Completed,Phase 4,Odense University Hospital,Odense University Hospital,"Department of Endocrinology, Odense University Hospital",Drug,Denmark,18.0,85.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT00150137
NCT00151723,hyperthyroidism,"Subclinical Hyperthyroidism ""To Treat or Not to Treat?"" A Dutch Multicenter Trial",Does Radioiodine Treatment Prevent Atrial Fibrillation and Bone Loss in Endogenous Subclinical Hyperthyroidism?,Hyperthyroidism,2005-09-08,,,Interventional,Unknown status,Not Applicable,Radboud University Medical Center,Radboud University Medical Center,Academical Medical Centre Amsterdam|Martini Ziekenhuis Groningen|University Hospital Groningen|Radboud University Medical Centre Nijmegen|Maxima Medisch Centrum,Procedure,Netherlands,40.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT00151723
NCT00169806,hyperparathyroidism,Randall's Plaques: Pathogenesis and Relationship to Nephrolithiasis,Randall's Plaque Study: Pathogenesis and Relationship to Nephrolithiasis,Cystinuria|Hypercalciuria|Hyperparathyroidism|Nephrocalcinosis|Renal Calculi,2005-09-12,2025-12-31,2025-12-31,Interventional,Recruiting,Not Applicable,Indiana Kidney Stone Institute,Indiana Kidney Stone Institute|Indiana University School of Medicine|University of Chicago,IU Health Methodist Hospital,Other,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00169806
NCT00176748,thyroid cancer,Phase 2 Study of the Anti-Angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer Who Are Refractory to or Not Suitable Candidates for 131I Treatment,Treatment for Patients With Metastatic Thyroid Cancer,Thyroid Cancer,2005-09-09,2006-08-31,2009-06-30,Interventional,Completed,Phase 2,University of Michigan Rogel Cancer Center,Pfizer|University of Michigan Rogel Cancer Center,University of Michigan Cancer Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00176748
NCT00181168,thyroid cancer,Utility of Recombinant Human Thyrotropin (rTSH) PET-CT Fusion Scanning to Identify Residual Well-differentiated Epithelial Thyroid Cancer,Recombinant Thyrotropin PET-CT Fusion Scanning in Thyroid Cancer,Thyroid Cancer,2005-09-12,2003-09-30,2003-09-30,Interventional,Completed,Phase 2,Johns Hopkins University,"Genzyme, a Sanofi Company|Gustave Roussy, Cancer Campus, Grand Paris|Johns Hopkins University|M.D. Anderson Cancer Center",Johns Hopkins Division of Endocrinology & Metabolism|M.D. Anderson Cancer Center|Institute Gustave Roussy,Drug,France|United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00181168
NCT00196729,thyroid neoplasms,"A Randomized, Controlled, Open-Label, Multi-National Pilot Study of Thyroid Remnant Ablation Comparing the Safety and Ablation Rate Following 131I Administration Using Thyrogen® Versus the Safety and Ablation Rate Following 131I Administration in the Hypothyroid State",Comparison of the Safety and Successful Ablation of Thyroid Remnant in Post-thyroidectomized Euthyroid Patients (i.e. Patients Administered Thyrogen) Versus Hypothyroid Patients (no Thyrogen) Following 131I Administration,Thyroid Neoplasms,2005-09-13,,2003-09-30,Interventional,Completed,Phase 3,Sanofi,"Genzyme, a Sanofi Company",,Drug,,20.0,68.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00196729
NCT00205348,hypothyroidism,Swallowing Function Before and After Surgery for Thyroid Goiter,Swallowing Function Before and After Surgery for Thyroid Goiter,Hypothyroidism,2005-09-13,2009-01-31,2009-01-31,Observational,Completed,,"University of Wisconsin, Madison","University of Wisconsin, Madison",,,,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT00205348
NCT00206375,hypothyroidism,Concomitant Use of Growth Hormone and GnRH Agonist in Adolescent Patients With Acquired Hypothyroidism,Growth Hormone and GnRH Agonist in Adolescents With Acquired Hypothyroidism,Hypothyroidism,2005-09-13,2011-09-30,2011-11-30,Interventional,Terminated,Phase 4,Baylor College of Medicine,Baylor College of Medicine|Eli Lilly and Company|TAP Pharmaceutical Products Inc.,Baylor college of Medicine,Drug|Drug,United States,8.0,17.0,[0-17],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT00206375
NCT00215605,thyroid carcinoma,A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL184 Administered Orally to Subjects With Advanced Malignancies,Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies,Cancer|Lymphoma|Thyroid Carcinoma,2005-09-20,2011-04-30,2012-07-31,Interventional,Completed,Phase 1,Exelixis,Exelixis,University of Chicago|Johns Hopkins University|Memorial Sloan Kettering Cancer Center|Fox Chase Cancer Center|Univ. of Texas MD Anderson Cancer Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00215605
NCT00223158,thyroid cancer,L-T3 Preparation for I131 Whole Body Scintigraphy: A Randomized Controlled Trial,Evaluation Study of L-T3 Utility in the Follow-up of Patients With Thyroid Cancer,Thyroid Cancer,2005-09-19,2005-05-31,2005-05-31,Interventional,Completed,Not Applicable,Université de Sherbrooke,Patrice Perron|Theramed co.,Centre Hospitalier Universitaire de Sherbrooke,Drug,Canada,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00223158
NCT00230802,hypothyroidism,Thyroid Hormone Dose Adjustments During Pregnancy in Women With Primary Hypothyroidism.,Thyroid Hormone Dose Adjustment in Pregnancy,Hypothyroidism|Pregnancy,2005-09-29,2010-07-31,2010-07-31,Interventional,Completed,Not Applicable,Brigham and Women's Hospital,Brigham and Women's Hospital|Harvard Medical School (HMS and HSDM),Brigham and Women's Hospital,Drug|Drug|Drug,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT00230802
NCT00251316,thyroid cancer,The Effects of Lithium Carbonate on Low Dose Radioiodine Ablation in Early Thyroid Cancer Treatment,Effect of Lithium Carbonate on Low-Dose Radioiodine Therapy in Early Thyroid Cancer,Differentiated Thyroid Carcinoma|Thyroid Cancer,2005-11-09,2011-12-31,2011-12-31,Interventional,Completed,Phase 2,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"National Institutes of Health Clinical Center, 9000 Rockville Pike",Drug|Drug,United States,16.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00251316
NCT00271427,autoimmune thyroiditis,Selenium Treatment in Autoimmune Thyroiditis: Long Term Follow-Up With Variable Doses,Selenium Treatment in Autoimmune Thyroiditis (AIT),Autoimmune Thyroiditis|Hashimotos Thyroiditis,2005-12-30,,2005-08-31,Interventional,Completed,Not Applicable,Ege University,Ege University,"Dep. of Nuc. Med., Ege University Faculty of Medicine.",Drug,Turkey,15.0,70.0,[0-17]|[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT00271427
NCT00275171,nodular goiter,"The Effect of 0.1 mg Recombinant Human Thyrotropin (rhTSH) on Thyroid Radioiodine-uptake and the Degree of Goiter Reduction Following 131I-therapy, in Patients With Benign Non-toxic Nodular Goiter. A Randomized, Double-blind, Placebo-controlled Trial.","rhTSH, Radioiodine Uptake and Goiter Reduction Following 131I Therapy in Patients With Benign Nontoxic Nodular Goiter",Nodular Goiter,2006-01-09,2009-04-30,2009-09-30,Interventional,Completed,Phase 2,Odense University Hospital,Steen Bonnema,Odense University Hospital,Drug|Drug|Other,Denmark,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00275171
NCT00277589,"goiter, nodular","TSH-adapted Therapy in a Large Randomized, Observer-blind, Placebo-controlled, Prospective Treatment Study of Patients With Nodular Goiter",LISA-study : Levothyroxin in Nodular Goiter,"Goiter, Nodular",2006-01-13,2008-12-31,2008-12-31,Interventional,Completed,Phase 4,Sanofi,Sanofi,Sanofi-Aventis Administrative Office,Drug|Drug|Drug|Drug,Germany,18.0,65.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00277589
NCT00279721,thyroid neoplasms,Phase II Study of Intensity-modulated Radiation (IMRT)With Simultaneous Integrated Boost (SIB) as Adjuvant Treatment for High Risk Resected Well-differentiated Thyroid Cancer.,Phase II Study of IMRT With SIB as Adjuvant Treatment for High Risk Resected Well-differentiated Thyroid Cancer.,Thyroid Neoplasms,2006-01-18,2010-06-30,2010-06-30,Interventional,Completed,Phase 2,AHS Cancer Control Alberta,Alberta Health Services,,Procedure,,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00279721
NCT00280852,anaplastic thyroid cancer,A Retrospective Review of Multimodality Management of Anaplastic Thyroid Cancer,Review of Multimodality Management of Anaplastic Thyroid Cancer,Anaplastic Thyroid Cancer,2006-01-20,2006-06-30,2006-06-30,Observational,Completed,,AHS Cancer Control Alberta,Alberta Health Services,Tom Baker Cancer Centre,,Canada,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT00280852
NCT00287144,hypothyroidism,Observations of Leng Term Effects From Post Partum Thyroiditis.,Post Partum Thyroiditis 2: Long Term Observations,Hypothyroidism,2006-02-02,2015-12-31,2016-12-31,Observational,Withdrawn,,Sykehuset Telemark,Sykehuset Telemark,Sykehuset Telemark HF,,Norway,0.0,120.0,[0-17]|[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT00287144
NCT00295763,differentiated thyroid cancer,Follow-up of Thyroid Cancer Patients From Study THYR-008-00 Who Received Thyroid Remnant Ablation Using Either the Hypothyroid or the Thyrogen Method.,"A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen.",Differentiated Thyroid Cancer,2006-02-22,2006-07-31,2006-09-30,Interventional,Completed,Phase 3,Sanofi,"Genzyme, a Sanofi Company",University of Colorado Health Sciences Centre|Johns Hopkins University|Ohio State University|MD Anderson Cancer Centre|LHRI Research Services|Centre Rene Huguenin|Institut Gustave Roussy|University of Wurzburg|University of Pisa,Drug,Canada|France|Germany|Italy|United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Differentiated thyroid cancer, all",https://clinicaltrials.gov/ct2/show/NCT00295763
NCT00336102,hypothyroidism,Thyroid Function & Breast Cancer: A Pilot Study to Estimate the Prevalence of Thyroid Dysfunction in Women Diagnosed With Breast Cancer and the Magnitude of Change in Thyroid Function Post-Chemotherapy,Thyroid Dysfunction in Women With Newly Diagnosed Breast Cancer Compared to Healthy Volunteers,Breast Cancer|Fatigue|Hypothyroidism,2006-06-08,2015-06-30,2015-06-30,Observational,Completed,,University of South Florida,National Cancer Institute (NCI)|University of South Florida,"CCOP - Western Regional, Arizona|North Colorado Medical Center|McKee Medical Center|Cancer Centers of Central Florida, PA|H. Lee Moffitt Cancer Center and Research Institute at University of South Florida|Northeast Georgia Cancer Care, LLC - Medical Oncology|Medical College of Georgia Cancer Center|MBCCOP - Medical College of Georgia Cancer Center|Saint Anthony's Hospital at Saint Anthony's Health Center|Good Samaritan Regional Health Center|MBCCOP - LSU Health Sciences Center|Feist-Weiller Cancer Center at Louisiana State University Health Sciences|CCOP - Beaumont|William Beaumont Hospital - Royal Oak Campus|William Beaumont Hospital - Troy Campus|MeritCare Bemidji|Southeast Cancer Center|Saint Francis Medical Center|David C. Pratt Cancer Center at St. John's Mercy|St. John's Regional Health Center|CCOP - Cancer Research for the Ozarks|Hulston Cancer Center at Cox Medical Center South|CCOP - St. Louis-Cape Girardeau|Newark Beth Israel Medical Center|MBCCOP - Our Lady of Mercy Comprehensive Cancer Center|Our Lady of Mercy Medical Center Comprehensive Cancer Center|Mission Hospitals - Memorial Campus|Rutherford Internal Medicine Associates, PA|CCOP - Southeast Cancer Control Consortium|Southeastern Medical Oncology Center - Goldsboro|Moses Cone Regional Cancer Center at Wesley Long Community Hospital|Pardee Memorial Hospital|Iredell Memorial Hospital|Southeastern Medical Oncology Center - Wilson|Forsyth Regional Cancer Center at Forsyth Medical Center|CCOP - MeritCare Hospital|Roger Maris Cancer Center at MeritCare Hospital|AnMed Cancer Center|Gibbs Regional Cancer Center at Spartanburg Regional Medical Center|CCOP - Scott and White Hospital|Scott and White Cancer Institute",Other|Procedure|Procedure,United States,20.0,80.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT00336102
NCT00339716,thyroid cancer,Scientific Protocol for the Study of Thyroid Cancer and Other Thyroid Disease in Belarus Following the Chernobyl Accident,Scientific Protocol for the Study of Thyroid Cancer and Other Thyroid Disease in Belarus Following the Chernobyl Accident,Non-Cancer Thyroid Disease|Non Thyroid Cancer|Thyroid Cancer,2006-06-19,2020-03-11,2020-03-11,Observational,Completed,,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),Republican Resear ch Center for Radiation Medicine and Human Ecology|Ministry of Health Republic of Belarus,,Belarus,30.0,51.0,[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00339716
NCT00341094,thyroid cancer,Scientific Protocol for the Study of Thyroid Cancer and Other Thyroid Diseases in Ukraine Following the Chernobyl Accident,Scientific Protocol for the Study of Thyroid Cancer and Other Thyroid Disease in Ukraine Following the Chernobyl Accident,Non-Cancer Thyroid Disease|Non Thyroid Cancer|Thyroid Cancer,2006-06-19,2020-10-08,2020-10-08,Observational,Completed,,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),"Research Institute of Endocrinology and Metabolism, Kiev, Ukraine",,Ukraine,18.0,48.0,[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00341094
NCT00341185,thyroid cancer,Studies of Thyroid Abnormalities in Northeastern Kazakhstan Associated With Nuclear Weapons Testing,Studies of Thyroid Abnormalities in Northeastern Kazakhstan Associated With Nuclear Weapons Testing,Thyroid Cancer,2006-06-19,,2016-11-18,Observational,Completed,,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),Semipalatinsk State Medical Academy,,Kazakhstan,63.0,71.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00341185
NCT00342407,thyroid cancer,The Incidence of Breast and Other Cancers Among Female Flight Attendants,The Incidence of Breast and Other Cancers Among Female Flight Attendants,Breast Cancer|Melanoma|Non-Melanoma Skin Cancer|Thyroid Cancer,2006-06-19,2005-12-31,2020-04-09,Observational,Completed,,National Institutes of Health Clinical Center (CC),Centers for Disease Control and Prevention|National Cancer Institute (NCI)|National Institute for Occupational Safety and Health (NIOSH/CDC),National Institute for Occupational Safety and Health (NIOSH),,United States,18.0,100.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00342407
NCT00342446,thyroid cancer,Follow-Up Study of Women Evaluated and Treated for Infertility,A Follow-up Study of Women Evaluated and Treated for Infertility,"Breast Cancer|Colorectal Cancer, Melanoma|Endometrial Cancer|Ovarian Cancer|Thyroid Cancer",2006-06-19,,,Observational,Active not recruiting,,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),Columbia University,,United States,44.0,88.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00342446
NCT00348413,graves ophthalmopathy,"Comparison of Efficacy and Safety of Intravenous Pulsed Methylprednisolone and Oral Methotrexate Versus Intravenous Pulsed Methylprednisolone and Oral Placebo in the Treatment of Active Moderate and Severe Thyroid Eye Disease - a Prospective, Randomized, Double-blind, Parallel, Controlled Multidisciplinary Clinical Trial and Imaging Study.",Thyroid Treatment Trial,Graves Ophthalmopathy,2006-07-03,2008-07-31,2008-07-31,Interventional,Completed,Not Applicable,Singapore National Eye Centre,International Stem Cell Forum|Singapore National Eye Centre,Singapore National Centre,Drug,Singapore,21.0,60.0,[18-65],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT00348413
NCT00354523,thyroid cancer,A Phase I/II Study to Evaluate the Efficacy and Toxicity of Imatinib Mesylate in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma,Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma,Solid Tumor|Thyroid Cancer,2006-07-18,2006-11-30,2013-08-31,Interventional,Terminated,Phase 1/Phase 2,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center|Novartis Pharmaceuticals,UT MD Anderson Cancer Center,Drug|Drug|Drug,United States,16.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00354523
NCT00356512,hypoparathyroidism,Physiologic Regulation of FGF-23,Physiologic Regulation of FGF-23,Hypoparathyroidism,2006-07-25,2009-09-02,,Observational,Completed,,National Institutes of Health Clinical Center (CC),National Institute of Dental and Craniofacial Research (NIDCR),"National Institutes of Health Clinical Center, 9000 Rockville Pike",,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00356512
NCT00358956,thyroid cancer,"A Phase II, Open-Label Study To Assess The Efficacy and Tolerability of ZD6474 (ZACTIMA™ ) 100 mg Monotherapy In Subjects With Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer",A Study To Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer,Thyroid Cancer,2006-07-28,2008-01-31,2014-05-31,Interventional,Completed,Phase 2,Sanofi,"Genzyme, a Sanofi Company",Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug,Australia|Canada|Italy|Netherlands|Romania|Spain|Switzerland|United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00358956
NCT00359385,hyperparathyroidism,The Effects of Alendronate After Cure of Primary Hyperparathyroidism,The Effects of Alendronate After Cure of Primary Hyperparathyroidism,Hyperparathyroidism,2006-08-01,2009-09-30,2009-09-30,Interventional,Withdrawn,Phase 4,Columbia University,Columbia University|Merck Sharp & Dohme Corp.,CUMC,Drug,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00359385
NCT00373711,thyroid cancer,"Comparison of I-124 PET/CT, F-18 FDG PET/CT and I-123 Whole Body Scintigraphy for Recurrent Thyroid Cancer Detection","Comparison of I-124 PET/CT, F-18 FDG PET/CT & I-123 Whole Body Scintigraphy for Recurrent Thyroid CA",Thyroid Cancer,2006-09-06,,,Observational,Withdrawn,,Stanford University,Stanford University,,Drug|Drug|Drug,,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00373711
NCT00374595,hyperparathyroidism,Vascular Risk After Kidney Transplantation,Vascular Risk After Kidney Transplantation,Cardiovascular Disease|Chronic Kidney Disease|Diabetes|Hyperparathyroidism|Vitamin D Deficiency,2006-09-08,2019-03-29,2019-04-30,Observational,Unknown status,,University of Nebraska,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|University of Nebraska,University of Nebraska Medical Center,,United States,19.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00374595
NCT00377312,hyperparathyroidism,Determining the Maximal Safe Dose of a Continuous Infusion of Parathyroid Hormone(1-34): Effects on Bone Formation,7 Day Continuous Parathyroid Hormone IV Infusion,"Bone Diseases, Endocrine|Hyperparathyroidism|Osteoporosis",2006-09-14,2007-12-31,2007-12-31,Interventional,Completed,Early Phase 1,University of Pittsburgh,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|University of Pittsburgh,University of Pittsburgh Medical Center,Drug,United States,24.0,35.0,[18-65],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00377312
NCT00379899,hyperparathyroidism,A Randomized Study to Evaluate the Effects of Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease (CKD) Receiving Hemodialysis,ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis,Calcification|Cardiovascular Disease|Chronic Kidney Disease|Chronic Renal Failure|Coronary Artery Calcification|End Stage Renal Disease|Hyperparathyroidism|Kidney Disease|Nephrology|Secondary Hyperparathyroidism|Vascular Calcification,2006-09-21,2009-05-31,2009-11-30,Interventional,Completed,Phase 4,Amgen,Amgen,,Drug,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00379899
NCT00381641,thyroid gland hurthle cell carcinoma,"Phase II Trial of Sunitinib (SU11248) in Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers and Medullary Thyroid Cancers",Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery,Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Carcinoma|Refractory Thyroid Gland Carcinoma|Stage III Thyroid Gland Follicular Carcinoma AJCC v7|Stage III Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVB Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7|Stage IV Thyroid Gland Follicular Carcinoma AJCC v7|Stage IV Thyroid Gland Medullary Carcinoma AJCC v7|Stage IV Thyroid Gland Papillary Carcinoma AJCC v7|Thyroid Gland Hurthle Cell Carcinoma|Unresectable Thyroid Gland Carcinoma,2006-09-26,2016-12-31,,Interventional,Active not recruiting,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),University of Chicago Comprehensive Cancer Center|Decatur Memorial Hospital|NorthShore University HealthSystem-Evanston Hospital|Ingalls Memorial Hospital|Duly Health and Care Joliet|Loyola University Medical Center|Illinois CancerCare-Peoria|Central Illinois Hematology Oncology Center|Southern Illinois University School of Medicine|Fort Wayne Medical Oncology and Hematology Inc-Parkview|Northern Indiana Cancer Research Consortium|University of Maryland/Greenebaum Cancer Center|University of Michigan Comprehensive Cancer Center|Oncology Care Associates PLLC|Mercy Hospital Saint Louis|M D Anderson Cancer Center|Medical College of Wisconsin,Other|Other|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Hurthle cell thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00381641
NCT00385983,goiter,Total Thyroidectomy With Harmonic Scalpel® Versus Standard Surgery. Open Multicentric Randomized Controlled Trial,Total Thyroidectomy With Harmonic Scalpel®,Goiter|Thyroid Neoplasm|Thyroid Nodule,2006-10-10,,,Interventional,Unknown status,Phase 4,Brazilian Society of Head and Neck Surgery,Brazilian Society of Head and Neck Surgery|Johnson & Johnson,Hospital Araujo Jorge|Hospital Erasto Gaertner|Instituto Nacional de Cancer INCA|Hospital do Cancer de Natal|Hospital do Cancer AC Camargo|Hospital Heliopolis|Hospital Sao Paulo-UNIFESP|Instituto Arnaldo Vieira de Carvalho|Santa Casa de Misericordia,Device,Brazil,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00385983
NCT00385983,thyroid nodule,Total Thyroidectomy With Harmonic Scalpel® Versus Standard Surgery. Open Multicentric Randomized Controlled Trial,Total Thyroidectomy With Harmonic Scalpel®,Goiter|Thyroid Neoplasm|Thyroid Nodule,2006-10-10,,,Interventional,Unknown status,Phase 4,Brazilian Society of Head and Neck Surgery,Brazilian Society of Head and Neck Surgery|Johnson & Johnson,Hospital Araujo Jorge|Hospital Erasto Gaertner|Instituto Nacional de Cancer INCA|Hospital do Cancer de Natal|Hospital do Cancer AC Camargo|Hospital Heliopolis|Hospital Sao Paulo-UNIFESP|Instituto Arnaldo Vieira de Carvalho|Santa Casa de Misericordia,Device,Brazil,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT00385983
NCT00389441,thyroid neoplasms,A Pivotal Phase 2 Study Of The Anti-Angiogenesis Agent AG-013736 In Patients With 131I-Refractory Metastatic Or Unresectable Locally-Advanced Thyroid Cancer,Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer,Thyroid Neoplasms,2006-10-16,2012-09-30,2012-09-30,Interventional,Completed,Phase 2,Pfizer,Pfizer,Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site|Pfizer Investigational Site,Drug,Canada|China|Czech Republic|India|Italy|Poland|Spain|United Kingdom|United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00389441
NCT00395538,hypoparathyroidism,Effects of PTH Replacement on Bone in Hypoparathyroidism,Effects of PTH Replacement on Bone in Hypoparathyroidism,DiGeorge Syndrome|Hypoparathyroidism,2006-11-02,2017-09-30,2017-10-04,Interventional,Terminated,Phase 3,National Institutes of Health Clinical Center (CC),National Institute of Dental and Craniofacial Research (NIDCR),"National Institutes of Health Clinical Center, 9000 Rockville Pike",Drug,United States,18.0,70.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00395538
NCT00395902,hyperparathyroidism,A Retrospective Evaluation of Sensipar Use in Renal Transplant Recipients,Post Transplant Study,Hyperparathyroidism|Kidney Tansplant|Secondary Hyperparathyroidism,2006-11-02,,,Observational,Completed,,Amgen,Amgen,,Drug,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00395902
NCT00400465,graves disease,Is the Routine Pressure Dressing After Thyroidectomy Necessary? A Prospective Randomized Controlled Study,Is the Routine Pressure Dressing After Thyroidectomy Necessary?,Goiter|Graves Disease|Thyroid Neoplasms|Thyroid Nodules,2006-11-14,2007-08-31,2007-09-30,Interventional,Completed,Phase 4,Khon Kaen University,Khon Kaen University,"Deapartment of Otolaryngology, Srinagarind Hospital, Khonkaen University",Procedure|Procedure,Thailand,0.0,120.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT00400465
NCT00400465,thyroid neoplasms,Is the Routine Pressure Dressing After Thyroidectomy Necessary? A Prospective Randomized Controlled Study,Is the Routine Pressure Dressing After Thyroidectomy Necessary?,Goiter|Graves Disease|Thyroid Neoplasms|Thyroid Nodules,2006-11-14,2007-08-31,2007-09-30,Interventional,Completed,Phase 4,Khon Kaen University,Khon Kaen University,"Deapartment of Otolaryngology, Srinagarind Hospital, Khonkaen University",Procedure|Procedure,Thailand,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00400465
NCT00400465,goiter,Is the Routine Pressure Dressing After Thyroidectomy Necessary? A Prospective Randomized Controlled Study,Is the Routine Pressure Dressing After Thyroidectomy Necessary?,Goiter|Graves Disease|Thyroid Neoplasms|Thyroid Nodules,2006-11-14,2007-08-31,2007-09-30,Interventional,Completed,Phase 4,Khon Kaen University,Khon Kaen University,"Deapartment of Otolaryngology, Srinagarind Hospital, Khonkaen University",Procedure|Procedure,Thailand,0.0,120.0,[0-17]|[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00400465
NCT00403390,congenital hypothyroidism,Generic vs. Name-Brand Levothyroxine: Assessment of Bioequivalence Using TSH as a Marker in Children With Permanent Hypothyroidism,Generic vs. Name-Brand Levothyroxine,Congenital Hypothyroidism|Hypothyroidism,2006-11-21,2009-12-31,2010-03-31,Interventional,Completed,Not Applicable,Boston Children's Hospital,Boston Children's Hospital,Children's Hospital Boston,Drug|Drug,United States,3.0,18.0,[0-17]|[18-65],Hypothyroidism,Congenital hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT00403390
NCT00403598,parathyroid diseases,,Preliminary Study for Identification of Calcium-Binding Proteins in the Serum in Various Metabolic Bone Disorders,Osteitis Deformans|Osteoporosis|Parathyroid Diseases,2006-11-23,,,Observational,Unknown status,,Sheba Medical Center,Ben-Gurion University of the Negev|Sheba Medical Center,"Sheba Medical Center, Tel Hashomer",,Israel,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT00403598
NCT00405405,thyroid gland cancer,A Phase I Study of the Combination of Chemoradiotherapy With Biologic Therapy for Advanced Head and Neck Cancer,Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer,Head and Neck Cancer|Melanoma|Parotid Gland Cancer|Stage IV Head and Neck Cancer|Thyroid Gland Cancer,2006-11-29,2010-06-30,2010-06-30,Interventional,Completed,Phase 1,Thomas Jefferson University,"Genentech, Inc.|Sidney Kimmel Cancer Center at Thomas Jefferson University",Thomas Jefferson University,Drug|Drug|Drug|Drug|Radiation,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00405405
NCT00410761,thyroid cancer,"An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMATM) Versus Placebo in Subjects With Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer",An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer,Thyroid Cancer,2006-12-06,2009-07-31,2022-12-31,Interventional,Active not recruiting,Phase 3,Sanofi,"Genzyme, a Sanofi Company",Investigational Site Number 3|Investigational Site Number 8|Investigational Site Number 9|Investigational Site Number 11|Investigational Site Number 15|Investigational Site Number 18|Investigational Site Number 17|Investigational Site Number 2|Investigational Site Number 7|Investigational Site Number 14|Investigational Site Number 10|Investigational Site Number 6|Investigational Site Number 22|Investigational Site Number 19|Investigational Site Number 13|Investigational Site Number 21|Investigational Site Number 1001|Investigational Site Number 1901|Investigational Site Number 1101|Investigational Site Number 1102|Investigational Site Number 2301|Investigational Site Number 2302|Investigational Site Number 1203|Investigational Site Number 1202|Investigational Site Number 1201|Investigational Site Number 1204|Investigational Site Number 1205|Investigational Site Number 3601|Investigational Site Number 2701|Investigational Site Number 2802|Investigational Site Number 2803|Investigational Site Number 2801|Investigational Site Number 2002|Investigational Site Number 2001|Investigational Site Number 2005|Investigational Site Number 1601|Investigational Site Number 1401|Investigational Site Number 1402|Investigational Site Number 2506|Investigational Site Number 2502|Investigational Site Number 2503|Investigational Site Number 2501|Investigational Site Number 2505|Investigational Site Number 2504|Investigational Site Number 1501|Investigational Site Number 2403|Investigational Site Number 2402|Investigational Site Number 2404|Investigational Site Number 2902|Investigational Site Number 2901|Investigational Site Number 1701|Investigational Site Number 1702|Investigational Site Number 1703|Investigational Site Number 2602|Investigational Site Number 2601|Investigational Site Number 1801|Investigational Site Number 3301|Investigational Site Number 3402|Investigational Site Number 3401|Investigational Site Number 3003|Investigational Site Number 3001|Investigational Site Number 3002|Investigational Site Number 3102|Investigational Site Number 3101|Investigational Site Number 2101|Investigational Site Number 2102,Drug,"Australia|Austria|Belgium|Brazil|Canada|Czechia|Denmark|France|Germany|Hungary|India|Italy|Korea, Republic of|Mexico|Netherlands|Poland|Portugal|Romania|Russian Federation|Serbia|Spain|Sweden|Switzerland|United States",18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00410761
NCT00417612,hyperparathyroidism,The Role of Parathyroid Hormone in the Pathogenesis of Skeletal Disease in X-linked Hypophosphatemic Rickets (XLH),Effectiveness of Paricalcitol in Reducing Parathyroid Hormone (PTH) Levels in X-linked Hypophosphatemic Rickets,"Hyperparathyroidism|Hypophosphatemia, Familial",2006-12-28,2012-08-31,2012-08-31,Interventional,Completed,Phase 3,Yale University,National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|Yale University,Yale University School of Medicine,Drug|Other,United States,9.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00417612
NCT00432146,graves disease,Positive Effect of Lugol's Solution on the Blood Flow and Microvessel Density of Thyroid Gland in the Patients With Graves' Disease,Effect of Lugol's Solution in the Patients With Graves' Disease,Graves Disease,2007-02-05,,2006-09-30,Observational,Completed,,Istanbul University,Istanbul University,,Drug,,14.0,61.0,[0-17]|[18-65],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT00432146
NCT00435851,thyroid cancer,Medico-Economic Comparison of Four Strategies of Radioiodine Ablation in Thyroid Carcinoma Patients - Estimabl,Medico-Economic Comparison of Four Strategies of Radioiodine Ablation in Thyroid Carcinoma Patients,Thyroid Cancer,2007-02-15,,,Interventional,Unknown status,Phase 3,"Gustave Roussy, Cancer Campus, Grand Paris","Gustave Roussy, Cancer Campus, Grand Paris|National Cancer Institute, France",Institut Gustave Roussy,Drug,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00435851
NCT00437931,hyperthyroidism,,Color Flow Doppler Ultrasound in Subclinical Thyroid Dysfunction,Hyperthyroidism|Subclinical Hypothyroidism|Thyroid Dysfunction,2007-02-19,2008-02-29,2008-02-29,Observational,Completed,,"HaEmek Medical Center, Israel","HaEmek Medical Center, Israel","Haemek Medical Center, Department of Radiology",,Israel,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT00437931
NCT00439478,thyroid cancer,The Dental Safety Profile of High-Dose Radioiodine Therapy for Thyroid Cancer,Dental Safety Profile of High-Dose Radioiodine Therapy,Thyroid Cancer,2007-02-22,,2006-09-30,Observational,Completed,,"University Hospital, Basel, Switzerland","University Hospital, Basel, Switzerland",University Hospital,Drug,Switzerland,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00439478
NCT00451880,papillary thyroid cancer,A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL281 Administered Orally to Subjects With Solid Tumors,Study of XL281 in Adults With Solid Tumors,Cancer|Colorectal Cancer|Melanoma|Non-small-cell Lung Cancer|Papillary Thyroid Cancer,2007-03-23,2011-10-31,2011-10-31,Interventional,Completed,Phase 1,Exelixis,Exelixis,Premiere Oncology of Arizona|H. Lee Moffitt Cancer Center & Research Institute|Barbara Ann Karmanos Cancer Institute|Memorial Sloan Kettering Cancer Center|Sarah Cannon Research Institute|Mary Crowley Cancer Research Center,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT00451880
NCT00452049,hyperparathyroidism,"Observational Study to Evaluate the Effect of Parathyroidectomy on Renal Function, Endothelial Function and Blood Pressure","The Effect of Parathyroidectomy on Renal Function, Endothelial Function, and Blood Pressure",Hyperparathyroidism|Hypertension,2007-03-23,,,Observational,Unknown status,,Universitaire Ziekenhuizen Leuven,Universitaire Ziekenhuizen Leuven,University Hopsital Leuven,Procedure,Belgium,18.0,85.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00452049
NCT00454077,thyroid cancer,Recombinant Human TSH (rhTSH)-Aided Radioiodine (131) Therapy for Thyroid Remnant Ablation in Differentiated Thyroid Cancer Patients: a Comparison Between 1850 MBq and 3700 MBq Activities,rhTSH-Thyroid Ablation With 1850 MBq of 131I,Thyroid Cancer,2007-03-28,,2006-09-30,Observational,Completed,,University of Siena,University of Siena,"Section of Endcrinology, University of Siena",Procedure,Italy,18.0,90.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00454077
NCT00454220,multinodular goiter,"Study to Evaluate the Dose, Safety and Effectiveness of Modified-Release Recombinant Human Thyroid Stimulating Hormone (MRrhTSH) When Used in Conjunction With Radioiodine for the Treatment of Multinodular Goiter.","Study to Determine the Dose, the Safety and Effectiveness of a New Drug, Modified Release rhTSH, in Patients With Multinodular Goiter",Multinodular Goiter,2007-03-28,2011-07-31,2011-07-31,Interventional,Completed,Phase 2,Sanofi,"Genzyme, a Sanofi Company",,Other|Drug|Drug,Brazil|Canada|Denmark|France|Germany|Italy|Netherlands|United States,35.0,80.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00454220
NCT00459459,thyroid neoplasms,,Prognostic Significance of Fine-Needle Aspiration Cytology Features in Papillary Thyroid Carcinoma,Thyroid Neoplasms,2007-04-11,,2006-12-31,Observational,Completed,,National Taiwan University Hospital,National Taiwan University Hospital,"Shyang-Rong, Shih",Procedure,Taiwan,10.0,90.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00459459
NCT00467506,thyroid neoplasms,Phase II Two-step Radioimmunotherapy Clinical Study in Medullary Thyroid Carcinoma,Phase II Two-step Radioimmunotherapy Clinical Study in Medullary Thyroid Carcinoma,Thyroid Neoplasms,2007-04-27,2011-01-31,2011-01-31,Interventional,Completed,Phase 2,Nantes University Hospital,Nantes University Hospital,Centre François Baclesse|CHU de Grenoble|hôpital du Cluzeau|CHU|Hôpital de la timone|CHU|CHU|Centre René Huguenin|Centre René Gauducheau|Centre Paul Strauss|Centre Claudius Régaud,Drug,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00467506
NCT00470496,recurrent thyroid cancer,"A Phase I Study of Surgery Plus Intraoperative Photodynamic Therapy (PDT) in Patients With Resectable, Primary or Recurrent Head and Neck Cancer",Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer,Recurrent Adenoid Cystic Carcinoma of the Oral Cavity|Recurrent Basal Cell Carcinoma of the Lip|Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Recurrent Lymphoepithelioma of the Nasopharynx|Recurrent Lymphoepithelioma of the Oropharynx|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Recurrent Mucoepidermoid Carcinoma of the Oral Cavity|Recurrent Salivary Gland Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Thyroid Cancer|Recurrent Verrucous Carcinoma of the Larynx|Recurrent Verrucous Carcinoma of the Oral Cavity|Stage I Adenoid Cystic Carcinoma of the Oral Cavity|Stage I Basal Cell Carcinoma of the Lip|Stage I Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage I Follicular Thyroid Cancer|Stage II Adenoid Cystic Carcinoma of the Oral Cavity|Stage II Basal Cell Carcinoma of the Lip|Stage II Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage II Follicular Thyroid Cancer|Stage II Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage II Lymphoepithelioma of the Nasopharynx|Stage II Lymphoepithelioma of the Oropharynx|Stage II Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage II Mucoepidermoid Carcinoma of the Oral Cavity|Stage I Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage II Papillary Thyroid Cancer|Stage II Salivary Gland Cancer|Stage II Squamous Cell Carcinoma of the Hypopharynx|Stage II Squamous Cell Carcinoma of the Larynx|Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage II Squamous Cell Carcinoma of the Oropharynx|Stage II Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage II Verrucous Carcinoma of the Larynx|Stage II Verrucous Carcinoma of the Oral Cavity|Stage I Lymphoepithelioma of the Nasopharynx|Stage I Lymphoepithelioma of the Oropharynx|Stage I Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage I Mucoepidermoid Carcinoma of the Oral Cavity|Stage I Papillary Thyroid Cancer|Stage I Salivary Gland Cancer|Stage I Squamous Cell Carcinoma of the Hypopharynx|Stage I Squamous Cell Carcinoma of the Larynx|Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage I Squamous Cell Carcinoma of the Oropharynx|Stage I Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage I Verrucous Carcinoma of the Larynx|Stage I Verrucous Carcinoma of the Oral Cavity,2007-05-03,2011-10-28,2018-08-30,Interventional,Completed,Phase 1,Roswell Park Cancer Institute,National Cancer Institute (NCI)|Roswell Park Cancer Institute,Roswell Park Cancer Institute,Drug|Drug|Procedure,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Recurrent Thyroid Cancer,https://clinicaltrials.gov/ct2/show/NCT00470496
NCT00471458,hyperthyroidism,Follow-up Study of Hyperthyroid Patients Treated With RAI in 1965-2002: Morbidity in Long-Term Follow-up,Follow-up Study of the RAI-Treated Hyperthyroid Patients,Atrial Fibrillation|Cardiovascular Diseases|Hyperthyroidism,2007-05-09,,2003-12-31,Observational,Completed,,Tampere University,Tampere University,"Tampere University Hospital, Department of Internal Medicine",,Finland,0.0,120.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT00471458
NCT00473265,hypoparathyroidism,Bone Properties in Hypoparathyroidism: Effects of PTH,Bone Properties in Hypoparathyroidism: Effects of PTH,Hypoparathyroidism,2007-05-14,2011-01-31,2014-06-30,Interventional,Completed,Phase 2/Phase 3,Columbia University,John P. Bilezikian|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Columbia University,Drug,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00473265
NCT00480428,thyroid cancer,Study to Improve Thyroid Doses From Fallout Exposure in Kazakhstan,Radiation Exposure and Thyroid Disease in Kazakhstan,Other Thyroid Disease|Thyroid Cancer|Thyroid Nodules,2007-05-30,,2017-08-17,Observational,Completed,,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),Semipalatinsk State Medical Academy,,Kazakhstan,65.0,90.0,[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00480428
NCT00488644,hypothyroidism,Combined Levothyroxine/Liothyronine Supplementation in Hypothyroid Patients With Brain Tumors,Combined Levothyroxine/Liothyronine Supplementation in Hypothyroid Patients With Brain Tumors,Brain Tumor|Hypothyroidism,2007-06-19,2010-03-31,2010-03-31,Interventional,Terminated,Not Applicable,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center,UT MD Anderson Cancer Center,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT00488644
NCT00493103,congenital hypothyroidism,Congenital Hypothyroidism Due to Thyroglobulin Mutations in an Inbred Brazilian Family: A Novel Compound Heterozygous Constellation and Intronic Mutation Related to Fetal Goiter.,TG Gene Mutations and Congenital Hypothyroidism,Congenital Hypothyroidism,2007-06-25,,2007-06-30,Observational,Completed,,University of Sao Paulo,Fundação de Amparo à Pesquisa do Estado de São Paulo|University of Sao Paulo,,,,0.0,120.0,[0-17]|[18-65]|[65 and more],Hypothyroidism,Congenital hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT00493103
NCT00497484,pseudohypoparathyroidism,Evaluation of rhGH Replacement Therapy in Patients With Pseudohypoparathyroidism Type Ia (PHP Ia),Evaluation of rhGH Replacement Therapy in Patients With Pseudohypoparathyroidism Type Ia (PHP Ia),"Growth Hormone Deficiency, Dwarfism|Pseudohypoparathyroidism",2007-07-05,,,Interventional,Unknown status,Not Applicable,University of Milan,Eli Lilly and Company|University of Milan,"Endocrine Unit, Dpt. of Medical Sciences, Fondazione Policlinico IRCCS",Drug,Italy,1.0,18.0,[0-17]|[18-65],Parathyroid diseases,pseudohypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00497484
NCT00497575,congenital hypothyroidism,,Diagnosis and Follow-up of Patients With Subclinical Hypothyroidism,Congenital Hypothyroidism|Follow-Up|L-Thyroxine,2007-07-05,,2006-09-30,Observational,Completed,,Zhejiang University,Zhejiang University,,,,0.0,5.0,[0-17],Hypothyroidism,Congenital hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT00497575
NCT00501215,hyperparathyroidism,Pilot Study on the Effect of Parathyroidectomy on Sleep,Effect of Parathyroidectomy on Sleep,Hyperparathyroidism,2007-07-12,2017-07-09,2017-07-09,Interventional,Completed,Not Applicable,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center,University of Texas MD Anderson Cancer Center,Procedure|Behavioral|Procedure|Behavioral,United States,21.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00501215
NCT00505479,congenital hypothyroidism,,Iodine Status in Pregnant Women and Their Newborns: is Congenital Hypothyroidism Related to Iodine Deficiency in Pregnancy?,Congenital Hypothyroidism|Iodine Deficiency|Pregnancy,2007-07-20,,2010-05-31,Observational,Unknown status,,Zhejiang University,Zhejiang University,Children's Hospital Zhejiang University School of Medicine,,China,20.0,40.0,[18-65],Hypothyroidism,Congenital hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT00505479
NCT00507429,anaplastic thyroid cancer,A Phase II/III Study to Evaluate the Safety and Efficacy of Combretastatin A-4 Phosphate in Combination With Paclitaxel and Carboplatin in Comparison With Paclitaxel and Carboplatin Against Anaplastic Thyroid Carcinoma [FACT],Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer,Anaplastic Thyroid Cancer,2007-07-25,2011-10-31,2011-11-30,Interventional,Terminated,Phase 2/Phase 3,Mateon Therapeutics,Mateon Therapeutics,"USC/Norris Comprehensive Cancer Center|University of Colorado Cancer Center|Yale University, School of Medicine|Winship Cancer Institute, Emory University|Sidney Kimmel Comprehensive Cancer Care Center at John Hopkins|University of Minnesota Otolaryngology Department|Ireland Cancer Center/Division od Hematology|Oregon Health and Science University|University of Texas M.D. Anderson Cancer Center|West Virginia University|Belarus National Medical University|Regional Oncology Dispensary with Inpatient Sector|Specialized Hospital for Active Treatment of Oncology|Universtiy Multiprofile Hospital, ISUI, Clinic of Oncotherapy|University Hospital, Cairo|Mediciti Hospital|All India Institute of Medical Sciences|Apollo Cancer Institute|Kidwai Memorial Hospital|Shirdi Sai Baba Cancer Hospital|Tata Memorial Centre|Ruby Hall Clinic|Christian Medial College|Telaviv Sourasky Medical Center, Head and Neck Service Division of Oncology|Lo Studio E la Cura|INT Napoli Fondazione Pascale|Istituto Oncologico Veneto (IOV) - IRCCS|Azienda Ospedaliero - Universitaria Pisana|Zaklad Medyczny Nuklearnej i Endykrynologii|Klinika Nowotworow Glowy i Szyji|Institutul Oncologic|SC Meditech SRL|Centr of Medical Oncology|Clinical County Hospital Sibiu|Emergency Clinical County Hospital ""Sf. loan cel Nou""|City Clinical Oncology Dispensary|Ukrainian Academy of Medical Science|Regional Clinical Oncology Dispensary|Beatson Oncology Centre, Gartnavel General Hospital|Royal Marsden Hospital and Institute of Cancer Research|Southampton Hospital Oncology Centre",Drug|Drug|Drug,Belarus|Bulgaria|Egypt|India|Israel|Italy|Poland|Romania|Russian Federation|Ukraine|United Kingdom|United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT00507429
NCT00510640,thyroid carcinoma,"Phase 2 of Sunitinib (Sutent) in Patients With Locally Advanced or Metastatic Anaplastic, Differentiated or Medullar Thyroid Cancer",Thyroid Cancer and Sunitinib,Cancer|Thyroid Carcinoma,2007-08-01,2012-03-31,2012-03-31,Interventional,Completed,Phase 2,"University Hospital, Bordeaux","Pfizer|University Hospital, Bordeaux","Centre Paul Papin - 2 rue Moll|Département Endocrinolo-Diabéto-Nutrition - CHU d'Angers - 4 rue de Larray|Service d'Oncologie Médicale et de Radiothérapie - Hôpital Saint André - 1 rue Jean Burguet|Fédération Endocrinologie - Groupe Hospitalier Est - Hôpital neurologique - CHU Lyon - 59 Boulevard Pinel|Service d'Endocrinologie et maladies métaboliques, Clinique Marc Linquette - rue du Pr Laguesse|Centre Léon Bérard - Département de Médecine - 28 rue Laennec|Service d'Endocrinologie, CHU Timone, AP-HM - 254 rue St Pierre|Service des Maladies Endocriniennes - Hôpital Lapeyronie - 191 avenue du Doyen Gaston Giraud|Centre Paul Lamarque - Va d'Aurelle - CRLC Val d'Aurelle - 208 rue des Apothicaires|Centre Antoine Lacassagne - 33 avenue de Valombrose|Service d'Endocrinologie - Hôpital de l'Archet I - Route Saint Antoine de Jinestière|Service de Cancérologie Médicale - HEGP - 20 rue Leblanc|Service d'Oncologie Médicale, Institut Claudius Regaud - 20-24 rue du Pont Saint Pierre|Service d'endocrinologie et Maladies Métaboliques, Groupe Hospitalier Rangueil-Larrey CHU Toulouse - avenue Prof Jean Poulhes|Service d'Endocrinologie - CHU de Nancy, Hôpital de Brabois - rue du Morvan",Drug,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00510640
NCT00513032,hyperparathyroidism,Effects of Methylene Blue on Propofol Requirement During Anaesthesia Induction and Surgery,Interaction Between Anaesthetics and Methylene Blue,Hyperparathyroidism,2007-08-07,,2007-04-30,Observational,Completed,,"University Hospital, Geneva","University Hospital, Geneva","Service d'Anesthésiologie, Hôpitaux Universitaires de Genève, Rue Micheli-du-Crest",Drug,Switzerland,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00513032
NCT00514046,medullary thyroid carcinoma,"Phase I/II Trial of Vandetanib (ZD6474, ZACTIMA) in Children and Adolescents With Hereditary Medullary Thyroid Carcinoma",Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer,Medullary Thyroid Carcinoma|Multiple Endocrine Neoplasia Type 2A|Multiple Endocrine Neoplasia Type 2B,2007-08-08,2019-12-10,2020-11-01,Interventional,Completed,Phase 1/Phase 2,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),"National Institutes of Health Clinical Center, 9000 Rockville Pike",Drug,United States,5.0,18.0,[0-17]|[18-65],Thyroid neoplasms,"Thyroid cancer, medullary",https://clinicaltrials.gov/ct2/show/NCT00514046
NCT00519896,thyroid gland medullary carcinoma,Phase II Study of Sunitinib in Iodine Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of Thyroid With Functional Imaging Correlation,Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer,Recurrent Thyroid Cancer|Stage IVA Follicular Thyroid Cancer|Stage IVA Papillary Thyroid Cancer|Stage IVB Follicular Thyroid Cancer|Stage IVB Papillary Thyroid Cancer|Stage IVC Follicular Thyroid Cancer|Stage IVC Papillary Thyroid Cancer|Thyroid Gland Medullary Carcinoma,2007-08-21,2015-05-31,2015-09-30,Interventional,Completed,Phase 2,University of Washington,National Cancer Institute (NCI)|University of Washington,Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, medullary",https://clinicaltrials.gov/ct2/show/NCT00519896
NCT00519896,recurrent thyroid cancer,Phase II Study of Sunitinib in Iodine Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of Thyroid With Functional Imaging Correlation,Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer,Recurrent Thyroid Cancer|Stage IVA Follicular Thyroid Cancer|Stage IVA Papillary Thyroid Cancer|Stage IVB Follicular Thyroid Cancer|Stage IVB Papillary Thyroid Cancer|Stage IVC Follicular Thyroid Cancer|Stage IVC Papillary Thyroid Cancer|Thyroid Gland Medullary Carcinoma,2007-08-21,2015-05-31,2015-09-30,Interventional,Completed,Phase 2,University of Washington,National Cancer Institute (NCI)|University of Washington,Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Recurrent Thyroid Cancer,https://clinicaltrials.gov/ct2/show/NCT00519896
NCT00524238,hypothyroidism,"Impact of Hypothyroidism on Glucose, Lipid, and Amino Acid Turnover",Metabolic Changes in Hypothyroid Patients,Hypothyroidism,2007-08-31,2006-08-31,2006-08-31,Interventional,Completed,Not Applicable,University of Aarhus,University of Aarhus,Aarhus University Hospital,Drug,Denmark,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT00524238
NCT00525122,hyperthyroidism,,Treatment of M.Graves With Radioactive Iodine: Follow-up Study,Hyperthyroidism,2007-09-04,,,Observational,Unknown status,,"Medisch Centrum Rijnmond-Zuid, Netherlands","Medisch Centrum Rijnmond-Zuid, Netherlands",MCRZ,,Netherlands,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT00525122
NCT00527267,hyperparathyroidism,A Phase 3 Study to Assess the Efficacy and Safety of an Oral Calcimimetic Agent (AMG 073) in Secondary Hyperparathyroidism of End Stage Renal Disease Treated With Hemodialysis,Safety and Efficacy Study of AMG 073 in Hemodialysis Subjects,Hyperparathyroidism,2007-09-06,2003-04-30,2003-04-30,Interventional,Completed,Phase 3,Amgen,Amgen,,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00527267
NCT00537095,thyroid neoplasms,"A Randomized, Double Blind, Placebo-controlled Phase II, Multi-Centre Study to Assess the Efficacy and Safety of Vandetanib (ZD6474) in Patients With Locally Advanced or Metastatic Papillary or Follicular Thyroid Carcinoma Failing or Unsuitable for Radioiodine Therapy",Efficacy and Safety of Vandetanib (ZD6474) in Patients With Metastatic Papillary or Follicular Thyroid Cancer,Thyroid Neoplasms,2007-09-27,2009-12-31,2022-12-31,Interventional,Active not recruiting,Phase 2,Sanofi,"Genzyme, a Sanofi Company",Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug|Other,Belgium|Denmark|France|Norway|Spain|Sweden|Switzerland,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00537095
NCT00537797,thyroid neoplasms,Limited Neck FDG-PET Imaging for Indeterminate Thyroid Nodules,Accuracy of FDG-PET Scanning to Diagnose Malignant Thyroid Nodules,Thyroid Neoplasms,2007-09-28,2011-09-30,2014-02-28,Interventional,Completed,Not Applicable,Washington University School of Medicine,Washington University School of Medicine,Washington University School of Medicine|St. Louis University School of Medicine|VAMC,Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00537797
NCT00538720,hyperparathyroidism,Pilot Study to Detect and Assess the Effect of Vitamin D Replacement on Gland Size by 4DCT in Patients With Primary Hyperparathyroidism (PHPT),Effects of Vitamin D Replacement in Patients With Primary Hyperparathyroidism (PHPT),Hyperparathyroidism,2007-10-02,2018-05-30,2018-05-30,Interventional,Completed,Phase 1,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center,University of Texas MD Anderson Cancer Center,Drug|Device,United States,21.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00538720
NCT00551486,thyroid neoplasms,Diagnostic Value of Pyrosequencing for the BRAFV600E Mutation in Ultrasound-Guided Fine-Needle Aspiration Biopsy Samples of Thyroid Incidentalomas,Pyrosequencing of the BRAFV600E Mutation,Thyroid Neoplasms,2007-10-30,,2006-12-31,Observational,Completed,,Chungnam National University,Chungnam National University,Chungnam National University Hospital,Procedure,"Korea, Republic of",20.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00551486
NCT00552253,thyroid nodule,Levothyroxine Treatment in Thyroid Benign Nodular Goiter,Levothyroxine Treatment in Thyroid Benign Nodular Goiter,Thyroid Nodule,2007-10-30,2008-07-31,2008-07-31,Interventional,Completed,Not Applicable,National Taiwan University Hospital,National Taiwan University Hospital,National Taiwan University Hospital,Drug,Taiwan,20.0,90.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT00552253
NCT00552487,hashimoto disease,Isolated ACTH Deficiency in Patients With Hashimoto Thyroiditis,Isolated ACTH Deficiency in Patients With Hashimoto Thyroiditis,Adrenal Insufficiency|Hashimoto Disease,2007-10-31,,2006-07-31,Interventional,Completed,Not Applicable,University of Wuerzburg,University of Wuerzburg,"University of Wuerzburg, Department of Endocrinology",Drug,Germany,18.0,120.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT00552487
NCT00565864,hypothyroidism,Neurocognitive and Metabolic Effects of Mild Hypothyroidism,Neurocognitive and Metabolic Effects of Mild Hypothyroidism,Hypothyroidism,2007-11-28,2013-08-31,2013-08-31,Interventional,Completed,Phase 4,Oregon Health and Science University,Oregon Health and Science University,Oregon Health and Science University,Drug,United States,20.0,75.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT00565864
NCT00566488,hypoparathyroidism,"Parathyroid and Thymus Transplantation in DiGeorge Syndrome, #931",Parathyroid and Thymus Transplantation in DiGeorge #931,Complete DiGeorge Syndrome|DiGeorge Syndrome|Hypoparathyroidism,2007-11-30,2007-08-31,2019-12-31,Interventional,Completed,Phase 1,Enzyvant Therapeutics GmBH,Enzyvant Therapeutics GmBH|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Food and Drug Administration (FDA)|National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health (NIH),Duke University Medical Center,Biological,United States,0.0,24.0,[0-17]|[18-65],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00566488
NCT00568438,thyroid cancer,Immunohistochemical & Immunoblot Analysis of NIS (Na+/I-Symporter) in Archival and Frozen Human Tissue Samples,Immunohistochemical & Immunoblot Analysis of NIS (Na+/I-Symporter) in Archival & Frozen Tissue Sample,Breast Cancer|Salivary Gland Neoplasms|Stomach Neoplasms|Thyroid Cancer,2007-12-04,2020-04-30,2020-04-30,Observational,Unknown status,,Stanford University,Stanford University,Stanford University School of Medicine,,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00568438
NCT00569920,parathyroid diseases,"Nausea and Pain Prophylaxis During Thyroid Surgery, a Comparison of Low-Dose and High-Dose Dexamethasone to Placebo",Nausea and Pain Prophylaxis During Thyroid Surgery,Parathyroid Diseases|Thyroid Diseases,2007-12-07,2008-12-31,2008-12-31,Interventional,Completed,Not Applicable,Sykehuset Telemark,Sykehuset Telemark,"Surgery Unit, Porsgrunn, Acute Care Clinic, Telemark Hospital",Drug|Drug|Drug,Norway,18.0,70.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT00569920
NCT00569920,thyroid diseases,"Nausea and Pain Prophylaxis During Thyroid Surgery, a Comparison of Low-Dose and High-Dose Dexamethasone to Placebo",Nausea and Pain Prophylaxis During Thyroid Surgery,Parathyroid Diseases|Thyroid Diseases,2007-12-07,2008-12-31,2008-12-31,Interventional,Completed,Not Applicable,Sykehuset Telemark,Sykehuset Telemark,"Surgery Unit, Porsgrunn, Acute Care Clinic, Telemark Hospital",Drug|Drug|Drug,Norway,18.0,70.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT00569920
NCT00571077,thyroid neoplasms,Electrical Impedance Scanning of Thyroid Nodules Prior to Thyroid Surgery: a Prospective Study,Electrical Impedance Scanning of Thyroid Nodules Prior to Thyroid Surgery: a Prospective Study,Thyroid Neoplasms|Thyroid Nodules,2007-12-10,,2007-12-31,Observational,Completed,,Hadassah Medical Organization,Hadassah Medical Organization|Walter Reed Army Medical Center,Walter Reed Army MEdicla Center|Hadassah-Hebrew University Medical Center,Device,Israel|United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00571077
NCT00571090,thyroid nodule,Evaluation of Thyroid Fine Needle Aspiration Biopsies: Prediction of Thyroid Cancer From Ultrasonographic Characteristics of Thyroid Nodules,Prediction of Thyroid Cancer From Ultrasonographic Characteristics of Thyroid Nodules,Thyroid Nodule,2007-12-10,2012-07-31,2013-07-31,Observational,Completed,,Istanbul Science University,Group Florence Nightingale|Istanbul Science University,Group Florence Nightingale,Procedure,Turkey,15.0,89.0,[0-17]|[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT00571090
NCT00573573,hyperparathyroidism,Phase 1 Study to Evaluate the Efficacy of Using Energy Specific Far Infrared Radiation Treatment for Hyperparathyroidism.,Energy Specific Far Infrared Radiation Treatment for Hyperparathyroidism,Hyperparathyroidism,2007-12-12,2009-03-31,2009-07-31,Interventional,Unknown status,Phase 1,GAAD Medical Research Institute Inc.,GAAD Medical Research Institute Inc.,The Centre for Incurable Diseases,Radiation,Canada,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00573573
NCT00580788,hyperparathyroidism,Determining the Maximal Safe Dose of a Continuous Infusion of Parathyroid Hormone-related Protein(1-36): Effects on Bone Formation,One Week Parathyroid Hormone-related Protein (PTHrP) IV Dose Escalation Study,Humoral Hypercalcemia of Malignancy|Hyperparathyroidism|Osteoporosis,2007-12-20,2009-12-31,2009-12-31,Interventional,Completed,Early Phase 1,University of Pittsburgh,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|University of Pittsburgh,University of Pittsburgh Medical Center,Drug,United States,24.0,35.0,[18-65],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00580788
NCT00581828,hypoparathyroidism,Does Treatment of Hypovitaminosis D Increase Calcium Absorption?,Does Treatment of Hypovitaminosis D Increase Calcium Absorption?,Hypercalcemia|Hypercalciuria|Hypoparathyroidism|Osteopenia|Osteoporosis|Vitamin D Deficiency,2007-12-19,2008-07-31,2008-12-31,Interventional,Completed,Phase 4,"University of Wisconsin, Madison","University of Wisconsin, Madison",University of Wisconsin Hospital and Clinics,Drug,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00581828
NCT00582712,medullary thyroid cancer,An Initial Study of Lithium in Patients With Medullary Thyroid Cancer,An Initial Study of Lithium in Patients With Medullary Thyroid Cancer,Medullary Thyroid Cancer,2007-12-19,2009-05-31,2012-04-30,Interventional,Terminated,Phase 2,"University of Wisconsin, Madison","University of Wisconsin, Madison",Uniersity of Wisconsin Comprehensive Cancer Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, medullary",https://clinicaltrials.gov/ct2/show/NCT00582712
NCT00591032,low t3 syndrome,Development of Rational and Standardized Diagnostics and Staging for a Differentiated Risk Stratification of Non-thyroidal Illness Syndrome,Approach to a Quantitative Follow-up of Non-thyroidal Illness Syndrome,Euthyroid Sick Syndromes|Low T3 Syndrome|Non-thyroidal Illness Syndrome|TACITUS,2007-12-26,2017-11-30,2020-12-31,Observational,Active not recruiting,,Ruhr University of Bochum,Private Sponsor (Chantal C. Guilhemotonia-Urban)|Ruhr University of Bochum|Wissenschaftskommission des Universitaetsklinikums Bergmannsheil,"Department for medical informatics, biometry and epidemiology, Ruhr-University of Bochum|Institute of Clinical Chemistry, Transfusion and Laboratory Medicine, Universitätsklinikum Bergmannsheil, Ruhr-Universität Bochum|Medical Hospital II, Bergmannsheil University Hospitals, Ruhr University of Bochum|Medizinische Klinik I, Universitätsklinikum Bergmannsheil, Ruhr-Universität Bochum|Diabetes-Zentrum, Mathias-Spital|Abteilung für Laboratoriums- und Transfusionsmedizin, Westpfalz-Klinikum Kaiserslautern",,Germany,0.0,120.0,[0-17]|[18-65]|[65 and more],Euthyroid Sick Syndromes,Euthyroid Sick Syndromes,https://clinicaltrials.gov/ct2/show/NCT00591032
NCT00598364,thyroid cancer,Molecular Markers in the Diagnostic and Prognostic Evaluation of Thyroid Cancer,Molecular Markers in Thyroid Cancer,Thyroid Cancer,2008-01-10,2010-10-31,2010-10-31,Observational [Patient Registry],Completed,,OHSU Knight Cancer Institute,OHSU Knight Cancer Institute,Oregon Health & Science University,,United States,1.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00598364
NCT00603941,anaplastic thyroid cancer,"A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel in Subjects With Advanced Anaplastic Thyroid Cancer","A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel",Anaplastic Thyroid Cancer,2008-01-15,2011-12-31,2011-12-31,Interventional,Terminated,Phase 1/Phase 2,"Daiichi Sankyo, Inc.","Daiichi Sankyo, Inc.","Univ of Colorado Cancer Center|Mayo Clinic|Massachusetts General Hospital|Mayo Clinic|Washington University, Siteman Cancer Center|Ohio State Univ|Oregon Health Science Univ|University of Pennsylvania Maloney Hospital|Vanderbilt Ingram Cancer Center|Eastern Virginia Medical School",Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT00603941
NCT00604318,thyroid cancer,"Is it Possible to Increase Quality of Life, Using Recombinant TSH Instead of Withdrawal of Thyroid Hormone Treatment, Before Iodine Uptake in Patients With Thyroid Cancer?","Quality of Life, Recombinant TSH (Thyrogen) and Thyroid Cancer",Thyroid Cancer,2008-01-17,2012-02-29,2012-02-29,Interventional,Completed,Phase 4,Copenhagen University Hospital at Herlev,Copenhagen University Hospital at Herlev|Odense University Hospital,"Dept of Oncology, Herlev Hospital",Drug,Denmark,18.0,75.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00604318
NCT00615537,thyroid neoplasms,Pilot Study on Laser Ablation of Symptomatic Benign Thyroid Masses,Pilot Study on Laser Ablation of Symptomatic Benign Thyroid Masses,Nodular Goiter|Thyroid Cancer|Thyroid Neoplasms|Thyroid Nodule,2008-02-03,2011-01-31,2011-01-31,Interventional,Completed,Not Applicable,"BioTex, Inc.","BioTex, Inc.|Rhode Island Hospital",Rhode Island Hospital - Department of Diagnostic Imaging Research,Procedure,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00615537
NCT00615537,nodular goiter,Pilot Study on Laser Ablation of Symptomatic Benign Thyroid Masses,Pilot Study on Laser Ablation of Symptomatic Benign Thyroid Masses,Nodular Goiter|Thyroid Cancer|Thyroid Neoplasms|Thyroid Nodule,2008-02-03,2011-01-31,2011-01-31,Interventional,Completed,Not Applicable,"BioTex, Inc.","BioTex, Inc.|Rhode Island Hospital",Rhode Island Hospital - Department of Diagnostic Imaging Research,Procedure,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00615537
NCT00615537,thyroid nodule,Pilot Study on Laser Ablation of Symptomatic Benign Thyroid Masses,Pilot Study on Laser Ablation of Symptomatic Benign Thyroid Masses,Nodular Goiter|Thyroid Cancer|Thyroid Neoplasms|Thyroid Nodule,2008-02-03,2011-01-31,2011-01-31,Interventional,Completed,Not Applicable,"BioTex, Inc.","BioTex, Inc.|Rhode Island Hospital",Rhode Island Hospital - Department of Diagnostic Imaging Research,Procedure,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT00615537
NCT00625846,thyroid gland anaplastic carcinoma,A Phase II Study of GW 786034 (Pazopanib) in Advanced Thyroid Cancer,Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer,Recurrent Thyroid Gland Carcinoma|Stage III Differentiated Thyroid Gland Carcinoma AJCC v7|Stage III Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7|Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v7|Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v7|Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v7|Stage IVB Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVC Differentiated Thyroid Gland Carcinoma AJCC v7|Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v7|Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7|Thyroid Gland Anaplastic Carcinoma,2008-02-27,2018-12-21,2019-08-13,Interventional,Completed,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Mayo Clinic in Arizona|University of Colorado Hospital|Mayo Clinic in Florida|University of Iowa/Holden Comprehensive Cancer Center|Johns Hopkins University/Sidney Kimmel Cancer Center|Wayne State University/Karmanos Cancer Institute|Fairview Ridges Hospital|Fairview-Southdale Hospital|Unity Hospital|Minnesota Oncology Hematology PA-Maplewood|Abbott-Northwestern Hospital|Mayo Clinic|Park Nicollet Clinic - Saint Louis Park|United Hospital|Washington University School of Medicine|University of Wisconsin Hospital and Clinics|Sir Charles Gairdner Hospital|Chinese University of Hong Kong-Prince of Wales Hospital|National University Hospital Singapore|National Cancer Centre|Johns Hopkins Singapore|National Taiwan University Hospital,Other|Drug,Australia|China|Singapore|Taiwan|United States,19.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT00625846
NCT00647140,thyroid carcinoma,Clinical Evaluation of 18F-DOPA Positron Emission Tomography in Medullary Thyroid Cancer.,Clinical Evaluation of 18F-DOPA Positron Emission Tomography in Medullary Thyroid Cancer,Medullary Carcinoma|Thyroid Carcinoma|Thyroid Neoplasm,2008-03-26,2009-08-31,2010-02-28,Interventional,Terminated,Phase 2,Assistance Publique - Hôpitaux de Paris,Assistance Publique - Hôpitaux de Paris,Hôpital Antoine Beclere,Other,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00647140
NCT00651625,thyroid nodule,Randomized Controlled Trial of the Reciprocating Procedure Device Versus the Conventional Syringe in Syringe-and-Needle Procedures,Reciprocating Medical Devices - a Study of a New Safety Device,Cancer|Osteoarthritis|Rheumatoid Arthritis|Thyroid Nodule|Trauma,2008-03-21,2010-01-31,2010-08-31,Interventional,Completed,Not Applicable,University of New Mexico,University of New Mexico,University of New Mexico Health Sciences Center,Device|Device,United States,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT00651625
NCT00665795,dysthyroid orbitopathy,Morphometric Analysis of Orbital Structures in Graves´ Orbitopathy Using Multidetector Computed Tomography Scan and Color Doppler Imaging.,Morphometric Analysis of Orbital Structures in Graves´ Orbitopathy,Dysthyroid Orbitopathy,2008-04-22,2013-11-30,2013-11-30,Observational,Completed,,University of Sao Paulo,University of Sao Paulo,General Hospital - University of Sao Paulo - School of Medicine,,Brazil,20.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT00665795
NCT00668811,papillary thyroid cancer,Sutent Adjunctive Treatment of Differentiated Thyroid Cancer,Sutent Adjunctive Treatment of Differentiated Thyroid Cancer,Differentiated Thyroid Cancer|Follicular Thyroid Cancer|Papillary Thyroid Cancer,2008-04-25,2015-09-30,2015-12-31,Interventional,Completed,Phase 2,Medstar Health Research Institute,Medstar Health Research Institute|Pfizer,MedStar Washington Hospital Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT00668811
NCT00668811,follicular thyroid cancer,Sutent Adjunctive Treatment of Differentiated Thyroid Cancer,Sutent Adjunctive Treatment of Differentiated Thyroid Cancer,Differentiated Thyroid Cancer|Follicular Thyroid Cancer|Papillary Thyroid Cancer,2008-04-25,2015-09-30,2015-12-31,Interventional,Completed,Phase 2,Medstar Health Research Institute,Medstar Health Research Institute|Pfizer,MedStar Washington Hospital Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT00668811
NCT00668811,differentiated thyroid cancer,Sutent Adjunctive Treatment of Differentiated Thyroid Cancer,Sutent Adjunctive Treatment of Differentiated Thyroid Cancer,Differentiated Thyroid Cancer|Follicular Thyroid Cancer|Papillary Thyroid Cancer,2008-04-25,2015-09-30,2015-12-31,Interventional,Completed,Phase 2,Medstar Health Research Institute,Medstar Health Research Institute|Pfizer,MedStar Washington Hospital Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Differentiated thyroid cancer, all",https://clinicaltrials.gov/ct2/show/NCT00668811
NCT00673010,thyroid cancer,Lesion Dosimetry With 124-Iodine in Metastatic Thyroid Carcinoma,Lesion Dosimetry With 124-Iodine in Metastatic Thyroid Carcinoma,Thyroid Cancer,2008-05-06,2023-03-31,2023-03-31,Interventional,Active not recruiting,Phase 1,Memorial Sloan Kettering Cancer Center,"Gustave Roussy, Cancer Campus, Grand Paris|Memorial Sloan Kettering Cancer Center",Memorial Sloan Kettering Cancer Center,Radiation,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00673010
NCT00677469,graves disease,Low Doses of Cholestyramine in the Treatment of Hyperthyroidism,Low Doses of Cholestyramine in the Treatment of Hyperthyroidism,Graves Disease,2008-05-12,2008-01-31,2008-01-31,Interventional,Completed,Not Applicable,Shiraz University of Medical Sciences,Shiraz University of Medical Sciences,Endocrine and Metabolism Research Center,Drug|Drug|Drug,"Iran, Islamic Republic of",20.0,60.0,[18-65],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT00677469
NCT00687778,thyroid cancer,,11C-Acetate PET/CT Non-FDG-Avid Tumors,"Carcinoma, Hepatocellular|Carcinoma, Lobular|GIST|Indolent Lymphoma|Lung Cancer|Neuroendocrine Tumors|Soft Tissue Sarcomas|Teratoma|Thyroid Cancer|Uterine Malignancies",2008-05-28,2009-06-30,2010-06-30,Observational,Unknown status,,Tel-Aviv Sourasky Medical Center,Tel-Aviv Sourasky Medical Center,"Department of Nuclear Medicine, Tel Aviv Sourasky Medical Center",,Israel,18.0,90.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00687778
NCT00691990,goiter,Classic Total Thyroidectomy With or Without Drains,Classic Total Thyroidectomy With or Without Drains,Goiter,2008-06-05,2009-12-31,2011-07-31,Interventional,Completed,Not Applicable,Aristotle University Of Thessaloniki,AHEPA University Hospital|Aristotle University Of Thessaloniki,"3rd Department of Surgery, AHEPA University Hospital",Procedure,Greece,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00691990
NCT00692835,goiter,Immediate Postoperative Course of Patients With Mini Video Assisted Total Thyroidectomy (miVAT) Versus Classic Total Thyroidectomy (cTT),Immediate Postoperative Course of Patients With Mini Video Assisted Total Thyroidectomy (miVAT) Versus Classic Total Thyroidectomy (cTT),Goiter,2008-06-05,2009-12-31,2012-09-30,Interventional,Completed,Not Applicable,Aristotle University Of Thessaloniki,AHEPA University Hospital|Aristotle University Of Thessaloniki,"3rd Department of Surgery, AHEPA University Hospital",Procedure|Procedure,Greece,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00692835
NCT00693147,goiter,Late Postoperative Course of Patients With Mini Video Assisted Thyroidectomy (miVAT) Versus Classic Thyroidectomy (T),Late Postoperative Course of Patients With Mini Video Assisted Thyroidectomy (miVAT) Versus Classic Thyroidectomy (T),Goiter,2008-06-05,2009-12-31,2012-09-30,Interventional,Completed,Not Applicable,Aristotle University Of Thessaloniki,AHEPA University Hospital|Aristotle University Of Thessaloniki,"3rd Department of Surgery, AHEPA University Hospital",Procedure,Greece,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00693147
NCT00704730,thyroid cancer,"An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 Versus Placebo in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer",Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer,Thyroid Cancer,2008-06-23,2011-10-31,2020-09-30,Interventional,Completed,Phase 3,Exelixis,Exelixis,"University of Alabama at Birmingham, Comprehensive Cancer Center|TGEN Clinical Research Service at Scottsdale Healthcare|University of Arkansas for Medical Sciences|UCLA|Stanford Cancer Center|University of Colorado Cancer Center|Yale University, School of Medicine|Washington Cancer Institute|H. Lee Moffet Cancer Center and Research Institute|University of Chicago|Indiana University Melvin and Bren Simon Cancer Center|University of Iowa|Kansas University Medical Center|Johns Hopkins University|Massachusetts General Hospital|Henry Ford Health System|Mayo Clinic|Capitol Comprehensive Cancer Care Clinic and Research Institute|Washington University School of Medicine|Nebraska Methodist Hospital|Ohio State University, James Cancer Hospital|Oregon Health & Science University|St. Luke's Hospital & Health Network|Hospital of the University of Pennsylvania|Hollings Cancer Center|Vanderbilt University Medical Center|Vermont Cancer Center at Fletcher Allen Health Care|Peninsula Cancer Institute|Multiple site locations|Cliniques Universitaires St. Luc|Universitair Ziekenhuis|Multiple site locations|CHUM - Hopital Saint-Luc|Klinik fuer Nuklearmedizin des Universitaetsklinikums Essen|Gemeinschaftspraxis|Universitaetsklinikum Leipzig|Johannes-Gutenberg Universitaet Mainz|Klinikum der Ludwig-Maximilians-Universitaet Muenchen|Ludwig-Maximilians-Universitaet Muenchen|Universitaetsklinikum Tuebingen|Universitaetsklinikum Wuerzburg|Kidwai Institute of Oncology|Indo-American Cancer Institute and Research Center|SEAROC Cancer Institute, S.K. Soni Hospital|Netaji Subhash Chandra Bose Cancer Hospital Research Institute|Central India Cancer Research Institute|Shatabdi Superspeciality Hospital|All India Institute of Medical Sciences|Deenanath Mangeshkar Hospital & Research Center|Ruby Hall Clinic|Multiple site locations|Multiple site locations|Multiple site locations",Drug|Drug,"Austria|Belgium|Brazil|Canada|Chile|Denmark|France|Germany|Greece|India|Israel|Italy|Korea, Republic of|Netherlands|Peru|Poland|Portugal|Russian Federation|Saudi Arabia|Spain|Sweden|Switzerland|United Kingdom|United States",18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00704730
NCT00715572,hypothyroidism,Combined Therapy With L-Thyroxine and L-Triiodothyronine Compared to L-Thyroxine Alone in the Treatment of Primary Hypothyroidism,Combined Therapy With L-Thyroxine and L-Triiodothyronine Compared to L-Thyroxine Alone,Hypothyroidism,2008-07-11,2004-02-29,2004-05-31,Interventional,Completed,Not Applicable,I.M. Sechenov First Moscow State Medical University,I.M. Sechenov First Moscow State Medical University,,Drug|Drug,,18.0,48.0,[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT00715572
NCT00718770,thyroid cancer,Rexinoid Therapy for Poorly Differentiated Thyroid Cancer: A Pilot Clinical Trial and Correlation to Retinoid and PPARy Receptor Expression,A Pilot Clinical Trial for Poorly Differentiated Thyroid Cancer - Correlation to Retinoid and Peroxisome-proliferator-activated Receptor (PPARy) Expression,Thyroid Cancer,2008-07-17,2013-01-31,2013-02-28,Interventional,Completed,Early Phase 1,"University of Colorado, Denver","American Cancer Society, Inc.|Eisai Inc.|University of Colorado, Denver",University of Colorado Cancer Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00718770
NCT00719615,thyroid cancer,The Relationship Between Vitamin D and Thyroid Cancer,Assess Vitamin D Levels in Those With & Without Thyroid Cancer,Thyroid Cancer,2008-07-17,2009-03-31,2009-06-30,Observational,Completed,,University of Nebraska,University of Nebraska,University of Nebraska Medical Center,,United States,19.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00719615
NCT00730210,hypoparathyroidism,Treatment of Hypoparathyroidism With Subcutaneous PTH (1-84) Injections: Effects on Muscle Function and Quality of Life,Treatment of Hypoparathyroidism With Subcutaneous PTH (1-84) Injections: Effects on Muscle Function and Quality of Life,Hypoparathyroidism,2008-08-04,2010-08-31,2010-08-31,Interventional,Completed,Phase 2,University of Aarhus,University of Aarhus,"Osteoporoseklinikken, Aarhus University Hospital",Drug|Drug,Denmark,25.0,80.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00730210
NCT00732615,hypoparathyroidism,"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Investigate the Use of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH[1-84]) for the Treatment of Adults With Hypoparathyroidism",Use of NPSP558 in the Treatment of Hypoparathyroidism,Hypoparathyroidism,2008-08-08,2011-09-28,2011-09-28,Interventional,Completed,Phase 3,Takeda,Shire,"Mayo Clinic-Scottsdale|Advance Medical Research LLC|Diabetes Associates|University of California-San Francisco VA Medical Center|Palm Springs Research Institute|Mayo Clinic Jacksonville|University of Chicago Medical Center|Indiana University School of Medicine|Massachusetts General Hospital|Michigan Bone and Mineral Clinic PC|Mayo Clinic Rochester|Columbia University Medical Center|University Physicians Group|Physicians East|University of Cincinnati Bone Health and Osteoporosis Center|Children's Hospital of Philadelphia|Cetero Research DGD Research Inc.|Hillcrest Family Health Center|The Vancouver Clinic|Chetre Hospitalier Universitaire de Liege|Heritage Medical Research Clinic|Capital District Health Authority, QEII Health Sciences Centre|Oakville Bone Center|Aarhus University Hospital|Odense University Hospital|Hôpital Européen Georges Pompidou|Semmelweis University Medical School|University of Pécs, School of Medicine|University of Szeged|University Hospital of Careggi|Royal Liverpool University Hospital",Drug|Drug,Belgium|Canada|Denmark|France|Hungary|Italy|United Kingdom|United States,18.0,85.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00732615
NCT00743782,hypoparathyroidism,Comparing Pump vs. Subcutaneous Injection Delivery of PTH 1-34 in the Management of Chronic Hypoparathyroidism,Comparing Pump With Subcutaneous Injection Delivery of PTH 1-34 in the Management of Chronic Hypoparathyroidism,Hypocalcemia|Hypoparathyroidism,2008-08-28,2014-04-07,2014-04-07,Interventional,Completed,Early Phase 1,National Institutes of Health Clinical Center (CC),Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),"National Institutes of Health Clinical Center, 9000 Rockville Pike",Drug,United States,7.0,70.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00743782
NCT00744302,hyperparathyroidism,Study of 1.25 mmol/L Calcium Dialysate on Mineral Metabolism in Haemodialysis Patients.,Study of 1.25 mmol/L Calcium Dialysate on Mineral Metabolism in Haemodialysis Patients.,Hypercalcemia|Hyperparathyroidism,2008-08-28,2009-12-31,2009-12-31,Interventional,Completed,Phase 2,Sun Yat-sen University,Sun Yat-sen University,"The 1st Affiliated Hospital, Sun Yet-sen University",Drug,China,14.0,65.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00744302
NCT00747760,hypothyroidism,The Prevalence of TSH Receptor Mutation Among the Arab Population of Israel,TSH Receptor Mutations Among a Consanguineous Community,Hypothyroidism,2008-09-04,2006-07-31,2006-12-31,Observational,Completed,,"HaEmek Medical Center, Israel","HaEmek Medical Center, Israel|National Institutes of Health (NIH)",Samuell Refetoff|Ha'Emek Medical Center,,Israel|United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT00747760
NCT00749697,thyroid carcinoma,Investigating Absorbed Radiation Dose Delivered to Differentiated Thyroid Cancer Metastases Following Administration of Fixed Activity of Radioactive Iodine,Radioiodine Dosimetry Protocol for Thyroid Cancer Metastases,Metastatic Sites Lung Bone Nodal|Thyroid Carcinoma,2008-09-05,2010-01-31,2010-07-31,Interventional,Unknown status,Not Applicable,Royal Marsden NHS Foundation Trust,Royal Marsden NHS Foundation Trust,Royal Marsden NHS Foundation Trust,Other,United Kingdom,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00749697
NCT00754182,thyroid neoplasms,Comparison of Esthetic Results Between Subcuticular Suture and Synthetic Glue in Thyroidectomy Incision: a RCT,Subcuticular Suture Versus Synthetic Glue in Thyroidectomy Incision,Goiter|Parathyroid Pathologies|Thyroid Neoplasms,2008-09-16,2010-05-31,2010-05-31,Interventional,Completed,Not Applicable,Azienda Ospedaliero-Universitaria di Modena,Azienda Ospedaliero-Universitaria di Modena,Policlinico di Modena,Device|Device,Italy,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00754182
NCT00754182,goiter,Comparison of Esthetic Results Between Subcuticular Suture and Synthetic Glue in Thyroidectomy Incision: a RCT,Subcuticular Suture Versus Synthetic Glue in Thyroidectomy Incision,Goiter|Parathyroid Pathologies|Thyroid Neoplasms,2008-09-16,2010-05-31,2010-05-31,Interventional,Completed,Not Applicable,Azienda Ospedaliero-Universitaria di Modena,Azienda Ospedaliero-Universitaria di Modena,Policlinico di Modena,Device|Device,Italy,0.0,120.0,[0-17]|[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00754182
NCT00770016,hypothyroidism,Insulin Sensitivity and Metabolism Before and After Treatment in Patients With Hypothyroidism,Insulin Sensitivity and Metabolism Before and After Treatment in Patients With Hypothyroidism,Hypothyroidism,2008-10-08,2010-01-31,2011-01-31,Interventional,Terminated,Not Applicable,University of Aarhus,"MR Research Center, Skejby Sygehus, Brendstrupgaardsvej 100, 8200 Aarhus N|University of Aarhus","Medical department M (Endocrinology and Diabetes), Aarhus University Hospital, Aarhus Sygehus,",Drug,Denmark,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT00770016
NCT00782366,graves disease,Proof-of-Principle Trial of Communication to Patients Receiving Predictive Genetic Risk Assessment,Predictive Genetic Risk Assessment Trial,Atrial Fibrillation|Breast Cancer|Celiac Disease|Colon Cancer|Diabetes Type 2|Graves Disease|Lung Cancer|Myocardial Infarction|Obesity|Osteoarthritis|Prostate Cancer,2008-10-29,2010-01-31,2010-01-31,Observational,Completed,,Mayo Clinic,Mayo Clinic,Mayo Clinic,Genetic,United States,18.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT00782366
NCT00784303,thyroid cancer,"Phase II, Multicenter, Open-label, Single Arm Trial to Evaluate the Safety and Efficacy of Oral E7080 in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology","Evaluating the Safety and Efficacy of Oral Lenvatinib in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology",Thyroid Cancer,2008-10-30,2011-04-11,2019-03-29,Interventional,Completed,Phase 2,Eisai Inc.,Eisai Inc.,,Drug|Drug,Australia|France|Italy|Poland|United Kingdom|United States,18.0,99.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00784303
NCT00786552,thyroid cancer,"Phase 2 Trial of Pemetrexed (Alimta™) Combined With Paclitaxel in Patients With Recurrent/Advanced Follicular, Papillary or Anaplastic Thyroid Cancer",Pemetrexed + Paclitaxel in Patients With Recurrent/Advanced Thyroid Cancer,Thyroid Cancer,2008-11-05,2012-11-30,2013-11-30,Interventional,Unknown status,Phase 2,University Hospital Schleswig-Holstein,University Hospital Schleswig-Holstein,"Medical Center II, University of Kiel",Drug,Germany,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00786552
NCT00793689,hypoparathyroidism,Comparison of the Prognostic Value of Perioperative Parathormone Measurement and Sodium Bicarbonate Infusion Test in the Evaluation of Parathyroid Function After Total Thyroidectomy,Perioperative Parathormone Measurement and Sodium Bicarbonate Infusion Test After Total Thyroidectomy,Hypoparathyroidism,2008-11-18,2009-09-30,2009-10-31,Observational,Completed,,Aristotle University Of Thessaloniki,AHEPA University Hospital|Aristotle University Of Thessaloniki,AHEPA University Hospital,,Greece,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00793689
NCT00794053,thyroid cancer,The Role of Sentinel Lymph Node Biopsy (SLNB) In the Management of Differentiated Thyroid Cancer,The Usefulness of Staining Lymph Nodes During Operations for Cancer Thyroid in Detecting the Nodes That Have Cancer,Lymph Node Metastasis|Thyroid Cancer,2008-11-18,2008-12-31,2009-04-30,Interventional,Completed,Phase 3,University of Alexandria,University of Alexandria,Alexandria University Hospitals,Procedure,Egypt,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00794053
NCT00795782,thyroid cancer,Prophylactic Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma: A Prospective Randomized Controlled Trial,Prophylactic Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma,Thyroid Cancer,2008-11-19,2012-06-30,2014-06-30,Interventional,Completed,Phase 3,Samsung Medical Center,Samsung Medical Center,Samsung Medical Center,Procedure,"Korea, Republic of",18.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00795782
NCT00796913,hyperthyroidism,Prospective Randomized Study of Therapy Withdrawal vs Continued Low Dose Medical Therapy in Patients With Graves' Disease Entering Remission During ATD Therapy,Remission Induction and Sustenance in Graves' Disease 2,Graves Disease|Hyperthyroidism,2008-11-21,2015-05-15,2015-05-15,Interventional,Completed,Not Applicable,Aalborg University Hospital,Aalborg University Hospital,,Other,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT00796913
NCT00796913,graves disease,Prospective Randomized Study of Therapy Withdrawal vs Continued Low Dose Medical Therapy in Patients With Graves' Disease Entering Remission During ATD Therapy,Remission Induction and Sustenance in Graves' Disease 2,Graves Disease|Hyperthyroidism,2008-11-21,2015-05-15,2015-05-15,Interventional,Completed,Not Applicable,Aalborg University Hospital,Aalborg University Hospital,,Other,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT00796913
NCT00800358,hyperparathyroidism,"A Multi Centre, Open Label, Parallel Group, Randomized Controlled Trial to Compare the Safety and Efficacy of Oral Paricalcitol Versus Oral Calcitriol in the Treatment of Secondary Hyperparathyroidism in Dialysis Patients",Safety and Efficacy Study of Paricalcitol Versus Calcitriol in the Treatment of Secondary Hyperparathyroidism,Hyperparathyroidism|Kidney Disease,2008-11-30,2009-10-31,2009-12-31,Interventional,Completed,Not Applicable,"Penang Hospital, Malaysia","Ministry of Health, Malaysia|Penang Hospital, Malaysia","Hospital Sultanah Bahiyah Haemodialysis Unit KM 6 Jalan Langgar|Hemodialysis Unit, Raja Perempuan Zainab II Hospital|Hemodialysis Unit, Tengku Ampuan Afzan Hospital|Clinical Research Centre, Penang Hospital|Haemodialysis Unit, Seberang Jaya Hospital|Hemodialysis Unit, Taiping Hospital|Nephrology Department, Tengku Ampuan Rahimah Hospital|Hemodialysis Unit, Kuala Lumpur Hospital|Haemodialysis Unit, Serdang Hospital|Hemodialysis Unit, Tuanku Ja'afar Seremban Hospital|Haemodialysis Unit, Melaka Hospital",Drug|Drug,Malaysia,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00800358
NCT00818896,hypothyroidism,A Model Statewide Trial to Detect and Treat Maternal Hypothyroidism in Pregnancy,Maternal Hypothyroidism in Pregnancy,Hypothyroidism,2009-01-06,2011-08-31,2011-09-30,Observational,Completed,,Women and Infants Hospital of Rhode Island,Women and Infants Hospital of Rhode Island,Women & Infants Hospital,,United States,17.0,44.0,[0-17]|[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT00818896
NCT00822289,hyperthyroidism,Effect of Radioactive Iodine on Eradication of Helicobacter Pylori in Patients Treated for Thyroid Diseases,The Effect of Radioactive Iodine Administration for Thyroid Diseases on H.Pylori Eradication,Helicobacter Pylori Infected Patients|Hyperthyroidism|Thyroid Cancer Patients,2009-01-13,,,Observational,Unknown status,,Rabin Medical Center,Rabin Medical Center,,,,18.0,85.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT00822289
NCT00824226,hypoparathyroidism,Effect of Magnesium Treatment on Plasma Calcium in Hypoparathyroid Patients,Magnesium Treatment in Hypoparathyroidism,Hypoparathyroidism,2009-01-15,2011-08-31,2011-08-31,Interventional,Completed,Not Applicable,University of Tartu,University of Tartu,Tartu University Hospital,Dietary Supplement,Estonia,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00824226
NCT00856401,hypoparathyroidism,Phase II Trial of Parathyroid Hormone for the Treatment of Hypoparathyroidism,ADD-ON Study to Existing Hypoparathyroidism Studies,Hypoparathyroidism,2009-03-04,2020-12-31,2021-06-30,Interventional,Unknown status,Phase 3,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Columbia University Medical Center,Drug,United States,18.0,85.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00856401
NCT00858104,thyroid nodule,Multicentric Randomized Controlled Study of Percutaneous Laser Ablation Versus Follow Up in Benign Thyroid Nodules. Long Term Results,Percutaneous Laser Ablation in Benign Thyroid Nodules.Long Term Results,Thyroid Nodule,2009-03-06,2010-03-31,2013-05-31,Interventional,Completed,Phase 4,Elesta S.R.L.,Elesta S.R.L.,Ospedale Regina Apostolorum|Azienda Ospedaliera di Perugia - Osp. S.Maria della Misericordia|Azienda Ospedaliero-Universitaria di Pisa - Presidio di Cisanello|Arcispedale S. Maria Nuova,Procedure,Italy,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT00858104
NCT00877630,thyroid nodule,Minimal Invasiveness of Endoscopic Thyroidectomy,Minimal Invasiveness of Endoscopic Thyroidectomy,Thyroid Nodule,2009-04-07,2007-05-31,2007-05-31,Observational,Completed,,Second Military Medical University,Second Military Medical University,Minimally Invasive Surgical Center of Changzhang Hospital,,China,0.0,120.0,[0-17]|[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT00877630
NCT00880503,medullary thyroid carcinoma,Multidrug Resistance Molecular Target Analysis of Human Samples Collected in Clinical Trials Performed Outside of the Intramural National Cancer Institute,Collection of Tissue Samples for Study of Multidrug Resistance,Breast Cancer|Breast Carcinoma|Medullary Thyroid Carcinoma,2009-04-10,,2018-02-08,Observational,Completed,,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),"Childrens Hospital, Pittsburgh",,United States,18.0,99.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, medullary",https://clinicaltrials.gov/ct2/show/NCT00880503
NCT00887666,hyperparathyroidism,"Pilot Study: Hypovitaminosis D, Hyperparathyroidism and Hypomagnesemia in Patients With Congestive Heart Failure","Pilot Study: Hypovitaminosis D, Hyperparathyroidism and Hypomagnesemia in Patients With Congestive Heart Failure",Congestive Heart Failure|Hyperparathyroidism|Hypovitaminosis D,2009-04-23,2008-10-31,2008-10-31,Observational,Completed,,State University of New York - Downstate Medical Center,State University of New York - Downstate Medical Center,SUNY Downstate Medical Center,,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00887666
NCT00896454,thyroid cancer,"A Single-arm, Multicenter, Proof-of-concept Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium Despite Recent Treatment With IV Bisphosphonates",Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium,Breast Cancer|Colon Cancer|Endocrine Cancer|Head and Neck Cancer|Hodgkin's Lymphoma|Hypercalcemia of Malignancy|Kidney Cancer|Lung Cancer|Lymphoma|Metastatic Cancer|Multiple Myeloma|Non-Hodgkin's Lymphoma|Non-Small Cell Lung Cancer|Parathyroid Neoplasms|Renal Cancer|Thyroid Cancer,2009-05-07,2012-09-13,2013-08-21,Interventional,Completed,Phase 2,Amgen,Amgen,Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug,Canada|France|Italy|Poland|United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00896454
NCT00896454,parathyroid neoplasms,"A Single-arm, Multicenter, Proof-of-concept Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium Despite Recent Treatment With IV Bisphosphonates",Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium,Breast Cancer|Colon Cancer|Endocrine Cancer|Head and Neck Cancer|Hodgkin's Lymphoma|Hypercalcemia of Malignancy|Kidney Cancer|Lung Cancer|Lymphoma|Metastatic Cancer|Multiple Myeloma|Non-Hodgkin's Lymphoma|Non-Small Cell Lung Cancer|Parathyroid Neoplasms|Renal Cancer|Thyroid Cancer,2009-05-07,2012-09-13,2013-08-21,Interventional,Completed,Phase 2,Amgen,Amgen,Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug,Canada|France|Italy|Poland|United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00896454
NCT00905866,hyperparathyroidism,Evaluation of Quality of Life in Patients Undergoing Parathyroidectomy,Quality of Life in Patients Undergoing Parathyroidectomy,Hyperparathyroidism|Parathyroidectomy,2009-05-18,2011-07-31,2011-07-31,Observational,Completed,,Mackay Memorial Hospital,Mackay Memorial Hospital,Mackay Memorial Hospital,Other,Taiwan,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00905866
NCT00923247,medullary thyroid carcinoma,"A Targeted Ph I/II Trial of ZD6474 (Vandetanib; CAPRELSA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Ca (MTC)","A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)",Medullary Thyroid Carcinoma,2009-06-17,2016-04-01,2016-12-09,Interventional,Terminated,Phase 1/Phase 2,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),"National Institutes of Health Clinical Center, 9000 Rockville Pike",Drug|Drug,United States,18.0,80.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, medullary",https://clinicaltrials.gov/ct2/show/NCT00923247
NCT00926978,thyroid cancer,Comparison of I-124 and I-131 Radiopharmacokinetics in Patients Who Have Well-differentiated Thyroid Cancer and Are Prepared With Recombinant Human TSH Injection (rhTSH),Comparison of Iodine-124 (I-124) and Iodine-131 (I-131) Radiopharmacokinetics in Patients Prepared With Recombinant Human TSH Injection (rhTSH),Thyroid Cancer,2009-06-17,2018-10-31,2018-10-31,Interventional,Terminated,Not Applicable,Medstar Health Research Institute,Medstar Health Research Institute,Washington Hospital Center,Radiation,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00926978
NCT00929318,thyroid neoplasms,Clinical Investigations on Cytokin-Gradients in Hypo/Euthyroid Patients. Evaluation of Expression of Different Pro-and Anti-Inflammatory Cyto-/Chemokines in Skin Wounds After Surgery of Benign Goitres (Struma Multinodosa) or Malignant Diseases of Thyroid Gland (Papillary Thyroid Carcinoma) in Correlation to the Status of Wound Healing of the Neck Wound,Influence of Thyroid Hormones on the Woundhealing Process,Thyroid Carcinoma|Thyroid Neoplasms,2009-06-26,2009-12-31,2010-04-30,Interventional,Unknown status,Not Applicable,Hannover Medical School,"Genzyme, a Sanofi Company|Hannover Medical School","Medizinische Hoochschule Hannover, Allgemein-, Viszeral-und Transplantationscirurgie OE 6220",Procedure|Procedure,Germany,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00929318
NCT00936858,thyroid cancer,A Phase II Trial Using RAD001 for Patients With Radioiodine Refractory Thyroid Cancer,RAD001 for Patients With Radioiodine Refractory Thyroid Cancer,Thyroid Cancer,2009-07-09,2020-02-27,2020-02-27,Interventional,Completed,Phase 2,Dana-Farber Cancer Institute,Dana-Farber Cancer Institute|Massachusetts General Hospital|M.D. Anderson Cancer Center|MOUNT SINAI HOSPITAL|Novartis,Massachusetts General Hospital|Dana-Farber Cancer Institute|Mt. Sinai Medical Center|MD Anderson Cancer Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00936858
NCT00941551,recurrent goiter,Five-year Follow up of a Randomized Clinical Trial of Unilateral Thyroid Lobectomy With or Without Levothyroxine Treatment Postoperatively,Thyroid Lobectomy With or Without Levothyroxine Treatment Postoperatively,Recurrent Goiter,2009-07-16,2003-12-31,2008-12-31,Observational,Completed,,Jagiellonian University,Jagiellonian University,"Jagiellonian University, College of Medicine, Department of Endocrine Surgery, 3rd Chair of General Surgery",Drug|Drug,Poland,18.0,65.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00941551
NCT00946296,hyperthyroidism,Impact of SSKI Pre-Treatment on Blood Loss in Thyroidectomy for Graves Disease,Impact of SSKI Pre-Treatment on Blood Loss in Thyroidectomy for Graves Disease,Graves Disease|Hyperthyroidism,2009-07-22,2013-04-30,2013-04-30,Interventional,Completed,Phase 4,"University of Massachusetts, Worcester","University of Massachusetts, Worcester",UMASS Memorial Health Care,Drug,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT00946296
NCT00946296,graves disease,Impact of SSKI Pre-Treatment on Blood Loss in Thyroidectomy for Graves Disease,Impact of SSKI Pre-Treatment on Blood Loss in Thyroidectomy for Graves Disease,Graves Disease|Hyperthyroidism,2009-07-22,2013-04-30,2013-04-30,Interventional,Completed,Phase 4,"University of Massachusetts, Worcester","University of Massachusetts, Worcester",UMASS Memorial Health Care,Drug,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT00946296
NCT00946894,goiter,Five-year Follow up of a Randomized Clinical Trial of Total Thyroidectomy Versus Dunhill Operation Versus Bilateral Subtotal Thyroidectomy for Multinodular Non-toxic Goiter.,Outcomes of Different Thyroid Resections for Multinodular Non-toxic Goiter,Goiter,2009-07-23,2003-12-31,2008-12-31,Interventional,Completed,Not Applicable,Jagiellonian University,Jagiellonian University,"Jagiellonian University, College of Medicine, Department of Endocrine Surgery, 3rd Chair of General Surgery",Procedure|Procedure|Procedure,Poland,18.0,65.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT00946894
NCT00948337,thyroid cancer,"A Randomized Controlled Trial on the Effect of Intervention With Health Educational Material on Knowledge, Attitude, and Behavior in Cancer Survivors",A Study With Health Educational Material on Health Promotion in Cancer Survivors,Breast Cancer|Colon Cancer|Stomach Cancer|Thyroid Cancer,2009-07-28,2009-11-30,2010-12-31,Interventional,Unknown status,Phase 2,"National Cancer Center, Korea","National Cancer Center, Korea",National Cancer Center|Samsung Medical Center,Behavioral,"Korea, Republic of",18.0,80.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00948337
NCT00954837,thyroid cancer,Utility of a Second Ultrasound-guided Fine Needle Aspiration for the Detection of Thyroid Cancer in the Management of Single Thyroid Nodules or Multinodular Goitre.,Assessment of Repeat Fine Needle Aspiration (FNA) to Detect Thyroid Cancer,Thyroid Cancer,2009-07-30,2011-12-31,2012-12-31,Interventional,Withdrawn,Not Applicable,Assistance Publique - Hôpitaux de Paris,Assistance Publique - Hôpitaux de Paris,,Procedure,,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00954837
NCT00970359,thyroid cancer,Reacquisition of RAI Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244: A Pilot Study,Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244,Thyroid Cancer,2009-09-01,2013-04-30,2013-04-30,Interventional,Completed,Not Applicable,Memorial Sloan Kettering Cancer Center,"AstraZeneca|Genzyme, a Sanofi Company|Memorial Sloan Kettering Cancer Center",Memorial Sloan-Kettering Cancer Center,Biological,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00970359
NCT00975000,hyperparathyroidism,"A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Using Cinacalcet to Correct Hypercalcemia in Renal Transplant Recipients With Autonomous Hyperparathyroidism",Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients,Chronic Allograft Nephropathy|Chronic Kidney Disease|Chronic Renal Failure|Disordered Mineral Metabolism|End Stage Renal Disease|Hyperparathyroidism|Hypophosphatemia|Kidney Disease|Kidney Transplantation|Post Renal Transplantation,2009-09-10,2012-09-13,2013-04-16,Interventional,Completed,Phase 3,Amgen,Amgen,Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug|Drug,Australia|Austria|Belgium|Canada|France|Germany|Italy|Poland|Spain|Switzerland|United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT00975000
NCT00984191,papillary thyroid cancer,99mTechnetium-MIBI SPECT-CT for Pre-operative Evaluation of Cervical Lymph Node Metastasis in Papillary Thyroid Carcinoma; A Pilot Study,Pilot 99mTechnetium-MIBI Single Photon Emission Computed Tomography - Computed Tomography (SPECT-CT) in Papillary Carcinoma (CA) Thyroid,Papillary Thyroid Cancer,2009-09-24,2011-10-31,2011-11-30,Interventional,Unknown status,Not Applicable,Chulalongkorn University,Chulalongkorn University,King Chulalongkorn Hospital,Radiation,Thailand,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT00984191
NCT00984282,thyroid neoplasms,A Double-Blind Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer,Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer,Thyroid Neoplasms,2009-09-24,2012-08-31,2017-08-30,Interventional,Completed,Phase 3,Bayer,Amgen|Bayer,Asan Medical Center,Drug|Drug,"Austria|Belgium|Bulgaria|China|Denmark|France|Germany|Italy|Japan|Korea, Republic of|Netherlands|Poland|Russian Federation|Saudi Arabia|Spain|Sweden|United Kingdom|United States",18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00984282
NCT00993837,thyroid carcinoma,Comparison of Effectiveness and Safety of Thyroidectomy for Thyroid Carcinoma in Patients Undergo Endoscopic Surgery and Those Receive Conversion,Feasibility of Endoscopic Thyroidectomy for Thyroid Carcinoma,Thyroid Carcinoma,2009-09-29,2011-12-31,2012-06-30,Interventional,Unknown status,Not Applicable,Second Military Medical University,Second Military Medical University,Changzheng Hospital,Procedure,China,18.0,45.0,[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT00993837
NCT01003652,multinodular goiter,Harmonic Focus Shears Versus Clamp-and-technique for Total Thyroidectomy,Clinical Trial on Harmonic Focus Shears,Multinodular Goiter,2009-10-27,2008-12-31,2008-12-31,Observational,Completed,,Cliniques universitaires Saint-Luc- Université Catholique de Louvain,Cliniques universitaires Saint-Luc- Université Catholique de Louvain,Cliniques universitaires Saint-Luc- Université Catholique de Louvain,Procedure,Belgium,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01003652
NCT01005654,thyroid neoplasms,Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms,Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms,Adrenal Neoplasm|Endocrine Tumors|Neuroblastoma|Parathyroid Neoplasms|Thyroid Neoplasms,2009-10-30,,,Observational,Recruiting,,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),"National Institutes of Health Clinical Center, 9000 Rockville Pike",,United States,4.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01005654
NCT01005654,parathyroid neoplasms,Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms,Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms,Adrenal Neoplasm|Endocrine Tumors|Neuroblastoma|Parathyroid Neoplasms|Thyroid Neoplasms,2009-10-30,,,Observational,Recruiting,,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),"National Institutes of Health Clinical Center, 9000 Rockville Pike",,United States,4.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01005654
NCT01013597,thyroid carcinoma,A Phase II Trial of LBH589 in Patients With Metastatic Medullary Thyroid Cancer and Radioactive Iodine Resistant Differentiated Thyroid Cancer,Trial of LBH589 in Metastatic Thyroid Cancer,Thyroid Carcinoma,2009-10-28,2013-08-31,2016-02-29,Interventional,Completed,Phase 2,"University of Wisconsin, Madison","Novartis Pharmaceuticals|University of Wisconsin, Madison",St. Vincent Regional Cancer Center CCOP|University of Wisconsin - Madison|Medical College of Wisconsin,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01013597
NCT01025453,thyroid cancer,Phase II Study Evaluating the Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer,Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer,Thyroid Cancer,2009-12-02,2018-01-16,2018-01-16,Interventional,Completed,Phase 2,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center|National Comprehensive Cancer Network|Pfizer,Memorial Sloan-Kettering at Basking Ridge|Memorial Sloan-Kettering Cancer Center @ Suffolk|Memorial Sloan Kettering Cancer Center|Memorial Sloan-Kettering at Mercy Medical Center|Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center,Drug,United States,21.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01025453
NCT01039714,hypoparathyroidism,Preoperative Vitamin D Levels as a Prognostic Factor for Postoperative Hypocalcemia and Hypoparathyroidism After Total Thyroidectomy,Vitamin D Levels and Postoperative Hypocalcemia After Total Thyroidectomy,Hypocalcemia|Hypoparathyroidism|Thyroidectomy|Vitamin D Deficiency,2009-09-29,2010-04-30,2010-05-31,Observational,Unknown status,,Aristotle University Of Thessaloniki,Aristotle University Of Thessaloniki,"AHEPA University Hospital Thessaloniki, Greece",,Greece,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01039714
NCT01039818,graves disease,Comparison of Different Doses of 131I in Severe Graves' Hyperthyroidism: A Clinical Trial With Historical Control,Comparison of Different Doses of 131I in Severe Graves' Hyperthyroidism,Graves Disease,2009-12-24,2011-08-31,2011-08-31,Interventional,Completed,Phase 3,Hospital de Clinicas de Porto Alegre,Federal University of Rio Grande do Sul|Hospital de Clinicas de Porto Alegre,"Thyroid Unit, Endocrine Division, Hospital de Clínicas de Porto Alegre",Radiation|Radiation,Brazil,18.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT01039818
NCT01042626,hyperparathyroidism,"Dissimilar PTH, Gastrin, and Ionized Calcium Response to Oral Peptones in Normocalcemic Primary Hyperparathyroidism, Hypercalcemic Primary Hyperparathyroidism and Healthy Subjects",Oral Peptones Load in Normocalcemic and Hypercalcemic Primary Hyperparathyroidism and Healthy Subjects,Hypercalcemia|Hyperparathyroidism,2010-01-04,2005-01-31,2005-01-31,Interventional,Completed,Not Applicable,University of Eastern Piedmont,University of Eastern Piedmont|University of Milan,L. Sacco Hospital (Vialba),Other,Italy,18.0,90.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01042626
NCT01043107,thyroid cancer,Study on the Relationship Between The Computer Radiation and The Recrudesce Rate of Thyroid Cancer,Relationship Between Computer and Cancer,Thyroid Cancer,2010-01-05,,,Observational,Unknown status,,Guangdong Provincial People's Hospital,Guangdong Provincial People's Hospital,Guangdong General Hospital,,China,10.0,60.0,[0-17]|[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01043107
NCT01050465,hypothyroidism,MedlinePlus Health Prescriptions: Developing a Real World Approach for Clinic Use,MedlinePlus Health Prescriptions: Developing a Pragmatic Approach for Clinic Use,Acne Vulgaris|Allergic Rhinitis|Anxiety|Asthma|Back Pain|Bursitis|Chronic Obstructive Pulmonary Disease|Coronary Artery Disease|Cough|Depression|Diabetes Mellitus|Diarrhea|Fibromyalgia|Gastroesophageal Reflux|Headache|HIV Infections|Hyperlipidemia|Hypertension|Hypothyroidism|Influenza|Irritable Bowel Syndrome|Menopause|Migraine Disorders|Obesity|Obstructive Sleep Apnea|Osteoarthritis|Prostatic Hyperplasia|Senile Osteoporosis|Shoulder Pain|Sinusitis|Sleep Initiation and Maintenance Disorders|Smoking Cessation|Tobacco Use Cessation|Urinary Incontinence|Urinary Tract Infection|Vaginitis|Vertigo,2010-01-13,2010-10-31,2010-12-31,Interventional,Completed,Not Applicable,University of Missouri-Columbia,National Library of Medicine (NLM)|University of Missouri-Columbia,,Other,,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01050465
NCT01074684,thyroid cancer,"Defining Predictive Factors of Clinical, Laboratory and Imaging Criteria Routinely Used in the Diagnosis of Thyroid Cancer: Observational, Prospective Multicentered Study","Predictive Factors of Clinical, Laboratory and Imaging Findings Routinely Used in Diagnosing Thyroid Cancer",Thyroid Cancer,2010-02-23,2021-12-31,2022-12-31,Observational,Active not recruiting,,"National Cancer Institute, Naples","National Cancer Institute, Naples",Università di Cagliari|Azienda Ospedaliera Unviersitaria Careggi - Firenze|ASL TO/4 Ospedale di Ivrea|Istituto Nazionale dei Tumori|Azienda Ospedaliera Universitaria di Padova|Università Cattolica del Sacro Cuore di Roma Policlinico Gemelli|Ospedale di Taormina|Università degli studi di Perugia - Sede di Terni,,Italy,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01074684
NCT01095341,hyperthyroidism,Postoperative Hyperthyroidism After Parathyroidectomy,Postoperative Hyperthyroidism,Hyperthyroidism,2010-03-29,2009-04-30,2009-04-30,Observational,Completed,,Heidelberg University,Heidelberg University,University Hospital Heidelberg,Other,Germany,18.0,90.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01095341
NCT01100619,papillary thyroid cancer,A Phase 1 Drug-Drug Interaction Study of the Effects of XL184 on the Pharmacokinetics of a Single Oral Dose of Rosiglitazone in Subjects With Solid Tumors,A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors,Follicular Thyroid Cancer|Huerthle Cell Thyroid Cancer|Papillary Thyroid Cancer|Renal Cell Carcinoma,2010-03-22,2012-08-31,,Interventional,Completed,Phase 1,Exelixis,Exelixis,City of Hope Comprehensive Cancer Center|Dana Farber Cancer Institute|Montefiore Medical Center|Hospital of the University of Pennsylvania|The University of Texas M.D. Anderson Cancer Center,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT01100619
NCT01100619,follicular thyroid cancer,A Phase 1 Drug-Drug Interaction Study of the Effects of XL184 on the Pharmacokinetics of a Single Oral Dose of Rosiglitazone in Subjects With Solid Tumors,A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors,Follicular Thyroid Cancer|Huerthle Cell Thyroid Cancer|Papillary Thyroid Cancer|Renal Cell Carcinoma,2010-03-22,2012-08-31,,Interventional,Completed,Phase 1,Exelixis,Exelixis,City of Hope Comprehensive Cancer Center|Dana Farber Cancer Institute|Montefiore Medical Center|Hospital of the University of Pennsylvania|The University of Texas M.D. Anderson Cancer Center,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT01100619
NCT01100619,huerthle cell thyroid cancer,A Phase 1 Drug-Drug Interaction Study of the Effects of XL184 on the Pharmacokinetics of a Single Oral Dose of Rosiglitazone in Subjects With Solid Tumors,A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors,Follicular Thyroid Cancer|Huerthle Cell Thyroid Cancer|Papillary Thyroid Cancer|Renal Cell Carcinoma,2010-03-22,2012-08-31,,Interventional,Completed,Phase 1,Exelixis,Exelixis,City of Hope Comprehensive Cancer Center|Dana Farber Cancer Institute|Montefiore Medical Center|Hospital of the University of Pennsylvania|The University of Texas M.D. Anderson Cancer Center,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Hurthle cell thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01100619
NCT01102127,thyroid cancer,Accuracy of Ultrasound Elastastography in Thyroid Nodular Disease.,Elastography in Thyroid Nodules,Nodular Goiter|Thyroid Cancer,2010-04-12,2010-09-30,2010-09-30,Observational,Completed,,Castilla-León Health Service,Castilla-León Health Service,Complejo Asistencial de León,Device,Spain,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01102127
NCT01102127,nodular goiter,Accuracy of Ultrasound Elastastography in Thyroid Nodular Disease.,Elastography in Thyroid Nodules,Nodular Goiter|Thyroid Cancer,2010-04-12,2010-09-30,2010-09-30,Observational,Completed,,Castilla-León Health Service,Castilla-León Health Service,Complejo Asistencial de León,Device,Spain,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01102127
NCT01102205,hashimoto disease,Evaluation of Oxidative Stress and Effect of Levothyroxine Treatment on Oxidative Stress in Hashimoto Disease,Evaluation of Oxidative Stress and Effect of Levothyroxine Treatment on Oxidative Stress in Hashimoto Disease,Hashimoto Disease,2010-04-09,2010-04-30,2010-10-31,Observational,Completed,,Vakif Gureba Training and Research Hospital,Vakif Gureba Training and Research Hospital,Vakif Gureba Training and Research Hospital,,Turkey,18.0,95.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT01102205
NCT01105923,hyperthyroidism,Making Accurate Problem Lists in the EHR,Study of an Intervention to Improve Problem List Accuracy and Use,Asthma|Attention Deficit Disorder With Hyperactivity|Breast Cancer|Congestive Heart Failure|COPD|Coronary Artery Disease|Diabetes|Glaucoma|Hemophilia|Hypertension|Hyperthyroidism|Hypothyroidism|Myasthenia Gravis|Osteopenia|Osteoporosis|Renal Failure|Renal Insufficiency|Sickle Cell Disease|Stroke,2010-04-15,2010-11-30,2017-11-30,Interventional,Unknown status,Not Applicable,Brigham and Women's Hospital,Brigham and Women's Hospital,Brigham and Women's Hospital,Other,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01105923
NCT01105923,hypothyroidism,Making Accurate Problem Lists in the EHR,Study of an Intervention to Improve Problem List Accuracy and Use,Asthma|Attention Deficit Disorder With Hyperactivity|Breast Cancer|Congestive Heart Failure|COPD|Coronary Artery Disease|Diabetes|Glaucoma|Hemophilia|Hypertension|Hyperthyroidism|Hypothyroidism|Myasthenia Gravis|Osteopenia|Osteoporosis|Renal Failure|Renal Insufficiency|Sickle Cell Disease|Stroke,2010-04-15,2010-11-30,2017-11-30,Interventional,Unknown status,Not Applicable,Brigham and Women's Hospital,Brigham and Women's Hospital,Brigham and Women's Hospital,Other,United States,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01105923
NCT01114503,graves ophthalmopathy,"A Randomised, Comparator Controlled, Two Part, Open-label Study to Evaluate the Safety, Tolerability and Pharmacodynamics of Multiple Doses of Otelixizumab in Patients With Thyroid Orbitopathy",A Safety and Tolerability Study of Otelixizumab in Thyroid Eye Disease,Graves Ophthalmopathy,2010-04-29,2012-08-29,2012-08-29,Interventional,Terminated,Phase 2,GlaxoSmithKline,GlaxoSmithKline,GSK Investigational Site,Drug|Drug|Drug|Drug|Drug|Drug,United Kingdom,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT01114503
NCT01126060,thyroid carcinoma,Efficacy of Fibrin Sealant to Reduce the Amount of Postoperative Drain in Patients With Harmonic Scalpel-assisted Total Thyroidectomy With Anterior Compartment Neck Dissections,Efficacy of Fibrin Sealant to Reduce the Amount of Post-thyroidectomy Drain,Thyroid Carcinoma|Thyroidectomy,2010-04-15,2011-01-31,2011-01-31,Interventional,Completed,Phase 3,Samsung Medical Center,Samsung Medical Center,Samsung Medical Center,Drug|Procedure,"Korea, Republic of",20.0,80.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01126060
NCT01129492,autoimmune thyroiditis,"Low-Level Laser Therapy in Chronic Autoimmune Thyroiditis: Randomized, Placebo Controlled Clinical Trial",Low-Level Laser Therapy in Chronic Autoimmune Thyroiditis,Autoimmune Thyroiditis,2010-05-14,2009-03-31,2009-03-31,Interventional,Completed,Phase 2,University of Sao Paulo General Hospital,Conselho Nacional de Desenvolvimento Científico e Tecnológico|Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.|Fundação de Amparo à Pesquisa do Estado de São Paulo|University of Sao Paulo General Hospital,University of Sao Paulo General Hospital,Device,Brazil,20.0,60.0,[18-65],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT01129492
NCT01141309,thyroid cancer,Phase II Study Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer,Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer,Thyroid Cancer,2010-06-09,2022-06-30,2022-06-30,Interventional,Active not recruiting,Phase 2,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Memoral Sloan Kettering Cancer Center|Memorial Sloan Kettering Cancer Center @ Suffolk|Memorial Sloan Kettering Westchester|Memorial Sloan Kettering Cancer Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01141309
NCT01143987,hyperparathyroidism,Effect of Cinacalcet Treatment on Vascular Arterial Stiffness Among Peritoneal Dialysis Patients With Secondary Hyperparathyroidism,Cincalcet and Vascular Arterial Stiffness Among Peritoneal Dialysis Patients With Secondary Hyperparathyroidism,Arterial Stiffness|Hyperparathyroidism,2010-06-10,2013-02-28,2013-02-28,Interventional,Completed,Phase 4,Chinese University of Hong Kong,Chinese University of Hong Kong,"Prince of Wales Hospital, Chinese University of Hong Kong",Drug,Hong Kong,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01143987
NCT01145040,hyperthyroidism,NOMOTHETICOS: Nonlinear Modelling of Thyroid Hormones' Effect on Thyrotropin Incretion in Confirmed Open-loop Situation. A Correlation Study,NOMOTHETICOS: Nonlinear Modelling of Thyroid Hormones' Effect on Thyrotropin Incretion in Confirmed Open-loop Situation,Hyperthyroidism|Hypothyroidism,2010-06-14,2018-07-31,2021-01-31,Observational,Active not recruiting,,Ruhr University of Bochum,Ruhr University of Bochum,"Klinikum Ludwigsburg-Bietigheim|Institute for diagnostical radiology, interventional radiology and nuclear medicine, Bergmannsheil University Hospitals, Ruhr University of Bochum|Medical Hospital I, Bergmannsheil University Hospitals, Ruhr University of Bochum",,Germany,14.0,120.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01145040
NCT01145040,hypothyroidism,NOMOTHETICOS: Nonlinear Modelling of Thyroid Hormones' Effect on Thyrotropin Incretion in Confirmed Open-loop Situation. A Correlation Study,NOMOTHETICOS: Nonlinear Modelling of Thyroid Hormones' Effect on Thyrotropin Incretion in Confirmed Open-loop Situation,Hyperthyroidism|Hypothyroidism,2010-06-14,2018-07-31,2021-01-31,Observational,Active not recruiting,,Ruhr University of Bochum,Ruhr University of Bochum,"Klinikum Ludwigsburg-Bietigheim|Institute for diagnostical radiology, interventional radiology and nuclear medicine, Bergmannsheil University Hospitals, Ruhr University of Bochum|Medical Hospital I, Bergmannsheil University Hospitals, Ruhr University of Bochum",,Germany,14.0,120.0,[0-17]|[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01145040
NCT01150318,thyroid neoplasms,Study of the Testicular Function After Iodine 131 Therapy in Patients With Papillary Carcinoma,Testicular Function After Iodine 131 Therapy in Papillary Carcinoma Patients,Thyroid Neoplasms,2010-04-29,2010-06-30,2010-06-30,Interventional,Completed,Not Applicable,Assistance Publique - Hôpitaux de Paris,Assistance Publique - Hôpitaux de Paris,"Saint Antoine Hospital, Endocrinology Unit",Drug,France,18.0,55.0,[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01150318
NCT01153945,thyroid cancer,Association Between Cancer Cells and Normal Vs. Low Levels of Thyroid Hormones in the Serum,Association Between Cancer Cells and Normal Versus (Vs.) Low Levels of Thyroid Hormones in the Serum,Thyroid Cancer,2010-06-29,2011-07-31,2011-07-31,Observational,Withdrawn,,Meir Medical Center,Meir Medical Center,Meir Medical Center,,Israel,20.0,80.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01153945
NCT01163565,thyroid nodule,A Prospective Randomized Equivalence Trial to Evaluate the Safety of the Ligasure in Thyroid Surgery,A Prospective Randomized Equivalence Trial to Evaluate the Safety of the Ligasure in Thyroid Surgery,Grave's Disease|Multinodular Goitre|Thyroid Nodule,2010-07-14,2012-09-30,2012-12-31,Interventional,Completed,Not Applicable,University of Alberta,Medtronic - MITG|University of Alberta,Walter C Mackenzie Health Sciences Centre,Device,Canada,18.0,85.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT01163565
NCT01163669,hyperparathyroidism,A Prospective Cohort Study to Describe the Evolution of Persistent Hyperparathyroidism in Kidney Transplant Recipients,A Prospective Cohort Study to Describe the Evolution of Persistent Hyperparathyroidism in Kidney Transplant Recipients,Hyperparathyroidism,2010-07-14,2012-11-30,2012-11-30,Observational,Completed,,The Cleveland Clinic,Amgen|The Cleveland Clinic,Cleveland Clinic,,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01163669
NCT01173289,thyroid cancer,A Phase II Study of External Beam Radiotherapy for Locoregionally Advanced or Recurrent Differentiated Thyroid Carcinoma,Study of External Beam Radiotherapy to Thyroid Carcinoma,Thyroid Cancer,2010-07-22,2015-08-31,2015-08-31,Interventional,Completed,Phase 2,"National Cancer Center, Korea","National Cancer Center, Korea","National Cancer Center, Korea",Radiation,"Korea, Republic of",18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01173289
NCT01191762,hyperparathyroidism,The Effect of Sevelamer Carbonate on Critical Variables in the Pathogenesis of Secondary Hyperparathyroidism,Sevelamer and Secondary Hyperparathyroidism in Chronic Kidney Disease,Chronic Kidney Disease|Hyperparathyroidism,2010-08-27,2012-08-31,2013-04-30,Interventional,Completed,Phase 3,"Phelps, Kenneth R., M.D.","Genzyme, a Sanofi Company|Kenneth R. Phelps, M.D.",Stratton Veterans Affairs Medical Center,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01191762
NCT01197183,hypothyroidism,Survey for the Initial Treatment of Hypothyroidism in France,"Observational Study With Prospective and/or Retrospective Follow-up, Without Modifying Patient Treatment and Follow-up Practices for the Initial Treatment of Hypothyroidism in France",Hypothyroidism,2010-08-18,2009-05-31,2009-09-30,Observational,Completed,,"Merck KGaA, Darmstadt, Germany","Merck KGaA, Darmstadt, Germany",Merck Lipha Santé Laboratories,,France,35.0,60.0,[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01197183
NCT01199614,hypoparathyroidism,"HEXT: The Hypoparathyroidism Studies, EXTended: The Effect of PTH on the Skeleton in Hypoparathyroidism",HEXT (Hypo EXTended): Effect of PTH on Skeleton in Hypoparathyroidism,Hypoparathyroidism,2010-09-09,2020-12-31,2020-12-31,Interventional,Unknown status,Phase 3,Columbia University,John P. Bilezikian|NPS Pharma|Shire,Columbia University Medical Center,Drug,United States,18.0,85.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01199614
NCT01204359,hypothyroidism,"""5010 Clinical Research Programme""of Sun Yat-sen University",The Prospective Study of Standard Treatment of Graves Disease Iodine 131 and Prevention of Adverse Reactions,Exophthalmos|Hypothyroidism,2010-09-15,2016-07-31,2016-12-31,Interventional,Unknown status,Phase 3,Sun Yat-sen University,Sun Yat-sen University,Sun Yat-sen Memorial Hospital|Ningyi Jiang,Radiation,China,8.0,90.0,[0-17]|[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01204359
NCT01221896,hyperparathyroidism,,Input of C11-Choline PET/CT in Localization of Parathyroid Adenoma,Hyperparathyroidism,2010-10-14,2014-01-31,,Observational,Unknown status,,Hadassah Medical Organization,Hadassah Medical Organization,Hadassah Hebrew University Medical Center,Procedure,Israel,18.0,80.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01221896
NCT01223638,congenital hypothyroidism,,The Prevalence of Hearing Loss Among Children With Congenital Hypothyroidism,Congenital Hypothyroidism|Hearing Loss,2010-10-03,2012-12-31,2015-06-30,Observational,Withdrawn,,"HaEmek Medical Center, Israel","HaEmek Medical Center, Israel",Ha'Emek Medical Center,Other,Israel,2.0,30.0,[0-17]|[18-65],Hypothyroidism,Congenital hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01223638
NCT01226810,hyperparathyroidism,A Novel Approach to Ultrafast Parathyroid SPECT Imaging Using a Solid State CZT SPECT Camera,The Novel Approach of Minimally Invasive Parathyroid Surgery Requires Precise Identification and Localization of the Lesion Prior to Exploration,Hypercalcemia|Hyperparathyroidism,2010-10-21,,,Observational,Unknown status,,Rambam Health Care Campus,Rambam Health Care Campus,Rambam Healthcare Campus,,Israel,18.0,75.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01226810
NCT01226914,goiter,"A Randomized, Double-Blind, Placebo-Controlled Trial Comparing Wound Drainage and Post-operative Complications With and Without the Use of EVICEL™ Fibrin Sealant in Thyroidectomy",A Trial Comparing Wound Drainage and Post-operative Complications With and Without the Use of EVICEL™ Fibrin Sealant in Thyroidectomy,Goiter|Thyroid Neoplasm,2010-10-21,2014-07-31,2014-07-31,Interventional,Completed,Not Applicable,Medical University of South Carolina,"Ethicon, Inc.|Medical University of South Carolina",,Drug,,18.0,99.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01226914
NCT01227499,thyrotoxicosis,Differential Diagnosis Value of Peak Systolic Velocity of Thyroid Superior Artery Using Color Flow Doppler Sonography in Transient Thyrotoxicosis Caused by Thyroiditis and Graves Disease,Differential Diagnosis of STA-PSV in Thyrotoxicosis,Graves Disease|Peak Systolic Velocity of Superior Thyroid Artery|Thyroiditis|Thyrotoxicosis,2010-10-22,2011-11-30,2011-11-30,Observational,Completed,,Huashan Hospital,Fudan University|xiaolong zhao|Zhongda Hospital,Xiaolong Zhao,,China,15.0,85.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01227499
NCT01227499,graves disease,Differential Diagnosis Value of Peak Systolic Velocity of Thyroid Superior Artery Using Color Flow Doppler Sonography in Transient Thyrotoxicosis Caused by Thyroiditis and Graves Disease,Differential Diagnosis of STA-PSV in Thyrotoxicosis,Graves Disease|Peak Systolic Velocity of Superior Thyroid Artery|Thyroiditis|Thyrotoxicosis,2010-10-22,2011-11-30,2011-11-30,Observational,Completed,,Huashan Hospital,Fudan University|xiaolong zhao|Zhongda Hospital,Xiaolong Zhao,,China,15.0,85.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT01227499
NCT01227499,thyroiditis,Differential Diagnosis Value of Peak Systolic Velocity of Thyroid Superior Artery Using Color Flow Doppler Sonography in Transient Thyrotoxicosis Caused by Thyroiditis and Graves Disease,Differential Diagnosis of STA-PSV in Thyrotoxicosis,Graves Disease|Peak Systolic Velocity of Superior Thyroid Artery|Thyroiditis|Thyrotoxicosis,2010-10-22,2011-11-30,2011-11-30,Observational,Completed,,Huashan Hospital,Fudan University|xiaolong zhao|Zhongda Hospital,Xiaolong Zhao,,China,15.0,85.0,[0-17]|[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT01227499
NCT01236547,thyroid gland anaplastic carcinoma,"A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer",Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer,Thyroid Gland Anaplastic Carcinoma,2010-11-05,2020-03-09,,Interventional,Active not recruiting,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI)|NRG Oncology,University of Alabama at Birmingham Cancer Center|The Kirklin Clinic at Acton Road|Cancer Center at Saint Joseph's|Saint Joseph's Hospital and Medical Center|Arizona Oncology-Deer Valley Center|Arizona Oncology Services Foundation|Sutter Cancer Centers Radiation Oncology Services-Auburn|Alta Bates Summit Medical Center-Herrick Campus|Mills-Peninsula Medical Center|Sutter Cancer Centers Radiation Oncology Services-Cameron Park|Eden Hospital Medical Center|Sutter Cancer Centers Radiation Oncology Services-Roseville|Sutter Medical Center Sacramento|California Pacific Medical Center-Pacific Campus|UCSF Medical Center-Mount Zion|UCSF Medical Center-Parnassus|Sutter Cancer Centers Radiation Oncology Services-Vacaville|Sutter Solano Medical Center/Cancer Center|Christiana Gynecologic Oncology LLC|Delaware Clinical and Laboratory Physicians PA|Helen F Graham Cancer Center|Medical Oncology Hematology Consultants PA|Christiana Care Health System-Christiana Hospital|Beebe Health Campus|Christiana Care Health System-Wilmington Hospital|Mayo Clinic in Florida|Moffitt Cancer Center|Emory University Hospital Midtown|Emory University Hospital/Winship Cancer Institute|Radiation Oncology Associates PC|Parkview Hospital Randallia|University of Kansas Cancer Center|The James Graham Brown Cancer Center at University of Louisville|Mary Bird Perkins Cancer Center|Touro Infirmary|Greater Baltimore Medical Center|Sinai Hospital of Baltimore|Boston Medical Center|Henry Ford Cancer Institute-Downriver|Henry Ford Macomb Hospital-Clinton Township|Henry Ford Medical Center-Fairlane|Henry Ford Hospital|West Michigan Cancer Center|Henry Ford Medical Center-Columbus|Henry Ford West Bloomfield Hospital|Fairview Ridges Hospital|Mercy Hospital|Fairview Southdale Hospital|Unity Hospital|Minnesota Oncology Hematology PA-Maplewood|Abbott-Northwestern Hospital|Hennepin County Medical Center|North Memorial Medical Health Center|Mayo Clinic in Rochester|Metro Minnesota Community Oncology Research Consortium|Park Nicollet Clinic - Saint Louis Park|Regions Hospital|United Hospital|Ridgeview Medical Center|Rice Memorial Hospital|University of Mississippi Medical Center|Billings Clinic Cancer Center|Memorial Sloan Kettering Basking Ridge|New York-Presbyterian/Brooklyn Methodist Hospital|Memorial Sloan Kettering Commack|Memorial Sloan Kettering Westchester|Memorial Sloan Kettering Cancer Center|Memorial Sloan Kettering Sleepy Hollow|Memorial Sloan Kettering Nassau|UNC Lineberger Comprehensive Cancer Center|Summa Health System - Akron Campus|Summa Health System - Barberton Campus|University of Cincinnati Cancer Center-UC Medical Center|Case Western Reserve University|Cleveland Clinic Foundation|Ohio State University Comprehensive Cancer Center|Mercy Cancer Center-Elyria|Summa Health Medina Medical Center|UH Seidman Cancer Center at Lake Health Mentor Campus|UH Seidman Cancer Center at Southwest General Hospital|University Hospitals Parma Medical Center|UH Seidman Cancer Center at Firelands Regional Medical Center|University of Cincinnati Cancer Center-West Chester|University of Oklahoma Health Sciences Center|UPMC-Heritage Valley Health System Beaver|UPMC Cancer Centers - Arnold Palmer Pavilion|Penn State Milton S Hershey Medical Center|UPMC-Johnstown/John P. Murtha Regional Cancer Center|UPMC Cancer Center at UPMC McKeesport|UPMC-Coraopolis/Heritage Valley Radiation Oncology|UPMC Cancer Center-Natrona Heights|UPMC Jameson|Thomas Jefferson University Hospital|UPMC-Presbyterian Hospital|UPMC-Saint Margaret|UPMC-Shadyside Hospital|UPMC Jefferson Regional Radiation Oncology|UPMC-Passavant Hospital|UPMC-Saint Clair Hospital Cancer Center|UPMC Cancer Center at UPMC Northwest|UPMC Uniontown Hospital Radiation Oncology|UPMC Washington Hospital Radiation Oncology|Prisma Health Cancer Institute - Spartanburg|Prisma Health Cancer Institute - Faris|Prisma Health Cancer Institute - Eastside|Prisma Health Cancer Institute - Greer|Prisma Health Cancer Institute - Seneca|Parkland Memorial Hospital|UT Southwestern/Simmons Cancer Center-Dallas|M D Anderson Cancer Center|American Fork Hospital / Huntsman Intermountain Cancer Center|Sandra L Maxwell Cancer Center|Logan Regional Hospital|Intermountain Medical Center|McKay-Dee Hospital Center|Utah Valley Regional Medical Center|Dixie Medical Center Regional Cancer Center|Utah Cancer Specialists-Salt Lake City|LDS Hospital|Sentara Cancer Institute at Sentara CarePlex Hospital|Sentara Norfolk General Hospital|Sentara Virginia Beach General Hospital|Green Bay Oncology at Saint Vincent Hospital|Saint Vincent Hospital Cancer Center Green Bay|Green Bay Oncology Limited at Saint Mary's Hospital|Saint Vincent Hospital Cancer Center at Saint Mary's|University of Wisconsin Carbone Cancer Center|Holy Family Memorial Hospital|Bay Area Medical Center|Medical College of Wisconsin,Radiation|Drug|Drug|Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT01236547
NCT01240590,anaplastic thyroid cancer,A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC),A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC),Anaplastic Thyroid Cancer|Solid Tumor,2010-11-11,2015-08-31,2016-12-31,Interventional,Completed,Phase 1/Phase 2,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),"National Institutes of Health Clinical Center, 9000 Rockville Pike",Drug|Drug,United States,18.0,90.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT01240590
NCT01263951,differentiated thyroid cancer,A Phase II Study of Everolimus and Sorafenib in Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Sorafenib Alone,Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone,Differentiated Thyroid Cancer,2010-11-29,2021-02-01,2022-05-31,Interventional,Active not recruiting,Phase 2,Thomas Jefferson University,Bayer|Novartis Pharmaceuticals|Thomas Jefferson University,Hospital of the University of Pennsylvania,Drug|Drug,United States,18.0,89.0,[18-65]|[65 and more],Thyroid neoplasms,"Differentiated thyroid cancer, all",https://clinicaltrials.gov/ct2/show/NCT01263951
NCT01265381,thyroid cancer,Thyroid Cancer Among Chornobyl Clean-up Workers in Ukraine: Pilot Study,Thyroid Cancer Among Chornobyl Clean-up Workers in Ukraine: Pilot Study,Thyroid Cancer,2010-12-22,2020-02-26,2020-02-26,Observational,Terminated,,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),Research Center for Radiation Medicine,,Ukraine,18.0,65.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01265381
NCT01268098,hypoparathyroidism,"A Randomized, Dose-blinded Study to Investigate the Safety and Efficacy of NPSP558, a Recombinant Human Parathyroid Hormone [rhPTH(1-84)], at Fixed Doses of 25 µg and 50 µg for the Treatment of Adults With Hypoparathyroidism",Study of Safety and Efficacy of a rhPTH[1-84] of Fixed Doses of 25 and 50 mcg in Adults With Hypoparathyroidism (RELAY),Hypoparathyroidism,2010-12-28,2011-09-23,2011-11-11,Interventional,Completed,Phase 3,Takeda,Shire,Advance Medical Research LLC|University of Chicago Medical Center|Indiana University School of Medicine|Massachusetts General Hospital|Michigan Bone & Mineral Clinic PC|Mayo Clinic Rochester|Columbia University Medical Center|University Physicians Group|Physician East PA|University of Cincinnati Bone Health and Osteoporosis Center|Cetero Research DGD Research Inc.|The Vancouver Clinic,Drug,United States,18.0,85.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01268098
NCT01270321,thyroid cancer,A 3-Arm Randomized Phase II Trial Evaluating Single Agent and Combined Efficacy of Pasireotide and Everolimus in Adult Patients With Radioiodine-Refractory Differentiated and Medullary Thyroid Cancer,Pasireotide & Everolimus in Adult Patients With Radioiodine-Refractory Differentiated & Medullary Thyroid Cancer,Thyroid Cancer,2011-01-04,2019-02-28,2019-02-28,Interventional,Completed,Phase 2,Emory University,Emory University|Novartis,Emory University Hospital Midtown|Emory University Winship Cancer Institute|University of Pittsburgh Cancer Institute,Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01270321
NCT01272414,graves ophthalmopathy,,Use of Botox in the Management of Thyroid Related Upper Eyelid Retraction,Graves Ophthalmopathy,2011-01-06,2012-01-31,2012-02-29,Interventional,Withdrawn,Phase 4,University of Toronto,Allergan|University of Toronto,Mount Sinai Hospital,Drug|Drug,Canada,18.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT01272414
NCT01273714,goiter,Subtotal Versus Total Thyroidectomy for Benign Thyroid Disease - a Prospective Case-control Surgical Outcome Study.,Subtotal Versus Total Thyroidectomy for Benign Goiter,Goiter,2011-01-07,2004-12-31,2009-12-31,Interventional,Completed,Not Applicable,Jagiellonian University,Jagiellonian University,"Jagiellonian Univerity, Medical College, 3rd Department of general Surgery",Procedure,Poland,18.0,65.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01273714
NCT01277510,hyperparathyroidism,"A Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of Cinacalcet HCl in Pediatric Subjects With Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Dialysis",Pediatric Chronic Kidney Disease Safety and Efficacy,"Chronic Kidney Disease|Hyperparathyroidism|Hyperparathyroidism, Secondary|Kidney Disease|Secondary Hyperparathyroidism",2011-01-13,2014-04-30,,Interventional,Terminated,Phase 3,Amgen,Amgen,Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug|Drug|Drug,Australia|Belgium|Germany|Hungary|Mexico|Poland|Russian Federation|Slovakia|Spain|United States,6.0,17.0,[0-17],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01277510
NCT01280214,thyroid disease,Peribulbar and Subconjunctival Kenalog Injection for Thyroid Orbitopathy,Local Triamcinolone Injection in Active Thyroid Orbitopathy,Thyroid Disease,2011-01-15,2013-02-28,2013-02-28,Interventional,Unknown status,Not Applicable,"HaEmek Medical Center, Israel","HaEmek Medical Center, Israel",,Drug,,18.0,120.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT01280214
NCT01280292,central hypothyroidism,"Central Hypothyroidism,a New Laboratory Approach for Hormone Measurement","Central Hypothyroidism, a Novel Laboratory Measurement",Central Hypothyroidism,2011-01-19,2013-02-28,2013-07-31,Interventional,Unknown status,Not Applicable,Sheba Medical Center,Sheba Medical Center,,Drug,,18.0,90.0,[18-65]|[65 and more],Hypothyroidism,Secondary hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01280292
NCT01292044,thyroid neoplasms,The Role of Elastography in the Diagnosis of Thyroid Nodules,The Role of Elastography in the Diagnosis of Thyroid Nodules,Thyroid Neoplasms|Thyroid Nodule,2011-02-08,2014-08-31,2014-08-31,Interventional,Completed,Not Applicable,Centre Hospitalier Universitaire de Nīmes,Centre Hospitalier Universitaire de Nīmes,CHU de Nîmes - Hôpital Universitaire Carémeau,Other,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01292044
NCT01292044,thyroid nodule,The Role of Elastography in the Diagnosis of Thyroid Nodules,The Role of Elastography in the Diagnosis of Thyroid Nodules,Thyroid Neoplasms|Thyroid Nodule,2011-02-08,2014-08-31,2014-08-31,Interventional,Completed,Not Applicable,Centre Hospitalier Universitaire de Nīmes,Centre Hospitalier Universitaire de Nīmes,CHU de Nîmes - Hôpital Universitaire Carémeau,Other,France,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT01292044
NCT01297309,hypoparathyroidism,"A Long-term Open-label Study Investigating the Safety and Tolerability of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH[1-84]), for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study (RACE)","A Open-label Study Investigating the Safety and Tolerability of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH [1-84]), for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study (RACE)",Hypoparathyroidism,2011-02-11,2018-06-08,2018-06-08,Interventional,Completed,Phase 3,Takeda,Shire,Advance Medical Research LLC|Mayo Clinic Jacksonville|University of Chicago Medical Center|Indiana University School of Medicine|Massachusetts General Hospital|Michigan Bone & Mineral Clinic PC|Mayo Clinic Rochester|Columbia University Medical Center|University Physicians Group|Physician East PA|University of Cincinnati Bone Health and Osteoporosis Center|Children's Hospital of Philadelphia|Cetero Research DGD Research Inc.|The Vancouver Clinic,Drug,United States,18.0,85.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01297309
NCT01297699,thyroid eye disease,"Clinical Trial Phase III, Parallel Group, Randomized, Placebo-controlled, Double-blind, Multicenter Study to Evaluate the Efficacy and Safety of Tocilizumab Administration in Patients With Moderate-to-severe or Sight-threatening Graves' Ophthalmopathy (GO), That Had Not Responded Adequately to Treatment With Intravenous Corticoid Pulses.",Tocilizumab Treatment in Graves´ Ophthalmopathy (Graves´ Orbitopathy or Thyroid Eye Disease),Graves´ Ophthalmopathy|Thyroid Associated Ophthalmopathies|Thyroid Eye Disease,2011-02-16,2015-10-31,2015-12-31,Interventional,Completed,Phase 3,Hospital Clinico Universitario de Santiago,Fundación Ramón Domínguez|Hospital Clinico Universitario de Santiago,Hospital Clínico de Santiago|Hospital Santa Creu i Sant Pau|Hospital Clínico San Carlos|Hospital Universitario Ramón y Cajal|Centro Oftalmológico Moreiras|Hospital Universitario Virgen del Rocío|Hospital Universitario Virgen Macarena|Hospital Universitario La Fe|Hospital Clínico Universitario Lozano Blesa,Drug|Drug,Spain,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT01297699
NCT01298323,medullary thyroid cancer,"A Randomized,Int.,Open-Label Phase III Study to Assess the Effect of a Patient Outreach Program on the Percentage of Time Patients With Locally Advanced or Metastatic MTC Experience Grade 2 or Higher AEs in the First 12 Months of Treatment With Vandetanib",Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment,Locally Advanced or Metastatic Medullary Thyroid Cancer|Medullary Thyroid Cancer,2011-02-16,2013-04-30,2022-12-31,Interventional,Active not recruiting,Phase 3,Sanofi,"Genzyme, a Sanofi Company",Investigational Site Number 301|Investigational Site Number 401|Investigational Site Number 501|Investigational Site Number 701|Investigational Site Number 702|Investigational Site Number 901|Investigational Site Number 1001|Investigational Site Number 1002|Investigational Site Number 1003|Investigational Site Number 1301|Investigational Site Number 1302|Investigational Site Number 1901|Investigational Site Number 2001|Investigational Site Number 2201|Investigational Site Number 2602|Investigational Site Number 2603|Investigational Site Number 2601|Investigational Site Number 3001|Investigational Site Number 3501|Investigational Site Number 3502|Investigational Site Number 4001|Investigational Site Number 4104|Investigational Site Number 4101|Investigational Site Number 4102|Investigational Site Number 6001|Investigational Site Number 5702|Investigational Site Number 5703|Investigational Site Number 6201|Investigational Site Number 6204|Investigational Site Number 6202|Investigational Site Number 6203|Investigational Site Number 7201|Investigational Site Number 2802|Investigational Site Number 2801,Behavioral|Drug,"Australia|Austria|Belgium|Brazil|Bulgaria|Canada|China|Czechia|Denmark|Finland|Germany|Greece|India|Israel|Italy|Korea, Republic of|Poland|Russian Federation|Sweden|United Kingdom",18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, medullary",https://clinicaltrials.gov/ct2/show/NCT01298323
NCT01306916,hyperthyroidism,Coexisting Thyroid Disease and Hyperparathyroidism,Coexisting Thyroid Disease and Hyperparathyroidism,Hyperthyroidism,2011-01-12,2010-12-31,2012-07-31,Observational,Completed,,Walter Reed Army Medical Center,Walter Reed Army Medical Center,Walter Reed Army Medical Center,,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01306916
NCT01307761,thyroid cancer,An Easy Sonographic Scoring System for Predicting Malignant Thyroid Nodules,An Easy Sonographic Scoring System for Predicting Malignant Thyroid Nodules,Thyroid Cancer,2011-02-21,2012-12-31,2013-08-31,Observational,Unknown status,,Far Eastern Memorial Hospital,Far Eastern Memorial Hospital,Far Eastern Memorial Hospital,,Taiwan,18.0,90.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01307761
NCT01311089,papillary thyroid carcinoma,A Comparative Study of Robotic Thyroidectomy Using Transaxillary Approach Versus Conventional Open Thyroidectomy : Postoperative Body Image Change and Cosmetic Satisfaction,A Comparative Study of Robotic Thyroidectomy Using Transaxillary Approach Versus Conventional Open Thyroidectomy,Papillary Thyroid Carcinoma,2011-03-08,2011-09-30,2011-09-30,Observational,Completed,,Yonsei University,Yonsei University,Severance Hospital,,"Korea, Republic of",20.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT01311089
NCT01320813,graves disease,Randomized Trial Comparing Complication Rates Associated With Robot-assisted Thyroidectomy to External Thyroidectomy,Trial Comparing Complication Rates Associated With Robot-assisted Thyroidectomy to External Thyroidectomy,Goiter|Graves Disease|Thyroiditis|Thyroid Nodule,2011-03-22,2013-09-30,2013-09-30,Interventional,Terminated,Not Applicable,Centre Hospitalier Universitaire de Nīmes,Centre Hospitalier Universitaire de Nīmes,CHU de Nîmes - Hôpital Universitaire Carémeau,Procedure|Procedure,France,18.0,85.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT01320813
NCT01320813,thyroiditis,Randomized Trial Comparing Complication Rates Associated With Robot-assisted Thyroidectomy to External Thyroidectomy,Trial Comparing Complication Rates Associated With Robot-assisted Thyroidectomy to External Thyroidectomy,Goiter|Graves Disease|Thyroiditis|Thyroid Nodule,2011-03-22,2013-09-30,2013-09-30,Interventional,Terminated,Not Applicable,Centre Hospitalier Universitaire de Nīmes,Centre Hospitalier Universitaire de Nīmes,CHU de Nîmes - Hôpital Universitaire Carémeau,Procedure|Procedure,France,18.0,85.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT01320813
NCT01320813,goiter,Randomized Trial Comparing Complication Rates Associated With Robot-assisted Thyroidectomy to External Thyroidectomy,Trial Comparing Complication Rates Associated With Robot-assisted Thyroidectomy to External Thyroidectomy,Goiter|Graves Disease|Thyroiditis|Thyroid Nodule,2011-03-22,2013-09-30,2013-09-30,Interventional,Terminated,Not Applicable,Centre Hospitalier Universitaire de Nīmes,Centre Hospitalier Universitaire de Nīmes,CHU de Nîmes - Hôpital Universitaire Carémeau,Procedure|Procedure,France,18.0,85.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01320813
NCT01320813,thyroid nodule,Randomized Trial Comparing Complication Rates Associated With Robot-assisted Thyroidectomy to External Thyroidectomy,Trial Comparing Complication Rates Associated With Robot-assisted Thyroidectomy to External Thyroidectomy,Goiter|Graves Disease|Thyroiditis|Thyroid Nodule,2011-03-22,2013-09-30,2013-09-30,Interventional,Terminated,Not Applicable,Centre Hospitalier Universitaire de Nīmes,Centre Hospitalier Universitaire de Nīmes,CHU de Nîmes - Hôpital Universitaire Carémeau,Procedure|Procedure,France,18.0,85.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT01320813
NCT01321554,thyroid cancer,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)",Thyroid Cancer,2011-03-10,2013-11-15,2019-03-19,Interventional,Completed,Phase 3,Eisai Inc.,Eisai Inc.,Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 2|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 2|Facility 1|Facility 1|Facility 1|Facility 1|Facility 2|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 2|Facility 1|Facility 1|Facility 1|Facility 2|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 2|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 2|Facility 3|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 2|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 2|Facility 3|Facility 4|Facility 5|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 2|Facility 1|Facility 1|Facility 1|Eisai Trial Site 1|Eisai Trial Site 2|Eisai Trial Site 1|Eisai Trial Site 1|Eisai Trial Site 1|Eisai Trial Site 1|Facility 1|Facility 1|Facility 1|Facility 2|Facility 3|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 2|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 2|Facility 1|Facility 1|Facility 2|Facility 1|Facility 1|Facility 2|Facility 3|Facility 4|Facility 5|Facility 1|Facility 1|Facility 1|Facility 1|Facility 2|Facility 1|Facility 1|Facility 1|Facility 1|Facility 1|Facility 2|Facility 3|Facility 1|Facility 2|Facility 1|Facility 1,Drug|Drug|Drug,"Argentina|Australia|Austria|Belgium|Brazil|Canada|Chile|Czechia|Denmark|France|Germany|Italy|Japan|Korea, Republic of|Poland|Portugal|Romania|Russian Federation|Spain|Sweden|Thailand|United Kingdom|United States",18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01321554
NCT01325857,thyroid cancer,Analgesic Efficacy of Bilateral Superficial Cervical Plexus Block in Robot-assisted Endoscopic Thyroidectomy Using a Transaxillary Approach,Analgesic Efficacy of Bilateral Superficial Cervical Plexus Block in Robot-assisted Endoscopic Thyroidectomy Using a Transaxillary Approach,Thyroid Cancer,2011-03-28,2012-02-29,2012-02-29,Interventional,Completed,Not Applicable,Yonsei University,Yonsei University,Severance Hospital,Procedure|Procedure|Procedure,"Korea, Republic of",20.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01325857
NCT01333267,hyperparathyroidism,Comparison of Skeletal and Mineral Metabolism Responses in Healthy African-Americans and Caucasians Using a Continuous Seven-Day Parathyroid Hormone (PTH) or Parathyroid Hormone-related Protein (PTHrP) Infusion,One Week Comparison Study of PTH and PTHrP Infusions,"Bone Diseases, Endocrine|Hypercalcemia of Malignancy|Hyperparathyroidism|Osteoporosis",2011-04-08,2017-07-31,2017-07-31,Interventional,Withdrawn,Phase 1,University of Pittsburgh,University of Pittsburgh,University of Pittsburgh Medical Center,Drug|Drug|Drug,United States,24.0,35.0,[18-65],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01333267
NCT01338597,thyroid tumor,Clinical Benefits of Reduced Subcutaneous Dissection in Endoscopic Thyroidectomy,Impact of Dissection Area on the Clinical Outcome of Endoscopic Thyroidectomy,Thyroid Tumor,2011-04-11,2011-12-31,2012-06-30,Interventional,Unknown status,Not Applicable,Second Military Medical University,Second Military Medical University,"Department of General Surgery, Changzheng Hospital",Procedure,China,18.0,50.0,[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01338597
NCT01349634,cretinism,A Study to Measure the Effect of Switching the Salt Supply From Non-iodized to Iodized on Cognitive Development in Ethiopia,The Effects of Iodized Salt on Cognitive Development in Ethiopia,Cretinism|Goiter|Iodine Deficiency,2011-04-20,2014-05-31,2014-05-31,Interventional,Completed,Not Applicable,McGill University,Ethiopian Health and Nutrition Research Institute|McGill University|Micronutrient Initiative,McGill University,Other,Canada,5.0,61.0,[0-17]|[18-65],Hypothyroidism,Congenital hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01349634
NCT01349634,goiter,A Study to Measure the Effect of Switching the Salt Supply From Non-iodized to Iodized on Cognitive Development in Ethiopia,The Effects of Iodized Salt on Cognitive Development in Ethiopia,Cretinism|Goiter|Iodine Deficiency,2011-04-20,2014-05-31,2014-05-31,Interventional,Completed,Not Applicable,McGill University,Ethiopian Health and Nutrition Research Institute|McGill University|Micronutrient Initiative,McGill University,Other,Canada,5.0,61.0,[0-17]|[18-65],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01349634
NCT01354639,papillary thyroid carcinoma,Comparative Study of Surgical Completeness After Robotic Thyroidectomy Versus Conventional Open Thyroidectomy,Comparative Study of Surgical Completeness After Robotic Thyroidectomy Versus Conventional Open Thyroidectomy,Papillary Thyroid Carcinoma,2011-05-13,2011-10-31,2011-10-31,Observational,Completed,,Yonsei University,Yonsei University,Severance Hospital,,"Korea, Republic of",20.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT01354639
NCT01358136,hypothyroidism,ThyrOp: Individual Subclinical Hypothyroidism After Hemithyroidectomy for Benign Nontoxic Goiter - Focus on Weight Gain and Mitochondrial Dysfunction,ThyrOp: A Study of Individual Subclinical Hypothyroidism After Hemithyroidectomy for Benign Nontoxic Goiter,Goiter|Hypothyroidism|Weight Gain,2011-05-18,2012-08-31,2013-12-31,Observational,Unknown status,,Naestved Hospital,"Denmark:Department of Otorhinolaryngology Slagelse Hospital, Hospital South|Naestved Hospital|Region Zealand","Slagelse Hospital, Hospital South",,Denmark,18.0,75.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01358136
NCT01358136,goiter,ThyrOp: Individual Subclinical Hypothyroidism After Hemithyroidectomy for Benign Nontoxic Goiter - Focus on Weight Gain and Mitochondrial Dysfunction,ThyrOp: A Study of Individual Subclinical Hypothyroidism After Hemithyroidectomy for Benign Nontoxic Goiter,Goiter|Hypothyroidism|Weight Gain,2011-05-18,2012-08-31,2013-12-31,Observational,Unknown status,,Naestved Hospital,"Denmark:Department of Otorhinolaryngology Slagelse Hospital, Hospital South|Naestved Hospital|Region Zealand","Slagelse Hospital, Hospital South",,Denmark,18.0,75.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01358136
NCT01373736,medullary thyroid carcinoma,,123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors,Carcinoid Tumors|Medullary Thyroid Carcinoma|Neuroblastoma|Paraganglioma|Pheochromocytoma,2011-06-13,,,Interventional,Unknown status,Phase 3,Vancouver Coastal Health,Vancouver Coastal Health,Vancouver Coastal Health,Drug,Canada,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, medullary",https://clinicaltrials.gov/ct2/show/NCT01373736
NCT01374659,thyroid cancer,Effectiveness of [124I]-PET/CT and [18F]-FDG-PET/CT for Localizing Recurrence in Patients With Differentiated Thyroid Carcinoma Who Have Elevated Serum Thyroglobulin Levels But Are Tumor-negative on Conventional Imaging Studies,Diagnostic Utility of [18F]-FDG-PET/CT and [124I]-PET/CT for Detection of Recurrence in Differentiated Thyroid Carcinoma,Recurrence|Thyroid Cancer,2011-06-15,2011-06-30,2012-08-31,Observational,Unknown status,,Korean Association of Endocrine Surgeons,Korean Association of Endocrine Surgeons,Jandee Lee,,"Korea, Republic of",15.0,85.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01374659
NCT01376648,hyperthyroidism,Study on the Relationship Between the Thyroid Hormones and the Activity of Brown Adipose Tissue in Human,Thyroid Hormones Effect on Brown Adipose Tissue,Hyperthyroidism,2011-06-17,2012-05-31,2012-05-31,Observational,Unknown status,,Huashan Hospital,Huashan Hospital,Huashan Hospital,,China,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01376648
NCT01379170,hypothyroidism,"Effects of Thyroid Hormone Treatment on Mitochondrial Function, Ectopic Fat Accumulation, Insulin Sensitivity and Brown Adipose Tissue in Type 2 Diabetes Mellitus",Thyroid Study Type 2 Diabetes Mellitus (T2DM),Diabetes|Hypothyroidism,2011-06-21,2014-12-31,2014-12-31,Interventional,Unknown status,Phase 4,Maastricht University Medical Center,Maastricht University Medical Center,Maastricht University Medical Centre,Drug,Netherlands,40.0,65.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01379170
NCT01379196,graves ophthalmopathy,Use of Azithromycin as Immunomodulatory Therapy in Grave&Apos;s Orbitopathy,Use of Azithromycin as Immunomodulatory Therapy in Grave&Apos;s Orbitopathy,Graves Ophthalmopathy,2011-05-11,2014-11-30,2014-12-31,Interventional,Withdrawn,Phase 1/Phase 2,Rabin Medical Center,Rabin Medical Center,,Drug,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT01379196
NCT01384786,thyroid cancer,The Incidence of Thyroid Cancer in 4474 Patients Treated for Hyperthyroidism or Goiter,The Incidence of Thyroid Cancer in 4474 Patients Treated for Hyperthyroidism or Goiter,Hyperthyreosis and Goiter|Thyroid Cancer,2011-06-28,,2005-07-31,Observational,Completed,,Copenhagen University Hospital at Herlev,Copenhagen University Hospital at Herlev,herlev Hospital,,Denmark,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01384786
NCT01392222,thyroid cancer,Treatment Decision-Making Among Patients Diagnosed With Papillary Microcarcinoma and Their Significant Others,Treatment Decision-Making Among Patients Diagnosed With Papillary Microcarcinoma and Their Significant Others,Papillary Microcarcinoma|Thyroid Cancer,2011-06-29,2017-06-30,2017-06-30,Observational,Completed,,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Behavioral|Behavioral,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01392222
NCT01398085,thyroid cancer,Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients,IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients,Thyroid Cancer,2011-07-06,2023-03-31,2031-03-31,Interventional,Active not recruiting,Phase 2/Phase 3,"University College, London","Cancer Research UK|University College, London",University Hospitals Birmingham NHS Foundation Trust|Brighton and Sussex University Hospitals NHS Trust|University Hospital Bristol NHS Foundation Trust|Cambridge University Hospitals NHS Foundation Trust|East Kent Hospitals University NHS Foundation Trust|Mid Essex Hospitals Services NHS Trust|Gloucestershire Hospitals NHS Trust|Royal Derby hospital NHS foundation trust|NHS Lothian|Royal Devon and Exeter NHS Trust|Glasgow and Clyde NHS Trust|The Royal Surrey County Hospital NHS Foundation Trust|Ipswich Hospital NHS Trust|Leeds Teaching Hospitals NHS Trust|University Hospitals of Leicester NHS Trust|Royal Marsden NHS Foundation Trust|Imperial College Healthcare NHS Trust|Barts Health NHS Trust|Guys and St Thomas' NHS Foundation Trust|University College London Hospitals NHS Foundation Trust|Maidstone and Tunbridge Wells NHS Trust|The Christie NHS Foundation Trust|South Tees Hospitals NHS Trust|Velindre NHS Trust|Newcastle upon Tyne Hospitals NHS Foundation Trust|Norfolk and Norwich University Hospitals NHS Trust|Nottingham University Hospitals NHS Trust|Portsmouth Hospitals NHS Trust|Sheffield Teaching Hospitals NHS Foundation Trust|Southend University Hospitals NHS Trust|East and North Herts|Royal Wolverhampton NHS Trust,Radiation,United Kingdom,16.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01398085
NCT01403324,thyroid cancer,Comparison of Dosimetry Following Preparation With Either rhTSH or After Withdrawal of Thyroid Hormone Suppression Therapy in Patients With Metastatic or Locally Advanced Differentiated Thyroid Cancer,Comparison of Dosimetry After rhTSH or Withdrawal of Thyroid Hormone in Metastatic or Locally Advanced Thyroid Cancer,Metastases|Thyroid Cancer,2011-07-26,2016-06-30,2016-06-30,Interventional,Terminated,Not Applicable,"Gustave Roussy, Cancer Campus, Grand Paris","Gustave Roussy, Cancer Campus, Grand Paris",Institut Gustave Roussy,Drug,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01403324
NCT01408368,goiter,Five-year Follow up of a Randomized Clinical Trial of Bilateral Subtotal Thyroidectomy Versus Total Thyroidectomy for Graves' Disease.,Subtotal Versus Total Thyroidectomy for Graves' Disease,Goiter|Thyroid,2011-08-02,2009-12-31,2010-12-31,Interventional,Completed,Not Applicable,Jagiellonian University,Jagiellonian University,"Jagiellonian University, College of Medicine, Department of Endocrine Surgery, 3rd Chair of General Surgery",Procedure|Procedure,Poland,18.0,65.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01408368
NCT01412762,thyroid cancer,Measuring Patient Expectations for Thyroid Surgery: Development of a Patient-Reported Outcomes Instrument,Measuring Patient Expectations for Thyroid Surgery,Thyroid Cancer,2011-08-03,2024-07-31,2024-07-31,Observational,Active not recruiting,,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Behavioral|Behavioral,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01412762
NCT01413113,recurrent thyroid cancer,"A Phase I Clinical Trial of Pazopanib in Combination With Escalating Doses of Radioactive 131I in Patients With Well-Differentiated Thyroid Carcinoma Refractory to Radioiodine, Despite Having Some Uptake",Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery,Recurrent Thyroid Cancer|Stage IVA Follicular Thyroid Cancer|Stage IVA Papillary Thyroid Cancer|Stage IVB Follicular Thyroid Cancer|Stage IVB Papillary Thyroid Cancer|Stage IVC Follicular Thyroid Cancer|Stage IVC Papillary Thyroid Cancer,2011-07-20,2013-11-30,2015-10-31,Interventional,Completed,Phase 1,University of Washington,GlaxoSmithKline|National Cancer Institute (NCI)|National Comprehensive Cancer Network|University of Washington,Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium,Drug|Radiation,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Recurrent Thyroid Cancer,https://clinicaltrials.gov/ct2/show/NCT01413113
NCT01417442,papillary thyroid carcinoma,Association Of Prognosis And BRAF V600E Mutations In Papillary Thyroid Carcinoma,BRAF V600E Mutations In Papillary Thyroid Carcinoma,Papillary Thyroid Carcinoma,2011-07-06,2012-07-31,2012-07-31,Interventional,Unknown status,Early Phase 1,Bezmialem Vakif University,Bezmialem Vakif University,Yeliz Emine Ersoy,Genetic,Turkey,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT01417442
NCT01424878,medullary thyroid carcinoma,Study of Molecular Pathways in Medullary Thyroid Carcinoma (MTC) and Correlation of Molecular Data With Clinical Behavior of the MTC in Individuals Patients,Study of Molecular Pathways in Medullary Thyroid Carcinoma and Correlation of Molecular Data With Clinical Behavior of the MTC in Individuals Patients,Medullary Thyroid Carcinoma|Multiple Endocrine Neoplasia Type 2,2011-08-26,,2014-02-12,Observational,Completed,,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),"National Cancer Institute (NCI), 9000 Rockville Pike",,United States,2.0,80.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, medullary",https://clinicaltrials.gov/ct2/show/NCT01424878
NCT01428167,thyroid cancer,Is There Any Association Between Thyroid Cancer and Hashimotos Thyroiditis?,Hashimotos Thyroiditis and Thyroid Cancer,Hashimotos Thyroiditis|Thyroid Cancer,2011-08-10,2012-05-31,2012-05-31,Observational,Completed,,"The University of Texas Medical Branch, Galveston","The University of Texas Medical Branch, Galveston","University of Texas Medical Branch, Galveston , Endocrine Department",,United States,18.0,80.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01428167
NCT01433809,thyroid carcinoma,Biomarkers in Thyroid Cancer,Biomarkers to Distinguish Benign From Malignant Thyroid Neoplasm,"Cancer of the Thyroid|Neoplasms, Thyroid|Thyroid Adenoma|Thyroid Cancer|Thyroid Carcinoma",2011-09-12,2013-05-31,2013-05-31,Observational,Completed,,Mayo Clinic,Norman Eberhardt,Mayo Clinic in Rochester,,United States,18.0,90.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01433809
NCT01437254,thyroid neoplasms,A Phase I Study of Cyclotron-produced Tc-99m Pertechnetate (CPERT) in Patients With Thyroid Cancer,To Compare Safety and the General Imaging Pattern of Cyclotron Produced Technetium vs. Generator Produced Technetium in Patients With Thyroid Cancer,Thyroid Neoplasms,2011-09-19,2012-04-30,2015-01-31,Interventional,Completed,Phase 1,AHS Cancer Control Alberta,"AHS Cancer Control Alberta|Edmonton PET Centre|Natural Resources, Canada",Cross Cancer Institute,Drug|Drug,Canada,18.0,79.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01437254
NCT01438554,thyroid cancer,"Phase I Study Determining the Safety and Tolerability of Combination Therapy With Pazopanib, a VEGFR/PDGFR/Raf Inhibitor, and GSK1120212, a MEK Inhibitor, in Advanced Solid Tumors Enriched With Patients With Advanced Differentiated Thyroid Cancer, Soft Tissue Sarcoma, and Cholangiocarcinoma","Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma",Cholangiocarcinoma|Soft-tissue Sarcoma|Solid Tumors|Thyroid Cancer,2011-08-23,2016-04-30,2018-08-31,Interventional,Completed,Phase 1,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,National Comprehensive Cancer Network|Novartis|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|MD Anderson Cancer Center,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01438554
NCT01441154,tall cell variant thyroid cancer,Pharmacokinetic and Pharmacodynamic Studies of Liothyronine. A Study on the Metabolic Effects of Thyroid Hormone,Metabolic Effects of Synthetic Thyroid Hormone for Thyroid Cancer Treatment,Follicular Thyroid Cancer|Hurthle Cell Thyroid Cancer|Malignant Struma Ovarii|Papillary Thyroid Cancer|Tall Cell Variant Thyroid Cancer,2011-09-24,2013-12-12,2013-12-12,Observational,Completed,,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"National Institutes of Health Clinical Center, 9000 Rockville Pike",,United States,18.0,99.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT01441154
NCT01441154,follicular thyroid cancer,Pharmacokinetic and Pharmacodynamic Studies of Liothyronine. A Study on the Metabolic Effects of Thyroid Hormone,Metabolic Effects of Synthetic Thyroid Hormone for Thyroid Cancer Treatment,Follicular Thyroid Cancer|Hurthle Cell Thyroid Cancer|Malignant Struma Ovarii|Papillary Thyroid Cancer|Tall Cell Variant Thyroid Cancer,2011-09-24,2013-12-12,2013-12-12,Observational,Completed,,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"National Institutes of Health Clinical Center, 9000 Rockville Pike",,United States,18.0,99.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT01441154
NCT01441154,hurthle cell thyroid cancer,Pharmacokinetic and Pharmacodynamic Studies of Liothyronine. A Study on the Metabolic Effects of Thyroid Hormone,Metabolic Effects of Synthetic Thyroid Hormone for Thyroid Cancer Treatment,Follicular Thyroid Cancer|Hurthle Cell Thyroid Cancer|Malignant Struma Ovarii|Papillary Thyroid Cancer|Tall Cell Variant Thyroid Cancer,2011-09-24,2013-12-12,2013-12-12,Observational,Completed,,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"National Institutes of Health Clinical Center, 9000 Rockville Pike",,United States,18.0,99.0,[18-65]|[65 and more],Thyroid neoplasms,Hurthle cell thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01441154
NCT01455181,hypoparathyroidism,"A 6-Month Open-label Study Investigating the Safety and Tolerability of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH [1-84]), for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study","A Study to Investigate the Safety and Tolerability of NPSP558, for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study in Hungary",Hypoparathyroidism,2011-09-15,2012-04-26,2012-04-26,Interventional,Completed,Phase 3,Takeda,Shire,"Semmelweis University Medical School|University of Pécs, School of Medicine|University of Szeged",Drug,Hungary,18.0,85.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01455181
NCT01481402,low t3 syndrome,"Liothyronine and Heart Failure. The Long Term Effect of Liothyronine on Heart Function, Body Composition and Metabolic Status",Liothyronine and Heart Failure. The Long Term Effect of Liothyronine on Left Ventricular Ejection Fraction (LVEF),Heart Failure|Low T3 Syndrome,2011-11-25,2014-02-28,2014-02-28,Interventional,Completed,Not Applicable,Herlev Hospital,Jens Faber,"Herlev Hospital, Dept. of Endocrinology",Drug|Drug,Denmark,18.0,120.0,[18-65]|[65 and more],Euthyroid Sick Syndromes,Euthyroid Sick Syndromes,https://clinicaltrials.gov/ct2/show/NCT01481402
NCT01487057,thyroid carcinoma,"""Evaluation of Lipid Metabolic Status and of Cardiovascular Risk at Patients With Thyroid Carcinoma, Radically Treated and With Chronic Thyroid Hormonal Substitution""",Lipid Metabolic Status in Thyroid Carcinoma,Dyslipidemias|Hormone Replacement|Risk Reduction Behavior|Thyroid Carcinoma,2011-12-05,2012-02-29,2012-05-31,Observational,Completed,,Prof. Dr. I. Chiricuta Institute of Oncology,Iuliu Hatieganu University of Medicine and Pharmacy|Prof. Dr. I. Chiricuta Institute of Oncology,"Institute of Oncology ""Prof.dr.I.Chiricuta""",,Romania,18.0,80.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01487057
NCT01488721,congenital hypothyroidism,"Clinical Evaluation of the xMAP® NeoPlex4™ Assay for Detection of T4, TSH, 17-OHP and IRT Using the NeoPlex System",Clinical Evaluation of NeoPlex4 Assay and NeoPlex System,"Adrenal Hyperplasia, Congenital|Congenital Hypothyroidism|Cystic Fibrosis",2011-12-06,2012-02-29,2012-04-30,Observational,Completed,,Luminex Molecular Diagnostics,Luminex Corporation,New York State Department of Health|Tennessee Department of Health|Unified State Laboratories: Public Health,,United States,0.0,7.0,[0-17],Hypothyroidism,Congenital hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01488721
NCT01496313,thyroid cancer,"An International, Randomised, Double-Blind, Two-Arm Study To Evaluate The Safety And Efficacy Of Vandetanib 150 And 300mg/Day In Patients With Unresectable Locally Advanced Or Metastatic Medullary Thyroid Carcinoma With Progressive Or Symptomatic Disease",To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer,Thyroid Cancer,2011-12-02,2014-04-30,2022-12-31,Interventional,Active not recruiting,Phase 4,Sanofi,"Genzyme, a Sanofi Company",Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug|Drug,Czechia|India|Israel|Italy|Netherlands|Poland|Russian Federation|United Kingdom|United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01496313
NCT01498341,hypoparathyroidism,"Hypoparathyroidism, Autosomal Dominant Hypocalcaemia and Pseudohypoparathyroidism in Denmark - Epidemiology, Causes, Symptoms and Prognoses",Hypoparathyroidism in Denmark,Hypoparathyroidism,2011-12-20,2012-05-31,2012-05-31,Observational,Completed,,University of Aarhus,University of Aarhus,"Department of Internal Medicine and Endocrinology, Aarhus University Hospital, Tage-Hansens Gade",,Denmark,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01498341
NCT01501110,euthyroid sick syndrome,Evaluation of the Effects of N-acetylcysteine on Thyroid Hormone Levels in the Low T3 Syndrome,Effects of N-acetylcysteine on Low T3 Syndrome,Acute Myocardial Infarction|Euthyroid Sick Syndrome|Ischemic Heart Disease,2011-11-25,2013-07-31,2013-11-30,Interventional,Completed,Phase 4,Federal University of Rio Grande do Sul,Federal University of Rio Grande do Sul|Hospital de Clinicas de Porto Alegre|Programa de pós-graduação em endocrinologia,Hospital de Clínicas de Porto Alegre|Instituto de Cardiologia,Drug,Brazil,18.0,80.0,[18-65]|[65 and more],Euthyroid Sick Syndromes,Euthyroid Sick Syndromes,https://clinicaltrials.gov/ct2/show/NCT01501110
NCT01502410,papillary thyroid cancer,"A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma","Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer",Childhood Hepatocellular Carcinoma|Papillary Thyroid Cancer|Previously Treated Childhood Rhabdomyosarcoma|Recurrent Childhood Liver Cancer|Recurrent Childhood Rhabdomyosarcoma|Recurrent Thyroid Cancer|Recurrent Wilms Tumor and Other Childhood Kidney Tumors,2011-12-29,2014-06-30,2014-06-30,Interventional,Completed,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Children's Hospital of Alabama|University of Alabama at Birmingham|University of Arkansas for Medical Sciences|Southern California Permanente Medical Group|Miller Children's Hospital|Children's Hospital Los Angeles|Children's Hospital Central California|Childrens Hospital of Orange County|Rady Children's Hospital - San Diego|University of California San Francisco Medical Center-Parnassus|Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center|Connecticut Children's Medical Center|Alfred I duPont Hospital for Children|Children's National Medical Center|Lee Memorial Health System|Nemours Children's Clinic - Jacksonville|Florida Hospital|Nemours Children's Clinic - Orlando|Nemours Children's Clinic - Pensacola|All Children's Hospital|Saint Joseph Children's Hospital of Tampa|Children's Healthcare of Atlanta - Egleston|University of Hawaii|Saint Luke's Mountain States Tumor Institute|Lurie Children's Hospital-Chicago|University of Illinois|University of Chicago|Saint Jude Midwest Affiliate|Southern Illinois University|Riley Hospital for Children|University of Kentucky|Kosair Children's Hospital|Tulane University Health Sciences Center|Sinai Hospital of Baltimore|Mark O Hatfield-Warren Grant Magnuson Clinical Center|Dana-Farber Cancer Institute|Dana-Farber Harvard Cancer Center|Wayne State University/Karmanos Cancer Institute|Bronson Methodist Hospital|University of Minnesota Medical Center-Fairview|Mayo Clinic|University of Mississippi Medical Center|The Childrens Mercy Hospital|Washington University School of Medicine|Children's Hospital and Medical Center of Omaha|Hackensack University Medical Center|Morristown Memorial Hospital|UMDNJ - Robert Wood Johnson University Hospital|Overlook Hospital|University of New Mexico Cancer Center|Montefiore Medical Center - Moses Campus|Roswell Park Cancer Institute|Columbia University Medical Center|Memorial Sloan-Kettering Cancer Center|University of Rochester|State University of New York Upstate Medical University|University of North Carolina|Carolinas Medical Center|Novant Health Presbyterian Medical Center|Wake Forest University Health Sciences|Children's Hospital Medical Center of Akron|Cincinnati Children's Hospital Medical Center|Rainbow Babies and Childrens Hospital|Nationwide Children's Hospital|Dayton Children's Hospital|University of Oklahoma Health Sciences Center|Oregon Health and Science University|Children's Hospital of Philadelphia|Children's Oncology Group|Children's Hospital of Pittsburgh of UPMC|BI-LO Charities Children's Cancer Center|Greenville Cancer Treatment Center|East Tennessee Childrens Hospital|Vanderbilt-Ingram Cancer Center|Driscoll Children's Hospital|Medical City Dallas Hospital|University of Texas Southwestern Medical Center|Cook Children's Medical Center|Baylor College of Medicine|Childrens Hospital-King's Daughters|Seattle Children's Hospital|Providence Sacred Heart Medical Center and Children's Hospital|Midwest Children's Cancer Center|Sydney Children's Hospital|Princess Margaret Hospital for Children|British Columbia Children's Hospital|IWK Health Centre|McMaster Children's Hospital at Hamilton Health Sciences|Hospital for Sick Children|The Montreal Children's Hospital of the MUHC|Centre Hospitalier Universitaire Sainte-Justine|Centre Hospitalier Universitaire de Quebec,Drug|Other|Other,Australia|Canada|United States,2.0,30.0,[0-17]|[18-65],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT01502410
NCT01502410,recurrent thyroid cancer,"A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma","Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer",Childhood Hepatocellular Carcinoma|Papillary Thyroid Cancer|Previously Treated Childhood Rhabdomyosarcoma|Recurrent Childhood Liver Cancer|Recurrent Childhood Rhabdomyosarcoma|Recurrent Thyroid Cancer|Recurrent Wilms Tumor and Other Childhood Kidney Tumors,2011-12-29,2014-06-30,2014-06-30,Interventional,Completed,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Children's Hospital of Alabama|University of Alabama at Birmingham|University of Arkansas for Medical Sciences|Southern California Permanente Medical Group|Miller Children's Hospital|Children's Hospital Los Angeles|Children's Hospital Central California|Childrens Hospital of Orange County|Rady Children's Hospital - San Diego|University of California San Francisco Medical Center-Parnassus|Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center|Connecticut Children's Medical Center|Alfred I duPont Hospital for Children|Children's National Medical Center|Lee Memorial Health System|Nemours Children's Clinic - Jacksonville|Florida Hospital|Nemours Children's Clinic - Orlando|Nemours Children's Clinic - Pensacola|All Children's Hospital|Saint Joseph Children's Hospital of Tampa|Children's Healthcare of Atlanta - Egleston|University of Hawaii|Saint Luke's Mountain States Tumor Institute|Lurie Children's Hospital-Chicago|University of Illinois|University of Chicago|Saint Jude Midwest Affiliate|Southern Illinois University|Riley Hospital for Children|University of Kentucky|Kosair Children's Hospital|Tulane University Health Sciences Center|Sinai Hospital of Baltimore|Mark O Hatfield-Warren Grant Magnuson Clinical Center|Dana-Farber Cancer Institute|Dana-Farber Harvard Cancer Center|Wayne State University/Karmanos Cancer Institute|Bronson Methodist Hospital|University of Minnesota Medical Center-Fairview|Mayo Clinic|University of Mississippi Medical Center|The Childrens Mercy Hospital|Washington University School of Medicine|Children's Hospital and Medical Center of Omaha|Hackensack University Medical Center|Morristown Memorial Hospital|UMDNJ - Robert Wood Johnson University Hospital|Overlook Hospital|University of New Mexico Cancer Center|Montefiore Medical Center - Moses Campus|Roswell Park Cancer Institute|Columbia University Medical Center|Memorial Sloan-Kettering Cancer Center|University of Rochester|State University of New York Upstate Medical University|University of North Carolina|Carolinas Medical Center|Novant Health Presbyterian Medical Center|Wake Forest University Health Sciences|Children's Hospital Medical Center of Akron|Cincinnati Children's Hospital Medical Center|Rainbow Babies and Childrens Hospital|Nationwide Children's Hospital|Dayton Children's Hospital|University of Oklahoma Health Sciences Center|Oregon Health and Science University|Children's Hospital of Philadelphia|Children's Oncology Group|Children's Hospital of Pittsburgh of UPMC|BI-LO Charities Children's Cancer Center|Greenville Cancer Treatment Center|East Tennessee Childrens Hospital|Vanderbilt-Ingram Cancer Center|Driscoll Children's Hospital|Medical City Dallas Hospital|University of Texas Southwestern Medical Center|Cook Children's Medical Center|Baylor College of Medicine|Childrens Hospital-King's Daughters|Seattle Children's Hospital|Providence Sacred Heart Medical Center and Children's Hospital|Midwest Children's Cancer Center|Sydney Children's Hospital|Princess Margaret Hospital for Children|British Columbia Children's Hospital|IWK Health Centre|McMaster Children's Hospital at Hamilton Health Sciences|Hospital for Sick Children|The Montreal Children's Hospital of the MUHC|Centre Hospitalier Universitaire Sainte-Justine|Centre Hospitalier Universitaire de Quebec,Drug|Other|Other,Australia|Canada|United States,2.0,30.0,[0-17]|[18-65],Thyroid neoplasms,Recurrent Thyroid Cancer,https://clinicaltrials.gov/ct2/show/NCT01502410
NCT01510002,papillary thyroid cancer,Prophylactic Central Neck Dissection for Papillary Thyroid Cancer,Prophylactic Central Neck Dissection for Papillary Thyroid Cancer,Papillary Thyroid Cancer,2012-01-09,2011-09-30,2011-12-31,Interventional,Completed,Not Applicable,Jagiellonian University,Jagiellonian University,"Jagiellonian Univerity, Medical College, 3rd Department of General Surgery",Procedure|Procedure,Poland,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT01510002
NCT01511393,medullary thyroid carcinoma,Medullary Thyroid Carcinoma Surveillance Study: A Case-Series Registry,An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC),"Diabetes|Diabetes Mellitus, Type 2|Medullary Thyroid Carcinoma|Weight Management",2011-11-30,2035-12-31,2035-12-31,Observational [Patient Registry],Enrolling by invitation,,Novo Nordisk A/S,"AstraZeneca|Eli Lilly and Company|Novo Nordisk A/S|United BioSource, LLC","United BioSource, LLC",Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, medullary",https://clinicaltrials.gov/ct2/show/NCT01511393
NCT01512212,thyroid cancer,New Thyroid Fine Needle Biopsy Apparatus,New Thyroid Fine Needle Aspiration Biopsy Apparatus,Thyroid Cancer,2012-01-10,2012-06-30,2012-09-30,Interventional,Unknown status,Not Applicable,SB Istanbul Education and Research Hospital,Bezmialem Vakif University|SB Istanbul Education and Research Hospital,Bezmialem Vakif University,Procedure,Turkey,17.0,85.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01512212
NCT01534897,papillary thyroid carcinoma,Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436,Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436,Papillary Thyroid Carcinoma,2012-02-10,2014-03-31,2014-03-31,Interventional,Completed,Not Applicable,Massachusetts General Hospital,GlaxoSmithKline|Massachusetts General Hospital,Massachusetts General Hospital,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT01534897
NCT01536678,hypothyroidism,"Bioequivalence of Two Levothyroxine Tablet Formulations in Healthy Indian Volunteers: A Single-dose, Randomized, Open-label, Crossover Study",Bioequivalence of Two Levothyroxine Tablet Formulations in Healthy Indian Volunteers,Hypothyroidism,2012-02-02,2012-04-30,2012-04-30,Interventional,Completed,Phase 4,GlaxoSmithKline,GlaxoSmithKline,GSK Investigational Site,Drug|Drug,India,18.0,50.0,[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01536678
NCT01539499,thyroid disease,Complications of Endocrine Surgery: Data From the United Health System Consortium,Complications of Endocrine Surgery: Data From the United HealthSystem Consortium,Endocrine Gland|Parathyroid Disease|Thyroid Disease,2012-02-21,2017-08-31,2017-08-31,Observational,Completed,,University of Arkansas,University of Arkansas,University of Arkansas for Medical Sciences,,United States,18.0,90.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT01539499
NCT01539655,medullary thyroid cancer,"A Phase I, Randomized, Open-label, Single-center Study to Assess the Pharmacokinetics of Vandetanib (CAPRELSA) in Healthy Subjects When a Single Oral Dose of Vandetanib 300 mg is Administered Alone and in Combination With Omeprazole or Ranitidine",Study in Healthy Volunteers to Assess Effect of Omeprazole and Ranitidine on the Pharmacokinetics of Vandetanib,Medullary Thyroid Cancer,2012-02-10,2012-09-30,2012-09-30,Interventional,Completed,Phase 1,Sanofi,Sanofi,Research Site,Drug|Drug|Drug,United States,18.0,50.0,[18-65],Thyroid neoplasms,"Thyroid cancer, medullary",https://clinicaltrials.gov/ct2/show/NCT01539655
NCT01551498,"thyroiditis, autoimmune","A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Trial to Evaluate the Safety and Potential Effects of the Dietary Supplement Anatabloc on Antithyroid Autoantibodies and Thyroid Function in Autoimmune Thyroiditis",Evaluating the Dietary Supplement Anatabloc in Thyroid Health-ASAP (Antabloc Supplementation Autoimmune Prevention),"Thyroiditis, Autoimmune",2012-03-05,2013-01-31,2013-02-28,Interventional,Completed,Phase 2,"Rock Creek Pharmaceuticals, Inc.","Rock Creek Pharmaceuticals, Inc.","Metabolic Research Institute, Inc.|Florida Medical Clinic, P.A.|Robert J. Becker, M.D., LTD|Associated Endocrinologists, P.C.|New Jersey Physicians, LLC|Texas Diabetes & Endocrinology|North Texas Endocrine Center|Research Institute of Dallas|Texas Diabetes & Endocrinology",Dietary Supplement|Dietary Supplement,United States,18.0,70.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT01551498
NCT01552434,thyroid gland neoplasm,"A Phase I Trial of Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid, or Cetuximab in Patients With Advanced Malignancy and Other Indications",Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease,Advanced Malignant Neoplasm|Castleman Disease|Digestive System Carcinoma|Erdheim-Chester Disease|Lip and Oral Cavity Carcinoma|Lymphangioleiomyomatosis|Malignant Endocrine Neoplasm|Malignant Female Reproductive System Neoplasm|Malignant Male Reproductive System Neoplasm|Malignant Neoplasm|Malignant Respiratory Tract Neoplasm|Malignant Thoracic Neoplasm|Malignant Urinary System Neoplasm|Mesothelial Neoplasm|Metastatic Malignant Neoplasm|Metastatic Urothelial Carcinoma|Neurofibromatosis Type 2|Recurrent Adult Soft Tissue Sarcoma|Recurrent Breast Carcinoma|Recurrent Childhood Soft Tissue Sarcoma|Recurrent Digestive System Carcinoma|Recurrent Female Reproductive System Carcinoma|Recurrent Male Reproductive System Carcinoma|Recurrent Malignant Neoplasm|Recurrent Pharyngeal Carcinoma|Recurrent Thyroid Gland Carcinoma|Refractory Malignant Neoplasm|Soft Tissue Neoplasm|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage III Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7|Stage III Pharyngeal Cancer|Stage IVA Pharyngeal Cancer|Stage IVB Pharyngeal Cancer|Stage IV Breast Cancer AJCC v6 and v7|Stage IVC Pharyngeal Cancer|Stage IV Pharyngeal Cancer|Thyroid Gland Neoplasm,2012-03-07,2022-03-31,2022-03-31,Interventional,Active not recruiting,Phase 1,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center|National Cancer Institute (NCI),M D Anderson Cancer Center,Biological|Biological|Other|Other|Drug|Drug,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01552434
NCT01560299,graves disease,,Evaluation of Optimal Time of Methimazole Discontinuation Before Radio-iodine Therapy in Hyperthyroid Grave's Patients,Graves Disease,2012-03-01,2012-01-31,2012-01-31,Interventional,Completed,Not Applicable,Mashhad University of Medical Sciences,Mashhad University of Medical Sciences,Mashad University of Medical Sciences,Drug|Drug|Drug,"Iran, Islamic Republic of",18.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT01560299
NCT01565486,thyroid cancer,Comparison of Surgical Outcomes Between Papillary Thyroid Cancer Patients Treated With the Harmonic ACE® Scalpel and LigaSure Precise™ Instrument During Conventional Thyroidectomy: A Single-blind Prospective Randomized Controlled Trial,Safety and Efficacy Study of Ultrasonic Coagulation Device and Bipolar Energy Sealing System,Thyroid Cancer,2011-09-02,2013-01-31,2017-08-31,Interventional,Unknown status,Not Applicable,Seoul St. Mary's Hospital,Seoul St. Mary's Hospital,Seoul St. Mary's Hospital,Device|Device,"Korea, Republic of",20.0,80.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01565486
NCT01573520,hyperparathyroidism,A Randomized Trial Comparing an Integrated Care Approach Using Electronic Cinacalcet Adherence Data Versus Usual Care to Improve Secondary Hyperparathyroidism in Hemodialysis Patients,Treatment Adhesion in Dialysis Patients Treated With Cinacalcet,Chronic Kidney Disease|Hyperparathyroidism,2012-03-23,2011-11-30,2011-11-30,Interventional,Completed,Phase 4,Centre Hospitalier Universitaire Vaudois,Michel Burnier,Centre Hospitalier Universitaire Vaudois,Other,Switzerland,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01573520
NCT01586520,differentiated thyroid cancer,Diagnosing Thyroid Cancer Using a Blood Test,Diagnosing Thyroid Cancer Using a Blood Test,Differentiated Thyroid Cancer,2012-04-25,2014-10-31,2016-12-31,Observational,Completed,,Newcastle-upon-Tyne Hospitals NHS Trust,Newcastle-upon-Tyne Hospitals NHS Trust,"Sir Bobby Robson Cancer Researhc Unit|Sir Bobby Robson Cancer Research Unit, Northern Centre for cancer care",,United Kingdom,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Differentiated thyroid cancer, all",https://clinicaltrials.gov/ct2/show/NCT01586520
NCT01588288,"goiter, nodular",Diagnosis Interest of Galectin 3 Dosage in Nodular and Multinodular Goiter Pretreatment,Galectin 3 Dosage in Diagnosis of Nodular and Multinodular Goiter,"Goiter, Nodular",2012-04-25,2016-06-30,2016-06-30,Interventional,Completed,Not Applicable,"University Hospital, Rouen","University Hospital, Rouen",Centre Henri Becquerel|CHRouen,Procedure,France,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01588288
NCT01616108,graves disease,Bupivacaine Injection of Eye Muscles to Treat Strabismus,Bupivacaine Injection of Eye Muscles to Treat Strabismus,"Esotropia|Exotropia|Graves Disease|Ptosis, Eyelid|Strabismus",2012-06-07,2019-09-30,2020-09-30,Interventional,Unknown status,Phase 2/Phase 3,Smith-Kettlewell Eye Research Institute,Eidactics|Smith-Kettlewell Eye Research Institute|Strabismus Research Foundation|Sutter Health,Strabismus Research Foundation,Drug,United States,8.0,95.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT01616108
NCT01616316,thyroid cancer,Efficacy of Subfascial Approach in Thyroidectomy to Quality of Life in Thyroid Disease Patients: Prospective Randomized Study,Efficacy of Subfascial Approach in Thyroidectomy to Quality of Life in Thyroid Disease Patients,Thyroid Cancer,2012-01-18,2012-01-31,2012-02-29,Interventional,Completed,Phase 2/Phase 3,Samsung Medical Center,Samsung Medical Center,Samsung medical center,Procedure|Procedure,"Korea, Republic of",20.0,65.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01616316
NCT01625520,medullary thyroid cancer,"Mono Centre, Open Label Proof of Concept Study SOM230 in Progressive Medullary Thyroid Cancer Patients and the Combination With RAD001 Upon Progression",SOM230 Alone or in Combination With RAD001 in Patients With Medullary Thyroid Cancer,Medullary Thyroid Cancer,2012-05-25,2016-03-31,,Interventional,Completed,Phase 2,Federico II University,Federico II University,"Department of Molecular and Clinical Endocrinology and Oncology, ""Federico II"" University of Naples",Drug,Italy,18.0,80.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, medullary",https://clinicaltrials.gov/ct2/show/NCT01625520
NCT01631305,euthyroid sick syndrome,Efficacy and Safety of Levothyroxine in Critical Children With Euthyroid Sick Syndrome in a Pediatric Intensive Care Unit.,Levothyroxine for Children With Euthyroid Sick Syndrome,Euthyroid Sick Syndrome,2012-06-26,2013-12-31,2013-12-31,Interventional,Completed,Phase 4,Sinaloa Pediatric Hospital,Sinaloa Pediatric Hospital,Sinaloa Pediatric Hospital,Drug|Other,Mexico,1.0,17.0,[0-17],Euthyroid Sick Syndromes,Euthyroid Sick Syndromes,https://clinicaltrials.gov/ct2/show/NCT01631305
NCT01640184,hyperparathyroidism,Study of the Efficacy and Safety on the Ultrasonic Ablation Treatment for Secondary Hyperthyroidism in Chronic Kidney Disease Patients.,Efficacy and Safety of Ultrasonic Ablation to Treat Secondary Hyperparathyroidism in Chronic Kidney Disease Patients,Disorders of Parathyroid Gland|Hyperparathyroidism,2012-07-09,2014-11-30,2014-11-30,Interventional,Completed,Not Applicable,Capital Medical University,"Beijing Municipal Science & Technology Commission|Dongliang Zhang, MD",Beijing Chao-Yang Hospital|Beijing Friendship Hospital,Procedure|Drug|Procedure,China,18.0,75.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01640184
NCT01641679,differentiated thyroid cancer,Recurrent Differentiated Thyroid Cancer: Towards Personalized Treatment Based on Evaluation of Tumor Characteristics With PET (THYROPET,PET Evaluation of Recurrent Differentiated Thyroid Cancer,Differentiated Thyroid Cancer|Thyroid Neoplasms,2012-07-12,2015-08-31,2016-01-31,Observational,Unknown status,,The Netherlands Cancer Institute,"Amsterdam UMC, location VUmc|The Netherlands Cancer Institute|UMC Utrecht",Rijnstate Hospital|UMC St. Radboud Nijmegen|Bernard Verbeeten Institute|Jeroen Bosch Hospital|Catharina Hospital|Medical Center Alkmaar|St. Lucas Andreas Hospital|VUmc Medical Center|Medical spectrum Twente|Isala Clinics|Meander Medical Center|St. Antonius hospital|Leiden University Medical Center|University Medical Center Groningen|University Medical Center Utrecht,,Netherlands,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Differentiated thyroid cancer, all",https://clinicaltrials.gov/ct2/show/NCT01641679
NCT01647750,hypothyroidism,"Study of Optimal Replacement of Thyroxine in the Elderly (SORTED) SORTED 1 - a Randomised Controlled Trial (Pilot Study), SORTED 2 - Qualitative Interviews, SORTED 3 - Retrospective Cohort",Study of Optimal Replacement of Thyroxine in the Elderly,Hypothyroidism,2012-07-16,2014-08-31,2014-08-31,Interventional,Completed,Phase 4,Newcastle-upon-Tyne Hospitals NHS Trust,"National Institute for Health Research, United Kingdom|Newcastle-upon-Tyne Hospitals NHS Trust",Bensham Hospital|Clinical Research Facility,Drug|Drug,United Kingdom,80.0,120.0,[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01647750
NCT01649206,thyroid nodule,Thyroid Nodules Treated With Percutaneous Radiofrequency Thermal Ablation: a Comparative Study,Percutaneous Radiofrequency Thermal Ablation in Compressive Thyroid Nodules,Thyroid Nodule,2012-07-16,2011-01-31,2011-06-30,Interventional,Completed,Phase 3,Federico II University,Federico II University,"""Federico II"" University of Naples, Department of Clinical and Molecular Endocrinology and Oncology",Procedure,Italy,18.0,87.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT01649206
NCT01656070,hyperparathyroidism,Vitamin D Status and T Cell Phenotype in HIV-infected Youth Supplemented With Cholecalciferol: a Randomized Clinical Trial.,Vitamin D Supplementation in HIV-infected Youth,HIV Disease|Hyperparathyroidism|Hypovitaminosis D|Vitamin D Deficiency,2012-07-31,2012-07-31,2012-07-31,Interventional,Completed,Phase 2,University of Milan,University of Milan,Department of Paediatrics - L. Sacco Hospital,Drug|Drug,Italy,0.0,30.0,[0-17]|[18-65],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01656070
NCT01658085,multinodular goiter,"Harmonic FOCUS Versus Conventional Technique in Total Thyroidectomy for Benign Thyroid Disease. A Randomized, Prospective Study",Budget Impact of Harmonic FOCUS in Thyroidectomy,Multinodular Goiter,2012-07-17,2010-03-31,2012-08-31,Observational,Unknown status,,Hospital Universitari de Bellvitge,Hospital Universitari de Bellvitge,Hospital UIniversitari de Bellvitge,Device|Device,Spain,18.0,80.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01658085
NCT01659385,"thyroid cancer, papillary","Assessment of Serum Leptin Levels in Females With Papillary Thyroid Carcinoma, Benign Thyroid Nodules, and Normal Controls",Leptin Levels in Papillary Thyroid Cancer,"Leptin Levels|Thyroid Cancer, Papillary",2012-08-03,2013-06-30,2013-06-30,Observational,Completed,,University of Nebraska,University of Nebraska,University of Nebraska Medical Center,,United States,19.0,75.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT01659385
NCT01660984,medullary thyroid cancer,Longitudinal Assessment and Natural History Study of Children and Adults With MEN2A or MEN2B With or Without Medullary Thyroid Carcinoma,Natural History Study of Children and Adults With Medullary Thyroid Cancer,Medullary Thyroid Cancer,2012-08-07,,,Observational,Recruiting,,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),"National Institutes of Health Clinical Center, 9000 Rockville Pike",,United States,4.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, medullary",https://clinicaltrials.gov/ct2/show/NCT01660984
NCT01668238,thyroid tumor,Detection of Benign and Malignant Thyroid and Breast Tumors by Fourier Transform Infrared Spectrometry,Detection of Benign and Malignant Thyroid and Breast Tumors by Fourier Transform Infrared Spectrometry,Breast Tumor|Thyroid Tumor,2012-08-07,2012-09-30,2012-09-30,Observational,Unknown status,,Peking University,Peking University|XU Zhi,Peking University Third Hospital,,China,18.0,80.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01668238
NCT01691781,hyperparathyroidism,The Renin-Angiotensin-Aldosterone System and Parathyroid Hormone Control: The RAAS-PARC Study,The Renin-Angiotensin-Aldosterone System and Parathyroid Hormone Control: The RAAS-PARC Study,Hyperparathyroidism,2012-09-20,2016-08-31,2016-12-31,Interventional,Completed,Not Applicable,Brigham and Women's Hospital,Brigham and Women's Hospital,Brigham and Women's Hospital,Drug,United States,18.0,80.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01691781
NCT01700699,differentiated thyroid cancer,Impact of BRAFV600E Intratumor Heterogeneity on the Efficacy of Tyrosine Kinase Inhibitors in the Treatment of Radioiodine-resistant Thyroid Cancer,Impact of BRAFV600E Intratumor Heterogeneity in Thyroid Cancer Treated With Tyrosine Kinase Inhibitors,Differentiated Thyroid Cancer,2012-09-22,2013-10-31,2013-10-31,Observational,Unknown status,,University of Salerno,University of Salerno,"Department of Medicine and Surgery, Univeristy of Salerno",,Italy,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Differentiated thyroid cancer, all",https://clinicaltrials.gov/ct2/show/NCT01700699
NCT01701349,anaplastic thyroid cancer,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Fosbretabulin Tromethamine (CA4P) in Combination With Paclitaxel and Carboplatin in Anaplastic Thyroid Carcinoma (FACT2)",Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid Cancer,Anaplastic Thyroid Cancer,2012-10-02,2017-04-30,2017-12-31,Interventional,Withdrawn,Phase 3,Mateon Therapeutics,Mateon Therapeutics,,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT01701349
NCT01707056,thyroid carcinoma,The Effect of Coffee Consumption on the Intestinal Absorption of Levothyroxine Thyroid Hormone Replacement in Patients With Thyroid Carcinoma,The Effect of Coffee on the Absorption of Thyroid Hormone in Patients With Thyroid Carcinoma,Hypothyroidism|Thyroid Carcinoma,2012-10-05,2015-06-30,2016-06-30,Interventional,Withdrawn,Not Applicable,Medstar Health Research Institute,Georgetown University|Medstar Health Research Institute,Georgetown University Hospital|Washington Hospital Center|MedStar St. Mary's Hospital,Other|Other|Other|Other,United States,18.0,60.0,[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01707056
NCT01707056,hypothyroidism,The Effect of Coffee Consumption on the Intestinal Absorption of Levothyroxine Thyroid Hormone Replacement in Patients With Thyroid Carcinoma,The Effect of Coffee on the Absorption of Thyroid Hormone in Patients With Thyroid Carcinoma,Hypothyroidism|Thyroid Carcinoma,2012-10-05,2015-06-30,2016-06-30,Interventional,Withdrawn,Not Applicable,Medstar Health Research Institute,Georgetown University|Medstar Health Research Institute,Georgetown University Hospital|Washington Hospital Center|MedStar St. Mary's Hospital,Other|Other|Other|Other,United States,18.0,60.0,[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01707056
NCT01709292,thyroid cancer,Pharmacodynamic Study of Vemurafenib in the Neoadjuvant Setting in Patients With Locally Advanced Thyroid Cancer,Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer,Thyroid Cancer,2012-07-25,2022-09-30,2023-09-30,Interventional,Active not recruiting,Phase 2,M.D. Anderson Cancer Center,"Genentech, Inc.|M.D. Anderson Cancer Center",University of Texas MD Anderson Cancer Center,Drug|Drug|Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01709292
NCT01709435,thyroid gland medullary carcinoma,"A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors",Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors,Recurrent Malignant Solid Neoplasm|Recurrent Melanoma|Recurrent Primary Central Nervous System Neoplasm|Recurrent Thyroid Gland Carcinoma|Refractory Malignant Solid Neoplasm|Refractory Primary Central Nervous System Neoplasm|Thyroid Gland Medullary Carcinoma,2012-10-16,2018-12-31,2019-12-31,Interventional,Completed,Phase 1,National Cancer Institute (NCI),National Cancer Institute (NCI),Children's Hospital of Alabama|Children's Hospital of Orange County|UCSF Medical Center-Parnassus|UCSF Medical Center-Mission Bay|Children's National Medical Center|Children's Healthcare of Atlanta - Egleston|Lurie Children's Hospital-Chicago|Riley Hospital for Children|National Institutes of Health Clinical Center|C S Mott Children's Hospital|University of Minnesota/Masonic Cancer Center|Washington University School of Medicine|NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center|Cincinnati Children's Hospital Medical Center|Oregon Health and Science University|Children's Hospital of Philadelphia|Childrens Oncology Group|Children's Hospital of Pittsburgh of UPMC|St. Jude Children's Research Hospital|Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center|Seattle Children's Hospital|Children's Hospital of Wisconsin|Hospital for Sick Children,Drug|Other|Other,Canada|United States,2.0,18.0,[0-17]|[18-65],Thyroid neoplasms,"Thyroid cancer, medullary",https://clinicaltrials.gov/ct2/show/NCT01709435
NCT01723202,papillary thyroid cancer,A Randomized Phase 2 Study of Single Agent Dabrafenib (BRAFi) vs. Combination Regimen Dabrafenib (BRAFi) and Trametinib (MEKi) in Patients With BRAF Mutated Thyroid Carcinoma,Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer,Follicular Thyroid Cancer|Insular Thyroid Cancer|Papillary Thyroid Cancer|Recurrent Thyroid Cancer,2012-10-22,2022-12-31,2022-12-31,Interventional,Active not recruiting,Phase 2,Ohio State University Comprehensive Cancer Center,Manisha Shah|National Comprehensive Cancer Network,"University of California, San Diego|University of Chicago Medical Center|Massachusetts General Hospital, Harvard Medical School|Ohio State University Medical Center|The University of Texas-MD Anderson Cancer Center",Drug|Drug|Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT01723202
NCT01723202,follicular thyroid cancer,A Randomized Phase 2 Study of Single Agent Dabrafenib (BRAFi) vs. Combination Regimen Dabrafenib (BRAFi) and Trametinib (MEKi) in Patients With BRAF Mutated Thyroid Carcinoma,Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer,Follicular Thyroid Cancer|Insular Thyroid Cancer|Papillary Thyroid Cancer|Recurrent Thyroid Cancer,2012-10-22,2022-12-31,2022-12-31,Interventional,Active not recruiting,Phase 2,Ohio State University Comprehensive Cancer Center,Manisha Shah|National Comprehensive Cancer Network,"University of California, San Diego|University of Chicago Medical Center|Massachusetts General Hospital, Harvard Medical School|Ohio State University Medical Center|The University of Texas-MD Anderson Cancer Center",Drug|Drug|Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT01723202
NCT01723202,insular thyroid cancer,A Randomized Phase 2 Study of Single Agent Dabrafenib (BRAFi) vs. Combination Regimen Dabrafenib (BRAFi) and Trametinib (MEKi) in Patients With BRAF Mutated Thyroid Carcinoma,Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer,Follicular Thyroid Cancer|Insular Thyroid Cancer|Papillary Thyroid Cancer|Recurrent Thyroid Cancer,2012-10-22,2022-12-31,2022-12-31,Interventional,Active not recruiting,Phase 2,Ohio State University Comprehensive Cancer Center,Manisha Shah|National Comprehensive Cancer Network,"University of California, San Diego|University of Chicago Medical Center|Massachusetts General Hospital, Harvard Medical School|Ohio State University Medical Center|The University of Texas-MD Anderson Cancer Center",Drug|Drug|Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Poorly differentiated thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01723202
NCT01723202,recurrent thyroid cancer,A Randomized Phase 2 Study of Single Agent Dabrafenib (BRAFi) vs. Combination Regimen Dabrafenib (BRAFi) and Trametinib (MEKi) in Patients With BRAF Mutated Thyroid Carcinoma,Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer,Follicular Thyroid Cancer|Insular Thyroid Cancer|Papillary Thyroid Cancer|Recurrent Thyroid Cancer,2012-10-22,2022-12-31,2022-12-31,Interventional,Active not recruiting,Phase 2,Ohio State University Comprehensive Cancer Center,Manisha Shah|National Comprehensive Cancer Network,"University of California, San Diego|University of Chicago Medical Center|Massachusetts General Hospital, Harvard Medical School|Ohio State University Medical Center|The University of Texas-MD Anderson Cancer Center",Drug|Drug|Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Recurrent Thyroid Cancer,https://clinicaltrials.gov/ct2/show/NCT01723202
NCT01727973,hyperthyroidism,"Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy: a Prospective, Uncontrolled Pilot Study",Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy,"Autoimmune Diseases|Endocrine System Diseases|Eye Diseases|Eye Diseases, Hereditary|Graves Disease|Graves Ophthalmopathy|Hyperthyroidism|Immune System Diseases|Thyroid Diseases",2012-11-12,2013-11-30,2013-11-30,Interventional,Completed,Phase 1/Phase 2,Sun Yat-sen University,Sun Yat-sen University,Zhongshan Ophthalmic Center,Drug,China,18.0,60.0,[18-65],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01727973
NCT01727973,graves disease,"Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy: a Prospective, Uncontrolled Pilot Study",Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy,"Autoimmune Diseases|Endocrine System Diseases|Eye Diseases|Eye Diseases, Hereditary|Graves Disease|Graves Ophthalmopathy|Hyperthyroidism|Immune System Diseases|Thyroid Diseases",2012-11-12,2013-11-30,2013-11-30,Interventional,Completed,Phase 1/Phase 2,Sun Yat-sen University,Sun Yat-sen University,Zhongshan Ophthalmic Center,Drug,China,18.0,60.0,[18-65],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT01727973
NCT01727973,graves ophthalmopathy,"Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy: a Prospective, Uncontrolled Pilot Study",Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy,"Autoimmune Diseases|Endocrine System Diseases|Eye Diseases|Eye Diseases, Hereditary|Graves Disease|Graves Ophthalmopathy|Hyperthyroidism|Immune System Diseases|Thyroid Diseases",2012-11-12,2013-11-30,2013-11-30,Interventional,Completed,Phase 1/Phase 2,Sun Yat-sen University,Sun Yat-sen University,Zhongshan Ophthalmic Center,Drug,China,18.0,60.0,[18-65],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT01727973
NCT01727973,thyroid diseases,"Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy: a Prospective, Uncontrolled Pilot Study",Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy,"Autoimmune Diseases|Endocrine System Diseases|Eye Diseases|Eye Diseases, Hereditary|Graves Disease|Graves Ophthalmopathy|Hyperthyroidism|Immune System Diseases|Thyroid Diseases",2012-11-12,2013-11-30,2013-11-30,Interventional,Completed,Phase 1/Phase 2,Sun Yat-sen University,Sun Yat-sen University,Zhongshan Ophthalmic Center,Drug,China,18.0,60.0,[18-65],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT01727973
NCT01728623,thyroid cancer,A Phase 2 Study of E7080 in Subjects With Advanced Thyroid Cancer,A Study of E7080 in Subjects With Advanced Thyroid Cancer,Thyroid Cancer,2012-09-07,2015-07-09,2015-10-01,Interventional,Completed,Phase 2,Eisai Inc.,"Eisai Co., Ltd.",,Drug,Japan,20.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01728623
NCT01730638,medullary thyroid carcinoma,Pharmacokinetic and Imaging Optimization Study of Pretargeted Immuno-PET Using the Anti-CEA x Anti-HSG TF2 Bispecific Antibody and 68Ga-IMP-288 Peptide in Patients With Recurrences of Medullary Thyroid Carcinoma.,ImmunoTEP for Patients With Medullary Thyroid Carcinoma.,Medullary Thyroid Carcinoma,2012-11-12,2016-12-31,2016-12-31,Interventional,Completed,Phase 1/Phase 2,Nantes University Hospital,"Gilead Sciences|Institut National de la Santé Et de la Recherche Médicale, France|Nantes University Hospital","Angers Hospital|Nantes Hospital|Institut de Cancérologie de l'ouest, René Gauducheau",Drug,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, medullary",https://clinicaltrials.gov/ct2/show/NCT01730638
NCT01736163,thyroid cancer,"A Retrospective, Non-interventional Study of Patients With T4 Tumours Comparing the Thyroid Remnant Ablation Success Following Thyrogen and 131I Administration Versus Thyroid Hormone Withdrawal and 131I Administration",A Retrospective Observational Study Comparing Two Different Treatment Options in Thyroid Cancer Patients With T4 Tumours,Thyroid Cancer,2012-11-26,2012-08-31,2012-08-31,Observational,Completed,,Sanofi,"Genzyme, a Sanofi Company",Hanover University School of Medicine|Klinikum Großhadern|Policlinico S.Orsola-Malpighi|Instituto Oncologico Veneto|Istituti Fisioterapici Ospitalieri (IFO)|Portuguese Institute of Oncology|Hospital Universitario Reina Sofía|Hospital Universitario Virgen de las Nieves|Hospital Universitario Dr Peset,Drug|Drug|Other,Germany|Italy|Portugal|Spain,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01736163
NCT01736878,medullary thyroid carcinoma,"Randomized Double-blind Placebo Controlled Phase II Study to Evaluate the Efficacy and Safety of Sorafenib Treatment in Patients With Advanced (Recurrent, Persistent and/or Metastasizing) Medullary Thyroid Carcinoma",Efficacy and Safety Study of Sorafenib to Treat Advanced Medullary Thyroid Carcinoma,Medullary Thyroid Carcinoma,2012-10-23,2013-04-30,2013-04-30,Interventional,Withdrawn,Phase 2,Eanm Research Ltd,Eanm Research Ltd,"University Hospital Ulm, Clinic for Nuclear Medicine",Drug,Germany,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, medullary",https://clinicaltrials.gov/ct2/show/NCT01736878
NCT01738243,thyroid eye disease,Phase IV Study of Hyaluronic Acid Gels for Upper Lid Retraction in Active Stage Thyroid Eye Disease,Hyaluronic Acid Gels for Upper Lid Retraction in Active Stage Thyroid Eye Disease,Thyroid Eye Disease,2012-10-06,2021-09-30,2021-09-30,Interventional,Terminated,Phase 4,"University of California, Los Angeles","University of California, Los Angeles",Jules Stein Eye Institute|The Jules Stein Eye Institute at UCLA,Drug|Drug,United States,21.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT01738243
NCT01739634,medullary thyroid cancer,The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer,The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer,Diarrhea|Medullary Thyroid Cancer,2012-11-29,2013-12-31,2013-12-31,Interventional,Unknown status,Phase 1/Phase 2,Salient Pharmaceuticals Incorporated,Salient Pharmaceuticals Incorporated,MD Anderson Cancer Center,Drug,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, medullary",https://clinicaltrials.gov/ct2/show/NCT01739634
NCT01744743,hypothyroidism,Preconceptional Thyroid Screening and Childhood Nerocognitive Function,Preconceptional Thyroid Screening and Childhood Nerocognitive Function,Hypothyroidism,2012-10-20,2014-12-31,2015-12-31,Interventional,Unknown status,Not Applicable,Fudan University,Fudan University|Shanghai Municipal Health Bureau|Shanghai Municipal Science and Technology Commission,"Obstetrics and Gynecology Hospital, Fudan University",Procedure,China,18.0,55.0,[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01744743
NCT01744769,hypothyroidism,Effects of Thyroid Hormone Withdrawal on Metabolic and Cardiovascular Parameters During Radioactive Iodine Therapy in Differentiated Thyroid Cancer,Effects of Thyroid Hormone Withdrawal on Metabolic Parameters During Radioactive Iodine Therapy in Thyroid Cancer,Hypothyroidism,2012-12-05,2013-05-31,2013-05-31,Observational,Unknown status,,Konkuk University Medical Center,Konkuk University Medical Center,Konkuk University Medical Center,,"Korea, Republic of",18.0,80.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01744769
NCT01747512,thyroid neoplasms,A Phase II/III Study of Cyclotron-produced Tc-99m Pertechnetate (C-PERT) Efficacy and Safety in Patients With Conformed and Suspected Thyroid Cancer or Head and Neck Cancer,An Imaging Study in Patients With Thyroid Cancer or Head and Neck Cancer With Pertechnetate Made in a Cyclotron (C-PERT),Head and Neck Neoplasms|Thyroid Neoplasms,2012-12-10,2013-05-31,,Interventional,Withdrawn,Phase 2,AHS Cancer Control Alberta,AHS Cancer Control Alberta|Cross Cancer Institute,,Drug|Drug,,18.0,79.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01747512
NCT01756534,goiter,The Effectiveness of an Oxidized Cellulose Patch Hemostatic Agent in Thyroid Surgery: a Prospective Randomized Controlled Study,Oxidized Cellulose Hemostatic Agent in Thyroid Surgery: a Prospective Randomized Controlled Study,Goiter|Thyroid Diseases|Thyroid Nodule,2012-12-19,2013-03-31,2013-12-31,Interventional,Unknown status,Not Applicable,Tel-Aviv Sourasky Medical Center,Tel-Aviv Sourasky Medical Center,Tel Aviv Medical Center,Device,Israel,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01756534
NCT01756534,thyroid nodule,The Effectiveness of an Oxidized Cellulose Patch Hemostatic Agent in Thyroid Surgery: a Prospective Randomized Controlled Study,Oxidized Cellulose Hemostatic Agent in Thyroid Surgery: a Prospective Randomized Controlled Study,Goiter|Thyroid Diseases|Thyroid Nodule,2012-12-19,2013-03-31,2013-12-31,Interventional,Unknown status,Not Applicable,Tel-Aviv Sourasky Medical Center,Tel-Aviv Sourasky Medical Center,Tel Aviv Medical Center,Device,Israel,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT01756534
NCT01756534,thyroid diseases,The Effectiveness of an Oxidized Cellulose Patch Hemostatic Agent in Thyroid Surgery: a Prospective Randomized Controlled Study,Oxidized Cellulose Hemostatic Agent in Thyroid Surgery: a Prospective Randomized Controlled Study,Goiter|Thyroid Diseases|Thyroid Nodule,2012-12-19,2013-03-31,2013-12-31,Interventional,Unknown status,Not Applicable,Tel-Aviv Sourasky Medical Center,Tel-Aviv Sourasky Medical Center,Tel Aviv Medical Center,Device,Israel,18.0,120.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT01756534
NCT01757470,medullary thyroid cancer,Effectiveness of Risk Minimisation Interventions for Vandetanib in Canada,Vandetanib Risk Minimisation Effectiveness,Medullary Thyroid Cancer,2012-12-18,2014-02-28,2014-02-28,Observational,Completed,,Sanofi,"Genzyme, a Sanofi Company",Research Site,,Canada,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, medullary",https://clinicaltrials.gov/ct2/show/NCT01757470
NCT01757834,thyroid nodule,Efficacy of Shear Wave Ultrasound Elastography in Noninvasive Diagnosis of Thyroid Nodules,Shear Wave Ultrasound Elastography in Noninvasive Diagnosis of Thyroid Nodules,Thyroid Nodule,2012-12-12,2015-07-31,2015-08-31,Interventional,Unknown status,Not Applicable,University of Washington,National Cancer Institute (NCI)|University of Washington,University of Washington Medical Center,Device,United States,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT01757834
NCT01761149,nodular goiter,"Comparison of Different Doses of Remifentanil on Postoperative Pain in Patients Undergoing Thyroidectomy: a Prospective, Double-blinded Randomized Control Trial",Effect of Higher Doses of Remifentanil on Postoperative Pain in Patients Undergoing Thyroidectomy,Nodular Goiter,2012-12-30,2013-03-31,,Interventional,Unknown status,Phase 4,Central South University,Central South University,"Department of Anesthesiology, The Second Xiangya Hospital",Drug,China,18.0,60.0,[18-65],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01761149
NCT01769157,hypothyroidism,"Single-center, Randomized, Double-Blinded, Comparative Study of the Effectiveness of L-carnitine in Patients'Fatigue Degree Changing With Hypothyroidism Who Take Levothyroxine",Effects of L-carnitine on Hypothyroidism,Hypothyroidism,2013-01-10,2013-06-30,2013-06-30,Interventional,Completed,Phase 4,Korea University Anam Hospital,IlDong Pharmaceutical Co Ltd|Korea University Anam Hospital,Korea University Anam Hospital,Drug|Drug,"Korea, Republic of",20.0,70.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01769157
NCT01771523,goiter,Is the Use of Drain for Thyroid Surgery Realistic?,Is the Use of Drain for Thyroid Surgery Realistic?,Goiter,2011-08-03,2013-01-31,2013-01-31,Interventional,Completed,Not Applicable,Maltepe University,Maltepe University,"Maltepe University School of Medicine, General Surgery Department",Procedure|Device,Turkey,0.0,120.0,[0-17]|[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01771523
NCT01774279,anaplastic thyroid cancer,interNational Anaplastic Thyroid Cancer Tissue Bank and Database (iNATT).,interNational Anaplastic Thyroid Cancer Tissue Bank and Database (iNATT),Anaplastic Thyroid Cancer,2013-01-18,2025-02-28,2025-03-31,Observational [Patient Registry],Recruiting,,Velindre NHS Trust,Velindre NHS Trust,"Beaumont Hospital|St Vincent's Hospital|Galway University Hospital|Addenbrookes Hospital|Velindre Hospital|University Hospitals of Coventry and Warwickshire|Castle Hill Hospital|St James' Institute|Royal Marsden Hospital|Norfolk and Norwich University Hospital NHS Foundation Trust|Nottingham University NHS Trust|Barking, Havering and Redbridge University Hospitals NHS Trust|Weston Park Hospital|Royal Shrewsbury Hospital|New Cross Hospital",Other,Ireland|United Kingdom,18.0,100.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT01774279
NCT01776385,tumor of the thyroid,Detection and Characterization of Circulating Tumor Cells in Patients With Malignant Pleural Mesothelioma: Towards a New Phase in the Understanding of the Natural History of This Cancer?,The ISET (Isolation by Size of Epithelial Tumor Cells) and the CellSearch Methods in Malignant Pleural Mesothelioma,Benign Tumor of the Thyroid|Mesothelioma|Parathyroid Neoplasms|Pleural Neoplasms|Pneumothorax|Tumor of the Thyroid,2012-03-23,2017-12-31,2018-03-31,Interventional,Completed,Not Applicable,Centre Hospitalier Universitaire de Nice,Centre Hospitalier Universitaire de Nice,CHU de Nice - LPCE- Hôpital de Pasteur - 30 ave de la voie Romaine,Other|Other,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01776385
NCT01776385,parathyroid neoplasms,Detection and Characterization of Circulating Tumor Cells in Patients With Malignant Pleural Mesothelioma: Towards a New Phase in the Understanding of the Natural History of This Cancer?,The ISET (Isolation by Size of Epithelial Tumor Cells) and the CellSearch Methods in Malignant Pleural Mesothelioma,Benign Tumor of the Thyroid|Mesothelioma|Parathyroid Neoplasms|Pleural Neoplasms|Pneumothorax|Tumor of the Thyroid,2012-03-23,2017-12-31,2018-03-31,Interventional,Completed,Not Applicable,Centre Hospitalier Universitaire de Nice,Centre Hospitalier Universitaire de Nice,CHU de Nice - LPCE- Hôpital de Pasteur - 30 ave de la voie Romaine,Other|Other,France,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01776385
NCT01778400,thyroid nodule,Single Session Treatment of RFA Versus EA for Predominantly Cystic Thyroid Nodules: A Randomized Controlled Trial,RFA (Radiofrequency Ablation) Versus EA (Ethanol Ablation) for Predominantly Cystic Thyroid Nodules,Thyroid Nodule,2013-01-25,2013-05-31,2014-01-31,Interventional,Unknown status,Not Applicable,Asan Medical Center,Asan Medical Center,Asan Medical Center,Procedure|Procedure,"Korea, Republic of",20.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT01778400
NCT01780584,low t3 syndrome,Oral Triiodothyronine Normalizes T3 Levels After Surgery For Pediatric Congenital Heart Disease,Can Oral T3 Normalize Thyroid Hormone Levels Following Cardiopulmonary Bypass in Children?,Low T3 Syndrome,2013-01-28,2010-09-30,2010-10-31,Interventional,Completed,Phase 2,National Cardiovascular Center Harapan Kita Hospital Indonesia,National Cardiovascular Center Harapan Kita Hospital Indonesia,Pediatric Cardiac ICU National Cardiovascular Center Harapan Kita Jakarta,Drug|Drug|Drug,Indonesia,0.0,24.0,[0-17]|[18-65],Euthyroid Sick Syndromes,Euthyroid Sick Syndromes,https://clinicaltrials.gov/ct2/show/NCT01780584
NCT01781767,thyroid cancer,,Changes in Metabolic Status in Patients With Total Thyroidectomy,Thyroid Cancer,2013-01-27,2014-07-31,2014-07-31,Observational,Unknown status,,Tel-Aviv Sourasky Medical Center,Tel-Aviv Sourasky Medical Center,Tel Aviv Sourasky Medical Center,,Israel,18.0,65.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01781767
NCT01792492,thyroid neoplasms,The Role of an Optical Probe in the Detection of Thyroid Cancer and Normal Thyroid Tissue in a Thyroidectomy Specimen: A Pilot Study,The Role of an Optical Probe in Thyroid Cancer Diagnosis: Pilot Study,Thyroid Cancer|Thyroid Neoplasms|Thyroid Nodule,2011-07-08,2010-03-31,2015-11-30,Observational,Completed,,Boston Medical Center,Boston Medical Center,Boston Medical Center,,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01792492
NCT01792492,thyroid nodule,The Role of an Optical Probe in the Detection of Thyroid Cancer and Normal Thyroid Tissue in a Thyroidectomy Specimen: A Pilot Study,The Role of an Optical Probe in Thyroid Cancer Diagnosis: Pilot Study,Thyroid Cancer|Thyroid Neoplasms|Thyroid Nodule,2011-07-08,2010-03-31,2015-11-30,Observational,Completed,,Boston Medical Center,Boston Medical Center,Boston Medical Center,,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT01792492
NCT01798966,thyroid eye disease,The Effects of Orbital Decompression Surgery on Intraocular Pressure Patterns in Patient With Thyroid Eye Disease Undergoing 24 Hour Continuous IOP Monitoring With the SENSIMED Triggerfish®,Twenty-four Hour Intraocular Pressure Patterns in Patients With Uncontrolled Thyroid Eye Disease,Thyroid Eye Disease,2013-02-21,2013-06-30,2013-06-30,Interventional,Completed,Not Applicable,Sensimed AG,"Sensimed AG|University of California, San Diego","Shiley Eye Center, University of California, San Diego",Device,United States,18.0,90.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT01798966
NCT01800617,hypothyroidism,Phase II Single Daily-Dose Response Study of a New Liothyronine Sodium (T3) Preparation With Sustained Effects in Hypothyroid Patients,A Study of T3 Therapy in Patients With Hypothyroidism,Hypothyroidism,2013-02-18,2014-07-31,,Interventional,Completed,Phase 2,"Ipe, LLC","Ipe, LLC",Georgetown University Hospital,Drug,United States,18.0,65.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01800617
NCT01801033,hypothyroidism,Effects of Pharmacologic Block of Type-1 Deiodinase on Thyroid Hormone Action and on the Circulating Levels of T3 in Hypothyroid Patients,Effects of Thyroid Hormone Enzyme Blocking on Hypothyroidism,Hypothyroidism|Thyroidectomy,2013-02-26,2013-11-29,2013-11-29,Observational,Withdrawn,,National Institutes of Health Clinical Center (CC),"National Heart, Lung, and Blood Institute (NHLBI)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",,,,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01801033
NCT01805856,thyroid disease,Antimicrobial Prophylaxis for the Prevention of Surgical Site Infection in Thyroid and Parathyroid Surgery,Antimicrobial Prophylaxis in Thyroid and Parathyroid Surgery,Parathyroid Disease|Thyroid Disease,2013-03-05,2012-05-31,2012-05-31,Interventional,Completed,Not Applicable,Ito Hospital,Ito Hospital,Ito Hospital,Drug|Drug,Japan,10.0,90.0,[0-17]|[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT01805856
NCT01811199,thyroid cancer,Dexamethasone Reduces Postoperative Emesis by Decreasing PGF2α and LTC4 Levels,Dexamethasone Reduces Postoperative Emesis by Decreasing PGF2α and LTC4 Levels,Breast Cancer|Thyroid Cancer,2013-03-06,2013-04-30,2013-05-31,Observational,Unknown status,,Marmara University,Marmara University,Marmara University School of Medicine,,Turkey,18.0,65.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01811199
NCT01811212,tall cell variant thyroid gland papillary carcinoma,Phase II Study of Cabozantinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on Prior VEGFR-Targeted Therapy,Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer,Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Carcinoma|Stage III Thyroid Gland Follicular Carcinoma|Stage III Thyroid Gland Papillary Carcinoma|Stage II Thyroid Gland Follicular Carcinoma|Stage II Thyroid Gland Papillary Carcinoma|Stage I Thyroid Gland Follicular Carcinoma|Stage I Thyroid Gland Papillary Carcinoma|Stage IVA Thyroid Gland Follicular Carcinoma|Stage IVA Thyroid Gland Papillary Carcinoma|Stage IVB Thyroid Gland Follicular Carcinoma|Stage IVB Thyroid Gland Papillary Carcinoma|Stage IVC Thyroid Gland Follicular Carcinoma|Stage IVC Thyroid Gland Papillary Carcinoma|Tall Cell Variant Thyroid Gland Papillary Carcinoma|Thyroid Gland Oncocytic Follicular Carcinoma,2013-03-12,2015-07-13,2017-10-09,Interventional,Completed,Phase 2,National Cancer Institute (NCI),Exelixis|National Cancer Institute (NCI),MedStar Georgetown University Hospital|Mayo Clinic in Florida|University of Chicago Comprehensive Cancer Center|Massachusetts General Hospital Cancer Center|Mayo Clinic|Ohio State University Comprehensive Cancer Center|M D Anderson Cancer Center,Drug|Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT01811212
NCT01811212,thyroid gland oncocytic follicular carcinoma,Phase II Study of Cabozantinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on Prior VEGFR-Targeted Therapy,Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer,Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Carcinoma|Stage III Thyroid Gland Follicular Carcinoma|Stage III Thyroid Gland Papillary Carcinoma|Stage II Thyroid Gland Follicular Carcinoma|Stage II Thyroid Gland Papillary Carcinoma|Stage I Thyroid Gland Follicular Carcinoma|Stage I Thyroid Gland Papillary Carcinoma|Stage IVA Thyroid Gland Follicular Carcinoma|Stage IVA Thyroid Gland Papillary Carcinoma|Stage IVB Thyroid Gland Follicular Carcinoma|Stage IVB Thyroid Gland Papillary Carcinoma|Stage IVC Thyroid Gland Follicular Carcinoma|Stage IVC Thyroid Gland Papillary Carcinoma|Tall Cell Variant Thyroid Gland Papillary Carcinoma|Thyroid Gland Oncocytic Follicular Carcinoma,2013-03-12,2015-07-13,2017-10-09,Interventional,Completed,Phase 2,National Cancer Institute (NCI),Exelixis|National Cancer Institute (NCI),MedStar Georgetown University Hospital|Mayo Clinic in Florida|University of Chicago Comprehensive Cancer Center|Massachusetts General Hospital Cancer Center|Mayo Clinic|Ohio State University Comprehensive Cancer Center|M D Anderson Cancer Center,Drug|Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Hurthle cell thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01811212
NCT01811212,poorly differentiated thyroid gland carcinoma,Phase II Study of Cabozantinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on Prior VEGFR-Targeted Therapy,Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer,Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Carcinoma|Stage III Thyroid Gland Follicular Carcinoma|Stage III Thyroid Gland Papillary Carcinoma|Stage II Thyroid Gland Follicular Carcinoma|Stage II Thyroid Gland Papillary Carcinoma|Stage I Thyroid Gland Follicular Carcinoma|Stage I Thyroid Gland Papillary Carcinoma|Stage IVA Thyroid Gland Follicular Carcinoma|Stage IVA Thyroid Gland Papillary Carcinoma|Stage IVB Thyroid Gland Follicular Carcinoma|Stage IVB Thyroid Gland Papillary Carcinoma|Stage IVC Thyroid Gland Follicular Carcinoma|Stage IVC Thyroid Gland Papillary Carcinoma|Tall Cell Variant Thyroid Gland Papillary Carcinoma|Thyroid Gland Oncocytic Follicular Carcinoma,2013-03-12,2015-07-13,2017-10-09,Interventional,Completed,Phase 2,National Cancer Institute (NCI),Exelixis|National Cancer Institute (NCI),MedStar Georgetown University Hospital|Mayo Clinic in Florida|University of Chicago Comprehensive Cancer Center|Massachusetts General Hospital Cancer Center|Mayo Clinic|Ohio State University Comprehensive Cancer Center|M D Anderson Cancer Center,Drug|Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Poorly differentiated thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01811212
NCT01812395,goiter,Is Superior Laryngeal Nerve Really Safe During Thyroidectomy Using Ultrasonic Dissector.,Thyroidectomy Using Ultrasonic Dissector: Is Superior Laryngeal Nerve Really Safe ?,Goiter,2013-03-08,2014-03-31,2014-04-30,Interventional,Unknown status,Not Applicable,S.B. Konya Education and Research Hospital,S.B. Konya Education and Research Hospital,Konya Education and Research Hospital,Device|Procedure,Turkey,18.0,65.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT01812395
NCT01813136,thyroid carcinoma,"A Randomized, Multicenter, Open-label, Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma",Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma,Thyroid Carcinoma,2013-03-11,2019-01-31,2019-01-31,Interventional,Completed,Phase 2,Centre Leon Berard,Centre Leon Berard|GlaxoSmithKline,CHU Angers|CHU Bordeaux|Institut Bergonié|Centre François Baclesse|CHRU Lille Hôpital Claude Huriez|Centre Leon Berard|Hôpital de la Timone APHM|Centre Antoine Lacassagne|Hôpital Saint-Louis APHP|Hôpital de la Pitié Salpêtrière APHP|Institut Jean Godinot|Institut Claudius Régaud|Institut Gustave Roussy,Drug|Drug,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01813136
NCT01815021,hypoparathyroidism,"A Randomized, Two Phase, Adaptive Then Crossover Open-label, Study Comparing Amorphous Calcium Carbonate (ACC) Supplement Versus Commercially Available Crystalline Calcium Supplements (CCS) in the Management of Primary Hypoparathyroidism.",A Study Comparing Amorphous Calcium Carbonate (ACC) Versus Crystalline Calcium CCS) in Hypoparathyroidism Patients,Hypoparathyroidism,2013-03-07,2014-06-30,2014-06-30,Interventional,Completed,Phase 1/Phase 2,Amorphical Ltd.,Amorphical Ltd.,Rambam Health Care Campus,Dietary Supplement|Dietary Supplement,Israel,18.0,80.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01815021
NCT01831869,hypothyroidism,The Beneficial Effect of L-Thyroxine Long -Term Replacement on Lipid Profiles and Atherosclerosis in Subclinical Hypothyroidism: A Prospective Study,Effect of L-Thyroxine on Lipid Profiles and Atherosclerosis in Subclinical Hypothyroidism,Endocrine System Diseases|Hypothyroidism|Thyroid Diseases,2013-04-07,2022-04-30,2022-04-30,Interventional,Unknown status,Phase 4,Shandong Provincial Hospital,Shandong Provincial Hospital,Shandong Provincial Hospital,Drug,China,18.0,60.0,[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01831869
NCT01831869,thyroid diseases,The Beneficial Effect of L-Thyroxine Long -Term Replacement on Lipid Profiles and Atherosclerosis in Subclinical Hypothyroidism: A Prospective Study,Effect of L-Thyroxine on Lipid Profiles and Atherosclerosis in Subclinical Hypothyroidism,Endocrine System Diseases|Hypothyroidism|Thyroid Diseases,2013-04-07,2022-04-30,2022-04-30,Interventional,Unknown status,Phase 4,Shandong Provincial Hospital,Shandong Provincial Hospital,Shandong Provincial Hospital,Drug,China,18.0,60.0,[18-65],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT01831869
NCT01833650,thyroid cancer,A Randomized Controlled Trial of the Effectiveness of Candy and Honey in Decreasing Salivary Gland Damage Following Radioiodine Therapy for Thyroid Cancer,The Use of Candy and Honey in Decreasing Salivary Gland Damage Following Radioiodine Therapy for Thyroid Cancer,Thyroid Cancer,2013-04-11,2018-08-31,2018-09-30,Interventional,Completed,Not Applicable,Cyprus University of Technology,Bank of Cyprus Oncology Centre|Cyprus University of Technology,Bank of Cyprus Oncology,Dietary Supplement,Cyprus,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01833650
NCT01837433,subacute thyroiditis,Efficiency and Safety Study of Short-term Prednisone to Treat Moderate and Severe Subacute Thyroiditis,Short-term Prednisone to Treat STA Study(SPTSS),Subacute Thyroiditis,2013-04-06,2014-12-31,2014-12-31,Interventional,Completed,Phase 4,Xinqiao Hospital of Chongqing,Xinqiao Hospital of Chongqing,"The Second Affiliated Hospital, Third Military Medical University",Drug|Drug,China,18.0,70.0,[18-65]|[65 and more],Thyroiditis,De Quervain's thyroiditis,https://clinicaltrials.gov/ct2/show/NCT01837433
NCT01838629,thyroid nodule,,the Effect of Universal Salt Iodization on Thyroid Diseases,Thyroid Nodule,2013-04-19,2012-06-30,2012-06-30,Observational [Patient Registry],Completed,,Hangzhou Center of Disease Control and Prevention,Weimin Xu,Hangzhou Center of Disease Control and Prevention,,China,6.0,86.0,[0-17]|[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT01838629
NCT01838642,thyroid neoplasms,A Phase II Study of Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer,Ponatinib for Advanced Medullary Thyroid Cancer,Thyroid Neoplasms,2013-04-20,2015-12-31,2016-01-31,Interventional,Terminated,Phase 2,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),"National Institutes of Health Clinical Center, 9000 Rockville Pike",Drug,United States,18.0,99.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01838642
NCT01840332,thyroid cancer,Method of Endogenous TSH Stimulation in the Follow-up of Differentiated Thyroid Cancer,Method of Endogenous TSH Stimulation in the Follow-up of Differentiated Thyroid Cancer,Thyroid Cancer,2013-04-22,2014-02-28,2014-02-28,Interventional,Completed,Not Applicable,University of Tartu,University of Tartu,East Tallinn Central Hospital|Tartu University Hospital,Drug,Estonia,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01840332
NCT01843062,differentiated thyroid cancer,"A Randomised, Double Blind Study to Compare the Complete Remission Rate Following a 5-Week Course of Selumetinib or Placebo and Single Dose Adjuvant Radioactive Iodine Therapy in Patients With Differentiated Thyroid Cancer",Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer,Differentiated Thyroid Cancer,2013-03-14,2018-05-18,2019-03-06,Interventional,Terminated,Phase 3,AstraZeneca,AstraZeneca,Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug|Drug|Drug,Brazil|Denmark|France|Germany|Italy|Poland|Sweden|United States,18.0,130.0,[18-65],Thyroid neoplasms,"Differentiated thyroid cancer, all",https://clinicaltrials.gov/ct2/show/NCT01843062
NCT01848171,hypothyroidism,Effects of Long-term L-thyroxine Replacement on Serum Lipid and Atherosclerosis in Patients With Hypothyroidism,Effects of L-thyroxine Replacement on Serum Lipid and Atherosclerosis in Hypothyroidism,Endocrine System Diseases|Hypothyroidism|Thyroid Diseases,2013-05-02,2023-07-31,2023-07-31,Interventional,Active not recruiting,Phase 4,Shandong Provincial Hospital,Shandong Provincial Hospital,Shandong Provincial Hospital,Drug,China,40.0,75.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01848171
NCT01848171,thyroid diseases,Effects of Long-term L-thyroxine Replacement on Serum Lipid and Atherosclerosis in Patients With Hypothyroidism,Effects of L-thyroxine Replacement on Serum Lipid and Atherosclerosis in Hypothyroidism,Endocrine System Diseases|Hypothyroidism|Thyroid Diseases,2013-05-02,2023-07-31,2023-07-31,Interventional,Active not recruiting,Phase 4,Shandong Provincial Hospital,Shandong Provincial Hospital,Shandong Provincial Hospital,Drug,China,40.0,75.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT01848171
NCT01862510,hypothyroidism,Detection of Celiac Disease in Patients With Hypothyroidism,Detection of Celiac Disease in Patients With Hypothyroidism,Celiac Disease|Celiac Sprue|Hypothyroidism|Malabsorption,2013-05-20,2014-12-31,2014-12-31,Observational,Completed,,University of Vermont,University of Vermont,Fletcher Allen Health Care,,United States,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01862510
NCT01865838,thyroid carcinoma,A Study Into the Effect of Seprafilm on Post Operative Adhesions After Open Total Thyroidectomy.,A Study Into the Effect of Seprafilm in Open Total Thyroidectomy,Thyroid Carcinoma,2013-05-14,2014-09-30,2014-09-30,Interventional,Terminated,Not Applicable,"National Cancer Centre, Singapore","National Cancer Centre, Singapore|Singapore General Hospital",Singapore General Hospital|National Cancer Centre Singapore,Device,Singapore,21.0,75.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01865838
NCT01868997,thyroid associated ophthalmopathies,"A Multicenter, Double-Masked, Placebo-Controlled, Efficacy And Safety Study Of RV 001, An Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), Administered Every 3 Weeks (q3W) By Intravenous (IV) Infusion In Patients Suffering From Active Thyroid Eye Disease (TED)",Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease,Thyroid Associated Ophthalmopathies|Thyroid-Associated Ophthalmopathy,2013-05-02,2016-03-31,2017-02-22,Interventional,Completed,Phase 2,"Horizon Pharma USA, Inc.","Horizon Pharma USA, Inc.","Jules Stein Eye Institute at UCLA|University of Denver|Emory University Department of Ophthalmology|University of Iowa Hospitals and Clinics, Department of Ophthalmology|Kellogg Eye Center at University of Michigan|Washington University Department of Ophthalmology|University of Nebraska Medical Center Department of Ophthalmology|Casey Eye Institute at Oregon Health and Science University|Hamilton Eye Institute at University of Tennessee|Eye Wellness Center|Medical College of Wisconsin, The Eye Institute|Johannes Gutenberg University Medical Center|Fondazione Ca' Granda Ospedale Policlinico Graves GO Center|University of Pisa, Azienda Ospedaliera|Moorfields Eye Hospital",Drug|Drug,Germany|Italy|United Kingdom|United States,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT01868997
NCT01872429,hyperparathyroidism,,Short- and Long-Term Impact of Subtotal Parathyroidectomy on the Achievement of Bone and Mineral Parameters Recommended by Clinical Practice Guidelines in Dialysis Patients,Hyperparathyroidism,2013-06-05,2013-04-30,2013-04-30,Observational,Completed,,Far Eastern Memorial Hospital,Far Eastern Memorial Hospital,Far Eastern Memorial Hospital,,Taiwan,20.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01872429
NCT01876784,differentiated thyroid cancer,"A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA™; SAR390530 (Formerly AstraZeneca ZD6474)) 300 mg in Patients With Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy.","Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer",Differentiated Thyroid Cancer,2013-06-11,2015-08-30,2022-12-31,Interventional,Active not recruiting,Phase 3,Sanofi,"Genzyme, a Sanofi Company",Research Site|Research Site|Research Site|Research Site|Research Site|Washington University|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site|Research Site,Drug|Drug,Brazil|China|Czechia|Denmark|France|Italy|Japan|Poland|Russian Federation|Spain|Sweden|United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Differentiated thyroid cancer, all",https://clinicaltrials.gov/ct2/show/NCT01876784
NCT01882816,thyroid cancer,A Phase II Study of Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Non-Anaplastic Non-Medullary Thyroid Cancer,Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Non-Anaplastic Non-Medullary Thyroid Cancer,Thyroid Cancer,2013-06-13,2021-11-04,2021-11-04,Interventional,Completed,Phase 2,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Basking Ridge|Memorial Sloan Kettering Monmouth|Memorial Sloan Kettering Commack|Memorial Sloan Kettering Westchester|Memorial Sloan Kettering Cancer Center|Memorial Sloan Kettering Rockville Centre,Radiation|Device|Drug|Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01882816
NCT01893450,graves ophthalmopathy,"Comparison of the Effect of Bromocriptine and Pentoxifylline in Mild to Moderate Autoimmune Ophthalmopathy. A Randomized, Controlled, Single Blind, Clinical Trial.",Bromocriptine and Pentoxifylline in Ophthalmopathy Autoimmune Treatment,Graves Ophthalmopathy,2013-06-28,2013-06-30,2013-06-30,Interventional,Terminated,Not Applicable,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,Drug|Drug|Drug,Mexico,18.0,45.0,[18-65],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT01893450
NCT01896479,medullary thyroid cancer,"A Randomized, Double-blind Study To Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to a 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients","A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer",Medullary Thyroid Cancer,2013-07-08,2020-07-31,2022-12-31,Interventional,Active not recruiting,Phase 4,Exelixis,Exelixis,,Drug|Drug|Drug|Drug,"Australia|Canada|Croatia|France|Hungary|Israel|Italy|Korea, Republic of|Netherlands|Poland|Romania|Russian Federation|Spain|Sweden",18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, medullary",https://clinicaltrials.gov/ct2/show/NCT01896479
NCT01907997,thyroid cancer,,Effects of Systemic Lidocaine on Postoperative Quality of Recovery After Robot-assisted Thyroidectomy,Thyroid Cancer,2013-07-17,2015-03-31,2015-05-31,Interventional,Completed,Not Applicable,Yonsei University,Yonsei University,"Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institue, Yonsei universiy college of medicine",Drug|Drug,"Korea, Republic of",20.0,65.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01907997
NCT01915485,medullary thyroid cancer,The Use of Lu177 in the Treatment of Progressive and Unresectable Metastatic Medullary Thyroid Cancer,Radiolabeled Molecules for Medullary Thyroid Cancer,Medullary Thyroid Cancer,2013-08-01,2016-11-30,2017-02-28,Interventional,Unknown status,Phase 4,"Instituto Nacional de Cancer, Brazil","Instituto Nacional de Cancer, Brazil",Instituto Nacional do Cancer do Rio de Janeiro,Radiation,Brazil,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, medullary",https://clinicaltrials.gov/ct2/show/NCT01915485
NCT01916018,congenital hypothyroidism,Phenotype and Genotype Analysis in Congenital Hypothyroidism Due to Thyroid Dysgenesis. The Use of Genetic Analysis in the Early Care of Children With Thyroid Dysgenesis,Clinical and Genetic Analysis in Congenital Hypothyroidism Due to Thyroid Dysgenesis.,Congenital Hypothyroidism,2013-08-02,2017-03-17,2017-03-17,Interventional,Completed,Not Applicable,Assistance Publique - Hôpitaux de Paris,Assistance Publique - Hôpitaux de Paris,"Pediatric endocrinology gynecology and diabetology, Hôpital Necker Enfants Malades, Assistance Publique - Hôpitaux de Paris , Université Paris Descartes, INSERM unit U 845",Other,France,0.0,120.0,[0-17]|[18-65]|[65 and more],Hypothyroidism,Congenital hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01916018
NCT01916304,hypothyroidism,"A Multicentre, Open-label Switch Study to Investigate the Necessity of Dose Adjustment After Switching From L-Thyroxine Christiaens® to the New Levothyroxine Sodium Test Formulation in (Near) Total Thyroidectomised Patients.",Study of Dose Adjustment From Levothyroxine to a New Levothyroxine Sodium Test Formulation,Hypothyroidism,2013-08-01,2014-06-30,2014-06-30,Interventional,Completed,Phase 2,Takeda,Takeda,,Drug,Belgium,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01916304
NCT01921452,hypothyroidism,A Single-center Interventional Study to Verify Clinical Utility of the Quantitative and the Qualitative POC TSH Test Kits Compared With the Third Generation TSH Test Kit,Study to Verify Clinical Utility of Point-of-Care (POC) Thyroid Stimulating Hormone (TSH) Test Kits as Compared to Third Generation TSH Test Kit,Hypothyroidism,2013-08-09,2014-02-28,2014-02-28,Interventional,Completed,Phase 4,"Merck KGaA, Darmstadt, Germany","Merck KGaA, Darmstadt, Germany",Research site,Device|Device|Device,China,0.0,120.0,[0-17]|[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01921452
NCT01922440,hypoparathyroidism,PARADIGHM (Physicians Advancing Disease Knowledge in Hypoparathyroidism): A Registry for Patients With Chronic Hypoparathyroidism,A Registry for Participants With Chronic Hypoparathyroidism,Hypoparathyroidism,2013-08-01,2034-11-30,2034-11-30,Observational [Patient Registry],Recruiting,,Takeda,"Takeda|Takeda Development Center Americas, Inc.","University of Alabama at Birmingham|University of Arizona Medical Center|Children's Hospital Los Angeles|Cedars-Sinai Medical Center|Dr. Joselito Cabaccan|University of Colorado Hospital|Yale University|Hanson Clinical Research Center|Thyroid & Endocrine Center of Florida|East-West Medical Research Institute|Suburban Endocrinology & Diabetes|University of Chicago Medical Center|Northshore University Health System|Loyola University Medical Center|Indiana University Hospital|Tilak Mallik, MD F.A.C.E., LCC|Model Clinical Research|Medstar Union Memorial Hospital|Massachusetts General Hospital|Brigham and Women's Hospital|Harvard Medical School|Boston Medical Center|University of Minnesota|Mayo Clinic - Rochester|University of Missouri|Diabetes & Endocrine Associates, Methodist Physicians Clinic Diabetes and Endocrine Specialists|Palm Research Center, Inc.|Northern Nevada Endocrinology|Rutgers Robert Wood Johnson Medical School|Rutgers-Robert Wood Johnson Medical School|Albany Med Endocrine Specialists|Brokhin Medical PC|Gerald Friedman Diabetes Institute|Columbia University Medical Center|Endocrine Associates of Long Island, P.C.|University Physicians Group Research Division|State University Of New York Upstate Medical University|Mecklenburg Medical Group|Physicians East, PA|Cleveland Clinic|Ohio State University Wexner Medical Center|Ohio Health Research Institute|Endocrinology Associates of Armstrong|The Children's Hospital of Philadelphia|Thomas Jefferson University|Alleghany General Hospital|Hallett Center for Diabetes and Endocrinology|University of South Carolina|Texas Diabetes and Endocrinology, P.A.|Thyroid Endocrinology and Diabetes|Academy of Diabetes Thyroid and Endocrine|Diabetes and Thyroid Center of Fort Worth, PLLC|University of Vermont|University of Wisconsin|Medizinische Universitaetsklinik Graz, Universitätsklinik Für Innere Medizin Graz|AKH Wien, Universitaetsklinik fuer Innere Medizin III|Nova Scotia Health Authority|McMaster University|Aallborg University Hospital|Aarhus Universitetshospital|Nordsjaellands Hospital - Hillerod|Regions Hospitalet Viborg|Diakonie-Klinikum Stuttgart|Medizinische Hochschule Hannover|University Hospital Duesseldorf|University of Leipzig|Universitaetsklinik Aachen|Charite-Universitiitsmedizin Berlin (CCM)|Praxis an der Kaiserreiche|Medizinische Fakultaet Carl Gustav Carus Technische Universitaet Dresden|Endokrinologikum Frankfurt|MVZ endokrinologikum Göttingen|Universitaet Zur Luebeck|Medicover Neuroendokrinologie MVZ|Medicover Neu-Ulm Mvz|Medicover Oldenburg MVZ|Medicover Saarbuecken Mvz|Endokrinologie Zentrum Ulm|Universitaetsklinikum Wuerzburg|General Hospital Of Athens - Korgialenio-Benakio E.E.S.|General Hospital of Athens Georgios Gennimatas|General Hospital of Athens Alexandra|AHEPA University General Hospital of Thessaloniki|Hippokrateion General Hospital of Thessaloniki|Azienda Ospedaliero-Universitaria Careggi|Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico|Azienda Ospedaliera San Giovanni Addolorata|Azienda Ospedaliero-Universitaria Citta della Salute e della Scienza - Ospedale Molinette|Haukeland University Hospital|Spesialistsentret Pilestredet Park|Hospital Del Mar|Hospital Universitario San Cecilio|Hospital Universitario 12 de Octubre|Universitetssjukhuset I Linkoping|Universitetssjukhuset I Orebro|Karolinska Universitetssjukhuset Solna|Akademiska Sjukhuset - Uppsala University Hospital|Queen Elizabeth Hospital-Mindelsohn Way|University of Hospitals of Leicester|Norfolk And Norwich University Hospital - Norwich Medical School",Other,Austria|Canada|Denmark|Germany|Greece|Italy|Norway|Spain|Sweden|United Kingdom|United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01922440
NCT01927406,thyroid eye disease,The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.,The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.,Glaucoma|Ocular Hypertension|Thyroid Eye Disease,2013-08-16,2016-12-31,2016-12-31,Interventional,Withdrawn,Phase 4,Stanford University,Stanford University,Stanford Hospital and Clinics,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT01927406
NCT01927887,follicular thyroid cancer lymph node metastasis,Pre-Operative Nodal Staging of Thyroid Cancer Using Ultra-Small Superparamagnetic Iron Oxide Magnetic Resonance Imaging (USPIO MRI): Preliminary Study,Pre-Operative Nodal Staging of Thyroid Cancer Using USPIO MRI: Preliminary Study,Follicular Thyroid Cancer Lymph Node Metastasis|Metastatic Medullary Thyroid Cancer|Papillary Carcinoma of Thyroid Gland,2013-08-20,2015-04-30,2016-04-30,Interventional,Completed,Not Applicable,Massachusetts General Hospital,Massachusetts General Hospital,Massachusetts General Hospital,Drug|Device,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT01927887
NCT01935856,hyperparathyroidism,"A Dose Escalation, Single and Multiple Dose, Phase 1/2 Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis",Phase 1/2 Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis,Hyperparathyroidism,2013-09-02,2014-03-31,2014-03-31,Interventional,Completed,Phase 1/Phase 2,"Kyowa Kirin Co., Ltd.","Kyowa Kirin Co., Ltd.","For additional information regarding investigative sites for this trial, contact Kyowa Hakko Kirin",Drug,Japan,20.0,74.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT01935856
NCT01945229,hyperthyroidism,Thumb-ECG Ambulant Screening for Atrial Fibrillation in Patients Treated for Hyperthyroidism (TAMBOURINE),Thumb-ECG Ambulant Screening for Atrial Fibrillation in Patients Treated for Hyperthyroidism (TAMBOURINE),Atrial Fibrillation|Hyperthyroidism,2013-09-13,2020-08-31,2020-08-31,Observational,Terminated,,Karolinska Institutet,Karolinska Institutet,"Medicine Clinic, Sahlgrenska University Hospital|Endocrinology Clinik, Karolinska University Hospital|Medicine Clinic, Danderyds Hospital",,Sweden,0.0,120.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT01945229
NCT01947023,metastatic thyroid gland carcinoma,A Phase 1 Study of Dabrafenib in Combination With Lapatinib in BRAF Mutant Thyroid Cancer,Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery,Metastatic Thyroid Gland Carcinoma|Unresectable Thyroid Gland Carcinoma,2013-09-16,2022-07-01,2022-07-01,Interventional,Active not recruiting,Phase 1,National Cancer Institute (NCI),National Cancer Institute (NCI),Memorial Sloan Kettering Cancer Center,Drug|Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Metastatic Thyroid Cancer,https://clinicaltrials.gov/ct2/show/NCT01947023
NCT01954134,thyroid neoplasms,P53 Antibody; Is it an Indicator of Dedifferentiated Thyroid Cancer?,P53 in Differentiated Thyroid Cancer,Thyroid Neoplasms,2013-09-11,2013-01-31,2013-01-31,Observational,Completed,,Cumhuriyet University,Cumhuriyet University,"Cumhuriyet University, School of Medicine, Dept. of Nuclear Medicine",,Turkey,16.0,80.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01954134
NCT01964144,thyroid cancer,,"An Open-label, Multicenter, Phase II Study of Dovitinib in Advanced Thyroid Cancer",Thyroid Cancer,2013-10-09,2014-10-31,2014-10-31,Interventional,Completed,Phase 2,Yonsei University,Yonsei University,"Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine",Drug,"Korea, Republic of",20.0,90.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01964144
NCT01964508,thyroid cancer,The Use of a microRNA Panel to Identify Thyroid Malignancy in FNA Leftover Cells and the Effect of These microRNAs on Target Genes.,microRNA in Thyroid Cancer,FNA|microRNA|Thyroid Cancer|Thyroid Nodule,2013-10-14,2015-12-30,2015-12-30,Observational [Patient Registry],Completed,,Hadassah Medical Organization,Hadassah Medical Organization,Hadassah Medical Organization,Other,Israel,18.0,75.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01964508
NCT01964508,thyroid nodule,The Use of a microRNA Panel to Identify Thyroid Malignancy in FNA Leftover Cells and the Effect of These microRNAs on Target Genes.,microRNA in Thyroid Cancer,FNA|microRNA|Thyroid Cancer|Thyroid Nodule,2013-10-14,2015-12-30,2015-12-30,Observational [Patient Registry],Completed,,Hadassah Medical Organization,Hadassah Medical Organization,Hadassah Medical Organization,Other,Israel,18.0,75.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT01964508
NCT01974284,papillary thyroid cancer,Percutaneous Ethanol Injection for Primary Papillary Thyroid Microcarcinoma,Percutaneous Ethanol Injection for Primary Papillary Thyroid Microcarcinoma,Papillary Thyroid Cancer,2013-10-25,2017-03-02,2017-06-29,Interventional,Terminated,Not Applicable,Yale University,Yale University,Endocrine Surgery Smilow Cancer Hospital at Yale-New Haven,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT01974284
NCT01994200,thyroid cancer,Developing and Implementing an Interdisciplinary Team-Based Care Approach (ITCA-ThyCa) For Newly Diagnosed Thyroid Cancer Patients: Randomized Controlled Trial,Developing and Implementing an Interdisciplinary Team-Based Care Approach (ITCA-ThyCa) for Thyroid Cancer Patients,Thyroid Cancer,2013-11-19,2016-06-30,2016-06-30,Interventional,Withdrawn,Phase 1/Phase 2,Jewish General Hospital,"Genzyme, a Sanofi Company|Jewish General Hospital",Jewish General Hospital,Other|Other,Canada,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT01994200
NCT01997554,hypothyroidism,Validation of a New TSH Test for Early Screening of Hypothyroidism,Validation of a New TSH Test,Euthyroidism|Hypothyroidism|Sub-clinical Hypothyroidism,2013-10-28,2014-08-31,2014-08-31,Interventional,Completed,Not Applicable,Hospices Civils de Lyon,Hospices Civils de Lyon,Centre Hospitalier de Chambéry|Centre Hospitalier Lyon Sud,Other,France,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT01997554
NCT01999790,graves ophthalmopathy,Comparison Study Between Two Techniques for Correction of Upper Lid Retraction in Patients With Grave's Orbitopathy,Comparison Study Between Two Techniques for Correction of Upper Lid Retraction in Patients With Grave's Orbitopathy,Graves Ophthalmopathy,2013-11-17,2014-12-31,2015-02-28,Interventional,Unknown status,Not Applicable,University of Sao Paulo,University of Sao Paulo,Hospital das Clinicas - FMUSP,Procedure|Procedure,Brazil,21.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT01999790
NCT02005250,hyperthyroidism,Bone Structure and Strength Evaluated by Extreme-CT Scan Before and After Treatment of Hyper- and Hypothyroidism,Bone Structure and Strength Evaluated by Extreme-CT Scan Before and After Treatment of Hyper- and Hypothyroidism,Hyperthyroidism|Hypothyroidism,2013-12-03,2016-10-31,2020-01-01,Observational,Completed,,Odense University Hospital,Steen Bonnema,Odense University Hospital,,Denmark,18.0,85.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02005250
NCT02005250,hypothyroidism,Bone Structure and Strength Evaluated by Extreme-CT Scan Before and After Treatment of Hyper- and Hypothyroidism,Bone Structure and Strength Evaluated by Extreme-CT Scan Before and After Treatment of Hyper- and Hypothyroidism,Hyperthyroidism|Hypothyroidism,2013-12-03,2016-10-31,2020-01-01,Observational,Completed,,Odense University Hospital,Steen Bonnema,Odense University Hospital,,Denmark,18.0,85.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT02005250
NCT02012231,thyroid cancer,"A Phase I/IIa Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PLX8394 in Patients With Advanced, Unresectable Solid Tumors","Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.",Cholangiocarcinoma|Colorectal Cancer|Hairy Cell Leukemia|Histiocytosis|Melanoma|Non-small Cell Lung Cancer|Thyroid Cancer,2013-12-05,2014-09-30,2015-06-30,Interventional,Terminated,Phase 1,Fore Biotherapeutics,Fore Biotherapeutics,Scottsdale Healthcare|Huntsman Cancer Institute|Evergreen Hematology & Oncology,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02012231
NCT02012686,thyroid cancer,The Effect of Transcutaneous Electrical Nerve Stimulation for Reduction of Posterior Neck Pain After Thyroidectomy,The Effect of Transcutaneous Electrical Nerve Stimulation on Posterior Neck Pain After Thyroidectomy,Neck Pain|Thyroid Cancer,2013-12-04,2014-01-31,2014-02-28,Interventional,Completed,Not Applicable,Yonsei University,Yonsei University,"Department of Anesthesiology and Pain Medicine, Gangnam Severance Hospital, Anesthesia and Pain Research Institute, Yonsei University College of Medicine",Device,"Korea, Republic of",20.0,60.0,[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02012686
NCT02012699,thyroid cancer,Integrated Cancer Repository for Cancer Research,Integrated Cancer Repository for Cancer Research,Anal Cancer|Bile Duct Cancer|Bladder Cancer|Breast Cancer|CNS Cancer|CNS Tumor|Colon Cancer|Duodenal Cancer|Endometrial Cancer|Esophageal Cancer|Familial Adenomatous Polyposis|Gallbladder Cancer|Gastric Cancer|GIST|Healthy Control|Hypopharyngeal Cancer|Kidney Cancer|Laryngeal Cancer|Leukemia|Lip Cancer|Liver Cancer|Lung Cancer|Lynch Syndrome|Melanoma|Mesothelioma|Multiple Myeloma|Nasal Cavity Cancer|Nasopharyngeal Cancer|Neuroendocrine Tumors|Oral Cavity Cancer|Oropharyngeal Cancer|Ovarian Cancer|Pancreatic Cancer|Paranasal Sinus Cancer|Penile Cancer|Peritoneal Surface Malignancies|Plasma Cell Dyscrasia|Prostate Cancer|Rectal Cancer|Salivary Gland Cancer|Sarcoma|Skin Cancer|Small Intestine Cancer|Testicular Cancer|Thymus Cancer|Thyroid Cancer|Unknown Primary Tumor|Ureter Cancer|Urethral Cancer|Vaginal Cancer,2013-12-02,2099-12-31,2099-12-31,Observational [Patient Registry],Recruiting,,University of Nebraska,University of Nebraska,"Penrose Cancer Center|Porter Adventist Hospital|Mercy Regional Medical Center|St. Anthony Hospital|Littleton Cancer Center|Longmont Cancer Center|Avista Cancer Center|Parker Adventist Hospital|St. Mary Corwin Medical Center|St. Anthony North Cancer Center|Florida Hospital Memorial Medical Center|Florida Hospital DeLand|Florida Hospital FISH|Florida Hospital Flagler|Rush-Copley Cancer Care Center|Trinity Medical Center|Rush-Copley Healthcare Center|Parkview Research Center|Community Health Network|Community Cancer Center South|Community Cancer Center North|Community Howard Regional Hospital|Methodist Jennie Edmundson Hospital|Genesis Medical Center|Abben Cancer Center|Covenant Medical Center, Inc|Saint Luke's Cancer Instititue - South|Tulane University|Breast Care Specialists of Maine|Northwest Hospital|William E Kahlert Regional Cancer Center|Holyoke Medical Center|University of Michigan Health System|Riverwood Healthcare Center|Essentia Health-St. Joseph's Medical Center|Essentia Health - Duluth Clinic|St. Luke's Hospital of Duluth|Lake Region Healthcare|Avera Cancer Institute- Marshall|Mercy Hospital - Joplin|Saint Luke's Cancer Institute - East|Saint Luke's Cancer Institute|Saint Luke's Cancer Institute - Kansas City North|Saint Luke's Cancer Institute - Liberty|Heartland Regional Medical Center dba Mosaic Life Care|Bozeman Health Deaconess Hospital|Logan Health|Providence St. Patrick Hospital Montana Cancer Center|Mary Lanning Healthcare/Morrison Cancer Center|Faith Regional Health Services, Carson Cancer Center|Great Plains Regional Medical Center|Avera St. Anthony's Hospital|Methodist Estabrook Cancer Center|Nebraska Methodist Health System|University of Nebraska Medical Center|Regional West Health Services|C.R. Wood Cancer Center, Glens Falls Hospital|Faxton St. Luke's Healthcare/Mohawk Valley|Cape Fear Valley Health System|Essentia Health|Trinity Hospital Cancer Care Center|Aultman Alliance Community Hospital|Aultman Hospital|University of Pittsburgh|Avera Medical Group Oncology and Hematology Aberdeen|Avera Cancer Institute|Avera Cancer Institute|Sanford Health|Avera Cancer Center Yankton|Avera Sacred Heart Hospital|Yankton Medical Clinic|Rutland Regional Medical Center|Mary Washington Hospital|Ascension St. Elizabeth Hospital|Wheaton Franciscan Healthcare - Elmbrook Memorial Hospital|Wheaton Franciscan Healthcare - Reiman Cancer Care|Columbia St. Mary's|Columbia St. Mary's|Ascension Mercy Hospital|Wheaton Franciscan Healthcare - All Saints|Wheaton Franciscan Healthcare - Wauwatosa Cancer Care",,United States,19.0,110.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02012699
NCT02013479,autoimmune thyroiditis,The Chronic Autoimmune Thyroiditis Quality Of Life Selenium Trial,Selenium Supplementation in Autoimmune Thyroiditis,Autoimmune Thyroiditis,2013-12-03,2022-08-31,2022-12-31,Interventional,Active not recruiting,Not Applicable,Odense University Hospital,"Bispebjerg Hospital|Hospital of South West Denmark|Pharma Nord|Region of Southern Denmark|Rigshospitalet, Denmark|Steen Bonnema|The Danish Medical Research Council|University of Southern Denmark","Clinic of Medical Endocrinology, Copenhagen University Hospital, Rigshospitalet|Department of Endocrinology and Gastroenterology, Bispebjerg Hospital|Department of Internal Medicine, Hospital of South West Denmark|Department of Endorcrinology and Metabolism, Odense University Hospital",Dietary Supplement|Dietary Supplement,Denmark,18.0,120.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT02013479
NCT02018276,thyroid cancer,,Effect of Perioperative Intravenous Lidocaine Infusion and Magnesium Infusion on the Functional Recovery After General Anesthesia in the Patients Undergoing Thyroid Surgery,Thyroid Cancer,2013-12-16,2014-10-31,2014-10-31,Interventional,Completed,Not Applicable,Yonsei University,Yonsei University,"Department of Anesthesiology and Pain MedicineSeverance Hospital, Yonsei University Health System",Drug|Drug,"Korea, Republic of",20.0,65.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02018276
NCT02062632,thyroid gland carcinoma,"A Pilot, Double-Blind, Randomized, Two-Arm Crossover Study of Doxepin Versus Placebo for Esophagitis-Induced Pain in Patients Receiving Radiotherapy to the Thorax With or Without Chemotherapy",Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy,Esophageal Carcinoma|Hypopharyngeal Carcinoma|Laryngeal Carcinoma|Lymphoma|Mesothelioma|Metastatic Malignant Neoplasm in the Lung|Metastatic Malignant Neoplasm in the Pleura|Metastatic Malignant Neoplasm in the Spinal Cord|Non-Small Cell Lung Carcinoma|Sarcoma|Small Cell Lung Carcinoma|Thymic Carcinoma|Thymoma|Thyroid Gland Carcinoma,2014-02-12,2015-05-29,2017-11-06,Interventional,Terminated,Phase 2,Mayo Clinic,Mayo Clinic|National Cancer Institute (NCI),Mayo Clinic|University of Nebraska Medical Center|Green Bay Oncology Limited at Saint Mary's Hospital,Drug|Other|Other|Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02062632
NCT02084732,thyroid cancer,Safety and Efficacy of Sorafenib in Patients With Advanced Thyroid Cancer: a Phase II Clinical Study,Safety and Efficacy of Sorafenib in Patients With Advanced Thyroid Cancer: a Phase II Clinical Study,Thyroid Cancer,2014-03-07,2019-11-01,2019-11-01,Interventional,Completed,Phase 2,"Instituto Nacional de Cancerologia, Columbia","Instituto Nacional de Cancerologia, Columbia",Instituto Nacional de Cancerología,Drug,Colombia,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02084732
NCT02088645,"thyroid cancer, medullary",177Lu-PP-F11N for Receptor Targeted Therapy and Imaging (Theranostics) of Metastatic Medullary Thyroid Cancer - a Pilot and a Phase I Study.,177Lu-PP-F11N for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer.,"Neuroendocrine Tumor GEP Grade 1-3|Neuroendocrine Tumor of the Lung Grade 1 and 2|Neuroendocrine Tumor of the Thymus Grade 1 and 2|Thyroid Cancer, Medullary",2014-02-19,2021-12-31,2022-03-31,Interventional,Recruiting,Phase 1,"University Hospital, Basel, Switzerland","Center for Proton Therapy, Paul Scherrer Institute, Villigen,Switzerland|Krebsforschung Schweiz, Bern, Switzerland|University Hospital, Basel, Switzerland|University Hospital Freiburg|University Hospital, Zürich","University Hospital Basel, Clinic for radiology and nuclear medicine",Drug,Switzerland,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, medullary",https://clinicaltrials.gov/ct2/show/NCT02088645
NCT02094079,hypothyroidism,Monitoring and Evaluation of the Levothyroxin Replacement Therapy in Pregnant Women,Monitoring and Evaluation of the Levothyroxin Replacement Therapy in Pregnant Women With Hypothyroidism,Hypothyroidism,2014-03-18,2015-03-31,2015-03-31,Observational,Completed,,Herlev Hospital,Birte Nygaard,"Endocrine Unit O, Herlev Hospital, University of Copenhagen",Other,Denmark,18.0,45.0,[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT02094079
NCT02107794,hyperthyroidism,Shared Decision Making in Graves Disease - Graves Disease (GD) Choice,Shared Decision Making in Graves Disease - Graves Disease (GD) Choice,Graves' Disease|Hyperthyroidism|Thyroid Disease,2014-03-24,2015-04-30,2015-04-30,Interventional,Completed,Not Applicable,Mayo Clinic,Mayo Clinic,Mayo Clinic,Other,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02107794
NCT02107794,thyroid disease,Shared Decision Making in Graves Disease - Graves Disease (GD) Choice,Shared Decision Making in Graves Disease - Graves Disease (GD) Choice,Graves' Disease|Hyperthyroidism|Thyroid Disease,2014-03-24,2015-04-30,2015-04-30,Interventional,Completed,Not Applicable,Mayo Clinic,Mayo Clinic,Mayo Clinic,Other,United States,18.0,120.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT02107794
NCT02112370,goiter,Phase 3 Study of Ropivacaine (With Epinephrine) in BABA Endoscopic and Robotic Thyroidectomy,Efficacy of Ropivacaine (With Epinephrine) in BABA Endoscopic and Robotic Thyroidectomy,Goiter|Thyroid Neoplasm,2014-04-07,2016-05-31,2016-06-30,Interventional,Completed,Phase 3,Seoul National University Hospital,Seoul National University Bundang Hospital|Seoul National University Hospital,Seoul National University Bundang Hospital|Seoul National University Hospital,Drug|Other,"Korea, Republic of",18.0,70.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02112370
NCT02112643,thyroid associated ophthalmopathies,Selenium - ITEDS: A North American Study,Selenium in Mild Thyroid Eye Disease in North America,Thyroid Associated Ophthalmopathies,2014-04-08,2016-11-16,2016-11-16,Interventional,Withdrawn,Phase 3,Columbia University,Columbia University|International Thyroid Eye Disease Society,,Drug|Dietary Supplement,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT02112643
NCT02114658,thyroid carcinoma,"A Multi-center, Single-arm, Open-label Phase II Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Sorafenib in Japanese Patients With Anaplastic Thyroid Carcinoma or Locally Advanced or Metastatic Medullary Thyroid Carcinoma",Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients,Thyroid Carcinoma,2014-04-08,2015-02-23,2016-08-02,Interventional,Completed,Phase 2,Bayer,Bayer,,Drug,Japan,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02114658
NCT02133040,hyperthyroidism,Identification and Regulation of Brown Adipose Tissue (BAT) in Humans. Implications for Energy Expenditure in Humans and in the Treatment of Obesity and Related Metabolic Diseases,Effects of Hyperthyroidism on Amount and Activity of Brown Adipose Tissue,Hyperthyroidism,2014-05-05,2018-05-10,2020-05-10,Observational,Unknown status,,Aarhus University Hospital,Aarhus University Hospital|Novo Nordisk A/S,Aarhus University Hospital,,Denmark,50.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02133040
NCT02140476,papillary thyroid cancer,Comparative Analysis Between A Bipolar Vessel Sealing and Cutting Device and the Tie and Suture Technique in Thyroidectomy: A Two Institution Randomized Clinical Trial,Comparative Analysis Between Bipolar Device and Conventional Tie & Suture Technique in Thyroidectomy,Papillary Thyroid Cancer|Thyroid Goiter,2014-05-09,2015-05-31,2015-07-31,Interventional,Unknown status,Not Applicable,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,Ethicon Endo-Surgery|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|University of Sao Paulo,"Hospital Das Clinicas, Universidad de Sao Paulo|Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán",Device|Procedure,Brazil|Mexico,18.0,65.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT02140476
NCT02145143,thyroid carcinoma,"Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study","Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study",Thyroid Carcinoma,2014-05-20,2023-05-31,2023-05-31,Interventional,Active not recruiting,Not Applicable,Memorial Sloan Kettering Cancer Center,"Genentech, Inc.|Memorial Sloan Kettering Cancer Center",Memorial Sloan Kettering Cancer Center,Drug|Device|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02145143
NCT02150772,thyroid nodule,Shear Wave Elastography in the Diagnosis and Risk-stratification of Thyroid Nodules - a Prospective Study,The Diagnostic Value of Shear Wave Elastography,Thyroid Nodule,2014-04-14,2016-03-31,2016-03-31,Interventional,Completed,Not Applicable,University of Aarhus,University of Aarhus,"Øre-Næse-Halsafdeling H, Aarhus University Hospital",Procedure,Denmark,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT02150772
NCT02152137,anaplastic thyroid cancer,"A Phase 2 Study of Efatutazone, an Oral PPAR Agonist, In Combination With Paclitaxel in Patients With Advanced Anaplastic Thyroid Cancer",Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer,Anaplastic Thyroid Cancer|Recurrent Thyroid Cancer,2014-05-29,2019-02-27,,Interventional,Active not recruiting,Phase 2,Alliance for Clinical Trials in Oncology,"Alliance for Clinical Trials in Oncology|Daiichi Sankyo, Inc.|National Cancer Institute (NCI)",Anchorage Associates in Radiation Medicine|Anchorage Radiation Therapy Center|Alaska Breast Care and Surgery LLC|Alaska Oncology and Hematology LLC|Alaska Regional Hospital|Alaska Women's Cancer Care|Anchorage Oncology Centre|Katmai Oncology Group|Providence Alaska Medical Center|Mayo Clinic Hospital|Mayo Clinic in Arizona|Providence Saint Joseph Medical Center/Disney Family Cancer Center|University of Colorado Hospital|Smilow Cancer Hospital Care Center at Saint Francis|Smilow Cancer Center/Yale-New Haven Hospital|Yale University|Beebe Medical Center|Christiana Gynecologic Oncology LLC|Delaware Clinical and Laboratory Physicians PA|Helen F Graham Cancer Center|Medical Oncology Hematology Consultants PA|Regional Hematology and Oncology PA|Christiana Care Health System-Christiana Hospital|Beebe Health Campus|Nanticoke Memorial Hospital|Christiana Care Health System-Wilmington Hospital|Mayo Clinic in Florida|Hawaii Oncology Inc-Pali Momi|Pali Momi Medical Center|The Cancer Center of Hawaii-Pali Momi|Hawaii Cancer Care Inc-POB II|Queen's Medical Center|Straub Clinic and Hospital|University of Hawaii Cancer Center|Hawaii Cancer Care Inc-Liliha|Hawaii Oncology Inc-Kuakini|Kuakini Medical Center|The Cancer Center of Hawaii-Liliha|Kapiolani Medical Center for Women and Children|Wilcox Memorial Hospital and Kauai Medical Clinic|Saint Alphonsus Cancer Care Center-Boise|Saint Luke's Mountain States Tumor Institute|Saint Alphonsus Cancer Care Center-Caldwell|Kootenai Medical Center|Walter Knox Memorial Hospital|Saint Luke's Mountain States Tumor Institute - Fruitland|Idaho Urologic Institute-Meridian|Saint Luke's Mountain States Tumor Institute - Meridian|Saint Alphonsus Medical Center-Nampa|Saint Luke's Mountain States Tumor Institute - Nampa|Kootenai Cancer Center|Kootenai Cancer Clinic|Saint Luke's Mountain States Tumor Institute-Twin Falls|Northwestern University|Cancer Center of Kansas - Chanute|Cancer Center of Kansas - Dodge City|Cancer Center of Kansas - El Dorado|Cancer Center of Kansas - Fort Scott|Central Care Cancer Center - Garden City|Central Care Cancer Center - Great Bend|Cancer Center of Kansas-Independence|Cancer Center of Kansas-Kingman|Lawrence Memorial Hospital|Kansas Institute of Medicine Cancer and Blood Center|Minimally Invasive Surgery Hospital|Cancer Center of Kansas-Liberal|Cancer Center of Kansas-Manhattan|Cancer Center of Kansas - McPherson|Cancer Center of Kansas - Newton|Menorah Medical Center|Saint Luke's South Hospital|Cancer Center of Kansas - Parsons|Cancer Center of Kansas - Pratt|Cancer Center of Kansas - Salina|Cancer Center of Kansas - Wellington|Associates In Womens Health|Cancer Center of Kansas-Wichita Medical Arts Tower|Cancer Center of Kansas - Wichita|Via Christi Regional Medical Center|Cancer Center of Kansas - Winfield|Mercy Medical Center|Saint Joseph Mercy Hospital|University of Michigan Comprehensive Cancer Center|IHA Hematology Oncology Consultants-Brighton|Saint Joseph Mercy Brighton|IHA Hematology Oncology Consultants-Canton|Saint Joseph Mercy Canton|Caro Cancer Center|IHA Hematology Oncology Consultants-Chelsea|Saint Joseph Mercy Chelsea|Hematology Oncology Consultants-Clarkston|Newland Medical Associates-Clarkston|Beaumont Hospital-Dearborn|Henry Ford Hospital|Ascension Saint John Hospital|Great Lakes Cancer Management Specialists-Doctors Park|Genesee Cancer and Blood Disease Treatment Center|Genesee Hematology Oncology PC|Genesys Hurley Cancer Institute|Hurley Medical Center|Great Lakes Cancer Management Specialists-Van Elslander Cancer Center|Lymphoma Clinic of Michigan|Michigan Breast Specialists-Grosse Pointe Woods|Allegiance Health|Sparrow Hospital|Hope Cancer Clinic|Saint Mary Mercy Hospital|Great Lakes Cancer Management Specialists-Macomb Medical Campus|Michigan Breast Specialists-Macomb Township|Saint Mary's Oncology/Hematology Associates of Marlette|21st Century Oncology-Pontiac|Hope Cancer Center|Newland Medical Associates-Pontiac|Saint Joseph Mercy Oakland|Lake Huron Medical Center|Great Lakes Cancer Management Specialists-Rochester Hills|Saint Mary's of Michigan|Oncology Hematology Associates of Saginaw Valley PC|Bhadresh Nayak MD PC-Sterling Heights|Saint Joseph Health System-Tawas City|Advanced Breast Care Center PLLC|Bhadresh Nayak MD PC-Warren|Great Lakes Cancer Management Specialists-Macomb Professional Building|Macomb Hematology Oncology PC|Michigan Breast Specialists-Warren|Saint John Macomb-Oakland Hospital|Saint Mary's Oncology/Hematology Associates of West Branch|Huron Gastroenterology PC|IHA Hematology Oncology Consultants-Ann Arbor|Sanford Joe Lueken Cancer Center|Fairview Ridges Hospital|Mercy Hospital|Fairview-Southdale Hospital|Unity Hospital|Fairview Maple Grove Medical Center|Minnesota Oncology Hematology PA-Maplewood|Saint John's Hospital - Healtheast|Abbott-Northwestern Hospital|Hennepin County Medical Center|Health Partners Inc|New Ulm Medical Center|North Memorial Medical Health Center|Mayo Clinic|Park Nicollet Clinic - Saint Louis Park|Regions Hospital|United Hospital|Saint Francis Regional Medical Center|Lakeview Hospital|Ridgeview Medical Center|Rice Memorial Hospital|Minnesota Oncology Hematology PA-Woodbury|Fairview Lakes Medical Center|Central Care Cancer Center - Bolivar|Centerpoint Medical Center LLC|Freeman Health System|Saint Luke's Hospital of Kansas City|Heartland Hematology and Oncology Associates Incorporated|Research Medical Center|Saint Luke's East - Lee's Summit|Liberty Radiation Oncology Center|Delbert Day Cancer Institute at PCRMC|Heartland Regional Medical Center|Saint Louis Cancer and Breast Institute-South City|Washington University School of Medicine|Mercy Hospital Saint Louis|Mercy Hospital Springfield|CoxHealth South Hospital|Community Hospital of Anaconda|Billings Clinic Cancer Center|Bozeman Deaconess Hospital|Benefis Healthcare- Sletten Cancer Institute|Great Falls Clinic|Saint Peter's Community Hospital|Kalispell Regional Medical Center|Saint Patrick Hospital - Community Hospital|Community Medical Hospital|Sanford Bismarck Medical Center|Roger Maris Cancer Center|Sanford Broadway Medical Center|University of Cincinnati/Barrett Cancer Center|Ohio State University Comprehensive Cancer Center|University Pointe|University of Oklahoma Health Sciences Center|Oklahoma Cancer Specialists and Research Institute-Tulsa|Saint Alphonsus Medical Center-Baker City|Saint Charles Health System|Clackamas Radiation Oncology Center|Providence Oncology and Hematology Care Southeast|Bay Area Hospital|Providence Newberg Medical Center|Saint Alphonsus Medical Center-Ontario|Providence Willamette Falls Medical Center|Providence Portland Medical Center|Providence Saint Vincent Medical Center|Saint Charles Health System-Redmond|Lehigh Valley Hospital-Cedar Crest|Lehigh Valley Hospital - Muhlenberg|Geisinger Medical Center|Pocono Medical Center|Geisinger Medical Center-Cancer Center Hazleton|Lehigh Valley Hospital-Hazleton|Geisinger Medical Oncology-Lewisburg|Lewistown Hospital|Geisinger Cancer Services-Pottsville|Community Medical Center|Geisinger Medical Oncology-Selinsgrove|Geisinger Medical Group|Geisinger Wyoming Valley/Henry Cancer Center|Greenville Health System Cancer Institute-Easley|Greenville Health System Cancer Institute-Andrews|Greenville Health System Cancer Institute-Butternut|Greenville Health System Cancer Institute-Faris|Greenville Memorial Hospital|Greenville Health System Cancer Institute-Eastside|Greenville Health System Cancer Institute-Greer|Greenville Health System Cancer Institute-Seneca|Greenville Health System Cancer Institute-Spartanburg|Sanford Cancer Center Oncology Clinic|Sanford USD Medical Center - Sioux Falls|Providence Regional Cancer System-Aberdeen|Cancer Care Center at Island Hospital|Swedish Cancer Institute-Eastside Oncology Hematology|PeaceHealth Saint Joseph Medical Center|Harrison HealthPartners Hematology and Oncology-Bremerton|Providence Regional Cancer System-Centralia|Swedish Medical Center-Edmonds|Providence Regional Cancer Partnership|Swedish Cancer Institute-Issaquah|Kadlec Clinic Hematology and Oncology|Providence Regional Cancer System-Lacey|PeaceHealth Saint John Medical Center|Jefferson Healthcare|Harrison HealthPartners Hematology and Oncology-Poulsbo|Minor and James Medical PLLC|Pacific Gynecology Specialists|Swedish Medical Center-Ballard Campus|Kaiser Permanente Washington|Swedish Medical Center-First Hill|Swedish Medical Center-Cherry Hill|PeaceHealth United General Medical Center|Providence Regional Cancer System-Shelton|Rockwood Clinic Cancer Treatment Center-Valley|Rockwood Cancer Treatment Center-DHEC-Downtown|Evergreen Hematology and Oncology PS|Rockwood North Cancer Treatment Center|PeaceHealth Southwest Medical Center|Providence Saint Mary Regional Cancer Center|North Star Lodge Cancer Center at Yakima Valley Memorial Hospital|Providence Regional Cancer System-Yelm|Froedtert and the Medical College of Wisconsin|Cancer Center of Western Wisconsin|Billings Clinic-Cody|Welch Cancer Center,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT02152137
NCT02152137,recurrent thyroid cancer,"A Phase 2 Study of Efatutazone, an Oral PPAR Agonist, In Combination With Paclitaxel in Patients With Advanced Anaplastic Thyroid Cancer",Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer,Anaplastic Thyroid Cancer|Recurrent Thyroid Cancer,2014-05-29,2019-02-27,,Interventional,Active not recruiting,Phase 2,Alliance for Clinical Trials in Oncology,"Alliance for Clinical Trials in Oncology|Daiichi Sankyo, Inc.|National Cancer Institute (NCI)",Anchorage Associates in Radiation Medicine|Anchorage Radiation Therapy Center|Alaska Breast Care and Surgery LLC|Alaska Oncology and Hematology LLC|Alaska Regional Hospital|Alaska Women's Cancer Care|Anchorage Oncology Centre|Katmai Oncology Group|Providence Alaska Medical Center|Mayo Clinic Hospital|Mayo Clinic in Arizona|Providence Saint Joseph Medical Center/Disney Family Cancer Center|University of Colorado Hospital|Smilow Cancer Hospital Care Center at Saint Francis|Smilow Cancer Center/Yale-New Haven Hospital|Yale University|Beebe Medical Center|Christiana Gynecologic Oncology LLC|Delaware Clinical and Laboratory Physicians PA|Helen F Graham Cancer Center|Medical Oncology Hematology Consultants PA|Regional Hematology and Oncology PA|Christiana Care Health System-Christiana Hospital|Beebe Health Campus|Nanticoke Memorial Hospital|Christiana Care Health System-Wilmington Hospital|Mayo Clinic in Florida|Hawaii Oncology Inc-Pali Momi|Pali Momi Medical Center|The Cancer Center of Hawaii-Pali Momi|Hawaii Cancer Care Inc-POB II|Queen's Medical Center|Straub Clinic and Hospital|University of Hawaii Cancer Center|Hawaii Cancer Care Inc-Liliha|Hawaii Oncology Inc-Kuakini|Kuakini Medical Center|The Cancer Center of Hawaii-Liliha|Kapiolani Medical Center for Women and Children|Wilcox Memorial Hospital and Kauai Medical Clinic|Saint Alphonsus Cancer Care Center-Boise|Saint Luke's Mountain States Tumor Institute|Saint Alphonsus Cancer Care Center-Caldwell|Kootenai Medical Center|Walter Knox Memorial Hospital|Saint Luke's Mountain States Tumor Institute - Fruitland|Idaho Urologic Institute-Meridian|Saint Luke's Mountain States Tumor Institute - Meridian|Saint Alphonsus Medical Center-Nampa|Saint Luke's Mountain States Tumor Institute - Nampa|Kootenai Cancer Center|Kootenai Cancer Clinic|Saint Luke's Mountain States Tumor Institute-Twin Falls|Northwestern University|Cancer Center of Kansas - Chanute|Cancer Center of Kansas - Dodge City|Cancer Center of Kansas - El Dorado|Cancer Center of Kansas - Fort Scott|Central Care Cancer Center - Garden City|Central Care Cancer Center - Great Bend|Cancer Center of Kansas-Independence|Cancer Center of Kansas-Kingman|Lawrence Memorial Hospital|Kansas Institute of Medicine Cancer and Blood Center|Minimally Invasive Surgery Hospital|Cancer Center of Kansas-Liberal|Cancer Center of Kansas-Manhattan|Cancer Center of Kansas - McPherson|Cancer Center of Kansas - Newton|Menorah Medical Center|Saint Luke's South Hospital|Cancer Center of Kansas - Parsons|Cancer Center of Kansas - Pratt|Cancer Center of Kansas - Salina|Cancer Center of Kansas - Wellington|Associates In Womens Health|Cancer Center of Kansas-Wichita Medical Arts Tower|Cancer Center of Kansas - Wichita|Via Christi Regional Medical Center|Cancer Center of Kansas - Winfield|Mercy Medical Center|Saint Joseph Mercy Hospital|University of Michigan Comprehensive Cancer Center|IHA Hematology Oncology Consultants-Brighton|Saint Joseph Mercy Brighton|IHA Hematology Oncology Consultants-Canton|Saint Joseph Mercy Canton|Caro Cancer Center|IHA Hematology Oncology Consultants-Chelsea|Saint Joseph Mercy Chelsea|Hematology Oncology Consultants-Clarkston|Newland Medical Associates-Clarkston|Beaumont Hospital-Dearborn|Henry Ford Hospital|Ascension Saint John Hospital|Great Lakes Cancer Management Specialists-Doctors Park|Genesee Cancer and Blood Disease Treatment Center|Genesee Hematology Oncology PC|Genesys Hurley Cancer Institute|Hurley Medical Center|Great Lakes Cancer Management Specialists-Van Elslander Cancer Center|Lymphoma Clinic of Michigan|Michigan Breast Specialists-Grosse Pointe Woods|Allegiance Health|Sparrow Hospital|Hope Cancer Clinic|Saint Mary Mercy Hospital|Great Lakes Cancer Management Specialists-Macomb Medical Campus|Michigan Breast Specialists-Macomb Township|Saint Mary's Oncology/Hematology Associates of Marlette|21st Century Oncology-Pontiac|Hope Cancer Center|Newland Medical Associates-Pontiac|Saint Joseph Mercy Oakland|Lake Huron Medical Center|Great Lakes Cancer Management Specialists-Rochester Hills|Saint Mary's of Michigan|Oncology Hematology Associates of Saginaw Valley PC|Bhadresh Nayak MD PC-Sterling Heights|Saint Joseph Health System-Tawas City|Advanced Breast Care Center PLLC|Bhadresh Nayak MD PC-Warren|Great Lakes Cancer Management Specialists-Macomb Professional Building|Macomb Hematology Oncology PC|Michigan Breast Specialists-Warren|Saint John Macomb-Oakland Hospital|Saint Mary's Oncology/Hematology Associates of West Branch|Huron Gastroenterology PC|IHA Hematology Oncology Consultants-Ann Arbor|Sanford Joe Lueken Cancer Center|Fairview Ridges Hospital|Mercy Hospital|Fairview-Southdale Hospital|Unity Hospital|Fairview Maple Grove Medical Center|Minnesota Oncology Hematology PA-Maplewood|Saint John's Hospital - Healtheast|Abbott-Northwestern Hospital|Hennepin County Medical Center|Health Partners Inc|New Ulm Medical Center|North Memorial Medical Health Center|Mayo Clinic|Park Nicollet Clinic - Saint Louis Park|Regions Hospital|United Hospital|Saint Francis Regional Medical Center|Lakeview Hospital|Ridgeview Medical Center|Rice Memorial Hospital|Minnesota Oncology Hematology PA-Woodbury|Fairview Lakes Medical Center|Central Care Cancer Center - Bolivar|Centerpoint Medical Center LLC|Freeman Health System|Saint Luke's Hospital of Kansas City|Heartland Hematology and Oncology Associates Incorporated|Research Medical Center|Saint Luke's East - Lee's Summit|Liberty Radiation Oncology Center|Delbert Day Cancer Institute at PCRMC|Heartland Regional Medical Center|Saint Louis Cancer and Breast Institute-South City|Washington University School of Medicine|Mercy Hospital Saint Louis|Mercy Hospital Springfield|CoxHealth South Hospital|Community Hospital of Anaconda|Billings Clinic Cancer Center|Bozeman Deaconess Hospital|Benefis Healthcare- Sletten Cancer Institute|Great Falls Clinic|Saint Peter's Community Hospital|Kalispell Regional Medical Center|Saint Patrick Hospital - Community Hospital|Community Medical Hospital|Sanford Bismarck Medical Center|Roger Maris Cancer Center|Sanford Broadway Medical Center|University of Cincinnati/Barrett Cancer Center|Ohio State University Comprehensive Cancer Center|University Pointe|University of Oklahoma Health Sciences Center|Oklahoma Cancer Specialists and Research Institute-Tulsa|Saint Alphonsus Medical Center-Baker City|Saint Charles Health System|Clackamas Radiation Oncology Center|Providence Oncology and Hematology Care Southeast|Bay Area Hospital|Providence Newberg Medical Center|Saint Alphonsus Medical Center-Ontario|Providence Willamette Falls Medical Center|Providence Portland Medical Center|Providence Saint Vincent Medical Center|Saint Charles Health System-Redmond|Lehigh Valley Hospital-Cedar Crest|Lehigh Valley Hospital - Muhlenberg|Geisinger Medical Center|Pocono Medical Center|Geisinger Medical Center-Cancer Center Hazleton|Lehigh Valley Hospital-Hazleton|Geisinger Medical Oncology-Lewisburg|Lewistown Hospital|Geisinger Cancer Services-Pottsville|Community Medical Center|Geisinger Medical Oncology-Selinsgrove|Geisinger Medical Group|Geisinger Wyoming Valley/Henry Cancer Center|Greenville Health System Cancer Institute-Easley|Greenville Health System Cancer Institute-Andrews|Greenville Health System Cancer Institute-Butternut|Greenville Health System Cancer Institute-Faris|Greenville Memorial Hospital|Greenville Health System Cancer Institute-Eastside|Greenville Health System Cancer Institute-Greer|Greenville Health System Cancer Institute-Seneca|Greenville Health System Cancer Institute-Spartanburg|Sanford Cancer Center Oncology Clinic|Sanford USD Medical Center - Sioux Falls|Providence Regional Cancer System-Aberdeen|Cancer Care Center at Island Hospital|Swedish Cancer Institute-Eastside Oncology Hematology|PeaceHealth Saint Joseph Medical Center|Harrison HealthPartners Hematology and Oncology-Bremerton|Providence Regional Cancer System-Centralia|Swedish Medical Center-Edmonds|Providence Regional Cancer Partnership|Swedish Cancer Institute-Issaquah|Kadlec Clinic Hematology and Oncology|Providence Regional Cancer System-Lacey|PeaceHealth Saint John Medical Center|Jefferson Healthcare|Harrison HealthPartners Hematology and Oncology-Poulsbo|Minor and James Medical PLLC|Pacific Gynecology Specialists|Swedish Medical Center-Ballard Campus|Kaiser Permanente Washington|Swedish Medical Center-First Hill|Swedish Medical Center-Cherry Hill|PeaceHealth United General Medical Center|Providence Regional Cancer System-Shelton|Rockwood Clinic Cancer Treatment Center-Valley|Rockwood Cancer Treatment Center-DHEC-Downtown|Evergreen Hematology and Oncology PS|Rockwood North Cancer Treatment Center|PeaceHealth Southwest Medical Center|Providence Saint Mary Regional Cancer Center|North Star Lodge Cancer Center at Yakima Valley Memorial Hospital|Providence Regional Cancer System-Yelm|Froedtert and the Medical College of Wisconsin|Cancer Center of Western Wisconsin|Billings Clinic-Cody|Welch Cancer Center,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Recurrent Thyroid Cancer,https://clinicaltrials.gov/ct2/show/NCT02152137
NCT02152228,hypoparathyroidism,A Pilot Study to Assess the Safety and Efficacy of Oral PTH (1-34) in the Treatment of Hypoparathyroidism,A Pilot Study to Assess the Safety and Efficacy of Oral PTH (1-34) in the Treatment of Hypoparathyroidism,Hypoparathyroidism,2014-04-22,2015-06-30,2015-07-31,Interventional,Completed,Phase 2,Entera Bio Ltd.,Entera Bio Ltd.,Lin Medical Center,Drug,Israel,18.0,80.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02152228
NCT02152995,poorly differentiated thyroid gland carcinoma,"A Phase 2 Study of Trametinib in Combination With Radioiodine (RAI) for RAS Mutant or RAS/RAF Wild-Type, RAI-Refractory Recurrent and/or Metastatic Thyroid Cancers",Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer,Metastatic Thyroid Gland Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Carcinoma|Refractory Thyroid Gland Carcinoma|Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7|Stage IV Thyroid Gland Follicular Carcinoma AJCC v7|Stage IV Thyroid Gland Papillary Carcinoma AJCC v7,2014-05-29,2021-08-25,2023-01-12,Interventional,Active not recruiting,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Memorial Sloan Kettering Cancer Center,Procedure|Other|Radiation|Other|Other|Procedure|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Poorly differentiated thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02152995
NCT02152995,metastatic thyroid gland carcinoma,"A Phase 2 Study of Trametinib in Combination With Radioiodine (RAI) for RAS Mutant or RAS/RAF Wild-Type, RAI-Refractory Recurrent and/or Metastatic Thyroid Cancers",Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer,Metastatic Thyroid Gland Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Carcinoma|Refractory Thyroid Gland Carcinoma|Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7|Stage IV Thyroid Gland Follicular Carcinoma AJCC v7|Stage IV Thyroid Gland Papillary Carcinoma AJCC v7,2014-05-29,2021-08-25,2023-01-12,Interventional,Active not recruiting,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Memorial Sloan Kettering Cancer Center,Procedure|Other|Radiation|Other|Other|Procedure|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Metastatic Thyroid Cancer,https://clinicaltrials.gov/ct2/show/NCT02152995
NCT02155049,thyroid associated ophthalmopathies,Phase 3 Study of Treatment of Soft Tissue Expansion and Exophthalmos in Inactive Thyroid Eye Disease Patients Using Drops of Prostaglandin Analogues.,Treatment of Soft Tissue Expansion in Inactive Thyroid Eye Disease Patients Using Drops of Prostaglandin Analogues,Thyroid Associated Ophthalmopathies,2014-05-21,2017-05-31,2017-05-31,Interventional,Completed,Phase 3,Rabin Medical Center,Rabin Medical Center,"Ophthalmology clinics, Rabin Medical Center",Drug,Israel,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT02155049
NCT02156362,thyroid cancer,Determination of Pronostics Factors for Advanced Thyroid Carcinoma (pT3 pT4 or M1 at Diagnosis),Determination of Pronostics Factors for Advanced Thyroid Carcinoma (pT3 pT4 or M1 at Diagnosis),Thyroid Cancer,2012-05-29,2023-05-31,2023-05-31,Interventional,Active not recruiting,Not Applicable,Hospices Civils de Lyon,Hospices Civils de Lyon,Hospices Civils de Lyon-Centre de Médecine Nucléaire Groupement Hospitalier Est 59 boulevard Pinel,Other,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02156362
NCT02178345,papillary thyroid cancer,Predictive MRI Metrics for Tumor Aggressiveness in Papillary Thyroid Cancer,Predictive MRI Metrics for Tumor Aggressiveness in Papillary Thyroid Cancer,Papillary Thyroid Cancer,2014-06-25,2021-12-03,2021-12-03,Observational,Completed,,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Procedure|Procedure,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT02178345
NCT02185560,thyroid carcinoma,Drug Use Investigation of Sorafenib/ NEXAVAR® for Unresectable Differentiated Thyroid Carcinoma (DTC),"Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib",Thyroid Carcinoma,2014-07-04,2020-02-27,2024-06-30,Observational,Active not recruiting,,Bayer,Bayer,,Drug,Japan,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02185560
NCT02190214,hyperthyroidism,Thyroid Disorders in Malaysian: A Nationwide Multicentre Study,Thyroid Disorders in Malaysia: A Nationwide Multicentre Study,Genetic Susceptibility|Graves Disease|Hashimoto's Thyroiditis|Hyperthyroidism|Hypothyroidism|Iodine Deficiency|Subclinical Hyperthyroidism|Subclinical Hypothyroidism,2014-07-09,2016-09-30,2016-09-30,Observational,Completed,,International Islamic University Malaysia,International Islamic University Malaysia|International Medical University|Malaysian Endocrine and Metabolic Society|National University of Malaysia|University of Malaya,,,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02190214
NCT02190214,graves disease,Thyroid Disorders in Malaysian: A Nationwide Multicentre Study,Thyroid Disorders in Malaysia: A Nationwide Multicentre Study,Genetic Susceptibility|Graves Disease|Hashimoto's Thyroiditis|Hyperthyroidism|Hypothyroidism|Iodine Deficiency|Subclinical Hyperthyroidism|Subclinical Hypothyroidism,2014-07-09,2016-09-30,2016-09-30,Observational,Completed,,International Islamic University Malaysia,International Islamic University Malaysia|International Medical University|Malaysian Endocrine and Metabolic Society|National University of Malaysia|University of Malaya,,,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02190214
NCT02190214,hypothyroidism,Thyroid Disorders in Malaysian: A Nationwide Multicentre Study,Thyroid Disorders in Malaysia: A Nationwide Multicentre Study,Genetic Susceptibility|Graves Disease|Hashimoto's Thyroiditis|Hyperthyroidism|Hypothyroidism|Iodine Deficiency|Subclinical Hyperthyroidism|Subclinical Hypothyroidism,2014-07-09,2016-09-30,2016-09-30,Observational,Completed,,International Islamic University Malaysia,International Islamic University Malaysia|International Medical University|Malaysian Endocrine and Metabolic Society|National University of Malaysia|University of Malaya,,,,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT02190214
NCT02194920,thyroid carcinoma,Arathyroid Reimplantation in Forearm Subcutaneous Tissue During Thyroidectomy: a Simple Way to Avoid Ipoparathyroidism and Evaluate Graft Function,Parathyroid Reimplantation in Forearm Subcutaneous Tissue During Thyroidectomy: a Simple Way to Avoid Ipoparathyroidism and Evaluate Graft Function,Graves Diseases|Multinodular Goiter|Thyroid Carcinoma|Thyroid Goiter,2014-07-03,2014-10-31,2014-11-30,Observational,Completed,,University of Roma La Sapienza,University of Roma La Sapienza,"General Surgery Unit, ICOT Hospital",Procedure,Italy,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02194920
NCT02194920,multinodular goiter,Arathyroid Reimplantation in Forearm Subcutaneous Tissue During Thyroidectomy: a Simple Way to Avoid Ipoparathyroidism and Evaluate Graft Function,Parathyroid Reimplantation in Forearm Subcutaneous Tissue During Thyroidectomy: a Simple Way to Avoid Ipoparathyroidism and Evaluate Graft Function,Graves Diseases|Multinodular Goiter|Thyroid Carcinoma|Thyroid Goiter,2014-07-03,2014-10-31,2014-11-30,Observational,Completed,,University of Roma La Sapienza,University of Roma La Sapienza,"General Surgery Unit, ICOT Hospital",Procedure,Italy,0.0,120.0,[0-17]|[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02194920
NCT02203682,hyperthyroidism,The Effect of Subantimicrobial Dose Doxycycline in Mild Thyroid-Associated Ophthalmopathy,Doxycycline Treatment in Mild Thyroid-Associated Ophthalmopathy,"Autoimmune Diseases|Endocrine System Diseases|Eye Diseases, Hereditary|Graves Disease|Graves Ophthalmopathy|Hyperthyroidism|Immune System Diseases|Thyroid-associated Ophthalmopathy|Thyroid Diseases",2014-07-28,2022-07-31,2022-07-31,Interventional,Recruiting,Phase 2,Sun Yat-sen University,Sun Yat-sen University,Zhongshan Ophthalmic Center,Drug|Drug,China,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02203682
NCT02203682,graves disease,The Effect of Subantimicrobial Dose Doxycycline in Mild Thyroid-Associated Ophthalmopathy,Doxycycline Treatment in Mild Thyroid-Associated Ophthalmopathy,"Autoimmune Diseases|Endocrine System Diseases|Eye Diseases, Hereditary|Graves Disease|Graves Ophthalmopathy|Hyperthyroidism|Immune System Diseases|Thyroid-associated Ophthalmopathy|Thyroid Diseases",2014-07-28,2022-07-31,2022-07-31,Interventional,Recruiting,Phase 2,Sun Yat-sen University,Sun Yat-sen University,Zhongshan Ophthalmic Center,Drug|Drug,China,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02203682
NCT02203682,graves ophthalmopathy,The Effect of Subantimicrobial Dose Doxycycline in Mild Thyroid-Associated Ophthalmopathy,Doxycycline Treatment in Mild Thyroid-Associated Ophthalmopathy,"Autoimmune Diseases|Endocrine System Diseases|Eye Diseases, Hereditary|Graves Disease|Graves Ophthalmopathy|Hyperthyroidism|Immune System Diseases|Thyroid-associated Ophthalmopathy|Thyroid Diseases",2014-07-28,2022-07-31,2022-07-31,Interventional,Recruiting,Phase 2,Sun Yat-sen University,Sun Yat-sen University,Zhongshan Ophthalmic Center,Drug|Drug,China,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT02203682
NCT02203682,thyroid diseases,The Effect of Subantimicrobial Dose Doxycycline in Mild Thyroid-Associated Ophthalmopathy,Doxycycline Treatment in Mild Thyroid-Associated Ophthalmopathy,"Autoimmune Diseases|Endocrine System Diseases|Eye Diseases, Hereditary|Graves Disease|Graves Ophthalmopathy|Hyperthyroidism|Immune System Diseases|Thyroid-associated Ophthalmopathy|Thyroid Diseases",2014-07-28,2022-07-31,2022-07-31,Interventional,Recruiting,Phase 2,Sun Yat-sen University,Sun Yat-sen University,Zhongshan Ophthalmic Center,Drug|Drug,China,18.0,70.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT02203682
NCT02205801,thyroid neoplasms,A Randomized Control Trial Comparing Bilateral Superficial Cervical Plexus Block and Local Wound Infiltration in Thyroidectomy and Parathyroidectomy,Study of the Efficacy of Local Analgesia as an Adjunct to General Anesthesia in Thyroidectomy and Parathyroidectomy,"Goiter, Nodular|Graves' Disease|Hyperparathyroidism|Thyroid Neoplasms|Thyroid Nodule",2014-07-29,2017-02-10,2017-02-17,Interventional,Completed,Not Applicable,University of Chicago,University of Chicago,University of Chicago Medical Center,Procedure|Procedure|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02205801
NCT02205801,hyperparathyroidism,A Randomized Control Trial Comparing Bilateral Superficial Cervical Plexus Block and Local Wound Infiltration in Thyroidectomy and Parathyroidectomy,Study of the Efficacy of Local Analgesia as an Adjunct to General Anesthesia in Thyroidectomy and Parathyroidectomy,"Goiter, Nodular|Graves' Disease|Hyperparathyroidism|Thyroid Neoplasms|Thyroid Nodule",2014-07-29,2017-02-10,2017-02-17,Interventional,Completed,Not Applicable,University of Chicago,University of Chicago,University of Chicago Medical Center,Procedure|Procedure|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02205801
NCT02205801,"goiter, nodular",A Randomized Control Trial Comparing Bilateral Superficial Cervical Plexus Block and Local Wound Infiltration in Thyroidectomy and Parathyroidectomy,Study of the Efficacy of Local Analgesia as an Adjunct to General Anesthesia in Thyroidectomy and Parathyroidectomy,"Goiter, Nodular|Graves' Disease|Hyperparathyroidism|Thyroid Neoplasms|Thyroid Nodule",2014-07-29,2017-02-10,2017-02-17,Interventional,Completed,Not Applicable,University of Chicago,University of Chicago,University of Chicago Medical Center,Procedure|Procedure|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02205801
NCT02205801,thyroid nodule,A Randomized Control Trial Comparing Bilateral Superficial Cervical Plexus Block and Local Wound Infiltration in Thyroidectomy and Parathyroidectomy,Study of the Efficacy of Local Analgesia as an Adjunct to General Anesthesia in Thyroidectomy and Parathyroidectomy,"Goiter, Nodular|Graves' Disease|Hyperparathyroidism|Thyroid Neoplasms|Thyroid Nodule",2014-07-29,2017-02-10,2017-02-17,Interventional,Completed,Not Applicable,University of Chicago,University of Chicago,University of Chicago Medical Center,Procedure|Procedure|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT02205801
NCT02208544,thyroid neoplasms,Efficacy of [18F]-2-fluoro-2-deoxy-D-glucose Positron Emission Tomography (FDG-PET) in Evaluation of Cytological Indeterminate Thyroid Nodules Prior to Surgery: a Multicentre Cost-effectiveness Study,FDG-PET/CT in Evaluation of Cytological Indeterminate Thyroid Nodules to Prevent Unnecessary Surgery (EfFECTS),Thyroid Neoplasms|Thyroid Nodule,2014-07-22,2020-01-01,2022-02-15,Interventional,Completed,Not Applicable,Radboud University Medical Center,Dutch Cancer Society|Radboud University Medical Center,Radboudumc|MUMC|AMC|VUmc|MeanderMC|LUMC|ErasmusMC|Onze Lieve Vrouwe Gasthuis|Rijnstate|Reinier de Graaf Ziekenhuis|UMCG|St. Antonius|HagaZiekenhuis|UMCU|Isala Klinieken,Procedure|Device|Radiation,Netherlands,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02208544
NCT02208544,thyroid nodule,Efficacy of [18F]-2-fluoro-2-deoxy-D-glucose Positron Emission Tomography (FDG-PET) in Evaluation of Cytological Indeterminate Thyroid Nodules Prior to Surgery: a Multicentre Cost-effectiveness Study,FDG-PET/CT in Evaluation of Cytological Indeterminate Thyroid Nodules to Prevent Unnecessary Surgery (EfFECTS),Thyroid Neoplasms|Thyroid Nodule,2014-07-22,2020-01-01,2022-02-15,Interventional,Completed,Not Applicable,Radboud University Medical Center,Dutch Cancer Society|Radboud University Medical Center,Radboudumc|MUMC|AMC|VUmc|MeanderMC|LUMC|ErasmusMC|Onze Lieve Vrouwe Gasthuis|Rijnstate|Reinier de Graaf Ziekenhuis|UMCG|St. Antonius|HagaZiekenhuis|UMCU|Isala Klinieken,Procedure|Device|Radiation,Netherlands,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT02208544
NCT02210741,graves disease,Next-generation Sequencing (NGS) of Peripheral Blood Immune Repertoire in Graves' Disease,Next-generation Sequencing (NGS) of Peripheral Blood Immune Repertoire in Graves' Disease,Graves Disease,2014-08-04,2024-02-29,2024-02-29,Observational,Not yet recruiting,,National Taiwan University Hospital,National Taiwan University Hospital,National Taiwan University Hospital,,Taiwan,20.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02210741
NCT02223052,thyroid cancer,"A Phase 1, Open-label, Multicenter, Randomized, 2-Period, Crossover Study to Evaluate the Bioequivalence and Food Effect Bioavailability of CC-486 (Oral Azacitidine) Tablets in Adult Cancer Subjects",Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies,Acute Myeloid Leukemia|Breast Cancer|Genitourinary|Glioblastoma Multiforme|Hematological Neoplasms|Hodgkin's Lymphoma|Leukemia|Lymphoma|Melanoma|Metastatic Breast Cancer|Multiple Myeloma|Myelodysplastic Syndromes|Neoplasms|Non-Hodgkin's Lymphoma|Non-Small Cell Lung Cancer|Osteosarcoma|Renal Cell Carcinoma|Sarcoma|Small Cell Lung Cancer|Thyroid Cancer,2014-08-20,2018-06-11,2018-12-18,Interventional,Completed,Phase 1,Celgene,Celgene,Scottsdale Healthcare Research Institute|Mayo Clinic - Arizona|University of Arizona Cancer Center|University of Iowa|Henry Ford Health System|Cancer Institute of New Jersey|Cleveland Clinic Foundation|Greenville Hospital System|Vanderbilt- Ingram Cancer Center|The Methodist Hospital Research Institute l,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02223052
NCT02225509,thyroid cancer,Clinical Validation of the Diagnostic Performance of a Molecular Signature to Determine the Malignant or Benign Profile of a Thyroid Nodule With Indeterminate Cytological Analysis,Clinical Validation of a Molecular Signature to Detect Cancer in Thyroid Nodules With Indeterminate Cytology,Thyroid Cancer|Thyroid Nodule,2014-08-19,2016-12-31,,Interventional,Unknown status,Not Applicable,Diaxonhit,Diaxonhit,,Procedure,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02225509
NCT02225509,thyroid nodule,Clinical Validation of the Diagnostic Performance of a Molecular Signature to Determine the Malignant or Benign Profile of a Thyroid Nodule With Indeterminate Cytological Analysis,Clinical Validation of a Molecular Signature to Detect Cancer in Thyroid Nodules With Indeterminate Cytology,Thyroid Cancer|Thyroid Nodule,2014-08-19,2016-12-31,,Interventional,Unknown status,Not Applicable,Diaxonhit,Diaxonhit,,Procedure,France,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT02225509
NCT02240563,autoimmune thyroiditis,Long-term Follow-up After Treatment of Chronic Autoimmune Thyroiditis With Low Level Laser,Low Level Laser Therapy for Autoimmune Thyroiditis,Autoimmune Thyroiditis,2014-06-23,2016-03-31,2016-03-31,Interventional,Completed,Not Applicable,University of Sao Paulo General Hospital,Fundação de Amparo à Pesquisa do Estado de São Paulo|University of Sao Paulo General Hospital,"University of Sao Paulo General Hospital, Radiology Institute|University of Sao Paulo General Hospital",Procedure|Procedure,Brazil,20.0,60.0,[18-65],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT02240563
NCT02244463,anaplastic thyroid cancer,A Phase II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer,A Phase II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer,Anaplastic Thyroid Cancer|Thyroid Cancer,2014-09-17,2022-12-31,2023-12-31,Interventional,Active not recruiting,Phase 2,Dana-Farber Cancer Institute,"Dana-Farber Cancer Institute|Millennium Pharmaceuticals, Inc.",Hoag Memorial Hospital Presbyterian|Dana-Farber Cancer Institute|University of Michigan Medical School,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT02244463
NCT02278198,differentiated thyroid cancer,Evaluation of Thyroid Stunning From a Diagnostic Dose of I-123,Evaluation of Thyroid Stunning From a Diagnostic Dose of I-123,Differentiated Thyroid Cancer,2014-10-27,2019-09-20,2019-09-20,Interventional,Completed,Phase 1,"University of Colorado, Denver","University of Colorado, Denver",Fawn N White,Drug,United States,21.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Differentiated thyroid cancer, all",https://clinicaltrials.gov/ct2/show/NCT02278198
NCT02280330,hypothyroidism,Iodine Intake & Status of Preschoolers Given Micronutrient Powder for 6 Months,Iodine Status of Preschoolers Given Micronutrient Powder for 6 Months,Hypothyroidism|Iodine Deficiency|Iodine Deficiency Disorder,2014-10-27,2015-03-31,2015-03-31,Interventional,Completed,Phase 4,Nutrition Center of the Philippines,Nutrition Center of the Philippines,La Trinidad Benguet Day Care Centers,Dietary Supplement|Other,Philippines,4.0,6.0,[0-17],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT02280330
NCT02301520,hypothyroidism,"Vitamin D Deficiency, Iodine Deficiency and Lead Levels in Haitian Infants and Children.","Vitamin D, Iodine, and Lead Levels in Haitian Infants and Children.",Hypothyroidism|Iodine Deficiency|Lead Intoxication|Rickets|Vitamin D Deficiency,2014-11-23,2015-06-30,2015-06-30,Observational,Completed,,Boston Children's Hospital,"Boston Children's Hospital|Fondation Haitienne de Diabete et de Maladies Cardiovasculaires (FHADIMAC)|Kay Mackenson Clinic, Inc.",Kay Mackenson Clinic|FHADIMAC,,Haiti,9.0,6.0,[0-17],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT02301520
NCT02302768,thyroiditis autoimmune,Effect of Supplementation of Two Doses of L-selenomethionine (Semet; 80 and 160 mcg) Versus Placebo in Patients With Chronic Autoimmune Thyroiditis (AIT) With Normal Thyroid Function.,Effect of Semet (80 and 160 mcg) Versus Placebo in Euthyroid Patients With AIT,Thyroiditis Autoimmune,2014-11-20,2014-01-31,2015-01-31,Interventional,Unknown status,Phase 2,University of Siena,IBSA Institut Biochimique SA|University of Siena,,Dietary Supplement|Other,,18.0,65.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT02302768
NCT02303444,thyroid neoplasms,RIFTOS MKI - Radioactive Iodine reFractory Asymptomatic Patients in Differentiated Thyroid Cancer - an Observational Study to Assess the Use of Multikinase Inhibitors,An Observational Study in Differentiated Thyroid Cancer Which is Radioactive Iodine (RAI) Refractory to Assess the Use of Multikinase Inhibitors,Thyroid Neoplasms,2014-11-25,2020-06-10,2020-07-24,Observational,Completed,,Bayer,Bayer,,Drug|Drug,Algeria|Argentina|Brazil|Egypt|France|Germany|Greece|India|Japan|Lebanon|Mexico|Netherlands|Philippines|Russian Federation|Saudi Arabia|Spain|Taiwan|Turkey|United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02303444
NCT02304757,differentiated thyroid cancer,Prospective Trial of 99Tc-MDP and Fosamax in Postmenopausal Women With Differentiated Thyroid Cancer and Osteoporosis Treated With Supraphysiological Doses of Thyroid Hormone,99Tc-MDP in Postmenopausal Women With Differentiated Thyroid Cancer and Osteoporosis,Differentiated Thyroid Cancer|Osteoporosis,2014-11-24,2019-12-30,2019-12-30,Interventional,Completed,Not Applicable,"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","Xinhua Hospital, Shanghai Jiao Tong University School of Medicine",Nuclear Medicine Xinhua Hospital,Drug|Drug,China,45.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Differentiated thyroid cancer, all",https://clinicaltrials.gov/ct2/show/NCT02304757
NCT02307175,congenital hypothyroidism,A Phase I Study of 99m Tc Pertechnetate Produced in High Energy Cyclotron (CYCLOTEC) in Patients With Thyroid Scan Indication,A Study of 99m Tc Pertechnetate Produced in High Energy Cyclotron in Patients With Thyroid Scan Indication,Autoimmune Thyroid Disease|Congenital Hypothyroidism,2014-09-24,2016-08-31,2016-10-31,Observational,Completed,,Centre de recherche du Centre hospitalier universitaire de Sherbrooke,Centre de recherche du Centre hospitalier universitaire de Sherbrooke,Centre hospitalier universitaire de Sherbrooke,,Canada,18.0,80.0,[18-65]|[65 and more],Hypothyroidism,Congenital hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT02307175
NCT02316691,thyroid eye disease,B-cell Depletion Therapy With Rituximab for Thyroid Eye Disease,B-cell Depletion Therapy With Rituximab for Thyroid Eye Disease,Thyroid Eye Disease,2014-12-08,2019-11-30,2019-11-30,Observational,Terminated,,University of Pittsburgh,University of Pittsburgh,University of Pittsburgh,,United States,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT02316691
NCT02317926,hypothyroidism,,Desiccated Thyroid Extract Versus Synthetic T3/T4 Combination (ThyrolarTM) Versus L-T4 Alone in the Therapy of Primary Hypothyroidism With Special Attention to the Gene Polymorphism,Hypothyroidism,2014-12-08,2018-05-31,,Interventional,Unknown status,Not Applicable,Walter Reed National Military Medical Center,Walter Reed National Military Medical Center,Walter Reed National Military Medical Center,Drug|Drug|Drug,United States,18.0,65.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT02317926
NCT02318160,autoimmune thyroiditis,Oxidative Status in Children and Adolescents With Autoimmune Thyroiditis: A Tertiary Center Study From Upper Egypt,Oxidative Status in Children With Autoimmune Thyroiditis,Autoimmune Thyroiditis,2014-12-11,2014-03-31,2014-03-31,Observational [Patient Registry],Completed,,Assiut University,Assiut University,,Other,,6.0,18.0,[0-17]|[18-65],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT02318160
NCT02323724,papillary thyroid carcinoma,APPLICATION OF MOLECULAR TECHNIQUES FOR IMPROVING THE DIAGNOSIS AND TREATMENT OF NODULAR THYROID LESIONS.,APPLICATION OF MOLECULAR TECHNIQUES FOR IMPROVING THE DIAGNOSIS AND TREATMENT OF NODULAR THYROID LESIONS.,Papillary Thyroid Carcinoma,2014-12-18,2015-07-31,2015-07-31,Observational,Completed,,Corporacion Parc Tauli,Corporacion Parc Tauli,Corporació Sanitària Parc Taulí,Genetic,Spain,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT02323724
NCT02329379,goiter,Therapeutic Role of Levothyroxine on the Patients With Atypia of Undetermined Significance (AUS) Goiter,The Role of Levothyroxine on Goiter With Atypia of Undetermined Significance,Goiter,2014-12-29,2015-12-31,2015-12-31,Interventional,Withdrawn,Phase 4,"National Defense Medical Center, Taiwan",Sheng-Chiang Su,,Drug,,20.0,70.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02329379
NCT02339142,graves ophthalmopathy,Combined Radiotherapy and Intravenous Steroids for Early Progressive Thyroid Eye Disease,Combined Radiotherapy and Intravenous Steroids for Early Progressive Thyroid Eye Disease,Graves Ophthalmopathy,2015-01-12,2018-12-31,2019-12-31,Interventional,Unknown status,Phase 4,University of British Columbia,University of British Columbia,,Radiation|Drug,,35.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT02339142
NCT02347683,thyroid cancer,Optimal Measurement of Thyroglobulin Measurement Following Thyroidectomy,Optimal Measurement of Thyroglobulin Measurement Following Thyroidectomy,Thyroid Cancer,2015-01-21,2016-02-29,2016-02-29,Observational,Completed,,University of Nebraska,University of Nebraska,University of Nebraska Medical Center,,United States,19.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02347683
NCT02352766,thyroid nodule,Role of NGS-based ThyroSeq Panel in Cancer Diagnosis in Thyroid Nodules,Role of NGS-based ThyroSeq Panel in Cancer Diagnosis in Thyroid Nodules,Thyroid Nodule,2015-01-28,2019-02-15,2019-02-15,Observational,Completed,,University of Pittsburgh,"Duke University|Johns Hopkins University|Medstar Health Research Institute|Ohio State University|University of Cincinnati|University of Colorado, Denver|University of Pennsylvania|University of Pittsburgh|University of Wisconsin, Madison",University of Pittsburgh,,United States,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT02352766
NCT02363647,medullary thyroid cancer,Personalized Cancer Therapy for Patients With Metastatic Medullary Thyroid or Metastatic Colon Cancer,Personalized Cancer Therapy for Patients With Metastatic Medullary Thyroid or Metastatic Colon Cancer,Colon Cancer|Medullary Thyroid Cancer,2015-02-03,2021-06-30,2021-06-30,Interventional,Suspended,Not Applicable,Icahn School of Medicine at Mount Sinai,Icahn School of Medicine at Mount Sinai,Icahn School of Medicine at Mount Sinai,Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, medullary",https://clinicaltrials.gov/ct2/show/NCT02363647
NCT02364102,hypothyroidism,Effect of Restoration of Euthyroidism in Patients With Primary Hypothyroidism on Brown Adipose Tissue Thermogenesis - the ThyroBAT Study,Effect of Hypothyroidism on Brown Adipose Tissue,Hypothyroidism,2015-02-09,2017-08-31,2017-08-31,Observational,Completed,,"University Hospital, Basel, Switzerland","University Hospital, Basel, Switzerland","University Hospital Basel, Department of Endocrinology",,Switzerland,18.0,65.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT02364102
NCT02374593,congenital hypothyroidism,Targeted Levothyroxine Dosing in Infants With Congenital Hypothyroidism,Targeted Levothyroxine Dosing in Infants With Congenital Hypothyroidism,Congenital Hypothyroidism,2015-02-18,2016-05-31,2016-05-31,Interventional,Completed,Not Applicable,Indiana University,Erica Eugster,Riley Hospital for Children,Drug|Device,United States,0.0,2.0,[0-17],Hypothyroidism,Congenital hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT02374593
NCT02375451,hyperthyroidism,Effect of Childhood Radioiodine Therapy on Salivary Function,Effect of Childhood Radioiodine Therapy on Salivary Function,Hyperthyroidism|Thyroid Cancer|Xerostomia,2014-10-03,2016-09-30,2016-09-30,Observational,Completed,,Boston Children's Hospital,Boston Children's Hospital,Boston Children's Hospital,Other,United States,3.0,55.0,[0-17]|[18-65],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02375451
NCT02375451,thyroid cancer,Effect of Childhood Radioiodine Therapy on Salivary Function,Effect of Childhood Radioiodine Therapy on Salivary Function,Hyperthyroidism|Thyroid Cancer|Xerostomia,2014-10-03,2016-09-30,2016-09-30,Observational,Completed,,Boston Children's Hospital,Boston Children's Hospital,Boston Children's Hospital,Other,United States,3.0,55.0,[0-17]|[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02375451
NCT02376088,graves disease,Characteristics of Islet β-cell Functions in Chinese Patients With Graves' Disease,Characteristics of Islet β-cell Functions in Chinese Patients With Graves' Disease,Graves Disease,2015-02-18,2014-06-30,2014-06-30,Observational,Completed,,Qilu Hospital of Shandong University,Weikai Hou,,Drug,,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02376088
NCT02383927,thyroid cancer,An Open Label Phase II Study of Tipifarnib in Advanced Non-Hematological Malignancies With HRAS Mutations,Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations,HRAS Mutant Tumor|Other Squamous Cell Carcinoma (SCC) With HRAS Mutant Tumor|Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)|Thyroid Cancer,2015-02-20,2020-11-30,2020-11-30,Interventional,Completed,Phase 2,"Kura Oncology, Inc.","Kura Oncology, Inc.","University of California, Los Angeles|Wihship Cancer Institute of Emory University|Dana-Farber Cancer Institute|University of Michigan Comprehensive Cancer Center|Mayo Clinic|Memorial Sloan-Kettering Cancer Center|Oklahoma University Health Sciences Center|Fox Chase Cancer Center|The University of Texas MD Anderson Cancer Center|University Hospital Antwerp|Cliniques universitaires Saint-Luc|CHU|Insitut Bergonie|Centre Léon Bérard|Centre Antoine Lacassagne|Institute Gustave Roussy (IGR)|University Hospital Wuerazburg|Attikon University Hospital|Instituto Nazionale Tumori|Asan Medical Center|Samsung Medical Center|University Medical Center|Hospital Vall d' Hebron|Hospital Clinic de Barcelona|Hospital del Mar|Hospital Universitario Doce de Octubre|Hospital Universitario La Paz|MD Anderson Cancer Center Madrid|START, Centro Integral Oncologico Clara Campal|Hospital Universitario Virgen de la Victoria|Complejo Hospitalario de Navarro|Hospital Universitario Virgen de la Rocio|Hospital Universitario y Politécnico La Fe|Royal Marsden|University College Hospital",Drug,"Belgium|France|Germany|Greece|Italy|Korea, Republic of|Netherlands|Spain|United Kingdom|United States",18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02383927
NCT02390739,metastatic thyroid cancer,Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing Human Thyroglobulin to Patients With Thyroglobulin Expressing Thyroid Cancer,Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing Human Thyroglobulin to People With Thyroglobulin Expressing Thyroid Cancer,Metastatic Thyroid Cancer,2015-03-17,2017-03-22,2017-03-22,Interventional,Withdrawn,Phase 1/Phase 2,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),,Drug|Drug|Drug|Biological,,18.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,Metastatic Thyroid Cancer,https://clinicaltrials.gov/ct2/show/NCT02390739
NCT02390934,thyroid cancer,Single Arm Phase II Trial Evaluating the Efficacy of Radium 223 in Radioactive Iodine Refractory Bone Metastases From Differentiated Thyroid Cancer,Efficacy of Radium 223 in Radioactive Iodine Refractory Bone Metastases From Differentiated Thyroid Cancer,Thyroid Cancer,2014-10-01,2019-04-02,2019-04-02,Interventional,Completed,Phase 2,"Gustave Roussy, Cancer Campus, Grand Paris","Gustave Roussy, Cancer Campus, Grand Paris",Gustave Roussy,Radiation,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02390934
NCT02393183,thyroid eye disease,"The Effect of a New Antioxidant Combination (ASTED) on Mild Thyroid Eye Disease, a Placebo Controlled Randomized Clinical Trial",The Effect of a New Antioxidant Combination (ASTED) on Mild Thyroid Eye Disease (TED),Thyroid Eye Disease,2015-03-07,2022-06-15,2022-12-15,Interventional,Withdrawn,Phase 2/Phase 3,Iran University of Medical Sciences,Iran University of Medical Sciences,Rassoul Akram Hospital,Drug|Dietary Supplement|Other,"Iran, Islamic Republic of",18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT02393183
NCT02393690,poorly differentiated thyroid gland carcinoma,Randomized Double-Blind Phase II Study of Radioactive Iodine (RAI) in Combination With Placebo or Selumetinib for the Treatment of RAI-Avid Recurrent/Metastatic Thyroid Cancers,Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer,Metastatic Thyroid Gland Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Carcinoma|Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7|Stage IV Thyroid Gland Follicular Carcinoma AJCC v7|Stage IV Thyroid Gland Papillary Carcinoma AJCC v7,2015-03-16,2020-07-17,2022-12-31,Interventional,Active not recruiting,Phase 2,Academic and Community Cancer Research United,Academic and Community Cancer Research United|National Cancer Institute (NCI),UC San Diego Moores Cancer Center|Hoag Memorial Hospital|University of Colorado Hospital|MedStar Georgetown University Hospital|Dana-Farber Cancer Institute|Mayo Clinic in Rochester|Memorial Sloan Kettering Cancer Center|Duke University Medical Center|Ohio State University Comprehensive Cancer Center|Vanderbilt University/Ingram Cancer Center|M D Anderson Cancer Center,Radiation|Other|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Poorly differentiated thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02393690
NCT02393690,metastatic thyroid gland carcinoma,Randomized Double-Blind Phase II Study of Radioactive Iodine (RAI) in Combination With Placebo or Selumetinib for the Treatment of RAI-Avid Recurrent/Metastatic Thyroid Cancers,Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer,Metastatic Thyroid Gland Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Carcinoma|Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7|Stage IV Thyroid Gland Follicular Carcinoma AJCC v7|Stage IV Thyroid Gland Papillary Carcinoma AJCC v7,2015-03-16,2020-07-17,2022-12-31,Interventional,Active not recruiting,Phase 2,Academic and Community Cancer Research United,Academic and Community Cancer Research United|National Cancer Institute (NCI),UC San Diego Moores Cancer Center|Hoag Memorial Hospital|University of Colorado Hospital|MedStar Georgetown University Hospital|Dana-Farber Cancer Institute|Mayo Clinic in Rochester|Memorial Sloan Kettering Cancer Center|Duke University Medical Center|Ohio State University Comprehensive Cancer Center|Vanderbilt University/Ingram Cancer Center|M D Anderson Cancer Center,Radiation|Other|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Metastatic Thyroid Cancer,https://clinicaltrials.gov/ct2/show/NCT02393690
NCT02397109,dysthyroid ophthalmopathies,Study Of The Agreement Between The mDixon TSE Sequence And Conventional MRI Sequences In The Evaluation Of Dysimmune Orbitopathies,mDixon TSE MRI Sequence And Conventional MRI Sequences In Dysimmune Orbitopathies (DDX),Dysthyroid Ophthalmopathies,2015-03-19,2020-09-30,2020-09-30,Observational,Completed,,Fondation Ophtalmologique Adolphe de Rothschild,Fondation Ophtalmologique Adolphe de Rothschild,Fondation Ophtalmologique Adolphe de Rothschild,,France,18.0,90.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT02397109
NCT02404441,anaplastic thyroid cancer,Open Label Multicenter Phase I/II Study of the Safety and Efficacy of PDR001 Administered to Patients With Advanced Malignancies,Phase I/II Study of PDR001 in Patients With Advanced Malignancies,Anaplastic Thyroid Cancer|Melanoma|Non-small Sell Lung Cancer (NSCLC)|Other Solid Tumors|Triple Negative Breast Cancer,2015-03-20,2020-07-21,2020-07-21,Interventional,Completed,Phase 1/Phase 2,Novartis,Novartis Pharmaceuticals,The Sidney Kimmel Cancer Center at Johns Hopkins Hospital Johns Hopkins|Massachusetts General Hospital|Oregon Health and Science University SC-10|Sarah Cannon Research Institute SCRI RC|University of Texas MD Anderson Cancer Center MD Anderson PSC|Huntsman Cancer Institute Univ. of Utah HCI|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site,Biological,Canada|France|Germany|Hungary|Italy|Lebanon|Netherlands|Norway|Poland|Spain|Taiwan|Thailand|Turkey|United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT02404441
NCT02410928,thyroid nodule,Comparison of the Vocal Cord Imaging Techniques After Thyroidectomy,Comparison of the Vocal Cord Imaging Techniques After Thyroidectomy,Thyroid Nodule,2015-02-14,2015-06-30,2015-07-31,Interventional,Completed,Not Applicable,Diskapi Teaching and Research Hospital,Diskapi Teaching and Research Hospital,Diskapi Yildirim Beyazit Teaching and Research Hospital,Device|Device|Device,Turkey,19.0,70.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT02410928
NCT02411461,pseudohypoparathyroidism,Early-onset Obesity and Cognitive Impairment in Children With Pseudohypoparathyroidism,Early-onset Obesity and Cognitive Impairment in Children With Pseudohypoparathyroidism,Albright Hereditary Osteodystrophy|Pseudohypoparathyroidism,2015-02-25,2017-01-31,2017-01-31,Observational,Completed,,Vanderbilt University Medical Center,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Vanderbilt University Medical Center,Vanderbilt University,,United States,6.0,18.0,[0-17]|[18-65],Parathyroid diseases,pseudohypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02411461
NCT02412150,thyroid tumor,Effect of Dexmedetomidine Infusion for Postoperative Outcome and Smooth Emergence After Thyroidectomy,Effect of Dexmedetomidine After Thyroidectomy,Thyroid Tumor,2015-03-31,2020-11-21,2020-11-25,Interventional,Completed,Not Applicable,Chosun University Hospital,Chosun University Hospital,Chosun University Hospital,Drug|Drug|Procedure|Other|Behavioral|Behavioral|Other|Behavioral|Other|Other|Other|Drug|Drug,"Korea, Republic of",20.0,60.0,[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02412150
NCT02418247,thyroid neoplasms,Phase Ⅱ Non-randomized Multicenter Controlled Trial About Effect of Remnant Ablation Therapy on the Recurrence in Low-risk Differentiated Thyroid Cancer Patients,Minimize Radioactive Iodine Ablation Of Remnant Thyroid in Differentiated Thyroid Cancer,Thyroid Neoplasms,2015-04-13,2017-12-31,2020-12-31,Interventional,Unknown status,Phase 2/Phase 3,"National Cancer Center, Korea","National Cancer Center, Korea","Chungnam National University Hospital|National Cancer Center, Korea|Seoul National University Boramae Medical Center|Seoul National University Hospital|Seoul National University Bundang Hospital",Drug|Drug,"Korea, Republic of",18.0,79.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02418247
NCT02418390,"thyroid cancer, papillary",The Efficacy and Safety of Prophylactic Central Lymph Node Dissection in Papillary Thyroid Carcinoma,The Efficacy and Safety of Prophylactic Central Lymph Node Dissection in Papillary Thyroid Carcinoma,"Thyroid Cancer, Papillary",2015-04-07,2022-02-28,2022-02-28,Interventional,Unknown status,Not Applicable,Seoul National University Hospital,Seoul National University Hospital,Seoul National University Hospital,Procedure,"Korea, Republic of",20.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT02418390
NCT02422368,thyroid eye disease,"The Effect of a New Antioxidant Combination (ASTED) on Moderate to Severe Thyroid Eye Disease, a Double Blind Placebo Controlled Randomized Clinical Trial",The Effect of a New Antioxidant Combination (ASTED) on Moderate to Severe Thyroid Eye Disease,Thyroid Eye Disease,2015-04-11,2024-06-30,2024-11-30,Interventional,Withdrawn,Phase 2/Phase 3,Iran University of Medical Sciences,Iran University of Medical Sciences,Private Thyroid eye disease clinic|Rassoul Akram Hospital,Drug|Drug,"Iran, Islamic Republic of",18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT02422368
NCT02430714,thyroid neoplasms,Post-marketing Surveillance of Lenvatinib Mesylate (Lenvima Capsule) in Patients With Unresectable Thyroid Cancer (Study LEN01T),Post-marketing Surveillance of Lenvatinib Mesylate (Lenvima Capsule) in Patients With Unresectable Thyroid Cancer (Study LEN01T),Thyroid Neoplasms,2015-04-27,2016-11-06,2016-11-06,Observational,Completed,,Eisai Inc.,"Eisai Co., Ltd.",,Drug,Japan,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02430714
NCT02432599,hyperparathyroidism,Interest of the F18-choline as a Second Line of the Tracer for Detection of Parathyroid Adenomas,Interest of the F18-choline as a Second Line of the Tracer for Detection of Parathyroid Adenomas,Hyperparathyroidism,2015-04-29,2017-02-28,2017-02-28,Interventional,Completed,Phase 2,Centre Francois Baclesse,Centre Francois Baclesse,CHU|Centre François Baclesse,Radiation,France,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02432599
NCT02442661,papillary thyroid cancer,Clinical Validation of a Predictive Model for the Presence of Cervical Lymph Node Metastasis in Papillary Thyroid Cancer,Clinical Validation of a Predictive Model for the Presence of Cervical Lymph Node Metastasis in Papillary Thyroid Cancer,Papillary Thyroid Cancer,2015-04-22,2016-12-31,2017-05-31,Observational,Completed,,"University of Colorado, Denver","University of Colorado, Denver",Rebecca J Guigli,,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT02442661
NCT02456701,thyroid cancer,"Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI Refractory Thyroid Cancers With the Combination of BRAF Inhibitor Vemurafenib and Anti-ErbB3 Antibody KTN3379: A Pilot Study With a Phase 1 Run-in",Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379,Thyroid Cancer,2015-05-20,2016-10-13,2016-10-13,Interventional,Completed,Phase 1,Celldex Therapeutics,Celldex Therapeutics|Memorial Sloan Kettering Cancer Center,Memorial Sloan-Kettering Cancer Center,Biological|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02456701
NCT02462512,thyroid nodule,Validation of Diagnostic Performance of Ultrasound Elastography for Detection of Thyroid Cancer,Diagnostic Performance of Ultrasound Elastography for Detection of Thyroid Cancer,Elastography|Thyroid Nodule,2015-04-20,2016-03-31,2017-08-31,Observational,Unknown status,,Seoul St. Mary's Hospital,Dong Jun Lim,Seoul St Mary's Hospital,,"Korea, Republic of",18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT02462512
NCT02465060,thyroid gland carcinoma,Molecular Analysis for Therapy Choice (MATCH),"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)",Advanced Malignant Solid Neoplasm|Bladder Carcinoma|Breast Carcinoma|Cervical Carcinoma|Colon Carcinoma|Colorectal Carcinoma|Endometrial Carcinoma|Esophageal Carcinoma|Gastric Carcinoma|Glioma|Head and Neck Carcinoma|Kidney Carcinoma|Liver and Intrahepatic Bile Duct Carcinoma|Lung Carcinoma|Lymphoma|Malignant Uterine Neoplasm|Melanoma|Ovarian Carcinoma|Pancreatic Carcinoma|Plasma Cell Myeloma|Prostate Carcinoma|Rectal Carcinoma|Recurrent Bladder Carcinoma|Recurrent Breast Carcinoma|Recurrent Cervical Carcinoma|Recurrent Colon Carcinoma|Recurrent Colorectal Carcinoma|Recurrent Esophageal Carcinoma|Recurrent Gastric Carcinoma|Recurrent Glioma|Recurrent Head and Neck Carcinoma|Recurrent Liver Carcinoma|Recurrent Lung Carcinoma|Recurrent Lymphoma|Recurrent Malignant Solid Neoplasm|Recurrent Melanoma|Recurrent Ovarian Carcinoma|Recurrent Pancreatic Carcinoma|Recurrent Plasma Cell Myeloma|Recurrent Prostate Carcinoma|Recurrent Rectal Carcinoma|Recurrent Skin Carcinoma|Recurrent Thyroid Gland Carcinoma|Recurrent Uterine Corpus Cancer|Refractory Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Plasma Cell Myeloma|Skin Carcinoma|Thyroid Gland Carcinoma|Uterine Corpus Cancer,2015-06-03,2025-12-31,2025-12-31,Interventional,Recruiting,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),University of Alabama at Birmingham Cancer Center|Thomas Hospital|Mobile Infirmary Medical Center|University of South Alabama Mitchell Cancer Institute|Anchorage Associates in Radiation Medicine|Anchorage Radiation Therapy Center|Alaska Breast Care and Surgery LLC|Alaska Oncology and Hematology LLC|Alaska Regional Hospital|Alaska Women's Cancer Care|Anchorage Oncology Centre|Katmai Oncology Group|Providence Alaska Medical Center|Fairbanks Memorial Hospital|CTCA at Western Regional Medical Center|Kingman Regional Medical Center|Cancer Center at Saint Joseph's|Saint Joseph's Hospital and Medical Center|Mayo Clinic Hospital in Arizona|Mayo Clinic in Arizona|Mercy Hospital Fort Smith|CHI Saint Vincent Cancer Center Hot Springs|Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro|University of Arkansas for Medical Sciences|Kaiser Permanente-Anaheim|Kaiser Permanente-Deer Valley Medical Center|Mission Hope Medical Oncology - Arroyo Grande|PCR Oncology|Sutter Auburn Faith Hospital|Sutter Cancer Centers Radiation Oncology Services-Auburn|AIS Cancer Center at San Joaquin Community Hospital|Kaiser Permanente-Baldwin Park|Kaiser Permanente-Bellflower|Alta Bates Summit Medical Center-Herrick Campus|Providence Saint Joseph Medical Center/Disney Family Cancer Center|Mills-Peninsula Medical Center|Sutter Cancer Centers Radiation Oncology Services-Cameron Park|Eden Hospital Medical Center|Community Cancer Institute|University Oncology Associates|John Muir Medical Center-Concord Campus|City of Hope Corona|UC Irvine Health Cancer Center-Newport|Sutter Davis Hospital|City of Hope Comprehensive Cancer Center|Epic Care-Dublin|Kaiser Permanente Dublin|Bay Area Breast Surgeons Inc|Epic Care Partners in Cancer Care|Kaiser Permanente-Fontana|Kaiser Permanente-Fremont|Palo Alto Medical Foundation-Fremont|Fresno Cancer Center|Kaiser Permanente-Fresno|Saint Jude Medical Center|Marin Cancer Care Inc|Marin General Hospital|Kaiser Permanente - Harbor City|Kaiser Permanente-Irvine|UC San Diego Moores Cancer Center|Loma Linda University Medical Center|Kaiser Permanente Los Angeles Medical Center|Los Angeles County-USC Medical Center|USC / Norris Comprehensive Cancer Center|Kaiser Permanente West Los Angeles|Cedars Sinai Medical Center|Contra Costa Regional Medical Center|Fremont - Rideout Cancer Center|Memorial Medical Center|Kaiser Permanente-Modesto|Community Hospital of Monterey Peninsula|Pacific Cancer Care-Monterey|Palo Alto Medical Foundation-Camino Division|Palo Alto Medical Foundation-Gynecologic Oncology|USC Norris Oncology/Hematology-Newport Beach|Sutter Cancer Research Consortium|Alta Bates Summit Medical Center - Summit Campus|Bay Area Tumor Institute|Kaiser Permanente Oakland-Broadway|Kaiser Permanente-Oakland|Kaiser Permanente-Ontario|Saint Joseph Hospital - Orange|UC Irvine Health/Chao Family Comprehensive Cancer Center|Desert Regional Medical Center|Palo Alto Medical Foundation Health Care|Stanford Cancer Institute Palo Alto|VA Palo Alto Health Care System|Kaiser Permanente - Panorama City|Keck Medical Center of USC Pasadena|Kaiser Permanente-Rancho Cordova Cancer Center|Eisenhower Medical Center|Kaiser Permanente- Marshall Medical Offices|Kaiser Permanente-Redwood City|Kaiser Permanente-Richmond|Kaiser Permanente-Riverside|Rohnert Park Cancer Center|Kaiser Permanente-Roseville|Sutter Cancer Centers Radiation Oncology Services-Roseville|Sutter Roseville Medical Center|The Permanente Medical Group-Roseville Radiation Oncology|Kaiser Permanente Downtown Commons|Sutter Medical Center Sacramento|University of California Davis Comprehensive Cancer Center|Kaiser Permanente-South Sacramento|South Sacramento Cancer Center|Kaiser Permanente - Sacramento|Saint Helena Hospital|UC San Diego Medical Center - Hillcrest|Kaiser Permanente-San Diego Mission|Kaiser Permanente-San Diego Zion|Rady Children's Hospital - San Diego|Sharp Memorial Hospital|Naval Medical Center -San Diego|California Pacific Medical Center-Pacific Campus|Kaiser Permanente-San Francisco|Kaiser Permanente-Santa Teresa-San Jose|Kaiser Permanente San Leandro|Pacific Central Coast Health Center-San Luis Obispo|Kaiser Permanente-San Marcos|Mills Health Center|Kaiser Permanente-San Rafael|Kaiser San Rafael-Gallinas|Kaiser Permanente Medical Center - Santa Clara|Palo Alto Medical Foundation-Santa Cruz|Mission Hope Medical Oncology - Santa Maria|Kaiser Permanente-Santa Rosa|Sutter Pacific Medical Foundation|Kaiser Permanente Cancer Treatment Center|Kaiser Permanente-South San Francisco|Saint Joseph's Medical Center|Kaiser Permanente-Stockton|Palo Alto Medical Foundation-Sunnyvale|Gene Upshaw Memorial Tahoe Forest Cancer Center|City of Hope Upland|Sutter Cancer Centers Radiation Oncology Services-Vacaville|Kaiser Permanente Medical Center-Vacaville|Kaiser Permanente-Vallejo|Sutter Solano Medical Center/Cancer Center|Kaiser Permanente-Walnut Creek|Epic Care Cyberknife Center|John Muir Medical Center-Walnut Creek|City of Hope West Covina|Presbyterian Intercommunity Hospital|Kaiser Permanente-Woodland Hills|Rocky Mountain Cancer Centers-Aurora|The Medical Center of Aurora|University of Colorado Hospital|Boulder Community Hospital|Boulder Community Foothills Hospital|Rocky Mountain Cancer Centers-Boulder|Rocky Mountain Cancer Centers - Centennial|Penrose-Saint Francis Healthcare|Rocky Mountain Cancer Centers-Penrose|UCHealth Memorial Hospital Central|Memorial Hospital North|Saint Francis Cancer Center|Cancer Center of Colorado at Sloan's Lake|Denver Health Medical Center|Kaiser Permanente-Franklin|National Jewish Health-Main Campus|The Women's Imaging Center|Porter Adventist Hospital|Colorado Blood Cancer Institute|Presbyterian - Saint Lukes Medical Center - Health One|Rocky Mountain Cancer Centers-Midtown|SCL Health Saint Joseph Hospital|Rocky Mountain Cancer Centers-Rose|Rose Medical Center|Mercy Medical Center|Southwest Oncology PC|Mountain Blue Cancer Care Center - Swedish|Rocky Mountain Cancer Centers - Swedish|Swedish Medical Center|Poudre Valley Hospital|Mountain Blue Cancer Care Center|National Jewish Health-Western Hematology Oncology|Saint Mary's Hospital and Regional Medical Center|Grand Valley Oncology|North Colorado Medical Center|Rocky Mountain Cancer Centers-Greenwood Village|Good Samaritan Medical Center|Kaiser Permanente-Rock Creek|Rocky Mountain Cancer Centers-Lakewood|Saint Anthony Hospital|Rocky Mountain Cancer Centers-Littleton|Littleton Adventist Hospital|Kaiser Permanente-Lone Tree|Rocky Mountain Cancer Centers-Sky Ridge|Sky Ridge Medical Center|Longmont United Hospital|Rocky Mountain Cancer Centers-Longmont|McKee Medical Center|Parker Adventist Hospital|Rocky Mountain Cancer Centers-Parker|Saint Mary Corwin Medical Center|Rocky Mountain Cancer Centers - Pueblo|National Jewish Health-Northern Hematology Oncology|Rocky Mountain Cancer Centers-Thornton|SCL Health Lutheran Medical Center|Smilow Cancer Hospital-Derby Care Center|Smilow Cancer Hospital Care Center-Fairfield|Smilow Cancer Hospital Care Center at Glastonbury|Smilow Cancer Hospital Care Center at Greenwich|Smilow Cancer Hospital Care Center - Guiford|Smilow Cancer Hospital Care Center at Saint Francis|Smilow Cancer Center/Yale-New Haven Hospital|Yale University|Yale-New Haven Hospital North Haven Medical Center|Eastern Connecticut Hematology and Oncology Associates|Smilow Cancer Hospital-Orange Care Center|Stamford Hospital/Bennett Cancer Center|Smilow Cancer Hospital-Torrington Care Center|Smilow Cancer Hospital Care Center-Trumbull|Smilow Cancer Hospital-Waterbury Care Center|Smilow Cancer Hospital Care Center - Waterford|Veterans Affairs Connecticut Healthcare System-West Haven Campus|Beebe South Coastal Health Campus|Beebe Medical Center|Christiana Gynecologic Oncology LLC|Delaware Clinical and Laboratory Physicians PA|Helen F Graham Cancer Center|Medical Oncology Hematology Consultants PA|Christiana Care Health System-Christiana Hospital|Beebe Health Campus|TidalHealth Nanticoke / Allen Cancer Center|Christiana Care Health System-Wilmington Hospital|MedStar Georgetown University Hospital|MedStar Washington Hospital Center|Sibley Memorial Hospital|Mount Sinai Comprehensive Cancer Center at Aventura|UM Sylvester Comprehensive Cancer Center at Coral Gables|UM Sylvester Comprehensive Cancer Center at Coral Springs|Broward Health North|UM Sylvester Comprehensive Cancer Center at Deerfield Beach|Holy Cross Hospital|Broward Health Medical Center|University of Florida Health Science Center - Gainesville|Memorial Regional Hospital/Joe DiMaggio Children's Hospital|UM Sylvester Comprehensive Cancer Center at Hollywood|Mayo Clinic in Florida|The Watson Clinic|Mount Sinai Medical Center|University of Miami Miller School of Medicine-Sylvester Cancer Center|Miami Cancer Institute|UM Sylvester Comprehensive Cancer Center at Kendall|Health Central|Orlando Health Cancer Institute|Memorial Hospital West|UM Sylvester Comprehensive Cancer Center at Plantation|Saint Joseph's Hospital/Children's Hospital-Tampa|Moffitt Cancer Center|Indian River Medical Center|University Cancer and Blood Center LLC|Emory University Hospital Midtown|Piedmont Hospital|Emory University Hospital/Winship Cancer Institute|Emory Saint Joseph's Hospital|Northside Hospital|Augusta University Medical Center|Northeast Georgia Medical Center Braselton|John B Amos Cancer Center|Northside Hospital-Forsyth|Dekalb Medical Center|Northside Hospital - Duluth|Northeast Georgia Medical Center-Gainesville|The Longstreet Clinic - Gainesville|Northside Hospital - Gwinnett|Central Georgia Gynecologic Oncology|Medical Center of Central Georgia|CTCA at Southeastern Regional Medical Center|Harbin Clinic Medical Oncology and Clinical Research|Low Country Cancer Care|Memorial Health University Medical Center|Summit Cancer Care-Memorial|Lewis Cancer and Research Pavilion at Saint Joseph's/Candler|Summit Cancer Care-Candler|Suburban Hematology Oncology Associates - Snellville|Lewis Hall Singletary Oncology Center|South Georgia Medical Center/Pearlman Cancer Center|Hawaii Cancer Care - Savio|Pali Momi Medical Center|Queen's Cancer Center - Pearlridge|Straub Pearlridge Clinic|The Cancer Center of Hawaii-Pali Momi|The Queen's Medical Center - West Oahu|Hawaii Cancer Care Inc - Waterfront Plaza|Island Urology|Queen's Cancer Cenrer - POB I|Queen's Medical Center|Straub Clinic and Hospital|University of Hawaii Cancer Center|Hawaii Cancer Care Inc-Liliha|Hawaii Diagnostic Radiology Services LLC|Kuakini Medical Center|Queen's Cancer Center - Kuakini|The Cancer Center of Hawaii-Liliha|Kaiser Permanente Moanalua Medical Center|Kapiolani Medical Center for Women and Children|Straub Medical Center - Kahului Clinic|Castle Medical Center|Wilcox Memorial Hospital and Kauai Medical Clinic|Saint Alphonsus Cancer Care Center-Boise|Saint Luke's Cancer Institute - Boise|Saint Alphonsus Cancer Care Center-Caldwell|Kootenai Health - Coeur d'Alene|Walter Knox Memorial Hospital|Saint Luke's Cancer Institute - Fruitland|Idaho Urologic Institute-Meridian|Saint Luke's Cancer Institute - Meridian|Saint Alphonsus Medical Center-Nampa|Saint Luke's Cancer Institute - Nampa|Kootenai Clinic Cancer Services - Post Falls|Kootenai Cancer Clinic|Saint Luke's Cancer Institute - Twin Falls|Saint Anthony's Health|Rush - Copley Medical Center|Saint Joseph Medical Center|Illinois CancerCare-Bloomington|Illinois CancerCare-Canton|Memorial Hospital of Carbondale|SIH Cancer Institute|Illinois CancerCare-Carthage|Centralia Oncology Clinic|Mount Sinai Hospital Medical Center|Northwestern University|John H Stroger Jr Hospital of Cook County|Rush University Medical Center|University of Illinois|Swedish Covenant Hospital|University of Chicago Comprehensive Cancer Center|Advocate Illinois Masonic Medical Center|AMG Crystal Lake - Oncology|Carle on Vermilion|Cancer Care Specialists of Illinois - Decatur|Decatur Memorial Hospital|Northwestern Medicine Cancer Center Kishwaukee|Illinois CancerCare-Dixon|Carle Physician Group-Effingham|Crossroads Cancer Center|AMITA Health Alexian Brothers Medical Center|Elmhurst Memorial Hospital|Illinois CancerCare-Eureka|NorthShore University HealthSystem-Evanston Hospital|Saint Francis Hospital|Illinois CancerCare-Galesburg|Western Illinois Cancer Treatment Center|Northwestern Medicine Cancer Center Delnor|NorthShore University HealthSystem-Glenbrook Hospital|Ingalls Memorial Hospital|NorthShore University HealthSystem-Highland Park Hospital|Duly Health and Care Joliet|Presence Saint Mary's Hospital|Illinois CancerCare-Kewanee Clinic|Northwestern Medicine Lake Forest Hospital|AMG Libertyville - Oncology|Illinois CancerCare-Macomb|Carle Physician Group-Mattoon/Charleston|Loyola University Medical Center|Marjorie Weinberg Cancer Center at Loyola-Gottlieb|Trinity Medical Center|Good Samaritan Regional Health Center|Edward Hospital/Cancer Center|UC Comprehensive Cancer Center at Silver Cross|Cancer Care Center of O'Fallon|University of Chicago Medicine-Orland Park|Illinois CancerCare-Ottawa Clinic|Radiation Oncology of Northern Illinois|Illinois CancerCare-Pekin|OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center|Illinois CancerCare-Peoria|OSF Saint Francis Radiation Oncology at Peoria Cancer Center|Methodist Medical Center of Illinois|OSF Saint Francis Medical Center|Illinois CancerCare-Peru|Valley Radiation Oncology|Edward Hospital/Cancer Center?Plainfield|Illinois CancerCare-Princeton|Hematology Oncology Associates of Illinois - Skokie|North Shore Medical Center|Central Illinois Hematology Oncology Center|Southern Illinois University School of Medicine|Springfield Clinic|Memorial Medical Center|Southwest Illinois Health Services LLP|Carle Cancer Center|The Carle Foundation Hospital|Northwestern Medicine Cancer Center Warrenville|Illinois CancerCare - Washington|Rush-Copley Healthcare Center|Midwestern Regional Medical Center|Michiana Hematology Oncology PC-Crown Point|Michiana Hematology Oncology PC-Elkhart|Deaconess Clinic Downtown|Indiana University/Melvin and Bren Simon Cancer Center|Sidney and Lois Eskenazi Hospital|Community Cancer Center East|Community Cancer Center South|Community Cancer Center North|Springmill Medical Center|Community Howard Regional Health|IU Health Arnett Cancer Care|Franciscan Saint Anthony Health-Michigan City|Woodland Cancer Care Center|Memorial Regional Cancer Center Day Road|Michiana Hematology Oncology PC-Mishawaka|Baptist Health Floyd|Chancellor Center for Oncology|Michiana Hematology Oncology PC-Plymouth|Reid Health|Memorial Hospital of South Bend|Michiana Hematology Oncology PC-Westville|Mary Greeley Medical Center|McFarland Clinic PC - Ames|McFarland Clinic PC-Boone|Saint Anthony Regional Hospital|Physicians' Clinic of Iowa PC|Mercy Hospital|Oncology Associates at Mercy Medical Center|Medical Oncology and Hematology Associates-West Des Moines|Mercy Cancer Center-West Lakes|Jennie Edmundson Memorial Hospital|Alegent Health Mercy Hospital|Heartland Oncology and Hematology LLP|Greater Regional Medical Center|Iowa Methodist Medical Center|Medical Oncology and Hematology Associates-Des Moines|Broadlawns Medical Center|Medical Oncology and Hematology Associates-Laurel|Mercy Medical Center - Des Moines|Iowa Lutheran Hospital|JCHC McCreery Cancer Center|McFarland Clinic PC-Trinity Cancer Center|Trinity Regional Medical Center|McFarland Clinic PC-Jefferson|McFarland Clinic PC-Marshalltown|Ottumwa Regional Health Center|Siouxland Regional Cancer Center|Methodist West Hospital|Mercy Medical Center-West Lakes|Coffeyville Regional Medical Center|Newman Regional Health|University of Kansas Clinical Research Center|Central Care Cancer Center - Garden City|Saint Catherine Hospital|Central Care Cancer Center - Great Bend|Saint Rose Ambulatory and Surgery Center|HaysMed University of Kansas Health System|University of Kansas Cancer Center-West|University of Kansas Cancer Center|Lawrence Memorial Hospital|Kansas Institute of Medicine Cancer and Blood Center|Minimally Invasive Surgery Hospital|Olathe Health Cancer Center|Menorah Medical Center|University of Kansas Cancer Center-Overland Park|Saint Luke's South Hospital|Ascension Via Christi - Pittsburg|Salina Regional Health Center|University of Kansas Health System Saint Francis Campus|University of Kansas Hospital-Westwood Cancer Center|Flaget Memorial Hospital|Baptist Health Corbin|Commonwealth Cancer Center-Corbin|Oncology Hematology Care Inc-Crestview|Saint Elizabeth Medical Center South|Baptist Health Hardin|Saint Elizabeth Fort Thomas|Baptist Health Lexington|Saint Joseph Radiation Oncology Resource Center|Saint Joseph Hospital East|University of Kentucky/Markey Cancer Center|Saint Joseph London|Jewish Hospital|The James Graham Brown Cancer Center at University of Louisville|Baptist Health Louisville|Saints Mary and Elizabeth Hospital|UofL Health Medical Center Northeast|Baptist Health Madisonville/Merle Mahr Cancer Center|Baptist Health Paducah|Jewish Hospital Medical Center South|LSU Health Baton Rouge-North Clinic|Baton Rouge General Medical Center|Our Lady of The Lake|Hematology/Oncology Clinic PLLC|Louisiana Hematology Oncology Associates LLC|Mary Bird Perkins Cancer Center|Ochsner Health Center-Summa|Our Lady of the Lake Physicians Group - Medical Oncology|The NeuroMedical Center-Clinic|Medical Center of Baton Rouge|Our Lady of the Lake Medical Oncology|Ochsner High Grove|Mary Bird Perkins Cancer Center - Covington|Northshore Oncology Associates-Covington|Ochsner Hematology Oncology North Shore - Covington (West Region)|Women's Cancer Care-Covington|Ochsner Medical Center West Bank|Mary Bird Perkins Cancer Center - Houma|Oncology Center of The South Incorporated|Terrebonne General Medical Center|Ochsner Medical Center Kenner|West Jefferson Medical Center|East Jefferson General Hospital|Robert Veith MD LLC|Ochsner LSU Health Monroe Medical Center|Louisiana State University Health Science Center|Tulane University Health Sciences Center|University Medical Center New Orleans|Ochsner Medical Center Jefferson|LSU Health Sciences Center at Shreveport|CHRISTUS Highland Medical Center|Harold Alfond Center for Cancer Care|Eastern Maine Medical Center|Waldo County General Hospital|MaineHealth/SMHC Cancer Care and Blood Disorders-Biddeford|Lafayette Family Cancer Center-EMMC|Maine Center for Cancer Medicine-Kennebunk|Stephens Memorial Hospital|Penobscot Bay Medical Center|MaineHealth/SMHC Cancer Care and Blood Disorders-Sanford|Maine Center for Cancer Medicine-Scarborough|Maine Medical Center- Scarborough Campus|Maine Medical Partners - South Portland|Maine Center for Cancer Medicine-Topsham|Anne Arundel Medical Center|University of Maryland/Greenebaum Cancer Center|Greater Baltimore Medical Center|Sinai Hospital of Baltimore|MedStar Union Memorial Hospital|MedStar Franklin Square Medical Center/Weinberg Cancer Institute|MedStar Good Samaritan Hospital|Johns Hopkins University/Sidney Kimmel Cancer Center|Walter Reed National Military Medical Center|National Institutes of Health Clinical Center|Western Maryland Regional Medical Center|University of Maryland Shore Medical Center at Easton|Christiana Care - Union Hospital|Frederick Memorial Hospital|FMH James M Stockman Cancer Institute|MedStar Montgomery Medical Center|Northwest Hospital Center|TidalHealth Peninsula Regional|Holy Cross Hospital|William E Kahlert Regional Cancer Center/Sinai Hospital|Beverly Hospital|Tufts Medical Center|Massachusetts General Hospital Cancer Center|Boston Medical Center|Beth Israel Deaconess Medical Center|Dana-Farber Cancer Institute|Lahey Hospital and Medical Center|Simonds-Sinon Regional Cancer Center|MetroWest Medical Center-Framingham Union Hospital|Addison Gilbert Hospital|Lowell General Hospital|Lahey Medical Center-Peabody|Mercy Medical Center|Baystate Medical Center|Winchester Hospital|UMass Memorial Medical Center - University Campus|Hickman Cancer Center|Saint Joseph Mercy Hospital|C S Mott Children's Hospital|University of Michigan Comprehensive Cancer Center|Bronson Battle Creek|IHA Hematology Oncology Consultants-Brighton|Saint Joseph Mercy Brighton|Henry Ford Cancer Institute-Downriver|IHA Hematology Oncology Consultants-Canton|Saint Joseph Mercy Canton|Caro Cancer Center|IHA Hematology Oncology Consultants-Chelsea|Saint Joseph Mercy Chelsea|Hematology Oncology Consultants-Clarkston|Newland Medical Associates-Clarkston|Henry Ford Macomb Hospital-Clinton Township|Beaumont Hospital - Dearborn|Henry Ford Medical Center-Fairlane|Wayne State University/Karmanos Cancer Institute|Henry Ford Hospital|Ascension Saint John Hospital|Great Lakes Cancer Management Specialists-Doctors Park|Michigan State University Clinical Center|Green Bay Oncology - Escanaba|Beaumont Hospital - Farmington Hills|Genesee Cancer and Blood Disease Treatment Center|Genesee Hematology Oncology PC|Genesys Hurley Cancer Institute|Hurley Medical Center|Helen DeVos Children's Hospital at Spectrum Health|Mercy Health Saint Mary's|Spectrum Health at Butterworth Campus|Academic Hematology Oncology Specialists|Great Lakes Cancer Management Specialists-Van Elslander Cancer Center|Michigan Breast Specialists-Grosse Pointe Woods|William Beaumont Hospital-Grosse Pointe|Allegiance Health|Bronson Methodist Hospital|West Michigan Cancer Center|Borgess Medical Center|Karmanos Cancer Institute at McLaren Greater Lansing|Sparrow Hospital|Hope Cancer Clinic|Saint Mary Mercy Hospital|Great Lakes Cancer Management Specialists-Macomb Medical Campus|Michigan Breast Specialists-Macomb Township|Saint Mary's Oncology/Hematology Associates of Marlette|Mid-Michigan Medical Center - Midland|Monroe Cancer Center|Toledo Clinic Cancer Centers-Monroe|Mercy Health Mercy Campus|Lakeland Hospital Niles|Cancer and Hematology Centers of Western Michigan - Norton Shores|Ascension Providence Hospitals - Novi|Henry Ford Medical Center-Columbus|21st Century Oncology-Pontiac|Hope Cancer Center|Newland Medical Associates-Pontiac|Saint Joseph Mercy Oakland|Huron Medical Center PC|Lake Huron Medical Center|Spectrum Health Reed City Hospital|Great Lakes Cancer Management Specialists-Rochester Hills|Michigan Cancer Specialists|Oakland Colon Rectal Associates|Beaumont Children's Hospital-Royal Oak|Cancer Care Associates PC|Comprehensive Medical Center PLLC|Hematology Oncology Consultants PC|Oakland Medical Group|William Beaumont Hospital-Royal Oak|Ascension Saint Mary's Hospital|Oncology Hematology Associates of Saginaw Valley PC|Lakeland Medical Center Saint Joseph|Marie Yeager Cancer Center|Henry Ford Macomb Health Center - Shelby Township|Ascension Providence Hospitals - Southfield|Bhadresh Nayak MD PC-Sterling Heights|Premier Hematology Oncology Care|Mitchell Folbe MD PC|Ascension Saint Joseph Hospital|Munson Medical Center|Michigan Institute of Urology-Town Center|Claudia BR Herke MD PC|William Beaumont Hospital - Troy|Hematology Oncology Consultants PC-Troy|Advanced Breast Care Center PLLC|Great Lakes Cancer Management Specialists-Macomb Professional Building|Macomb Hematology Oncology PC|Michigan Breast Specialists-Warren|Saint John Macomb-Oakland Hospital|Henry Ford West Bloomfield Hospital|Saint Mary's Oncology/Hematology Associates of West Branch|Henry Ford Wyandotte Hospital|Metro Health Hospital|Huron Gastroenterology PC|IHA Hematology Oncology Consultants-Ann Arbor|Riverwood Healthcare Center|Sanford Joe Lueken Cancer Center|Essentia Health Saint Joseph's Medical Center|Fairview Ridges Hospital|Minnesota Oncology - Burnsville|Cambridge Medical Center|Mercy Hospital|Essentia Health - Deer River Clinic|Essentia Health Saint Mary's - Detroit Lakes Clinic|Essentia Health Cancer Center|Essentia Health Saint Mary's Medical Center|Miller-Dwan Hospital|Fairview Southdale Hospital|Lake Region Healthcare Corporation-Cancer Care|Essentia Health - Fosston|Unity Hospital|Essentia Health Hibbing Clinic|Fairview Clinics and Surgery Center Maple Grove|Minnesota Oncology Hematology PA-Maplewood|Saint John's Hospital - Healtheast|Abbott-Northwestern Hospital|Hennepin County Medical Center|Health Partners Inc|University of Minnesota/Masonic Cancer Center|Monticello Cancer Center|New Ulm Medical Center|Essentia Health - Park Rapids|Fairview Northland Medical Center|North Memorial Medical Health Center|Mayo Clinic in Rochester|Park Nicollet Clinic - Saint Louis Park|Regions Hospital|United Hospital|Essentia Health Sandstone|Saint Francis Regional Medical Center|Lakeview Hospital|Essentia Health Virginia Clinic|Ridgeview Medical Center|Rice Memorial Hospital|Minnesota Oncology Hematology PA-Woodbury|Sanford Cancer Center Worthington|Fairview Lakes Medical Center|Baptist Memorial Hospital and Cancer Center-Golden Triangle|Baptist Cancer Center-Grenada|Hattiesburg Clinic - Hematology/Oncology Clinic|Forrest General Hospital / Cancer Center|University of Mississippi Medical Center|Baptist Memorial Hospital and Cancer Center-Union County|Baptist Memorial Hospital and Cancer Center-Oxford|Singing River Hospital|Baptist Memorial Hospital and Cancer Center-Desoto|Central Care Cancer Center - Bolivar|Parkland Health Center-Bonne Terre|Cox Cancer Center Branson|Saint Francis Medical Center|Southeast Cancer Center|Saint Luke's Hospital|University of Missouri - Ellis Fischel|Siteman Cancer Center at West County Hospital|Parkland Health Center - Farmington|Centerpoint Medical Center LLC|Capital Region Southwest Campus|Freeman Health System|Mercy Hospital Joplin|Truman Medical Centers|Saint Luke's Hospital of Kansas City|The University of Kansas Cancer Center-South|Research Medical Center|University of Kansas Cancer Center - North|University of Kansas Cancer Center - Lee's Summit|Saint Luke's East - Lee's Summit|Liberty Radiation Oncology Center|University of Kansas Cancer Center at North Kansas City Hospital|Delbert Day Cancer Institute at PCRMC|Mercy Clinic-Rolla-Cancer and Hematology|Heartland Regional Medical Center|Saint Louis Cancer and Breast Institute-South City|Washington University School of Medicine|Mercy Hospital South|Siteman Cancer Center-South County|Missouri Baptist Medical Center|Siteman Cancer Center at Christian Hospital|Mercy Hospital Saint Louis|Siteman Cancer Center at Saint Peters Hospital|Sainte Genevieve County Memorial Hospital|Mercy Hospital Springfield|CoxHealth South Hospital|Missouri Baptist Sullivan Hospital|Missouri Baptist Outpatient Center-Sunset Hills|Community Hospital of Anaconda|Billings Clinic Cancer Center|Saint Vincent Healthcare|Saint Vincent Frontier Cancer Center|Bozeman Deaconess Hospital|Saint James Community Hospital and Cancer Treatment Center|Benefis Healthcare- Sletten Cancer Institute|Saint Peter's Community Hospital|Kalispell Regional Medical Center|Saint Patrick Hospital - Community Hospital|Community Medical Hospital|Nebraska Medicine-Bellevue|CHI Health Saint Francis|Heartland Hematology and Oncology|CHI Health Good Samaritan|Nebraska Hematology and Oncology|Nebraska Cancer Research Center|Saint Elizabeth Regional Medical Center|Southeast Nebraska Cancer Center - 68th Street Place|Faith Regional Health Services Carson Cancer Center|Great Plains Health Callahan Cancer Center|Nebraska Cancer Specialists/Oncology Hematology West PC - MECC|Nebraska Methodist Hospital|Oncology Associates PC|Nebraska Medicine-Village Pointe|Alegent Health Immanuel Medical Center|Hematology and Oncology Consultants PC|Alegent Health Bergan Mercy Medical Center|Nebraska Cancer Specialists - Omaha|Alegent Health Lakeside Hospital|Oncology Hematology West PC|Creighton University Medical Center|University of Nebraska Medical Center|Midlands Community Hospital|Regional West Medical Center Cancer Center|Carson Tahoe Regional Medical Center|Cancer and Blood Specialists-Henderson|Comprehensive Cancer Centers of Nevada - Henderson|Comprehensive Cancer Centers of Nevada-Horizon Ridge|Las Vegas Cancer Center-Henderson|OptumCare Cancer Care at Seven Hills|Comprehensive Cancer Centers of Nevada-Southeast Henderson|GenesisCare USA - Henderson|Las Vegas Urology - Green Valley|Las Vegas Urology - Pebble|Urology Specialists of Nevada - Green Valley|Las Vegas Urology - Pecos|Desert West Surgery|OptumCare Cancer Care at Charleston|University Medical Center of Southern Nevada|Cancer and Blood Specialists-Shadow|Radiation Oncology Centers of Nevada Central|Urology Specialists of Nevada - Central|GenesisCare USA - Las Vegas|HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway|Sunrise Hospital and Medical Center|HealthCare Partners Medical Group Oncology/Hematology-San Martin|Las Vegas Prostate Cancer Center|Las Vegas Urology - Sunset|Urology Specialists of Nevada - Southwest|Radiation Oncology Centers of Nevada Southeast|Cancer Therapy and Integrative Medicine|Ann M Wierman MD LTD|Cancer and Blood Specialists-Tenaya|Comprehensive Cancer Centers of Nevada - Northwest|GenesisCare USA - Vegas Tenaya|HealthCare Partners Medical Group Oncology/Hematology-Tenaya|Las Vegas Urology - Cathedral Rock|Las Vegas Urology - Smoke Ranch|OptumCare Cancer Care at MountainView|Urology Specialists of Nevada - Northwest|Alliance for Childhood Diseases/Cure 4 the Kids Foundation|Comprehensive Cancer Centers of Nevada - Town Center|Comprehensive Cancer Centers of Nevada-Summerlin|Summerlin Hospital Medical Center|Las Vegas Cancer Center-Medical Center|Comprehensive Cancer Centers of Nevada|GenesisCare USA - Fort Apache|OptumCare Cancer Care at Fort Apache|HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills|Comprehensive Cancer Centers of Nevada - Central Valley|Hope Cancer Care of Nevada-Pahrump|Center of Hope at Renown Medical Center|Renown Regional Medical Center|Saint Mary's Regional Medical Center|Radiation Oncology Associates|New Hampshire Oncology Hematology PA-Concord|Dartmouth Hitchcock Medical Center|Norris Cotton Cancer Center-Manchester|Elliot Hospital|Solinsky Center for Cancer Care|Norris Cotton Cancer Center-Nashua|Ocean Medical Center|AtlantiCare Health Park-Cape May Court House|AtlantiCare Surgery Center|Trinitas Hospital and Comprehensive Cancer Center - Williamson Street Campus|Hunterdon Medical Center|Hackensack University Medical Center|Bayshore Community Hospital|Monmouth Medical Center Southern Campus|Saint Barnabas Medical Center|Monmouth Medical Center|Southern Ocean County Medical Center|Memorial Sloan Kettering Monmouth|Morristown Medical Center|Inspira Medical Center Mullica Hill|Jersey Shore Medical Center|Rutgers Cancer Institute of New Jersey|Newark Beth Israel Medical Center|Capital Health Medical Center-Hopewell|Riverview Medical Center/Booker Cancer Center|Sidney Kimmel Cancer Center Washington Township|Overlook Hospital|Inspira Medical Center Vineland|Lovelace Medical Center-Downtown|University of New Mexico Cancer Center|Southwest Gynecologic Oncology Associates Inc|New Mexico Oncology Hematology Consultants|Presbyterian Kaseman Hospital|Memorial Medical Center - Las Cruces|Presbyterian Rust Medical Center/Jorgensen Cancer Center|Christus Saint Vincent Regional Cancer Center|South Shore University Hospital|Montefiore Medical Center-Einstein Campus|Montefiore Medical Center-Weiler Hospital|Children's Hospital at Montefiore|Montefiore Medical Center - Moses Campus|State University of New York Downstate Medical Center|Roswell Park Cancer Institute|Arnot Ogden Medical Center/Falck Cancer Center|Glens Falls Hospital|Memorial Sloan Kettering Westchester|Northwell Health/Center for Advanced Medicine|North Shore University Hospital|Long Island Jewish Medical Center|Lenox Hill Hospital|Mount Sinai Hospital|NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center|Manhattan Eye Ear and Throat Hospital|Memorial Sloan Kettering Cancer Center|NYP/Weill Cornell Medical Center|Rochester General Hospital|University of Rochester|Stony Brook University Medical Center|State University of New York Upstate Medical University|SUNY Upstate Medical Center-Community Campus|Dickstein Cancer Treatment Center|Mission Hospital|AdventHealth Infusion Center Asheville|Messino Cancer Centers|Hope Women's Cancer Centers-Asheville|Waverly Hematology Oncology|UNC Lineberger Comprehensive Cancer Center|Novant Health Presbyterian Medical Center|Novant Health Carolina Surgical - Randolph|Oncology Specialists of Charlotte|Southern Oncology Specialists-Charlotte|Southeastern Medical Oncology Center-Clinton|AdventHealth Infusion Center Haywood|Durham VA Medical Center|Duke University Medical Center|Southeastern Medical Oncology Center-Goldsboro|Wayne Memorial Hospital|Novant Health Breast Surgery - Greensboro|Hendersonville Hematology and Oncology at Pardee|Margaret R Pardee Memorial Hospital|AdventHealth Hendersonville|Novant Health Cancer Institute - Huntersville|Novant Health Presbyterian Medical Center Huntersville|Southern Oncology Specialists-Huntersville|Onslow Memorial Hospital|Southeastern Medical Oncology Center-Jacksonville|Novant Health Cancer Institute - Kernersville|Matthews Radiation Oncology Center|Novant Health Cancer Specialists-Matthews|Lake Norman Radiation Oncology Center-Mooresville|Novant Health Cancer Institute - Mooresville|Novant Health Cancer Institute - Mount Airy|FirstHealth of the Carolinas-Moore Regional Hospital|Duke Raleigh Hospital|Novant Health Cancer Institute - Rowan|Rowan Regional Medical Center|Novant Health Cancer Institute - Statesville|Novant Health Cancer Institute - Thomasville|Marion L Shepard Cancer Center at Vidant Beaufort Hospital|AdventHealth Infusion Center Weaverville|Novant Health Cancer Institute - Wilkesboro|Novant Health Forsyth Medical Center|Novant Health Oncology Specialists|Winston-Salem Health Care|Wake Forest University Health Sciences|Sanford Bismarck Medical Center|Essentia Health Cancer Center-South University Clinic|Sanford South University Medical Center|Sanford Broadway Medical Center|Sanford Clinic North-Fargo|Sanford Roger Maris Cancer Center|Essentia Health - Jamestown Clinic|Trinity Cancer Care Center|Aultman Alliance Community Hospital|UHHS-Chagrin Highlands Medical Center|Indu and Raj Soin Medical Center|Strecker Cancer Center-Belpre|Saint Elizabeth Boardman Hospital|Cleveland Clinic Mercy Hospital|Mercy Hematology and Oncology Associates Inc|Aultman Health Foundation|Dayton Physicians LLC-Miami Valley South|Miami Valley Hospital South|Geauga Hospital|Adena Regional Medical Center|Oncology Hematology Care Inc-Eden Park|Oncology Hematology Care Inc-Mercy West|The Christ Hospital|Good Samaritan Hospital - Cincinnati|Cincinnati Children's Hospital Medical Center|Oncology Hematology Care Inc-Anderson|Oncology Hematology Care Inc-Kenwood|Bethesda North Hospital|Oncology Hematology Care Inc-Blue Ash|TriHealth Cancer Institute-Westside|TriHealth Cancer Institute-Anderson|Case Western Reserve University|MetroHealth Medical Center|Cleveland Clinic Foundation|Ohio State University Comprehensive Cancer Center|Mount Carmel East Hospital|Columbus Oncology and Hematology Associates Inc|Riverside Methodist Hospital|Grant Medical Center|The Mark H Zangmeister Center|Mount Carmel Health Center West|Doctors Hospital|Good Samaritan Hospital - Dayton|Miami Valley Hospital|Dayton Physician LLC-Miami Valley Hospital North|Miami Valley Hospital North|Delaware Health Center-Grady Cancer Center|Delaware Radiation Oncology|Grady Memorial Hospital|Columbus Oncology and Hematology Associates|Dublin Methodist Hospital|Hematology Oncology Center Incorporated|Mercy Cancer Center-Elyria|Oncology Hematology Care Inc-Healthplex|Armes Family Cancer Center|Blanchard Valley Hospital|Orion Cancer Care|Atrium Medical Center-Middletown Regional Hospital|Dayton Physicians LLC-Atrium|Dayton Physicians LLC-Wayne|Wayne Hospital|Mount Carmel Grove City Hospital|Greater Dayton Cancer Center|First Dayton Cancer Care|Kettering Medical Center|Fairfield Medical Center|Saint Rita's Medical Center|Marietta Memorial Hospital|OhioHealth Marion General Hospital|Toledo Clinic Cancer Centers-Maumee|Toledo Radiation Oncology at Northwest Ohio Onocolgy Center|UH Seidman Cancer Center at Landerbrook Health Center|UH Seidman Cancer Center at Lake Health Mentor Campus|UH Seidman Cancer Center at Southwest General Hospital|Dayton Physicians LLC-Signal Point|Knox Community Hospital|Licking Memorial Hospital|Newark Radiation Oncology|Saint Charles Hospital|University Hospitals Parma Medical Center|Mercy Health Perrysburg Cancer Center|Southern Ohio Medical Center|UH Seidman Cancer Center at Firelands Regional Medical Center|Dayton Physicians LLC-Wilson|Springfield Regional Cancer Center|Springfield Regional Medical Center|Trinity's Tony Teramana Cancer Center|ProMedica Flower Hospital|ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital|Saint Vincent Mercy Medical Center|University of Toledo|Mercy Health - Saint Anne Hospital|Toledo Clinic Cancer Centers-Toledo|Dayton Physicians LLC-Upper Valley|Upper Valley Medical Center|University Hospitals Sharon Health Center|Saint Joseph Warren Hospital|Saint Ann's Hospital|UH Seidman Cancer Center at Saint John Medical Center|UHHS-Westlake Medical Center|Saint Elizabeth Youngstown Hospital|Genesis Healthcare System Cancer Care Center|Cancer Centers of Southwest Oklahoma Research|University of Oklahoma Health Sciences Center|Integris Southwest Medical Center|Mercy Hospital Oklahoma City|Integris Cancer Institute of Oklahoma|Cancer Treatment Centers of America|Oklahoma Cancer Specialists and Research Institute-Tulsa|Saint Alphonsus Medical Center-Baker City|Saint Charles Health System|Clackamas Radiation Oncology Center|Providence Cancer Institute Clackamas Clinic|Bay Area Hospital|Good Samaritan Hospital|Legacy Mount Hood Medical Center|Providence Newberg Medical Center|Saint Alphonsus Medical Center-Ontario|Providence Willamette Falls Medical Center|Legacy Good Samaritan Hospital and Medical Center|Providence Portland Medical Center|Providence Saint Vincent Medical Center|Kaiser Permanente Northwest|Oregon Health and Science University|Saint Charles Health System-Redmond|Legacy Meridian Park Hospital|Jefferson Abington Hospital|Lehigh Valley Hospital-Cedar Crest|UPMC Altoona|UPMC-Heritage Valley Health System Beaver|Lehigh Valley Hospital - Muhlenberg|Bryn Mawr Hospital|UPMC Hillman Cancer Center at Butler Health System|UPMC Camp Hill|Carlisle Regional Cancer Center|Christiana Care Health System-Concord Health Center|Chambersburg Hospital|Main Line Health Center-Collegeville|UPMC Hillman Cancer Center - Passavant - Cranberry|Geisinger Medical Center|Doylestown Hospital|Pocono Medical Center|Easton Hospital|Ephrata Cancer Center|Ephrata Community Hospital|UPMC Hillman Cancer Center Erie|UPMC Hamot|Main Line Health Center-Exton|UPMC Cancer Center at UPMC Horizon|Adams Cancer Center|UPMC Cancer Centers - Arnold Palmer Pavilion|Oncology Hematology Associates|Cherry Tree Cancer Center|UPMC Pinnacle Harrisburg|UPMC Pinnacle Cancer Center/Community Osteopathic Campus|Geisinger Medical Center-Cancer Center Hazleton|Lehigh Valley Hospital-Hazleton|Penn State Milton S Hershey Medical Center|IRMC Cancer Center|UPMC-Johnstown/John P. Murtha Regional Cancer Center|Armstrong Center for Medicine and Health|Lancaster General Ann B Barshinger Cancer Institute|Lancaster General Hospital|Sechler Family Cancer Center|Geisinger Medical Oncology-Lewisburg|Lewistown Hospital|UPMC Cancer Center at UPMC McKeesport|Holy Redeemer Hospital and Medical Center|UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion|Riddle Memorial Hospital|Forbes Hospital|UPMC Hillman Cancer Center - Monroeville|UPMC-Coraopolis/Heritage Valley Radiation Oncology|UPMC Hillman Cancer Center - Part of Frick Hospital|Arnold Palmer Cancer Center Medical Oncology Norwin|Allegheny Valley Hospital|UPMC Cancer Center-Natrona Heights|UPMC Hillman Cancer Center - New Castle|Suburban Community Hospital and Cancer Center|Paoli Memorial Hospital|Drexel University School of Medicine|Thomas Jefferson University Hospital|Fox Chase Cancer Center|Jefferson Torresdale Hospital|Eastern Regional Medical Center|Nazareth Hospital|Phoenixville Hospital|Allegheny General Hospital|UPMC-Magee Womens Hospital|Oncology Hematology Association|UPMC-Saint Margaret|UPMC-Mercy Hospital|West Penn Hospital|University of Pittsburgh Cancer Institute (UPCI)|UPMC-Passavant Hospital|UPMC-Saint Clair Hospital Cancer Center|Geisinger Cancer Services-Pottsville|Penn State Health Saint Joseph Medical Center|Guthrie Medical Group PC-Robert Packer Hospital|Hematology and Oncology Associates of North East Pennsylvania|Community Medical Center|Geisinger Medical Oncology-Selinsgrove|UPMC Cancer Center at UPMC Northwest|Geisinger Medical Group|Mount Nittany Medical Center|UPMC Cancer Center-Uniontown|UPMC Cancer Center-Washington|Chester County Hospital|UPMC West Mifflin-Cancer Center Jefferson|Reading Hospital|Geisinger Wyoming Valley/Henry Cancer Center|UPMC Susquehanna|Divine Providence Hospital|Asplundh Cancer Pavilion|Lankenau Medical Center|WellSpan Health-York Cancer Center|WellSpan Health-York Hospital|UPMC Memorial|Newport Hospital|Rhode Island Hospital|Women and Infants Hospital|Miriam Hospital|Smilow Cancer Hospital Care Center - Westerly|AnMed Health Cancer Center|Beaufort Memorial Hospital|Prisma Health Cancer Institute - Spartanburg|Roper Hospital|Charleston Oncology - Roper|Lowcountry Hematology Oncology PA-North Charleston|Bon Secours Saint Francis Hospital|Charleston Oncology - Saint Francis|Lowcountry Hematology Oncology PA-West Ashley|Medical University of South Carolina|Prisma Health Cancer Institute - Easley|McLeod Regional Medical Center|Gibbs Cancer Center-Gaffney|Tidelands Georgetown Memorial Hospital|Greenville Health System Cancer Institute-Andrews|Saint Francis Hospital|Prisma Health Cancer Institute - Butternut|Prisma Health Cancer Institute - Faris|Prisma Health Greenville Memorial Hospital|Saint Francis Cancer Center|Prisma Health Cancer Institute - Eastside|Self Regional Healthcare|Prisma Health Cancer Institute - Greer|Gibbs Cancer Center-Pelham|South Carolina Cancer Specialists PC|The Radiation Oncology Center-Hilton Head/Bluffton|Lowcountry Hematology Oncology PA-Mount Pleasant|Prisma Health Cancer Institute - Seneca|North Grove Medical Park|Spartanburg Medical Center|Spartanburg Medical Center - Mary Black Campus|MGC Hematology Oncology-Union|Avera Cancer Institute-Aberdeen|Rapid City Regional Hospital|Sanford Cancer Center Oncology Clinic|Avera Cancer Institute|Sanford USD Medical Center - Sioux Falls|Memorial Hospital|Integrity Oncology PLLC-Collierville|Cookeville Regional Medical Center|Vanderbilt-Ingram Cancer Center Cool Springs|Pulmonary Medicine Center of Chattanooga-Hixson|Tennessee Cancer Specialists-Dowell Springs|Thompson Cancer Survival Center|Thompson Cancer Survival Center - West|Thompson Oncology Group-Maryville|Baptist Memorial Hospital and Cancer Center-Memphis|Family Cancer Center-Memphis|Vanderbilt Breast Center at One Hundred Oaks|Meharry Medical College|Vanderbilt University/Ingram Cancer Center|Thompson Oncology Group-Oak Ridge|Memorial GYN Plus|Dell Seton Medical Center at The University of Texas|Saint Joseph Regional Cancer Center|MD Anderson in The Woodlands|Parkland Memorial Hospital|Baylor University Medical Center|UT Southwestern/Simmons Cancer Center-Dallas|UT Southwestern/Simmons Cancer Center-Fort Worth|Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center|Houston Methodist Hospital|M D Anderson Cancer Center|Memorial Hermann Texas Medical Center|MD Anderson West Houston|Memorial Hermann Northeast Hospital|MD Anderson League City|Covenant Medical Center-Lakeside|UT Southwestern Clinical Center at Richardson/Plano|Cancer Therapy and Research Center at The UT Health Science Center at San Antonio|Methodist Children's Hospital of South Texas|University Hospital|University of Texas Health Science Center at San Antonio|MD Anderson in Sugar Land|Memorial Hermann The Woodlands Hospital|American Fork Hospital / Huntsman Intermountain Cancer Center|Sandra L Maxwell Cancer Center|Farmington Health Center|Logan Regional Hospital|Intermountain Medical Center|McKay-Dee Hospital Center|Utah Valley Regional Medical Center|Riverton Hospital|Dixie Medical Center Regional Cancer Center|Utah Cancer Specialists-Salt Lake City|Huntsman Cancer Institute/University of Utah|LDS Hospital|South Jordan Health Center|Central Vermont Medical Center/National Life Cancer Treatment|University of Vermont Medical Center|University of Vermont and State Agricultural College|Norris Cotton Cancer Center-North|Danville Regional Medical Center|Inova Schar Cancer Institute|Inova Fair Oaks Hospital|Inova Fairfax Hospital|Augusta Health Center for Cancer and Blood Disorders|Hematology Oncology Associates of Fredericksburg Inc|Centra Lynchburg Hematology-Oncology Clinic Inc|Sovah Health Martinsville|Bon Secours Memorial Regional Medical Center|Bon Secours Westchester Emergency Center|Bon Secours Saint Francis Medical Center|Children's Hospital of The King's Daughters|Bon Secours Saint Mary's Hospital|Virginia Cancer Institute|Bon Secours Cancer Institute at Reynolds Crossing|VCU Massey Cancer Center at Stony Point|Virginia Commonwealth University/Massey Cancer Center|Providence Regional Cancer System-Aberdeen|Cancer Care Center at Island Hospital|MultiCare Auburn Medical Center|Virginia Mason Bainbridge Island Medical Center|Overlake Medical Center|Swedish Cancer Institute-Eastside Oncology Hematology|PeaceHealth Saint Joseph Medical Center|Harrison HealthPartners Hematology and Oncology-Bremerton|Harrison Medical Center|Highline Medical Center-Main Campus|Providence Regional Cancer System-Centralia|Swedish Cancer Institute-Edmonds|Saint Elizabeth Hospital|Providence Regional Cancer Partnership|Virginia Mason Federal Way Medical Center|Saint Francis Hospital|Tacoma/Valley Radiation Oncology Centers-Gig Harbor|MultiCare Gig Harbor Medical Park|Swedish Cancer Institute-Issaquah|Kadlec Clinic Hematology and Oncology|Northwest Cancer Clinic|Providence Regional Cancer System-Lacey|Saint Clare Hospital|PeaceHealth Saint John Medical Center|Virginia Mason Lynnwood Medical Center|Skagit Valley Hospital Regional Cancer Care Center|Skagit Valley Hospital|Jefferson Healthcare|Harrison HealthPartners Hematology and Oncology-Poulsbo|Peninsula Cancer Center|MultiCare Good Samaritan Hospital|Tacoma/Valley Radiation Oncology Centers-Puyallup|Valley Medical Center|Virginia Mason Medical Center|Minor and James Medical PLLC|Pacific Gynecology Specialists|Swedish Medical Center-Ballard Campus|Fred Hutchinson Cancer Research Center|Seattle Cancer Care Alliance|Kaiser Permanente Washington|Swedish Medical Center-First Hill|Swedish Medical Center-Cherry Hill|University of Washington Medical Center - Montlake|PeaceHealth United General Medical Center|Providence Regional Cancer System-Shelton|MultiCare Deaconess Cancer and Blood Specialty Center - Valley|MultiCare Deaconess Cancer and Blood Specialty Center - Downtown|Providence Sacred Heart Medical Center and Children's Hospital|Spokane Valley Cancer Center-Mayfair|Spokane Valley Cancer Center-Mission|Evergreen Hematology and Oncology PS|MultiCare Deaconess Cancer and Blood Specialty Center - North|Tacoma/Valley Radiation Oncology Centers-Jackson Hall|Franciscan Research Center-Northwest Medical Plaza|Mary Bridge Children's Hospital and Health Center|MultiCare Tacoma General Hospital|Northwest Medical Specialties PLLC|Tacoma/Valley Radiation Oncology Centers-Saint Joe's|PeaceHealth Southwest Medical Center|Legacy Cancer Institute Medical Oncology and Day Treatment|Legacy Salmon Creek Hospital|Providence Saint Mary Regional Cancer Center|Wenatchee Valley Hospital and Clinics|North Star Lodge Cancer Center at Yakima Valley Memorial Hospital|Providence Regional Cancer System-Yelm|United Hospital Center|West Virginia University Charleston Division|Edwards Comprehensive Cancer Center|WVUH-Berkely Medical Center|Monongalia Hospital|West Virginia University Healthcare|Camden Clark Medical Center|Wheeling Hospital/Schiffler Cancer Center|Langlade Hospital and Cancer Center|Ascension Saint Elizabeth Hospital|Duluth Clinic Ashland|Northwest Wisconsin Cancer Center|Ascension Southeast Wisconsin Hospital - Elmbrook Campus|Aurora Cancer Care-Southern Lakes VLCC|Ascension Calumet Hospital|Marshfield Clinic-Chippewa Center|Aurora Saint Luke's South Shore|HSHS Sacred Heart Hospital|Marshfield Clinic Cancer Center at Sacred Heart|Marshfield Medical Center-EC Cancer Center|Aurora Health Center-Fond du Lac|Ascension Saint Francis - Reiman Cancer Center|Ascension Southeast Wisconsin Hospital - Franklin|Aurora Health Care Germantown Health Center|Aurora Cancer Care-Grafton|Green Bay Oncology at Saint Vincent Hospital|Saint Vincent Hospital Cancer Center Green Bay|Green Bay Oncology Limited at Saint Mary's Hospital|Saint Vincent Hospital Cancer Center at Saint Mary's|Aurora BayCare Medical Center|Mercyhealth Hospital and Cancer Center - Janesville|Aurora Cancer Care-Kenosha South|Gundersen Lutheran Medical Center|Marshfield Clinic - Ladysmith Center|University of Wisconsin Carbone Cancer Center|Holy Family Memorial Hospital|Aurora Bay Area Medical Group-Marinette|Saint Vincent Hospital Cancer Center at Marinette|Marshfield Medical Center-Marshfield|Marshfield Medical Center|Aspirus Medford Hospital|Ascension Columbia Saint Mary's Hospital Ozaukee|Aurora Cancer Care-Milwaukee|Ascension Southeast Wisconsin Hospital - Saint Joseph Campus|Ascension Columbia Saint Mary's Hospital - Milwaukee|Ascension Saint Francis Hospital|Aurora Saint Luke's Medical Center|Medical College of Wisconsin|Aurora Sinai Medical Center|Marshfield Clinic-Minocqua Center|ProHealth D N Greenwald Center|Cancer Center of Western Wisconsin|ProHealth Oconomowoc Memorial Hospital|Saint Vincent Hospital Cancer Center at Oconto Falls|Ascension Mercy Hospital|Vince Lombardi Cancer Clinic - Oshkosh|Ascension All Saints Hospital|Aurora Cancer Care-Racine|Ascension Saint Mary's Hospital|Saint Mary's Hospital|Lakeview Medical Center-Marshfield Clinic|Marshfield Medical Center-Rice Lake|HSHS Saint Nicholas Hospital|Vince Lombardi Cancer Clinic-Sheboygan|Ascension Saint Michael's Hospital|Marshfield Clinic Stevens Point Center|Saint Vincent Hospital Cancer Center at Sturgeon Bay|Green Bay Oncology - Sturgeon Bay|Aurora Medical Center in Summit|Vince Lombardi Cancer Clinic-Two Rivers|Aurora Cancer Care-Waukesha|ProHealth Waukesha Memorial Hospital|UW Cancer Center at ProHealth Care|Aspirus Regional Cancer Center|Marshfield Clinic-Wausau Center|Ascension Medical Group Southeast Wisconsin - Mayfair Road|Aurora Cancer Care-Milwaukee West|Aurora West Allis Medical Center|Diagnostic and Treatment Center|Marshfield Medical Center - Weston|Aspirus Cancer Care - Wisconsin Rapids|Marshfield Clinic - Wisconsin Rapids Center|Cheyenne Regional Medical Center-West|Big Horn Basin Cancer Center|Billings Clinic-Cody|Welch Cancer Center|FHP Health Center-Guam|Cancer Center-Metro Medical Center Bayamon|Doctors Cancer Center|San Juan Community Oncology Group|San Juan City Hospital,Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Other|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Drug|Other|Drug|Drug|Biological|Drug|Drug|Biological|Drug|Biological|Drug|Drug|Drug|Drug|Biological|Biological|Drug|Drug,Guam|Puerto Rico|United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02465060
NCT02465424,medullary thyroid cancer,Assessing Quality of Life Tools in Medullary Thyroid Cancer Patients,Assessing Quality of Life Tools in Medullary Thyroid Cancer Patients,Medullary Thyroid Cancer,2015-06-01,2017-12-31,2017-12-31,Observational,Completed,,Velindre NHS Trust,Velindre NHS Trust,Velindre Hospital|University Hospitals of Coventry and Warwickshire|Western general Hospital|Imperial Hospital|St. Bartholomew's Hospital|Christie Hospital|Weston Park Hospital,Other,United Kingdom,16.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, medullary",https://clinicaltrials.gov/ct2/show/NCT02465424
NCT02467244,hypothyroidism,"Effect of Levothyroxine on Serum Adiponectin, Insulin Resistance and Cardiovascular Risk in Patients With Hypothyroidism","Effect of Levothyroxine on Serum Adiponectin, Insulin Resistance and Cardiovascular Risk in Patients With Hypothyroidism",Hypothyroidism,2015-06-04,2018-09-30,2018-12-30,Observational,Completed,,"All India Institute of Medical Sciences, Bhubaneswar","All India Institute of Medical Sciences, Bhubaneswar","AIIMS, Bhubaneswar",Drug,India,18.0,65.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT02467244
NCT02468921,goiter,The Impact of Surgical Treatment of Benign Non-toxic Goiter on the Voice Function,Goitres Influence on Voice Function - The Impact of Surgery,Goiter,2015-01-19,2018-10-31,2018-10-31,Observational,Unknown status,,University of Southern Denmark,Odense University Hospital|University of Southern Denmark,Odense University Hospital,Procedure,Denmark,20.0,80.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02468921
NCT02472080,thyroid cancer,Open Labeled Phase II Study Evaluating Efficacy and Safety of Chemotherapy With Gemcitabine - Oxaliplatin Combination for Advanced Refractory Thyroid Cancer Patients,Gemcitabine - Oxaliplatin for Advanced Refractory Thyroid Cancer Patients: a Phase II Study,Thyroid Cancer,2015-05-12,2018-04-01,2019-01-15,Interventional,Terminated,Phase 2,Assistance Publique - Hôpitaux de Paris,Assistance Publique - Hôpitaux de Paris,Groupe Hospitalier Pitié Salpetriere,Drug,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02472080
NCT02491567,graves disease,Study of DNA Methylation in Children and Adolescents With Autoimmune Thyroid Diseases,DNA Methylation and Autoimmune Thyroid Diseases,Graves Disease|Hashimoto Thyroiditis,2014-12-23,2016-09-30,2018-04-30,Observational,Completed,,Aristotle University Of Thessaloniki,Aristotle University Of Thessaloniki,"Unit of Pediatric Endocrinology, Diabetes and Metabolism-4th Department of Pediatrics, Medical School of Aristotle University of Thessaloniki",,Greece,4.0,18.0,[0-17]|[18-65],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02491567
NCT02499471,hyperthyroidism,Brown Adipose Tissue Activity and Thyroid Hormone,Brown Adipose Tissue Activity and Thyroid Hormone,Hyperthyroidism|Hypothyroidism|Obesity,2015-07-06,2012-12-31,2014-07-31,Interventional,Completed,Not Applicable,Maastricht University Medical Center,Maastricht University Medical Center,Maastricht UMC,Other,Netherlands,18.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02499471
NCT02499471,hypothyroidism,Brown Adipose Tissue Activity and Thyroid Hormone,Brown Adipose Tissue Activity and Thyroid Hormone,Hyperthyroidism|Hypothyroidism|Obesity,2015-07-06,2012-12-31,2014-07-31,Interventional,Completed,Not Applicable,Maastricht University Medical Center,Maastricht University Medical Center,Maastricht UMC,Other,Netherlands,18.0,65.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT02499471
NCT02512978,hypothyroidism,Thyroid Hormone Replacement for Hypothyroidism and Acute Myocardial Infarction,Thyroid Hormone Replacement for Hypothyroidism and Acute Myocardial Infarction(ThyroHeart-AMI),Hypothyroidism|Myocardial Infarction,2015-07-27,2018-12-31,2019-06-30,Interventional,Unknown status,Phase 4,"Chinese Academy of Medical Sciences, Fuwai Hospital","Beijing Anzhen Hospital|Beijing Chao Yang Hospital|Beijing Friendship Hospital|Beijing Municipal Science & Technology Commission|Chinese Academy of Medical Sciences, Fuwai Hospital|Peking Union Medical College Hospital|Peking University Third Hospital|The Luhe Teaching Hospital of the Capital Medical University",Fuwai Cardiovascular Hospital,Drug,China,18.0,75.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT02512978
NCT02514187,hyperthyroidism,A Blinded Study Evaluating the Accuracy and Safety of Cyclotron-produced 99mTc in Adult Patients,A Blinded Study Evaluating the Accuracy and Safety of Cyclotron-produced 99mTc in Adult Patients,Hyperthyroidism,2015-07-27,2017-04-30,2017-04-30,Interventional,Completed,Not Applicable,British Columbia Cancer Agency,"British Columbia Cancer Agency|Canadian Institutes of Health Research (CIHR)|Centre for Probe Development and Commercialization|Lawson Health Research Institute|Natural Resources, Canada|TRIUMF",Vancouver General Hospital - Nuclear Medicine|Hamilton Health Sciences Centre|London Regional Health Sciences Centre,Drug|Drug,Canada,19.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02514187
NCT02515084,thyroid cancer,Preliminary Study of the Interest of Diffusion-weighted Magnetic Resonance Imaging in the Early Detection of Differentiated Thyroid Carcinoma Cervical Recurrence. Comparison with18F-FDG PET/CT,Comparison DW-MRI vs FDG PET/CT in the Detection of Early Recurrence of Cervical Well-differentiated Thyroid Carcinoma,Relapse|Thyroid Cancer,2015-07-24,2015-07-31,2016-07-31,Interventional,Completed,Phase 2,Centre Henri Becquerel,Centre Henri Becquerel,Centre Henri Becquerel,Device|Device,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02515084
NCT02524041,hyperparathyroidism,Association Between Serum Periostin Levels and Cortical Porosity in Patients With Secondary Hyperparathyroidism,Association Between Serum Periostin Levels and Cortical Porosity in Patients With Secondary Hyperparathyroidism,Hyperparathyroidism,2015-08-13,2016-04-30,2016-04-30,Interventional,Completed,Not Applicable,Centre Hospitalier Universitaire de Saint Etienne,"Centre Hospitalier Universitaire de Saint Etienne|University Hospital, Geneva",CHU de SAINT-ETIENNE,Device|Other,France,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02524041
NCT02548715,hypothyroidism,Levothyroxine Treatment of Subclinical Hypothyroidism After Non-thyroid Head and Neck Surgery: A Randomized Controlled Trial,Levothyroxine Treatment for Subclinical Hypothyroidism After Head and Neck Surgery,Hypothyroidism|Neoplasms|Postoperative Complications,2015-09-08,2017-07-31,2017-07-31,Interventional,Unknown status,Phase 2/Phase 3,University of Alberta,University of Alberta,,Drug|Drug,,18.0,80.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT02548715
NCT02551120,pseudohypoparathyroidism,"Characterization of Patients With Idiopathic Hypoparathyroidism, Autosomal Dominant Hypocalcaemia and Pseudohypoparathyroidism",Characterization of Patients With Non-surgical Hypoparathyroidism and Pseudohypoparathyroidism,Autosomal Dominant Hypocalcaemia|Idiopathic Hypoparathyroidism|Pseudohypoparathyroidism,2015-06-17,2017-08-31,2020-08-31,Observational,Unknown status,,University of Aarhus,University of Aarhus,Aarhus University Hospital,,Denmark,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,pseudohypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02551120
NCT02561533,papillary thyroid carcinoma,Immunohistochemical Detection of the BRAFV600E Mutation on Cytological Specimen in PTC,Detection of BRAF Mutation on FNAB From Papillary Thyroid Carcinoma,Papillary Thyroid Carcinoma,2015-09-17,2017-07-31,2017-07-31,Interventional,Completed,Not Applicable,University of Aarhus,University of Aarhus,Aarhus University Hospital,Other,Denmark,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT02561533
NCT02567877,hypothyroidism,Is Levothyroxine Alone Adequate Thyroid Hormone Replacement for All Patients?,Is Levothyroxine Alone Adequate Thyroid Hormone Replacement?,Hypothyroidism|Postsurgical Hypothyroidism,2015-10-01,2025-06-30,2025-06-30,Observational,Recruiting,,"University of Colorado, Denver","Charite University, Berlin, Germany|University of Colorado, Denver",University of Colorado Anschutz Medical Campus,Procedure|Drug,United States,18.0,75.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT02567877
NCT02568267,papillary thyroid cancer,"An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements","Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)","Adult Solid Tumor|Breast Cancer|Cholangiocarcinoma|Colorectal Cancer|Head and Neck Neoplasms|Lymphoma, Large-Cell, Anaplastic|Melanoma|Neuroendocrine Tumors|Non-Small Cell Lung Cancer|Ovarian Cancer|Pancreatic Cancer|Papillary Thyroid Cancer|Primary Brain Tumors|Renal Cell Carcinoma|Salivary Gland Cancers|Sarcomas",2015-10-02,2024-12-31,2025-04-01,Interventional,Recruiting,Phase 2,Hoffmann-La Roche,Hoffmann-La Roche,"Western Regional Medical Center at Cancer Treatment Centers of America|Dignity Health St Joseph's Hospital and Medical Center|Mayo Clinic|City of Hope Cancer Center; Division of Medical Oncology & Experimental Therapeutics|Scripps Clinic|University of California San Diego Moores Cancer Center; Dept of Lung Cancer|University of Southern California Medical Center|Univ Of California Irvine College Of Medicine; 300194620|Southern California Kaiser Permanente|UCSF Mount Zion Medical Ctr|Sarcoma Oncology Center|University of Colorado Cancer Center|Yale University|Georgetown University Medical Center Lombardi Cancer Center|Florida Cancer Specialists - Sarasota|H. Lee Moffitt Cancer Center and Research Inst.|Cleveland Clinic Florida|University Cancer & Blood Center, LLC; Research|Winship Cancer Institute|Southeastern Regional Medical Center, Inc.|University of Hawaii Cancer Center|Northwestern University|Advocate Medical Group - Park Ridge, Luther Lane - Oncology|Midwestern Regional Medical Center|Weinberg Cancer Institution at Franklin Square|Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Dana Farber Cancer Institute|University of Michigan Comprehensive Cancer Center; Clinical Trials Office|Karmanos Cancer Center|Henry Ford Hospital|Regents of the University of Minnesota|Washington University|Comprehensive Cancer Centers of Nevada (CCCN) - Central Valley|Dartmouth Hitchcock Medical Center|North Shore Hem Onc Associates|Memorial Sloan Kettering Cancer Center|Levine Cancer Institute|Duke Cancer Institute|Cleveland Clinic|OSU, James Cancer Hospital|Cancer Treatment Centers of America; Tulsa|Providence Portland Medical Center|Oregon Health & Science Univ|Cancer Treatment Centers of America - Eastern Regional Medical Center|Mary Crowley Medical Research Center|University Hospital Medical Oncology Clinic; Harold C. Simmons Comprehensive Cancer Center|University of Texas MD Anderson Cancer Center|Baylor Scott & White Health|University of Utah Hospitals & Clinics|Virginia Cancer Specialists, PC|Virginia Oncology Associates - Hampton|University of Washington Seattle Cancer Care Alliance|Wheaton Franciscan Cancer Care-All Saints|Border Medical Oncology Research Unit|Liverpool Hospital|Newcastle Private Hospital|Flinders Medical Centre|Austin Health|Antwerp University Hospital|Beijing Cancer Hospital|Sichuan Provincial Cancer Hospital|Cancer Center of Guangzhou Medical University|Harbin Medical University Cancer Hospital|Fudan University Shanghai Cancer Center|Shanghai chest hospital|Shenzhen People's Hospital|Tianjin Cancer Hospital|Union Hospital Tongji Medical College Huazhong University of Science and Technology|Zhejiang Cancer Hospital|Institut de Cancerologie de l Ouest|Institut Bergonie; Oncologie|Centre Oscar Lambret; Chir Cancerologie General|Centre Leon Berard; Departement Oncologie Medicale|Hôpital de la Timone; Oncologie Médicale Hématologie & Soins Palliatifs|Hôpital Nord - AP-HM Marseille#; Service d'Oncologie Multidisciplinaire|Institut de Recherche en Cancérologie de Montpellier|Hôpital Européen Georges Pompidou; Hématologie Oncologie|Institut Curie; Oncologie Medicale|Institut De Cancerologie De L'ouest - Rene Gauducheau - Biology|Institut Claudius Regaud; Departement Oncologie Medicale|Institut Gustave Roussy; Pathologie Thoracique|Charite Universitaetsmedizin Berlin - Campus Charite Mitte ; Charite Comprehensive Cancer Center|Evang. Lungenklinik Berlin Klinik für Pneumologie|Universitaetsklinikum Carl Gustav Carus TU Dresden|Asklepios-Fachkliniken Muenchen-Gauting; Onkologie|Universitaetsmedizin Goettingen; Abteilung Haematologie und Onkologie|NCT Uniklinikum Heidelberg; Medizinische Onkologie|Universitaetsklinikum Koeln; Innere Medizin I, Haematologie|Hong Kong Integrated Oncology Centre|Princess Margaret Hospital|The University of Hong Kong|Queen Elizabeth Hospital|The Chinese University of Hong Kong|Seconda Università degli Studi di Napoli; Servizio Epato-Gastroenterologia|Università Campus Bio-Medico di Roma; Oncologia Medica|Azienda Ospedaliero Universitaria San Martino; Lung Cancer Unit|Fondazione IRCCS Istituto Nazionale dei Tumori|Azienda Socio Sanitaria Territoriale Niguarda (Ospedale Niguarda Ca' Granda); Oncologico -Onc.Falck|Fondazione del Piemonte per l'Oncologia - IRCCS;Ematologia|Azienda Ospedaliero-Universitaria S.Luigi Gonzaga; SSD Oncologia Polmonare|A.O Città della Salute e della Scienza di Torino; Colorectal Cancer Unit (CRCU) - SSCVD|Azienda Ospedaliero Universitaria Pisana; Uff. Sperim. Clin. U.O. Farmaceutica|Azienda Ospedaliera di Perugia Ospedale S. Maria della Misericordia ; S.C. Oncologia Medica|IOV - Istituto Oncologico Veneto - IRCCS; Oncologia Medica II|Aichi Cancer Center Hospital; Respiratory Medicine|NHO Shikoku Cancer Center; Dept of Respiratory Medicine|NHO Kyushu Cancer Center|Hyogo Cancer Center, Dept of Respiratory Medicine|National Cancer Center Hospital; Dept of Respiratory Medicine|Miyagi Cancer Center; Respiratory Medicine|Niigata Cancer Center Hospital; Internal Medicine|OSAKA CITY GENERAL HOSPITAL;Medical Oncology|Kindai University Hospital; Medical Oncology|Shizuoka Cancer Center; Respiratory Internal Medicine|Chungbuk National University Hospital|Seoul National University Hospital|Severance Hospital, Yonsei University Health System|Samsung Medical Center|Asan Medical Center.|NKI The Netherlands Cancer Institute|Leids Universitair Medisch Centrum|Uniwersyteckie Centrum Kliniczne; Klinika Onkologii i Radioterapii|Centrum Onkologii-Instytut im.M.Sklodowskiej Curie; Dept of Nuclear Med. and Endocrine Oncology|Mazowieckie Centrum Leczenia Chorob Pluc i Gruzlicy; Dept of Pulmonology & subdiv. of oncology|Szpital Kliniczny Przemienienia Panskiego Uni. Medycznego im. Karola Marcinkowskiego; Chemotherapy|Centrum Onkologii Instytut im. M. Sklodowskiej-Curie, Klinika Nowotworow Ukladu Chlonnego|National University Hospital; Haematology/Oncology|National Cancer Centre|Centro Nacional de Investigaciones Oncológicas(CNIO); Gastrointestinal Cancer Clinical Research Unit|Vall d´Hebron Institute of Oncology (VHIO), Barcelona|Hospital Universitario de La Princesa; Servicio de Oncologia|Hospital Universitario Ramon y Cajal; Servicio de Farmacia|Hospital Universitario Clínico San Carlos; Servicio de Oncologia|Hospital Universitario 12 de Octubre; Servicio de Oncologia|Hospital Universitario La Paz; Servicio de Oncologia|Centro Integral Oncologico Clara Campal; Servicio de Oncología|Hospital Clinico Universitario Virgen de la Victoria; Servicio de Oncologia|Hospital Universitario Virgen del Rocio; Servicio de Oncologia|Changhua Christian Hospital|National Cheng Kung University Hospital|Taipei Veterans General Hospital|National Taiwan University Hospital|Taichung Veterans General Hospital|Addenbrookes Hospital|Sarah Cannon Research Institute|Christie Hospital Nhs Trust; Medical Oncology",Drug,"Australia|Belgium|China|France|Germany|Hong Kong|Italy|Japan|Korea, Republic of|Netherlands|Poland|Singapore|Spain|Taiwan|United Kingdom|United States",18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT02568267
NCT02577367,hypothyroidism,The Effect of Holding Tube Feeding When Administering Levothyroxine on the Mean Percentage of Levothyroxine Dosage Increase in Patients With Hypothyroidism Started on Enteral Feeding,Mean Percentage of Levothyroxine Dosage Increase in Patients With Hypothyroidism Started on Enteral Feeding,Hypothyroidism,2015-09-14,2020-04-08,2020-04-08,Interventional,Withdrawn,Phase 4,Maimonides Medical Center,Jocelyne Karam|Maimonides Medical Center,Maimonides Medical Center,Drug,United States,18.0,100.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT02577367
NCT02586337,differentiated thyroid cancer,"A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Compare the Efficacy and Safety of Anlotinib Versus Placebo in Patients With 131I-Refractory Differentiated Thyroid Cancer(ALTER01032)",Study of Anlotinib in Patients With Differentiated Thyroid Cancer(ALTER01032),Differentiated Thyroid Cancer,2015-10-22,2019-12-31,2019-12-31,Interventional,Unknown status,Phase 2/Phase 3,"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","Cancer Institute and Hospital, Chinese Academy of Medical Sciences|Beijing Tongren Hospital|Peking Union Medical College Hospital|Chongqing Cancer Hospital|Fujian Cancer Hospital|Gansu Province Tumor Hospital|Sun Yat-Sen University Cancer Center|Harbin medical university affiliated tumor hospital|Henan Province Tumor Hospital|Union Hospital Tongji Medical College Huazhong University of Science and Technology|Hunan Province Tumor Hospital|Jiangsu province tumor hospital|Jilin Cancer Hospital|Liaoning Province Tumor Hospital|Cancer Hospital of Fudan University|West China Hospital Of Sichuan University|20th Floor, Block C, Lake Road, Hexi District, Tianjin Medical University Cancer Institute and Hospital .|The First Affiliated Hospital of Kunming Medical University|Zhejiang Cancer Hospital",Drug|Drug,China,18.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,"Differentiated thyroid cancer, all",https://clinicaltrials.gov/ct2/show/NCT02586337
NCT02586350,medullary thyroid carcinoma,"A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Compare the Efficacy and Safety of Anlotinib Versus Placebo in Patients With Medullary Thyroid Carcinoma(ALTER01031)",Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031),Medullary Thyroid Carcinoma,2015-10-22,2018-09-30,2018-09-30,Interventional,Completed,Phase 2/Phase 3,"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","Cancer Institute and Hospital, Chinese Academy of Medical Sciences|Beijing Tongren Hospital|Peking Union Medical College Hospital|Chongqing Cancer Hospital|Fujian Cancer Hospital|Gansu Province Tumor Hospital|Sun Yat-Sen University Cancer Center|Harbin medical university affiliated tumor hospital|Henan Province Tumor Hospital|Union Hospital Tongji Medical College Huazhong University of Science and Technology|Hunan Province Tumor Hospital|Jiangsu province tumor hospital|Jilin Cancer Hospital|Liaoning Province Tumor Hospital|Cancer Hospital of Fudan University|West China Hospital Of Sichuan University|20th Floor, Block C, Lake Road, Hexi District, Tianjin Medical University Cancer Institute and Hospital .|The First Affiliated Hospital of Kunming Medical University|Zhejiang Cancer Hospital",Drug|Drug,China,18.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, medullary",https://clinicaltrials.gov/ct2/show/NCT02586350
NCT02591160,hyperparathyroidism,Optimal Hydrochlorothiazide Cessation in Diagnosis of Hyperparathyroidism,Optimal HCTZ Cessation for Diagnosis of Hyperparathyroidism,Hyperparathyroidism,2015-10-27,2017-09-13,2017-09-13,Interventional,Completed,Not Applicable,University of Missouri-Columbia,University of Missouri-Columbia,University of Missouri,Procedure,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02591160
NCT02592356,thyroid gland medullary carcinoma,Effects of Tyrosine Kinase Inhibitors on Body Composition in Endocrine Tumors -- A Pilot Study,Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer,Differentiated Thyroid Gland Carcinoma|Malignant Adrenal Gland Pheochromocytoma|Malignant Paraganglioma|Thyroid Gland Medullary Carcinoma,2015-10-27,2022-11-30,2022-11-30,Interventional,Active not recruiting,Not Applicable,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center|National Cancer Institute (NCI),M D Anderson Cancer Center,Procedure|Procedure|Procedure|Other|Other|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, medullary",https://clinicaltrials.gov/ct2/show/NCT02592356
NCT02602717,thyroid cancer,,"The Evaluation of the Diagnostic Properties of Intra-operative In-situ Thyroglobin Levels of Cervical Lymph Nodes, in the Discrimination Between Benign and Malignant Lymph Nodes in Thyroid Cancer: a Prospective Multicentre Study.",Thyroid Cancer,2015-10-22,2017-05-17,2018-12-31,Interventional,Unknown status,Not Applicable,Assistance Publique Hopitaux De Marseille,Assistance Publique Hopitaux De Marseille,APHM,Other,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02602717
NCT02614495,thyroid carcinoma,"A Multi-center , Opened, Phase II Study of Safety and Efficacy of Sulfatinib in Advanced Medullary Thyroid Carcinoma ( MTC) and Iodine-refractory Differentiated Thyroid Carcinoma (DTC)",Study of Sulfatinib in Treating Advanced Medullary Thyroid Carcinoma and Iodine-refractory Differentiated Thyroid Carcinoma,Thyroid Carcinoma,2015-11-24,2018-09-30,2018-09-30,Interventional,Completed,Phase 2,Hutchison Medipharma Limited,Hutchison Medipharma Limited,Peking Union Medical College Hospital|Fudan University Shanghai Cancer Center,Drug,China,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02614495
NCT02628067,thyroid carcinoma,A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158),Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158),Advanced Cancer|Advanced Solid Tumors|Anal Cancer|Anal Carcinoma|Bile Duct Cancer|Biliary Cancer|Carcinoid Tumor|Cervical Cancer|Cervical Carcinoma|Cholangiocarcinoma|Colorectal Carcinoma|Endometrial Cancer|Endometrial Carcinoma|Mesothelioma|Neuroendocrine Tumor|Parotid Gland Cancer|Salivary Cancer|Salivary Gland Cancer|Salivary Gland Carcinoma|Small Cell Lung Cancer (SCLC)|Small Cell Lung Carcinoma|Thyroid Cancer|Thyroid Carcinoma|Vulvar Cancer|Vulvar Carcinoma,2015-12-09,2026-06-18,2026-06-18,Interventional,Recruiting,Phase 2,Merck Sharp & Dohme Corp.,Merck Sharp & Dohme Corp.,"Call for Information (Investigational Site 0202)|Call for Information (Investigational Site 0017)|Call for Information (Investigational Site 0015)|Call for Information (Investigational Site 0010)|Call for Information (Investigational Site 0209)|Call for Information (Investigational Site 0008)|Call for Information (Investigational Site 0004)|Merck Sharp & Dohme|MSD Brasil|Merck Canada|Merck Sharp & Dohme (China) Ltd.|MDS Colombia SAS|Merck Sharp & Dohme|MSD France|MSD Sharp & Dohme GmbH|Merck Sharp & Dohme Co. Ltd.|MSD Italia S.r.l.|MSD Korea LTD|Merck Sharp & Dohme BV|MSD Norge A/S|Merck Sharp & Dohme (I.A.) Corporation|Merck Sharp & Dohme IDEA, Inc.|MSD (Pty) LTD South Africa|Merck Sharp and Dohme de Espana S.A.|Merck Sharp & Dohme (I.A.) Corp.",Biological|Biological,"Australia|Brazil|Canada|China|Colombia|Denmark|France|Germany|Israel|Italy|Korea, Republic of|Netherlands|Norway|Philippines|Russian Federation|South Africa|Spain|Taiwan|United States",18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02628067
NCT02638077,differentiated thyroid cancer,"A Multi-center, Prospective Study to Observe the Initial Management of Patients With Differentiated Thyroid Cancer in the Real World in China (DTCC Study)",Initial Management in Patients With Differentiated Thyroid Cancer in the Real World in China,Differentiated Thyroid Cancer,2015-12-18,2017-04-30,2017-04-30,Observational,Unknown status,,Huazhong University of Science and Technology,Chinese PLA General Hospital|First Hospital of China Medical University|Gansu Cancer Hospital|Huazhong University of Science and Technology|Jilin University|Sir Run Run Shaw Hospital|The First Affiliated Hospital of Kunming Medical College|Tongji Hospital|West China Hospital,"Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",,China,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Differentiated thyroid cancer, all",https://clinicaltrials.gov/ct2/show/NCT02638077
NCT02644707,autoimmune thyroiditis,L-selenomethionine Supplementation in Children and Adolescents With Autoimmune Thyroiditis: a Randomized Blind Placebo-controlled Clinical Trial,Selenium Supplementation in Youths With Autoimmune Thyroiditis,Autoimmune Thyroiditis,2015-12-29,2016-10-31,2018-08-31,Interventional,Completed,Phase 4,Aristotle University Of Thessaloniki,Aristotle University Of Thessaloniki,"Unit of Pediatric Endocrinology, Diabetes and Metabolism-4th Department of Pediatrics, Medical School of Aristotle University of Thessaloniki",Dietary Supplement|Other,Greece,4.0,18.0,[0-17]|[18-65],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT02644707
NCT02648399,thyroid papillary carcinoma,,Prospective Study on the Clinical Prognosis of Bilateral Central Lymph Node Dissection in the Patients With Unilateral Thyroid Papillary Carcinoma,Thyroid Papillary Carcinoma,2015-12-13,2016-12-31,2016-12-31,Interventional,Unknown status,Not Applicable,Fujian Medical University,Fujian Medical University,Fujian Medical University Union Hospital,Procedure|Procedure,China,15.0,60.0,[0-17]|[18-65],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT02648399
NCT02651818,goiter,The Impact of Surgical Treatment of Benign Non-toxic Goiter on Quality of Life,Changes in Quality of Life Following Surgical Treatment of Benign Non-toxic Goiter,Goiter,2016-01-06,2017-10-24,2017-10-24,Observational,Completed,,University of Southern Denmark,University of Southern Denmark,Odense University Hospital,Procedure,Denmark,20.0,80.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02651818
NCT02657369,"thyroid carcinoma, anaplastic","An Open-Label, Single-Arm, Multicenter, Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)",A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC),"Thyroid Carcinoma, Anaplastic",2016-01-13,2018-09-26,2018-09-26,Interventional,Terminated,Phase 2,Eisai Inc.,Eisai Inc.,,Drug,Australia|France|Italy|United Kingdom|United States,18.0,99.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT02657369
NCT02657551,thyroid cancer,A Phase II Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer,A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer,Thyroid Cancer,2015-11-09,2022-12-31,2023-12-31,Interventional,Recruiting,Phase 2,Dana-Farber Cancer Institute,Bayer|Dana-Farber Cancer Institute,Yale Cancer Center|Dana-Farber Cancer Institute,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02657551
NCT02658513,thyroid carcinoma,Evaluation of Lancet Blood Sampling for Radioiodine Dosimetry in Thyroid Cancer,Evaluation of Lancet Blood Sampling for Radioiodine Dosimetry in Thyroid Cancer,Cancer of the Thyroid|Cancer of Thyroid|Thyroid Cancer|Thyroid Carcinoma,2015-12-24,2019-03-31,2019-03-31,Observational,Completed,,Royal Surrey County Hospital NHS Foundation Trust,Royal Surrey County Hospital NHS Foundation Trust,Royal Surrey County Hospital NHS Foundation Trust,Other|Other,United Kingdom,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02658513
NCT02688608,anaplastic thyroid cancer,Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/ Undifferentiated Thyroid Cancer,Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer,Anaplastic Thyroid Cancer,2016-01-20,2020-10-31,2021-10-31,Interventional,Completed,Phase 2,Stanford University,Merck Sharp & Dohme Corp.|Saad A Khan,UT Southwestern Medical Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT02688608
NCT02689609,hypothyroidism,Dosimetric Predictors of Hypothyroidism After Radical Intensity-modulated Radiation Therapy for Non-metastatic Nasopharyngeal Carcinoma,Post-radiation Hypothyroidism After IMRT for Nasopharyngeal Carcinoma,Complications|Hypothyroidism,2016-02-15,2013-12-31,2016-12-31,Observational [Patient Registry],Completed,,The University of Hong Kong,City University of Hong Kong|The University of Hong Kong,,Radiation,,18.0,80.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT02689609
NCT02702388,thyroid cancer,"A Multicenter, Randomized, Double-Blind Phase 2 Trial of Lenvatinib (E7080) in Subjects With 131I-Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 mg Daily Will Provide Comparable Efficacy to a 24-mg Starting Dose, But Have a Better Safety Profile","A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile",Thyroid Cancer,2016-03-03,2019-12-12,2020-09-10,Interventional,Completed,Phase 2,Eisai Inc.,Eisai Inc.|Merck Sharp & Dohme Corp.,Facility#1|Facility #1|Facility #1|Facility #1|Facility #1|Facility #2|Facility #1|Facility #1|Facility#2|Facility#1|Facility #1|Facility #1|Facility #1|Facility #2|Facility #1|Facility #1|Facility #1|Facility #1|Royal Brisbane and Women's Hospital|Facility#2|Facility #1|Facility #1|Facility #1|Facility #1|Facility #1|Facility #1|Facility #1|Facility #2|Facility #1|Facility #1|Facility #1|Facility #1|Facility #1|Facility #1|Facility #1|Facility #1|Facility #1|Facility #1|Facility #2|Facility #1|Facility #2|Facility #1|Facility #1|Facility #1|Facility #2|Facility #1|Facility #1|Facility #1|Facility #1|Facility #1|Facility #2|Facility #1|Facility #1|Facility #1|Facility #6|Facility #1|Facility #2|Facility #3|Facility #2|Facility #3|Facility #4|Facility #5|Facility #1|Facility #1|Facility #6|Facility #7|Facility #2|Facility #4|Facility #2|Facility #1|Facility #1|Facility#1|Facility #1|Facility #3|Facility #4|Facility #1|Facility #2|Facility #2|Facility #1|Facility #1|Facility #4|Facility #3|Facility #4|Facility #1|Facility #2|Facility #1|Facility #3|Facility #1|Facility #2|Facility #1|Facility #2|Facility #1|Facility #2|Facility #1|Facility #2|Facility #3|Facility #1|Facility #1|Facility #1|Facility #1|Facility #1,Drug|Drug,"Australia|Belgium|Canada|Denmark|France|Germany|Israel|Italy|Korea, Republic of|Poland|Romania|Russian Federation|Spain|Sweden|United Kingdom|United States",18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02702388
NCT02706743,thyroid neoplasms,Effect of Radioiodine Remnant Ablation on Quality of Life in Patients With Differentiated Thyroid Cancer:a Prospective Cohort Study,Assessment of Quality of Life After Adjunct Radioiodine Therapy in Patients With Differentiated Thyroid Cancer,Thyroid Neoplasms,2015-05-29,2016-12-31,2016-12-31,Observational,Unknown status,,"Southern Medical University, China","Southern Medical University, China","Zhujiang Hospital,Southern Medical University",,China,18.0,75.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02706743
NCT02709889,medullary thyroid cancer,An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors,Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors,Glioblastoma|High Grade Gastroenteropancreatic Neuroendocrine Carcinoma|Large-Cell Neuroendocrine Carcinoma|Malignant Melanoma|Medullary Thyroid Cancer|Neuroendocrine Prostate Cancer|Other Neuroendocrine Carcinoma|Other Solid Tumors,2016-03-02,2019-08-27,2019-08-27,Interventional,Terminated,Phase 1/Phase 2,AbbVie,AbbVie,"Banner MD Anderson Cancer Ctr /ID# 155424|Mayo Clinic - Scottsdale /ID# 155419|University of California, Los Angeles /ID# 155429|Univ California, San Francisco /ID# 155409|Cedars-Sinai Medical Center - West Hollywood /ID# 155428|Univ of Colorado Cancer Center /ID# 155415|Sarah Cannon Research Institute at HealthONE - Denver /ID# 155420|University of Florida - Archer /ID# 155414|Moffitt Cancer Center /ID# 170220|Emory University Hospital /ID# 155417|University of Kentucky Chandler Medical Center /ID# 155423|Johns Hopkins University /ID# 155412|Massachusetts General Hospital /ID# 155411|Dana-Farber Cancer Institute /ID# 171044|Mayo Clinic - Rochester /ID# 155416|Washington University-School of Medicine /ID# 155425|Rutgers Cancer Institute of NJ /ID# 162010|University of New Mexico /ID# 205054|Roswell Park Comprehensive Cancer Center /ID# 162015|Weill Cornell Medical College /ID# 155418|Duke University Medical Center /ID# 155421|Univ Hosp Cleveland /ID# 155410|Oregon Health and Science University /ID# 162011|Greenville Hospital System /ID# 155427|Mary Crowley Cancer Research /ID# 162014|Texas Oncology - Forth Worth /ID# 162045|University of Texas MD Anderson Cancer Center /ID# 155413|University of Utah /ID# 155426|Virginia Cancer Specialists /ID# 162006|Northwest Cancer Specialists, P.C. /ID# 155431",Drug|Drug,United States,18.0,99.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, medullary",https://clinicaltrials.gov/ct2/show/NCT02709889
NCT02710799,hyperthyroidism,Evaluation of the Effectivity of Teleconsultations for Improving the Referrals From Primary Care to Specialized Care of Patients With Chronic Endocrinological Conditions,Evaluation of the Effects of Teleconsultations on a Endocrinology Referral List,Diabetes Mellitus|Goiter|Hyperthyroidism|Hypothyroidism|Obesity|Thyroid Nodule,2016-03-07,2016-06-30,2016-06-30,Interventional,Completed,Not Applicable,Hospital de Clinicas de Porto Alegre,Hospital de Clinicas de Porto Alegre|Programa de Pesquisa e Pós-Graduação em Epidemiologia da UFRGS|Secretaria Estadual da Saúde do Estado do Rio Grande do Sul|TelessaúdeRS / UFRGS,Secretaria Estadual da Saúde,Other|Other,Brazil,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02710799
NCT02710799,hypothyroidism,Evaluation of the Effectivity of Teleconsultations for Improving the Referrals From Primary Care to Specialized Care of Patients With Chronic Endocrinological Conditions,Evaluation of the Effects of Teleconsultations on a Endocrinology Referral List,Diabetes Mellitus|Goiter|Hyperthyroidism|Hypothyroidism|Obesity|Thyroid Nodule,2016-03-07,2016-06-30,2016-06-30,Interventional,Completed,Not Applicable,Hospital de Clinicas de Porto Alegre,Hospital de Clinicas de Porto Alegre|Programa de Pesquisa e Pós-Graduação em Epidemiologia da UFRGS|Secretaria Estadual da Saúde do Estado do Rio Grande do Sul|TelessaúdeRS / UFRGS,Secretaria Estadual da Saúde,Other|Other,Brazil,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT02710799
NCT02710799,goiter,Evaluation of the Effectivity of Teleconsultations for Improving the Referrals From Primary Care to Specialized Care of Patients With Chronic Endocrinological Conditions,Evaluation of the Effects of Teleconsultations on a Endocrinology Referral List,Diabetes Mellitus|Goiter|Hyperthyroidism|Hypothyroidism|Obesity|Thyroid Nodule,2016-03-07,2016-06-30,2016-06-30,Interventional,Completed,Not Applicable,Hospital de Clinicas de Porto Alegre,Hospital de Clinicas de Porto Alegre|Programa de Pesquisa e Pós-Graduação em Epidemiologia da UFRGS|Secretaria Estadual da Saúde do Estado do Rio Grande do Sul|TelessaúdeRS / UFRGS,Secretaria Estadual da Saúde,Other|Other,Brazil,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT02710799
NCT02710799,thyroid nodule,Evaluation of the Effectivity of Teleconsultations for Improving the Referrals From Primary Care to Specialized Care of Patients With Chronic Endocrinological Conditions,Evaluation of the Effects of Teleconsultations on a Endocrinology Referral List,Diabetes Mellitus|Goiter|Hyperthyroidism|Hypothyroidism|Obesity|Thyroid Nodule,2016-03-07,2016-06-30,2016-06-30,Interventional,Completed,Not Applicable,Hospital de Clinicas de Porto Alegre,Hospital de Clinicas de Porto Alegre|Programa de Pesquisa e Pós-Graduação em Epidemiologia da UFRGS|Secretaria Estadual da Saúde do Estado do Rio Grande do Sul|TelessaúdeRS / UFRGS,Secretaria Estadual da Saúde,Other|Other,Brazil,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT02710799
NCT02711059,hyperparathyroidism,"Insulin Resistance in Primary Hyperparathyroidism, a Non-classical Manifestation",Insulin Resistance in Primary Hyperparathyroidism,Diabetes|Hypercalcemia|Hyperparathyroidism,2015-10-18,2021-12-31,2022-06-30,Interventional,Withdrawn,Not Applicable,Karolinska University Hospital,Karolinska University Hospital,Karolinska University Hospital,Procedure,Sweden,50.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02711059
NCT02713269,thyroid gland carcinoma,A Phase II Clinical Trial Evaluating the Efficacy of Combining Thermal Ablation and Spine Stereotactic Radiosurgery for Patients With Spine Metastases With Moderate to Severe Epidural Involvement,Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord,Malignant Digestive System Neoplasm|Metastatic Head and Neck Carcinoma|Metastatic Kidney Carcinoma|Metastatic Malignant Neoplasm in the Spine|Metastatic Malignant Neoplasm of Unknown Primary|Metastatic Melanoma|Prostate Carcinoma Metastatic in the Bone|Sarcoma|Solid Neoplasm|Spinal Cord Compression|Stage IV Breast Cancer AJCC v6 and v7|Stage IV Lung Non-Small Cell Cancer AJCC v7|Thyroid Gland Carcinoma,2016-03-15,2022-07-01,2022-07-01,Interventional,Recruiting,Phase 2,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center|National Cancer Institute (NCI),M D Anderson Cancer Center,Procedure|Other|Other|Radiation|Procedure,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02713269
NCT02714946,thyroid nodule,Prospective Randomized Comparative Study of the Effectiveness and Safety of Ultrasound-guided Laser and Radiofrequency Ablation for the Treatment of Benign Thyroid Nodules,Laser Ablation Versus Radiofrequency Ablation for Thyroid Nodules,Thyroid Nodule,2016-02-19,2019-09-30,2020-01-31,Interventional,Unknown status,Not Applicable,Campus Bio-Medico University,Campus Bio-Medico University,Santa Maria Goretti Hospital,Device|Device,Italy,18.0,65.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT02714946
NCT02726282,thyroid cancer,Impact of Papillary Microcarcinoma Terminology on Patients Treatment Preferences,Impact of Papillary Microcarcinoma Terminology on Patients Treatment Preferences: a Cross Sectional Survey,Thyroid Cancer,2016-03-29,2017-03-31,2017-03-31,Observational,Withdrawn,,Mayo Clinic,Mayo Clinic,Mayo Clinic,,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02726282
NCT02726503,anaplastic thyroid cancer,Phase II Study Assessing the Efficacy and Safety of Lenvatinib for Anaplastic Thyroid Cancer (HOPE),Phase II Study Assessing the Efficacy and Safety of Lenvatinib for Anaplastic Thyroid Cancer,Anaplastic Thyroid Cancer,2016-03-29,2020-02-25,2020-03-20,Interventional,Completed,Phase 2,"Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan","Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan",Nagoya University Hospital|Fujita Health University Hospital|IUHW Ichikawa Hospital|National Cancer Center Hospital East|Japanese Red Cross Narita Hospital|Kuma Hospital|Kobe Univbersity Hospital|University of Tsukuba Hospital|Iwate Medical University Hospital|Kitasato University Hospital|Showa University Northern Yokohama Hospital|Kanagawa Cancer Center|Miyaghi Cancer Center|Tohoku University Hospital|Shinsyu University School of Medicine Department of Surgery|Nara Hospital Kinki University Faculty of Medicine|Nara Medical University|Osaka Police Hospital|Osaka City University Graduate School of Medicine and Faculty of Medicine|Nippon Medical School Hospital|The Cancer Institute Hospital of JFCR|Ito Hospital|Tokyo Medical University Hospital,Drug,Japan,20.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT02726503
NCT02731352,thyroid cancer,Study of Apatinib in Patients With Local Advanced/Metastatic Iodine-131（131I）-Refractory/Resistant Differentiated Thyroid Cancer,Study of Apatinib in Patients With Differentiated Thyroid Cancer,Thyroid Cancer,2016-03-07,2020-02-27,2021-02-28,Interventional,Completed,Phase 2,Peking Union Medical College Hospital,Peking Union Medical College Hospital,Peking Union Medical College Hospital,Drug|Drug,China,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02731352
NCT02747888,thyroid cancer,Hereditary Risk Factors for Thyroid Cancer,Hereditary Risk Factors for Thyroid Cancer,Thyroid Cancer,2016-03-31,2022-03-01,2022-03-01,Interventional,Recruiting,Not Applicable,Dana-Farber Cancer Institute,Dana-Farber Cancer Institute,Dana Farber Cancer Institute,Genetic,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02747888
NCT02747979,hyperparathyroidism,The Effect and Safety of Combination Hemodialysis and Hemoperfusion on Severe Renal Osteopathy and Itching in Uremia Patients,The Effect and Safety of Hemodialysis and Hemoperfusion on Severe Renal Osteopathy and Itching in Uremia Patients,Hyperparathyroidism|Insomnia|Ostalgia|Refractory Pruritus,2015-05-21,2010-05-31,2010-05-31,Interventional,Completed,Phase 2/Phase 3,Sun Yat-sen University,Sun Yat-sen University,"The 1st Affiliated Hospital, Sun Yet-sen University",Other|Other|Other,China,16.0,75.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02747979
NCT02758158,thyroid neoplasms,Clinical Evaluation of a Prototype Tri-modal Imaging Instrument for Thyroid Cancer,Tri-modal Imaging Instrument for Thyroid Cancer,Thyroid Cancer|Thyroid Neoplasms|Thyroid Nodule,2016-03-09,2017-02-28,2017-02-28,Interventional,Completed,Not Applicable,"University Health Network, Toronto","University Health Network, Toronto",Princess Margaret Cancer Centre,Device,Canada,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02758158
NCT02758158,thyroid nodule,Clinical Evaluation of a Prototype Tri-modal Imaging Instrument for Thyroid Cancer,Tri-modal Imaging Instrument for Thyroid Cancer,Thyroid Cancer|Thyroid Neoplasms|Thyroid Nodule,2016-03-09,2017-02-28,2017-02-28,Interventional,Completed,Not Applicable,"University Health Network, Toronto","University Health Network, Toronto",Princess Margaret Cancer Centre,Device,Canada,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT02758158
NCT02766283,hypothyroidism,Observational Study on Hypothyroidism in Young Children Following Iodine Contrast Exposure,Observational Study on Hypothyroidism in Young Children Following Iodine Contrast Exposure,Hypothyroidism,2016-05-06,2016-08-30,2016-08-30,Observational,Completed,,Bayer,Bayer,,Drug,Israel,0.0,3.0,[0-17],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT02766283
NCT02767245,thyrotoxicosis,Efficacy of Thiamine Supplement for Improve Cardiovascular Function in Patients With Severe Hyperthyroidism,Thiamine Supplement in Patients With Severe Hyperthyroidism,Thyrotoxicosis,2016-05-09,2016-07-31,2016-07-31,Interventional,Completed,Not Applicable,Ramathibodi Hospital,Ramathibodi Hospital,"Faculty of Medicine Ramathibodi Hospital, Mahidol University",Drug,Thailand,15.0,120.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02767245
NCT02768753,thyroid papillary carcinoma,Comparison Between the Axillary Bilateral-breast Approach (ABBA) and Bilateral Axillo-breast Approach (BABA) for Robotic Thyroidectomy,Comparison Between the Axillary Bilateral-breast Approach (ABBA) and Bilateral Axillo-breast Approach (BABA) for Robotic Thyroidectomy,Thyroidectomy|Thyroid Papillary Carcinoma,2016-05-02,2017-04-30,2017-04-30,Interventional,Completed,Not Applicable,Jinan Military General Hospital,Jinan Military General Hospital,"Department of thyroid and breast surgery, General Hospital of Jinan Military Area",Procedure|Procedure,China,18.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT02768753
NCT02772705,hyperthyroidism,Comparison of Standardized Update Value Using Single-photo Emission Computed Tomography and Computed Tomography Between Grave's Disease (Hyperthyroidism) Patients and Normal Humans,Comparison of SUV Using SPECT/CT Between Grave's Disease Patients and Normal Humans,Emission-Computed|Hyperthyroidism|Single-Photon|Tomography,2016-05-09,2016-08-31,2017-01-31,Observational,Unknown status,,West China Hospital,"Air Force Military Medical University, China|Beijing Tongren Hospital|Guangzhou Panyu Central Hospital|Hebei General Hospital|The First Affiliated Hospital of Zhengzhou University|Tianjin Medical University General Hospital|West China Hospital|Zhejiang Cancer Hospital",Beijing Tongren Hospital|Guangzhou Panyu Central Hospital|Hebei General Hospital|The First Affiliated Hospital of Zhengzhou University|The People's Hospital of Inner Mongolia Autonomous Region|Fourth Military Medical Universit|West China Hospital|Tianjin Medical University General Hospital|Zhejiang Cancer Hospital,,China,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02772705
NCT02773667,thyroid carcinoma,Relationship Between Estimated Glomerular Filtration Rate and Biological Half-life of 131I. Prospective Analysis in Patients With Differentiated Thyroid Carcinoma.,Renal Tracer Elimination in Thyroid Cancer Patients Treated With 131-Iodine,Thyroid Carcinoma,2016-05-11,2022-07-31,2022-07-31,Observational,Recruiting,,Jena University Hospital,Jena University Hospital,University Hospital Jena,,Germany,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02773667
NCT02778412,thyroiditis,Determination of the Utility of Plasma Circulating Tumor DNA (ctDNA) Measurements for Detection of Thyroid Cancer in Patients Undergoing Diagnostic Fine Needle Aspirations of the Thyroid,ctDNA in Patients With Thyroid Nodules,Thyroid Adenoma|Thyroid Cancer|Thyroiditis|Thyroid Nodules,2016-05-16,2017-08-31,2017-08-31,Observational,Terminated,,Pathway Genomics,Pathway Genomics,Thyroid & Endocrine Center of Florida,,United States,18.0,120.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT02778412
NCT02778412,thyroid cancer,Determination of the Utility of Plasma Circulating Tumor DNA (ctDNA) Measurements for Detection of Thyroid Cancer in Patients Undergoing Diagnostic Fine Needle Aspirations of the Thyroid,ctDNA in Patients With Thyroid Nodules,Thyroid Adenoma|Thyroid Cancer|Thyroiditis|Thyroid Nodules,2016-05-16,2017-08-31,2017-08-31,Observational,Terminated,,Pathway Genomics,Pathway Genomics,Thyroid & Endocrine Center of Florida,,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02778412
NCT02781844,hypoparathyroidism,"An Open-Label, Randomized, Crossover Study to Assess the Pharmacokinetic and Pharmacodynamic Profiles of Once Daily and Twice Daily Dose Regimens of Recombinant Human Parathyroid Hormone (rhPTH[1-84]) Administered Subcutaneously to Subjects With Hypoparathyroidism",Study to Assess the Blood Concentrations and Actions of Recombinant Human Parathyroid Hormone (rhPTH [1-84]) When Given Once and Twice Daily to Participants With Hypoparathyroidism,Hypoparathyroidism,2016-04-19,2019-03-08,2019-03-08,Interventional,Completed,Phase 1,Takeda,Shire,"Providence Clinical Research|Indiana University|University Of Kentucky School of Medicine|Crescent City Clinical Research Center, LLC|Massachusetts General Hospital|Mayo Clinic - PPDS|Columbia University Medical Center|Ohio State University Wexner Medical Center|Thomas Jefferson University|New Orleans Center for Clinical Research (NOCCR) - Knoxville|CHU de Quebec-Universite Laval|Aarhus Universitetshospital|Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont|Semmelweis Egyetem|Pécsi Tudományegyetem",Drug|Drug|Drug,Canada|Denmark|Hungary|United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02781844
NCT02798965,graves disease,Prevalence of Circulating Parvovirus Genome in Recently Diagnosed Graves' Disease: a Case-control Study,Prevalence of Circulating Parvovirus Genome in Recently Diagnosed Graves' Disease: a Case-control Study,Graves Disease,2016-06-09,2014-05-31,2014-05-31,Interventional,Completed,Not Applicable,"Centre Hospitalier Universitaire, Amiens","Centre Hospitalier Universitaire, Amiens",CHU Amiens,Biological,France,18.0,99.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02798965
NCT02812888,hyperthyroidism,Serum Betatrophin Levels and Its Influencing Factors in Patients With Hyperthyroidism,Serum Betatrophin Levels and Its Influencing Factors in Patients With Hyperthyroidism,Hyperthyroidism,2016-06-20,2017-03-31,2017-06-30,Observational [Patient Registry],Unknown status,,The First People's Hospital of Xuzhou,Hu Hao,"The First People's Hospital of Xuzhou,",Drug,China,18.0,60.0,[18-65],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02812888
NCT02814032,papillary thyroid carcinoma,Differences Protein Expression in Papillary Thyroid Carcinoma,Proteomics of Papillary Thyroid Carcinoma,Papillary Thyroid Carcinoma,2016-06-23,2016-12-31,2017-06-30,Observational,Unknown status,,The Affiliated Hospital of Inner Mongolia Medical University,The Affiliated Hospital of Inner Mongolia Medical University,Shan Jin,,China,18.0,65.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT02814032
NCT02826746,thyroid neoplasms,,Effect of Intravenous Magnesium on Postoperative Sore Throat After Thyroidectomy,Thyroid Neoplasms,2016-07-06,2019-03-31,2019-03-31,Interventional,Completed,Not Applicable,Ajou University School of Medicine,Ajou University School of Medicine,"Department of Anesthesiology and Pain Medicine, Ajou University School of Medicine",Drug|Drug,"Korea, Republic of",20.0,85.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02826746
NCT02834013,thyroid gland carcinoma,DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors,Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,"Acinar Cell Carcinoma|Adenoid Cystic Carcinoma|Adrenal Cortex Carcinoma|Adrenal Gland Pheochromocytoma|Anal Canal Neuroendocrine Carcinoma|Anal Canal Undifferentiated Carcinoma|Angiosarcoma|Apocrine Neoplasm|Appendix Mucinous Adenocarcinoma|Bartholin Gland Transitional Cell Carcinoma|Basal Cell Carcinoma|Bladder Adenocarcinoma|Breast Metaplastic Carcinoma|Cervical Adenocarcinoma|Cholangiocarcinoma|Chordoma|Colorectal Squamous Cell Carcinoma|Desmoid Fibromatosis|Endometrial Transitional Cell Carcinoma|Endometrioid Adenocarcinoma|Esophageal Neuroendocrine Carcinoma|Esophageal Undifferentiated Carcinoma|Extrahepatic Bile Duct Carcinoma|Extramammary Paget Disease|Fallopian Tube Adenocarcinoma|Fallopian Tube Transitional Cell Carcinoma|Fibromyxoid Tumor|Gallbladder Carcinoma|Gastric Neuroendocrine Carcinoma|Gastric Squamous Cell Carcinoma|Gastric Undifferentiated Carcinoma|Gastrointestinal Stromal Tumor|Gestational Trophoblastic Tumor|Giant Cell Carcinoma|Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type|Intestinal Neuroendocrine Carcinoma|Intrahepatic Cholangiocarcinoma|Lung Carcinoid Tumor|Lung Sarcomatoid Carcinoma|Major Salivary Gland Carcinoma|Malignant Odontogenic Neoplasm|Malignant Peripheral Nerve Sheath Tumor|Malignant Solid Neoplasm|Malignant Testicular Sex Cord-Stromal Tumor|Metastatic Malignant Neoplasm of Unknown Primary|Metastatic Pituitary Neuroendocrine Tumor|Minimally Invasive Lung Adenocarcinoma|Mixed Mesodermal (Mullerian) Tumor|Mucinous Adenocarcinoma|Mucinous Cystadenocarcinoma|Nasal Cavity Adenocarcinoma|Nasal Cavity Carcinoma|Nasopharyngeal Carcinoma|Nasopharyngeal Papillary Adenocarcinoma|Nasopharyngeal Undifferentiated Carcinoma|Oral Cavity Carcinoma|Oropharyngeal Undifferentiated Carcinoma|Ovarian Adenocarcinoma|Ovarian Germ Cell Tumor|Ovarian Mucinous Adenocarcinoma|Ovarian Squamous Cell Carcinoma|Ovarian Transitional Cell Carcinoma|Pancreatic Acinar Cell Carcinoma|Pancreatic Neuroendocrine Carcinoma|Paraganglioma|Paranasal Sinus Adenocarcinoma|Paranasal Sinus Carcinoma|Parathyroid Gland Carcinoma|PEComa|Peritoneal Mesothelioma|Placental Choriocarcinoma|Primary Peritoneal High Grade Serous Adenocarcinoma|Pseudomyxoma Peritonei|Rare Disorder|Scrotal Squamous Cell Carcinoma|Seminal Vesicle Adenocarcinoma|Seminoma|Serous Cystadenocarcinoma|Small Intestinal Adenocarcinoma|Small Intestinal Squamous Cell Carcinoma|Spindle Cell Neoplasm|Squamous Cell Carcinoma of the Penis|Teratoma With Somatic-Type Malignancy|Testicular Non-Seminomatous Germ Cell Tumor|Thyroid Gland Carcinoma|Tracheal Carcinoma|Transitional Cell Carcinoma|Ureter Adenocarcinoma|Ureter Squamous Cell Carcinoma|Urethral Adenocarcinoma|Urethral Squamous Cell Carcinoma|Vaginal Adenocarcinoma|Vaginal Squamous Cell Carcinoma, Not Otherwise Specified|Vulvar Carcinoma",2016-07-13,2023-10-31,2023-10-31,Interventional,Recruiting,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),University of Alabama at Birmingham Cancer Center|University of South Alabama Mitchell Cancer Institute|Anchorage Associates in Radiation Medicine|Anchorage Radiation Therapy Center|Alaska Breast Care and Surgery LLC|Alaska Oncology and Hematology LLC|Alaska Women's Cancer Care|Anchorage Oncology Centre|Katmai Oncology Group|Providence Alaska Medical Center|Fairbanks Memorial Hospital|CTCA at Western Regional Medical Center|Kingman Regional Medical Center|Cancer Center at Saint Joseph's|Highlands Oncology Group PA - Fayetteville|Mercy Hospital Fort Smith|CHI Saint Vincent Cancer Center Hot Springs|Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro|University of Arkansas for Medical Sciences|Highlands Oncology Group|Highlands Oncology Group - Springdale|Kaiser Permanente-Anaheim|Kaiser Permanente-Deer Valley Medical Center|Mission Hope Medical Oncology - Arroyo Grande|PCR Oncology|Sutter Auburn Faith Hospital|Sutter Cancer Centers Radiation Oncology Services-Auburn|AIS Cancer Center at San Joaquin Community Hospital|Kaiser Permanente-Baldwin Park|Kaiser Permanente-Bellflower|Alta Bates Summit Medical Center-Herrick Campus|Providence Saint Joseph Medical Center/Disney Family Cancer Center|Mills-Peninsula Medical Center|Sutter Cancer Centers Radiation Oncology Services-Cameron Park|Eden Hospital Medical Center|UC Irvine Health Cancer Center-Newport|Sutter Davis Hospital|City of Hope Comprehensive Cancer Center|Epic Care-Dublin|Kaiser Permanente Dublin|Bay Area Breast Surgeons Inc|Epic Care Partners in Cancer Care|Kaiser Permanente-Fontana|Kaiser Permanente-Fremont|Palo Alto Medical Foundation-Fremont|Kaiser Permanente-Fresno|Kaiser Permanente - Harbor City|Keck Medicine of USC Huntington Beach|Kaiser Permanente-Irvine|UC San Diego Moores Cancer Center|Loma Linda University Medical Center|Kaiser Permanente Los Angeles Medical Center|Los Angeles County-USC Medical Center|USC / Norris Comprehensive Cancer Center|Kaiser Permanente West Los Angeles|Cedars Sinai Medical Center|Contra Costa Regional Medical Center|Fremont - Rideout Cancer Center|Mercy UC Davis Cancer Center|Memorial Medical Center|Kaiser Permanente-Modesto|Palo Alto Medical Foundation-Camino Division|Palo Alto Medical Foundation-Gynecologic Oncology|Providence Queen of The Valley|USC Norris Oncology/Hematology-Newport Beach|Sutter Cancer Research Consortium|Alta Bates Summit Medical Center - Summit Campus|Bay Area Tumor Institute|Kaiser Permanente-Oakland|Kaiser Permanente-Ontario|Saint Joseph Hospital - Orange|UC Irvine Health/Chao Family Comprehensive Cancer Center|Desert Regional Medical Center|Palo Alto Medical Foundation Health Care|Kaiser Permanente - Panorama City|Keck Medical Center of USC Pasadena|Eisenhower Medical Center|Kaiser Permanente- Marshall Medical Offices|Kaiser Permanente-Redwood City|Kaiser Permanente-Richmond|Kaiser Permanente-Riverside|Kaiser Permanente-Roseville|Sutter Cancer Centers Radiation Oncology Services-Roseville|Sutter Roseville Medical Center|Kaiser Permanente Downtown Commons|Sutter Medical Center Sacramento|University of California Davis Comprehensive Cancer Center|Kaiser Permanente-South Sacramento|Kaiser Permanente - Sacramento|Kaiser Permanente-San Diego Mission|Kaiser Permanente-San Diego Zion|Sharp Memorial Hospital|California Pacific Medical Center-Pacific Campus|Kaiser Permanente-San Francisco|Kaiser Permanente-Santa Teresa-San Jose|Kaiser Permanente San Leandro|Pacific Central Coast Health Center-San Luis Obispo|Kaiser Permanente-San Marcos|Mills Health Center|Kaiser Permanente-San Rafael|Kaiser San Rafael-Gallinas|Kaiser Permanente Medical Center - Santa Clara|Palo Alto Medical Foundation-Santa Cruz|Mission Hope Medical Oncology - Santa Maria|Kaiser Permanente-Santa Rosa|Providence Medical Foundation - Santa Rosa|Sutter Pacific Medical Foundation|Providence Santa Rosa Memorial Hospital|Kaiser Permanente-South San Francisco|Kaiser Permanente-Stockton|Palo Alto Medical Foundation-Sunnyvale|Gene Upshaw Memorial Tahoe Forest Cancer Center|Sutter Cancer Centers Radiation Oncology Services-Vacaville|Kaiser Permanente Medical Center-Vacaville|Kaiser Permanente-Vallejo|Sutter Solano Medical Center/Cancer Center|Kaiser Permanente-Walnut Creek|Epic Care Cyberknife Center|Kaiser Permanente-Woodland Hills|Rocky Mountain Cancer Centers-Aurora|The Medical Center of Aurora|University of Colorado Hospital|Boulder Community Hospital|Boulder Community Foothills Hospital|Rocky Mountain Cancer Centers-Boulder|Rocky Mountain Cancer Centers - Centennial|Penrose-Saint Francis Healthcare|Rocky Mountain Cancer Centers-Penrose|UCHealth Memorial Hospital Central|Memorial Hospital North|Saint Francis Cancer Center|Cancer Center of Colorado at Sloan's Lake|Denver Health Medical Center|Kaiser Permanente-Franklin|National Jewish Health-Main Campus|The Women's Imaging Center|Porter Adventist Hospital|Colorado Blood Cancer Institute|Presbyterian - Saint Lukes Medical Center - Health One|Rocky Mountain Cancer Centers-Midtown|SCL Health Saint Joseph Hospital|Rocky Mountain Cancer Centers-Rose|Rose Medical Center|Mercy Medical Center|Southwest Oncology PC|Mountain Blue Cancer Care Center - Swedish|Rocky Mountain Cancer Centers - Swedish|Swedish Medical Center|The Melanoma and Skin Cancer Institute|Poudre Valley Hospital|Valley View Hospital Cancer Center|Mountain Blue Cancer Care Center|National Jewish Health-Western Hematology Oncology|Saint Mary's Hospital and Regional Medical Center|Grand Valley Oncology|North Colorado Medical Center|Rocky Mountain Cancer Centers-Greenwood Village|Good Samaritan Medical Center|Kaiser Permanente-Rock Creek|Rocky Mountain Cancer Centers-Lakewood|Saint Anthony Hospital|Rocky Mountain Cancer Centers-Littleton|Littleton Adventist Hospital|Kaiser Permanente-Lone Tree|Rocky Mountain Cancer Centers-Sky Ridge|Sky Ridge Medical Center|Longmont United Hospital|Rocky Mountain Cancer Centers-Longmont|McKee Medical Center|Parker Adventist Hospital|Rocky Mountain Cancer Centers-Parker|Saint Mary Corwin Medical Center|Rocky Mountain Cancer Centers - Pueblo|National Jewish Health-Northern Hematology Oncology|Rocky Mountain Cancer Centers-Thornton|SCL Health Lutheran Medical Center|Smilow Cancer Hospital-Derby Care Center|Smilow Cancer Hospital Care Center-Fairfield|Smilow Cancer Hospital Care Center - Guiford|Smilow Cancer Hospital Care Center at Saint Francis|Smilow Cancer Center/Yale-New Haven Hospital|Yale University|Yale-New Haven Hospital North Haven Medical Center|Stamford Hospital/Bennett Cancer Center|Smilow Cancer Hospital Care Center-Trumbull|Smilow Cancer Hospital-Waterbury Care Center|Veterans Affairs Connecticut Healthcare System-West Haven Campus|Beebe South Coastal Health Campus|Beebe Medical Center|Delaware Clinical and Laboratory Physicians PA|Helen F Graham Cancer Center|Medical Oncology Hematology Consultants PA|Christiana Care Health System-Christiana Hospital|Beebe Health Campus|TidalHealth Nanticoke / Allen Cancer Center|Christiana Care Health System-Wilmington Hospital|MedStar Georgetown University Hospital|Sibley Memorial Hospital|AdventHealth Altamonte|Mount Sinai Comprehensive Cancer Center at Aventura|Holy Cross Hospital|University of Florida Health Science Center - Gainesville|Memorial Regional Hospital/Joe DiMaggio Children's Hospital|AdventHealth Kissimmee|Mount Sinai Medical Center|AdventHealth Medical Group Urology at Orlando|AdventHealth Orlando|Orlando Health Cancer Institute|AdventHealth East Orlando|Memorial Hospital West|Moffitt Cancer Center-International Plaza|Moffitt Cancer Center - McKinley Campus|Moffitt Cancer Center|AdventHealth Winter Park|Emory University Hospital Midtown|Piedmont Hospital|Emory University Hospital/Winship Cancer Institute|Emory Saint Joseph's Hospital|John B Amos Cancer Center|Atlanta VA Medical Center|Piedmont Fayette Hospital|Harbin Clinic Medical Oncology and Clinical Research|Low Country Cancer Care|Lewis Cancer and Research Pavilion at Saint Joseph's/Candler|Summit Cancer Care-Candler|South Georgia Medical Center/Pearlman Cancer Center|Hawaii Cancer Care - Savio|Pali Momi Medical Center|Queen's Cancer Center - Pearlridge|The Cancer Center of Hawaii-Pali Momi|The Queen's Medical Center - West Oahu|Hawaii Cancer Care Inc - Waterfront Plaza|Island Urology|Queen's Cancer Cenrer - POB I|Queen's Medical Center|Straub Clinic and Hospital|University of Hawaii Cancer Center|Hawaii Cancer Care Inc-Liliha|Hawaii Diagnostic Radiology Services LLC|Kuakini Medical Center|Queen's Cancer Center - Kuakini|The Cancer Center of Hawaii-Liliha|Kaiser Permanente Moanalua Medical Center|Kapiolani Medical Center for Women and Children|Straub Medical Center - Kahului Clinic|Castle Medical Center|Wilcox Memorial Hospital and Kauai Medical Clinic|Saint Alphonsus Cancer Care Center-Boise|Saint Luke's Cancer Institute - Boise|Saint Alphonsus Cancer Care Center-Caldwell|Kootenai Health - Coeur d'Alene|Walter Knox Memorial Hospital|Saint Luke's Cancer Institute - Fruitland|Idaho Urologic Institute-Meridian|Saint Luke's Cancer Institute - Meridian|Saint Alphonsus Medical Center-Nampa|Saint Luke's Cancer Institute - Nampa|Kootenai Clinic Cancer Services - Post Falls|Kootenai Cancer Clinic|Saint Luke's Cancer Institute - Twin Falls|Saint Anthony's Health|Rush - Copley Medical Center|Saint Joseph Medical Center|Illinois CancerCare-Bloomington|Loyola Center for Health at Burr Ridge|Illinois CancerCare-Canton|Memorial Hospital of Carbondale|SIH Cancer Institute|Illinois CancerCare-Carthage|Centralia Oncology Clinic|Mount Sinai Hospital Medical Center|Northwestern University|John H Stroger Jr Hospital of Cook County|Rush University Medical Center|University of Chicago Comprehensive Cancer Center|Advocate Illinois Masonic Medical Center|Carle on Vermilion|Cancer Care Specialists of Illinois - Decatur|Decatur Memorial Hospital|Northwestern Medicine Cancer Center Kishwaukee|Illinois CancerCare-Dixon|Carle Physician Group-Effingham|Crossroads Cancer Center|Illinois CancerCare-Eureka|Illinois CancerCare-Galesburg|Western Illinois Cancer Treatment Center|Northwestern Medicine Cancer Center Delnor|Ingalls Memorial Hospital|Loyola Medicine Homer Glen|Presence Saint Mary's Hospital|Illinois CancerCare-Kewanee Clinic|Northwestern Medicine Lake Forest Hospital|Illinois CancerCare-Macomb|Carle Physician Group-Mattoon/Charleston|Loyola University Medical Center|Marjorie Weinberg Cancer Center at Loyola-Gottlieb|Good Samaritan Regional Health Center|UC Comprehensive Cancer Center at Silver Cross|Cancer Care Center of O'Fallon|University of Chicago Medicine-Orland Park|Illinois CancerCare-Ottawa Clinic|Illinois CancerCare-Pekin|OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center|Illinois CancerCare-Peoria|OSF Saint Francis Radiation Oncology at Peoria Cancer Center|Methodist Medical Center of Illinois|OSF Saint Francis Medical Center|Illinois CancerCare-Peru|Valley Radiation Oncology|Illinois CancerCare-Princeton|Southern Illinois University School of Medicine|Springfield Clinic|Memorial Medical Center|Southwest Illinois Health Services LLP|Carle Cancer Center|The Carle Foundation Hospital|Northwestern Medicine Cancer Center Warrenville|Illinois CancerCare - Washington|Rush-Copley Healthcare Center|Midwestern Regional Medical Center|IU Health West Hospital|IU Health North Hospital|Deaconess Clinic Downtown|Parkview Regional Medical Center|Indiana University/Melvin and Bren Simon Cancer Center|Sidney and Lois Eskenazi Hospital|Springmill Medical Center|Memorial Regional Cancer Center Day Road|Chancellor Center for Oncology|Reid Health|Memorial Hospital of South Bend|Mary Greeley Medical Center|McFarland Clinic PC - Ames|McFarland Clinic PC-Boone|Saint Anthony Regional Hospital|Mercy Hospital|Oncology Associates at Mercy Medical Center|Medical Oncology and Hematology Associates-West Des Moines|Mercy Cancer Center-West Lakes|Alegent Health Mercy Hospital|Greater Regional Medical Center|Iowa Methodist Medical Center|Medical Oncology and Hematology Associates-Des Moines|Broadlawns Medical Center|Medical Oncology and Hematology Associates-Laurel|Mercy Medical Center - Des Moines|Iowa Lutheran Hospital|McFarland Clinic PC-Trinity Cancer Center|Trinity Regional Medical Center|McFarland Clinic PC-Jefferson|McFarland Clinic PC-Marshalltown|Methodist West Hospital|Mercy Medical Center-West Lakes|Cancer Center of Kansas - Chanute|Coffeyville Regional Medical Center|Cancer Center of Kansas - Dodge City|Cancer Center of Kansas - El Dorado|University of Kansas Clinical Research Center|Cancer Center of Kansas - Fort Scott|Central Care Cancer Center - Garden City|Saint Catherine Hospital|Central Care Cancer Center - Great Bend|HaysMed University of Kansas Health System|Cancer Center of Kansas-Independence|University of Kansas Cancer Center-West|University of Kansas Cancer Center|Cancer Center of Kansas-Kingman|Lawrence Memorial Hospital|Cancer Center of Kansas-Liberal|Cancer Center of Kansas-Manhattan|Cancer Center of Kansas - McPherson|Cancer Center of Kansas - Newton|Olathe Health Cancer Center|University of Kansas Cancer Center-Overland Park|University of Kansas Hospital-Indian Creek Campus|Cancer Center of Kansas - Parsons|Ascension Via Christi - Pittsburg|Cancer Center of Kansas - Pratt|Cancer Center of Kansas - Salina|Salina Regional Health Center|University of Kansas Health System Saint Francis Campus|Cancer Center of Kansas - Wellington|University of Kansas Hospital-Westwood Cancer Center|Associates In Womens Health|Cancer Center of Kansas-Wichita Medical Arts Tower|Ascension Via Christi Hospitals Wichita|Cancer Center of Kansas - Wichita|Wesley Medical Center|Cancer Center of Kansas - Winfield|Flaget Memorial Hospital|Commonwealth Cancer Center-Corbin|Saint Joseph Radiation Oncology Resource Center|Saint Joseph Hospital East|Saint Joseph London|Jewish Hospital|Saints Mary and Elizabeth Hospital|UofL Health Medical Center Northeast|Jewish Hospital Medical Center South|Baton Rouge General Medical Center|Hematology/Oncology Clinic PLLC|Ochsner Health Center-Summa|Medical Center of Baton Rouge|Ochsner High Grove|Ochsner Medical Center Kenner|East Jefferson General Hospital|LSU Healthcare Network / Metairie Multi-Specialty Clinic|Louisiana State University Health Science Center|Tulane University Health Sciences Center|University Medical Center New Orleans|Ochsner Medical Center Jefferson|Eastern Maine Medical Center|Lafayette Family Cancer Center-EMMC|Greater Baltimore Medical Center|Johns Hopkins University/Sidney Kimmel Cancer Center|National Institutes of Health Clinical Center|Western Maryland Regional Medical Center|Frederick Memorial Hospital|FMH James M Stockman Cancer Institute|Lahey Hospital and Medical Center|Lahey Medical Center-Peabody|Mercy Medical Center|Baystate Medical Center|Hickman Cancer Center|Saint Joseph Mercy Hospital|University of Michigan Comprehensive Cancer Center|Bronson Battle Creek|IHA Hematology Oncology Consultants-Brighton|Saint Joseph Mercy Brighton|University of Michigan - Brighton Center for Specialty Care|Henry Ford Cancer Institute-Downriver|IHA Hematology Oncology Consultants-Canton|Saint Joseph Mercy Canton|Caro Cancer Center|IHA Hematology Oncology Consultants-Chelsea|Saint Joseph Mercy Chelsea|Hematology Oncology Consultants-Clarkston|Newland Medical Associates-Clarkston|Henry Ford Macomb Hospital-Clinton Township|Beaumont Hospital - Dearborn|Henry Ford Medical Center-Fairlane|Henry Ford Hospital|Ascension Saint John Hospital|Great Lakes Cancer Management Specialists-Doctors Park|Green Bay Oncology - Escanaba|Genesee Cancer and Blood Disease Treatment Center|Genesee Hematology Oncology PC|Genesys Hurley Cancer Institute|Hurley Medical Center|Helen DeVos Children's Hospital at Spectrum Health|Mercy Health Saint Mary's|Spectrum Health at Butterworth Campus|Academic Hematology Oncology Specialists|Great Lakes Cancer Management Specialists-Van Elslander Cancer Center|Michigan Breast Specialists-Grosse Pointe Woods|Allegiance Health|Bronson Methodist Hospital|West Michigan Cancer Center|Ascension Borgess Cancer Center|Borgess Medical Center|Sparrow Hospital|Hope Cancer Clinic|Saint Mary Mercy Hospital|Great Lakes Cancer Management Specialists-Macomb Medical Campus|Michigan Breast Specialists-Macomb Township|Green Bay Oncology-Manistique|Saint Mary's Oncology/Hematology Associates of Marlette|Monroe Cancer Center|Toledo Clinic Cancer Centers-Monroe|Mercy Health Mercy Campus|Lakeland Hospital Niles|Cancer and Hematology Centers of Western Michigan - Norton Shores|Ascension Providence Hospitals - Novi|Henry Ford Medical Center-Columbus|21st Century Oncology-Pontiac|Hope Cancer Center|Newland Medical Associates-Pontiac|Saint Joseph Mercy Oakland|Huron Medical Center PC|Lake Huron Medical Center|Spectrum Health Reed City Hospital|Great Lakes Cancer Management Specialists-Rochester Hills|Ascension Saint Mary's Hospital|Oncology Hematology Associates of Saginaw Valley PC|Lakeland Medical Center Saint Joseph|Marie Yeager Cancer Center|Henry Ford Macomb Health Center - Shelby Township|Ascension Providence Hospitals - Southfield|Bhadresh Nayak MD PC-Sterling Heights|Ascension Saint Joseph Hospital|Munson Medical Center|Advanced Breast Care Center PLLC|Great Lakes Cancer Management Specialists-Macomb Professional Building|Macomb Hematology Oncology PC|Michigan Breast Specialists-Warren|Saint John Macomb-Oakland Hospital|Henry Ford West Bloomfield Hospital|Saint Mary's Oncology/Hematology Associates of West Branch|Henry Ford Wyandotte Hospital|Metro Health Hospital|Huron Gastroenterology PC|IHA Hematology Oncology Consultants-Ann Arbor|Riverwood Healthcare Center|Sanford Joe Lueken Cancer Center|Essentia Health Saint Joseph's Medical Center|Fairview Ridges Hospital|Minnesota Oncology - Burnsville|Cambridge Medical Center|Mercy Hospital|Essentia Health - Deer River Clinic|Essentia Health Saint Mary's - Detroit Lakes Clinic|Essentia Health Cancer Center|Essentia Health Saint Mary's Medical Center|Miller-Dwan Hospital|Fairview Southdale Hospital|Lake Region Healthcare Corporation-Cancer Care|Essentia Health - Fosston|Unity Hospital|Essentia Health Hibbing Clinic|Fairview Clinics and Surgery Center Maple Grove|Minnesota Oncology Hematology PA-Maplewood|Saint John's Hospital - Healtheast|Abbott-Northwestern Hospital|Hennepin County Medical Center|Health Partners Inc|Monticello Cancer Center|New Ulm Medical Center|Essentia Health - Park Rapids|Fairview Northland Medical Center|North Memorial Medical Health Center|Park Nicollet Clinic - Saint Louis Park|Regions Hospital|United Hospital|Essentia Health Sandstone|Saint Francis Regional Medical Center|Lakeview Hospital|Sanford Thief River Falls Medical Center|Essentia Health Virginia Clinic|Ridgeview Medical Center|Rice Memorial Hospital|Minnesota Oncology Hematology PA-Woodbury|Sanford Cancer Center Worthington|Fairview Lakes Medical Center|Baptist Memorial Hospital and Cancer Center-Golden Triangle|Baptist Cancer Center-Grenada|Gulfport Memorial Hospital|Hattiesburg Clinic - Hematology/Oncology Clinic|Forrest General Hospital / Cancer Center|University of Mississippi Medical Center|Baptist Memorial Hospital and Cancer Center-Union County|Baptist Memorial Hospital and Cancer Center-Oxford|Baptist Memorial Hospital and Cancer Center-Desoto|Saint Louis Cancer and Breast Institute-Ballwin|Central Care Cancer Center - Bolivar|Parkland Health Center-Bonne Terre|Cox Cancer Center Branson|Saint Francis Medical Center|Southeast Cancer Center|Saint Luke's Hospital|Siteman Cancer Center at West County Hospital|Parkland Health Center - Farmington|Capital Region Southwest Campus|Freeman Health System|Mercy Hospital Joplin|Truman Medical Centers|Kansas City Veterans Affairs Medical Center|The University of Kansas Cancer Center-South|University of Kansas Cancer Center - North|University of Kansas Cancer Center - Lee's Summit|Delbert Day Cancer Institute at PCRMC|Mercy Clinic-Rolla-Cancer and Hematology|Heartland Regional Medical Center|Saint Louis Cancer and Breast Institute-South City|Washington University School of Medicine|Mercy Hospital South|Siteman Cancer Center-South County|Missouri Baptist Medical Center|Siteman Cancer Center at Christian Hospital|Mercy Hospital Saint Louis|Siteman Cancer Center at Saint Peters Hospital|Sainte Genevieve County Memorial Hospital|Mercy Hospital Springfield|CoxHealth South Hospital|Missouri Baptist Sullivan Hospital|Missouri Baptist Outpatient Center-Sunset Hills|Mercy Hospital Washington|Community Hospital of Anaconda|Billings Clinic Cancer Center|Saint Vincent Healthcare|Saint Vincent Frontier Cancer Center|Bozeman Deaconess Hospital|Saint James Community Hospital and Cancer Treatment Center|Benefis Healthcare- Sletten Cancer Institute|Great Falls Clinic|Saint Peter's Community Hospital|Kalispell Regional Medical Center|Community Medical Hospital|CHI Health Saint Francis|Heartland Hematology and Oncology|CHI Health Good Samaritan|Saint Elizabeth Regional Medical Center|Nebraska Cancer Specialists/Oncology Hematology West PC - MECC|Nebraska Methodist Hospital|Oncology Associates PC|Alegent Health Immanuel Medical Center|Hematology and Oncology Consultants PC|Alegent Health Bergan Mercy Medical Center|Alegent Health Lakeside Hospital|Creighton University Medical Center|Midlands Community Hospital|Carson Tahoe Regional Medical Center|Cancer and Blood Specialists-Henderson|Comprehensive Cancer Centers of Nevada - Henderson|Comprehensive Cancer Centers of Nevada-Horizon Ridge|Las Vegas Cancer Center-Henderson|OptumCare Cancer Care at Seven Hills|Comprehensive Cancer Centers of Nevada-Southeast Henderson|GenesisCare USA - Henderson|Las Vegas Urology - Green Valley|Las Vegas Urology - Pebble|Urology Specialists of Nevada - Green Valley|Las Vegas Urology - Pecos|Desert West Surgery|OptumCare Cancer Care at Charleston|University Medical Center of Southern Nevada|Hope Cancer Care of Nevada|Cancer and Blood Specialists-Shadow|Radiation Oncology Centers of Nevada Central|Urology Specialists of Nevada - Central|GenesisCare USA - Las Vegas|HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway|Sunrise Hospital and Medical Center|HealthCare Partners Medical Group Oncology/Hematology-San Martin|Las Vegas Prostate Cancer Center|Las Vegas Urology - Sunset|Urology Specialists of Nevada - Southwest|Radiation Oncology Centers of Nevada Southeast|Cancer Therapy and Integrative Medicine|Ann M Wierman MD LTD|Cancer and Blood Specialists-Tenaya|Comprehensive Cancer Centers of Nevada - Northwest|GenesisCare USA - Vegas Tenaya|HealthCare Partners Medical Group Oncology/Hematology-Tenaya|Las Vegas Urology - Cathedral Rock|Las Vegas Urology - Smoke Ranch|OptumCare Cancer Care at MountainView|Urology Specialists of Nevada - Northwest|Alliance for Childhood Diseases/Cure 4 the Kids Foundation|Comprehensive Cancer Centers of Nevada - Town Center|Comprehensive Cancer Centers of Nevada-Summerlin|Summerlin Hospital Medical Center|Las Vegas Cancer Center-Medical Center|Comprehensive Cancer Centers of Nevada|GenesisCare USA - Fort Apache|OptumCare Cancer Care at Fort Apache|HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills|Comprehensive Cancer Centers of Nevada - Central Valley|University Cancer Center|Hope Cancer Care of Nevada-Pahrump|Renown Regional Medical Center|Saint Mary's Regional Medical Center|Radiation Oncology Associates|Dartmouth Hitchcock Medical Center|Norris Cotton Cancer Center-Manchester|Norris Cotton Cancer Center-Nashua|Morristown Medical Center|Chilton Medical Center|Overlook Hospital|Inspira Medical Center Vineland|Lovelace Medical Center-Saint Joseph Square|University of New Mexico Cancer Center|Southwest Gynecologic Oncology Associates Inc|New Mexico Oncology Hematology Consultants|Presbyterian Kaseman Hospital|Memorial Medical Center - Las Cruces|Presbyterian Rust Medical Center/Jorgensen Cancer Center|Christus Saint Vincent Regional Cancer Center|Montefiore Medical Center-Einstein Campus|Montefiore Medical Center-Weiler Hospital|Montefiore Medical Center - Moses Campus|Roswell Park Cancer Institute|Arnot Ogden Medical Center/Falck Cancer Center|Glens Falls Hospital|Laura and Isaac Perlmutter Cancer Center at NYU Langone|University of Rochester|Stony Brook University Medical Center|AdventHealth Infusion Center Asheville|Southeastern Medical Oncology Center-Clinton|AdventHealth Infusion Center Haywood|Southeastern Medical Oncology Center-Goldsboro|Wayne Memorial Hospital|Margaret R Pardee Memorial Hospital|AdventHealth Hendersonville|Onslow Memorial Hospital|Southeastern Medical Oncology Center-Jacksonville|Vidant Oncology-Kenansville|Vidant Oncology-Kinston|Vidant Oncology-Richlands|AdventHealth Infusion Center Weaverville|Sanford Bismarck Medical Center|Essentia Health Cancer Center-South University Clinic|Sanford South University Medical Center|Sanford Broadway Medical Center|Sanford Roger Maris Cancer Center|Essentia Health - Jamestown Clinic|Indu and Raj Soin Medical Center|Strecker Cancer Center-Belpre|Saint Elizabeth Boardman Hospital|Cleveland Clinic Mercy Hospital|Mercy Hematology and Oncology Associates Inc|Dayton Physicians LLC-Miami Valley South|Miami Valley Hospital South|Adena Regional Medical Center|Good Samaritan Hospital - Cincinnati|Oncology Hematology Care Inc-Kenwood|Bethesda North Hospital|TriHealth Cancer Institute-Westside|TriHealth Cancer Institute-Anderson|MetroHealth Medical Center|Cleveland Clinic Foundation|Ohio State University Comprehensive Cancer Center|Mount Carmel East Hospital|Columbus Oncology and Hematology Associates Inc|Riverside Methodist Hospital|Grant Medical Center|The Mark H Zangmeister Center|Mount Carmel Health Center West|Doctors Hospital|Good Samaritan Hospital - Dayton|Miami Valley Hospital|Dayton Physician LLC-Miami Valley Hospital North|Miami Valley Hospital North|Delaware Health Center-Grady Cancer Center|Delaware Radiation Oncology|Grady Memorial Hospital|Columbus Oncology and Hematology Associates|Dublin Methodist Hospital|Armes Family Cancer Center|Blanchard Valley Hospital|Orion Cancer Care|Atrium Medical Center-Middletown Regional Hospital|Dayton Physicians LLC-Atrium|Dayton Physicians LLC-Wayne|Wayne Hospital|Mount Carmel Grove City Hospital|Greater Dayton Cancer Center|First Dayton Cancer Care|Kettering Medical Center|Fairfield Medical Center|Saint Rita's Medical Center|OhioHealth Mansfield Hospital|Marietta Memorial Hospital|OhioHealth Marion General Hospital|Toledo Clinic Cancer Centers-Maumee|Toledo Radiation Oncology at Northwest Ohio Onocolgy Center|Dayton Physicians LLC-Signal Point|Knox Community Hospital|Licking Memorial Hospital|Newark Radiation Oncology|Mercy Health Perrysburg Cancer Center|Southern Ohio Medical Center|North Coast Cancer Care|Dayton Physicians LLC-Wilson|Springfield Regional Cancer Center|Springfield Regional Medical Center|ProMedica Flower Hospital|ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital|Saint Vincent Mercy Medical Center|Mercy Health - Saint Anne Hospital|Toledo Clinic Cancer Centers-Toledo|Dayton Physicians LLC-Upper Valley|Upper Valley Medical Center|South Pointe Hospital|Saint Joseph Warren Hospital|Saint Ann's Hospital|Saint Elizabeth Youngstown Hospital|Genesis Healthcare System Cancer Care Center|Cancer Centers of Southwest Oklahoma Research|University of Oklahoma Health Sciences Center|Mercy Hospital Oklahoma City|Cancer Treatment Centers of America|Oklahoma Cancer Specialists and Research Institute-Tulsa|Saint Alphonsus Medical Center-Baker City|Saint Charles Health System|Clackamas Radiation Oncology Center|Providence Cancer Institute Clackamas Clinic|Bay Area Hospital|Legacy Mount Hood Medical Center|Providence Newberg Medical Center|Saint Alphonsus Medical Center-Ontario|Providence Willamette Falls Medical Center|Legacy Good Samaritan Hospital and Medical Center|Providence Portland Medical Center|Providence Saint Vincent Medical Center|Kaiser Permanente Northwest|Oregon Health and Science University|Saint Charles Health System-Redmond|Legacy Meridian Park Hospital|Lehigh Valley Hospital-Cedar Crest|UPMC-Heritage Valley Health System Beaver|Lehigh Valley Hospital - Muhlenberg|Christiana Care Health System-Concord Health Center|UPMC Hillman Cancer Center - Passavant - Cranberry|Doylestown Hospital|Pocono Medical Center|Saint Vincent Hospital|UPMC Cancer Centers - Arnold Palmer Pavilion|Lehigh Valley Hospital-Hazleton|Jefferson Hospital|UPMC-Johnstown/John P. Murtha Regional Cancer Center|UPMC Cancer Center at UPMC McKeesport|Forbes Hospital|UPMC Hillman Cancer Center - Monroeville|UPMC-Coraopolis/Heritage Valley Radiation Oncology|UPMC Hillman Cancer Center - Part of Frick Hospital|Arnold Palmer Cancer Center Medical Oncology Norwin|Thomas Jefferson University Hospital|Eastern Regional Medical Center|Temple University Hospital|Allegheny General Hospital|UPMC-Magee Womens Hospital|UPMC-Presbyterian Hospital|UPMC-Saint Margaret|West Penn Hospital|University of Pittsburgh Cancer Institute (UPCI)|UPMC-Shadyside Hospital|UPMC-Passavant Hospital|UPMC-Saint Clair Hospital Cancer Center|Pottstown Hospital|UPMC Cancer Center at UPMC Northwest|UPMC Uniontown Hospital Radiation Oncology|UPMC Cancer Center-Washington|UPMC Washington Hospital Radiation Oncology|UPMC West Mifflin-Cancer Center Jefferson|Wexford Health and Wellness Pavilion|Prisma Health Cancer Institute - Spartanburg|Medical University of South Carolina|Prisma Health Cancer Institute - Laurens|Prisma Health Cancer Institute - Easley|Gibbs Cancer Center-Gaffney|Tidelands Georgetown Memorial Hospital|Saint Francis Hospital|Prisma Health Cancer Institute - Butternut|Prisma Health Cancer Institute - Faris|Prisma Health Greenville Memorial Hospital|Saint Francis Cancer Center|Prisma Health Cancer Institute - Eastside|Prisma Health Cancer Institute - Greer|Gibbs Cancer Center-Pelham|Prisma Health Cancer Institute - Seneca|North Grove Medical Park|Spartanburg Medical Center|Spartanburg Medical Center - Mary Black Campus|MGC Hematology Oncology-Union|Sanford Cancer Center Oncology Clinic|Sanford USD Medical Center - Sioux Falls|Memorial Hospital|Baptist Memorial Hospital and Cancer Center-Collierville|Vanderbilt-Ingram Cancer Center Cool Springs|Pulmonary Medicine Center of Chattanooga-Hixson|Baptist Memorial Hospital and Cancer Center-Memphis|Vanderbilt Breast Center at One Hundred Oaks|Meharry Medical College|Vanderbilt University/Ingram Cancer Center|Memorial GYN Plus|Saint Joseph Regional Cancer Center|Parkland Memorial Hospital|Baylor University Medical Center|UT Southwestern/Simmons Cancer Center-Dallas|UT Southwestern/Simmons Cancer Center-Fort Worth|Lyndon Baines Johnson General Hospital|M D Anderson Cancer Center|UT Southwestern Clinical Center at Richardson/Plano|University Hospital|University of Texas Health Science Center at San Antonio|American Fork Hospital / Huntsman Intermountain Cancer Center|Sandra L Maxwell Cancer Center|Farmington Health Center|Logan Regional Hospital|Intermountain Medical Center|McKay-Dee Hospital Center|Utah Valley Regional Medical Center|Riverton Hospital|Dixie Medical Center Regional Cancer Center|Utah Cancer Specialists-Salt Lake City|Huntsman Cancer Institute/University of Utah|LDS Hospital|South Jordan Health Center|Central Vermont Medical Center/National Life Cancer Treatment|University of Vermont Medical Center|University of Vermont and State Agricultural College|Norris Cotton Cancer Center-North|Virginia Commonwealth University/Massey Cancer Center|Providence Regional Cancer System-Aberdeen|Cancer Care Center at Island Hospital|MultiCare Auburn Medical Center|Virginia Mason Bainbridge Island Medical Center|Overlake Medical Center|PeaceHealth Saint Joseph Medical Center|Harrison HealthPartners Hematology and Oncology-Bremerton|Harrison Medical Center|Highline Medical Center-Main Campus|Providence Regional Cancer System-Centralia|Swedish Cancer Institute-Edmonds|Saint Elizabeth Hospital|Providence Regional Cancer Partnership|Virginia Mason Federal Way Medical Center|Saint Francis Hospital|Tacoma/Valley Radiation Oncology Centers-Gig Harbor|MultiCare Gig Harbor Medical Park|Swedish Cancer Institute-Issaquah|Kadlec Clinic Hematology and Oncology|Northwest Cancer Clinic|Providence Regional Cancer System-Lacey|Saint Clare Hospital|PeaceHealth Saint John Medical Center|Virginia Mason Lynnwood Medical Center|Skagit Valley Hospital Regional Cancer Care Center|Skagit Valley Hospital|Jefferson Healthcare|Harrison HealthPartners Hematology and Oncology-Poulsbo|Peninsula Cancer Center|MultiCare Good Samaritan Hospital|Tacoma/Valley Radiation Oncology Centers-Puyallup|Valley Medical Center|Virginia Mason Medical Center|Pacific Gynecology Specialists|Swedish Medical Center-Ballard Campus|Fred Hutchinson Cancer Research Center|Seattle Cancer Care Alliance|Kaiser Permanente Washington|Swedish Medical Center-First Hill|University of Washington Medical Center - Montlake|PeaceHealth United General Medical Center|Providence Regional Cancer System-Shelton|MultiCare Deaconess Cancer and Blood Specialty Center - Valley|MultiCare Deaconess Cancer and Blood Specialty Center - Downtown|Spokane Valley Cancer Center-Mayfair|Spokane Valley Cancer Center-Mission|MultiCare Deaconess Cancer and Blood Specialty Center - North|Tacoma/Valley Radiation Oncology Centers-Jackson Hall|Franciscan Research Center-Northwest Medical Plaza|Mary Bridge Children's Hospital and Health Center|MultiCare Tacoma General Hospital|Northwest Medical Specialties PLLC|Tacoma/Valley Radiation Oncology Centers-Saint Joe's|PeaceHealth Southwest Medical Center|Legacy Cancer Institute Medical Oncology and Day Treatment|Legacy Salmon Creek Hospital|Providence Saint Mary Regional Cancer Center|Wenatchee Valley Hospital and Clinics|North Star Lodge Cancer Center at Yakima Valley Memorial Hospital|Providence Regional Cancer System-Yelm|Edwards Comprehensive Cancer Center|Ascension Saint Elizabeth Hospital|Duluth Clinic Ashland|Northwest Wisconsin Cancer Center|Ascension Southeast Wisconsin Hospital - Elmbrook Campus|Ascension Calumet Hospital|Marshfield Clinic-Chippewa Center|Marshfield Clinic Cancer Center at Sacred Heart|Marshfield Medical Center-EC Cancer Center|Ascension Saint Francis - Reiman Cancer Center|Ascension Southeast Wisconsin Hospital - Franklin|Saint Vincent Hospital Cancer Center Green Bay|Saint Vincent Hospital Cancer Center at Saint Mary's|Gundersen Lutheran Medical Center|Marshfield Clinic - Ladysmith Center|Holy Family Memorial Hospital|Saint Vincent Hospital Cancer Center at Marinette|Marshfield Medical Center-Marshfield|Ascension Columbia Saint Mary's Hospital Ozaukee|Ascension Southeast Wisconsin Hospital - Saint Joseph Campus|Ascension Columbia Saint Mary's Hospital - Milwaukee|Ascension Saint Francis Hospital|Marshfield Clinic-Minocqua Center|Cancer Center of Western Wisconsin|Saint Vincent Hospital Cancer Center at Oconto Falls|Ascension Mercy Hospital|Ascension All Saints Hospital|Ascension Saint Mary's Hospital|Marshfield Medical Center-Rice Lake|HSHS Saint Nicholas Hospital|Ascension Saint Michael's Hospital|Marshfield Clinic Stevens Point Center|Saint Vincent Hospital Cancer Center at Sturgeon Bay|Marshfield Clinic-Wausau Center|Ascension Medical Group Southeast Wisconsin - Mayfair Road|Marshfield Medical Center - Weston|Marshfield Clinic - Wisconsin Rapids Center|Cheyenne Regional Medical Center-West|Billings Clinic-Cody|Welch Cancer Center|FHP Health Center-Guam,Procedure|Biological|Biological,Guam|United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02834013
NCT02838927,hypoparathyroidism,Epi-Hypo: Survey on Epidemiology of Hypoparathyroidism in France,Survey on Epidemiology of Hypoparathyroidism in France,Hypoparathyroidism,2016-07-09,2030-09-30,2031-09-30,Observational,Recruiting,,European Georges Pompidou Hospital,European Georges Pompidou Hospital|Oscar - Filière Santé Maladies Rares,"Felix Guyon Hospital|Hôpital Privé de Provence|Amiens University Hospital|Clinic Auch Area|Henri Mondor Hospital|Jean Minjoz Hospital|Avicenne Hospital, AP-HP|Jean Verdier Hospital, AP-HP|University Hospital|Bourgoin Jallieu Hospital|La Cavale Blanche Hospital|Côte de Nacre Hospital|Henri Mondor Hospital, APHP|Dax-Côte d'Argent Hospital|University Hospital|Grenoble Alpes Hospital|CHD Vendée|Kremlin-Bicêtre Hospital, APHP|Le Mans Hospital|Libourne Hospital|Claude Huriez Hospital|Edouard Herriot Hospital, HCL|La Conception Hospital, AP-HM|Clinic Metz Area|Mercy Hospital|Arnaud de Villeneuve Hospital|Clinic area|Brabois Hospital|University Hospital|University Hospital|Georges Renon Hospital|Caremeau Hospital|European Georges Pompidou Hospital, APHP|Clinic Paris Area|Cochin Hospital, APHP|Lariboisière Hospital, APHP|Necker Hospital, AP-HP|Pitié-Salpêtrière Hospital, APHP|Tenon Hospital, APHP|Clinic Poitiers Area|Laennec Hospital|Reims University Hospital|Clinic Rennes Area|Charles Nicolle Hospital|Clinic Area|Clinique du Landy|Hautepierre Hospital|Sainte Anne Hospital, HIA|Larrey Hospital|Guy Chatiliez Hospital|Bretonneau Hospital|Valenciennes Hospital|CHIV - Lucie et Raymond Aubrac",Other,France,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02838927
NCT02845336,thyroid eye disease,An Open Label Trial of Celecoxib in the Treatment of Mild Thyroid Eye Disease,Celecoxib for Thyroid Eye Disease,Thyroid Eye Disease,2016-07-20,2019-06-30,2019-06-30,Interventional,Terminated,Phase 2,Johns Hopkins University,Johns Hopkins University,"Wilmer Eye Institute, Johns Hopkins University",Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT02845336
NCT02856347,medullary thyroid cancer,Prospective Study Evaluating the Medullary Thyroid Cancer Management's Care Using PET ( Positron Emission Tomography) F-DOPA in Patients With a High Level of Postoperative Residual Thyrocalcitonin,Prospective Study Evaluating the Medullary Thyroid Cancer Management's Care Using PET F-DOPA in Patients With a High Level of Postoperative Residual Thyrocalcitonin,Medullary Thyroid Cancer,2016-07-27,2020-12-20,2020-12-20,Interventional,Completed,Not Applicable,Institut Claudius Regaud,Institut Claudius Regaud,CHU Haut-Lévêque|CHU Limoges|CHU Timone|ICM Montpellier|Institut Claudius Regaud,Other,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, medullary",https://clinicaltrials.gov/ct2/show/NCT02856347
NCT02867592,thyroid gland medullary carcinoma,"Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors","Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors",Adrenal Cortex Carcinoma|Alveolar Soft Part Sarcoma|Central Nervous System Neoplasm|Childhood Clear Cell Sarcoma of Soft Tissue|Clear Cell Sarcoma of Soft Tissue|Ewing Sarcoma|Hepatoblastoma|Hepatocellular Carcinoma|Osteosarcoma|Recurrent Adrenal Cortex Carcinoma|Recurrent Alveolar Soft Part Sarcoma|Recurrent Clear Cell Sarcoma of Soft Tissue|Recurrent Ewing Sarcoma|Recurrent Hepatoblastoma|Recurrent Hepatocellular Carcinoma|Recurrent Kidney Wilms Tumor|Recurrent Malignant Solid Neoplasm|Recurrent Osteosarcoma|Recurrent Primary Malignant Central Nervous System Neoplasm|Recurrent Renal Cell Carcinoma|Recurrent Rhabdomyosarcoma|Recurrent Soft Tissue Sarcoma|Recurrent Thyroid Gland Medullary Carcinoma|Refractory Clear Cell Sarcoma of Soft Tissue|Refractory Ewing Sarcoma|Refractory Hepatoblastoma|Refractory Hepatocellular Carcinoma|Refractory Malignant Solid Neoplasm|Refractory Osteosarcoma|Refractory Primary Central Nervous System Neoplasm|Refractory Primary Malignant Central Nervous System Neoplasm|Refractory Renal Cell Carcinoma|Refractory Rhabdomyosarcoma|Refractory Soft Tissue Sarcoma|Refractory Thyroid Gland Medullary Carcinoma|Renal Cell Carcinoma|Rhabdomyosarcoma|Solid Neoplasm|Thyroid Gland Medullary Carcinoma|Wilms Tumor,2016-08-15,2021-06-30,2022-07-01,Interventional,Active not recruiting,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),Children's Hospital of Alabama|Providence Alaska Medical Center|Arkansas Children's Hospital|Kaiser Permanente-Anaheim|Kaiser Permanente-Bellflower|Kaiser Permanente Downey Medical Center|Kaiser Permanente-Fontana|Loma Linda University Medical Center|Children's Hospital Los Angeles|Kaiser Permanente Los Angeles Medical Center|Valley Children's Hospital|UCSF Benioff Children's Hospital Oakland|Kaiser Permanente-Oakland|Children's Hospital of Orange County|Lucile Packard Children's Hospital Stanford University|University of California Davis Comprehensive Cancer Center|Kaiser Permanente-San Diego Mission|Rady Children's Hospital - San Diego|UCSF Medical Center-Mission Bay|Children's Hospital Colorado|Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center|Connecticut Children's Medical Center|Yale University|Alfred I duPont Hospital for Children|Kaiser Permanente-Capitol Hill Medical Center|MedStar Georgetown University Hospital|Children's National Medical Center|Golisano Children's Hospital of Southwest Florida|University of Florida Health Science Center - Gainesville|Nemours Children's Clinic-Jacksonville|University of Miami Miller School of Medicine-Sylvester Cancer Center|Nicklaus Children's Hospital|AdventHealth Orlando|Arnold Palmer Hospital for Children|Nemours Children's Hospital|Nemours Children's Clinic - Pensacola|Johns Hopkins All Children's Hospital|Children's Healthcare of Atlanta - Egleston|Straub Clinic and Hospital|Kaiser Permanente Moanalua Medical Center|Kapiolani Medical Center for Women and Children|Saint Luke's Cancer Institute - Boise|Lurie Children's Hospital-Chicago|University of Illinois|University of Chicago Comprehensive Cancer Center|Carle on Vermilion|Carle Physician Group-Effingham|Carle Physician Group-Mattoon/Charleston|Saint Jude Midwest Affiliate|Carle Cancer Center|The Carle Foundation Hospital|Riley Hospital for Children|Saint Vincent Hospital and Health Care Center|Blank Children's Hospital|Iowa Methodist Medical Center|Iowa Lutheran Hospital|University of Iowa/Holden Comprehensive Cancer Center|University of Kentucky/Markey Cancer Center|Norton Children's Hospital|Children's Hospital New Orleans|Eastern Maine Medical Center|Lafayette Family Cancer Center-EMMC|Sinai Hospital of Baltimore|Johns Hopkins University/Sidney Kimmel Cancer Center|National Institutes of Health Clinical Center|Massachusetts General Hospital Cancer Center|Dana-Farber Cancer Institute|C S Mott Children's Hospital|Wayne State University/Karmanos Cancer Institute|Ascension Saint John Hospital|Huron Medical Center PC|Beaumont Children's Hospital-Royal Oak|Children's Hospitals and Clinics of Minnesota - Minneapolis|University of Minnesota/Masonic Cancer Center|Mayo Clinic in Rochester|University of Mississippi Medical Center|Siteman Cancer Center at West County Hospital|Children's Mercy Hospitals and Clinics|Cardinal Glennon Children's Medical Center|Barnes-Jewish Hospital|Washington University School of Medicine|Siteman Cancer Center-South County|Mercy Hospital Saint Louis|Siteman Cancer Center at Saint Peters Hospital|Children's Hospital and Medical Center of Omaha|University of Nebraska Medical Center|Comprehensive Cancer Centers of Nevada-Horizon Ridge|Sunrise Hospital and Medical Center|Alliance for Childhood Diseases/Cure 4 the Kids Foundation|Summerlin Hospital Medical Center|Hope Cancer Care of Nevada-Pahrump|Radiation Oncology Associates|Dartmouth Hitchcock Medical Center|Hackensack University Medical Center|Morristown Medical Center|Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital|Roswell Park Cancer Institute|NYU Winthrop Hospital|The Steven and Alexandra Cohen Children's Medical Center of New York|Laura and Isaac Perlmutter Cancer Center at NYU Langone|NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center|State University of New York Upstate Medical University|UNC Lineberger Comprehensive Cancer Center|Carolinas Medical Center/Levine Cancer Institute|Southeastern Medical Oncology Center-Clinton|Duke University Medical Center|Southeastern Medical Oncology Center-Goldsboro|Wayne Memorial Hospital|East Carolina University|Southeastern Medical Oncology Center-Jacksonville|Cincinnati Children's Hospital Medical Center|Rainbow Babies and Childrens Hospital|MetroHealth Medical Center|Cleveland Clinic Foundation|Nationwide Children's Hospital|Dayton Children's Hospital|ProMedica Flower Hospital|ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital|University of Oklahoma Health Sciences Center|Oregon Health and Science University|Children's Hospital of Philadelphia|Children's Hospital of Pittsburgh of UPMC|Medical University of South Carolina|Saint Francis Hospital|BI-LO Charities Children's Cancer Center|Saint Francis Cancer Center|East Tennessee Childrens Hospital|Saint Jude Children's Research Hospital|The Children's Hospital at TriStar Centennial|Medical City Dallas Hospital|UT Southwestern/Simmons Cancer Center-Dallas|El Paso Children's Hospital|Texas Tech University Health Sciences Center-El Paso|Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center|Children's Hospital of San Antonio|University of Vermont and State Agricultural College|University of Virginia Cancer Center|Children's Hospital of The King's Daughters|Seattle Children's Hospital|Providence Sacred Heart Medical Center and Children's Hospital|Gundersen Lutheran Medical Center|University of Wisconsin Carbone Cancer Center|Children's Hospital of Wisconsin,Drug|Drug|Other,United States,2.0,30.0,[0-17]|[18-65],Thyroid neoplasms,"Thyroid cancer, medullary",https://clinicaltrials.gov/ct2/show/NCT02867592
NCT02869620,thyroid neoplasms,Institut Paoli Calmettes Thyroid Cancer Database,Institut Paoli Calmettes Thyroid Cancer Database,Thyroid Neoplasms,2016-08-11,2030-01-31,2030-12-31,Observational [Patient Registry],Recruiting,,Institut Paoli-Calmettes,Institut Paoli-Calmettes,Institut Paoli-Calmettes,Other,France,18.0,95.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02869620
NCT02870569,differentiated thyroid cancer,"A Multicenter, Randomized, Open-Label,Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer",Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer,Differentiated Thyroid Cancer,2016-08-12,2018-07-02,2018-12-31,Interventional,Completed,Phase 2,"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","Suzhou Zelgen Biopharmaceuticals Co.,Ltd",Peking Union Medical College Hospital,Drug|Drug,China,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Differentiated thyroid cancer, all",https://clinicaltrials.gov/ct2/show/NCT02870569
NCT02878044,thyroid cancer,Shared Decision Making in Patients With Thyroid Nodules,Shared Decision Making in Patients With Thyroid Nodules,Thyroid Cancer|Thyroid Nodule,2016-08-16,2019-05-23,2019-05-23,Interventional,Completed,Not Applicable,Mayo Clinic,Mayo Clinic,Mayo Clinic Jacksonville|Mayo Clinic in Rochester,Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02878044
NCT02878044,thyroid nodule,Shared Decision Making in Patients With Thyroid Nodules,Shared Decision Making in Patients With Thyroid Nodules,Thyroid Cancer|Thyroid Nodule,2016-08-16,2019-05-23,2019-05-23,Interventional,Completed,Not Applicable,Mayo Clinic,Mayo Clinic,Mayo Clinic Jacksonville|Mayo Clinic in Rochester,Other,United States,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT02878044
NCT02886949,thyrotoxicosis,"The Relationship of Vascular Cell Adhesion Molecule 1, C-reactive Protein, Brain-derived Neurotrophic Factor, Orexin and Depressive Symptoms in the Subjects With Thyroid Disease",The Association Between Autoimmune or Inflammation and Thyroid Disease,THYROTOXICOSIS,2015-09-02,2020-12-31,2024-12-31,Observational,Recruiting,,Taichung Veterans General Hospital,Taichung Veterans General Hospital,"Division of Endocrinology and Metabolism, Department of Internal Medicine, Taichung Veterans General Hospital",,Taiwan,20.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT02886949
NCT02891668,hypothyroidism,"Hypothyroidism, Metabolism and Quality of Life - Focus on QOL, REE, Cognitive Function and Body Composition","Hypothyroidism, Metabolism and Quality of Life - Focus on QOL, REE, Cognitive Function and Body Composition",Hypothyroidism,2016-05-17,2018-05-20,2018-05-20,Observational,Completed,,Herlev Hospital,Herlev Hospital,"Department of internal Medicine, Herlev Hospital",Drug,Denmark,20.0,75.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT02891668
NCT02901873,parathyroid diseases,Phase 1 Study of Electrical Impedance Spectroscopy in Thyroid and Parathyroid Surgery,EIS in Thyroid and Parathyroid Surgery,Parathyroid Diseases|Thyroidectomy,2016-09-12,2017-06-27,2017-06-27,Interventional,Completed,Not Applicable,Sheffield Teaching Hospitals NHS Foundation Trust,Sheffield Teaching Hospitals NHS Foundation Trust,Royal Hallamshire Hospital,Device,United Kingdom,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT02901873
NCT02910466,hypoparathyroidism,"A Phase 4, Open-Label, Single-Center Clinical Study of Extended Use of rhPTH(1-84) in Hypoparathyroidism",A Study of Extended Use of Recombinant Human Parathyroid Hormone (rhPTH(1-84)) in Hypoparathyroidism,Chronic Hypoparathyroidism|Hypoparathyroidism,2016-09-20,2019-12-20,2019-12-20,Interventional,Completed,Phase 4,Takeda,Shire,Columbia University Medical Center,Drug,United States,18.0,85.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02910466
NCT02911155,thyroid cancer,Cancer and Other Disease Risks in U.S. Nuclear Medicine Technologists,Cancer and Other Disease Risks in U.S. Nuclear Medicine Technologists,Brain Cancer|Breast Cancer|Circulatory Disease|Thyroid Cancer,2016-09-21,2020-05-01,2020-05-01,Observational,Completed,,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),"University of Minnesota, School of Public Health Environmental Health Sciences",,United States,18.0,100.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02911155
NCT02917863,hypothyroidism,Randomized Crossover Trial for the Evaluation of the Possible Effects in the Intestine of Two Different Pharmaceutical Forms of L - Thyroxine in Patients With Primary Acquired Hypothyroidism,Randomized Crossover Trial for the Evaluation of the Possible Effects in the Intestine of Two Different Pharmaceutical Forms of L - Thyroxine in Patients With Primary Acquired Hypothyroidism,Hypothyroidism,2016-09-07,2018-05-31,2019-05-31,Interventional,Unknown status,Phase 4,Meyer Children's Hospital,Meyer Children's Hospital,Meyer Children's Hospital,Drug|Drug,Italy,3.0,18.0,[0-17]|[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT02917863
NCT02924532,hypoparathyroidism,Diagnostic Value of Immediate Postoperative Dose of Parathyroid Hormone as a Marker for the Occurrence of Hypoparathyroidism After Total Thyroidectomy: A Retrospective Observational Study,Postoperative Dose of Parathyroid Hormone as a Marker for the Occurrence of Hypoparathyroidism After Total Thyroidectomy,Hypoparathyroidism,2016-09-13,2013-12-31,,Observational,Completed,,Centre Hospitalier Universitaire de Nīmes,Centre Hospitalier Universitaire de Nīmes,,Biological,,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02924532
NCT02938702,thyroid cancer,,Active Surveillance on Papillary Thyroid Microcarcinoma,Papillary Thyroid Microcarcinoma|Thyroid Cancer,2016-02-17,2025-03-31,2030-03-31,Observational,Active not recruiting,,Seoul National University Hospital,Seoul National University Hospital,Seoul National University Hospital,,"Korea, Republic of",18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02938702
NCT02946918,thyroid cancer,Levothyroxine Replacement With Liquid Gel Capsules or Tablets in Post-thyroidectomy Stage in Low Risk Differentiated Thyroid Cancer Patients,Levothyroxine Replacement With Liquid Gel Capsules vs Tablets Post-thyroidectomy,Postsurgical Hypothyroidism|Thyroid Cancer,2016-10-21,2019-11-04,2019-11-04,Interventional,Terminated,Phase 4,University of Texas Southwestern Medical Center,Akrimax Pharmaceuticals|University of Texas Southwestern Medical Center,University of Texas Southwestern Medical Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02946918
NCT02947035,thyroid cancer,Molecular Testing to Direct Extent of Initial Thyroid Surgery,Molecular Testing to Direct Extent of Initial Thyroid Surgery,Thyroid Cancer,2016-10-20,2023-02-01,2023-02-28,Interventional,Recruiting,Phase 2,University of Pittsburgh,University of Pittsburgh,University of Pittsburgh|Medical College of Wisconsin,Procedure|Procedure,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02947035
NCT02947399,thyroid cancer,Comparison of I-124 and I-131 Radiopharmacokinetics In Patient With Well Differentiated Thyroid Cancer After Thyroid Hormone Withdrawal,Comparison of I-124 and I-131 Radiopharmacokinetics in DTC Patients With Thyroid Hormone Withdrawal,Thyroid Cancer,2016-10-25,2018-10-31,2018-10-31,Interventional,Terminated,Not Applicable,Medstar Health Research Institute,Medstar Health Research Institute,Washington Hospital Center,Radiation,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02947399
NCT02952612,"thyroid cancer, papillary",Active Surveillance of Papillary Thyroid Microcarcinoma (PTMC) in Catholic Medical Center,Active Surveillance of Papillary Thyroid Microcarcinoma,"Thyroid Cancer, Papillary",2016-10-31,2017-10-31,2021-10-31,Observational,Unknown status,,Seoul St. Mary's Hospital,Dong Jun Lim,Seoul St Mary's Hospital,,"Korea, Republic of",18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT02952612
NCT02953288,thyroid cancer,Differential Diagnosis and Clinical Treatment Strategies of Thyroid Nodules.,Differential Diagnosis and Clinical Treatment Strategies of Thyroid Nodules.,Thyroid Cancer,2016-11-01,2017-06-30,2018-12-31,Observational,Unknown status,,Shanghai 10th People's Hospital,Shanghai 10th People's Hospital,"Department of Endocrinology, Shanghai Tenth People's Hospital",,China,18.0,65.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02953288
NCT02959827,hypothyroidism,Iodinated Contrast Agents and Risk of Hypothyroidism in Young Children in the United States,Iodinated Contrast Agents and Risk of Hypothyroidism in Young Children in the United States,Hypothyroidism,2016-10-11,2017-06-15,2017-06-15,Observational,Completed,,Bayer,Bayer,Oakland,Drug,United States,0.0,3.0,[0-17],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT02959827
NCT02973802,graves disease,"Safety and Proof of Principle Study of ATX-GD-59 in Male and Female Subjects With Graves' Disease Not Currently Treated With Anti-thyroid Therapy: An Open Label Study, With an Upward Titration Over Five Dose Levels Administered by Intradermal Injection",ATX-GD-59 in Patients With Graves Disease Not Treated With Anti-thyroid Therapy,Graves Disease,2016-11-14,2018-02-14,2018-02-14,Interventional,Completed,Phase 1,Apitope International NV,"Apitope International NV|European Commission|Quintiles, Inc.",Queen Elizabeth Hospital|University Hospital of Wales|Royal Devon and Exeter Hospital|St James's University Hospital|Hammersmith Hospital|Kings College Hospital|The Christie|Royal Victoria Infirmary,Biological,United Kingdom,18.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02973802
NCT02973997,tall cell variant thyroid gland papillary carcinoma,"Combination Targeted Therapy With Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers: A Phase II Study",Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC),Columnar Cell Variant Thyroid Gland Papillary Carcinoma|Follicular Variant Thyroid Gland Papillary Carcinoma|Metastatic Thyroid Gland Follicular Carcinoma|Metastatic Thyroid Gland Papillary Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Follicular Carcinoma|Recurrent Thyroid Gland Papillary Carcinoma|Stage III Differentiated Thyroid Gland Carcinoma AJCC v7|Stage III Thyroid Gland Follicular Carcinoma AJCC v7|Stage III Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7|Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v7|Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVC Differentiated Thyroid Gland Carcinoma AJCC v7|Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7|Stage IV Thyroid Gland Follicular Carcinoma AJCC v7|Stage IV Thyroid Gland Papillary Carcinoma AJCC v7|Tall Cell Variant Thyroid Gland Papillary Carcinoma|Thyroid Gland Hurthle Cell Carcinoma|Unresectable Differentiated Thyroid Gland Carcinoma|Unresectable Thyroid Gland Carcinoma,2016-11-23,2022-10-08,2024-09-30,Interventional,Active not recruiting,Phase 2,Academic and Community Cancer Research United,Academic and Community Cancer Research United|National Cancer Institute (NCI),Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center|University of Colorado Hospital|Massachusetts General Hospital Cancer Center|University of Michigan Comprehensive Cancer Center|Memorial Sloan Kettering Cancer Center|Ohio State University Comprehensive Cancer Center|M D Anderson Cancer Center,Other|Drug|Drug|Biological,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT02973997
NCT02973997,thyroid gland hurthle cell carcinoma,"Combination Targeted Therapy With Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers: A Phase II Study",Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC),Columnar Cell Variant Thyroid Gland Papillary Carcinoma|Follicular Variant Thyroid Gland Papillary Carcinoma|Metastatic Thyroid Gland Follicular Carcinoma|Metastatic Thyroid Gland Papillary Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Follicular Carcinoma|Recurrent Thyroid Gland Papillary Carcinoma|Stage III Differentiated Thyroid Gland Carcinoma AJCC v7|Stage III Thyroid Gland Follicular Carcinoma AJCC v7|Stage III Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7|Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v7|Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVC Differentiated Thyroid Gland Carcinoma AJCC v7|Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7|Stage IV Thyroid Gland Follicular Carcinoma AJCC v7|Stage IV Thyroid Gland Papillary Carcinoma AJCC v7|Tall Cell Variant Thyroid Gland Papillary Carcinoma|Thyroid Gland Hurthle Cell Carcinoma|Unresectable Differentiated Thyroid Gland Carcinoma|Unresectable Thyroid Gland Carcinoma,2016-11-23,2022-10-08,2024-09-30,Interventional,Active not recruiting,Phase 2,Academic and Community Cancer Research United,Academic and Community Cancer Research United|National Cancer Institute (NCI),Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center|University of Colorado Hospital|Massachusetts General Hospital Cancer Center|University of Michigan Comprehensive Cancer Center|Memorial Sloan Kettering Cancer Center|Ohio State University Comprehensive Cancer Center|M D Anderson Cancer Center,Other|Drug|Drug|Biological,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Hurthle cell thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02973997
NCT02973997,poorly differentiated thyroid gland carcinoma,"Combination Targeted Therapy With Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers: A Phase II Study",Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC),Columnar Cell Variant Thyroid Gland Papillary Carcinoma|Follicular Variant Thyroid Gland Papillary Carcinoma|Metastatic Thyroid Gland Follicular Carcinoma|Metastatic Thyroid Gland Papillary Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Follicular Carcinoma|Recurrent Thyroid Gland Papillary Carcinoma|Stage III Differentiated Thyroid Gland Carcinoma AJCC v7|Stage III Thyroid Gland Follicular Carcinoma AJCC v7|Stage III Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7|Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v7|Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVC Differentiated Thyroid Gland Carcinoma AJCC v7|Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7|Stage IV Thyroid Gland Follicular Carcinoma AJCC v7|Stage IV Thyroid Gland Papillary Carcinoma AJCC v7|Tall Cell Variant Thyroid Gland Papillary Carcinoma|Thyroid Gland Hurthle Cell Carcinoma|Unresectable Differentiated Thyroid Gland Carcinoma|Unresectable Thyroid Gland Carcinoma,2016-11-23,2022-10-08,2024-09-30,Interventional,Active not recruiting,Phase 2,Academic and Community Cancer Research United,Academic and Community Cancer Research United|National Cancer Institute (NCI),Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center|University of Colorado Hospital|Massachusetts General Hospital Cancer Center|University of Michigan Comprehensive Cancer Center|Memorial Sloan Kettering Cancer Center|Ohio State University Comprehensive Cancer Center|M D Anderson Cancer Center,Other|Drug|Drug|Biological,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Poorly differentiated thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02973997
NCT02986607,hypoparathyroidism,Corticosteroid Rhythms in Hypoparathyroid Patients,Corticosteroid Rhythms in Hypoparathyroid Patients,Hyperparathyroidism|Hypoparathyroidism,2016-12-05,2018-01-31,2018-06-30,Interventional,Unknown status,Early Phase 1,University of Bergen,Haukeland University Hospital|University of Bergen,Haukeland University Hospital,Drug,Norway,18.0,60.0,[18-65],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02986607
NCT02986607,hyperparathyroidism,Corticosteroid Rhythms in Hypoparathyroid Patients,Corticosteroid Rhythms in Hypoparathyroid Patients,Hyperparathyroidism|Hypoparathyroidism,2016-12-05,2018-01-31,2018-06-30,Interventional,Unknown status,Early Phase 1,University of Bergen,Haukeland University Hospital|University of Bergen,Haukeland University Hospital,Drug,Norway,18.0,60.0,[18-65],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT02986607
NCT02988817,thyroid cancer,"First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of Axl-specific Antibody-drug Conjugate (Enapotamab Vedotin, HuMax®-AXL-ADC) in Patients With Solid Tumors",Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors,Cervical Cancer|Endometrial Cancer|Melanoma|Non Small Cell Lung Cancer|Ovarian Cancer|Sarcoma|Thyroid Cancer,2016-12-01,2021-11-12,2021-11-12,Interventional,Completed,Phase 1/Phase 2,Genmab,Genmab,"Mayo Clinic Scottsdale|University of Colorado Cancer Center|Yale University, Smilow Cancer Center at Yale New Haven Hospital|Mayo Clinic Jacksonville|Moffitt Cancer Center|Emory University School of Medicine, Winship Cancer Institute|University of Iowa|Dana-Farber Cancer Institute|University of Michigan Comprehensive Cancer Center|Mayo Clinic Rochester|Washington University|Roswell Park Comprehensive Cancer Center|NYU Medical Center|Herbert Irving Comprehensive Cancer Center|Duke Cancer Institute|Fox Chase Cancer Center|Mary Crowley Cancer Reearch Center|MD Anderson|Huntsman Cancer Institute|University of Wisconsin Carbone Cancer Center|Universitair Ziekenhuizen Leuven|Institut Roi Albert II - Cliniques Universitaires Saint Luc|Universitair Ziekenhuis Brussel - Oncologisch Centrum|Medische oncologie, Oncologisch Centrum - AZ Groeninge|U.Z. Leuven Gasthuisberg, Department of General Medical Oncology|CHU de Liège, Medical Oncology et. Domaine Universitaire du Sart Tilman|Rigshospitalet, Copenhagen University Hospital|The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital|Leiden University Medical Centre|Erasmus MC, Medical Oncology|UMC Utrecht Cancer Center|Hospital Unversitario Vall D'hebron|Oncologia Mèdica/ Medical Oncology Department Institut Catalá d'Oncologia (ICO)|University Hospital of Girona|Hospital Universitario 12 Octubre|Hospital Virgen de la Victoria|University Hospital Lozano Blesa, Aragón Health Research Institute (IIS Aragón)|Universtity College London Hospitals|The Royal Marsden NHS Foundation Trust|The Christie NHS Foundation Trust Clinical Trials Unit|Sir Bobby Robson Clinical Trials Unit at the Northern Centre for Cancer Care, Freeman Hospital",Biological,Belgium|Denmark|Netherlands|Spain|United Kingdom|United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT02988817
NCT02993302,graves disease,Effects Of Oral Alfacalcidol On Maturation Of Dendritic Cells In Graves' Disease Patients,Effects Of Oral Alfacalcidol On Maturation Of Dendritic Cells In Graves' Disease Patients,Graves Disease,2016-12-07,2015-03-31,2015-03-31,Interventional,Completed,Phase 2,Dr Cipto Mangunkusumo General Hospital,Dr Cipto Mangunkusumo General Hospital|Indonesia University,,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT02993302
NCT02993562,hypothyroidism,Levothyroxine Substitution Therapy in Hypothyroid Patients - Impact on Appetite and Food Intake,"Hypothyroidism, Metabolism and Food Intake",Hypothyroidism,2016-10-20,2018-08-30,2018-08-30,Observational,Completed,,Herlev Hospital,"Center for Diabetes Research, Herlev and Gentofte Hospital.|Herlev Hospital","Center for Diabetes Research, Herlev and Gentofte Hospitals",Drug,Denmark,20.0,75.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT02993562
NCT03002623,differentiated thyroid cancer,A Phase II Trial of CUDC-907 in Patients With Metastatic and Locally Advanced Thyroid Cancer,CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer,Differentiated Thyroid Cancer|Poorly Differentiated and Undifferentiated Thyroid Cancer|Thyroid Neoplasms,2016-12-22,2018-02-12,2018-02-12,Interventional,Terminated,Phase 2,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),National Institutes of Health Clinical Center,Drug,United States,18.0,99.0,[18-65]|[65 and more],Thyroid neoplasms,"Differentiated thyroid cancer, all",https://clinicaltrials.gov/ct2/show/NCT03002623
NCT03006289,thyroid cancer,Relationship of Metabolic Syndrome and Its Components With Thyroid Cancer,Relationship of Metabolic Syndrome and Its Components With Thyroid Cancer,Thyroid Cancer,2016-12-26,2017-10-31,2017-11-30,Observational,Unknown status,,Qianfoshan Hospital,Lin Liao,,,,8.0,80.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03006289
NCT03009279,thyroid nodule,Relationship of Metabolic Syndrome and Its Components With Thyroid Nodule(s),Relationship of Metabolic Syndrome and Its Components With Thyroid Nodule(s),Metabolic Syndrome|Thyroid Nodule,2016-12-26,2017-11-30,2017-12-31,Observational,Unknown status,,Qianfoshan Hospital,Lin Liao,,,,15.0,90.0,[0-17]|[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03009279
NCT03009357,thyrotoxicosis,"Clinical Application of Continuous Monitoring Data for the Pulse Rate, Exercise, and Calorie Intake by Wearable Activity Trackers in the Patients With Thyrotoxicosis",Clinical Application of Pulse Rate-monitoring Activity Trackers in Thyrotoxicosis,Graves Disease|Thyroiditis|Thyrotoxicosis,2016-12-29,2017-06-30,2017-08-31,Observational,Completed,,Seoul National University Bundang Hospital,Seoul National University Bundang Hospital,Seoul National University Bundang Hospital,,"Korea, Republic of",20.0,60.0,[18-65],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03009357
NCT03009357,graves disease,"Clinical Application of Continuous Monitoring Data for the Pulse Rate, Exercise, and Calorie Intake by Wearable Activity Trackers in the Patients With Thyrotoxicosis",Clinical Application of Pulse Rate-monitoring Activity Trackers in Thyrotoxicosis,Graves Disease|Thyroiditis|Thyrotoxicosis,2016-12-29,2017-06-30,2017-08-31,Observational,Completed,,Seoul National University Bundang Hospital,Seoul National University Bundang Hospital,Seoul National University Bundang Hospital,,"Korea, Republic of",20.0,60.0,[18-65],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT03009357
NCT03009357,thyroiditis,"Clinical Application of Continuous Monitoring Data for the Pulse Rate, Exercise, and Calorie Intake by Wearable Activity Trackers in the Patients With Thyrotoxicosis",Clinical Application of Pulse Rate-monitoring Activity Trackers in Thyrotoxicosis,Graves Disease|Thyroiditis|Thyrotoxicosis,2016-12-29,2017-06-30,2017-08-31,Observational,Completed,,Seoul National University Bundang Hospital,Seoul National University Bundang Hospital,Seoul National University Bundang Hospital,,"Korea, Republic of",20.0,60.0,[18-65],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT03009357
NCT03013257,graves disease,"A Randomized, Open-label, Parallel-group Study to Explore the Efficacy of High-intensity Focused Ultrasound (HIFU) Versus Fixed-dose Radioiodine-131 in the Treatment of Relapsed Graves' Disease",HIFU vs RAI in the Relapsed Graves' Disease,Graves Disease,2017-01-04,2022-04-30,2022-12-31,Interventional,Recruiting,Not Applicable,The University of Hong Kong,The University of Hong Kong,Queen Mary Hospital,Device,Hong Kong,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT03013257
NCT03024151,thyroid cancer,"The Effects of T4 Mono Replacement Versus T4/T3 Combination Replacement on Psychological Distress After Total Thyroidectomy in Thyroid Cancer Patients; Prospective, Randomized, Double Blind, T4 Comparative Clinical Study",The Effects of T4 Versus T4/T3 on Psychological Distress After Total Thyroidectomy in Thyroid Cancer Patients,Anxiety|Depression|Distress|Fatigue|Thyroid Cancer,2017-01-10,2017-11-30,2017-11-30,Interventional,Completed,Not Applicable,Inje University,Dongnam Institute of Radiological & Medical Sciences|Inje University,Dong sik Bae|Dongsik Bae,Drug|Drug,"Korea, Republic of",20.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03024151
NCT03027349,hyperparathyroidism,,"Serum Calcium to Phosphorous Ratio (Ca/P) as a Simple, Inexpensive Screening Tool in the Diagnosis of Primary Hyperparathyroidism",Hyperparathyroidism,2017-01-18,2017-02-28,2017-02-28,Observational,Completed,,Azienda USL Modena,Azienda USL Modena,Azienda USL of Modena,Other,Italy,18.0,90.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03027349
NCT03029429,pseudohypoparathyroidism,Phase 2 Study of Theophylline Treatment for Pseudohypoparathyroidism,Theophylline Treatment for Pseudohypoparathyroidism,Albright Hereditary Osteodystrophy|Pseudohypoparathyroidism,2017-01-18,2023-07-01,2023-11-01,Interventional,Recruiting,Phase 2,Vanderbilt University Medical Center,Harvard University|Vanderbilt University Medical Center,Ashley Shoemaker,Drug|Drug,United States,13.0,99.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,pseudohypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03029429
NCT03031639,thyroid neoplasms,Khon Kaen University's Thyroidectomy Registry,Khon Kaen University's Thyroidectomy Registry,Thyroid Cancer|Thyroid Neoplasms|Thyroid Nodule,2017-01-20,2021-01-12,2021-01-12,Observational [Patient Registry],Completed,,Khon Kaen University,Khon Kaen University,"Department of Otolaryngology, Khonkaen University",Procedure,Thailand,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03031639
NCT03031639,thyroid nodule,Khon Kaen University's Thyroidectomy Registry,Khon Kaen University's Thyroidectomy Registry,Thyroid Cancer|Thyroid Neoplasms|Thyroid Nodule,2017-01-20,2021-01-12,2021-01-12,Observational [Patient Registry],Completed,,Khon Kaen University,Khon Kaen University,"Department of Otolaryngology, Khonkaen University",Procedure,Thailand,0.0,120.0,[0-17]|[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03031639
NCT03034707,parathyroid diseases,Interference of Biotin Supplementation in Biotin-streptavidin Platforms for Hormone Testing,Interference of Biotin Supplementation in Biotin-streptavidin Platforms for Hormone Testing,Parathyroid Diseases|Thoracic Diseases,2017-01-17,2016-10-31,2018-12-31,Interventional,Completed,Not Applicable,University of Minnesota,Boston Medical Center|Children's Mercy Hospital Kansas City|Johns Hopkins University|University of Minnesota,,Dietary Supplement,,18.0,70.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT03034707
NCT03037385,"thyroid cancer, papillary","A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors","Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors","Adenocarcinoma|Adenocarcinoma, Papillary|Bronchial Neoplasms|Carcinoma|Carcinoma, Bronchogenic|Carcinoma, Neuroendocrine|Carcinoma, Non-Small-Cell Lung|Colonic Diseases|Colonic Neoplasms|Colorectal Neoplasms|Digestive System Disease|Digestive System Neoplasm|Endocrine Gland Neoplasm|Endocrine System Diseases|Gastrointestinal Disease|Gastrointestinal Neoplasms|Head and Neck Neoplasms|Intestinal Disease|Intestinal Neoplasms|Lung Diseases|Lung Neoplasm|Medullary Thyroid Cancer|Neoplasms|Neoplasms by Histologic Type|Neoplasms by Site|Neoplasms, Germ Cell and Embryonal|Neoplasms, Glandular and Epithelial|Neoplasms, Nerve Tissue|Neuroectodermal Tumors|Neuroendocrine Tumors|Respiratory Tract Disease|Respiratory Tract Neoplasms|RET-altered Colon Cancer|RET-altered Non Small Cell Lung Cancer|RET-altered Papillary Thyroid Cancer|RET-altered Solid Tumors|Thoracic Neoplasms|Thyroid Cancer, Papillary|Thyroid Diseases|Thyroid Neoplasm",2017-01-20,2023-12-31,2024-02-29,Interventional,Active not recruiting,Phase 1/Phase 2,Hoffmann-La Roche,Hoffmann-La Roche,"Mayo Clinic|UC Irvine Medical Center|University of Colorado Cancer Center|Georgetown University Medical Center|Mayo Clinic|University of Miami Hospitals and Clinics, Sylvester Comprehensive Cancer Center|Maryland Oncology Hematology, PA - Columbia|Massachusetts General Hospital|University of Michigan|Mayo Clinic|Washington University School of Medicine, Siteman Cancer Center|Albany Medical Center|Jack D. Weiler Hospital|Cornell University|Oregon Health and Science University|University of Pennsylvania Hospital|UPMC CancerCenter|Texas Oncology - Austin|Texas Oncology - Baylor Charles A. Sammons Cancer Center|University of Texas MD Anderson Cancer Center|University of Washington, Seattle Cancer Care Alliance|Antwerp University Hospital|Beijing Cancer Hospital|West China Hospital, Sichuan University|Sichuan Cancer Hospital & Institute|Chongqing Cancer Hospital|Fujian Provincial Cancer Hospital|First Affiliated Hospital of Gannan Medical University|Sun Yat-sen University Cancer Center|Guangdong Provincial People's Hospital|Nanfang Hospital of Southern Medical University|Zhejiang Provincial People's Hospital|Zhejiang Cancer Hospital|Anhui Provincial Cancer Hospital|Jinan Central Hospital|Gansu Provincial Cancer Hospital|Fudan University Shanghai Cancer Center|Liaoning Cancer Hospital & Institute|Tianjin Medical University Cancer Institute and Hospital|Union Hospital, Tongji Medical College, Huazhong University of Science and Technology|Henan Cancer Hospital|Institut Bergonié|CHRU de Lille - Hôpital Claude Hurier Servide d'Endocrinologie et Diabétologie|Centre Leon Berard|Centre Antoine Lacassagne|Hospital Tenon|Institut Curie|CHU de Rennes - Hôpital Pontchaillou|Insitut Claudius Regaud|Gustave Roussy|HELIOS Klinikum Emil von Behring|Universitätsklinikum Essen|Thoraxklinik Heidelberg|Klinikum der Universitat Munchen|Pius-Hospital Oldenberg|The Chinese University of Hong Kong|Istituto Europeo di Oncologia Sviluppo Nuovi Farmaci per Terapie Innovative|Grande Ospedale Metropolitano Niguarda|Ospedale Santa Maria delle Croci|Istituto Nazionale Tumori Regina Elena|Seoul National University Hospital|Severance Hospital|Asan Medical Center|Samsung Medical Center|Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis|University Medical Center Groningen|National Cancer Centre Singapore|Hospital Universitari Vall d'Hebron|Hospital Clinic Barcelona|Hospital Duran I Reynals|Hospital Universitario Ramon y Cajal|Hospital Universitario 12 de Octubre Servicio de Oncologia Medica|National Taiwan University Hospital|Taipei Veterans General Hospital|NHS Grampian - Aberdeen Royal Infirmary|Sarah Cannon Research Institute|Guy's Hospital St. Thomas NHS Foundation Trust|NIHR UCLH Clinical Research Facility, University College of London NHS Foundation Trust|The Christie NHS Foundation Trust",Drug,"Belgium|China|France|Germany|Hong Kong|Italy|Korea, Republic of|Netherlands|Singapore|Spain|Taiwan|United Kingdom|United States",18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT03037385
NCT03037385,medullary thyroid cancer,"A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors","Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors","Adenocarcinoma|Adenocarcinoma, Papillary|Bronchial Neoplasms|Carcinoma|Carcinoma, Bronchogenic|Carcinoma, Neuroendocrine|Carcinoma, Non-Small-Cell Lung|Colonic Diseases|Colonic Neoplasms|Colorectal Neoplasms|Digestive System Disease|Digestive System Neoplasm|Endocrine Gland Neoplasm|Endocrine System Diseases|Gastrointestinal Disease|Gastrointestinal Neoplasms|Head and Neck Neoplasms|Intestinal Disease|Intestinal Neoplasms|Lung Diseases|Lung Neoplasm|Medullary Thyroid Cancer|Neoplasms|Neoplasms by Histologic Type|Neoplasms by Site|Neoplasms, Germ Cell and Embryonal|Neoplasms, Glandular and Epithelial|Neoplasms, Nerve Tissue|Neuroectodermal Tumors|Neuroendocrine Tumors|Respiratory Tract Disease|Respiratory Tract Neoplasms|RET-altered Colon Cancer|RET-altered Non Small Cell Lung Cancer|RET-altered Papillary Thyroid Cancer|RET-altered Solid Tumors|Thoracic Neoplasms|Thyroid Cancer, Papillary|Thyroid Diseases|Thyroid Neoplasm",2017-01-20,2023-12-31,2024-02-29,Interventional,Active not recruiting,Phase 1/Phase 2,Hoffmann-La Roche,Hoffmann-La Roche,"Mayo Clinic|UC Irvine Medical Center|University of Colorado Cancer Center|Georgetown University Medical Center|Mayo Clinic|University of Miami Hospitals and Clinics, Sylvester Comprehensive Cancer Center|Maryland Oncology Hematology, PA - Columbia|Massachusetts General Hospital|University of Michigan|Mayo Clinic|Washington University School of Medicine, Siteman Cancer Center|Albany Medical Center|Jack D. Weiler Hospital|Cornell University|Oregon Health and Science University|University of Pennsylvania Hospital|UPMC CancerCenter|Texas Oncology - Austin|Texas Oncology - Baylor Charles A. Sammons Cancer Center|University of Texas MD Anderson Cancer Center|University of Washington, Seattle Cancer Care Alliance|Antwerp University Hospital|Beijing Cancer Hospital|West China Hospital, Sichuan University|Sichuan Cancer Hospital & Institute|Chongqing Cancer Hospital|Fujian Provincial Cancer Hospital|First Affiliated Hospital of Gannan Medical University|Sun Yat-sen University Cancer Center|Guangdong Provincial People's Hospital|Nanfang Hospital of Southern Medical University|Zhejiang Provincial People's Hospital|Zhejiang Cancer Hospital|Anhui Provincial Cancer Hospital|Jinan Central Hospital|Gansu Provincial Cancer Hospital|Fudan University Shanghai Cancer Center|Liaoning Cancer Hospital & Institute|Tianjin Medical University Cancer Institute and Hospital|Union Hospital, Tongji Medical College, Huazhong University of Science and Technology|Henan Cancer Hospital|Institut Bergonié|CHRU de Lille - Hôpital Claude Hurier Servide d'Endocrinologie et Diabétologie|Centre Leon Berard|Centre Antoine Lacassagne|Hospital Tenon|Institut Curie|CHU de Rennes - Hôpital Pontchaillou|Insitut Claudius Regaud|Gustave Roussy|HELIOS Klinikum Emil von Behring|Universitätsklinikum Essen|Thoraxklinik Heidelberg|Klinikum der Universitat Munchen|Pius-Hospital Oldenberg|The Chinese University of Hong Kong|Istituto Europeo di Oncologia Sviluppo Nuovi Farmaci per Terapie Innovative|Grande Ospedale Metropolitano Niguarda|Ospedale Santa Maria delle Croci|Istituto Nazionale Tumori Regina Elena|Seoul National University Hospital|Severance Hospital|Asan Medical Center|Samsung Medical Center|Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis|University Medical Center Groningen|National Cancer Centre Singapore|Hospital Universitari Vall d'Hebron|Hospital Clinic Barcelona|Hospital Duran I Reynals|Hospital Universitario Ramon y Cajal|Hospital Universitario 12 de Octubre Servicio de Oncologia Medica|National Taiwan University Hospital|Taipei Veterans General Hospital|NHS Grampian - Aberdeen Royal Infirmary|Sarah Cannon Research Institute|Guy's Hospital St. Thomas NHS Foundation Trust|NIHR UCLH Clinical Research Facility, University College of London NHS Foundation Trust|The Christie NHS Foundation Trust",Drug,"Belgium|China|France|Germany|Hong Kong|Italy|Korea, Republic of|Netherlands|Singapore|Spain|Taiwan|United Kingdom|United States",18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, medullary",https://clinicaltrials.gov/ct2/show/NCT03037385
NCT03037385,thyroid diseases,"A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors","Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors","Adenocarcinoma|Adenocarcinoma, Papillary|Bronchial Neoplasms|Carcinoma|Carcinoma, Bronchogenic|Carcinoma, Neuroendocrine|Carcinoma, Non-Small-Cell Lung|Colonic Diseases|Colonic Neoplasms|Colorectal Neoplasms|Digestive System Disease|Digestive System Neoplasm|Endocrine Gland Neoplasm|Endocrine System Diseases|Gastrointestinal Disease|Gastrointestinal Neoplasms|Head and Neck Neoplasms|Intestinal Disease|Intestinal Neoplasms|Lung Diseases|Lung Neoplasm|Medullary Thyroid Cancer|Neoplasms|Neoplasms by Histologic Type|Neoplasms by Site|Neoplasms, Germ Cell and Embryonal|Neoplasms, Glandular and Epithelial|Neoplasms, Nerve Tissue|Neuroectodermal Tumors|Neuroendocrine Tumors|Respiratory Tract Disease|Respiratory Tract Neoplasms|RET-altered Colon Cancer|RET-altered Non Small Cell Lung Cancer|RET-altered Papillary Thyroid Cancer|RET-altered Solid Tumors|Thoracic Neoplasms|Thyroid Cancer, Papillary|Thyroid Diseases|Thyroid Neoplasm",2017-01-20,2023-12-31,2024-02-29,Interventional,Active not recruiting,Phase 1/Phase 2,Hoffmann-La Roche,Hoffmann-La Roche,"Mayo Clinic|UC Irvine Medical Center|University of Colorado Cancer Center|Georgetown University Medical Center|Mayo Clinic|University of Miami Hospitals and Clinics, Sylvester Comprehensive Cancer Center|Maryland Oncology Hematology, PA - Columbia|Massachusetts General Hospital|University of Michigan|Mayo Clinic|Washington University School of Medicine, Siteman Cancer Center|Albany Medical Center|Jack D. Weiler Hospital|Cornell University|Oregon Health and Science University|University of Pennsylvania Hospital|UPMC CancerCenter|Texas Oncology - Austin|Texas Oncology - Baylor Charles A. Sammons Cancer Center|University of Texas MD Anderson Cancer Center|University of Washington, Seattle Cancer Care Alliance|Antwerp University Hospital|Beijing Cancer Hospital|West China Hospital, Sichuan University|Sichuan Cancer Hospital & Institute|Chongqing Cancer Hospital|Fujian Provincial Cancer Hospital|First Affiliated Hospital of Gannan Medical University|Sun Yat-sen University Cancer Center|Guangdong Provincial People's Hospital|Nanfang Hospital of Southern Medical University|Zhejiang Provincial People's Hospital|Zhejiang Cancer Hospital|Anhui Provincial Cancer Hospital|Jinan Central Hospital|Gansu Provincial Cancer Hospital|Fudan University Shanghai Cancer Center|Liaoning Cancer Hospital & Institute|Tianjin Medical University Cancer Institute and Hospital|Union Hospital, Tongji Medical College, Huazhong University of Science and Technology|Henan Cancer Hospital|Institut Bergonié|CHRU de Lille - Hôpital Claude Hurier Servide d'Endocrinologie et Diabétologie|Centre Leon Berard|Centre Antoine Lacassagne|Hospital Tenon|Institut Curie|CHU de Rennes - Hôpital Pontchaillou|Insitut Claudius Regaud|Gustave Roussy|HELIOS Klinikum Emil von Behring|Universitätsklinikum Essen|Thoraxklinik Heidelberg|Klinikum der Universitat Munchen|Pius-Hospital Oldenberg|The Chinese University of Hong Kong|Istituto Europeo di Oncologia Sviluppo Nuovi Farmaci per Terapie Innovative|Grande Ospedale Metropolitano Niguarda|Ospedale Santa Maria delle Croci|Istituto Nazionale Tumori Regina Elena|Seoul National University Hospital|Severance Hospital|Asan Medical Center|Samsung Medical Center|Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis|University Medical Center Groningen|National Cancer Centre Singapore|Hospital Universitari Vall d'Hebron|Hospital Clinic Barcelona|Hospital Duran I Reynals|Hospital Universitario Ramon y Cajal|Hospital Universitario 12 de Octubre Servicio de Oncologia Medica|National Taiwan University Hospital|Taipei Veterans General Hospital|NHS Grampian - Aberdeen Royal Infirmary|Sarah Cannon Research Institute|Guy's Hospital St. Thomas NHS Foundation Trust|NIHR UCLH Clinical Research Facility, University College of London NHS Foundation Trust|The Christie NHS Foundation Trust",Drug,"Belgium|China|France|Germany|Hong Kong|Italy|Korea, Republic of|Netherlands|Singapore|Spain|Taiwan|United Kingdom|United States",18.0,120.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT03037385
NCT03044600,hyperparathyroidism,Gene Expression in Hyperparathyroidism: Identifying Molecular Differences in MEN1 Patients Versus Young MEN1 Negative Patients,Gene Expression in Hyperparathyroidism,Hyperparathyroidism|Parathyroid Disease,2017-02-03,2017-10-18,2017-10-18,Observational,Terminated,,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center,University of Texas MD Anderson Cancer Center,Other|Other,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03044600
NCT03048708,autoimmune thyroiditis,Changes in Thyroid Function Tests and Texture Following Bariatric Surgery Induced Weight Loss,Thyroid in Bariatric Surgery,Autoimmune Thyroiditis|Insulin Resistance|Obesity|Thyroid,2017-02-07,2013-12-31,2016-08-31,Interventional,Completed,Not Applicable,University Hospitals Coventry and Warwickshire NHS Trust,University Hospitals Coventry and Warwickshire NHS Trust,,Procedure,,18.0,65.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT03048708
NCT03048877,differentiated thyroid cancer,"A Randomized, Double-Blind, Placebo-Controlled Study of Apatinib in Locally Advanced or Metastatic Radioactive Iodine-refractory Differentiated Thyroid Cancer",Efficacy of Apatinib in Radioactive Iodine-refractory Differentiated Thyroid Cancer,Differentiated Thyroid Cancer,2017-02-03,2020-03-25,2022-07-31,Interventional,Active not recruiting,Phase 3,Peking Union Medical College Hospital,Peking Union Medical College Hospital,Nanjing PLA 81 Hospital|Peking Union Medical College Hospital,Drug|Drug,China,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Differentiated thyroid cancer, all",https://clinicaltrials.gov/ct2/show/NCT03048877
NCT03053115,hypothyroidism,"Combined Replacement Therapy With Levothyroxine and Liothyronine in Thyroidectomized Patients: Effects on Peripheral Tissues. A Prospective, Randomized, Controlled, Double-blind Study",Combined Replacement Therapy With Levothyroxine and Liothyronine in Thyroidectomized Patients,Hypothyroidism,2016-11-25,2021-12-31,2021-12-31,Interventional,Active not recruiting,Phase 2/Phase 3,Azienda USL Modena,Azienda USL Modena,AziendaUSLModena,Drug|Drug|Drug,Italy,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03053115
NCT03053999,hyperparathyroidism,Variables That Are Correlated to Developing Multiple Endocrine Neoplasia (MEN) and Pancreatic Neuroendocrine Tumors (PNET),Variables That Are Correlated to Developing Multiple Endocrine Neoplasia (MEN) and Pancreatic Neuroendocrine Tumors (PNET),Hyperparathyroidism|Multiple Endocrine Neoplasia|Pancreatic Neuroendocrine Tumors,2017-02-13,2022-10-31,2023-10-31,Observational,Recruiting,,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center,University of Texas MD Anderson Cancer Center,Other|Other,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03053999
NCT03057925,thyroid nodule,Ultrasound-guided Percutaneous Microwave Ablation for Benign Thyroid Nodules,Ultrasound-guided Percutaneous Microwave Ablation for Benign Thyroid Nodules,Thyroid Nodule,2017-02-12,2017-12-31,2018-12-31,Interventional,Unknown status,Not Applicable,First Affiliated Hospital of Wenzhou Medical University,First Affiliated Hospital of Wenzhou Medical University|Wenjun Wu,The First Affiliated Hospital of Wenzhou Medical University,Device,China,18.0,70.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03057925
NCT03064542,hyperthyroidism,"The Role of Thyroid Status in Regulating Brown Adipose Tissue Activity, White Adipose Tissue Partitioning and Resting Energy Expenditure","The Role of Thyroid Status in Regulating Brown Adipose Tissue Activity, White Adipose Tissue Partitioning and Resting Energy Expenditure",Hyperthyroidism,2017-02-09,2024-10-24,2024-10-24,Observational [Patient Registry],Active not recruiting,,"Clinical Nutrition Research Centre, Singapore","Agency for Science, Technology and Research|Clinical Nutrition Research Centre, Singapore","Tan Tock Seng Hospital, Endocrinology Clinic",Drug,Singapore,21.0,50.0,[18-65],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03064542
NCT03065218,thyroid cancer,"Evaluation of 99mTc Sestamibi Scans In Patients Who Have Differentiated Thyroid Cancer, Elevated Serum Thyroglobulin Levels, and Negative Diagnostic Imaging Studies",99mTc Sestamibi Scans In Thyroglobulin Positive Scan Negative Differentiated Thyroid Cancer (DTC) Patients,Thyroid Cancer,2016-10-27,2021-02-15,2021-02-15,Interventional,Terminated,Phase 4,Medstar Health Research Institute,Medstar Health Research Institute,Washington Hospital Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03065218
NCT03066076,graves disease,Prospective Randomized Clinical Trial of Total Thyroidectomy (Tx) Versus Thionamides (Anti-Thyroid Drugs) in Patients With Moderate-to-Severe Graves' Ophthalmopathy - a 1-year Follow-up,Total Thyroidectomy Versus Thionamides in Patients With Moderate-to-Severe Graves' Ophthalmopathy,Graves Disease|Graves Ophthalmopathy|Graves' Ophthalmopathy Worsened,2017-01-27,2019-02-01,2019-06-01,Interventional,Unknown status,Phase 3,Medical University of Vienna,Medical University of Vienna,Department of Surgery and Department of Ophthalmology Medical University Vienna,Drug|Procedure,Austria,18.0,85.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT03066076
NCT03066076,graves ophthalmopathy,Prospective Randomized Clinical Trial of Total Thyroidectomy (Tx) Versus Thionamides (Anti-Thyroid Drugs) in Patients With Moderate-to-Severe Graves' Ophthalmopathy - a 1-year Follow-up,Total Thyroidectomy Versus Thionamides in Patients With Moderate-to-Severe Graves' Ophthalmopathy,Graves Disease|Graves Ophthalmopathy|Graves' Ophthalmopathy Worsened,2017-01-27,2019-02-01,2019-06-01,Interventional,Unknown status,Phase 3,Medical University of Vienna,Medical University of Vienna,Department of Surgery and Department of Ophthalmology Medical University Vienna,Drug|Procedure,Austria,18.0,85.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT03066076
NCT03072654,"goiter, nodular",Thyroidectomy Improves Tracheal Anatomy and Airflow in Patients With Nodular Goiter: A Prospective Cohort Study,Tracheal Anatomy After Thyroidectomy,"Goiter, Nodular",2017-03-02,2017-03-01,2017-03-02,Observational,Completed,,University of Southern Denmark,University of Southern Denmark,,Procedure,,20.0,80.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03072654
NCT03085056,anaplastic thyroid cancer,A Pilot Study of Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer,Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer,Anaplastic Thyroid Cancer,2017-03-15,2023-09-30,2023-09-30,Interventional,Active not recruiting,Early Phase 1,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center|Novartis,Memoral Sloan Kettering Basking Ridge (Limited Protocol Activities)|Memoral Sloan Kettering Monmouth (Limited Protocol Activities)|Memorial Sloan Kettering Bergen (Limited Protocol Activities)|Memorial Sloan Kettering Cancer Center @ Commack (Limited Protocol Activities)|Memoral Sloan Kettering Westchester (Limited Protocol Activities)|Memorial Sloan Kettering Cancer Center|Memorial Sloan Kettering Nassau (Limited Protocol Activities),Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT03085056
NCT03085615,euthyroid sick syndromes,Feeding the Critically Ill During Phases of Altered Redox Status (FEDOX): a Prospective Randomized Trial,Feeding the Critically Ill During Phases of Altered Redox Status,Acute Respiratory Distress Syndrome|Euthyroid Sick Syndromes|Oxidative Stress|Systemic Inflammatory Response Syndrome,2017-03-15,2018-06-04,2018-10-13,Interventional,Completed,Not Applicable,University of Illinois at Chicago,American Society for Parenteral and Enteral Nutrition|Rush University Medical Center|University of Illinois at Chicago,Rush University Medical Center,Other,United States,18.0,120.0,[18-65]|[65 and more],Euthyroid Sick Syndromes,Euthyroid Sick Syndromes,https://clinicaltrials.gov/ct2/show/NCT03085615
NCT03095963,hypothyroidism,Effects of Probiotics Assumption on Serum Thyroid Hormone and TSH Levels in Hypothyroid Patients on Levothyroxine Treatment,Interaction Between Levothyroxine and Probiotics in Hypothyroid Patients,Hypothyroidism,2017-03-15,2016-10-25,2016-10-25,Interventional,Completed,Not Applicable,Azienda USL Modena,Azienda USL Modena,,Other|Drug,,18.0,65.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03095963
NCT03099356,metastatic thyroid cancer,"An Open Label Phase II Trial Evaluating the Efficacy of Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer","Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer",Metastatic Thyroid Cancer,2017-03-28,2022-05-12,2023-05-12,Interventional,Recruiting,Phase 2,University of Michigan Rogel Cancer Center,University of Michigan Rogel Cancer Center,University of Michigan Cancer Center,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Metastatic Thyroid Cancer,https://clinicaltrials.gov/ct2/show/NCT03099356
NCT03103607,thyroid eye disease,Evaluation of the Disappearance of Graves' Orbitopathy in the Long Term,Disappearance of Graves' Orbitopathy,Thyroid Eye Disease,2017-03-27,2014-12-31,2016-02-28,Observational,Completed,,University of Pisa,University of Pisa,,Diagnostic Test|Diagnostic Test,,18.0,100.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT03103607
NCT03103776,"thyroiditis, autoimmune",Involvement of Polyomaviruses in the Pathogenesis of Autoimmune Thyroiditis and Goitrigenesis.,Involvement of Polyomaviruses in the Pathogenesis of Autoimmune Thyroiditis and Goitrigenesis.,"Polyoma Virus Infection|Thyroiditis, Autoimmune",2017-03-31,2018-10-31,2018-10-31,Interventional,Unknown status,Not Applicable,"Centre Hospitalier Universitaire, Amiens","Centre Hospitalier Universitaire, Amiens",CHU Amiens Picardie,Other,France,18.0,120.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT03103776
NCT03106337,thyroid nodule,A Multivariate Analysis of Factors Predictive of Carcinoma in Follicular Neoplasms of the Thyroid Gland,Diagnostic Accuracy of Shear-Wave Elastography for the Preoperative Risk Stratification of Follicular Lesions of the Thyroid,Follicular Neoplasm|Thyroid Nodule,2014-04-25,2012-04-30,2012-04-30,Interventional,Completed,Not Applicable,Massachusetts General Hospital,Massachusetts General Hospital,Massachusetts General Hospital,Device,United States,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03106337
NCT03110835,thyroid diseases,Use of Low-dose Radioiodine for Ablation of Thyroid Remnants in Patients With Graves' Disease Following Thyroidectomy,Low-dose Radioiodine Ablation in Graves' Disease,Thyroid Diseases,2017-03-14,2017-03-28,2017-03-28,Observational,Completed,,University of Pisa,University of Pisa,,Radiation,,18.0,80.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT03110835
NCT03122847,graves ophthalmopathy,The Effect of 4.5 Gram Methylprednisolone Administered Once Weekly for 12 Weeks on Bone Metabolism in Graves´ Ophthalmopathy,Glucocorticoids and Bone in Graves' Ophthalmopathy,Graves Ophthalmopathy,2017-04-18,2022-07-31,2023-07-31,Observational,Active not recruiting,,Aarhus University Hospital,Odense University Hospital|Torben Harsløf,Aarhus University Hospital|Odense University Hospital,Drug,Denmark,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT03122847
NCT03127098,thyroid cancer,"Phase 1b/2 Study of ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer","QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer",Breast Cancer|Colon Cancer|Lung Cancer|Ovarian Cancer|Pancreatic Cancer|Thyroid Cancer,2017-04-20,2017-12-07,2017-12-07,Interventional,Completed,Phase 1/Phase 2,"NantCell, Inc.","NantCell, Inc.",Medical Oncology Associates,Biological|Biological,United States,21.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03127098
NCT03128255,thyroid nodule,"I-124 PET/US for Benign Thyroid Diseases - Blinded, Multicentric Assessment of Augmented Thyroid Work-up Versus Regular Thyroid Diagnostics",Fusion UltraSound Imaging Of the Thyroid GlaNd With I-124 PET. Evaluation of Nodule Allocation.,Thyroid Diseases|Thyroid Goitre|Thyroid Nodule,2017-04-20,2017-07-31,2018-04-30,Observational,Unknown status,,Jena University Hospital,GE Healthcare|Jena University Hospital,University Hospital Jena,Other,Germany,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03128255
NCT03128255,thyroid diseases,"I-124 PET/US for Benign Thyroid Diseases - Blinded, Multicentric Assessment of Augmented Thyroid Work-up Versus Regular Thyroid Diagnostics",Fusion UltraSound Imaging Of the Thyroid GlaNd With I-124 PET. Evaluation of Nodule Allocation.,Thyroid Diseases|Thyroid Goitre|Thyroid Nodule,2017-04-20,2017-07-31,2018-04-30,Observational,Unknown status,,Jena University Hospital,GE Healthcare|Jena University Hospital,University Hospital Jena,Other,Germany,18.0,120.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT03128255
NCT03131726,graves ophthalmopathy,Treatment of Graves´Ophthalmopathy With Simvastatin (GO-DS),Treatment of Graves´Ophthalmopathy With Simvastatin (GO-DS),Graves Ophthalmopathy|Thyroid Associated Ophthalmopathy|Thyroid Associated Orbitopathy,2017-03-10,2024-01-26,2024-03-30,Interventional,Recruiting,Phase 3,Lund University,Lund University,"Dpt. of Endocrinology, SUS Malmö",Drug,Sweden,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT03131726
NCT03139747,thyroid cancer,UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib Alone,UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib Alone,Thyroid Cancer,2017-05-02,2022-05-30,2022-05-30,Interventional,Suspended,Phase 2,Thomas Jefferson University,Thomas Jefferson University,Abramson Cancer Center of the University of Pennsylvania,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03139747
NCT03150108,hypoparathyroidism,"A Phase 1, Open-label, Randomized, Cross-over Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single Dose of rhPTH(1-84) Administered Subcutaneously in Japanese Healthy Subjects Compared With Matched Non-Hispanic, Caucasian Healthy Adult Subjects and to Assess Dose Proportionality of 3 Doses of rhPTH(1-84) in the Japanese Subjects",Study of rhPTH(1-84) in Japanese Healthy Subjects Compared With Matched Caucasian Healthy Adult Subjects,Hypoparathyroidism,2017-05-01,2017-06-26,2017-06-26,Interventional,Completed,Phase 1,Takeda,Shire,Glendale Adventist Medical Center,Drug|Drug|Drug,United States,18.0,65.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03150108
NCT03157128,medullary thyroid cancer,"A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)","A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)",Any Solid Tumor|Colon Cancer|Medullary Thyroid Cancer|Non-Small Cell Lung Cancer,2017-05-09,2022-11-21,2023-11-21,Interventional,Recruiting,Phase 1/Phase 2,Eli Lilly and Company,"Eli Lilly and Company|Loxo Oncology, Inc.","Mayo Clinic of Scottsdale|City of Hope National Medical Center|University of California - San Diego|UCLA Medical Center|Hoag Memorial Hospital Presbyterian|Irvine Medical Center|UCSF Medical Center at Mission Bay|Kaiser Permanente|Kaiser Permanente Medical Center|Sarah Cannon Research Institute at HealthOne|Yale Cancer Center|Johns Hopkins University|Mayo Clinic in Florida|Memorial Hospital Pembroke|Emory University|University of Chicago Medicine-Comprehensive Cancer Center|Ochsner Clinic Foundation|University of Maryland Medical Center|Massachusetts General Hospital|Dana-Farber Cancer Institute|University of Michigan|START Midwest|Mayo Clinic|Washington University Medical School|Comprehensive Cancer Centers of Nevada|Roswell Park Cancer Institute|NYU Langone|Memorial Sloan Kettering Cancer Center|University of North Carolina|Cleveland Clinic Foundation|Ohio State University Hospital|Oregon Health and Science University|University of Pennsylvania Hospital|Thomas Jefferson University|Sarah Cannon Research Institute SCRI|Vanderbilt University Medical Center|University of Texas Southwestern Medical Center at Dallas|University of Texas MD Anderson Cancer Center|Huntsman Cancer Institute|Virginia Cancer Specialists, PC|University of Wisconsin-Madison Hospital and Health Clinic|Royal North Shore Hospital|Peter MacCallum Cancer Centre|BC Cancer Vancouver|Rigshospitalet|Hôpital Européen Georges Pompidou|Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest|Centre Leon Berard|APHM Hôpital de la Timone|Institut du Cancer de Montpellier - Val d'aurelle|Gustave Roussy|Universitätsklinikum Würzburg A. ö. R.|Universitätsklinikum Köln|Prince of Wales Hospital|Sheba Medical Center|Shaare Zedek Medical Center|Soroka Medical Center - Pediatric Outpatient Clinic|Hadassah Medical Center|Istituto Nazionale dei Tumori|Nagoya University Hospital|National Cancer Center Hospital East|Hokkaido University Hospital|Hyogo Cancer Center|Kanazawa University Hospital|Kindai University Hospital|Shizuoka Cancer Center|National Cancer Center Hospital|Japanese Foundation for Cancer Research|Tottori University Hospital|National Hospital Organization Kyushu Cancer Center|Okayama University Hospital|Osaka City General Hospital|National Cancer Center|Seoul National University Bundang Hospital|Asan Medical Center|Samsung Medical Center|Severance Hospital, Yonsei University Health System|National Cancer Centre Singapore|Hospital Universitari Vall d'Hebron|Hospital Universitario Fundación Jiménez Díaz|Hospital Madrid Norte Sanchinarro|Kantonsspital Luzern|Taichung Veterans General Hospital|National Taiwan University Hospital|Royal Marsden Hospital",Drug,"Australia|Canada|Denmark|France|Germany|Hong Kong|Israel|Italy|Japan|Korea, Republic of|Singapore|Spain|Switzerland|Taiwan|United Kingdom|United States",12.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, medullary",https://clinicaltrials.gov/ct2/show/NCT03157128
NCT03157466,thyroid diseases,Diaphragmatic Efficiency After Thyroid Hormone Replacement Therapy in Ventilated Patients With the Nonthyroidal Illness Syndrome: a Physiological Study,Respiratory Muscle Function After Thyroid Hormone Replacement Therapy in Nonthyroidal Illness Syndrome,Respiratory Failure|Thyroid Diseases,2017-05-12,2018-05-01,2018-05-01,Observational,Completed,,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,Fondazione Policlinico Universitario Agostino Gemelli,,Italy,18.0,120.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT03157466
NCT03158961,thyroid diseases,A Prospective Evaluation of the Feasibility and Safety of the Transoral Endoscopic Thyroidectomy Vestibular Approach (TOETVA) as a Treatment for Benign Thyroid Nodules,The Feasibility and Safety of the TOETVA for Benign Thyroid Nodules,Thyroid Diseases,2017-05-15,2019-05-31,2019-07-31,Interventional,Completed,Not Applicable,The University of Hong Kong,The University of Hong Kong,Queen Mary Hospital,Procedure,Hong Kong,18.0,120.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT03158961
NCT03160274,thyroid neoplasms,"Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions","Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions",Associated Conditions|Bone Cancer|Inherited Cancer Syndrome|Kidney Neoplasms|Other Cancer|Paraganglioma|Pheochromocytoma|Thyroid Neoplasms,2017-05-05,2030-12-31,2030-12-31,Observational [Patient Registry],Recruiting,,The University of Texas Health Science Center at San Antonio,National Institute of General Medical Sciences (NIGMS)|The University of Texas Health Science Center at San Antonio,University of Texas Health Science Center,Genetic,United States,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03160274
NCT03160482,thyroid nodule,Evaluation of PACE4 Isoforms as Biomarkers in Thyroid Cancer,PACE4 in Thyroid Cancer,Thyroid Nodule,2017-05-16,2018-01-15,2018-01-15,Observational,Completed,,Université de Sherbrooke,Robert Day,CIUSSS de l'Estrie - CHUS,Diagnostic Test,Canada,18.0,100.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03160482
NCT03170804,thyroid cancer,Registry for Genomic Profiling of Nodular Thyroid Disease and Thyroid Cancer,Genomic Profiling of Nodular Thyroid Disease and Thyroid Cancer,Thymic Carcinoma|Thyroid Cancer|Thyroid Diseases|Thyroid Nodule,2017-05-25,2018-01-01,2020-01-01,Observational [Patient Registry],Unknown status,,Aventura Hospital and Medical Center,Aventura Hospital and Medical Center,Aventura Hospital and Medical Center,,United States,16.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03170804
NCT03170804,thyroid nodule,Registry for Genomic Profiling of Nodular Thyroid Disease and Thyroid Cancer,Genomic Profiling of Nodular Thyroid Disease and Thyroid Cancer,Thymic Carcinoma|Thyroid Cancer|Thyroid Diseases|Thyroid Nodule,2017-05-25,2018-01-01,2020-01-01,Observational [Patient Registry],Unknown status,,Aventura Hospital and Medical Center,Aventura Hospital and Medical Center,Aventura Hospital and Medical Center,,United States,16.0,120.0,[0-17]|[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03170804
NCT03170804,thyroid diseases,Registry for Genomic Profiling of Nodular Thyroid Disease and Thyroid Cancer,Genomic Profiling of Nodular Thyroid Disease and Thyroid Cancer,Thymic Carcinoma|Thyroid Cancer|Thyroid Diseases|Thyroid Nodule,2017-05-25,2018-01-01,2020-01-01,Observational [Patient Registry],Unknown status,,Aventura Hospital and Medical Center,Aventura Hospital and Medical Center,Aventura Hospital and Medical Center,,United States,16.0,120.0,[0-17]|[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT03170804
NCT03170960,differentiated thyroid cancer,A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors,Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors,Castration-resistant Prostate Cancer|Colorectal Cancer|Differentiated Thyroid Cancer|Endometrial Cancer|Gastric Cancer|Gastroesophageal Junction Adenocarcinoma|Head and Neck Cancer|Hepatocellular Carcinoma|Lower Esophageal Cancer|Non-Small Cell Lung Cancer|Ovarian Cancer|Renal Cell Carcinoma|Triple Negative Breast Cancer|Urothelial Carcinoma,2017-05-23,2022-12-31,2022-12-31,Interventional,Active not recruiting,Phase 1/Phase 2,Exelixis,Exelixis,Exelixis Clinical Site #53|Exelixis Clinical Site #18|Exelixis Clinical Site #1|Exelixis Clinical Site #20|Exelixis Clinical Site #46|Exelixis Clinical Site #51|Exelixis Clinical Site #62|Exelixis Clinical Site #21|Exelixis Clinical Site #34|Exelixis Clinical Site #50|Exelixis Clinical Site #42|Exelixis Clinical Site #48|Exelixis Clinical Site #16|Exelixis Clinical Site #76|Exelixis Clinical Site #60|Exelixis Clinical Site #79|Exelixis Clinical Site #32|Exelixis Clinical Site #23|Exelixis Clinical Site #57|Exelixis Clinical Site #24|Exelixis Clinical Site #10|Exelixis Clinical Site #3|Exelixis Clinical Site #17|Exelixis Clinical Site #65|Exelixis Clinical Site #43|Exelixis Clinical Site #35|Exelixis Clinical Site #59|Exelixis Clinical Site #61|Exelixis Clinical Site #38|Exelixis Clinical Site #27|Exelixis Clinical Site #31|Exelixis Clinical Site #37|Exelixis Clinical Site #40|Exelixis Clinical Site #11|Exelixis Clinical Site #67|Exelixis Clinical Site #49|Exelixis Clinical Site #64|Exelixis Clinical Site #71|Exelixis Clinical Site #6|Exelixis Clinical Site #102|Exelixis Clinical Site #45|Exelixis Clinical Site #41|Exelixis Clinical Site #15|Exelixis Clinical Site #55|Exelixis Clinical Site #66|Exelixis Clinical Site #95|Exelixis Clinical Site #13|Exelixis Clinical Site #26|Exelixis Clinical Site #114|Exelixis Clinical Site #29|Exelixis Clinical Site #39|Exelixis Clinical Site #44|Exelixis Clinical Site #33|Exelixis Clinical Site #63|Exelixis Clinical Site #2|Exelixis Clinical Site #30|Exelixis Clinical Site #14|Exelixis Clinical Site #98|Exelixis Clinical Site #101|Exelixis Clinical Site #115|Exelixis Clinical Site #112|Exelixis Clinical Site #123|Exelixis Clinical Site #99|Exelixis Clinical Site #52|Exelixis Clinical Site #54|Exelixis Clinical Site #88|Exelixis Clinical Site #8|Exelixis Clinical Site #92|Exelixis Clinical Site #93|Exelixis Clinical Site #87|Exelixis Clinical Site #69|Exelixis Clinical Site #97|Exelixis Clinical Site #89|Exelixis Clinical Site #109|Exelixis Clinical Site #104|Exelixis Clinical Site #80|Exelixis Clinical Site #78|Exelixis Clinical Site #7|Exelixis Clinical Site #68|Exelixis Clinical Site #72|Exelixis Clinical Site #82|Exelixis Clinical Site #119|Exelixis Clinical Site #107|Exelixis Clinical Site #105|Exelixis Clinical Site #56|Exelixis Clinical Site #36|Exelixis Clinical Site #84|Exelixis Clinical Site #47|Exelixis Clinical Site #108|Exelixis Clinical Site #103|Exelixis Clinical Site #25|Exelixis Clinical Site #4|Exelixis Clinical Site #85|Exelixis Clinical Site #121|Exelixis Clinical Site #110|Exelixis Clinical Site #12|Exelixis Clinical Site #74|Exelixis Clinical Site #91|Exelixis Clinical Site #94|Exelixis Clinical Site #70|Exelixis Clinical Site #113|Exelixis Clinical Site #116|Exelixis Clinical Site #96|Exelixis Clinical Site #90|Exelixis Clinical Site #117|Exelixis Clinical Site #75|Exelixis Clinical Site #58|Exelixis Clinical Site #83|Exelixis Clinical Site #86|Exelixis Clinical Site #28|Exelixis Clinical Site #9|Exelixis Clinical Site #73|Exelixis Clinical Site #118|Exelixis Clinical Site #77|Exelixis Clinical Site #106|Exelixis Clinical Site #111|Exelixis Clinical Site #22|Exelixis Clinical Site #5|Exelixis Clinical Site #81|Exelixis Clinical Site #100|Exelixis Clinical Site #122|Exelixis Clinical Site #120|Exelixis Clinical Site #124|Exelixis Clinical Site #19,Drug|Drug|Drug|Drug,Australia|Belgium|France|Germany|Italy|Netherlands|Spain|United Kingdom|United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Differentiated thyroid cancer, all",https://clinicaltrials.gov/ct2/show/NCT03170960
NCT03174925,thyroid gland nodule,Elastography in Thyroid Nodule Evaluation,Ultrasound Elastography in Imaging Patients With Thyroid Nodules,Malignant Thyroid Gland Neoplasm|Thyroid Gland Nodule,2017-05-18,2018-02-13,2019-02-13,Interventional,Completed,Not Applicable,Stanford University,Stanford University,"Stanford University, School of Medicine",Device,United States,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03174925
NCT03176485,differentiated thyroid cancer,"Pilot Study to Evaluate the Signaling Pathway Modulation Demonstrated by Raf, MEK, and Kinase Inhibitors In Human Skin With or Without Solar Simulated Light","Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors",Colon Cancer|Differentiated Thyroid Cancer|HCC|Hepatocellular Carcinoma|Melanoma|Metastatic Cancer|Metastatic Colon Cancer|Metastatic Melanoma|Renal Cell Carcinoma,2017-06-01,2018-11-01,2018-11-01,Interventional,Completed,Not Applicable,University of Arizona,University of Arizona,University of Arizona Cancer Center,Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Differentiated thyroid cancer, all",https://clinicaltrials.gov/ct2/show/NCT03176485
NCT03180892,hypothyroidism,Non-immune Related Hypothyroidism in Iodine Sufficient Area,Non-immune Related Hypothyroidism in Iodine Sufficient Area,Hypothyroidism,2017-06-02,2016-12-31,2016-12-31,Observational [Patient Registry],Completed,,Samsung Medical Center,Samsung Medical Center,,Other,,18.0,80.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03180892
NCT03181100,poorly differentiated thyroid gland carcinoma,Atezolizumab Combinations With Chemotherapy for Anaplastic and Poorly Differentiated Thyroid Carcinomas,Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer,Metastatic Thyroid Gland Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v8|Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8|Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8|Thyroid Gland Anaplastic Carcinoma|Unresectable Thyroid Gland Carcinoma,2017-06-06,2023-07-27,2023-07-27,Interventional,Recruiting,Phase 2,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center|National Cancer Institute (NCI),M D Anderson Cancer Center,Drug|Biological|Drug|Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Poorly differentiated thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03181100
NCT03181100,thyroid gland anaplastic carcinoma,Atezolizumab Combinations With Chemotherapy for Anaplastic and Poorly Differentiated Thyroid Carcinomas,Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer,Metastatic Thyroid Gland Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v8|Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8|Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8|Thyroid Gland Anaplastic Carcinoma|Unresectable Thyroid Gland Carcinoma,2017-06-06,2023-07-27,2023-07-27,Interventional,Recruiting,Phase 2,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center|National Cancer Institute (NCI),M D Anderson Cancer Center,Drug|Biological|Drug|Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT03181100
NCT03181100,metastatic thyroid gland carcinoma,Atezolizumab Combinations With Chemotherapy for Anaplastic and Poorly Differentiated Thyroid Carcinomas,Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer,Metastatic Thyroid Gland Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v8|Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8|Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8|Thyroid Gland Anaplastic Carcinoma|Unresectable Thyroid Gland Carcinoma,2017-06-06,2023-07-27,2023-07-27,Interventional,Recruiting,Phase 2,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center|National Cancer Institute (NCI),M D Anderson Cancer Center,Drug|Biological|Drug|Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Metastatic Thyroid Cancer,https://clinicaltrials.gov/ct2/show/NCT03181100
NCT03183752,thyroid nodule,The Role of Insulin Resistance and the Effect of Metformin Use on Volume of Benign Thyroid Nodules,Insulin Resistance and Metformin Use on Volume of Benign Thyroid Nodules,Insulin Resistance|Thyroid Nodule,2017-06-08,2018-10-17,2019-04-17,Interventional,Completed,Not Applicable,Hospital Universitário Clementino Fraga Filho,Hospital Universitário Clementino Fraga Filho,Patricia Santos,Drug|Drug,Brazil,18.0,80.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03183752
NCT03191643,differentiated thyroid cancer,18F-FDG PET-guided External Beam Radiotherapy in Iodine-refractory Differentiated Thyroid Cancer,PET-guided External Beam Radiotherapy in Differentiated Thyroid Cancer,Differentiated Thyroid Cancer,2017-06-15,2016-01-31,2016-01-31,Observational,Completed,,IRCCS Azienda Ospedaliero-Universitaria di Bologna,IRCCS Azienda Ospedaliero-Universitaria di Bologna,,,,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Differentiated thyroid cancer, all",https://clinicaltrials.gov/ct2/show/NCT03191643
NCT03195296,graves ophthalmopathy,T and B Cells Infiltrating Orbital Tissues in Graves' Orbitopathy (GO) and Their Relation With GO Features,T and B Cells in Graves' Orbitopathy,Graves Ophthalmopathy,2017-06-19,2017-05-31,2017-05-31,Observational,Completed,,University of Pisa,University of Pisa,,Other,,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT03195296
NCT03196518,thyroid cancer,PET Imaging of Thyroid Tissue Expressing Sodium-iodine Symporter Using the New Tracer 18F-tetrafluoroborate (18F-TFB),Study of PET Imaging With 18F-TFB in Patients With Thyroid Cancer,Thyroid Cancer,2017-06-21,2023-06-30,2023-06-30,Interventional,Recruiting,Not Applicable,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Procedure|Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03196518
NCT03202160,goiter,Cases of Goiter in Children Attending Assiut University Children Hospital,Causes of Goiter in Children Attending Assiut University Children Hospital,Goiter,2017-06-27,2019-04-15,2019-09-15,Observational,Unknown status,,Assiut University,Assiut University,,,,0.0,18.0,[0-17]|[18-65],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03202160
NCT03203668,hyperparathyroidism,Diagnostic Value of 18F-fluorocholine PET/CT Imaging in Localization of Hyperfunctioning Parathyroid Tissue in Hyperparathyroidism,18F-fluorocholine PET/CT Imaging in Hyperparathyroidism,Hyperparathyroidism,2017-04-17,2020-12-31,2020-12-31,Interventional,Unknown status,Not Applicable,University Medical Centre Ljubljana,Institute of Oncology Ljubljana|University Medical Centre Ljubljana,"Department for nuclear medicine, University medical centre Ljubljana",Radiation,Slovenia,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03203668
NCT03215095,thyroid cancer,"Radioiodine (RAI) in Combination With Durvalumab (Medi4736) for RAI-avid, Recurrent/Metastatic Thyroid Cancers",RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers,Thyroid Cancer,2017-07-11,2023-07-31,2023-07-31,Interventional,Active not recruiting,Early Phase 1,Memorial Sloan Kettering Cancer Center,AstraZeneca|MedImmune LLC|Memorial Sloan Kettering Cancer Center,Memoral Sloan Kettering Basking Ridge|Memoral Sloan Kettering Monmouth|Memorial Sloan Kettering Bergen|Memorial Sloan Kettering Commack|Memorial Sloan Kettering Westchester|Memorial Sloan Kettering Cancer Center|Memorial Sloan Kettering Nassau,Drug|Radiation,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03215095
NCT03246659,medullary thyroid carcinoma,Phase I Clinical Trial Using a Novel CCK-2/Gastrin Receptor-localizing Radiolabelled Peptide Probe for Personalized Diagnosis and Therapy of Patients With Progressive or Metastatic Medullary Thyroid Carcinoma,Radiolabelled CCK-2/Gastrin Receptor Analogue for Personalized Theranostic Strategy in Advanced MTC,Medullary Thyroid Carcinoma,2017-07-28,2018-11-30,2018-11-30,Interventional,Completed,Phase 1,"Azienda Ospedaliero, Universitaria Pisana","Erasmus Medical Center|INRASTES, NCSR Demokritos, Athens, Greece|Jagiellonian University|Medical University Innsbruck|NATIONAL CENTRE FOR NUCLEAR RESEARCH, Poland|Paola Anna Erba|University Hospital Freiburg|University Medical Centre Ljubljana","Department of Nuclear Medicine, Innsbruck Medical University|Department of Nuclear Medicine, University Hospital Freiburg|Erasmus University Rotterdam|Department of Endocrinology, Jagiellonian University Medical College|Department of Nuclear Medicine, University Medical Centre Ljubljana",Drug|Drug,Austria|Germany|Netherlands|Poland|Slovenia,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, medullary",https://clinicaltrials.gov/ct2/show/NCT03246659
NCT03246958,thyroid cancer,"A Phase 2 Study of Nivolumab Plus Ipilimumab in RAI Refractory, Aggressive Thyroid Cancer With Exploratory Cohorts in Medullary and Anaplastic Thyroid Cancer",Nivolumab Plus Ipilimumab in Thyroid Cancer,Thyroid Cancer,2017-08-08,2022-12-31,2025-03-31,Interventional,Active not recruiting,Phase 2,Dana-Farber Cancer Institute,Bristol-Myers Squibb|Dana-Farber Cancer Institute,Dana Farber Cancer Institute,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03246958
NCT03257566,hypothyroidism,Risk Factors of Incidence of Hypothyroidism in Patients With Type 1 Diabetes,Hypothyroidism in Patients With Type 1 Diabetes,Hypothyroidism,2017-08-15,2019-07-31,2019-09-30,Observational,Unknown status,,Assiut University,Assiut University,,,,8.0,15.0,[0-17],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03257566
NCT03257930,thyroid nodule,Percutaneous Ethanol Injection for Benign Cystic Thyroid Nodules,Percutaneous Ethanol Injection for Benign Cystic Thyroid Nodules,Thyroid Nodule,2017-08-17,2018-07-11,2019-01-01,Interventional,Completed,Phase 1,Assiut University,hassan harby mohamed,Assiut University,Drug,Egypt,15.0,60.0,[0-17]|[18-65],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03257930
NCT03268785,thyroid cancer,Intra-operative Rapid Identification of Lymph Node and Parathyroid by Fine Needle Puncture for Thyroid Carcinoma,Intra-operative Rapid Identification of Lymph Node and Parathyroid,Hypocalcemia|Hypoparathyroidism Postprocedural|Parathyroid; Absent|Thyroid Cancer,2017-08-28,2018-08-01,2020-08-01,Interventional,Unknown status,Not Applicable,Xijing Hospital,Xijing Hospital,Xijing hospital|Xijing Hospital,Diagnostic Test,China,18.0,60.0,[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03268785
NCT03278964,graves ophthalmopathy,"Comparative Morphometric, Functional and Psychosocial Analysis Between the Results of Two Surgical Techniques of Orbital Decompression in Patients With Graves Orbitopathy",Analysis Between the Results of Two Surgical Techniques of Orbital Decompression in Patients With Graves Orbitopathy,Graves Ophthalmopathy,2017-09-04,2019-01-31,2019-01-31,Interventional,Completed,Not Applicable,University of Sao Paulo General Hospital,University of Sao Paulo General Hospital,University of Sao Paulo General Hospital,Procedure,Brazil,21.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT03278964
NCT03285230,thyroid cancer,The French E3N Prospective Cohort Study (Etude Epidémiologique auprès de Femmes de la Mutuelle Générale de l'Education Nationale),The French E3N Prospective Cohort Study,Asthma|Breast Cancer|Cardiovascular Diseases|Colo-rectal Cancer|Crohn Disease|Depression|Diabetes|Endometrial Cancer|Endometriosis|Hypertension|Inflammatory Bowel Diseases|Melanoma|Parkinson Disease|Thyroid Cancer,2017-07-27,1991-11-15,2025-12-15,Observational,Active not recruiting,,"Institut National de la Santé Et de la Recherche Médicale, France","Gustave Roussy, Cancer Campus, Grand Paris|Institut National de la Santé Et de la Recherche Médicale, France|Ligue contre le cancer, France|Université Paris-Sud",,,,40.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03285230
NCT03289403,autoimmune thyroiditis,The Role of Immunomodulatory Treatment in Success of ICSI in Patients Who Have Infertility With Autoimmune Thyroiditis,The Role of Immunomodulatory Treatment in Success of ICSI in Patients With Autoimmune Thyroiditis,Autoimmune Thyroiditis|Infertility,2017-09-17,2019-09-15,2019-10-20,Interventional,Completed,Phase 2,Aljazeera Hospital,Aljazeera Hospital,Aljazeera (Al Gazeera) hospital,Drug|Drug,Egypt,18.0,35.0,[18-65],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT03289403
NCT03294005,thyroid cancer,Clinical Prediction Thyroid Cancer With Thyroid Ultrasonography,Clinical Prediction Thyroid Cancer With Thyroid Ultrasonography,Thyroid Cancer,2017-09-22,2020-06-30,2020-06-30,Observational,Completed,,China Medical University Hospital,China Medical University Hospital,China Medical University Hospital,Diagnostic Test,Taiwan,20.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03294005
NCT03295955,thyroid nodule,Comparing Efficacy of Postoperative Antibiotic Use in Transoral Thyroidectomy: a Prospective Randomized Controlled Trial Study,Comparing Efficacy of Postoperative Oral Antibiotic Use in Trans-Oral Thyroidectomy,Surgical Wound Infection|Thyroid Nodule,2017-09-20,2018-09-03,2018-12-03,Interventional,Unknown status,Not Applicable,Seoul National University Hospital,Seoul National University Hospital,Jin Wook Yi,Drug,"Korea, Republic of",20.0,70.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03295955
NCT03298867,thyroid eye disease,"A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating Teprotumumab (HZN-001) Treatment in Subjects With Active Thyroid Eye Disease","Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study",Graves' Orbitopathy|Thyroid Eye Disease,2017-09-27,2019-02-13,2020-11-30,Interventional,Completed,Phase 3,"Horizon Pharma USA, Inc.","Horizon Pharma USA, Inc.","Macro, Llc|Cedars-Sinai Medical Center|The Lennar Foundation Medical|Bascom Palmer Eye Institute|Kellogg Eye Center at University of Michigan|Casey Eye Institute at Oregon Health and Science University|Hamilton Eye Institute at University of Tennessee Health Science Center|Eye Wellness Center|Medical College of Wisconsin, The Eye Institute|University Hospital Essen, Department of Ophthalmology|Johannes Gutenberg University Medical Center|Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico|University of Pisa, Department of Clinical and Experimental Medicine|University of Pisa,Department of Clinical and Experimental Medicine, Endocrinology Unit",Biological|Other,Germany|Italy|United States,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT03298867
NCT03300765,thyroid cancer,Intensity Modulated Radiation Therapy Combined With Apatinib for Inoperable or Iodine Refractory Thyroid Cancer: A Phase II Single-arm Study,Trail Evaluating Apatinib With IMRT for Inoperable or Iodine Refractory Thyroid Cancer,Thyroid Cancer,2017-09-26,2019-07-01,2020-05-01,Interventional,Unknown status,Phase 2,Fudan University,"Xiayun He, MD",Fudan University Shanghai Cancer Center,Drug|Radiation,China,18.0,80.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03300765
NCT03303053,hyperthyroidism,"A Multi-center, Open Label, Randomised Parallel- Group Study to Compare the Efficacy of Cholestyramine Plus Standard Treatment Versus Prednisolone Plus Standard Treatment Versus Standard Treatment Alone in Treatment of Overt Hyperthyroidism",Efficacy and Safety of Cholestyramine and Prednisolone as Adjunctive Therapy in Treatment of Overt Hyperthyroidism,Graves Disease|Hyperthyroidism,2017-09-13,2018-03-01,2018-03-01,Interventional,Unknown status,Phase 3,"Clinical Research Centre, Malaysia","Clinical Research Centre, Malaysia|Ministry of Health, Malaysia",Hospital Queen Elizabeth 2|Hospital Ampang|Hospital Putrajaya,Drug|Drug|Drug,Malaysia,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03303053
NCT03303053,graves disease,"A Multi-center, Open Label, Randomised Parallel- Group Study to Compare the Efficacy of Cholestyramine Plus Standard Treatment Versus Prednisolone Plus Standard Treatment Versus Standard Treatment Alone in Treatment of Overt Hyperthyroidism",Efficacy and Safety of Cholestyramine and Prednisolone as Adjunctive Therapy in Treatment of Overt Hyperthyroidism,Graves Disease|Hyperthyroidism,2017-09-13,2018-03-01,2018-03-01,Interventional,Unknown status,Phase 3,"Clinical Research Centre, Malaysia","Clinical Research Centre, Malaysia|Ministry of Health, Malaysia",Hospital Queen Elizabeth 2|Hospital Ampang|Hospital Putrajaya,Drug|Drug|Drug,Malaysia,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT03303053
NCT03324022,graves ophthalmopathy,Observing the Relationship of Fibroblast Growth Factor and Fibroblast in Thyroid Eye Disease,Observing the Relationship of Fibroblast Growth Factor and Fibroblast in Thyroid Eye Disease,Graves Ophthalmopathy,2017-10-16,2017-12-25,2020-12-25,Observational,Unknown status,,National Taiwan University Hospital,National Taiwan University Hospital,"National Taiwan University Hospital Taipei, Taiwan",,Taiwan,20.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT03324022
NCT03324880,hypoparathyroidism,"A Randomized, Double-blind, Placebo-controlled, Adaptive Study to Evaluate Symptom Improvement and Metabolic Control Among Adult Subjects With Symptomatic Hypoparathyroidism Treated With Recombinant Human Parathyroid Hormone [rhPTH(1-84)]",A Study to Learn if Recombinant Human Parathyroid Hormone [rhPTH(1-84)] Can Improve Symptoms and Metabolic Control in Adults With Hypoparathyroidism (BALANCE),Hypoparathyroidism,2017-10-10,2022-05-10,2022-05-10,Interventional,Recruiting,Phase 4,Takeda,Shire,"University of Chicago|Michigan Bone and Mineral Clinic|Mayo Clinic - PPDS|Physicians East PA|Ohio State University Wexner Medical Center|Children's Hospital of Philadelphia|UZ Gent|UZ Leuven|Nova Scotia Health Authority (Capital District Health Authority)|Bone Research and Education Centre|CHU de Quebec-Universite Laval|Eastern Health - Health Sciences Center- General Hospital|Aarhus Universitetshospital|Odense Universitetshospital|CHU Angers|Hopital Jean Minjoz|CHU Bicêtre|CHRU Lille|Universitätsklinikum Carl Gustav Carus an der TU Dresden|Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico|Universita di Firenze, Dipartimento di Chirurgia e Medicina Traslazionale (DCMT)|Università Campus Bio Medico Di Roma|VU Medisch Centrum|Leids Universitair Medisch Centrum|Erasmus MC|Haukeland Universitetssykehus|Oslo Universitetssykehus HF Rikshospitalet|Oslo Universitetssykehus Aker|Centro Hospitalar E Universitário de Coimbra EPE|Unidade Local de Saúde de Matosinhos SA|Centro Hospitalar de São João, E.P.E.|C.H. Regional Reina Sofia - PPDS|Hospital Universitario Quironsalud Madrid|Hospital Universitario Fundacion Jimenez Diaz|Hospital Universitario 12 de Octubre|Karolinska Universitetssjukhuset Solna|Sahlgrenska Universitetssjukhuset|Skanes Universitetssjukhus Lund|Ninewells Hospital - PPDS|Norfolk and Norwich University Hospital|Queen Elizabeth Hospital|Leicester Royal Infirmary|Manchester Royal Infirmary - PPDS",Biological|Biological,Belgium|Canada|Denmark|France|Germany|Italy|Netherlands|Norway|Portugal|Spain|Sweden|United Kingdom|United States,18.0,85.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03324880
NCT03331172,thyroid nodule,Efficacy and Safety of High Intensity Focused Ultrasound (HIFU) Reapplication in Benign Thyroid Nodules That Had Less-than Adequate Shrinkage Following Single-session HIFU Treatment.,HIFU Reapplication in Benign Nodules,Thyroid Nodule,2017-10-27,2018-06-30,2018-08-30,Interventional,Completed,Not Applicable,The University of Hong Kong,The University of Hong Kong,Queen Mary Hospital,Device,Hong Kong,19.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03331172
NCT03342001,hypothyroidism,Assessing Quality of Life Changes Using Calcitonin in Patients With Hypothyroidism on Biochemical Replacement With Levothyroxine,Hypothyroidism Treated With Calcitonin,Hypothyroidism,2017-11-09,2019-06-30,2019-08-14,Interventional,Completed,Phase 4,"University of Maryland, Baltimore","University of Maryland, Baltimore",University of Maryland Center for Diabetes and Endocrinology,Drug,United States,18.0,88.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03342001
NCT03359668,papillary thyroid cancer,CT Detection of Metastatic Lymphadenopathy in Papillary Thyroid Cancer,CT Detection of Metastatic Lymphadenopathy in Papillary Thyroid Cancer,Papillary Thyroid Cancer,2017-11-16,2017-04-20,2017-04-20,Interventional,Completed,Not Applicable,"University Health Network, Toronto","University Health Network, Toronto",,Diagnostic Test,,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT03359668
NCT03360890,thyroid cancer,Synergy of Pembrolizumab Anti-PD-1 Immunotherapy With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors. The iPRIME Study.,Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors,Salivary Gland Cancer|Thyroid Cancer,2017-11-20,2022-09-30,2022-09-30,Interventional,Recruiting,Phase 2,University of Chicago,University of Chicago,University of Chicago Comprehensive Cancer Center,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03360890
NCT03364738,hypoparathyroidism,An Open-label Study Investigating the Safety and Efficacy of rhPTH(1-84) in Subjects With Hypoparathyroidism,Safety and Efficacy Study of rhPTH(1-84) in Subjects With Hypoparathyroidism,Hypoparathyroidism,2017-11-20,2020-04-14,2020-04-14,Interventional,Terminated,Phase 3,Takeda,Shire,"University of Kentucky Medical Center|Crescent City Clinical Research Center, LLC|Northern Nevada Endocrinology - Lisa Abbott MD|Ohio State University|Thomas Jefferson University, Jefferson Rheumatology Associates|Bone Research and Education Centre|CHU de Quebec-Universite Laval|Aarhus Universitetshospital|Semmelweis Egyetem|Pecsi Tudomanyegyetem, I. sz. Belgyogyaszati Klinika",Biological,Canada|Denmark|Hungary|United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03364738
NCT03375931,thyroid cancer,The Effects of Preoperative Prayer on Postoperative Quality of Recovery in Patients Undergoing Thyroidectomy,The Effects of Preoperative Prayer on Postoperative Quality of Recovery in Patients Undergoing Thyroidectomy,Thyroid Cancer,2017-12-05,2020-05-31,2020-05-31,Interventional,Unknown status,Not Applicable,Yonsei University,Yonsei University,"Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institute, Yonsei University College of Medicine",Behavioral|Behavioral,"Korea, Republic of",20.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03375931
NCT03377829,thyroid cancer,A Multicenter Prospective Controlled Trial of Laser Ablation Versus Surgery for the Treatment of Papillary Thyroid Microcarcinoma,A Multicenter Trial of PLA vs. Surgery for Treating PTMC,Thyroid Cancer|Treatment Related Cancer,2017-11-26,2021-08-31,2022-12-31,Interventional,Recruiting,Not Applicable,Ruijin Hospital,WeiWei Zhan,"Ultrasound Department, Chinese PLA General Hospital|Ultrasound Department of the Third Hospital Affiliated to Zhongshan University|Ultrasound Department, the Second Affiliated Hospital of Harbin Medical Univercity|Ultrasound Department, the Xiangya Third Hospital of Zhongnan University|Ultrasound Department, the First Affliction Hospital of Nanjing Medical University|Ultrasound Department, the First Affiliated Hospital of Soochow University|Ultrasound Department, First people's Hospital Affiliated to Medical School of Shanghai Jiaotong University|Ultrasound Department, Ruijin Hospital Affiliated to Medical School of Shanghai Jiaotong University|The department of ultrasound ,second affiliated hospital of xi'an jiaotong university|Department of Ultrasonography, Zhejiang Cancer Hospital|Department of Ultrasound Medicine, the First Hospital Affiliated to Medical School of Zhejiang University|Department of Endocrinology, Regina Apostolorum Hospital|Diagnostic Imaging, Regina Apostolorum Hospital",Procedure|Procedure,China|Italy,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03377829
NCT03379181,hyperthyroidism,Thermogenesis in Hyperthyroidism and Effect of Anti-Adrenergic Therapy,Thermogenesis in Hyperthyroidism and Effect of Anti-Adrenergic Therapy,Hyperthyroidism,2017-12-07,2020-02-12,2020-02-12,Interventional,Completed,Phase 4,"University Hospital, Basel, Switzerland","University Hospital, Basel, Switzerland","University Hospital Basel, Department of Endocrinology",Drug,Switzerland,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03379181
NCT03392402,thyroid cancer,Prospective Validation of the Molecular Classifier for the Fine Needle-based Assessment of Malignancy Risk in Thyroid Nodules,Molecular Classifier for the Fine Needle-based Assessment of Malignancy Risk in Thyroid Nodules,Thyroid Cancer|Thyroid Neoplasm|Thyroid Nodule,2018-01-02,2020-03-31,2020-12-31,Observational,Completed,,Maria Sklodowska-Curie National Research Institute of Oncology,Maria Sklodowska-Curie National Research Institute of Oncology,"Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology",,Poland,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03392402
NCT03392402,thyroid nodule,Prospective Validation of the Molecular Classifier for the Fine Needle-based Assessment of Malignancy Risk in Thyroid Nodules,Molecular Classifier for the Fine Needle-based Assessment of Malignancy Risk in Thyroid Nodules,Thyroid Cancer|Thyroid Neoplasm|Thyroid Nodule,2018-01-02,2020-03-31,2020-12-31,Observational,Completed,,Maria Sklodowska-Curie National Research Institute of Oncology,Maria Sklodowska-Curie National Research Institute of Oncology,"Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology",,Poland,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03392402
NCT03393728,hyperthyroidism,Short Term Effects of Propanolol on Heart Rate Variability of Hyperthyroidism,Heart Rate Variability and Hyperthyroidism: Evaluation of the Short-term Effects of Propanolol,Hyperthyroidism,2017-12-21,2008-12-30,2009-09-30,Interventional,Completed,Phase 4,Yaounde Central Hospital,Yaounde Central Hospital,,Drug,,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03393728
NCT03395925,thyroid nodule,Evaluation of the Thyroid Volume After Radiofrequency Ablation of Thyroid Nodules and Recurrent Thyroid,Evaluation of the Thyroid Volume After Radiofrequency Ablation of Thyroid Nodules and Recurrent Thyroid,Thyroid Nodule,2017-12-17,2021-10-30,2022-01-30,Interventional,Active not recruiting,Not Applicable,Olympus Surgical Technologies Europe,Olympus Surgical Technologies Europe,Johann-Wolfgang Goethe University,Device,Germany,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03395925
NCT03397238,thyroid cancer,Myeloid Cell Reprogramming in the Context of Radioiodine Therapy in Patients With Non-Medullary Thyroid Carcinoma,Myeloid Cell Reprogramming in Thyroid Carcinoma,Thyroid Cancer,2017-12-18,2019-11-26,2021-01-05,Observational,Completed,,Radboud University Medical Center,Radboud University Medical Center,Radboudumc,,Netherlands,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03397238
NCT03411187,papillary thyroid carcinoma,Study on the Application of Convenient Foot-control Exhaust Method in Endoscopic Thyroidectomy,Study on the Application of Convenient Foot-control Exhaust Method in Endoscopic Thyroidectomy,Endoscopy|Papillary Thyroid Carcinoma|Thyroid Cancer|Thyroidectomy,2018-01-19,2018-06-30,2018-12-30,Interventional,Unknown status,Not Applicable,Fujian Medical University,"Bo Wang,MD",Wen-xin ZHAO,Device|Device,China,18.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT03411187
NCT03416686,differentiated thyroid cancer,Radiofrequency in Differentiated Thyroid Cancer Metastatic Lymph Node: Prospective Study of Safety and Efficacy,Radiofrequency in Differentiated Thyroid Cancer Metastatic Lymph Node: Prospective Study of Safety and Efficacy,Differentiated Thyroid Cancer,2017-12-07,2021-02-28,2021-02-28,Interventional,Unknown status,Not Applicable,Assistance Publique - Hôpitaux de Paris,Assistance Publique - Hôpitaux de Paris,Hôpital Saint Louis,Device,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Differentiated thyroid cancer, all",https://clinicaltrials.gov/ct2/show/NCT03416686
NCT03432299,thyroid cancer,Radiofrequency Ablation of Low Risk Papillary Thyroid Microcarcinoma: Safety and Efficacy,Radiofrequency Ablation of Low Risk Papillary Thyroid Microcarcinoma,Papillary Thyroid Microcarcinoma|Thyroid Cancer,2018-01-22,2023-07-31,2023-12-31,Interventional,Recruiting,Not Applicable,Seoul National University Hospital,Seoul National University Hospital,Seoul National University Hospital,Procedure,"Korea, Republic of",19.0,60.0,[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03432299
NCT03434067,hyperthyroidism,The Application of Rapid PTH Test Paper in Operation of Hyperparathyroidism,The Application of Rapid PTH Test Paper in Operation of Hyperparathyroidism,Hyperthyroidism|Immunochromatographic|PTH|Thyroidectomy,2018-01-27,2018-06-30,2018-12-30,Observational [Patient Registry],Unknown status,,Fujian Medical University,"Bo Wang,MD",Wen-xin ZHAO,,China,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03434067
NCT03437174,hypoparathyroidism,Burden of Illness and Disease Associated Emergencies in Chronic Hypoparathyroidism,Burden of Illness in Hypoparathyroidism,Hypoparathyroidism,2018-02-10,2017-12-01,2018-01-01,Observational,Completed,,University of Wuerzburg,"Charite University, Berlin, Germany|Endocrine Practice, Oldenburg, Germany|Ludwig-Maximilians - University of Munich|Praxis Endokrinologie in Charlottenburg, Berlin|University Medical Center Rostock|University of Wuerzburg","Endokrinologie in Charlottenburg|Charite Berlin|Ludwig-Maximilians-Universität|University Hospital Rostock|Dept. of Endocrinology and Diabetology, Dept. of Medicine I, University Hospital Wuerzburg",,Germany,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03437174
NCT03444246,hyperthyroidism,"A Parallel, Double-blind, Randomized Controlled Trial for the Evaluation of the Treatment and Outcome of Hyperthyroidism With Iodized Salt and Non Iodized Salt",A Trial for the Evaluation of the Treatment and Outcome of Hyperthyroidism With Iodized Salt and Non Iodized Salt,Hyperthyroidism,2018-02-06,2019-03-01,2019-06-01,Interventional,Unknown status,Not Applicable,Xijing Hospital,Xijing Hospital,"Xijing Hospital, Fourth Military Medical university",Dietary Supplement|Dietary Supplement,China,18.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03444246
NCT03449108,poorly differentiated thyroid gland carcinoma,Clinical Study to Assess Efficacy and Safety of LN-145/LN-145-S1 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types,"LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas",Bone Sarcoma|Dedifferentiated Chondrosarcoma|Giant Cell Tumor of Bone|Malignancy in Giant Cell Tumor of Bone|Malignant Solid Neoplasm|Ovarian Carcinosarcoma|Platinum-Resistant Ovarian Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Osteosarcoma|Recurrent Ovarian Carcinoma|Refractory Osteosarcoma|Soft Tissue Sarcoma|Thyroid Gland Anaplastic Carcinoma|Thyroid Gland Squamous Cell Carcinoma|Undifferentiated High Grade Pleomorphic Sarcoma of Bone,2018-02-22,2023-06-30,2024-06-30,Interventional,Recruiting,Phase 2,M.D. Anderson Cancer Center,"Iovance Biotherapeutics, Inc.|M.D. Anderson Cancer Center|National Cancer Institute (NCI)",M D Anderson Cancer Center,Biological|Biological|Biological|Drug|Drug|Biological|Biological|Other|Other,United States,16.0,70.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Poorly differentiated thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03449108
NCT03449108,thyroid gland anaplastic carcinoma,Clinical Study to Assess Efficacy and Safety of LN-145/LN-145-S1 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types,"LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas",Bone Sarcoma|Dedifferentiated Chondrosarcoma|Giant Cell Tumor of Bone|Malignancy in Giant Cell Tumor of Bone|Malignant Solid Neoplasm|Ovarian Carcinosarcoma|Platinum-Resistant Ovarian Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Osteosarcoma|Recurrent Ovarian Carcinoma|Refractory Osteosarcoma|Soft Tissue Sarcoma|Thyroid Gland Anaplastic Carcinoma|Thyroid Gland Squamous Cell Carcinoma|Undifferentiated High Grade Pleomorphic Sarcoma of Bone,2018-02-22,2023-06-30,2024-06-30,Interventional,Recruiting,Phase 2,M.D. Anderson Cancer Center,"Iovance Biotherapeutics, Inc.|M.D. Anderson Cancer Center|National Cancer Institute (NCI)",M D Anderson Cancer Center,Biological|Biological|Biological|Drug|Drug|Biological|Biological|Other|Other,United States,16.0,70.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT03449108
NCT03449108,thyroid gland squamous cell carcinoma,Clinical Study to Assess Efficacy and Safety of LN-145/LN-145-S1 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types,"LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas",Bone Sarcoma|Dedifferentiated Chondrosarcoma|Giant Cell Tumor of Bone|Malignancy in Giant Cell Tumor of Bone|Malignant Solid Neoplasm|Ovarian Carcinosarcoma|Platinum-Resistant Ovarian Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Osteosarcoma|Recurrent Ovarian Carcinoma|Refractory Osteosarcoma|Soft Tissue Sarcoma|Thyroid Gland Anaplastic Carcinoma|Thyroid Gland Squamous Cell Carcinoma|Undifferentiated High Grade Pleomorphic Sarcoma of Bone,2018-02-22,2023-06-30,2024-06-30,Interventional,Recruiting,Phase 2,M.D. Anderson Cancer Center,"Iovance Biotherapeutics, Inc.|M.D. Anderson Cancer Center|National Cancer Institute (NCI)",M D Anderson Cancer Center,Biological|Biological|Biological|Drug|Drug|Biological|Biological|Other|Other,United States,16.0,70.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid Gland Squamous Cell Carcinoma,https://clinicaltrials.gov/ct2/show/NCT03449108
NCT03454464,thyroid cancer,"To Evaluate the Practicable, Thoroughness and Clinical Value of Bilateral Central Compartment Dissection While Preserve Contrary Thyroid Glands",Evaluation of Central Compartment Dissection Without Thyroidectomy,Central Compartment Neck Dissction|Thyroid Cancer|Thyroidectomy,2018-02-07,2018-12-31,2018-12-31,Interventional,Unknown status,Not Applicable,Fujian Medical University,Fujian Medical University,Wen-xin ZHAO,Procedure|Procedure,China,18.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03454464
NCT03454477,papillary thyroid carcinoma,"From the Endoscope to the Robot, the Initial Experience of Robotic Thyroidectomy is Summarized","Comparison Between Robotic, Endoscopic and Traditional Open Surgery in Thyroidectomy",Endoscopy|Papillary Thyroid Carcinoma|Robotics|Thyroidectomy,2018-02-07,2018-10-01,2018-10-01,Interventional,Unknown status,Not Applicable,Fujian Medical University,Fujian Medical University,Wen-xin ZHAO,Procedure|Procedure|Device,China,18.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT03454477
NCT03461211,thyroid eye disease,"Multicenter, Safety and Efficacy, Open-Label Extension Study Evaluating Teprotumumab (HZN-001) Treatment in Subjects With Thyroid Eye Disease",Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study,Thyroid Eye Disease,2018-03-05,2020-06-08,2021-02-17,Interventional,Completed,Phase 3,"Horizon Pharma USA, Inc.","Horizon Pharma USA, Inc.","Macro, Llc|Cedars-Sinai Medical Center|Bascom Palmer Eye Institute|Kellogg Eye Center at University of Michigan|Casey Eye Institute at Oregon Health and Science|Hamilton Eye Institute at University of Tennessee Health|Eye Wellness Center|Medical College of Wisconsin, The Eye Institute|University Hospital Essen, Department of Ophthalmology|Johannes Gutenberg University Medical Center|Fondazione IRCCS Ca Granda Ospedale Maggiore|University of Pisa, Department of Clinical and Experimental Medicine|Azienda Ospedaliero Universitaria Pisana",Biological,Germany|Italy|United States,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT03461211
NCT03463889,thyroid gland carcinoma,Gallium-68 Prostate Specific Membrane Antigen (68Ga-PSMA) PET for Imaging of Thyroid Cancer: A Feasibility Study,Gallium-68 Prostate Specific Membrane Antigen PET in Diagnosing Patients With Thyroid Cancer,Thyroid Gland Carcinoma,2018-02-09,2020-09-30,2020-10-31,Interventional,Terminated,Phase 2,"University of California, San Francisco","University of California, San Francisco","University of California, San Francisco",Drug|Procedure|Procedure,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03463889
NCT03465176,hypothyroidism,The Effect of Aroma on Fatigue Scores Among Women With Hypothyroidism,The Effect of Aroma on Fatigue Scores Among Women With Hypothyroidism,Fatigue|Hypothyroidism,2018-03-08,2018-03-30,2018-05-31,Interventional,Completed,Not Applicable,Franklin Health Research,Franklin Health Research,Franklin Institute of Wellness,Other|Other,United States,18.0,55.0,[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03465176
NCT03469011,papillary thyroid cancer,A Phase I Dose Escalation Trial to Determine if Imatinib Treatment Restores Sodium Iodide Symporter Function and Sensitivity to Radioiodine Treatment in Metastatic Thyroid Cancer Patients,A Study to Try to Bring Back Radioiodine Sensitivity in Patients With Advanced Thyroid Cancer.,Papillary Thyroid Cancer,2018-03-12,2021-12-31,2021-12-31,Interventional,Recruiting,Phase 1,AHS Cancer Control Alberta,AHS Cancer Control Alberta|Alberta Cancer Foundation,Cross Cancer Institute,Drug,Canada,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT03469011
NCT03469310,thyroid neoplasms,Minimizing Narcotic Analgesics After Thyroid or Parathyroid Surgery,Minimizing Narcotic Analgesics After Endocrine Surgery,Parathyroid Adenoma|Parathyroid Diseases|Parathyroid Hyperplasia|Thyroid Cancer|Thyroid Diseases|Thyroid Goitre|Thyroid Neoplasms|Thyroid Nodule,2018-03-07,2019-12-21,2020-10-02,Interventional,Completed,Phase 4,DHR Health Institute for Research and Development,Minerva A Romero Arenas,GME General Surgery Clinic,Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03469310
NCT03469310,thyroid nodule,Minimizing Narcotic Analgesics After Thyroid or Parathyroid Surgery,Minimizing Narcotic Analgesics After Endocrine Surgery,Parathyroid Adenoma|Parathyroid Diseases|Parathyroid Hyperplasia|Thyroid Cancer|Thyroid Diseases|Thyroid Goitre|Thyroid Neoplasms|Thyroid Nodule,2018-03-07,2019-12-21,2020-10-02,Interventional,Completed,Phase 4,DHR Health Institute for Research and Development,Minerva A Romero Arenas,GME General Surgery Clinic,Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03469310
NCT03469310,thyroid diseases,Minimizing Narcotic Analgesics After Thyroid or Parathyroid Surgery,Minimizing Narcotic Analgesics After Endocrine Surgery,Parathyroid Adenoma|Parathyroid Diseases|Parathyroid Hyperplasia|Thyroid Cancer|Thyroid Diseases|Thyroid Goitre|Thyroid Neoplasms|Thyroid Nodule,2018-03-07,2019-12-21,2020-10-02,Interventional,Completed,Phase 4,DHR Health Institute for Research and Development,Minerva A Romero Arenas,GME General Surgery Clinic,Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT03469310
NCT03469544,thyroid cancer,Long Non Coding RNA HOTAIR and Midkine as Biomarkers in Thyroid Cancer,Long Non Coding RNA HOTAIR and Midkine as Biomarkers in Thyroid Cancer,Thyroid Cancer,2018-03-10,2019-12-29,2020-03-29,Observational,Unknown status,,Assiut University,Assiut University,,Other,,20.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03469544
NCT03470259,papillary thyroid cancer,Detection of Thyroid Cancer and Central Lymph Node Metastases Using EMI-137 Enhanced Molecular Fluorescent Guided Imaging: a Multicentre Feasibility and,Precision Thyroid Cancer Surgery With Molecular Fluorescent Guided Imaging,Lymph Node Metastases|Papillary Thyroid Cancer,2018-02-21,2019-12-31,2019-12-31,Interventional,Completed,Phase 1,University Medical Center Groningen,Erasmus Medical Center|University Medical Center Groningen,University Medical Center Groningen|Erasmus Medical Center,Drug|Device|Device,Netherlands,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT03470259
NCT03475953,thyroid cancer,A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors,A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors,"Biliary Tract Cancer|Colorectal Cancer Not MSI-H or MMR-deficient|Gastro-enteropancreatic Neuroendocrine Tumor|GIST|Hepatocellular Carcinoma|Non-small Cell Lung Cancer|Oesophageal or Gastric Carcinoma|Soft-tissue Sarcoma|Solid Tumor, Adult|Thyroid Cancer",2018-02-20,2020-12-31,2022-12-31,Interventional,Recruiting,Phase 1/Phase 2,Institut Bergonié,"Bayer|Institut Bergonié|Merck KGaA, Darmstadt, Germany",Institut Bergonié|Centre Hospitalier Régional Universitaire - CHU Morvan|Centre Léon Bérard|Institut de Cancérologie de Montpellier|Institut Curie|IUCT Oncopôle - Institut Claudius Regaud|Institut Gustave Roussy,Drug|Drug|Drug|Drug|Drug,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03475953
NCT03479801,thyroid neoplasms,"Comparative Study of Surgical Results in Endoscopic Thyroidectomy Via Oral Approach, Via Breast Approach and Conventional Open Thyroidectomy","Comparative Study in Oral, Breast Approach and Open Thyroidectomy",Thyroid Neoplasms,2018-03-15,2018-12-31,2018-12-31,Observational,Unknown status,,"Second Affiliated Hospital, School of Medicine, Zhejiang University","Second Affiliated Hospital, School of Medicine, Zhejiang University",SAHZhejiangU,Procedure,China,15.0,55.0,[0-17]|[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03479801
NCT03483337,thyroid cancer,Quantitative Imaging Tools to Derive DW-MRI Oncological Biomarkers,New MRI Biomarkers in Head and Neck Cancers,Head and Neck Cancer|Thyroid Cancer,2018-03-19,2024-03-31,2024-03-31,Observational,Recruiting,,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Other|Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03483337
NCT03484884,thyroid cancer,A Feasibility Study of Non-Invasive Cerenkov Luminescence Imaging in Patients With Cancer,A Study of Optical Imaging With Light From Radiotracers in Cancer Patients,Thyroid Cancer,2018-03-20,2023-03-31,2023-03-31,Observational,Recruiting,,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Memorial Sloan - Kettering Cancer Center,Diagnostic Test,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03484884
NCT03488134,thyroid cancer,"A Prospective Study of Predicting Prognosis and Recurrence of Thyroid Cancer Via New Biomarkers, Urinary Exosomal Thyroglobulin and Galectin-3","Predicting Prognosis and Recurrence of Thyroid Cancer Via New Biomarkers, Urinary Exosomal Thyroglobulin and Galectin-3",Thyroid Cancer,2018-03-28,2022-01-31,2023-07-31,Observational [Patient Registry],Active not recruiting,,National Taiwan University Hospital,National Taiwan University Hospital,National Taiwan University Hospital,,Taiwan,20.0,80.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03488134
NCT03496363,hypothyroidism,Evaluation of Thyroid Function in Children With Congenital Heart Disease,Hypothyroidism With Congenital Heart Disease (CHD),CHD|Hypothyroidism,2018-03-10,2019-05-01,2020-05-01,Observational,Unknown status,,Assiut University,Assiut University,,Diagnostic Test,,0.0,3.0,[0-17],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03496363
NCT03498417,graves disease,Serum Antibodies Against the Insulin-like Growth Factor-1 Receptor (IGF-1R) in Graves' Disease and Graves' Orbitopathy,Anti-insulin-like Growth Factor-1 Receptor (IGF-1R) Antibodies in Graves' Disease and Graves' Orbitopathy,Autoimmune Thyroiditis|Graves Disease|Graves Ophthalmopathy,2018-03-30,2018-07-20,2018-07-20,Observational,Completed,,University of Pisa,University of Pisa,"Endocrinology Unit I, University of Pisa",Diagnostic Test,Italy,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT03498417
NCT03498417,graves ophthalmopathy,Serum Antibodies Against the Insulin-like Growth Factor-1 Receptor (IGF-1R) in Graves' Disease and Graves' Orbitopathy,Anti-insulin-like Growth Factor-1 Receptor (IGF-1R) Antibodies in Graves' Disease and Graves' Orbitopathy,Autoimmune Thyroiditis|Graves Disease|Graves Ophthalmopathy,2018-03-30,2018-07-20,2018-07-20,Observational,Completed,,University of Pisa,University of Pisa,"Endocrinology Unit I, University of Pisa",Diagnostic Test,Italy,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT03498417
NCT03498417,autoimmune thyroiditis,Serum Antibodies Against the Insulin-like Growth Factor-1 Receptor (IGF-1R) in Graves' Disease and Graves' Orbitopathy,Anti-insulin-like Growth Factor-1 Receptor (IGF-1R) Antibodies in Graves' Disease and Graves' Orbitopathy,Autoimmune Thyroiditis|Graves Disease|Graves Ophthalmopathy,2018-03-30,2018-07-20,2018-07-20,Observational,Completed,,University of Pisa,University of Pisa,"Endocrinology Unit I, University of Pisa",Diagnostic Test,Italy,18.0,80.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT03498417
NCT03500666,thyroid carcinoma,A Comparative Study of Robot Assisted BABA Approach and Chest Breast Approach for Lateral Neck Dissection,Comparative Study of Robot BABA Approach and Chest Breast Approach for Lateral Neck Dissection,Endoscopic Surgery|Robot Surgery|Thyroid Carcinoma,2018-04-02,2018-12-31,2018-12-31,Interventional,Unknown status,Not Applicable,Fujian Medical University,Fujian Medical University,Fujian Medical University Union Hospital|Wen-xin ZHAO,Device|Device,China,18.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03500666
NCT03506048,thyroid gland papillary carcinoma,A Phase 2 Study of Lenvatinib in Combination With Radioactive Iodine Therapy in Patients With Progressive RAI-Sensitive Differentiated Thyroid Cancer,Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer,Differentiated Thyroid Gland Carcinoma|Thyroid Gland Follicular Carcinoma|Thyroid Gland Papillary Carcinoma,2018-04-13,2021-06-24,2021-06-24,Interventional,Terminated,Phase 2,Emory University,Eisai Inc.|Emory University,Emory University Hospital/Winship Cancer Institute,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT03506048
NCT03506048,thyroid gland follicular carcinoma,A Phase 2 Study of Lenvatinib in Combination With Radioactive Iodine Therapy in Patients With Progressive RAI-Sensitive Differentiated Thyroid Cancer,Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer,Differentiated Thyroid Gland Carcinoma|Thyroid Gland Follicular Carcinoma|Thyroid Gland Papillary Carcinoma,2018-04-13,2021-06-24,2021-06-24,Interventional,Terminated,Phase 2,Emory University,Eisai Inc.|Emory University,Emory University Hospital/Winship Cancer Institute,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT03506048
NCT03510143,thyroid gland carcinoma,"Effect of Polyglycolic Acid Mesh (Neoveil) for Reducing Drain Amount and Chyle Leakage After Thyroid Cancer Surgery: A Prospective, Randomized Controlled Study",Effect of Polyglycolic Acid Mesh (Neoveil) in Thyroid Cancer Surgery,Thoracic Duct Leak|Thyroid Cancer|Thyroid Gland Carcinoma,2018-03-20,2020-05-01,2020-12-31,Interventional,Unknown status,Not Applicable,Seoul National University Hospital,Green Cross Corporation|Seoul National University Hospital,Jin Wook Yi,Device,"Korea, Republic of",20.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03510143
NCT03514251,thyroid cancer,Study on Application of Suturing Parathyroid Markers in Thyroid Cancer Surgery,Study on Application of Suturing Parathyroid Markers in Thyroid Cancer Surgery,Complication of Surgical Procedure|Hypoparathyroidism|Marker; Structural|Parathyroid Function Low Adverse Event|Thyroid Cancer,2018-04-20,2018-09-30,2018-09-30,Interventional,Unknown status,Not Applicable,Fujian Medical University,"Bo Wang,MD",Fujian Medical University Union Hospital,Procedure,China,18.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03514251
NCT03514251,hypoparathyroidism,Study on Application of Suturing Parathyroid Markers in Thyroid Cancer Surgery,Study on Application of Suturing Parathyroid Markers in Thyroid Cancer Surgery,Complication of Surgical Procedure|Hypoparathyroidism|Marker; Structural|Parathyroid Function Low Adverse Event|Thyroid Cancer,2018-04-20,2018-09-30,2018-09-30,Interventional,Unknown status,Not Applicable,Fujian Medical University,"Bo Wang,MD",Fujian Medical University Union Hospital,Procedure,China,18.0,70.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03514251
NCT03516773,hypoparathyroidism,An Evaluation of the Pharmacokinetics and Pharmacodynamics of Oral Parathyroid Hormone [PTH (1-34)] and NATPARA® in Patients With Hypoparathyroidism,Oral PTH(1-34) PK and PD Study in Patients With Hypoparathyroidism,Hypoparathyroidism,2018-04-23,2018-12-05,2019-02-24,Interventional,Completed,Phase 2,Entera Bio Ltd.,Entera Bio Ltd.,Clinical Research Center Hadassah Ein Kerem Medical Center,Drug|Drug,Israel,18.0,80.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03516773
NCT03517267,thyroid nodule,Validation of the New Thyroid Imaging Reporting and Data System (TIRADS) From 2017 Risk Assessment of Thyroid Nodules in Comparison to the American Thyroid Association (ATA) Guidelines From 2015,Thyroid Imaging Reporting and Data System (TIRADS ) Versus Thyroid Association (ATA) Guidelines,Thyroid Nodule,2018-03-28,2019-06-30,2019-06-30,Observational [Patient Registry],Unknown status,,Rambam Health Care Campus,Rambam Health Care Campus,Rambam Medical Center,Diagnostic Test,Israel,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03517267
NCT03517579,graves disease,Personalized Treatment Planning for Radio-iodine Therapy of Thyroid Disease,Personalized Treatment in Thyroid Disorders,Graves Disease|Thyroid Cancer,2018-04-03,2024-10-15,2024-12-15,Interventional,Recruiting,Not Applicable,Johns Hopkins University,Johns Hopkins University,Johns Hopkins Hospital,Device,United States,21.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT03517579
NCT03517579,thyroid cancer,Personalized Treatment Planning for Radio-iodine Therapy of Thyroid Disease,Personalized Treatment in Thyroid Disorders,Graves Disease|Thyroid Cancer,2018-04-03,2024-10-15,2024-12-15,Interventional,Recruiting,Not Applicable,Johns Hopkins University,Johns Hopkins University,Johns Hopkins Hospital,Device,United States,21.0,65.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03517579
NCT03530033,thyroid cancer,"Lidocaine Reduces Muscle Tremor Caused by Electric Energy Devices, Which is Beneficial for Intraoperative Recurrent Laryngeal Nerve Monitoring During Endoscopic Thyroid Lateral Neck Dissection",Lidocaine Reduces Muscle Tremor is Beneficial for Intraoperative Recurrent Laryngeal Nerve Monitoring,Accessory Nerve Injuries|EMG: Repetitive Nerve Stimulation Abnormality|Neck Cancer|Recurrent Laryngeal Nerve Injuries|Thyroid Cancer,2018-05-08,2018-10-31,2018-10-31,Interventional,Unknown status,Not Applicable,Fujian Medical University,"Bo Wang,MD",Fujian Medical University Union Hospital,Drug,China,18.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03530033
NCT03535090,graves ophthalmopathy,High-dose Intravenous Methylprednisolone Therapy in Patients With Graves' Orbitopathy is Associated With the Increased Activity of Factor VIII,Coagulation After Intravenous Methylprednisolone Administration,Blood Coagulation|Graves' Disease|Graves Ophthalmopathy|Venous Thromboembolism,2018-04-29,2014-12-31,2014-12-31,Observational,Completed,,Medical University of Warsaw,Piotr Miskiewicz,,Drug,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT03535090
NCT03547648,thyroid neoplasms,Comparison of the Effect of Three Different Peak Airway Pressures on Determining Intraoperative Bleeding Points in Thyroidectomies,Effect of Three Different Peak Airway Pressures on Determining Intraoperative Bleeding in Thryroidectomies,Thyroid Neoplasms|Thyroid Nodule,2018-05-23,2018-11-16,2018-11-16,Interventional,Completed,Not Applicable,Istanbul University,Istanbul University,Turkey,Procedure,Turkey,18.0,60.0,[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03547648
NCT03547648,thyroid nodule,Comparison of the Effect of Three Different Peak Airway Pressures on Determining Intraoperative Bleeding Points in Thyroidectomies,Effect of Three Different Peak Airway Pressures on Determining Intraoperative Bleeding in Thryroidectomies,Thyroid Neoplasms|Thyroid Nodule,2018-05-23,2018-11-16,2018-11-16,Interventional,Completed,Not Applicable,Istanbul University,Istanbul University,Turkey,Procedure,Turkey,18.0,60.0,[18-65],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03547648
NCT03555487,parathyroid diseases,Clinical Value of 18F -Fluorocholine (18F-FCH) PET in Localizing Parathyroid Lesions: Comparison With 99mTc-sestamibi (MIBI) Scan.,Clinical Value of 18F-FCH PET in Localizing Parathyroid Lesions: Comparison With MIBI Scan.,Parathyroid Diseases,2018-05-20,2018-06-30,2018-10-01,Interventional,Completed,Phase 3,National Taiwan University Hospital,National Taiwan University Hospital,National Taiwan Univeristy Hospital,Drug,Taiwan,20.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT03555487
NCT03565536,"thyroid cancer, anaplastic",Prospective Study of Nexavar for Neoadjuvant Treatment of Anaplastic Thyroid Cancer,Nexavar for Neoadjuvant Treatment of Anaplastic Thyroid Cancer,"Thyroid Cancer, Anaplastic",2018-05-26,2019-04-30,2019-10-30,Interventional,Unknown status,Phase 2,Fujian Medical University,Fujian Medical University,Fujian Medical University Union Hospital,Drug|Procedure|Radiation,China,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT03565536
NCT03570021,thyroid cancer,ESTIMation of the ABiLity of Prophylactic Central Compartment Neck Dissection to Modify Outcomes in Low-risk Differentiated Thyroid Cancer,ESTIMation of the ABiLity of Prophylactic Central Compartment Neck Dissection to Modify Outcomes in Low-risk Differentiated Thyroid Cancer,Thyroid Cancer,2018-06-15,2026-06-30,2026-06-30,Interventional,Recruiting,Phase 3,"Gustave Roussy, Cancer Campus, Grand Paris","Gustave Roussy, Cancer Campus, Grand Paris",Gustave Roussy,Procedure|Procedure,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03570021
NCT03573960,thyroid neoplasms,"Prospective Single Arm Post Marketing Phase IV Study to Assess the Safety and Efficacy of Lenvatinib in Subjects With Locally Recurrent or Metastatic, Progressive, Radioiodine Refractory Differentiated Thyroid Cancer",A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer,Thyroid Neoplasms,2018-06-19,2022-12-31,2022-12-31,Interventional,Active not recruiting,Phase 4,Eisai Inc.,Eisai Pharmaceuticals India Pvt. Ltd,"All India Institute of Medical Sciences|Indraprastha Apollo Hospital|Shetty's Hospital|Deenanath Mangeshkar Hospital|All India Institute of Medical Sciences|S. P. Medical College & A. G. Hospitals|Tata Memorial Hospital|BL Kapoor Hospital, New Delhi|Indrayani Hospital, Alandi|City Cancer Centre",Drug,India,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03573960
NCT03577951,thyroid cancer,Comparing the Two Ways of Creating a High Position and Low Position Operating Space in Endoscopic Thyroid Surgery,Comparing the Establishment of Operation Space Between High Position and Low Position in Endoscopic Thyroid Surgery,Endoscopy|Thyroid Cancer,2018-06-24,2018-08-31,2018-10-31,Interventional,Unknown status,Not Applicable,Fujian Medical University,Fujian Medical University,Fujian Medical University Union Hospital,Procedure|Procedure,China,18.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03577951
NCT03590080,graves disease,Blood Pressure Profile and NT-proBNP Dynamics in Response to Intravenous Methylprednisolone Pulse Therapy of Severe Graves' Orbitopathy,Impact of Intravenous Methylprednisolone Treatment on Blood Pressure,Blood Pressure|Graves Disease|Graves Ophthalmopathy|Heart Failure|Hypertension,2018-06-30,2015-12-30,2015-12-30,Observational,Completed,,Medical University of Warsaw,Medical University of Warsaw,,Drug,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT03590080
NCT03590080,graves ophthalmopathy,Blood Pressure Profile and NT-proBNP Dynamics in Response to Intravenous Methylprednisolone Pulse Therapy of Severe Graves' Orbitopathy,Impact of Intravenous Methylprednisolone Treatment on Blood Pressure,Blood Pressure|Graves Disease|Graves Ophthalmopathy|Heart Failure|Hypertension,2018-06-30,2015-12-30,2015-12-30,Observational,Completed,,Medical University of Warsaw,Medical University of Warsaw,,Drug,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT03590080
NCT03602495,differentiated thyroid cancer,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Donafenib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer",A Phase 3 Study of Donafenib in Patients With Radioiodine-refractory Differentiated Thyroid Cancer,Differentiated Thyroid Cancer,2018-07-18,2021-02-28,2021-07-15,Interventional,Terminated,Phase 3,"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","Suzhou Zelgen Biopharmaceuticals Co.,Ltd",Peking Union Medical College Hospital,Drug|Drug,China,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Differentiated thyroid cancer, all",https://clinicaltrials.gov/ct2/show/NCT03602495
NCT03612908,hyperthyroidism,TSHβX1 Splice Variant Expression and D2 Thr92Ala Polymorphism Analysis in Pregnant Women With Thyroid Diseases,TSHβX1 and D2 THR92ALA in Pregnancy,Hyperthyroidism|Hypothyroidism|Pregnancy Related,2018-07-20,2017-12-15,2018-06-30,Observational,Completed,,Materno-Perinatal Hospital of the State of Mexico,Ciprés Grupo Médico CGM SC|Materno-Perinatal Hospital of the State of Mexico|Universidad Autonoma del Estado de Mexico,"Materno-Perinatal Hospital ""Mónica Pretelini""",,Mexico,18.0,44.0,[18-65],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03612908
NCT03612908,hypothyroidism,TSHβX1 Splice Variant Expression and D2 Thr92Ala Polymorphism Analysis in Pregnant Women With Thyroid Diseases,TSHβX1 and D2 THR92ALA in Pregnancy,Hyperthyroidism|Hypothyroidism|Pregnancy Related,2018-07-20,2017-12-15,2018-06-30,Observational,Completed,,Materno-Perinatal Hospital of the State of Mexico,Ciprés Grupo Médico CGM SC|Materno-Perinatal Hospital of the State of Mexico|Universidad Autonoma del Estado de Mexico,"Materno-Perinatal Hospital ""Mónica Pretelini""",,Mexico,18.0,44.0,[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03612908
NCT03615456,goiter,Sutureless Thyroidectomy Versus Conventional Thyroidectomy: Prospective Randomized Clinical Trial,Sutureless Versus Conventional Thyroidectomy,Goiter,2018-07-30,2018-02-28,2018-05-12,Interventional,Completed,Not Applicable,Mansoura University,Mansoura University,Mansoura university hospital,Procedure|Procedure,Egypt,18.0,70.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT03615456
NCT03623516,papillary thyroid cancer,Overdiagnosis of Thyroid Cancer in the Marne and Ardennes Departments of France From 1975 to 2014,Overdiagnosis of Thyroid Cancer in the Marne and Ardennes Departments of France From 1975 to 2014,Papillary Thyroid Cancer,2018-07-19,2014-12-01,2014-12-01,Observational,Completed,,CHU de Reims,CHU de Reims,Damien JOLLY,,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT03623516
NCT03624751,thyroid cancer,Follow up for Patients With Thyroid Cancer Planed for Radioiodine Scan or Treatment,Follow up for Patients With Thyroid Cancer Planed for Radioiodine Scan or Treatment,Thyroid Cancer,2018-05-24,2028-06-30,2030-06-30,Observational,Recruiting,,Taichung Veterans General Hospital,Taichung Veterans General Hospital,Division of Endocrinology and Metabolism in Taichung Veterans General Hospital,Radiation,Taiwan,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03624751
NCT03627611,hypothyroidism,"A Randomized Crossover Study, Examining Differential Effects of Levothyroxine and Liothyronine",Identification of Non-responders to Levothyroxine Therapy,Biomarkers|Endocrine System Diseases|Hypothyroidism,2018-05-25,2020-06-22,2020-06-22,Interventional,Completed,Phase 2,Oslo University Hospital,Hormonlaboratoriet|Oslo University Hospital|Spesialistsenteret Pilestredet Park,Oslo University Hospital,Drug|Drug,Norway,18.0,65.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03627611
NCT03630120,papillary thyroid cancer,Adaptive Tyrosine Kinase Inhibitor Therapy In Patients With Advanced Progressive Thyroid Cancer,Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer,"Differentiated Thyroid Cancer|Follicular Thyroid Cancer|Papillary Thyroid Cancer|Poorly Differentiated Thyroid Gland Carcinoma|Thyroid Cancer|Thyroid Cancer, Medullary",2018-08-10,2019-11-14,2019-12-05,Interventional,Terminated,Phase 2,H. Lee Moffitt Cancer Center and Research Institute,H. Lee Moffitt Cancer Center and Research Institute,H. Lee Moffitt Cancer Center and Research Institute,Drug|Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT03630120
NCT03630120,follicular thyroid cancer,Adaptive Tyrosine Kinase Inhibitor Therapy In Patients With Advanced Progressive Thyroid Cancer,Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer,"Differentiated Thyroid Cancer|Follicular Thyroid Cancer|Papillary Thyroid Cancer|Poorly Differentiated Thyroid Gland Carcinoma|Thyroid Cancer|Thyroid Cancer, Medullary",2018-08-10,2019-11-14,2019-12-05,Interventional,Terminated,Phase 2,H. Lee Moffitt Cancer Center and Research Institute,H. Lee Moffitt Cancer Center and Research Institute,H. Lee Moffitt Cancer Center and Research Institute,Drug|Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT03630120
NCT03630120,differentiated thyroid cancer,Adaptive Tyrosine Kinase Inhibitor Therapy In Patients With Advanced Progressive Thyroid Cancer,Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer,"Differentiated Thyroid Cancer|Follicular Thyroid Cancer|Papillary Thyroid Cancer|Poorly Differentiated Thyroid Gland Carcinoma|Thyroid Cancer|Thyroid Cancer, Medullary",2018-08-10,2019-11-14,2019-12-05,Interventional,Terminated,Phase 2,H. Lee Moffitt Cancer Center and Research Institute,H. Lee Moffitt Cancer Center and Research Institute,H. Lee Moffitt Cancer Center and Research Institute,Drug|Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Differentiated thyroid cancer, all",https://clinicaltrials.gov/ct2/show/NCT03630120
NCT03630120,poorly differentiated thyroid gland carcinoma,Adaptive Tyrosine Kinase Inhibitor Therapy In Patients With Advanced Progressive Thyroid Cancer,Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer,"Differentiated Thyroid Cancer|Follicular Thyroid Cancer|Papillary Thyroid Cancer|Poorly Differentiated Thyroid Gland Carcinoma|Thyroid Cancer|Thyroid Cancer, Medullary",2018-08-10,2019-11-14,2019-12-05,Interventional,Terminated,Phase 2,H. Lee Moffitt Cancer Center and Research Institute,H. Lee Moffitt Cancer Center and Research Institute,H. Lee Moffitt Cancer Center and Research Institute,Drug|Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Poorly differentiated thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03630120
NCT03630120,"thyroid cancer, medullary",Adaptive Tyrosine Kinase Inhibitor Therapy In Patients With Advanced Progressive Thyroid Cancer,Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer,"Differentiated Thyroid Cancer|Follicular Thyroid Cancer|Papillary Thyroid Cancer|Poorly Differentiated Thyroid Gland Carcinoma|Thyroid Cancer|Thyroid Cancer, Medullary",2018-08-10,2019-11-14,2019-12-05,Interventional,Terminated,Phase 2,H. Lee Moffitt Cancer Center and Research Institute,H. Lee Moffitt Cancer Center and Research Institute,H. Lee Moffitt Cancer Center and Research Institute,Drug|Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, medullary",https://clinicaltrials.gov/ct2/show/NCT03630120
NCT03631771,hypothyroidism,"A Multicenter, Prospective Study to Evaluate the Risk of Hypothyroidism in Pediatric Patients Administered Intravascular Iohexol, Iodixanol, Iopromide, or Ioversol. THYROPED.",Pediatric Risk of Hypothyroidism With Iodinated Contrast Media,Hypothyroidism,2018-08-13,2024-08-31,2025-02-28,Interventional,Withdrawn,Phase 4,GE Healthcare,Bayer|GE Healthcare|Guerbet/Liebel-Flarsheim,,Drug|Drug|Drug|Drug,,0.0,3.0,[0-17],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03631771
NCT03636945,medullary thyroid carcinoma,Evaluation of the Clinical Performance of 18F-FDOPA PET-CT in the Preoperative Initial Assessment of Medullary Thyroid Carcinoma: Multicenter Prospective Study,Evaluation of 18F-FDOPA PET-CT in the Preoperative Initial Assessment of Medullary Thyroid Carcinoma,Medullary Thyroid Carcinoma,2018-08-16,2021-03-31,2021-09-30,Interventional,Unknown status,Not Applicable,Assistance Publique Hopitaux De Marseille,Assistance Publique Hopitaux De Marseille,Assistance Publique Des Hopitaux de Marseille,Other,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, medullary",https://clinicaltrials.gov/ct2/show/NCT03636945
NCT03639662,follicular thyroid cancer,Psychological Impact of a Sophrological Accompaniment During the Announcement of Thyroid Cancer Compared With Usual Initial Management: Multicenter Randomized Prospective Study,Psychological Impact of a Sophrological Accompaniment During the Announcement of Thyroid Cancer,Follicular Thyroid Cancer,2018-08-17,2022-03-31,2022-11-30,Interventional,Not yet recruiting,Not Applicable,Assistance Publique Hopitaux De Marseille,Assistance Publique Hopitaux De Marseille,Assistance Publique Des Hopitaux de Marseille,Other,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT03639662
NCT03640247,parathyroid diseases,Are Narcotic Pain Medications Necessary Following Thyroidectomy and Parathyroidectomy,Pain Medications Following Thyroidectomy and Parathyroidectomy,Parathyroid Diseases|Thyroid Disease,2018-07-24,2019-12-01,2019-12-01,Interventional,Completed,Phase 1,MetroHealth Medical Center,MetroHealth Medical Center,MetroHealth Medical Center,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT03640247
NCT03640247,thyroid disease,Are Narcotic Pain Medications Necessary Following Thyroidectomy and Parathyroidectomy,Pain Medications Following Thyroidectomy and Parathyroidectomy,Parathyroid Diseases|Thyroid Disease,2018-07-24,2019-12-01,2019-12-01,Interventional,Completed,Phase 1,MetroHealth Medical Center,MetroHealth Medical Center,MetroHealth Medical Center,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT03640247
NCT03641638,postpartum thyroiditis,Correlation Between Different Levels of Thyroid Peroxidase Antibody and Postpartum Thyroiditis in Early Pregancy,Correlation Between Different Levels of Thyroid Peroxidase Antibody and Postpartum Thyroiditis in Early Pregnancy,Postpartum Thyroiditis,2018-07-08,2020-10-31,2020-12-31,Observational,Unknown status,,China National Nuclear Corporation 416 Hospital,China National Nuclear Corporation 416 Hospital,China National Nuclear corporation 416 Hospital,,China,18.0,35.0,[18-65],Thyroiditis,Other thyroiditis,https://clinicaltrials.gov/ct2/show/NCT03641638
NCT03643055,medullary thyroid cancer,Diagnostic Value of 18F-Fluorocholine PET/CT for the Detection of Medullary Thyroid Cancer,18F-Fluorocholine PET/CT in Medullary Thyroid Cancer,Medullary Thyroid Cancer,2018-08-20,2021-03-03,2024-09-03,Observational,Active not recruiting,,University Medical Centre Ljubljana,Institute of Oncology Ljubljana|University Medical Centre Ljubljana,"Department for nuclear medicine, University medical centre Ljubljana",Diagnostic Test,Slovenia,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, medullary",https://clinicaltrials.gov/ct2/show/NCT03643055
NCT03647358,thyroid carcinoma,Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma,Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma,Metastatic Thyroid Carcinoma|Thyroid Carcinoma,2018-08-22,2022-08-31,2022-08-31,Interventional,Recruiting,Phase 1,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center|Weill Cornell Medical Center,Device|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03647358
NCT03647657,"thyroid cancer, medullary",177Lu-PP-F11N in Combination With Sacubitril for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer (Lumed Phase 0/B),177Lu-PP-F11N in Combination With Sacubitril for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer,"Thyroid Cancer, Medullary",2018-08-20,2021-12-14,2021-12-14,Interventional,Completed,Early Phase 1,"University Hospital, Basel, Switzerland","Center for Proton Therapy, Paul Scherrer Institute, Villigen,Switzerland|Krebsforschung Schweiz, Bern, Switzerland|University Hospital, Basel, Switzerland|University Hospital Freiburg|University Hospital, Zürich","University Hospital Basel, Clinic for radiology and nuclear medicine",Drug|Drug,Switzerland,18.0,64.0,[18-65],Thyroid neoplasms,"Thyroid cancer, medullary",https://clinicaltrials.gov/ct2/show/NCT03647657
NCT03657654,thyroid cancer,Voice Outcomes Following Thyroidectomy Compared to Surgeries That Do Not Involve Risk to the Laryngeal Nerves,Voice Outcomes Following Thyroidectomy,Thyroid Cancer|Thyroid Nodule,2018-08-29,2021-12-15,2021-12-15,Observational,Recruiting,,University of Virginia,University of Virginia,University of Virginia,Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03657654
NCT03657654,thyroid nodule,Voice Outcomes Following Thyroidectomy Compared to Surgeries That Do Not Involve Risk to the Laryngeal Nerves,Voice Outcomes Following Thyroidectomy,Thyroid Cancer|Thyroid Nodule,2018-08-29,2021-12-15,2021-12-15,Observational,Recruiting,,University of Virginia,University of Virginia,University of Virginia,Other,United States,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03657654
NCT03667157,graves disease,Influence of Methylprednisolone Pulse Therapy on Liver Function in Patients With Graves' Orbitopathy,Liver Function After Intravenous Methylprednisolone Administration,"Acute Liver Failure|Acute Liver Injury|Acute Liver Injury, Drug Induced|Dysthyroid Ophthalmopathy|Dysthyroid Orbitopathy|Glucocorticoids Toxicity|Graves Disease|Graves Ophthalmopathy|Liver Diseases|Liver Dysfunction|Liver Failure|Liver Injury|Liver Insufficiency|Methylprednisolone Adverse Reaction",2018-09-08,2016-10-30,2016-10-30,Interventional,Completed,Phase 4,Medical University of Warsaw,Medical University of Warsaw,,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT03667157
NCT03667157,graves ophthalmopathy,Influence of Methylprednisolone Pulse Therapy on Liver Function in Patients With Graves' Orbitopathy,Liver Function After Intravenous Methylprednisolone Administration,"Acute Liver Failure|Acute Liver Injury|Acute Liver Injury, Drug Induced|Dysthyroid Ophthalmopathy|Dysthyroid Orbitopathy|Glucocorticoids Toxicity|Graves Disease|Graves Ophthalmopathy|Liver Diseases|Liver Dysfunction|Liver Failure|Liver Injury|Liver Insufficiency|Methylprednisolone Adverse Reaction",2018-09-08,2016-10-30,2016-10-30,Interventional,Completed,Phase 4,Medical University of Warsaw,Medical University of Warsaw,,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT03667157
NCT03676348,thyroid cancer,"Health Related Quality of Life in Thyroid Cancer Patients, and in Patients With Thyroid Nodules Suspicious of Cancer",HRQOL in Thyroid Cancer and Thyroid Tumours,Quality of Life|Thyroid Cancer|Thyroid Nodule,2018-09-17,2023-04-30,2028-04-30,Observational,Recruiting,,Oslo University Hospital,Oslo University Hospital,"ENT department, Oslo University Hospital",,Norway,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03676348
NCT03676348,thyroid nodule,"Health Related Quality of Life in Thyroid Cancer Patients, and in Patients With Thyroid Nodules Suspicious of Cancer",HRQOL in Thyroid Cancer and Thyroid Tumours,Quality of Life|Thyroid Cancer|Thyroid Nodule,2018-09-17,2023-04-30,2028-04-30,Observational,Recruiting,,Oslo University Hospital,Oslo University Hospital,"ENT department, Oslo University Hospital",,Norway,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03676348
NCT03676647,thyroid gland nodule,Retrospective-Prospective Collection of Thyroid Specimens After FNA,Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules,Thyroid Gland Nodule,2018-09-17,2023-12-31,2023-12-31,Observational,Recruiting,,City of Hope Medical Center,City of Hope Medical Center|National Cancer Institute (NCI),City of Hope Medical Center,Other,United States,19.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03676647
NCT03680222,thyroid cancer,Effect of Reversed Tracking Method of Stimulating Cricothyroid Muscles on the Identification and Protection of EBSLN in Thyroid Surgery,Effect of Reversed Tracking Method for Identification of EBSLN in Thyroid Surgery,Recurrent Laryngeal Nerve Injuries|Thyroid Cancer,2018-09-09,2019-09-30,2020-09-30,Interventional,Unknown status,Not Applicable,Fujian Medical University,Fujian Medical University,Fujian Medical University Union Hospital,Procedure,China,18.0,60.0,[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03680222
NCT03690388,differentiated thyroid cancer,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects With Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy",A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy,Differentiated Thyroid Cancer,2018-09-26,2020-08-19,2022-12-31,Interventional,Active not recruiting,Phase 3,Exelixis,Exelixis,Exelixis Clinical Site #2|Exelixis Clinical Site #98|Exelixis Clinical Site #69|Exelixis Clinical Site #10|Exelixis Clinical Site #3|Exelixis Clinical Site #9|Exelixis Clinical Site #21|Exelixis Clinical Site #4|Exelixis Clinical Site #94|Exelixis Clinical Site #93|Exelixis Clinical Site #6|Exelixis Clinical Site #164|Exelixis Clinical Site #54|Exelixis Clinical Site #153|Exelixis Clinical Site #80|Exelixis Clinical Site #78|Exelixis Clinical Site #22|Exelixis Clinical Site #63|Exelixis Clinical Site #42|Exelixis Clinical Site #11|Exelixis Clinical Site #118|Exelixis Clinical Site #76|Exelixis Clinical Site #19|Exelixis Clinical Site #7|Exelixis Clinical Site #5|Exelixis Clinical Site #1|Exelixis Clinical Site #75|Exelixis Clinical Site #134|Exelixis Clinical Site #68|Exelixis Clinical Site #8|Exelixis Clinical Site #113|Exelixis Clinical Site #96|Exelixis Clinical Site #97|Exelixis Clinical Site #129|Exelixis Clinical Site #17|Exelixis Clinical Site #25|Exelixis Clinical Site #86|Exelixis Clinical Site #24|Exelixis Clinical Site #12|Exelixis Clinical Site #62|Exelixis Clinical Site #119|Exelixis Clinical Site #90|Exelixis Clinical Site #31|Exelixis Clinical Site #26|Exelixis Clinical Site #74|Exelixis Clinical Site #100|Exelixis Clinical Site #27|Exelixis Clinical Site #35|Exelixis Clinical Site #39|Exelixis Clinical Site #140|Exelixis Clinical Site #38|Exelixis Clinical Site #40|Exelixis Clinical Site #116|Exelixis Clinical Site #92|Exelixis Clinical Site #47|Exelixis Clinical Site #20|Exelixis Clinical Site #18|Exelixis Clinical Site #107|Exelixis Clinical Site #83|Exelixis Clinical Site #145|Exelixis Clinical Site #137|Exelixis Clinical Site #138|Exelixis Clinical Site #105|Exelixis Clinical Site #104|Exelixis Clinical Site #32|Exelixis Clinical Site #44|Exelixis Clinical Site #67|Exelixis Clinical Site #45|Exelixis Clinical Site #72|Exelixis Clinical Site #102|Exelixis Clinical Site #91|Exelixis Clinical Site #82|Exelixis Clinical Site #152|Exelixis Clinical Site #95|Exelixis Clinical Site #121|Exelixis Clinical Site #156|Exelixis Clinical Site #125|Exelixis Clinical Site #163|Exelixis Clinical Site #124|Exelixis Clinical Site #151|Exelixis Clinical Site #155|Exelixis Clinical Site #131|Exelixis Clinical Site #154|Exelixis Clinical Site #160|Exelixis Clinical Site #159|Exelixis Clinical Site #139|Exelixis Clinical Site #28|Exelixis Clinical Site #46|Exelixis Clinical Site #37|Exelixis Clinical Site #43|Exelixis Clinical Site #41|Exelixis Clinical Site #58|Exelixis Clinical Site #109|Exelixis Clinical Site #135|Exelixis Clinical Site #132|Exelixis Clinical Site #144|Exelixis Clinical Site #143|Exelixis Clinical Site #29|Exelixis Clinical Site #120|Exelixis Clinical Site #103|Exelixis Clinical Site #110|Exelixis Clinical Site #115|Exelixis Clinical Site #108|Exelixis Clinical Site #56|Exelixis Clinical Site #123|Exelixis Clinical Site #87|Exelixis Clinical Site #127|Exelixis Clinical Site #111|Exelixis Clinical Site #70|Exelixis Clinical Site #79|Exelixis Clinical Site #36|Exelixis Clinical Site #34|Exelixis Clinical Site #158|Exelixis Clinical Site #133|Exelixis Clinical Site #147|Exelixis Clinical Site #148|Exelixis Clinical Site #161|Exelixis Clinical Site #128|Exelixis Clinical Site #117|Exelixis Clinical Site #15|Exelixis Clinical Site #61|Exelixis Clinical Site #59|Exelixis Clinical Site #149|Exelixis Clinical Site #150|Exelixis Clinical Site #142|Exelixis Clinical Site #146|Exelixis Clinical Site #48|Exelixis Clinical Site #55|Exelixis Clinical Site #157|Exelixis Clinical Site #49|Exelixis Clinical Site #53|Exelixis Clinical Site #84|Exelixis Clinical Site #85|Exelixis Clinical Site #106|Exelixis Clinical Site #89|Exelixis Clinical Site #52|Exelixis Clinical Site #66|Exelixis Clinical Site #14|Exelixis Clinical Site #99|Exelixis Clinical Site #114|Exelixis Clinical Site #30|Exelixis Clinical Site #13|Exelixis Clinical Site #16|Exelixis Clinical Site #33|Exelixis Clinical Site #73|Exelixis Clinical Site #23|Exelixis Clinical Site #81|Exelixis Clinical Site #136|Exelixis Clinical Site #112|Exelixis Clinical Site #77|Exelixis Clinical Site #101|Exelixis Clinical Site #126|Exelixis Clinical Site #122|Exelixis Clinical Site #141|Exelixis Clinical Site #130|Exelixis Clinical Site #88|Exelixis Clinical Site #71|Exelixis Clinical Site #162|Exelixis Clinical Site #51|Exelixis Clinical Site #64|Exelixis Clinical Site #50|Exelixis Clinical Site #60|Exelixis Clinical Site #65|Exelixis Clinical Site #57,Drug|Drug,"Argentina|Australia|Austria|Belgium|Brazil|Canada|Croatia|Czechia|France|Germany|Hong Kong|Hungary|Israel|Italy|Korea, Republic of|Mexico|Netherlands|Poland|Romania|Russian Federation|Spain|Taiwan|Thailand|United Kingdom|United States",16.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Differentiated thyroid cancer, all",https://clinicaltrials.gov/ct2/show/NCT03690388
NCT03700762,thyroid nodule,Application of Ultrasonic Gray-scale Ratio in Differentiating Benign From Malignant Thyroid Nodules.,Application of Ultrasonic Gray-scale Ratio in Differentiating Benign From Malignant Thyroid Nodules.,Thyroid Nodule,2018-07-07,2019-10-01,2020-10-01,Observational,Unknown status,,First People's Hospital of Hangzhou,First People's Hospital of Hangzhou,The first people's hospital of Hangzhou,Diagnostic Test,China,0.0,120.0,[0-17]|[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03700762
NCT03708627,graves ophthalmopathy,The Role of Bimatoprost in Graves' Periorbitopathy,Bimatoprost as a Treatment for Graves' Orbitopathy,Graves Ophthalmopathy,2018-10-13,2022-05-31,2022-06-30,Interventional,Recruiting,Early Phase 1,Johns Hopkins University,Johns Hopkins University,University of Washington,Drug,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT03708627
NCT03720210,amiodarone-induced thyrotoxicosis,Pilot Study for Treatment of Amiodarone-Induced Thyroiditis With Radiofrequency Ablation,Radiofrequency Ablation for Amiodarone-induced Thyrotoxicosis,Amiodarone-Induced Thyrotoxicosis,2018-10-17,2020-12-07,2020-12-07,Interventional,Terminated,Not Applicable,Mayo Clinic,Mayo Clinic,Mayo Clinic in Rochester,Device,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03720210
NCT03728959,hypoparathyroidism,Effects of a Liquid Meal and Gut Hormones (GIP and GLP-2) on Bone Remodeling in Participants With Hypoparathyroidism (KS-4-HypoPT).,Effects of a Liquid Meal and Gut Hormones (GIP and GLP-2) on Bone Remodeling in Participants With Hypoparathyroidism.,Hypoparathyroidism,2018-10-31,2019-04-12,2019-04-12,Interventional,Completed,Not Applicable,University of Copenhagen,Hvidovre University Hospital|University of Copenhagen,Hvidovre University Hospital,Other|Other|Other|Other,Denmark,18.0,76.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03728959
NCT03747029,hypoparathyroidism,Serum Calcium to Phosphorous (Ca/P) Ratio in the Diagnosis of Ca-P Metabolism Disorders: a Multicentre Study,Serum Calcium to Phosphorous (Ca/P) Ratio in the Diagnosis of Ca-P Metabolism Disorders: a Multicentre Study,Hyperparathyroidism|Hypoparathyroidism|Parathyroid Diseases|Phosphorus and Calcium Disorders,2018-11-16,2018-12-31,2018-12-31,Observational,Completed,,Azienda Ospedaliero-Universitaria di Modena,Azienda Ospedaliero-Universitaria di Modena,Azienda Ospedaliero - Universitaria di Modena,Other,Italy,18.0,90.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03747029
NCT03747029,hyperparathyroidism,Serum Calcium to Phosphorous (Ca/P) Ratio in the Diagnosis of Ca-P Metabolism Disorders: a Multicentre Study,Serum Calcium to Phosphorous (Ca/P) Ratio in the Diagnosis of Ca-P Metabolism Disorders: a Multicentre Study,Hyperparathyroidism|Hypoparathyroidism|Parathyroid Diseases|Phosphorus and Calcium Disorders,2018-11-16,2018-12-31,2018-12-31,Observational,Completed,,Azienda Ospedaliero-Universitaria di Modena,Azienda Ospedaliero-Universitaria di Modena,Azienda Ospedaliero - Universitaria di Modena,Other,Italy,18.0,90.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03747029
NCT03753919,metastatic thyroid cancer,"A Phase II Study of Durvalumab (MEDI4736) Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma - The DUTHY Trial","Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial",Metastatic Thyroid Cancer|Metastatic Thyroid Follicular Carcinoma|Metastatic Thyroid Papillary Carcinoma,2018-11-20,2022-07-31,2022-12-31,Interventional,Recruiting,Phase 2,Grupo Espanol de Tumores Neuroendocrinos,Grupo Espanol de Tumores Neuroendocrinos|MFAR,Instituto Catalán de Oncología de Hospitalet|Hospital Provincial de Castellón|Hospital Clínic Barcelona|Hospital Universitari Vall d'Hebron|MD Anderson Cancer Center|Hospital Clínico San Carlos|Hospital Universitario 12 de Octubre|Hospital Universitario HM Sanchinarro|Hospital Universitario La Paz|Hospital Universitario Ramón y Cajal|Hospital General Universitario Morales Meseguer|Hospital Universitario Virgen de la Victoria|Clínica Universidad de Navarra|Instituto Valenciano de Oncología|Complejo Hospitalario Universitario de Vigo (CHUVI),Drug|Drug,Spain,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Metastatic Thyroid Cancer,https://clinicaltrials.gov/ct2/show/NCT03753919
NCT03754621,hypothyroidism,What is the Rational Upper Limit for TSH and T4 During First and Second Trimester Pregnancy in West Black Sea Region of Turkey,Upper Limit for TSH of First and Second Trimester Pregnancy in Turkey,Hypothyroidism|Pregnancy Early|Thyroid|Thyroid Dysfunction,2018-11-23,2019-07-02,2019-07-15,Observational,Unknown status,,Bartin State Hospital,Bartin State Hospital,Bartin State Hospital,Diagnostic Test,Turkey,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03754621
NCT03757637,differentiated thyroid cancer,"Yeur-Hur Lai, PhD, RN, School of Nursing, College of Medicine, National Taiwan University",Compare the Effects of NLSCP and Interactive ICT Supported HAP on Differentiate Diagnosed Thyroid Cancer Patients,Differentiated Thyroid Cancer,2018-11-27,2022-12-31,2022-12-31,Interventional,Recruiting,Not Applicable,National Taiwan University Hospital,National Taiwan University Hospital,"Department of Surgery, National Taiwan University Hospital, No.7, Chung-Shan South Road, Taipei, TAIWAN, R.O.C.",Other|Other,Taiwan,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Differentiated thyroid cancer, all",https://clinicaltrials.gov/ct2/show/NCT03757637
NCT03765333,thyroid cancer,"Descriptive Observational Epidemiological Study on the Characteristics of Thyroid Cancer in Patients Treated in Oncology Services of Spanish Centers: National Registry of Thyroid Cancer - Differentiated, Medullary and Anaplastic",GETNE Registration of Thyroid Cancer,Thyroid Cancer,2018-11-20,2021-09-30,2021-11-30,Observational,Recruiting,,Grupo Espanol de Tumores Neuroendocrinos,Grupo Espanol de Tumores Neuroendocrinos,Hospital Universitari Vall d'Hebron,,Spain,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03765333
NCT03772496,thyroid nodule,"A Multicenter, Double-blind, Prospective Cohort Study of Diagnostic Significance of Circulating Tumor Cells in Patients With Thyroid Nodules",Diagnostic Significance of CTCs in Patients With Thyroid Nodules (Circulating Tumor Cells),Diagnoses Disease|Thyroid Nodule,2018-11-23,2019-12-20,2020-02-20,Interventional,Unknown status,Not Applicable,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","Beijing Chao Yang Hospital|Cancer Institute and Hospital, Chinese Academy of Medical Sciences|China-Japan Friendship Hospital|Chinese PLA General Hospital","Cancer Hospital, Chinese Academy of Medical Science",Diagnostic Test|Diagnostic Test,China,18.0,70.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03772496
NCT03779906,hypothyroidism,"A Prospective, Multicenter Observational Study to Evaluate Thyroid Function of Pediatric Subjects From Birth to 3 Years Exposed to ISOVUE® (Iopamidol Injection)",Thyroid Function of Pediatric Subjects Following Isovue® Administration,Hypothyroidism,2018-12-17,2024-12-01,2025-01-31,Interventional,Recruiting,Phase 4,"Bracco Diagnostics, Inc","Bracco Diagnostics, Inc",Children's Hospital and Medical Center,Drug,United States,0.0,3.0,[0-17],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03779906
NCT03787121,thyroid cancer,Estimation of Economic Consequences Linked With Different Care Management Pathways of Differentiated Thyroid Cancers : Involvement of Overtreatment,Estimation of Economic Consequences Linked With Different Care Management Pathways of Differentiated Thyroid Cancers,Thyroid Cancer,2018-12-24,2020-12-31,2020-12-31,Observational,Completed,,"University Hospital, Toulouse","University Hospital, Toulouse",University HospitalToulouse,Procedure,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03787121
NCT03794375,differentiated thyroid cancer,Impact of Primary Care Transfer for Thyroid Cancer Patients,Primary Care Transfer for Thyroid Cancer Patients,Differentiated Thyroid Cancer,2018-12-28,2022-12-31,2024-12-31,Interventional,Enrolling by invitation,Not Applicable,Hospital de Clinicas de Porto Alegre,Hospital de Clinicas de Porto Alegre,Hospital de Clínicas de Porto Alegre,Other|Other,Brazil,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Differentiated thyroid cancer, all",https://clinicaltrials.gov/ct2/show/NCT03794375
NCT03823859,hyperthyroidism,Metabolomics of Thyroid Hormones,Metabolomics of Thyroid Hormones,Central Hypothyroidism|Hyperthyroidism|Hypothyroidism,2019-01-28,2021-07-28,2021-12-31,Observational [Patient Registry],Active not recruiting,,"University Hospital, Basel, Switzerland","ETH Zurich|University Hospital, Basel, Switzerland","University Hospital Basel, Department of Endocrinology",Diagnostic Test|Diagnostic Test|Diagnostic Test,Switzerland,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03823859
NCT03823859,central hypothyroidism,Metabolomics of Thyroid Hormones,Metabolomics of Thyroid Hormones,Central Hypothyroidism|Hyperthyroidism|Hypothyroidism,2019-01-28,2021-07-28,2021-12-31,Observational [Patient Registry],Active not recruiting,,"University Hospital, Basel, Switzerland","ETH Zurich|University Hospital, Basel, Switzerland","University Hospital Basel, Department of Endocrinology",Diagnostic Test|Diagnostic Test|Diagnostic Test,Switzerland,18.0,80.0,[18-65]|[65 and more],Hypothyroidism,Secondary hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03823859
NCT03826680,thyroid cancer,"The Relationship of Modified Cormack Lehane Scores Between Preoperative Awake Flexible Fiberoptic Laryngoscopy and Intraoperative Direct Laryngoscopy in Thyroidectomies, a Prospective, Clinical Study",Modified Cormack Lehane Scores Evaluated by Laryngoscopy During Awake Versus Under General Anesthesia,Thyroid Adenoma|Thyroid Cancer|Thyroid Nodule,2019-01-29,2020-06-30,2020-07-31,Interventional,Unknown status,Not Applicable,Istanbul University,Istanbul University,"Istanbul University- Cerrahpasa Department of Anesthesiology, general surgery, ENT surgery",Procedure|Procedure,Turkey,18.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03826680
NCT03826680,thyroid nodule,"The Relationship of Modified Cormack Lehane Scores Between Preoperative Awake Flexible Fiberoptic Laryngoscopy and Intraoperative Direct Laryngoscopy in Thyroidectomies, a Prospective, Clinical Study",Modified Cormack Lehane Scores Evaluated by Laryngoscopy During Awake Versus Under General Anesthesia,Thyroid Adenoma|Thyroid Cancer|Thyroid Nodule,2019-01-29,2020-06-30,2020-07-31,Interventional,Unknown status,Not Applicable,Istanbul University,Istanbul University,"Istanbul University- Cerrahpasa Department of Anesthesiology, general surgery, ENT surgery",Procedure|Procedure,Turkey,18.0,70.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03826680
NCT03838692,medullary thyroid cancer,A Study of Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer (MTC),Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer,Medullary Thyroid Cancer,2019-02-11,2021-06-14,2021-06-14,Interventional,Withdrawn,Phase 2,Columbia University,"Antonio Fojo|Millennium Pharmaceuticals, Inc.",,Drug,,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, medullary",https://clinicaltrials.gov/ct2/show/NCT03838692
NCT03841617,thyroid cancer,The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer,The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer,Thyroid Cancer,2019-02-13,2024-02-01,2029-02-01,Interventional,Recruiting,Phase 2,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),National Institutes of Health Clinical Center,Drug|Radiation|Radiation|Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03841617
NCT03871387,thyroid neoplasms,The Effects of Deep Neuromuscular Blockade During Robot-assisted Transaxillary Thyroidectomy on Postoperative Pain and Sensory Change; Prospective Randomized Control Trial,The Effects of Deep Neuromuscular Blockade During Robot-assisted Transaxillary Thyroidectomy on Postoperative Pain and Sensory Change,Thyroid Neoplasms,2019-02-26,2020-02-24,2020-02-24,Interventional,Completed,Not Applicable,Yonsei University,Yonsei University,"Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine",Drug|Drug,"Korea, Republic of",20.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03871387
NCT03884140,thyroid nodule,Clinical Diagnostic Evaluation of Thyroid Nodules,Clinical Diagnostic Approach for Cases of Thyroid Nodules,Thyroid Nodule,2019-03-19,2022-06-01,2022-09-01,Observational [Patient Registry],Not yet recruiting,,Assiut University,Assiut University,,,,18.0,75.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03884140
NCT03887611,thyroid nodule,A Multi-center Study of Differential Diagnosis Thyroid Nodules by Ultrasound Artificial Intelligence and Ultrasound Elastography,Application of Ultrasound Artificial Intelligence and Elastography in Differential Diagnosis of Thyroid Nodules,Thyroid Nodule,2019-03-21,2020-01-18,2020-03-18,Observational,Unknown status,,Tongji Hospital,"Affiliated Hospital of Jiangsu University|Anqing People's Hospital|Enshi State Central Hospital|Huai'an First People's Hospital|Huainan People's Hospital|Huangshi Central Hospital, China|Jiangxia District First People's Hospital|Lianyungang Third People's Hospital|Macheng People's Hospital|Taizhou Hospital|The Central Hospital of Lishui City|The First People's Hospital of Yichang|The Second Hospital of Anhui Medical University|The Second People's Hospital of Yichang|Wenzhou Central Hospital|WISCO General Hospital|Wuhan Hospital of Traditional Chinese and Western Medicine|Xiangyang Central Hospital|Xiangyang First People's Hospital|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|Xin-Wu Cui|Xuzhou First People's Hospital",Xin-Wu Cui,Device,China,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT03887611
NCT03889769,papillary thyroid cancer,Evaluation of Accuracy of One-Step Nucleic Acid Amplification (OSNA) in Diagnosis of Lymph Node Metastases of Papillary Thyroid Carcinoma,Evaluation of Accuracy of One-Step Nucleic Acid Amplification (OSNA) in Diagnosis of Lymph Node Metastases of Papillary Thyroid Carcinoma,Lymph Node Metastases|Papillary Thyroid Cancer,2019-03-23,2019-04-01,2019-09-30,Observational,Unknown status,,University of Cagliari,University of Cagliari,Policlinico di Monserrato,Diagnostic Test,Italy,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT03889769
NCT03891043,thyroid orbitopathy,Oral Supplementation With Selenium in Patients With Mild Thyroid Orbitopathy to Reduce Its,Oral Supplementation With Selenium in Patients With Mild Thyroid Orbitopathy,Thyroid Orbitopathy,2019-03-15,2016-04-30,2016-04-30,Interventional,Completed,Not Applicable,Instituto de Oftalmología Fundación Conde de Valenciana,Instituto de Oftalmología Fundación Conde de Valenciana,,Dietary Supplement|Other,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT03891043
NCT03892993,thyroid gland medullary carcinoma,"Designing a Decision Aid to Help People With Medullary Thyroid Cancer Make Decisions With Their Doctors About Whether to Start or Stop New Drugs, Enroll in Clinical Trials, or Continue With Active Surveillance","Patient Decision Aid in Supporting Decision-Making About When to Start or Stop New Drugs, Join Clinical Trials, or Continue Active Surveillance in Patients With Medullary Thyroid Cancer and Their Caregivers",Thyroid Gland Medullary Carcinoma,2019-02-21,2023-04-19,2024-04-19,Interventional,Recruiting,Not Applicable,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center|National Cancer Institute (NCI),M D Anderson Cancer Center,Other|Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, medullary",https://clinicaltrials.gov/ct2/show/NCT03892993
NCT03899792,papillary thyroid cancer,A Phase 1/2 Study of the Oral RET Inhibitor LOXO 292 in Pediatric Patients With Advanced RET-Altered Solid or Primary Central Nervous System Tumors,A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors,Infantile Fibrosarcoma|Infantile Myofibromatosis|Medullary Thyroid Cancer|Papillary Thyroid Cancer|Soft Tissue Sarcoma,2019-02-06,2023-03-26,2024-03-26,Interventional,Recruiting,Phase 1/Phase 2,Eli Lilly and Company,"Eli Lilly and Company|Loxo Oncology, Inc.",Childrens Hospital of Los Angeles|Lucile Packard Children's Hospital|The Children's Hospital for Cancer and Blood Disorders|Nemours Children's Health|Dana-Farber Cancer Institute|University of Minnesota Hospital|Memorial Sloan Kettering Cancer Center|Cincinnati Children's Hospital Medical Center|Children's Hospital of Philadelphia|St. Jude Children's Research Hospital|University of Texas Southwestern Medical Center at Dallas|Texas Childrens Hospital|Seattle Children's Hospital Research Foundation|The Children's Hospital at Westmead|Royal Children's Hospital|The Hospital for Sick Children|Rigshospitalet|Gustave Roussy|Universitätsklinikum Heidelberg|Fondazione IRCCS Istituto Nazionale dei Tumori|Hokkaido University Hospital|National Cancer Center Hospital|Hiroshima University Hospital|Kyoto University Hospital|Seoul National University Hospital|Hospital Universitari Vall d'Hebron|University College Hospital - London,Drug,"Australia|Canada|Denmark|France|Germany|Italy|Japan|Korea, Republic of|Spain|United Kingdom|United States",6.0,21.0,[0-17]|[18-65],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT03899792
NCT03899792,medullary thyroid cancer,A Phase 1/2 Study of the Oral RET Inhibitor LOXO 292 in Pediatric Patients With Advanced RET-Altered Solid or Primary Central Nervous System Tumors,A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors,Infantile Fibrosarcoma|Infantile Myofibromatosis|Medullary Thyroid Cancer|Papillary Thyroid Cancer|Soft Tissue Sarcoma,2019-02-06,2023-03-26,2024-03-26,Interventional,Recruiting,Phase 1/Phase 2,Eli Lilly and Company,"Eli Lilly and Company|Loxo Oncology, Inc.",Childrens Hospital of Los Angeles|Lucile Packard Children's Hospital|The Children's Hospital for Cancer and Blood Disorders|Nemours Children's Health|Dana-Farber Cancer Institute|University of Minnesota Hospital|Memorial Sloan Kettering Cancer Center|Cincinnati Children's Hospital Medical Center|Children's Hospital of Philadelphia|St. Jude Children's Research Hospital|University of Texas Southwestern Medical Center at Dallas|Texas Childrens Hospital|Seattle Children's Hospital Research Foundation|The Children's Hospital at Westmead|Royal Children's Hospital|The Hospital for Sick Children|Rigshospitalet|Gustave Roussy|Universitätsklinikum Heidelberg|Fondazione IRCCS Istituto Nazionale dei Tumori|Hokkaido University Hospital|National Cancer Center Hospital|Hiroshima University Hospital|Kyoto University Hospital|Seoul National University Hospital|Hospital Universitari Vall d'Hebron|University College Hospital - London,Drug,"Australia|Canada|Denmark|France|Germany|Italy|Japan|Korea, Republic of|Spain|United Kingdom|United States",6.0,21.0,[0-17]|[18-65],Thyroid neoplasms,"Thyroid cancer, medullary",https://clinicaltrials.gov/ct2/show/NCT03899792
NCT03905369,thyroid cancer,Focus on Values to Stimulate Shared Decisions in Patients With Thyroid Cancer: A Multifaceted COMmunication BOoster (COMBO),Focus on Values to Stimulate Shared Decisions,Thyroid Cancer,2019-03-21,2022-09-01,2023-03-01,Interventional,Recruiting,Not Applicable,Radboud University Medical Center,Dutch Cancer Society|Radboud University Medical Center,Rijnstate hospital|CWZ|Radboudumc|MUMC|Catharina hospital|AUMC|AVL|Haga|LUMC|UMCG|UMC Utrecht,Other|Other,Netherlands,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03905369
NCT03914300,thyroid gland papillary carcinoma,Phase II Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab (CaboNivoIpi) in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Whose Cancer Progressed After One Prior VEGFR-Targeted Therapy,"Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer",Differentiated Thyroid Gland Carcinoma|Follicular Variant Thyroid Gland Papillary Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Refractory Differentiated Thyroid Gland Carcinoma|Refractory Thyroid Gland Carcinoma|Tall Cell Variant Thyroid Gland Papillary Carcinoma|Thyroid Gland Follicular Carcinoma|Thyroid Gland Hurthle Cell Carcinoma|Thyroid Gland Papillary Carcinoma,2019-04-11,2023-01-15,2023-01-15,Interventional,Suspended,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),City of Hope Comprehensive Cancer Center|Los Angeles County-USC Medical Center|USC / Norris Comprehensive Cancer Center|USC Norris Oncology/Hematology-Newport Beach|Moffitt Cancer Center-International Plaza|Moffitt Cancer Center - McKinley Campus|Moffitt Cancer Center|University of Kansas Clinical Research Center|HaysMed University of Kansas Health System|University of Kansas Cancer Center|Olathe Health Cancer Center|University of Kansas Cancer Center-Overland Park|Ascension Via Christi - Pittsburg|Salina Regional Health Center|University of Kansas Health System Saint Francis Campus|University of Kansas Hospital-Westwood Cancer Center|University of Kentucky/Markey Cancer Center|Dana-Farber Cancer Institute|Mayo Clinic in Rochester|Truman Medical Centers|University of Kansas Cancer Center - North|University of Kansas Cancer Center - Lee's Summit|University of Kansas Cancer Center at North Kansas City Hospital|Memorial Sloan Kettering Basking Ridge|Memorial Sloan Kettering Monmouth|Memorial Sloan Kettering Bergen|Memorial Sloan Kettering Commack|Memorial Sloan Kettering Westchester|Memorial Sloan Kettering Cancer Center|Memorial Sloan Kettering Nassau|Ohio State University Comprehensive Cancer Center|University of Pittsburgh Cancer Institute (UPCI)|University of Utah Sugarhouse Health Center|Huntsman Cancer Institute/University of Utah,Drug|Biological|Biological,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT03914300
NCT03914300,thyroid gland follicular carcinoma,Phase II Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab (CaboNivoIpi) in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Whose Cancer Progressed After One Prior VEGFR-Targeted Therapy,"Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer",Differentiated Thyroid Gland Carcinoma|Follicular Variant Thyroid Gland Papillary Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Refractory Differentiated Thyroid Gland Carcinoma|Refractory Thyroid Gland Carcinoma|Tall Cell Variant Thyroid Gland Papillary Carcinoma|Thyroid Gland Follicular Carcinoma|Thyroid Gland Hurthle Cell Carcinoma|Thyroid Gland Papillary Carcinoma,2019-04-11,2023-01-15,2023-01-15,Interventional,Suspended,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),City of Hope Comprehensive Cancer Center|Los Angeles County-USC Medical Center|USC / Norris Comprehensive Cancer Center|USC Norris Oncology/Hematology-Newport Beach|Moffitt Cancer Center-International Plaza|Moffitt Cancer Center - McKinley Campus|Moffitt Cancer Center|University of Kansas Clinical Research Center|HaysMed University of Kansas Health System|University of Kansas Cancer Center|Olathe Health Cancer Center|University of Kansas Cancer Center-Overland Park|Ascension Via Christi - Pittsburg|Salina Regional Health Center|University of Kansas Health System Saint Francis Campus|University of Kansas Hospital-Westwood Cancer Center|University of Kentucky/Markey Cancer Center|Dana-Farber Cancer Institute|Mayo Clinic in Rochester|Truman Medical Centers|University of Kansas Cancer Center - North|University of Kansas Cancer Center - Lee's Summit|University of Kansas Cancer Center at North Kansas City Hospital|Memorial Sloan Kettering Basking Ridge|Memorial Sloan Kettering Monmouth|Memorial Sloan Kettering Bergen|Memorial Sloan Kettering Commack|Memorial Sloan Kettering Westchester|Memorial Sloan Kettering Cancer Center|Memorial Sloan Kettering Nassau|Ohio State University Comprehensive Cancer Center|University of Pittsburgh Cancer Institute (UPCI)|University of Utah Sugarhouse Health Center|Huntsman Cancer Institute/University of Utah,Drug|Biological|Biological,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT03914300
NCT03914300,thyroid gland hurthle cell carcinoma,Phase II Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab (CaboNivoIpi) in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Whose Cancer Progressed After One Prior VEGFR-Targeted Therapy,"Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer",Differentiated Thyroid Gland Carcinoma|Follicular Variant Thyroid Gland Papillary Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Refractory Differentiated Thyroid Gland Carcinoma|Refractory Thyroid Gland Carcinoma|Tall Cell Variant Thyroid Gland Papillary Carcinoma|Thyroid Gland Follicular Carcinoma|Thyroid Gland Hurthle Cell Carcinoma|Thyroid Gland Papillary Carcinoma,2019-04-11,2023-01-15,2023-01-15,Interventional,Suspended,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),City of Hope Comprehensive Cancer Center|Los Angeles County-USC Medical Center|USC / Norris Comprehensive Cancer Center|USC Norris Oncology/Hematology-Newport Beach|Moffitt Cancer Center-International Plaza|Moffitt Cancer Center - McKinley Campus|Moffitt Cancer Center|University of Kansas Clinical Research Center|HaysMed University of Kansas Health System|University of Kansas Cancer Center|Olathe Health Cancer Center|University of Kansas Cancer Center-Overland Park|Ascension Via Christi - Pittsburg|Salina Regional Health Center|University of Kansas Health System Saint Francis Campus|University of Kansas Hospital-Westwood Cancer Center|University of Kentucky/Markey Cancer Center|Dana-Farber Cancer Institute|Mayo Clinic in Rochester|Truman Medical Centers|University of Kansas Cancer Center - North|University of Kansas Cancer Center - Lee's Summit|University of Kansas Cancer Center at North Kansas City Hospital|Memorial Sloan Kettering Basking Ridge|Memorial Sloan Kettering Monmouth|Memorial Sloan Kettering Bergen|Memorial Sloan Kettering Commack|Memorial Sloan Kettering Westchester|Memorial Sloan Kettering Cancer Center|Memorial Sloan Kettering Nassau|Ohio State University Comprehensive Cancer Center|University of Pittsburgh Cancer Institute (UPCI)|University of Utah Sugarhouse Health Center|Huntsman Cancer Institute/University of Utah,Drug|Biological|Biological,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Hurthle cell thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03914300
NCT03914300,poorly differentiated thyroid gland carcinoma,Phase II Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab (CaboNivoIpi) in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Whose Cancer Progressed After One Prior VEGFR-Targeted Therapy,"Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer",Differentiated Thyroid Gland Carcinoma|Follicular Variant Thyroid Gland Papillary Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Refractory Differentiated Thyroid Gland Carcinoma|Refractory Thyroid Gland Carcinoma|Tall Cell Variant Thyroid Gland Papillary Carcinoma|Thyroid Gland Follicular Carcinoma|Thyroid Gland Hurthle Cell Carcinoma|Thyroid Gland Papillary Carcinoma,2019-04-11,2023-01-15,2023-01-15,Interventional,Suspended,Phase 2,National Cancer Institute (NCI),National Cancer Institute (NCI),City of Hope Comprehensive Cancer Center|Los Angeles County-USC Medical Center|USC / Norris Comprehensive Cancer Center|USC Norris Oncology/Hematology-Newport Beach|Moffitt Cancer Center-International Plaza|Moffitt Cancer Center - McKinley Campus|Moffitt Cancer Center|University of Kansas Clinical Research Center|HaysMed University of Kansas Health System|University of Kansas Cancer Center|Olathe Health Cancer Center|University of Kansas Cancer Center-Overland Park|Ascension Via Christi - Pittsburg|Salina Regional Health Center|University of Kansas Health System Saint Francis Campus|University of Kansas Hospital-Westwood Cancer Center|University of Kentucky/Markey Cancer Center|Dana-Farber Cancer Institute|Mayo Clinic in Rochester|Truman Medical Centers|University of Kansas Cancer Center - North|University of Kansas Cancer Center - Lee's Summit|University of Kansas Cancer Center at North Kansas City Hospital|Memorial Sloan Kettering Basking Ridge|Memorial Sloan Kettering Monmouth|Memorial Sloan Kettering Bergen|Memorial Sloan Kettering Commack|Memorial Sloan Kettering Westchester|Memorial Sloan Kettering Cancer Center|Memorial Sloan Kettering Nassau|Ohio State University Comprehensive Cancer Center|University of Pittsburgh Cancer Institute (UPCI)|University of Utah Sugarhouse Health Center|Huntsman Cancer Institute/University of Utah,Drug|Biological|Biological,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Poorly differentiated thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03914300
NCT03926585,hypothyroidism,Longtime Effect of Combination Treatment With L-thyroxine (L-T4) and Liothyronine (L-T3) in Patients With Persistent Hypothyroid Symptoms - Relation to Polymorphisms (SNP) in the DIO2 and the MCT10 Gene,Variations in the DIO2 and MCT10 Genes and Effect of Triiodothyronine Treatment,Hypothyroidism,2019-04-15,2022-04-30,2022-04-30,Observational,Recruiting,,Herlev Hospital,Birte Nygaard,Herlev Hospital,,Denmark,18.0,80.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03926585
NCT03941184,graves disease,Determining the Association Between Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity,Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity,"Addison Disease|Ankylosing Spondylitis|Antiphospholipid Antibody Syndrome|Celiac Disease|Crohn Disease|Dermatomyositis|Graves Disease|Guillain-Barre Syndrome|Hashimoto Thyroiditis|Hepatitis, Autoimmune|Multiple Sclerosis|Myasthenia Gravis|Pernicious Anemia|Polymyalgia Rheumatica|Polymyositis|Primary Biliary Cirrhosis|Psoriasis|Raynaud|Rheumatoid Arthritis|SCAD|Sjögren Syndrome|Systemic Lupus Erythematosus|Systemic Sclerosis|Takayasu Arteritis|Type 1 Diabetes Mellitus|Ulcerative Colitis|Uveitis|Vasculitis|Vitiligo",2019-04-01,2020-11-10,2020-11-10,Observational,Completed,,Mayo Clinic,Mayo Clinic,Mayo Clinic,,United States,18.0,110.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT03941184
NCT03942380,thyroid neoplasms,Cell-free Tumor DNAand HPV-DNA in Blood Samples From Newly Diagnosed Patients With Head and Neck Cancer,Cell-free Tumor DNA in Head and Neck Cancer Patients,Head and Neck Cancer|Head and Neck Neoplasms|Head and Neck Squamous Cell Carcinoma|Hypopharynx Cancer|Hypopharynx Carcinoma|Hypopharynx Neoplasm|Larynx Cancer|Larynx Carcinoma|Larynx Neoplasm|Nasopharyngeal Cancer|Nasopharyngeal Carcinoma|Nasopharynx Neoplasm|Oral Cancer|Oral Cavity Cancer|Oral Neoplasm|Oropharynx Cancer|Oropharynx Carcinoma|Oropharynx Neoplasm|Salivary Gland Cancer|Salivary Gland Carcinoma|Salivary Gland Neoplasms|Sinonasal Cancer|Sinonasal Carcinoma|Sinonasal Neoplasm|Thyroid Cancer|Thyroid Carcinoma|Thyroid Neoplasms,2019-04-15,2025-02-01,2025-02-01,Interventional,Recruiting,Not Applicable,"Rigshospitalet, Denmark","Christian von Buchwald|Copenhagen University Hospital, Denmark|Department of Otorhinolaryngology, Head and Neck Surgery and Audiology","University Hospital of Copenhagen, Rigshospitalet",Diagnostic Test,Denmark,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03942380
NCT03951532,hyperthyroidism,Morbidity and Mortality Associated With the Care Journey in Children and Adolescents With Hyperthyroidism,Morbidity and Mortality Associated With the Care Journey in Children and Adolescents With Hyperthyroidism,Hyperthyroidism,2019-03-12,2020-12-31,2020-12-31,Observational,Completed,,Assistance Publique - Hôpitaux de Paris,Assistance Publique - Hôpitaux de Paris,Hôpital Robert Debré,,France,6.0,17.0,[0-17],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT03951532
NCT03968510,hyperparathyroidism,The Effect of Parathyroidectomy on Swallowing Related Quality of Life in Primary Hyperparathyroidism,Swalqol in Primary Hyperparathyroidism,Hyperparathyroidism,2019-03-20,2020-07-01,2020-11-01,Observational [Patient Registry],Completed,,Uşak University,Uşak University,Uşak University,Procedure,Turkey,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03968510
NCT03969108,graves disease,Diagnostic Accuracy Study of Indocyanine Green for Parathyroid Perfusion Assessment,Diagnostic Accuracy Study of Indocyanine Green for Parathyroid Perfusion Assessment,Graves Disease|Thyroid Cancer|Thyroid Goiter,2019-05-24,2019-11-12,2019-11-13,Interventional,Completed,Phase 4,"University Health Network, Toronto","University Health Network, Toronto",University Health Network,Drug,Canada,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT03969108
NCT03969108,thyroid cancer,Diagnostic Accuracy Study of Indocyanine Green for Parathyroid Perfusion Assessment,Diagnostic Accuracy Study of Indocyanine Green for Parathyroid Perfusion Assessment,Graves Disease|Thyroid Cancer|Thyroid Goiter,2019-05-24,2019-11-12,2019-11-13,Interventional,Completed,Phase 4,"University Health Network, Toronto","University Health Network, Toronto",University Health Network,Drug,Canada,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03969108
NCT03973450,endocrine neoplasia,"Epidemiology of Pituitary Tumours: Prevalence of Associated Endocrine and Non-endocrine Tumours and Potential Implications in the Management and Follow-up of Patients""",Epidemiology of Pituitary Tumours: Prevalence of Associated Neoplasia,Endocrine Neoplasia|Familial Tumor Syndrome|Hyperparathyroidism|Pituitary Tumor|Solid Tumor,2019-05-25,2021-11-30,2022-02-28,Observational,Recruiting,,Neuromed IRCCS,Neuromed IRCCS,Neuromed,Other,Italy,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03973450
NCT03973450,hyperparathyroidism,"Epidemiology of Pituitary Tumours: Prevalence of Associated Endocrine and Non-endocrine Tumours and Potential Implications in the Management and Follow-up of Patients""",Epidemiology of Pituitary Tumours: Prevalence of Associated Neoplasia,Endocrine Neoplasia|Familial Tumor Syndrome|Hyperparathyroidism|Pituitary Tumor|Solid Tumor,2019-05-25,2021-11-30,2022-02-28,Observational,Recruiting,,Neuromed IRCCS,Neuromed IRCCS,Neuromed,Other,Italy,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT03973450
NCT03975231,thyroid gland anaplastic carcinoma,A Phase I Trial of Concurrent Intensity Modulated Radiation Therapy (IMRT) and Dabrafenib/Trametinib in BRAF Mutated Anaplastic Thyroid Cancer,"Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer",BRAF NP_004324.2:p.V600E|BRAF V600K Mutation Present|Thyroid Gland Anaplastic Carcinoma,2019-06-03,2025-04-30,2025-04-30,Interventional,Recruiting,Phase 1,City of Hope Medical Center,City of Hope Medical Center|National Cancer Institute (NCI),City of Hope Medical Center|Ohio State University Comprehensive Cancer Center,Drug|Radiation|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT03975231
NCT03977207,hypothyroidism,A Randomized Controlled Trial of Thyroid Hormone Supplementation in Hemodialysis Patients,A Randomized Controlled Trial of Thyroid Hormone Supplementation in Hemodialysis Patients,Hemodialysis|Hypothyroidism|Thyroid; Functional Disturbance,2019-05-28,2024-06-30,2024-06-30,Interventional,Recruiting,Not Applicable,"University of California, Irvine","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|University of California, Irvine",University of California Irvine,Drug|Drug,United States,18.0,75.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03977207
NCT03978351,thyroid cancer,The Role of Midkine in Diagnosis of Thyroid Cancer,The Role of Midkine in Diagnosis of Thyroid Cancer,Thyroid Cancer,2018-11-24,2020-11-30,2020-12-31,Observational,Unknown status,,Assiut University,Assiut University,,,,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT03978351
NCT03986437,differentiated thyroid cancer,A Prospective Study to Collect Images in Patients Treated With Iodine-131 as Part of a European Research Project in Radiation Protection.,A Prospective Study to Collect Images in Patients Treated With Iodine-131 as Part of a European Research Project in Radiation Protection.,Differentiated Thyroid Cancer,2019-06-11,2021-05-21,2021-05-21,Observational,Completed,,Institut Claudius Regaud,Institut Claudius Regaud,IUCT-O,,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Differentiated thyroid cancer, all",https://clinicaltrials.gov/ct2/show/NCT03986437
NCT03988517,hypothyroidism,A Prospective Study Comparing Two-time Points of Thyroid Hormone Replacement During the Holy Month of Ramadan,Comparing Two-time Points of Thyroid Hormone Replacement During the Holy Month of Ramadan,Hypothyroidism,2019-06-11,2018-01-08,2018-01-08,Interventional,Completed,Not Applicable,Hamad Medical Corporation,Hamad Medical Corporation,Hamad General Hospital,Other,Qatar,18.0,70.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT03988517
NCT04000880,thyroid cancer,Adapting MultiPLe Behavior Interventions That eFfectively Improve (AMPLIFI) Cancer Survivor Health,Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health,Breast Cancer|Colorectal Cancer|Endometrial Cancer|Kidney Cancer|Multiple Myeloma|Non-Hodgkin Lymphoma|Ovary Cancer|Prostate Cancer|Thyroid Cancer,2019-06-21,2024-08-31,2024-08-31,Interventional,Recruiting,Not Applicable,University of Alabama at Birmingham,National Cancer Institute (NCI)|University of Alabama at Birmingham|University of Tennessee Health Science Center,University of Alabama at Birmingham|University of Tennessee Health Science Center,Behavioral|Other|Other|Other,United States,50.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04000880
NCT04009291,hypoparathyroidism,"PaTH Forward: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial With an Open-Label Extension, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Subcutaneously Daily in Adults With Hypoparathyroidism","A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism",Endocrine System Diseases|Hypoparathyroidism|Parathyroid Diseases,2019-06-20,2020-03-06,2023-03-31,Interventional,Active not recruiting,Phase 2,Ascendis Pharma A/S,Ascendis Pharma A/S,Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site,Combination Product|Combination Product,Canada|Denmark|Germany|Italy|Norway|United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04009291
NCT04028479,thyroid cancer,The Registry of Oncology Outcomes Associated With Testing and Treatment (ROOT),The Registry of Oncology Outcomes Associated With Testing and Treatment,"Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Adenocarcinoma|Adenocystic Carcinoma|Adrenal Cancer|Anal Cancer|Appendix Cancer|Astrocytoma|Bile Duct Cancer|Bladder Cancer|Bone Cancer|Brain Stem Neoplasms|Brain Tumor|Breast Cancer|Cancer, Advanced|Cancer of Colon|Cancer of Pancreas|Carcinoid Tumor|Cervical Cancer|Cholangiocarcinoma|Chondrosarcoma|Chronic Myeloid Leukemia|CNS Cancer|Colon Cancer|Colorectal Cancer|Esophageal Cancer|Esophagus Cancer|Fallopian Tube Cancer|Gestational Trophoblastic Tumor|Glioblastoma|Head and Neck Neoplasms|Hepatic Cancer|Kidney Cancer|Larynx Cancer|Liposarcoma|Liver Cancer|Lung Cancer|Melanoma|Mesothelioma|Multiple Endocrine Neoplasia|Multiple Myeloma|Nasopharyngeal Carcinoma|Neuroendocrine Tumors|Non Hodgkin Lymphoma|Osteosarcoma|Ovarian Cancer|Pancreatic Cancer|Parathyroid Neoplasms|Parotid Tumor|Penile Cancer|Pharynx Cancer|Pheochromocytoma|Prostate Cancer|Pulmonary Carcinoma|Rectal Cancer|Renal Cell Carcinoma|Salivary Gland Cancer|Sarcoma|Sarcoma, Kaposi|Sarcoma,Soft Tissue|Skin Cancer|Small Bowel Cancer|Small Cell Carcinoma|Stomach Cancer|Synovial Sarcoma|Testicular Cancer|Testis Cancer|Thymus Cancer|Thyroid Cancer|Tongue Cancer|Unknown Primary Tumors|Ureter Cancer|Uterine Cancer|Vaginal Cancer|Vulvar Cancer|Waldenstrom Macroglobulinemia",2019-07-17,2029-10-01,2031-10-01,Observational [Patient Registry],Recruiting,,Taproot Health,Taproot Health,Teton Cancer Institute,Diagnostic Test|Drug|Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04028479
NCT04028479,parathyroid neoplasms,The Registry of Oncology Outcomes Associated With Testing and Treatment (ROOT),The Registry of Oncology Outcomes Associated With Testing and Treatment,"Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Adenocarcinoma|Adenocystic Carcinoma|Adrenal Cancer|Anal Cancer|Appendix Cancer|Astrocytoma|Bile Duct Cancer|Bladder Cancer|Bone Cancer|Brain Stem Neoplasms|Brain Tumor|Breast Cancer|Cancer, Advanced|Cancer of Colon|Cancer of Pancreas|Carcinoid Tumor|Cervical Cancer|Cholangiocarcinoma|Chondrosarcoma|Chronic Myeloid Leukemia|CNS Cancer|Colon Cancer|Colorectal Cancer|Esophageal Cancer|Esophagus Cancer|Fallopian Tube Cancer|Gestational Trophoblastic Tumor|Glioblastoma|Head and Neck Neoplasms|Hepatic Cancer|Kidney Cancer|Larynx Cancer|Liposarcoma|Liver Cancer|Lung Cancer|Melanoma|Mesothelioma|Multiple Endocrine Neoplasia|Multiple Myeloma|Nasopharyngeal Carcinoma|Neuroendocrine Tumors|Non Hodgkin Lymphoma|Osteosarcoma|Ovarian Cancer|Pancreatic Cancer|Parathyroid Neoplasms|Parotid Tumor|Penile Cancer|Pharynx Cancer|Pheochromocytoma|Prostate Cancer|Pulmonary Carcinoma|Rectal Cancer|Renal Cell Carcinoma|Salivary Gland Cancer|Sarcoma|Sarcoma, Kaposi|Sarcoma,Soft Tissue|Skin Cancer|Small Bowel Cancer|Small Cell Carcinoma|Stomach Cancer|Synovial Sarcoma|Testicular Cancer|Testis Cancer|Thymus Cancer|Thyroid Cancer|Tongue Cancer|Unknown Primary Tumors|Ureter Cancer|Uterine Cancer|Vaginal Cancer|Vulvar Cancer|Waldenstrom Macroglobulinemia",2019-07-17,2029-10-01,2031-10-01,Observational [Patient Registry],Recruiting,,Taproot Health,Taproot Health,Teton Cancer Institute,Diagnostic Test|Drug|Other,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04028479
NCT04031339,thyroid neoplasms,"Multicenter, Prospective, Observational Study of Clinical Outcomes of Thyroid Cancer",Study of Clinical Outcomes of Thyroid Cancer,Thyroid Neoplasms,2019-06-25,2025-01-31,2025-01-31,Observational,Recruiting,,University of Roma La Sapienza,Catholic University of the Sacred Heart|Italian Thyroid Cancer Observatory (ITCO) Foundation|University of Roma La Sapienza,"Ospedali Riuniti di Ancona|Università degli Studi di Bari|Azienda Unità Sanitaria di Bologna - Ospedale Maggiore|University of Bologna, S. Orsola Malpighi Hospital|ASST Valle Olona - Ospedale di Busto Arsizio|University of Florence|Ente Ospedaliero Ospedali Galliera|Sapienza University of Rome, Santa Maria Goretti Hospital|Tinchi Pisticci Hospital|University of Milan, Fondazione IRCCS, National Cancer Institute of Milan|University of Modena and Reggio Emilia|University of Naples Federico II|University of Parma|Bio-Medical Campus University|Sapienza University of Rome, Sant'Andrea Hospital|Sapienza University of Rome|University of Siena|University of Turin, Gradenigo Hospital|University of Turin, Molinette Hospital",Procedure,Italy,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04031339
NCT04040673,thyroid cancer,Evaluation of the Role of Vibrational Spectroscopy in the Diagnosis of Premalignant and Malignant Disease of the Thyroid RAFTER (RAman For Thyroid cancER),RAman For Thyroid cancER,Thyroid Cancer|Thyroid Diseases,2019-07-29,2022-10-01,2022-10-01,Observational,Not yet recruiting,,Gloucestershire Hospitals NHS Foundation Trust,Gloucestershire Hospitals NHS Foundation Trust,Biophotonics Research Unit,Procedure|Device,United Kingdom,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04040673
NCT04040673,thyroid diseases,Evaluation of the Role of Vibrational Spectroscopy in the Diagnosis of Premalignant and Malignant Disease of the Thyroid RAFTER (RAman For Thyroid cancER),RAman For Thyroid cancER,Thyroid Cancer|Thyroid Diseases,2019-07-29,2022-10-01,2022-10-01,Observational,Not yet recruiting,,Gloucestershire Hospitals NHS Foundation Trust,Gloucestershire Hospitals NHS Foundation Trust,Biophotonics Research Unit,Procedure|Device,United Kingdom,18.0,120.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04040673
NCT04040946,hyperparathyroidism,Phase III Trial Comparing 2 Diagnostic Strategies for Preoperative Localization of Parathyroid Adenoma in Primary Hyperparathyroidism:TEMP / CT With Tc99m-sestaMIBI or PET / CT With F18-choline in First Intention,Trial Comparing 2 Diagnostic Strategies for Preoperative Localization of Parathyroid Adenoma in Primary Hyperparathyroidism:TEMP / CT With Tc99m-sestaMIBI or PET / CT With F18-choline in First Intention,F18-choline|Hyperparathyroidism|Parathyroid Adenoma,2019-07-29,2022-09-30,2023-03-31,Interventional,Recruiting,Phase 3,Centre Francois Baclesse,Centre Francois Baclesse|Fondation de l'Avenir,CHU Brest|Centre François Baclesse|Centre Eugène Marquis|CHU,Diagnostic Test|Diagnostic Test,France,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04040946
NCT04051099,hyperparathyroidism,Bilateral Superficial Cervical Plexus Block Combined With Intravenous Sedation Versus General Anesthesia in Selected Patients for Thyroid/Parathyroid Surgery ; a Prospective Randomized Control Trial,Bilateral Superficial Cervical Plexus Block in Thyroid/Parathyroid Surgery,Benign Tumor of Thyroid|Hyperparathyroidism,2018-03-27,2021-09-30,2021-12-15,Interventional,Recruiting,Not Applicable,Mahidol University,Mahidol University,"Faculty of Medicine Siriraj Hospital, Mahidol University",Procedure|Drug|Procedure|Procedure,Thailand,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04051099
NCT04053647,hypoparathyroidism,Quality of Life Evaluation (SF-36) in Patients With Permanent Hypoparathyroidism After Total Thyroidectomy,Quality of Life Evaluation (SF-36) in Patients With Permanent Hypoparathyroidism After Total Thyroidectomy (Qol-Hypopara),Hypoparathyroidism|Quality of Life,2019-05-22,2020-06-24,2020-06-24,Observational,Completed,,Nantes University Hospital,"Central Hospital, Nancy, France|Centre Hospitalier le Mans|Nantes University Hospital|Pitié-Salpêtrière Hospital|University Hospital, Angers|University Hospital, Limoges",CHU Angers|Centre Hospitalier Le Mans|CHU Limoges|CHU Nancy|CHU Nantes|AP-HP La Pitié Salpétrière,Other,France,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04053647
NCT04059380,hypoparathyroidism,Evaluation of iMmune Function in Post-surgical and AuToimmune HYpoparathyroidism: The EMPATHY Study,Evaluation of iMmune Function in Post-surgical and AuToimmune HYpoparathyroidism (EMPATHY),Hypoparathyroidism|Hypoparathyroidism Due to Impaired Parathormone Secretion|Hypoparathyroidism Postprocedural,2019-08-14,2020-06-30,2020-07-31,Observational,Unknown status,,University of Roma La Sapienza,University of Roma La Sapienza,"Department of Experimental Medicine, ""Sapienza"" University of Rome",,Italy,18.0,80.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04059380
NCT04061980,metastatic thyroid gland carcinoma,Encorafenib/Binimetinib With or Without Nivolumab for Patients With Metastatic BRAF V600 Mutant Thyroid Cancer,Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer,BRAF NP_004324.2:p.V600M|BRAF V600E Mutation Present|Metastatic Thyroid Gland Carcinoma|Refractory Thyroid Gland Carcinoma|Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v8|Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v8|Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8,2019-08-18,2022-07-30,2024-08-01,Interventional,Recruiting,Phase 2,Providence Health & Services,Providence Health & Services,Providence Portland Medical Center,Drug|Drug|Biological,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Metastatic Thyroid Cancer,https://clinicaltrials.gov/ct2/show/NCT04061980
NCT04072731,thyroid cancer,SREBP1 as a Potential Biomarker Promotes Cell Proliferation and Invasion in Thyroid Cancer,SREBP1 as a Potential Biomarker Promotes Cell Proliferation and Invasion in Thyroid Cancer,Thyroid Cancer,2018-01-16,2017-07-30,2018-01-01,Observational,Completed,,People's Hospital of Zhengzhou University,People's Hospital of Zhengzhou University,the Affiliated Cancer Hospital of Xiangya Medical School,Other,China,18.0,60.0,[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04072731
NCT04076514,papillary thyroid cancer,The Role of Central Neck Dissection in Stage N0 Papillary Thyroid Carcinoma,The Role of Central Neck Dissection in Stage N0 Papillary Thyroid Carcinoma,Papillary Thyroid Cancer,2019-08-28,2020-09-30,2020-11-01,Observational,Recruiting,,Assiut University,Assiut University,Ahmed Kamel,Procedure,Egypt,16.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT04076514
NCT04080505,graves disease,Does the Use of Pre-operative SSKI Actually Reduce Vascularity and Improve Surgical Outcomes for Total Thyroidectomy in Graves' Disease?,Does Potassium Iodide (SSKI) Reduce Vascularity in Graves' Thyroidectomy?,Graves Disease,2019-09-04,2021-12-31,2022-12-31,Interventional,Recruiting,Phase 3,Columbia University,Columbia University,Columbia University Medical Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04080505
NCT04096612,thyroid eye disease,The Therapeutic Effect of Dysthyroid Optic Neuropathy,The Therapeutic Effect of Dysthyroid Optic Neuropathy,Thyroid Eye Disease,2018-12-27,2018-12-31,2019-12-31,Interventional,Unknown status,Not Applicable,Sun Yat-sen University,Sun Yat-sen University,Zhongshan Opthalmic Center,Procedure,China,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT04096612
NCT04098991,hypothyroidism,Improving White Matter Integrity With Thyroid Hormone,Improving White Matter Integrity With Thyroid Hormone,Hypothyroidism,2018-02-27,2019-11-08,2019-11-08,Observational,Completed,,University of Illinois at Chicago,National Institute of Neurological Disorders and Stroke (NINDS)|University of Illinois at Chicago,University of Illinois at Chicago,Drug,United States,21.0,60.0,[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04098991
NCT04104529,thyroid cancer,Establishment of a Monocentric and Prospective Clinico-biological Database in Patients Treated With Metabolic Radiotherapy in the Nuclear Medicine Department,Clinico-biological Database in Patients Treated With Metabolic Radiotherapy in the Nuclear Medicine Department,Neuroendocrine Tumors|Prostate Cancer|Thyroid Cancer,2019-09-24,2024-10-31,2024-10-31,Interventional,Recruiting,Not Applicable,Institut du Cancer de Montpellier - Val d'Aurelle,Institut du Cancer de Montpellier - Val d'Aurelle,Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle,Other,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04104529
NCT04124705,hypothyroidism,"A Multicenter, Randomized, Double-blind, Dose-conversion Study to Evaluate the Safety and Efficacy of Hormone Replacement Therapy With Armour® Thyroid Compared to Synthetic T4 (Levothyroxine) in Previously Hypothyroid Participants Who Are Euthyroid on T4 Replacement Therapy",A Study of Armour® Thyroid Compared to Synthetic T4 (Levothyroxine) in Previously Hypothyroid Participants,Euthyroid|Hypothyroidism|Thyroid Disease|Thyroid Gland|Thyroid Hormones,2019-10-10,2021-06-22,2021-06-22,Interventional,Completed,Phase 2,Allergan,Allergan,"Central Research Associates|Atria Research|Marin Endocrine Care and Research|Diabetes/Lipid Management & Research Center|Center of Excellence in Diabetes and Endocrinology|Care Access Research|San Fernando Valley Health Institute|Creekside Endocrine Associates|The Center for Diabetes and Endocrine Care|Metabolic Research Institute|Atlanta Diabetes Associates|Columbus Regional Research Institute|Physicians Research Associates|Kentucky Diabetes Endocrinology Center|L-MARC Research Center|Mountain Diabetes and Endocrine Center|OnSite Clinical Solutions|Physicia's East Endocrinology|Texas Diabetes & Endocrinology, P.A.|Texas Diabetes & Endocrinology, P.A.|North Texas Endocrine Center|Research Institute of Dallas|Academy of Diabetes, Thyroid and Endocrine|Texas Diabetes & Endocrinology, P.A.|Diabetes and Glandular Disease Clinic|Rainier Clinical Research Center|MultiCare Rockwood Clinic Diabetes & Endocrinology Center|Multicare Institute for Research and Innovation",Drug|Drug,United States,18.0,75.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04124705
NCT04124705,thyroid disease,"A Multicenter, Randomized, Double-blind, Dose-conversion Study to Evaluate the Safety and Efficacy of Hormone Replacement Therapy With Armour® Thyroid Compared to Synthetic T4 (Levothyroxine) in Previously Hypothyroid Participants Who Are Euthyroid on T4 Replacement Therapy",A Study of Armour® Thyroid Compared to Synthetic T4 (Levothyroxine) in Previously Hypothyroid Participants,Euthyroid|Hypothyroidism|Thyroid Disease|Thyroid Gland|Thyroid Hormones,2019-10-10,2021-06-22,2021-06-22,Interventional,Completed,Phase 2,Allergan,Allergan,"Central Research Associates|Atria Research|Marin Endocrine Care and Research|Diabetes/Lipid Management & Research Center|Center of Excellence in Diabetes and Endocrinology|Care Access Research|San Fernando Valley Health Institute|Creekside Endocrine Associates|The Center for Diabetes and Endocrine Care|Metabolic Research Institute|Atlanta Diabetes Associates|Columbus Regional Research Institute|Physicians Research Associates|Kentucky Diabetes Endocrinology Center|L-MARC Research Center|Mountain Diabetes and Endocrine Center|OnSite Clinical Solutions|Physicia's East Endocrinology|Texas Diabetes & Endocrinology, P.A.|Texas Diabetes & Endocrinology, P.A.|North Texas Endocrine Center|Research Institute of Dallas|Academy of Diabetes, Thyroid and Endocrine|Texas Diabetes & Endocrinology, P.A.|Diabetes and Glandular Disease Clinic|Rainier Clinical Research Center|MultiCare Rockwood Clinic Diabetes & Endocrinology Center|Multicare Institute for Research and Innovation",Drug|Drug,United States,18.0,75.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04124705
NCT04126941,hypoparathyroidism,Bi-daily Injection of Subcutaneous Teriparatide in Children With Hypoparathyroidism: Single-center Experience,Monocentric Study on the Use of Teriparatide in Children With hypoparathyroïdism,Hypoparathyroidism,2019-10-11,2020-06-30,2020-12-31,Observational,Unknown status,,Hospices Civils de Lyon,Hospices Civils de Lyon,"Service de Néphrologie, Rhumatologie et Dermatologie Pédiatriques - Hôpital Femme Mère Enfant",Other,France,2.0,18.0,[0-17]|[18-65],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04126941
NCT04128631,thyroid cancer,Role of of F-18-fluoro-deoxy-glucose (FDG) PET/CT in Thyroid Cancer Patients With Negative I-131whole Body Scan and Elevated Thyroglobulin Level or Positive Anti Thyroglobulin Antibodies,Thyroid Cancer and (FDG)PET/CT Scan,Thyroid Cancer,2019-09-26,2020-09-01,2020-12-01,Observational [Patient Registry],Unknown status,,Assiut University,Assiut University,,,,10.0,80.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04128631
NCT04129411,papillary thyroid cancer,Pilot Study for the Treatment of Papillary Thyroid Carcinoma With Radiofrequency Ablation,Treatment of Papillary Thyroid Carcinoma With Radiofrequency Ablation,Papillary Thyroid Cancer|Papillary Thyroid Microcarcinoma,2019-10-04,2022-03-31,2022-03-31,Interventional,Recruiting,Not Applicable,Mayo Clinic,Mayo Clinic,Mayo Clinic,Device,United States,18.0,85.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT04129411
NCT04133870,thyroid cancer,Exploratory Study of the Molecular Profile of Thyroid Cancer,Identification of Molecular Biomarkers for Thyroid Cancer,Thyroid Cancer,2017-01-26,2018-04-30,2020-07-30,Observational,Unknown status,,Royal Marsden NHS Foundation Trust,Royal Marsden NHS Foundation Trust,Royal Marsden NHS Foundation Trust,,United Kingdom,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04133870
NCT04135573,graves disease,Mechanism of NK Cell Disfunction in Graves' Disease,The Relationship Between NK Cell and Graves' Disease,Graves Disease,2019-01-03,2022-06-30,2022-06-30,Observational [Patient Registry],Active not recruiting,,Shandong Provincial Hospital,Shandong Provincial Hospital,Shandong Provincial Hospital,,China,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04135573
NCT04136912,thyroid cancer,High Frame Rate 3-D Super Resolution Ultrasound Microvascular Imaging,3-D Super Resolution Ultrasound Microvascular Imaging,Breast Cancer|Thyroid Cancer,2019-10-21,2023-12-31,2023-12-31,Interventional,Not yet recruiting,Phase 2,UNC Lineberger Comprehensive Cancer Center,National Cancer Institute (NCI)|UNC Lineberger Comprehensive Cancer Center,Univeristy of North Carolina Chapel Hill,Drug|Device,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04136912
NCT04137185,differentiated thyroid cancer,"Phase I/II Clinical Trial of Dose-tolerance, Pharmacokinetics and Iodine Uptake For Recombinant Human Thyroid Stimulating Hormone In Post-thyroidectomized Patients","Clinical Trial of Dose-tolerance, Pharmacokinetics and Iodine Uptake For rhTSH In Post-thyroidectomized Patients",Differentiated Thyroid Cancer,2019-09-20,2022-12-30,2022-12-30,Interventional,Recruiting,Phase 1/Phase 2,"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","Suzhou Zelgen Biopharmaceuticals Co.,Ltd",Peking Union Medical College Hospital,Drug,China,18.0,75.0,[18-65]|[65 and more],Thyroid neoplasms,"Differentiated thyroid cancer, all",https://clinicaltrials.gov/ct2/show/NCT04137185
NCT04139096,thyroid neoplasms,Genetic Susceptibility to Radiation Induced Thyroid Cancer,Genetic Susceptibility to Radiation Induced Thyroid Cancer,Genetic Susceptibility|Radiation Exposure|Thyroid Neoplasms,2019-10-09,2020-04-30,2020-04-30,Observational,Unknown status,,"Institut National de la Santé Et de la Recherche Médicale, France","Institut National de la Santé Et de la Recherche Médicale, France",Gustae Roussy,,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04139096
NCT04141306,thyroid cancer,"Radioiodine-avid Bone Metastases From Differentiated Thyroid Cancer Without Structural Abnormality, a Singular Entity With Heterogeneous Outcomes.",Radioiodine-avid Bone Metastases From Thyroid Cancer Without Structural Abnormality,Bone Metastases|Thyroid Cancer,2019-10-22,2019-12-31,2019-12-31,Observational,Unknown status,,Hospices Civils de Lyon,Hospices Civils de Lyon,,Other|Other|Other|Other|Other|Other,,18.0,80.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04141306
NCT04160637,parathyroid dysfunction,Early Postoperative Serum Parathyroid Hormone Levels as a Predictor of Hypocalcaemia After Total Thyroidectomy: A Prospective Non-Randomized Study,Is There Benefit From Early Postoperative PTH Monitoring?,Hormone Disturbance|Hypocalcemia|Parathyroid Dysfunction|Postoperative Complications|Thyroid,2019-11-09,2019-12-01,2019-12-31,Observational,Unknown status,,"University Hospital ""Sestre Milosrdnice""","University Hospital ""Sestre Milosrdnice""",University Hospital Center Sestre milosrdnice,Diagnostic Test,Croatia,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT04160637
NCT04161391,medullary thyroid cancer,"A Phase 1/2 Study of TPX-0046, A Novel Oral RET/SRC Inhibitor in Adult Subjects With Advanced/Metastatic Solid Tumors Harboring Oncogenic RET Fusions or Mutations","Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations",Advanced Solid Tumor|Medullary Thyroid Cancer|Metastatic Solid Tumor|Non Small Cell Lung Cancer|RET Gene Mutation,2019-11-11,2025-12-31,2026-11-30,Interventional,Recruiting,Phase 1/Phase 2,"Turning Point Therapeutics, Inc.","Turning Point Therapeutics, Inc.","UCI Health - Chao Family Comprehensive Cancer Center|UC San Diego Moores Cancer Center|University of Colorado, Denver|Sarah Cannon Research Institute at HealthONE|Georgetown University Medical Center|Moffitt Cancer Center|Winship Cancer Institute, Emory University|University of Chicago Medical Center|Massachusetts General Hospital|Karmanos Cancer Institute|Memorial Sloan Kettering Cancer Center|Fox Chase Cancer Center|MD Anderson Cancer Center|Virginia Cancer Specialists|The University of Washington, Seattle Cancer Care Alliance|Severance Hospital, Yonsei University Health System",Drug,"Korea, Republic of|United States",18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, medullary",https://clinicaltrials.gov/ct2/show/NCT04161391
NCT04171622,poorly differentiated thyroid gland carcinoma,Lenvatinib in Combination With Pembrolizumab for Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer,Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer,Metastatic Thyroid Gland Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8|Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8|Thyroid Gland Squamous Cell Carcinoma|Unresectable Thyroid Gland Carcinoma,2019-11-19,2022-08-31,2022-08-31,Interventional,Not yet recruiting,Phase 2,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center|National Cancer Institute (NCI),M D Anderson Cancer Center,Drug|Biological,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Poorly differentiated thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04171622
NCT04171622,thyroid gland squamous cell carcinoma,Lenvatinib in Combination With Pembrolizumab for Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer,Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer,Metastatic Thyroid Gland Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8|Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8|Thyroid Gland Squamous Cell Carcinoma|Unresectable Thyroid Gland Carcinoma,2019-11-19,2022-08-31,2022-08-31,Interventional,Not yet recruiting,Phase 2,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center|National Cancer Institute (NCI),M D Anderson Cancer Center,Drug|Biological,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid Gland Squamous Cell Carcinoma,https://clinicaltrials.gov/ct2/show/NCT04171622
NCT04171622,metastatic thyroid gland carcinoma,Lenvatinib in Combination With Pembrolizumab for Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer,Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer,Metastatic Thyroid Gland Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8|Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8|Thyroid Gland Squamous Cell Carcinoma|Unresectable Thyroid Gland Carcinoma,2019-11-19,2022-08-31,2022-08-31,Interventional,Not yet recruiting,Phase 2,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center|National Cancer Institute (NCI),M D Anderson Cancer Center,Drug|Biological,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Metastatic Thyroid Cancer,https://clinicaltrials.gov/ct2/show/NCT04171622
NCT04197960,papillary thyroid carcinoma,A Prospective Multicenter Study to Compare the Therapeutic Outcomes of Microwave Ablation With Surgical Resection for Micropapillary Thyroid Carcinoma,Microwave Ablation and Surgical Resection for Micropapillary Thyroid Carcinoma,Papillary Thyroid Carcinoma,2019-12-04,2020-09-30,2022-12-31,Interventional,Not yet recruiting,Not Applicable,Chinese PLA General Hospital,Chinese PLA General Hospital,Chinese PLA General Hospital,Procedure|Procedure,China,18.0,75.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT04197960
NCT04209179,hypoparathyroidism,"A Randomized, Double-Blind, Multiple Ascending Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PCO371 in Patients With Hypoparathyroidism","A Clinical Study Investigating the Safety, Tolerability, PK and PD of PCO371 in Patients With Hypoparathyroidism",Hypoparathyroidism,2019-11-28,2020-12-28,2021-05-25,Interventional,Terminated,Phase 1,Chugai Pharmaceutical,Chugai Pharmaceutical,"The Lundquist Institute|University of Chicago|Indiana University School of Medicine|University of Kentucky|Massachusetts General Hospital|Mayo Clinic|Ohio State University Wexner Medical Center|Thomas Jefferson University|Endocrinologie et néphrologie Centre de recherche du CHU de Québec|McMaster University Bone Research & Education Centre|Semmelweis Egyetem, Általános Orvostudományi Kar, Belgyógyászati és Onkológiai Klinika",Drug|Drug,Canada|Hungary|United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04209179
NCT04211337,medullary thyroid cancer,"A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)",A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer,Medullary Thyroid Cancer,2019-12-24,2024-05-20,2026-11-13,Interventional,Recruiting,Phase 3,Eli Lilly and Company,"Eli Lilly and Company|Loxo Oncology, Inc.","University of Alabama at Birmingham|Mayo Clinic Hospital|City of Hope National Medical Center|UCLA Medical Center|University of California, Davis - Health Systems|UCSF Medical Center at Mission Bay|Los Angeles Biomedical Research Institute at Harbor - UCLA Medical|Mayo Clinic in Florida|Emory University|University of Chi Med Center|Massachusetts General Hospital|University of Michigan|Mayo Clinic|Washington University Medical School|Memorial Sloan Kettering Cancer Center|University of Cincinnati Cancer Institute|Ohio State University Medical Center|University of Pennsylvania Hospital|Thomas Jefferson University|University of Texas MD Anderson Cancer Center|University of Wisconsin-Madison Hospital and Health Clinic|Chris O'Brien Lifehouse|Royal North Shore Hospital|Peter MacCallum Cancer Centre|The Alfred Hospital|Sir Charles Gairdner Hospital|Universitair Ziekenhuis Antwerpen|Centre Hospitalier Universitaire Sart Tilman|Oncocentro BH|Hospital de Cancer de Londrina|Hospital de Clinicas de Porto Alegre|Instituto de Educação, Pesquisa e Gestão em Saúde|Fundação Pio XII - Hospital de Câncer de Barretos|Clinica Onco Star|Hospital PUC-CAMPINAS|Hospital das Clinicas da FMRP|INCA Hospital do Câncer III|Oncoclinicas Rio de Janeiro S.A.|Soc. Beneficente de Senhoras Hospital Sirio Libanes-Oncology|Icesp - Instituto Do Câncer Do Estado de São Paulo|Centro Paulista de Oncologia|London Health Science Centre - Victoria Hospital|Princess Margaret Hospital|Anhui Provincial Hospital|Beijing Tongren Hospital affiliated to Capital Medical Unive|The First Affiliated Hospital of Fujian Medical University|Gansu Province Cancer Hospital|Sun Yat-sen University Cancer Center|Harbin Medical University Cancer Hospital|Henan Cancer Hospital|Hunan Cancer Hospital|Jilin Cancer Hospital|Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School|Jinan Central Hospital|Fudan University Shanghai Cancer Center|West China Hospital of Sichuan University|First Affiliated Hospital of Kunming Medical University|Zhejiang Provincial People's Hospital|Sir Run Run Shaw Hospital|Zhejiang Cancer Hospital|Chongqing Cancer Hospital|Tianjin Medical University Cancer Institute and Hospital|Fakultni nemocnice Brno|Fakultni nemocnice Olomouc|Fakultni Nemocnice v Motole|Assistance Publique Hôpitaux de Marseille - Hôpital Nord|Centre Georges François Leclerc|Centre Hospitalier Universitaire d'Angers|Centre Jean Perrin - Centre Régional de Lutte contre le Cancer d'Auvergne|Centre Leon Berard|Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest|Centre François Baclesse|Hôpital C. HURIEZ|Hopital Pitie Salpetriere -Unité Thyroïde-Tumeurs Endocrines|Institut de cancérologie Strasbourg Europe|Institut Claudius Regaud|Gustave Roussy|Klinikum der Universität München Großhadern|Universitätsklinikum Würzburg A. ö. R.|Medizinische Hochschule Hanover|Universitätsmedizin Johannes Gutenberg Universität Mainz|Charité Campus Mitte|Universitaetsklinikum Essen|Studiengesellschaft Hämato-Onkologie Hamburg - Prof Laack & Partner|Otto-von-Guericke-Universität|Alexandra General Hospital of Athens|University General Hospital of Heraklion|European Interbalkan Medical Center|Regional Cancer Centre|HCG Manavata Cancer Centre|Ruby Hall Clinic and Grant Medical Foundation|Deenanath Mangeshkar Hospital & Research Centre|Apollo Gleneagles Hospitals Kolkata|Postgraduate Institute of Medical Education & Research|Hadassah Medical Center|Rabin Medical Center|Sheba Medical Center|Istituto Nazionale dei Tumori|Ospedale San Luca, IRCCS Istituto Auxologico|Polic.Umberto I -Univ. La Sapienza|A.O.U. Senese Policlinico Santa Maria alle Scotte|Istituto Oncologico Veneto IRCCS|Ospedale Garibaldi-Nesima|Azienda Ospedaliera Universitaria Federico II|Azienda Ospedlaliero-Univeristaria Pisana, Stabilimento Ospedaliero di Cisanello|I.F.O. Istituto Nazionale Tumori Regina Elena|Azienda Ospedaliero-Universitaria S.Giovanni Battista|Aichi Cancer Center Hospital|National Cancer Center Hospital East|Hokkaido University Hospital|Kobe University Hospital|Yokohama City University Hospital|Osaka University Hospital|Japanese Foundation for Cancer Research|National Hospital Organization Kyushu Medical Center|National Cancer Center|Seoul National University Bundang Hospital|Chonnam National University Hwasun Hospital|Seoul National University Hospital|Severance Hospital, Yonsei University Health System|Samsung Medical Center|Nederlands Kanker Instituut - Antoni van Leeuwenhoek|University Medical Center Groningen|Leids Universitair Medisch Centrum|Maastricht UMC+|Erasmus Medisch Centrum|Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie|Swietokrzyskie Centrum Onkologii, Samodzielny Publiczny Zaklad Opieki Zdrowotnej|National medical research center of radiology Obninsk|Clinic of advanced medical technologies n. a. Nicolay I. Pirogov (policlinic, hospital)|LLC Evimed|Blokhin Cancer Research Center|National Medical Research Center of Endocrinology of Ministry of Health Dept|Saint-Petersburg City Clinical Oncology Dispensary|Hospital Universitario Virgen de la Victoria|Hospital Universitari Vall d'Hebron|Hospital Universitari de Girona Dr. Josep Trueta|Hospital Universitario Ramón y Cajal|Clinica Universidad de Navarra|Clinica Universitaria De Navarra|Institut Catala d'Oncologia|Hospital General Universitario Gregorio Marañon|Hospital Clinico San Carlos|Hospital Universitario 12 de Octubre|Hospital Universitario La Paz|Hospital Universitario Miguel Servet|China Medical University Hospital|National Cheng-Kung Uni. Hosp.|National Taiwan University Hospital|Gartnavel General Hospital|University College Hospital - London|Royal Marsden NHS Trust|Velindre Cancer Centre|Weston Park Hospital|Royal Marsden Hospital",Drug|Drug|Drug,"Australia|Belgium|Brazil|Canada|China|Czechia|France|Germany|Greece|India|Israel|Italy|Japan|Korea, Republic of|Netherlands|Poland|Russian Federation|Spain|Taiwan|United Kingdom|United States",12.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, medullary",https://clinicaltrials.gov/ct2/show/NCT04211337
NCT04224792,thyroid cancer,Effects of Exercise Training on Fatigue in Thyroid Cancer Survivors,Effects of Exercise Training on Fatigue in Thyroid Cancer Survivors,Thyroid Cancer,2020-01-08,2024-09-30,2024-12-30,Interventional,Not yet recruiting,Not Applicable,Mayo Clinic,Mayo Clinic,Mayo Clinic in Rochester,Other|Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04224792
NCT04236232,hypothyroidism,The Impact of Subclinical Hypothyroidism on the Cardiovascular System,The Impact of Subclinical Hypothyroidism on Cardiovascular System,Hypothyroidism,2019-09-24,2021-05-01,2021-06-01,Observational,Unknown status,,Assiut University,Assiut University,,Diagnostic Test,,18.0,55.0,[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04236232
NCT04238624,anaplastic thyroid cancer,"A Pilot Study of the Addition of Cemiplimab, an Antibody to PD-1, to the Treatment of Subjects With BRAF-Mutant Anaplastic Thyroid Cancer Who Are No Longer Responding to Dabrafenib and Trametinib",Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer,Anaplastic Thyroid Cancer|BRAF Gene Mutation|BRAF Mutation-Related Tumors|Thyroid Cancer,2020-01-21,2022-06-20,2022-06-20,Interventional,Recruiting,Phase 2,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Memoral Sloan Kettering Basking Ridge (Limited Protocol Activities)|Memoral Sloan Kettering Monmouth (Limited Protocol Activities)|Memorial Sloan Kettering Bergen (Limited Protocol Activities)|Memorial Sloan Kettering Cancer Center @ Commack (Limited Protocol Activities)|Memoral Sloan Kettering Westchester (Limited Protocol Activities)|Memorial Sloan Kettering Cancer Center|Memorial Sloan Kettering Nassau (Limited Protocol Activities),Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT04238624
NCT04239521,graves disease,"The Epidemiology, Management, and the Associated Burden of Mental Health, Atopic and Autoimmune Conditions, and Common Infections in Alopecia Areata","The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata",Acute Bronchitis|Allergic Rhinitis|Alopecia Areata|Ankylosing Spondylitis|Anxiety Disorders|Asthma|Atopic Dermatitis|Celiac Disease|Crohn Disease|Depressive Episode|Gastrointestinal Infection|Genital Infection|Graves Disease|Hashimoto Thyroiditis|Herpes Simplex|Herpes Zoster|Infection|Infection Viral|Influenza|Lower Resp Tract Infection|Multiple Sclerosis|Pernicious Anemia|Pneumonia|Polymyalgia Rheumatica|Psoriasis|Psoriatic Arthritis|Recurrent Depressive Disorder|Rheumatoid Arthritis|Sjogren's Syndrome|Skin Infection|Systemic Lupus Erythematosus|Type 1 Diabetes|Ulcerative Colitis|Upper Respiratory Tract Infection|Urinary Tract Infections|Vitiligo,2020-01-09,2021-10-31,2021-12-31,Observational,Active not recruiting,,Momentum Data,Momentum Data|Pfizer|University of Oxford|University of Surrey,Momentum Data Ltd,Other,United Kingdom,0.0,120.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04239521
NCT04240821,pseudohypoparathyroidism,Open-Label Extension Study of Theophylline for Treatment of Pseudohypoparathyroidism,Theophylline for Treatment of Pseudohypoparathyroidism,Albright Hereditary Osteodystrophy|Pseudohypoparathyroidism|Pseudohypoparathyroidism Type 1a,2020-01-21,2025-06-30,2025-06-30,Interventional,Enrolling by invitation,Phase 2,Vanderbilt University Medical Center,Ashley Shoemaker,Vanderbilt University Medical Center,Drug,United States,2.0,99.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,pseudohypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04240821
NCT04248114,thyroid nodule,The Natural Neck Crease as an Anatomic Landmark for Thyroid Surgery Incision,Skin-crease Thyroidectomy,Thyroid Nodule,2020-01-28,2018-08-31,2018-08-31,Observational,Completed,,Western Galilee Hospital-Nahariya,Western Galilee Hospital-Nahariya,,Diagnostic Test,,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04248114
NCT04248166,thyroid cancer,Diagnosis of Thyroid Cancer Using Photoacoustic Imaging,Thyroid Cancer and Photoacoustic Imaging,Thyroid Cancer|Thyroid Nodule,2020-01-28,2020-06-30,2020-12-31,Interventional,Unknown status,Not Applicable,Seoul St. Mary's Hospital,Pohang University of Science and Technology|Seoul St. Mary's Hospital,Seoul St. Mary's hospital,Device,"Korea, Republic of",19.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04248166
NCT04248166,thyroid nodule,Diagnosis of Thyroid Cancer Using Photoacoustic Imaging,Thyroid Cancer and Photoacoustic Imaging,Thyroid Cancer|Thyroid Nodule,2020-01-28,2020-06-30,2020-12-31,Interventional,Unknown status,Not Applicable,Seoul St. Mary's Hospital,Pohang University of Science and Technology|Seoul St. Mary's Hospital,Seoul St. Mary's hospital,Device,"Korea, Republic of",19.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04248166
NCT04252001,thyroid dysgenesis,Growing up With the Young Endocrine Support System (YESS!): Innovative E-technology to Improve Transition From Paediatric to Adult Care,Growing up With the Young Endocrine Support System (YESS!),Addison's Disease|Androgen Insensitivity Syndrome|Combined Pituitary Hormone Deficiency|Congenital Adrenal Hyperplasia|Growth Hormone Deficiency|Hypogonadotropic Hypogonadism|Klinefelter Syndrome|Thyroid Dysgenesis|Turner Syndrome,2020-01-21,2022-12-01,2023-12-01,Interventional,Not yet recruiting,Not Applicable,Erasmus Medical Center,dr. Laura C. G. de Graaff-Herder,Ghent University Hospital|Erasmus Medical Center|Hospital Infantil Universitario Niño Jesús|Queen Elizabeth University Hospital|Royal Hospital for Children|The Royal London Hospital (Barts Health NHS Trust)|University College London Hospital (UCL Institute of Child Health),Device|Device|Other,Belgium|Netherlands|Spain|United Kingdom,15.0,20.0,[0-17]|[18-65],Hypothyroidism,Congenital hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04252001
NCT04268407,thyroid nodule,2-day Prophylactic Antibiotic is Effective in Transoral Endoscopic Thyroidectomy,2-day Prophylactic Antibiotic is Effective in Transoral Endoscopic Thyroidectomy,Thyroid Nodule,2020-02-07,2021-07-31,2021-12-31,Interventional,Unknown status,Not Applicable,Chang Gung Memorial Hospital,Chang Gung Memorial Hospital,,Drug,,20.0,80.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04268407
NCT04274829,thyroid cancer,Predictive Factors of Lymph Node Metastasis in Patients With Papillary Microcarcinoma of the Thyroid,Predictive Factors of Lymph Node Metastasis in Patients With Papillary Microcarcinoma of the Thyroid,Lymph Node Metastases|Thyroid Cancer,2020-02-15,2018-01-31,2020-02-29,Observational,Completed,,University of Cagliari,University of Cagliari,AOU Cagliari,Procedure,Italy,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04274829
NCT04280081,medullary thyroid cancer,"A Phase 2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including Rearranged in Transfection (RET) Fusion-Positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation","A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation",Medullary Thyroid Cancer|Solid Tumor,2020-02-20,2021-03-25,2025-11-20,Interventional,Active not recruiting,Phase 2,Eli Lilly and Company,"Eli Lilly and Company|Loxo Oncology, Inc.","Nanfang Affiliated Hospital South Medical University|The First Affiated Hospital Of Guangzhou Medical Collage|Hunan Cancer Hospital|Jilin Province Tumor Hospital|Jinan Central Hospital|Shanghai Chest Hospital|Zhejiang Cancer Hospital|First Affiliated Hosp of College of Med, Zhejiang University|Zhejiang Provincial People's Hospital|Beijing Cancer Hospital|Fudan University Shanghai Cancer Center|Shanghai East Hospital|Tianjin Medical University Cancer Institute & Hospital",Drug,China,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, medullary",https://clinicaltrials.gov/ct2/show/NCT04280081
NCT04281875,thyroid neoplasms,Assessing Benefits of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Total Thyroidectomy.,Assessing Benefits of NIRAF Detection for Identifying Parathyroid Glands During Total Thyroidectomy.,Postoperative Hypoparathyroidism|Thyroid Cancer|Thyroid Neoplasms,2020-02-19,2023-03-31,2023-09-30,Interventional,Recruiting,Not Applicable,Vanderbilt-Ingram Cancer Center,National Cancer Institute (NCI)|Vanderbilt-Ingram Cancer Center,Vanderbilt University Medical Center,Device,United States,18.0,99.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04281875
NCT04285476,thyroid cancer,Study of the Predictive Value of a Signature of 10 microRNA in Thyroid Cytologies of Undetermined Type,Predictive Value of 10 microRNA in Thyroid Cytologies of Undetermined Type,Thyroid Cancer,2020-02-24,2022-07-31,2023-03-31,Interventional,Recruiting,Not Applicable,Institut du Cancer de Montpellier - Val d'Aurelle,Institut du Cancer de Montpellier - Val d'Aurelle,CHU de Toulouse|Institut régional du Cancer de Montpellier,Diagnostic Test,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04285476
NCT04290663,thyroid cancer,Multicentric Phase III Trial Comparing Two Strategies in Intermediate-risk Differentiated Thyroid Cancer Patients: Systematic Radioiodine Administration (3.7 GBq I131 After rhTSH) Versus Decision of Radioiodine Treatment Guided by a Post-operative Work-up Based on Serum Tg Values and Diagnostic RAI Scintigraphy,Systematic Radioiodine Administration (3.7 GBq I131 After rhTSH) Versus Decision of Radioiodine Treatment Guided by a Post-operative Work-up,Intermediate Risk|Thyroid Cancer,2020-02-20,2026-02-28,2028-02-29,Interventional,Recruiting,Phase 3,Centre Francois Baclesse,Centre Francois Baclesse|French cancer Institute INCa,Centre Francois Baclesse,Drug|Other,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04290663
NCT04299425,parathyroid neoplasms,Evaluating Impact of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy,Evaluating Impact of NIRAF Detection for Identifying Parathyroid Glands During Parathyroidectomy,Hypercalcemia|Parathyroid Adenoma|Parathyroid Cancer|Parathyroid Hyperplasia|Parathyroid Neoplasms|Primary Hyperparathyroidism,2020-03-04,2023-03-31,2023-09-30,Interventional,Recruiting,Not Applicable,Vanderbilt-Ingram Cancer Center,National Cancer Institute (NCI)|Vanderbilt-Ingram Cancer Center,Vanderbilt University Medical Center,Device,United States,18.0,99.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04299425
NCT04304573,parathyroid dysfunction,Is Correcting Total Serum Calcium Levels for Serum Albumin Necessary in Assessing Symptomatic Hypocalcemia After Total Thyroidectomy: a Prospective Cohort Study,Is Correcting Total Serum Calcium Levels Important After Thyroidectomy,Calcium Disorder|Hormone Disturbance|Hypocalcemia|Parathyroid Dysfunction|Postoperative Complications|Thyroid,2020-03-09,2020-08-09,2020-09-09,Observational,Unknown status,,"University Hospital ""Sestre Milosrdnice""","University Hospital ""Sestre Milosrdnice""",University Hospital Center Sestre milosrdnice,Diagnostic Test,Croatia,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT04304573
NCT04309136,thyroid cancer,The Efficacy and Safety of Anlotinib in Neoadjuvant Treatment in Locally Advanced Thyroid Cancer: a Single-arm Phase II Clinical Trial,Anlotinib Neoadjuvant Treatment in Locally Advanced Thyroid Cancer,Thyroid Cancer,2020-03-12,2021-02-01,2022-06-01,Interventional,Active not recruiting,Phase 2,Fudan University,Fudan University,Fudan University Shanghai Cancer Center,Drug|Procedure|Procedure,China,14.0,80.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04309136
NCT04311606,thyroid eye disease,Anti-VEGF Therapy for Acute Thyroid Eye Disease (AcTED Study),Anti-VEGF Therapy for Acute Thyroid Eye Disease,Thyroid Eye Disease,2020-03-12,2025-09-30,2027-01-01,Interventional,Recruiting,Phase 2,Massachusetts Eye and Ear Infirmary,Massachusetts Eye and Ear Infirmary|Regeneron Pharmaceuticals,Mass Eye and Ear,Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT04311606
NCT04312087,thyroid cancer,Lateral Neck Lymph Node Mapping in Papillary Thyroid Carcinoma,Lateral Neck Lymph Node Mapping in Thyroid Cancer,Thyroid Cancer,2020-03-14,2021-08-01,2022-12-31,Interventional,Recruiting,Not Applicable,Fudan University,Fudan University,Fudan University Shanghai Cancer Center,Procedure|Procedure|Procedure,China,14.0,80.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04312087
NCT04312646,thyroid nodule,Added Value of Ultrasound Elasatography in Characterization of Thyroid Nodules,Elastography in Thyroid Nodules,Thyroid Nodule,2020-03-16,2021-04-01,2022-04-01,Observational,Unknown status,,Assiut University,Assiut University,,Device,,0.0,120.0,[0-17]|[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04312646
NCT04316845,hyperparathyroidism,18F-Fluorocholine PET/CT in the Pre-operative Localization of Hyperfunctional Parathyroid Gland in Primary and Secondary Hyperparathyroidism,18F-fluorocholine PET/CT for Hyperparathyroidism,Hyperparathyroidism,2020-03-17,2019-11-06,2019-12-31,Interventional,Completed,Not Applicable,Buddhist Tzu Chi General Hospital,Buddhist Tzu Chi General Hospital,Hualien Tzu Chi Hospital,Diagnostic Test,Taiwan,20.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04316845
NCT04320901,thyroid cancer,Comparative Analysis Between Harmonic Versus LigaSure in Transoral Endoscopic Thyroidectomy: A Randomized Controlled Trial,Energy Device Study in Transoral Endoscopic Thyroidectomy,Thyroid Cancer|Thyroid Nodule,2020-03-20,2022-12-31,2023-02-28,Interventional,Recruiting,Not Applicable,Inha University Hospital,Inha University Hospital,Inha University Hospital,Device|Device,"Korea, Republic of",20.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04320901
NCT04320901,thyroid nodule,Comparative Analysis Between Harmonic Versus LigaSure in Transoral Endoscopic Thyroidectomy: A Randomized Controlled Trial,Energy Device Study in Transoral Endoscopic Thyroidectomy,Thyroid Cancer|Thyroid Nodule,2020-03-20,2022-12-31,2023-02-28,Interventional,Recruiting,Not Applicable,Inha University Hospital,Inha University Hospital,Inha University Hospital,Device|Device,"Korea, Republic of",20.0,70.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04320901
NCT04321954,differentiated thyroid cancer,A Phase 2 Study of Neoadjuvant Lenvatinib in Locally Advanced Invasive Thyroid Cancer,Lenvatinib in Locally Advanced Invasive Thyroid Cancer,Advanced Cancer|Differentiated Thyroid Cancer,2020-03-24,2023-09-30,2024-03-31,Interventional,Recruiting,Phase 2,Massachusetts Eye and Ear Infirmary,Eisai Inc.|Massachusetts Eye and Ear Infirmary,Massachusetts General Hospital Cancer Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Differentiated thyroid cancer, all",https://clinicaltrials.gov/ct2/show/NCT04321954
NCT04327999,thyroid carcinoma,Effect of Artificial Tears on Radioiodine Levels in the Nasolacrimal Duct System of Patients Following Radioiodine Therapy for Thyroid Carcinoma,Effect of Artificial Tears on Radioiodine Levels in the Nasolacrimal Duct System,Radioactive Iodine Level|Thyroid Carcinoma,2020-03-04,2023-07-31,2024-07-31,Interventional,Recruiting,Phase 2,Vanderbilt-Ingram Cancer Center,Vanderbilt-Ingram Cancer Center,Vanderbilt University Medical Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04327999
NCT04332770,hypothyroidism,Clinical Application of Continuous Monitoring Data for Biosignals by Commercially Available Wearable Devices in the Patients With Hypothyroidism,Biosignals by Wearable Devices in Hypothyroidism,Hypothyroidism,2019-12-13,2020-10-15,2020-10-15,Observational,Completed,,Seoul National University Bundang Hospital,Seoul National University Bundang Hospital,Seoul National University Bundang Hospital,Other,"Korea, Republic of",20.0,60.0,[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04332770
NCT04336696,papillary thyroid carcinoma,"Is Routine Dissection of Central Lymph Node Necessary for Papillary Thyroid Carcinoma, T1-2 N0?","Is Routine Dissection of Central Lymph Node Necessary for Papillary Thyroid Carcinoma, T1-2 N0?",Papillary Thyroid Carcinoma,2020-04-01,2020-04-03,2020-05-03,Interventional,Unknown status,Not Applicable,Zagazig University,Bassem Mohamed Sieda,Zagazig University Hospitals,Procedure,Egypt,42.0,55.0,[18-65],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT04336696
NCT04339478,thyroid cancer,Does Parathyroid Autofluorescence Reduces Unintensional Parathyroidectomy During Total Thyroidectomy With Central Lymph Node Compartment Dissection,Does Parathyroid Autofluorescence Reduces Unintensional Parathyroidectomy During Total Thyroidectomy With Central Lymph Node Compartment Dissection,Thyroid Cancer|Thyroidectomy With Central Lymph Node Dissection,2020-04-06,2022-03-30,2022-08-30,Observational,Recruiting,,Aristotle University Of Thessaloniki,Aristotle University Of Thessaloniki|The Hashemite University|Umraniye Education and Research Hospital,"1st Propedeutic Department of Surgery, AHEPA University General Hospital, Aristotle University of Thessaloniki|Department of Surgery, Faculty of Medicine, Hashemite University|Umraniye Education and Research Hospital",,Greece|Jordan|Turkey,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04339478
NCT04344886,thyroid disease,Optimization and Individualization of Diagnostic Scintigraphy Protocol and Minimally Invasive Radio-guided Parathyroid Surgery Using Quantitative Analysis of Scintigraphy Results on Hybrid SPECT-CT Imaging,Optimization and Individualization of Diagnostic Scintigraphy Protocol and Minimally Invasive Radio-guided Parathyroid Surgery,Parathyroid Adenoma|Parathyroid Diseases|Primary Hyperparathyroidism|Thyroid Disease,2020-04-09,2020-11-30,2020-12-31,Interventional,Unknown status,Not Applicable,University Hospital Ostrava,University Hospital Ostrava,University Hospital Ostrava,Procedure|Procedure|Procedure|Procedure,Czechia,18.0,120.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04344886
NCT04346901,hyperthyroidism,Comparative Study of mMASI Before and After Hyperthyroid Therapy in Hyperthyroid Subjects With Melasma,Comparative Study of mMASI Before and After Hyperthyroid Therapy in Hyperthyroid Subjects With Melasma,Hyperthyroidism|Melasma,2020-04-10,2020-01-27,2020-02-15,Interventional,Completed,Phase 1,Indonesia University,"Dr.dr.Irma Bernadette, SpKK (K)",dr. Cipto Mangunkusumo Hospital,Drug,Indonesia,18.0,60.0,[18-65],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04346901
NCT04354324,papillary thyroid cancer,Treatment Efficacy and Safety of Low-dose Radioiodine Ablation for Intermediate-risk Differentiated Thyroid Carcinoma Patients Without Metastasis: a Double-blind Randomized Clinical Trial,Treatment Efficacy and Safety of Low-dose Radioiodine Ablation for Intermediate-risk Differentiated Thyroid Carcinoma,Papillary Thyroid Cancer,2020-03-01,2024-06-30,2024-06-30,Interventional,Not yet recruiting,Not Applicable,Zhujiang Hospital,Zhujiang Hospital,,Drug,,16.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT04354324
NCT04359979,thyroid eye disease,Treatment With Tamsulosin for Upper Eyelid Retraction Related to Thyroid Eye Disease.,Tamsulosin for Thyroid Lid Retraction,Eyelid Diseases|Thyroid Eye Disease,2020-04-21,2021-05-31,2021-12-31,Interventional,Recruiting,Not Applicable,Sheba Medical Center,Sheba Medical Center,Sheba Medical Center,Drug,Israel,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT04359979
NCT04372225,hypoparathyroidism,Predicting Risk Factors of Postoperative Hypocalcemia After Total Thyroidectomy: is Safe Discharge Without Supplementation Possible?,Predicting Risk Factors of Postoperative Hypocalcemia After Total Thyroidectomy,Hypoparathyroidism,2020-04-25,2020-04-25,2020-04-25,Observational,Completed,,Aix Marseille Université,Aix Marseille Université,Conception Hospital,Other,France,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04372225
NCT04391244,differentiated thyroid cancer,Investigating National Solutions for Personalised Iodine-131 Radiation Exposure - Measuring Absorbed Dose to Tumour and Organs at Risk Following Routine Iodine Ablation Therapy,Investigating National Solutions for Personalised Iodine-131 Radiation Exposure,Differentiated Thyroid Cancer,2020-05-12,2022-07-31,2022-07-31,Observational,Recruiting,,Royal Marsden NHS Foundation Trust,European Commission|Royal Marsden NHS Foundation Trust,The Royal Marsden NHS Foundation Trust,,United Kingdom,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Differentiated thyroid cancer, all",https://clinicaltrials.gov/ct2/show/NCT04391244
NCT04391439,graves disease,Increased Heart Rhythm in Response to High-dose Intravenous Methylprednisolone Pulse Therapy of Moderate-to-severe Graves' Orbitopathy,Heart Rhythm After Intravenous Methylprednisolone Administration,Blood Pressure|Graves Disease|Graves Ophthalmopathy|Heart Failure|Heart Rhythm Disorder|Hypertension,2020-05-05,2020-02-20,2020-02-20,Observational,Completed,,Medical University of Warsaw,Medical University of Warsaw,,Drug,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04391439
NCT04391439,graves ophthalmopathy,Increased Heart Rhythm in Response to High-dose Intravenous Methylprednisolone Pulse Therapy of Moderate-to-severe Graves' Orbitopathy,Heart Rhythm After Intravenous Methylprednisolone Administration,Blood Pressure|Graves Disease|Graves Ophthalmopathy|Heart Failure|Heart Rhythm Disorder|Hypertension,2020-05-05,2020-02-20,2020-02-20,Observational,Completed,,Medical University of Warsaw,Medical University of Warsaw,,Drug,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT04391439
NCT04396912,"thyroid cancer, papillary","Post-thyroidectomy Vocal Cord Paralysis Along With Hypocalcemia: Prospective, Matched-randomized Observational Cohort Compatible With STROBE Guidelines",Post-thyroidectomy Vocal Cord Paralysis Along With Hypocalcemia: STROBE - Guided Prospective Cohort,"Calcium Deficiency|Iatrogenic Hypocalcemia|Iatrogenic Hypoparathyroidism|Multinodular Goiter|PTH|Thyroid Cancer|Thyroid Cancer, Papillary|Thyroid Neoplasms|Thyroid Nodule|Vocal Cord; Injury, Superficial|Vocal Cord Paralysis|Vocal Cord Paresis",2020-05-15,2021-06-01,2021-06-01,Observational,Recruiting,,Umraniye Education and Research Hospital,Umraniye Education and Research Hospital,"Umraniye Education and Research Hospital, Health Sciences University",Procedure,Turkey,17.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT04396912
NCT04396912,multinodular goiter,"Post-thyroidectomy Vocal Cord Paralysis Along With Hypocalcemia: Prospective, Matched-randomized Observational Cohort Compatible With STROBE Guidelines",Post-thyroidectomy Vocal Cord Paralysis Along With Hypocalcemia: STROBE - Guided Prospective Cohort,"Calcium Deficiency|Iatrogenic Hypocalcemia|Iatrogenic Hypoparathyroidism|Multinodular Goiter|PTH|Thyroid Cancer|Thyroid Cancer, Papillary|Thyroid Neoplasms|Thyroid Nodule|Vocal Cord; Injury, Superficial|Vocal Cord Paralysis|Vocal Cord Paresis",2020-05-15,2021-06-01,2021-06-01,Observational,Recruiting,,Umraniye Education and Research Hospital,Umraniye Education and Research Hospital,"Umraniye Education and Research Hospital, Health Sciences University",Procedure,Turkey,17.0,120.0,[0-17]|[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT04396912
NCT04396912,thyroid nodule,"Post-thyroidectomy Vocal Cord Paralysis Along With Hypocalcemia: Prospective, Matched-randomized Observational Cohort Compatible With STROBE Guidelines",Post-thyroidectomy Vocal Cord Paralysis Along With Hypocalcemia: STROBE - Guided Prospective Cohort,"Calcium Deficiency|Iatrogenic Hypocalcemia|Iatrogenic Hypoparathyroidism|Multinodular Goiter|PTH|Thyroid Cancer|Thyroid Cancer, Papillary|Thyroid Neoplasms|Thyroid Nodule|Vocal Cord; Injury, Superficial|Vocal Cord Paralysis|Vocal Cord Paresis",2020-05-15,2021-06-01,2021-06-01,Observational,Recruiting,,Umraniye Education and Research Hospital,Umraniye Education and Research Hospital,"Umraniye Education and Research Hospital, Health Sciences University",Procedure,Turkey,17.0,120.0,[0-17]|[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04396912
NCT04400474,anaplastic thyroid cancer,Exploratory Basket Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. CABATEN Study,Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study,Adenocarcinoma|Anaplastic Thyroid Cancer|Neuroendocrine Tumor|Paraganglioma|Pheochromocytoma,2020-05-12,2023-03-31,2024-03-31,Interventional,Recruiting,Phase 2,Grupo Espanol de Tumores Neuroendocrinos,Grupo Espanol de Tumores Neuroendocrinos|Ipsen|Roche Pharma AG,Hospital Germans Trias i Pujol - ICO Badalona|Hospital Duran i Reynals - ICO L'Hospitalet|Hospital General Universitario Elche|Hospital Universitari Vall d'Hebron|MD Anderson Cancer Center|Hospital Universitario Ramón y Cajal|Hospital Universitario 12 de Octubre|Hospital Universitario La Paz|Hospital General Universitario Morales Meseguer|Hospital Universitario Virgen de la Victoria|Hospital Universitario Central de Asturias|Hospital Universitario Marqués de Valdecilla|Hospital Universitario Virgen del Rocío|Hospital Universitario de Canarias|Hospital Universitario Miguel Servet,Drug,Spain,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT04400474
NCT04410601,thyroiditis,Pre-and Post-operative Risk Factors Affecting the Incidence and Severity of Dysphagia Following Total Thyroidectomy: An International Multi-centric Prospective Randomized Controlled Clinical Trial (RCT),Post-thyroidectomy Dysphagia: An International Multicentric CONSORT - Compatible RCT,"Dysphagia Comes and Goes|Dysphagia, Esophageal|Dysphagia, Oral Phase|Thyroid Cancer|Thyroid Goiter|Thyroiditis|Thyroid Neoplasms|Thyroid Nodule (Benign)",2020-05-15,2021-06-30,2021-06-30,Interventional,Recruiting,Not Applicable,Umraniye Education and Research Hospital,Umraniye Education and Research Hospital,"Umraniye Education and Research Hospital, Health Sciences University",Procedure,Turkey,17.0,120.0,[0-17]|[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT04410601
NCT04410601,thyroid neoplasms,Pre-and Post-operative Risk Factors Affecting the Incidence and Severity of Dysphagia Following Total Thyroidectomy: An International Multi-centric Prospective Randomized Controlled Clinical Trial (RCT),Post-thyroidectomy Dysphagia: An International Multicentric CONSORT - Compatible RCT,"Dysphagia Comes and Goes|Dysphagia, Esophageal|Dysphagia, Oral Phase|Thyroid Cancer|Thyroid Goiter|Thyroiditis|Thyroid Neoplasms|Thyroid Nodule (Benign)",2020-05-15,2021-06-30,2021-06-30,Interventional,Recruiting,Not Applicable,Umraniye Education and Research Hospital,Umraniye Education and Research Hospital,"Umraniye Education and Research Hospital, Health Sciences University",Procedure,Turkey,17.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04410601
NCT04411290,thyroid papillary carcinoma,"Correlation of Malignancy Predictors, Bethesda (I-VI) and TI-RADS Scores (I-V) With Final Histopathology in Patients Undergoing Total Thyroidectomy 34 Years After Chernobyl Disaster: Multi-centric Trial","Malignancy Predictors, Bethesda and TI-RADS Scores Correlated With Final Histopathology in Thyroid Diseases","Aspiration|Multifocal Dysplasia|Multinodular Goiter, Adolescent|Solitary Thyroid Nodule|Thyroid Cancer, Papillary|Thyroid Carcinoma|Thyroid Diseases|Thyroid Goiter|Thyroid Neoplasms|Thyroid Nodule|Thyroid Papillary Carcinoma",2020-05-15,2021-06-01,2021-06-01,Observational,Enrolling by invitation,,Umraniye Education and Research Hospital,Umraniye Education and Research Hospital,"Umraniye Education and Research Hospital, Health Sciences Universit",Procedure,Turkey,17.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT04411290
NCT04411290,thyroid nodule,"Correlation of Malignancy Predictors, Bethesda (I-VI) and TI-RADS Scores (I-V) With Final Histopathology in Patients Undergoing Total Thyroidectomy 34 Years After Chernobyl Disaster: Multi-centric Trial","Malignancy Predictors, Bethesda and TI-RADS Scores Correlated With Final Histopathology in Thyroid Diseases","Aspiration|Multifocal Dysplasia|Multinodular Goiter, Adolescent|Solitary Thyroid Nodule|Thyroid Cancer, Papillary|Thyroid Carcinoma|Thyroid Diseases|Thyroid Goiter|Thyroid Neoplasms|Thyroid Nodule|Thyroid Papillary Carcinoma",2020-05-15,2021-06-01,2021-06-01,Observational,Enrolling by invitation,,Umraniye Education and Research Hospital,Umraniye Education and Research Hospital,"Umraniye Education and Research Hospital, Health Sciences Universit",Procedure,Turkey,17.0,120.0,[0-17]|[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04411290
NCT04411290,thyroid diseases,"Correlation of Malignancy Predictors, Bethesda (I-VI) and TI-RADS Scores (I-V) With Final Histopathology in Patients Undergoing Total Thyroidectomy 34 Years After Chernobyl Disaster: Multi-centric Trial","Malignancy Predictors, Bethesda and TI-RADS Scores Correlated With Final Histopathology in Thyroid Diseases","Aspiration|Multifocal Dysplasia|Multinodular Goiter, Adolescent|Solitary Thyroid Nodule|Thyroid Cancer, Papillary|Thyroid Carcinoma|Thyroid Diseases|Thyroid Goiter|Thyroid Neoplasms|Thyroid Nodule|Thyroid Papillary Carcinoma",2020-05-15,2021-06-01,2021-06-01,Observational,Enrolling by invitation,,Umraniye Education and Research Hospital,Umraniye Education and Research Hospital,"Umraniye Education and Research Hospital, Health Sciences Universit",Procedure,Turkey,17.0,120.0,[0-17]|[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04411290
NCT04420689,thyroid neoplasms,Phase 1/2 Trial of ALM-488 in Patients Undergoing Head & Neck Surgery,A Study of ALM-488 to Highlight Nerves in Patients Undergoing Head & Neck Surgery,Head and Neck Neoplasms|Imaging|Nerve Injury|Parotid Neoplasm|Surgery|Thyroid Neoplasms,2020-06-03,2021-06-25,2022-02-15,Interventional,Completed,Phase 1/Phase 2,"Alume Biosciences, Inc.","Alume Biosciences, Inc.",University of California San Diego|Stanford University|Harvard-Mass Eye & Ear,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04420689
NCT04420754,anaplastic thyroid cancer,A Multi Center Phase I Study of AIC100 in Relapsed and/or Refractory Advanced Thyroid Cancer and Anaplastic Thyroid Cancer,Study of AIC100 in Relapsed/Refractory Thyroid Cancer,Anaplastic Thyroid Cancer|Relapsed/Refractory Poorly Differentiated Thyroid Cancer,2020-06-03,2023-07-31,2024-07-31,Interventional,Recruiting,Phase 1,"AffyImmune Therapeutics, Inc.","AffyImmune Therapeutics, Inc.",Weill Cornell Medical College,Biological,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT04420754
NCT04425512,thyroid cancer,Delta Neutrophil Index and Neutrophil Lymphocyte Ratio in Differentiation of Thyroid Malignancy and Nodular Goiter,Delta Neutrophil Index and Neutrophil Lymphocyte Ratio in Thyroid Malignancy,Delta Neutrophyl Index|Immature Granulocyte Count|Neutrophyl to Lymphocyte Ratio|Thyroid Cancer|Thyroid Diseases|Thyroid Nodule,2020-04-23,2019-11-01,2019-11-01,Interventional,Completed,Not Applicable,Kahramanmaras Sutcu Imam University,Kahramanmaras Sutcu Imam University,,Diagnostic Test,,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04425512
NCT04425512,thyroid nodule,Delta Neutrophil Index and Neutrophil Lymphocyte Ratio in Differentiation of Thyroid Malignancy and Nodular Goiter,Delta Neutrophil Index and Neutrophil Lymphocyte Ratio in Thyroid Malignancy,Delta Neutrophyl Index|Immature Granulocyte Count|Neutrophyl to Lymphocyte Ratio|Thyroid Cancer|Thyroid Diseases|Thyroid Nodule,2020-04-23,2019-11-01,2019-11-01,Interventional,Completed,Not Applicable,Kahramanmaras Sutcu Imam University,Kahramanmaras Sutcu Imam University,,Diagnostic Test,,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04425512
NCT04425512,thyroid diseases,Delta Neutrophil Index and Neutrophil Lymphocyte Ratio in Differentiation of Thyroid Malignancy and Nodular Goiter,Delta Neutrophil Index and Neutrophil Lymphocyte Ratio in Thyroid Malignancy,Delta Neutrophyl Index|Immature Granulocyte Count|Neutrophyl to Lymphocyte Ratio|Thyroid Cancer|Thyroid Diseases|Thyroid Nodule,2020-04-23,2019-11-01,2019-11-01,Interventional,Completed,Not Applicable,Kahramanmaras Sutcu Imam University,Kahramanmaras Sutcu Imam University,,Diagnostic Test,,18.0,120.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04425512
NCT04433936,thyroid eye disease,Corneal Tomographic Analysis Among Patients With Thyroid Gland Dysfunction.,Corneal Tomographic Parameters in TGD,Corneal Ectasia|Keratoconus|Thyroid Eye Disease,2020-06-13,2018-06-01,2018-06-01,Observational,Completed,,Mansoura University,Ameera Gamal Abdelhameed,Mansoura University,Diagnostic Test,Egypt,0.0,120.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT04433936
NCT04447183,differentiated thyroid cancer,A Phase II Study of the Safety and Effectiveness of rhTSH in Radioiodine Treatment for Patients With Differentiated Thyroid Cancer.,The Safety and Effectiveness of rhTSH in Radioiodine Treatment for Patients With Differentiated Thyroid Cancer.,Differentiated Thyroid Cancer,2020-06-23,2022-02-28,2022-10-31,Interventional,Recruiting,Phase 2,"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","Suzhou Zelgen Biopharmaceuticals Co.,Ltd",Peking Union Medical College Hospital,Drug|Other,China,18.0,75.0,[18-65]|[65 and more],Thyroid neoplasms,"Differentiated thyroid cancer, all",https://clinicaltrials.gov/ct2/show/NCT04447183
NCT04458233,thyroid nodule,FNA Guided Ultrasonography Needle Technique Axial Vs Lateral Approach Study,FNA Guided Ultrasonography Needle Technique Axial Vs Lateral Approach Study,Thyroid Nodule,2020-06-30,2021-06-01,2021-07-01,Interventional,Recruiting,Not Applicable,Ziv Hospital,Ziv Hospital,Ziv Medical Center,Procedure,Israel,18.0,85.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04458233
NCT04459273,thyroid gland carcinoma,PET Biodistribution Study of 68Ga-FAPI-46 in Patients With Different Malignancies: An Exploratory Biodistribution Study With Histopathology Validation,Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers,Bladder Carcinoma|Cervical Carcinoma|Cholangiocarcinoma|Hematopoietic and Lymphoid Cell Neoplasm|Hepatocellular Carcinoma|Malignant Adrenal Gland Neoplasm|Malignant Brain Neoplasm|Malignant Pleural Neoplasm|Malignant Skin Neoplasm|Malignant Solid Neoplasm|Malignant Testicular Neoplasm|Malignant Thymus Neoplasm|Neuroendocrine Neoplasm|Thyroid Gland Carcinoma|Urothelial Carcinoma,2020-07-01,2023-07-01,2024-07-01,Interventional,Recruiting,Phase 1,Jonsson Comprehensive Cancer Center,Jonsson Comprehensive Cancer Center,UCLA / Jonsson Comprehensive Cancer Center,Procedure|Drug|Procedure,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04459273
NCT04462471,"thyroid cancer, papillary",A Phase Ib Trial of Vemurafenib Plus Copanlisib to Enhance Radioiodine Avidity in Radioiodine-Refractory Thyroid Cancers,Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers,"BRAF V600E Mutation Positive|Thyroid Cancer|Thyroid Cancer, Follicular|Thyroid Cancer (Follicular Cell)|Thyroid Cancer, Papillary|Thyroid Carcinoma",2020-07-02,2023-12-31,2024-12-31,Interventional,Recruiting,Phase 1,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Memoral Sloan Kettering Basking Ridge (Limited Protocol Activities)|Memoral Sloan Kettering Monmouth (Limited protocol activities)|Memorial Sloan Kettering Bergen (Limited Protocol Activities)|Memorial Sloan Kettering Cancer Center @ Commack (Limited Protocol Activities)|Memoral Sloan Kettering Westchester (Limited protocol activities)|Memorial Sloan-Kettering Cancer Center (All protocol activities)|Memorial Sloan Kettering Nassau (Limited protocol activities),Diagnostic Test|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT04462471
NCT04462471,thyroid cancer (follicular cell),A Phase Ib Trial of Vemurafenib Plus Copanlisib to Enhance Radioiodine Avidity in Radioiodine-Refractory Thyroid Cancers,Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers,"BRAF V600E Mutation Positive|Thyroid Cancer|Thyroid Cancer, Follicular|Thyroid Cancer (Follicular Cell)|Thyroid Cancer, Papillary|Thyroid Carcinoma",2020-07-02,2023-12-31,2024-12-31,Interventional,Recruiting,Phase 1,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Memoral Sloan Kettering Basking Ridge (Limited Protocol Activities)|Memoral Sloan Kettering Monmouth (Limited protocol activities)|Memorial Sloan Kettering Bergen (Limited Protocol Activities)|Memorial Sloan Kettering Cancer Center @ Commack (Limited Protocol Activities)|Memoral Sloan Kettering Westchester (Limited protocol activities)|Memorial Sloan-Kettering Cancer Center (All protocol activities)|Memorial Sloan Kettering Nassau (Limited protocol activities),Diagnostic Test|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT04462471
NCT04463719,thyroid cancer,Adequate Selection of Patients for Thyroid Biopsy: Evaluation of a Shared Decision Making Conversation Aid,AIM2: Adequate Selection of Patients for Thyroid Biopsy: Evaluation of a Shared Decision Making Conversation Aid,Thyroid Cancer|Thyroid Nodules,2020-07-06,2022-06-30,2025-06-30,Interventional,Not yet recruiting,Not Applicable,University of Florida,National Cancer Institute (NCI)|University of Florida,University of Florida|Mayo Clinic,Behavioral|Behavioral,United States,18.0,99.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04463719
NCT04472026,thyroid cancer,Adequate Selection of Patients for Thyroid Biopsy: Evaluation of a Shared Decision Making Conversation Aid,AIM1: Adequate Selection of Patients for Thyroid Biopsy: Evaluation of a Shared Decision Making Conversation Aid,Thyroid Cancer|Thyroid Nodules,2020-07-10,2022-06-30,2025-06-30,Interventional,Recruiting,Not Applicable,University of Florida,National Cancer Institute (NCI)|University of Florida,University of Florida|Mayo Clinic,Behavioral,United States,18.0,99.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04472026
NCT04472988,hashimoto,The Effects of Eye Movement Desensitization and Reprocessing on Autoimmune Thyroiditis in Adults: a Randomized Controlled Trial,Eye Movement Desensitization and Reprocessing on Autoimmune Thyroiditis in Adults,Hashimoto,2020-07-07,2020-12-05,2021-03-23,Interventional,Completed,Not Applicable,University of Bucharest,University of Bucharest,University of Bucharest,Behavioral|Other|Drug,Romania,18.0,55.0,[18-65],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT04472988
NCT04477798,thyroid nodule,Protein Classifier for Thyroid Indeterminate Nodules： a Multi-center Prospective Clinical Study,Protein Classifier for Thyroid Indeterminate Nodules,Thyroid Nodule,2020-07-10,2021-07-01,2021-12-31,Interventional,Recruiting,Not Applicable,Zhejiang University,Luo Dingcun,Hangzhou First People's Hospital Affiliated to Zhejiang University Medical College,Diagnostic Test,China,18.0,70.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04477798
NCT04481893,thyroid cancer,Interest of the Virtual Reality Headset in the Management of Perioperative Stress in Patients Candidates for Total Thyroidectomy,Interest of the Virtual Reality Headset in the Management of Perioperative Stress in Patients Candidates for Total Thyroidectomy,Thyroid Cancer|Thyroidectomy,2020-07-07,2024-04-30,2024-04-30,Interventional,Recruiting,Not Applicable,Centre Francois Baclesse,Centre Francois Baclesse,Centre François Baclesse|CHU CAEN|Clinique Mathilde,Behavioral,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04481893
NCT04482907,thyroid nodule,Randomized Placebo Controlled Clinical Study of Anethum Graveolens L. (Dill) in Thyroiditis and Nodular Goiter Patients,Effect of Dill in Thyroiditis and Nodular Goiter Patients,Thyroid Nodule,2020-07-16,2019-12-16,2020-04-05,Interventional,Completed,Not Applicable,Bezmialem Vakif University,Bezmialem Vakif University,Sabahattin Destek,Dietary Supplement,Turkey,18.0,76.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04482907
NCT04485975,thyrotoxicosis,Preoperative Therapeutic Plasma Exchange and Surgical Treatment in Thyrotoxicosis Patients: a Single-centre Retrospective Cohort Study,Therapeutic Plasma Exchange in Thyrotoxicosis,Thyrotoxicosis,2020-06-30,2019-02-01,2020-04-01,Observational,Completed,,Baskent University,Baskent University,,Device,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04485975
NCT04488406,graves ophthalmopathy,Genetics and Epigenetics of Graves' Orbitopathy,Genetics and Epigenetics of Graves' Orbitopathy,Graves Ophthalmopathy,2020-07-17,2020-03-31,2020-03-31,Observational,Completed,,University of Pisa,University of Pisa,Ospedale Cisanello-Endocrinology I and II,Other,Italy,18.0,85.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT04488406
NCT04488640,thyroid nodule,Compliance of Thyroid Fine Needle Aspiration Biopsy and Trucut Biopsy Results With Thyroid Imaging Reporting and Data System Score and Surgical Pathology,Compliance of Thyroid Fine Needle Aspiration Biopsy and Trucut Biopsy Results With TIRADS Score and Surgical Pathology,Thyroid Nodule,2020-07-15,2020-01-01,2020-05-01,Observational,Completed,,Bezmialem Vakif University,Bezmialem Vakif University,,Procedure,,24.0,85.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04488640
NCT04495985,thyroid cancer,Breast Uptake on Radioiodine Scan and Serum Prolactin in Thyroid Cancer Patients Prepared by Thyroid Hormone Withdrawal or Recombinant Human Thyrotropin: A Prospective Study,CASE 1320: RAI Uptake and Serum Prolactin in Thyroid Cancer,Thyroid Cancer,2020-06-10,2023-06-30,2023-08-31,Observational,Enrolling by invitation,,The Cleveland Clinic,The Cleveland Clinic,Cleveland Clinic,,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04495985
NCT04500925,papillary thyroid cancer,The Incidence of Postoperative Re-stratification for Recurrence in Well-differentiated Thyroid Cancer - A Single Tertiary Israeli Center Experience,The Incidence of Postoperative Re-stratification for Recurrence in Well-differentiated Thyroid Cancer - A Single Tertiary Israeli Center Experience,Papillary Thyroid Cancer|Well Differentiated Thyroid Carcinoma,2020-07-31,2018-01-01,2020-01-01,Observational,Completed,,Tel-Aviv Sourasky Medical Center,Tel-Aviv Sourasky Medical Center,,Procedure,,38.0,61.0,[18-65],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT04500925
NCT04521348,thyroid cancer,A Phase II Study to Explore the Safety and Efficacy of Multiple Target Kinase Inhibitor(mTKI) Combined With Anti-Programmed Death-1(PD-1) Antibody in the Treatment of Advanced Thyroid Cancer,Multiple Target Kinase Inhibitor and Anti-Programmed Death-1 Antibody in Patients With Advanced Thyroid Cancer,Thyroid Cancer,2019-10-25,2022-06-30,2023-06-30,Interventional,Recruiting,Phase 2,Fudan University,Fudan University,Fudan University Shanghai Cancer Center,Drug,China,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04521348
NCT04522570,medullary thyroid cancer,Ultrasound Guided Percutaneous Thermal Ablation of Cervical Metastases From Thyroid Carcinoma,Thermal Ablation of Cervical Metastases From Thyroid Carcinoma,Lymph Node Metastases|Medullary Thyroid Cancer|Thyroid Neoplasia|Well-Differentiated Thyroid Cancer,2020-08-10,2022-12-31,2023-12-31,Interventional,Recruiting,Not Applicable,Instituto do Cancer do Estado de São Paulo,Instituto do Cancer do Estado de São Paulo,Instituto do Cancer do Estado de São Paulo,Device|Device|Device,Brazil,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, medullary",https://clinicaltrials.gov/ct2/show/NCT04522570
NCT04524884,thyroid cancer,The Efficacy and Safety of Anti-PD-1 Antibody Toripalimab Combined With Surufatinib for Locally Advanced Thyroid Cancer: a Phase II Study,Toripalimab Combined With Surufatinib for Locally Advanced Thyroid Cancer: a Phase II Study,Thyroid Cancer,2020-08-20,2022-04-30,2022-09-30,Interventional,Not yet recruiting,Phase 2,Fudan University,Fudan University,"270 Dongan Road, Fudan University Shanghai Cancer Center",Drug|Drug,China,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04524884
NCT04528225,hypothyroidism,Hypothyroidism After Postoperative Radiation Therapy in Patients With Breast Cancer：a Prospective Clinical Study,A Prospective Study of Hypothyroidism After Radiotherapy for Breast Cancer,Breast Neoplasms|Hypothyroidism|Radiation Toxicity,2020-08-22,2020-02-24,2020-02-24,Observational,Completed,,Chinese Academy of Medical Sciences,Chinese Academy of Medical Sciences,"Cancer Hospital, Chinese Academy of Medical Sciences",,China,18.0,70.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04528225
NCT04544111,papillary thyroid cancer,Phase II Study of PDR001 in Combination With MAPK Pathway Inhibitors in Patients With Radioiodine-Refractory Thyroid Cancer,PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer,"Follicular Thyroid Cancer|Hurthle Cell Thyroid Neoplasia|Hurthle Cell Tumor|Papillary Thyroid Cancer|Poorly Differentiated Thyroid Gland Carcinoma|Thyroid Cancer|Thyroid Cancer, Follicular",2020-09-03,2022-09-02,2022-09-02,Interventional,Recruiting,Phase 2,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Memoral Sloan Kettering Basking Ridge (Limited Protocol Activities)|Memoral Sloan Kettering Monmouth (Limited protocol activities)|Memorial Sloan Kettering Bergen (Limited Protocol Activities)|Memorial Sloan Kettering Cancer Center @ Suffolk - Commack (Limited Protocol Activities)|Memoral Sloan Kettering Westchester (Limited protocol activities)|Memorial Sloan Kettering Cancer Center (All Protocol Activities)|Memorial Sloan Kettering Nassau (Limited protocol activities),Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT04544111
NCT04544111,"thyroid cancer, follicular",Phase II Study of PDR001 in Combination With MAPK Pathway Inhibitors in Patients With Radioiodine-Refractory Thyroid Cancer,PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer,"Follicular Thyroid Cancer|Hurthle Cell Thyroid Neoplasia|Hurthle Cell Tumor|Papillary Thyroid Cancer|Poorly Differentiated Thyroid Gland Carcinoma|Thyroid Cancer|Thyroid Cancer, Follicular",2020-09-03,2022-09-02,2022-09-02,Interventional,Recruiting,Phase 2,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Memoral Sloan Kettering Basking Ridge (Limited Protocol Activities)|Memoral Sloan Kettering Monmouth (Limited protocol activities)|Memorial Sloan Kettering Bergen (Limited Protocol Activities)|Memorial Sloan Kettering Cancer Center @ Suffolk - Commack (Limited Protocol Activities)|Memoral Sloan Kettering Westchester (Limited protocol activities)|Memorial Sloan Kettering Cancer Center (All Protocol Activities)|Memorial Sloan Kettering Nassau (Limited protocol activities),Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT04544111
NCT04544111,hurthle cell tumor,Phase II Study of PDR001 in Combination With MAPK Pathway Inhibitors in Patients With Radioiodine-Refractory Thyroid Cancer,PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer,"Follicular Thyroid Cancer|Hurthle Cell Thyroid Neoplasia|Hurthle Cell Tumor|Papillary Thyroid Cancer|Poorly Differentiated Thyroid Gland Carcinoma|Thyroid Cancer|Thyroid Cancer, Follicular",2020-09-03,2022-09-02,2022-09-02,Interventional,Recruiting,Phase 2,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Memoral Sloan Kettering Basking Ridge (Limited Protocol Activities)|Memoral Sloan Kettering Monmouth (Limited protocol activities)|Memorial Sloan Kettering Bergen (Limited Protocol Activities)|Memorial Sloan Kettering Cancer Center @ Suffolk - Commack (Limited Protocol Activities)|Memoral Sloan Kettering Westchester (Limited protocol activities)|Memorial Sloan Kettering Cancer Center (All Protocol Activities)|Memorial Sloan Kettering Nassau (Limited protocol activities),Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Hurthle cell thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04544111
NCT04544111,poorly differentiated thyroid gland carcinoma,Phase II Study of PDR001 in Combination With MAPK Pathway Inhibitors in Patients With Radioiodine-Refractory Thyroid Cancer,PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer,"Follicular Thyroid Cancer|Hurthle Cell Thyroid Neoplasia|Hurthle Cell Tumor|Papillary Thyroid Cancer|Poorly Differentiated Thyroid Gland Carcinoma|Thyroid Cancer|Thyroid Cancer, Follicular",2020-09-03,2022-09-02,2022-09-02,Interventional,Recruiting,Phase 2,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Memoral Sloan Kettering Basking Ridge (Limited Protocol Activities)|Memoral Sloan Kettering Monmouth (Limited protocol activities)|Memorial Sloan Kettering Bergen (Limited Protocol Activities)|Memorial Sloan Kettering Cancer Center @ Suffolk - Commack (Limited Protocol Activities)|Memoral Sloan Kettering Westchester (Limited protocol activities)|Memorial Sloan Kettering Cancer Center (All Protocol Activities)|Memorial Sloan Kettering Nassau (Limited protocol activities),Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Poorly differentiated thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04544111
NCT04551170,pseudohypoparathyroidism,Phase 2 Study of Theophylline Treatment for Pseudohypoparathyroidism,Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old,Albright Hereditary Osteodystrophy|Pseudohypoparathyroidism|Pseudohypoparathyroidism Type 1a,2020-09-09,2025-06-30,2025-06-30,Interventional,Recruiting,Phase 2,Vanderbilt University Medical Center,Vanderbilt University Medical Center,Vanderbilt University Medical Center,Drug|Drug,United States,2.0,12.0,[0-17],Parathyroid diseases,pseudohypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04551170
NCT04552769,undifferentiated thyroid cancer,Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer,Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer,Anaplastic Thyroid Cancer|Thyroid Cancer|Undifferentiated Thyroid Cancer,2020-09-11,2022-09-30,2023-09-30,Interventional,Recruiting,Phase 2,Stanford University,Stanford University,Stanford University,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT04552769
NCT04554680,thyroid cancer,Phase II Clinical Trial in Radioactive Iodine-Refractory Advanced Thyroid Carcinoma Evaluating BRAF & MEK Blockade Therapy for Re-differentiation- Applying a Novel Time-Dependent Concept,Clinical Trial in RAI-Refractory Thyroid Carcinoma Evaluating BRAF & MEK Blockade for Re-differentiation Therapy,Thyroid Cancer,2020-08-29,2021-12-31,2022-04-30,Interventional,Recruiting,Phase 2,"National University Hospital, Singapore","National University Hospital, Singapore|Singapore General Hospital",National University Hospital,Drug,Singapore,21.0,99.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04554680
NCT04560426,thyroid cancer,Protective Effect of Intraoperative Parathyroid Gland Auxiliary Recognition System in Thyroid Malignant Tumor Operation,Protective Effect of Intraoperative Parathyroid Gland Auxiliary Recognition System in Thyroid Malignant Tumor Operation,Intraoperative Monitoring|Parathyroid|Thyroid Cancer,2020-08-29,2021-10-31,2022-10-31,Interventional,Not yet recruiting,Not Applicable,Fudan University,Fudan University,Fudan University Shanghai Cancer Center,Device,China,20.0,50.0,[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04560426
NCT04563780,differentiated thyroid cancer,The Prognostic Value of Post Thyroidectomy 99mTCpertechnetate Thyroid Scan in Patient With Differentiated Thyroid Cancer,The Prognostic Value of Post Thyroidectomy 99mTCpertechnetate Thyroid Scan in Patient With Differentiated Thyroid Cancer,Differentiated Thyroid Cancer,2020-09-21,2021-12-31,2021-12-31,Observational,Recruiting,,Assiut University,Assiut University,Aya Khaled Mahmoud,Device,Egypt,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Differentiated thyroid cancer, all",https://clinicaltrials.gov/ct2/show/NCT04563780
NCT04569513,parathyroid diseases,The Analysis of Thyroidectomy and Parathyroidectomy,The Analysis of Thyroidectomy and Parathyroidectomy,Parathyroid Diseases|Thyroid Diseases,2020-05-11,2024-06-30,2024-12-31,Observational,Recruiting,,National Taiwan University Hospital,National Taiwan University Hospital,Ting-Chun Kuo,Biological,Taiwan,20.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT04569513
NCT04569513,thyroid diseases,The Analysis of Thyroidectomy and Parathyroidectomy,The Analysis of Thyroidectomy and Parathyroidectomy,Parathyroid Diseases|Thyroid Diseases,2020-05-11,2024-06-30,2024-12-31,Observational,Recruiting,,National Taiwan University Hospital,National Taiwan University Hospital,Ting-Chun Kuo,Biological,Taiwan,20.0,120.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04569513
NCT04569604,hypoparathyroidism,Impaired Quality of Life and Cognitive Function in Patients With Hypoparathyroidism Might be Explained by Disturbed Capillary Flow Patterns in the Brain,QoL and Cognitive Function in Patients With Hypoparathyroidism,Hypoparathyroidism|Pseudo Hypoparathyroidism,2019-09-02,2020-10-01,2021-12-01,Observational,Completed,,University of Aarhus,University of Aarhus,"Clinic for Osteoporosis, Aarhus University Hospital",Diagnostic Test|Diagnostic Test|Diagnostic Test|Diagnostic Test|Diagnostic Test,Denmark,18.0,70.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04569604
NCT04570033,hyperparathyroidism,The Utility of 18F-fluorocholine PET/CT in the Imaging of Parathyroid Adenomas,The Utility of 18F-fluorocholine PET/CT in the Imaging of Parathyroid Adenomas,Hyperparathyroidism|Parathyroid Adenoma,2020-09-21,2020-01-01,2020-01-01,Interventional,Completed,Not Applicable,"Military Institute of Medicine, Poland","Medical University of Warsaw|Military Institute of Medicine, Poland",,Diagnostic Test,,0.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04570033
NCT04574817,anaplastic thyroid cancer,"A Single-arm, Open-lable, Multicenter, Phase II Clinical Study of HX008 in Subjects With Anaplastic Thyroid Cancer",Study of HX008 for the Treatment of Anaplastic Thyroid Cancer (ATC),Anaplastic Thyroid Cancer,2020-09-29,2022-05-30,2023-05-30,Interventional,Not yet recruiting,Phase 2,Taizhou Hanzhong biomedical co. LTD,Taizhou Hanzhong biomedical co. LTD,"Cancer Hospital, Chinese Academy of Medical Sciences",Drug,China,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT04574817
NCT04574947,parathyroid neoplasms,Intravenous Or Topical Lidocaine And Neuromonitoring in Thyroid Surgery (IOLANT Study),Lidocaine And Neuromonitoring in Thyroid Surgery,Anesthesia|Parathyroid Neoplasms|Thyroid Neoplasm,2020-09-24,2021-11-15,2021-12-01,Interventional,Recruiting,Phase 4,"Saint Petersburg State University, Russia","Saint Petersburg State University, Russia",St. Petersburg State University Hospital,Drug|Drug|Procedure|Procedure,Russian Federation,45.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04574947
NCT04579757,anaplastic thyroid cancer,An Open-Label Phase Ib/II Study of Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors,Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors,Anaplastic Thyroid Cancer|Colorectal Cancer|Gastric Cancer|Metastatic Solid Tumor|Neuroendocrine Tumors|Small Cell Lung Cancer|Soft Tissue Sarcoma,2020-09-02,2024-04-30,2024-06-30,Interventional,Recruiting,Phase 1/Phase 2,Hutchison Medipharma Limited,BeiGene|Hutchison Medipharma Limited,"Arizona Oncology Associated, PC-HOPE|City of Hope|Rocky Mountain Cancer Centers Midtown|Johns Hopkins University - Sibley Memorial Hospital|Emory University - Winship Cancer Institute|Holden Comprehensive Cancer Center, University of Iowa|Memorial Sloan Kettering Cancer Center|University Hospitals Cleveland Medical Center|University of Pennsylvania, Perelman Center for Advanced Medicine|Prisma Health - Upstate (ITOR)|Sarah Cannon|Vanderbilt University Medical Center|Mary Crowley Cancer Research|Texas Oncology - Baylor Charles A. Sammons Cancer Center|Texas Oncology, P.A.|The University of Texas MD Anderson Cancer Center|Texas Oncology, P.A.|Virginia Cancer Specialists, PC",Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT04579757
NCT04580199,thyroid nodule,"Surgical (Total or Hemithyroidectomy)Versus Non Surgical (Ethanol Ablation ,RF Ablation ,Laser Ablation) Management of Thyroid Nodule",Surgical Versus Non Surgical Management of Thyroid Nodule,Thyroid Nodule,2020-10-02,2021-12-01,2022-12-01,Interventional,Not yet recruiting,Not Applicable,Assiut University,Mahmoud Fahd,,Procedure,,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04580199
NCT04583735,thyroid eye disease,"A Phase 4, Randomized, Double-masked, Placebo-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of TEPEZZA® in Treating Patients With Chronic (Inactive) Thyroid Eye Disease",A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease,Chronic (Inactive) Thyroid Eye Disease|Thyroid Eye Disease,2020-10-06,2022-09-30,2023-04-30,Interventional,Recruiting,Phase 4,"Horizon Pharma USA, Inc.","Horizon Therapeutics USA, Inc.",Perlman Medical Offices / UCSD|MACRO Trials|Univ of Colorado Dept of Ophthalmology|Bascom Palmer Eye Institute / Univ of Miami|Mayo Clinic|Washington University|Hamilton Eye Institute / U Tennessee|Neuro-Eye Clinical Trials|Medical College of Wisconsin,Biological|Drug,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT04583735
NCT04589624,thyroid gland carcinoma,Pilot Study of Metabolic Guidance for Therapy in Patients With Thyroid Cancer,An Investigational Scan (hpMRI) for Monitoring Treatment Response in Patients With Thyroid Cancer Undergoing Radiation Therapy and/or Systemic Therapy,Thyroid Gland Carcinoma,2020-09-20,2022-12-31,2022-12-31,Interventional,Recruiting,Early Phase 1,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center|National Cancer Institute (NCI),M D Anderson Cancer Center,Drug|Procedure|Procedure,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04589624
NCT04589884,parathyroid diseases,Intraoperative EXamination Using MAChine-learning-based HYperspectral for diagNosis & Autonomous Anatomy Assessment,Intraoperative EXamination Using MAChine-learning-based HYperspectral for diagNosis & Autonomous Anatomy Assessment,Digestive Cancer|Digestive Perfusion|Liver Cancer|Liver Metastases|Parathyroid Diseases|Thyroid Diseases,2020-10-09,2024-09-22,2024-10-22,Observational,Recruiting,,IHU Strasbourg,ARC Foundation for Cancer Research|IHU Strasbourg,"Service de Chirurgie Digestive et Endocrinienne, NHC",Other,France,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT04589884
NCT04589884,thyroid diseases,Intraoperative EXamination Using MAChine-learning-based HYperspectral for diagNosis & Autonomous Anatomy Assessment,Intraoperative EXamination Using MAChine-learning-based HYperspectral for diagNosis & Autonomous Anatomy Assessment,Digestive Cancer|Digestive Perfusion|Liver Cancer|Liver Metastases|Parathyroid Diseases|Thyroid Diseases,2020-10-09,2024-09-22,2024-10-22,Observational,Recruiting,,IHU Strasbourg,ARC Foundation for Cancer Research|IHU Strasbourg,"Service de Chirurgie Digestive et Endocrinienne, NHC",Other,France,18.0,120.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04589884
NCT04594720,"thyroid cancer, papillary",Using Circulating Biomarkers to Identify Thyroid Cancer From the Patients With Thyroid Nodules,Circulating Biomarkers to Identify Thyroid Cancer,"Benign Thyroid Tumor|Thyroid Cancer|Thyroid Cancer, Papillary",2020-10-16,2019-10-31,2020-09-30,Observational,Completed,,Chang Gung Memorial Hospital,Chang Gung Memorial Hospital,Kaohsiung Chang Gung Memorial Hospital,Other|Other,Taiwan,20.0,100.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT04594720
NCT04598815,graves ophthalmopathy,"A Phase II, Randomized, Superiority, Adaptive, Open-label, Single-center, Clinical Trial to Evaluate the Efficacy of Sirolimus (Rapamycin) in Patients With Graves' Disease and Moderate-to-severe and Active Graves' Orbitopathy (GO)",Sirolimus for Graves' Orbitopathy (GO),Graves Ophthalmopathy,2020-10-16,2025-01-01,2025-01-01,Interventional,Not yet recruiting,Phase 2,University of Pisa,University of Pisa,Ospedale Cisanello-Endocrinology II,Drug,Italy,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT04598815
NCT04600349,autoimmune thyroiditis,The Influence of Identity Oriented Psychotrauma Therapy on Hashimoto Disease Activity: a Randomized Controlled Trial,Identity Oriented Psychotrauma Therapy on Hashimoto in Adults,Autoimmune Thyroiditis,2020-10-19,2020-12-30,2021-03-01,Interventional,Completed,Not Applicable,University of Bucharest,University of Bucharest,University of Bucharest,Behavioral|Drug,Romania,18.0,60.0,[18-65],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT04600349
NCT04612894,thyroid cancer,The Efficacy and Safety of Anti-PD-1 Antibody Camrelizumab Combined With Apatinib for Neoadjuvant Therapy in Locally Advanced Thyroid Cancer: a Phase II Study,Camrelizumab and Apatinib for Neoadjuvant Therapy in Thyroid Cancer,Thyroid Cancer,2020-10-30,2022-12-01,2023-12-31,Interventional,Not yet recruiting,Phase 2,Fudan University,Fudan University,Fudan University Shanghai Cancer Center,Drug|Procedure|Procedure,China,14.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04612894
NCT04613323,hashimoto disease,Management of Thyroid Function in Hashimoto's Thyroiditis During Pregnancy: Real-word Experience in a Secondary Endocrine Centre in Italy,Management of Thyroid Function in Hashimoto's Thyroiditis During Pregnancy,Hashimoto Disease|Pregnancy Related|Thyroid Dysfunction,2020-07-14,2022-07-01,2022-09-01,Observational,Not yet recruiting,,Centro Diagnostico Priamar,Centro Diagnostico Priamar,,,,18.0,120.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT04613323
NCT04614389,thyroid nodule,Utility of Contrast-Enhanced Sonography and Shear Wave Elastography in Conjunction With ACR TI-RADS for the Evaluation of Thyroid Nodules,Utility of Contrast-Enhanced Sonography and Shear Wave Elastography,Thyroid Nodule,2019-09-25,2021-04-30,2021-07-01,Interventional,Recruiting,Not Applicable,University of Southern California,Siemens Medical Solutions USA - CSG|University of Southern California,USC Department of Radiology,Other|Other|Device,United States,18.0,70.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04614389
NCT04619316,metastatic thyroid cancer,Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK Inhibition: A Single Center Pilot Study,Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK Inhibition,Metastatic Thyroid Cancer,2020-11-01,2021-12-31,2022-06-30,Interventional,Recruiting,Phase 2,"University Hospital, Essen","University Hospital, Essen",Manuel M. Weber,Drug|Drug,Germany,18.0,85.0,[18-65]|[65 and more],Thyroid neoplasms,Metastatic Thyroid Cancer,https://clinicaltrials.gov/ct2/show/NCT04619316
NCT04623801,thyroid cancer,Pilot Study to Evaluate the Safety and Efficacy of Percutaneous Laser Ablation of Thyroid Papillary Microcarcinoma,Laser Ablation of Papillary Thyroid Microcarcinoma,Papillary Thyroid Microcarcinoma|Thyroid|Thyroid Cancer,2020-11-06,2022-10-31,2022-10-31,Interventional,Recruiting,Phase 2,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Procedure,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04623801
NCT04624477,papillary thyroid carcinoma,Active Surveillance or Surgery for Primary Management of Very Low Risk Papillary Thyroid Cancer: How Often Are the Long-term Disease Management Goals Achieved?,Active Surveillance and Surgery Outcomes in Low Risk Papillary Thyroid Cancer,Papillary Microcarcinoma of the Thyroid|Papillary Thyroid Cancer|Papillary Thyroid Carcinoma,2020-10-27,2025-03-31,2030-03-31,Observational,Recruiting,,"University Health Network, Toronto","Canadian Cancer Society (CCS)|Canadian Institutes of Health Research (CIHR)|Centre hospitalier de l'Université de Montréal (CHUM)|CHU de Quebec-Universite Laval|Dalhousie University|Lawson Health Research Institute|McMaster University|Ottawa Hospital Research Institute|University Health Network, Toronto|University of British Columbia|University of Calgary",Nova Scotia Health|Lawson Health Research Institute|Ottawa Hospital Research Institute|University Health Network|CHU de Québec - Université Laval,,Canada,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT04624477
NCT04644315,"thyroid cancer, papillary","A Phase II, Open-Label, Single Arm Decentralized Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors",A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors,"Brain Neoplasms|Bronchial Neoplasms|Carcinoma, Bronchogenic|Central Nervous System|Cholangiocarcinoma|Colonic Diseases|Colorectal Neoplasms|Digestive System Diseases|Digestive System Neoplasms|Gastrointestinal Diseases|Gastrointestinal Neoplasms|Head and Neck Neoplasms|Intestinal Diseases|Intestinal Neoplasms|Lymphoma, Large-Cell, Anaplastic|Melanoma|Neoplasms|Neoplasms by Site|Neuroendocrine Tumors|Ovarian Neoplasms|Pancreatic Neoplasms|Respiratory Tract Diseases|Respiratory Tract Neoplasms|Salivary Gland Neoplasms|Sarcoma|Thoracic Neoplasms|Thyroid Cancer, Papillary|Thyroid Neoplasms",2020-11-20,2025-08-01,2025-12-01,Interventional,Recruiting,Phase 2,Hoffmann-La Roche,Hoffmann-La Roche,"Science 37, Inc|Science 37-Basem; Dept 004- Basem|Science 37-Beg; Dept 001 Dr. M. Beg|Science 37-Ben; Dept 003-Ben|Science 37-Cannon; Dept 002-Cannon|Science 37-Kurzrock; Dept 005-Kurzrock|Science 37-Thomas; Dept 006-Thomas|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine|Homebased Telemedicine",Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT04644315
NCT04647006,thyroid nodule,"Comparison of Transoral Endoscopic Thyroidectomy Vestibular Approach and Open Conventional Thyroidectomy for Inflammatory Responses, Pain and Patient Satisfaction: A Prospective Study",Comparison of TOETVA and Conventional Thyroidectomy,Surgery|Thyroid|Thyroid Nodule,2020-10-06,2020-01-28,2020-03-30,Interventional,Completed,Not Applicable,Basaksehir Cam & Sakura Şehir Hospital,MUnlu|Sisli Hamidiye Etfal Training and Research Hospital,Sisli Etfal Research Hospiatl,Procedure,Turkey,18.0,65.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04647006
NCT04648722,hypothyroidism,Higher Post-operative Levothyroxine Substitution Dose Needed in Right Compared to Left Lobe Hemithyroidectomy - a Retrospective Cohort Study,Higher Levothyroxine Requirements After Right-side Hemithyroidectomy,Hemithyroidectomy|Hypothyroidism,2020-11-22,2020-06-12,2020-06-12,Observational,Completed,,Medical University of Vienna,Medical University of Vienna,Medical University of Vienna,Procedure,Austria,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04648722
NCT04664413,papillary thyroid cancer,Correlations Between Percentage of BRAFV600E Alleles and Outcome in Thyroid Carcinoma,Percentage of BRAFV600E Alleles and Outcome in Thyroid Carcinoma,Papillary Thyroid Cancer,2020-12-05,2021-04-30,2021-05-30,Observational,Not yet recruiting,,University of Salerno,University of Salerno,"Department of Medicine and Surgery, Univeristy of Salerno",,Italy,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT04664413
NCT04666103,thyroid carcinoma,Preserving Function Integrity of Neck Anatomy in Thyroid Surgery: A Randomized Clinical Trial,Function Integrity of Neck Anatomy in Thyroid Surgery,Ablation; Retina|Thyroid Carcinoma|Thyroid Nodule (Benign),2020-12-07,2021-12-31,2026-12-12,Interventional,Recruiting,Not Applicable,Wuhan University,Wuhan University,Zhongnan Hospital of Wuhan University,Procedure,China,18.0,75.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04666103
NCT04671719,hypoparathyroidism,Autotaxin in Patients With GNAS/PTH Abnormalities,Determination of Circulating Autotaxin in Patients With GNAS or PTH Abnormalities,Adult Children|Albright Syndrome|Fibrous Dysplasia|Hyperparathyroidism|Hypoparathyroidism|Pseudo Hypoparathyroidism,2020-12-11,2024-03-10,2024-03-10,Observational,Recruiting,,Hospices Civils de Lyon,Hospices Civils de Lyon,"Centre de compétence des maladies rares de l'insulino-sécrétion et de l'insulino-sensibilité|Centre de référence Dysplasie Fibreuse des os Service rhumatologie et pathologie osseuse Hôpital Edouard Herriot, Lyon|Centre de Référence des Maladies Rares du Métabolisme du Calcium et du Phosphate Service d'Endocrinologie et Diabète de l'Enfant Hôpital Bicêtre Paris Saclay",Biological,France,10.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04671719
NCT04671719,hyperparathyroidism,Autotaxin in Patients With GNAS/PTH Abnormalities,Determination of Circulating Autotaxin in Patients With GNAS or PTH Abnormalities,Adult Children|Albright Syndrome|Fibrous Dysplasia|Hyperparathyroidism|Hypoparathyroidism|Pseudo Hypoparathyroidism,2020-12-11,2024-03-10,2024-03-10,Observational,Recruiting,,Hospices Civils de Lyon,Hospices Civils de Lyon,"Centre de compétence des maladies rares de l'insulino-sécrétion et de l'insulino-sensibilité|Centre de référence Dysplasie Fibreuse des os Service rhumatologie et pathologie osseuse Hôpital Edouard Herriot, Lyon|Centre de Référence des Maladies Rares du Métabolisme du Calcium et du Phosphate Service d'Endocrinologie et Diabète de l'Enfant Hôpital Bicêtre Paris Saclay",Biological,France,10.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04671719
NCT04675710,thyroid gland anaplastic carcinoma,Pembrolizumab in Combination With Dabrafenib and Trametinib as a Neoadjuvant Strategy Prior to Surgery in BRAF-Mutated Anaplastic Thyroid Cancer,"Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer",Thyroid Gland Anaplastic Carcinoma|Thyroid Gland Squamous Cell Carcinoma,2020-12-05,2024-06-30,2024-06-30,Interventional,Recruiting,Phase 2,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center,M D Anderson Cancer Center,Procedure|Drug|Radiation|Biological|Other|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT04675710
NCT04675710,thyroid gland squamous cell carcinoma,Pembrolizumab in Combination With Dabrafenib and Trametinib as a Neoadjuvant Strategy Prior to Surgery in BRAF-Mutated Anaplastic Thyroid Cancer,"Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer",Thyroid Gland Anaplastic Carcinoma|Thyroid Gland Squamous Cell Carcinoma,2020-12-05,2024-06-30,2024-06-30,Interventional,Recruiting,Phase 2,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center,M D Anderson Cancer Center,Procedure|Drug|Radiation|Biological|Other|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid Gland Squamous Cell Carcinoma,https://clinicaltrials.gov/ct2/show/NCT04675710
NCT04680650,thyroid nodule,Comparison of Anesthesia Effects of Sevoflurane and Propofol Combined With Dexmedetomidine in Intraoperative Neuromonitoring During Thyroidectomy,Comparison of Anesthesia Effects of Sevoflurane and Propofol Combined With Dexmedetomidine in Intraoperative Neuromonitoring During Thyroidectomy,Thyroid Nodule,2020-12-11,2021-03-31,2021-03-31,Interventional,Active not recruiting,Not Applicable,Affiliated Cancer Hospital & Institute of Guangzhou Medical University,Affiliated Cancer Hospital & Institute of Guangzhou Medical University,Cancer Center of Guangzhou Medical University,Drug|Drug,China,18.0,65.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04680650
NCT04682340,hyperthyroidism,Analysis of Bisphenol A Concentration in Serum in Women of Reproductive Age With Autoimmune Thyroid Disease,Analysis of BPA Concentration in Serum in Women of Reproductive Age With Autoimmune Thyroid Disease,Graves Disease|Hashimoto Disease|Hyperthyroidism|Hypothyroidism,2020-12-13,2021-10-30,2022-01-19,Observational,Completed,,Jagiellonian University,Jagiellonian University,Jagiellonian University Medical College,Diagnostic Test,Poland,18.0,45.0,[18-65],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04682340
NCT04682340,graves disease,Analysis of Bisphenol A Concentration in Serum in Women of Reproductive Age With Autoimmune Thyroid Disease,Analysis of BPA Concentration in Serum in Women of Reproductive Age With Autoimmune Thyroid Disease,Graves Disease|Hashimoto Disease|Hyperthyroidism|Hypothyroidism,2020-12-13,2021-10-30,2022-01-19,Observational,Completed,,Jagiellonian University,Jagiellonian University,Jagiellonian University Medical College,Diagnostic Test,Poland,18.0,45.0,[18-65],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04682340
NCT04682340,hashimoto disease,Analysis of Bisphenol A Concentration in Serum in Women of Reproductive Age With Autoimmune Thyroid Disease,Analysis of BPA Concentration in Serum in Women of Reproductive Age With Autoimmune Thyroid Disease,Graves Disease|Hashimoto Disease|Hyperthyroidism|Hypothyroidism,2020-12-13,2021-10-30,2022-01-19,Observational,Completed,,Jagiellonian University,Jagiellonian University,Jagiellonian University Medical College,Diagnostic Test,Poland,18.0,45.0,[18-65],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT04682340
NCT04682340,hypothyroidism,Analysis of Bisphenol A Concentration in Serum in Women of Reproductive Age With Autoimmune Thyroid Disease,Analysis of BPA Concentration in Serum in Women of Reproductive Age With Autoimmune Thyroid Disease,Graves Disease|Hashimoto Disease|Hyperthyroidism|Hypothyroidism,2020-12-13,2021-10-30,2022-01-19,Observational,Completed,,Jagiellonian University,Jagiellonian University,Jagiellonian University Medical College,Diagnostic Test,Poland,18.0,45.0,[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04682340
NCT04686006,graves disease,"Effectiveness of Classical Potassium Iodide Therapy for the Treatment of Untreated Patients With Graves' Hyperthyroidism, Avoiding Thionamide Drugs With Serious Side Effects of Agranulocytosis, Liver Injury, Vasculitis, Embryopathy or Frequent Side Effects of Skin Eruption",Effective Iodide Therapy for Untreated Patients With Graves' Hyperthyroidism Avoiding Thionamide Drugs With Many Side Effects,Graves Disease,2020-12-22,2005-07-01,,Observational,Completed,,Kyushu University,Kyushu University,,Drug,,15.0,90.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04686006
NCT04693377,metastatic thyroid gland carcinoma,Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases,"Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial",Castration-Resistant Prostate Carcinoma|Metastatic Colorectal Carcinoma|Metastatic Malignant Neoplasm in the Bone|Metastatic Malignant Solid Neoplasm|Metastatic Melanoma|Metastatic Prostate Carcinoma|Metastatic Renal Cell Carcinoma|Metastatic Sarcoma|Metastatic Thyroid Gland Carcinoma|Metastatic Urothelial Carcinoma|Stage IVA Colorectal Cancer AJCC v8|Stage IVA Prostate Cancer AJCC v8|Stage IVB Colorectal Cancer AJCC v8|Stage IVB Prostate Cancer AJCC v8|Stage IVC Colorectal Cancer AJCC v8|Stage IV Colorectal Cancer AJCC v8|Stage IV Prostate Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v8,2020-10-13,2023-04-01,2023-04-01,Interventional,Recruiting,Not Applicable,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center,M D Anderson Cancer Center,Procedure|Other|Radiation,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Metastatic Thyroid Cancer,https://clinicaltrials.gov/ct2/show/NCT04693377
NCT04693936,hashimoto disease,Study of Metabolic Pathways for the Identification of Biomarkers in Hashimoto's Thyroiditis and Psoriasis,Metabolic Biomarkers in Hashimoto's Thyroiditis and Psoriasis,Hashimoto Disease|Psoriasis,2020-12-23,2023-01-31,2024-01-31,Interventional,Recruiting,Not Applicable,University of Crete,University of Crete,"Metabolomic Medicine, Private Health Clinics",Combination Product,Greece,18.0,60.0,[18-65],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT04693936
NCT04701203,hypoparathyroidism,"PaTHway TRIAL: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial, With an Open-Label Extension, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Subcutaneously Daily in Adults With Hypoparathyroidism","A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Daily in Adults With Hypoparathyroidism",Endocrine System Diseases|Hypoparathyroidism|Parathyroid Diseases,2021-01-06,2022-01-12,2025-01-31,Interventional,Active not recruiting,Phase 3,Ascendis Pharma A/S,Ascendis Pharma Bone Diseases A/S,Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site|Ascendis Pharma Investigational Site,Combination Product|Combination Product,Canada|Denmark|Germany|Hungary|Italy|Norway|United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04701203
NCT04704349,parathyroid diseases,Latest Imaging SPECT System Evaluation Phase 1,Latest Imaging SPECT System Evaluation Phase 1,Dementia|Heart Diseases|Kidney Diseases|Neoplasms|Parathyroid Diseases|Parkinsonian Disorders|Pulmonary Embolism|Rheumatic Disease|Thyroid Diseases,2021-01-06,2021-01-27,2021-01-27,Interventional,Completed,Not Applicable,Centre Hospitalier Régional d'Orléans,Centre Hospitalier Régional d'Orléans,CHR d'Orleans,Radiation,France,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT04704349
NCT04704349,thyroid diseases,Latest Imaging SPECT System Evaluation Phase 1,Latest Imaging SPECT System Evaluation Phase 1,Dementia|Heart Diseases|Kidney Diseases|Neoplasms|Parathyroid Diseases|Parkinsonian Disorders|Pulmonary Embolism|Rheumatic Disease|Thyroid Diseases,2021-01-06,2021-01-27,2021-01-27,Interventional,Completed,Not Applicable,Centre Hospitalier Régional d'Orléans,Centre Hospitalier Régional d'Orléans,CHR d'Orleans,Radiation,France,18.0,120.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04704349
NCT04704414,graves ophthalmopathy,Exophthalmometry With 3D Face Scanners,Exophthalmometry With 3D Face Scanners,Exophthalmos|Graves Ophthalmopathy|Orbital Fractures|Orbital Tumor,2021-01-06,2021-12-31,2022-12-31,Interventional,Recruiting,Not Applicable,University of Zurich,University of Zurich,"Ophthalmology Department, University Hospital Zurich",Device,Switzerland,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT04704414
NCT04706962,thyroid cancer,"A Phase 1, Open-Label, Dose Escalation and Expansion Study of TH1902 in Patients With Advanced Solid Tumors",TH1902 in Patients With Advanced Solid Tumors,Cutaneous Melanoma|Endometrial Cancer|Epithelial Ovarian Cancer|Hormone Receptor-positive Breast Cancer|Prostate Cancer|Small-cell Lung Cancer|Solid Tumor|Thyroid Cancer|TNBC - Triple-Negative Breast Cancer,2021-01-07,2023-03-31,2023-03-31,Interventional,Recruiting,Phase 1,Theratechnologies,PPD|Theratechnologies,Cedars-Sinai|Karmanos Cancer Institute|START Midwest|Gettysburg Cancer Center|Mary Crowley Cancer Research|University of Texas MD Anderson Cancer Center,Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04706962
NCT04712760,congenital hypothyroidism,Congenital Hypothyroidism in Children With Eutopic Gland or Thyroid Hemiagenesis: Predictive Factors for Transient vs Permanent Hypothyroidism.,Congenital Hypothyroidism in Children With Eutopic Gland or Thyroid Hemiagenesis: Predictive Factors for Transient vs Permanent Hypothyroidism.,Congenital Hypothyroidism,2021-01-11,2021-03-01,2021-04-01,Observational,Recruiting,,"Central Hospital, Nancy, France","Central Hospital, Nancy, France",CHRU Nancy,,France,0.0,42.0,[0-17]|[18-65],Hypothyroidism,Congenital hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04712760
NCT04730726,thyroid nodule,In Vivo Multispectral Optoacoustic Imaging of Thyroid Nodules,In Vivo Multispectral Optoacoustic Imaging of Thyroid Nodules,Thyroid Nodule,2021-01-26,2021-12-01,2022-04-01,Interventional,Recruiting,Not Applicable,University Medical Center Groningen,University Medical Center Groningen,University Medical Center Groningen,Device,Netherlands,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04730726
NCT04731467,papillary thyroid cancer,"A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors",A Study of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors,Colorectal Adenocarcinoma|Melanoma|Non Small Cell Lung Cancer|Ovarian Cancer|Pancreatic Cancer|Papillary Thyroid Cancer|Solid Tumor,2021-01-24,2024-02-29,2024-03-31,Interventional,Recruiting,Phase 1/Phase 2,Purple Biotech Ltd.,Bristol-Myers Squibb|Famewave Ltd.,HonorHealth Research Institute|Yale University|Barbara Ann Karmanos Cancer Institute|The University of Texas M.D. Anderson Cancer Center|Rambam Health Care Campus|Sheba Medical Center,Drug|Drug|Drug|Drug,Israel|United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT04731467
NCT04731740,poorly differentiated thyroid gland carcinoma,Pembrolizumab in Combination With Standard 1st Line Therapy (Lenvatinib / Chemotherapy) for Locally Advanced or Metastatic Poorly Differentiated or Anaplastic Thyroid Cancer,Pembrolizumab and Lenvatinib/Chemotherapy for Poorly Differentiated/Anaplastic Thyroid Cancer,Metastatic Thyroid Gland Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Thyroid Gland Anaplastic Carcinoma by AJCC V8 Stage,2021-01-26,2023-12-28,2023-12-28,Interventional,Suspended,Phase 2,"Saint Petersburg State University, Russia","Saint Petersburg State University, Russia",Saint-Petersburg State University (SPSU) N.I.Pirogov Clinic of High Medical Technologies,Drug|Biological|Drug,Russian Federation,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Poorly differentiated thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04731740
NCT04731740,metastatic thyroid gland carcinoma,Pembrolizumab in Combination With Standard 1st Line Therapy (Lenvatinib / Chemotherapy) for Locally Advanced or Metastatic Poorly Differentiated or Anaplastic Thyroid Cancer,Pembrolizumab and Lenvatinib/Chemotherapy for Poorly Differentiated/Anaplastic Thyroid Cancer,Metastatic Thyroid Gland Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Thyroid Gland Anaplastic Carcinoma by AJCC V8 Stage,2021-01-26,2023-12-28,2023-12-28,Interventional,Suspended,Phase 2,"Saint Petersburg State University, Russia","Saint Petersburg State University, Russia",Saint-Petersburg State University (SPSU) N.I.Pirogov Clinic of High Medical Technologies,Drug|Biological|Drug,Russian Federation,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Metastatic Thyroid Cancer,https://clinicaltrials.gov/ct2/show/NCT04731740
NCT04734457,congenital hypothyroidism,Final Height in Patients With Congenital Hypothyroidism Diagnosed by Neonatal Screening,Final Height in Patients With CH Diagnosed by the Screening,Congenital Hypothyroidism,2021-01-11,2022-03-01,2022-04-01,Observational,Not yet recruiting,,Ain Shams University,Ain Shams University,Ain Shams University,Drug,Egypt,0.0,120.0,[0-17]|[18-65]|[65 and more],Hypothyroidism,Congenital hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04734457
NCT04737330,thyroid eye disease,"A Two-year Multi-center Phase 3 Study to Investigate the Efficacy and Safety of Secukinumab in Adult Patients With Active, Moderate to Severe Thyroid Eye Disease (ORBIT), With a Randomized, Parallel-group, Double-blind, Placebo-controlled, 16-week Treatment Period, and a Follow-up/Retreatment Period",A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED),Graves Orbitopathy|Thyroid Eye Disease,2020-11-20,2023-04-27,2025-02-05,Interventional,Recruiting,Phase 3,Novartis,Novartis Pharmaceuticals,Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site,Drug|Drug,Germany,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT04737330
NCT04739566,thyroid gland anaplastic carcinoma,Dabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive Anaplastic Thyroid Cancer (ANAPLAST-NEO),Dabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive Anaplastic Thyroid Cancer,Thyroid Gland Anaplastic Carcinoma,2021-01-29,2024-01-22,2026-01-22,Interventional,Recruiting,Phase 2,"Saint Petersburg State University, Russia","Saint Petersburg State University, Russia",Saint-Petersburg State University (SPSU) N.I.Pirogov Clinic of High Medical Technologies,Drug|Drug,Russian Federation,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT04739566
NCT04742608,thyroid gland carcinoma,Isolation and Characterization of Extracellular Vesicles in Patients With Thyroid Nodules and Thyroid Cancer,Development of Liquid Biopsy Technologies for Noninvasive Cancer Diagnostics in Patients With Suspicious Thyroid Nodules or Thyroid Cancer,Thyroid Gland Carcinoma|Thyroid Gland Nodule,2021-02-03,2023-02-01,2024-02-01,Observational,Recruiting,,Jonsson Comprehensive Cancer Center,Jonsson Comprehensive Cancer Center,UCLA / Jonsson Comprehensive Cancer Center,Procedure|Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04742608
NCT04742608,thyroid gland nodule,Isolation and Characterization of Extracellular Vesicles in Patients With Thyroid Nodules and Thyroid Cancer,Development of Liquid Biopsy Technologies for Noninvasive Cancer Diagnostics in Patients With Suspicious Thyroid Nodules or Thyroid Cancer,Thyroid Gland Carcinoma|Thyroid Gland Nodule,2021-02-03,2023-02-01,2024-02-01,Observational,Recruiting,,Jonsson Comprehensive Cancer Center,Jonsson Comprehensive Cancer Center,UCLA / Jonsson Comprehensive Cancer Center,Procedure|Other,United States,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04742608
NCT04742959,thyroid cancer,"A Phase Ib/II, Multicenter, Open-Label Study of TT-00420 Tablet, as Monotherapy or in Combination Regimens, in Patients With Advanced Solid Tumors",Study of TT-00420 Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors,Advanced Solid Tumor|Bladder Cancer|Cholangiocarcinoma|Gallbladder Cancer|Gastric Cancer|HER2-negative Breast Cancer|Prostate Cancer|Sarcoma|Small-cell Lung Cancer|Thyroid Cancer|Triple Negative Breast Cancer,2021-02-02,2022-04-01,2022-12-01,Interventional,Recruiting,Phase 1/Phase 2,"TransThera Sciences (Nanjing), Inc.","TransThera Sciences (Nanjing), Inc.",City of Hope|The University of Chicago|Rutgers Cancer Institute|MD Anderson Cancer Center,Drug|Combination Product,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04742959
NCT04745793,parathyroid diseases,Precise Recognition With Enhanced Vision of Endocrine Neck Targets,Precise Recognition With Enhanced Vision of Endocrine Neck Targets,Parathyroid Diseases|Thyroid Diseases,2021-02-04,2024-02-04,2024-03-04,Observational,Recruiting,,IHU Strasbourg,IHU Strasbourg,"Service de Chirurgie Digestive et Endocrinienne, NHC",Other,France,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT04745793
NCT04745793,thyroid diseases,Precise Recognition With Enhanced Vision of Endocrine Neck Targets,Precise Recognition With Enhanced Vision of Endocrine Neck Targets,Parathyroid Diseases|Thyroid Diseases,2021-02-04,2024-02-04,2024-03-04,Observational,Recruiting,,IHU Strasbourg,IHU Strasbourg,"Service de Chirurgie Digestive et Endocrinienne, NHC",Other,France,18.0,120.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04745793
NCT04747275,hypothyroidism,Use of Liquid Stable Levothyroxine in Trisomy 21 Pediatric Patients,Use of Liquid Stable Levothyroxine in Trisomy 21 Pediatric Patients,Hypothyroidism|Trisomy 21,2021-02-03,2022-05-31,2022-07-31,Interventional,Recruiting,Phase 4,Children's Mercy Hospital Kansas City,Children's Mercy Hospital Kansas City,Children's Mercy Hospital,Drug|Drug,United States,2.0,4.0,[0-17],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04747275
NCT04750460,hypoparathyroidism,"The Effect of Teriparatide on the Early Postoperative Hypocalcemia After Parathyroidectomy in Dialysis Patients: a Pilot, Randomized Trial",Injection of Teriparatide to Prevent Hypocalcemia After Parathyroidectomy in Dialysis Patients (TeriCa).,Chronic Kidney Disease-Mineral and Bone Disorder|Dialysis|Hypocalcemia|Hypoparathyroidism|Secondary Hyperparathyroidism,2021-02-02,2021-07-31,2021-07-31,Interventional,Enrolling by invitation,Phase 3,"Saint Petersburg State University, Russia","Saint Petersburg State University, Russia",Saint-Petersburg State University Hospital,Drug,Russian Federation,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04750460
NCT04752202,hashimoto disease,The Influence of Reducing Diets on Changes in Thyroid Parameters in Women Suffering From Obesity and Hashimoto's Disease,The Influence of Reducing Diets on Changes in Thyroid Parameters in Obese Women With Hashimoto's Disease,Hashimoto Disease|Obesity,2021-02-02,2019-04-19,2019-10-31,Interventional,Completed,Not Applicable,Medical University of Bialystok,Medical University of Bialystok,Department of Dietetic and Clinical Nutrition; Medical University of Bialystok,Behavioral|Behavioral,Poland,18.0,65.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT04752202
NCT04754607,thyroiditis,"Effects of Low-Level Laser Therapy on Oxidative Stress Levels, Fatigue and Quality of Life in Patients With Hashimoto Thyroiditis",Effects of Low-Level Laser Therapy on Oxidative Stress Levels...,Autoimmune Diseases|Autoimmune Thyroiditis|Hashimoto Thyroiditis|Thyroid Diseases|Thyroiditis,2021-02-12,2022-04-15,2022-06-30,Interventional,Recruiting,Not Applicable,Istanbul Medipol University Hospital,Istanbul Medipol University Hospital,Sumeyye TUNC,Other,Turkey,18.0,65.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT04754607
NCT04754607,thyroid diseases,"Effects of Low-Level Laser Therapy on Oxidative Stress Levels, Fatigue and Quality of Life in Patients With Hashimoto Thyroiditis",Effects of Low-Level Laser Therapy on Oxidative Stress Levels...,Autoimmune Diseases|Autoimmune Thyroiditis|Hashimoto Thyroiditis|Thyroid Diseases|Thyroiditis,2021-02-12,2022-04-15,2022-06-30,Interventional,Recruiting,Not Applicable,Istanbul Medipol University Hospital,Istanbul Medipol University Hospital,Sumeyye TUNC,Other,Turkey,18.0,65.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04754607
NCT04759053,thyroid nodule,"Effectiveness of Core-Needle US Guided Biopsy as Primary Tool For Diagnosis of Thyroid Nodules, A Prospective Study",Effectiveness of Core-Needle US Guided Biopsy as Primary Tool For Diagnosis of Thyroid Nodules,Thyroid Diseases|Thyroid Gland; Node|Thyroid Nodule,2021-02-09,2018-01-01,2018-02-01,Interventional,Completed,Not Applicable,Kafrelsheikh University,Alexandria University|Kafrelsheikh University,,Procedure|Procedure,,18.0,65.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04759053
NCT04759053,thyroid diseases,"Effectiveness of Core-Needle US Guided Biopsy as Primary Tool For Diagnosis of Thyroid Nodules, A Prospective Study",Effectiveness of Core-Needle US Guided Biopsy as Primary Tool For Diagnosis of Thyroid Nodules,Thyroid Diseases|Thyroid Gland; Node|Thyroid Nodule,2021-02-09,2018-01-01,2018-02-01,Interventional,Completed,Not Applicable,Kafrelsheikh University,Alexandria University|Kafrelsheikh University,,Procedure|Procedure,,18.0,65.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04759053
NCT04759911,thyroid gland papillary carcinoma,Neoadjuvant Treatment With Selpercatinib in RET-Altered Thyroid Cancers,Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer,Malignant Thyroid Gland Neoplasm|Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Carcinoma|Thyroid Gland Anaplastic Carcinoma|Thyroid Gland Medullary Carcinoma|Thyroid Gland Papillary Carcinoma|Thyroid Gland Squamous Cell Carcinoma,2021-02-08,2024-09-10,2024-09-10,Interventional,Recruiting,Phase 2,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center,M D Anderson Cancer Center,Other|Other|Drug|Procedure,United States,12.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT04759911
NCT04759911,poorly differentiated thyroid gland carcinoma,Neoadjuvant Treatment With Selpercatinib in RET-Altered Thyroid Cancers,Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer,Malignant Thyroid Gland Neoplasm|Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Carcinoma|Thyroid Gland Anaplastic Carcinoma|Thyroid Gland Medullary Carcinoma|Thyroid Gland Papillary Carcinoma|Thyroid Gland Squamous Cell Carcinoma,2021-02-08,2024-09-10,2024-09-10,Interventional,Recruiting,Phase 2,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center,M D Anderson Cancer Center,Other|Other|Drug|Procedure,United States,12.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Poorly differentiated thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04759911
NCT04759911,thyroid gland anaplastic carcinoma,Neoadjuvant Treatment With Selpercatinib in RET-Altered Thyroid Cancers,Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer,Malignant Thyroid Gland Neoplasm|Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Carcinoma|Thyroid Gland Anaplastic Carcinoma|Thyroid Gland Medullary Carcinoma|Thyroid Gland Papillary Carcinoma|Thyroid Gland Squamous Cell Carcinoma,2021-02-08,2024-09-10,2024-09-10,Interventional,Recruiting,Phase 2,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center,M D Anderson Cancer Center,Other|Other|Drug|Procedure,United States,12.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT04759911
NCT04759911,thyroid gland squamous cell carcinoma,Neoadjuvant Treatment With Selpercatinib in RET-Altered Thyroid Cancers,Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer,Malignant Thyroid Gland Neoplasm|Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Carcinoma|Thyroid Gland Anaplastic Carcinoma|Thyroid Gland Medullary Carcinoma|Thyroid Gland Papillary Carcinoma|Thyroid Gland Squamous Cell Carcinoma,2021-02-08,2024-09-10,2024-09-10,Interventional,Recruiting,Phase 2,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center,M D Anderson Cancer Center,Other|Other|Drug|Procedure,United States,12.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid Gland Squamous Cell Carcinoma,https://clinicaltrials.gov/ct2/show/NCT04759911
NCT04759911,thyroid gland medullary carcinoma,Neoadjuvant Treatment With Selpercatinib in RET-Altered Thyroid Cancers,Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer,Malignant Thyroid Gland Neoplasm|Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Carcinoma|Thyroid Gland Anaplastic Carcinoma|Thyroid Gland Medullary Carcinoma|Thyroid Gland Papillary Carcinoma|Thyroid Gland Squamous Cell Carcinoma,2021-02-08,2024-09-10,2024-09-10,Interventional,Recruiting,Phase 2,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center,M D Anderson Cancer Center,Other|Other|Drug|Procedure,United States,12.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, medullary",https://clinicaltrials.gov/ct2/show/NCT04759911
NCT04760171,medullary thyroid cancer,An ex Vivo Study to Purify Amyloid Fibrils and Solve Their 3D Structures Using Amyloid Proteins From Medullary Thyroid Cancer and Laryngeal Amyloidosis,Amyloid Proteins From Medullary Thyroid Cancer and Laryngeal Amyloidosis,Alzheimer Disease|Amyloid|Dementia|Medullary Thyroid Cancer,2021-02-10,2023-02-28,2026-02-28,Observational,Not yet recruiting,,The Leeds Teaching Hospitals NHS Trust,The Leeds Teaching Hospitals NHS Trust|University of Leeds,,,,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, medullary",https://clinicaltrials.gov/ct2/show/NCT04760171
NCT04760288,thyroid cancer,"A Phase III, Randomized, Open-Label Study of Pralsetinib Versus Standard of Care for Treatment of RET-Mutated Medullary Thyroid Cancer.",A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).,Thyroid Cancer,2021-02-17,2026-04-15,2028-04-15,Interventional,Not yet recruiting,Phase 3,Hoffmann-La Roche,Hoffmann-La Roche,"The Lundquist Institute for BioMedical Innovation at Harbor-UCLA Medical Cente|Instituto de Investigaciones Metabolicas (Idim)|Centro Médico Privado CEMAIC|Instituto Medico de la Fundacion Estudios Clinicos|Sanatorio Britanico de Rosario|Centro de Investigación Clínica - Clínica Viedma|Macquarie University Hospital|Royal North Shore Hospital|Ashford Cancer Center Research|The Alfred Hospital;Clinical Trial Pharmacy|Medizinische Universität Graz; Klinische Abteilung für Allgemeine HNO|CETUS Hospital Dia Oncologia|Hospital de Clinicas de Porto Alegre (HCPA) - PPDS|Irmandade Da Santa Casa de Misericordia de Porto Alegre|Fundação Pio XII Hospital de Câncer de Barretos|Instituto Do Câncer Do Estado de São Paulo Octávio Frias de Oliveira|Multiprofile Hospital for Active Treatment Uni Hospital; Department of medicinal oncology|Complex Oncology Center Plovdiv; Department of Medical Oncology and Oncology Diseases in Pneumology|University Multiprofile Hospital For Active Treatment ""Sveti Ivan Rilski"" EAD; clinical hematology|Tom Baker Cancer Centre; Dept of Pathology|Cross Cancer Institute; Clinical Trials|McGill University Health Center; Glen-Cedars Cancer Centre, Oncology Pharmacy|Centre Hospitalier Universitaire de Sherbrooke; Pharmacie de Chimiotherapie|Clinical Hospital Centre Osijek; Hematology|Clinical Hospital Sestre Milosrdnice|Klinicki bolnicki centar Zagreb|Odense Universitetshospital, Onkologisk Afdeling, Klinisk Forsknings Enhed|Hôtel Dieu -Angers; Pharmacie / Secteur Essais Cliniques|EDOG - Institut Bergonie - PPDS|Centre Hospitalier Universitaire Lyon; Institut Hématologique et d'Oncologie Pédiatrique|CHU Nantes|Centre Antoine Lacassagne Centre Régional de Lutte Contre Le Cancer|Hopital Cochin|Institut Curie; Pharmacie|Hôpital Saint-Louis|ICANS|Institut Universitaire de Cancer de Toulouse Oncopole; IUCT- Oncopole|Attikon University General Hospital|University of Athens Medical School - Regional General Hospital Alexandra|Kianous Stavros|Semmelweis Egyetem, II. Belgyógyászati Klinika|Debreceni Egyetem Klinikai Kozpont|Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont|Panchshil Hospital|Unity Hospital-Surat|Tata Memorial Hospital; Dept of Medical Oncology|HCG NCHRI Cancer Center|Deenanath Mangeshkar Hospital & Research Centre|Sparsh Hospitals & Critical Care (P) Ltd.|Dayanand Medical College and Hospital|Hadassah Medical Center|C.H. Regional Reina Sofia - PPDS|National Cancer Center|Seoul National University Hospital|Samsung Medical Center - PPDS|VU Medisch Centrum|Saint Louis University Hospital of Sacred Heart|St. Luke's Medical Center - Quezon City|Centrum Onkologii-Instytut Im. Marii Skłodowskiej Curie; I Klinika Radioterapii i Chemioterapii|Centrum Onkologii Instytut im. Marii Sklodowskiej-Curie w Krakowie - Apteka/Pharmacy; Pharmacy|Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E.|Instituto Portugues de Oncologia Do Porto Francisco Gentil Epe|Institutul National de Endocrinologie ""C. I. Parhon""; Sectorul 1 BUCUREȘTI|Prof Dr I Chiricuta Institute of Oncology; Oncology Department|Onco Clinic Consult SA|CHUS - H. Clinico U. de Santiago|Clinica Universidad Navarra; Servicio de Farmacia|Hospital Universitario Vall d'Hebron|Hospital Clinic de Barcelona|MD Anderson Cancer Center Madrid - España; Servicio de Farmacia|Hospital Universitario Ramon y Cajal|Hospital Universitario HM Sanchinarro - CIOCC; Farmacia - Ensayos Clínicos|Hospital Regional Universitario de Malaga|Hospital Universitario Virgen del Rocio|Phramongkutklao Hospital|Siriraj Hospital, Mahidol Uni ; Division of Rheumatology, Dept. of Medicine|Chulalongkorn University Hospital; Hematology|SI Institute for general and urgent surgery n.a. V.T.Zaitseva of NAMS of Ukraine|Municipal Non-profit Enterprise ""City Clinical Hospital # 4"" of Dnipro City Council - PPDS|Ukr. Scientific Practical Center of Endocrine Surgery,Transplantation of Endocrine organs&Tissues|Clinic Verum Expert LLC|Treatment and Diagnostic Center of LLC Specialized Clinic Prognosis Optima|St Bartholomew's Hospital|Guys Hospital; Guys Cancer Center|The Christie NHS Foundation Trust|The Royal Marsden NHS Foundation Trust - Royal Marsden Hospital (RMH) - Sutton",Drug|Drug|Drug,"Argentina|Australia|Austria|Brazil|Bulgaria|Canada|Croatia|Denmark|France|Greece|Hungary|India|Israel|Italy|Korea, Republic of|Netherlands|Philippines|Poland|Portugal|Romania|Spain|Thailand|Ukraine|United Kingdom|United States",12.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04760288
NCT04778865,hashimoto disease,Effect of Vitamin D Supplementation on Autoimmunity and Thyroid Function in Subjects With Hashimoto's Thyroiditis and Vitamin D Deficiency: Clinical Pilot Trial.,Effect of Treatment for Vitamin D Deficiency on Thyroid Function and Autoimmunity in Hashimoto's Thyroiditis.,Hashimoto Disease|Treatment Levothyroxine|Vitamin D Deficiency,2021-02-24,2021-12-31,2021-12-31,Interventional,Recruiting,Not Applicable,Universidad de Valparaiso,Universidad de Valparaiso,Escuela de Nutrición. Facultad de Farmacia. Universidad de Valparaíso.,Dietary Supplement|Dietary Supplement,Chile,18.0,60.0,[18-65],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT04778865
NCT04782856,thyroid cancer,Energy Metabolism in Thyroidectomized Patients,Energy Metabolism in Thyroidectomized Patients,Hypothyroidism|Thyroid Cancer|Thyroid Goiter,2021-03-01,2023-05-31,2023-05-31,Interventional,Recruiting,Phase 2,Virginia Commonwealth University,Virginia Commonwealth University,Virginia Commonwealth University,Drug|Drug|Drug,United States,18.0,89.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04782856
NCT04782856,hypothyroidism,Energy Metabolism in Thyroidectomized Patients,Energy Metabolism in Thyroidectomized Patients,Hypothyroidism|Thyroid Cancer|Thyroid Goiter,2021-03-01,2023-05-31,2023-05-31,Interventional,Recruiting,Phase 2,Virginia Commonwealth University,Virginia Commonwealth University,Virginia Commonwealth University,Drug|Drug|Drug,United States,18.0,89.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04782856
NCT04784208,hypothyroidism,A Study to Determine the Validity and Sensitivity of 'Questionnaire to Screen for HYpothyroidism' (Q'SHY),A Study to Determine the Validity and Sensitivity of 'Questionnaire to Screen for HYpothyroidism' (Q'SHY),Healthy|Hypothyroidism,2021-02-25,2022-06-30,2022-06-30,Observational,Recruiting,,Abbott,Abbott,"Dr.Prasanna Kumar|Dr. MV Rama Mohan, MD, DM",Diagnostic Test,India,18.0,65.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04784208
NCT04785443,thyroid diseases,Contribution of Indocyanine Green Angiography in the Detection of Parathyroids and the Prevention of Hypoparathyroidism Post Total Thyroidectomy,Contribution of ICG Angiography in the Detection of Parathyroids and the Prevention of Hypoparathyroidism Post Total Thyroidectomy,Thyroid Diseases,2021-02-25,2024-06-30,2025-03-31,Interventional,Recruiting,Phase 3,"University Hospital, Brest","University Hospital, Brest",CHRU de Brest,Drug|Procedure,France,18.0,120.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04785443
NCT04787328,medullary thyroid carcinoma,"A Single-arm, Open-Label, Multicenter Phase II Study to Evaluate the Efficacy and Safety of HA121-28 Tablets in Patients With Medullary Thyroid Carcinoma (MTC)",A Study of HA121-28 Tablets in Patients With Medullary Thyroid Carcinoma (MTC),Medullary Thyroid Carcinoma,2021-02-24,2023-03-31,2025-03-31,Interventional,Recruiting,Phase 2,"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","Beijing Tongren Hospital|Cancer Institute and Hospital, Chinese Academy of Medical Sciences|Fujian Cancer Hospital|Gansu Province Tumor Hospital|Sun Yat-Sen University Cancer Center|Henan Province Tumor Hospital|Jiangsu province tumor hospital|Cancer Hospital of Fudan University|Sichuan Cancer Hospital|Tianjin Medical University Cancer Institute and Hospital|Tianjin People's Hospital|The First Affiliated Hospital of Kunming Medical University|Zhejiang Provincial People's Hospital",Drug,China,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, medullary",https://clinicaltrials.gov/ct2/show/NCT04787328
NCT04789993,graves disease,Additional Autoimmune Diseases With Type 1 Diabetes in Children and Adolescents at Diabetes Diagnostic and During Follow-up : a Monocentric Study in France,Additional Autoimmune Diseases With Type 1 Diabetes in Pediatrics at Diabetes Diagnosis and During Follow-up,Addison Disease|Autoimmune Diseases|Celiac Disease|Graves Disease|Hashimoto Disease|Type 1 Diabetes|Vitiligo,2021-02-20,2021-03-31,2021-04-30,Observational,Enrolling by invitation,,"Central Hospital, Nancy, France","Central Hospital, Nancy, France",Hôpital d'Enfants de Brabois,Other,France,6.0,120.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04789993
NCT04789993,hashimoto disease,Additional Autoimmune Diseases With Type 1 Diabetes in Children and Adolescents at Diabetes Diagnostic and During Follow-up : a Monocentric Study in France,Additional Autoimmune Diseases With Type 1 Diabetes in Pediatrics at Diabetes Diagnosis and During Follow-up,Addison Disease|Autoimmune Diseases|Celiac Disease|Graves Disease|Hashimoto Disease|Type 1 Diabetes|Vitiligo,2021-02-20,2021-03-31,2021-04-30,Observational,Enrolling by invitation,,"Central Hospital, Nancy, France","Central Hospital, Nancy, France",Hôpital d'Enfants de Brabois,Other,France,6.0,120.0,[0-17]|[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT04789993
NCT04795947,hypothyroidism,Correlation Between Thyroid Function and Quality of Life in Well-controlled Hypothyroidism Patients,Correlation Between Thyroid Function and Quality of Life in Hypothyroidism,Hypothyroidism,2021-03-10,2021-11-01,2021-11-01,Observational,Active not recruiting,,Beijing Chao Yang Hospital,Beijing Chao Yang Hospital,BeijingCYH,Behavioral,China,18.0,75.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04795947
NCT04802876,thyroid carcinoma,Efficacy of Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors Defined by a Single and Pre-specified Cutoff,Efficacy of Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors,Anal Carcinoma|Bladder Carcinoma|Carcinoma of Unknown Primary|Cervical Carcinoma|Cholangiocarcinoma|Colorectal Adenocarcinoma|Esophageal Adenocarcinoma|Head and Neck Squamous Cell Carcinoma|Hepatocellular Carcinoma|HER2-positive Breast Cancer|Hormone Receptor Positive / HER2-negative Breast Cancer|Kidney Clear Cell Carcinoma|Lung Adenocarcinoma|Lung Adenocarcinoma EGFR-mutated/ ALK Traslocation|Lung Squamous Cell Carcinoma|Melanoma|Mesothelioma|MSI-H Colorectal Cancer|Other Histology|Ovarian Serous Cystadenocarcinoma|Pancreatic Adenocarcinoma|Prostate Adenocarcinoma|Sarcoma|Small Cell Lung Cancer|Squamous Esophageal Carcinoma|Stomach Adenocarcinoma|Thyroid Carcinoma|Triple Negative Breast Cancer|Uterine Carcinosarcoma|Uterine Endometrial Carcinoma|Uveal Melanoma,2021-03-14,2023-12-31,2024-12-11,Interventional,Recruiting,Phase 2,SOLTI Breast Cancer Research Group,Novartis|SOLTI Breast Cancer Research Group,Ico Badalona|Hospital Universitari Sant Joan de Reus|IOB - H. Quironsalud Barcelona|Hospital Vall Hebron|Hospital Clinic Barcelona|Complejo Asistencial Universitario de León|Fundación Jiménez Díaz|Hospital Universitario 12 de Octubre|Instituto Valenciano de Oncología (IVO)|Hospital Clínico Universitario de Valencia,Drug,Spain,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04802876
NCT04806269,thyrotoxicosis,"Clinical Application of Continuous Monitoring Data for the Pulse Rate, Exercise, and Symptom Survey by Wearable Device in the Patients With Thyroid Dysfunction",Biosignals by Wearables in Thyroid Dysfunction,Hypothyroidism|Thyrotoxicosis,2021-01-26,2022-05-30,2022-12-31,Observational,Recruiting,,Seoul National University Bundang Hospital,Seoul National University Bundang Hospital,Seoul National University Bundang Hospital,Device,"Korea, Republic of",18.0,60.0,[18-65],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04806269
NCT04806269,hypothyroidism,"Clinical Application of Continuous Monitoring Data for the Pulse Rate, Exercise, and Symptom Survey by Wearable Device in the Patients With Thyroid Dysfunction",Biosignals by Wearables in Thyroid Dysfunction,Hypothyroidism|Thyrotoxicosis,2021-01-26,2022-05-30,2022-12-31,Observational,Recruiting,,Seoul National University Bundang Hospital,Seoul National University Bundang Hospital,Seoul National University Bundang Hospital,Device,"Korea, Republic of",18.0,60.0,[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04806269
NCT04821336,thyroid cancer,"Cholesterol Metabolites (Dendrogenin A or DDA, 6-oxo-cholestane-3β,5α-diol or OCDO,...) Quantification in Malignant Versus Normal Human Thyroid Tissue Refractory to Iodine",Cholesterol Metabolites Analysis in Human Thyroid and Iodine Resistance,Thyroid Cancer,2021-03-25,2022-06-30,2022-06-30,Observational,Not yet recruiting,,Institut Claudius Regaud,Cancer Research Center of Toulouse|Institut Claudius Regaud,Institut Claudius regaud IUCT Oncopole,Other,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04821336
NCT04825964,hyperthyroidism,Comparison of Exercise Capacity and Physical Activity Levels in Patients With Hyperthyroid and Healthy Controls,"Exercise Capacity, Physical Activity Levels in Patients With Hyperthyroid",Hyperthyroidism,2021-03-20,2021-11-30,2021-12-31,Observational,Completed,,Gazi University,Gazi University,"Gazi University Facutly of Health Sciences Department of Physiotheraphy and Rehabilitation, Cardiopulmonary Rehabilitation Unit",,Turkey,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04825964
NCT04831957,hypothyroidism,Hypothyroidism After the TAVI Procedure in Elderly Patients,Hypothyroidism After the TAVI Procedure in Elderly Patients,Hypothyroidism|TAVI,2021-03-19,2023-12-31,2023-12-31,Interventional,Recruiting,Not Applicable,Universitair Ziekenhuis Brussel,Universitair Ziekenhuis Brussel,UZ brussel,Diagnostic Test,Belgium,70.0,120.0,[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04831957
NCT04853680,thyroid cancer,A Prospective Randomized Controlled Study of Whether Anti-adhesion Barrier Can Prevent Voice Quality After Thyroidectomy.,Effect of Anti-adhesion Barrier on the Voice Quality After Thyroidectomy.,Thyroid Cancer|Thyroid Nodule|Voice Disorders,2021-04-11,2023-06-30,2023-07-30,Interventional,Recruiting,Not Applicable,Inha University Hospital,Inha University Hospital,Inha University Hospital,Device,"Korea, Republic of",20.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04853680
NCT04853680,thyroid nodule,A Prospective Randomized Controlled Study of Whether Anti-adhesion Barrier Can Prevent Voice Quality After Thyroidectomy.,Effect of Anti-adhesion Barrier on the Voice Quality After Thyroidectomy.,Thyroid Cancer|Thyroid Nodule|Voice Disorders,2021-04-11,2023-06-30,2023-07-30,Interventional,Recruiting,Not Applicable,Inha University Hospital,Inha University Hospital,Inha University Hospital,Device,"Korea, Republic of",20.0,70.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04853680
NCT04856488,hyperthyroidism,Preoperative Lugol's Solution in Graves' Disease and Toxic Nodular Goiter,Preoperative Lugol's Solution in Graves' Disease and Toxic Nodular Goiter,Hyperthyroidism,2021-04-06,2023-08-31,2024-02-29,Interventional,Recruiting,Phase 3,Karolinska University Hospital,Jan Calissendorff,"Department of Endocrinology, Karolinska University Hospital",Drug,Sweden,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04856488
NCT04857086,differentiated thyroid cancer,A Multi-center Study to Observe Five-year Outcomes of the Initial Management in Patients With Differentiated Thyroid Cancer in the Real World in China (The Second Stage of DTCC),The Initial Management in Patients With Differentiated Thyroid Cancer in the Real World in China,Differentiated Thyroid Cancer,2021-04-20,2022-07-30,2023-03-28,Observational,Recruiting,,Huazhong University of Science and Technology,"China-Japan Union Hospital, Jilin University|Chinese PLA General Hospital|First Hospital of China Medical University|Gansu Cancer Hospital|Huazhong University of Science and Technology|Sir Run Run Shaw Hospital|The First Affiliated Hospital of Kunming Medical College|Tongji Hospital|West China Hospital|Wuhan Union Hospital, China","Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",,China,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Differentiated thyroid cancer, all",https://clinicaltrials.gov/ct2/show/NCT04857086
NCT04858867,differentiated thyroid cancer,Reinducing Radioiodine-sensitivity in Radioiodine-refractory Differentiated Thyroid Cancer Using Lenvatinib (RESET),Reinducing Radioiodine-sensitivity in Radioiodine-refractory DTC Using Lenvatinib (RESET),Differentiated Thyroid Cancer,2021-04-09,2024-01-01,2024-06-01,Interventional,Recruiting,Not Applicable,Leiden University Medical Center,Leiden University Medical Center,Leiden University Medical Center,Radiation|Radiation,Netherlands,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Differentiated thyroid cancer, all",https://clinicaltrials.gov/ct2/show/NCT04858867
NCT04860622,hypothyroidism,Normal Range of TSH and FT4 in Pregnancy,Normal Range of TSH and FT4 in Pregnancy,Dysfunction|Hypothyroidism|Iodine Deficiency|Pregnancy Related|Thyroid,2021-04-22,2021-08-15,2021-09-01,Observational [Patient Registry],Completed,,Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital,Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital,Sehit Prof Dr Ilhan Varank Sancaktepe Training and Research Hospital,Diagnostic Test,Turkey,18.0,50.0,[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04860622
NCT04868045,thyroid cancer,Evaluation of The Development of Central Resistance to Thyroid Hormone After Prolonged Exposure to Excess Thyroid Hormone in Thyroid Cancer Patients,Study of Resistance to Thyroid Hormone After Long-term Exposure in People With Thyroid Cancer,Thyroid Cancer,2021-04-28,2023-04-30,2023-04-30,Interventional,Recruiting,Phase 1,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,Drug|Drug|Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04868045
NCT04876287,thyroid cancer,Salivary dysfuncTion After Radioiodine Treatment,Salivary dysfuncTion After Radioiodine Treatment,Thyroid Cancer,2021-04-26,2021-04-26,2021-04-26,Observational,Completed,,Institut de Radioprotection et de Surete Nucleaire,Institut de Radioprotection et de Surete Nucleaire,Pitié-Salpêtrière hospital,Drug,France,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04876287
NCT04876534,graves ophthalmopathy,"Multicenter, Randomized, Observer-blind, Controlled Study of the Anti-IL-6 Receptor Antibody Tocilizumab (TCZ) or Methylprednisolone (MP) Treatment in Patients With Active Moderate-severe Graves' Orbitopathy",Tocilizumab in Active Moderate-severe Graves' Orbitopathy,Graves Ophthalmopathy,2021-05-03,2022-12-18,2023-12-18,Interventional,Recruiting,Phase 2,"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","Azienda Ospedaliera ""Sant'Andrea""|Azienda Ospedaliero, Universitaria Pisana|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|Istituto Auxologico Italiano|Mauriziano Umberto I Hospital","Istituto Auxologico Italiano|Azienda Ospedaliero, Universitaria Pisana|Azienda Ospedaliera ""Sant'Andrea""|Mauriziano Umberto I Hospital",Drug|Drug,Italy,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT04876534
NCT04877665,hypothyroidism,Establishing Reference Intervals for Thyroid Stimulating Hormone in Children Under the Age of Two Years,Establishing RIs for TSH in Children Under the Age of Two Years,Hypothyroidism,2021-05-05,2019-03-30,2019-03-30,Observational [Patient Registry],Completed,,"Aga Khan University Hospital, Pakistan","Aga Khan University Hospital, Pakistan",The Aga Khan University,,Pakistan,1.0,24.0,[0-17]|[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04877665
NCT04878614,hypothyroidism,Comparison of Levothyroxine Formulation in Hypothyroid Patients With Enteral Feeding,Comparison of Levothyroxine Formulation in Hypothyroid Patients With Enteral Feeding,Hypothyroidism,2021-05-04,2022-04-30,2023-04-30,Interventional,Recruiting,Phase 4,"University of California, Los Angeles","University of California, Los Angeles",UCLA Center for Human Nutrition,Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT04878614
NCT04879355,thyroid nodule,The Use of Spinal Needles for Ultrasound-guided Fine Needle Aspiration From Thyroid Nodules - a Protocol for a Multicentre Randomised Controlled Trial,Spinal Needles in Ultrasound-guided Fine Needle Aspirations From Thyroid Nodules,Thyroid Nodule,2021-03-07,2022-11-01,2023-12-01,Interventional,Not yet recruiting,Not Applicable,Zealand University Hospital,"Herlev Hospital|Preben Homøe|Rigshospitalet, Denmark",,Device|Device,,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04879355
NCT04880798,differentiated thyroid cancer,Effect of Thyrotropin Level on Iodine Uptake: a Prospective 124I PET/CT Study in Metastatic Differentiated Thyroid Cancer,Effect of Thyrotropin Level on Iodine Uptake in Metastatic Differentiated Thyroid Cancer,Differentiated Thyroid Cancer,2021-05-06,2022-12-31,2022-12-31,Interventional,Recruiting,Not Applicable,Peking Union Medical College Hospital,Beijing Cancer Hospital|Peking Union Medical College Hospital,Peking Union Medical College Hospital|Beijing Cancer Hospital,Diagnostic Test,China,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Differentiated thyroid cancer, all",https://clinicaltrials.gov/ct2/show/NCT04880798
NCT04892303,recurrent thyroid cancer,Combination Radiotherapy and Radiopharmaceutical Therapy Treatment Planning for Thyroid Cancer,Combination Radiotherapy and Radiopharmaceutical Therapy Treatment Planning for Thyroid Cancer,Recurrent Thyroid Cancer,2021-05-03,2025-03-31,2025-08-31,Interventional,Recruiting,Phase 1,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,National Cancer Institute (NCI)|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,The Johns Hopkins SKCCC,Combination Product,United States,18.0,85.0,[18-65]|[65 and more],Thyroid neoplasms,Recurrent Thyroid Cancer,https://clinicaltrials.gov/ct2/show/NCT04892303
NCT04904159,thyroid cancer,A New Scoring System in the Diagnosis of Thyroid Gland Pathologies,Scoring System for Thyroid Gland Pathologies,Thyroid Cancer|Thyroid Nodule,2021-05-17,2023-01-01,2023-05-01,Observational [Patient Registry],Enrolling by invitation,,Dr. Lutfi Kirdar Kartal Training and Research Hospital,Dr. Lutfi Kirdar Kartal Training and Research Hospital,Kartal Dr Lutfi Kirdar Tranining and Research Hospital,Procedure|Procedure,Turkey,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04904159
NCT04904159,thyroid nodule,A New Scoring System in the Diagnosis of Thyroid Gland Pathologies,Scoring System for Thyroid Gland Pathologies,Thyroid Cancer|Thyroid Nodule,2021-05-17,2023-01-01,2023-05-01,Observational [Patient Registry],Enrolling by invitation,,Dr. Lutfi Kirdar Kartal Training and Research Hospital,Dr. Lutfi Kirdar Kartal Training and Research Hospital,Kartal Dr Lutfi Kirdar Tranining and Research Hospital,Procedure|Procedure,Turkey,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04904159
NCT04905641,thyroid nodule,The Feasibility of Bilateral Intermediate Cervical Plexus Block for Thyroidectomy/Parathyroidectomy Under Moderate Sedation; Retrospective Study,The Feasibility of Bilateral Intermediate Cervical Plexus Block for Thyroidectomy/Parathyroidectomy,Parathyroid Adenoma|Thyroid Nodule,2021-05-26,2017-05-25,2017-07-31,Observational,Completed,,Mahidol University,Mahidol University,"Faculty of Medicine Siriraj Hospital, Mahidol University",Procedure,Thailand,0.0,120.0,[0-17]|[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT04905641
NCT04922801,hyperthyroidism,OPTIMISING MOLECULAR RADIONUCLIDE THERAPY: The Role of Quantitative SPECT/CT & PET/CT and Radiation Dosimetry (SELFIE),Optimising Molecular Radionuclide Therapy,Hyperthyroidism|Neuroendocrine Tumors|Thyroid Cancer|Thyroid Carcinoma,2021-05-17,2022-04-20,2022-06-30,Observational [Patient Registry],Recruiting,,King's College London,Guy's and St Thomas' NHS Foundation Trust|King's College London,Guy's and St Thomas Hospitals Foundation Trust,Diagnostic Test|Diagnostic Test|Diagnostic Test|Device|Diagnostic Test,United Kingdom,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04922801
NCT04922801,thyroid carcinoma,OPTIMISING MOLECULAR RADIONUCLIDE THERAPY: The Role of Quantitative SPECT/CT & PET/CT and Radiation Dosimetry (SELFIE),Optimising Molecular Radionuclide Therapy,Hyperthyroidism|Neuroendocrine Tumors|Thyroid Cancer|Thyroid Carcinoma,2021-05-17,2022-04-20,2022-06-30,Observational [Patient Registry],Recruiting,,King's College London,Guy's and St Thomas' NHS Foundation Trust|King's College London,Guy's and St Thomas Hospitals Foundation Trust,Diagnostic Test|Diagnostic Test|Diagnostic Test|Device|Diagnostic Test,United Kingdom,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04922801
NCT04927468,graves ophthalmopathy,The Management of Large-angle Strabismus in Grave's Ophthalmopathy With Supramaximal Rectus Recession,Supramaximal Rectus Recession for Strabismus in Grave's Ophthalmopathy,"Graves Ophthalmopathy|Strabismus, Mechanical",2021-06-08,2023-07-01,2023-07-01,Interventional,Not yet recruiting,Not Applicable,Sun Yat-sen University,Sun Yat-sen University,,Procedure|Procedure,,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT04927468
NCT04931576,thyroid cancer,The Feasibility of no Drainage During Transoral Endoscopic Thyroidectomy Via the Vestibular Approach in Treatment of Papillary Thyroid Carcinoma,No Drainage During Transoral Endoscopic Thyroidectomy Vestibular Approach(TOETVA),Drainage|Thyroid Cancer,2021-06-14,2023-06-01,2023-10-01,Interventional,Not yet recruiting,Not Applicable,"Second Affiliated Hospital, School of Medicine, Zhejiang University","Second Affiliated Hospital, School of Medicine, Zhejiang University",,Procedure,,18.0,55.0,[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04931576
NCT04932135,hyperthyroidism,Resting Heart Rate Monitoring for Optimized Treatment and Surveillance of Hyperthyroidism,Resting Heart Rate Monitoring for Optimized Treatment and Surveillance of Hyperthyroidism,Graves Disease|Hyperthyroidism,2021-06-14,2022-12-31,2023-03-31,Observational,Recruiting,,"University Hospital, Basel, Switzerland","University Hospital, Basel, Switzerland",University Hospital Basel,Diagnostic Test,Switzerland,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04932135
NCT04932135,graves disease,Resting Heart Rate Monitoring for Optimized Treatment and Surveillance of Hyperthyroidism,Resting Heart Rate Monitoring for Optimized Treatment and Surveillance of Hyperthyroidism,Graves Disease|Hyperthyroidism,2021-06-14,2022-12-31,2023-03-31,Observational,Recruiting,,"University Hospital, Basel, Switzerland","University Hospital, Basel, Switzerland",University Hospital Basel,Diagnostic Test,Switzerland,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT04932135
NCT04940052,differentiated thyroid cancer,"A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Dabrafenib Plus Trametinib in Previously Treated Patients With Locally Advanced or Metastatic, Radio-active Iodine Refractory BRAFV600E Mutation-positive Differentiated Thyroid Cancer (DTC)","Study of Efficacy and Safety of Dabrafenib Plus Trametinib in Previously Treated Patients With Locally Advanced or Metastatic, Radio-active Iodine Refractory BRAFV600E Mutation-positive Differentiated Thyroid Cancer",Differentiated Thyroid Cancer,2021-06-22,2024-02-19,2026-10-30,Interventional,Recruiting,Phase 3,Novartis,Novartis Pharmaceuticals,Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site|Novartis Investigative Site,Drug|Drug|Drug|Drug,"China|India|Korea, Republic of|Malaysia|Taiwan|Turkey",18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Differentiated thyroid cancer, all",https://clinicaltrials.gov/ct2/show/NCT04940052
NCT04946123,hyperthyroidism,Association of Methimazole With L-carnitine and Selenium in Patients With Hyperthyroidism,Hyperthyroidism: Methimazole Plus L-carnitine and Selenium,Hyperthyroidism,2021-06-15,2022-06-30,2022-07-31,Interventional,Recruiting,Not Applicable,Lo.Li.Pharma s.r.l,Lo.Li.Pharma s.r.l,Azienda Ospedaliero-Universitaria Città della scienza e degli studi di Torino,Dietary Supplement,Italy,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT04946123
NCT04948437,papillary thyroid cancer,Urinary Exosomal Biomarkers of Thyroglobulin and Galectin-3 for Prognosis and Follow-up in Patients of Well-differentiated Thyroid Cancer,Urinary Exosomal Biomarkers of Thyroglobulin and Galectin-3 for Prognosis and Follow-up in Patients of Thyroid Cancer,Follicular Thyroid Cancer|Papillary Thyroid Cancer|Thyroid Cancer,2021-06-24,2024-10-31,2026-10-31,Observational,Recruiting,,National Taiwan University Hospital,National Taiwan University Hospital,"Chih-Yuan Wang, M.D",,Taiwan,20.0,80.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT04948437
NCT04948437,follicular thyroid cancer,Urinary Exosomal Biomarkers of Thyroglobulin and Galectin-3 for Prognosis and Follow-up in Patients of Well-differentiated Thyroid Cancer,Urinary Exosomal Biomarkers of Thyroglobulin and Galectin-3 for Prognosis and Follow-up in Patients of Thyroid Cancer,Follicular Thyroid Cancer|Papillary Thyroid Cancer|Thyroid Cancer,2021-06-24,2024-10-31,2026-10-31,Observational,Recruiting,,National Taiwan University Hospital,National Taiwan University Hospital,"Chih-Yuan Wang, M.D",,Taiwan,20.0,80.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT04948437
NCT04952012,"thyroiditis, autoimmune",The Effect of Thyroid Antibodies on Female Reproductive Function and Pregnancy Outcomes,The Effect of Thyroid Antibodies on Female Reproductive Function and Pregnancy Outcomes,"Thyroiditis, Autoimmune",2021-06-20,2021-11-30,2022-11-30,Observational,Recruiting,,"Second Affiliated Hospital, School of Medicine, Zhejiang University","Changxing People's Hospital|First People's Hospital of Yuhang|Second Affiliated Hospital, School of Medicine, Zhejiang University|Taizhou Women and Children's Hospital Affiliated to Wenzhou Medical University","Second Affiliated Hospital, School of Medicine, Zhejiang University",Drug,China,18.0,45.0,[18-65],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT04952012
NCT04952493,thyroid cancer,"The Efficacy and Safety of Anlotinib Hydrochloride or Penpulimab In Combination With RAI in Patients With Local Advanced or Metastatic Differentiated Thyroid Cancer: A Randomized, Open-label, Exploratory Clinical Trial",Anlotinib or Penpulimab in Combination With RAI for DTC,Thyroid Cancer,2021-06-27,2023-07-20,2024-07-20,Interventional,Recruiting,Phase 2,Peking Union Medical College Hospital,"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.|Peking Union Medical College Hospital",Peking Union Medical College Hospital,Drug|Drug|Drug,China,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT04952493
NCT04964284,differentiated thyroid cancer,"A Randomized, Open-label, Multi-center, Controlled Phase Ⅲ Study to Evaluate the Safety and Efficacy of Recombinant Human Thryoid Stimulating Hormone（rhTSH） for Adjuvant Radioiodine Ablation Therapy in Postoperative Patients With Differentiated Thyroid Cancer",Efficacy and Safety Study of rhTSH for Adjuvant Radioiodine Ablation Therapy in Patients With Differentiated Thyroid Cancer,Differentiated Thyroid Cancer,2021-07-06,2022-09-30,2022-12-31,Interventional,Recruiting,Phase 3,"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","Suzhou Zelgen Biopharmaceuticals Co.,Ltd",Peking Union Medical College Hospital,Biological|Radiation,China,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Differentiated thyroid cancer, all",https://clinicaltrials.gov/ct2/show/NCT04964284
NCT04969926,pseudohypoparathyroidism,Natural History Study of Parathyroid Disorders,Natural History Study of Parathyroid Disorders,"Inheritable Bone Diseases|Multiple Endocrine Neoplasia, Type 1|Parathyroid Cancer|Primary Hyperparathyroidism|Pseudohypoparathyroidism",2021-07-20,2031-01-22,2031-01-22,Observational,Recruiting,,National Institutes of Health Clinical Center (CC),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),National Institutes of Health Clinical Center,,United States,6.0,120.0,[0-17]|[18-65]|[65 and more],Parathyroid diseases,pseudohypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT04969926
NCT04970134,medullary thyroid carcinoma,Spanish Observational Study for MOLecular Characterization of THYroid Carcinoma MOLTHY Project,Spanish Study for Molecular Characterization of Thyroid Carcinoma,Differentiated Thyroid Carcinoma|Medullary Thyroid Carcinoma,2021-07-16,2023-03-31,2024-03-31,Observational,Recruiting,,Grupo Español de Tratamiento de Tumores de Cabeza y Cuello,Grupo Español de Tratamiento de Tumores de Cabeza y Cuello,Hospital Universitario Durán i Reinals|Fundació Althaia|Consorci Corporació Sanitària Parc Taulí de Sabadell|Hospital Universitario Vall d'Hebron|Hospital Clínic de Barcelona|Institut Català d'Oncologia Girona - ICO Girona|Hospital Universitario Ramón y Cajal|Hospital Universitario La Paz|Hospital universitario Marqués de Valdecilla|Hospital General Universitario de Valencia|Hospital Universitario y Politécnico La Fe|Hospital Universitario Miguel Servet,Other|Other|Other,Spain,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, medullary",https://clinicaltrials.gov/ct2/show/NCT04970134
NCT04971473,differentiated thyroid cancer,"An Open, Single-arm, Self-controlled, Multi-center Phase 3 Study to Compare the Efficacy and Safety of rhTSH as An Adjunctive Diagnostic Tool in Differentiated Thyroid Cancer Patients Who Had Been Thyroidectomized Vs. Patients Who After Thyroid Hormone Withdrawal",Comparison of the Efficacy and Safety of rhTSH as An Adjunctive Diagnostic Tool in Differentiated Thyroid Cancer Patients Who Had Been Thyroidectomized Vs. Patients Who After Thyroid Hormone Withdrawal,Differentiated Thyroid Cancer,2021-07-07,2023-06-30,2023-07-31,Interventional,Recruiting,Phase 3,"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","Suzhou Zelgen Biopharmaceuticals Co.,Ltd",Peking Union Medical College Hospital,Biological,China,18.0,75.0,[18-65]|[65 and more],Thyroid neoplasms,"Differentiated thyroid cancer, all",https://clinicaltrials.gov/ct2/show/NCT04971473
NCT04976816,thyroid eye disease,Local Betamethasone Versus Triamcinolone Injection in Management of Thyroid-Related Upper Lid Retraction With and Without Proptosis,Local Betamethasone Versus Triamcinolone Injection in Management of Thyroid Eye Disease,Thyroid Eye Disease,2021-07-13,2022-12-31,2023-01-31,Interventional,Not yet recruiting,Phase 4,Assiut University,Assiut University,,Procedure|Procedure|Procedure|Procedure,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT04976816
NCT05002998,thyroid eye disease,"A Phase 3b/4, Double-masked, Randomized, International, Parallel-assignment, Multicenter Trial in Patients With Thyroid Eye Disease to Evaluate the Safety and Tolerability of Different Dosing Durations of Teprotumumab",TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study,Thyroid Eye Disease,2021-07-19,2025-08-31,2025-08-31,Interventional,Recruiting,Phase 4,"Horizon Pharma USA, Inc.","Horizon Therapeutics USA, Inc.",University of Colorado - Eye Center|Bascom Palmer Eye Institute|Washington University in St. Louis|University of Nebraska Medical Center,Drug|Drug,United States,18.0,80.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT05002998
NCT05003856,thyroid gland papillary carcinoma,Radiofrequency Ablation Use in Thyroid Nodule,Radiofrequency Ablation for the Treatment of Benign or Low Risk Thyroid Nodule,Benign Thyroid Gland Neoplasm|Recurrent Thyroid Gland Carcinoma|Thyroid Gland Follicular Tumor of Uncertain Malignant Potential|Thyroid Gland Nodule|Thyroid Gland Papillary Carcinoma,2021-08-05,2025-06-30,2025-06-30,Interventional,Not yet recruiting,Phase 4,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center,M D Anderson Cancer Center,Other|Procedure,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT05003856
NCT05003856,thyroid gland nodule,Radiofrequency Ablation Use in Thyroid Nodule,Radiofrequency Ablation for the Treatment of Benign or Low Risk Thyroid Nodule,Benign Thyroid Gland Neoplasm|Recurrent Thyroid Gland Carcinoma|Thyroid Gland Follicular Tumor of Uncertain Malignant Potential|Thyroid Gland Nodule|Thyroid Gland Papillary Carcinoma,2021-08-05,2025-06-30,2025-06-30,Interventional,Not yet recruiting,Phase 4,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center,M D Anderson Cancer Center,Other|Procedure,United States,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT05003856
NCT05012033,thyroid eye disease,Evaluation of High Dose Prednisolone Pharmacokinetics in the Acute and Chronic Setting,Evaluation of High Dose Prednisolone Pharmacokinetics in the Acute and Chronic Setting,Asthma|COPD Exacerbation Acute|Inflammatory Disease|Thyroid Eye Disease|Vasculitis,2021-07-30,2026-03-26,2026-03-26,Observational,Not yet recruiting,,Imperial College London,Imperial College London,Imperial College Healthcare NHS Trust,Other,United Kingdom,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT05012033
NCT05014698,differentiated thyroid cancer,IDEntification of New Predisposition Genes in Differentiated THYroid Cancer,IDEntification of New Predisposition Genes in Differentiated THYroid Cancer,"Differentiated Thyroid Cancer|Thyroid Cancer, Nonmedullary",2021-08-05,2025-02-28,2025-02-28,Interventional,Recruiting,Not Applicable,Nantes University Hospital,Nantes University Hospital,Vendée Hospital|Nantes University Hospital,Genetic,France,8.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Differentiated thyroid cancer, all",https://clinicaltrials.gov/ct2/show/NCT05014698
NCT05015127,thyroid ophthalmopathy,"A Randomized, Double-blind, Placebo-controlled, Phase 2/3 Operational Seamless Design Clinical Study to Evaluate the Efficacy and Safety of HBM9161 Subcutaneous Injection in Chinese Patients With Active, Moderate to Severe Thyroid Eye Disease (TED)",A Study to Evaluate the Efficacy and Safety of HBM9161 on Moderate to Severe Thyroid Eye Disease,Thyroid Ophthalmopathy,2021-08-03,2022-10-31,2022-12-31,Interventional,Recruiting,Phase 2/Phase 3,Harbour BioMed (Guangzhou) Co. Ltd.,Harbour BioMed (Guangzhou) Co. Ltd.,"Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine",Drug|Drug|Drug|Drug,China,18.0,70.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT05015127
NCT05015725,hypothyroidism,"A Single Center Cross-sectional Study to Evaluate the Relationship Between Serum rT3 Concentrations, T3/T4 Ratio, and Symptoms/Quality of Life in Treated Hypothyroid Patients","The Relationship Between Serum rT3 Concentrations, T3/T4 Ratio, and Symptoms/Quality of Life in Treated Hypothyroid Patients",Hypothyroidism,2021-06-30,2022-07-05,2022-07-05,Observational,Recruiting,,Semmelweis University,Semmelweis University,Semmelweis University - Departement Medicine and Oncology,Diagnostic Test,Hungary,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT05015725
NCT05022641,parathyroid neoplasms,Evaluating Impact of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy,Evaluating Impact of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy,Hypercalcemia|Parathyroid Adenoma|Parathyroid Cancer|Parathyroid Neoplasms|Primary Hyperparathyroidism,2021-08-22,2023-08-31,2023-08-31,Interventional,Recruiting,Not Applicable,University of Michigan,National Cancer Institute (NCI)|University of Michigan|Vanderbilt University,The University of Michigan,Device,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05022641
NCT05022667,thyroid neoplasms,Assessing Benefits of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Total Thyroidectomy,Assessing Benefits of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Total Thyroidectomy,Endocrine Gland Neoplasms|Endocrine System Diseases|Head and Neck Neoplasms|Hypoparathyroidism|Neoplasms|Neoplasms by Site|Parathyroid Diseases|Thyroid Diseases|Thyroid Neoplasms,2021-08-22,2023-08-31,2023-08-31,Interventional,Recruiting,Not Applicable,University of Michigan,National Cancer Institute (NCI)|University of Michigan|Vanderbilt University,The University of Michigan,Device,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05022667
NCT05022667,hypoparathyroidism,Assessing Benefits of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Total Thyroidectomy,Assessing Benefits of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Total Thyroidectomy,Endocrine Gland Neoplasms|Endocrine System Diseases|Head and Neck Neoplasms|Hypoparathyroidism|Neoplasms|Neoplasms by Site|Parathyroid Diseases|Thyroid Diseases|Thyroid Neoplasms,2021-08-22,2023-08-31,2023-08-31,Interventional,Recruiting,Not Applicable,University of Michigan,National Cancer Institute (NCI)|University of Michigan|Vanderbilt University,The University of Michigan,Device,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT05022667
NCT05022667,thyroid diseases,Assessing Benefits of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Total Thyroidectomy,Assessing Benefits of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Total Thyroidectomy,Endocrine Gland Neoplasms|Endocrine System Diseases|Head and Neck Neoplasms|Hypoparathyroidism|Neoplasms|Neoplasms by Site|Parathyroid Diseases|Thyroid Diseases|Thyroid Neoplasms,2021-08-22,2023-08-31,2023-08-31,Interventional,Recruiting,Not Applicable,University of Michigan,National Cancer Institute (NCI)|University of Michigan|Vanderbilt University,The University of Michigan,Device,United States,18.0,120.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT05022667
NCT05024929,papillary thyroid cancer,Targeted Therapy to Increase RAI Uptake in Patients With Metastatic Papillary Thyroid Cancer,Targeted Therapy to Increase RAI Uptake in Metastatic PTC,Papillary Thyroid Cancer|Pediatric Cancer,2021-08-23,2031-02-01,2033-02-01,Observational,Recruiting,,Children's Hospital of Philadelphia,Children's Hospital of Philadelphia,Children's Hospital of Philadelphia,Procedure,United States,0.0,21.0,[0-17]|[18-65],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT05024929
NCT05025046,thyroid cancer,"Prospective, Blinded, Multi-center Clincal Study of NGS-based Thyroscan Genomic Classifier in the Diagnosis of Thyroid Nodules",NGS-based Thyroscan Genomic Classifier in the Diagnosis of Thyroid Nodules,Thyroid Cancer|Thyroid Nodule,2021-08-25,2022-06-30,2022-06-30,Observational,Recruiting,,Rigen Biotech,"Guangdong Provincial People's Hospital|RenJi Hospital|Rigen Biotech|Shenzhen People's Hospital|The First People's Hospital of Changzhou|Tianjin Medical University Cancer Institute and Hospital|Zhejiang Provincial People's Hospital|Zhongshan People's Hospital, Guangdong, China",Zhongshan City People's Hospital|The First Peple's Hospital of Changzhou|Guangdong Provincial People's Hospital|Zhejiang Provincial People's Hospital|Shanghai Jiaotong University School of Medicine|Shenzhen People's Hospital|Tianjin Medical University Center Hospital,Diagnostic Test,China,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05025046
NCT05025046,thyroid nodule,"Prospective, Blinded, Multi-center Clincal Study of NGS-based Thyroscan Genomic Classifier in the Diagnosis of Thyroid Nodules",NGS-based Thyroscan Genomic Classifier in the Diagnosis of Thyroid Nodules,Thyroid Cancer|Thyroid Nodule,2021-08-25,2022-06-30,2022-06-30,Observational,Recruiting,,Rigen Biotech,"Guangdong Provincial People's Hospital|RenJi Hospital|Rigen Biotech|Shenzhen People's Hospital|The First People's Hospital of Changzhou|Tianjin Medical University Cancer Institute and Hospital|Zhejiang Provincial People's Hospital|Zhongshan People's Hospital, Guangdong, China",Zhongshan City People's Hospital|The First Peple's Hospital of Changzhou|Guangdong Provincial People's Hospital|Zhejiang Provincial People's Hospital|Shanghai Jiaotong University School of Medicine|Shenzhen People's Hospital|Tianjin Medical University Center Hospital,Diagnostic Test,China,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT05025046
NCT05033496,hypothyroidism,The Yield of Postnatal Thyroid Function Test in Term Newborn Infants in the Well Baby Nursery in Addition to the National Screening Test Program,The Yield of Postnatal Thyroid Function Test in the Well Baby Nursery,Hypothyroidism,2021-08-25,2020-12-31,2021-10-03,Observational,Completed,,Hillel Yaffe Medical Center,Hillel Yaffe Medical Center,Hillel Yaffe medical center,Diagnostic Test,Israel,0.0,30.0,[0-17]|[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT05033496
NCT05043584,hypoparathyroidism,Prevention of Postoperative Hypoparathyroidism Following Thyroid Surgery by Using Intraoperative Autofluorescence,"Near-infrared Autofluorescence (NIRAF) in Total Thyroidectomy: Impact in Low-volume, Non-parathyroid Centers",Autofluorescence|Hypocalcemia|Hypoparathyroidism|Thyroidectomy,2021-09-05,2023-09-30,2024-03-31,Interventional,Recruiting,Not Applicable,Regional Hospital West Jutland,Hospital of South West Jutland|Regional Hospital West Jutland,"Department of Otorhinolaryngology, Hospital South West Jutland|Department of Otorhinolaryngology, Regional Hospital West Jutland",Device,Denmark,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT05043584
NCT05049551,hyperthyroidism,Quantitative Analysis of 99mTc-Pertechnetate Thyroid Uptake With a Large Field CZT Gamma Camera: Feasibility and Comparison Between SPECT/CT and Planar Acquisitions,Thyroid Uptake Quantification on a New Generation of Gamma Camera,Hyperthyroidism,2021-09-09,2020-06-22,2020-09-07,Observational,Completed,,Centre Hospitalier Princesse Grace,Centre Hospitalier Princesse Grace,Centre Hospitalier Princesse Grace,,Monaco,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT05049551
NCT05052359,follicular thyroid cancer,Aberrant Helix Pomatia Agglutinin Binding Glycan Expression Changes With the Phenotype of Follicular Thyroid Tumours,Aberrant Helix Pomatia Agglutinin Binding Glycan Expression in Follicular Thyroid Tumours,Follicular Thyroid Cancer,2021-09-02,2021-08-01,2021-09-01,Observational,Completed,,"National University Health System, Singapore","National University Health System, Singapore",National University Hospital,Diagnostic Test,Singapore,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, follicular",https://clinicaltrials.gov/ct2/show/NCT05052359
NCT05054634,thyroid cancer,Psycho-oncological Intervention Through Counselling in Patients With Differentiated Thyroid Cancer in Treatment With Radioiodine: A Non-randomized Controlled Study,Psycho-oncological Intervention Through Counselling in Patients With Differentiated Thyroid Cancer in Treatment With Radioiodine,Thyroid Cancer,2021-09-03,2014-09-30,2015-03-31,Observational,Completed,,Quironsalud,Quironsalud,Hospital Quironsalud Torrevieja,Behavioral,Spain,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05054634
NCT05070091,hyperthyroidism,The Impact of Pituitary-thyroid and Pituitary-adrenal Axes Function on COVID-19 Clinical Course.,The Impact of Pituitary-thyroid and Pituitary-adrenal Axes Function on COVID-19 Clinical Course.,Adrenal Insufficiency|COVID-19|Hyperthyroidism|Hypothyroidism|Low Triiodothyronine Syndrome|Subacute Thyroiditis,2021-10-04,2021-12-01,2021-12-01,Observational,Completed,,Medical University of Gdansk,"Medical University of Gdansk|National Center for Research and Development, Poland",7 Szpital Marynarki Wojennej|Medical University of Gdansk,,Poland,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT05070091
NCT05070091,subacute thyroiditis,The Impact of Pituitary-thyroid and Pituitary-adrenal Axes Function on COVID-19 Clinical Course.,The Impact of Pituitary-thyroid and Pituitary-adrenal Axes Function on COVID-19 Clinical Course.,Adrenal Insufficiency|COVID-19|Hyperthyroidism|Hypothyroidism|Low Triiodothyronine Syndrome|Subacute Thyroiditis,2021-10-04,2021-12-01,2021-12-01,Observational,Completed,,Medical University of Gdansk,"Medical University of Gdansk|National Center for Research and Development, Poland",7 Szpital Marynarki Wojennej|Medical University of Gdansk,,Poland,18.0,120.0,[18-65]|[65 and more],Thyroiditis,De Quervain's thyroiditis,https://clinicaltrials.gov/ct2/show/NCT05070091
NCT05070091,hypothyroidism,The Impact of Pituitary-thyroid and Pituitary-adrenal Axes Function on COVID-19 Clinical Course.,The Impact of Pituitary-thyroid and Pituitary-adrenal Axes Function on COVID-19 Clinical Course.,Adrenal Insufficiency|COVID-19|Hyperthyroidism|Hypothyroidism|Low Triiodothyronine Syndrome|Subacute Thyroiditis,2021-10-04,2021-12-01,2021-12-01,Observational,Completed,,Medical University of Gdansk,"Medical University of Gdansk|National Center for Research and Development, Poland",7 Szpital Marynarki Wojennej|Medical University of Gdansk,,Poland,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT05070091
NCT05070091,low triiodothyronine syndrome,The Impact of Pituitary-thyroid and Pituitary-adrenal Axes Function on COVID-19 Clinical Course.,The Impact of Pituitary-thyroid and Pituitary-adrenal Axes Function on COVID-19 Clinical Course.,Adrenal Insufficiency|COVID-19|Hyperthyroidism|Hypothyroidism|Low Triiodothyronine Syndrome|Subacute Thyroiditis,2021-10-04,2021-12-01,2021-12-01,Observational,Completed,,Medical University of Gdansk,"Medical University of Gdansk|National Center for Research and Development, Poland",7 Szpital Marynarki Wojennej|Medical University of Gdansk,,Poland,18.0,120.0,[18-65]|[65 and more],Euthyroid Sick Syndromes,Euthyroid Sick Syndromes,https://clinicaltrials.gov/ct2/show/NCT05070091
NCT05077865,hashimoto disease,"A Double-blind, Placebo-controlled, Randomized, Single Ascending and Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Oral Dose of MYMD1 Capsules in Healthy Male and Female Adult Subjects","Single Ascending and Multiple Dose Study to Evaluate Safety, Tolerability, and PK of MYMD1 in Healthy Male and Female Adult Subjects",Hashimoto Disease,2021-10-01,2021-08-10,2021-08-10,Interventional,Completed,Phase 1,"MyMD Pharmaceuticals, Inc.","MyMD Pharmaceuticals, Inc.","Clinical Research of West Florida, Inc",Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT05077865
NCT05078853,differentiated thyroid cancer,Thyroglobulin Point of Care Assay for Rapid Detection of Metastatic Differentiated Thyroid Carcinoma- A Multi-Center Validation Study,Thyroglobulin Point of Care Assay for Rapid Detection of Metastatic Differentiated Thyroid Carcinoma,Differentiated Thyroid Cancer|Lymph Node Metastases,2021-09-27,2022-12-31,2022-12-31,Observational,Recruiting,,Soroka University Medical Center,Soroka University Medical Center,Barzilai Medical Center|Soroka University Medical Center,Device,Israel,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Differentiated thyroid cancer, all",https://clinicaltrials.gov/ct2/show/NCT05078853
NCT05088187,thyroid cancer,Longitudinal Evaluation of Objective Cognitive Function and Quality of Life in Patients Undergoing Surgery for Malignant and Benign Thyroid Nodules,Cognition and QoL After Thyroid Surgery,"Cognitive Decline|Survivorship|Symptoms, Cognitive|Thyroid Cancer|Thyroid Nodule",2021-10-11,2023-11-01,2026-11-01,Observational,Not yet recruiting,,Karolinska University Hospital,Karolinska University Hospital|The Netherlands Cancer Institute,,,,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05088187
NCT05088187,thyroid nodule,Longitudinal Evaluation of Objective Cognitive Function and Quality of Life in Patients Undergoing Surgery for Malignant and Benign Thyroid Nodules,Cognition and QoL After Thyroid Surgery,"Cognitive Decline|Survivorship|Symptoms, Cognitive|Thyroid Cancer|Thyroid Nodule",2021-10-11,2023-11-01,2026-11-01,Observational,Not yet recruiting,,Karolinska University Hospital,Karolinska University Hospital|The Netherlands Cancer Institute,,,,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT05088187
NCT05098600,autoimmune hyperthyroidism,"The Epidemiology, Management and Associated Conditions in Alopecia Areata in Czech Republic: A University-clinic-based Retrospective Cohort Study","The Epidemiology, Management and Comorbidities in Alopecia Areata in Czech Republic","Alopecia Areata|Alopecia Areata (& Ophiasis)|Alopecia Barbae|Alopecia Diffuse|Alopecia Totalis|Alopecia Universalis|Anemia, Pernicious|Ankylosing Spondylitis|Atopic Asthma|Atopic Dermatitis|Atopic Rhinitis|Autoimmune Diseases|Autoimmune Hyperthyroidism|Autoimmune Hypothyroidism|COVID-19 Pandemic|Crohn Disease|Diabetes Mellitus, Type 1|Down Syndrome|Infections|Inflammatory Bowel Diseases|Lupus Erythematosus|Multiple Sclerosis|Psoriasis|Rheumatoid Arthritis|Ulcerative Colitis|Vaccine Reaction|Vitiligo",2021-10-16,2021-12-31,2022-01-10,Observational,Active not recruiting,,Faculty Hospital Kralovske Vinohrady,Faculty Hospital Kralovske Vinohrady,Teaching Hospital of Royal Vineguards,Other,Czechia,0.0,120.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT05098600
NCT05102292,anaplastic thyroid cancer,"An Open Label, Multicenter Phase Ib/II Clinical Study to Evaluate Efficacy , Safety and PK of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 Mutation",The Efficacy and Safety of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 Mutation,Anaplastic Thyroid Cancer|ATC,2021-10-20,2023-05-30,2024-12-30,Interventional,Recruiting,Phase 1/Phase 2,Shanghai Henlius Biotech,Shanghai Henlius Biotech,Fudan University Affiliated Oncology Hospital,Drug,China,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, anaplastic",https://clinicaltrials.gov/ct2/show/NCT05102292
NCT05103956,goiter,"Regular Treatment Versus Hemostatic Patch/Collagen Sealant and Polyethylene Glycol (Hemopatch) in the Immediate Postoperative of the Thyroidectomy, Unicentric Study, Non-inferiority, Open and Randomized (Tiropatch Study)",Hemostatic Patch/Collagen Sealant and Polyethylene Glycol (Hemopatch) in the Postoperative of the Thyroidectomy.,Goiter,2021-10-07,2022-04-01,2022-04-01,Observational,Recruiting,,Fundación Pública Andaluza para la gestión de la Investigación en Sevilla,Fundación Pública Andaluza para la gestión de la Investigación en Sevilla,Hospital Universitario Virgen del Rocío,,Spain,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT05103956
NCT05114980,hypoparathyroidism,Parathyroid Allotransplantation in Medically Refractory Hypoparathyroidism,Parathyroid Allotransplantation in Medically Refractory Hypoparathyroidism,Hypoparathyroidism,2021-10-29,2024-01-31,2025-01-31,Interventional,Recruiting,Not Applicable,University of Alabama at Birmingham,University of Alabama at Birmingham,University of Alabama at Birmingham,Procedure,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT05114980
NCT05117853,thyroid disease,The Use of Autofluorescence and Indocyanine Green to Avoid Hypocalcemia After Total Thyroidectomy: A Randomized Clinical Trial,Autofluorescence and Indocyanine Green to Avoid Hypocalcemia After Thyroidectomy,Hypoparathyroidism Postprocedural|Thyroid Disease,2021-10-21,2024-10-31,2025-05-31,Interventional,Recruiting,Phase 3,Onze Lieve Vrouw Hospital,Onze Lieve Vrouw Hospital,Onze Lieve Vrouw Hospital,Drug|Procedure,Belgium,18.0,120.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT05117853
NCT05118542,hyperthyroidism,"Effect of Hyperthyroidism and Its Treatment in Graves' Disease to Early Marker of Atherosclerosis: Review on the Pathway of Insulin Resistance, Lipid, Inflammation, and Endothelial Dysfunction to Pulse Wave Velocity and Carotid Intima-Media Thickness",Effect of Hyperthyroidism and Its Treatment in Graves' Disease to Early Marker of Atherosclerosis,Atherosclerosis of Artery|Graves Disease|Hyperthyroidism|Pathophysiology,2021-10-06,2020-06-01,2020-08-01,Interventional,Completed,Phase 3,Indonesia University,Indonesia University,University of Indonesia,Drug|Drug,Indonesia,18.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT05118542
NCT05118542,graves disease,"Effect of Hyperthyroidism and Its Treatment in Graves' Disease to Early Marker of Atherosclerosis: Review on the Pathway of Insulin Resistance, Lipid, Inflammation, and Endothelial Dysfunction to Pulse Wave Velocity and Carotid Intima-Media Thickness",Effect of Hyperthyroidism and Its Treatment in Graves' Disease to Early Marker of Atherosclerosis,Atherosclerosis of Artery|Graves Disease|Hyperthyroidism|Pathophysiology,2021-10-06,2020-06-01,2020-08-01,Interventional,Completed,Phase 3,Indonesia University,Indonesia University,University of Indonesia,Drug|Drug,Indonesia,18.0,65.0,[18-65]|[65 and more],Hyperthyroidism,Graves' disease,https://clinicaltrials.gov/ct2/show/NCT05118542
NCT05124938,thyroid cancer,Assessment of CA19-9 in Patients' With Thyroid Malignancies,Assessment of CA 19-9 in Patients' With Thyroid Malignancies,Thyroid Cancer,2021-10-26,2022-06-01,2022-12-01,Observational,Not yet recruiting,,Sohag University,Sohag University,Sohag faculty of medicine,Diagnostic Test,Egypt,1.0,80.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05124938
NCT05126147,graves ophthalmopathy,A Randomized Controlled Trial on the Effect of Hydroxychloroquine in Graves' Orbitopathy,Hydroxychloroquine in Graves' Orbitopathy,Graves Ophthalmopathy,2021-10-05,2023-12-01,2024-12-01,Interventional,Not yet recruiting,Phase 4,National Taiwan University Hospital,National Taiwan University Hospital,National Taiwan University Hospital,Drug,Taiwan,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT05126147
NCT05132205,papillary thyroid cancer,Radiofrequency Ablation of Papillary Thyroid Microcarcinoma,Radiofrequency Ablation of Papillary Thyroid Microcarcinoma,Papillary Thyroid Cancer,2021-11-10,2024-09-28,2024-09-28,Interventional,Recruiting,Not Applicable,Johns Hopkins University,Johns Hopkins University,Johns Hopkins Hospital,Procedure,United States,18.0,100.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT05132205
NCT05132478,thyroid cancer,The Effect of Surgeon Emotional Support on Treatment Choice for Low-risk Thyroid Cancer: a Randomized Hypothetical Choice Experiment,The Effect of Surgeon Emotional Support on Treatment Choice for Low-risk Thyroid Cancer,Benign Thyroid Nodule|Thyroid Cancer|Thyroid Nodule,2021-11-12,2023-11-30,2023-11-30,Interventional,Recruiting,Not Applicable,"University of Wisconsin, Madison","National Cancer Institute (NCI)|University of Michigan|University of Wisconsin, Madison",University of Wisconsin Carbone Cancer Center,Other|Other,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05132478
NCT05132478,thyroid nodule,The Effect of Surgeon Emotional Support on Treatment Choice for Low-risk Thyroid Cancer: a Randomized Hypothetical Choice Experiment,The Effect of Surgeon Emotional Support on Treatment Choice for Low-risk Thyroid Cancer,Benign Thyroid Nodule|Thyroid Cancer|Thyroid Nodule,2021-11-12,2023-11-30,2023-11-30,Interventional,Recruiting,Not Applicable,"University of Wisconsin, Madison","National Cancer Institute (NCI)|University of Michigan|University of Wisconsin, Madison",University of Wisconsin Carbone Cancer Center,Other|Other,United States,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT05132478
NCT05143918,hypothyroidism,Assessment of Quality of Life Among Hypothyroid Patients in Assiut University Hospitals,Quality of Life Among Egyptian Hypothyroid Patients,Hypothyroidism,2021-11-23,2022-12-30,2023-12-30,Observational,Not yet recruiting,,Assiut University,Assiut University,,Other,,18.0,60.0,[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT05143918
NCT05152927,endocrine gland neoplasms,Evaluating Impact of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy,Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy,"Adenoma|Endocrine Gland Neoplasms|Hypercalcemia|Hyperparathyroidism|Hyperparathyroidism, Primary|Neoplasms, Glandular and Epithelial|Parathyroid Adenoma|Parathyroid Diseases|Parathyroid Dysfunction|Parathyroid Neoplasms",2021-11-29,2025-01-31,2025-01-31,Interventional,Recruiting,Not Applicable,"University of California, San Francisco","National Cancer Institute (NCI)|University of California, San Francisco|Vanderbilt University Medical Center","University of California, San Francisco",Device,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05152927
NCT05152927,parathyroid neoplasms,Evaluating Impact of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy,Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy,"Adenoma|Endocrine Gland Neoplasms|Hypercalcemia|Hyperparathyroidism|Hyperparathyroidism, Primary|Neoplasms, Glandular and Epithelial|Parathyroid Adenoma|Parathyroid Diseases|Parathyroid Dysfunction|Parathyroid Neoplasms",2021-11-29,2025-01-31,2025-01-31,Interventional,Recruiting,Not Applicable,"University of California, San Francisco","National Cancer Institute (NCI)|University of California, San Francisco|Vanderbilt University Medical Center","University of California, San Francisco",Device,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05152927
NCT05152927,hyperparathyroidism,Evaluating Impact of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy,Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy,"Adenoma|Endocrine Gland Neoplasms|Hypercalcemia|Hyperparathyroidism|Hyperparathyroidism, Primary|Neoplasms, Glandular and Epithelial|Parathyroid Adenoma|Parathyroid Diseases|Parathyroid Dysfunction|Parathyroid Neoplasms",2021-11-29,2025-01-31,2025-01-31,Interventional,Recruiting,Not Applicable,"University of California, San Francisco","National Cancer Institute (NCI)|University of California, San Francisco|Vanderbilt University Medical Center","University of California, San Francisco",Device,United States,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT05152927
NCT05172921,thyroid cancer,The Role of Environmental Factors in Thyroid Cancer,Environmental Factors and Thyroid Cancer,Thyroid Cancer,2021-12-23,2030-01-31,2030-01-31,Observational [Patient Registry],Recruiting,,Icahn School of Medicine at Mount Sinai,Icahn School of Medicine at Mount Sinai,Icahn School of Medicine at Mount Sinai,,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05172921
NCT05175404,thyroid cancer,Use of 18F-PSMA-11 PET for Detection of Lesions in Iodine Refractory Thyroid Cancers,Use of 18F-PSMA-11 PET for Detection of Lesions in Iodine Refractory Thyroid Cancers,Thyroid Cancer,2021-12-14,2022-12-31,2022-12-31,Interventional,Recruiting,Phase 2,"University Hospital, Ghent","University Hospital, Ghent",University hospital Ghent,Diagnostic Test,Belgium,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05175404
NCT05176639,thyroid eye disease,"A Multiple Ascending Dose (MAD) Safety, Tolerability and Efficacy Study of VRDN 001, a Humanized Monoclonal Antibody Directed Against the IGF-1 Receptor, in Normal Healthy Volunteers (NHVs) and Subjects With Thyroid Eye Disease (TED)","A Safety, Tolerability and Efficacy Study of VRDN 001 in Healthy Volunteers and Persons With Thyroid Eye Disease (TED)",Thyroid Eye Disease,2021-12-15,2023-06-30,2023-12-31,Interventional,Recruiting,Phase 1/Phase 2,"Viridian Therapeutics, Inc.","Viridian Therapeutics, Inc.","Sarasota Retina Institute|TKL Research, Inc.|Neuro-Eye Clinical Trials",Drug|Drug|Drug|Drug,United States,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT05176639
NCT05178186,thyroid carcinoma,Impact of the COVID-19 Pandemic on Surgery for Thyroid Cancer: an International Multicenter Study,Impact of the COVID-19 Pandemic on Surgery for Thyroid Cancer,Thyroid Carcinoma,2021-12-30,2022-02-15,2022-03-30,Interventional,Enrolling by invitation,Not Applicable,University of Cagliari,University of Cagliari,AOU Cagliari,Procedure,Italy,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05178186
NCT05180214,thyroid nodule,The Effect of Adding Ketorolac to Bupivacaine in Superficial Cervical Plexus Block in Thyroid Surgery.,Analgesia for Thyroidectomy Using Bilateral Superficial Cervical Plexus Block With Bupivacaine Only or Adding Ketorolac to it.,Thyroid Goiter|Thyroid Nodule,2021-12-17,2021-08-19,2021-09-15,Interventional,Completed,Phase 2,Sohag University,Sohag University,Sohag University Faculty of Medicine,Drug|Drug,Egypt,20.0,50.0,[18-65],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT05180214
NCT05182931,thyroid cancer,"A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study)","A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study)",Thyroid Cancer,2021-11-23,2024-12-30,2025-12-30,Interventional,Not yet recruiting,Phase 2,Olivia Newton-John Cancer Research Institute,"Austin Health|Eastern Health|Monash Health|Olivia Newton-John Cancer Research Institute|Peter MacCallum Cancer Centre, Australia|Royal Brisbane and Women's Hospital|Royal North Shore Hospital|Sir Charles Gairdner Hospital|The Alfred",Royal North Shore Hospital|Royal Brisbane and Women's Hospital|Eastern Health|Monash Health|Austin Health|Alfred Hospital|Sir Charles Gairdner Hospital|Peter MacCallum Cancer Centre,Drug|Drug,Australia,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05182931
NCT05191927,thyroid papillary carcinoma,A Nomogram Model to Predict Central Lymphnode Metastasis in Thyroid Papillary Carcinoma Suitable for Primary Hospitals,A Nomogram Model to Predict Central Lymphnode Metastasis in Thyroid Papillary Carcinoma,Thyroid Papillary Carcinoma,2021-11-17,2021-01-01,2021-08-01,Observational,Completed,,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|The First Affiliated Hospital of Zhengzhou University,Sun Yat-sen Memorial Hospital of Sun Yat-Sen University,Other,China,0.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT05191927
NCT05216718,thyroid nodule,Prospective Randomized Controlled Study on Mini-flap Bilateral Axillo-breast Approach Robotic Thyroidectomy : Effect on Postoperative Pain and Sensation,Mini-flap BABA (Bilateral Axillo-breast Approach) Robotic Thyroidectomy is Safe,Thyroid Nodule,2021-12-30,2022-12-31,2023-12-01,Interventional,Not yet recruiting,Not Applicable,Inje University,Inje University,Dong sik Bae,Procedure|Procedure,"Korea, Republic of",19.0,69.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT05216718
NCT05218395,thyroid cancer,Association Between Persistent Organic Pollutants and Type 2 Diabetes /Thyroid Cancer,Association Between Persistent Organic Pollutants and Type 2 Diabetes /Thyroid Cancer,Organic Pollutant|Thyroid Cancer|Type 2 Diabetes,2022-01-20,2024-12-29,2025-12-30,Observational,Recruiting,,Qianfoshan Hospital,Chinese Academy of Sciences|Qianfoshan Hospital,Xiaoling Guan,,China,18.0,75.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05218395
NCT05228184,congenital hypothyroidism,A Randomized Comparative Study Between Liquid (Tirosint®-SOL) and Tablet Formulations of Levothyroxine in Neonates and Infants With Congenital Hypothyroidism,Use of Tirosint®-SOL or Tablet Formulations of Levothyroxine in Pediatric Patients With Congenital Hypothyroidism (CH),Congenital Hypothyroidism,2021-12-21,2023-06-15,2023-06-15,Interventional,Recruiting,Phase 4,IBSA Institut Biochimique SA,Cromsource|IBSA Institut Biochimique SA,CHOC Children's Hospital|Ann & Robert H. Lurie Children's Hospital of Chicago|Children's Mercy Hospital and Clinics|Icahn School of Medicine at Mount Sinai|Cook Children's Health Care Systems,Drug|Drug,United States,0.0,9.0,[0-17],Hypothyroidism,Congenital hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT05228184
NCT05229341,thyroid gland carcinoma,Evaluation of DNA Methylation Signatures in Diagnosis and Management of Thyroid Nodules,Evaluation of DNA Methylation Signatures for the Diagnosis and Management of Thyroid Nodules,Thyroid Gland Carcinoma,2022-02-04,2026-10-22,2026-10-22,Interventional,Recruiting,Not Applicable,City of Hope Medical Center,City of Hope Medical Center|National Cancer Institute (NCI),City of Hope Medical Center,Procedure|Other|Procedure,United States,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05229341
NCT05240911,thyroid neoplasms,Compare a New Method to the Traditional One to Estimate Levothyroxine Dose for Patients Needing Replacement Therapy After Total or Completion Thyroidectomy,Individual Dosing of Levothyroxine After Thyroidectomy,Hypothyroidism|Surgery|Thyroid Neoplasms,2022-02-06,2023-02-10,2023-06-10,Interventional,Recruiting,Not Applicable,"Second Affiliated Hospital, School of Medicine, Zhejiang University","Second Affiliated Hospital, School of Medicine, Zhejiang University",Second Affiliated Hospital Zhejiang University School of Medicine,Drug,China,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05240911
NCT05240911,hypothyroidism,Compare a New Method to the Traditional One to Estimate Levothyroxine Dose for Patients Needing Replacement Therapy After Total or Completion Thyroidectomy,Individual Dosing of Levothyroxine After Thyroidectomy,Hypothyroidism|Surgery|Thyroid Neoplasms,2022-02-06,2023-02-10,2023-06-10,Interventional,Recruiting,Not Applicable,"Second Affiliated Hospital, School of Medicine, Zhejiang University","Second Affiliated Hospital, School of Medicine, Zhejiang University",Second Affiliated Hospital Zhejiang University School of Medicine,Drug,China,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT05240911
NCT05241626,thyroid eye disease,Anterior Segment Optical Coherence Tomography Study of the Tear Film and Cornea in Thyroid Eye Diseases.,AS-OCT of the Cornea in Thyroid Diseases,Thyroid Eye Disease,2022-02-04,2022-10-29,2022-10-29,Observational,Enrolling by invitation,,Minia University,Minia University,Minia Faculty of medicine|Minia University hospital,Diagnostic Test,Egypt,0.0,120.0,[0-17]|[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT05241626
NCT05241834,thyroid neoplasms,"A Phase 1 Study of Oral LOXO-260 in Patients With RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation Refractory to Selective RET Inhibitors",A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment,"Carcinoma, Non-Small-Cell Lung|Thyroid Neoplasms",2022-02-08,2026-04-30,2026-04-30,Interventional,Not yet recruiting,Phase 1,Eli Lilly and Company,"Eli Lilly and Company|Loxo Oncology, Inc.",Sarah Cannon Cancer Center,Drug,United States,12.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05241834
NCT05243979,parathyroid diseases,"The Relation Between Thyroid , Parathyroid Hormones and Estimated Glomerular Filtration Rate in Chronic Kidney Disease Patients in Assiut","The Relation Between Thyroid , Parathyroid Hormones and eGFR in CKD Patients in Assiut",CKD|Parathyroid Diseases|Thyroid,2022-02-08,2023-03-01,2023-04-01,Observational,Not yet recruiting,,Assiut University,Assiut University,,Radiation,,18.0,80.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT05243979
NCT05247476,"thyroid cancer, papillary",Type 2 Deiodinase Gene Polymorphism and the Treatment of Hypothyroidism Caused,Type 2 Deiodinase Gene Polymorphism and the Treatment of Hypothyroidism Caused by Thyroidectomy in Thyroid Cancer Patients.,"Hypothyroidism|Thyroid Cancer, Papillary",2022-02-09,2022-03-31,2022-09-30,Interventional,Recruiting,Phase 4,Zhongshan Hospital Xiamen University,Zhongshan Hospital Xiamen University,Yan Ling,Drug|Drug,China,18.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT05247476
NCT05247476,hypothyroidism,Type 2 Deiodinase Gene Polymorphism and the Treatment of Hypothyroidism Caused,Type 2 Deiodinase Gene Polymorphism and the Treatment of Hypothyroidism Caused by Thyroidectomy in Thyroid Cancer Patients.,"Hypothyroidism|Thyroid Cancer, Papillary",2022-02-09,2022-03-31,2022-09-30,Interventional,Recruiting,Phase 4,Zhongshan Hospital Xiamen University,Zhongshan Hospital Xiamen University,Yan Ling,Drug|Drug,China,18.0,70.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT05247476
NCT05252884,hyperthyroidism,Comparison of Routine Prophylactic Calcium + Calcitriol and Selective Use Based on PTH for the Prevention of Postoperative Hypocalcemia in Patients With Total Thyroidectomy. Randomized Clinical Trial,Calcium+Calcitriol Versus PTH for the Prevention of Hypocalcemia in Thyroidectomy. Randomized Clinical Trial,Goiter|Hyperthyroidism|Thyroid Cancer|Thyroiditis,2022-02-13,2023-08-31,2023-12-31,Interventional,Not yet recruiting,Not Applicable,Centro de Excelencia en Enfermedades de Cabeza y Cuello,Centro de Excelencia en Enfermedades de Cabeza y Cuello|IPS universitaria,IPS Universitaria,Diagnostic Test|Drug,Colombia,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Hyperthyroidism,https://clinicaltrials.gov/ct2/show/NCT05252884
NCT05252884,thyroiditis,Comparison of Routine Prophylactic Calcium + Calcitriol and Selective Use Based on PTH for the Prevention of Postoperative Hypocalcemia in Patients With Total Thyroidectomy. Randomized Clinical Trial,Calcium+Calcitriol Versus PTH for the Prevention of Hypocalcemia in Thyroidectomy. Randomized Clinical Trial,Goiter|Hyperthyroidism|Thyroid Cancer|Thyroiditis,2022-02-13,2023-08-31,2023-12-31,Interventional,Not yet recruiting,Not Applicable,Centro de Excelencia en Enfermedades de Cabeza y Cuello,Centro de Excelencia en Enfermedades de Cabeza y Cuello|IPS universitaria,IPS Universitaria,Diagnostic Test|Drug,Colombia,18.0,120.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT05252884
NCT05252884,thyroid cancer,Comparison of Routine Prophylactic Calcium + Calcitriol and Selective Use Based on PTH for the Prevention of Postoperative Hypocalcemia in Patients With Total Thyroidectomy. Randomized Clinical Trial,Calcium+Calcitriol Versus PTH for the Prevention of Hypocalcemia in Thyroidectomy. Randomized Clinical Trial,Goiter|Hyperthyroidism|Thyroid Cancer|Thyroiditis,2022-02-13,2023-08-31,2023-12-31,Interventional,Not yet recruiting,Not Applicable,Centro de Excelencia en Enfermedades de Cabeza y Cuello,Centro de Excelencia en Enfermedades de Cabeza y Cuello|IPS universitaria,IPS Universitaria,Diagnostic Test|Drug,Colombia,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05252884
NCT05252884,goiter,Comparison of Routine Prophylactic Calcium + Calcitriol and Selective Use Based on PTH for the Prevention of Postoperative Hypocalcemia in Patients With Total Thyroidectomy. Randomized Clinical Trial,Calcium+Calcitriol Versus PTH for the Prevention of Hypocalcemia in Thyroidectomy. Randomized Clinical Trial,Goiter|Hyperthyroidism|Thyroid Cancer|Thyroiditis,2022-02-13,2023-08-31,2023-12-31,Interventional,Not yet recruiting,Not Applicable,Centro de Excelencia en Enfermedades de Cabeza y Cuello,Centro de Excelencia en Enfermedades de Cabeza y Cuello|IPS universitaria,IPS Universitaria,Diagnostic Test|Drug,Colombia,18.0,120.0,[18-65]|[65 and more],Goiter,Goiter,https://clinicaltrials.gov/ct2/show/NCT05252884
NCT05260255,hyperparathyroidism,The Effect of Vitamin D Supplementation on Disease Activity of Systemic Lupus Erythematosus Patients: A Randomized Clinical Trial in Rajavithi Hospital,Effect of Vitamin D Supplement on Disease Activity in SLE,Hyperparathyroidism|Hypocalcemia|Systemic Lupus Erythematosus (Disorder)|Vitamin D Deficiency,2021-05-12,2022-05-01,2022-12-01,Interventional,Recruiting,Not Applicable,Rajavithi Hospital,Rajavithi Hospital,Rajavithi Hospital,Drug|Drug,Thailand,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT05260255
NCT05263141,papillary thyroid carcinoma,"Single-center, Prospective, Non-Randomized Control Clinical Trial of Retro-Auricular Single-Site Endoscopic Versus Open Surgery in Patients With Early Stage Papillary Thyroid Carcinoma",Retro-Auricular Single-Site Endoscopic to Papillary Thyroid Carcinoma,Papillary Thyroid Carcinoma,2022-02-20,2023-06-30,2023-06-30,Interventional,Recruiting,Not Applicable,Sun Yat-sen University,Sun Yat-sen University,Sun Yat-Sen University Cancer Center,Procedure|Procedure,China,18.0,70.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, papillary",https://clinicaltrials.gov/ct2/show/NCT05263141
NCT05264857,thyroid nodule,Decision Aid for Management of Thyroid Nodules and Early Thyroid Cancer,Decision Aid and Thyroid Nodules Management,Thyroid Nodule,2022-02-17,2026-09-30,2026-09-30,Interventional,Recruiting,Not Applicable,Stony Brook University,Stony Brook University,Stony Brook University Cancer Center,Behavioral,United States,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT05264857
NCT05265819,thyroid cancer,Effect of Exergaming Exercises and Mediterranean Diet on Thyroid Cancer Patients Following Total Thyroidectomy,Effect of Exergaming Exercises and Mediterranean Diet on Thyroid Cancer Patients Following Total Thyroidectomy,Thyroid Cancer,2022-02-23,2022-12-05,2022-12-05,Interventional,Not yet recruiting,Not Applicable,Cairo University,Nabil Mahmoud Ismail Abdel-Aal,,Device|Dietary Supplement|Drug,,18.0,45.0,[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05265819
NCT05270798,euthyroid sick syndromes,Triiodothyronine Hormone Replacement Therapy in Patients With Septic Shock With Euthyroid Sick Syndrome,Thyroid Hormone Replacement in Patients With Septic Shock,Euthyroid Sick Syndromes|Septic Shock,2022-02-26,2023-03-15,2023-03-15,Interventional,Not yet recruiting,Phase 2,Cantonal Hospital Zenica,Cantonal Hospital Zenica,,Drug,,18.0,120.0,[18-65]|[65 and more],Euthyroid Sick Syndromes,Euthyroid Sick Syndromes,https://clinicaltrials.gov/ct2/show/NCT05270798
NCT05275374,thyroid cancer,A Dose-escalation and Expansion Phase I/IIa Study of XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation (ENHANCE),XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation,BRAF V600 Mutation|Cancer|Colorectal Cancer|Melanoma|Nonsmall Cell Lung Cancer|Thyroid Cancer,2022-02-20,2024-12-31,2026-12-31,Interventional,Not yet recruiting,Phase 1/Phase 2,"Xynomic Pharmaceuticals, Inc.","Xynomic Pharmaceuticals, Inc.",,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05275374
NCT05275946,thyroid cancer,"Phase I Investigator-initiated Clinical Trial in Patients With Differentiated Thyroid Cancer (Papillary Cancer, Follicular Cancer) by the Targeted Alpha Therapy Drug TAH-1005 ([211At] NaAt) (Alpha-T1 Study)",Targeted Alpha Therapy Using Astatine (At-211) Against Differentiated Thyroid Cancer,Thyroid Cancer,2022-01-22,2023-09-30,2024-03-31,Interventional,Recruiting,Phase 1,Osaka University,Osaka University,Osaka University Hospital,Drug,Japan,0.0,18.0,[0-17]|[18-65],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05275946
NCT05276063,thyroid eye disease,"A Phase 2b, Randomized, Double-Mask, Placebo-Controlled, Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)","A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)",Endocrine System Diseases|Exophthalmos|Eye Diseases|Graves Ophthalmopathy|Graves Orbitopathy|Hashimoto|IGF1R|Orbital Diseases|Proptosis|Thyroid Associated Ophthalmopathy|Thyroid Diseases|Thyroid Eye Disease,2022-03-02,2023-05-15,2025-06-13,Interventional,Not yet recruiting,Phase 2/Phase 3,"VasaraGen, Inc.","VasaraGen, Inc.",,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT05276063
NCT05276063,hashimoto,"A Phase 2b, Randomized, Double-Mask, Placebo-Controlled, Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)","A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)",Endocrine System Diseases|Exophthalmos|Eye Diseases|Graves Ophthalmopathy|Graves Orbitopathy|Hashimoto|IGF1R|Orbital Diseases|Proptosis|Thyroid Associated Ophthalmopathy|Thyroid Diseases|Thyroid Eye Disease,2022-03-02,2023-05-15,2025-06-13,Interventional,Not yet recruiting,Phase 2/Phase 3,"VasaraGen, Inc.","VasaraGen, Inc.",,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],Thyroiditis,Hashimoto,https://clinicaltrials.gov/ct2/show/NCT05276063
NCT05276063,thyroid diseases,"A Phase 2b, Randomized, Double-Mask, Placebo-Controlled, Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)","A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)",Endocrine System Diseases|Exophthalmos|Eye Diseases|Graves Ophthalmopathy|Graves Orbitopathy|Hashimoto|IGF1R|Orbital Diseases|Proptosis|Thyroid Associated Ophthalmopathy|Thyroid Diseases|Thyroid Eye Disease,2022-03-02,2023-05-15,2025-06-13,Interventional,Not yet recruiting,Phase 2/Phase 3,"VasaraGen, Inc.","VasaraGen, Inc.",,Drug|Drug,,18.0,120.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT05276063
NCT05278364,medullary thyroid cancer,"A Phase I, Open-Label, Single-arm , Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antineoplastic Activity of SY-5007 in Patients With RET-altered Advanced Solid Tumor.","A Phase I Study to Evaluate the Safety, Pharmacokinetics and Efficacy of SY-5007 in Patients With Advanced Solid Tumors",Medullary Thyroid Cancer|Non-Small Cell Lung Cancer|Solid Tumor,2022-03-08,2023-03-01,2023-06-01,Interventional,Recruiting,Phase 1,Shouyao Holdings (Beijing) Co. LTD,Shouyao Holdings (Beijing) Co. LTD,Shanghai Pulmonary Hospital|Tianjin People's Hospital,Drug,China,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,"Thyroid cancer, medullary",https://clinicaltrials.gov/ct2/show/NCT05278364
NCT05294393,parathyroid diseases,Evaluation of Ropivacaine and Ropivacaine Plus Magnesium Sulphate Infiltration for Postoperative Analgesia in Patients Undergoing Thyroidectomy,Ropivacaine Plus Magnesium Sulphate Infiltration,"Anesthesia, Local|Parathyroid Diseases|Postoperative Pain|Thyroid Diseases",2022-03-01,2024-01-21,2024-01-21,Interventional,Enrolling by invitation,Phase 4,Aristotle University Of Thessaloniki,Aristotle University Of Thessaloniki,Aristotle University,Drug|Drug|Drug,Greece,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Parathyroid diseases,https://clinicaltrials.gov/ct2/show/NCT05294393
NCT05294393,thyroid diseases,Evaluation of Ropivacaine and Ropivacaine Plus Magnesium Sulphate Infiltration for Postoperative Analgesia in Patients Undergoing Thyroidectomy,Ropivacaine Plus Magnesium Sulphate Infiltration,"Anesthesia, Local|Parathyroid Diseases|Postoperative Pain|Thyroid Diseases",2022-03-01,2024-01-21,2024-01-21,Interventional,Enrolling by invitation,Phase 4,Aristotle University Of Thessaloniki,Aristotle University Of Thessaloniki,Aristotle University,Drug|Drug|Drug,Greece,18.0,120.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT05294393
NCT05299632,hyperparathyroidism,Pre-operative Localization of Parathyroid Adenomas Using F-18 PSMA PET/CT: A Pilot Study,F-18 PSMA for Localization of Parathyroid Adenoma,Hyperparathyroidism,2022-03-09,2023-03-31,2023-12-31,Observational,Recruiting,,Emory University,Emory University,Emory Saint Joseph's Hospital|Emory University Hospital (EUH)|Emory Johns Creek Hospital,Diagnostic Test|Diagnostic Test,United States,18.0,99.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT05299632
NCT05314790,hypothyroidism,"Management of Patients With Diagnosis of Hypothyroidism, as Hospitalized and as Outpatients, in Internal Medicine Units: Observational Study Before & After Educational Programme","Management of Patients With Diagnosis of Hypothyroidism, as Hospitalized and as Outpatients, in Internal Medicine Units: Observational Study Before & After Educational Programme",Hypothyroidism,2022-01-20,2018-01-01,2019-01-01,Observational,Completed,,"Fadoi Foundation, Italy","Fadoi Foundation, Italy","ULSS1 Belluno San Martino|Ospedale Versilia|Ospedale di Canicattì|Ospedale di Castiglione del Lago, Medicina del Trasimeno|Garibaldi Nesima|Ospedale G.B. Morgagni - P.L. Pierantoni|Ospedale G.P. Delogu|Ospedale Gubbio-Gualdo Tadino|Ospedale ""F. Veneziale""|ASL Latina|Ospedale S. Andrea|Ospedale S. Croce di Moncalieri - ASL TO5|Ospedale Del Mare|Ospedale Fatebenefratelli|Ospedale Maggiore di Novara|Ospedale Civico di Partinico|Ospedale ""Bianchi-Melacrino-Morelli""|Casa Sollievo della Sofferenza|AOU di Sassari|Ospedale San Paolo",Other,Italy,18.0,120.0,[18-65]|[65 and more],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT05314790
NCT05323669,thyroid cancer,Study of Molecular-genetic Profile of Thyroid Nodules,Molecular Profile of Thyroid Nodules,Thyroid Cancer|Thyroid Nodule,2022-04-05,2023-12-29,2024-12-31,Observational,Not yet recruiting,,Belarusian State Medical University,Belarusian State Medical University|Minsk City Clinical Oncologic Centre|The Institute of Genetics and Cytology National Academy of Sciences of Belarus,,Diagnostic Test,,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05323669
NCT05323669,thyroid nodule,Study of Molecular-genetic Profile of Thyroid Nodules,Molecular Profile of Thyroid Nodules,Thyroid Cancer|Thyroid Nodule,2022-04-05,2023-12-29,2024-12-31,Observational,Not yet recruiting,,Belarusian State Medical University,Belarusian State Medical University|Minsk City Clinical Oncologic Centre|The Institute of Genetics and Cytology National Academy of Sciences of Belarus,,Diagnostic Test,,18.0,120.0,[18-65]|[65 and more],Nodule,Nodule,https://clinicaltrials.gov/ct2/show/NCT05323669
NCT05328076,thyroid cancer,Analysis of Parathyroid Vascularization During Total Thyroidectomy Using Quantitative Real-time Indocyanine Green Angiography,Parathyroid Vascularization During Total Thyroidectomy Using Indocyanine Green Angiography,Hypoparathyroidism|Thyroid|Thyroid Cancer|Vascularization,2022-04-07,2023-04-30,2023-05-31,Observational,Recruiting,,IRCCS San Raffaele,IRCCS San Raffaele,San Raffaele Hospital,Drug|Device,Italy,18.0,120.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05328076
NCT05328076,hypoparathyroidism,Analysis of Parathyroid Vascularization During Total Thyroidectomy Using Quantitative Real-time Indocyanine Green Angiography,Parathyroid Vascularization During Total Thyroidectomy Using Indocyanine Green Angiography,Hypoparathyroidism|Thyroid|Thyroid Cancer|Vascularization,2022-04-07,2023-04-30,2023-05-31,Observational,Recruiting,,IRCCS San Raffaele,IRCCS San Raffaele,San Raffaele Hospital,Drug|Device,Italy,18.0,120.0,[18-65]|[65 and more],Parathyroid diseases,Hypoparathyroidism,https://clinicaltrials.gov/ct2/show/NCT05328076
NCT05334069,thyroid gland carcinoma,Blinded Reference Set for Multicancer Early Detection Blood Tests,Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection,Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Ann Arbor Stage III Lymphoma|Ann Arbor Stage II Lymphoma|Ann Arbor Stage I Lymphoma|Ann Arbor Stage IV Lymphoma|Chronic Lymphocytic Leukemia|Chronic Myeloid Leukemia|Gastroesophageal Junction Adenocarcinoma|Head and Neck Carcinoma|Hematopoietic and Lymphoid Cell Neoplasm|Invasive Breast Carcinoma|Kidney Carcinoma|Malignant Hepatobiliary Neoplasm|Malignant Solid Neoplasm|Melanoma|Muscle-Invasive Bladder Carcinoma|RISS Stage III Plasma Cell Myeloma|RISS Stage II Plasma Cell Myeloma|RISS Stage I Plasma Cell Myeloma|Sarcoma|Stage I Bladder Cancer AJCC v6 and v7|Stage I Breast Cancer AJCC v7|Stage I Colorectal Cancer AJCC v6 and v7|Stage I Esophageal Cancer AJCC V7|Stage I Gastric Cancer AJCC V7|Stage II Bladder Cancer AJCC v6 and v7|Stage II Breast Cancer AJCC v6 and v7|Stage II Colorectal Cancer AJCC v7|Stage II Esophageal Cancer AJCC v7|Stage II Gastric Cancer AJCC v7|Stage III Bladder Cancer AJCC v6 and v7|Stage III Breast Cancer AJCC v7|Stage III Colorectal Cancer AJCC v7|Stage III Esophageal Cancer AJCC v7|Stage III Gastric Cancer AJCC v7|Stage III Lung Cancer AJCC v7|Stage III Ovarian Cancer AJCC v6 and v7|Stage III Pancreatic Cancer AJCC v6 and v7|Stage III Prostate Cancer AJCC v7|Stage III Uterine Corpus Cancer AJCC v7|Stage II Lung Cancer AJCC v7|Stage II Ovarian Cancer AJCC v6 and v7|Stage II Pancreatic Cancer AJCC v6 and v7|Stage II Prostate Cancer AJCC v7|Stage II Uterine Corpus Cancer AJCC v7|Stage I Lung Cancer AJCC v7|Stage I Ovarian Cancer AJCC v6 and v7|Stage I Pancreatic Cancer AJCC v6 and v7|Stage I Prostate Cancer AJCC v7|Stage I Uterine Corpus Cancer AJCC v7|Stage IV Bladder Cancer AJCC v7|Stage IV Breast Cancer AJCC v6 and v7|Stage IV Colorectal Cancer AJCC v7|Stage IV Esophageal Cancer AJCC v7|Stage IV Gastric Cancer AJCC v7|Stage IV Lung Cancer AJCC v7|Stage IV Ovarian Cancer AJCC v6 and v7|Stage IV Pancreatic Cancer AJCC v6 and v7|Stage IV Prostate Cancer AJCC v7|Stage IV Uterine Corpus Cancer AJCC v7|Thyroid Gland Carcinoma,2022-04-12,2025-01-31,2025-02-28,Observational,Not yet recruiting,,Alliance for Clinical Trials in Oncology,Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI),,Other|Procedure,,40.0,75.0,[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05334069
NCT05334771,hypothyroidism,Early Detection of Endolymphatic Hydrops in Hypothyroid Patients,Early Detection of Endolymphatic Hydrops in Hypothyroid Patients,Hypothyroidism,2022-03-11,2024-03-31,2025-04-30,Observational,Not yet recruiting,,Assiut University,Assiut University,,Device,,25.0,50.0,[18-65],Hypothyroidism,Hypothyroidism,https://clinicaltrials.gov/ct2/show/NCT05334771
NCT05345119,graves ophthalmopathy,"An Observational, Retrospective, Single-center, Clinical Study to Evaluate the Efficacy of Sirolimus (Rapamycin) in Patients With Graves' Disease and Moderate-to-severe and Active Graves' Orbitopathy (GO)",Sirolimus in Graves' Orbitopathy,Graves Ophthalmopathy,2022-04-19,2021-06-15,2021-06-15,Observational,Completed,,University of Pisa,University of Pisa,Endocrinologia II,Drug|Drug,Italy,18.0,75.0,[18-65]|[65 and more],Hyperthyroidism,Orbitopathy,https://clinicaltrials.gov/ct2/show/NCT05345119
NCT05346419,hyperparathyroidism,Risedronate With High-dose Vitamin D Resolves Hyperparathyroidism and Hypovitaminosis D But Not Osteoporosis in Mexican Postmenopausal Patients,Antiresorptive Effect of Treatment With Risedronate and Vitamin D in Postmenopausal Patients,Hyperparathyroidism|Hypovitaminosis D|Postmenopausal Osteoporosis,2022-04-15,2022-02-03,2022-02-26,Interventional,Completed,Not Applicable,Hospital Regional 1o de Octubre,"Hospital Regional 1o de Octubre|National Polytechnic Institute, Mexico|Universidad Nacional Autonoma de Mexico",Peri-postmenopause and bone metabolism clinic. Regional Hospital October 1st ISSSTE,Drug|Drug,Mexico,40.0,78.0,[18-65]|[65 and more],Parathyroid diseases,Hyperparathyroidism,https://clinicaltrials.gov/ct2/show/NCT05346419
NCT05355701,thyroid cancer,"A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTI TUMOR ACTIVITY OF PF-07799933 (ARRY-440) AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS",A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors.,Colorectal Cancer|Glioma|Melanoma|Non-Small-Cell Lung Cancer|Thyroid Cancer,2022-04-26,2026-02-23,2027-08-27,Interventional,Not yet recruiting,Phase 1,Pfizer,Pfizer,,Drug|Drug|Biological,,16.0,120.0,[0-17]|[18-65]|[65 and more],Thyroid neoplasms,Thyroid cancer,https://clinicaltrials.gov/ct2/show/NCT05355701
NCT02868476,thyroid diseases,Long Period Observation of Biochemical Survey and Ultrasonography in Thyroid Diseases and Subclinical Thyroid Diseases,Long Period Observation of Biochemical Survey and Ultrasonography in Thyroid Diseases and Subclinical Thyroid Diseases,Thyroid Diseases,2016-08-05,2017-05-26,2024-07-30,Observational [Patient Registry],Active not recruiting,,National Taiwan University Hospital,National Taiwan University Hospital,,,,20.0,80.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT02868476
NCT03191188,thyroid disease,A Pilot Feasibility Trial of Thyroid Hormone Replacement in Dialysis Patients,A Pilot Feasibility Trial of Thyroid Hormone Replacement in Dialysis Patients,"Kidney Diseases, Chronic|Thyroid Disease",2017-06-13,2021-07-31,2021-07-31,Interventional,Recruiting,Not Applicable,"University of California, Irvine","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|University of California, Irvine",University Dialysis Center of Orange,Drug|Drug,United States,18.0,75.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT03191188
NCT03369405,thyroid diseases,Thyroid Insufficiency as a Modifying Factor for Chronic Periodontitis,Thyroid Disease and Chronic Periodontitis,Chronic Periodontitis|Thyroid Diseases,2017-11-28,2022-08-01,2022-08-01,Observational,Active not recruiting,,University at Buffalo,University at Buffalo,"School of Dental Medicine, University at Buffalo",Other,United States,35.0,120.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT03369405
NCT03414021,thyroid diseases,Quantification in Nuclear Medicine: Interest of the in SPECT-CT Scan SUVspect in Thea New Generation of Gamma-cameras With Semiconductor. Data Collection for the Constitution of an Observatory of Scintigraphies,Interest of the SPECT-CT Scan SUVspect in the New Generation of Gamma-cameras With Semiconductor,Bone Diseases|Brain Diseases|Heart Diseases|Kidney Diseases|Thyroid Diseases,2018-01-23,2023-01-30,2023-01-30,Observational,Recruiting,,Lille Catholic University,Lille Catholic University,Humanitep|Hopital Privé Le Bois,Diagnostic Test,France,18.0,120.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT03414021
NCT04279184,thyroid diseases,Urinary Incontinence and Endocrine Factors.,Urinary Incontinence and Endocrine Factors. A Part of Lolland-Falster Health Study (LOFUS).,Diabetes|Thyroid Diseases|Urinary Incontinence,2020-01-16,2020-02-29,2021-02-28,Observational,Recruiting,,Nykøbing Falster County Hospital,Nykøbing Falster County Hospital|Region Zealand|University of Southern Denmark|Zealand University Hospital,Randi Jepsen,,Denmark,18.0,120.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04279184
NCT04351945,thyroid diseases,A Study of Endocrine Changes and Their Correction in Heart and Lung Transplant Recipients and Donors,Endocrine Changes and Their Correction in Heart and Lung Transplant Recipients and Donors,Cortisol Deficiency|Diabetes Insipidus|Endocrine System Diseases|End-stage Heart Failure|End Stage Lung Disease|Thyroid Diseases,2020-04-15,2022-05-15,2022-07-01,Observational,Active not recruiting,,Semmelweis University Heart and Vascular Center,Semmelweis University|Semmelweis University Heart and Vascular Center,Heart and Vascular Center,Procedure,Hungary,18.0,120.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04351945
NCT04427904,thyroid diseases,Bupivacaine Versus Lidocaine Infiltration for Postoperative Pain in Thyroid Surgery: A Randomized Controlled Trial,Bupivacaine Versus Lidocaine Infiltration for Postoperative Pain in Thyroid Surgery,"Anesthesia, Local|Postoperative Pain|Thyroid Diseases",2020-05-26,2023-12-31,2024-12-31,Interventional,Not yet recruiting,Phase 2,St. Joseph's Healthcare Hamilton,St. Joseph's Healthcare Hamilton,St. Joeseph's Healthcare Hamilton,Drug|Drug,Canada,18.0,100.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04427904
NCT04471597,thyroid diseases,Topical Bupivacaine Effect On The Response To Awake Extubation During Emergence From General Anesthesia In Patients Undergoing Elective Thyroidectomy. A Randomized Controlled Study,Topical Bupivacaine Effect On The Response To Awake Extubation During Emergence From General Anesthesia,Thyroid Diseases,2020-07-12,2022-04-01,2022-05-01,Interventional,Recruiting,Not Applicable,Zagazig University,Zagazig University,"Faculty of medicine, zagazig university",Drug|Drug,Egypt,21.0,60.0,[18-65],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04471597
NCT04542278,thyroid diseases,Randomized Controlled Trial of Preoperative Steroids in Autoimmune Thyroid Disease,Preoperative Steroids in Autoimmune Thyroid Disease,Thyroid Diseases,2020-09-01,2022-10-31,2022-10-31,Interventional,Active not recruiting,Phase 4,"University of Wisconsin, Madison","University of Wisconsin, Madison",University of Wisconsin Hospital and Clinics,Drug,United States,18.0,120.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04542278
NCT04794257,thyroid diseases,Clinical Validation of NerveTrend vs. Conventional i-IONM Mode of NIM Vital in Prevention of Recurrent Laryngeal Nerve Events During Bilateral Thyroid Surgery.,NerveTrend vs. i-IONM in Prevention of Recurrent Laryngeal Nerve Events During Bilateral Thyroid Surgery.,Recurrent Laryngeal Nerve Injuries|Surgery|Thyroid Diseases,2021-03-07,2022-12-31,2023-03-31,Interventional,Recruiting,Not Applicable,Jagiellonian University,Marcin Barczynski,"Department of Endocrine Surgery, Jagiellonian University College of Medicine",Device,Poland,18.0,65.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04794257
NCT04842942,thyroid diseases,The Safety and Feasibility of Transoral Endoscopic Thyroidectomy Vestibular Approach,The Safety and Feasibility of Transoral Endoscopic Thyroidectomy Vestibular Approach,Surgery|Thyroid Diseases,2021-02-19,2021-12-31,2022-07-31,Interventional,Recruiting,Phase 1,"University Health Network, Toronto","University Health Network, Toronto",Univeristy Health Network,Procedure,Canada,18.0,80.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04842942
NCT04943146,thyroid diseases,An Assessment of Aspirin Plus Prednisone Treatment for Euthyroid Women With Thyroid Autoimmunity Undergoing In Vitro Fertilization,An Assessment of Aspirin Plus Prednisone Treatment for Euthyroid Women With Thyroid Autoimmunity,Thyroid Diseases,2021-06-21,2021-06-30,2022-03-31,Observational,Recruiting,,"Second Affiliated Hospital, School of Medicine, Zhejiang University","Ningbo Women and Children's Hospital|People's Hospital of Jinhua|Second Affiliated Hospital, School of Medicine, Zhejiang University",People's Hospital of Jinhua|Ningbo Women and Children's Hospital,Drug,China,18.0,40.0,[18-65],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT04943146
NCT05036525,thyroid diseases,"Evaluation of the Efficacy and Safety of a High Molecular Weight Native Hyaluronic Acid Gel (HANBIO BarriGel) in Adhesion Prevention After Open Thyroidectomy: a Prospective, Randomized Controlled, Single Blind Study.",Evaluation of the Efficacy and Safety of a Hyaluronic Acid Gel in Adhesion Prevention After Open Thyroidectomy.,Adhesion|Thyroid Diseases,2021-09-02,2023-06-30,2023-06-30,Interventional,Not yet recruiting,Not Applicable,HAN Biomedical Inc,HAN Biomedical Inc,,Device,,20.0,70.0,[18-65]|[65 and more],Non specific thyroid deseases,Non specific thyroid deseases,https://clinicaltrials.gov/ct2/show/NCT05036525
